PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Onouchi, T; Kishino-Kaneko, Y; Kameshita, I; Ishida, A; Sueyoshi, N				Onouchi, Takashi; Kishino-Kaneko, Yoshimi; Kameshita, Isamu; Ishida, Atsuhiko; Sueyoshi, Noriyuki			Regulation of Ca2+/calmodulin-dependent protein kinase phosphatase (CaMKP/PPM1F) by protocadherin-gamma C5 (Pcdh-gamma C5)	ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS			English	Article						PPM1F; Protocadherin; CaM kinase; N-cadherin; PPM1A/PP2C alpha; gamma-secretase	N-CADHERIN; ACTIVATION; CAMKP; PHOSPHORYLATION; P120-CATENIN; EXPRESSION; ZEBRAFISH; PROMOTER; ADHESION; CATENIN	Ca2+/calmodulin-dependent protein kinase phosphatase (CaMKP/PPM1F) is a Ser/Thr protein phosphatase that belongs to the PPM family. It is important to identify an endogenous regulator of CaMKP. Using an Escherichia coli two-hybrid screening method, we identified the C-terminal cytoplasmic fragment of protocadherin gamma subfamily C5 (Pcdh-gamma C5), which was generated by intracellular processing, as a CaMKP-binding protein. Dephosphorylation of phosphorylated Ca2+/calmodulin-dependent protein kinase I (CaMKI) by CaMKP was significantly activated by the C-terminal cytoplasmic fragment, Pcdh-gamma C5(715-944), both in vitro and in cells, suggesting that the C-terminal fragment functions as an endogenous activator of CaMKP. The nuclear translocation of the fragment was blocked by its binding to cytoplasmic CaMKP to form a ternary complex with CaMKI. Taken together, these results strongly suggest that the C-terminal cytoplasmic fragment of Pcdh-gamma C5 acts as a scaffold for CaMKP and CaMKI to regulate CaMKP,activity. These findings may provide new insights into the reversible regulation of CaMKP in cells. (C) 2015 Elsevier Inc. All rights reserved.	[Onouchi, Takashi; Kishino-Kaneko, Yoshimi; Kameshita, Isamu; Sueyoshi, Noriyuki] Kagawa Univ, Dept Life Sci, Fac Agr, Takamatsu, Kagawa 7610795, Japan; [Ishida, Atsuhiko] Hiroshima Univ, Lab Mol Brain Sci, Grad Sch Integrated Arts & Sci, Higashihiroshima 7398521, Japan	Ishida, A (reprint author), Hiroshima Univ, Lab Mol Brain Sci, Grad Sch Integrated Arts & Sci, Higashihiroshima 7398521, Japan.	aishida@hiroshima-u.ac.jp; sueyoshi@ag.kagawa-u.ac.jp			JSPS [25850244, 25350978, 15K01824]; Kagawa University;  [15J07644]	This work was supported in part by JSPS Grant-in-Aid for Scientific Research (Grant Numbers 25850244, 25350978, 15K01824), Grant-in-Aid for JSPS Fellows (Grant Number 15J07644), and Kagawa University Specially Promoted Research Fund 2013.	Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Li YF, 2012, J NEUROSCI, V32, P11780, DOI 10.1523/JNEUROSCI.0969-12.2012; Baba H, 2012, ARCH BIOCHEM BIOPHYS, V526, P9, DOI 10.1016/j.abb.2012.06.005; Kameshita I, 1999, FEBS LETT, V456, P249, DOI 10.1016/S0014-5793(99)00958-8; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Marambaud P, 2003, CELL, V114, P635, DOI 10.1016/j.cell.2003.08.008; McLachlan RW, 2011, CYTOSKELETON, V68, P32, DOI 10.1002/cm.20492; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Harvey BP, 2004, J BIOL CHEM, V279, P24889, DOI 10.1074/jbc.M400656200; Onouchi T, 2012, BIOCHEM BIOPH RES CO, V422, P703, DOI 10.1016/j.bbrc.2012.05.062; Yoshida K, 1999, FEBS LETT, V460, P93, DOI 10.1016/S0014-5793(99)01309-5; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Sueyoshi N, 2009, ARCH BIOCHEM BIOPHYS, V488, P48, DOI 10.1016/j.abb.2009.06.003; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Fujisawa H, 2001, J BIOCHEM-TOKYO, V129, P193; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Kinoshita S, 2004, J BIOCHEM, V135, P619, DOI 10.1093/jb.mvh075; Kitani T, 1999, J BIOCHEM-TOKYO, V125, P1022; Shimomura S, 2007, ARCH BIOCHEM BIOPHYS, V463, P218, DOI 10.1016/j.abb.2007.03.036; Buchanan SM, 2010, P NATL ACAD SCI USA, V107, P17774, DOI 10.1073/pnas.1013105107; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Marion S, 2014, J BIOL CHEM, V289, P11715, DOI 10.1074/jbc.M113.544312; Tada Y, 2006, ARCH BIOCHEM BIOPHYS, V452, P174, DOI 10.1016/j.abb.2006.06.005; Ishida A, 2002, ARCH BIOCHEM BIOPHYS, V408, P229, DOI 10.1016/S0003-9861(02)00592-1; Ishida A, 1998, J BIOL CHEM, V273, P1904, DOI 10.1074/jbc.273.4.1904; Gee KR, 1999, ANAL BIOCHEM, V273, P41, DOI 10.1006/abio.1999.4202; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Voss M, 2011, CELL SIGNAL, V23, P114, DOI 10.1016/j.cellsig.2010.08.010; Kameshita I, 2003, ANAL BIOCHEM, V322, P215, DOI 10.1016/j.ab.2003.08.014; Li YF, 2010, J COMP NEUROL, V518, P3439, DOI 10.1002/cne.22390; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Koh CG, 2002, CURR BIOL, V12, P317, DOI 10.1016/S0960-9822(02)00652-8; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Phang HQ, 2014, J CELL SCI, V127, P727, DOI 10.1242/jcs.126482; Sueyoshi N., 2007, BIOCHEM BIOPH RES CO, V363, P205	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-9861	1096-0384		ARCH BIOCHEM BIOPHYS	Arch. Biochem. Biophys.	NOV 1	2015	585						109	120		10.1016/j.abb.2015.09.014		12	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CU2NR	WOS:000363360700013		
J	Tsuda, Y; Yasunaga, H; Horiguchi, H; Ogawa, S; Kawano, H; Tanaka, S				Tsuda, Yusuke; Yasunaga, Hideo; Horiguchi, Hiromasa; Ogawa, Sumito; Kawano, Hirotaka; Tanaka, Sakae			Association between dementia and postoperative complications after hip fracture surgery in the elderly: analysis of 87,654 patients using a national administrative database	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Dementia; Hip fracture; Complications	ALZHEIMERS-DISEASE; COHORT; ARTHROPLASTY; PREVENTION; INFECTION; RISK	Mortality following hip fracture surgery is higher in patients with dementia than those without; however, few large-scale studies have investigated postoperative in-hospital complications in such patients. The aim of this study was to elucidate the complications that occur after hip fracture surgery in patients with and without dementia using a large national database. We retrospectively identified patients aged a parts per thousand yen70 years who underwent hemiarthroplasty, osteosynthesis for femoral neck fracture or osteosynthesis for intertrochanteric fracture, and compared the occurrence of postoperative complications between patients with and without dementia. Multivariate logistic regression analysis was performed to adjust for patient characteristics and hospital factors. A total of 87,654 patients were included in this study, including 9419 with dementia. Compared with the non-dementia group, the dementia group showed a higher incidence of overall postoperative complications [odds ratio (OR) 1.45; p < 0.001), surgical site infection (OR 1.58; p = 0.004), urinary tract infection (OR 1.87; p < 0.001) and respiratory complications (OR 1.49; p < 0.001). The rate of postoperative complications was higher for all types of hip fracture surgery. The occurrence of a postoperative complication was significantly higher in patients aged a parts per thousand yen80 years (OR 1.37; p < 0.001) and those with dementia (OR 1.45; p < 0.001), any type of malignancy (OR 1.42; p < 0.001), a history of cardiovascular disease (OR 1.33; p < 0.001), a history of cerebrovascular disease (OR 1.15; p = 0.029), chronic renal failure (OR 1.36; p < 0.001), liver cirrhosis (OR 1.41; p < 0.001) or blood transfusion after surgery (OR 1.49; p < 0.001). Our results highlight the need to pay particular attention to surgical site infection, urinary tract infection and respiratory complications in patients with preoperative dementia after hip fracture surgery. These results provide additional useful evidence to inform the management of these patients.	[Tsuda, Yusuke; Kawano, Hirotaka; Tanaka, Sakae] Univ Tokyo, Grad Sch Med, Dept Orthoped Surg, Bunkyo Ku, Tokyo 1138655, Japan; [Yasunaga, Hideo] Univ Tokyo, Sch Publ Hlth, Dept Hlth Econ & Epidemiol Res, Bunkyo Ku, Tokyo 1138655, Japan; [Horiguchi, Hiromasa] Natl Hosp Org Headquarters, Dept Clin Data Management & Res, Clin Res Ctr, Meguro Ku, Tokyo 1528621, Japan; [Ogawa, Sumito] Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan	Tsuda, Y (reprint author), Univ Tokyo, Grad Sch Med, Dept Orthoped Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	ytsuda-tuk@umin.ac.jp; yasunagah-tky@umin.ac.jp; hiromasa-tky@umin.ac.jp; suogawa-tky@umin.ac.jp; hkawano-tky@umin.net; tanakas-ort@h.u-tokyo.ac.jp			Grants for Research on Policy Planning and Evaluation from the Ministry of Health, Labour and Welfare, Japan [H27-Policy-Designated-009, H27-Policy-Strategy-011]	This work was supported by Grants for Research on Policy Planning and Evaluation from the Ministry of Health, Labour and Welfare, Japan (Grant Numbers H27-Policy-Designated-009 and H27-Policy-Strategy-011).	Andrew DD, 2012, INJURY, V43, P1182; Ridgeway S, 2005, J BONE JOINT SURG BR, V87B, P844, DOI 10.1302/0301-620X.87B6.15121; Hagino H, 2010, J ORTHOP SCI, V15, P737, DOI 10.1007/s00776-010-1543-4; Fakih MG, 2013, AM J INFECT CONTROL, V41, P950, DOI 10.1016/j.ajic.2013.04.019; Hu CJ, 2012, WORLD J SURG, V36, P2051, DOI 10.1007/s00268-012-1609-x; Hubbard AE, 2010, EPIDEMIOLOGY, V21, P467, DOI 10.1097/EDE.0b013e3181caeb90; Banerjee S, 2013, J KNEE SURG, V26, P395, DOI 10.1055/s-0033-1357491; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140-6736(06)68891-0; Liao JC, 2013, SPINE J, V13, P908, DOI 10.1016/j.spinee.2013.02.028; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Lai SW, 2013, J AM GERIATR SOC, V61, P1231, DOI 10.1111/jgs.12349; Asada Takashi, 2012, Rinsho Shinkeigaku, V52, P962; Bozic KJ, 2010, J BONE JT SURG AM, V94, P794; HORNER J, 1994, ALZ DIS ASSOC DIS, V8, P177; Pugely AJ, 2013, J ORTHOP TRAUMA, V28, P63; Stenvall M, 2012, ARCH GERONTOL GERIAT, V54, P284; Sue EE, 2010, J AM ACAD NURSE PRAC, V22, P17; Wagner Pablo, 2012, Geriatr Orthop Surg Rehabil, V3, P55, DOI 10.1177/2151458512450708; Yasunaga H, 2012, BMC HEALTH SERV RES, V28, P129	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	NOV	2015	135	11					1511	1517		10.1007/s00402-015-2321-8		7	Orthopedics; Surgery	Orthopedics; Surgery	CU1HF	WOS:000363270600005		
J	Koga, J; Nakano, T; Dahlman, JE; Figueiredo, JL; Zhang, HM; Decano, J; Khan, OF; Niida, T; Iwata, H; Aster, JC; Yagita, H; Anderson, DG; Ozaki, CK; Aikawa, M				Koga, Jun-ichiro; Nakano, Toshiaki; Dahlman, James E.; Figueiredo, Jose-Luiz; Zhang, Hengmin; Decano, Julius; Khan, Omar F.; Niida, Tomiharu; Iwata, Hiroshi; Aster, Jon C.; Yagita, Hideo; Anderson, Daniel G.; Ozaki, C. Keith; Aikawa, Masanori			Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development Implications for the Treatment of Vein Graft Failure	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						endothelial cells; inflammation; lipid; macrophage; nanoparticles	EXTREMITY BYPASS-SURGERY; IN-VIVO; ATHEROSCLEROSIS; BLOCKADE; CELLS; PATHOGENESIS; DISEASE; GROWTH; TRIAL; MICE	Objective Despite its large clinical impact, the underlying mechanisms for vein graft failure remain obscure and no effective therapeutic solutions are available. We tested the hypothesis that Notch signaling promotes vein graft disease. Approach and Results We used 2 biotherapeutics for Delta-like ligand 4 (Dll4), a Notch ligand: (1) blocking antibody and (2) macrophage- or endothelial cell (EC)-targeted small-interfering RNA. Dll4 antibody administration for 28 days inhibited vein graft lesion development in low-density lipoprotein (LDL) receptor-deficient (Ldlr(-/-)) mice, and suppressed macrophage accumulation and macrophage expression of proinflammatory M1 genes. Dll4 antibody treatment for 7 days after grafting also reduced macrophage burden at day 28. Dll4 silencing via macrophage-targeted lipid nanoparticles reduced lesion development and macrophage accumulation, whereas EC-targeted Dll4 small-interfering RNA produced no effects. Gain-of-function and loss-of-function studies suggested in vitro that Dll4 induces proinflammatory molecules in macrophages. Macrophage Dll4 also stimulated smooth muscle cell proliferation and migration and suppressed their differentiation. Conclusions These results suggest that macrophage Dll4 promotes lesion development in vein grafts via macrophage activation and crosstalk between macrophages and smooth muscle cells, supporting the Dll4-Notch axis as a novel therapeutic target.	[Koga, Jun-ichiro; Nakano, Toshiaki; Figueiredo, Jose-Luiz; Niida, Tomiharu; Aikawa, Masanori] Brigham & Womens Hosp, Ctr Excellence Vasc Biol, Boston, MA 02115 USA; [Figueiredo, Jose-Luiz; Zhang, Hengmin; Decano, Julius; Iwata, Hiroshi; Aikawa, Masanori] Brigham & Womens Hosp, Ctr Interdisciplinary Cardiovasc Sci, Boston, MA 02115 USA; [Aikawa, Masanori] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA; [Aster, Jon C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Ozaki, C. Keith] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Vasc & Endovasc Surg,Dept Surg, Boston, MA 02115 USA; [Dahlman, James E.; Khan, Omar F.; Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Dahlman, James E.; Khan, Omar F.; Anderson, Daniel G.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Dahlman, James E.; Khan, Omar F.; Anderson, Daniel G.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA; [Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan	Aikawa, M (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Excellence Vasc Biol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	maikawa@rics.bwh.harvard.edu			National Institutes of Health [R01HL107550]; American Heart Association [0655878T, 12GRNT9510001, 12GRNT1207025]; Good Samaritan Foundation; Shapiro Family Foundation; Banyu Fellowship Program from the Banyu Life Science Foundation International	This study was supported by a grant from the National Institutes of Health (R01HL107550 to M. Aikawa), the American Heart Association (0655878T to M. Aikawa; 12GRNT9510001 and 12GRNT1207025 to C.K. Ozaki), the Good Samaritan Foundation (to C.K. Ozaki), the Shapiro Family Foundation (to C.K. Ozaki), and the Banyu Fellowship Program from the Banyu Life Science Foundation International (to J. Koga).	Motwani JG, 1998, CIRCULATION, V97, P916; Thurston G, 2007, NAT REV CANCER, V7, P327, DOI 10.1038/nrc2130; SHIMOKAMA T, 1991, MODERN PATHOL, V4, P101; Courties G, 2014, J AM COLL CARDIOL, V63, P1556, DOI 10.1016/j.jacc.2013.11.023; Mohtashami M, 2013, INT IMMUNOL, V25, P601, DOI 10.1093/intimm/dxt027; Tatewaki H, 2007, J VASC SURG, V45, P1236, DOI 10.1016/j.jvs.2007.01.066; Yamanda S, 2009, BLOOD, V113, P3631, DOI 10.1182/blood-2008-07-170381; Fukushima A, 2008, IMMUNOL LETT, V121, P140, DOI 10.1016/j.imlet.2008.10.006; Yu P, 2010, J VASC SURG, V52, P444, DOI 10.1016/j.jvs.2010.03.048; Ridker PM, 2012, CIRCULATION, V126, P2739, DOI 10.1161/CIRCULATIONAHA.112.122556; Majesky MW, 2011, ARTERIOSCL THROM VAS, V31, P1530, DOI 10.1161/ATVBAHA.110.221549; Jiang ZH, 2009, FEBS LETT, V583, P3536, DOI 10.1016/j.febslet.2009.10.015; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; FitzGibbon GM, 1996, J AM COLL CARDIOL, V28, P616, DOI 10.1016/0735-1097(96)00206-9; AIKAWA M, 1993, CIRC RES, V73, P1000; Owens CD, 2008, VASC MED, V13, P63, DOI 10.1177/1358863X07083432; QIAO JH, 1991, AM HEART J, V122, P955, DOI 10.1016/0002-8703(91)90457-S; Allman D, 2002, IMMUNOL REV, V187, P75, DOI 10.1034/j.1600-065X.2002.18707.x; Kenagy RD, 2009, J VASC SURG, V49, P1282, DOI 10.1016/j.jvs.2008.12.020; Fowkes FGR, 2013, LANCET, V382, P1329, DOI 10.1016/S0140-6736(13)61249-0; Libby P, 2002, NAT MED, V8, P1257, DOI 10.1038/nm1102-1257; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680; Coelho T, 2013, NEW ENGL J MED, V369, P819, DOI 10.1056/NEJMoa1208760; Owens CD, 2007, J VASC SURG, V45, P944, DOI 10.1016/j.jvs.2007.01.025; Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520; Aikawa M, 2004, CARDIOVASC PATHOL, V13, P125, DOI 10.1016/S1054-8807(04)00004-3; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Mochizuki K, 2013, J IMMUNOL, V190, P3772, DOI 10.4049/jimmunol.1202820; Eefting D, 2009, J VASC SURG, V50, P152, DOI 10.1016/j.jvs.2009.03.027; Fitzgerald K, 2014, LANCET, V383, P60, DOI 10.1016/S0140-6736(13)61914-5; Bigas A, 2013, BLOOD CELL MOL DIS, V51, P264, DOI 10.1016/j.bcmd.2013.07.005; Fukuda D, 2012, P NATL ACAD SCI USA, V109, pE1868, DOI 10.1073/pnas.1116889109; Conte MS, 2006, J VASC SURG, V43, P742, DOI 10.1016/j.jvs.2005.12.058; Fung E, 2007, CIRCULATION, V115, P2948, DOI 10.1161/CIRCULATIONAHA.107.675462; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525; Dahlman JE, 2014, NAT NANOTECHNOL, V9, P648, DOI [10.1038/nnano.2014.84, 10.1038/NNANO.2014.84]; Laranjeiro R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034553; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/nmat3765, 10.1038/NMAT3765]; Robbins CS, 2013, NAT MED, V19, P1166, DOI 10.1038/nm.3258; Aikawa M, 2001, CIRCULATION, V103, P276; Leuschner F, 2011, NAT BIOTECHNOL, V29, P1005, DOI 10.1038/nbt.1989; COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I; LUSCHER TF, 1991, CURR OPIN CARDIOL, V6, P868; Wood S, 2015, J IMMUNOL, V194, P2899, DOI 10.4049/jimmunol.1402034; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; de Vries MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047134; Leuschner F, 2015, EUR HEART J, V36, P1478, DOI 10.1093/eurheartj/ehu225; Novobrantseva TI, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2011.3; Twine CP, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001487.pub2; Wal A C, 1994, Cardiovasc Pathol, V3, P81, DOI 10.1016/1054-8807(94)90037-X	50	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1079-5642	1524-4636		ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	NOV	2015	35	11					2343	2353		10.1161/ATVBAHA.115.305516		11	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	CU1SV	WOS:000363302500012		
J	Truong, TNT; Jongwanich, J; Ramstetter, ED				Thi Ngoc Thuyen Truong; Jongwanich, Juthathip; Ramstetter, Eric D.			Productivity spillovers from foreign multinationals and trade protection: firm-level analysis of Vietnamese manufacturing	ASIAN-PACIFIC ECONOMIC LITERATURE			English	Article							DIRECT-INVESTMENT; POSITIVE SPILLOVERS; TECHNOLOGY-TRANSFER; DOMESTIC FIRMS; PANEL-DATA; GROWTH; FDI; LIBERALIZATION; MOBILITY; REGIMES	This paper examines how the presence of foreign multinational enterprises (MNEs) affects productivity in domestic private firms in Vietnamese manufacturing in 2005-10. The paper also examines how import protection has affected these productivity spillovers and how spillovers from wholly foreign MNEs and joint ventures differ. The most consistent result suggests wholly foreign MNEs impart negative spillovers while joint ventures tend to generate positive spillovers. Theory and random effects estimates also indicate that import protection reduces local firm productivity and weakens the effect of spillovers from all MNEs; but this result is not obtained when a fixed effects estimator is used. Results are similar in samples of labour-intensive industries, which include close to three fourths of all sample firms, but differ markedly for more capital-intensive groups.	[Thi Ngoc Thuyen Truong] Asian Inst Technol, Pathum Thani, Thailand; [Thi Ngoc Thuyen Truong] Univ Dalat, Da Lat, Vietnam; [Jongwanich, Juthathip] Thammasat Univ, Bangkok, Thailand; [Ramstetter, Eric D.] Int Ctr Study East Asian Dev, Kitakyushu, Fukuoka, Japan; [Ramstetter, Eric D.] Kyushu Univ, Grad Sch Econ, Fukuoka 812, Japan	Truong, TNT (reprint author), Asian Inst Technol, Pathum Thani, Thailand.						Hale G, 2011, PAC ECON REV, V16, P135, DOI 10.1111/j.1468-0106.2011.00539.x; Kathuria V, 2002, OXFORD ECON PAP, V54, P688, DOI 10.1093/oep/54.4.688; Kohpaiboon A, 2003, J DEV STUD, V40, P55, DOI 10.1080/00220380412331293767; Kokko A, 2001, WELTWIRTSCH ARCH, V137, P124, DOI 10.1007/BF02707603; Gorg H, 2005, SCAND J ECON, V107, P693, DOI 10.1111/j.1467-9442.2005.00427.x; Le HQ, 2011, J ASIA PAC ECON, V16, P183, DOI 10.1080/13547860.2011.564746; Khalifah NA, 2009, ASIAN ECON J, V23, P143, DOI 10.1111/j.1467-8381.2009.02011.x; Fosfuri A, 2001, J INT ECON, V53, P205, DOI 10.1016/S0022-1996(00)00069-6; Kohpaiboon A, 2006, WORLD DEV, V34, P541, DOI 10.1016/j.worlddev.2005.08.006; Chand S, 1999, ECON REC, V75, P28, DOI 10.1111/j.1475-4932.1999.tb02431.x; Athukorala PC, 2006, WORLD ECON, V29, P161, DOI 10.1111/j.1467-9701.2006.00776.x; Blalock G, 2008, J INT ECON, V74, P402, DOI 10.1016/j.jinteco.2007.05.011; Meyer KE, 2009, J INT BUS STUD, V40, P1075, DOI 10.1057/jibs.2008.111; KOKKO A, 1994, J DEV ECON, V43, P279, DOI 10.1016/0304-3878(94)90008-6; Ramaswamy KV, 1999, SMALL BUS ECON, V13, P131, DOI 10.1023/A:1008146426387; WANG JY, 1992, EUR ECON REV, V36, P137, DOI 10.1016/0014-2921(92)90021-N; Gorg H, 2004, WORLD BANK RES OBSER, V19, P171, DOI 10.1093/wbro/lkh019; Aitken BJ, 1999, AM ECON REV, V89, P605, DOI 10.1257/aer.89.3.605; Ruan J, 2008, EUR REV AGRIC ECON, V35, P439, DOI 10.1093/erae/jbn034; Javorcik BS, 2008, J DEV ECON, V85, P194, DOI 10.1016/j.jdeveco.2006.08.005; Djankov S, 2000, WORLD BANK ECON REV, V14, P49; Anwar S., 2011, RES INT BUS FINANC, V25, P39; Asian Development Bank, 2013, KEY IND AS PAC 2013; Bhagwati J., 1973, INT TRADE MONEY; BHAGWATI JN, 1985, J POLICY MODEL, V7, P23, DOI 10.1016/0161-8938(85)90026-2; Blomstrom M., 1996, IMPACT FOREIGN INVES; BRECHER RA, 1977, J INT ECON, V7, P317, DOI 10.1016/0022-1996(77)90048-4; BRECHER RA, 1983, J INT ECON, V14, P277, DOI 10.1016/0022-1996(83)90005-3; Bui T., 2012, DEPOCEN WP SERIES; Chen E. K. Y., 1983, MULTINATIONAL CORPOR; Czinkota M. R., 1999, INT BUSINESS; De Mello L., 1997, J DEV STUD, V34, P11; Dunning JH, 2008, MULTINATIONAL ENTERPRISES AND THE GLOBAL ECONOMY, 2ND EDITION, P1; General Statistics Office, 2004, FIRM LEV DAT ENT SUR; General Statistics Office, 2014, DAT DOWNL GSO WEBS; Gorg H., 2001, ECON J, V111, P723, DOI DOI 10.1111/1468-0297.00669; HADDAD M, 1993, J DEV ECON, V42, P51, DOI 10.1016/0304-3878(93)90072-U; Javorcik, 2004, AM ECON REV, V94, P605; Katz J., 1987, TECHNOLOGY CREATION; Kohpaiboon A., 2006, MULTINATIONAL ENTERP; Kokko A., 2005, ASIAN ECON PAP, V4, P152; Lipsey R. E., 2005, IMPACT INWARD FDI HO, P23; Moran T., 2002, RELATIONSHIP TRADE F; MUTRAP, 2010, QUAL QUANT AN IMP AS; Nguyen L. P., 2008, SSRN WORKING PAPER S; Nguyen N. A., 2008, FDI VIETNAM IS THERE; Nguyen T. T. A., 2006, IMPACTS FOREIGN DIRE; Pham X. K., 2008, VIETN DEV FOR HAN; Ramstetter Eric D., 2013, Journal of Asian Economics, V25, DOI 10.1016/j.asieco.2012.12.001; Takii S, 2005, J DEV ECON, V76, P521, DOI 10.1016/j.jdeveco.2004.01.006; Winkler J., 2012, PROVINCIAL COMPETITI; Wooldridge J. M., 2009, INTRO ECONOMETRICS M	52	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0818-9935	1467-8411		ASIAN-PAC ECON LIT	Asian-Pac Econ. Lit.	NOV	2015	29	2					30	46		10.1111/apel.12117		17	Economics	Business & Economics	CU3LW	WOS:000363427900003		
J	Shimizu, Y; Sato, S; Koyamatsu, J; Yamanashi, H; Nagayoshi, M; Kadota, K; Maeda, T				Shimizu, Yuji; Sato, Shimpei; Koyamatsu, Jun; Yamanashi, Hirotomo; Nagayoshi, Mako; Kadota, Koichiro; Maeda, Takahiro			Circulating CD34-positive cells, glomerular filtration rate and triglycerides in relation to hypertension	ATHEROSCLEROSIS			English	Article						CD34-positive cell; Glomerular filtration rate; Triglycerides; Hypertension	CHRONIC KIDNEY-DISEASE; JAPANESE GENERAL-POPULATION; COMMUNITY-BASED POPULATION; HEMATOPOIETIC STEM-CELLS; PULSE-WAVE VELOCITY; VASCULAR INDEX CAVI; BLOOD-PRESSURE; CAROTID ATHEROSCLEROSIS; ENDOTHELIAL DYSFUNCTION; ARTERIAL STIFFNESS	Objective: Serum triglycerides have been reported to be independently associated with the development of chronic kidney disease (CKD), which is known to play a role in vascular disturbance. On the other hand, circulating CD34-positve cells, including endothelial progenitor cells, are reported to contribute to vascular repair. However, no studies have reported on the correlation between triglycerides and the number of CD34-positive cells. Since hypertension is well known factor for vascular impairment, the degree of correlation between serum triglycerides and circulating CD34-positve cells should account for hypertension status. Methods: We conducted a cross-sectional study of 274 elderly Japanese men aged >= 60years (range 60-79 years) undergoing general health checkups. Results: Multiple linear regression analysis of non-hypertensive subjects adjusting for classical cardiovascular risk factors showed that although triglyceride levels (1SD increments; 64 mg/dL) did not significantly correlate with glomerular filtration rate (GFR) (beta = -2.06, p = 0.163), a significant positive correlation was seen between triglycerides and the number of circulating CD34-positive cells (beta = 0.50, beta = 0.004). In hypertensive subjects, a significant inverse correlation between triglycerides and GFR was observed (beta = -2.66, p = 0.035), whereas no significant correlation between triglycerides and the number of circulating CD34-positive cells was noted (beta = -0.004, p = 0.974). Conclusion: Since endothelial progenitor cells (CD34-positive cells) have been reported to contribute to vascular repair, our results indicate that in non-hypertensive subjects, triglycerides may stimulate an increase in circulating CD34-positive cells (vascular repair) by inducing vascular disturbance. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Shimizu, Yuji; Sato, Shimpei; Koyamatsu, Jun; Nagayoshi, Mako; Kadota, Koichiro; Maeda, Takahiro] Nagasaki Univ, Dept Community Med, Grad Sch Biomed Sci, Nagasaki, Nagasaki 8528523, Japan; [Yamanashi, Hirotomo; Maeda, Takahiro] Nagasaki Univ, Dept Isl & Community Med, Grad Sch Biomed Sci, Nagasaki, Nagasaki 8528523, Japan	Shimizu, Y (reprint author), Nagasaki Univ, Dept Community Med, Grad Sch Biomed Sci, Sakamoto 1-12-4, Nagasaki, Nagasaki 8528523, Japan.	shimizuyuji@nagasaki-u.ac.jp			Japan Society for the Promotion of Science [25291107, 15K07243]	This study was supported by Grants-in-Aids for Scientific Research from the Japan Society for the Promotion of Science (No. 25291107 and No. 15K07243). We are grateful to the staff of Goto city office for their outstanding support.	Fox CS, 2004, JAMA-J AM MED ASSOC, V291, P844, DOI 10.1001/jama.291.7.844; Puddu P, 2000, ACTA CARDIOL, V55, P221, DOI 10.2143/AC.55.4.2005744; Ishizaka N, 2007, HYPERTENS RES, V30, P1035, DOI 10.1291/hypres.30.1035; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Yambe T, 2004, BIOMED PHARMACOTHER, V58, pS95, DOI 10.1016/S0753-3322(04)80015-5; Wen JH, 2015, INT J CLIN EXP MED, V8, P4342; Kubozono T, 2009, J ATHEROSCLER THROMB, V16, P840; FARQUHAR JW, 1966, J CLIN INVEST, V45, P1648, DOI 10.1172/JCI105472; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Taguchi A, 2004, CIRCULATION, V109, P2972, DOI 10.1161/01.CIR.0000133311.25587.DE; Barnett D, 1999, CLIN LAB HAEMATOL, V21, P301, DOI 10.1046/j.1365-2257.1999.00253.x; Shimizu M, 2015, ATHEROSCLEROSIS, V238, P207, DOI 10.1016/j.atherosclerosis.2014.12.013; Sata M, 2002, NAT MED, V8, P403, DOI 10.1038/nm0402-403; Endemann DH, 2004, J AM SOC NEPHROL, V15, P1983, DOI 10.1097/01.ASN.0000132474.50966.DA; Yamashina A, 2003, HYPERTENS RES, V26, P801, DOI 10.1291/hypres.26.801; Yamagata K, 2007, KIDNEY INT, V71, P159, DOI 10.1038/sj.ki.5002017; Kitamura A, 2004, ATHEROSCLEROSIS, V172, P353, DOI 10.1016/j.atherosclerosis.2003.10.012; Shirai K, 2006, J ATHEROSCLER THROMB, V13, P101; Imai E, 2009, CLIN EXP NEPHROL, V13, P621, DOI 10.1007/s10157-009-0199-x; Fadini GP, 2006, EUR HEART J, V27, P2247, DOI 10.1093/eurheartj/ehl198; Ohara T, 2013, STROKE, V44, P3537, DOI 10.1161/STROKEAHA.113.002957; Aronson D, 2003, J HYPERTENS, V21, P3, DOI 10.1097/01.hjh.0000042892.24999.92; STALDER M, 1981, DIABETOLOGIA, V21, P544; Antonio G.C., 2011, CIR CIR, V79, P115; Chang JB, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-228; Saito Takao, 2013, Nihon Rinsho, V71, P1618; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Tsuruya K., 2015, AM J KIDNEY DIS	30	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0021-9150	1879-1484		ATHEROSCLEROSIS	Atherosclerosis	NOV	2015	243	1					71	76		10.1016/j.atherosclerosis.2015.08.035		6	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CU1FQ	WOS:000363266000011		
J	Ijichi, T; Nakazawa, G; Torii, S; Nakano, M; Yoshikawa, A; Morino, Y; Ikari, Y				Ijichi, Takeshi; Nakazawa, Gaku; Torii, Sho; Nakano, Masataka; Yoshikawa, Ayako; Morino, Yoshihiro; Ikari, Yuji			Evaluation of coronary arterial calcification - Ex-vivo assessment by optical frequency domain imaging	ATHEROSCLEROSIS			English	Article						Histology; Intracoronary imaging; Intravascular ultrasound; Optical frequency domain imaging	SIROLIMUS-ELUTING STENT; ACUTE MYOCARDIAL-INFARCTION; INTRAVASCULAR ULTRASOUND; COHERENCE TOMOGRAPHY; ROTATIONAL ATHERECTOMY; ATHEROSCLEROTIC LESIONS; RANDOMIZED-TRIAL; PLAQUE; IMPLANTATION; DISEASE	Aims: The purpose of this study was to determine the diagnostic ability of optical frequency domain imaging (OFDI) to carry out quantitative and qualitative evaluation of coronary calcification in comparing with ex vivo human autopsy heart specimens. Methods: Analysis was carried out in 25 coronary artery specimen obtained from 16 cadavers that were imaged ex-vivo imaging by OFDI and intravascular ultrasound (IVUS). Of 235 cross-sections obtained for histologic evaluation, 149 were classified as showing calcified plaques, and in this group a comparison between histology versus co-registered images by OFDI and IVUS was performed. Results: Maximum thickness of calcification measured by OFDI was well correlated with histology (r(s) = 0.70, p < 0.0001) whereas IVUS was not useful for quantitative analysis because of the presence of acoustic shadows occurring behind calcifications. Furthermore qualitative evaluation could be carried out using OFDI, for calcifications with vague or invisible outer borders by OFDI had lipid contents (lipid pool or histologic necrotic core) more frequently as compared to those with a clear outer border (79% vs. 24%, p < 0.0001). We also found that calcified nodules, a well-recognized thrombogenic substrate, demonstrated atypical appearance in OFDI, showing irregular surfaces with high attenuation. Conclusion: OFDI demonstrated a greater ability than IVUS to provide quantitative and qualitative evaluation of coronary arterial calcification. Precise recognition of calcified plaque morphology by OFDI may serve to determine the treatment strategy of patients having atherosclerotic coronary disease. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Ijichi, Takeshi; Nakazawa, Gaku; Torii, Sho; Nakano, Masataka; Yoshikawa, Ayako; Ikari, Yuji] Tokai Univ, Sch Med, Isehara, Kanagawa 2591193, Japan; [Morino, Yoshihiro] Iwate Med Univ, Morioka, Iwate 0208505, Japan	Nakazawa, G (reprint author), Tokai Univ, Dept Cardiol, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	gnakazawa@tokai-u.jp			Abbott Vascular; Medtronic; Boston Scientific; Daiichi-Sankyo; Sanofi Aventis; Kaneka Medics; Asahi Intech; Terumo Corp.	Gaku Nakazawa, MD: Receives Research Grant; Abbott Vascular, Terumo Corp., Medtronic, Boston Scientific, Daiichi-Sankyo.; Yoshihiro Morino, MD: Receives Research Grant; Daiichi-Sankyo, Sanofi Aventis.; Yuji Ikari, MD: Company Sponsored Research Support; Boston Scientific, Abbott Vascular, Kaneka Medics, Asahi Intech, Terumo Corp.	Okubo M, 2008, CIRC J, V72, P1631, DOI 10.1253/circj.CJ-07-0936; Sakakura K, 2013, HEART LUNG CIRC, V22, P399, DOI 10.1016/j.hlc.2013.03.001; Nakano M, 2012, JACC-CARDIOVASC IMAG, V5, P71, DOI 10.1016/j.jcmg.2011.09.015; Serruys PW, 2009, NEW ENGL J MED, V360, P961, DOI 10.1056/NEJMoa0804626; Sawada T, 2008, EUR HEART J, V29, P1136, DOI 10.1093/eurheartj/ehn132; Jia HB, 2013, J AM COLL CARDIOL, V62, P1748, DOI 10.1016/j.jacc.2013.05.071; Kume T, 2006, AM J CARDIOL, V97, P1172, DOI 10.1016/j.amjcard.2005.11.035; Kume T, 2007, CIRC J, V71, P643, DOI 10.1253/circj.71.643; Maurovich-Horvat P, 2012, RADIOLOGY, V265, P393, DOI 10.1148/radiol.12111891; Tearney GJ, 2012, J AM COLL CARDIOL, V59, P1058, DOI 10.1016/j.jacc.2011.09.079; Cavusoglu E, 2004, CATHETER CARDIO INTE, V62, P485, DOI 10.1002/ccd.20081; Serruys PW, 2010, NEW ENGL J MED, V363, P136, DOI 10.1056/NEJMoa1004130; Onuma Y, 2010, CATHETER CARDIO INTE, V76, P634, DOI 10.1002/ccd.22541; Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5; MINTZ GS, 1992, J AM COLL CARDIOL, V20, P1149; Virmani R, 2006, J AM COLL CARDIOL, V47, pC13, DOI 10.1016/j.jacc.2005.10.065; Valgimigli M, 2008, JAMA-J AM MED ASSOC, V299, P1788, DOI 10.1001/jama.299.15.joc80026; Lee JB, 2011, AM J CARDIOL, V108, P1547, DOI 10.1016/j.amjcard.2011.07.014; Kubo T, 2014, J ATHEROSCLER THROMB, V21, P895; Kume T, 2011, EUROINTERVENTION, V6, P768, DOI 10.4244/EIJV6I6A130; Bourantas CV, 2014, HEART, V100, P1158, DOI 10.1136/heartjnl-2013-305180; Wexler L, 1996, CIRCULATION, V94, P1175; Moussa I, 1997, CIRCULATION, V96, P128; Windecker S, 2008, LANCET, V372, P1163, DOI 10.1016/S0140-6736(08)61244-1; Kubo T, 2007, J AM COLL CARDIOL, V50, P933, DOI 10.1016/j.jacc.2007.04.082; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262; Sonoda S, 2004, J AM COLL CARDIOL, V43, P1959, DOI 10.1016/j./jacc.2004.01.044; Serruys PW, 2004, HEART, V90, P995, DOI 10.1136/hrt.2003.028811; Valgimigli M, 2005, JAMA-J AM MED ASSOC, V293, P2109, DOI 10.1001/jama.293.17.2109; Cheneau E, 2003, CIRCULATION, V108, P43, DOI 10.1161/01.CIR.0000078636.71728.40; Tanigawa J, 2008, CIRC J, V72, P157, DOI 10.1253/circj.72.157; Windecker S, 2005, NEW ENGL J MED, V353, P653, DOI 10.1056/NEJMoa051175; Honda Yohsuke, 2014, Cardiovasc Interv Ther, V29, P315, DOI 10.1007/s12928-014-0274-4; Takahashi Kentaro, 2013, Cardiovasc Interv Ther, V28, P333, DOI 10.1007/s12928-013-0177-9	34	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0021-9150	1879-1484		ATHEROSCLEROSIS	Atherosclerosis	NOV	2015	243	1					242	247		10.1016/j.atherosclerosis.2015.09.002		6	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CU1FQ	WOS:000363266000035		
J	Vallejo-Vaz, AJ; Seshasai, SRK; Della Cole,; Hovingh, GK; Kastelein, JJP; Mata, P; Raal, FJ; Santos, RD; Soran, H; Watts, GF; Abifadel, M; Aguilar-Salinas, CA; Akram, A; Alnouri, F; Alonso, R; Al-Rasadi, K; Banach, M; Bogsrud, MP; Bourbon, M; Bruckert, E; Car, J; Corral, P; Descamps, O; Dieplinger, H; Durst, R; Freiberger, T; Gaspar, IM; Genest, J; Harada-Shiba, M; Jiang, LX; Kayikcioglu, M; Lam, CSP; Latkovskis, G; Laufs, U; Liberopoulos, E; Nilsson, L; Nordestgaard, BG; O'Donoghue, JM; Sahebkar, A; Schunkert, H; Shehab, A; Stoll, M; Su, TC; Susekov, A; Widen, E; Catapano, AL; Ray, KK				Vallejo-Vaz, Antonio J.; Seshasai, Sreenivasa Rao Kondapally; Della Cole; Hovingh, G. Kees; Kastelein, John J. P.; Mata, Pedro; Raal, Frederick J.; Santos, Raul D.; Soran, Handrean; Watts, Gerald F.; Abifadel, Marianne; Aguilar-Salinas, Carlos A.; Akram, Asif; Alnouri, Fahad; Alonso, Rodrigo; Al-Rasadi, Khalid; Banach, Maciej; Bogsrud, Martin P.; Bourbon, Mafalda; Bruckert, Eric; Car, Josip; Corral, Pablo; Descamps, Olivier; Dieplinger, Hans; Durst, Ronen; Freiberger, Tomas; Gaspar, Isabel M.; Genest, Jaques; Harada-Shiba, Mariko; Jiang, Lixin; Kayikcioglu, Meral; Lam, Carolyn S. P.; Latkovskis, Gustavs; Laufs, Ulrich; Liberopoulos, Evangelos; Nilsson, Lennart; Nordestgaard, Borge G.; O'Donoghue, John M.; Sahebkar, Amirhossein; Schunkert, Heribert; Shehab, Abdulla; Stoll, Mario; Su, Ta-Chen; Susekov, Andrey; Widen, Elisabeth; Catapano, Alberico L.; Ray, Kausik K.			Familial hypercholesterolaemia: A global call to arms	ATHEROSCLEROSIS			English	Article						Familial hypercholesterolaemia	PREVALENCE; CLINICIAN; GUIDANCE; DISEASE; RISK		[Vallejo-Vaz, Antonio J.; Ray, Kausik K.] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England; [Seshasai, Sreenivasa Rao Kondapally; Della Cole] St Georges Univ London, Cardiovasc & Cell Sci Res Inst, London, England; [Hovingh, G. Kees; Kastelein, John J. P.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Mata, Pedro] Fdn Hipercolesterolemia Familiar, Madrid, Spain; [Raal, Frederick J.] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa; [Santos, Raul D.] Univ Sao Paulo, Med Sch Hosp, Heart Inst InCor, Sao Paulo, Brazil; [Soran, Handrean] Univ Manchester, Fac Med & Hlth Sci, Manchester, Lancs, England; [Watts, Gerald F.] Univ Western Australia, Royal Perth Hosp, Cardiovasc Med, Perth, WA 6009, Australia; [Abifadel, Marianne] St Joseph Univ, Fac Pharm, Lab Biochem & Mol Therapeut, Beirut, Lebanon; [Aguilar-Salinas, Carlos A.] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Akram, Asif; Car, Josip] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Global eHlth Unit, London, England; [Alnouri, Fahad] Prince Sultan Cardiac Ctr Riyadh, Cardiovasc Prevent & Rehabil Unit, Riyadh, Saudi Arabia; [Alonso, Rodrigo] Lipid Clin, Dept Nutr, Clin Condes, Santiago, Chile; [Al-Rasadi, Khalid] Sultan Qaboos Univ Hosp, Muscat, Oman; [Banach, Maciej] Med Univ Lodz, Dept Hypertens, Lodz, Poland; [Bogsrud, Martin P.] Natl Advisory Unit Familial Hypercholesterolemia, Oslo, Norway; [Bourbon, Mafalda] Univ Lisbon, Inst Nacl Saude Doutor Ricardo Jorge & BioISI, Biosyst & Integrat Sci Inst, P-1699 Lisbon, Portugal; [Bruckert, Eric] Hop La Pitie Salpetriere, Endocrinol Metab & Prevent Cardiovasc, Inst & IHU Cardiometab ICAN E3M, Paris, France; [Car, Josip] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 639798, Singapore; [Corral, Pablo] FASTA Univ, Sch Med, Mar Del Plata, Buenos Aires, Argentina; [Descamps, Olivier] Hop Jolimont, Haine St Paul, Belgium; [Dieplinger, Hans] Med Univ Innsbruck, Austrian Atherosclerosis Soc, A-6020 Innsbruck, Austria; [Durst, Ronen] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel; [Freiberger, Tomas] Masaryk Univ, Ctr Cardiovasc Surg & Transplantat Brno & Ceitec, Brno, Czech Republic; [Gaspar, Isabel M.] Univ Lisbon, Lisbon Med Sch, Ctr Hosp Lisboa Ocidental & Genet Lab, Dept Med Genet, P-1699 Lisbon, Portugal; [Genest, Jaques] McGill Univ, Montreal, PQ, Canada; [Harada-Shiba, Mariko] Natl Cerebral & Cardiovasc Ctr Res Inst, Osaka, Japan; [Jiang, Lixin] Natl Ctr Cardiovasc Dis, Beijing, Peoples R China; [Kayikcioglu, Meral] Ege Univ, Sch Med, Dept Cardiol, Izmir, Turkey; [Lam, Carolyn S. P.] Natl Heart Ctr Singapore, Singapore, Singapore; [Lam, Carolyn S. P.] Duke Natl Univ Singapore, Singapore, Singapore; [Latkovskis, Gustavs] Univ Latvia, Latvian Res Inst Cardiol, Paul Stradins Clin Univ Hosp, Riga, Latvia; [Laufs, Ulrich] Univ Saarland, Homburg, Germany; [Liberopoulos, Evangelos] Univ Ioannina, Sch Med, GR-45110 Ioannina, Greece; [Nilsson, Lennart] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden; [Nordestgaard, Borge G.] Univ Copenhagen, Copenhagen Univ Hosp, Herlev & Gentofte Hosp, Copenhagen, Denmark	Ray, KK (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England.	k.ray@imperial.ac.uk	Santos, Raul/A-1170-2010; Banach, Maciej/A-1271-2009	Santos, Raul/0000-0002-9860-6582; Banach, Maciej/0000-0001-6690-6874			Austin MA, 2004, AM J EPIDEMIOL, V160, P407, DOI 10.1093/aje/kwh236; Nordestgaard BG, 2013, EUR HEART J, V34, P3478, DOI 10.1093/eurheartj/eht273; Benn M, 2012, J CLIN ENDOCR METAB, V97, P3956, DOI 10.1210/jc.2012-1563; Neil A, 2008, EUR HEART J, V29, P2625, DOI 10.1093/eurheartj/ehn422; Ademi Z, 2013, INT J CARDIOL, V167, P2391, DOI 10.1016/j.ijcard.2013.01.280; Huijgen R, 2012, EUR HEART J, V33, P2325, DOI 10.1093/eurheartj/ehs038; Sjouke B, 2015, EUR HEART J, V36, P560, DOI 10.1093/eurheartj/ehu058; Cuchel M, 2014, EUR HEART J, V35, P2146, DOI 10.1093/eurheartj/ehu274; Do R, 2015, NATURE, V518, P102, DOI 10.1038/nature13917; Versmissen J, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2423; Wiegman A, 2015, EUR HEART J; World Health Organization (WHO), 2015, INT CLASS DIS ICD 10	12	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0021-9150	1879-1484		ATHEROSCLEROSIS	Atherosclerosis	NOV	2015	243	1					257	259		10.1016/j.atherosclerosis.2015.09.021		3	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CU1FQ	WOS:000363266000037		
J	Kitagawa, T; Yamamoto, H; Sentani, K; Takahashi, S; Tsushima, H; Senoo, A; Yasui, W; Sueda, T; Kihara, Y				Kitagawa, Toshiro; Yamamoto, Hideya; Sentani, Kazuhiro; Takahashi, Shinya; Tsushima, Hiroshi; Senoo, Atsuhiro; Yasui, Wataru; Sueda, Taijiro; Kihara, Yasuki			The relationship between inflammation and neoangiogenesis of epicardial adipose tissue and coronary atherosclerosis based on computed tomography analysis	ATHEROSCLEROSIS			English	Article						Coronary atherosclerosis; Epicardial adipose tissue; Inflammation; Neoangiogenesis	ARTERY CALCIUM; FAT VOLUME; PLAQUE CHARACTERISTICS; CT ANGIOGRAPHY; CARDIAC CT; RISK; ASSOCIATION; PROGRESSION; CALCIFICATION; PREDICTOR	Objective: Previous studies indicate that epicardial adipose tissue (EAT) biologically contributes to the progression of coronary atherosclerosis. We evaluated the relationship between EAT pathology, represented by inflammation and neoangiogenesis, and coronary atherosclerosis on computed tomography (CT) images. Methods: We performed CT examination in 45 patients scheduled for cardiac surgery (coronary artery bypass graft [CABG], n = 21; non-CABG, n = 24) to assess visceral adipose tissue (VAT) area, EAT volume, coronary calcium score (CCS), and presence of non-calcified coronary plaque (NCP) on CT angiography. Each patient was assessed with the numbers of CD68(+) individual macrophages and CD31(+) neovessels in six random high-power fields (400x) of EAT samples subsequently obtained during cardiac surgery. Results: In three groups based on CCS (mild, 0-100; moderate, 101-400; severe, >400), the moderate group had the most extensive macrophage infiltration (p = 0.0025) and neoangiogenesis (p = 0.0036) in EAT. The patients with NCP had more extensive macrophage infiltration (p = 0.010) and neoangiogenesis (p = 0.0043) in EAT than those without. On multivariate analysis adjusted for age, sex, CABG versus. non-CABG, VAT area, and EAT volume, moderate CCS and the presence of NCP showed significant correlations with increased macrophage infiltration (beta = 0.65; p < 0.0001, and beta = 0.49; p = 0.0089, respectively) and neoangiogenesis (beta = 0.55; p = 0.0011, and beta = 0.53; p = 0.012, respectively) in EAT. Conclusion: Inflammation and neoangiogenesis in EAT independently correlate with moderate coronary calcification and presence of NCP, suggesting that these two factors may have a role in promoting coronary atherosclerosis. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Kitagawa, Toshiro; Yamamoto, Hideya; Tsushima, Hiroshi; Senoo, Atsuhiro; Kihara, Yasuki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Cardiovasc Med, Hiroshima 7348551, Japan; [Sentani, Kazuhiro; Yasui, Wataru] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima 7348551, Japan; [Takahashi, Shinya; Sueda, Taijiro] Hiroshima Univ Hosp, Dept Cardiovasc Surg, Hiroshima, Japan	Kitagawa, T (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Cardiovasc Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	toshirok@hiroshima-u.ac.jp			Japan Heart Foundation Research Grant; MSD Research Grant; JSPS KAKENHI [26870395]	This study was supported by a Japan Heart Foundation Research Grant, by an MSD Research Grant, and by a JSPS KAKENHI Grant-in-Aid for Scientific Research (Grant Number 26870395).	Sacks HS, 2007, AM HEART J, V153, P907, DOI 10.1016/j.ahj.2007.03.019; Kremen J, 2006, J CLIN ENDOCR METAB, V91, P4620, DOI 10.1210/jc.2006-1044; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Oka T, 2012, INT J CARDIOL, V161, P45, DOI 10.1016/j.ijcard.2011.04.021; Alexopoulos N, 2010, ATHEROSCLEROSIS, V210, P150, DOI 10.1016/j.atherosclerosis.2009.11.020; Nakanishi R, 2011, ATHEROSCLEROSIS, V218, P363, DOI 10.1016/j.atherosclerosis.2011.07.093; Kitagawa T, 2014, INT J CARDIOL, V174, P744, DOI 10.1016/j.ijcard.2014.04.089; Iacobellis G, 2011, TRENDS ENDOCRIN MET, V22, P450, DOI 10.1016/j.tem.2011.07.003; Ohashi N, 2009, ATHEROSCLEROSIS, V202, P192, DOI 10.1016/j.atherosclerosis.2008.04.019; Parisi V, 2015, INT J CARDIOL, V186, P167, DOI 10.1016/j.ijcard.2015.03.201; Villaret A, 2010, DIABETES, V59, P2755, DOI 10.2337/db10-0398; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI2000319246; Alexopoulos N, 2014, ATHEROSCLEROSIS, V233, P104, DOI 10.1016/j.atherosclerosis.2013.12.023; Detrano R, 2008, NEW ENGL J MED, V358, P1336, DOI 10.1056/NEJMoa072100; Ohashi N, 2010, JACC-CARDIOVASC IMAG, V3, P908, DOI 10.1016/j.jcmg.2010.06.014; Cheng KH, 2008, INT J OBESITY, V32, P268, DOI 10.1038/sj.ijo.0803726; Morin RL, 2003, CIRCULATION, V107, P917, DOI 10.1161/01.CIR.0000048965.56529.C2; Schlett CL, 2012, ATHEROSCLEROSIS, V222, P129, DOI 10.1016/j.atherosclerosis.2012.02.029; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; Mazurek T, 2003, CIRCULATION, V108, P2460, DOI 10.1161/01.CIR.0000099542.57313.C5; Yerramasu A, 2012, ATHEROSCLEROSIS, V220, P223, DOI 10.1016/j.atherosclerosis.2011.09.041; Otaki Y, 2011, J CARDIOVASC COMPUT, V5, P310, DOI 10.1016/j.jcct.2011.06.007; Tsushima H, 2015, CIRC J, V79, P1084, DOI 10.1253/circj.CJ-14-1169; Yamamoto H, 2011, CIRC J, V75, P2424, DOI 10.1253/circj.CJ-11-0087; Sun K, 2011, J CLIN INVEST, V121, P2094, DOI 10.1172/JCI45887; Kitagawa T, 2007, AM HEART J, V154, P1191, DOI 10.1016/j.ahj.2007.07.020; Virmani R, 2005, ARTERIOSCL THROM VAS, V25, P2054, DOI 10.1161/01.ATV.0000178991.71605.18; Rajani R, 2013, J CARDIOVASC COMPUT, V7, P125, DOI 10.1016/j.jcct.2013.02.003; Budoff MJ, 2007, J AM COLL CARDIOL, V49, P1860, DOI 10.1016/j.jacc.2006.10.079; Hirata Y, 2011, J AM COLL CARDIOL, V58, P248, DOI 10.1016/j.jacc.2011.01.048; Kitagawa T., 2015, DATA SET VO IN PRESS; Kitagawa T, 2009, JACC-CARDIOVASC IMAG, V2, P153, DOI 10.1016/j.jcmg.2008.09.015; Mahabadi AA, 2014, JACC-CARDIOVASC IMAG, V7, P909, DOI 10.1016/j.jcmg.2014.07.002; Tanami Y, 2015, CIRC-CARDIOVASC IMAG, V8, DOI 10.1161/CIRCIMAGING.114.002676	34	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0021-9150	1879-1484		ATHEROSCLEROSIS	Atherosclerosis	NOV	2015	243	1					293	299		10.1016/j.atherosclerosis.2015.09.013		7	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CU1FQ	WOS:000363266000042		
J	Inagaki, J; Moritake, H; Nishikawa, T; Hyakuna, N; Okada, M; Suenobu, S; Nagai, K; Honda, Y; Shimomura, M; Fukano, R; Noguchi, M; Kurauchi, K; Tanioka, S; Okamura, J				Inagaki, Jiro; Moritake, Hiroshi; Nishikawa, Takuro; Hyakuna, Nobuyuki; Okada, Masahiko; Suenobu, So-ichi; Nagai, Kozo; Honda, Yuko; Shimomura, Maiko; Fukano, Reiji; Noguchi, Maiko; Kurauchi, Koichiro; Tanioka, Shinji; Okamura, Jun			Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation	BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION			English	Article						Chronic graft-versus-host disease; Children; Nonrelapse mortality; Functional impairment; Performance status; National Institutes of Health consensus criteria	ACUTE MYELOID-LEUKEMIA; RELAPSE RISK EVIDENCE; BONE-MARROW; CHILDHOOD LEUKEMIA; CMV REACTIVATION; UNRELATED DONORS; BLOOD; SURVIVORS; SEVERITY; IMPACT	We report the long-term morbidity and mortality of 105 pediatric patients who developed chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). According to the consensus criteria of the National Institutes of Health, the global severity of cGVHD was mild in 26 patients (25%), moderate in 30 patients (29%), and severe in 49 patients (47%). Patients with severe cGVHD had a significantly lower cumulative incidence of cGVHD remission and higher probability of continuing cGVHD at 8 years from cGVHD diagnosis compared with those with mild or moderate cGVHD. The 10-year cumulative incidence of nonrelapse mortality in severe cGVHD patients was significantly higher and the probability of disease-free survival was significantly lower than those among patients with mild and moderate cGVHD. Of the 59 patients who survived for more than 5 years, 20 (34%) (4 with moderate and 16 with severe cGVHD) had persistent functional impairment caused by cGVHD with a Karnofsky/Lansky performance score of 90% in 3 patients, 80% in 4 patients, and below 70% in 13 patients at the time of relapse, death, or last follow-up. Better therapeutic strategies are needed to lower the incidence of severe cGVHD, considering the longer life expectancy of pediatric HSCT survivors. (C) 2015 American Society for Blood and Marrow Transplantation.	[Inagaki, Jiro; Fukano, Reiji; Noguchi, Maiko; Kurauchi, Koichiro; Tanioka, Shinji; Okamura, Jun] Kyushu Natl Canc Ctr, Dept Pediat, Fukuoka 8111395, Japan; [Moritake, Hiroshi] Miyazaki Univ, Fac Med, Div Pediat, Miyazaki, Japan; [Nishikawa, Takuro] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Pediat, Kagoshima 890, Japan; [Hyakuna, Nobuyuki] Hosp Univ Ryukyus, Ctr Bone Marrow Transplantat, Div Pediat, Nishihara, Okinawa, Japan; [Okada, Masahiko] Nagasaki Univ, Sch Med, Dept Pediat, Nagasaki 852, Japan; [Suenobu, So-ichi] Oita Univ, Fac Med, Dept Pediat, Div Gen Pediat & Emergency Med, Oita 87011, Japan; [Nagai, Kozo] Saga Univ, Fac Med, Dept Pediat, Saga 840, Japan; [Honda, Yuko] Univ Occupat & Environm Hlth, Sch Med, Dept Pediat, Kitakyushu, Fukuoka 807, Japan; [Shimomura, Maiko] Yamaguchi Univ, Dept Pediat, Yamaguchi, Japan	Inagaki, J (reprint author), Kyushu Natl Canc Ctr, Dept Pediat, Minami Ku, 3-1-1 Notame, Fukuoka 8111395, Japan.	inagakij@nk-cc.go.jp					Al-Homsi AS, 2015, BIOL BLOOD MARROW TR, V21, P604, DOI 10.1016/j.bbmt.2014.08.014; Ozawa S, 2007, BRIT J HAEMATOL, V137, P142, DOI 10.1111/j.1365-2141.2007.06543.x; Green ML, 2013, BLOOD, V122, P1316, DOI 10.1182/blood-2013-02-487074; Parsons SK, 2012, BIOL BLOOD MARROW TR, V18, P162, DOI 10.1016/j.bbmt.2011.12.501; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; Friedrichs B, 2010, LANCET ONCOL, V11, P331, DOI 10.1016/S1470-2045(09)70352-3; Berbis J, 2013, BIOL BLOOD MARROW TR, V19, P1065, DOI 10.1016/j.bbmt.2013.04.015; Storek J, 2015, BIOL BLOOD MARROW TR, V21, P959, DOI 10.1016/j.bbmt.2014.11.676; Hovi L, 2010, BONE MARROW TRANSPL, V45, P738, DOI 10.1038/bmt.2009.221; Pavletic SZ, 2005, AM J HEMATOL, V78, P265, DOI 10.1002/ajh.20275; Sanders JE, 2010, BONE MARROW TRANSPL, V45, P746, DOI 10.1038/bmt.2009.224; Lee JW, 2011, YONSEI MED J, V52, P779, DOI 10.3349/ymj.2011.52.5.779; Diaz MA, 2004, BONE MARROW TRANSPL, V34, P433, DOI 10.1038/sj.bmt.1704589; Stewart BL, 2004, BLOOD, V104, P3501, DOI 10.1182/blood-2004-01-0200; Vigorito AC, 2009, BLOOD, V114, P702, DOI 10.1182/blood-2009-03-208983; Bhatia S, 2007, BLOOD, V110, P3784, DOI 10.1182/blood-2007-03-082933; Elmaagacli AH, 2011, BLOOD, V118, P1402, DOI 10.1182/blood-2010-08-304121; Cho BS, 2009, LEUKEMIA, V23, P78, DOI 10.1038/leu.2008.276; Lee SJ, 2003, BIOL BLOOD MARROW TR, V9, P215, DOI 10.1053/bbmt.2003.50026; Armenian SH, 2011, BLOOD, V118, P1413, DOI 10.1182/blood-2011-01-331835; Pidala J, 2011, HAEMATOL-HEMATOL J, V96, P1678, DOI 10.3324/haematol.2011.049841; Zecca M, 2002, BLOOD, V100, P1192, DOI 10.1182/blood-2001-11-0059; Fraser CJ, 2006, BLOOD, V108, P2867, DOI 10.1182/blood-2006-02-003954; Lee SJ, 2002, BLOOD, V100, P406, DOI 10.1182/blood.V100.2.406; Vogelsang GB, 2001, BLOOD, V97, P1196, DOI 10.1182/blood.V97.5.1196; Wingard JR, 2011, J CLIN ONCOL, V29, P2230, DOI 10.1200/JCO.2010.33.7212; Jacobsohn DA, 2011, BLOOD, V118, P4472, DOI 10.1182/blood-2011-04-349068; Michel G, 2007, BONE MARROW TRANSPL, V40, P897, DOI 10.1038/sj.bmt.1705821; Flowers MED, 2011, BLOOD, V117, P3214, DOI 10.1182/blood-2010-08-302109; Bresters D, 2010, BONE MARROW TRANSPL, V45, P79, DOI 10.1038/bmt.2009.92; Alsultan A, 2011, BONE MARROW TRANSPL, V46, P668, DOI 10.1038/bmt.2010.174; Anasetti C, 2012, NEW ENGL J MED, V367, P1487, DOI 10.1056/NEJMoa1203517; Eapen M, 2007, BIOL BLOOD MARROW TR, V13, P1461, DOI 10.1016/j.bbmt.2007.08.006; Inamoto Y, 2014, HAEMATOLOGICA, V99, P1618, DOI 10.3324/haematol.2014.109611; Jeljeli M, 2014, BRIT J HAEMATOL, V166, P229, DOI 10.1111/bjh.12875	35	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1083-8791	1523-6536		BIOL BLOOD MARROW TR	Biol. Blood Marrow Transplant.	NOV	2015	21	11					1973	1980		10.1016/j.bbmt.2015.07.025		8	Hematology; Immunology; Transplantation	Hematology; Immunology; Transplantation	CU2MI	WOS:000363357200017		
J	Takenaka, K; Nishida, T; Asano-Mori, Y; Oshima, K; Ohashi, K; Mori, T; Kanamori, H; Miyamura, K; Kato, C; Kobayashi, N; Uchida, N; Nakamae, H; Ichinohe, T; Morishima, Y; Suzuki, R; Yamaguchi, T; Fukuda, T				Takenaka, Katsuto; Nishida, Tetsuya; Asano-Mori, Yuki; Oshima, Kumi; Ohashi, Kazuteru; Mori, Takehiko; Kanamori, Heiwa; Miyamura, Koichi; Kato, Chiaki; Kobayashi, Naoki; Uchida, Naoyuki; Nakamae, Hirohisa; Ichinohe, Tatsuo; Morishima, Yasuo; Suzuki, Ritsuro; Yamaguchi, Takuhiro; Fukuda, Takahiro			Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group	BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION			English	Article						Cytomegalovirus; Allogeneic hematopoietic stem; cell transplantation; Risk of relapse; Nonrelapse mortality	CMV REACTIVATION; BONE-MARROW; RETROSPECTIVE ANALYSIS; PREEMPTIVE THERAPY; UNRELATED DONOR; HOST-DISEASE; DOUBLE-BLIND; RECIPIENTS; INFECTION; IMPACT	Cytomegalovirus (CMV) infection is a major infectious complication after allogeneic hematopoietic cell transplantation (allo-HSCT). Recently, it was reported that CMV reactivation is associated with a decreased risk of relapse in patients with acute myeloid leukemia (AML). The aim of this study was to evaluate the impact of early CMV reactivation on the incidence of disease relapse after allo-HSCT in a large cohort of patients. The Japan Society for Hematopoietic Cell Transplantation's Transplantation-Related Complication Working Group retrospectively surveyed the database of the Transplant Registry Unified Management Program at the Japan Society for Hematopoietic Cell Transplantation. Patients with AML (n = 1836), acute lymphoblastic leukemia (ALL, n = 911), chronic myeloid leukemia (CML, n = 223), and myelodysplastic syndrome (MDS, n = 569) who underwent their first allo-HSCT from HLA-matched related or unrelated donors between 2000 and 2009 and who survived without disease relapse until day 100 after transplantation were analyzed. Patients who received umbilical cord blood transplantation were not included. Patients underwent surveillance by pp65 antigenemia from the time of engraftment, and the beginning of preemptive therapy was defined as CMV reactivation. Cox proportional hazards models were used to evaluate the risk factors of relapse, nonrelapse, and overall mortality. CMV reactivation and acute/chronic graft-versus-host disease (GVHD) were evaluated as time-dependent covariates. CMV reactivation was associated with a decreased incidence of relapse in patients with AML (20.3% versus 26.4%, P = .027), but not in patients with ALL, CML, or MDS. Among 1836 patients with AML, CMV reactivation occurred in 795 patients (43.3%) at a median of 42 days, and 436 patients (23.7%) relapsed at a median of 221 days after allo-HSCT. Acute GVHD grades II to IV developed in 630 patients (34.3%). By multivariate analysis considering competing risk factors, 3 factors were significantly associated with a decreased risk of AML relapse and 1 factor with an increased risk of AML relapse: CMV reactivation (hazard ratio [HR],.77; 95% confidence interval [CI],.59 to.99), unrelated donor compared with related donor (HR,.59; 95% CI,.42 to.84), development of chronic GVHD (HR,.77; 95% CI,.60 to.99), and pretransplantation advanced disease status compared with standard disease status (HR, 1.99; 95% CI, 1.56 to 2.52). However, CMV reactivation was associated with increased nonrelapse mortality (HR, 1.60; 95% CI, 1.18 to 2.17) and overall mortality (HR, 1.37; 95% CI, 1.11 to 1.69). A beneficial effect of CMV reactivation on subsequent risk of relapse was observed in patients with AML but not in those with other hematological malignancies. However, this benefit was nullified by the increased nonrelapse mortality. The underlying mechanism is unclear; however, immunological activation against CMV reactivation plays an essential role in this association. Thus, immune augmentation treatment options, including vaccination and adoptive T cell transfer, may be useful to take advantage of the efficacy of CMV reactivation with minimal increase in nonrelapse mortality. (C) 2015 American Society for Blood and Marrow Transplantation.	[Takenaka, Katsuto] Kyushu Univ Hosp, Dept Hematol & Oncol, Fukuoka 8128582, Japan; [Nishida, Tetsuya] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi 4648601, Japan; [Asano-Mori, Yuki; Uchida, Naoyuki] Toranomon Gen Hosp, Dept Hematol, Tokyo, Japan; [Oshima, Kumi; Ichinohe, Tatsuo] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, Hiroshima, Japan; [Ohashi, Kazuteru] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Div Hematol, Tokyo, Japan; [Mori, Takehiko] Keio Univ, Sch Med, Dept Med, Div Hematol, Tokyo 160, Japan; [Kanamori, Heiwa] Kanagawa Canc Ctr, Dept Hematol, Yokohama, Kanagawa 2410815, Japan; [Miyamura, Koichi] Japanese Red Cross Nagoya First Hosp, Dept Hematol, Nagoya, Aichi, Japan; [Kato, Chiaki] Meitetsu Hosp, Dept Hematol, Nagoya, Aichi, Japan; [Kobayashi, Naoki] Sapporo Hokuyu Hosp, Dept Hematol, Sapporo, Hokkaido, Japan; [Nakamae, Hirohisa] Osaka City Univ Hosp, Dept Hematol, Osaka, Japan; [Morishima, Yasuo] Aichi Canc Ctr, Res Inst, Div Epidemiol & Prevent, Nagoya, Aichi 464, Japan; [Suzuki, Ritsuro] Nagoya Univ, Grad Sch Med, Dept Hematopoiet Stem Cell Transplantat Data Mana, Nagoya, Aichi 4648601, Japan; [Yamaguchi, Takuhiro] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Miyagi 980, Japan; [Fukuda, Takahiro] Natl Canc Ctr, Dept Hematopoiet Stem Cell Transplantat, Tokyo, Japan	Takenaka, K (reprint author), Kyushu Univ Hosp, Dept Hematol & Oncol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	takenaka@intmed1.med.kyushu-u.ac.jp			JSPS KAKENHI [26461424]	This work was supported by JSPS KAKENHI Grant Number 26461424.	Yanada M, 2003, BONE MARROW TRANSPL, V32, P801, DOI 10.1038/sj.bmt.1704232; Boeckh M, 1996, BLOOD, V88, P4063; Kollman C, 2001, BLOOD, V98, P2043, DOI 10.1182/blood.V98.7.2043; Atsuta Y, 2007, INT J HEMATOL, V86, P269, DOI 10.1532/IJH97.06239; Behrendt CE, 2009, BIOL BLOOD MARROW TR, V15, P54, DOI 10.1016/j.bbmt.2008.10.023; LONNQVIST B, 1986, BRIT J HAEMATOL, V63, P671; Green ML, 2013, BLOOD, V122, P1316, DOI 10.1182/blood-2013-02-487074; Ljungman P, 2002, CLIN INFECT DIS, V34, P1094, DOI 10.1086/339329; Ljungman P, 2003, BLOOD, V102, P4255, DOI 10.1182/blood-2002-10-3263; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; Kanda Y, 2013, BRIT J HAEMATOL, V161, P566, DOI 10.1111/bjh.12279; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Kharfan-Dabaja MA, 2012, LANCET INFECT DIS, V12, P290, DOI 10.1016/S1473-3099(11)70344-9; Manjappa S, 2014, BIOL BLOOD MARROW TR, V20, P46, DOI 10.1016/j.bbmt.2013.10.003; Boeckh M, 2004, BLOOD, V103, P2003, DOI 10.1182/blood-2003-10-3616; Elmaagacli AH, 2011, BLOOD, V118, P1402, DOI 10.1182/blood-2010-08-304121; Nichols WG, 2002, J INFECT DIS, V185, P273, DOI 10.1086/338624; Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004; Ljungman P, 2008, BONE MARROW TRANSPL, V42, P227, DOI 10.1038/bmt.2008.162; Remberger M, 2002, LANCET, V359, P888, DOI 10.1016/S0140-6736(02)07926-6; Schmidt-Hieber M, 2013, BLOOD, V122, P3359, DOI 10.1182/blood-2013-05-499830; Foley B, 2012, BLOOD, V119, P2665, DOI 10.1182/blood-2011-10-386995; Ito S, 2013, BONE MARROW TRANSPL, V48, P1313, DOI 10.1038/bmt.2013.49; Boeckh M, 2003, BIOL BLOOD MARROW TR, V9, P543, DOI 10.1016/S1083-8791(03)00287-8; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Farina L, 2009, LEUKEMIA, V23, P1131, DOI 10.1038/leu.2009.1; Sasazuki T, 1998, NEW ENGL J MED, V339, P1177, DOI 10.1056/NEJM199810223391701; Ljungman P, 2010, INFECT DIS CLIN N AM, V24, P319, DOI 10.1016/j.idc.2010.01.008; Challa-Malladi M, 2011, CANCER CELL, V20, P728, DOI 10.1016/j.ccr.2011.11.006; Boeckh M, 2009, BLOOD, V113, P5711, DOI 10.1182/blood-2008-10-143560; Della Chiesa M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00458; Fine JP, 1999, J AM STAT ASSOC, V94, P456; GLUCKSBE.H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Jang JE, 2015, ANN HEMATOL, V94, P275, DOI 10.1007/s00277-014-2190-1; Jeljeli M, 2014, BRIT J HAEMATOL, V166, P229, DOI 10.1111/bjh.12875; Mariotti Jacopo, 2014, Biol Blood Marrow Transplant, V20, P885, DOI 10.1016/j.bbmt.2014.02.015; Ramanathan M, 2014, BLOOD, V124, P47; Thomson KJ, 2012, BLOOD, V119, P1088, DOI 10.1182/blood-2011-10-383943; Thomson KJ, 2012, BLOOD, V119, P90; Venstrom JM, 2012, NEW ENGL J MED, V367, P805, DOI 10.1056/NEJMoa1200503	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1083-8791	1523-6536		BIOL BLOOD MARROW TR	Biol. Blood Marrow Transplant.	NOV	2015	21	11					2008	2016		10.1016/j.bbmt.2015.07.019		9	Hematology; Immunology; Transplantation	Hematology; Immunology; Transplantation	CU2MI	WOS:000363357200022		
J	Aoki, J; Numata, A; Yamamoto, E; Fujii, E; Tanaka, M; Kanamori, H				Aoki, Jun; Numata, Ayumi; Yamamoto, Eri; Fujii, Eriko; Tanaka, Masatsugu; Kanamori, Heiwa			Impact of Human Herpesvirus-6 Reactivation on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation	BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION			English	Article						Human herpesvirus-6; Allogeneic hematopoietic stem cell transplantation	BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; HHV-6 REACTIVATION; 6 INFECTION; HUMAN-HERPESVIRUS-6 REACTIVATION; CONDITIONING REGIMEN; PREEMPTIVE THERAPY; ENCEPHALITIS; BLOOD; PLASMA	Human herpesvirus-6 (HHV-6) is known to reactivate after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and may be associated with development of acute graft-versus-host disease (GVHD) and non-relapse mortality (NRM). However, the clinical significance of HHV-6 reactivation after allo-HSCT remains unclear. Therefore, we conducted a retrospective analysis to elucidate the impact of HHV-6 reactivation on transplantation outcomes. Of 236 patients who underwent allo-HSCT, 138 (58.5%) developed HHV-6 reactivation and 98 (41.5%) did not. Univariate analysis indicated that at 3 years, patients with HHV-6 reactivation had significantly higher NRM (27.7% versus 13.7%, P = .003) and worse overall survival (42.1% versus 59.0%, P = .008) than those without reactivation. In multivariate analysis, HHV-6 reactivation was associated with higher incidence of acute GVHD (hazard ratio [HR], 1.87; P = .01), cytomegalovirus reactivation (HR, 2.24; P < .001), and NRM (HR, 2.73; P = .007). Subgroup analysis stratified according to conditioning intensity indicated that a significant impact of HHV-6 reactivation on acute GVHD was observed only in patients who received myeloablative conditioning (MAC). These results indicate that HHV-6 reactivation was associated with development of acute GVHD, cytomegalovirus reactivation, and NRM. Furthermore, adverse impact of HHV-6 reactivation on transplantation outcomes was prominent in the setting of MAC. (C) 2015 American Society for Blood and Marrow Transplantation.	[Aoki, Jun; Numata, Ayumi; Yamamoto, Eri; Fujii, Eriko; Tanaka, Masatsugu; Kanamori, Heiwa] Kanagawa Canc Ctr, Dept Hematol, Yokohama, Kanagawa 2418515, Japan; [Numata, Ayumi] Kanagawa Canc Ctr, Dept Med Oncol, Yokohama, Kanagawa 2418515, Japan	Aoki, J (reprint author), Kanagawa Canc Ctr, Dept Hematol, Asahi Ku, 2-3-2 Nakao, Yokohama, Kanagawa 2418515, Japan.	jaoki-thk@umin.ac.jp			Kanagawa Cancer Foundation	This work was supported by a grant from Kanagawa Cancer Foundation.	Wang LR, 2008, BONE MARROW TRANSPL, V42, P673, DOI 10.1038/bmt.2008.238; Yoshikawa T, 2001, BONE MARROW TRANSPL, V28, P77, DOI 10.1038/sj.bmt.1703099; Zerr DM, 2012, BIOL BLOOD MARROW TR, V18, P1700, DOI 10.1016/j.bbmt.2012.05.012; Ogata M, 2008, BONE MARROW TRANSPL, V41, P279, DOI 10.1038/sj.bmt.1705907; Perez-Simon JA, 2005, BRIT J HAEMATOL, V130, P394, DOI 10.1111/j.1365-2141.2005.05614.x; Hentrich M, 2005, BRIT J HAEMATOL, V128, P66, DOI 10.1111/j.1365-2141.2004.05254.x; Gotoh M, 2014, TRANSPL INFECT DIS, V16, P440, DOI 10.1111/tid.12229; Betts BC, 2011, BIOL BLOOD MARROW TR, V17, P1562, DOI 10.1016/j.bbmt.2011.04.004; Cone RW, 1999, J INFECT DIS, V179, P311, DOI 10.1086/314581; Giralt S, 2009, BIOL BLOOD MARROW TR, V15, P367, DOI 10.1016/j.bbmt.2008.12.497; YAMANISHI K, 1988, LANCET, V1, P1065; Morris ES, 2007, BRIT J HAEMATOL, V137, P3, DOI 10.1111/j.1365-2141.2007.06510.x; Agut H, 2015, CLIN MICROBIOL REV, V28, P313, DOI 10.1128/CMR.00122-14; Dulery R, 2012, BIOL BLOOD MARROW TR, V18, P1080, DOI 10.1016/j.bbmt.2011.12.579; de Pagter PJA, 2008, BIOL BLOOD MARROW TR, V14, P831, DOI 10.1016/j.bbmt.2008.04.016; KONDO K, 1991, J GEN VIROL, V72, P1401, DOI 10.1099/0022-1317-72-6-1401; Kadakia MP, 1996, BLOOD, V87, P5341; Wang LR, 2006, BIOL BLOOD MARROW TR, V12, P1031, DOI 10.1016/j.bbmt.2006.06.001; Chevallier P, 2010, BONE MARROW TRANSPL, V45, P1204, DOI 10.1038/bmt.2009.326; Ljungman P, 2000, BRIT J HAEMATOL, V111, P774, DOI 10.1046/j.1365-2141.2000.02422.x; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Ishiyama K, 2011, BONE MARROW TRANSPL, V46, P863, DOI 10.1038/bmt.2010.201; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Zerr DM, 2001, CLIN INFECT DIS, V33, P763, DOI 10.1086/322642; Yamane A, 2007, BIOL BLOOD MARROW TR, V13, P100, DOI 10.1016/j.bbmt.2006.09.003; Sakai R, 2011, BIOL BLOOD MARROW TR, V17, P1389, DOI 10.1016/j.bbmt.2011.01.014; Scheurer ME, 2013, BONE MARROW TRANSPL, V48, P574, DOI 10.1038/bmt.2012.180; OKUNO T, 1989, J CLIN MICROBIOL, V27, P651; Ogata M, 2013, CLIN INFECT DIS, V57, P671, DOI 10.1093/cid/cit358; Zerr DM, 2005, CLIN INFECT DIS, V40, P932, DOI 10.1086/428060; Ogata M, 2006, J INFECT DIS, V193, P68, DOI 10.1086/498531; Ogata M, 2015, BONE MARROW TRANSPL, V50, P1030, DOI 10.1038/bmt.2015.76; de Pagter PJ, 2008, J CLIN VIROL, V43, P361, DOI 10.1016/j.jcv.2008.08.008	33	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1083-8791	1523-6536		BIOL BLOOD MARROW TR	Biol. Blood Marrow Transplant.	NOV	2015	21	11					2017	2022		10.1016/j.bbmt.2015.07.022		6	Hematology; Immunology; Transplantation	Hematology; Immunology; Transplantation	CU2MI	WOS:000363357200023		
J	Chiba, T; Matsuda, A; Ichikawa, S				Chiba, Takuya; Matsuda, Akira; Ichikawa, Satoshi			Structure-activity relationship study of syringolin A as a potential anticancer agent	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Proteasome inhibitor; Cancer; Structure-activity relationship	MULTIPLE-MYELOMA; PROTEASOME; CARFILZOMIB; PEPTIDES	A detailed structure-activity relationship of syringolin A (1), which is a promising antitumor natural product, was described. We previously developed syringolin A analog 2 as a potent proteasome inhibitor by the structure-based drug design of syringolin A. In this Letter, we synthesized a range of analogs of 2, having a different length of the lipophilic chain and substituted aryl group, and their cytotoxicity against human cancer cells was evaluated. It turned out that these modifications greatly affected the cytotoxicity. Further optimization would lead to develop a novel proteasome inhibitor. (C) 2015 Elsevier Ltd. All rights reserved.	[Chiba, Takuya; Matsuda, Akira; Ichikawa, Satoshi] Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Matsuda, Akira; Ichikawa, Satoshi] Hokkaido Univ, Ctr Res & Educ Drug Discovery, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Ichikawa, S (reprint author), Hokkaido Univ, Fac Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	ichikawa@pharm.hokudai.ac.jp			JSPS [22659020, 24102502, 25293026]	This research was supported by JSPS Grant-in-Aid for Challenging Exploratory Research (SI, Grant number 22659020), Scientific Research on Innovative Areas 'Chemical Biology of Natural Products' (SI, Grant number 24102502), and Scientific Research (B) (SI, Grant number 25293026). We thank Taiho Pharmaceutical Co., Ltd for evaluation of cytotoxicity.	Archer CR, 2012, BIOCHEMISTRY-US, V51, P6880, DOI 10.1021/bi300841r; Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078-0432.CCR-03-0781; Chiba T, 2014, ANGEW CHEM INT EDIT, V53, P4836, DOI 10.1002/anie.201402428; Chatterjee J, 2008, ACCOUNTS CHEM RES, V41, P1331, DOI 10.1021/ar8000603; Pirrung MC, 2010, ORG LETT, V12, P2402, DOI 10.1021/ol100761z; Groll M, 2008, NATURE, V452, P755, DOI 10.1038/nature06782; Herndon TM, 2013, CLIN CANCER RES, V19, P4559, DOI 10.1158/1078-0432.CCR-13-0755; Kisselev AF, 2012, CHEM BIOL, V19, P99, DOI 10.1016/j.chembiol.2012.01.003; Cheng RP, 2001, CHEM REV, V101, P3219, DOI 10.1021/cr000045i; Waspi U, 1998, MOL PLANT MICROBE IN, V11, P727, DOI 10.1094/MPMI.1998.11.8.727; Clerc J, 2011, CHEM COMMUN, V47, P385, DOI 10.1039/c0cc02238a; Alsina M, 2012, CLIN CANCER RES, V18, P4830, DOI 10.1158/1078-0432.CCR-11-3007; Murata S, 2009, NAT REV MOL CELL BIO, V10, P104, DOI 10.1038/nrm2630; Clerc J, 2009, P NATL ACAD SCI USA, V106, P6507, DOI 10.1073/pnas.0901982106; Groll M., 2010, EUR J ORG CHEM, P3991; Lü Shuqing, 2013, Biomark Res, V1, P13, DOI 10.1186/2050-7771-1-13	16	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	NOV 1	2015	25	21					4872	4877		10.1016/j.bmcl.2015.06.015		6	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CU1IV	WOS:000363275400034		
J	Kutsumura, N; Nakajima, R; Koyama, Y; Miyata, Y; Saitoh, T; Yamamoto, N; Iwata, S; Fujii, H; Nagase, H				Kutsumura, Noriki; Nakajima, Ryo; Koyama, Yasuaki; Miyata, Yoshiyuki; Saitoh, Tsuyoshi; Yamamoto, Naoshi; Iwata, Satoshi; Fujii, Hideaki; Nagase, Hiroshi			Investigation of 7-benzylidenenaltrexone derivatives as a novel structural antitrichomonal lead compound	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Trichomonas; DOR; BNTX; Opioid; Antagonist	RESISTANT TRICHOMONAS-VAGINALIS; METRONIDAZOLE-RESISTANT; NITROIMIDAZOLE DERIVATIVES; PLASMODIUM-CHABAUDI; PROSTATE-CANCER; DRUG-RESISTANT; STRAINS; SUSCEPTIBILITY; INFECTIONS; ACTIVATION	We evaluated antitrichomonal effects of delta opioid receptor (DOR) agonists and antagonists. Although all the agonists were inactive, the DOR antagonists BNTX (2a) and its derivatives 2b-d showed antitrichomonal activity with MIC of 20-40 mu M. In addition, the development of a more effective synthetic method for the BNTX derivatives was achieved by using the Knoevenagel condensation. (C) 2015 Elsevier Ltd. All rights reserved.	[Kutsumura, Noriki; Nakajima, Ryo; Koyama, Yasuaki; Saitoh, Tsuyoshi; Yamamoto, Naoshi; Nagase, Hiroshi] Univ Tsukuba, Int Inst Integrat Sleep Med WPI IIIS, Tsukuba, Ibaraki 3058575, Japan; [Miyata, Yoshiyuki; Iwata, Satoshi] Keio Univ, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Fujii, Hideaki] Kitasato Univ, Sch Pharm, Minato Ku, Tokyo 1088641, Japan	Nagase, H (reprint author), Univ Tsukuba, Int Inst Integrat Sleep Med WPI IIIS, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	nagase.hiroshi.gt@u.tsukuba.ac.jp			JSPS KAKENHI [15K16553]	This work was supported by JSPS KAKENHI (Grant-in-Aid for Young Scientists (B)) Grant Number 15K16553.	Secor WE, 2014, AM J TROP MED HYG, V90, P800, DOI 10.4269/ajtmh.13-0723; ELLIS JE, 1994, MICROBIOL-UK, V140, P2489; Coombs GH, 2004, J BIOL CHEM, V279, P5249, DOI 10.1074/jbc.M304359200; Stark JR, 2009, J NATL CANCER I, V101, P1406, DOI 10.1093/jnci/djp306; Rasoloson D, 2001, PARASITOLOGY, V123, P45, DOI 10.1017/S0031182001008022; GARBER GE, 1987, J CLIN MICROBIOL, V25, P1275; Vidakovic M, 2003, ANTIMICROB AGENTS CH, V47, P302, DOI 10.1128/AAC.47.1.302-308.2003; Cudmore SL, 2004, CLIN MICROBIOL REV, V17, P783, DOI 10.1128/CMR.17.4.783-793.2004; YARLETT N, 1986, BIOCHEM PHARMACOL, V35, P1703, DOI 10.1016/0006-2952(86)90327-8; Miyata Y, 2012, BIOORG MED CHEM LETT, V22, P5174, DOI 10.1016/j.bmcl.2012.06.085; Feng Y, 2012, CURR DRUG TARGETS, V13, P230; Midlej V, 2010, PARASITOLOGY, V137, P65, DOI 10.1017/S0031182009991041; Hrdy I, 2005, ANTIMICROB AGENTS CH, V49, P5033, DOI 10.1128/AAC.49.12.5033-5036.2005; Pal C, 2012, ANTIOXID REDOX SIGN, V17, P555, DOI 10.1089/ars.2011.4436; LLOYD D, 1986, BIOCHEM PHARMACOL, V35, P61, DOI 10.1016/0006-2952(86)90556-3; PORTOGHESE PS, 1991, J MED CHEM, V34, P1292, DOI 10.1021/jm00108a008; Sutcliffe S, 2009, INT J CANCER, V124, P2082, DOI 10.1002/ijc.24144; Upcroft P, 2001, CLIN MICROBIOL REV, V14, P150, DOI 10.1128/CMR.14.1.150-164.2001; JOHNSON PJ, 1993, PARASITOL TODAY, V9, P183, DOI 10.1016/0169-4758(93)90143-4; Huppert JS, 2013, J INFECT DIS, V207, P1462, DOI 10.1093/infdis/jit039; Beltran NC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065148; Lossick J. G., 1990, TRICHOMONADS PARASIT, P324; Miyata Y, 2011, BIOORG MED CHEM LETT, V21, P4710, DOI 10.1016/j.bmcl.2011.06.085; Puente-Rivera J, 2014, INT J BIOCHEM CELL B, V54, P255, DOI 10.1016/j.biocel.2014.04.005; QUON DVK, 1992, P NATL ACAD SCI USA, V89, P4402, DOI 10.1073/pnas.89.10.4402; Spence AR, 2014, BJU INT, V114, pE90, DOI 10.1111/bju.12741; World Health Organization, 2011, PREV INC SEL SEX TRA; Yang YL, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-55	28	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	NOV 1	2015	25	21					4890	4892		10.1016/j.bmcl.2015.06.002		3	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CU1IV	WOS:000363275400038		
J	Ghosh, AK; Takayama, J; Kassekert, LA; Ella-Menye, JR; Yashchuk, S; Agniswamy, J; Wang, YF; Aoki, M; Amano, M; Weber, IT; Mitsuya, H				Ghosh, Arun K.; Takayama, Jun; Kassekert, Luke A.; Ella-Menye, Jean-Rene; Yashchuk, Sofiya; Agniswamy, Johnson; Wang, Yuan-Fang; Aoki, Manabu; Amano, Masayuki; Weber, Irene T.; Mitsuya, Hiroaki			Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						HIV-1 protease; Inhibitors; Design; Synthesis; Antiviral; Isophthalamide	ACTIVE ANTIRETROVIRAL THERAPY; RESOLUTION CRYSTAL-STRUCTURES; BETA-SECRETASE INHIBITORS; COMBAT DRUG-RESISTANCE; LIGAND; INFECTION; COMPLEXES; MUTANTS	We describe the design, synthesis and biological evaluation of a series of novel HIV-1 protease inhibitors bearing isophthalamide derivatives as the P2-P3 ligands. We have investigated a range of acyclic and heterocyclic amides as the extended P2-P3 ligands. These inhibitors displayed good to excellent HIV-1 protease inhibitory activity. Also, a number of inhibitors showed very good antiviral activity in MT cells. Compound 5n has shown an enzyme K-i of 0.17 nM and antiviral IC50 of 14 nM. An X-ray crystal structure of inhibitor 5o-bound to HIV-1 protease was determined at 1.11 angstrom resolution. This structure revealed important molecular insight into the inhibitor-HIV-1 protease interactions in the active site. (C) 2015 Elsevier Ltd. All rights reserved.	[Ghosh, Arun K.; Takayama, Jun; Kassekert, Luke A.; Ella-Menye, Jean-Rene; Yashchuk, Sofiya] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; [Ghosh, Arun K.; Takayama, Jun; Kassekert, Luke A.; Ella-Menye, Jean-Rene; Yashchuk, Sofiya] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA; [Agniswamy, Johnson; Wang, Yuan-Fang; Weber, Irene T.] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA; [Agniswamy, Johnson; Wang, Yuan-Fang; Weber, Irene T.] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA; [Aoki, Manabu; Amano, Masayuki; Mitsuya, Hiroaki] Kumamoto Univ Med, Dept Hematol, Kumamoto 8608556, Japan; [Aoki, Manabu; Amano, Masayuki; Mitsuya, Hiroaki] Kumamoto Univ Med, Dept Infect Dis, Kumamoto 8608556, Japan; [Mitsuya, Hiroaki] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, Bethesda, MD 20892 USA; [Mitsuya, Hiroaki] Natl Ctr Global Hlth & Med, Ctr Clin Sci, Shinjuku Ku, Tokyo 1628655, Japan	Ghosh, AK (reprint author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	akghosh@purdue.edu			National Institutes of Health [GM53386, GM62920]; U.S. Department of Energy, Basic Energy Sciences, Office of Science [W-31-109-Eng-38]; Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health; Ministry of Education, Culture, Sports, Science, and Technology of Japan (Monbu Kagakusho); Ministry of Health, Welfare, and Labor of Japan; Cooperative Research Project on Clinical and Epidemiological Studies of Emerging and Reemerging Infectious Diseases (Renkei Jigyo) of Monbu-Kagakusho	This research was supported by the National Institutes of Health (Grant GM53386, A.K.G. and Grant GM62920, I.T.W.). X-ray data were collected at the Southeast Regional Collaborative Access Team (SER-CAT) beamline 22BM at the Advanced Photon Source, Argonne National Laboratory. Use of the Advanced Photon Source was supported by the U.S. Department of Energy, Basic Energy Sciences, Office of Science, under Contract No. W-31-109-Eng-38. This work was also supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, and in part by a Grant-in-Aid for Scientific Research (Priority Areas) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Monbu Kagakusho), a Grant for Promotion of AIDS Research from the Ministry of Health, Welfare, and Labor of Japan, and the Grant to the Cooperative Research Project on Clinical and Epidemiological Studies of Emerging and Reemerging Infectious Diseases (Renkei Jigyo) of Monbu-Kagakusho. The authors would like to thank the Purdue University Center for Cancer Research, which supports the shared NMR and mass spectrometry facilities.	Patel K, 2008, CLIN INFECT DIS, V46, P507, DOI 10.1086/526524; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; BAKER GL, 1981, J ORG CHEM, V46, P2954, DOI 10.1021/jo00327a023; Hue S, 2009, J VIROL, V83, P2645, DOI 10.1128/JVI.01556-08; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Ghosh AK, 2010, CHEMMEDCHEM, V5, P1850, DOI 10.1002/cmdc.201000318; Gupta R, 2008, CLIN INFECT DIS, V47, P712, DOI 10.1086/590943; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; Ghosh AK, 2006, CHEMMEDCHEM, V1, P939, DOI 10.1002/cmdc.200600103; Ghosh AK, 2006, J MED CHEM, V49, P5252, DOI 10.1021/jm060561m; Ghosh AK, 2007, J MED CHEM, V50, P2399, DOI 10.1021/jm061338s; Ghosh AK, 2008, J MED CHEM, V51, P6021, DOI 10.1021/jm8004543; Thompson MA, 2012, JAMA-J AM MED ASSOC, V308, P387, DOI 10.1001/jama.2012.7961; Kozisek M, 2007, J MOL BIOL, V374, P1005, DOI 10.1016/j.jmb.2007.09.083; Ghosh AK, 2009, J MED CHEM, V52, P2163, DOI 10.1021/jm900064c; Ghosh AK, 2014, ORG BIOMOL CHEM, V12, P6842, DOI 10.1039/c4ob00738g; Ghosh AK, 2008, BIOORG MED CHEM LETT, V18, P1031, DOI 10.1016/j.bmcl.2007.12.028; Ghosh AK, 2011, J MED CHEM, V54, P622, DOI 10.1021/jm1012787; Ghosh AK, 2012, ANGEW CHEM INT EDIT, V51, P1778, DOI 10.1002/anie.201102762; Conway B, 2009, FUTURE VIROL, V4, P39, DOI 10.2217/17460794.4.1.39; Ghosh AK, 2005, J MED CHEM, V48, P3576, DOI 10.1021/jm050019i; NARASIMHAN S, 1995, SYNTHETIC COMMUN, V25, P1689, DOI 10.1080/00397919508015853; Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003; Mahalingam B, 2001, PROTEINS, V43, P455, DOI 10.1002/prot.1057; Boyd MA, 2009, CURR OPIN HIV AIDS, V4, P194, DOI 10.1097/COH.0b013e328329fc8d; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI 10.1056/NEJMoa1105243; Diffenbach C. W., 2011, ANN INTERN MED, V154, P766; Ghosh A. K., 2007, BIOORGAN MED CHEM, V15, P756; Ghosh AK, 2010, METH PRIN MED CHEM, V45, P205; Horn R. K., 2004, J MED CHEM, V47, P158; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930	34	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	NOV 1	2015	25	21					4903	4909		10.1016/j.bmcl.2015.05.052		7	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CU1IV	WOS:000363275400041		
J	Zhang, T; Andre, P; Bateman, TJ; Chen, YH; Desai, K; Ellsworth, K; Geissler, WM; Guo, LQ; Hruza, A; Jian, TY; Meng, DF; Parker, DL; Qian, XX; Reichert, P; Sherer, EC; Shu, M; Smith, CJ; Sonatore, LM; Tschirret-Guth, R; Nolting, AF; Orr, R; Campeau, LC; Araki, K; Nishimura, T; Sakurada, I; Wood, HB				Zhang, Ting; Andre, Patrick; Bateman, Thomas J.; Chen, Yi-Heng; Desai, Kunal; Ellsworth, Kenneth; Geissler, Wayne M.; Guo, Liangqin; Hruza, Alan; Jian, Tianying; Meng, Dongfang; Parker, Dann L., Jr.; Qian, Xiaoxia; Reichert, Paul; Sherer, Edward C.; Shu, Min; Smith, Cameron J.; Sonatore, Lisa M.; Tschirret-Guth, Richard; Nolting, Andrew F.; Orr, Robert; Campeau, Louis-Charles; Araki, Kazuto; Nishimura, Teruyuki; Sakurada, Isao; Wood, Harold B.			Development of a novel class of potent and selective FIXa inhibitors	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						Benzimidazole; FIXa inhibitor; TGA; Structure based drug design	THROMBIN GENERATION; ACCURATE DOCKING; FACTOR XA; HEMOPHILIA; DISCOVERY; MORTALITY; GLIDE	Using structure based drug design (SBDD), a novel class of potent coagulation Factor IXa (FIXa) inhibitors was designed and synthesized. High selectivity over FXa inhibition was achieved. Selected compounds demonstrated oral bioavailability in rat IV/PO pharmacokinetic (PK) studies. Finally, the pharmacodynamics (PD) of this class of molecules was evaluated in Thrombin Generation Assay (TGA) in Corn Trypsin Inhibitor (CTI) citrated human plasma and demonstrated characteristics of a FIXa inhibitor. (C) 2015 Elsevier Ltd. All rights reserved.	[Zhang, Ting; Chen, Yi-Heng; Guo, Liangqin; Jian, Tianying; Meng, Dongfang; Parker, Dann L., Jr.; Qian, Xiaoxia; Shu, Min; Smith, Cameron J.; Wood, Harold B.] Merck & Co Inc, Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; [Andre, Patrick; Desai, Kunal] Merck & Co Inc, Merck Res Labs, Dept Cardiometab Dis, Rahway, NJ 07065 USA; [Bateman, Thomas J.; Tschirret-Guth, Richard] Merck & Co Inc, Merck Res Labs, Dept Pharmacokinet, Rahway, NJ 07065 USA; [Ellsworth, Kenneth; Geissler, Wayne M.; Sonatore, Lisa M.] Merck & Co Inc, Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA; [Hruza, Alan; Reichert, Paul] Merck & Co Inc, Merck Res Labs, Dept Struct Chem, Rahway, NJ 07065 USA; [Sherer, Edward C.] Merck & Co Inc, Merck Res Labs, Dept Chem Modeling & Informat, Rahway, NJ 07065 USA; [Nolting, Andrew F.; Orr, Robert; Campeau, Louis-Charles] Merck & Co Inc, Merck Res Labs, Dept Proc Chem, Rahway, NJ 07065 USA; [Araki, Kazuto; Nishimura, Teruyuki; Sakurada, Isao] Mochida Pharmaceut Co LTD, Discovery Res, Shinjuku Ku, Tokyo 1608515, Japan	Zhang, T (reprint author), Merck & Co Inc, Merck Res Labs, Dept Med Chem, POB 2000, Rahway, NJ 07065 USA.	ting_zhang3@merck.com					Sramek A, 2003, LANCET, V362, P351, DOI 10.1016/S0140-6736(03)14021-4; Vijaykumar D, 2006, BIOORG MED CHEM LETT, V16, P2796, DOI 10.1016/j.bmcl.2006.01.123; Darby SC, 2007, BLOOD, V110, P815, DOI 10.1182/blood-2006-10-050435; Pinto DJP, 2007, J MED CHEM, V50, P5339, DOI 10.1021/jm070245n; De Smedt E, 2008, THROMB HAEMOSTASIS, V100, P343, DOI 10.1160/TH08-01-0029; Hemker HC, 2000, THROMB HAEMOSTASIS, V83, P589; Heikal NM, 2013, AM J CLIN PATHOL, V140, P680, DOI 10.1309/AJCPAGOR4Q2IIKUG; Weltermann A, 2003, J THROMB HAEMOST, V1, P28, DOI 10.1046/j.1538-7836.2003.00038.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Feuerstein GZ, 1999, THROMB HAEMOSTASIS, V82, P1443; Kravtsov DV, 2009, BLOOD, V114, P452, DOI 10.1182/blood-2009-02-203604; Wang SM, 2010, J MED CHEM, V53, P1465, DOI 10.1021/jm901475e; Wong PC, 2011, J THROMB THROMBOLYS, V31, P478, DOI 10.1007/s11239-011-0551-3; Wang SM, 2010, J MED CHEM, V53, P1473, DOI 10.1021/jm901476x; Khurana JM, 2002, SYNTHETIC COMMUN, V32, P1265, DOI 10.1081/SCC-120003619; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s; Meneyrol J, 2013, J MED CHEM, V56, P9441, DOI 10.1021/jm4005835; Parker Jr D. L., 2015, BIOORG MED CHEM LETT; You J., 2003, J ORG CHEM, V68, P8007	20	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X	1464-3405		BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	NOV 1	2015	25	21					4945	4949		10.1016/j.bmcl.2015.04.057		5	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	CU1IV	WOS:000363275400049		
J	Takayama, K; Akimoto, M; Taguchi, H; Nakagawa, S; Hiroi, K				Takayama, Kohei; Akimoto, Masayuki; Taguchi, Hogara; Nakagawa, Satoko; Hiroi, Kano			Transconjunctival sutureless intrascleral intraocular lens fixation using intrascleral tunnels guided with catheter and 30-gauge needles	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							IMPLANTATION	We invented a new method for fixing an intraocular lens (IOL) in the scleral tunnel without using a wide conjunctival incision. Modified bent catheter needles were used to penetrate the IOL haptics through the sclerotomy sites. The IOL haptics were inserted into 30-guage (G) scleral tunnels guided by double 30-G needles piercing the sclera. All procedures were performed through the conjunctiva without wide incision. The procedure does not require special forceps, trocars or fibrin glue, only catheter and 30-G needles. The aid of an assistant was not required to support the IOL haptic. The procedures were easily learnt based on our previous method. As with other transconjunctival sutureless surgeries, patients feel less discomfort and the conjunctiva can be conserved for future glaucoma surgery. Complications included two cases of vitreous haemorrhage (16.7%), and one case each of postoperative hypotony, and iris capture (8.3%). Astigmatism induced by intraocular aberration was the same as we reported previously. Our method for fixing the IOL into the scleral tunnel is innovative, less expensive, less invasive and quick. This modified method is a good alternative for fixing IOL haptics into the sclera.	[Takayama, Kohei; Akimoto, Masayuki; Taguchi, Hogara; Nakagawa, Satoko; Hiroi, Kano] Osaka Red Cross Hosp, Tennoji Ku, Osaka 5438555, Japan	Akimoto, M (reprint author), Osaka Red Cross Hosp, Tennoji Ku, 5-30 Fudegasakicho, Osaka 5438555, Japan.	masayuki@akimoto3.com					Akimoto M, 2014, J CATARACT REFR SURG, V40, P179, DOI 10.1016/j.jcrs.2013.12.009; Akimoto M, 2015, J CATARACT REFR SURG, V41, P257, DOI 10.1016/j.jcrs.2014.08.030; Agarwal A, 2008, J CATARACT REFR SURG, V34, P1433, DOI 10.1016/j.jcrs.2008.04.040; Ohta T, 2014, J CATARACT REFR SURG, V40, P2, DOI 10.1016/j.jcrs.2013.11.003; Gabor SGB, 2007, J CATARACT REFR SURG, V33, P1851, DOI 10.1016/j.jcrs.2007.07.013; Saleh M, 2013, J CATARACT REFR SURG, V39, P81, DOI 10.1016/j.jcrs.2012.08.063; Yamane S, 2014, OPHTHALMOLOGY, V121, P61, DOI 10.1016/j.ophtha.2013.08.043; Totan Y, 2012, EYE, V26, P788, DOI 10.1038/eye.2012.19; López-Guajardo L, 2010, Arch Soc Esp Oftalmol, V85, P278, DOI 10.1016/j.oftal.2010.07.007; Prasad S., 2012, 30 ANN M AM SOC RET; Rodriguez-Agirretxe I, 2009, J CATARACT REFR SURG, V35, P2051, DOI 10.1016/j.jcrs.2009.06.044; Yamane S, 2014, WORLD OPHTH C APR 2	12	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	NOV	2015	99	11					1457	1459		10.1136/bjophthalmol-2014-306579		3	Ophthalmology	Ophthalmology	CU4BA	WOS:000363469800003		
J	Hayashi, K; Ogawa, S; Manabe, S; Hirata, A				Hayashi, Ken; Ogawa, Soichiro; Manabe, Shin-ichi; Hirata, Akira			Visual outcomes in eyes with a distance-dominant diffractive multifocal intraocular lens with low near addition power	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							CONTRAST SENSITIVITY; IMPLANTATION; EXCHANGE; SURGERY; ACUITY	Aim To compare monocular and binocular visual function between eyes with a distance-dominant diffractive multifocal intraocular lens (IOL) with low addition power (+2.5 dioptres (D)) and eyes with a monofocal IOL. Methods Sixty-four eyes of 32 patients undergoing implantation of a diffractive multifocal IOL (Alcon ReSTOR +2.5 D, SN6AD2) with a +2.5 D addition and 64 eyes of 32 age-matched patients undergoing implantation of a monofocal IOL (SN60WF) were recruited. At 3 months postoperatively, visual acuity (VA) from far to near distances, contrast VA and that with glare (glare VA), glare disability and glare and halo symptoms were evaluated. Results For monocular and binocular VA, mean uncorrected and distance-corrected near VA at 0.3 m and intermediate VA at 0.5 m were significantly better in the multifocal group than in the monofocal group (p <= 0.0412). VA at other distances did not differ significantly between groups. Photopic and mesopic contrast VA and glare VA and glare disability were similar between groups. The percentage of patients who reported glare symptoms did not differ significantly between groups, while the percentage of patients who reported halo symptoms was greater in the multifocal group (p=0.0009). Conclusions A distance-dominant diffractive multifocal IOL with +2.5 D near addition provided useful VA at far and intermediate distances. Contrast sensitivity with and without glare and glare symptom with this multifocal IOL were comparable between the multifocal and monofocal IOLs, although halo symptoms were more prominent with the multifocal IOL.	[Hayashi, Ken; Ogawa, Soichiro; Manabe, Shin-ichi; Hirata, Akira] Hayashi Eye Hosp, Dept Ophthalmol, Fukuoka 8120011, Japan	Hayashi, K (reprint author), Hayashi Eye Hosp, Dept Ophthalmol, Hakata Ku, 4-23-35 Hakataekimae, Fukuoka 8120011, Japan.	hayashi-ken@hayashi.or.jp		HAYASHI, KEN/0000-0002-7297-1477	Alcon Japan Ltd [J-11-037]	The clinical trial of a diffractive multifocal intraocular lens with near addition power of +2.5 dioptres (AcrySof ReSTOR +2.5 D, SN6AD2) was funded by Alcon Japan Ltd (J-11-037).	Alio JL, 2013, J REFRACT SURG, V29, P756, DOI 10.3928/1081597X-20131021-05; Lin HT, 2012, INT J OPHTHALMOL-CHI, V5, P76, DOI 10.3980/j.issn.2222-3959.2012.01.16; Hayashi K, 2006, BRIT J OPHTHALMOL, V90, P1019, DOI 10.1136/bjo.2006.090712; Hayashi K, 2009, JPN J OPHTHALMOL, V53, P100, DOI 10.1007/s10384-008-0626-7; Montes-Mico R, 2004, OPHTHALMOLOGY, V111, P85, DOI 10.1016/S0161-6420(03)00862-5; Kohnen T, 2006, OPHTHALMOLOGY, V113, P578, DOI 10.1016/j.ophtha.2005.11.020; Tassignon MJ, 2014, ACTA OPHTHALMOL, V92, P265, DOI 10.1111/aos.12093; Mester U, 2007, J CATARACT REFR SURG, V33, P1033, DOI 10.1016/j.jcrs.2007.02.037; Hayashi K, 1997, OPHTHALMOLOGY, V104, P793; Kamiya K, 2014, AM J OPHTHALMOL, V158, P215, DOI 10.1016/j.ajo.2014.04.010; Alio JL, 2011, J CATARACT REFR SURG, V37, P638, DOI 10.1016/j.jcrs.2010.10.056; Hayashi K, 2005, OPHTHALMOLOGY, V112, P1550, DOI 10.1016/j.ophtha.2005.03.024; Buckhurst PJ, 2012, INVEST OPHTH VIS SCI, V53, P3920, DOI 10.1167/iovs.11-9234; Hayashi K, 2009, OPHTHALMOLOGY, V116, P401, DOI 10.1016/j.ophtha.2008.09.052; Hayashi K, 2009, J CATARACT REFR SURG, V35, P2070, DOI 10.1016/j.jcrs.2009.07.010; Galor A, 2009, J CATARACT REFR SURG, V35, P1706, DOI 10.1016/j.jcrs.2009.05.022; Pieh S, 1998, J CATARACT REFR SURG, V24, P659; Cham PJT, 2006, J CATARACT REFR SURG, V32, P1459; Gundersen Kjell Gunnar, 2013, Clin Ophthalmol, V7, P1979, DOI 10.2147/OPTH.S52922; Harling G, 2001, J CATARACT REFR SURG, V27, P245; Hayashi K, 2015, ACTA OPHTHALMOL, V93, pE287, DOI 10.1111/aos.12591; Hayashi K, 2015, J CATARACT REFR SURG, V41, P78; Madrid-Costa D, 2013, J REFRACT SURG, V29, P749, DOI 10.3928/1081597X-20131021-04; Pedrotti Emilio, 2014, J Refract Surg, V30, P754, DOI 10.3928/1081597X-20141021-07; Pieh S, 2001, BRIT J OPHTHALMOL, V85, P816, DOI 10.1136/bjo.85.7.816	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	NOV	2015	99	11					1466	1470		10.1136/bjophthalmol-2014-306476		5	Ophthalmology	Ophthalmology	CU4BA	WOS:000363469800005		
J	Kaido, M; Kawashima, M; Yokoi, N; Fukui, M; Ichihashi, Y; Kato, H; Yamatsuji, M; Nishida, M; Fukagawa, K; Kinoshita, S; Tsubota, K				Kaido, Minako; Kawashima, Motoko; Yokoi, Norihiko; Fukui, Masaki; Ichihashi, Yoshiyuki; Kato, Hiroaki; Yamatsuji, Motoko; Nishida, Mitsuko; Fukagawa, Kazumi; Kinoshita, Shigeru; Tsubota, Kazuo			Advanced dry eye screening for visual display terminal workers using functional visual acuity measurement: the Moriguchi study	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							OSAKA; DISEASE; QUESTIONNAIRE; RELIABILITY; PREVALENCE; VALIDITY; QUALITY; FATIGUE; INDEX; USERS	Purpose To evaluate the validity of a dry eye (DE) screening method in visual display terminal (VDT) workers using functional visual acuity (VA) measurement combined with a symptoms questionnaire, and to make recommendations regarding practical use of the screening. Methods This prospective cross-sectional study included 369 young and middle-age office workers, who use VDTs. Subjects completed two types of DE questionnaires and underwent DE testing and functional VA measurement. Subjects were assigned to DE and non-DE groups. Sensitivity and specificity of the DE prediction value were assessed. According to the probability distribution of DE and non-DE calculated by the discriminant analysis formula, we classified subjects into three categories based on the most appropriate cut-off levels. Positive predictive value (PPV) and negative predictive value (NPV) of the DE prediction value were also assessed. Results Of 369 subjects, 218 and 151 subjects were assigned to the DE and non-DE groups, respectively. Sensitivity and specificity were 93.1% and 43.7%, respectively. Based on the probability prediction, the cutoff levels were defined as probability prediction >= 85%, 45%<= probability prediction <85% and probability prediction <45%. Subjects with a probability prediction >= 85% were defined positive (N=130), while those with values <45% were defined as negative (N=73). The PPV and NPV were 83.8% and 80.8%, respectively. Conclusions Acceptable PPV and NPV were obtained by setting three discriminate categories. This improved version of the DE screening method may be acceptable for practical use in VDT workers.	[Kaido, Minako; Kawashima, Motoko; Fukui, Masaki; Ichihashi, Yoshiyuki; Tsubota, Kazuo] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo 1608582, Japan; [Yokoi, Norihiko; Kato, Hiroaki; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan; [Yamatsuji, Motoko] Yamatsuji Clin, Osaka, Japan; [Nishida, Mitsuko] Panasonic Corp, AVC Networks Co, IT Prod Business Div, Hlth Care Sect, Osaka, Japan; [Fukagawa, Kazumi] Ryogoku Eye Clin, Tokyo, Japan	Kaido, M (reprint author), Keio Univ, Dept Ophthalmol, Sch Med, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.	fwiw1193@mb.infoweb.ne.jp					Abib AH, 1998, OCCUP ERGON, V1, P285; ALTMAN DG, 1994, BRIT MED J, V309, P102; Uchino M, 2013, AM J OPHTHALMOL, V156, P759, DOI 10.1016/j.ajo.2013.05.040; Kaido M, 2007, CORNEA, V26, pS29, DOI 10.1097/ICO.0b013e31812f6913; Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615; TODA I, 1993, ACTA OPHTHALMOL, V71, P347; Westhoff G, 2012, RHEUMATOLOGY, V51, P262, DOI 10.1093/rheumatology/ker208; Sakane Y, 2013, JAMA OPHTHALMOL, V131, P1331, DOI 10.1001/jamaophthalmol.2013.4503; HIKICHI T, 1995, GRAEF ARCH CLIN EXP, V233, P555, DOI 10.1007/BF00404705; Thorud HMS, 2012, OPTOMETRY VISION SCI, V89, pE452, DOI 10.1097/OPX.0b013e31824c1801; TODA I, 1995, OPHTHALMOLOGY, V102, P302; Aaras A, 1997, ERGONOMICS, V40, P1255, DOI 10.1080/001401397187496; Kaido M, 2014, INVEST OPHTH VIS SCI, V55, P3275, DOI 10.1167/iovs.13-13000; Kaido M, 2006, AM J OPHTHALMOL, V142, P917, DOI 10.1016/j.ajo.2006.07.055; Koh S, 2008, CORNEA, V27, P275, DOI 10.1097/ICO.0b013e31815be9c8; Nichols KK, 2004, CORNEA, V23, P365, DOI 10.1097/00003226-200405000-00010; Montes-Mico R, 2004, J CATARACT REFR SURG, V30, P1649, DOI 10.1016/j.jcrs.2004.02.041; Uchino M, 2014, AM J OPHTHALMOL, V157, P294, DOI 10.1016/j.ajo.2013.10.014; Begley CG, 2002, CORNEA, V21, P664, DOI 10.1097/00003226-200210000-00007; Fletcher RH, 2005, CLIN EPIDEMIOLOGY ES, P35; Fuentes-Páez G, 2011, Arch Soc Esp Oftalmol, V86, P3, DOI 10.1016/j.oftal.2010.07.004; Kawashima M, 2014, BRIT J OPHTHALMOL, V98, P418, DOI 10.1136/bjophthalmol-2013-303953; McMonnies C W, 1987, J Am Optom Assoc, V58, P588; Shimazaki J., 2007, J EYE, V24, P181; VANBIJST.OP, 1969, ARCH OPHTHALMOL-CHIC, V82, P10	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	NOV	2015	99	11					1488	1492		10.1136/bjophthalmol-2015-306640		5	Ophthalmology	Ophthalmology	CU4BA	WOS:000363469800009		
J	Takahashi, Y; Nakamura, Y; Kakizaki, H				Takahashi, Yasuhiro; Nakamura, Yasuhisa; Kakizaki, Hirohiko			Eight-flap anastomosis in external dacryocystorhinostomy	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							INVOLUTIONAL ENTROPION; FLAP ANASTOMOSIS; OUTCOMES; INTUBATION; EPIPHORA	Aims To examine the surgical outcome of external dacryocystorhinostomy (DCR) with eight-flap anastomosis (8-flap ex-DCR). Methods A retrospective chart review was performed for 55 sides of 51 patients with nasolacrimal duct obstruction who underwent 8-flap ex-DCR. The patients were followed up postoperatively at 1, 2, 4, 8 and 12 weeks, and evaluations were continued with 12-week follow-ups until postoperative 12 months. Anatomical success was defined as no reflux on lacrimal irrigation at 12 months. Functional success was defined as no epiphora at postoperative 12 months. The presence of epistaxis and postoperative surgical site infections were checked in all patients. The presence of granulation tissue around the ostium, under nasal endoscopy, was also examined on 14 sides of 14 patients, at each visit. Results Anatomical success was demonstrated on all sides, and functional success was obtained from 54 sides (98.2%) of 50 patients. One patient experienced postoperative intermittent epiphora on one side. The patients did not show granulation tissue, epistaxis or surgical site infection throughout the observation period. Conclusions The 8-flap ex-DCR showed complete anatomical success and favourable functional success with no postoperative complications.	[Takahashi, Yasuhiro; Nakamura, Yasuhisa; Kakizaki, Hirohiko] Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan	Kakizaki, H (reprint author), Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan.	cosme@d1.dion.ne.jp					Ali MJ, 2014, BRIT J OPHTHALMOL, V98, P1678, DOI 10.1136/bjophthalmol-2014-305510; Ali MJ, 2015, OPHTHAL PLAST RECONS, V31, P219, DOI 10.1097/IOP.0000000000000261; Ari S, 2009, CURR THER RES CLIN E, V70, P267, DOI 10.1016/j.curtheres.2009.08.003; Baldeschi L, 2004, AM J OPHTHALMOL, V138, P840, DOI 10.1016/j.ajo.2004.06.032; TOS M, 1995, RHINOLOGY, P241; Chan W, 2012, CLIN EXP OPHTHALMOL, V40, P749, DOI 10.1111/j.1442-9071.2012.02791.x; Yazici B, 2003, ARCH OPHTHALMOL-CHIC, V121, P76; Saiju R, 2009, BRIT J OPHTHALMOL, V93, P1220, DOI 10.1136/bjo.2008.147819; Madge SN, 2009, CLIN EXP OPHTHALMOL, V37, P620, DOI 10.1111/j.1442-9071.2009.02094.x; Nishimoto H, 2013, OPHTHAL PLAST RECONS, V29, P492, DOI 10.1097/IOP.0b013e3182a64f88; Erdogan G, 2010, OPHTHAL PLAST RECONS, V26, P277, DOI 10.1097/IOP.0b013e3181c3252c; Hodgson N, 2014, OPHTHAL PLAST RECONS, V30, P24, DOI 10.1097/IOP.0b013e3182a7502e; Serin D, 2007, OPHTHAL PLAST RECONS, V23, P28, DOI 10.1097/IOP.0b013e31802dd766; Balikoglu-Yilmaz M, 2015, OPHTHAL PLAST RECONS, V31, P13, DOI 10.1097/IOP.0000000000000159; Bukhari Amal A, 2013, Clin Ophthalmol, V7, P2281, DOI 10.2147/OPTH.S55508; Cohen AJ, 2012, SMITH NESIS OPHTHALM, P689; Elmorsy Shawky Mahmoud, 2010, Orbit, V29, P197, DOI 10.3109/01676831003669961; Khurana AK, 2003, OPHTHALMOLOGY, P341; Lee H, 2014, BRIT J OPHTHALMOL, V98, P1579, DOI 10.1136/bjophthalmol-2013-304830; Morgan N. J., 1995, Rhinology (Utrecht), V33, P224; Nakamura Y., 2002, PRACTICAL OPHTHALMOL, V80, P66; Nakamura Y, 1999, JPN REV CLIN OPHTHAL, V93, P633; Roy H., 2011, SHORT TXB SURG, P354; Shams PN, 2014, JAMA OPHTHALMOL, V132, P1127, DOI 10.1001/jamaophthalmol.2014.1093; Takahashi Y, J CRANIOFAC IN PRESS	25	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	NOV	2015	99	11					1527	1530		10.1136/bjophthalmol-2014-306570		4	Ophthalmology	Ophthalmology	CU4BA	WOS:000363469800017		
J	Katagiri, S; Hayashi, T; Ohkuma, Y; Sekiryu, T; Takeuchi, T; Gekka, T; Kondo, M; Iwata, T; Tsuneoka, H				Katagiri, Satoshi; Hayashi, Takaaki; Ohkuma, Yasuhiro; Sekiryu, Tetsuju; Takeuchi, Tomokazu; Gekka, Tamaki; Kondo, Mineo; Iwata, Takeshi; Tsuneoka, Hiroshi			Mutation analysis of BEST1 in Japanese patients with Best's vitelliform macular dystrophy	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							VMD2 GENE; FUNCTIONAL IMPLICATIONS; DISEASE; FAMILY; DEGENERATION; RETINOPATHY; FREQUENCY; SPECTRUM; PROTEIN; IMPG1	Purpose To describe the clinical and genetic features of Japanese patients with Best's vitelliform macular dystrophy (BVMD). Patients and methods This study examined 22 patients, including 16 probands from 16 families with BVMD. Comprehensive ophthalmic examinations were performed, including dilated funduscopy, full-field electroretinography (ERG) and electro-oculography (EOG). BEST1 mutation analysis was performed by Sanger sequencing. Results All 16 probands exhibited characteristic BVMD fundus appearances, abnormal EOG, and normal ERG responses with the exception of one diabetic retinopathy proband. Genetic analysis identified 12 BEST1 variants in 13 probands (81%). Of these, 10 variants (p.T2A, p.R25W, p.F80L, p.V81M, p.A195V, p.R218H, p.G222E, p.V242M, p.D304del and p.E306D) have been previously reported in BVMD, while two variants (p.S7N and p.P346H) were novel, putative disease-causing variants. Single BEST1 variants were found in 12 probands. The one proband with compound heterozygous variants (p.S7N and p.R218H) exhibited typical BVMD phenotypes (pseudohypopyon stage and vitelliruptive stage in the right and left eyes, respectively). Conclusions Twelve different variants, two of which (p.S7N and p.P346H) were novel, were identified in the 13 Japanese families with BVMD. Compound heterozygous variants were found in one proband exhibiting a typical BVMD phenotype. Our results suggest that BEST1 variants do play a large role in Japanese patients with BVMD.	[Katagiri, Satoshi; Hayashi, Takaaki; Ohkuma, Yasuhiro; Takeuchi, Tomokazu; Gekka, Tamaki; Tsuneoka, Hiroshi] Jikei Univ, Sch Med, Dept Ophthalmol, Tokyo 1058461, Japan; [Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan; [Kondo, Mineo] Mie Univ, Sch Med, Dept Ophthalmol, Tsu, Mie, Japan; [Iwata, Takeshi] Natl Hosp Org Tokyo, Med Ctr, Natl Inst Sensory Organs, Div Mol & Cellular Biol, Tokyo, Japan	Hayashi, T (reprint author), Jikei Univ, Sch Med, Dept Ophthalmol, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	taka@jikei.ac.jp			Ministry of Health, Labor and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan [25462738]	This study was supported by grants from the Ministry of Health, Labor and Welfare of Japan, and the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant-in-Aid for Scientific Research (C) 25462738) (TH).	Lacassagne E, 2011, MOL VIS, V17, P309; Pineiro-Gallego T, 2011, MOL VIS, V17, P1607; Davidson AE, 2009, AM J HUM GENET, V85, P581, DOI 10.1016/j.ajhg.2009.09.015; Burgess R, 2008, AM J HUM GENET, V82, P19, DOI 10.1016/j.ajhg.2007.08.004; Marquardt A, 1998, HUM MOL GENET, V7, P1517, DOI 10.1093/hmg/7.9.1517; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Bakall B, 1999, HUM GENET, V104, P383, DOI 10.1007/s004390050972; Sodi A, 2007, J FR OPHTALMOL, V30, P616, DOI 10.1016/S0181-5512(07)89667-7; Boon CJF, 2009, PROG RETIN EYE RES, V28, P187, DOI 10.1016/j.preteyeres.2009.04.002; NOBLE KG, 1978, BRIT J OPHTHALMOL, V62, P561, DOI 10.1136/bjo.62.8.561; Iannaccone A, 2011, ARCH OPHTHALMOL-CHIC, V129, P211, DOI 10.1001/archophthalmol.2010.367; Kramer F, 2000, EUR J HUM GENET, V8, P286, DOI 10.1038/sj.ejhg.5200447; Atchaneeyasakul LO, 2008, OPHTHALMIC GENET, V29, P139, DOI 10.1080/13816810802087394; Meunier I, 2011, OPHTHALMOLOGY, V118, P1130, DOI 10.1016/j.ophtha.2010.10.010; Sodi A, 2012, MOL VIS, V18, P2736; Bitner H, 2011, INVEST OPHTH VIS SCI, V52, P5332, DOI 10.1167/iovs.11-7174; Kinnick TR, 2011, RETINA-J RET VIT DIS, V31, P581, DOI 10.1097/IAE.0b013e318203ee60; Guziewicz KE, 2011, INVEST OPHTH VIS SCI, V52, P4497, DOI 10.1167/iovs.10-6385; Boon CJF, 2013, OPHTHALMOLOGY, V120, P809, DOI 10.1016/j.ophtha.2012.09.057; Schatz P, 2006, OPHTHALMIC GENET, V27, P51, DOI 10.1080/13816810600677990; Caldwell GM, 1999, GENOMICS, V58, P98, DOI 10.1006/geno.1999.5808; Lotery AJ, 2000, INVEST OPHTH VIS SCI, V41, P1291; Takeuchi T, 2010, INVEST OPHTH VIS SCI, V51, P1643, DOI 10.1167/iovs.09-4497; Manes G, 2013, AM J HUM GENET, V93, P571, DOI 10.1016/j.ajhg.2013.07.018; Bitner H, 2012, AM J OPHTHALMOL, V154, P403, DOI 10.1016/j.ajo.2012.02.036; Best F, 1905, Z AUGENHEILKD, V13, P199, DOI DOI 10.1159/000290318; Marchant D, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.044511; Marchant D, 2001, Hum Mutat, V17, P235, DOI 10.1002/humu.9; Meunier I, 2014, OPHTHALMOLOGY, V121, P2406, DOI 10.1016/j.ophtha.2014.06.028; Shiose Satomi, 2009, Oman J Ophthalmol, V2, P143, DOI 10.4103/0974-620X.57317; Yanagi Yasuo, 2002, Ophthalmic Genet, V23, P129, DOI 10.1076/opge.23.2.129.2213	31	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	NOV	2015	99	11					1577	1582		10.1136/bjophthalmol-2015-306830		6	Ophthalmology	Ophthalmology	CU4BA	WOS:000363469800026		
J	Hosogai, M; Shima, N; Nakatani, Y; Inoue, T; Iso, T; Yokoo, H; Yorifuji, H; Akiyama, H; Kishi, S; Isomura, H				Hosogai, Mayumi; Shima, Nobuyuki; Nakatani, Yoko; Inoue, Teruki; Iso, Tatsuya; Yokoo, Hideaki; Yorifuji, Hiroshi; Akiyama, Hideo; Kishi, Shoji; Isomura, Hiroki			Analysis of human cytomegalovirus replication in primary cultured human corneal endothelial cells	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							VIRAL REPLICATION; DNA-REPLICATION; INFECTED CELLS; GENE-PRODUCTS; EYE; LOCALIZATION; EXPRESSION; PROTEINS; PROMOTER; FEATURES	Background/aims Since the first case of human cytomegalovirus (HCMV)-induced corneal endotheliitis in which HCMV DNA was detected from the patient's aqueous humour using PCR, the clinical evidence for HCMV endotheliitis has been accumulating. However, it remains to be confirmed whether HCMV can efficiently replicate in corneal endothelial cells. We, therefore, sought to determine whether primary cultured human corneal endothelial cells (HCECs) could support HCMV replication. Methods Human foreskin fibroblasts (HFFs) have been shown to be fully permissive for HCMV replication, and are commonly used as an in vitro model for HCMV lytic replication. Therefore, primary cultured HCECs or HFFs were infected with the vascular endotheliotropic HCMV strain TB40/E or laboratory strain Towne. We then compared viral mRNA and protein expression, genome replication and growth between the TB40/E-infected and Towne-infected HCECs and HFFs. Results When HCECs were infected with TB40/E or Towne, rounded cells resembling owl's eyes as well as viral antigens were detected. Viral mRNA synthesis and protein expression proceeded efficiently in the HCECs and HFFs infected with TB40/E or Towne at a high multiplicity of infection (MOI). Similarly, the viral genome was also effectively replicated, with UL44-a viral DNA polymerase processivity factor-foci observed in the nuclei of HCECs. HCECs produced a substantial number of infectious virions after infection with TB40/E at both a high and low MOI. Conclusions Primary cultured HCECs could efficiently support HCMV replication after infection at both a high and low MOI.	[Hosogai, Mayumi; Nakatani, Yoko; Inoue, Teruki; Isomura, Hiroki] Gunma Univ, Grad Sch Med, Dept Virol & Prevent Med, Maebashi, Gunma 3718511, Japan; [Hosogai, Mayumi; Akiyama, Hideo; Kishi, Shoji] Gunma Univ, Grad Sch Med, Dept Ophthalmol, Maebashi, Gunma 3718511, Japan; [Shima, Nobuyuki] Tokyo Univ Hosp, Dept Ophthalmol, Tokyo 113, Japan; [Inoue, Teruki] Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gunma 3718511, Japan; [Iso, Tatsuya] Gunma Univ, Grad Sch Med, Dept Med & Biol Sci, Maebashi, Gunma 3718511, Japan; [Yokoo, Hideaki] Gunma Univ, Grad Sch Med, Dept Human Pathol, Maebashi, Gunma 3718511, Japan; [Yorifuji, Hiroshi] Gunma Univ, Grad Sch Med, Dept Anat, Maebashi, Gunma 3718511, Japan	Isomura, H (reprint author), Gunma Univ, Grad Sch Med, Dept Virol & Prevent Med, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan.	shojikishi@gunma-u.ac.jp; hisomura@gunma-u.ac.jp			 [24659309];  [26462678]	This work was supported by a Grant-in-Aid for Challenging Exploratory Research (similar to 2013) (24659309 to HI), and a Grant-in-Aid for Scientific Research (26462678 to HA).	Isomura H, 2011, J VIROL, V85, P6629, DOI 10.1128/JVI.00384-11; Seto E, 2014, VIROLOGY, V458, P151, DOI 10.1016/j.virol.2014.04.022; Penfold MET, 1997, VIROLOGY, V239, P46, DOI 10.1006/viro.1997.8848; HERRIOT R, 1994, NEW ENGL J MED, V331, P649; Sinzger C, 2008, J GEN VIROL, V89, P359, DOI 10.1099/vir.0.83286-0; Shima N, 2011, INVEST OPHTH VIS SCI, V52, P8711, DOI 10.1167/iovs.11-7592; Kahl M, 2000, J VIROL, V74, P7628, DOI 10.1128/JVI.74.16.7628-7635.2000; Hertel L, 2003, J VIROL, V77, P7563, DOI 10.1128/JVI.77.13.7563-7574.2003; Kobayashi A, 2012, AM J OPHTHALMOL, V153, P445, DOI 10.1016/j.ajo.2011.07.026; Isomura H, 2007, J VIROL, V81, P6197, DOI 10.1128/JVI.00089-07; Stinski MF, 2014, METHODS MOL BIOL, V1119, P1, DOI 10.1007/978-1-62703-788-4_1; Isomura H, 2004, J VIROL, V78, P12788, DOI 10.1128/JVI.78.23.12788-12799.2004; WEINSHENKER BG, 1988, J IMMUNOL, V140, P1625; Nevels M, 2004, J VIROL, V78, P7803, DOI 10.1128/JVI.78.14.7803-7812.2004; WATHEN MW, 1982, J VIROL, V41, P462; Koizumi N, 2006, AM J OPHTHALMOL, V141, P564, DOI 10.1016/j.ajo.2005.09.021; PERCIVALLE E, 1993, J CLIN INVEST, V92, P663, DOI 10.1172/JCI116635; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Luo MH, 2008, J VIROL, V82, P9994, DOI 10.1128/JVI.00943-08; Tugizov S, 1996, J GEN VIROL, V77, P61, DOI 10.1099/0022-1317-77-1-61; STENBERG RM, 1985, J VIROL, V56, P665; Koizumi N, 2015, BRIT J OPHTHALMOL, V99, P54, DOI 10.1136/bjophthalmol-2013-304625; Mocarski ESST, 2013, CYTOMEGALOVIRUSES FI; Renzette N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003735; Tandon R, 2015, VIRUSES-BASEL, V7, P899, DOI 10.3390/v7030899	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	NOV	2015	99	11					1583	1590		10.1136/bjophthalmol-2014-306486		8	Ophthalmology	Ophthalmology	CU4BA	WOS:000363469800027		
J	Bobkov, V; Tanaka, M				Bobkov, Vladimir; Tanaka, Mieko			On positive solutions for (p, q)-Laplace equations with two parameters	CALCULUS OF VARIATIONS AND PARTIAL DIFFERENTIAL EQUATIONS			English	Article							P-LAPLACIAN; ELLIPTIC-EQUATIONS; EIGENVALUE; WEIGHT	We study the existence and non-existence of positive solutions for the (p, q)-Laplace equation , where , under the zero Dirichlet boundary condition in . The main result of our research is the construction of a continuous curve in plane, which becomes a threshold between the existence and non-existence of positive solutions. Furthermore, we provide the example of domains for which the corresponding first Dirichlet eigenvalue of is not monotone w.r.t. .	[Bobkov, Vladimir] RAS, Ufa Sci Ctr, Inst Math, Ufa 450008, Russia; [Tanaka, Mieko] Tokyo Univ Sci, Dept Math, Shinjyuku Ku, Tokyo 1628601, Japan	Tanaka, M (reprint author), Tokyo Univ Sci, Dept Math, Shinjyuku Ku, Kagurazaka 1-3, Tokyo 1628601, Japan.	bobkovve@gmail.com; tanaka@ma.kagu.tus.ac.jp			Russian Foundation for Basic Research [13-01-00294, 14-01-31054]	The first author was partially supported by the Russian Foundation for Basic Research (Project Nos. 13-01-00294 and 14-01-31054).	Allegretto W., 1998, NONLINEAR ANAL, V32, P819, DOI 10.1016/S0362-546X(97)00530-0; ANANE A, 1987, CR ACAD SCI I-MATH, V305, P725; Il'Yasov Y, 2001, CR ACAD SCI I-MATH, V333, P533, DOI 10.1016/S0764-4442(01)01924-3; Benedikt J, 2012, J MATH ANAL APPL, V393, P311, DOI 10.1016/j.jmaa.2012.03.054; Benouhiba N, 2013, NONLINEAR ANAL-THEOR, V77, P74, DOI 10.1016/j.na.2012.09.012; Cherfils L, 2005, COMMUN PUR APPL ANAL, V4, P9; Huang YX, 1997, P AM MATH SOC, V125, P3347, DOI 10.1090/S0002-9939-97-03961-0; Miyajima S, 2012, J FUNCT ANAL, V262, P1921, DOI 10.1016/j.jfa.2011.11.028; Tanaka M, 2014, J MATH ANAL APPL, V419, P1181, DOI 10.1016/j.jmaa.2014.05.044; Mihailescu M, 2011, COMMUN PUR APPL ANAL, V10, P701, DOI 10.3934/cpaa.2011.10.701; Cuesta M, 1999, J DIFFER EQUATIONS, V159, P212, DOI 10.1006/jdeq.1999.3645; Benouhiba N., 2012, INT J PURE APPL MATH, V50, P727; Bobkov V., 2014, ARXIV14065275; Drabek P., 2013, METHODS NONLINEAR AN; Gongbao L., 2009, ACTA MATH SCI B, V29, P903; Ilasov Y.S., 2007, FUNCT ANAL APPL, V41, P18; Kajikiya R., BIFURCATION PO UNPUB; KAWOHL B., 2003, COMMENT MATH U CAROL, V44, P659; LIEBERMAN GM, 1988, NONLINEAR ANAL-THEOR, V12, P1203, DOI 10.1016/0362-546X(88)90053-3; LIEBERMAN GM, 1991, COMMUN PART DIFF EQ, V16, P311, DOI 10.1080/03605309108820761; Mawhin J., 1989, CRITICAL POINT THEOR; Motreanu D., MINIMAX THE IN PRESS; Pucci P, 2007, PROG NONLINEAR DIFFE, V73, P1; Ramos Quoirin H., 2012, J MATH ANAL APPL, V387, P189; Tanaka M., 2014, J NONLINEAR FUNCT AN, V2014, P1; Yin H., 2012, NONLINEAR ANAL, V75, P3021; Zeidler E., 1985, NONLINEAR FUNCTIONAL	27	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0944-2669	1432-0835		CALC VAR PARTIAL DIF	Calc. Var. Partial Differ. Equ.	NOV	2015	54	3					3277	3301		10.1007/s00526-015-0903-5		25	Mathematics, Applied; Mathematics	Mathematics	CT8HO	WOS:000363056100033		
J	Ogura, K; Fujiwara, T; Yasunaga, H; Matsui, H; Jeon, DG; Cho, WH; Hiraga, H; Ishii, T; Yonemoto, T; Kamoda, H; Ozaki, T; Kozawa, E; Nishida, Y; Morioka, H; Hiruma, T; Kakunaga, S; Ueda, T; Tsuda, Y; Kawano, H; Kawai, A				Ogura, Koichi; Fujiwara, Tomohiro; Yasunaga, Hideo; Matsui, Hiroki; Jeon, Dae-Geun; Cho, Wan Hyeong; Hiraga, Hiroaki; Ishii, Takeshi; Yonemoto, Tsukasa; Kamoda, Hiroto; Ozaki, Toshifumi; Kozawa, Eiji; Nishida, Yoshihiro; Morioka, Hideo; Hiruma, Toru; Kakunaga, Shigeki; Ueda, Takafumi; Tsuda, Yusuke; Kawano, Hirotaka; Kawai, Akira			Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study	CANCER			English	Article						external validation; nomogram; osteosarcoma; prognosis; survival	HIGH-GRADE OSTEOSARCOMA; HIGH-DOSE METHOTREXATE; ADJUVANT CHEMOTHERAPY; PROGNOSTIC-FACTORS; PATHOLOGICAL FRACTURES; POSTOPERATIVE NOMOGRAM; EXTREMITY OSTEOSARCOMA; PROSPECTIVE TRIAL; ONCOLOGY-GROUP; BONE SARCOMAS	BACKGROUNDIn this era of individualized cancer treatment, data that could be applied to predicting the survival of patients with osteosarcoma are still limited because of the rarity of the disease and the difficulty in accumulating a sufficient number of patients. Therefore, a multi-institutional collaboration was implemented to develop and externally validate nomograms that would predict metastasis-free survival (MFS) and overall survival (OAS) for patients with nonmetastatic osteosarcoma. METHODSThis study retrospectively examined 1070 patients treated with neoadjuvant chemotherapy and surgery for nonmetastatic osteosarcoma. Data from Japanese patients (n = 557) were used to develop multivariate nomograms based on Cox regression. Six clinical and pathologic variables were built into nomograms estimating the probability of MFS and OAS 3 and 5 years after diagnosis. The model was internally validated for discrimination and calibration with bootstrap resampling and was externally validated with an independent patient cohort from Korea (n = 513). RESULTSA patient's age, tumor site, and histologic response were found to have a stronger influence on MFS and OAS in the model than sex, tumor size, or pathologic fracture. The nomograms and calibration plots based on these results well predicted the probability of MFS (concordance index, 0.631) and OAS (concordance index, 0.679). The concordance indices for external validation were 0.682 for MFS and 0.665 for OAS. CONCLUSIONSThe nomograms were externally validated and verified to be useful for the prediction of MFS and OAS and for the assessment of the postoperative prognosis. They can be used for counseling patients and for establishing appropriate surveillance strategies after surgery. Cancer 2015;121:3844-3852. (c) 2015 American Cancer Society. Prognostic nomograms for osteosarcoma have been developed and externally validated through multi-institutional collaboration. These prognostic nomograms are the first to be developed and externally validated for osteosarcoma.	[Ogura, Koichi; Fujiwara, Tomohiro; Kawai, Akira] Natl Canc Ctr, Dept Musculoskeletal Oncol, Tokyo 1040045, Japan; [Ogura, Koichi; Tsuda, Yusuke; Kawano, Hirotaka] Tokyo Univ Hosp, Dept Orthoped Surg, Tokyo 113, Japan; [Fujiwara, Tomohiro; Ozaki, Toshifumi] Okayama Univ, Dept Orthoped Surg, Okayama 7008530, Japan; [Yasunaga, Hideo; Matsui, Hiroki] Univ Tokyo, Sch Publ Hlth, Dept Hlth Econ & Epidemiol Res, Tokyo, Japan; [Jeon, Dae-Geun; Cho, Wan Hyeong] Korea Canc Ctr Hosp, Dept Orthoped Surg, Seoul, South Korea; [Hiraga, Hiroaki] Hokkaido Canc Ctr, Dept Orthoped Surg, Sapporo, Hokkaido, Japan; [Ishii, Takeshi; Yonemoto, Tsukasa; Kamoda, Hiroto] Chiba Canc Ctr, Dept Orthoped Surg, Chiba 2608717, Japan; [Kozawa, Eiji; Nishida, Yoshihiro] Nagoya Univ, Dept Orthoped Surg, Nagoya, Aichi 4648601, Japan; [Morioka, Hideo] Keio Univ, Dept Orthoped Surg, Tokyo, Japan; [Hiruma, Toru] Kanagawa Canc Ctr, Dept Orthoped Surg, Yokohama, Kanagawa, Japan; [Kakunaga, Shigeki; Ueda, Takafumi] Osaka Natl Hosp, Dept Orthoped Surg, Osaka, Japan	Kawai, A (reprint author), Natl Canc Ctr, Dept Musculoskeletal Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	akawai@ncc.go.jp			Ministry of Education and Science [22390296]; National Cancer Center Research and Development Fund [23-A-10]	This study was funded by a Grant-in-Aid for Scientific Research from the Ministry of Education and Science (B, no. 22390296) and by the National Cancer Center Research and Development Fund (23-A-10).	Heck RK, 2003, CLIN ORTHOP RELAT R, P64, DOI 10.1097/01.blo.0000093898.12372.6c; DAVIS AM, 1994, J CLIN ONCOL, V12, P423; Abudu A, 1996, J BONE JOINT SURG BR, V78B, P694; Aksnes LH, 2006, ACTA ONCOL, V45, P38, DOI 10.1080/02841860500466624; LINK MP, 1986, NEW ENGL J MED, V314, P1600, DOI 10.1056/NEJM198606193142502; Bacci G, 2003, CANCER, V97, P3068, DOI 10.1002/cncr.11456; LINK MP, 1991, CLIN ORTHOP RELAT R, P8; Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031; Wunder JS, 2000, J CLIN ONCOL, V18, P2685; JAFFE N, 1987, CANCER, V59, P701, DOI 10.1002/1097-0142(19870215)59:4<701::AID-CNCR2820590407>3.0.CO;2-V; Bramer JAM, 2007, EUR J CANCER, V43, P1944, DOI 10.1016/j.ejca.2007.07.004; Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Goorin AM, 2003, J CLIN ONCOL, V21, P1574, DOI 10.1200/JCO.2003.08.165; EILBER F, 1987, J CLIN ONCOL, V5, P21; Bianco FJ, 2006, EUR UROL, V50, P884, DOI 10.1016/j.eururo.2006.07.043; Carsi B, 2002, CLIN ORTHOP RELAT R, P53; Bacci G, 2006, CANCER, V106, P1154, DOI 10.1002/cncr.21724; Crews KR, 2004, CANCER-AM CANCER SOC, V100, P1724, DOI 10.1002/cncr.20152; Kim MS, 2007, CLIN ORTHOP RELAT R, P157, DOI 10.1097/BLO.0b013e318142b27d; Kim MS, 2009, ANN ONCOL, V20, P955, DOI 10.1093/annonc/mdn723; Wilkins RM, 2003, ANN SURG ONCOL, V10, P498, DOI 10.1245/ASO.2003.03.061; Scully SP, 2002, J BONE JOINT SURG AM, V84A, P49; Bacci G, 2002, ONCOL REP, V9, P171; Patel SJ, 2002, AM J CLIN ONCOL-CANC, V25, P489, DOI 10.1097/00000421-200210000-00014; Ouyang ZX, 2013, ONCOL LETT, V6, P970, DOI 10.3892/ol.2013.1487; Iwamoto Y, 2009, J ORTHOP SCI, V14, P397, DOI 10.1007/s00776-009-1347-6; Laverdiere C, 2005, CLIN CANCER RES, V11, P2561, DOI 10.1158/1078-0432.CCR-04-1089; Kattan MW, 2002, J CLIN ONCOL, V20, P791, DOI 10.1200/JCO.20.3.791; Iwamoto Y, 2012, JPN J CLIN ONCOL, V42, P467, DOI 10.1093/jjco/hys059; Edge SB, 2010, AJCC CANC STAGING MA, P281; Kim SH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-666; ROSEN G, 1983, J CANCER RES CLIN, V106, P55, DOI 10.1007/BF00625054	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0008-543X	1097-0142		CANCER-AM CANCER SOC	Cancer	NOV 1	2015	121	21					3844	3852		10.1002/cncr.29575		9	Oncology	Oncology	CU1EH	WOS:000363262100015		
J	Yamazaki, N; Uhara, H; Fukushima, S; Uchi, H; Shibagaki, N; Kiyohara, Y; Tsutsumida, A; Namikawa, K; Okuyama, R; Otsuka, Y; Tokudome, T				Yamazaki, N.; Uhara, H.; Fukushima, S.; Uchi, H.; Shibagaki, N.; Kiyohara, Y.; Tsutsumida, A.; Namikawa, K.; Okuyama, R.; Otsuka, Y.; Tokudome, T.			Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Ipilimumab; Dacarbazine; Immune-checkpoint inhibitor; Melanoma; Phase 2 study; Japanese patients	CLINICAL ACTIVITY; EFFICACY; COMBINATION; BLOCKADE; CANCER; CTLA-4; TRIAL	Purpose Ipilimumab (IPI), a monoclonal antibody against immune-checkpoint receptor cytotoxic T lymphocyte antigen- 4, is designed to enhance antitumor T cell function. IPI 10 mg/kg plus dacarbazine (DTIC) significantly improved overall survival in a phase 3 study involving predominantly Caucasian patients, with an adverse event (AE) profile similar to that of IPI monotherapy. We conducted a single-arm, phase 2 study to evaluate the safety and efficacy of IPI plus DTIC in Japanese patients. Methods Previously untreated patients with unresectable stage III or IV melanoma received IPI 10 mg/kg plus DTIC 850 mg/m(2) every 3 weeks for four doses (q3w x 4), followed by DTIC q3w x 4 and then IPI every 12 weeks until disease progression or intolerable toxicity. Results All 15 treated patients reported drug-related AEs, the most common of which were increases in alanine aminotransferase (n = 12, 80 %) and aspartate aminotransferase (n = 11, 73 %). Treatment-related serious AEs were reported in 11 (73 %) patients. Nine patients (60 %) discontinued treatment due to drug-related toxicities. Immunerelated AEs (irAEs) were reported in 14 patients (93 %). The most frequent irAEs were liver (n = 12, 80 %) and skin (n = 10, 67 %) toxicities. Five deaths were reported; all were caused by progressive disease. Efficacy evaluation showed one complete response, one partial response and four patients with stable disease. Best overall response rate was 13 % (2/15), and the disease control rate was 40 % (6/15). The study was terminated early due to frequent, high-grade liver toxicities. Conclusions IPI 10 mg/kg plus DTIC 850 mg/m(2) was not considered tolerable in the Japanese patient population. ClinicalTrials. gov identifier: NCT01681212.	[Yamazaki, N.; Tsutsumida, A.; Namikawa, K.] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan; [Uhara, H.; Okuyama, R.] Shinshu Univ, Sch Med, Dept Dermatol, Matsumoto, Nagano 390, Japan; [Fukushima, S.] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan; [Uchi, H.] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka, Japan; [Shibagaki, N.] Yamanashi Univ Hosp, Dept Dermatol, Shimogawa, Yamanashi, Japan; [Kiyohara, Y.] Shizuoka Canc Ctr, Div Dermatol, Shizuoka, Japan; [Otsuka, Y.; Tokudome, T.] Bristol Myers KK, Res & Dev, Shinjuku Ku, Tokyo 1631328, Japan	Tokudome, T (reprint author), Bristol Myers KK, Res & Dev, Shinjuku Ku, 6-5-1 Nishishinjuku, Tokyo 1631328, Japan.	takuto0806@gmail.com			Bristol-Myers K.K.	Bristol-Myers K.K. provided funding to all study sites and institutions to cover investigators' expenses for undertaking this trial.	Peggs KS, 2006, CURR OPIN IMMUNOL, V18, P206, DOI 10.1016/j.coi.2006.01.011; FROSCH PJ, 1979, J CANCER RES CLIN, V95, P281, DOI 10.1007/BF00410649; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Weber J, 2009, CLIN CANCER RES, V15, P5591, DOI 10.1158/1078-0432.CCR-09-1024; Wolchok JD, 2010, LANCET ONCOL, V11, P155, DOI 10.1016/S1470-2045(09)70334-1; Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492; Horinouchi H, 2015, INVEST NEW DRUG, V33, P881, DOI 10.1007/s10637-015-0243-5; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338; Maio M, 2015, J CLIN ONCOL, V33, P1191, DOI 10.1200/JCO.2014.56.6018; DANCYGIER H, 1983, HEPATO-GASTROENTEROL, V30, P93; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Schmidt H, 2009, EJC SUPPL, V7, P577; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; O'Day SJ, 2010, ANN ONCOL, V21, P1712, DOI 10.1093/annonc/mdq013; GREENSTONE MA, 1981, BRIT MED J, V282, P1744; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Bristol-Myers Squibb Company, YERVOY IP PRESCR INF; Bristol-Myers Squibb Company, 2011, YERVOY IP RISK EV MI; Fukushima S, 2015, 31 ANN M JAP SKIN CA; Hamid O, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-204; Hodi FS, 2010, NEW ENGL J MED, V363, P1290; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Nokihara H, 2013, J THORAC ONCOL S2, V8, P11	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	NOV	2015	76	5					969	975		10.1007/s00280-015-2870-0		7	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CU0YR	WOS:000363245800010		
J	Shinke, H; Masuda, S; Togashi, Y; Ikemi, Y; Ozawa, A; Sato, T; Kim, YH; Mishima, M; Ichimura, T; Bonventre, JV; Matsubara, K				Shinke, Haruka; Masuda, Satohiro; Togashi, Yousuke; Ikemi, Yasuaki; Ozawa, Aiko; Sato, Tomoko; Kim, Young Hak; Mishima, Michiaki; Ichimura, Takaharu; Bonventre, Joseph V.; Matsubara, Kazuo			Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Cisplatin; Acute kidney injury; Biomarker; Lung cancer	GELATINASE-ASSOCIATED LIPOCALIN; RENAL INJURY; CARDIAC-SURGERY; TOXICITY; COMBINATION; KIM-1; RAT	Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based chemotherapy. However, traditional markers of kidney function, such as serum creatinine, are suboptimal, because they are not sensitive measures of proximal tubular injury. We aimed to determine whether the new urinary biomarkers such as kidney injury molecule-1 (KIM-1), monocyte chemotactic protein-1 (MCP-1), and neutrophil gelatinase-associated lipocalin (NGAL) could detect cisplatin-induced AKI in lung cancer patients in comparison with the conventional urinary proteins such as N-acetyl-beta-d-glucosaminidase (NAG) and beta 2-microglobulin. We measured KIM-1, MCP-1, NGAL, NAG, and beta 2-microglobulin concentrations in urine samples from 11 lung cancer patients, which were collected the day before cisplatin administration and on days 3, 7, and 14. Subsequently, we evaluated these biomarkers by comparing their concentrations in 30 AKI positive (+) and 12 AKI negative (-) samples and performing receiver operating characteristic (ROC) curve analyses. The urinary levels normalized with urine creatinine of KIM-1 and MCP-1, but not NGAL, NAG, and beta 2-microglobulin in AKI (+) samples were significantly higher than those in AKI (-) samples. In addition, ROC curve analyses revealed that KIM-1 and MCP-1, but not NGAL, could detect AKI with high accuracy (area under the curve [AUC] = 0.858, 0.850, and 0.608, respectively). The combination of KIM-1 and MCP-1 outperformed either biomarker alone (AUC = 0.871). Urinary KIM-1 and MCP-1, either alone or in combination, may represent biomarkers of cisplatin-induced AKI in lung cancer patients.	[Shinke, Haruka; Masuda, Satohiro; Ozawa, Aiko; Sato, Tomoko; Matsubara, Kazuo] Kyoto Univ Hosp, Dept Clin Pharmacol & Therapeut, Sakyo Ku, Kyoto 6068507, Japan; [Masuda, Satohiro; Ikemi, Yasuaki; Matsubara, Kazuo] Kyoto Univ Hosp, Dept Pharm, Sakyo Ku, Kyoto 6068507, Japan; [Togashi, Yousuke; Kim, Young Hak; Mishima, Michiaki] Kyoto Univ Hosp, Dept Resp Med, Sakyo Ku, Kyoto 6068507, Japan; [Ichimura, Takaharu; Bonventre, Joseph V.] Harvard Univ, Sch Med, Harvard Inst Med, Renal Div,Brigham & Womens Hosp, Boston, MA 02115 USA	Masuda, S (reprint author), Kyushu Univ Hosp, Dept Pharm, Higashi Ku, Fukuoka 8128582, Japan.	satomsdb@pharm.med.kyushu-u.ac.jp			Ministry of Education, Science, Culture, Sports, and Technology of Japan (MEXT); Ministry of Health, Labour, and Welfare of Japan [08062855]; Council for Science and Technology Policy of the Japan Society for the Promotion of Science [LS073]	This work was supported in part by a Grant-in-Aid for Scientific Research (KAKENHI) from the Ministry of Education, Science, Culture, Sports, and Technology of Japan (MEXT); a Grant-in-Aid for Research on Biological Markers for New Drug Development and Health and Labour Sciences Research Grants from the Ministry of Health, Labour, and Welfare of Japan (08062855); and a funding program for Next Generation World-Leading Researchers (LS073 to SM) from the Council for Science and Technology Policy of the Japan Society for the Promotion of Science.	Mishra J, 2003, J AM SOC NEPHROL, V14, P2534, DOI 10.1097/01.ASN.0000088027.54400.C6; Sieber M, 2009, TOXICOL SCI, V109, P336, DOI 10.1093/toxsci/kfp070; Mishra J, 2004, AM J NEPHROL, V24, P307, DOI 10.1159/000078452; Nishihara K, 2013, BIOCHEM PHARMACOL, V85, P570, DOI 10.1016/j.bcp.2012.12.019; Yonezawa A, 2005, BIOCHEM PHARMACOL, V70, P1823, DOI 10.1016/j.bcp.2005.09.020; HAYES DM, 1977, CANCER, V39, P1372, DOI 10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J; Lin HYH, 2013, KAOHSIUNG J MED SCI, V29, P304, DOI 10.1016/j.kjms.2012.10.004; Liang XL, 2010, BIOMARKERS, V15, P332, DOI 10.3109/13547501003706558; Bonventre JV, 2009, NEPHROL DIAL TRANSPL, V24, P3265, DOI 10.1093/ndt/gfp010; Katagiri D, 2012, ANN THORAC SURG, V93, P577, DOI 10.1016/j.athoracsur.2011.10.048; Tekce BK, 2015, ANN CLIN BIOCHEM, V52, P88, DOI 10.1177/0004563214528312; Ichimura T, 1998, J BIOL CHEM, V273, P4135, DOI 10.1074/jbc.273.7.4135; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Vaidya VS, 2009, KIDNEY INT, V76, P108, DOI 10.1038/ki.2009.96; Bonventre JV, 2010, NAT BIOTECHNOL, V28, P436, DOI 10.1038/nbt0510-436; Vaidya VS, 2010, NAT BIOTECHNOL, V28, P478, DOI 10.1038/nbt.1623; Rice JC, 2002, RENAL FAILURE, V24, P703, DOI 10.1081/JDI-120015673; Gaspari F, 2010, NEPHRON CLIN PRACT, V115, pC154, DOI 10.1159/000312879; Mishra J, 2005, LANCET, V365, P1231, DOI 10.1016/S0140-6736(05)74811-X; Ichimura T, 2004, AM J PHYSIOL-RENAL, V286, pF552, DOI 10.1152/ajprenal.00285.2002; Peres Luis Alberto Batista, 2014, J Bras Nefrol, V36, P280, DOI 10.5935/0101-2800.20140041	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	NOV	2015	76	5					989	996		10.1007/s00280-015-2880-y		8	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CU0YR	WOS:000363245800012		
J	Yamazaki, N; Kiyohara, Y; Uhara, H; Fukushima, S; Uchi, H; Shibagaki, N; Tsutsumida, A; Yoshikawa, S; Okuyama, R; Ito, Y; Tokudome, T				Yamazaki, N.; Kiyohara, Y.; Uhara, H.; Fukushima, S.; Uchi, H.; Shibagaki, N.; Tsutsumida, A.; Yoshikawa, S.; Okuyama, R.; Ito, Y.; Tokudome, T.			Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Ipilimumab; Immune-checkpoint inhibitor; Melanoma; Phase II study; Japanese patients	REGULATORY T-CELLS; ANTI-CTLA-4 ANTIBODIES; METASTATIC MELANOMA; ADVERSE EVENTS; CANCER-IMMUNOTHERAPY; ANTITUMOR-ACTIVITY; BLOCKADE; MANAGEMENT; NIVOLUMAB; EFFICACY	Ipilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma. Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015). Data are reported from 20 patients. Fifteen patients (75 %) received all four doses of ipilimumab during induction. Twelve patients (60 %) had at least one drug-related adverse event (AE), and no patients discontinued due to a drug-related AE. There were no deaths related to study drug. The most common drug-related AEs were rash (n = 7), pyrexia (n = 3), increased aspartate aminotransferase (AST; n = 3), and increased alanine aminotransferase (ALT; n = 3). Twelve patients (60 %) reported immune-related AEs (irAEs); most frequent were skin (n = 9) and liver (n = 3) disorders. Grade 3 irAEs were ALT and AST elevation (n = 2) and diabetes mellitus (n = 1). Two patients had a partial response and two had stable disease, yielding a 20 % disease control rate. Median overall survival and progression-free survival were 8.71 and 2.74 months, respectively. Ipilimumab 3 mg/kg had a manageable AE profile in this Japanese patient population with clinical outcomes similar to that in Caucasian patients. NCT01990859.	[Yamazaki, N.; Tsutsumida, A.] Natl Canc Ctr, Dept Dermatol Oncol, Tokyo, Japan; [Kiyohara, Y.; Yoshikawa, S.] Shizuoka Canc Ctr, Div Dermatol, Shizuoka, Japan; [Uhara, H.; Okuyama, R.] Shinshu Univ, Sch Med, Dept Dermatol, Matsumoto, Nagano 390, Japan; [Fukushima, S.] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto, Japan; [Uchi, H.] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka 812, Japan; [Shibagaki, N.] Univ Yamanashi Hosp, Dept Dermatol, Yamanashi, Japan; [Ito, Y.; Tokudome, T.] Bristol Myers KK, Res & Dev, Shinjuku Ku, Tokyo 1631328, Japan	Tokudome, T (reprint author), Bristol Myers KK, Res & Dev, Shinjuku Ku, 6-5-1 Nishishinjuku, Tokyo 1631328, Japan.	takuto0806@gmail.com			Bristol-Myers K.K.	Bristol-Myers K.K. provided funding to all study sites and institutions to cover investigators' expenses for undertaking this trial.	Weber J, 2009, CANCER IMMUNOL IMMUN, V58, P823, DOI 10.1007/s00262-008-0653-8; Peggs KS, 2006, CURR OPIN IMMUNOL, V18, P206, DOI 10.1016/j.coi.2006.01.011; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492; Kaehler KC, 2010, SEMIN ONCOL, V37, P485, DOI 10.1053/j.seminoncol.2010.09.003; Horinouchi H, 2015, INVEST NEW DRUG, V33, P881, DOI 10.1007/s10637-015-0243-5; McDermott D, 2013, ANN ONCOL, V24, P2694, DOI 10.1093/annonc/mdt291; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Selby MJ, 2013, CANCER IMMUNOL RES, V1, P32, DOI 10.1158/2326-6066.CIR-13-0013; Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI 10.1056/NEJMoa1504030; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Brennan FR, 2010, MABS-AUSTIN, V2, P233; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Wolchok JD, 2013, ANN NY ACAD SCI, V1291, P1, DOI 10.1111/nyas.12180; Bristol-Myers Squibb Company, 2015, OPDIVO NIV PRESCR IN; Bristol-Myers Squibb Company, 2015, YERVOY IP PRESCR INF; Bristol-Myers Squibb Company, 2011, YERVOY IP RISK EV MI; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	NOV	2015	76	5					997	1004		10.1007/s00280-015-2873-x		8	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CU0YR	WOS:000363245800013		
J	Mizugaki, H; Yamamoto, N; Nokihara, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Yagishita, S; Xiong, H; Qian, J; Hashiba, H; Shepherd, SP; Giranda, V; Tamura, T				Mizugaki, Hidenori; Yamamoto, Noboru; Nokihara, Hiroshi; Fujiwara, Yutaka; Horinouchi, Hidehito; Kanda, Shintaro; Kitazono, Satoru; Yagishita, Shigehiro; Xiong, Hao; Qian, Jane; Hashiba, Hideyuki; Shepherd, Stacie P.; Giranda, Vincent; Tamura, Tomohide			A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC)	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Veliparib (ABT-888); NSCLC; PARP; Carboplatin; Paclitaxel	POLYMERASE INHIBITOR; DNA-REPAIR; PACLITAXEL; SURVIVAL; THERAPY; TRIAL	Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to determine the recommended phase 2 dose (RPTD) of veliparib plus carboplatin and paclitaxel, and assess pharmacokinetics (PK), tolerability, and preliminary efficacy in Japanese patients with solid tumors. Carboplatin (AUC 6 mg/mL min) and paclitaxel (200 mg/m(2)) were administered on day 3 of a 21-day cycle. Oral veliparib (40, 80, or 120 mg BID) was administered on days 1-7. Patients received a parts per thousand currency sign6 cycles. Adverse events (AEs) were reported using NCI-CTCAE version 4.03, PK parameters were analyzed using noncompartmental methods, and responses were measured by RECIST version 1.1. Twelve patients with non-small cell lung cancer (NSCLC) were treated. Common treatment-emergent AEs, consistent with toxicities associated with carboplatin and paclitaxel, included leukopenia (100 %), neutropenia (100 %), anemia (83 %), thrombocytopenia (75 %), increased alanine aminotransferase (67 %), and increased aspartate aminotransferase (67 %). Grade 3/4 AEs (in a parts per thousand yen2 patients) included neutropenia (100 %), leukopenia (33 %), anemia (25 %), and hyponatremia (17 %). No AEs led to veliparib, carboplatin, or paclitaxel interruption; no DLTs were observed. The RPTD was determined to be 120 mg BID. Veliparib C (max) and AUC were approximately dose proportional. Six partial responses were observed. Veliparib PK was not impacted by carboplatin and paclitaxel. The safety profile was manageable. The 120 mg BID RPTD confirmed in Japanese patients is the dose being evaluated in global studies of veliparib. Preliminary efficacy suggests veliparib may enhance carboplatin and paclitaxel activity, providing benefit to patients with NSCLC.	[Mizugaki, Hidenori; Yamamoto, Noboru; Nokihara, Hiroshi; Fujiwara, Yutaka; Horinouchi, Hidehito; Kanda, Shintaro; Kitazono, Satoru; Yagishita, Shigehiro; Tamura, Tomohide] Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tokyo 1040045, Japan; [Xiong, Hao; Qian, Jane; Shepherd, Stacie P.; Giranda, Vincent] AbbVie Inc, N Chicago, IL USA; [Hashiba, Hideyuki] AbbVie GK, Tokyo, Japan	Yamamoto, N (reprint author), Natl Canc Ctr, Dept Thorac Oncol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	nbryamam@ncc.go.jp			AbbVie	AbbVie provided financial support for the study and participated in the design, study conduct, analysis and interpretation of the data, as well as the writing, review, and approval of the manuscript. The authors would like to thank the study coordinators and support staff. Data programming support was provided by Jing Xu (AbbVie US) and Yasuko Nishimura (AbbVie GK); medical writing support was provided by Leanne Lash. All are employees of AbbVie.	Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Olaussen KA, 2013, LUNG CANCER, V80, P216, DOI 10.1016/j.lungcan.2013.01.014; Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039; Bosken CH, 2002, J NATL CANCER I, V94, P1091; Kikuchi R, 2013, J PHARM SCI-US, V102, P4426, DOI 10.1002/jps.23737; LANGER CJ, 1995, J CLIN ONCOL, V13, P1860; Langer CJ, 2015, AM J CLIN ONCOL-CANC, V38, P422, DOI 10.1097/COC.0000000000000059; Ohe Y, 2007, ANN ONCOL, V18, P317, DOI 10.1093/annonc/mdl377; Kummar S, 2009, J CLIN ONCOL, V27, P2705, DOI 10.1200/JCO.2008.19.7681; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Appleman LJ, 2014, J CLIN ONCOL S; Ferlay J, 2013, IARC CANCERBASE; National Comprehensive Cancer Network, 2014, CLIN PRACT GUID NONS; Owonikoko TK, 2014, J CLIN ONCOL S, V32; Penning TD, 2009, J MED CHEM, V52, P514, DOI 10.1021/jm801171j; Puhalla SL, 2012, 2012 SAN ANT BREAST; Ramalingam S, 2014, EUR SOC MED ONCO SEP; Reck M, 2014, ANN ONCOL, V25, P27, DOI 10.1093/annonc/mdu199; Rugo HS, 2013, CANCER RES, V73, DOI 10.1158/0008-5472.SABCS13-S5-02; Zeng-Rong Nie, 1995, Cancer Research, V55, P4760	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	NOV	2015	76	5					1063	1072		10.1007/s00280-015-2876-7		10	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	CU0YR	WOS:000363245800020		
J	Takahashi, H; Sakakura, K; Kawabata-Iwakawa, R; Rokudai, S; Toyoda, M; Nishiyama, M; Chikamatsu, K				Takahashi, Hideyuki; Sakakura, Koichi; Kawabata-Iwakawa, Reika; Rokudai, Susumu; Toyoda, Minoru; Nishiyama, Masahiko; Chikamatsu, Kazuaki			Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma	CANCER IMMUNOLOGY IMMUNOTHERAPY			English	Article						Cancer-associated fibroblasts; Head and neck squamous cell carcinoma; Immunosuppression; Regulatory T cells; T cell apoptosis	T-CELLS; COLORECTAL-CANCER; ACTIVATION; SUPPRESSOR; ANTIBODIES; SURVIVAL; ADHESION; MODULATE; THERAPY; STROMA	Cancer-associated fibroblasts (CAFs) have been shown to play an important role in angiogenesis, invasion, and metastasis. In the present study, we determined whether CAFs within the tumor microenvironment (TME) in head and neck squamous cell carcinoma (HNSCC) contributed to promoting immunosuppression and evasion from immune surveillance. Six pairs of CAFs and normal fibroblasts (NFs) were established from the resected tumor tissues of patients with HNSCC. The effects of CAFs and NFs on the functions of T cells were comparatively analyzed. CAFs expressed the co-regulatory molecules, B7H1 and B7DC, whereas NFs did not. The expression levels of cytokine genes, including those for IL6, CXCL8, TNF, TGFB1, and VEGFA, were higher in CAFs. T cell proliferation was suppressed more by CAFs or their supernatants than by NFs. Moreover, PBMCs co-cultured with the supernatants of CAFs preferentially induced T cell apoptosis and regulatory T cells over those co-cultured with the supernatants of NFs. A microarray analysis revealed that the level of genes related to the leukocyte extravasation and paxillin signaling pathways was higher in CAFs than in NFs. These results demonstrated that CAFs collaborated with tumor cells in the TME to establish an immunosuppressive network that facilitated tumor evasion from immunological destruction.	[Takahashi, Hideyuki; Sakakura, Koichi; Toyoda, Minoru; Chikamatsu, Kazuaki] Gunma Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Maebashi, Gumma 3718511, Japan; [Kawabata-Iwakawa, Reika] Gunma Univ Initiat Adv Res, Div Integrate Oncol Res, Maebashi, Gumma 3718511, Japan; [Rokudai, Susumu; Nishiyama, Masahiko] Gunma Univ, Grad Sch Med, Dept Mol Pharmacol & Oncol, Maebashi, Gumma 3718511, Japan	Chikamatsu, K (reprint author), Gunma Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Maebashi, Gumma 3718511, Japan.	tikamatu@gunma-u.ac.jp			KAKENHI [15K10798, 25861525, 26670736]	This work was supported in part by KAKENHI (Grants-in-Aid for Scientific Research) (15K10798 to Koichi Sakakura, 25861525 to Minoru Toyoda, 26670736 to Kazuaki Chikamatsu). We thank Dr. Theresa L. Whiteside for her critical reading and comments.	Wada J, 2009, ANTICANCER RES, V29, P881; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Balsamo M, 2009, P NATL ACAD SCI USA, V106, P20847, DOI 10.1073/pnas.0906481106; Chen SF, 2013, J PATHOL, V231, P180, DOI 10.1002/path.4226; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Kyi C, 2014, FEBS LETT, V588, P368, DOI 10.1016/j.febslet.2013.10.015; Johansson AC, 2012, MOL CANCER RES, V10, P1158, DOI 10.1158/1541-7786.MCR-12-0030; Tong CCL, 2012, IMMUNOL RES, V54, P266, DOI 10.1007/s12026-012-8306-6; Elkord E, 2010, EXPERT OPIN BIOL TH, V10, P1573, DOI 10.1517/14712598.2010.529126; Knowles LM, 2009, CLIN CANCER RES, V15, P3740, DOI 10.1158/1078-0432.CCR-08-3252; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Jung DW, 2010, INT J CANCER, V127, P332, DOI 10.1002/ijc.25060; Talmadge JE, 2011, SEMIN CANCER BIOL, V21, P131, DOI 10.1016/j.semcancer.2010.12.002; Knosp CA, 2012, IMMUNOLOGY, V135, P101, DOI 10.1111/j.1365-2567.2011.03520.x; Ito M, 2012, CHEST, V142, P151, DOI 10.1378/chest.11-2458; Poschke I, 2011, CANCER IMMUNOL IMMUN, V60, P1161, DOI 10.1007/s00262-011-1012-8; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Mace TA, 2013, CANCER RES, V73, P3007, DOI 10.1158/0008-5472.CAN-12-4601; Rosenthal E, 2004, MOL CARCINOGEN, V40, P116, DOI 10.1002/mc.20024; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Rasanen K, 2010, EXP CELL RES, V316, P2713, DOI 10.1016/j.yexcr.2010.04.032; Hamid O, 2013, EXPERT OPIN BIOL TH, V13, P847, DOI 10.1517/14712598.2013.770836; Whiteside TL, 2010, J ALLERGY CLIN IMMUN, V125, pS272, DOI 10.1016/j.jaci.2009.09.045; Zhang J, 2013, PHARMACOL THERAPEUT, V137, P200, DOI 10.1016/j.pharmthera.2012.10.003; Augsten Martin, 2014, Front Oncol, V4, P62, DOI 10.3389/fonc.2014.00062; Nazareth MR, 2007, J IMMUNOL, V178, P5552; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659	33	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-7004	1432-0851		CANCER IMMUNOL IMMUN	Cancer Immunol. Immunother.	NOV	2015	64	11					1407	1417		10.1007/s00262-015-1742-0		11	Oncology; Immunology	Oncology; Immunology	CU0ZE	WOS:000363247400005		
J	Anayama, H; Fukuda, R; Yamate, J				Anayama, Hisashi; Fukuda, Ryo; Yamate, Jyoji			Adipose progenitor cells reside among the mature adipocytes: morphological research using an organotypic culture system	CELL BIOLOGY INTERNATIONAL			English	Article						adipose tissue; adipocytes; cell differentiation; culture technology; extracellular matrix; stem cells	MESENCHYMAL STEM-CELLS; EXTRACELLULAR-MATRIX; STROMAL CELLS; FAT-CELLS; TISSUE; DIFFERENTIATION; EXPRESSION; ADIPOGENESIS; OBESITY; NICHE	The precise localization and biological characteristics of the adipose progenitor cells are still a focus of debate. In this study, the localization of the adipose progenitor cells was determined using an organotypic culture system of adipose tissue slices. The tissue slices of subcutaneous white adipose tissue from rats were placed on a porous membrane and cultured at the interface between air and the culture medium for up to 5 days with or without adipogenic stimulation. The structure of adipose tissue components was sufficiently preserved during the culture and, following adipogenic stimulation with insulin, dexamethasone, and 3-isobutyl-1-methylxanthine, numerous multilocular adipocytes appeared in the interstitium among the mature adipocytes. Histomorphological 3-D observation using confocal laser microscopy revealed the presence of small mesenchymal cells containing little or no fat residing in the perivascular region and on the mature adipocytes and differentiation from the pre-existing mesenchymal cells to multilocular adipocytes. Immunohistochemistry demonstrated that these cells were initially present within the fibronectin-positive extracellular matrix (ECM). The adipose differentiation of the mesenchymal cells was confirmed by the enhanced expression of C/EBP- suggesting adipose differentiation and the concurrent advent of CD105-expressing mesenchymal cells within the interstitium of the mature adipocytes. Based on the above, the mesenchymal cells embedded in the ECM around the mature adipocytes were confirmed to be responsible for adipogenesis because the transition of the mesenchymal cells to the stem state contributed to the increase in the number of adipocytes in rat adipose tissue.	[Anayama, Hisashi; Fukuda, Ryo] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Drug Safety Res Labs, Fujisawa, Kanagawa 2518555, Japan; [Anayama, Hisashi; Yamate, Jyoji] Osaka Prefecture Univ, Vet Pathol, Izumisano, Osaka 5988531, Japan	Anayama, H (reprint author), Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Drug Safety Res Labs, 26-1 Muraoka Higashi,2 Chome, Fujisawa, Kanagawa 2518555, Japan.	hisashi.anayama@takeda.com					Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589; Zimmerlin L, 2010, CYTOM PART A, V77A, P22, DOI 10.1002/cyto.a.20813; Qayyum AA, 2012, REGEN MED, V7, P421, DOI [10.2217/rme.12.17, 10.2217/RME.12.17]; Gattazzo F, 2014, BBA-GEN SUBJECTS, V1840, P2506, DOI 10.1016/j.bbagen.2014.01.010; De Schauwer C, 2011, THERIOGENOLOGY, V75, P1431, DOI 10.1016/j.theriogenology.2010.11.008; Huang GR, 2012, TRENDS ENDOCRIN MET, V23, P16, DOI 10.1016/j.tem.2011.09.006; Liu J, 2005, CELL METAB, V2, P165, DOI 10.1016/j.cmet.2005.08.006; Han J, 2013, ORGANOGENESIS, V9, P118, DOI 10.4161/org.24708; Tsuji S, 2005, J NEUROSCI RES, V82, P443, DOI 10.1002/jnr.20665; Cawthorn WP, 2012, J LIPID RES, V53, P227, DOI 10.1194/jlr.R021089; HAUSMAN GJ, 1980, J LIPID RES, V21, P657; Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016; Maumus M, 2011, INT J OBESITY, V35, P1141, DOI 10.1038/ijo.2010.269; Baptista LS, 2009, OBES SURG, V19, P1304, DOI 10.1007/s11695-009-9899-2; Lijnen HR, 2008, CARDIOVASC RES, V78, P286, DOI 10.1093/cvr/cvm007; Suga H, 2009, BRIT J DERMATOL, V161, P819, DOI 10.1111/j.1365-2133.2009.09272.x; HAUSMAN GJ, 1981, J ANIM SCI, V52, P1442; Fernyhough ME, 2008, BIOCHEM BIOPH RES CO, V368, P455, DOI 10.1016/j.bbrc.2008.01.113; Lee K, 1998, MOL CELL BIOCHEM, V178, P269, DOI 10.1023/A:1006846910046; Sonoda E, 2008, ENDOCRINOLOGY, V149, P4794, DOI 10.1210/en.2008-0525; Majesky MW, 2012, CELLS TISSUES ORGANS, V195, P73, DOI 10.1159/000331413; Crossno JT, 2006, J CLIN INVEST, V116, P3220, DOI 10.1172/JCI285510; Hausman Dorothy B., 2008, V456, P201, DOI 10.1007/978-1-59745-245-8_15; Nie J, 2009, J BIOL CHEM, V284, P1279, DOI 10.1074/jbc.M808285200; Kim WS, 2014, EXPERT OPIN BIOL TH, V14, P1091, DOI 10.1517/14712598.2014.907785; Shim JH, 2013, MOL CELLS, V36, P556, DOI 10.1007/s10059-013-0260-1; Farmer SR, 2005, INT J OBESITY, V29, pS13, DOI 10.1038/sj.ijo.0802907; Miyazaki T, 2005, DIFFERENTIATION, V73, P69, DOI 10.1111/j.1432-0436.2005.07302004.x; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105; SUGIHARA H, 1987, J LIPID RES, V28, P1038; Zeve D, 2009, CELL STEM CELL, V5, P472, DOI 10.1016/j.stem.2009.10.014; Tran KV, 2012, CELL METAB, V15, P222, DOI 10.1016/j.cmet.2012.01.008; Zhu JG, 2012, CELL REPROGRAM, V14, P99, DOI 10.1089/cell.2011.0074; Mohsen-Kanson T, 2013, BIOCHEM BIOPH RES CO, V430, P871, DOI 10.1016/j.bbrc.2012.12.079; Hung SC, 2004, GENE, V340, P141, DOI 10.1016/.j.gene.2004.06.028; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; Nagayama M, 2007, J LIPID RES, V48, P9, DOI 10.1194/jlr.M600155-JLR200; Mariman ECM, 2010, CELL MOL LIFE SCI, V67, P1277, DOI 10.1007/s00018-010-0263-4; Gupta RK, 2012, CELL METAB, V15, P230, DOI 10.1016/j.cmet.2012.01.010; Nishimura S, 2007, DIABETES, V56, P1517, DOI 10.2337/db06-1749; Armani A, 2010, J CELL BIOCHEM, V110, P564, DOI 10.1002/jcb.22598; Baer PC, 2012, STEM CELLS INT, V2012, DOI DOI 10.1155/2012/812693; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; Mafi P, 2011, OPEN ORTHOP J, V5, P253, DOI DOI 10.2174/1874325001105010253; Ntambi JM, 2000, J NUTR, V130, P3122; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Vidi Pierre-Alexandre, 2013, Methods Mol Biol, V945, P193, DOI 10.1007/978-1-62703-125-7_13; Zych J, 2014, STEM CELLS DEV, V23, P2791, DOI 10.1089/scd.2013.0496	48	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-6995	1095-8355		CELL BIOL INT	Cell Biol. Int.	NOV	2015	39	11					1288	1298		10.1002/cbin.10503		11	Cell Biology	Cell Biology	CU1ZG	WOS:000363320300011		
J	Fujitsuka, M; Majima, T				Fujitsuka, Mamoru; Majima, Tetsuro			Photoinduced Electron Transfer of Porphyrin Isomers: Impact of Molecular Structures on Electron-Transfer Dynamics	CHEMISTRY-AN ASIAN JOURNAL			English	Review						electron transfer; isomers; photochemistry; photolysis; porphyrinoids	DONOR-ACCEPTOR DYAD; PHOTODYNAMIC THERAPY; PHOTOSENSITIZING PROPERTIES; REORGANIZATION ENERGIES; RADIOLYTIC REDUCTION; AXIAL COORDINATION; REDOX PROPERTIES; METAL-COMPLEXES; PORPHYCENE; ZINC	Porphyrins have been investigated for a long time in various fields of chemistry owing to their excellent redox and optical properties. Structural isomers of porphyrins have been synthesized, namely, porphycene, hemiporphycene, and corrphycene. Although the number of studies on these structural isomers is limited, they exhibit interesting properties suitable for various applications such as photovoltaic devices, photocatalysts, and photodynamic therapy. In the present review, we summarized their photoinduced electron-transfer processes, which are key steps of various photofunctions. Their electrochemical and photophysical properties are summarized as basic properties for the electron transfer. Furthermore, differences among these isomers in the electron-transfer processes are clarified, and its origin has been discussed on the basis of their molecular structures.	[Fujitsuka, Mamoru; Majima, Tetsuro] Osaka Univ, Inst Sci & Ind Res SANKEN, Ibaraki, Osaka 5670047, Japan	Fujitsuka, M (reprint author), Osaka Univ, Inst Sci & Ind Res SANKEN, Mihogaoka 8-1, Ibaraki, Osaka 5670047, Japan.	fuji@sanken.osaka-u.ac.jp; majima@sanken.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of the Japanese government [25220806, 25288035]	We appreciate collaborations with Professors Hisashi Shimakoshi, Masaaki Abe, and Yoshio Hisaeda, Kyushu University. This work has been partly supported by a Grant-in-Aid for Scientific Research (projects 25220806, 25288035, and others) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of the Japanese government.	Shimakoshi H, 2008, TETRAHEDRON LETT, V49, P6198, DOI 10.1016/j.tetlet.2008.08.003; Fujitsuka M, 2011, J PHOTOCH PHOTOBIO A, V217, P242, DOI 10.1016/j.jphotochem.2010.10.016; Cuesta L, 2009, J AM CHEM SOC, V131, P13538, DOI 10.1021/ja905284d; Hayashi T, 2001, ORGANOMETALLICS, V20, P3074, DOI 10.1021/om010141p; Fujitsuka M, 2010, J PHYS CHEM A, V114, P4156, DOI 10.1021/jp9119342; [Anonymous], 1986, ANGEW CHEM, V98, P262; GOTTFRIED V, 1995, J PHOTOCH PHOTOBIO B, V30, P115, DOI 10.1016/1011-1344(95)07180-A; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; Maeda D, 2010, INORG CHEM, V49, P2872, DOI 10.1021/ic902444x; Rubio N, 2006, PHOTOCH PHOTOBIO SCI, V5, P376, DOI 10.1039/b517686g; Costa RD, 2013, ADV MATER, V25, P2600, DOI 10.1002/adma.201300231; KLIMKANS A, 1994, CHEM PHYS, V189, P25, DOI 10.1016/0301-0104(94)80004-9; Gisselbrecht JP, 2000, INORG CHEM, V39, P2850, DOI 10.1021/ic9913031; Vogel E, 1997, ANGEW CHEM INT EDIT, V36, P1651, DOI 10.1002/anie.199716511; [Anonymous], 1993, ANGEW CHEM, V105, P1161; GISSELBRECHT JP, 1990, J AM CHEM SOC, V112, P8618, DOI 10.1021/ja00179a076; WESSEL T, 1993, ANGEW CHEM INT EDIT, V32, P1148, DOI 10.1002/anie.199311481; Hayes RT, 2004, J PHYS CHEM A, V108, P2375, DOI 10.1021/jp037176i; GOSMANN M, 1986, ANGEW CHEM INT EDIT, V25, P1100, DOI 10.1002/anie.198611001; Holten D, 2002, ACCOUNTS CHEM RES, V35, P57, DOI 10.1021/ar970264z; MARCUS RA, 1993, ANGEW CHEM INT EDIT, V32, P1111, DOI 10.1002/anie.199311113; [Anonymous], 1994, ANGEW CHEM, V106, P2402; BERMAN A, 1992, J PHYS CHEM-US, V96, P3041, DOI 10.1021/j100186a048; [Anonymous], 1986, ANGEW CHEM, V98, P1107; Arnbjerg J, 2007, J AM CHEM SOC, V129, P5188, DOI 10.1021/ja0688777; VOGEL E, 1986, ANGEW CHEM INT EDIT, V25, P257, DOI 10.1002/anie.198602571; Amini A, 2003, J PHOTOCH PHOTOBIO C, V4, P155, DOI 10.1016/S1389-5567(03)00027-3; Amashukeli X, 2004, J AM CHEM SOC, V126, P15566, DOI 10.1021/ja0351037; Braun J, 1996, J AM CHEM SOC, V118, P7231, DOI 10.1021/ja954146n; Baba T, 2008, CHEM LETT, V37, P264, DOI 10.1246/cl.2008.264; [Anonymous], 1997, ANGEW CHEM, V109, P1725; Gisselbrecht JP, 2001, J ELECTROANAL CHEM, V507, P244, DOI 10.1016/S0022-0728(01)00428-4; BRAUN J, 1994, J AM CHEM SOC, V116, P6593, DOI 10.1021/ja00094a014; Guldi DM, 1996, J PHYS CHEM-US, V100, P4097, DOI 10.1021/jp953009+; Fujitsuka M, 2009, J PHYS CHEM A, V113, P3330, DOI 10.1021/jp810617a; Szeimies RM, 1996, J PHOTOCH PHOTOBIO B, V34, P67, DOI 10.1016/1011-1344(95)07275-6; D'Souza F, 1999, INORG CHEM, V38, P2157, DOI 10.1021/ic981358n; Tsai HH, 2002, CHEM PHYS LETT, V353, P111; Fowler CJ, 2002, CHEM-EUR J, V8, P3485, DOI 10.1002/1521-3765(20020802)8:15<3485::AID-CHEM3485>3.0.CO;2-9; CALLOT HJ, 1995, NEW J CHEM, V19, P155; [Anonymous], 1993, ANGEW CHEM, V105, P1201; Guldi DM, 1996, J PHYS CHEM-US, V100, P13609, DOI 10.1021/jp960942j; Guldi DM, 1998, J PHYS CHEM A, V102, P960, DOI 10.1021/jp973341g; Kessel D, 2000, CANCER RES, V60, P6985; SESSLER JL, 1994, ANGEW CHEM INT EDIT, V33, P2308, DOI 10.1002/anie.199423081; ARAMENDIA PF, 1986, PHOTOCHEM PHOTOBIOL, V44, P555, DOI 10.1111/j.1751-1097.1986.tb04708.x; WASIELEWSKI MR, 1992, CHEM REV, V92, P435, DOI 10.1021/cr00011a005; Fujitsuka M, 2013, PHYS CHEM CHEM PHYS, V15, P5677, DOI 10.1039/c3cp43795g; Lo W.-C., 1997, J CHEM SOC CHEM COMM, P1205; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; Shimakoshi H, 2008, CHEM COMMUN, P2882, DOI 10.1039/b802730g; Waluk J, 2006, ACCOUNTS CHEM RES, V39, P945, DOI 10.1021/ar0680365	52	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2015	10	11					2320	2326		10.1002/asia.201500649		7	Chemistry, Multidisciplinary	Chemistry	CU4CD	WOS:000363472800001		
J	Kojima, M; Hayashi, H; Aotake, T; Ikeda, S; Suzuki, M; Aratani, N; Kuzuhara, D; Yamada, H				Kojima, Mitsuru; Hayashi, Hironobu; Aotake, Tatsuya; Ikeda, Shinya; Suzuki, Mitsuharu; Aratani, Naoki; Kuzuhara, Daiki; Yamada, Hiroko			Indolizino[5,6-b]quinoxaline Derivatives: Intramolecular Charge Transfer Characters and NIR Fluorescence	CHEMISTRY-AN ASIAN JOURNAL			English	Article						intramolecular charge transfer; pyrrole; quinoxaline; single-crystal structure; solvent effects	ORTHO-LINKED QUINOXALINE/DIPHENYLFLUORENE; QUINOXALINES; BIPOLAR	Indolizino[5,6-b]quinoxaline derivatives (1a and 1b) with a push-pull structure were prepared to show intramolecular charge-transfer properties. Compounds 1a and 1b are strongly fluorescent in aprotic solvents while symmetrical derivatives (2a and 2b) were non-fluorescent. The -expanded - linked dimer (10) of indolizino[5,6-b]quinoxaline 1b was serendipitously obtained to show NIR absorption over 800nm and the fluorescence edge reached to 1400nm.	[Kojima, Mitsuru; Hayashi, Hironobu; Aotake, Tatsuya; Ikeda, Shinya; Suzuki, Mitsuharu; Aratani, Naoki; Kuzuhara, Daiki; Yamada, Hiroko] Nara Inst Sci & Technol, Grad Sch Mat Sci, Ikoma, Nara 6300192, Japan; [Yamada, Hiroko] Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	Yamada, H (reprint author), Nara Inst Sci & Technol, Grad Sch Mat Sci, 8916-5 Takayama Cho, Ikoma, Nara 6300192, Japan.	hyamada@ms.naist.jp			KAKENHI from the Japan Society for the Promotion of Science (JSPS) [25288092, 26620167, 26105004, 15H00876]; program for promoting the enhancement of research universities in NAIST - Ministry of Education, Culture, Sports, Science and Technology (MEXT)	This work was partly supported by Grants-in-Aid for Scientific Research (KAKENHI) Nos. 25288092, 26620167, 26105004 and 15H00876 ('AnApple') from the Japan Society for the Promotion of Science (JSPS), and the program for promoting the enhancement of research universities in NAIST supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT). We thank Ms. A. Kuramoto, Ms. Y. Nishikawa, Mr. Y. Okajima and Mr. S. Katao at NAIST for help in absorption and emission measurement, mass spectrometry, fluorescence lifetime measurement, and single-crystal X-ray diffraction analysis, respectively.	Mamane V, 2004, CHEM-EUR J, V10, P4556, DOI 10.1002/chem.200400220; Burrows HD, 2006, J FLUORESC, V16, P227, DOI 10.1007/s10895-005-0048-6; Grabowski ZR, 2003, CHEM REV, V103, P3899, DOI 10.1021/cr940745l; Kudo K, 2011, CHEM COMMUN, V47, P3867, DOI 10.1039/c1cc10183h; Gers CF, 2014, J ORG CHEM, V79, P3296, DOI 10.1021/jo4025978; Kulkarni AP, 2005, MACROMOLECULES, V38, P1553, DOI 10.1021/ma048118d; Arcadi A, 2004, TETRAHEDRON LETT, V45, P2431, DOI 10.1016/j.tetlet.2004.01.058; Zhang XC, 1998, TETRAHEDRON, V54, P12465, DOI 10.1016/S0040-4020(98)00728-5; Chen CT, 2006, J AM CHEM SOC, V128, P10992, DOI 10.1021/ja062660v; BHOWMIK BB, 1984, SPECTROCHIM ACTA A, V40, P601, DOI 10.1016/0584-8539(84)80111-7; Son HJ, 2009, J ORG CHEM, V74, P3175, DOI 10.1021/jo9002147; Chen WQ, 2014, RSC ADV, V4, P25291, DOI 10.1039/c4ra02911a; Thomas KRJ, 2002, CHEM MATER, V14, P3852, DOI 10.1021/cm0202512; Chen WQ, 2014, TETRAHEDRON, V70, P6217, DOI 10.1016/j.tet.2014.01.026; Wei Y, 2009, J AM CHEM SOC, V131, P6698, DOI 10.1021/ja8090005; Miao Q, 2014, ADV MATER, V26, P5541, DOI 10.1002/adma.201305497; Campiani G, 1997, J MED CHEM, V40, P3670, DOI 10.1021/jm970376w; Frisch MJ, 2009, GAUSSIAN 09 REVISION; Ito S, 1998, CHEM COMMUN, P1661, DOI 10.1039/a803656j; Kobayashi K, 1998, CHEM LETT, P551, DOI 10.1246/cl.1998.551; KREHER R, 1978, TETRAHEDRON LETT, P4671	21	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2015	10	11					2337	2341		10.1002/asia.201500597		5	Chemistry, Multidisciplinary	Chemistry	CU4CD	WOS:000363472800004		
J	Ikeuchi, T; Agrawal, S; Ezoe, M; Mori, S; Kimura, M				Ikeuchi, Takuro; Agrawal, Saurabh; Ezoe, Masayuki; Mori, Shogo; Kimura, Mutsumi			Enhanced Charge Separation Efficiency in Pyridine-Anchored Phthalocyanine-Sensitized Solar Cells by Linker Elongation	CHEMISTRY-AN ASIAN JOURNAL			English	Article						dyes; pigments; energy conversion; phthalocyanines; solar cells; TiO2	FREE ORGANIC-DYES; FLUORESCENT DYES; TIO2; PORPHYRINS; RING	A series of zinc phthalocyanine sensitizers (PcS22-24) having a pyridine anchoring group are designed and synthesized to investigate the structural dependence on performance in dye-sensitized solar cells. The pyridine-anchor zinc phthalocyanine sensitizer PcS23 shows 79% incident-photon to current-conversion efficiency (IPCE) and 6.1% energy conversion efficiency, which are comparable with similar phthalocyanine dyes having a carboxylic acid anchoring group. Based on DFT calculations, the high IPCE is attributed with the mixture of an excited-state molecular orbital of the sensitizer and the orbitals of TiO2. Between pyridine and carboxylic acid anchor dyes, opposite trends are observed in the linker-length dependence of the IPCE. The red-absorbing PcS23 is applied for co-sensitization with a carboxyl-anchor organic dye D131 that has a complementary spectral response. The site-selective adsorption of PcS23 and D131 on the TiO2 surface results in a panchromatic photocurrent response for the whole visible-light region of sun light.	[Ikeuchi, Takuro; Agrawal, Saurabh; Mori, Shogo; Kimura, Mutsumi] Shinshu Univ, Fac Text Sci & Technol, Div Chem & Mat, Ueda, Nagano 3868567, Japan; [Ezoe, Masayuki] Yamamoto Chem Inc, Yao 5810034, Japan	Mori, S (reprint author), Shinshu Univ, Fac Text Sci & Technol, Div Chem & Mat, Ueda, Nagano 3868567, Japan.	shogmori@shinshu-u.ac.jp; mkimura@shinshu-u.ac.jp	Mori, Shogo/B-3817-2013		Japan Society for the Promotion of Science (JSPS) of Japan [15H02172, 22350086]	This work has been partially supported by Grants-in-Aid for Scientific Research (A) (No. 15H02172) and (B) (No. 22350086) from the Japan Society for the Promotion of Science (JSPS) of Japan.	Ogura RY, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3086891; Ooyama Y, 2014, J MATER CHEM A, V2, P3293, DOI 10.1039/c3ta15067d; Harima Y, 2013, J PHYS CHEM C, V117, P16364, DOI 10.1021/jp405835y; Mack J, 2011, CHEM REV, V111, P281, DOI 10.1021/cr9003049; Daphnomili D, 2012, RSC ADV, V2, P12899, DOI 10.1039/c2ra22129b; Nazeeruddin MK, 2001, J AM CHEM SOC, V123, P1613, DOI 10.1021/ja003299u; [Anonymous], 2011, ANGEW CHEM; Duncan WR, 2007, ANNU REV PHYS CHEM, V58, P143, DOI 10.1146/annurev.physchem.58.052306.144054; Mao JY, 2012, ANGEW CHEM INT EDIT, V51, P9873, DOI 10.1002/anie.201204948; Mishra A, 2009, ANGEW CHEM INT EDIT, V48, P2474, DOI 10.1002/anie.200804709; Yella A, 2011, SCIENCE, V334, P629, DOI 10.1126/science.1209688; Horiuchi T, 2004, J AM CHEM SOC, V126, P12218, DOI 10.1021/ja0488277; Ooyama Y, 2013, CHEM COMMUN, V49, P2548, DOI 10.1039/c3cc40498f; Ooyama Y, 2011, ANGEW CHEM INT EDIT, V50, P7429, DOI 10.1002/anie.201102552; Kimura M, 2010, CHEM LETT, V39, P946, DOI 10.1246/cl.2010.946; Ladomenou K, 2014, RSC ADV, V4, P21379, DOI 10.1039/c4ra00985a; Agrawal S, 2011, J MATER CHEM, V21, P11101, DOI 10.1039/c1jm10953g; Kimura M, 2012, ANGEW CHEM INT EDIT, V51, P4371, DOI 10.1002/anie.201108610; Ragoussi ME, 2013, EUR J ORG CHEM, V2013, P6475, DOI 10.1002/ejoc.201301009; Persson P, 2005, J PHYS CHEM B, V109, P11918, DOI 10.1021/jp050513y; [Anonymous], 2012, ANGEW CHEM; Shibayama N, 2014, CHEM COMMUN, V50, P6398, DOI 10.1039/c3cc49461f; Ooyama Y, 2011, CHEM-EUR J, V17, P14837, DOI 10.1002/chem.201101923; He HS, 2012, CHEM COMMUN, V48, P5910, DOI 10.1039/c2cc31440a; Stangel C, 2014, INORG CHEM, V53, P11871, DOI 10.1021/ic502283d; Chiba Y, 2006, JPN J APPL PHYS 2, V45, pL638, DOI 10.1143/JJAP.45.L638; Kameyama K, 2005, ANGEW CHEM INT EDIT, V44, P4763, DOI 10.1002/anie.200501199; Kimura M, 2013, CHEM-EUR J, V19, P7496, DOI 10.1002/chem.201300716; Horiuchi T, 2003, CHEM COMMUN, P3036, DOI 10.1039/b307819a; Kameyama K., 2005, ANGEW CHEM, V117, P4841, DOI 10.1002/ange.200501199; Kimura M., 2012, ANGEW CHEM, V124, P4447; Ikeuchi T, 2014, CHEM COMMUN, V50, P1941, DOI 10.1039/c3cc47714b; Lu J., 2013, CHEM-ASIAN J, V8, P946; Mishra A, 2009, ANGEW CHEM, V121, P2510, DOI DOI 10.1002/ANGE.200804709; OREGAN B, 1991, NATURE, V353, P737, DOI 10.1038/353737a0; Urabani M., 2014, CHEM REV, V114, P12330	36	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2015	10	11					2347	2351		10.1002/asia.201500756		5	Chemistry, Multidisciplinary	Chemistry	CU4CD	WOS:000363472800006		
J	Nishimura, T; Toyoda, K; Ito, T; Oaki, Y; Namatame, Y; Kato, T				Nishimura, Tatsuya; Toyoda, Ken; Ito, Takahiro; Oaki, Yuya; Namatame, Yukiko; Kato, Takashi			Liquid-Crystalline Biomacromolecular Templates for the Formation of Oriented Thin-Film Hybrids Composed of Ordered Chitin and Alkaline-Earth Carbonate	CHEMISTRY-AN ASIAN JOURNAL			English	Article						alkaline-earth carbonate; biomineralization; chitin; hybrids; liquid crystals	CALCIUM-CARBONATE; ORGANIC POLYMER; SELF-ORGANIZATION; BARIUM CARBONATE; CACO3 CRYSTALS; BRUSH MATRICES; STRONTIUM; VATERITE; GROWTH; BIREFRINGENCE	Macroscopically ordered inorganic thin films have been formed on unidirectionally oriented, liquid-crystalline chitin matrices. In the presence of poly(acrylic acid) (PAA), unidirectionally oriented chitin films act as templates for the formation of oriented thin-film crystals of alkaline-earth carbonates such as SrCO3 and BaCO3. The morphology and orientation of crystals are dependent on the metal ion concentration. For SrCO3 crystallization, unidirectional thin films and hexagonal-shaped thin films have been deposited from 200 and 25mm concentration strontium solutions, respectively.	[Nishimura, Tatsuya; Toyoda, Ken; Ito, Takahiro; Oaki, Yuya; Kato, Takashi] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; [Namatame, Yukiko] Rigaku Corp, Applicat Labs, Akishima, Tokyo 1968666, Japan	Nishimura, T (reprint author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan.	tatsuya@chembio.t.u-tokyo.ac.jp; kato@chiral.t.u-tokyo.ac.jp			KAKENHI [22107003, 15K17864, 15H02179]	This study was supported by KAKENHI 22107003, 15K17864, and 15H02179. The authors thank the Nanotechnology Platform of The University of Tokyo for TEM observations.	Kato T, 2006, ANGEW CHEM INT EDIT, V45, P38, DOI 10.1002/anie.200501384; Kajiyama S, 2014, SMALL, V10, P1634, DOI 10.1002/smll.201302745; Terada T, 2003, J CRYST GROWTH, V253, P435, DOI 10.1016/S0022-0248(03)01008-X; Wang TX, 2006, ANGEW CHEM INT EDIT, V45, P4451, DOI 10.1002/anie.200601038; Tagaya A, 2012, POLYM J, V44, P306, DOI 10.1038/pj.2011.141; Yu SH, 2005, NAT MATER, V4, P51, DOI 10.1038/nmat1263; Zhu FJ, 2013, CHEM-ASIAN J, V8, P3002, DOI 10.1002/asia.201300745; PRIETO M, 1989, J CRYST GROWTH, V98, P447, DOI 10.1016/0022-0248(89)90161-9; Zhu FJ, 2014, CRYSTENGCOMM, V16, P1496, DOI 10.1039/c3ce41649f; Suzuki M, 2009, SCIENCE, V325, P1388, DOI 10.1126/science.1173793; Yao HB, 2014, ADV MATER, V26, P163, DOI 10.1002/adma.201303470; Oaki Y, 2008, ADV MATER, V20, P3633, DOI 10.1002/adma.200800773; Nudelman F, 2010, NAT MATER, V9, P1004, DOI [10.1038/nmat2875, 10.1038/NMAT2875]; Xu SJ, 2014, CRYSTENGCOMM, V16, P1311, DOI 10.1039/c3ce41888j; Homeijer SJ, 2010, CRYST GROWTH DES, V10, P1040, DOI 10.1021/cg800918g; WEINER S, 1983, INT J BIOL MACROMOL, V5, P325, DOI 10.1016/0141-8130(83)90055-7; Krejci MR, 2011, CHEMSUSCHEM, V4, P470, DOI 10.1002/cssc.201000448; Tagaya A, 2003, SCIENCE, V301, P812, DOI 10.1126/science.1086966; Oaki Y, 2012, POLYM J, V44, P612, DOI 10.1038/pj.2012.29; Tanaka Y, 2012, POLYM J, V44, P586, DOI 10.1038/pj.2012.28; Falini G, 1998, CHEM-EUR J, V4, P1048, DOI 10.1002/(SICI)1521-3765(19980615)4:6<1048::AID-CHEM1048>3.0.CO;2-U; Wucher B, 2007, CHEM MATER, V19, P1111, DOI 10.1021/cm0620640; Han YL, 2014, POLYM J, V46, P499, DOI 10.1038/pj.2014.36; Han YL, 2014, CRYSTENGCOMM, V16, P3540, DOI 10.1039/c3ce42646g; Grunenfelder LK, 2014, SMALL, V10, P3207, DOI 10.1002/smll.201400559; Wu XH, 2013, ADV HEALTHC MATER, V2, P326, DOI 10.1002/adhm.201200205; Xu AW, 2007, J MATER CHEM, V17, P415, DOI 10.1039/b611918m; Yamamoto Y, 2010, POLYM J, V42, P583, DOI 10.1038/pj.2010.32; Garcia-Ruiz JM, 2009, SCIENCE, V323, P362, DOI 10.1126/science.1165349; Nishimura T, 2008, ANGEW CHEM INT EDIT, V47, P2800, DOI 10.1002/anie.200705062; Kubo N, 2013, CHEM LETT, V42, P174, DOI 10.1246/cl.2013.174; HEUER AH, 1992, SCIENCE, V255, P1098, DOI 10.1126/science.1546311; Guo XH, 2006, ANGEW CHEM INT EDIT, V45, P3977, DOI 10.1002/anie.200600029; Zhao Y, 2015, ANGEW CHEM INT EDIT, V54, P919, DOI 10.1002/anie.201408510; Kumagai H, 2012, FARADAY DISCUSS, V159, P483, DOI 10.1039/c2fd20057k; Al-Sawalmih A, 2008, ADV FUNCT MATER, V18, P3307, DOI 10.1002/adfm.200800520; CALVERT P, 1988, J MATER SCI, V23, P3801, DOI 10.1007/BF01106796; Wang SS, 2013, ANGEW CHEM INT EDIT, V52, P6317, DOI 10.1002/anie.201301184; Sakamoto T, 2011, ANGEW CHEM INT EDIT, V50, P5856, DOI 10.1002/anie.201008191; Sakamoto T, 2009, CRYST GROWTH DES, V9, P622, DOI 10.1021/cg8009628; Arakaki A, 2015, ORG BIOMOL CHEM, V13, P974, DOI 10.1039/c4ob01796j; Bauerlein E., 2007, HDB BIOMINERALIZATIO; Bauerlein E., 2000, BIOMINERALIZATION; Goodby J. W., 2014, HDB LIQUID CRYSTALS, V7; Guo X.-H., 2006, ANGEW CHEM, V118, P4081, DOI 10.1002/ange.200600029; Kato T., 2006, ANGEW CHEM, V118, P44, DOI DOI 10.1002/ANGE.200501384; Mann S., 2001, BIOMINERALIZATION PR; Nishimura T., 2008, ANGEW CHEM, V120, P2842, DOI 10.1002/ange.200705062; Nishimura T, 2015, POLYM J, V47, P235, DOI 10.1038/pj.2014.107; Nishio T, 2015, J APPL POLYM SCI, V132, DOI 10.1002/app.41455; Okumura K, 2015, MRS BULL, V40, P333, DOI 10.1557/mrs.2015.66; Saito T, 2014, MATER HORIZONS, V1, P321, DOI 10.1039/c3mh00134b; Sakamoto T., 2011, ANGEW CHEM, V123, P5978; Sakamoto T., CRYSTENGCOM IN PRESS, DOI [10.1039/C5CE00451A, DOI 10.1039/C5CE00451A]; Sugawara-Narutaki A, 2013, POLYM J, V45, P269, DOI 10.1038/pj.2012.171; Wang S.-S., 2013, ANGEW CHEM, V125, P6439; Wang T., 2006, ANGEW CHEM, V118, P4561, DOI 10.1002/ange.200601038; Zhao Y., 2015, ANGEW CHEM, V127, P933	58	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2015	10	11					2356	2360		10.1002/asia.201500462		5	Chemistry, Multidisciplinary	Chemistry	CU4CD	WOS:000363472800008		
J	Karanjit, S; Ehara, M; Sakurai, H				Karanjit, Sangita; Ehara, Masahiro; Sakurai, Hidehiro			Mechanism of the Aerobic Homocoupling of Phenylboronic Acid on Au-20<bold>(-)</bold>: A DFT Study	CHEMISTRY-AN ASIAN JOURNAL			English	Article						aerobic homocoupling; biphenyl; catalysis; density functional calculations; gold	SUPPORTED AU NANOPARTICLES; ARYL BORONIC ACIDS; ARYLBORONIC ACIDS; COUPLING REACTIONS; BASE-COMPLEXES; SUZUKI-MIYAURA; EFFICIENT; WATER; CATALYSTS; NANOCLUSTERS	The mechanism of the gold nanocluster-catalyzed aerobic homocoupling of arylboronic acids has been elucidated by means of DFT calculations with Au-20(-) as a model cluster for the Au:[poly(N-vinylpyrrolidin-2-one)] catalyst. We found that oxygen affects the adsorption of phenylboronic acid and, by lowering the energy barrier, a water molecule enhances dissociation of the C-B bond, which is probably the rate-determining step. The key role of oxygen is in activating the surface of the gold cluster by generating Lewis acidic sites for adsorption and activation of the phenylboronic acid, leading to the formation of biphenyl through a superoxo-like species. Moreover, the oxygen adsorbed on the Au nanocluster can act as an oxidant for phenylboronic acid, giving phenol as a byproduct. As shown by NBO analysis, the basic aqueous reaction medium facilitates the reductive elimination process by weakening the Au-C bond, thereby enhancing the formation of biphenyl. The coupling of phenyl and reductive elimination of biphenyl occur at the top or facet site with low-energy-barrier through spillover of phenyl group on Au NC. The present findings are useful for the interpretation or design of other coupling reactions with Au NC.	[Karanjit, Sangita; Sakurai, Hidehiro] Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan; [Ehara, Masahiro] Inst Mol Sci, Res Ctr Computat Sci, Okazaki, Aichi 4448585, Japan	Ehara, M (reprint author), Inst Mol Sci, Res Ctr Computat Sci, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.	ehara@ims.ac.jp; hsakurai@chem.eng.osaka-u.ac.jp			ACT-C, JST	This work was supported by ACT-C, JST.	Amatore C, 2008, EUR J ORG CHEM, P4567, DOI 10.1002/ejoc.200800631; Dhital RN, 2014, ASIAN J ORG CHEM, V3, P668, DOI 10.1002/ajoc.201300283; Okumura M, 2010, INT J QUANTUM CHEM, V110, P2903, DOI 10.1002/qua.22838; Parida KM, 2011, J MOL CATAL A-CHEM, V342-43, P11, DOI 10.1016/j.molcata.2011.04.002; Boekfa B, 2014, J PHYS CHEM C, V118, P22188, DOI 10.1021/jp5074472; Jin Z, 2009, ADV SYNTH CATAL, V351, P1575, DOI 10.1002/adsc.200900098; [Anonymous], 2005, ANGEW CHEM, DOI 10.1002/ange.200462560; Primo A, 2010, CHEM COMMUN, V46, P5593, DOI 10.1039/c0cc01137a; Mantina M, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3190492; Reddy KR, 2007, CATAL LETT, V114, P36, DOI 10.1007/s10562-007-9032-x; Burns MJ, 2007, ORG LETT, V9, P5397, DOI 10.1021/ol702291r; Wang L, 2013, J CATAL, V298, P186, DOI 10.1016/j.jcat.2012.11.020; Wang L, 2012, CHEM COMMUN, V48, P5476, DOI 10.1039/c2cc31115a; Okumura M, 2008, CHEM PHYS LETT, V459, P133, DOI 10.1016/j.cplett.2008.04.120; Adamo C, 2006, J AM CHEM SOC, V128, P6829, DOI 10.1021/ja0569959; Lei AW, 2002, TETRAHEDRON LETT, V43, P2525, DOI 10.1016/S0040-4039(02)00328-3; Bobuatong K, 2012, PHYS CHEM CHEM PHYS, V14, P3103, DOI 10.1039/c2cp23446g; Karanjit S, 2013, INT J QUANTUM CHEM, V113, P428, DOI 10.1002/qua.24056; Bongiorno A, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.106102; Mitsudo K, 2009, TETRAHEDRON, V65, P8384, DOI 10.1016/j.tet.2009.08.004; Horton DA, 2003, CHEM REV, V103, P893, DOI 10.1021/cr020033s; Sk MP, 2013, CHEM COMMUN, V49, P8235, DOI 10.1039/c3cc43726d; Roldan A, 2009, CHEMPHYSCHEM, V10, P348, DOI 10.1002/cphc.200800702; Yin LX, 2007, CHEM REV, V107, P133, DOI 10.1021/cr0505674; Sophiphun O, 2012, AUST J CHEM, V65, P1238, DOI 10.1071/CH12175; MorenoManas M, 1996, J ORG CHEM, V61, P2346, DOI 10.1021/jo9514329; Boronat M, 2011, J CATAL, V284, P138, DOI 10.1016/j.jcat.2011.09.010; Rahme K, 2013, RSC ADV, V3, P21016, DOI 10.1039/c3ra41873a; Yoshida H, 2003, TETRAHEDRON LETT, V44, P1541, DOI 10.1016/S0040-4039(03)00023-6; Sakurai H, 2007, J ORGANOMET CHEM, V692, P368, DOI 10.1016/j.jorganchem.2006.04.054; Carrettin S, 2005, ANGEW CHEM INT EDIT, V44, P2242, DOI 10.1002/anie.200462560; Nakatsuji H, 1997, SURF SCI, V387, P328, DOI 10.1016/S0039-6028(97)00368-3; Schon JH, 2001, NATURE, V413, P713, DOI 10.1038/35099520; Prastaro A, 2010, TETRAHEDRON LETT, V51, P2550, DOI 10.1016/j.tetlet.2010.03.015; Dhital RN, 2012, CHEM-ASIAN J, V7, P55, DOI 10.1002/asia.201100478; Tsunoyama H, 2004, LANGMUIR, V20, P11293, DOI 10.1021/la0478189; Cheng GJ, 2011, EUR J ORG CHEM, P2519, DOI 10.1002/ejoc.201001729; Cicco SR, 2010, EUR J ORG CHEM, P2275, DOI 10.1002/ejoc.201000021; Frisch M. J., 2012, GAUSSIAN 09 REVISION; Gonzalez-Arellano C, 2005, CHEM COMMUN, P1990, DOI 10.1039/b418897g; Kaboudin B, 2011, SYNTHESIS-STUTTGART, P91, DOI 10.1055/s-0030-1258321; Kaboudin B, 2011, EUR J ORG CHEM, P6656, DOI 10.1002/ejoc.201100994; Kar A, 2008, CHEM COMMUN, P386, DOI 10.1039/b714928j; Kirai N, 2009, EUR J ORG CHEM, P1864, DOI 10.1002/ejoc.200900173; Koza DJ, 2002, SYNTHESIS-STUTTGART, P2183, DOI 10.1055/s-2002-34855; Vogler T, 2008, ADV SYNTH CATAL, V350, P1963, DOI 10.1002/adsc.200800300	46	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2015	10	11					2397	2403		10.1002/asia.201500535		7	Chemistry, Multidisciplinary	Chemistry	CU4CD	WOS:000363472800013		
J	Hitosugi, S; Ohkubo, K; Kawashima, Y; Matsuno, T; Kamata, S; Nakamura, K; Kono, H; Sato, S; Fukuzumi, S; Isobe, H				Hitosugi, Shunpei; Ohkubo, Kei; Kawashima, Yuki; Matsuno, Taisuke; Kamata, Sho; Nakamura, Kosuke; Kono, Hirohiko; Sato, Sota; Fukuzumi, Shunichi; Isobe, Hiroyuki			Modulation of Energy Conversion Processes in Carbonaceous Molecular Bearings	CHEMISTRY-AN ASIAN JOURNAL			English	Article						electron transfer; fullerenes; molecular bearings; nanotubes; peapods	PHOTOINDUCED ELECTRON-TRANSFER; BOTTOM-UP SYNTHESIS; CHARGE SEPARATION; NANOTUBES; LI+AT-C-60; STATE; COMPLEXES; MOTION; C-70; CYCLOPARAPHENYLENES	The energetics and photodynamics of carbonaceous molecular bearings with discrete molecular structures were investigated. A series of supramolecular bearings comprising belt-persistent tubular cycloarylene and fullerene molecules accepted photonic stimuli to afford charge-separated species via a photoinduced electron transfer process. The energy conversion processes associated with the photoexcitation, however, differed depending on the molecular structure. A -lengthened tubular molecule allowed for the emergence of an intermediary triplet excited state at the bearing, which should lead to an energy conversion to thermal energy. On the other hand, low-lying charge-separated species induced by an endohedral lithium ion in fullerene enabled back electron transfer processes to occur without involving triplet excited species. The structure-photodynamics relationship was analyzed in terms of the Marcus theory to reveal a large electronic coupling in this dynamic supramolecular system.	[Hitosugi, Shunpei; Kamata, Sho; Nakamura, Kosuke; Kono, Hirohiko; Sato, Sota; Isobe, Hiroyuki] Tohoku Univ, Dept Chem, Aoba Ku, Sendai, Miyagi 9808578, Japan; [Ohkubo, Kei; Kawashima, Yuki; Fukuzumi, Shunichi] Osaka Univ, Grad Sch Engn, Dept Mat & Life Sci, ALCA, Suita, Osaka 5650871, Japan; [Ohkubo, Kei; Kawashima, Yuki; Fukuzumi, Shunichi] JST, SENTAN, Suita, Osaka 5650871, Japan; [Matsuno, Taisuke; Sato, Sota; Isobe, Hiroyuki] Tohoku Univ, Adv Inst Mat Res, Sendai, Miyagi 9808577, Japan; [Matsuno, Taisuke; Sato, Sota; Isobe, Hiroyuki] Tohoku Univ, JST, ERATO, Isobe Degenerate Integrat Project, Sendai, Miyagi 9808577, Japan; [Fukuzumi, Shunichi] Meijo Univ, Fac Sci & Technol, ALCA, Nagoya, Aichi 4688502, Japan; [Ohkubo, Kei; Fukuzumi, Shunichi] Ewha Womans Univ, Dept Chem & Nano Sci, Seoul 120750, South Korea	Fukuzumi, S (reprint author), Osaka Univ, Grad Sch Engn, Dept Mat & Life Sci, ALCA, 2-1 Yamada Oka, Suita, Osaka 5650871, Japan.	fukuzumi@chem.eng.osaka-u.ac.jp; isobe@m.tohoku.ac.jp	Ohkubo, Kei/E-5127-2012; Hitosugi, Shunpei/C-5854-2013; Isobe, Hiroyuki/C-2069-2008	Ohkubo, Kei/0000-0001-8328-9249; Isobe, Hiroyuki/0000-0001-8907-0694	KAKENHI [24241036, 25107708, 25102007, 26620154, 26288037, 15K05410]; JSPS	This study was partly supported by KAKENHI (24241036, 25107708, 25102007, 26620154, 26288037, 15K05410) and JSPS fellowship (Y.K. and S.K.). We thank Mr. R. Iizuka, Dr. M. Oinuma and Dr. S. Takahashi (Tohoku Univ.) for synthetic contributions and Central Glass Co. for the gift of hexafluoroisopropanol for the synthesis.	Ueno H, 2015, ANGEW CHEM INT EDIT, V54, P3707, DOI 10.1002/anie.201500544; Iwamoto T, 2013, CHEM-EUR J, V19, P14061, DOI 10.1002/chem.201302694; Sessler JL, 2008, J AM CHEM SOC, V130, P15256, DOI 10.1021/ja806813x; Matsuno T, 2014, PURE APPL CHEM, V86, P489, DOI 10.1515/pac-2014-5006; Sato S, 2014, P NATL ACAD SCI USA, V111, P8374, DOI 10.1073/pnas.1406518111; MARCUS RA, 1964, ANNU REV PHYS CHEM, V15, P155, DOI 10.1146/annurev.pc.15.100164.001103; Matsuno T, 2013, CHEM SCI, V4, P3179, DOI 10.1039/c3sc50645b; Davis CM, 2014, J PHYS CHEM C, V118, P13503, DOI 10.1021/jp504087b; Park J, 2011, J AM CHEM SOC, V133, P17156, DOI 10.1021/ja2079477; Canevet D, 2011, ANGEW CHEM INT EDIT, V50, P9248, DOI 10.1002/anie.201101297; Isobe H, 2015, CHEM SCI, V6, P2746, DOI 10.1039/c5sc00335k; Matsuno T, 2015, CHEM SCI, V6, P909, DOI 10.1039/c4sc02812k; Krive IV, 2006, LOW TEMP PHYS+, V32, P887, DOI 10.1063/1.2364474; Monthioux M, 2002, CARBON, V40, P1809, DOI 10.1016/S0008-6223(02)00102-1; Iwamoto T, 2014, CHEM-EUR J, V20, P14403, DOI 10.1002/chem.201403879; Kawashima Y, 2012, J PHYS CHEM A, V116, P8942, DOI 10.1021/jp3059036; Alvarez MP, 2014, FARADAY DISCUSS, V173, P157, DOI 10.1039/c4fd00103f; Cumings J, 2000, SCIENCE, V289, P602, DOI 10.1126/science.289.5479.602; Hitosugi S, 2014, ORG LETT, V16, P3352, DOI 10.1021/ol501381x; Koshino M, 2007, SCIENCE, V316, P853, DOI 10.1126/science.1138690; Xia JL, 2012, CHEM SCI, V3, P3018, DOI 10.1039/c2sc20719b; Bill NL, 2014, CHEM SCI, V5, P3888, DOI 10.1039/c4sc00803k; MARCUS RA, 1993, ANGEW CHEM INT EDIT, V32, P1111, DOI 10.1002/anie.199311113; Rice JH, 2002, CHEM PHYS, V279, P23, DOI 10.1016/S0301-0104(02)00442-1; Iikura H, 2001, J CHEM PHYS, V115, P3540, DOI 10.1063/1.1383587; MCLEAN AD, 1980, J CHEM PHYS, V72, P5639, DOI 10.1063/1.438980; Kamimura T, 2013, CHEM SCI, V4, P1451, DOI 10.1039/c3sc22065f; Hitosugi S, 2013, ORG LETT, V15, P3199, DOI 10.1021/ol400982r; Koshino M, 2008, NAT NANOTECHNOL, V3, P595, DOI 10.1038/nnano.2008.263; Honda T, 2010, J AM CHEM SOC, V132, P10155, DOI 10.1021/ja103889f; Hitosugi S, 2012, J AM CHEM SOC, V134, P12442, DOI 10.1021/ja305723j; Nakanishi Y, 2014, ANGEW CHEM INT EDIT, V53, P3102, DOI 10.1002/anie.201311268; Kottas GS, 2005, CHEM REV, V105, P1281, DOI 10.1021/cr0300993; Yamada M, 2014, J AM CHEM SOC, V136, P13240, DOI 10.1021/ja505391x; Isobe H, 2013, CHEM SCI, V4, P1293, DOI 10.1039/c3sc22181d; Kay ER, 2007, ANGEW CHEM INT EDIT, V46, P72, DOI 10.1002/anie.200504313; Lee J, 2002, NATURE, V415, P1005, DOI 10.1038/4151005a; Lewis SE, 2015, CHEM SOC REV, V44, P2221, DOI 10.1039/c4cs00366g; Tanaka M, 2006, J AM CHEM SOC, V128, P14625, DOI 10.1021/ja064678b; Fukuzumi S, 2011, J AM CHEM SOC, V133, P15938, DOI 10.1021/ja207588c; Kawashima Y, 2013, J PHYS CHEM C, V117, P21166, DOI 10.1021/jp407976b; Ohkubo K, 2012, CHEM COMMUN, V48, P4314, DOI 10.1039/c2cc31186k; Guldi DM, 2000, J PHYS CHEM A, V104, P8601, DOI 10.1021/jp0016838; Iwamoto T, 2011, ANGEW CHEM INT EDIT, V50, P8342, DOI 10.1002/anie.201102302; Solin N, 2007, CHEM LETT, V36, P1208, DOI 10.1246/cl.2007.1208; Canevet D., 2011, ANGEW CHEM, V123, P9416; Frisch G. W. T. M. J., 2013, GAUSSIAN 09 REVISION; Harnoy A., 2003, BEARING DESIGN MACHI; Hitosugi S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1505; Iwamoto T., 2011, ANGEW CHEM, V123, P8492; Kawashima Y, 2015, CHEM-ASIAN J, V10, P44, DOI 10.1002/asia.201403075; KRISHNAN R, 1980, J CHEM PHYS, V72, P650, DOI 10.1063/1.438955; Iijima S, 2002, PHYSICA B, V323, P1, DOI 10.1016/S0921-4526(02)00869-4; Marcus R. A., 1993, ANGEW CHEM, V105, DOI DOI 10.1002/ANGE.19931050804; Nakanishi Y., 2014, ANGEW CHEM, V126, P3166; Ueno H., 2015, ANGEW CHEM, V127, P3778; Utko P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1034	57	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2015	10	11					2404	2410		10.1002/asia.201500673		7	Chemistry, Multidisciplinary	Chemistry	CU4CD	WOS:000363472800014		
J	Aboelmagd, A; El-Safty, SA; Shenashen, MA; Elshehy, EA; Khairy, M; Sakaic, M; Yamaguchi, H				Aboelmagd, Ahmed; El-Safty, Sherif A.; Shenashen, Mohamed A.; Elshehy, Emad A.; Khairy, Mohamed; Sakaic, Masaru; Yamaguchi, Hitoshi			Nanomembrane Canister Architectures for the Visualization and Filtration of Oxyanion Toxins with One-Step Processing	CHEMISTRY-AN ASIAN JOURNAL			English	Article						anions; membranes; nanotubes; sensors; toxicology	ATOMIC FLUORESCENCE SPECTROMETRY; MESOPOROUS SILICA MONOLITHS; ENVIRONMENTAL WATER SAMPLES; LARGE PARTICLE MORPHOLOGY; PLASMA-MASS SPECTROMETRY; INORGANIC SELENIUM; HYDRIDE GENERATION; METAL-IONS; ULTRASENSITIVE DETERMINATION; BIOLOGICAL MACROMOLECULES	Nanomembrane canister-like architectures were fabricated by using hexagonal mesocylinder-shaped aluminosilica nanotubes (MNTs)-porous anodic alumina (PAA) hybrid nanochannels. The engineering pattern of the MNTs inside a 60m-long membrane channel enabled the creation of unique canister-like channel necks and cavities. The open-tubular canister architecture design provides controllable, reproducible, and one-step processing patterns of visual detection and rejection/permeation of oxyanion toxins such as selenite (SeO32-) in aquatic environments (i.e., in ground and river water sources) in the Ibaraki Prefecture of Japan. The decoration of organic ligand moieties such as omega chrome black blue (OCG) into inorganic Al2O3@tubular SiO2/Al2O3 canister membrane channel cavities led to the fabrication of an optical nanomembrane sensor (ONS). The OCG ligand was not leached from the canister as observed in washing, sensing, and recovery assays of selenite anions in solution, which enabled its multiple reuse. The ONS makes a variety of alternate processing analyses of selective quantification, visual detection, rejection/permeation, and recovery of toxic selenite quick and simple without using complex instrumentation. Under optimal conditions, the ONS canister exhibited a high selectivity toward selenite anions relative to other ions and a low-level detection limit of 0.0093m. Real analytical data showed that approximately 96% of SeO32- anions can be recovered from aquatic and wastewater samples. The ONS canister holds potential for field recovery applications of toxic selenite anions from water.	[Aboelmagd, Ahmed; El-Safty, Sherif A.; Shenashen, Mohamed A.; Elshehy, Emad A.; Khairy, Mohamed; Yamaguchi, Hitoshi] Natl Inst Mat Sci, Tsukuba, Ibaraki 3050047, Japan; [El-Safty, Sherif A.] Waseda Univ, Grad Sch Adv Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; [Sakaic, Masaru] Univ Tsukuba, Ctr Res Isotopes & Environm Dynam, Tsukuba, Ibaraki 3050076, Japan	El-Safty, SA (reprint author), Natl Inst Mat Sci, 1-2-1 Sengen, Tsukuba, Ibaraki 3050047, Japan.	sherif.elsafty@nims.go.jp	Khairy, Mohamed /O-2431-2015				Wake BD, 2004, TRAC-TREND ANAL CHEM, V23, P491, DOI 10.1016/s0165-9936(04)00736-8; Platschek B, 2006, ANGEW CHEM INT EDIT, V45, P1134, DOI 10.1002/anie.200503301; El-Safty SA, 2008, APPL CATAL A-GEN, V337, P121, DOI 10.1016/j.apcata.2007.11.039; Chen ML, 2009, ANAL CHIM ACTA, V631, P74, DOI 10.1016/j.aca.2008.10.019; Meoto S, 2014, J MATER CHEM A, V2, P5640, DOI 10.1039/c3ta15330d; Shenashen MA, 2014, PART PART SYST CHAR, V31, P293, DOI 10.1002/ppsc.201300181; Guidotti M, 1999, HRC-J HIGH RES CHROM, V22, P414, DOI 10.1002/(SICI)1521-4168(19990701)22:7<414::AID-JHRC414>3.0.CO;2-J; Shenashen MA, 2014, ANALYST, V139, P6393, DOI [10.1039/c4an00980k, 10.1039/C4AN00980K]; Akhtar N, 2015, SENSOR ACTUAT B-CHEM, V207, P158, DOI 10.1016/j.snb.2014.10.038; Nguyen H, 2011, J PHYS CHEM C, V115, P8466, DOI 10.1021/jp1116189; Khairy M, 2013, RSC ADV, V3, P23801, DOI 10.1039/c3ra44465a; Chung J, 2006, ENVIRON SCI TECHNOL, V40, P1664, DOI 10.1021/es051251g; Khairy M, 2012, CHEM COMMUN, V48, P10832, DOI 10.1039/c2cc35638d; Shenashen MA, 2013, SEP PURIF TECHNOL, V116, P73, DOI 10.1016/j.seppur.2013.05.011; Das SK, 2013, CHEMCATCHEM, V5, P3050, DOI 10.1002/cctc.201300192; Khajeh M, 2007, ANAL CHIM ACTA, V581, P208, DOI 10.1016/j.aca.2006.08.037; El-Safty SA, 2009, ADSORPTION, V15, P227, DOI 10.1007/s10450-009-9171-z; Hansen D, 1998, ENVIRON SCI TECHNOL, V32, P591, DOI 10.1021/es970502l; Martin CR, 1996, CHEM MATER, V8, P1739, DOI 10.1021/cm960166s; El-Safty SA, 2012, SENSOR ACTUAT B-CHEM, V166, P253, DOI 10.1016/j.snb.2012.02.055; El-Safty SA, 2008, ADV FUNCT MATER, V18, P1485, DOI 10.1002/adfm.200701059; Evans J, 2000, J PHYS CHEM B, V104, P10271, DOI 10.1021/jp000564p; El-Safty SA, 2003, CHEM MATER, V15, P2892, DOI 10.1021/cm0204829; El-Safty SA, 2009, J MATER SCI, V44, P6764, DOI 10.1007/s10853-009-3577-6; Feng GD, 2014, SENSOR ACTUAT B-CHEM, V193, P592, DOI 10.1016/j.snb.2013.11.115; El-Safty SA, 2007, CHEM-EUR J, V13, P9245, DOI 10.1002/chem.200700499; Gammelgaard B, 2011, ANAL BIOANAL CHEM, V399, P1743, DOI 10.1007/s00216-010-4212-8; Mulugeta M, 2010, J ANAL ATOM SPECTROM, V25, P169, DOI 10.1039/b919994m; Stripeikis J, 2001, SPECTROCHIM ACTA B, V56, P93, DOI 10.1016/S0584-8547(00)00296-2; Hoa ND, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/48/485503; Lee HY, 2009, ANGEW CHEM INT EDIT, V48, P1239, DOI 10.1002/anie.200804714; El-Safty SA, 2013, ADV HEALTHC MATER, V2, P854, DOI 10.1002/adhm.201200326; Pyrzynska K, 2001, TALANTA, V55, P657, DOI 10.1016/S0039-9140(01)00511-2; Hill JJ, 2009, CHEM MATER, V21, P1841, DOI 10.1021/cm803083s; Striemer CC, 2007, NATURE, V445, P749, DOI 10.1038/nature05532; El-Safty SA, 2011, SMALL, V7, P62, DOI 10.1002/smll.201001303; El-Safty SA, 2008, J PHYS CHEM C, V112, P5476, DOI 10.1021/jp0760096; Figueroa R, 2005, SPECTROCHIM ACTA B, V60, P1556, DOI 10.1016/j.sab.2005.10.009; El-Safty SA, 2002, J MATER CHEM, V12, P117; Hunter WJ, 2004, J CHROMATOGR A, V1038, P295, DOI 10.1016/j.chroma.2004.03.005; El-Safty SA, 2012, TRAC-TREND ANAL CHEM, V38, P98, DOI 10.1016/j.trac.2012.05.002; El-Safty SA, 2013, MICROPOR MESOPOR MAT, V166, P195, DOI 10.1016/j.micromeso.2012.03.021; El-Safty SA, 2012, APPL CATAL B-ENVIRON, V123, P162, DOI 10.1016/j.apcatb.2012.04.021; Zwolak I, 2012, CELL BIOL TOXICOL, V28, P31, DOI 10.1007/s10565-011-9203-9; Elshehy EA, 2014, SENSOR ACTUAT B-CHEM, V203, P363, DOI 10.1016/j.snb.2014.06.055; Derbalah A, 2015, CHEMPLUSCHEM, V80, P1119, DOI 10.1002/cplu.201500098; Sahin F, 2003, TALANTA, V60, P1003, DOI 10.1016/S0039-9140(03)00154-1; Balaji T, 2006, ANGEW CHEM INT EDIT, V45, P7202, DOI 10.1002/anie.200602453; El-Safty S, 2011, J MATER CHEM, V21, P5593, DOI 10.1039/c0jm03269g; Zaki AB, 2000, J COLLOID INTERF SCI, V221, P58, DOI 10.1006/jcis.1999.6553; Deng DY, 2012, J ANAL ATOM SPECTROM, V27, P270, DOI 10.1039/c1ja10244c; El-Safty SA, 2008, CHEM MATER, V20, P2644, DOI 10.1021/cm701966c; El-Safty SA, 2010, CHEM COMMUN, V46, P3917, DOI 10.1039/c001654c; Shenashen MA, 2013, J POROUS MAT, V20, P679, DOI 10.1007/s10934-012-9642-6; El-Safty SA, 2013, ENVIRON SCI POLLUT R, V20, P3863, DOI 10.1007/s11356-012-1309-y; RUDZINSKI WE, 1983, INORG CHIM A-ARTICLE, V69, P83, DOI 10.1016/S0020-1693(00)83555-0; El-Safty SA, 2013, COLLOID SURFACE B, V103, P288, DOI 10.1016/j.colsurfb.2012.10.040; El-Safty SA, 2015, ACS APPL MATER INTER, V7, P13217, DOI 10.1021/acsami.5b02969; El-Safty SA, 2008, J POROUS MAT, V15, P369, DOI 10.1007/s10934-007-9157-8; El-Safty SA, 2008, J PHYS CHEM C, V112, P4825, DOI 10.1021/jp0764283; El-Safty SA, 2012, CHEM COMMUN, V48, P6708, DOI 10.1039/c2cc30725a; Martinis EM, 2011, TALANTA, V85, P2182, DOI 10.1016/j.talanta.2011.07.065; Hoa ND, 2011, CHEM-EUR J, V17, P12896, DOI 10.1002/chem.201101122; ZHANG PC, 1990, ENVIRON SCI TECHNOL, V24, P1848, DOI 10.1021/es00082a010; Chen BB, 2006, RAPID COMMUN MASS SP, V20, P2894, DOI 10.1002/rcm.2679; El-Safty SA, 2005, J MATER CHEM, V15, P2590, DOI 10.1039/b500088b; Khairy M, 2014, CHEM COMMUN, V50, P1356, DOI 10.1039/c3cc48155g; El-Safty SA, 2011, J COLLOID INTERF SCI, V359, P9, DOI 10.1016/j.jcis.2011.01.006; Kickelbick G, 2005, SMALL, V1, P168, DOI 10.1002/smll.200400098; El-Safty SA, 2007, ADV FUNCT MATER, V17, P3731, DOI 10.1002/adfm.200700447; El-Safty S, 2011, ANAL CHIM ACTA, V694, P151, DOI 10.1016/j.aca.2011.03.035; El-Safty SA, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/37/375603; Revanasiddappa HD, 2002, ANAL BIOANAL CHEM, V374, P1121, DOI 10.1007/s00216-002-1581-7; El-Safty SA, 2013, SENSOR ACTUAT B-CHEM, V176, P1015, DOI 10.1016/j.snb.2012.09.040; Bidari A, 2008, MICROCHIM ACTA, V163, P243, DOI 10.1007/s00604-008-0003-8; Gezer N, 2011, J APPL POLYM SCI, V122, P1134, DOI 10.1002/app.34246; MARTIN CR, 1994, SCIENCE, V266, P1961, DOI 10.1126/science.266.5193.1961; El-Safty SA, 2008, APPL CATAL B-ENVIRON, V82, P169, DOI 10.1016/j.apcatb.2008.01.027; El-Safty SA, 2012, ADV FUNCT MATER, V22, P3013, DOI 10.1002/adfm.201200393; El-Safty SA, 2005, J PHYS CHEM B, V109, P9255, DOI 10.1021/jp050304d; Khairy M, 2013, NANOSCALE, V5, P7920, DOI 10.1039/c3nr02403b; El-Safty SA, 2012, TALANTA, V98, P69, DOI 10.1016/j.talanta.2012.06.046; El-Safty SA, 2008, ADV FUNCT MATER, V18, P1739, DOI 10.1002/adfm.200800035; El-Safty SA, 2011, TALANTA, V83, P1341, DOI 10.1016/j.talanta.2010.11.008; El-Safty SA, 2008, J COLLOID INTERF SCI, V319, P477, DOI 10.1016/j.jcis.2007.12.010; Fu JP, 2007, NAT NANOTECHNOL, V2, P121, DOI 10.1038/nnano.2006.206; El-Safty SA, 2013, SMALL, V9, P2288, DOI 10.1002/smll.201202407; Ravikovitch PI, 2002, LANGMUIR, V18, P1550, DOI 10.1021/la0107594; El-Safty SA, 2012, ANALYST, V137, P5278, DOI 10.1039/c2an35484e; El-Safty S, 2011, COLLOID SURFACE A, V377, P44, DOI 10.1016/j.colsurfa.2010.12.015; Saxena A, 2010, SEP PURIF TECHNOL, V70, P280, DOI 10.1016/j.seppur.2009.10.008; Mekawy MM, 2011, J COLLOID INTERF SCI, V355, P348, DOI 10.1016/j.jcis.2010.11.056; El-Safty SA, 2013, SENSOR ACTUAT B-CHEM, V183, P58, DOI 10.1016/j.snb.2013.03.041; El-Safty SA, 2012, J HAZARD MATER, V201, P23, DOI 10.1016/j.jhazmat.2011.10.088; El-Safty SA, 2003, ADV MATER, V15, P1893, DOI 10.1002/adma.200305174; El-Safty S, 2011, MICROPOR MESOPOR MAT, V138, P51, DOI 10.1016/j.micromeso.2010.09.030; B'Hymer C, 2006, J CHROMATOGR A, V1114, P1, DOI 10.1016/j.chroma.2006.02.063; Wu H, 2007, TALANTA, V71, P1762, DOI 10.1016/j.talanta.2006.08.011; Shenashen MA, 2013, J HAZARD MATER, V260, P833, DOI 10.1016/j.jhazmat.2013.06.025; Shenashen MA, 2013, J HAZARD MATER, V244, P726, DOI 10.1016/j.jhazmat.2012.11.006; Peak D, 2006, J COLLOID INTERF SCI, V303, P337, DOI 10.1016/j.jcis.2006.08.014; El-Safty SA, 2012, CHEM COMMUN, V48, P9652, DOI 10.1039/c2cc34788a; El-Safty SA, 2004, CHEM MATER, V16, P384, DOI 10.1021/cm034282o; Balaji T., 2006, ANGEW CHEM, V118, P7360, DOI 10.1002/ange.200602453; Biradar N. S., 1983, INORG CHIM ACTA, V18, P41; Cheng K. L., 1992, HDB ORGANIC ANAL REA, P350; El-Safty S. A., 2015, NANO RES, DOI 10.1007s12274-015815-x; El-Safty S. A., 2013, CHEM-EUR J, P25; El-Safty S. A., 2012, EUR J INORG CHEM, V33, P5439; El-Safty S. A., 2012, J ENV ANAL TOXICOL, V2, P147; El-Safty SA, 2011, TRAC-TREND ANAL CHEM, V30, P447, DOI 10.1016/j.trac.2011.01.004; El-Safy SA, 2005, ADV MATER, V17, P47, DOI 10.1002/adma.200401317; Gomez-Ariza JL, 1999, ANALYST, V124, P75, DOI 10.1039/a805447i; Hayden Thomas, 2007, Anal Chem, V79, P2611, DOI 10.1021/ac0718997; Ho W.S.W., 1992, MEMBRANE HDB; Hoa ND, 2011, ANAL METHODS-UK, V3, P1948, DOI 10.1039/c1ay05333g; Kapoor A., 1995, International Journal of Environmental Studies, V49, P137, DOI 10.1080/00207239508711016; Khairy M, 2012, APPL CATAL B-ENVIRON, V127, P1, DOI 10.1016/j.apcatb.2012.07.036; Khairy M., 2014, INT J LIFE CYCLE ASS, V10, P126; Khairy M, 2013, COLLOID SURFACE B, V111, P460, DOI 10.1016/j.colsurfb.2013.06.037; Khairy M., 2013, CURR CATAL, V2, P17; Khairy M, 2014, TRAC-TREND ANAL CHEM, V62, P56, DOI 10.1016/j.trac.2014.06.013; Khairy M, 2014, SENSOR ACTUAT B-CHEM, V193, P644, DOI 10.1016/j.snb.2013.11.113; Khairy M, 2015, J ENERGY CHEM, V24, P31, DOI 10.1016/S2095-4956(15)60281-9; Herrero Latorre C, 2013, Anal Chim Acta, V804, P37, DOI 10.1016/j.aca.2013.09.054; Lee H. Y., 2009, ANGEW CHEM, V121, P1265; Platschek B., 2006, ANGEW CHEM, V118, P1152, DOI 10.1002/ange.200503301; Pyrzynska K, 1998, ANAL CHIM ACTA, V363, P141, DOI 10.1016/S0003-2670(98)00122-6; Pyrzynska K, 2002, MICROCHIM ACTA, V140, P55, DOI 10.1007/s00604-001-0899-8; Shenashen MA, 2015, EUR J INORG CHEM, P179, DOI 10.1002/ejic.201402756; Shriver D. F., 1994, INORG CHEM; Tire K, 2000, J ANAL ATOM SPECTROM, V15, P1087, DOI 10.1039/b000555j; WHO Selenium in Drinking Water, 2011, WHOHSEWSH100114; Yang WL, 2014, MICROCHIM ACTA, V181, P197, DOI 10.1007/s00604-013-1101-9	134	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2015	10	11					2467	2478		10.1002/asia.201500565		12	Chemistry, Multidisciplinary	Chemistry	CU4CD	WOS:000363472800022		
J	Roy, D; Maekawa, H; Murai, M; Takai, K				Roy, David; Maekawa, Hiroyuki; Murai, Masahito; Takai, Kazuhiko			Short Synthesis of [5]- and [7]Phenacenes with Silyl Groups at the Axis Positions	CHEMISTRY-AN ASIAN JOURNAL			English	Article						bismuth; cyclization; organic field-effect transistors; phenacenes; polycycles	FIELD-EFFECT TRANSISTORS; H BOND ACTIVATION; STILBENE-LIKE PHOTOCYCLIZATIONS; ORGANIC SEMICONDUCTORS; THIN-FILMS; DEHYDROGENATIVE SILYLATION; AROMATIC-HYDROCARBONS; SUBSTITUTED PICENES; GRAPHITE RIBBONS; SUPERCONDUCTIVITY	[5]Phenacene with trimethylsilyl groups at the axis positions was synthesized by the ruthenium-catalyzed direct C-H arylation of a 1-formyl-7-phenanthrene-derived aldimine, followed by sequential Wittig olefination and bismuth-catalyzed cyclization of the resulting vinyl ethers. By using the same synthetic building blocks and sequential Wittig olefination and photocyclization, the number of fused benzene rings was readily increased to seven to afford 3,12-disilyl[7]phenacene. The introduction of silyl groups endowed the [n]phenacene frameworks with good solubility, as well as enabling further functionalization. The electronic structure of these new [n]phenacenes was determined by photophysical measurements and by density functional theory calculations, which clearly implied effective conjugation throughout the entire framework.	[Roy, David; Maekawa, Hiroyuki; Murai, Masahito; Takai, Kazuhiko] Okayama Univ, Grad Sch Nat Sci & Technol, Div Appl Chem, Kita Ku, Okayama 7008530, Japan; [Takai, Kazuhiko] Japan Sci & Technol Agcy, ACT C, Kawaguchi, Saitama 3320012, Japan	Murai, M (reprint author), Okayama Univ, Grad Sch Nat Sci & Technol, Div Appl Chem, Kita Ku, 3-1-1 Tsushimanaka, Okayama 7008530, Japan.	masahito.murai@okayama-u.ac.jp; ktakai@cc.okayama-u.ac.jp	Takai, Kazuhiko/B-2737-2008		MEXT, Japan [26870389]; Advanced Catalytic Transformation program for Carbon utilization (ACT-C) project of the Japan Science and Technology Agency (JST); MEXT Program for Promoting the Enhancement of Research Universities; ADEKA Award in Synthetic Organic Chemistry, Japan	This work was financially supported by a Grant-in-Aid for Young Scientists (B) (No. 26870389) from MEXT, Japan, the Advanced Catalytic Transformation program for Carbon utilization (ACT-C) project of the Japan Science and Technology Agency (JST), and the MEXT Program for Promoting the Enhancement of Research Universities. M.M. is grateful for the ADEKA Award in Synthetic Organic Chemistry, Japan, and thanks the Okayama Foundation for Science and Technology. The authors gratefully thank Mr. Takahisa Sakae (Okayama University) for performing the HRMS measurements.	Kawai N, 2012, J PHYS CHEM C, V116, P7983, DOI 10.1021/jp300052p; Amin AY, 2012, J AM CHEM SOC, V134, P16548, DOI 10.1021/ja307802q; Nagasaki Y, 2014, ORG ELECTRON, V15, P3070, DOI 10.1016/j.orgel.2014.08.043; Gbabode G, 2014, ACS APPL MATER INTER, V6, P13413, DOI 10.1021/am5015315; Shimo Y, 2015, J MATER CHEM C, V3, P7370, DOI 10.1039/c5tc00960j; Okamoto H, 2013, RES CHEM INTERMEDIAT, V39, P147, DOI 10.1007/s11164-012-0639-1; Minemawari H, 2011, NATURE, V475, P364, DOI 10.1038/nature10313; Alberico D, 2007, CHEM REV, V107, P174, DOI 10.1021/cr0509760; TAMAO K, 1983, TETRAHEDRON, V39, P983, DOI 10.1016/S0040-4020(01)88597-5; He XX, 2013, ORG ELECTRON, V14, P1673, DOI 10.1016/j.orgel.2013.03.035; Chang NH, 2013, ORG LETT, V15, P3558, DOI 10.1021/ol401375n; Kubozono Y, 2015, PHYSICA C, V514, P199, DOI 10.1016/j.physc.2015.02.015; Segawa Y, 2015, ANGEW CHEM INT EDIT, V54, P66, DOI 10.1002/anie.201403729; Kaji Y, 2011, ORG ELECTRON, V12, P2076, DOI 10.1016/j.orgel.2011.08.016; Mallory FB, 1997, J AM CHEM SOC, V119, P2119, DOI 10.1021/ja9638418; Mei JG, 2013, J AM CHEM SOC, V135, P6724, DOI 10.1021/ja400881n; Mallory FB, 1996, TETRAHEDRON LETT, V37, P7173, DOI 10.1016/0040-4039(96)01618-8; Murai M, 2014, ORG LETT, V16, P3828, DOI 10.1021/ol501744g; Eguchi R, 2013, PHYS CHEM CHEM PHYS, V15, P20611, DOI 10.1039/c3cp53598c; TAMAO K, 1983, ORGANOMETALLICS, V2, P1694, DOI 10.1021/om50005a041; Jin TA, 2014, CHEM-EUR J, V20, P3554, DOI 10.1002/chem.201304640; Wang Y, 2011, J AM CHEM SOC, V133, P10054, DOI 10.1021/ja204011j; Mitsui C, 2014, ADV MATER, V26, P4546, DOI 10.1002/adma.201400289; Mallory FB, 2013, J ORG CHEM, V78, P2040, DOI 10.1021/jo3020819; Inoue S, 2015, CHEM MATER, V27, P3809, DOI 10.1021/acs.chemmater.5b00810; Nakao Y, 2011, CHEM SOC REV, V40, P4893, DOI 10.1039/c1cs15122c; He XX, 2014, J PHYS CHEM C, V118, P5284, DOI 10.1021/jp4107469; Murai M, 2015, ORG LETT, V17, P708, DOI 10.1021/ol503723j; Mori H, 2014, J ORG CHEM, V79, P4973, DOI 10.1021/jo500543h; Murai M, 2015, ORG LETT, V17, P1798, DOI 10.1021/acs.orglett.5b00575; Anthony JE, 2006, CHEM REV, V106, P5028, DOI 10.1021/cr050966z; Murai M, 2014, ORG LETT, V16, P4134, DOI 10.1021/ol5018273; Li B, 2012, TETRAHEDRON, V68, P5179, DOI 10.1016/j.tet.2012.03.117; Takimiya K, 2011, ADV MATER, V23, P4347, DOI 10.1002/adma.201102007; Chang NH, 2013, CHEM LETT, V42, P1257, DOI 10.1246/cl.130584; Murai M, 2015, CHEM-EUR J, V21, P4566, DOI 10.1002/chem.201406508; Artioli GA, 2014, J MATER CHEM C, V2, P1577, DOI 10.1039/c3tc32326a; Pron A, 2010, CHEM SOC REV, V39, P2577, DOI 10.1039/b907999h; Okamoto H, 2008, J AM CHEM SOC, V130, P10470, DOI 10.1021/ja803291a; Wu JS, 2007, CHEM REV, V107, P718, DOI 10.1021/cr068010r; Li B, 2011, ACS CATAL, V1, P1221, DOI 10.1021/ns200331m; Anthony JE, 2008, ANGEW CHEM INT EDIT, V47, P452, DOI 10.1002/anie.200604045; Anthony J. E., 2008, ANGEW CHEM, V120, P460, DOI 10.1002/ange.200604045; Artioli Gianluca A, 2015, Chem Commun (Camb), V51, P1092, DOI 10.1039/c4cc07879a; Chang W.- T. T., 2011, CROSS COUPLING WITH, V75, P213, DOI DOI 10.1002/0471264180.OR075.03; Chen XC, 2015, ORG CHEM FRONT, V2, P536, DOI 10.1039/c5qo00039d; FLEMING I, 1995, J CHEM SOC PERK T 1, P317, DOI 10.1039/p19950000317; HATANAKA Y, 1991, SYNLETT, P845; HATANAKA Y, 1989, CHEM LETT, P1711, DOI 10.1246/cl.1989.1711; Iino H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7828; Kawasaki N, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3076124; Komura N, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4747201; Kubozono Y, 2014, EUR J INORG CHEM, P3806, DOI 10.1002/ejic.201402168; Okamoto H, 2014, SCI REP-UK, V4, DOI 10.1038/srep05330; Okamoto H, 2014, SCI REP-UK, V4, DOI 10.1038/srep05048; Segawa Y., 2015, ANGEW CHEM, V127, P68; Sugawara Y, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3540648; SUZUKI T, 1988, J CHEM SOC PERK T 2, P697, DOI 10.1039/p29880000697; Mitsuhashi R, 2010, NATURE, V464, P76, DOI 10.1038/nature08859; Wang XF, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1513; Yuan YB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4005	61	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2015	10	11					2518	2524		10.1002/asia.201500700		7	Chemistry, Multidisciplinary	Chemistry	CU4CD	WOS:000363472800028		
J	Nishiguchi, T; Akasaka, T				Nishiguchi, Tsuyoshi; Akasaka, Takashi			European Society of Cardiology (ESC) Congress Report From London 2015	CIRCULATION JOURNAL			English	Article						Cardiology; European Society of Cardiology; Guidelines; Meeting report	INTACT FIBROUS CAP; CORONARY	The Annual Congress of the European Society of Cardiology (ESC) was held in London from 29 August to 2 September 2015. It is the leading conference in cardiology in the world, with presentations on the latest scientific discoveries, innovations, technology, education, and clinical practices. More than 32,000 delegates and 5,000 exhibitors from 140 countries participated, sharing a number of scientific presentations, including 28 clinical hot lines, 18 clinical trial updates, 20 registry studies, 12 basic and translational science hot line studies, and 4,533 abstract studies. Japan had the highest number of accepted abstracts at the Congress, indicating the great contribution of Japanese scientists and the Japanese Circulation Society.	[Nishiguchi, Tsuyoshi; Akasaka, Takashi] Wakayama Med Univ, Dept Cardiovasc Med, Wakayama 6418509, Japan	Nishiguchi, T (reprint author), Wakayama Med Univ, Dept Cardiovasc Med, 811-1 Kimiidera, Wakayama 6418509, Japan.	akasat@wakayama-med.ac.jp					Adler Y, 2015, EUR HEART J, DOI [10.1093/eurheartj/ehv318, DOI 10.1093/EURHEARTJ/EHV318]; Cung TT, 2015, NEW ENGL J MED, V373, P1021, DOI 10.1056/NEJMoa1505489; Ong P, 2014, CIRCULATION, V129, P1723, DOI 10.1161/CIRCULATIONAHA.113.004096; Murohara T, 2015, CIRC J, V79, P1193, DOI 10.1253/circj.CJ-15-0396; Cowie MR, 2015, NEW ENGL J MED, V373, P1095, DOI 10.1056/NEJMoa1506459; Ozaki Y, 2014, J AM COLL CARDIOL, V63, P2745, DOI 10.1016/j.jacc.2013.09.087; Prati F, 2013, JACC-CARDIOVASC IMAG, V6, P283, DOI 10.1016/j.jcmg.2012.12.007; Matsumoto Y, 2013, CIRC J, V77, P2687, DOI 10.1253/circj.CJ-13-1213; Galie N, 2015, EUR HEART J, DOI [10.1093/eur-heartj/ehv317, DOI 10.1093/EUR-HEARTJ/EHV317]; Habib G, 2015, EUR HEART J, DOI [10.1093/eur-heartj/ehv319., DOI 10.1093/EUR-HEARTJ/EHV319]; Kohno T, 2015, CIRC J, V79, P34, DOI 10.1253/circj.CJ-14-1329; Marchal V, 2011, OECD ENV OUTLOOK 205; Muramatsu T, 2014, CIRC J, V78, P2610, DOI 10.1253/circj.CJ-14-1088; Nishimiya K, 2014, CIRC J, V78, P2516, DOI 10.1253/circj.CJ-14-0485; Priori SG, 2015, EUR HEART J, V36, P2793, DOI 10.1093/eurheartj/ehv316; Reddy VY, 2015, NEW ENGL J MED, DOI [10.1056/NEJMoa1507192, DOI 10.1056/NEJMOA1507192]; Roffi M, 2015, EUR HEART J, DOI [10.1093/eurheartj/ehv320, DOI 10.1093/EURHEARTJ/EHV320]; Shimokawa H, 2014, EUR HEART J, V35, P3180, DOI 10.1093/eurheartj/ehu427; Yamanaga K, 2015, AM J PHYSIOL-HEART C, V308, pH478, DOI 10.1152/ajpheart.00593.2014	19	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2306	2313		10.1253/circj.CJ-15-1049		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900003		
J	Yasaka, M				Yasaka, Masahiro			Low-Dose Warfarin With Prothrombin Time-International Normalized Ratio Between 1.6 and 2.6 for Very Old Japanese Patients	CIRCULATION JOURNAL			English	Editorial Material							NONVALVULAR ATRIAL-FIBRILLATION; J-RHYTHM REGISTRY; SECONDARY PREVENTION; ORAL ANTICOAGULANTS; OPTIMAL INTENSITY; THERAPY; STROKE; EVENTS; TRIAL		[Yasaka, Masahiro] Natl Hosp Org, Dept Cerebrovasc Med & Neurol, Kyushu Med Ctr, Fukuoka 8108563, Japan	Yasaka, M (reprint author), Natl Hosp Org, Dept Cerebrovasc Med & Neurol, Kyushu Med Ctr, Chuo Ku, 1-8-1 Jigyohama, Fukuoka 8108563, Japan.	yasaka@kyumed.jp					Atarashi H, 2011, CIRC J, V75, P1328, DOI 10.1253/circj.CJ-10-1119; Shen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098; Yamaguchi T, 2000, STROKE, V31, P817; Azoulay L, 2014, EUR HEART J, V35, P1881, DOI 10.1093/eurheartj/eht499; Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000; TAKANO K, 1994, AM J CARDIOL, V74, P935, DOI 10.1016/0002-9149(94)90590-8; SAKATA T, 1995, ARTERIOSCL THROM VAS, V15, P241; Inoue H, 2013, CIRC J, V77, P2264, DOI 10.1253/circj.CJ-13-0290; Hata J, 2013, CIRC J, V77, P1923, DOI 10.1253/circj.CJ-13-0786; Akao M, 2014, CIRC J, V78, P2166, DOI 10.1253/circj.CJ-14-0344; Fuster V, 2011, J AM COLL CARDIOL, V57, pE101, DOI 10.1016/j.jacc.2010.09.013; Yasaka M, 2001, INTERNAL MED, V40, P1183, DOI 10.2169/internalmedicine.40.1183; Yasaka M, 2012, CIRC J, V76, P2086, DOI 10.1253/circj.CJ-12-0923; Inoue H, 2014, CIRC J, V78, P2388, DOI 10.1253/circj.CJ-14-0507; JCS Joint Working Group, 2013, CIRC J, V78, P1997; Kodani E, 2015, CIRC J, V79, P2345, DOI 10.1253/circj.CJ-15-0621; Suzuki K, 2011, J JPN COLL ANGIOL, V51, P287; Yamashita T, 2015, J CARDIOL, V65, P175, DOI 10.1016/j.jjcc.2014.07.013; Yasaka M, 2014, CIRC J, V78, P2367, DOI 10.1253/circj.CJ-14-0720	19	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2314	2316		10.1253/circj.CJ-15-1004		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900004		
J	Maruyama, T; Fukata, M				Maruyama, Toru; Fukata, Mitsuhiro			Increased Coupling Interval Variability - Mechanistic, Diagnostic and Prognostic Implication of Premature Ventricular Contractions and Underlying Heart Diseases -	CIRCULATION JOURNAL			English	Editorial Material							SUDDEN CARDIAC DEATH; ARRHYTHMIAS; RISK; INFARCTION; FAILURE; ECTOPY		[Maruyama, Toru; Fukata, Mitsuhiro] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka 8128582, Japan	Maruyama, T (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	maruyama@artsci.kyushu-u.ac.jp					Dukes JW, 2015, J AM COLL CARDIOL, V66, P101, DOI 10.1016/j.jacc.2015.04.062; Munoz FD, 2011, J CARDIOVASC ELECTR, V22, P791, DOI 10.1111/j.1540-8167.2011.02021.x; Lerma C, 2013, EUROPACE, V15, P1304, DOI 10.1093/europace/eus415; LOWERY M, 1990, AM HEART J, V119, P301, DOI 10.1016/S0002-8703(05)80020-1; MICHELSON EL, 1978, CIRCULATION, V58, P1002; Sosnowski M, 2004, INT J CARDIOL, V94, P53, DOI 10.1016/j.ijcard.2003.04.006; Wit AL, 2012, HEART RHYTHM, V9, P308, DOI 10.1016/j.hrthm.2011.09.056; Bradfield JS, 2014, J AM COLL CARDIOL, V63, P2151, DOI 10.1016/j.jacc.2014.02.551; Murakoshi N, 2013, CIRC J, V77, P2419, DOI 10.1253/circj.CJ-13-1129; THANAVARO S, 1983, AM HEART J, V106, P484, DOI 10.1016/0002-8703(83)90690-7; JCS Joint Working Group, 2013, CIRC J, V77, P249; Lee CH, 2015, CIRC J, V79, P2360, DOI 10.1253/circj.CJ-15-0732; Satake H, 2015, CIRC J, V79, P381, DOI 10.1253/circj.CJ-14-0925	13	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2317	2319		10.1253/circj.CJ-15-0963		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900005		
J	Tatsuishi, W; Nakano, K				Tatsuishi, Wataru; Nakano, Kiyoharu			Long-Term Outcomes After St. Jude Medical Mechanical Valve Implantation	CIRCULATION JOURNAL			English	Editorial Material							THERAPEUTIC RANGE; AORTIC POSITION; PROSTHESIS; EXPERIENCE; REPLACEMENT; OBSTRUCTION; GUIDELINES; MORBIDITY; MORTALITY; PANNUS		[Tatsuishi, Wataru; Nakano, Kiyoharu] Tokyo Womens Med Univ, Dept Cardiovasc Surg, Med Ctr East, Tokyo 1168567, Japan	Tatsuishi, W (reprint author), Tokyo Womens Med Univ, Dept Cardiovasc Surg, Med Ctr East, Arakawa Ku, Nishiogu 2-1-10, Tokyo 1168567, Japan.	wataru0812_drt@ybb.ne.jp					Okumura K, 2011, CIRC J, V75, P2087, DOI 10.1253/circj.CJ-11-0350; Edmunds LH, 1996, J THORAC CARDIOV SUR, V112, P708, DOI 10.1016/S0022-5223(96)70055-7; Okuyama Y, 2014, CIRC J, V78, P1342, DOI 10.1253/circj.CJ-13-1256; NAKANO K, 1994, ANN THORAC SURG, V57, P697; Teshima H, 2010, ARTIF ORGANS, V34, P210, DOI 10.1111/j.1525-1594.2009.00800.x; Emery RW, 2005, ANN THORAC SURG, V79, P776, DOI 10.1016/j.athoracsur.2004.08.047; Ueda T, 2013, CIRC J, V77, P418, DOI 10.1253/circj.CJ-12-0290; Akins CW, 2008, J THORAC CARDIOV SUR, V135, P732, DOI 10.1016/j.jtcvs.2007.12.002; Toole JM, 2010, ANN THORAC SURG, V89, P1402, DOI 10.1016/j.athoracsur.2010.01.045; AOYAGI S, 1994, J THORAC CARDIOV SUR, V108, P1021; Hurwitz SE, 2009, J AM SOC ECHOCARDIOG, V22, DOI 10.1016/j.echo.2009.04.001; Minakata K, 2015, CIRC J, V79, P2380, DOI 10.1253/circj.CJ-15-0793; Okita Y, 2012, GUIDELINES SURG INTE	13	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2320	2321		10.1253/circj.CJ-15-1018		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900006		
J	Tsukamoto, O; Kitakaze, M				Tsukamoto, Osamu; Kitakaze, Masafumi			Recent Progress and Next Challenges in the Treatment of Symptomatic Heart Failure in Japan	CIRCULATION JOURNAL			English	Editorial Material							PRESERVED EJECTION FRACTION; ASSOCIATION; IMPACT; EVENTS; ASIA		[Tsukamoto, Osamu] Osaka Univ, Grad Sch Med, Dept Med Biochem, Suita, Osaka 5650871, Japan; [Kitakaze, Masafumi] Natl Cerebral & Cardiovasc Ctr, Dept Clin Med & Dev, Suita, Osaka, Japan	Tsukamoto, O (reprint author), Osaka Univ, Grad Sch Med, Dept Med Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	tsuka@medbio.med.osaka-u.ac.jp					Witte KKA, 2005, EUR HEART J, V26, P2238, DOI 10.1093/eurheartj/ehi442; Liu G, 2014, AM J CARDIOL, V113, P1198, DOI 10.1016/j.amjcard.2013.12.023; Slaughter MS, 2009, NEW ENGL J MED, V361, P2241, DOI 10.1056/NEJMoa0909938; Yamamoto K, 2014, J CARDIOL, V63, P424, DOI 10.1016/j.jjcc.2013.10.014; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Sakata Y, 2013, CIRC J, V77, P2209, DOI 10.1253/circj.CJ-13-0971; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Bain KT, 2009, AM HEART J, V158, P118, DOI 10.1016/j.ahj.2009.05.013; Kitakaze M, 2015, J AM COLL CARDIOL, V66, P196, DOI 10.1016/j.jacc.2015.05.035; Yoshida A, 2013, HYPERTENS RES, V36, P450, DOI 10.1038/hr.2012.200; Miura Y, 2013, CIRC J, V77, P2963, DOI 10.1253/circj.CJ-13-0746; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Mathew Sunil T, 2004, Am J Geriatr Cardiol, V13, P61, DOI 10.1111/j.1076-7460.2004.02121.x; Nochioka K, 2015, CIRC J, V79, P574, DOI 10.1253/circj.CJ-14-0865; Ushigome R, 2015, CIRC J, V79, P2396, DOI 10.1253/circj.CJ-15-0514	15	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2322	2323		10.1253/circj.CJ-15-1014		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900007		
J	Goda, A; Masuyama, T				Goda, Akiko; Masuyama, Tohru			Noninvasive Estimation of Pulmonary Vasculature - Why It Is Important -	CIRCULATION JOURNAL			English	Editorial Material							HEART-FAILURE; DOPPLER-ECHOCARDIOGRAPHY; EJECTION FRACTION; CLINICAL-TRIAL; HYPERTENSION; RESISTANCE		[Goda, Akiko; Masuyama, Tohru] Hyogo Coll Med, Dept Internal Med, Cardiovasc Div, Nishinomiya, Hyogo 6638501, Japan	Goda, A (reprint author), Hyogo Coll Med, Dept Internal Med, Cardiovasc Div, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	akiko-m@hyo-med.ac.jp					Redfield MM, 2013, JAMA-J AM MED ASSOC, V309, P1268, DOI 10.1001/jama.2013.2024; Abbas AE, 2003, J AM COLL CARDIOL, V41, P1021, DOI 10.1016/S0735-1097(02)02973-X; Scapellato F, 2001, J AM COLL CARDIOL, V37, P1813, DOI 10.1016/S0735-1097(01)01271-2; Cooper TJ, 2013, EUR J HEART FAIL, V15, P119, DOI 10.1093/eurjhf/hfs152; Tian Z, 2014, CIRC J, V78, P1240, DOI 10.1253/circj.CJ-13-1280; Taniguchi Y, 2013, CIRC J, V77, P2383, DOI 10.1253/circj.CJ-13-0172; Haddad F, 2009, J AM SOC ECHOCARDIOG, V22, P523, DOI 10.1016/j.echo.2009.01.021; Kouzu H, 2009, AM J CARDIOL, V103, P872, DOI 10.1016/j.amjcard.2008.11.039; Anand I, 2004, LANCET, V364, P347; Vachiery JL, 2013, J AM COLL CARDIOL, V62, pD100, DOI 10.1016/j.jacc.2013.10.033; Rajagopalan N, 2009, ECHOCARDIOGR-J CARD, V26, P489, DOI 10.1111/j.1540-8175.2008.00837.x; Bane O, 2015, MAGN RESON IMAGING, V33, P1224, DOI 10.1016/j.mri.2015.08.005; Schwartzenberg S, 2012, J AM COLL CARDIOL, V59, P442, DOI 10.1016/j.jacc.2011.09.062; Kanda T, 2015, CIRC J, V79, P2408, DOI 10.1253/circj.CJ-15-0575; Kasai Hajime, 2015, Respir Investig, V53, P210, DOI 10.1016/j.resinv.2015.03.002	15	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2324	2325		10.1253/circj.CJ-15-1032		2	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900008		
J	Hachiya, H; Hirao, K; Nakamura, H; Taniguchi, H; Miyazaki, S; Komatsu, Y; Kusa, S; Takagi, T; Iwasawa, J; Ichihara, N; Kuroi, A; Hayashi, T; Tanaka, Y; Iesaka, Y				Hachiya, Hitoshi; Hirao, Kenzo; Nakamura, Hiroaki; Taniguchi, Hiroshi; Miyazaki, Shinsuke; Komatsu, Yuki; Kusa, Shigeki; Takagi, Takamitsu; Iwasawa, Jin; Ichihara, Noboru; Kuroi, Akio; Hayashi, Tatsuya; Tanaka, Yasuaki; Iesaka, Yoshito			Electrocardiographic Characteristics Differentiating Epicardial Outflow Tract-Ventricular Arrhythmias Originating From the Anterior Interventricular Vein and Distal Great Cardiac Vein	CIRCULATION JOURNAL			English	Article						Cardiac veins; ECG; Outflow tract-ventricular arrhythmias	RADIOFREQUENCY CATHETER ABLATION; CIRCUMFLEX CORONARY-ARTERY; MITRAL ANNULUS; LEFT SINUS; TACHYCARDIA; VALSALVA; LEAD	Background: The aim of this study was to identify the ECG features that might differentiate between anterior interventricular vein (AIV) and distal great cardiac vein (d-GCV) outflow tract-ventricular arrhythmias (OT-VAs). Methods and Results: Radiofrequency catheter ablation was performed in 13 of 375 patients (3.5%) for AIV or d-GCV OT-VAs. We grouped the 13 patients by the origin, d-GCV (n= 9) or AIV (n= 4), and compared their ECGs and electrophysiological data. The OT-VA ECGs had S waves in lead I in all 13 patients. The voltage in the inferior lead III and peak deflection index showed no significant between-group differences (2.3 +/- 0.7 vs. 2.5 +/- 0.3 mV and 0.65 +/- 0.04 vs. 0.68 +/- 0.04 mV, respectively) for the d-GCV and AIV groups. There were also no significant between-group differences in the QaVL/QaVR, where Q denotes the amplitude of the Q wave in the suffix lead. However, the R/S ratio in V1 (1.7 +/- 1.0 [n= 5] vs. 0.2 +/- 0.05, P=0.04), and QRS duration (149 +/- 16.6 vs. 123 +/- 3.8 ms, P=0.012) were greater in the d-GCG group than in the AIV group. There were no significant between-group differences in the activation time or pace mapping score at the optimal ablation sites. Conclusions: A low R/S ratio in V1 and shorter QRS duration may help identify AIV sites of epicardial OT-VA origin.	[Hachiya, Hitoshi; Nakamura, Hiroaki; Taniguchi, Hiroshi; Miyazaki, Shinsuke; Komatsu, Yuki; Kusa, Shigeki; Takagi, Takamitsu; Iwasawa, Jin; Ichihara, Noboru; Kuroi, Akio; Iesaka, Yoshito] Tsuchiura Kyodo Gen Hosp, Dept Cardiol, Cardiovasc Ctr, Tsuchiura, Ibaraki 3000053, Japan; [Hayashi, Tatsuya; Tanaka, Yasuaki] Tokyo Med & Dent Univ, Dept Cardiovasc Med, Tokyo, Japan; [Hirao, Kenzo] Tokyo Med & Dent Univ, Heart Rhythm Ctr, Tokyo, Japan	Hachiya, H (reprint author), Tsuchiura Kyodo Gen Hosp, Dept Cardiol, Cardiovasc Ctr, 11-7 Manabe Shinmachi, Tsuchiura, Ibaraki 3000053, Japan.	hh8814.cvm@tmd.ac.jp					Sacks HS, 2007, AM HEART J, V153, P907, DOI 10.1016/j.ahj.2007.03.019; Takahashi Y, 2005, J CARDIOVASC ELECTR, V16, P1104, DOI 10.1111/j.1540-8167.2005.50124.x; Tanaka Y, 2011, CIRC J, V75, P1585, DOI 10.1253/circj.CJ-10-0941; Abularach MEJ, 2012, HEART RHYTHM, V9, P865, DOI 10.1016/j.hrthm.2012.01.022; Yamada T, 2010, CIRC-ARRHYTHMIA ELEC, V3, P616, DOI 10.1161/CIRCEP.110.939744; Liuba I, 2013, CIRC J, V77, P1957, DOI 10.1253/circj.CJ-13-07580; Ito S, 2005, PACE, V28, pS150, DOI 10.1111/j.1540-8159.2005.00081.x; Kumagai K, 2005, J CARDIOVASC ELECTR, V16, P1029, DOI 10.1111/j.1540-8167.2005.40749.x; Sosa E, 2000, J AM COLL CARDIOL, V35, P1442, DOI 10.1016/S0735-1097(00)00606-9; Daniels DV, 2006, CIRCULATION, V113, P1659, DOI 10.1161/CIRCULATIONAHA.105.611640; Tada H, 2005, J AM COLL CARDIOL, V45, P877, DOI 10.1016/j.jacc.2004.12.025; Kurosaki K, 2013, CIRC J, V77, P968, DOI 10.1253/circj.CJ-12-0864; Hachiya H, 2002, J CARDIOVASC ELECTR, V13, P551, DOI 10.1046/j.1540-8167.2002.00551.x; Ito S, 2003, J CARDIOVASC ELECTR, V14, P1280, DOI 10.1046/j.1540-8167.2003.03211.x; Nakamura K, 2013, INT J CARDIOL, V168, P5174, DOI 10.1016/j.ijcard.2013.07.261; Hachiya H, 2010, CIRC J, V74, P256, DOI 10.1253/circj.CJ-09-0540; Hirasawa Y, 2005, J CARDIOVASC ELECTR, V16, P1378, DOI 10.1111/j.1540-8167.2005.00257.x	17	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2335	2344		10.1253/circj.CJ-15-0476		10	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900012		
J	Kodani, E; Atarashi, H; Inoue, H; Okumura, K; Yamashita, T; Origasa, H				Kodani, Eitaro; Atarashi, Hirotsugu; Inoue, Hiroshi; Okumura, Ken; Yamashita, Takeshi; Origasa, Hideki		J-RHYTHM Registry Investigators	Use of Warfarin in Elderly Patients With Non-Valvular Atrial Fibrillation - Subanalysis of the J-RHYTHM Registry -	CIRCULATION JOURNAL			English	Article						Anticoagulation; Atrial fibrillation; International normalized ratio; Old age; Warfarin	INTERNATIONAL NORMALIZED RATIO; STROKE PREVENTION; JAPANESE PATIENTS; RISK-FACTOR; ORAL ANTICOAGULANT; PREDICTING STROKE; OPTIMAL INTENSITY; THERAPY; POPULATION; PREVALENCE	Background: To clarify the effects of warfarin therapy in very old patients with non-valvular atrial fibrillation (NVAF), a post-hoc analysis was performed using the data of the J-RHYTHM Registry. Methods and Results: A consecutive series of AF outpatients was enrolled from 158 institutions. Of 7,937 patients, 7,406 with NVAF (men, 70.8%; 69.8 +/- 10.0 years) were followed for 2 years or until an event occurred. Patients were divided into 3 age groups (<70, 70-84, and >= 85 years) and 5 subgroups according to international normalized ratio (INR; <1.6, 1.6-1.99, 2.0-2.59, 2.6-2.99, and >= 3.0). Prevalence of female sex, permanent AF, hypertension, coronary artery disease, heart failure, and history of ischemic stroke/transient ischemic attack was higher in the older groups. In the oldest group, 79.7% of patients received warfarin and their time in therapeutic range, using the Japanese target INR of 1.6-2.6, was 67.1%. Rate of thromboembolic events was lower in the age groups <70 and 70-84 years (P=0.027 and P<0.001, respectively) for patients receiving warfarin compared with those who were not. In the oldest group, the rate of thromboembolism plus major hemorrhage was lower at INR 1.6-2.59. Conclusions: Warfarin could have beneficial effects even in very old NVAF patients if INR is kept between 1.6 and 2.59.	[Kodani, Eitaro; Atarashi, Hirotsugu] Tama Nagayama Hosp, Nippon Med Sch, Dept Internal Med & Cardiol, Tokyo 2068512, Japan; [Inoue, Hiroshi] Toyama Univ, Grad Sch Med, Dept Internal Med 2, Toyama 930, Japan; [Okumura, Ken] Hirosaki Univ, Grad Sch Med, Dept Cardiol Resp Med & Nephrol, Aomori, Japan; [Yamashita, Takeshi] Cardiovasc Inst, Tokyo, Japan; [Origasa, Hideki] Toyama Univ, Div Biostat & Clin Epidemiol, Toyama 930, Japan	Kodani, E (reprint author), Tama Nagayama Hosp, Nippon Med Sch, Dept Internal Med & Cardiol, Tama Ku, 1-7-1 Nagayama, Tokyo 2068512, Japan.	kodani@nms.ac.jp			Japan Heart Foundation	The current study was presented in part at ESC Congress 2014 (Barcelona, Spain, 30 August 2014). Investigators in the J-RHYTHM Registry are listed in references 15, 16, and 30. The J-RHYTHM registry was supported by a grant from the Japan Heart Foundation.	Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Atarashi H, 2011, CIRC J, V75, P1328, DOI 10.1253/circj.CJ-10-1119; Hylek EM, 2007, CIRCULATION, V115, P2689, DOI 10.1161/CIRCULATIONHA.106.653048; Lip GYH, 2010, CHEST, V137, P263, DOI 10.1378/chest.09-1584; Ohsawa M, 2005, J EPIDEMIOL, V15, P194, DOI 10.2188/jea.15.194; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1; Furusho H, 2008, CIRC J, V72, P2058, DOI 10.1253/circj.CJ-08-0290; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; Connolly SJ, 2008, CIRCULATION, V118, P2029, DOI 10.1161/CIRCULATIONAHA.107.750000; Gorin L, 2011, CHEST, V140, P911, DOI 10.1378/chest.10-2436; Poli D, 2009, J AM COLL CARDIOL, V54, P999, DOI 10.1016/j.jacc.2009.05.046; Inoue H, 2013, CIRC J, V77, P2264, DOI 10.1253/circj.CJ-13-0290; Halvorsen S, 2014, EUR HEART J, V35, P1864, DOI 10.1093/eurheartj/ehu046; Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253; Akao M, 2014, CIRC J, V78, P2166, DOI 10.1253/circj.CJ-14-0344; Inoue H, 2006, CIRC J, V70, P651, DOI 10.1253/circj.70.651; Naganuma M, 2012, THROMB RES, V130, P21, DOI 10.1016/j.thromres.2011.11.005; Inoue H, 2009, INT J CARDIOL, V137, P102, DOI 10.1016/j.ijcard.2008.06.029; Atarashi H, 2011, J CARDIOL, V57, P95, DOI 10.1016/j.jjcc.2010.09.002; WOLF PA, 1991, STROKE, V22, P983; Marinigh R, 2010, J AM COLL CARDIOL, V56, P827, DOI 10.1016/j.jacc.2010.05.028; Yasaka M, 2001, INTERNAL MED, V40, P1183, DOI 10.2169/internalmedicine.40.1183; Miyasaka Y, 2006, CIRCULATION, V114, P119, DOI 10.1161/CIRCULATIONAHA.105.595140; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI DOI 10.1001/ARCHINTE.1995.00430050045005; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; JCS Joint Working Group, 2013, CIRC J, V78, P1997; Inoue H, 2011, CIRC J, V75, P2357, DOI 10.1253/circj.CJ-11-0427; Kodani E, 2015, CIRC J, V79, P325, DOI 10.1253/circj.CJ-14-1057; Yiin GSC, 2014, CIRCULATION, V130, P1236, DOI 10.1161/CIRCULATIONAHA.114.010942	30	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2345	+		10.1253/circj.CJ-15-0621		11	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900013		
J	Miyazaki, S; Taniguchi, H; Nakamura, H; Takagi, T; Iwasawa, J; Hachiya, H; Iesaka, Y				Miyazaki, Shinsuke; Taniguchi, Hiroshi; Nakamura, Hiroaki; Takagi, Takamitsu; Iwasawa, Jin; Hachiya, Hitoshi; Iesaka, Yoshito			Clinical Significance of Early Recurrence After Pulmonary Vein Antrum Isolation in Paroxysmal Atrial Fibrillation - Insight Into the Mechanism -	CIRCULATION JOURNAL			English	Article						Catheter ablation; Early recurrence; Paroxysmal atrial fibrillation; Pulmonary vein isolation	RADIOFREQUENCY CATHETER ABLATION; FOLLOW-UP; TRIAL; AF; CHADS(2); OUTCOMES; FEMALES	Background: Early recurrence of atrial fibrillation (ERAF) is common after pulmonary vein antrum isolation (PVAI); however, the definition, study population, and lesion set are not uniform in prior studies. We examined ERAF for paroxysmal AF while complying with the definition in the latest guidelines. Methods and Results: We included 471 patients undergoing empirical PVAI for paroxysmal AF. ERAF was observed in 180 patients (38.2%) including 49, 16, and 115 within 3, 4-7 days, and 8-90 days, respectively, after the index procedure. ERAF (hazard ratio 6.872; 95% confidence interval 4.803-9.382; P<0.0001) was the strongest factor associated with recurrence beyond 3 months (LR) in the multivariable model, and ERAF patients had worse outcomes than those without, regardless of the time to the first ERAF episode. There were no significant differences in the prevalence of PV reconnections and non-PV foci among 29 and 62 patients, respectively, who underwent redo procedures for ERAF within and more than 3 months after the index procedure, and 21 who underwent redo procedures for LR. Re-ablation was associated with a greater freedom from LR (HR 0.443; 95% CI 0.230-0.854; P=0.015). Conclusions: ERAF occurred in 38.2% of patients and was strongly associated with LR regardless of the time to the first ERAF episode. Re-ablation for ERAF significantly improved the freedom from recurrent atrial arrhythmias, regardless of the time to the first ERAF episode.	[Miyazaki, Shinsuke; Taniguchi, Hiroshi; Nakamura, Hiroaki; Takagi, Takamitsu; Iwasawa, Jin; Hachiya, Hitoshi; Iesaka, Yoshito] Tsuchiura Kyodo Gen Hosp, Cardiovasc Ctr, Tsuchiura, Ibaraki 3000053, Japan	Miyazaki, S (reprint author), Tsuchiura Kyodo Gen Hosp, Cardiovasc Ctr, Div Cardiol, 11-7 Manabeshin Machi, Tsuchiura, Ibaraki 3000053, Japan.	mshinsuke@k3.dion.ne.jp					Richter B, 2008, AM J CARDIOL, V101, P843, DOI 10.1016/j.amjcard.2007.11.021; Koyama T, 2010, J AM COLL CARDIOL, V56, P1463, DOI 10.1016/j.jacc.2010.04.057; Andrade JG, 2012, J CARDIOVASC ELECTR, V23, P1295, DOI 10.1111/j.1540-8167.2012.02399.x; Maroto LC, 2011, INTERACT CARDIOV TH, V12, P681, DOI 10.1510/icvts.2010.261842; Lim HS, 2014, CIRC-ARRHYTHMIA ELEC, V7, P83, DOI 10.1161/CIRCEP.113.000876; Patel D, 2010, HEART RHYTHM, V7, P167, DOI 10.1016/j.hrthm.2009.10.025; Haissaguerre M, 2000, CIRCULATION, V101, P1409; Katritsis DG, 2013, J AM COLL CARDIOL, V62, P2318, DOI 10.1016/j.jacc.2013.06.053; Lellouche N, 2008, J CARDIOVASC ELECTR, V19, P599, DOI 10.1111/j.1540-8167.2008.01188.x; Takigawa M, 2013, INT J CARDIOL, V168, P1984, DOI 10.1016/j.ijcard.2012.12.101; Kornej J, 2014, CIRC-ARRHYTHMIA ELEC, V7, P281, DOI 10.1161/CIRCEP.113.001182; Nakagawa H, 2009, HEART RHYTHM, V6, pS26, DOI 10.1016/j.hrthm.2009.07.029; Oral H, 2002, J AM COLL CARDIOL, V40, P100, DOI 10.1016/S0735-1097(02)01939-3; Weerasooriya R, 2011, J AM COLL CARDIOL, V57, P160, DOI 10.1016/j.jacc.2010.05.061; Verma A, 2013, JAMA INTERN MED, V173, P149, DOI 10.1001/jamainternmed.2013.1561; Andrade JG, 2014, CIRC-ARRHYTHMIA ELEC, V7, P69, DOI 10.1161/CIRCEP.113.000586; Jiang RH, 2014, HEART RHYTHM, V11, P969, DOI [10.1016/j.hrthm.2014.03.015, 10.1016/j.hrthm.2014.0.3.015]; Saad EB, 2011, CIRC-ARRHYTHMIA ELEC, V4, P615, DOI 10.1161/CIRCEP.111.963231; Richter B, 2012, CLIN RES CARDIOL, V101, P217, DOI 10.1007/s00392-011-0383-3; Nault I, 2010, EUR HEART J, V31, P1046, DOI 10.1093/eurheartj/ehq079; Miyazaki S, 2014, CIRC J, V78, P78, DOI 10.1253/circj.CJ-13-0838; Miyazaki S, 2011, HEART, V97, P668, DOI 10.1136/hrt.2009.186874; Calkins H, 2012, HEART RHYTHM, V9, P632, DOI 10.1016/j.hrthm.2011.12.016; JCS Joint Working Group, 2013, CIRC J, V77, P249; Takagi T, 2014, CIRC J, V78, P2637, DOI 10.1253/circj.CJ-14-0610	25	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2353	2359		10.1253/circj.CJ-15-0475		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900014		
J	Sugiyama, H; Fujimoto, K; Ishii, T; Nakanishi, T; Tomita, H				Sugiyama, Hisashi; Fujimoto, Kazuto; Ishii, Tetsuko; Nakanishi, Toshio; Tomita, Hideshi			Impact of Novel Balloon Catheter on Static Balloon Atrial Septostomy With Double Balloon Technique in Infants With Congenital Heart Disease	CIRCULATION JOURNAL			English	Article						Balloon atrial septostomy; Double balloon; Infant	GREAT-ARTERIES; COMPLETE TRANSPOSITION; ATRIOSEPTOSTOMY; OUTCOMES; SURGERY; STROKE	Background: The aim of this study was to investigate the feasibility of static balloon atrial septostomy (BAS) with the double balloon technique for infants. TMP PED balloon catheter, newly designed for static BAS in small children, was used in 3 infants. The balloon catheter has a low profile, short and round shoulder, and smooth deflation without slippage. Methods and Results: Three infants (transposition of the great arteries, n=2; pulmonary atresia with intact ventricular septum, n=1) underwent static BAS with double balloon for restrictive interatrial communication between December 2014 and March 2015. Hemodynamic and echocardiographic assessment was done before and after the procedure. Pressure gradient between left and right atrium decreased from 6, 7 and 9 mmHg to 2, 2 and 1 mmHg, respectively. Oxygen saturation in systemic artery increased from 72, 68 and 73% to 78, 70 and 79%, respectively. Maximum defect diameter increased from 3.5, 3.0 and 3.3 mm to 6.6x5.2, 9.0x6.2 and 8.1x5.1 mm, respectively. No complication was recorded. Conclusions: Static BAS with double balloon technique using the novel TMP PED balloon catheter was safe and effective in producing sufficient interatrial communication for 8-20 weeks in infants. Static BAS is a promising procedure to create interatrial communication in infants.	[Sugiyama, Hisashi; Ishii, Tetsuko; Nakanishi, Toshio] Tokyo Womens Med Univ, Pediat Cardiol, Tokyo 1628666, Japan; [Fujimoto, Kazuto; Tomita, Hideshi] Showa Univ, Northern Yokohama Hosp, Ctr Cardiovasc, Yokohama, Kanagawa, Japan	Sugiyama, H (reprint author), Tokyo Womens Med Univ, Pediat Cardiol, Shinjuku Ku, 8-1 Kawada, Tokyo 1628666, Japan.	psugiyama@hij.twmu.ac.jp					MATHEWS RA, 1979, CATHETER CARDIO DIAG, V5, P67, DOI 10.1002/ccd.1810050109; MITCHELL SE, 1994, PEDIATR CARDIOL, V15, P1, DOI 10.1007/BF00796998; Applegate SE, 2010, CATHETER CARDIO INTE, V76, P129, DOI 10.1002/ccd.22463; Doshi H, 2012, INTERACT CARDIOV TH, V15, P141, DOI 10.1093/icvts/ivr145; RASHKIND WJ, 1966, J AMER MED ASSOC, V196, P991; NECHES WH, 1973, AM J DIS CHILD, V125, P371; Hijazi ZM, 1997, CATHETER CARDIO DIAG, V40, P187, DOI 10.1002/(SICI)1097-0304(199702)40:2<187::AID-CCD17>3.0.CO;2-O; Mukherjee D, 2010, CARDIOL YOUNG, V20, P373, DOI 10.1017/S1047951110000296; McQuillen PS, 2006, CIRCULATION, V113, P280, DOI 10.1161/CIRCULATIONAHA.105.566752; RASHKIND WJ, 1971, RADIOL CLIN N AM, V9, P193; Chen JW, 2014, CIRC J, V78, P393, DOI 10.1253/circj.CJ-13-0970; RASHKIND WJ, 1968, CIRCULATION, V38, P453; RASHKIND WJ, 1983, INT J CARDIOL, V4, P369, DOI 10.1016/0167-5273(83)90099-2; BALLERINI L, 1993, AM HEART J, V125, P1760, DOI 10.1016/0002-8703(93)90768-5; JCS Joint Working Group, 2014, CIRC J, V78, P507; Shrivastava S, 1987, Indian Heart J, V39, P298; Tomita Hideshi, 2007, J Cardiol, V50, P259; VENABLES AW, 1970, BRIT HEART J, V32, P61	18	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2367	2371		10.1253/circj.CJ-15-0480		5	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900016		
J	Minakata, K; Tanaka, S; Okawa, Y; Kaneko, T; Okonogi, S; Usui, A; Abe, T; Tamura, N; Yanagi, S; Sakata, R				Minakata, Kenji; Tanaka, Shiro; Okawa, Yohei; Kaneko, Tatsuo; Okonogi, Shuichi; Usui, Akihiko; Abe, Tomonobu; Tamura, Nobushige; Yanagi, Shigeki; Sakata, Ryuzo			Twenty-Year Outcome of Aortic Valve Replacement With St. Jude Medical Mechanical Valves in Japanese Patients	CIRCULATION JOURNAL			English	Article						Anticoagulation-related adverse event; Aortic valve replacement; Mechanical valve; Reoperation	EDWARDS PERICARDIAL VALVE; FOLLOW-UP; PROSTHESIS; EXPERIENCE; POSITION; BIOPROSTHESIS; DURABILITY; GUIDELINES; AGE	Background: Bioprostheses have become increasingly popular for aortic valve replacement (AVR) in recent years, but mechanical valves are still the standard choice, especially for younger patients. The aim of this study was to assess the very long-term outcomes in Japanese patients who underwent AVR with St. Jude Medical (SJM) mechanical valves. Methods and Results: From 1991 to 2001, a total of 816 patients underwent AVR with SJM mechanical valves in 5 hospitals. Of these, 801 patients (mean age, 58.3 +/- 11.7 years) were analyzed in this study. There were 24 in-hospital deaths (3.0%). Mean follow-up duration was 11.6 +/- 6.7 years and the 10-year follow-up rate was 84.1%. Freedom from valve-related death at 5, 10, 15, and 20 years was 96.2%, 92.7%, 88.8%, and 86.6%, respectively. The linearized ratio of major bleeding events and thromboembolic events was 1.1% per patient-year and 1.0% per patient-year, respectively. Freedom from reoperation for the aortic prosthesis was 98.0% and 94.8% at 10 and 20 years, respectively. Conclusions: The SJM mechanical valve provided excellent long-term freedom from valve-related death and reoperation in patients undergoing AVR. Therefore, this valve should be recommended to younger patients who wish to avoid reoperation.	[Minakata, Kenji; Sakata, Ryuzo] Kyoto Univ, Grad Sch Med, Kyoto 6068507, Japan; [Tanaka, Shiro] Kyoto Univ, Grad Sch Publ Hlth, Kyoto 6068507, Japan; [Okawa, Yohei] Hokkaido Ohno Hosp, Ctr Cardiovasc, Sapporo, Hokkaido, Japan; [Kaneko, Tatsuo; Okonogi, Shuichi] Gunma Cardiovasc Ctr, Maebashi, Gumma, Japan; [Usui, Akihiko; Abe, Tomonobu] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan; [Tamura, Nobushige; Yanagi, Shigeki] Kumamoto City Hosp, Kumamoto, Japan	Minakata, K (reprint author), Kyoto Univ, Dept Cardiovasc Surg, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	minakata@kuhp.kyoto-u.ac.jp	Usui, Akihiko/I-7251-2014		Research Institute for Production Development (Kyoto, Japan)	This work was supported by an educational grant from the Research Institute for Production Development (Kyoto, Japan). We are indebted to the participating hospitals, investigators, and clinical research coordinators for their great contributions to data collection. The participating hospitals were as follows: Cardiovascular Center Hokkaido Ohno Hospital (Sapporo), Gunma Cardiovascular Center (Maebashi), Nagoya University Hospital (Nagoya), Kyoto University Hospital (Kyoto), and Kumamoto Central Hospital (Kumamoto). Clinical research coordinators: Ms Yui Kinoshita, Ms Asuka Takahashi, and Ms Miya Hanazawa.	Heneghan C, 2012, LANCET, V379, P322, DOI 10.1016/S0140-6736(11)61294-4; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Minakata K, 2014, CIRC J, V78, P882, DOI 10.1253/circj.CJ-13-1068; Soga Y, 2002, ANN THORAC SURG, V73, P474, DOI 10.1016/S0003-4975(01)03424-5; Jamieson WRE, 2011, J THORAC CARDIOV SUR, V142, P302, DOI 10.1016/j.jtcvs.2010.08.090; Hammermeister K, 2000, J AM COLL CARDIOL, V36, P1152, DOI 10.1016/S0735-1097(00)00834-2; Teshima H, 2003, J THORAC CARDIOV SUR, V126, P401, DOI 10.1016/S0022-5223(03)00702-5; Shen AYJ, 2007, J AM COLL CARDIOL, V50, P309, DOI 10.1016/j.jacc.2007.01.098; Zellner JL, 1999, ANN THORAC SURG, V68, P1210, DOI 10.1016/S0003-4975(99)00985-6; Forcillo J, 2013, ANN THORAC SURG, V96, P486, DOI 10.1016/j.athoracsur.2013.03.032; NAKANO K, 1994, ANN THORAC SURG, V57, P697; Akins CW, 2008, ANN THORAC SURG, V85, P1490, DOI 10.1016/j.athoracsur.2007.12.082; Yoshikawa K, 2008, ANN THORAC SURG, V85, P1303, DOI 10.1016/j.athoracsur.2007.12.031; Oxenham H, 2003, HEART, V89, P715, DOI 10.1136/heart.89.7.715; Tominaga R, 2005, ANN THORAC SURG, V79, P784, DOI 10.1016/j.athoracsur.2004.08.067; Emery RW, 2003, ANN THORAC SURG, V75, P1815, DOI 10.1016/S0003-4975(03)00016-X; Dvir D, 2014, JAMA-J AM MED ASSOC, V312, P162, DOI 10.1001/jama.2014.7246; BAUDET EM, 1995, J THORAC CARDIOV SUR, V109, P858, DOI 10.1016/S0022-5223(95)70309-8; Suri RM, 2013, CIRCULATION, V128, P1372, DOI 10.1161/CIRCULATIONAHA.113.001681; KHAN S, 1994, J THORAC CARDIOV SUR, V108, P1010; Minakata K, 2015, J CARDIAC SURG, V30, P405, DOI 10.1111/jocs.12537; Nishimura RA, 2014, CIRCULATION, V129, P2440, DOI 10.1161/CIR.0000000000000029; AOYAGI S, 1994, J THORAC CARDIOV SUR, V108, P1021; Becker RC, 2001, AM HEART J, V141, P1025, DOI 10.1067/mhj.2001.115492; David TE, 2010, ANN THORAC SURG, V90, P775, DOI 10.1016/j.athoracsur.2010.05.034; Debetaz LF, 1997, J THORAC CARDIOV SUR, V113, P134, DOI 10.1016/S0022-5223(97)70409-4; Masuda M, 2014, GEN THORAC CARDIOVAS, V62, P734; Nishida Takahiro, 2013, Gen Thorac Cardiovasc Surg, V61, P182, DOI 10.1007/s11748-013-0202-z; Nishida T, 2014, CIRC J, V78, P2688, DOI 10.1253/circj.CJ-14-0466; Okita Y, 2012, GUIDELINES SURG INTE; Stassano P, 2009, J AM COLL CARDIOL, V54, P1862, DOI 10.1016/j.jacc.2009.07.032; Svensson LG, 2013, ANN THORAC SURG S, V95, pS1; Taniguchi Shinichiro, 2012, Gen Thorac Cardiovasc Surg, V60, P561, DOI 10.1007/s11748-012-0124-1	33	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2380	2388		10.1253/circj.CJ-15-0793		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900018		
J	Ikehara, S; Iso, H; Wada, Y; Tanabe, N; Watanabe, Y; Kikuchi, S; Tamakoshi, A				Ikehara, Satoyo; Iso, Hiroyasu; Wada, Yasuhiko; Tanabe, Naohito; Watanabe, Yoshiyuki; Kikuchi, Shogo; Tamakoshi, Akiko		JACC Study Grp	Television Viewing Time and Mortality From Stroke and Coronary Artery Disease Among Japanese Men and Women - The Japan Collaborative Cohort Study -	CIRCULATION JOURNAL			English	Article						Cardiovascular disease; Mortality; Prospective cohort study; Television viewing time	ALL-CAUSE MORTALITY; TYPE-2 DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; SEDENTARY BEHAVIORS; FOLLOW-UP; METABOLIC SYNDROME; EPIC-NORFOLK; RISK; ADULTS	Background: No study has examined the association between television (TV) viewing time and mortality from stroke and coronary artery disease (CAD) in Japanese. Methods and Results: A total of 35,959 men and 49,940 women aged 40-79 years without a history of cardiovascular disease (CVD) and cancer were followed from 1988-1990 until 2009. During 19.2 median years of follow-up, there were 2,553 deaths from stroke, 1,206 from CAD and 5,835 from total CVD. Compared with viewing TV for <2 h/day, mortality from stroke, CAD and total CVD were higher for >= 6 h/day of TV viewing. The multivariable hazard ratios (HRs) for >= 6 h/day of TV viewing were 1.15 (95% confidence interval: 0.96-1.37) for stroke, 1.33 (1.03-1.72) for CAD and 1.19 (1.06-1.34) for total CVD. The corresponding HRs for each 1-h/day increment in TV viewing time were 1.01 (0.99-1.04), 1.04 (1.01-1.08) and 1.02 (1.01-1.04), respectively. The excess risk of mortality from CAD and total CVD was somewhat attenuated after further adjustment for potential mediators such as history of hypertension and diabetes: the multivariable HRs for >= 6 h/day of TV viewing were 1.24 (0.96-1.61) and 1.14 (1.02-1.28). The corresponding HRs for each 1-h/day increment in TV viewing time were 1.03 (1.00-1.07) and 1.01 (1.00-1.03). Conclusions: Prolonged TV viewing was associated with a small but significant increase in mortality from CAD and total CVD in Japanese.	[Ikehara, Satoyo] Osaka Med Coll, Dept Hyg & Publ Hlth, Takatsuki, Osaka 569, Japan; [Ikehara, Satoyo; Iso, Hiroyasu] Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Publ Hlth, Suita, Osaka 5650871, Japan; [Wada, Yasuhiko] Kochi Univ, Dept Nutr, Kochi 780, Japan; [Tanabe, Naohito] Univ Niigata Prefecture, Fac Human Life Studies, Dept Hlth & Nutr, Niigata, Japan; [Watanabe, Yoshiyuki] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Epidemiol Community Hlth & Med, Kyoto, Japan; [Kikuchi, Shogo] Aichi Med Univ, Dept Publ Hlth, Nagakute, Aichi 48011, Japan; [Tamakoshi, Akiko] Hokkaido Univ, Grad Sch Med, Dept Publ Hlth, Sapporo, Hokkaido, Japan	Ikehara, S (reprint author), Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Publ Hlth, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	s-ikehara@pbhel.med.osaka-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan; Japanese Ministry of Education, Culture, Sports, Science and Technology [61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 11181101, 17015022, 18014011, 20014026, 20390156]; Comprehensive Research on Cardiovascular and LifeStyle Related Diseases [H26-Junkankitou [Seisaku]-Ippan-001]	The authors thank all staff members involved in this study for their valuable help in conducting the baseline survey and follow-up. This study was supported by Grants-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan, Grants-in-Aid for Scientific Research on Priority Areas of Cancer, as well as Grants-in-Aid for Scientific Research on Priority Areas of Cancer Epidemiology from the Japanese Ministry of Education, Culture, Sports, Science and Technology: 61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102, 11181101, 17015022, 18014011, 20014026 and 20390156, and Comprehensive Research on Cardiovascular and LifeStyle Related Diseases: H26-Junkankitou [Seisaku]-Ippan-001.	Grontved A, 2011, JAMA-J AM MED ASSOC, V305, P2448, DOI 10.1001/jama.2011.812; Tamakoshi A, 2013, J EPIDEMIOL, V23, P227, DOI 10.2188/jea.JE20120161; Wijndaele K, 2011, INT J EPIDEMIOL, V40, P150, DOI 10.1093/ije/dyq105; Stamatakis E, 2011, J AM COLL CARDIOL, V57, P292, DOI 10.1016/j.jacc.2010.05.065; Jakes RW, 2003, EUR J CLIN NUTR, V57, P1089, DOI 10.1038/sj.ejcn.1601648; Hu FB, 2003, JAMA-J AM MED ASSOC, V289, P1785, DOI 10.1001/jama.289.14.1785; Dunstan DW, 2005, DIABETOLOGIA, V48, P2254, DOI 10.1007/s00125-005-1963-4; Wijndaele K, 2010, MED SCI SPORT EXER, V42, P1511, DOI 10.1249/MSS.0b013e3181d322ac; Warren TY, 2010, MED SCI SPORT EXER, V42, P879, DOI 10.1249/MSS.0b013e3181c3aa7e; Healy GN, 2008, MED SCI SPORT EXER, V40, P639, DOI 10.1249/MSS.0b013e3181607421; Hu FB, 2001, ARCH INTERN MED, V161, P1542, DOI 10.1001/archinte.161.12.1542; Dunstan DW, 2010, CIRCULATION, V121, P384, DOI 10.1161/CIRCULATIONAHA.109.894824; Hansen ALS, 2012, DIABETIC MED, V29, P918, DOI 10.1111/j.1464-5491.2012.03656.x; Yamashita T, 1997, JPN CIRC J, V61, P331, DOI 10.1253/jcj.61.331; Kim Y, 2013, INT J EPIDEMIOL, V42, P1040, DOI 10.1093/ije/dyt108; Dunstan DW, 2007, DIABETES CARE, V30, P516, DOI 10.2337/dc06-1996; Tamakoshi A, 2004, SLEEP, V27, P51; Cui R, 2014, CIRC J, V78, P649, DOI 10.1253/circj.CJ-13-1057; Lucas M, 2011, AM J EPIDEMIOL, V174, P1017, DOI 10.1093/aje/kwr218; Sanchez-Villegas A, 2008, MED SCI SPORT EXER, V40, P827, DOI 10.1249/MSS.0b013e31816348b9; Matthews CE, 2012, AM J CLIN NUTR, V95, P437, DOI 10.3945/ajcn.111.019620; Wennberg P, 2013, DIABETES CARE, V36, P2090, DOI 10.2337/dc12-1948; Clark BK, 2009, OBES REV, V10, P7, DOI 10.1111/j.1467-789X.2008.00508.x; ISO H, 1990, AM J EPIDEMIOL, V132, P993; BABA S, 1994, CIRCULATION, V89, P109; Ford ES, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-70; Kobayashi T, 2010, SLEEPING TIME KEEPS; Pereira SMP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031132; Sankai T, 1991, Nihon Koshu Eisei Zasshi, V38, P901; Wijndaele K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020058; Yatsuya H, 2014, CIRC J, V78, P2807, DOI 10.1253/circj.CJ-14-0850	31	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2389	2395		10.1253/circj.CJ-14-1335		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900019		
J	Ushigome, R; Sakata, Y; Nochioka, K; Miyata, S; Miura, M; Tadaki, S; Yamauchi, T; Sato, K; Onose, T; Tsuji, K; Abe, R; Oikawa, T; Kasahara, S; Takahashi, J; Shimokawa, H				Ushigome, Ryoichi; Sakata, Yasuhiko; Nochioka, Kotaro; Miyata, Satoshi; Miura, Masanobu; Tadaki, Soichiro; Yamauchi, Takeshi; Sato, Kenjiro; Onose, Takeo; Tsuji, Kanako; Abe, Ruri; Oikawa, Takuya; Kasahara, Shintaro; Takahashi, Jun; Shimokawa, Hiroaki		CHART-2 Investigators	Temporal Trends in Clinical Characteristics, Management and Prognosis of Patients With Symptomatic Heart Failure in Japan - Report From the CHART Studies -	CIRCULATION JOURNAL			English	Article						Beta-blocker; Prognosis; Statin; Symptomatic heart failure	PRESERVED EJECTION FRACTION; CORONARY-ARTERY-DISEASE; SUDDEN CARDIAC DEATH; PRIMARY PREVENTION; OUTCOMES; REGISTRY; POPULATION; PREVALENCE; FRAMINGHAM; MORTALITY	Background: Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure (HF) remain to be elucidated in Japan. Methods and Results: From the Chronic Heart Failure Analysis and Registry in the Tohoku District-1 (CHART-1; 2000-2005, n=1,278) and CHART-2 (2006-present, n=10,219) Studies, we enrolled 1,006 and 3,676 consecutive symptomatic stage C/D HF patients, respectively. As compared with the patients in the CHART-1 Study, those in the CHART-2 Study had similar age and sex prevalence, and were characterized by lower brain natriuretic peptide, higher prevalence of preserved left ventricular ejection fraction (LVEF) and higher prevalence of hypertension, diabetes mellitus and ischemic heart disease (IHD), particularly IHD with LVEF >= 50%. From CHART-1 to CHART-2, use of renin-angiotensin system inhibitors, beta-blockers and aldosterone antagonists was significantly increased, while that of loop diuretics and digitalis was decreased. Three-year incidences of all-cause death (24 vs. 15%; adjusted hazard ratio [adjHR], 0.73; P<0.001), cardiovascular death (17 vs. 7%; adjHR, 0.38; P<0.001) and hospitalization for HF (30 vs. 17%; adjHR, 0.51; P<0.001) were all significantly decreased from CHART-1 to CHART-2. In the CHART-2 Study, use of beta-blockers was associated with improved prognosis in patients with LVEF <50%, while that of statins was associated with improved prognosis in those with LVEF >= 50%. Conclusions: Along with implementation of evidence-based medications, the prognosis of HF patients has been improved in Japan.	[Ushigome, Ryoichi; Sakata, Yasuhiko; Nochioka, Kotaro; Miura, Masanobu; Tadaki, Soichiro; Yamauchi, Takeshi; Sato, Kenjiro; Onose, Takeo; Tsuji, Kanako; Abe, Ruri; Oikawa, Takuya; Kasahara, Shintaro; Takahashi, Jun; Shimokawa, Hiroaki] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 9808574, Japan; [Miyata, Satoshi; Shimokawa, Hiroaki] Tohoku Univ, Grad Sch Med, Dept Evidence Based Cardiovasc Med, Sendai, Miyagi 9808574, Japan	Sakata, Y (reprint author), Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	sakatayk@cardio.med.tohoku.ac.jp			Ministry of Health, Labour, and Welfare	We thank all members of the Tohoku Heart Failure Society and staff of the Department of Evidence-based Cardiovascular Medicine for their contribution (Appendix S1). This study was supported by Grants-in-Aid from a Research Grant from the Ministry of Health, Labour, and Welfare (H.S.).	Ambrosy AP, 2014, J AM COLL CARDIOL, V63, P1123, DOI 10.1016/j.jacc.2013.11.053; Owan TE, 2006, NEW ENGL J MED, V355, P251, DOI 10.1056/NEJMoa052256; HO KKL, 1993, CIRCULATION, V88, P107; Shiba N, 2004, CIRC J, V68, P427, DOI 10.1253/circj.68.427; Adams KF, 2005, AM HEART J, V149, P209, DOI 10.1016/j.ahj.2004.08.005; Ushigome R, 2015, CIRC J, V79, P1332, DOI 10.1253/circj.CJ-14-0939; Solomon SD, 2005, NEW ENGL J MED, V352, P2581, DOI 10.1056/NEJMoa043938; Hamaguchi S, 2012, CIRC J, V76, P1662, DOI 10.1253/circj.CJ-11-1355; Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7; Hoang A, 2014, HEART RHYTHM, V11, P849, DOI 10.1016/j.hrthm.2014.02.019; Steinberg BA, 2012, CIRCULATION, V126, P65, DOI 10.1161/CIRCULATIONAHA.111.080770; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Zellweger MJ, 2012, J AM COLL CARDIOL, V59, P793, DOI 10.1016/j.jacc.2011.11.024; Shiba N, 2011, CIRC J, V75, P823, DOI 10.1253/circj.CJ-11-0135; Kirtane AJ, 2009, CIRCULATION, V119, P3198, DOI 10.1161/CIRCULATIONAHA.108.826479; Swedberg K, 2010, LANCET, V376, P875, DOI 10.1016/S0140-6736(10)61198-1; Nieminen MS, 2006, EUR HEART J, V27, P2725, DOI 10.1093/eurheartj/ehl193; Hannan EL, 2012, CIRCULATION, V125, P1870, DOI 10.1161/CIRCULATIONAHA.111.071811; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Douglas PS, 2009, J AM COLL CARDIOL, V53, P1629, DOI 10.1016/j.jacc.2009.03.005; Bhatia RS, 2006, NEW ENGL J MED, V355, P260, DOI 10.1056/NEJMoa051530; Sakata Y, 2013, CIRC J, V77, P2209, DOI 10.1253/circj.CJ-13-0971; Okura Y, 2008, CIRC J, V72, P489, DOI 10.1253/circj.72.489; Tsutsui H, 2007, CIRC J, V71, P449, DOI 10.1253/circj.71.449; CIBIS-II Investigators and Committees, 1999, LANCET, V352, P9; JCS Joint Working Group, GUID DIAGN TREATM PA; JCS Joint Working Group, 2013, CIRC J, V77, P249; JCS Joint Working Group, GUID MAN DIL CARD SE; Kober L, 1995, NEW ENGL J MED, V80, P257; Nochioka K, 2015, CIRC J, V79, P574, DOI 10.1253/circj.CJ-14-0865; Satake H, 2015, CIRC J, V79, P381, DOI 10.1253/circj.CJ-14-0925; Shimokawa H, 2015, EUR J HEART FAIL, V17, P884, DOI 10.1002/ejhf.319; Yancy CW, 2013, CIRCULATION, V128, pE240, DOI 10.1161/CIR.0b013e31829e8776	36	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2396	+		10.1253/circj.CJ-15-0514		13	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900020		
J	Kanda, T; Fujita, M; Iida, O; Masuda, M; Okamoto, S; Ishihara, T; Nanto, K; Shiraki, T; Takahara, M; Sakata, Y; Uematsu, M				Kanda, Takashi; Fujita, Masashi; Iida, Osamu; Masuda, Masaharu; Okamoto, Shin; Ishihara, Takayuki; Nanto, Kiyonori; Shiraki, Tatsuya; Takahara, Mitsuyoshi; Sakata, Yasushi; Uematsu, Masaaki			Novel Echocardiographic Approach to the Accurate Measurement of Pulmonary Vascular Resistance Based on a Theoretical Formula in Patients With Left Heart Failure - Pilot Study -	CIRCULATION JOURNAL			English	Article						Pulmonary vascular resistance; Right heart catheterization; Transthoracic echocardiography	PULSED DOPPLER TECHNIQUE; NONINVASIVE ESTIMATION; ARTERY PRESSURE; TRICUSPID REGURGITATION; TASK-FORCE; HYPERTENSION; ASSOCIATION; CARDIOLOGY; CATHETERIZATION; ULTRASOUND	Background: Several non-invasive methods for measuring pulmonary vascular resistance (PVR) have been proposed to date, but they remain empirical, lacking sufficient accuracy to be used in clinical practice. The aims of this study were to propose a novel echocardiographic measurement of PVR based on a theoretical formula and investigate the feasibilty and accuracy of this method in patients with heart failure. Methods and Results: Echocardiography was performed in 27 patients before right heart catheterization. Peak tricuspid regurgitation pressure gradient (TRPG), pulmonary regurgitation pressure gradient in end-diastole (PRPG(ed)), and cardiac output derived from the time-velocity integral and the diameter in the left ventricular outflow tract (COLVOT) were measured. PVR based on a theoretical formula (PVRtheo) was calculated as (TRPG-PRPG(ed))/3CO(LVOT) in Wood units (WU). The results were compared with PVR obtained by right heart catheterization (PVRcath) using linear regression and Bland-Altman analysis. Mean PVRcath was 2.4 +/- 1.4 WU. PVRtheo correlated well with PVRcath (r=0.83, P<0.001). On Bland-Altman analysis the mean difference was 0.1 +/- 0.7 WU. The limits of agreements were smaller than for other non-invasive estimations previously reported. Conclusions: The new echocardiographic approach based on a theoretical formula provides a non-invasive and accurate assessment of PVR in patients with heart failure.	[Kanda, Takashi; Fujita, Masashi; Iida, Osamu; Masuda, Masaharu; Okamoto, Shin; Ishihara, Takayuki; Nanto, Kiyonori; Shiraki, Tatsuya; Uematsu, Masaaki] Kansai Rosai Hosp, Cardiovasc Ctr, Amagasaki, Hyogo 6608511, Japan; [Takahara, Mitsuyoshi] Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka, Japan; [Sakata, Yasushi] Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Suita, Osaka, Japan	Uematsu, M (reprint author), Kansai Rosai Hosp, Cardiovasc Ctr, 3-1-69 Inabaso, Amagasaki, Hyogo 6608511, Japan.	ueamatsu@kanrou.net					Hirashiki A, 2014, CIRC J, V78, P1245, DOI 10.1253/circj.CJ-13-1120; Abbas AE, 2003, J AM COLL CARDIOL, V41, P1021, DOI 10.1016/S0735-1097(02)02973-X; Scapellato F, 2001, J AM COLL CARDIOL, V37, P1813, DOI 10.1016/S0735-1097(01)01271-2; NICHOL PM, 1977, CIRCULATION, V55, P120; KITABATAKE A, 1983, CIRCULATION, V68, P302; Yeo TC, 1998, AM J CARDIOL, V81, P1157, DOI 10.1016/S0002-9149(98)00140-4; BERGER M, 1985, J AM COLL CARDIOL, V6, P359; Guazzi M, 2012, CIRCULATION, V126, P975, DOI 10.1161/CIRCULATIONAHA.111.085761; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, P685, DOI 10.1016/j.echo.2010.05.010; Haddad F, 2009, J AM SOC ECHOCARDIOG, V22, P523, DOI 10.1016/j.echo.2009.01.021; DABESTANI A, 1987, AM J CARDIOL, V59, P662, DOI 10.1016/0002-9149(87)91189-1; CURRIE PJ, 1985, CIRCULATION, V71, P1162; D'Alto M, 2013, INT J CARDIOL, V168, P4058, DOI 10.1016/j.ijcard.2013.07.005; SAKAI K, 1984, AM HEART J, V108, P516, DOI 10.1016/0002-8703(84)90417-4; Yancy CW, 2013, J AM COLL CARDIOL, V62, pE147, DOI 10.1016/j.jacc.2013.05.019; Kouzu H, 2009, AM J CARDIOL, V103, P872, DOI 10.1016/j.amjcard.2008.11.039; Chemla D, 2002, EUR RESPIR J, V20, P1314, DOI 10.1183/09031936.02.00068002; MARTIN RP, 1979, AM J CARDIOL, V43, P560, DOI 10.1016/0002-9149(79)90014-6; EYSMANN SB, 1989, CIRCULATION, V80, P353; McLaughlin VV, 2009, CIRCULATION, V119, P2250, DOI 10.1161/CIRCULATIONAHA.109.192230; MASUYAMA T, 1986, CIRCULATION, V74, P484; BRAUNWALD E, 1984, NEW ENGL J MED, V310, P459, DOI 10.1056/NEJM198402163100711; CHAN KL, 1987, J AM COLL CARDIOL, V9, P549; JCS Joint Working Group, 2011, CIRC J, V77, P2157; BLAND JM, 1986, LANCET, V1, P307; Roule V, 2010, CARDIOVASC ULTRASOUN, V8, DOI 10.1186/1476-7120-8-21; Rudski LG, 2010, J AM SOC ECHOCARDIOG, V23, p:, DOI DOI 10.1016/J.ECH0.2010.05.010	27	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2408	2413		10.1253/circj.CJ-15-0575		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900021		
J	Imamura, T; Kinugawa, K; Nitta, D; Komuro, I				Imamura, Teruhiko; Kinugawa, Koichiro; Nitta, Daisuke; Komuro, Issei			Complete Left Bundle Branch Block and Smaller Left Atrium Are Predictors of Response to Cardiac Resynchronization Therapy in Advanced Heart Failure	CIRCULATION JOURNAL			English	Article						Electrocardiography; Response; Ventricular assist device	SUPER-RESPONSE; DEVICE IMPLANTATION; POOR-PROGNOSIS; TRIAL	Background: We previously reported that cardiac resynchronization therapy with defibrillator (CRT-D) is not an appropriate rescue strategy in patients with advanced heart failure (HF), especially those dependent on inotrope infusion, and instead early ventricular assist device (VAD) implantation should be considered. Predictors of response to CRT in such populations, however, remain uncertain. Methods and Results: We studied 67 inpatients aged <65 years old with advanced HF, who received CRT-D between 2007 and 2014. Eleven patients (16%) were responders, in whom LVEF improved >10% at 6-month follow up. On logistic regression analysis, LA volume index (LAVI) <43 ml/m(2) (odds ratio (OR), 36.67; P=0.001) and complete left bundle branch block (CLBBB; OR, 6.663; P=0.032) were significant predictors of response to CRT-D among the baseline variables. Patients with both predictors were associated with improvements in LVEF and plasma B-type natriuretic peptide compared with those with none of these predictors during the 6-month follow up period (P<0.05 for both). VAD-free survival rate was significantly higher in the responders compared with the non-responders during the 2-year study period (86% vs. 52%, P=0.044). Conclusions: CLBBB and smaller LAVI are novel predictors of response in patients with advanced HF receiving CRT-D in real-world practice. Such responders may be better candidates for CRT-D and delay of cardiac replacement therapy.	[Imamura, Teruhiko; Kinugawa, Koichiro] Univ Tokyo, Grad Sch Med, Dept Therapeut Strategy Heart Failure, Tokyo 1138655, Japan; [Nitta, Daisuke; Komuro, Issei] Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Tokyo 1138655, Japan	Kinugawa, K (reprint author), Univ Tokyo, Grad Sch Med, Dept Therapeut Strategy Heart Failure, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kinugawa-tky@umin.ac.jp					Imamura T, 2014, CIRC J, V78, P1396, DOI 10.1253/circj.CJ-14-0077; Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540; Imamura T, 2014, J ARTIF ORGANS, V17, P23, DOI 10.1007/s10047-013-0748-7; Chung ES, 2008, CIRCULATION, V117, P2608, DOI 10.1161/CIRCULATIONAHA.107.743120; Imamura T, 2015, J CARD FAIL, V21, P535, DOI 10.1016/j.cardfail.2015.04.009; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685; Imamura T, 2014, CIRC J, V78, P2259, DOI 10.1253/circj.CJ-14-0368; Moss AJ, 2009, NEW ENGL J MED, V361, P1329, DOI 10.1056/NEJMoa0906431; Stefan L, 2012, EUROPACE, V14, P1608, DOI 10.1093/europace/eus075; Tian Y, 2013, EUROPACE, V15, P1499, DOI 10.1093/europace/eut049; Khatib M, 2014, EUR J HEART FAIL, V16, P802, DOI 10.1002/ejhf.102; Kinugawa K, 2011, CIRC J, V75, P2038, DOI 10.1253/circj.CJ-11-0621; Yanagisawa S, 2014, PACE, V37, P1553, DOI 10.1111/pace.12506; Ruschitzka F, 2013, NEW ENGL J MED, V369, P1395, DOI 10.1056/NEJMoa1306687; Hsu JC, 2012, J AM COLL CARDIOL, V59, P2366, DOI 10.1016/j.jacc.2012.01.065; Bajraktari G, 2015, ECHOCARDIOGR-J CARD, V32, P150, DOI 10.1111/echo.12775; Chandraprakasam Satish, 2015, Curr Heart Fail Rep, V12, P48, DOI 10.1007/s11897-014-0234-4; JCS Joint Working Group, 2013, CIRC J, V77, P249; Khazanie P, 2014, CIRC-HEART FAIL, V7, P926, DOI 10.1161/CIRCHEARTFAILURE.113.000838; Linde C, 2015, EUROPACE, V17, P171, DOI 10.1093/europace/euu283; Shah RM, 2015, EUROPACE, V17, P267, DOI 10.1093/europace/euu214	21	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2414	+		10.1253/circj.CJ-15-0769		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900022		
J	Shimabukuro, M; Saito, T; Higa, T; Nakamura, K; Masuzaki, H; Sata, M				Shimabukuro, Michio; Saito, Taro; Higa, Toru; Nakamura, Keita; Masuzaki, Hiroaki; Sata, Masataka		Fukuoka Diabetologists Grp	Risk Stratification of Coronary Artery Disease in Asymptomatic Diabetic Subjects Using Multidetector Computed Tomography	CIRCULATION JOURNAL			English	Article						Coronary atherosclerosis; Diabetes mellitus; Multidetector computed tomography; Sex difference	AMERICAN-HEART-ASSOCIATION; CARDIOVASCULAR-DISEASE; CARDIAC EVENTS; CT ANGIOGRAPHY; MORTALITY; RETINOPATHY; TRIAL; MELLITUS; WOMEN; MICROALBUMINURIA	Background: Patients with type 2 diabetes mellitus (T2DM) show a greater risk for coronary artery disease (CAD), but the risk stratification in asymptomatic CAD patients has not been established. This study investigated the prevalence and severity for asymptomatic CAD and predictors in T2DM patients. Methods and Results: In a multiclinic group, diabetic patients (320 men, 186 women) without known symptoms suggestive of CAD were recruited for multidetector computed tomography (MDCT). Patients were categorized according to severity of coronary atherosclerosis: Grade 1 (normal findings), Grade 2 (mild atherosclerosis without significant stenosis), Grade 3 (moderate stenosis/atherosclerosis, 50-74% stenosis), Grade 4 (moderate stenosis/atherosclerosis, 75-89% stenosis), Grade 5 (severe stenosis/atherosclerosis, >= 90% stenosis). The trend for severity grade of CAD was slightly higher in men than women (P=0.054). For critical lesions (combined Grades 3-5), the prevalence was almost equal (men 44% vs. women 37%; P=0.113). Multivariate models showed that in men, HbA(1c) >= 7.4%, dyslipidemia, duration of diabetes, retinopathy, and other type of cardiovascular diseases were predictors of critical lesions and in women, duration of diabetes and retinopathy were predictors. Conclusions: The prevalence and severity of asymptomatic CAD are comparably high in men and women with T2DM. Risk stratification by using MDCT might be useful to predict asymptomatic coronary lesions requiring coronary revascularization.	[Shimabukuro, Michio] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Cardiodiabet Med, Tokushima 7708503, Japan; [Sata, Masataka] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Cardiovasc Med, Tokushima 7708503, Japan; [Saito, Taro; Higa, Toru; Nakamura, Keita] Fukuoka Wajiro Hosp, Heart & Neurovasc Ctr, Fukuoka, Japan; [Masuzaki, Hiroaki] Univ Ryukyus, Grad Sch Med, Dept Internal Med 2, Div Endocrinol Diabet & Metab,Hematol,Rheumatol, Okinawa, Japan	Shimabukuro, M (reprint author), Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Cardiodiabet Med, 318-15 Kuramoto, Tokushima 7708503, Japan.	mshimabukuro-ur@umin.ac.jp; tsaito1948@me.com			Ministry of Education, Culture, Sports, Science, and Technology, Japan [20590651, 23591314, 20590542]; Ministry of Health, Labour, and Welfare (MHLW), Japan	This study was supported in parts by grants from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (20590651, 23591314, 20590542); the Ministry of Health, Labour, and Welfare (MHLW), Japan.	AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827; American Diabetes Association, 2015, DIABETES CARE S1, V38, pS49; Choi EK, 2007, DIABETIC MED, V24, P1003, DOI 10.1111/j.1464-5491.2007.02182.x; Miettinen H, 1996, DIABETES CARE, V19, P1445, DOI 10.2337/diacare.19.12.1445; Juutilainen A, 2007, DIABETES CARE, V30, P292, DOI 10.2337/dc06-1747; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Muhlestein JB, 2014, JAMA-J AM MED ASSOC, V312, P2234, DOI 10.1001/jama.2014.15825; Seino Y, 2010, J DIABETES INVEST, V1, P212, DOI 10.1111/j.2040-1124.2010.00074.x; Grundy SM, 1999, CIRCULATION, V100, P1134; Rana JS, 2012, DIABETES CARE, V35, P1787, DOI 10.2337/dc11-2403; Jeong HC, 2014, CIRC J, V78, P671, DOI 10.1253/circj.CJ-13-1038; Norhammar A, 2013, DIABETOLOGIA, V56, P1, DOI 10.1007/s00125-012-2694-y; Tanasescu M, 2004, AM J CLIN NUTR, V79, P999; Yuyun MF, 2005, CURR OPIN NEPHROL HY, V14, P271, DOI 10.1097/01.mnh.0000165895.90748.3b; Bax JJ, 2007, DIABETES CARE, V30, P2729, DOI 10.2337/dc07-9927; Shaw LJ, 2010, CIRC-CARDIOVASC IMAG, V3, P473, DOI 10.1161/CIRCIMAGING.109.860981; Sakata Y, 2014, CIRC J, V78, P428, DOI 10.1253/circj.CJ-13-1009; Ryden L, 2013, EUR HEART J, V34, P3035, DOI 10.1093/eurheartj/eht108; Reaven PD, 2008, DIABETES CARE, V31, P952, DOI 10.2337/dc07-1926; Scognamiglio R, 2006, J AM COLL CARDIOL, V47, P65, DOI 10.1016/j.jacc.2005.10.008; Young LH, 2009, JAMA-J AM MED ASSOC, V301, P1547, DOI 10.1001/jama.2009.476; Upchurch CT, 2012, J CLIN ENDOCR METAB, V97, P1434, DOI 10.1210/jc.2011-2122; Faglia E, 2002, DIABETES CARE, V25, P2032, DOI 10.2337/diacare.25.11.2032; Carrigan TP, 2009, EUR HEART J, V30, P362, DOI 10.1093/eurheartj/ehn605; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Cosson E, 2011, DIABETES CARE, V34, P2101, DOI 10.2337/dc11-0480; Valmadrid CT, 2000, ARCH INTERN MED, V160, P1093, DOI 10.1001/archinte.160.8.1093; Fox CS, 2012, LANCET, V380, P1662, DOI 10.1016/S0140-6736(12)61350-6; Kengne AP, 2011, EUR J CARDIOV PREV R, V18, P393, DOI 10.1177/1741826710394270; Cheung N, 2007, DIABETES CARE, V30, P1742, DOI 10.2337/dc07-0264; Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8; Sorajja P, 2005, CIRCULATION, V112, pI311, DOI 10.1161/CIRCULATIONAHA.104.525022; FRIEDEWA.WT, 1972, CLIN CHEM, V18, P499; Hwang Y, 2010, CLIN RADIOL, V65, P601, DOI 10.1016/j.crad.2010.04.009; Lievre MM, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-23; Taylor AJ, 2010, J AM COLL CARDIOL, V56, P1864, DOI 10.1016/j.jacc.2010.07.005	36	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2422	+		10.1253/circj.CJ-15-0325		10	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900023		
J	Okuyama, N; Matsuda, S; Yamashita, A; Moriguchi-Goto, S; Sameshima, N; Iwakiri, T; Matsuura, Y; Sato, Y; Asada, Y				Okuyama, Nozomi; Matsuda, Shuntaro; Yamashita, Atsushi; Moriguchi-Goto, Sayaka; Sameshima, Naoki; Iwakiri, Takashi; Matsuura, Yunosuke; Sato, Yuichiro; Asada, Yujiro			Human Coronary Thrombus Formation Is Associated With Degree of Plaque Disruption and Expression of Tissue Factor and Hexokinase II	CIRCULATION JOURNAL			English	Article						Acute myocardial infarction; Glycolysis; Macrophage polarization; Pathology; Vascular thrombogenicity	ACUTE MYOCARDIAL-INFARCTION; ATHEROSCLEROTIC LESIONS; MACROPHAGE POLARIZATION; KAPPA-B; RECEPTOR; ARTERIES; RUPTURE; HYPOXIA; STRESS; CELLS	Background: Atherosclerotic plaque thrombogenicity is a critical factor that affects thrombus formation and the onset of acute myocardial infarction (AMI). The aim of this study was to identify the vascular factors involved in thrombus formation and AMI onset. Methods and Results: Culprit lesions in 40 coronary arteries with thrombi at autopsy after lethal AMI and non-cardiac death (asymptomatic plaque disruption) were analyzed on histology. Thrombus size, ratio of thrombus to lumen area, length of plaque disruption, and immunopositive areas for tissue factor (TF) and hexokinase (HK)-II were significantly larger in coronary arteries with AMI than with asymptomatic plaque disruption. The size of coronary thrombus positively correlated with the length of plaque disruption (r=0.80) and with immunopositive areas for TF (r=0.38) and HK-II (r=0.40). Because both M1 and M2 macrophages express TF and HK-II in symptomatic plaques, we assessed TF and HK-II expression in M1- and M2-polarized macrophages. The expression of TF was increased and that of HK-II was decreased in M2-, compared with M1-polarized THP-1 macrophages. Inhibiting glycolysis enhanced TF expression in the macrophages partly via hypoxia inducible factor-1 alpha. Conclusions: The degree of plaque disruption and expression of TF and HK-II appear to be important vascular factors for AMI onset, and polarized macrophages make a distinct contribution to thrombogenicity and glucose metabolism.	[Okuyama, Nozomi; Yamashita, Atsushi; Sameshima, Naoki; Asada, Yujiro] Miyazaki Univ, Miyazaki Univ Hosp, Dept Pathol, Miyazaki 8891692, Japan; [Matsuda, Shuntaro] Miyazaki Univ, Miyazaki Univ Hosp, Div Community & Family Med, Miyazaki 8891692, Japan; [Iwakiri, Takashi; Matsuura, Yunosuke] Miyazaki Univ, Miyazaki Univ Hosp, Dept Internal Med, Miyazaki 8891692, Japan; [Moriguchi-Goto, Sayaka; Sato, Yuichiro] Miyazaki Univ, Miyazaki Univ Hosp, Fac Med, Dept Diagnost Pathol, Miyazaki 8891692, Japan	Yamashita, A (reprint author), Miyazaki Univ, Fac Med, Dept Pathol, 5200 Kihara, Miyazaki 8891692, Japan.	atsushi_yamashita@med.miyazaki-u.ac.jp			Ministry of Education, Science, Sports and Culture of Japan [25460440, 23390084]; Mitsui Life Welfare Foundation; National Cerebral and Cardiovascular Center [25-4-3]; Bayer Scholarship for Cardiovascular Research	This study was supported in part by Grants-in-Aid for Scientific Research in Japan (Nos. 25460440, 23390084) from the Ministry of Education, Science, Sports and Culture of Japan, Mitsui Life Welfare Foundation, Intramural Research Fund (25-4-3) for Cardiovascular Diseases of National Cerebral and Cardiovascular Center, and The Bayer Scholarship for Cardiovascular Research.	Owens AP, 2010, THROMB HAEMOSTASIS, V104, P432, DOI 10.1160/TH09-11-0771; Han XB, 2015, THROMB HAEMOSTASIS, V113, P505, DOI 10.1160/TH14-06-0509; HACKETT D, 1988, EUR HEART J, V9, P1317; Tavakoli S, 2013, J NUCL MED, V54, P1661, DOI 10.2967/jnumed.112.119099; Yamashita A, 2012, ATHEROSCLEROSIS, V224, P511, DOI 10.1016/j.atherosclerosis.2012.07.027; Burke AP, 2001, CIRCULATION, V103, P934; Yunoki K, 2009, EUR HEART J, V30, P1844, DOI 10.1093/eurheartj/ehp257; Sato Y, 2009, THROMB RES, V124, P19, DOI 10.1016/j.thromres.2008.08.026; Ogawa M, 2004, J NUCL MED, V45, P1245; Sumi T, 2010, J THROMB HAEMOST, V8, P1394, DOI 10.1111/j.1538-7836.2010.03843.x; Rodriguez-Prados JC, 2010, J IMMUNOL, V185, P605, DOI 10.4049/jimmunol.0901698; Mackman N, 2008, NATURE, V451, P914, DOI 10.1038/nature06797; Okada K, 2011, AM J CARDIOL, V107, P1426, DOI 10.1016/j.amjcard.2011.01.016; De Paoli F, 2014, CIRC J, V78, P1775, DOI 10.1253/circj.CJ-14-0621; Huo YQ, 2010, J BIOL CHEM, V285, P3713, DOI 10.1074/jbc.M109.058446; Stone GW, 2011, NEW ENGL J MED, V364, P226, DOI 10.1056/NEJMoa1002358; Park SH, 2012, ARTERIOSCL THROM VAS, V32, P2869, DOI 10.1161/ATVBAHA.112.254573; Nishihira K, 2013, CIRC J, V77, P1275, DOI 10.1253/circj.CJ-12-0911; Satomi T, 2013, J NUCL MED, V54, P999, DOI 10.2967/jnumed.112.110551; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Mauriello A, 2011, ATHEROSCLEROSIS, V218, P356, DOI 10.1016/j.atherosclerosis.2011.06.056; Rogers IS, 2010, JACC-CARDIOVASC IMAG, V3, P388, DOI 10.1016/j.jcmg.2010.01.004; Sluimer JC, 2008, J AM COLL CARDIOL, V51, P1258, DOI 10.1016/j.jacc.2007.12.025; Varnava AM, 2002, CIRCULATION, V105, P939, DOI 10.1161/hc0802.104327; BRAND K, 1991, MOL CELL BIOL, V11, P4732; Hatakeyama K, 1997, ATHEROSCLEROSIS, V133, P213, DOI 10.1016/S0021-9150(97)00132-9; Smits PC, 1999, HEART, V82, P461; Dehne N, 2010, EXP CELL RES, V316, P1179, DOI 10.1016/j.yexcr.2010.02.019; Haschemi A, 2012, CELL METAB, V15, P813, DOI 10.1016/j.cmet.2012.04.023; Matsuura Y, 2015, THROMB HAEMOSTASIS, V114, P158, DOI 10.1160/TH14-09-0794; Yamashita A, 2006, AM J CARDIOL, V97, P26, DOI 10.1016/j.amjcard.2005.07.105; Yamashita A, 2013, CIRC J, V77, P2626, DOI 10.1253/circj.CJ-12-1463; Yunoki K, 2013, J ATHEROSCLER THROMB, V20, P524; Ham M, 2013, MOL CELL BIOL, V33, P2425, DOI 10.1128/MCB.01260-12; Tawakol A, 2006, J AM COLL CARDIOL, V48, P1818, DOI 10.1016/j.jacc.2006.05.076; Sameshima N, 2014, J ATHEROSCLER THROMB, V21, P831	36	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2430	+		10.1253/circj.CJ-15-0394		10	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900024		
J	Nishi, T; Ariyoshi, N; Nakayama, T; Fujimoto, Y; Sugimoto, K; Takahara, M; Wakabayashi, S; Koshizaka, M; Hanaoka, H; Kobayashi, Y				Nishi, Takeshi; Ariyoshi, Noritaka; Nakayama, Takashi; Fujimoto, Yoshihide; Sugimoto, Kazumasa; Takahara, Masayuki; Wakabayashi, Shinichi; Koshizaka, Masaya; Hanaoka, Hideki; Kobayashi, Yoshio			Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Japanese Patients With Stable Coronary Artery Disease	CIRCULATION JOURNAL			English	Article						Clopidogrel; Percutaneous coronary intervention; Platelet resistance; Prasugrel	OF-CARE ASSAY; ANTIPLATELET THERAPY; STENT IMPLANTATION; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; GREATER INHIBITION; DOUBLE-BLIND; PRASFIT-ACS; REACTIVITY; INTERVENTION	Background: The pharmacodynamic effects of changing from standard-dose clopidogrel to low-dose (3.75 mg) prasugrel in Japanese patients are largely unknown. Methods and Results: A total of 53 consecutive Japanese patients with stable coronary artery disease (CAD) who received aspirin and clopidogrel were enrolled. Clopidogrel was switched to 3.75 mg prasugrel. At day 14, prasugrel was switched to 75 mg clopidogrel. Platelet reactivity was measured using the Verify Now assay at baseline, day 14, and day 28. VerifyNow P2Y12 reaction units (PRU) >208 was defined as high on-treatment platelet reactivity (HPR). The prevalence of HPR (18.9% vs. 41.5% vs. 44.2%, P<0.001) and the PRU level (154.3 +/- 54.2 vs. 196.2 +/- 55.5 vs. 194.6 +/- 55.8, P<0.001) were significantly lower on prasugrel maintenance therapy compared with the clopidogrel therapy before and after switching. The CYP2C19 genotypes that account for the 3 phenotypes (ie, extensive metabolizer, intermediate metabolizer, and poor metabolizer) had a significant impact on platelet reactivity with clopidogrel (174.9 +/- 54.0 vs. 193.1 +/- 56.5 vs. 240.6 +/- 25.4 PRU, P<0.001) but not prasugrel (147.0 +/- 51.9 vs. 147.5 +/- 58.3 vs. 184.4 +/- 38.3 PRU, P=0.15). Conclusions: Low-dose prasugrel achieves stronger platelet inhibition than clopidogrel in Japanese patients with stable CAD.	[Nishi, Takeshi; Nakayama, Takashi; Fujimoto, Yoshihide; Sugimoto, Kazumasa; Takahara, Masayuki; Wakabayashi, Shinichi; Kobayashi, Yoshio] Chiba Univ, Dept Cardiovasc Med, Grad Sch Med, Chiba 2608677, Japan; [Ariyoshi, Noritaka] Chiba Univ, Sch Med, Univ Hosp, Div Pharm, Chiba 2608677, Japan; [Ariyoshi, Noritaka; Koshizaka, Masaya; Hanaoka, Hideki] Chiba Univ, Sch Med, Univ Hosp, Clin Res Ctr, Chiba 2608677, Japan	Nishi, T (reprint author), Chiba Univ, Dept Cardiovasc Med, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608677, Japan.	takeshi24@hotmail.co.jp			Daiichi-Sankyo (Tokyo, Japan); Sanofi (Paris, France)	Y.K. received research funding from Daiichi-Sankyo (Tokyo, Japan) and Sanofi (Paris, France).	Angiolillo DJ, 2007, J AM COLL CARDIOL, V49, P1505, DOI 10.1016/j.jacc.2006.11.044; Parodi G, 2014, J THROMB THROMBOLYS, V38, P395, DOI 10.1007/s11239-013-1040-7; Wiviott SD, 2007, CIRCULATION, V116, P2923, DOI 10.1161/CIRCULATIONAHA.107.740324; Gurbel PA, 2005, J AM COLL CARDIOL, V46, P1820, DOI 10.1016/j.jacc.2005.07.041; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Angiolillo DJ, 2010, J AM COLL CARDIOL, V56, P1017, DOI 10.1016/j.jacc.2010.02.072; Price MJ, 2008, EUR HEART J, V29, P992, DOI 10.1093/eurheartj/ehn046; Roe MT, 2012, NEW ENGL J MED, V367, P1297, DOI 10.1056/NEJMoa1205512; Tantry US, 2013, J AM COLL CARDIOL, V62, P2261, DOI 10.1016/j.jacc.2013.07.101; Breet NJ, 2010, JAMA-J AM MED ASSOC, V303, P754, DOI 10.1001/jama.2010.181; Price MJ, 2009, CIRCULATION, V119, P2625, DOI 10.1161/CIRCULATIONAHA.107.696732; Jernberg T, 2006, EUR HEART J, V27, P1166, DOI 10.1093/eurheartj/ehi877; Stone GW, 2013, LANCET, V382, P614, DOI 10.1016/S0140-6736(13)61170-8; Patti G, 2008, J AM COLL CARDIOL, V52, P1128, DOI 10.1016/j.jacc.2008.06.038; Trenk D, 2012, J AM COLL CARDIOL, V59, P2159, DOI 10.1016/j.jacc.2012.02.026; Muller I, 2003, THROMB HAEMOSTASIS, V89, P783; Payne CD, 2008, PLATELETS, V19, P275, DOI 10.1080/09537100801891640; Gurbel PA, 2003, CIRCULATION, V107, P2908, DOI 10.1161/01.CIR.0000072771.11429.83; Saito S, 2014, CIRC J, V78, P1684, DOI 10.1253/circj.CJ-13-1482; Alexopoulos D, 2011, AM HEART J, V162, P733, DOI 10.1016/j.ahj.2011.07.026; Mehran R, 2008, AM HEART J, V156, P44, DOI 10.1016/j.ahj.2008.02.008; Kimura T, 2015, J ATHEROSCLER THROMB, V22, P557, DOI 10.5551/jat.26013; Marcucci R, 2009, CIRCULATION, V119, P237, DOI 10.1161/CIRCULATIONAHA.108.812636; Serebruany VL, 2005, J AM COLL CARDIOL, V45, P246, DOI 10.1016/j.jacc.2004.09.067; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Farid NA, 2010, J CLIN PHARMACOL, V50, P126, DOI 10.1177/0091270009343005; Suzuki S, 2007, CIRC J, V71, P761, DOI 10.1253/circj.71.761; Mallouk N, 2012, THROMB HAEMOSTASIS, V107, P494, DOI 10.1160/TH11-03-0202; Neubauer H, 2010, THROMB RES, V126, pE389, DOI 10.1016/j.thromres.2010.06.005; Cuisset T, 2006, J THROMB HAEMOST, V4, P542, DOI 10.1111/j.1538-7836.2005.01751.x; Hochholzer W, 2006, J AM COLL CARDIOL, V48, P1742, DOI 10.1016/j.jacc.2006.06.065; Isshiki T, 2014, CIRC J, V78, P2926, DOI 10.1253/circj.CJ-14-0266; Nakamura M, 2015, INT J CARDIOL, V182, P541, DOI 10.1016/j.ijcard.2015.01.026	33	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2439	2444		10.1253/circj.CJ-15-0546		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900025		
J	Goto, S; Huang, CH; Park, SJ; Emanuelsson, H; Kimura, T				Goto, Shinya; Huang, Chien-Hua; Park, Seung-Jung; Emanuelsson, Hakan; Kimura, Takeshi			Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese Patients With Acute Coronary Syndrome - Randomized, Double-Blind, Phase III PHILO Study -	CIRCULATION JOURNAL			English	Article						Acute coronary syndrome; Clopidogrel; East Asia; Japan; Ticagrelor	ACUTE MYOCARDIAL-INFARCTION; ELUTING STENT IMPLANTATION; ASSOCIATION TASK-FORCE; ST-SEGMENT ELEVATION; ANTIPLATELET THERAPY; HIGH-RISK; PLATELET INHIBITION; PRACTICE GUIDELINES; AMERICAN-COLLEGE; MANAGEMENT	Background: Few data on the relative efficacy and safety of new P2Y12 inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist. Methods and Results: The multicenter, double-blind, randomized PHILO trial compared the safety and efficacy of ticagrelor vs. clopidogrel in 801 patients with ACS (Japanese, n=721; Taiwanese, n=35; South Korean, n=44; unknown ethnicity, n=1). All were planned to undergo percutaneous coronary intervention and randomized within 24 h of symptom onset. Primary safety and efficacy endpoints were time to first occurrence of any major bleeding event and to any event from the composite of myocardial infarction, stroke or death from vascular causes, respectively. At 12 months, overall major bleeding occurred in 10.3% of ticagrelor-treated patients and in 6.8% of clopidogrel-treated patients (hazard ratio (HR), 1.54; 95% confidence interval (CI): 0.94-2.53); the composite primary efficacy endpoint occurred in 9.0% and in 6.3% of ticagrelor-and clopidogrel-treated patients, respectively (HR, 1.47; 95% CI: 0.88-2.44). For both analyses, the difference between groups was not statistically significant. Conclusions: In ACS patients from Japan, Taiwan and South Korea, event rates of primary safety and efficacy endpoints were higher, albeit not significantly, in ticagrelor-treated patients compared with clopidogrel-treated patients. This observation could be explained by the small sample size, imbalance in clinical characteristics and low number of events in the PHILO population.	[Goto, Shinya] Tokai Univ, Dept Med Cardiol, Sch Med, Isehara, Kanagawa 2591143, Japan; [Huang, Chien-Hua] Natl Taiwan Univ, Dept Emergency Med & Internal Med, Taipei 10764, Taiwan; [Park, Seung-Jung] Ulsan Sch Med, Div Cardiol, Ulsan, South Korea; [Emanuelsson, Hakan] AstraZeneca, Molndal, Sweden; [Kimura, Takeshi] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto, Japan	Goto, S (reprint author), Tokai Univ, Dept Med Cardiol, Sch Med, 143 Shimokasuya, Isehara, Kanagawa 2591143, Japan.	shinichi@is.icc.u-tokai.ac.jp			AstraZeneca	Medical writing support was provided by Jackie Phillipson and Lisa Michel (Zoetic Science) and funded by AstraZeneca. The authors would like to thank Professor Lars Berglund (Uppsala Clinical Research Centre) for his contribution to the independent data re-analysis.	Amsterdam EA, 2014, CIRCULATION, V130, pE344, DOI 10.1161/CIR.0000000000000134; Novack V, 2012, ARCH INTERN MED, V172, P502, DOI 10.1001/archinternmed.2011.2275; Goto S, 2008, THROMB HAEMOSTASIS, V100, P611, DOI 10.1160/TH08-06-0388; O'Donoghue ML, 2011, CIRCULATION, V123, P1843, DOI 10.1161/CIRCULATIONAHA.110.000786; Alexander JH, 2011, NEW ENGL J MED, V365, P699, DOI 10.1056/NEJMoa1105819; Cannon CP, 2010, LANCET, V375, P283, DOI 10.1016/S0140-6736(09)62191-7; Tricoci P, 2012, NEW ENGL J MED, V366, P20, DOI 10.1056/NEJMoa1109719; Armstrong D, 2014, J CARDIOVASC PHARM T, V19, P209, DOI 10.1177/1074248413511693; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Bhatt DL, 2004, JAMA-J AM MED ASSOC, V292, P2096, DOI 10.1001/jama.292.17.2096; O'Gara PT, 2013, CIRCULATION, V127, pE362, DOI 10.1161/CIR.0b013e3182742cf6; Hamm CW, 2011, EUR HEART J, V32, P2999, DOI 10.1093/eurheartj/ehr236; Bonello L, 2014, J AM COLL CARDIOL, V63, P872, DOI 10.1016/j.jacc.2013.09.067; Kimura T, 2009, CIRCULATION, V119, P987, DOI 10.1161/CIRCULATIONAHA.108.808311; Mahaffey KW, 2014, J AM COLL CARDIOL, V63, P1493, DOI 10.1016/j.jacc.2014.01.038; Li HY, 2012, CLIN DRUG INVEST, V32, P87, DOI 10.2165/11595930-000000000-00000; Ogawa H, 2013, CIRC J, V77, P2341, DOI 10.1253/circj.CJ-13-0209; Goto S, 2010, EUR HEART J, V31, P2601, DOI 10.1093/eurheartj/ehq320; Nakatani D, 2013, CIRC J, V77, P439, DOI 10.1253/circj.CJ-11-1059; Daida H, 2013, CIRC J, V77, P934, DOI 10.1253/circj.CJ-13-0174; Fox KAA, 2002, EUR HEART J, V23, P1177, DOI 10.1053/euhj.2001.3081; Wittfeldt A, 2013, J AM COLL CARDIOL, V61, P723, DOI 10.1016/j.jacc.2012.11.032; Ogawa H, 2009, J CARDIOL, V54, P171, DOI 10.1016/j.jjcc.2009.05.001; Goto S, 2009, HAMOSTASEOLOGIE, V29, P321; Liang ZY, 2013, EUROINTERVENTION, V9, P316, DOI 10.4244/EIJV9I3A53; Cattaneo M, 2014, J AM COLL CARDIOL, V63, P2503, DOI 10.1016/j.jacc.2014.03.031; Eikelboom JW, 2006, CIRCULATION, V114, P774, DOI 10.1161/CIRCULATIONHA.106.612812; Takii T, 2010, CIRC J, V74, P93, DOI 10.1253/circj.CJ-09-0619; Park DW, 2008, JACC-CARDIOVASC INTE, V1, P494, DOI 10.1016/j.jcin.2008.06.011; Goldberg RJ, 2004, AM J CARDIOL, V93, P288, DOI 10.1016/j.amjcard.2003.10.006; Manoukian SV, 2007, J AM COLL CARDIOL, V49, P1362, DOI 10.1016/j.jacc.2007.02.027; Goto S, 2014, CLIN CARDIOL, V37, P178, DOI 10.1002/clc.22233; Hiasa Y, 2014, Cardiovasc Interv Ther, V29, P324, DOI 10.1007/s12928-014-0277-1; James SK, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3527; Levine GN, 2014, NAT REV CARDIOL, V11, P597, DOI 10.1038/nrcardio.2014.104; Ozawa Shogo, 2004, Drug Metab Pharmacokinet, V19, P83, DOI 10.2133/dmpk.19.83; Yusuf S, 2001, NEW ENGL J MED, V345, P494	37	1	1	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2452	+		10.1253/circj.CJ-15-0112		12	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900027		
J	Okada, K; Yamada, S; Iwano, H; Nishino, H; Nakabachi, M; Yokoyama, S; Abe, A; Ichikawa, A; Kaga, S; Nishida, M; Hayashi, T; Murai, D; Mikami, T; Tsutsui, H				Okada, Kazunori; Yamada, Satoshi; Iwano, Hiroyuki; Nishino, Hisao; Nakabachi, Masahiro; Yokoyama, Shinobu; Abe, Ayumu; Ichikawa, Ayako; Kaga, Sanae; Nishida, Mutsumi; Hayashi, Taichi; Murai, Daisuke; Mikami, Taisei; Tsutsui, Hiroyuki			Myocardial Shortening in 3 Orthogonal Directions and Its Transmural Variation in Patients With Nonobstructive Hypertrophic Cardiomyopathy	CIRCULATION JOURNAL			English	Article						Ejection fraction; Hypertrophic cardiomyopathy; Myocardial function; Speckle-tracking echocardiography	LEFT-VENTRICULAR HYPERTROPHY; SPECKLE TRACKING ECHOCARDIOGRAPHY; EJECTION FRACTION; HEART-FAILURE; MAGNETIC-RESONANCE; STRAIN; DEFORMATION; MECHANICS; FIBROSIS; SOCIETY	Background: Although longitudinal strain (LS) is known to be reduced in patients with hypertrophic cardiomyopathy (HCM), it has not been elucidated whether or not circumferential strain (CS) is reduced. We aimed to determine whether multidirectional and layer-specific myocardial strain is reduced in patients with nonobstructive HCM. Methods and Results: Speckle-tracking echocardiography was performed in 41 HCM patients and 27 control subjects. Segmental and global LS and CS were measured in the inner, mid, and outer layers. Global LS was significantly lower in the HCM group than in controls in the inner (-10.3 +/- 2.9 vs. -14.8 +/- 2.0%, P<0.001), mid (-8.7 +/- 2.6 vs. -13.8 +/- 1.9%, P<0.001), and outer (-7.2 +/- 2.6 vs. -11.9 +/- 1.9%, P<0.001) layers. Global CS was preserved in the inner layer (-23.8 +/- 4.7 vs. -24.3 +/- 3.3%, P=0.69) but reduced in the mid (-10.3 +/- 3.1 vs. -13.3 +/- 2.5%, P<0.001) and outer layers (-6.7 +/- 2.3 vs. -8.6 +/- 2.3%, P=0.002). Differences in CS between the inner and outer layers correlated with segmental relative wall thickness (r=-0.20, P=0.002). Furthermore, only the absolute value of global CS in the inner layer positively correlated with left ventricular ejection fraction (r=0.32, P<0.01) among these multidirectional and layer-specific strains. Conclusions: In patients with HCM, not only the LS in all layers but also CS in the mid and outer layers was reduced, presumably reflecting impaired myocardial function. In contrast, CS in the inner layer was preserved, being associated with maintenance of chamber function.	[Okada, Kazunori; Abe, Ayumu; Kaga, Sanae; Mikami, Taisei] Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0608638, Japan; [Yamada, Satoshi; Iwano, Hiroyuki; Hayashi, Taichi; Murai, Daisuke; Tsutsui, Hiroyuki] Hokkaido Univ, Dept Cardiovasc Med, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan; [Nishino, Hisao; Nakabachi, Masahiro; Yokoyama, Shinobu; Ichikawa, Ayako; Nishida, Mutsumi] Hokkaido Univ Hosp, Div Lab & Transfus Med, Sapporo, Hokkaido 060, Japan	Yamada, S (reprint author), Hokkaido Univ, Dept Cardiovasc Med, Grad Sch Med, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	syamada@med.hokudai.ac.jp					Nagueh SF, 2011, J AM SOC ECHOCARDIOG, V24, P473, DOI 10.1016/j.echo.2011.03.006; Ganame J, 2007, EUR HEART J, V28, P2886, DOI 10.1093/eurheartj/ehm444; WIGLE ED, 1995, CIRCULATION, V92, P1680; Kouzu H, 2011, J AM SOC ECHOCARDIOG, V24, P192, DOI 10.1016/j.echo.2010.10.020; Arad M, 2002, HUM MOL GENET, V11, P2499, DOI 10.1093/hmg/11.20.2499; Ishizu T, 2014, HYPERTENSION, V63, P500, DOI 10.1161/HYPERTENSIONAHA.113.02149; Ishizu T, 2010, EUR J ECHOCARDIOGR, V11, P377, DOI 10.1093/ejechocard/jep221; STREETER DD, 1969, CIRC RES, V24, P339; Vinereanu D, 2001, AM J CARDIOL, V88, P53, DOI 10.1016/S0002-9149(01)01585-5; Serri K, 2006, J AM COLL CARDIOL, V47, P1175, DOI 10.1016/j.jacc.2005.10.061; Wang J, 2008, EUR HEART J, V29, P1283, DOI 10.1093/eurheartj/ehn141; AURIGEMMA GP, 1995, J AM COLL CARDIOL, V26, P195, DOI 10.1016/0735-1097(95)00153-Q; Yang H, 2010, J AM SOC ECHOCARDIOG, V23, P1081, DOI 10.1016/j.echo.2010.06.006; Inoue K, 2013, CIRC J, V77, P1040, DOI 10.1253/circj.CJ-12-0752; Cramariuc D, 2010, HEART, V96, P106, DOI 10.1136/hrt.2009.172569; Ozawa K, 2015, INT J CARDIOL, V184, P237, DOI 10.1016/j.ijcard.2015.01.070; Yang H, 2003, J AM SOC ECHOCARDIOG, V16, P233, DOI 10.1067/mje.2003.60; Nagueh SF, 2001, CIRCULATION, V104, P128; KRAMER CM, 1994, CIRCULATION, V90, P186; Ng ACT, 2009, AM J CARDIOL, V104, P1398, DOI 10.1016/j.amjcard.2009.06.063; Kato TS, 2004, CIRCULATION, V110, P3808, DOI 10.1161/01.CIR.0000150334.69355.00; Choi EY, 2013, EUR HEART J, V34, P2354, DOI 10.1093/eurheartj/eht133; Carasso S, 2008, J AM SOC ECHOCARDIOG, V21, P675, DOI 10.1016/j.echo.2007.10.021; Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308; Popovic ZB, 2008, J AM SOC ECHOCARDIOG, V21, P1299, DOI 10.1016/j.echo.2008.09.011; Sun JP, 2009, AM J CARDIOL, V103, P411, DOI 10.1016/j.amjcard.2008.09.102; Nunez L, 2013, CIRC J, V77, P2358, DOI 10.1253/circj.CJ-13-0294; Mor-Avi V, 2011, J AM SOC ECHOCARDIOG, V24, P277, DOI 10.1016/j.echo.2011.01.015; Kraigher-Krainer E, 2014, J AM COLL CARDIOL, V63, P447, DOI 10.1016/j.jacc.2013.09.052; de Simone G, 2002, Eur J Echocardiogr, V3, P192, DOI 10.1053/euje.2002.0163; Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003; Quiones MA, 2002, J AM SOC ECHOCARDIOG, V15, P167; SHIMIZU G, 1985, CIRCULATION, V71, P266; Urbano-Moral JA, 2014, CIRC-CARDIOVASC IMAG, V7, P11, DOI 10.1161/CIRCIMAGING.113.000842	34	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2471	2479		10.1253/circj.CJ-15-0646		9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900029		
J	Otaki, Y; Takahashi, H; Watanabe, T; Yamaura, G; Funayama, A; Arimoto, T; Shishido, T; Miyamoto, T; Kubota, I				Otaki, Yoichiro; Takahashi, Hiroki; Watanabe, Tetsu; Yamaura, Gensai; Funayama, Akira; Arimoto, Takanori; Shishido, Tetsuro; Miyamoto, Takuya; Kubota, Isao			Cystatin C-Based eGFR Is a Superior Prognostic Parameter to Creatinine-Based eGFR in Post-Endovascular Therapy Peripheral Artery Disease Patients	CIRCULATION JOURNAL			English	Article						Creatinine-based eGFR; Cystatin C-based eGFR; Muscle sarcopenia; Peripheral artery disease	CHRONIC KIDNEY-DISEASE; GLOMERULAR-FILTRATION-RATE; CARDIOVASCULAR EVENTS; SERUM CREATININE; ELDERLY PERSONS; MORTALITY; RISK; METAANALYSIS; OUTCOMES; PREDICT	Background: Kidney dysfunction is reportedly associated with adverse outcome in patients with peripheral artery disease (PAD). Estimated glomerular filtration rate (eGFR), a recently popularized index for assessing kidney function, is calculated using serum creatinine or cystatin C. Compared with creatinine-based eGFR (eGFRcr), cystatin C-based eGFR (eGFRcys) is less affected by age, gender, and muscle mass. We hypothesized that eGFRcys is a feasible prognostic biomarker despite muscle sarcopenia in patients with PAD. Methods and Results: We calculated both eGFRcr and eGFRcys according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline in 234 PAD patients who underwent endovascular therapy. Patients were prospectively followed during a median follow-up period of 964 days for the endpoint of major adverse cardiovascular and cerebrovascular events (MACCE). On multivariate Cox proportional hazard analysis eGFRcys, but not eGFRcr, was an independent predictor of MACCE. The C index was larger for eGFRcys than eGFRcr (0.69 vs. 0.57, P=0.0006). On Kaplan-Meier analysis the incidence of MACCE was increased with advancing chronic kidney disease stage based on eGFRcys, but not on eGFRcr, in patients with PAD. Net reclassification index was improved with the addition of eGFRcys to basic predictors. Conclusions: Compared with eGFRcr, eGFRcys may be a more reliable biomarker for MACCE and patient risk stratification.	[Otaki, Yoichiro; Takahashi, Hiroki; Watanabe, Tetsu; Yamaura, Gensai; Funayama, Akira; Arimoto, Takanori; Shishido, Tetsuro; Miyamoto, Takuya; Kubota, Isao] Yamagata Univ, Dept Cardiol Pulmonol & Nephrol, Sch Med, Yamagata 9909585, Japan	Watanabe, T (reprint author), Yamagata Univ, Dept Cardiol Pulmonol & Nephrol, Sch Med, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.	tewatana@med.id.yamagata-u.ac.jp			Ministry of Education Culture, Sport, Science, and Technology [26893025]	This study was supported, in part, by a grant-in-aid for Scientific Research (No. 26893025) from the Ministry of Education Culture, Sport, Science, and Technology.	FORBES GB, 1976, AM J CLIN NUTR, V29, P1359; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Garimella PS, 2012, AM J KIDNEY DIS, V60, P641, DOI 10.1053/j.ajkd.2012.02.340; Yamamoto T, 2013, CIRC J, V77, P2751, DOI 10.1253/circj.CJ-13-0179; de Boer IH, 2009, DIABETES CARE, V32, P1833, DOI 10.2337/dc09-0191; Reese PP, 2009, J AM SOC NEPHROL, V20, P2088, DOI 10.1681/ASN.2009080832; McAlister FA, 2004, CIRCULATION, V109, P1004, DOI 10.1161/01.CIR.0000116764.53225.A9; Angelidis C, 2013, CURR TOP MED CHEM, V13, P164; Dharnidharka VR, 2002, AM J KIDNEY DIS, V40, P221, DOI 10.1053/ajkd.2002.34487; [Anonymous], 2002, AM J KIDNEY DIS, V39, pS1; Shlipak MG, 2009, J AM SOC NEPHROL, V20, P2625, DOI 10.1681/ASN.2009050546; Shlipak MG, 2006, ANN INTERN MED, V145, P237; McDermott MM, 2012, J AM COLL CARDIOL, V59, P1159, DOI 10.1016/j.jacc.2011.12.019; Stevens LA, 2008, AM J KIDNEY DIS, V51, P395, DOI 10.1053/j.ajkd.2007.11.018; Larsson A, 2004, SCAND J CLIN LAB INV, V64, P25, DOI 10.1080/00365510410003723; Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197; Laterza OF, 2002, CLIN CHEM, V48, P699; Hokimoto S, 2015, CIRC J, V79, P1269, DOI 10.1253/circj.CJ-14-1308; Funayama A, 2011, CIRC J, V75, P2439, DOI 10.1253/circj.CJ-11-0008; Ruiz-Canela M, 2014, CIRC J, V78, P553, DOI 10.1253/circj.CJ-14-0062; Krolewski AS, 2012, DIABETES CARE, V35, P2311, DOI 10.2337/dc11-2220; Urbonaviciene G, 2011, ATHEROSCLEROSIS, V216, P440, DOI 10.1016/j.atherosclerosis.2011.02.016; Eckardt KU, 2009, AM J KIDNEY DIS, V53, P915, DOI 10.1053/j.ajkd.2009.04.001; Diehm C, 2009, CIRCULATION, V120, P2053, DOI 10.1161/CIRCULATIONAHA.109.865600; Fujihara M, 2015, CATHETER CARDIO INTE, V85, P870, DOI 10.1002/ccd.25722; Levey AS, 2015, JAMA-J AM MED ASSOC, V313, P837, DOI 10.1001/jama.2015.0602; Narumi T, 2015, EUR J INTERN MED, V26, P118; Otaki Y, 2015, BBA CLIN, V4, P35, DOI 10.1016/j.bbacli.2015.06.003; Patel VI, 2014, J VASC SURG, V59, P368, DOI 10.1016/j.jvs.2013.09.006; Shlipak MG, 2005, NEW ENGL J MED, V352, P2049, DOI 10.1056/NEJMoa043161; Wang GN, 2014, CLIN BIOCHEM, V47, P176, DOI 10.1016/j.clinbiochem.2014.07.013; Yamasaki S, 2015, J CARDIOL, V66, P430, DOI 10.1016/j.jjcc.2015.01.011	32	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2480	+		10.1253/circj.CJ-15-0762		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900030		
J	Shimokawahara, H; Ijuin, S; Nuruki, N; Sonoda, M				Shimokawahara, Hiroto; Ijuin, Shun; Nuruki, Norihito; Sonoda, Masahiro			Effectiveness of Dual-Energy Computed Tomography in Providing Information on Pulmonary Perfusion and Vessel Morphology in Chronic Thromboembolic Pulmonary Hypertension	CIRCULATION JOURNAL			English	Editorial Material							PROGNOSIS		[Shimokawahara, Hiroto; Ijuin, Shun; Nuruki, Norihito; Sonoda, Masahiro] Natl Hosp Org, Kagoshima Med Ctr, Dept Cardiol, Kagoshima 8920853, Japan	Shimokawahara, H (reprint author), Natl Hosp Org, Kagoshima Med Ctr, Dept Cardiol, 8-1 Shiroyama Cho, Kagoshima 8920853, Japan.	hiroto.shimokk@gmail.com					Sugimura K, 2012, CIRC J, V76, P485, DOI 10.1253/circj.CJ-11-1217; Yamaki S, 2014, CIRC J, V78, P476, DOI 10.1253/circj.CJ-13-1016; Shimokawahara H, 2014, CIRCULATION, V130, P448, DOI 10.1161/CIRCULATIONAHA.114.009633; Madani MM, 2012, ANN THORAC SURG, V94, P97, DOI 10.1016/j.athoracsur.2012.04.004; Tatebe S, 2013, CIRC J, V77, P1081, DOI 10.1253/circj.CJ-12-1493; Schweikert B, 2014, LANCET RESP MED, V2, P573	6	0	0	JAPANESE CIRCULATION SOC	TOYKO	18TH FLOOR IMPERIAL HOTEL TOWER, 1-1-1 UCHISAIWAI-CHO CHIYODA-KU, TOYKO, 100-0011, JAPAN	1346-9843	1347-4820		CIRC J	Circ. J.	NOV	2015	79	11					2517	2519		10.1253/circj.CJ-15-0537		3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU1ML	WOS:000363285900034		
J	Jin, ZW; Hata, F; Jin, Y; Murakami, G; Kinugasa, Y; Abe, SI				Jin, Zhe Wu; Hata, Fumitake; Jin, Yu; Murakami, Gen; Kinugasa, Yusuke; Abe, Shin-Ichi			The anococcygeal ligaments: Cadaveric study with application to our understanding of incontinence in the elderly	CLINICAL ANATOMY			English	Article						anococcygeal ligament; elastic fibers; longitudinal anal muscle; retinacula cutis; superficial fascia	TOTAL MESORECTAL EXCISION; EXTERNAL ANAL-SPHINCTER; LEVATOR ANI MUSCLE; ANATOMY; SPACE; IDENTIFICATION; MECHANISM; COMPLEX; FASCIA	The term anococcygeal ligament (ACL) has been used to refer to two distinct structures: a superficial fibrous band originating from the myosepta of the external anal sphincter (EAS) and running upwards to the coccyx (the superficial ACL); and a deep fibrous band originating from the periosteum of the coccyx, merging with the thick presacral fascia and attaching to the superior end of the EAS (the deep ACL). In the present work, elastic fiber histology and muscle immunohistochemistry of sagittal sections obtained from 15 donated elderly male cadavers showed that superficial ACL, corresponding to a superficial fascia or skin ligament, was composed of very tortuous elastic fibers, with a fine elastic fiber mesh at their coccygeal attachment; whereas the deep ACL was composed of almost straight collagen and elastic fibers, intermingled with the coccygeal periosteum. Due to the weak insertion into the coccyx and the wavy course, the superficial ACL is unlikely to provide, even in association with contraction of the longitudinal anal muscle, a stable mechanical support to maintain the configuration of the EAS. Being similar to the suspensory ligament of breast, tissue repair of the skin ligament would not have a mechanical role. In contrast, the deep ACL, in association with the thick presacral fascia, likely plays a role in maintaining a suitable positioning of the anorectum to the coccyx. However, their relative lack of smooth muscles compared with rich elastic fibers indicates that both ACLs may become permanently overextended under conditions of long-term mechanical stress. Clin. Anat. 28:1039-1047, 2015. (c) 2015 Wiley Periodicals, Inc.	[Jin, Zhe Wu; Jin, Yu] Yanbian Univ, Coll Med, Dept Anat Histol & Embryol, Yanji 133002, Jilin, Peoples R China; [Hata, Fumitake] Doto Hosp, Div Surg, Sapporo, Hokkaido, Japan; [Murakami, Gen] Iwamizawa Asuka Hosp, Div Internal Med, Iwamizawa, Japan; [Kinugasa, Yusuke] Shizuoka Canc Ctr Hosp, Div Colon & Rectal Surg, Susuno, Shizuoka, Japan; [Abe, Shin-Ichi] Tokyo Dent Coll, Dept Anat, Tokyo, Japan	Jin, Y (reprint author), Yanbian Univ, Coll Med, Dept Anat Histol & Embryol, 977 Gongyuan Rd, Yanji 133002, Jilin, Peoples R China.	yujinyb@sina.com					Kawase T, 2012, J ANAT, V221, P331, DOI 10.1111/j.1469-7580.2012.01542.x; HUSSAIN SM, 1995, RADIOLOGY, V197, P671; Kinugasa Y, 2007, BRIT J SURG, V94, P620, DOI 10.1002/bjs.5540; SHAFIK A, 1975, INVEST UROL, V13, P175; Hinderer UT, 2001, AESTHET PLAST SURG, V25, P404; MOTOHASHI O, 1995, ACTA NEUROCHIR, V136, P88, DOI 10.1007/BF01411441; Shafik A, 1999, WORLD J UROL, V17, P266, DOI 10.1007/s003450050144; Kurihara H, 2006, DIS COLON RECTUM, V49, pS37, DOI 10.1007/s10350-006-0736-6; Kusunoki M, 2008, SURG TODAY, V38, P691, DOI 10.1007/s00595-007-3699-x; Kinugasa Y, 2011, DIS COLON RECTUM, V54, P232, DOI 10.1007/DCR.0b013e318202388f; Kinugasa Y, 2012, YONSEI MED J, V53, P849, DOI 10.3349/ymj.2012.53.4.849; Nash LG, 2004, CLIN ANAT, V17, P287, DOI 10.1002/ca.10203; Kang J, 2012, ANN SURG ONCOL, V19, P154, DOI 10.1245/s10434-011-1952-4; Abu-Hijleh MF, 2006, SURG RADIOL ANAT, V28, P606, DOI 10.1007/s00276-006-0142-8; Benjamin M, 2006, J ANAT, V208, P471, DOI 10.1111/j.1469-7580.2006.00540.x; COURTNEY H, 1950, AM J SURG, V79, P155, DOI 10.1016/0002-9610(50)90208-X; Kim JH, 2015, INT J COLORECTAL DIS, V30, P43, DOI 10.1007/s00384-014-2038-0; Muro S, 2014, SURG RADIOL ANAT, V36, P551, DOI 10.1007/s00276-013-1228-8; Takada M, 2005, HEPATO-GASTROENTEROL, V52, P1722; AYOUB SF, 1979, ACTA ANAT, V105, P25; Arakawa Takashi, 2004, Anatomical Science International, V79, P72, DOI 10.1111/j.1447-073x.2004.00069.x; Garcia-Armengol J, 2008, COLORECTAL DIS, V10, P298, DOI 10.1111/j.1463-1318.2007.01472.x; Hinata N, 2014, BIOMED RES INT, V2014, P18; Sasaki H, 2014, OPEN J OBSTET GYNECO, V4, P144; Serikawa M, 2015, ANAT SCI INT	25	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0897-3806	1098-2353		CLIN ANAT	Clin. Anat.	NOV	2015	28	8					1039	1047		10.1002/ca.22629		9	Anatomy & Morphology	Anatomy & Morphology	CU3YA	WOS:000363461100018		
J	Desy, NM; Lipinski, LJ; Tanaka, S; Amrami, KK; Rock, MG; Spinner, RJ				Desy, Nicholas M.; Lipinski, Lindsay J.; Tanaka, Shota; Amrami, kimberly K.; Rock, Michael G.; Spinner, Robert J.			Recurrent intraneural ganglion cysts: Pathoanatomic patterns and treatment implications	CLINICAL ANATOMY			English	Article						articular theory; intraneural ganglion cyst; recurrence	SUPERIOR TIBIOFIBULAR JOINT; PERONEAL NERVE PALSY; ARTICULAR SYNOVIAL THEORY; LATERAL POPLITEAL NERVE; MUCOID PSEUDOCYSTS; PERIPHERAL-NERVES; TIBIAL NERVE; MRI FINDINGS; BRANCH; COMPRESSION	The etiology of intraneural ganglion cysts has been poorly understood. This has resulted in the development of multiple surgical treatment strategies and a high recurrence rate. We sought to analyze these recurrences in order to provide a pathoanatomic explanation and staging classification for intraneural cyst recurrence. An expanded literature search was performed to identify frequencies and patterns in cases of intraneural ganglion cyst recurrences following primary surgery. Two univariate analyses were completed to identify associations between the type of revision surgery and repeat cyst recurrences. The expanded literature search found an 11% recurrence rate following primary surgery, including 64 recurrences following isolated cyst decompression (Group 1); six after articular branch resection (Group 2); and none following surgical procedures that addressed the joint (Group 3). Eight cases did not specify the type of primary surgery. In group 1, forty-eight of the recurrences (75%) were in the parent nerve, three involved only the articular branch, and one travelled along the articular branch in a different distal direction without involving the main parent nerve. In group 2, only one case (17%) recurred/persisted within the parent nerve, one recurred within a persistent articular branch, and one formed within a persistent articular branch and travelled in a different distal direction. Intraneural recurrences most commonly occur following surgical procedures that only target the main parent nerve. We provide proven or theoretical explanations for all identified cases of intraneural recurrences for an occult or persistent articular branch pathway. Clin. Anat. 28:1058-1069, 2015. (c) 2015 Wiley Periodicals, Inc.	[Desy, Nicholas M.; Rock, Michael G.; Spinner, Robert J.] Mayo Clin, Dept Orthoped, Rochester, MN 55905 USA; [Lipinski, Lindsay J.] SUNY Buffalo, Sch Med & Biomed Sci, Dept Neurosurg, Buffalo, NY 14260 USA; [Tanaka, Shota] Univ Tokyo, Fac Med, Dept Neurosurg, Tokyo 113, Japan; [Amrami, kimberly K.] Mayo Clin, Dept Radiol, Rochester, MN 55905 USA; [Spinner, Robert J.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA; [Spinner, Robert J.] Mayo Clin, Dept Anat, Rochester, MN 55905 USA	Spinner, RJ (reprint author), Mayo Clin, Gonda 8-214, Rochester, MN 55905 USA.	spinner.robert@mayo.edu					ACCIARRI N, 1990, Journal of Foot Surgery, V29, P231; Ahn JH, 1972, J KOREAN ORTHOPED AS, V7, P344; Akcakaya MO, 2013, PEDIATR NEUROSURG, V49, P347, DOI 10.1159/000368838; Sanger J, 2006, J HAND SURG-AM, V31A, P40, DOI 10.1016/j.jhsa.2005.08.010; Spinner RJ, 2006, J NEUROSURG, V104, P551, DOI 10.3171/jns.2006.104.4.551; Hebert-Blouin MN, 2014, CLIN ANAT, V27, P548, DOI 10.1002/ca.22348; Spinner R, 2005, REV CHIR ORTHOP, V91, P492; Visser LH, 2006, NEUROLOGY, V67, P1473, DOI 10.1212/01.wnl.0000240070.98910.bc; BROOKS DM, 1952, J BONE JOINT SURG BR, V34, P391; Dubuisson AS, 1996, J NEUROSURG, V84, P280, DOI 10.3171/jns.1996.84.2.0280; Rosson GD, 2005, J AM PODIAT MED ASSN, V95, P459; Muramatsu K, 2013, ACTA NEUROCHIR, V155, P1757, DOI 10.1007/s00701-013-1768-z; Blitz NM, 2008, J FOOT ANKLE SURG, V47, P199, DOI 10.1053/j.jfas.2008.01.002; Kim JY, 2004, EUR RADIOL, V14, P106, DOI 10.1007/s00330-003-1969-6; ALLIEU Y, 1987, REV CHIR ORTHOP, V73, P243; Ogose A, 2014, NEUROLOGY, V83, pE95, DOI 10.1212/WNL.0000000000000714; Waldschmidt U, 2010, J PEDIATR SURG, V45, P259, DOI 10.1016/j.jpedsurg.2009.09.039; Spinner RJ, 2011, CLIN ANAT, V24, P268, DOI 10.1002/ca.21109; Spinner RJ, 2006, SKELETAL RADIOL, V35, P172, DOI 10.1007/s00256-005-0036-6; Piton C, 1997, REV CHIR ORTHOP, V83, P515; Chick G, 2001, J BONE JOINT SURG BR, V83B, P1020, DOI 10.1302/0301-620X.83B7.11654; PARKES A, 1961, J BONE JOINT SURG BR, V43, P784; Spinner RJ, 2000, J NEUROSURG, V92, P334, DOI 10.3171/jns.2000.92.2.0334; Spinner RJ, 2011, J NEUROSURG, V114, P217, DOI 10.3171/2010.4.JNS091969; Blitz NM, 2009, J FOOT ANKLE SURG, V48, P80, DOI 10.1053/j.jfas.2008.09.002; Harbaugh KS, 1997, J NEUROSURG, V87, P403, DOI 10.3171/jns.1997.87.3.0403; Lohmeyer JA, 2007, J PLAST RECONSTR AES, V60, P1338, DOI 10.1016/j.bjps.2006.03.048; Naam NH, 2015, J HAND SURG-AM, V40, P1625, DOI 10.1016/j.jhsa.2015.05.025; Hernandez AV, 2000, NEUROCIRUGIA, V11, P137; Spinner RJ, 2006, SKELETAL RADIOL, V35, P734, DOI 10.1007/s00256-006-0148-7; Kim JY, 2007, CLIN RADIOL, V62, P58, DOI 10.1016/j.crad.2006.07.013; Spinner RJ, 2008, ACTA NEUROCHIR, V150, P93, DOI 10.1007/s00701-007-1471-z; Uchida A, 2006, INT J UROL, V13, P471, DOI 10.1111/j.1442-2042.2006.01334.x; Drabek P, 2001, CESK SLOV NEUROL N, V64, P300; Spinner RJ, 2003, J NEUROSURG, V99, P330, DOI 10.3171/jns.2003.99.2.0330; LAGARRIGUE J, 1982, NEUROCHIRURGIE, V28, P131; Spinner RJ, 2008, SKELETAL RADIOL, V37, P79, DOI 10.1007/s00256-007-0400-9; Spinner RJ, 2009, J NEUROSURG, V111, P317, DOI 10.3171/2009.2.JNS081720; GARDNER E, 1948, ANAT REC, V101, P109, DOI 10.1002/ar.1091010111; Hersekli MA, 2004, ARCH ORTHOP TRAUM SU, V124, P711, DOI 10.1007/s00402-004-0717-y; Weyns F, 2012, ACTA NEUROCHIR, V154, P1741, DOI 10.1007/s00701-012-1444-8; ASSMUS H, 1975, J NEUROL, V209, P131, DOI 10.1007/BF00314606; WARREN R, 1946, ANN SURG, V124, P152; Kuntz C, 1996, NEUROSURGERY, V39, P750, DOI 10.1097/00006123-199610000-00021; Spinner RJ, 2003, J NEUROSURG, V99, P319, DOI 10.3171/jns.2003.99.2.0319; Tatagiba M, 1993, Zentralbl Neurochir, V54, P171; Spinner RJ, 2007, SKELETAL RADIOL, V36, P281, DOI 10.1007/s00256-006-0213-2; Spinner RJ, 2007, J NEUROSURG, V107, P296, DOI 10.3171/JNS-07/08/0296; Spinner RJ, 2010, ACTA NEUROCHIR, V152, P919, DOI 10.1007/s00701-009-0574-0; CLARK K, 1961, J BONE JOINT SURG BR, V43, P778; COAKLEY FV, 1995, CLIN RADIOL, V50, P168, DOI 10.1016/S0009-9260(05)83049-1; Rezzouk J, 2004, REV CHIR ORTHOP, V90, P143; Araki N, 2009, ORTHOPED SURG, V60, P353; Bazner UM, 2008, 59 ANN M GERM SOC NE; Botanlioglu H, 2013, 26 EUR MUSC ONC SOC; Campailla E, 1967, G Psichiatr Neuropatol, V95, P967; Cesmebasi A, 2015, CLIN ANAT, V28, P2, DOI 10.1002/ca.22473; Chang T-C, 2012, FORMOSAN J MUSCULOSK, V3, P108; Desy NM, J NEUROSURG IN PRESS; Gosk J, 2004, CASE REP CLIN PRACT, V5, P525; Grassi L, 1961, ARCH PUTTI CHIRURGIA, V14, P309; Gyula D, 2007, MAGYAR TRAUMATOL ORT, V50, P269; Hahn S-B, 2006, J KOREAN ORTHOP ASS, V41, P163; Herrin E, 1986, J Foot Surg, V25, P14; Ikeda K, 2010, RINSHO SEIKEI GEKA, V45, P189; Inobe T, 1993, 33 KOCH ORTH M KOCH; Janeczko Łukasz, 2014, Przegl Lek, V71, P231; Kim WK, 2013, J KOREAN ASS PAIN ME, V12, P32; Kong W-K, 2011, 51 ANN M KOR NEUR SO; Krishnan K, 2009, JOINT M BEN COUNTR B; Kushida K, 1981, CLIN ORTHOP SURG, V16, P900; Lee K-C, 2013, J KOREAN FOOT ANKLE, V17, P161; Lipinski LJ, 2015, ACTA NEUROCHIR, V157, P837, DOI 10.1007/s00701-014-2323-2; Merkulov VN, 2014, N N PRIOROVA, V3, P76; Miake Y, 1973, CASE POSTERIOR TIBIA; Nagano M, 1995, J JPN SOC SURG FOOT, V16, P61; Nakata N, 1998, ORTHOP SURG, V49, P1135; Oishi C, 2015, CLIN NEUROPHYSIOL, V126, pe53; Patel M R, 1997, Am J Orthop (Belle Mead NJ), V26, P562; Prasad NK, 2015, J FOOT ANKLE SURG, DOI [10.1053/j.jfas.2015.02.006, DOI 10.1053/J.JFAS.2015.02.006]; Ratanshi I, 2014, HAW ANN M AM SOC PER; Rein S, 2005, Handchir Mikrochir Plast Chir, V37, P267, DOI 10.1055/s-2005-865896; Sobol Garret L, 2015, Am J Orthop (Belle Mead NJ), V44, pE123; Spinner Robert J, 2010, J Surg Orthop Adv, V19, P143; Spinner Robert J, 2007, Neurosurg Focus, V22, pE16; Spinner Robert J, 2007, Neurosurg Focus, V22, pE27; Squires JH, 2014, PEDIATR RADIOL, V44, P488, DOI 10.1007/s00247-013-2814-y; Stamatis ED, 2010, J FOOT ANKLE SURG, V49; Suh J-S, 2002, J KOREAN SOC FOOT SU, V6, P242; Wadstein T, 1931, ACTA ORTHOP SCAND, V2, P221; Wang H, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/FOC.2009.26.2.E10; Yang H-J, 2010, KOR NEUR ASS ANN FAL; Yoneyama R, 2006, J E JPN ORTHOP TRAUM, V18, P185; Yoshihara H, 1999, ORTHOP SURG, V50, P1222	94	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0897-3806	1098-2353		CLIN ANAT	Clin. Anat.	NOV	2015	28	8					1058	1069		10.1002/ca.22615		12	Anatomy & Morphology	Anatomy & Morphology	CU3YA	WOS:000363461100020		
J	Beuers, U; Gershwin, ME; Gish, RG; Invernizzi, P; Jones, DEJ; Lindor, K; Ma, X; Mackay, IR; Pares, A; Tanaka, A; Vierling, JM; Poupon, R				Beuers, Ulrich; Gershwin, M. Eric; Gish, Robert G.; Invernizzi, Pietro; Jones, David E. J.; Lindor, Keith; Ma, Xiong; Mackay, Ian R.; Pares, Albert; Tanaka, Atsushi; Vierling, John M.; Poupon, Raoul			Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY			English	Article						Cholestasis; Cholangiopathy; Primary biliary cirrhosis	PRIMARY BILIARY-CIRRHOSIS; HCO3-UMBRELLA; CHOLANGIOCYTES; EXPRESSION		[Beuers, Ulrich] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; [Beuers, Ulrich] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands; [Gershwin, M. Eric] Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; [Gish, Robert G.] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA; [Invernizzi, Pietro] Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Milan, Italy; [Jones, David E. J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Lindor, Keith] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ USA; [Ma, Xiong] Shanghai Jiao Tong Univ, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol, Renji Hosp,Sch Med, Shanghai 200030, Peoples R China; [Mackay, Ian R.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; [Pares, Albert] Univ Barcelona, Hosp Clin, Liver Unit, IDIBAPS,CIBERehd, Barcelona, Spain; [Tanaka, Atsushi] Teikyo Univ, Sch Med, Dept Med, Tokyo 173, Japan; [Vierling, John M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Vierling, John M.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; [Poupon, Raoul] St Antoine Hosp, Serv Hepatol, Reference Ctr Inflammatory Biliary Dis, Paris, France	Beuers, U (reprint author), Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, Dept Gastroenterol & Hepatol, Meibergdreef 9, NL-1100 DE Amsterdam, Netherlands.	u.h.beuers@amc.uva.nl					Addison T, 1851, GUYS HOSP REP, V7, P265; AHRENS EH, 1950, MEDICINE, V29, P299; Sasaki M, 2013, LIVER INT, V33, P312, DOI 10.1111/liv.12049; Beuers U, 2010, HEPATOLOGY, V52, P1489, DOI 10.1002/hep.23810; Banales JM, 2012, HEPATOLOGY, V56, P687, DOI 10.1002/hep.25691; RUBIN E, 1965, AM J PATHOL, V46, P387; Odin JA, 2001, J CLIN INVEST, V108, P223, DOI 10.1172/JCI10716; Hohenester S, 2012, HEPATOLOGY, V55, P173, DOI 10.1002/hep.24691; Lindor KD, 2009, HEPATOLOGY, V50, P291, DOI 10.1002/hep.22906; Gershwin ME, 2008, HEPATOLOGY, V47, P737, DOI 10.1002/hep.22042; SHERLOCK S, 1959, GASTROENTEROLOGY, V37, P574; MACMAHON HE, 1949, ANN INTERN MED, V30, P121; Bianchi I, 2014, SEMIN LIVER DIS, V34, P255, DOI 10.1055/s-0034-1383725; Lleo A, 2010, HEPATOLOGY, V52, P987, DOI 10.1002/hep.23783; Lleo A, 2014, SEMIN LIVER DIS, V34, P273, DOI 10.1055/s-0034-1383727; Beuers U, 2015, J HEPATOL, V62, pS25, DOI 10.1016/j.jhep.2015.02.023; Dyson JK, 2015, NAT REV GASTRO HEPAT, V12, P147, DOI 10.1038/nrgastro.2015.12; EASL, 2009, J HEPATOL, V51, P237; Hanot V, 1876, ETUDE FORME CIRRHOSE; Hirschfield GM, 2013, ANNU REV PATHOL-MECH, V8, P303, DOI 10.1146/annurev-pathol-020712-164014; Sherlock S, 1968, DIS LIVER BILIARY SY, P305	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1542-3565	1542-7714		CLIN GASTROENTEROL H	Clin. Gastroenterol. Hepatol.	NOV	2015	13	11					1867	1869		10.1016/j.cgh.2015.08.025		3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CT9VW	WOS:000363165700008		
J	Genestreti, G; Tiseo, M; Kenmotsu, H; Kazushige, W; Di Battista, M; Cavallo, G; Carloni, F; Bongiovanni, A; Burgio, MA; Casanova, C; Metro, G; Scarpi, E; Korkmaz, T; Selcuk, S; Roopa, K; Califano, R				Genestreti, Giovenzio; Tiseo, Marcello; Kenmotsu, Hirotsugu; Kazushige, Wakuda; Di Battista, Monica; Cavallo, Giovanna; Carloni, Federica; Bongiovanni, Alberto; Burgio, Marco Angelo; Casanova, Claudia; Metro, Giulio; Scarpi, Emanuela; Korkmaz, Taner; Selcuk, Seber; Roopa, Kurup; Califano, Raffaele			Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis	CLINICAL LUNG CANCER			English	Article						Extended disease; Platinum sensitive; Rechallenge chemotherapy; SCLC; Second-line	2ND-LINE TREATMENT; PHASE-III; CHEMOTHERAPY; TOPOTECAN; GUIDELINES; THERAPY; RELAPSE	Small-cell lung cancer has a high chemotherapeutic sensitivity but with disappointing outcome results. Patients with "sensitive disease" are those who respond to treatment with a long relapse-free interval (RFI): in these cases rechallenge with first-line chemotherapy might represent a therapeutic opportunity. Our largest retrospective experience confirmed that rechallenge is feasible with interesting outcome results; there are no statistical differences between RFI and outcome. Introduction: Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide. Patients and Methods: Records of all SCLC patients treated in 7 institutions between January 2007 and December 2011 were reviewed. The primary end point was overall survival from the time of rechallenge (OS-R); secondary end points were progression-free survival (PFS) and overall survival from the time of diagnosis (OS-D). Survival curves were calculated using the Kaplan-Meier method. Results: Of the 2000 SCLC patients identified, 112 (5.6%) had sensitive disease treated with rechallenge platinum/etoposide; 65% were men with a median age of 64 years. At the time of diagnosis, 44% of patients had limited disease, 82% had an Eastern Cooperative Oncology Group performance status of 0 to 1. A median of 4 cycles of rechallenge was administered. Tumor response was 3% for complete response and 42% for partial response, 19% of patients maintained stable disease, 27% progressive disease, and 9% were not evaluable. Median PFS from the time of rechallenge was 5.5 months (95% confidence interval [CI], 4.4-6.3). Median OS-R and OS-D were 7.9 months (95% CI, 6.9-9.7) and 21.4 months (95% CI, 19.8-24.1), respectively. Subgroup analysis according to relapse-free interval (90-119 vs. 120-149 vs. > 150 days) did not show any statistically significant difference in PFS or OS-R. Conclusion: The outcome for SL chemotherapy for SCLC is poor. Rechallenge platinum/etoposide is a reasonable option with potentially better outcomes than standard chemotherapy.	[Genestreti, Giovenzio; Di Battista, Monica; Cavallo, Giovanna] AUSL Bologna, Dept Med Oncol, I-40139 Bologna, Italy; [Tiseo, Marcello] Univ Hosp Parma, Dept Med Oncol, Parma, Italy; [Kenmotsu, Hirotsugu; Kazushige, Wakuda] Shizouka Canc Ctr, Div Thorac Oncol, Shizuoka, Japan; [Carloni, Federica] Cervesi Hosp, AUSL Rimini, Dept Med Oncol, Cattolica, Italy; [Bongiovanni, Alberto; Burgio, Marco Angelo] IRCCS Ist Sci Romagnolo Studio & Cura Tumor IRST, Dept Med Oncol, Meldola, Italy; [Casanova, Claudia] Santa Maria delle Croci Hosp, Dept Med Oncol, Ravenna, Italy; [Metro, Giulio] S Maria delle Misericordia Hosp, Dept Med Oncol, Perugia, Italy; [Scarpi, Emanuela] IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Unit Biostat & Clin Trials, Meldola, Italy; [Korkmaz, Taner] Dr Luffi Kirdar Res & Training Hosp, Istanbul, Turkey; [Selcuk, Seber] Marmara Univ Hosp, Dept Med Oncol, Istanbul, Turkey; [Roopa, Kurup; Califano, Raffaele] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England	Genestreti, G (reprint author), AUSL Bologna, Dept Med Oncol, Via Altura 3, I-40139 Bologna, Italy.	g.genestreti@ausl.bologna.it	Califano, Raffaele/C-4055-2013	Califano, Raffaele/0000-0003-2611-5319			Jett JR, 2013, CHEST, V143, pE400, DOI 10.1378/chest.12-2363; Tiseo M, 2007, J THORAC ONCOL, V2, P764, DOI 10.1097/JTO.0b013e3180986262; O'Brien MER, 2006, J CLIN ONCOL, V24, P5441, DOI 10.1200/JCO.2006.06.5821; VINCENT M, 1988, CANCER CHEMOTH PHARM, V21, P45; Rosti G, 2006, ANN ONCOL, V17, P5, DOI 10.1093/annonc/mdj910; Govindan R, 2006, J CLIN ONCOL, V24, P4539, DOI 10.1200/JCO.2005.04.4859; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Kalemkerian GP, 2013, J NATL COMPR CANC NE, V11, P78; GIACCONE G, 1988, J CLIN ONCOL, V6, P1264; Korkmaz T, 2013, CLIN TRANSL ONCOL, V15, P535, DOI 10.1007/s12094-012-0960-6; Garassino MC, 2011, LUNG CANCER, V72, P378, DOI 10.1016/j.lungcan.2010.09.009; POSTMUS PE, 1987, EUR J CANCER CLIN ON, V23, P1409, DOI 10.1016/0277-5379(87)90128-3; Eckardt JR, 2007, J CLIN ONCOL, V25, P2086, DOI 10.1200/JCO.2006.08.3998; GIACCONE G, 1987, EUR J CANCER CLIN ON, V23, P1697, DOI 10.1016/0277-5379(87)90452-4; BATIST G, 1983, ANN INTERN MED, V98, P472; von Pawel J, 1999, J CLIN ONCOL, V17, P658; Ardizzoni A, 2014, EUR J CANCER, V50, P2211, DOI 10.1016/j.ejca.2014.06.002; Goto K, 2014, ASCO M ABSTRACTS S, V32, P7504; Nakamura A, 2014, P AM SOC CLIN ONCO S, V32; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Wakuda K, 2015, AM J CLIN ONCOL-CANC, V38, P28, DOI 10.1097/COC.0b013e318286907b	21	0	0	CIG MEDIA GROUP, LP	DALLAS	3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA	1525-7304	1938-0690		CLIN LUNG CANCER	Clin. Lung Cancer	NOV	2015	16	6					E223	E228		10.1016/j.cllc.2015.04.006		6	Oncology	Oncology	CU1GD	WOS:000363267500011		
J	Kudo, Y; Shimada, Y; Saji, H; Kato, Y; Yoshida, K; Matsubayashi, J; Nagase, S; Kakihana, M; Kajiwara, N; Ohira, T; Nagao, T; Ikeda, N				Kudo, Yujin; Shimada, Yoshihisa; Saji, Hisashi; Kato, Yasufumi; Yoshida, Koichi; Matsubayashi, Jun; Nagase, Seisuke; Kakihana, Masatoshi; Kajiwara, Naohiro; Ohira, Tatsuo; Nagao, Toshitaka; Ikeda, Norihiko			Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System	CLINICAL LUNG CANCER			English	Article						Brain metastasis; Epidermal growth factor receptor mutation; Non-small-cell lung cancer; Pathological stage; Postoperative recurrence survival	VINORELBINE PLUS CISPLATIN; TYROSINE KINASE INHIBITORS; ADJUVANT CHEMOTHERAPY; CANCER PATIENTS; EGFR MUTATION; POSTRECURRENCE SURVIVAL; BRAIN METASTASES; PULMONARY ADENOCARCINOMA; CURATIVE RESECTION; PHASE-III	Epidermal growth factor receptor (EGFR) status and pathological stage (p-stage) were shown to be essential prognostic factors for estimating survival after recurrence of lung adenocarcinoma. In patients with EGFR mutations, those with early p-stage tumors showed better survival after disease recurrence than those with advanced p-stage tumors. The EGFR mutation status and p-stage could also prompt the design of clinical trials on adjuvant therapy for patients after complete surgical resection. Background: The current staging system and epidermal growth factor receptor (EGFR) mutation status are key factors for predicting survival. However, the significance of these factors as predictors of survival after disease recurrence (PRS) has not been sufficiently elucidated. The objective of this study was to investigate the clinico-pathological factors, particularly the EGFR mutation status and pathological stage (p-stage), which affect PRS in patients with completely resected lung adenocarcinoma. Patients and Methods: We retrospectively reviewed the data of 198 consecutive lung adenocarcinoma patients with disease recurrence who previously underwent complete surgical resection in our hospital. Results: Of the 198 patients, 117 were examined for EGFR mutations (mutants). Mutants were detected in 57 patients (28.7%). The patients with mutants had a significantly better 3-year PRS (3y-PRS) rate (68.6%) than those with an EGFR wild type (WT) status (51.7%) or an unknown (UN) status (27.0%). The 3y-PRS rates for p-stage I to II (p-I-II) and p-stage III (p-III) were 52.5% and 29.3%, respectively. Multivariate survival analysis showed that the EGFR mutation status and p-stage had significant associations with favorable PRS. The 3y-PRS rate for mutants/p-I-II (81.4%) was significantly better than that for mutants/p-III (48.0%). Conversely, there was no significant difference between mutants/p-III and WT/UN/p-I-II (3y-PRS: 40.7%) or between mutants/p-III and WT/UN/p-III (3y-PRS: 24.4%). Conclusion: EGFR status and p-stage were shown to be essential prognostic factors for estimating PRS. In patients with mutants, those with early p-stage tumors showed better PRS than those with advanced p-stage tumors.	[Kudo, Yujin; Shimada, Yoshihisa; Saji, Hisashi; Kato, Yasufumi; Yoshida, Koichi; Nagase, Seisuke; Kakihana, Masatoshi; Kajiwara, Naohiro; Ohira, Tatsuo; Ikeda, Norihiko] Tokyo Med Univ, Dept Thorac Surg, Tokyo 1600023, Japan; [Saji, Hisashi] St Marianna Univ, Sch Med, Dept Chest Surg, Kawasaki, Kanagawa, Japan; [Matsubayashi, Jun; Nagao, Toshitaka] Tokyo Med Univ, Dept Anat Pathol, Tokyo 1600023, Japan	Kudo, Y (reprint author), Tokyo Med Univ, Dept Thorac Surg, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.	yjnkudo@gmail.com			Japan Society for the Promotion of Science [KAKENHI 26861129]	This study was supported by a Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (KAKENHI 26861129) to Y.K.	Yatabe Y, 2006, J MOL DIAGN, V8, P335, DOI 10.2353/jmoldx.2006.050104; Hendriks LEL, 2014, LUNG CANCER, V84, P86, DOI 10.1016/j.lungcan.2014.01.006; Nakagawa T, 2008, EUR J CARDIO-THORAC, V34, P499, DOI 10.1016/j.ejcts.2008.05.016; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Socinski MA, 2013, CHEST, V143, pE341, DOI 10.1378/chest.12-2361; ICHINOSE Y, 1994, J THORAC CARDIOV SUR, V108, P158; Saji H, 2013, CHEST, V143, P1618, DOI 10.1378/chest.12-0750; Zhang JZ, 2014, CANCER LETT, V351, P6, DOI 10.1016/j.canlet.2014.04.019; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Porta R, 2011, EUR RESPIR J, V37, P624, DOI 10.1183/09031936.00195609; Eichler AF, 2010, NEURO-ONCOLOGY, V12, P1193, DOI 10.1093/neuonc/noq076; Hung JJ, 2009, THORAX, V64, P192, DOI 10.1136/thx.2007.094912; Hamada C, 2009, J THORAC ONCOL, V4, P1511, DOI 10.1097/JTO.0b013e3181bbf1f2; Pao W, 2007, CLIN CANCER RES, V13, P4954, DOI 10.1158/1078-0432.CCR-07-1387; Park SJ, 2012, LUNG CANCER, V77, P556, DOI 10.1016/j.lungcan.2012.05.092; Takenaka T, 2015, EUR J CARDIO-THORAC, V47, P550, DOI 10.1093/ejcts/ezu227; Okami J, 2007, ONCOLOGY-BASEL, V72, P234, DOI 10.1159/000112947; Douillard JY, 2006, LANCET ONCOL, V7, P719, DOI 10.1016/S1470-2045(06)70804-X; Youlden DR, 2008, J THORAC ONCOL, V3, P819, DOI 10.1097/JTO.0b013e31818020eb; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; SORENSEN JB, 1988, J CLIN ONCOL, V6, P1474; Ohe Y, 2007, ANN ONCOL, V18, P317, DOI 10.1093/annonc/mdl377; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Saisho S, 2013, INTERACT CARDIOV TH, V16, P166, DOI 10.1093/icvts/ivs450; Sasaki H, 2005, CLIN CANCER RES, V11, P2924, DOI 10.1158/1078-0432.CCR-04-1904; Williams BA, 2006, ANN THORAC SURG, V81, P1021, DOI 10.1016/j.athoracsur.2005.09.020; Yoshida K, 2007, J THORAC ONCOL, V2, P22, DOI 10.1097/01243894-200701000-00006; Sonobe M, 2014, ANN SURG ONCOL, V21, P2546, DOI 10.1245/s10434-014-3630-9; Scagliotti GV, 2003, J NATL CANCER I, V95, P1453, DOI 10.1093/jnci/djg059; Jeon JH, 2015, EUR J CARDIO-THORAC, V47, P556, DOI 10.1093/ejcts/ezu177; Winton T, 2005, NEW ENGL J MED, V352, P2589, DOI 10.1056/NEJMoa043623; Kato H, 2004, NEW ENGL J MED, V350, P1713, DOI 10.1056/NEJMoa032792; Hung JJ, 2010, THORAX, V65, P241, DOI 10.1136/thx.2008.110825; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351; Choi Pil Jo, 2013, Korean J Thorac Cardiovasc Surg, V46, P449, DOI 10.5090/kjtcs.2013.46.6.449; Noronha V, 2014, CHEMOTHER RES PRACT, V2014; Sobin LH, 2010, TNM CLASSIFICATION M; Sugimura H., 2007, ANN THORAC SURG, V83, P417; Sugimura H, 2007, ANN THORAC SURG, V83, P409, DOI 10.1016/j.athoracsur.2006.08.046; Tsukioka Takuma, 2007, Gen Thorac Cardiovasc Surg, V55, P113, DOI 10.1007/s11748-006-0082-6; Yoshino I, 2001, Ann Thorac Cardiovasc Surg, V7, P204	43	0	0	CIG MEDIA GROUP, LP	DALLAS	3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA	1525-7304	1938-0690		CLIN LUNG CANCER	Clin. Lung Cancer	NOV	2015	16	6					E213	E221		10.1016/j.cllc.2015.04.005		9	Oncology	Oncology	CU1GD	WOS:000363267500010		
J	Sakamoto, K; Nakata, H; Yumoto, M; Sadato, N; Kakigi, R				Sakamoto, Kiwako; Nakata, Hiroki; Yumoto, Masato; Sadato, Norihiro; Kakigi, Ryusuke			Mastication accelerates Go/No-go decisional processing: An event-related potential study	CLINICAL NEUROPHYSIOLOGY			English	Article						Mastication; Gum; P300; N140; Go/No-go; ERP	CHEWING GUM; SOMATOSENSORY STIMULATION; ELECTROENCEPHALOGRAPHIC ACTIVITY; EXERCISE INTENSITY; ASSOCIATION CORTEX; AEROBIC EXERCISE; ERP COMPONENTS; REACTION-TIME; NOGO TASK; P300	Objective: The purpose of the present study was to investigate the effect of mastication on Go/No-go decisional processing using event-related potentials (ERPs). Method: Thirteen normal subjects underwent seven sessions of a somatosensory Go/No-go paradigm for approximately 4 min; Pre, and Post 1, 2, 3, 4, 5, and 6. The Control condition included the same seven sessions. The RT and standard deviation were recorded, and the peak amplitude and latency of the N140 and P300 components were analyzed. Results: The RT was significantly shorter in Mastication than in Control at Post 1-3 and 4-6. The peak latency of N140 was earlier in Mastication than in Control at Post 4-6. The latency of N140 was shortened by repeated sessions in Mastication, but not by those in Control. The peak latency of P300 was significantly shorter in Mastication than in Control at Post 4-6. The peak latency of P300 was significantly longer in Control with repeated sessions, but not in Mastication. Conclusions: These results suggest that mastication may influence response execution processing in Go trials, as well as response inhibition processing in No-go trials. Significance: Mastication accelerated Go/No-go decisional processing in the human brain. (C) 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Sakamoto, Kiwako; Nakata, Hiroki; Kakigi, Ryusuke] Natl Inst Physiol Sci, Dept Integrat Physiol, Okazaki, Aichi 4448585, Japan; [Nakata, Hiroki] Nara Womens Univ, Fac Human Life & Environm, Dept Hlth Sci, Nara 630, Japan; [Yumoto, Masato] Univ Tokyo, Grad Sch Med, Dept Clin Lab, Tokyo, Japan; [Sadato, Norihiro] Natl Inst Physiol Sci, Dept Cerebral Res, Tokyo, Japan	Sakamoto, K (reprint author), Natl Inst Physiol Sci, Dept Integrat Physiol, Okazaki, Aichi 4448585, Japan.	kiwakos@nips.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	This study was supported by the grant-in-aid "Strategic Research Program for Brain Sciences'' from the Ministry of Education, Culture, Sports, Science and Technology of Japan. A part of this study includes the results of "Development of biomarker candidates for social behavior,'' which was conducted under the strategic research program for Brain Sciences MEXT.	Nakata H, 2006, NEUROSCI LETT, V397, P318, DOI 10.1016/j.neulet.2005.12.041; Nakata H, 2009, NEUROREPORT, V20, P1149, DOI 10.1097/WNR.0b013e32832f81d6; Hillman CH, 2003, INT J PSYCHOPHYSIOL, V48, P307, DOI 10.1016/S0167-8760(03)00080-1; BRUNIA CHM, 1988, BIOL PSYCHOL, V26, P165, DOI 10.1016/0301-0511(88)90018-X; Morinushi T, 2000, PSYCHIAT CLIN NEUROS, V54, P645, DOI 10.1046/j.1440-1819.2000.00772.x; Nakata H, 2006, CLIN NEUROPHYSIOL, V117, P1669, DOI 10.1016/j.clinph.2006.03.032; Nakata H, 2010, NEUROSCI LETT, V478, P124, DOI 10.1016/j.neulet.2010.05.002; Hirano Y, 2008, NEUROSCI LETT, V436, P189, DOI 10.1016/j.neulet.2008.03.033; Valeriani M, 2001, MUSCLE NERVE, V24, P1677, DOI 10.1002/mus.1203; Tucha O, 2004, APPETITE, V42, P327, DOI 10.1016/j.appet.2004.01.003; Kamijo K, 2007, INT J PSYCHOPHYSIOL, V65, P114, DOI 10.1016/j.ijpsycho.2007.04.001; Inui K, 2003, NEUROSCIENCE, V120, P235, DOI 10.1016/S0306-4522(03)00261-6; Roche RAP, 2005, EXP BRAIN RES, V160, P60, DOI 10.1007/s00221-004-1985-z; Masumoto Y, 1998, PSYCHIAT CLIN NEUROS, V52, P587, DOI 10.1111/j.1440-1819.1998.tb02705.x; Huang MX, 2005, NEUROIMAGE, V28, P99, DOI 10.1016/j.neuroimage.2005.05.036; VANBOXTEL GJM, 1994, BIOL PSYCHOL, V38, P37, DOI 10.1016/0301-0511(94)90048-5; JODO E, 1990, ELECTROEN CLIN NEURO, V76, P249, DOI 10.1016/0013-4694(90)90019-G; Kopp B, 1996, ELECTROEN CLIN NEURO, V99, P19, DOI 10.1016/0921-884X(96)95617-9; NAKAMURA Y, 1995, NEUROSCI RES, V23, P1, DOI 10.1016/0168-0102(95)00925-J; Nakata H, 2004, CLIN NEUROPHYSIOL, V115, P361, DOI 10.1016/j.clinph.2003.09.013; Baker JR, 2004, APPETITE, V43, P207, DOI 10.1016/j.appet.2004.06.004; Sakamoto K, 2009, NEUROSCI RES, V64, P259, DOI 10.1016/j.neures.2009.03.008; Dietz V, 2003, CLIN NEUROPHYSIOL, V114, P1379, DOI 10.1016/S1388-2457(03)00120-2; Nakata H, 2005, EUR J NEUROSCI, V22, P1784, DOI 10.1111/j.1460-9568.2005.04368.x; Lund JP, 2006, DYSPHAGIA, V21, P167, DOI 10.1007/s00455-006-9027-6; YAMAGUCHI S, 1991, J NEUROSCI, V11, P2039; Ikeda A, 1996, ELECTROEN CLIN NEURO, V98, P206, DOI 10.1016/0013-4694(95)00239-1; Kida T, 2006, NEUROIMAGE, V32, P1355, DOI 10.1016/j.neuroimage.2006.05.015; Magnie MN, 2000, PSYCHOPHYSIOLOGY, V37, P369, DOI 10.1017/S0048577200981435; Yuste R, 2005, NAT REV NEUROSCI, V6, P477, DOI 10.1038/nrn1686; Kamijo K, 2004, EUR J APPL PHYSIOL, V92, P305, DOI 10.1007/s00421-004-1097-2; Tarkka IM, 1996, NEUROSCIENCE, V75, P275, DOI 10.1016/0306-4522(96)00287-4; Braver TS, 2001, CEREB CORTEX, V11, P825, DOI 10.1093/cercor/11.9.825; Doucet C, 1999, PSYCHOPHYSIOLOGY, V36, P351, DOI 10.1017/S0048577299980563; Nakata H, 2012, EUR J APPL PHYSIOL, V112, P207, DOI 10.1007/s00421-011-1973-5; Yagi Y, 1999, EUR J APPL PHYSIOL O, V80, P402, DOI 10.1007/s004210050611; Zehr EP, 2007, J PHYSIOL-LONDON, V582, P209, DOI 10.1113/jphysiol.2007.133843; Sakamoto K, 2009, CLIN NEUROPHYSIOL, V120, P41, DOI 10.1016/j.clinph.2008.10.001; Yamada Y, 2005, RESP PHYSIOL NEUROBI, V147, P177, DOI 10.1016/j.resp.2005.02.017; Stephens R, 2004, APPETITE, V43, P211, DOI 10.1016/j.appet.2004.07.006; SASAKI K, 1993, NEUROSCI RES, V18, P249, DOI 10.1016/0168-0102(93)90062-U; Falkenstein M, 1999, ACTA PSYCHOL, V101, P267, DOI 10.1016/S0001-6918(99)00008-6; Wilkinson L, 2002, APPETITE, V38, P235, DOI 10.1006/appe.2002.0473; Masumoto Y, 1999, PSYCHIAT CLIN NEUROS, V53, P17, DOI 10.1046/j.1440-1819.1999.00465.x; Johnson AJ, 2007, APPETITE, V48, P394, DOI 10.1016/j.appet.2006.10.003; Falkenstein M, 2002, J PSYCHOPHYSIOL, V16, P167, DOI 10.1027//0269-8803.16.3.167; Shibasaki H, 2006, CLIN NEUROPHYSIOL, V117, P2341, DOI 10.1016/j.clinph.2006.04.025; Smith A, 2009, HUM PSYCHOPHARM CLIN, V24, P239, DOI 10.1002/hup.1020; Nakata H, 2005, EXP BRAIN RES, V162, P293, DOI 10.1007/s00221-004-2195-4; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Nakata H, 2010, NEUROREPORT, V21, P1040, DOI 10.1097/WNR.0b013e32833f7bb5; Chu Nai-Shin, 1994, Journal of the Formosan Medical Association, V93, P343; Endo T, 1982, J TRANSPORT MED, V36, P195; Hirano Y, 2013, BRAIN COGNITION, V8, P376; Johnson Ray Jr, 2005, Brain Res Cogn Brain Res, V24, P386; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI DOI 10.1016/0013-4694(49)90219-9; Nageishi Y, 1993, J JAPANESE SOC MASTI, V3, P23; Nakamura Y, 1999, Electromyogr Clin Neurophysiol, V39, P71; Otomaru A, 2003, J JPN SOC MASTICAT S, V13, P67; Schmidt RA, 2000, MOTOR CONTROL LEARNI, P52; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Suzuki M, 1994, J MASTICA HLTH SCI, V4, P9; Suzuki M, 1989, JPN J AEROSPACE ENV, V26, P91; Suzuki M, 1992, J MASTICA HLTH SCI, V2, P55	64	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	NOV	2015	126	11					2099	2107		10.1016/j.clinph.2014.12.034		9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU4EG	WOS:000363479000009		
J	Ozaki, I; Kurata, K				Ozaki, Isamu; Kurata, Kiyoshi			The effects of voluntary control of respiration on the excitability of the primary motor hand area, evaluated by end-tidal CO2 monitoring	CLINICAL NEUROPHYSIOLOGY			English	Article						Voluntary breathing; Automatic breathing; Primary motor cortex; Transcranial magnetic stimulation; Hand muscles; Motor-evoked potential	MAGNETIC STIMULATION; CORTEX; MUSCLES; HYPERVENTILATION; BRAIN; MOTONEURONS; PROJECTION; RESPONSES; NEURONS; HUMANS	Objective: To investigate the effects of voluntary deep breathing on the excitability of the hand area in the primary motor cortex (M1). Methods: We applied near-threshold transcranial magnetic stimulation (TMS) over M1 during the early phase of inspiration or expiration in both normal automatic and voluntary deep, but not "forced'', breathing in eight healthy participants at rest. We monitored exhaled CO2 levels continuously, and recorded motor-evoked potentials (MEPs) simultaneously from the abductor pollicis brevis, first dorsal interosseous, abductor digiti minimi, flexor digitorum superficialis, and extensor incidis muscles. Results: We observed that, during voluntary deep breathing, MEP amplitude increased by up to 50% for all recorded muscles and the latency of MEPs decreased by approximately 1 ms, compared with normal automatic breathing. We found no difference in the amplitude or latency of MEPs between inspiratory and expiratory phases in either normal automatic or voluntary deep breathing. Conclusions: Voluntary deep breathing at rest facilitates MEPs following TMS over the hand area of M1, and MEP enhancement occurs throughout the full respiratory cycle. Significance: The M1 hand region is continuously driven by top-down neural signals over the entire respiratory cycle of voluntary deep breathing. (C) 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Ozaki, Isamu] Aomori Univ Hlth & Welf, Fac Hlth Sci, Dept Phys Therapy, Aomori 0308505, Japan; [Kurata, Kiyoshi] Hirosaki Univ, Grad Sch Med, Dept Physiol, Hirosaki, Aomori 0368562, Japan	Ozaki, I (reprint author), Aomori Univ Hlth & Welf, Fac Hlth Sci, Dept Phys Therapy, 58-1 Mase, Aomori 0308505, Japan.	isamu@auhw.ac.jp			KAKENHI [25350609]	This work was supported in part by KAKENHI 25350609 (Grant-in-Aid for Scientific Research (C)). The authors are very grateful to Mr. Tatsuya Iwabe for his technical assistance.	HENNEMAN E, 1965, J NEUROPHYSIOL, V28, P599; HENNEMAN E, 1965, J NEUROPHYSIOL, V28, P560; TANJI J, 1976, J NEUROPHYSIOL, V39, P1062; ROTHWELL JC, 1991, EXP PHYSIOL, V76, P159; SHINODA Y, 1981, NEUROSCI LETT, V23, P7, DOI 10.1016/0304-3940(81)90182-8; Li S, 2011, J NEUROPHYSIOL, V105, P512, DOI 10.1152/jn.00946.2010; Sparing R, 2007, J APPL PHYSIOL, V102, P406, DOI 10.1152/japplphysiol.00770.2006; Filippi MM, 2000, BRAIN RES, V881, P159, DOI 10.1016/S0006-8993(00)02837-7; Evans KC, 1999, J PHYSIOL-LONDON, V520, P383, DOI 10.1111/j.1469-7793.1999.00383.x; ROTHWELL JC, 1987, BRAIN, V110, P1173, DOI 10.1093/brain/110.5.1173; Klinger G, 2005, ARCH DIS CHILD, V90, pF49, DOI 10.1136/adc.2003.048785; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Seyal M, 1998, ELECTROMYOGR MOTOR C, V109, P263, DOI 10.1016/S0924-980X(98)00022-8; GANDEVIA SC, 1989, RESP PHYSIOL, V77, P203, DOI 10.1016/0034-5687(89)90007-8; Takai O, 2010, BRAIN LANG, V113, P39, DOI 10.1016/j.bandl.2010.01.008; Mason P, 2007, J NEUROPHYSIOL, V98, P1919, DOI 10.1152/jn.00813.2007; Fink GR, 1995, J PHYSIOL-LONDON, V489, P663; McKay LC, 2003, J APPL PHYSIOL, V95, P1170, DOI 10.1152/japplphysiol.00641.2002; Rathelot JA, 2006, P NATL ACAD SCI USA, V103, P8257, DOI 10.1073/pnas.0602933103; Kujirai K, 2006, J NEUROPHYSIOL, V96, P1337, DOI 10.1152/jn.01140.2005; Terao Y, 2002, J CLIN NEUROPHYSIOL, V19, P322, DOI 10.1097/00004691-200208000-00006; Heckman CJ, 2009, CLIN NEUROPHYSIOL, V120, P2040, DOI 10.1016/j.clinph.2009.08.009; Li S, 2006, MUSCLE NERVE, V34, P651, DOI 10.1002/mus.20592; DAY BL, 1989, J PHYSIOL-LONDON, V412, P449; CHENEY PD, 1985, J NEUROPHYSIOL, V53, P805; EPSTEIN MA, 1994, EPILEPSIA, V35, P1204, DOI 10.1111/j.1528-1157.1994.tb01790.x; Guz A, 1997, RESP PHYSIOL, V109, P197, DOI 10.1016/S0034-5687(97)00050-9; Iwabe T, 2014, NEUROSCI RES, V84, P47, DOI 10.1016/j.neures.2014.03.003; Rossini P., 1999, ELECTROENCEPHALOGR C, V91, P79; SCHEIBEL ME, 1966, ARCH ITAL BIOL, V104, P328	30	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	NOV	2015	126	11					2162	2169		10.1016/j.clinph.2014.12.032		8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU4EG	WOS:000363479000015		
J	Shimatani, Y; Nodera, H; Osaki, Y; Banzrai, C; Takayasu, K; Endo, S; Shibuta, Y; Kaji, R				Shimatani, Yoshimitsu; Nodera, Hiroyuki; Osaki, Yusuke; Banzrai, Chimeglkham; Takayasu, Kazuhiro; Endo, Sachiko; Shibuta, Yoshiko; Kaji, Ryuji			Upregulation of axonal HCN current by methylglyoxal: Potential association with diabetic polyneuropathy	CLINICAL NEUROPHYSIOLOGY			English	Article						Methylglyoxal; Diabetic neuropathy; Axonal excitability; HCN channel; Ih	HUMAN MOTOR AXONS; GLYCATION END-PRODUCTS; EXCITABILITY PROPERTIES; GLYCEMIC CONTROL; ALZHEIMERS-DISEASE; PERIPHERAL-NERVE; I-H; NEUROPATHY; CHANNEL; DYSFUNCTION	Objective: To describe functional changes of axonal ion channels by a metabolic derivative of glucose, methylglyoxal (MGO), and its potential contribution to diabetic neuropathy. Methods: (1) In wild-type male mice, multiple excitability measurements of sensory nerves were performed at baseline and 1 week after serial administration of MGO (50 mg/kg).(2) Excitability testing in patients with diabetic neuropathy (N = 17) and healthy controls (N = 12) were also conducted, and data were interpreted using mathematical modeling. Results: In the animal study, there was a decrease in threshold changes by long hyperpolarization and in superexcitability after administration of MGO. In the preliminary human study, the threshold changes by long hyperpolarizing current were decreased in patients with diabetes. Mathematical modeling showed increased hyperpolarization-activated cation current (Ih) in the MGO-treated mice and in patients with diabetes. Conclusion: Ih was upregulated after MGO administration in normal mice. Significance: MGO is associated with abnormal axonal excitability. Hyperexcitability in diabetic polyneuropathy may, at least in part, be caused by dysfunctional axonal hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. A future study with a large sample size of the diabetic patients would clarify this hypothesis. (C) 2015 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Shimatani, Yoshimitsu; Nodera, Hiroyuki; Osaki, Yusuke; Banzrai, Chimeglkham; Takayasu, Kazuhiro; Endo, Sachiko; Shibuta, Yoshiko; Kaji, Ryuji] Univ Tokushima, Dept Neurol, Tokushima 7708503, Japan; [Shibuta, Yoshiko] Natl Hosp Org, Takamatsu Med Ctr, Dept Neurol, Takamatsu, Kagawa, Japan	Nodera, H (reprint author), Univ Tokushima, Dept Neurol, 2-50-1 Kuramotocho, Tokushima 7708503, Japan.	hnodera@tokushima-u.ac.jp		Nodera, Hiroyuki/0000-0002-5357-5081	Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP, Japan [25-4]	This work was supported by Grants-in-Aid from the Intramural Research Grant (25-4) for Neurological and Psychiatric Disorders of NCNP, Japan.	Andersson DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077986; Nodera H, 2006, CLIN NEUROPHYSIOL, V117, P1902, DOI 10.1016/j.clinph.2006.01.018; Nakayama K, 2008, AM J NEPHROL, V28, P871, DOI 10.1159/000139653; Kiernan MC, 2000, BRAIN, V123, P2542, DOI 10.1093/brain/123.12.2542; Bierhaus A, 2012, NAT MED, V18, P926, DOI 10.1038/nm.2750; Tomlinson DR, 2008, NAT REV NEUROSCI, V9, P36, DOI 10.1038/nrn2294; Shibuta Y, 2010, J CLIN NEUROPHYSIOL, V27, P350, DOI 10.1097/WNP.0b013e3181f387ab; Hsu WH, 2013, J AGR FOOD CHEM, V61, P5996, DOI 10.1021/jf401197r; Eberhardt MJ, 2012, J BIOL CHEM, V287, P28291, DOI 10.1074/jbc.M111.328674; Kalapos MP, 2013, DIABETES RES CLIN PR, V99, P260, DOI 10.1016/j.diabres.2012.11.003; George A, 2007, MUSCLE NERVE, V36, P628, DOI 10.1002/mus.20851; Zochodne DW, 2008, CURR OPIN NEUROL, V21, P527, DOI 10.1097/WCO.0b013e32830b84cb; Wanat MJ, 2008, J PHYSIOL-LONDON, V586, P2157, DOI 10.1113/jphysiol.2007.150078; Tomlinson SE, 2010, MUSCLE NERVE, V41, P247, DOI 10.1002/mus.21482; Krishnan AV, 2008, BRAIN, V131, P1209, DOI 10.1093/brain/awn052; Howells J, 2012, J PHYSIOL-LONDON, V590, P1625, DOI 10.1113/jphysiol.2011.225573; Yang Q, 2001, BRAIN, V124, P1149, DOI 10.1093/brain/124.6.1149; Li JL, 2012, J NEUROL SCI, V317, P1, DOI 10.1016/j.jns.2012.02.018; Arnold R, 2013, CLIN NEUROPHYSIOL, V124, P2079, DOI 10.1016/j.clinph.2013.04.012; Jankelowitz SK, 2007, CLIN NEUROPHYSIOL, V118, P1397, DOI 10.1016/j.clinph.2007.02.025; DYCK PJ, 1989, NEUROLOGY, V39, P111; Krautwald M, 2010, EXP GERONTOL, V45, P744, DOI 10.1016/j.exger.2010.03.001; Horn S, 1996, MUSCLE NERVE, V19, P1268, DOI 10.1002/mus.880191002; Ohkawara S, 2012, J TOXICOL SCI, V37, P831; Moldovan M, 2004, J PHYSIOL-LONDON, V560, P795, DOI 10.1113/jphysiol.2004.069476; Yasuda H, 2003, PROG NEUROBIOL, V69, P229, DOI 10.1016/S0301-0082(03)00034-0; Bostock H, 1998, MUSCLE NERVE, V21, P137, DOI 10.1002/(SICI)1097-4598(199802)21:2<137::AID-MUS1>3.0.CO;2-C; Bae JS, 2008, CLIN NEUROPHYSIOL, V119, P2282, DOI 10.1016/j.clinph.2008.07.005; Krishnan AV, 2005, BRAIN, V128, P1178, DOI 10.1093/brain/awh476; Kwai NCG, 2013, DIABETES CARE, V36, P1272, DOI 10.2337/dc12-1310; Kitano Y, 2004, ANN NEUROL, V56, P462, DOI 10.1002/ana.20232; Chen K, 2006, J NEUROCHEM, V99, P1413, DOI 10.1111/j.1471-4159.2006.04181.x; Misawa S, 2006, CLIN NEUROPHYSIOL, V117, P815, DOI 10.1016/j.clinph.2005.11.019; Misawa S, 2005, CLIN NEUROPHYSIOL, V116, P1181, DOI 10.1016/j.clinph.2004.12.019; Odani H, 1999, BIOCHEM BIOPH RES CO, V256, P89, DOI 10.1006/bbrc.1999.0221; Kiernan MC, 2001, MUSCLE NERVE, V24, P883; Butterfield DA, 2011, FREE RADICAL RES, V45, P59, DOI 10.3109/10715762.2010.520014; Vistoli G, 2013, FREE RADICAL RES, V47, P3, DOI 10.3109/10715762.2013.815348; Misawa S, 2005, CLIN NEUROPHYSIOL, V116, P254, DOI 10.1016/j.clinph.2004.08.003; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a	40	1	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	NOV	2015	126	11					2226	2232		10.1016/j.clinph.2015.02.058		7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU4EG	WOS:000363479000022		
J	Jinguji, M; Kajiya, Y; Nakajo, M; Higashi, M; Yoshiura, T				Jinguji, Megumi; Kajiya, Yoriko; Nakajo, Masayuki; Higashi, Michiyo; Yoshiura, Takashi			A Case of Intraductal Papilloma of the Breast With High F-18-FDG Uptake on PET/CT	CLINICAL NUCLEAR MEDICINE			English	Article						intraductal papilloma; intracystic mass; breast tumor; FDG PET; GLUT-1; hexokinase-II	POSITRON-EMISSION-TOMOGRAPHY; FDG-PET; FLUORODEOXYGLUCOSE	We present a case of intraductal papilloma in the right breast of a 51-year-old woman with high F-18-FDG uptake. Its maximum standardized uptake value increased from 10.2 on early (1 h) PET/CT scan to 12.2 on delayed (2 h) PET/CT scan suggesting a primary breast cancer. However, histopathology proved it to be an intraductal papilloma. Immunohistochemically, strong expression of glucose transporter-1 and weak expression of hexokinase-II were noted in the papilloma. With the detection of a subareolar intracystic mass with high F-18-FDG uptake, intraductal papilloma should be included in the differential diagnosis.	[Jinguji, Megumi; Kajiya, Yoriko; Nakajo, Masayuki] Nanpuh Hosp, Dept Radiol, Kagoshima, Japan; [Jinguji, Megumi; Nakajo, Masayuki; Yoshiura, Takashi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Radiol, Kagoshima 8908544, Japan; [Higashi, Michiyo] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Kagoshima 8908544, Japan	Jinguji, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Radiol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.	megu@m.kufm.kagoshima-u.ac.jp					Adejolu M, 2012, AM J ROENTGENOL, V198, P304; OHUCHI N, 1984, BREAST CANCER RES TR, V4, P117, DOI 10.1007/BF01806394; Kumar R, 2006, BREAST CANCER RES TR, V98, P267, DOI 10.1007/s10549-006-9159-2; Kihara M, 2010, BREAST CANCER-TOKYO, V17, P68, DOI 10.1007/s12282-008-0092-6; CARDENOSA G, 1991, RADIOLOGY, V181, P751; Nguyen BD, 2005, CLIN NUCL MED, V30, P481, DOI 10.1097/01.rlu.0000167643.79962.1c; Avril N, 2000, J CLIN ONCOL, V18, P3495; WOODS ER, 1992, AM J ROENTGENOL, V159, P487; OMORI LM, 1993, J CLIN ULTRASOUND, V21, P489, DOI 10.1002/jcu.1870210803; Hirose Y, 2011, JPN J RADIOL, V29, P217, DOI 10.1007/s11604-010-0531-0; MacGrogan G, 2003, WHO CLASSIFICATION T, P76	11	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0363-9762	1536-0229		CLIN NUCL MED	Clin. Nucl. Med.	NOV	2015	40	11					905	907		10.1097/RLU.0000000000000873		3	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CT8CT	WOS:000363043300020		
J	Tanaka, A; Asano, K; Uyama, Y				Tanaka, A.; Asano, K.; Uyama, Y.			How Should Ethnicity-Related Information Be Included on Drug Labels? Considerations Based on Comparison of Multiregional Clinical Trial Data on the Label Between Japan and the United States	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Article								Clinical data on various ethnicities collected in multiregional clinical trials (MRCTs) have increased in regulatory review for drug approval. However, how such data should be included on the drug labels has not been discussed. We compared information related to ethnicities on the labels of drugs that were approved in both Japan and the United States, and discussed the issues to be considered for providing better information to healthcare professionals in this era of globalized drug development.	[Tanaka, A.; Uyama, Y.] Pharmaceut & Med Devices Agcy, Off Med Informat & Epidemiol, Tokyo 1000013, Japan; [Asano, K.] Pharmaceut & Med Devices Agcy, Off New Drug 1, Tokyo 1000013, Japan; [Uyama, Y.] Chiba Univ, Grad Sch Med, Dept Regulatory Sci Med, Chiba 2608670, Japan	Uyama, Y (reprint author), Pharmaceut & Med Devices Agcy, Off Med Informat & Epidemiol, Tokyo 1000013, Japan.	uyama-yoshiaki@pmda.go.jp					Asano K, 2013, CLIN PHARMACOL THER, V94, P195, DOI 10.1038/clpt.2013.106; Eshera N., 2015, AM J THER; Food and Drug Administration, 2005, GUID IND COLL RAC ET; Ministry of Health Labour and Welfare, 2007, BAS PRINC GLOB CLIN; Ministry of Public Management, 2010, FY2010 NAT CENS POP	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	NOV	2015	98	5					480	482		10.1002/cpt.197		3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CU3DU	WOS:000363405000014		
J	Pignatti, F; Ashby, D; Brass, EP; Eichler, HG; Frey, P; Hillege, HL; Hori, A; Levitan, B; Liberti, L; Loefstedt, RE; McAuslane, N; Micaleff, A; Noel, RA; Postmus, D; Renn, O; Sabourin, BJ; Salmonson, T; Walker, S				Pignatti, F.; Ashby, D.; Brass, E. P.; Eichler, H-G; Frey, P.; Hillege, H. L.; Hori, A.; Levitan, B.; Liberti, L.; Loefstedt, R. E.; McAuslane, N.; Micaleff, A.; Noel, R. A.; Postmus, D.; Renn, O.; Sabourin, B. J.; Salmonson, T.; Walker, S.			Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions	CLINICAL PHARMACOLOGY & THERAPEUTICS			English	Review							NONPRESCRIPTION DRUGS; DECISION-MAKING	Structured frameworks for benefit-risk analysis in drug licensing decisions are being implemented across a number of regulatory agencies worldwide. The aim of these frameworks is to aid the analysis and communication of the benefit-risk assessment throughout the development, evaluation, and supervision of medicines. In this review, authors from regulatory agencies, pharmaceutical companies, and academia share their views on the different frameworks and discuss future directions.	[Pignatti, F.; Eichler, H-G; Postmus, D.] European Med Agcy, London, England; [Ashby, D.] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England; [Brass, E. P.] Harbor UCLA Med Ctr, Dept Med, Torrance, CA 90509 USA; [Frey, P.] Food & Drug Adm, Silver Spring, MD USA; [Hillege, H. L.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Hori, A.] Pharmaceut & Med Devices Agcy, Tokyo, Japan; [Levitan, B.] Janssen Pharmaceut Res & Dev, Titusville, NJ USA; [Liberti, L.; McAuslane, N.; Walker, S.] CIRS, London, England; [Loefstedt, R. E.] Univ Surrey, Risk Res Grp, Ctr Environm Strategy, Guildford GU2 5XH, Surrey, England; [Micaleff, A.] Merck Serono, Geneva, Switzerland; [Noel, R. A.] Eli Lilly & Co, Indianapolis, IN 46285 USA; [Renn, O.] Univ Stuttgart, Inst Sozialwissensch, D-70174 Stuttgart, Germany; [Sabourin, B. J.] Hlth Canada, Ottawa, ON K1A 0L2, Canada; [Salmonson, T.] Lakemedelsverket, Uppsala, Sweden	Pignatti, F (reprint author), European Med Agcy, London, England.	francesco.pignatti@ema.europa.eu					Brass EP, 2013, J CLIN PHARMACOL, V53, P475, DOI 10.1002/jcph.22; Guo JJ, 2010, VALUE HEALTH, V13, P657, DOI 10.1111/j.1524-4733.2010.00725.x; Brass EP, 2011, CLIN PHARMACOL THER, V90, P791, DOI 10.1038/clpt.2011.231; Beasley BN, 2011, NEW ENGL J MED, V364, P1788, DOI 10.1056/NEJMp1103050; Unger EF, 2009, NEW ENGL J MED, V361, P942, DOI 10.1056/NEJMp0907122; Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034; Levitan BS, 2011, CLIN PHARMACOL THER, V89, P217, DOI 10.1038/clpt.2010.280; Brass EP, 2013, DIABETES CARE, V36, P1823, DOI 10.2337/dc13-0891; Eichler HG, 2012, BRIT J CLIN PHARMACO, V74, P731, DOI 10.1111/j.1365-2125.2012.04255.x; Eichler HG, 2009, NEW ENGL J MED, V360, P1378, DOI 10.1056/NEJMp0900092; Coplan PM, 2011, CLIN PHARMACOL THER, V89, P312, DOI 10.1038/clpt.2010.291; Noel R, 2012, DRUG INF J, V46, P736, DOI 10.1177/0092861512458908; Liberti L, 2013, CLIN PHARMACOL THER, V94, P305, DOI 10.1038/clpt.2013.127; Brass E.P., 2015, INT C PHARM THER RIS; Dombrowski C., 2012, INT GROUP FINDS HARM; European Medicines Agency, REFL PAP BEN RISK AS; European Medicines Agency, REG METH STAND IMPR; European Medicines Agency, GUID DOC CONT CO RAP; European Medicines Agency, BEN RISK METH PROJ W; European Medicines Agency, BEN RISK METH PROJ U; European Medicines Agency, ASS TEMPL GUID; European Medicines Agency, ASS REP AC; Gingery D., SYSTEMATIZING PATIEN; Hammond J. S., 1999, SMART CHOICES PRACTI; Hughes D., RECOMMENDATIONS REPO; Levitan B, 2014, THER INNOV REGUL SCI, V48, P564, DOI 10.1177/2168479014536500; Medicines and Healthcare Products Regulatory Agency, CHANG LEG CLASS MED; Mt-Isa S., REV METHODOLOGIES BE; New Zealand Medicines and Medical Devices Safety Authority, CHANG LEG CLASS MED; Pharmaceuticals and Medical Devices Agency, POINTS BE CONS REV S; Pharmaceuticals and Medical Devices Agency, RISK MAN PLAN GUID 2; Phillips L, 2011, DRUG DISCOV TODAY TE, V8, P3; Phillips LD, 2014, CH CRC BIOSTAT SER, P59; Renn O., 2005, WHITE PAPER RISK GOV; Sashegyi A, 2014, CH CRC BIOSTAT SER, P181; US Food and Drug Administration, 2010, BEL CARD REN DRUGS A; US Food and Drug Administration, STRUCT APPR BEN RISK; US Food and Drug Administration, 2009, RIV CARD REN DRUGS A; US Food and Drug Administration, 2011, RIV CARD REN DRUGS A; von Winterfeldt D., 1986, DECISION ANAL BEHAV; Walker S, 2015, THER INNOV REGUL SCI, V49, P17, DOI 10.1177/2168479014547421; Walker S., CIRS WORKSH JUN 2013	42	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9236	1532-6535		CLIN PHARMACOL THER	Clin. Pharmacol. Ther.	NOV	2015	98	5					522	533		10.1002/cpt.203		12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CU3DU	WOS:000363405000022		
J	Hiromoto, S				Hiromoto, Sachiko			Self-healing property of hydroxyapatite and octacalcium phosphate coatings on pure magnesium and magnesium alloy	CORROSION SCIENCE			English	Article						Magnesium; Ceramic; SEM; Oxide coatings	CHEMICAL SOLUTION DEPOSITION; ZN-ZR ALLOY; IN-VITRO; CORROSION BEHAVIOR; SPECTROPHOTOMETRIC DETERMINATION; HYDROTHERMAL TREATMENT; SURFACE MODIFICATION; CALCIUM-PHOSPHATE; HANKS SOLUTION; VIVO	Hydroxyapatite (HAP) and octacalcium phosphate (OCP) coatings were formed on AZ31 alloy and pure Mg, and the surfaces were scratched to expose the metal surface. The specimens were immersed in a cell-culture medium or 0.9% NaCl. Release of Mg ions was not accelerated by scratching. In both solutions, a corrosion product layer containing Mg and P was formed in the scratches; i.e., the coatings self-healed. The corrosion morphology of HAp-coated AZ31 was examined by periodic medium replacement or using a gelatine-added medium. The former enhanced calcium phosphate precipitation; the latter increased corrosion localization. (C) 2015 Elsevier Ltd. All rights reserved.	Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton WPI MANA, Biomat Unit, Tsukuba, Ibaraki 3050044, Japan	Hiromoto, S (reprint author), Natl Inst Mat Sci, Int Ctr Mat Nanoarchitecton WPI MANA, Biomat Unit, Tsukuba, Ibaraki 3050044, Japan.	hiromoto.sachiko@nims.go.jp			Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT) [25420742]; Light Metal Educational Foundation, Inc.; World Premier International Research Centre Initiative (WPI) on Materials Nanoarchitectonics (MANA), MEXT, Japan	The author thanks Ms. S. Sugita for her helpful technical support with the experiments. This work was partly supported by a Grant-in-Aid for Scientific Research(C) (25420742) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology (MEXT) and grants from the Light Metal Educational Foundation, Inc., and the World Premier International Research Centre Initiative (WPI) on Materials Nanoarchitectonics (MANA), MEXT, Japan.	Li LC, 2004, SURF COAT TECH, V185, P92, DOI 10.1016/j.surfcoat.2004.01.004; Kraus T, 2012, ACTA BIOMATER, V8, P1230, DOI 10.1016/j.actbio.2011.11.008; Pommiers S, 2014, CORROS SCI, V84, P135, DOI 10.1016/j.corsci.2014.03.021; MANN CK, 1956, ANAL CHEM, V28, P202, DOI 10.1021/ac60110a016; Shadanbaz S, 2014, J MATER SCI-MATER M, V25, P173, DOI 10.1007/s10856-013-5059-2; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; WATANABE H, 1977, BUNSEKI KAGAKU, V26, P635; Shadanbaz S, 2012, ACTA BIOMATER, V8, P20, DOI 10.1016/j.actbio.2011.10.016; Staiger MP, 2006, BIOMATERIALS, V27, P1728, DOI 10.1016/j.biomaterials.2005.10.003; Hiromoto S, 2010, MATER TRANS, V51, P2080, DOI 10.2320/matertrans.M2010192; Hornberger H, 2012, ACTA BIOMATER, V8, P2442, DOI 10.1016/j.actbio.2012.04.012; Hiromoto S, 2015, ACTA BIOMATER, V11, P520, DOI 10.1016/j.actbio.2014.09.026; Witte F, 2008, ORTHOPADE, V37, P125, DOI 10.1007/s00132-008-1193-9; Tomozawa M, 2010, SURF COAT TECH, V204, P3243, DOI 10.1016/j.surfcoat.2010.03.023; Yagi S, 2013, CORROS SCI, V73, P188, DOI 10.1016/j.corsci.2013.03.035; Yamamoto A, 2009, MAT SCI ENG C-BIO S, V29, P1559, DOI 10.1016/j.msec.2008.12.015; Kim SM, 2014, J BIOMED MATER RES A, V102, P429, DOI 10.1002/jbm.a.34718; Witte F, 2010, ACTA BIOMATER, V6, P1680, DOI 10.1016/j.actbio.2010.02.028; Hiromoto S, 2008, CORROS SCI, V50, P3561, DOI 10.1016/j.corsci.2008.09.026; Chai HW, 2012, J BIOMED MATER RES A, V100A, P293, DOI 10.1002/jbm.a.33267; Guan XM, 2014, ACS APPL MATER INTER, V6, P21525, DOI 10.1021/am506543a; Tomozawa M, 2011, ACTA MATER, V59, P355, DOI 10.1016/j.actamat.2010.09.041; Levesque J, 2008, ACTA BIOMATER, V4, P284, DOI 10.1016/j.actbio.2007.09.012; Hamdy AS, 2011, ELECTROCHIM ACTA, V56, P2493, DOI 10.1016/j.electacta.2010.11.103; Aramaki K, 2003, CORROS SCI, V45, P2361, DOI 10.1016/S0010-938X(03)00030-1; Hiromoto S, 2013, J MECH BEHAV BIOMED, V25, P1, DOI 10.1016/j.jmbbm.2013.04.021; Kuwahara H, 2001, MATER TRANS, V42, P1317, DOI 10.2320/matertrans.42.1317; Al-Abdullat Y, 2001, MATER TRANS, V42, P1777, DOI 10.2320/matertrans.42.1777; Stankiewicz A, 2013, J MATER SCI, V48, P8041, DOI 10.1007/s10853-013-7616-y; Niu JL, 2013, MAT SCI ENG C-MATER, V33, P4833, DOI 10.1016/j.msec.2013.08.008; Hiromoto S, 2009, ELECTROCHIM ACTA, V54, P7085, DOI 10.1016/j.electacta.2009.07.033; Ohtsu N, 2013, SURF COAT TECH, V218, P114, DOI 10.1016/j.surfcoat.2012.12.037; Hohn S, 2015, SURF SCI, V636, P47, DOI 10.1016/j.susc.2015.02.007; Heublein B, 2003, HEART, V89, P651, DOI 10.1136/heart.89.6.651; Hiromoto S, 2011, SURF COAT TECH, V205, P4711, DOI 10.1016/j.surfcoat.2011.04.036; Hofstetter J, 2015, CORROS SCI, V91, P29, DOI 10.1016/j.corsci.2014.09.008; Khana SA, 2008, MAT SCI ENG A-STRUCT, V474, P261, DOI 10.1016/j.msea.2007.04.078; Montemor MF, 2014, SURF COAT TECH, V258, P17, DOI 10.1016/j.surfcoat.2014.06.031; Song GL, 2011, WOODHEAD PUBL MATER, P1, DOI 10.1533/9780857091413; Sugawara M., 2003, BLOOD RHEOLOGY BLOOD, P75; Wang JL, 2012, J BIOMED MATER RES B, V100B, P1691, DOI 10.1002/jbm.b.32707; Witte F, 2006, BIOMATERIALS, V27, P1013, DOI 10.1016/j.biomaterials.2005.07.037; Zeng RC, 2008, ADV ENG MATER, V10, pB3, DOI 10.1002/adem.200800035	43	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0010-938X	1879-0496		CORROS SCI	Corrosion Sci.	NOV	2015	100						284	294		10.1016/j.corsci.2015.08.001		11	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CT8MG	WOS:000363070100026		
J	Liao, JS; Hotta, M				Liao, Jinsun; Hotta, Makoto			Atmospheric corrosion behavior of field-exposed magnesium alloys: Influences of chemical composition and microstructure	CORROSION SCIENCE			English	Article						Magnesium; Weight loss; SEM; Field-exposure; Atmospheric corrosion	MG-CA ALLOYS; IMPACT TOUGHNESS; GRAIN-SIZE; AZ91D; ZN; TEMPERATURE; REFINEMENT; MECHANISMS; RESISTANCE; EXTRUSION	Ten kinds of magnesium alloys with various chemical compositions and/or microstructures were exposed to actual atmospheric environments for three years, and the influences of chemical compositions and microstructures on atmospheric corrosion behavior of magnesium alloys were investigated. The results showed that the atmospheric corrosion resistance of magnesium alloys generally increased with the Al content in the alloys, but intermetallic phases had a considerable influence on the corrosion resistance. Grain refinement improved the corrosion resistance of magnesium alloys. It was also found that atmospheric corrosion rate increased with exposure time, and this phenomenon was explained in the present work. (C) 2015 Elsevier Ltd. All rights reserved.	[Liao, Jinsun; Hotta, Makoto] Kurimoto Ltd, Technol Dev Div, Osaka 5590021, Japan	Liao, JS (reprint author), Kurimoto Ltd, Technol Dev Div, 2-8-45 Suminoe, Osaka 5590021, Japan.	j_liao@kurimoto.co.jp					Zhang TL, 2011, MATER DESIGN, V32, P2742, DOI 10.1016/j.matdes.2011.01.012; Yang LJ, 2010, CORROS SCI, V52, P2188, DOI 10.1016/j.corsci.2010.03.011; Jeong YS, 2014, CORROS SCI, V82, P392, DOI 10.1016/j.corsci.2014.01.041; Esmaily M, 2015, CORROS SCI, V90, P420, DOI 10.1016/j.corsci.2014.10.040; Jonsson M, 2008, CORROS SCI, V50, P1406, DOI 10.1016/j.corsci.2007.12.005; Birbilis N, 2009, CORROS SCI, V51, P683, DOI 10.1016/j.corsci.2008.12.012; Andreatta F, 2006, ELECTROCHIM ACTA, V51, P3551, DOI 10.1016/j.electacta.2005.10.010; Hara N, 2007, CORROS SCI, V49, P166, DOI 10.1016/j.corsci.2006.05.033; Nam ND, 2009, CORROS SCI, V51, P2942, DOI 10.1016/j.corsci.2009.08.023; Song GL, 1999, CORROS SCI, V41, P249; Mathieu S, 2003, CORROS SCI, V45, P2741, DOI 10.1016/S0010-938X(03)00109-4; Liao JS, 2012, MAT SCI ENG A-STRUCT, V544, P10, DOI 10.1016/j.msea.2012.02.046; Ben Hamu G, 2009, J ALLOY COMPD, V468, P222, DOI 10.1016/j.jallcom.2008.01.084; del Valle JA, 2006, ACTA MATER, V54, P4247, DOI 10.1016/j.actamat.2006.05.018; LUNDER O, 1989, CORROSION, V45, P741; Zander D, 2015, CORROS SCI, V93, P222, DOI 10.1016/j.corsci.2015.01.027; HEHMANN F, 1989, J MATER SCI, V24, P2369; Arrabal R, 2015, CORROS SCI, V97, P38, DOI 10.1016/j.corsci.2015.04.004; MAKAR GL, 1990, J ELECTROCHEM SOC, V137, P414, DOI 10.1149/1.2086455; Feliu S, 2009, APPL SURF SCI, V255, P4102, DOI 10.1016/j.apsusc.2008.10.095; Song D, 2010, CORROS SCI, V52, P481, DOI 10.1016/j.corsci.2009.10.004; Yamasaki M, 2007, CORROS SCI, V49, P255, DOI 10.1016/j.corsci.2006.05.017; Song YW, 2012, CORROS SCI, V65, P322, DOI 10.1016/j.corsci.2012.08.037; Liao JS, 2012, CORROS SCI, V61, P208, DOI 10.1016/j.corsci.2012.04.039; Liu M, 2009, CORROS SCI, V51, P1115, DOI 10.1016/j.corsci.2009.02.017; Neil WC, 2009, CORROS SCI, V51, P387, DOI 10.1016/j.corsci.2008.11.005; Ballerini G, 2005, CORROS SCI, V47, P2173, DOI 10.1016/j.corsci.2004.09.018; Liao JS, 2011, MATER LETT, V65, P2995, DOI 10.1016/j.matlet.2011.06.028; Blawert C, 2010, CORROS SCI, V52, P2452, DOI 10.1016/j.corsci.2010.03.035; Song GL, 1999, ADV ENG MATER, V1, P11; Feliu S, 2011, CORROS SCI, V53, P1865, DOI 10.1016/j.corsci.2011.02.003; Zeng RC, 2015, CORROS SCI, V96, P23, DOI 10.1016/j.corsci.2015.03.018; Aung NN, 2010, CORROS SCI, V52, P589, DOI 10.1016/j.corsci.2009.10.018; Yin DS, 2008, T NONFERR METAL SOC, V18, P763, DOI 10.1016/S1003-6326(08)60131-4; Zhang T, 2011, CORROS SCI, V53, P1960, DOI 10.1016/j.corsci.2011.02.015; Song GL, 2012, CORROS SCI, V54, P97, DOI 10.1016/j.corsci.2011.09.005; Ha HY, 2013, CORROS SCI, V75, P426, DOI 10.1016/j.corsci.2013.06.027; Qu Q, 2011, CORROS SCI, V53, P1186, DOI 10.1016/j.corsci.2010.12.014; Ambat R, 2000, CORROS SCI, V42, P1433, DOI 10.1016/S0010-938X(99)00143-2; Liao JS, 2009, METALL MATER TRANS A, V40A, P2212, DOI 10.1007/s11661-009-9921-2; Jonsson M, 2007, J ELECTROCHEM SOC, V154, pC684, DOI 10.1149/1.2779957; Li YG, 2013, CORROS SCI, V69, P67, DOI 10.1016/j.corsci.2012.11.022; Liao JS, 2013, CORROS SCI, V71, P53, DOI 10.1016/j.corsci.2013.02.003; Yao HB, 2000, APPL SURF SCI, V158, P112, DOI 10.1016/S0169-4332(99)00593-0; Zhao MC, 2008, ADV ENG MATER, V10, P104, DOI 10.1002/adem.200700246; Cui ZY, 2013, CORROS SCI, V76, P243, DOI 10.1016/j.corsci.2013.06.047; Liao JS, 2009, SCRIPTA MATER, V61, P208, DOI 10.1016/j.scriptamat.2009.03.044; Guo K. W., 2011, RECENT PAT CORROS SC, V1, P72; LeBozec N, 2004, CORROSION, V60, P356; Liao J., 2005, ZAIRYO TO KANKYO, V54, P383; Luo AA, 2008, MAGNESIUM TECHNOLOGY, P3; Ralston K.D., 2010, CORROSION, V66; Song GL, 2004, CORROS SCI, V46, P955, DOI 10.1016/S0010-938X(03)00190-2	53	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0010-938X	1879-0496		CORROS SCI	Corrosion Sci.	NOV	2015	100						353	364		10.1016/j.corsci.2015.08.021		12	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CT8MG	WOS:000363070100033		
J	Tunthawiroon, P; Li, YP; Chiba, A				Tunthawiroon, Phacharaphon; Li, Yunping; Chiba, Akihiko			Influences of alloyed Si on the corrosion resistance of Co-Cr-Mo alloy to molten Al by iso-thermal oxidation in air	CORROSION SCIENCE			English	Article						Cobalt; SEM; Interfaces; Oxide coatings	STELLITE 6 ALLOYS; WORK TOOL STEEL; LIQUID AL; CO-29CR-6MO ALLOY; INTERFACIAL REACTIONS; INCONEL 617; SOLID CO; BEHAVIOR; ALUMINUM; FATIGUE	The corrosion resistance of Co-Cr-Mo alloys with various Si concentrations after oxidation to molten Al was investigated. Si was helpful in forming a more homogeneous, compact Cr2O3 film after oxidation. Correspondingly, the Cr2O3-dominant film was more effective in enhancing the corrosion resistance than the duplex film of CoO and Cr2O3 of alloy with low Si concentration. In addition, local defects such as the cracks acted as initiation sites of failure in oxide film. Ascribed to its higher stability, Si-rich layer beneath the oxide film delayed the reaction between Al and matrix even after the failure of oxide film. Crown Copyright (C) 2015 Published by Elsevier Ltd. All rights reserved.	[Tunthawiroon, Phacharaphon] Tohoku Univ, Grad Sch Engn, Sendai, Miyagi 9808577, Japan; [Li, Yunping] Cent S Univ, Dept Mat Sci & Engn, Changsha, Hunan, Peoples R China; [Chiba, Akihiko] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan	Li, YP (reprint author), Cent S Univ, Dept Mat Sci & Engn, Changsha, Hunan, Peoples R China.	lyping@csu.edu.cn			Program NICHe at Tohoku University, Japan	This research was partially supported by Program NICHe at Tohoku University, Japan. The author would like to thank Isamu Yoshii, Kimio Wako, and Issei Narita of IMR, Tohoku University, for contributing to the sample fabrication and preparation and EPMA analysis.	Birol Y, 2010, T NONFERR METAL SOC, V20, P1656, DOI 10.1016/S1003-6326(09)60354-X; SUNDQVIST M, 1993, TRIBOL INT, V26, P129, DOI 10.1016/0301-679X(93)90021-R; Tunthawiroon P, 2013, CORROS SCI, V77, P97, DOI 10.1016/j.corsci.2013.07.031; Hu ZQ, 2014, MATER DESIGN, V55, P353, DOI 10.1016/j.matdes.2013.10.012; Birol Y, 2010, MAT SCI ENG A-STRUCT, V527, P1938, DOI 10.1016/j.msea.2009.11.021; Li YP, 2013, CORROS SCI, V73, P72, DOI 10.1016/j.corsci.2013.03.026; Tang N, 2013, CORROS SCI, V75, P262, DOI 10.1016/j.corsci.2013.06.009; Yamanaka K, 2015, CORROS SCI, V94, P411, DOI 10.1016/j.corsci.2015.02.030; Birol Y, 2011, MAT SCI ENG A-STRUCT, V528, P1117, DOI 10.1016/j.msea.2010.10.037; Paul A, 2007, OXID MET, V67, P87, DOI 10.1007/s11085-006-9046-6; Wang L, 2015, CORROS SCI, V93, P19, DOI 10.1016/j.corsci.2015.01.004; Tang N, 2014, CORROS SCI, V78, P244, DOI 10.1016/j.corsci.2013.10.004; Birol Y, 2010, MAT SCI ENG A-STRUCT, V527, P6091, DOI 10.1016/j.msea.2010.06.015; Li YP, 2014, CORROS SCI, V84, P147, DOI 10.1016/j.corsci.2014.03.020; Chen Y, 2014, WEAR, V310, P51, DOI 10.1016/j.wear.2013.12.010; Tang N, 2011, CORROS SCI, V53, P4324, DOI 10.1016/j.corsci.2011.08.015; Tang N, 2012, CORROS SCI, V60, P32, DOI 10.1016/j.corsci.2012.04.015; Tunthawiroon P, 2015, CORROS SCI, V95, P88, DOI 10.1016/j.corsci.2015.02.036; Tang N, 2013, CORROS SCI, V73, P54, DOI 10.1016/j.corsci.2013.03.024; Chase M. W., 1998, J PHYS CHEM REF DATA, V9, P1; Chase M.W., 1974, J PHYS CHEM REF DATA, V3, P311; Hou H., 2009, J ENVIRON SCI, V21, P170; Thermo-Calc Software, NI BAS ALL DAT TCW 5; WALLWORK GR, 1976, REP PROG PHYS, V39, P401, DOI 10.1088/0034-4885/39/5/001	24	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0010-938X	1879-0496		CORROS SCI	Corrosion Sci.	NOV	2015	100						428	434		10.1016/j.corsci.2015.08.014		7	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CT8MG	WOS:000363070100040		
J	Hozumi, A; Horie, T; Sasakura, Y				Hozumi, Akiko; Horie, Takeo; Sasakura, Yasunori			Neuronal map reveals the highly regionalized pattern of the juvenile central nervous system of the ascidian Ciona intestinalis	DEVELOPMENTAL DYNAMICS			English	Article						neuron; ascidian; metamorphosis; juvenile	VERTEBRATE ORIGINS; ANCESTRAL CHORDATE; AMPHIOXUS GENOME; METAMORPHOSIS; GENES; PLACODES; RECEPTOR; PROTOCHORDATE; ORGANIZATION; EXPRESSION	Background: The dorsally located central nervous system (CNS) is an important hallmark of chordates. Among chordates, tunicate ascidians change their CNS remarkably by means of a metamorphosis from a highly regionalized larval CNS to an oval-shaped juvenile CNS without prominent morphological features. The neuronal organization of the CNS of ascidian tadpole larvae has been well described, but that in the CNS of postmetamorphosis juveniles has not been characterized well. Results: We investigated the number of neural cells, the number and position of differentiated neurons, and their axonal trajectories in the juvenile CNS of the ascidian Ciona intestinalis. The cell bodies of cholinergic, glutamatergic, and GABAergic/glycinergic neurons exhibited different localization patterns along the anterior-posterior axis in the juvenile CNS. Cholinergic neurons extended their axons toward the oral, atrial and body wall muscles and pharyngeal gill to regulate muscle contraction and ciliary movement. Conclusions: Unlike its featureless shape, the juvenile CNS is highly patterned along the anterior-posterior axis. This patterning may be necessary for exerting multiple roles in the regulation of adult tissues distributed throughout the body. This basic information of the juvenile CNS of Ciona will allow in-depth studies of molecular mechanisms underlying the reconstruction of the CNS during ascidian metamorphosis. (c) 2015 Wiley Periodicals, Inc.	[Hozumi, Akiko; Sasakura, Yasunori] Univ Tsukuba, Shimoda Marine Res Ctr, Shimoda, Shizuoka 4150025, Japan; [Horie, Takeo] PRESTO, Japan Sci & Technol Agcy, Kawaguchi, Saitama, Japan	Sasakura, Y (reprint author), Univ Tsukuba, Shimoda Marine Res Ctr, Shimoda, Shizuoka 4150025, Japan.	sasakura@shimoda.tsukuba.ac.jp			JSPS; MEXT; Toray Science and Technology Grant [23681039, DDS01702]	Grant sponsor: JSPS, MEXT, Toray Science and Technology Grant; Grant number: 23681039; Grant number: DDS01702.	Kourakis MJ, 2007, DEV BIOL, V312, P245, DOI 10.1016/j.ydbio.2007.09.020; Satoh N, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2014.1729; Ikuta T, 2007, DEV BIOL, V312, P631, DOI 10.1016/j.ydbio.2007.10.005; Horie T, 2011, NATURE, V469, P525, DOI 10.1038/nature09631; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Sasakura Y, 2003, P NATL ACAD SCI USA, V100, P7726, DOI 10.1073/pnas.1230736100; Putnam NH, 2008, NATURE, V453, P1064, DOI 10.1038/nature06967; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Sasakura Y, 2010, MOL GENET GENOMICS, V283, P99, DOI 10.1007/s00438-009-0500-4; Chiba S, 2004, ZOOL SCI, V21, P285, DOI 10.2108/zsj.21.285; Manni L, 2004, J EXP ZOOL PART B, V302B, P483, DOI 10.1002/jez.b.21013; Lemaire P, 2011, DEVELOPMENT, V138, P2143, DOI 10.1242/dev.048975; Ogasawara M, 1999, J EXP ZOOL, V285, P158, DOI 10.1002/(SICI)1097-010X(19990815)285:2<158::AID-JEZ8>3.0.CO;2-0; Horie T, 2010, ZOOL SCI, V27, P181, DOI 10.2108/zsj.27.181; Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; Kusakabe T, 2004, DEV BIOL, V276, P563, DOI 10.1016/j.ydbio.2004.09.037; Stolfi A, 2011, DEVELOPMENT, V138, P995, DOI 10.1242/dev.061507; Matsunobu S, 2015, DEV BIOL, V405, P71, DOI 10.1016/j.ydbio.2015.06.016; Takamura K, 1998, DEV GENES EVOL, V208, P1, DOI 10.1007/s004270050147; Joly JS, 2007, DEV DYNAM, V236, P1832, DOI 10.1002/dvdy.21124; Varju P, 2001, CELL TISSUE RES, V305, P239, DOI 10.1007/s004410100356; Satake H, 2004, J BIOL CHEM, V279, P53798, DOI 10.1074/jbc.M408161200; Nishino A, 2011, P NATL ACAD SCI USA, V108, P2599, DOI 10.1073/pnas.1013547108; Wada H, 1998, DEVELOPMENT, V125, P1113; Sasakura Y, 2012, DEVELOPMENT, V139, P2156, DOI 10.1242/dev.080234; Horie T, 2008, J COMP NEUROL, V508, P249, DOI 10.1002/cne.21678; Sasakura Y, 2012, DEV GROWTH DIFFER, V54, P420, DOI 10.1111/j.1440-169X.2012.01343.x; Tsutsui H, 1998, GEN COMP ENDOCR, V112, P426, DOI 10.1006/gcen.1998.7160; NICOL D, 1991, J COMP NEUROL, V309, P415, DOI 10.1002/cne.903090402; Holland LZ, 2008, GENOME RES, V18, P1100, DOI 10.1101/gr.073676.107; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Zhang F, 2006, NAT METHODS, V3, P785, DOI 10.1038/nmeth936; Brunet JF, 2002, CURR OPIN GENET DEV, V12, P435, DOI 10.1016/S0959-437X(02)00322-2; Zhang F, 2007, NATURE, V446, P633, DOI 10.1038/nature05744; Eiden LE, 1998, J NEUROCHEM, V70, P2227; CLONEY RA, 1982, AM ZOOL, V22, P817; Imai KS, 2009, DEVELOPMENT, V136, P285, DOI 10.1242/dev.026419; Yoshida R, 2004, GENESIS, V39, P130, DOI 10.1002/gene.20032; Corbo JC, 1997, DEVELOPMENT, V124, P589; JOHNSEN AH, 1990, J BIOL CHEM, V265, P3054; Pattyn A, 2000, DEVELOPMENT, V127, P1349; Kawada T, 2011, ENDOCRINOLOGY, V152, P2416, DOI 10.1210/en.2010-1348; Dufour HD, 2006, P NATL ACAD SCI USA, V103, P8727, DOI 10.1073/pnas.0600805103; Horie T, 2009, DEV GROWTH DIFFER, V51, P207, DOI 10.1111/j.1440-169X.2009.01105.x; Imai Kaoru S., 2002, Gene Expression Patterns, V2, P319, DOI 10.1016/S0925-4773(02)00383-0; Matsuoka T, 2005, GENESIS, V41, P61; Nishino A, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-6; Stolfi A, 2015, GENESIS, V53, P1, DOI 10.1002/dvg.22822; Treen N, 2014, DEVELOPMENT, V141, P481, DOI 10.1242/dev.099572; Willey A, 1893, Q J MICROSCOPICAL SC, V34, P317	50	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8388	1097-0177		DEV DYNAM	Dev. Dyn.	NOV	2015	244	11					1375	1393		10.1002/dvdy.24317		19	Anatomy & Morphology; Developmental Biology	Anatomy & Morphology; Developmental Biology	CU4QP	WOS:000363514900002		
J	Kaku, K; Kadowaki, T; Terauchi, Y; Okamoto, T; Sato, A; Okuyama, K; Ferreira, JCA; Goldstein, BJ				Kaku, K.; Kadowaki, T.; Terauchi, Y.; Okamoto, T.; Sato, A.; Okuyama, K.; Ferreira, J. C. Arjona; Goldstein, B. J.			Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance	DIABETES OBESITY & METABOLISM			English	Article						dipeptidyl peptidase-4 inhibitors; DPP-4; incretins; MK-0431	DIPEPTIDYL PEPTIDASE-4 INHIBITOR; BETA-CELL FUNCTION; TYPE-2 DIABETES-MELLITUS; FASTING GLUCOSE; CARDIOVASCULAR-DISEASE; IV INHIBITOR; PREVENTION; METFORMIN; INCRETIN; INSULIN	Aims: To evaluate the efficacy and tolerability of sitagliptin in subjects with impaired glucose tolerance (IGT). Methods: In a double-blind, parallel-group study, 242 Japanese subjects with IGT, determined by a 75-g oral glucose tolerance test (OGTT) at week - 1, were randomized (1 : 1 : 1) to placebo (n = 83), sitagliptin 25 mg (n = 82) or 50 mg (n = 77) once daily for 8 weeks. Glycaemic variables were assessed using another OGTT at week 7 and meal tolerance tests (MTTs) at weeks 0 and 8. Primary and secondary endpoints were percent change from baseline in glucose total area under the curve 0-2 h (AUC(0-2 h)) during the MTT and OGTT, respectively. Results: Least squares mean percent change from baseline in glucose AUC(0-2 h) during the MTT were -2.4, -9.5 and -11.5%, and during the OGTT were -3.7, -21.4 and -20.1% with placebo, sitagliptin 25 mg once daily, and 50 mg once daily, respectively (p < 0.001 for either sitagliptin dose vs placebo in both tests). Sitagliptin treatment enhanced early insulin response during the OGTT and decreased total insulin response, assessed as the total AUC(0-2 h) during the MTT. Sitagliptin treatment also suppressed glucagon response during the MTT. The incidence of adverse events, including hypoglycaemia, was low and generally similar in all treatment groups. Conclusions: Treatment with sitagliptin significantly reduced glucose excursions during both an MTT and an OGTT; this effect was associated with an increase in early insulin secretion after oral glucose loading as well as a blunted glucagon response during an MTT. Sitagliptin was generally well tolerated in subjects with IGT.	[Kaku, K.] Kawasaki Med Univ, Div Diabet Endocrinol & Metab, Kurashiki, Okayama, Japan; [Kadowaki, T.] Univ Tokyo, Grad Sch Med, Dept Diabet & Metab Dis, Tokyo, Japan; [Terauchi, Y.] Yokohama City Univ, Dept Endocrinol & Metab, Yokohama, Kanagawa 232, Japan; [Okamoto, T.; Sato, A.; Okuyama, K.] MSD KK, Tokyo, Japan; [Ferreira, J. C. Arjona; Goldstein, B. J.] Merck & Co Inc, Whitehouse Stn, Kenilworth, NJ 07033 USA	Okamoto, T (reprint author), Chiyoda Ku, Kitanomaru Sq,1-13-12, Tokyo 1028667, Japan.	taro.okamoto@merck.com			MSD KK, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ	The authors wish to thank the study investigators (Appendix SI) for their contributions to the execution of this study, and Edward A. O'Neill, Jennifer Rotonda, and Kristen Lewis (employees of Merck & Co., Inc., Whitehouse Station, NJ, USA) for editorial assistance and manuscript preparation. This study was sponsored by MSD KK, a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, the manufacturer of sitagliptin.	Ahrén Bo, 2010, Diabetes Metab Syndr Obes, V3, P31; Gerstein HC, 2007, DIABETES RES CLIN PR, V78, P305, DOI 10.1016/j.diabres.2007.05.004; [Anonymous], 2014, US PRESCRIBING INFOR; [Anonymous], 1997, DIABETES CARE, P1183; Brazg R, 2007, DIABETES OBES METAB, V9, P186, DOI 10.1111/j.1463-1326.2006.00691.x; Thornberry NA, 2007, CURR TOP MED CHEM, V7, P557, DOI 10.2174/156802607780091028; Rosenstock J, 2008, DIABETES CARE, V31, P30, DOI 10.2337/dc07-1616; Hage C, 2013, J INTERN MED, V273, P410, DOI 10.1111/joim.12032; Bock G, 2010, CLIN ENDOCRINOL, V73, P189, DOI 10.1111/j.1365-2265.2009.03764.x; Herman GA, 2006, J CLIN ENDOCR METAB, V91, P4612, DOI 10.1210/jc.2006-1009; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Tominaga M, 1999, DIABETES CARE, V22, P920, DOI 10.2337/diacare.22.6.920; Utzschneider KM, 2008, DIABETES CARE, V31, P108, DOI 10.2337/dc07-1441; Nakagami T, 2004, DIABETOLOGIA, V47, P385, DOI 10.1007/s00125-004-1334-6; Xu L, 2008, DIABETES OBES METAB, V10, P1212, DOI 10.1111/j.1463-1326.2008.00887.x; [Anonymous], 2013, EV BAS PRACT GUID TR; Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5; Alberti KGMM, 2007, DIABETIC MED, V24, P451, DOI 10.1111/j.1464-5491.2007.02157.x; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Kawamori R, 2009, LANCET, V373, P1607, DOI 10.1016/S0140-6736(09)60222-1; Rosenstock J, 2007, DIABETES OBES METAB, V9, P3, DOI 10.1111/j.1463-1326.2007.00768.x; DeFronzo RA, 2011, NEW ENGL J MED, V364, P1104, DOI 10.1056/NEJMoa1010949; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Engel Samuel S, 2013, Diabetes Ther, V4, P119, DOI 10.1007/s13300-013-0024-0; Liang K-Y, 2000, INDIAN J STAT, V62, P134; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; MITRAKOU A, 1992, NEW ENGL J MED, V326, P22, DOI 10.1056/NEJM199201023260104; Gerstein HC, 2006, LANCET, V368, P1096, DOI 10.1016/S0140-6736(06)69420-8; Standards of medical care in diabetes, 2015, DIABETES CARE S1, V38, pS1; Stratton IM, 2000, BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Tatosian Daniel A, 2013, Diabetes Ther, V4, P431, DOI 10.1007/s13300-013-0045-8; Borch-Johnsen K, 2001, ARCH INTERN MED, V161, P397; Knowler WC, 2002, NEW ENGL J MED, V346, P393	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-8902	1463-1326		DIABETES OBES METAB	Diabetes Obes. Metab.	NOV	2015	17	11					1033	1041		10.1111/dom.12507		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CU3VY	WOS:000363455300003		
J	Nakao, YM; Ueshima, K; Nohara, R; Mizunuma, Y; Segawa, I; Tanaka-Mizuno, S; Yasuno, S; Nakao, K; Hiramori, K; Kihara, Y				Nakao, Yoko M.; Ueshima, Kenji; Nohara, Ryuji; Mizunuma, Yoshimi; Segawa, Ikuo; Tanaka-Mizuno, Sachiko; Yasuno, Shinji; Nakao, Kazuwa; Hiramori, Katsuhiko; Kihara, Yasuki			Holter monitoring for the screening of cardiac disease in diabetes mellitus: The non-invasive Holter monitoring observation of new cardiac events in diabetics study	DIABETES & VASCULAR DISEASE RESEARCH			English	Article						Diabetes mellitus; cardiac disease; silent myocardial ischemia; Holter monitoring	CORONARY-ARTERY-DISEASE; SILENT-MYOCARDIAL-ISCHEMIA; EMISSION COMPUTED-TOMOGRAPHY; PROGNOSTIC VALUE; HEART-DISEASE; AMBULATORY ELECTROCARDIOGRAPHY; CARDIOVASCULAR-DISEASE; ASYMPTOMATIC PATIENTS; NONDIABETIC PATIENTS; TASK-FORCE	We investigated the usefulness of Holter monitoring to detect cardiac disease and predict future cardiovascular risk in asymptomatic diabetic patients. This is a multi-centre, prospective study in 406 asymptomatic diabetic patients. They were categorized into three groups based on findings of Holter monitoring. A total of 377 met inclusion criteria and were classified as low (n = 172), moderate (n = 136) and high risk (n = 69). In total, 86 in moderate and 53 in high risk receive further evaluation. In total, 29 in moderate and 25 in high risk were diagnosed as cardiac disease and 12 required additional treatment, including coronary intervention. Over 1.8years of mean follow-up, 11 (16.5 per 1000person-years) experienced cardiovascular events. The cumulative incidence in moderate and high risk was higher than that in low risk (p = 0.029 and p = 0.014, respectively). Our study suggests that Holter monitoring may be a useful screening tool to detect cardiac disease and predict future cardiovascular risk in asymptomatic diabetic patients.	[Nakao, Yoko M.; Ueshima, Kenji; Yasuno, Shinji] Kyoto Univ Hosp, Inst Adv Clin & Translat Sci, Dept EBM Res, Kyoto 6068507, Japan; [Nohara, Ryuji] Kitano Hosp, Tazuke Kofukai Med Res Inst, Osaka, Japan; [Mizunuma, Yoshimi] Mizunuma Med Clin, Morioka, Iwate, Japan; [Segawa, Ikuo] Kitakami Chuo Clin, Ctr Diabet, Kitakami, Iwate, Japan; [Tanaka-Mizuno, Sachiko] Shiga Univ Med Sci, Dept Med Stat, Otsu, Shiga 52021, Japan; [Nakao, Kazuwa] Kyoto Univ, Grad Sch Med, Med Innovat Ctr, Kyoto, Japan; [Hiramori, Katsuhiko] Morioh Co Ltd, Morioka, Iwate, Japan; [Kihara, Yasuki] Hiroshima Univ, Dept Cardiovasc Med, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan	Ueshima, K (reprint author), Kyoto Univ Hosp, Inst Adv Clin & Translat Sci, Dept EBM Res, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	ueshima.kenji.5m@kyoto-u.ac.jp			Japan Research Promotion Society for Cardiovascular Diseases	This study was financially supported by the Japan Research Promotion Society for Cardiovascular Diseases.	American Diabetes Association, 2007, DIABETES CARE S1, V30, pS4, DOI DOI 10.2337/DC07-S004; Chopra Sandeep, 2012, Indian J Endocrinol Metab, V16, P94, DOI 10.4103/2230-8210.91202; Greenland P, 2007, J AM COLL CARDIOL, V49, P378, DOI 10.1016/j.jacc.2006.10.001; Caracciolo EA, 1996, CIRCULATION, V93, P2097; Bansal S, 2011, DIABETES CARE, V34, P204, DOI 10.2337/dc10-1194; Gibson CM, 2007, J THROMB THROMBOLYS, V23, P135, DOI 10.1007/s11239-006-9015-6; Bax JJ, 2007, DIABETES CARE, V30, P2729, DOI 10.2337/dc07-9927; Chou R, 2011, ANN INTERN MED, V155, P375, DOI [10.7326/0003-4819-155-6-201109200-00006, 10.1059/0003-4819-155-6-201109200-00006]; Wackers FJT, 2004, DIABETES CARE, V27, P1954, DOI 10.2337/diacare.27.8.1954; Scognamiglio R, 2006, J AM COLL CARDIOL, V47, P65, DOI 10.1016/j.jacc.2005.10.008; Young LH, 2009, JAMA-J AM MED ASSOC, V301, P1547, DOI 10.1001/jama.2009.476; He ZX, 2000, CIRCULATION, V101, P244; Giri S, 2002, CIRCULATION, V105, P32, DOI 10.1161/hc5001.100528; Djaberi R, 2008, DIABETOLOGIA, V51, P1581, DOI 10.1007/s00125-008-1062-4; Crawford MH, 1999, CIRCULATION, V100, P886; Juutilainen A, 2005, DIABETES CARE, V28, P2901, DOI 10.2337/diacare.28.12.2901; Lakkireddy DR, 2005, AM HEART J, V150, P516, DOI 10.1016/j.ahj.2004.09.058; CHIARIELLO M, 1985, AM HEART J, V110, P529, DOI 10.1016/0002-8703(85)90070-5; Gaede P, 2003, NEW ENGL J MED, V348, P383; KOISTINEN MJ, 1990, BRIT MED J, V301, P92; Berman DS, 2004, J AM COLL CARDIOL, V44, P923, DOI 10.1016/j.jacc.2004.06.042; Fazel R, 2009, NEW ENGL J MED, V361, P849, DOI 10.1056/NEJMoa0901249; De Lorenzo A, 2002, AM J CARDIOL, V90, P827, DOI 10.1016/S0002-9149(02)02702-9; Gibbons RJ, 2002, J AM COLL CARDIOL, V40, P1531, DOI 10.1016/S0735-1097(02)02164-2; ARONOW WS, 1992, AM J CARDIOL, V69, P555, DOI 10.1016/0002-9149(92)91004-N; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Kjelsberg MO, 1996, CIRCULATION, V94, P946; Bloomgarden Zachary T, 2011, Diabetes Care, V34, pe24, DOI 10.2337/dc11-0007; Harris GD, 2007, CLIN DIABETES, V25, P126, DOI 10.2337/diaclin.25.4.126; Marin Huerta E, 1989, REV ESP CARDIOL, V42, P519; Puel J, 2004, DIABETES METAB, V30, p3S3	31	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1479-1641	1752-8984		DIABETES VASC DIS RE	Diabetes Vasc. Dis. Res.	NOV	2015	12	6					396	404		10.1177/1479164115595523		9	Endocrinology & Metabolism; Peripheral Vascular Disease	Endocrinology & Metabolism; Cardiovascular System & Cardiology	CU3XV	WOS:000363460600002		
J	Ikeda, H; Uzui, H; Morishita, T; Fukuoka, Y; Sato, T; Ishida, K; Kaseno, K; Arakawa, K; Amaya, N; Tama, N; Shiomi, Y; Lee, JD; Tada, H				Ikeda, Hiroyuki; Uzui, Hiroyasu; Morishita, Tetsuji; Fukuoka, Yoshitomo; Sato, Takehiko; Ishida, Kentaro; Kaseno, Kenichi; Arakawa, Kenichiro; Amaya, Naoki; Tama, Naoto; Shiomi, Yuichiro; Lee, Jong-Dae; Tada, Hiroshi			Effect of postprandial hyperglycaemia on coronary flow reserve in patients with impaired glucose tolerance and type 2 diabetes mellitus	DIABETES & VASCULAR DISEASE RESEARCH			English	Article						Postprandial hyperglycaemia; coronary flow reserve; coronary heart disease	ENDOTHELIUM-DEPENDENT VASODILATION; LONG-TERM; MATRIX-METALLOPROTEINASE; CARDIOVASCULAR MORTALITY; INTRACORONARY ADENOSINE; DISEASE; RISK; 1,5-ANHYDROGLUCITOL; SEVERITY; ARTERY	Background: This study investigated whether postprandial hyperglycaemia has an adverse effect on coronary microvascular function and left ventricular diastolic function. Methods: In all, 28 patients with type 2 diabetes mellitus with no significant stenosis in left anterior descending artery were enrolled. In all subjects, plasma 1,5-anhydroglucitol was measured, and coronary flow reserve in the left anterior descending artery was evaluated using a Doppler wire. Membrane type-1 matrix metalloproteinase expression on circulating peripheral blood mononuclear cells was measured by flow cytometry. Correlation analyses were performed for coronary flow reserve and 1,5-anhydroglucitol, other coronary risk factors, membrane type-1 matrix metalloproteinase and E/e'. Results: Strong correlations were found only between 1,5-anhydroglucitol and coronary flow reserve and membrane type-1 matrix metalloproteinase. On multiple regression analysis, 1,5-anhydroglucitol remained an independent predictor of coronary flow reserve (beta = 0.38, p = 0.048). Conclusion: Postprandial hyperglycaemia appears to have an adverse effect on coronary microvascular function, suggesting that improvement of postprandial hyperglycaemia may contribute to the improvement of coronary microvascular dysfunction.	[Ikeda, Hiroyuki; Uzui, Hiroyasu; Morishita, Tetsuji; Fukuoka, Yoshitomo; Sato, Takehiko; Ishida, Kentaro; Kaseno, Kenichi; Arakawa, Kenichiro; Amaya, Naoki; Tama, Naoto; Shiomi, Yuichiro; Lee, Jong-Dae; Tada, Hiroshi] Univ Fukui, Dept Cardiovasc Med, Eiheiji, Fukui 9101193, Japan	Uzui, H (reprint author), Univ Fukui, Dept Cardiovasc Med, 23-3 Shimoaizuki, Eiheiji, Fukui 9101193, Japan.	huzui@u-fukui.ac.jp					Sohn DW, 1997, J AM COLL CARDIOL, V30, P474, DOI 10.1016/S0735-1097(97)88335-0; GOULD KL, 1990, J AM COLL CARDIOL, V15, P459; Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486; Pijls NHJ, 1996, NEW ENGL J MED, V334, P1703, DOI 10.1056/NEJM199606273342604; Won JC, 2009, DIABETES RES CLIN PR, V84, P51, DOI 10.1016/j.diabres.2009.01.002; Ommen SR, 2000, CIRCULATION, V102, P1788; Erlinger TP, 2001, DIABETES CARE, V24, P1734, DOI 10.2337/diacare.24.10.1734; Uzui H, 2002, CIRCULATION, V106, P3024, DOI 10.1161/01.CIR.0000041433.94868.12; DAYANIKLI F, 1994, CIRCULATION, V90, P808; van de Hoef TP, 2014, CIRC-CARDIOVASC INTE, V7, P301, DOI 10.1161/CIRCINTERVENTIONS.113.001049; Miyamori H, 2000, BIOCHEM BIOPH RES CO, V267, P796, DOI 10.1006/bbrc.1999.2050; Uzui H, 2011, J DIABETES INVEST, V2, P148, DOI 10.1111/j.2040-1124.2010.00079.x; Shiraiwa T, 2005, BIOCHEM BIOPH RES CO, V336, P339, DOI 10.1016/j.bbrc.2005.08.158; Scognamiglio R, 2005, CIRCULATION, V112, P179, DOI 10.1161/CIRCULATIONAHA.104.495127; McGill JRB, 2004, DIABETES CARE, V27, P1859, DOI 10.2337/diacare.27.8.1859; Murthy VL, 2012, CIRCULATION, V126, P1858, DOI 10.1161/CIRCULATIONAHA.112.120402; Pitkanen OP, 1998, DIABETES, V47, P248, DOI 10.2337/diabetes.47.2.248; Monnier L, 2003, DIABETES CARE, V26, P881, DOI 10.2337/diacare.26.3.881; Rajavashisth TB, 1999, CIRCULATION, V99, P3103; Yamanouchi T, 1996, LANCET, V347, P1514, DOI 10.1016/S0140-6736(96)90672-8; Levitan EB, 2004, ARCH INTERN MED, V164, P2147, DOI 10.1001/archinte.164.19.2147; Kawano H, 1999, J AM COLL CARDIOL, V34, P146, DOI 10.1016/S0735-1097(99)00168-0; Casella G, 2004, AM HEART J, V148, P590, DOI 10.1016/j.ahj.2004.04.008; Williams SB, 1998, CIRCULATION, V97, P1695; De Luca G, 2011, JACC-CARDIOVASC INTE, V4, P1079, DOI 10.1016/j.jcin.2011.08.004; Marfella R, 2001, J CLIN INVEST, V108, P635, DOI 10.1172/JCI13727; Hanefeld M, 2004, EUR HEART J, V25, P10, DOI 10.1016/S0195-668X(03)00468-8; Nakagami T, 2006, EUR J CARDIOV PREV R, V13, P555, DOI 10.1097/01.hjr.0000183916.28354.69; Schachinger V, 2000, CIRCULATION, V101, P1899; Borch-Johnsen K, 2001, ARCH INTERN MED, V161, P397	30	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1479-1641	1752-8984		DIABETES VASC DIS RE	Diabetes Vasc. Dis. Res.	NOV	2015	12	6					405	410		10.1177/1479164115597866		6	Endocrinology & Metabolism; Peripheral Vascular Disease	Endocrinology & Metabolism; Cardiovascular System & Cardiology	CU3XV	WOS:000363460600003		
J	Groop, PH; Cooper, ME; Perkovic, V; Sharma, K; Schernthaner, G; Haneda, M; Hocher, B; Gordat, M; Cescutti, J; Woerle, HJ; von Eynatten, M				Groop, Per-Henrik; Cooper, Mark E.; Perkovic, Vlado; Sharma, Kumar; Schernthaner, Guntram; Haneda, Masakazu; Hocher, Berthold; Gordat, Maud; Cescutti, Jessica; Woerle, Hans-Juergen; von Eynatten, Maximilian			Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D trial	DIABETES & VASCULAR DISEASE RESEARCH			English	Article						Dipeptidyl peptidase-4 inhibition; linagliptin; type 2 diabetes; chronic kidney disease; glycaemic control; albuminuria	DPP-4 INHIBITION; CLINICAL-TRIALS; KIDNEY-DISEASE; BLOOD-PRESSURE; END-POINTS; RECEPTOR; EFFICACY; SAFETY; IV; NEPHROPATHY	Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects with Renal Disease with LINAgliptin (MARLINA-T2D), a multicentre, multinational, randomized, double-blind, placebo-controlled, parallel-group, phase 3b clinical trial, aims to further define the potential renal effects of dipeptidyl peptidase-4 inhibition beyond glycaemic control. A total of 350 eligible individuals with inadequately controlled type 2 diabetes and evidence of renal disease are planned to be randomized in a 1:1 ratio to receive either linagliptin 5mg or placebo in addition to their stable glucose-lowering background therapy for 24weeks. Two predefined main endpoints will be tested in a hierarchical manner: (1) change from baseline in glycated haemoglobin and (2) time-weighted average of percentage change from baseline in urinary albumin-to-creatinine ratio. Both endpoints are sufficiently powered to test for superiority versus placebo after 24weeks with =0.05. MARLINA-T2D is the first of its class to prospectively explore both the glucose- and albuminuria-lowering potential of a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes and evidence of renal disease.	[Groop, Per-Henrik] Biomedicum Helsinki, Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland; [Groop, Per-Henrik] Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, FIN-00290 Helsinki, Finland; [Groop, Per-Henrik; Cooper, Mark E.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia; [Perkovic, Vlado] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia; [Sharma, Kumar] Vet Med Res Fdn, Vet Affairs San Diego Healthcare Syst, Res Serv, San Diego, CA USA; [Sharma, Kumar] Vet Med Res Fdn, Vet Affairs San Diego Healthcare Syst, Div Nephrol Hypertens, San Diego, CA USA; [Sharma, Kumar] Univ Calif San Diego, Dept Med, Ctr Renal Translat Med, San Diego, CA 92103 USA; [Schernthaner, Guntram] Rudolfstiftung Hosp, Dept Internal Med, Vienna, Austria; [Haneda, Masakazu] Asahikawa Med Univ, Dept Med, Div Metab & Biosyst Sci, Asahikawa, Hokkaido, Japan; [Hocher, Berthold] Univ Potsdam, Inst Nutr Sci, Potsdam, Germany; [Gordat, Maud; Cescutti, Jessica] Boehringer Ingelheim GmbH & Co KG, Reims, France; [Woerle, Hans-Juergen; von Eynatten, Maximilian] Boehringer Ingelheim GmbH & Co KG, Ingelheim, France	Groop, PH (reprint author), Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol,Biomedicum Helsinki, C318b,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.	per-henrik.groop@helsinki.fi			Boehringer Ingelheim	MARLINA-T2D (TM) is funded and conducted by Boehringer Ingelheim, the manufacturer of linagliptin.	American Diabetes Association, 2014, DIABETES CARE S1, V37, pS14, DOI [DOI 10.2337/DC14-S014, 10.2337/dc14-S014]; Pala L, 2003, BIOCHEM BIOPH RES CO, V310, P28, DOI 10.1016/j.bbrc.2003.08.111; Kanasaki K, 2014, DIABETES, V63, P2120, DOI 10.2337/db13-1029; Monami M, 2011, CURR MED RES OPIN, V27, P57, DOI 10.1185/03007995.2011.602964; Fujita H, 2014, ENDOCR J, V61, P159; Liu WJ, 2012, J PHARMACOL EXP THER, V340, P248, DOI 10.1124/jpet.111.186866; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Cooper ME, 2015, AM J KIDNEY DIS, V66, P441, DOI 10.1053/j.ajkd.2015.03.024; Yang J, 2007, LIFE SCI, V81, P272, DOI 10.1016/j.lfs.2007.04.040; STILLER D, 1991, ACTA HISTOCHEM, V91, P105; Alter ML, 2012, KIDNEY BLOOD PRESS R, V36, P119, DOI 10.1159/000341487; Mega C, 2011, EXP DIABETES RES, DOI 10.1155/2011/162092; CHATELET F, 1986, AM J PATHOL, V122, P500; Eijkelkamp WBA, 2007, J AM SOC NEPHROL, V18, P1540, DOI 10.1681/ASN.200605445; Groop PH, 2013, DIABETES CARE, V36, P3460, DOI 10.2337/dc13-0323; Nakashima S, 2014, HORM METAB RES, V46, P717, DOI 10.1055/s-0034-1371892; Kothny W, 2012, DIABETES OBES METAB, V14, P1032, DOI 10.1111/j.1463-1326.2012.01634.x; Chan JCN, 2008, DIABETES OBES METAB, V10, P545, DOI 10.1111/j.1463-1326.2008.00914.x; de Zeeuw D, 2013, NEW ENGL J MED, V369, P2492, DOI 10.1056/NEJMoa1306033; Hattori S, 2011, ENDOCR J, V58, P69, DOI 10.1507/endocrj.K10E-382; Schlatter P, 2007, REGUL PEPTIDES, V141, P120, DOI 10.1016/j.regpep.2006.12.016; Nowicki M, 2011, INT J CLIN PRACT, V65, P1230, DOI 10.1111/j.1742-1241.2011.02812.x; Inrig JK, 2014, AM J KIDNEY DIS, V63, P771, DOI 10.1053/j.ajkd.2013.10.043; Groop PH, 2014, DIABETES OBES METAB, V16, P560, DOI 10.1111/dom.12281; Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684; Kroller-Schon S, 2012, CARDIOVASC RES, V96, P140, DOI 10.1093/cvr/cvs246; McGill JB, 2013, DIABETES CARE, V36, P237, DOI 10.2337/dc12-0706; Sharma K, 2013, J AM SOC NEPHROL, V24, P1901, DOI 10.1681/ASN.2013020126; Sakata K, 2013, DIABETES-METAB RES, V29, P624, DOI 10.1002/dmrr.2437; Ishibashi Y, 2013, CARDIOVASC DIABETOL, V12, DOI 10.1186/1475-2840-12-125; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; National Kidney Foundation, 2012, AM J KIDNEY DIS, V60, P850, DOI DOI 10.1053/J.AJKD.2012.07.005; Nistala R, 2014, OBESITY, V22, P2172, DOI 10.1002/oby.20833; Sharkovska Y, 2014, J HYPERTENS, V32, P2211, DOI 10.1097/HJH.0000000000000328	34	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1479-1641	1752-8984		DIABETES VASC DIS RE	Diabetes Vasc. Dis. Res.	NOV	2015	12	6					455	462		10.1177/1479164115579002		8	Endocrinology & Metabolism; Peripheral Vascular Disease	Endocrinology & Metabolism; Cardiovascular System & Cardiology	CU3XV	WOS:000363460600009		
J	Iguchi, T; Inoue, D; Tatsukawa, M; Yabushita, K; Sakaguchi, K; Kanazawa, S				Iguchi, T.; Inoue, D.; Tatsukawa, M.; Yabushita, K.; Sakaguchi, K.; Kanazawa, S.			Transpulmonary radiofrequency ablation of hepatocellular carcinoma contiguous to the heart	DIAGNOSTIC AND INTERVENTIONAL IMAGING			English	Letter									[Iguchi, T.; Inoue, D.] Fukuyama City Hosp, Dept Diagnost & Intervent Radiol, Fukuyama, Hiroshima 7218511, Japan; [Tatsukawa, M.; Yabushita, K.; Sakaguchi, K.] Fukuyama City Hosp, Dept Internal Med, Fukuyama, Hiroshima 7218511, Japan; [Iguchi, T.; Kanazawa, S.] Okayama Univ, Sch Med, Dept Radiol, Okayama 7008558, Japan	Iguchi, T (reprint author), Fukuyama City Hosp, Dept Diagnost & Intervent Radiol, 5-23-1 Zao Cho, Fukuyama, Hiroshima 7218511, Japan.	iguchi@ba2.so-net.ne.jp; ebized@uoen.com; ma34tatsu111@gmail.com; azuki_yabushita2002@yahoo.co.jp; kosakaguchi@city.fukuyama.hiroshima.jp; susumu@cc.okayama-u.ac.jp					Rhim H, 2008, AM J ROENTGENOL, V190, P91, DOI 10.2214/AJR.07.2384; Iguchi T, 2007, J VASC INTERV RADIOL, V18, P733, DOI 10.1016/j.jvir.2007.02.024; Yamakado K, 2010, AM J ROENTGENOL, V194, P530, DOI 10.2214/AJR.09.2917; Cazejust J, 2014, DIAGN INTERV IMAG, V95, P27, DOI 10.1016/j.diii.2013.04.015; de Baere T, 2014, DIAGN INTERV IMAG, V95, P677, DOI 10.1016/j.diii.2014.04.001; Seror O, 2014, DIAGN INTERV IMAG, V95, P665, DOI 10.1016/j.diii.2014.04.002	6	0	0	ELSEVIER MASSON	MILANO	VIA PALEOCAPA 7, 20121 MILANO, ITALY	2211-5684			DIAGN INTERV IMAG	Diagn. Interv. Imaging	NOV	2015	96	11					1207	1209		10.1016/j.diii.2015.06.016		3	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1KB	WOS:000363278900016		
J	Miyake, N; Chong, Y; Nishida, R; Nagasaki, Y; Kibe, Y; Kiyosuke, M; Shimomura, T; Shimono, N; Shimoda, S; Akashi, K				Miyake, Noriko; Chong, Yong; Nishida, Ruriko; Nagasaki, Yoji; Kibe, Yasushi; Kiyosuke, Makiko; Shimomura, Takeshi; Shimono, Nobuyuki; Shimoda, Shinji; Akashi, Koichi			A dramatic increase in the positive blood culture rates of Helicobacter cinaedi: the evidence of differential detection abilities between the Bactec and BacT/Alert systems	DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE			English	Article						Helicobacter cinaedi; Bacteremia; Blood culture system	FA PLUS; MEDIA; TIME; INFECTIONS	In our hospital, positive blood culture rates of Helicobacter cinaedi dramatically increased after introducing the Bactec system. A simulated culture model of H. cinaedi bacteremia demonstrated no positive signals using the Bad/Alert system, despite efficient growth in bottles. Clinically suspected H. cinaedi bacteremia should be monitored more closely when using the BacT/Alert system, preferably with subcultivation after 7 days of incubation. (C) 2015 Elsevier Inc. All rights reserved.	[Miyake, Noriko; Chong, Yong; Shimoda, Shinji; Akashi, Koichi] Kyushu Univ, Grad Sch Med Sci, Med & Biosyst Sci, Fukuoka 812, Japan; [Nishida, Ruriko; Kibe, Yasushi; Kiyosuke, Makiko] Kyushu Univ Hosp, Dept Clin Chem & Lab Med, Fukuoka 812, Japan; [Nagasaki, Yoji; Shimomura, Takeshi] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan; [Shimono, Nobuyuki] Kyushu Univ Hosp, Ctr Study Global Infect, Fukuoka 812, Japan	Chong, Y (reprint author), Kyushu Univ, Grad Sch Med Sci, Med & Biosyst Sci, Fukuoka 812, Japan.	ychong@gj9.so-net.ne.jp					Lee DH, 2013, J CLIN MICROBIOL, V51, P4150, DOI 10.1128/JCM.01935-13; Matsumoto T, 2007, J CLIN MICROBIOL, V45, P2853, DOI 10.1128/JCM.00465-07; Kirn TJ, 2014, J CLIN MICROBIOL, V52, P839, DOI 10.1128/JCM.03063-13; Araoka H, 2014, J CLIN MICROBIOL, V52, P1519, DOI 10.1128/JCM.00265-14; Minauchi K, 2010, INTERNAL MED, V49, P1733, DOI 10.2169/internalmedicine.49.3649; Fiori B, 2014, J CLIN MICROBIOL, V52, P3558, DOI 10.1128/JCM.01171-14; Sullivan KV, 2013, J CLIN MICROBIOL, V51, P4083, DOI 10.1128/JCM.02205-13; Doern CD, 2014, J CLIN MICROBIOL, V52, P1898, DOI 10.1128/JCM.00175-14; Zadroga R, 2013, CLIN INFECT DIS, V56, P790, DOI 10.1093/cid/cis1021; Kawamura Y, 2014, J INFECT CHEMOTHER, V20, P517, DOI 10.1016/j.jiac.2014.06.007	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0732-8893	1879-0070		DIAGN MICR INFEC DIS	Diagn. Microbiol. Infect. Dis.	NOV	2015	83	3					232	233		10.1016/j.diagmicrobio.2015.07.017		2	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CU2OO	WOS:000363363000006		
J	Nakamura, A; Komatsu, M; Kondo, A; Ohno, Y; Kohno, H; Nakamura, F; Matsuo, S; Ohnuma, K; Hatano, N; Kawano, S				Nakamura, Akihiro; Komatsu, Masaru; Kondo, Akira; Ohno, Yuki; Kohno, Hisashi; Nakamura, Fumihiko; Matsuo, Shuji; Ohnuma, Kenichiro; Hatano, Naoya; Kawano, Seiji			Rapid detection of B2-ST131 clonal group of extended-spectrum beta-lactamase-producing Escherichia coli by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry: discovery of a peculiar amino acid substitution in B2-ST131 clonal group	DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE			English	Article						MALDI-TOF MS; ESBL-producing Escherichia coli; B2-ST131; Proteomic analysis; Genomic analysis; YahO protein	COMPLETE GENOME SEQUENCE; EMERGENCE; STRAIN; K-12; COMMUNITY; OUTBREAK; O157-H7	One reason for the spread of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli worldwide is the global pandemic of the B2-ST131 clonal group. We searched for the specific biomarker peaks to distinguish between the B2-ST131 clonal group and other sequence type (ST) clonal groups isolated from clinical specimens obtained in our hospital. Biomarker peaks at m/z 7650 in the B2-ST131 group (sensitivity of 100% and specificity of 89.7%) and m/z 7707 in the other ST clonal groups showed the highest discrimination abilities. We further verified reproducibility against other Japanese clinical isolates obtained in another area of Japan. Differences between the molecular mass at the 7650 m/z and 7707 m/z peaks indicated an E34A amino acid substitution by proteomic and genomic analysis. Matrix-assisted laser desorption ionization-time-of-flight mass spectrometry rapidly and simply identified the B2-ST131 clonal group in routine examinations and will allow for adequate empirical therapy and the possibility to control both hospital infections and the global pandemic. (C) 2015 Elsevier Inc. All rights reserved.	[Nakamura, Akihiro; Ohno, Yuki; Kohno, Hisashi; Nakamura, Fumihiko] Tenri Hosp, Dept Lab Med, Div Clin Bacteriol, Tenri, Nara, Japan; [Nakamura, Akihiro; Komatsu, Masaru; Kondo, Akira; Matsuo, Shuji] Tenri Hlth Care Univ, Fac Hlth Care, Dept Clin Lab Sci, Tenri, Nara, Japan; [Nakamura, Akihiro; Ohnuma, Kenichiro; Kawano, Seiji] Kobe Univ, Grad Sch Med, Div Lab Med, Kobe, Hyogo, Japan; [Hatano, Naoya] Kobe Univ, Grad Sch Med, Integrated Ctr Mass Spectrometry, Kobe, Hyogo, Japan	Nakamura, A (reprint author), Tenri Hosp, Dept Lab Med, Div Clin Bacteriol, Tenri, Nara, Japan.	nakamurium@tenriyorozu.jp			JSPS KAKENHI [25860469]	This work was supported by JSPS KAKENHI grant number 25860469. We are grateful to the members of the JCHO Medical Technologists for their help during the collection of the isolates for reproducibility verification.	Wirth T, 2006, MOL MICROBIOL, V60, P1136, DOI 10.1111/j.1365-2958.2006.05172.x; Matsumura Y, 2012, J ANTIMICROB CHEMOTH, V67, P2612, DOI 10.1093/jac/dks278; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; Woerther PL, 2013, CLIN MICROBIOL REV, V26, P744, DOI 10.1128/CMR.00023-13; Hatano N, 2008, J PROTEOME RES, V7, P809, DOI 10.1021/pr700566d; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; Josten M, 2013, J CLIN MICROBIOL, V51, P1809, DOI 10.1128/JCM.00518-13; Griffin PM, 2012, J CLIN MICROBIOL, V50, P2918, DOI 10.1128/JCM.01000-12; Rogers BA, 2011, J ANTIMICROB CHEMOTH, V66, P1, DOI 10.1093/jac/dkq415; Lau AF, 2014, J CLIN MICROBIOL, V52, P2804, DOI 10.1128/JCM.00694-14; Clermont O, 2000, APPL ENVIRON MICROB, V66, P4555, DOI 10.1128/AEM.66.10.4555-4558.2000; Mora A, 2011, INT J ANTIMICROB AG, V37, P16, DOI 10.1016/j.ijantimicag.2010.09.012; Schlebusch S, 2010, EUR J CLIN MICROBIOL, V29, P1311, DOI 10.1007/s10096-010-0995-y; Colpan A, 2013, CLIN INFECT DIS, V57, P1256, DOI 10.1093/cid/cit503; Deng KP, 2011, APPL ENVIRON MICROB, V77, P3952, DOI 10.1128/AEM.02420-10; Johnson JR, 2013, J INFECT DIS, V207, P919, DOI 10.1093/infdis/jis933; Peirano G, 2010, INT J ANTIMICROB AG, V35, P316, DOI 10.1016/j.ijantimicag.2009.11.003; Seng P, 2009, CLIN INFECT DIS, V49, P543, DOI 10.1086/600885; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Johnson JR, 2009, ANTIMICROB AGENTS CH, V53, P2733, DOI 10.1128/AAC.00297-09; Christner M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101924; Clermont O, 2008, J ANTIMICROB CHEMOTH, V61, P1024; Hayashi K, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100049; Matsumura Y, 2014, J CLIN MICROBIOL, V52, P1034, DOI 10.1128/JCM.03196-13	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0732-8893	1879-0070		DIAGN MICR INFEC DIS	Diagn. Microbiol. Infect. Dis.	NOV	2015	83	3					237	244		10.1016/j.diagmicrobio.2015.06.024		8	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CU2OO	WOS:000363363000008		
J	Wang, HS; Liu, WJ; Jin, YL; Yu, MW; Jiang, HQ; Tamura, T; Maeda, Y; Makino, M				Wang, Hongsheng; Liu, Weijing; Jin, Yali; Yu, Meiwen; Jiang, Haiqin; Tamura, Toshiki; Maeda, Yumi; Makino, Masahiko			Detection of antibodies to both M. leprae PGL-I and MMP-II to recognize leprosy patients at an early stage of disease progression	DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE			English	Article						Leprosy; Phenolic glycolipid-I; Major membrane protein-II; Serology	MEMBRANE-PROTEIN-II; MYCOBACTERIUM-LEPRAE; SERODIAGNOSIS; DIAGNOSIS; DELAY	Antibodies, to phenolic glycolipid (PGL)-I and major membrane protein (MMP)-II were evaluated for serodiagnosis of leprosy in Southwest China, and the role in predicting the occurrence of the disease in household contacts (HHCs) of leprosy was examined. Using PGL-I (natural disaccharide-octyl-bovine serum albumin) antigen based diagnosis (IgM antibodies), we could detect 94.9% of multibacillary (MB) leprosy and 38.9% paucibacillaty (PB) leprosy patients, whereas using MMP-II (IgG antibody), 88.1% of MB and 61.1% of PB patients were positive. By combining the 2 tests and considering either test positive as positive, 100% of MB patients and 72.2% of PB patients were found to test positive. Of the HHCs of leprosy, 28.3% and 30% had positive levels of PGL-I and MMP-II Abs, respectively. Seven out of 21 HHCs, who had high Ab titer to either antigen, developed leprosy during the follow-up period of 3 years. These data suggest that the measurement of both anti-PGL-I as well as anti-MMP-II antibodies could facilitate early detection of leprosy. (C) 2015 Elsevier Inc. All rights reserved.	[Wang, Hongsheng; Liu, Weijing; Jin, Yali; Yu, Meiwen; Jiang, Haiqin] Chinese Acad Med Sci, Inst Dermatol, Nanjing 210042, Jiangsu, Peoples R China; [Wang, Hongsheng; Liu, Weijing; Jin, Yali; Yu, Meiwen; Jiang, Haiqin] Peking Union Med Coll, Nanjing 210042, Jiangsu, Peoples R China; [Tamura, Toshiki; Maeda, Yumi; Makino, Masahiko] Natl Inst Infect Dis, Leprosy Res Ctr, Dept Mycobacteriol, Tokyo 1890002, Japan	Maeda, Y (reprint author), Natl Inst Infect Dis, Leprosy Res Ctr, Dept Mycobacteriol, 4-2-1 Aoba Cho, Tokyo 1890002, Japan.	yumi@niid.go.jp			National Natural Science Foundation of China [81371751]; fund for Natural Science Foundation of Jiangsu Province [2014020044]; 'Research Program on Emerging and Re-emerging Infectious Diseases' from Japan Agency for Medical Research and development, AMED - US-Japan Cooperative Medical Science Program	The authors would like to thank the healthy volunteers for their cooperation and the field and laboratory staff for their kind assistance in collecting the sera. This work was supported by the National Natural Science Foundation of China (81371751), the fund for Natural Science Foundation of Jiangsu Province (2014020044) and 'Research Program on Emerging and Re-emerging Infectious Diseases' from Japan Agency for Medical Research and development, AMED in part by a US-Japan Cooperative Medical Science Program.	CHATTERJEE D, 1986, CARBOHYD RES, V156, P39, DOI 10.1016/S0008-6215(00)90098-3; Spencer JS, 2011, LEPROSY REV, V82, P344; Maeda Y, 2005, INFECT IMMUN, V73, P2744, DOI 10.1128/IAI.73.5.2744-2750.2005; Oskam L, 2003, LEPROSY REV, V74, P196; Kai M, 2008, CLIN VACCINE IMMUNOL, V15, P1755, DOI 10.1128/CVI.00148-08; Maeda Y, 2007, FEMS MICROBIOL LETT, V272, P202, DOI 10.1111/j.1574-6968.2007.00754.x; Deps PD, 2006, LEPROSY REV, V77, P41; HUNTER SW, 1981, J BACTERIOL, V147, P728; Chen XS, 2000, ANN TROP MED PARASIT, V94, P181; DESHPANDE RG, 1995, FEMS IMMUNOL MED MIC, V11, P163; Wu QX, 2002, INT J LEPROSY, V70, P1; Parkash O, 2006, SCAND J IMMUNOL, V64, P450, DOI 10.1111/j.1365-3083.2006.01824.x; Hatta M, 2009, LEPROSY REV, V80, P402; Reid AJ, 2001, QJM, V94, P207; Ridley D S, 1966, Int J Lepr Other Mycobact Dis, V34, P255; World Health Organization, 2012, WKLY EPIDEMIOL REC, V87, P317; World Health Organization (WHO), 2009, WKLY EPIDEMIOL REC, V84, P333; World Health Organization (WHO), 2010, ENH GLOB STRAT FURTH	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0732-8893	1879-0070		DIAGN MICR INFEC DIS	Diagn. Microbiol. Infect. Dis.	NOV	2015	83	3					274	277		10.1016/j.diagmicrobio.2015.07.012		4	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CU2OO	WOS:000363363000016		
J	Senoputra, MA; Shiratori, B; Hasibuan, FM; Koesoemadinata, RC; Apriani, L; Ashino, Y; Ono, K; Oda, T; Matsumoto, M; Suzuki, Y; Alisjahbana, B; Hattori, T				Senoputra, Muhammad Andrian; Shiratori, Beata; Hasibuan, Fakhrial Mirwan; Koesoemadinata, Raspati Cundarani; Apriani, Lika; Ashino, Yugo; Ono, Kenji; Oda, Tetsuya; Matsumoto, Makoto; Suzuki, Yasuhiko; Alisjahbana, Bachti; Hattori, Toshio			Diagnostic value of antibody responses to multiple antigens from Mycobacterium tuberculosis in active and latent tuberculosis	DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE			English	Article						Tuberculosis; Tubercular-glycolipid; Mycolic acid; Lipoarabinomannan; alpha-Crystallin	COMPLEX PULMONARY-DISEASE; MYCOLIC ACID SUBCLASSES; AVIUM-COMPLEX; IMMUNOGLOBULIN-G; IGG ANTIBODY; GLYCOPEPTIDOLIPID-CORE; RAPID SERODIAGNOSIS; GLYCOLIPID ANTIBODY; CLINICAL-EVALUATION; LIPID ANTIGENS	We investigated the antibody responses to 10 prospective Mycobacterium tuberculosis (MTB) antigens and evaluated their ability to discriminate between latent (LTBI) and active pulmonary tuberculosis (TB). Our results indicate that plasma levels of anti-alpha-crystallin (ACR), antilipoarabinomannan, anti-trehalose 6,6'-dimycolate, and anti-tubercular-glycolipid antigen antibodies were higher in patients with active TB, compared to those in the LTBI and control subjects. No differences in the antibodies were observed between the control and LTBI subjects. Antibodies against the glycolipid antigens could not distinguish between Mycobacterium avium complex (MAC)-negative TB patients and MAC-infected LTBI individuals. The most useful serological marker was antibodies to ACR, with MAC-negative TB patients having higher titers than those observed in MAC-positive LTBI and control subjects. Our data indicate that antibody to ACR is a promising target for the serological diagnosis of patients with active TB patients. When dealing with antiglycolipid antibodies, MAC coinfection should always be considered in serological studies. (C) 2015 Elsevier Inc. All rights reserved.	[Senoputra, Muhammad Andrian; Shiratori, Beata; Hasibuan, Fakhrial Mirwan; Ashino, Yugo; Hattori, Toshio] Tohoku Univ, Grad Sch Med, Div Emerging Infect Dis, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Senoputra, Muhammad Andrian; Hasibuan, Fakhrial Mirwan] Padjadjaran State Univ, Publ Hlth Sci Program, Fac Med, Bandung 40161, West Java, Indonesia; [Shiratori, Beata; Ashino, Yugo; Hattori, Toshio] Tohoku Univ, Int Res Inst Disaster Sci, Div Disaster Related Infect Dis, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Shiratori, Beata] Japan Int Corp Welf Serv, Minato Ku, Tokyo 1050001, Japan; [Koesoemadinata, Raspati Cundarani; Apriani, Lika; Alisjahbana, Bachti] Padjadjaran State Univ, Fac Med, TB HIV Res Ctr, Bandung 40161, West Java, Indonesia; [Ono, Kenji; Oda, Tetsuya; Matsumoto, Makoto] Otsuka Pharmaceut Co Ltd, Microbiol Res Inst, Tokushima 7710192, Japan; [Suzuki, Yasuhiko] Hokkaido Univ, Res Ctr Zoonosis Control, Div Global Epidemiol, Kita Ku, Sapporo, Hokkaido 0010020, Japan	Hattori, T (reprint author), Tohoku Univ, Grad Sch Med, Div Emerging Infect Dis, Aoba Ku, 21 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	an2_dri@rocketmail.com; beatabucekova@gmail.com; arial_dabbuss@yahoo.com; r.cundarani@gmail.com; likaaji@gmail.com; ya82@yahoo.co.jp; onok@otsuka.jp; odate@otsuka.jp; m_matsumoto@research.otsuka.co.jp; suzuki@czc.hokudai.ac.jp; b.alisjahbana@gmail.com; toshatto@med.tohoku.ac.jp			Scientific Research Expenses for Health and Welfare program from the Ministry of Health, Labour and Welfare, Japan; Science and Technology Research Partnership for Sustainable Development from the Japan Science and Technology Agency, Japan; Strategic Japanese-Thailand Cooperative Program on Biotechnology, JST; Research Centre for Zoonosis Control at Hokkaido University; International Research Institute of Disaster Science of Tohoku University	This work was supported by the Scientific Research Expenses for Health and Welfare program from the Ministry of Health, Labour and Welfare, Japan; the Science and Technology Research Partnership for Sustainable Development from the Japan Science and Technology Agency, Japan; Strategic Japanese-Thailand Cooperative Program on Biotechnology, JST; collaborative funding from the Research Centre for Zoonosis Control at Hokkaido University; and special research grant from the International Research Institute of Disaster Science of Tohoku University. We are grateful to Kyowa Medex, Japan, for providing Determiner TBGL Antibody ELISA Kit.	Balu S, 2011, J IMMUNOL, V186, P3113, DOI 10.4049/jimmunol.1003189; Stewart JN, 2006, MICROBIOL-SGM, V152, P233, DOI 10.1099/mic.0.28275-0; Guio H, 2010, TOHOKU J EXP MED, V220, P21, DOI 10.1620/tjem.220.21; Siddiqi UR, 2012, TOHOKU J EXP MED, V226, P313, DOI 10.1620/tjem.226.313; Sun ZG, 2011, INDIAN J MED RES, V133, P421; Simons S, 2011, EMERG INFECT DIS, V17, P343, DOI [10.3201/eid1703.100604, 10.3201/eid1703100604]; Kitada S, 2008, AM J RESP CRIT CARE, V177, P793, DOI 10.1164/rccm.200705-771OC; Pan JW, 1999, MICROBIOL IMMUNOL, V43, P863; Maekura R, 2001, J CLIN MICROBIOL, V39, P3603, DOI 10.1128/JCM.39.10.3603-3608.2001; Baumann R, 2013, TUBERCULOSIS, V93, P239, DOI 10.1016/j.tube.2012.09.003; Senol G, 2007, EUR RESPIR J, V29, P143, DOI 10.1183/09031936.06.00042706; Fujita Y, 2006, J MED MICROBIOL, V55, P189, DOI 10.1099/jmm.0.46087-0; Mizusawa M, 2008, CLIN VACCINE IMMUNOL, V15, P544, DOI 10.1128/CVI.00355-07; Davidow A, 2005, INFECT IMMUN, V73, P6846, DOI 10.1128/IAI.73.10.6846-6851.2005; Achkar JM, 2013, CELL HOST MICROBE, V13, P250, DOI 10.1016/j.chom.2013.02.009; Siddiqi UR, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/610707; Fujiwara N, 1999, FEMS IMMUNOL MED MIC, V24, P141, DOI 10.1111/j.1574-695X.1999.tb01275.x; MAEKURA R, 1993, AM REV RESPIR DIS, V148, P997; Armitige LY, 2000, INFECT IMMUN, V68, P767, DOI 10.1128/IAI.68.2.767-778.2000; Fujita Y, 2005, MICROBIOL-SGM, V151, P2065, DOI 10.1099/mic.0.27790-0; Katsube T, 2007, J BACTERIOL, V189, P8241, DOI 10.1128/JB.00550-07; Kitada S, 2005, CLIN DIAGN LAB IMMUN, V12, P44, DOI 10.1128/CDLI.12.1.44-51.2005; Siddiqi UR, 2012, INT J TUBERC LUNG D, V16, P532, DOI 10.5588/ijtld.10.0764; Achkar JM, 2012, CLIN VACCINE IMMUNOL, V19, P1898, DOI 10.1128/CVI.00501-12; Del Prete R, 1998, INT J TUBERC LUNG D, V2, P160; Cunningham AF, 1998, J BACTERIOL, V180, P801; Gomez MPSD, 2012, ISRN IMMUNOL, V2012; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; Kobayashi K, 2014, JPN J INFECT DIS, V67, P329, DOI 10.7883/yoken.67.329; Lewin A, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-91; Maiga M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036902; Michaud HA, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-10; Osada-Oka M, 2013, MICROBIOL IMMUNOL, V57, P30, DOI 10.1111/j.1348-0421.2012.12005.x; Perley CC, 2014, PLOS ONE, P9; Shiratori B, 2014, MEDIAT INFLAMM, V2014; Steingart KR, 2009, CLIN VACCINE IMMUNOL, V16, P260, DOI 10.1128/CVI.00355-08	36	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0732-8893	1879-0070		DIAGN MICR INFEC DIS	Diagn. Microbiol. Infect. Dis.	NOV	2015	83	3					278	285		10.1016/j.diagmicrobio.2015.07.021		8	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CU2OO	WOS:000363363000017		
J	Beuers, U; Gershwin, ME; Gish, RG; Invernizzi, P; Jones, DEJ; Lindor, K; Ma, X; Mackay, IR; Pares, A; Tanaka, A; Vierling, JM; Poupon, R				Beuers, Ulrich; Gershwin, M. Eric; Gish, Robert G.; Invernizzi, Pietro; Jones, David E. J.; Lindor, Keith; Ma, Xiong; Mackay, Ian R.; Pares, Albert; Tanaka, Atsushi; Vierling, John M.; Poupon, Raoul			Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'	DIGESTIVE AND LIVER DISEASE			English	Article						Cholangiopathy; Cholestasis; Primary biliary cirrhosis	PRIMARY BILIARY-CIRRHOSIS; HCO3-UMBRELLA; CHOLANGIOCYTES; EXPRESSION		[Beuers, Ulrich] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands; [Gershwin, M. Eric] Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; [Gish, Robert G.] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA; [Invernizzi, Pietro] Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Milan, Italy; [Jones, David E. J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Lindor, Keith] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ USA; [Ma, Xiong] Shanghai Jiao Tong Univ, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol, Renji Hosp,Sch Med, Shanghai 200030, Peoples R China; [Mackay, Ian R.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Pares, Albert] Univ Barcelona, CIBERehd, IDIBAPS, Barcelona, Spain; [Tanaka, Atsushi] Teikyo Univ, Sch Med, Dept Med, Tokyo 173, Japan; [Vierling, John M.] Baylor Coll Med, Dept Med & Surg, Houston, TX 77030 USA; [Poupon, Raoul] Hop St Antoine, Serv Hepatol, Reference Ctr Inflammatory Biliary Dis, F-75571 Paris, France	Beuers, U (reprint author), Acad Med Ctr, Dept Gastroenterol & Hepatol, Tytgat Inst Liver & Intestinal Res, Meibergdreef 9, NL-1100 DE Amsterdam, Netherlands.	u.h.beuers@amc.uva.nl					Addison T, 1851, GUYS HOSP REP, V7, P265; AHRENS EH, 1950, MEDICINE, V29, P299; Sasaki M, 2013, LIVER INT, V33, P312, DOI 10.1111/liv.12049; Beuers U, 2010, HEPATOLOGY, V52, P1489, DOI 10.1002/hep.23810; Banales JM, 2012, HEPATOLOGY, V56, P687, DOI 10.1002/hep.25691; RUBIN E, 1965, AM J PATHOL, V46, P387; Odin JA, 2001, J CLIN INVEST, V108, P223, DOI 10.1172/JCI10716; Hohenester S, 2012, HEPATOLOGY, V55, P173, DOI 10.1002/hep.24691; Lindor KD, 2009, HEPATOLOGY, V50, P291, DOI 10.1002/hep.22906; Gershwin ME, 2008, HEPATOLOGY, V47, P737, DOI 10.1002/hep.22042; SHERLOCK S, 1959, GASTROENTEROLOGY, V37, P574; MACMAHON HE, 1949, ANN INTERN MED, V30, P121; Bianchi I, 2014, SEMIN LIVER DIS, V34, P255, DOI 10.1055/s-0034-1383725; Lleo A, 2010, HEPATOLOGY, V52, P987, DOI 10.1002/hep.23783; Lleo A, 2014, SEMIN LIVER DIS, V34, P273, DOI 10.1055/s-0034-1383727; Beuers U, 2015, J HEPATOL, V62, pS25, DOI 10.1016/j.jhep.2015.02.023; Dyson JK, 2015, NAT REV GASTRO HEPAT, V12, P147, DOI 10.1038/nrgastro.2015.12; EASL, 2009, J HEPATOL, V51, P237; Hanot V, 1876, ETUDE FORME CIRRHOSE; Hirschfield GM, 2013, ANNU REV PATHOL-MECH, V8, P303, DOI 10.1146/annurev-pathol-020712-164014; Sherlock S, 1968, DIS LIVER BILIARY SY, P305	21	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1590-8658	1878-3562		DIGEST LIVER DIS	Dig. Liver Dis.	NOV	2015	47	11					924	926		10.1016/j.dld.2015.08.007		3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU4HV	WOS:000363489400006		
J	Mizoshita, T; Tanida, S; Joh, T				Mizoshita, Tsutomu; Tanida, Satoshi; Joh, Takashi			Adalimumab treatment in intestinal Behcet's disease: Relationship with ectopic mucin 5AC glycoprotein expression and endoscopic improvement	DIGESTIVE AND LIVER DISEASE			English	Letter									[Mizoshita, Tsutomu; Tanida, Satoshi; Joh, Takashi] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi 4678601, Japan	Mizoshita, T (reprint author), Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.	tmizoshi@med.nagoya-cu.ac.jp					Tanida S, 2015, CLIN GASTROENTEROL H, V13, P940, DOI 10.1016/j.cgh.2014.08.042; Mizoshita T, 2014, GASTROENT RES PRACT, DOI 10.1155/2014/687257; Hisamatsu T, 2014, J GASTROENTEROL, V49, P156, DOI 10.1007/s00535-013-0872-4; Lee HJ, 2012, WORLD J GASTROENTERO, V18, P5771, DOI 10.3748/wjg.v18.i40.5771; Mizoshita T, 2013, ISRN GASTROENTEROLOG, V2013	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1590-8658	1878-3562		DIGEST LIVER DIS	Dig. Liver Dis.	NOV	2015	47	11					991	992		10.1016/j.dld.2015.07.007		2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU4HV	WOS:000363489400020		
J	Adachi, K; Okamoto, S				Adachi, Kensuke; Okamoto, Shoichi			An unusual bowel complication during molecularly- targeted therapy	DIGESTIVE AND LIVER DISEASE			English	Editorial Material									[Adachi, Kensuke] Tokyo Metropolitan Tama Med Ctr, Dept Surg, Fuchu, Tokyo 1838524, Japan; [Okamoto, Shoichi] Tokyo Metropolitan Tama Med Ctr, Dept Resp Med, Fuchu, Tokyo 1838524, Japan	Adachi, K (reprint author), Tokyo Metropolitan Tama Med Ctr, Dept Surg, 2-8-29 Musashidai, Fuchu, Tokyo 1838524, Japan.	kensuke_adachi@tmhp.jp					Guiu S, 2011, SURGERY, V149, P297, DOI 10.1016/j.surg.2009.07.010	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1590-8658	1878-3562		DIGEST LIVER DIS	Dig. Liver Dis.	NOV	2015	47	11					E20	E20		10.1016/j.dld.2015.06.017		1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU4HV	WOS:000363489400002		
J	Yusni, EM; Tanaka, S				Yusni, Effendi Mohd; Tanaka, Shunitz			Removal behaviour of a thiazine, an azo and a triarylmethane dyes from polluted kaolinitic soil using electrokinetic remediation technology	ELECTROCHIMICA ACTA			English	Article						electro-kinetic remediation; kaolinite; electro-migration; electro-osmotic; pH controlling; thiazine dye; azo dye; triarylmethane dye	SEQUENCING BATCH REACTORS; METHYLENE-BLUE; PHOTOCATALYTIC DEGRADATION; CONTAMINATED SOILS; DECOLORIZATION; ADSORPTION; CARBON; DECOLOURIZATION; LEAD	In this study, we investigated the potentiality of the electro-kinetic remediation (EKR) technique for the removal of organic dyes polluted soil. Methylene blue (MB), methyl orange (MO), and phenol red (PR) are representing a thiazine, an azo, and a tryarilmethane dye respectively, which was spiked with kaolinite were selected as a model for pollutant dyes tests. An EKR tool (15 cm length) equipped with a DC electric current with the maximum values of 30 V. Graphite electrodes were used for both anode and cathode was set up for two weeks operation. As a result, only 40-55 % of dye was removed from the soil sections by using distilled water. However, by the addition of some electrolytes; the percentage of dyes removed from the soil increased from 73-76 % and 85-89 % for sodium sulphate, and monosodium dihydrogen phosphate, respectively. It resulted that 55-64 % of dyes was removed without controlling the pH. The significant improvement was achieved by controlling the pH of the system. By controlling the pH in the cathode chamber, only 23 % of MB, 25 % of MO, and 18 % of PR dyes remain in the soil sections, respectively. While by controlling the pH in the anode chamber, almost 90 % of tested dyes could be removed from the kaolinite chamber effectively. The movement of a thiazine dye, from the anode to the cathode chamber was controlled by electro-migration and electro-osmosis phenomena. An azo dye transported from the cathode to the anode chamber by a similar process. However, a triarylmethane dye was removed from the soil sections by only electro-osmosis process. For three kinds of tested dyes, it were found that electro-osmotic flow moving from the anode to the cathode directions. The ageing of dye affects the removal percentage of the dye. (C) 2015 Elsevier Ltd. All rights reserved.	[Yusni, Effendi Mohd; Tanaka, Shunitz] Hokkaido Univ, Grad Sch Environm Sci, Div Environm Sci Dev, Kita Ku, Sapporo, Hokkaido 0600810, Japan; [Yusni, Effendi Mohd] State Univ Padang, Fac Math & Nat Sci, Dept Chem, Air Tawar Padang 25131, West Sumatera, Indonesia	Tanaka, S (reprint author), Hokkaido Univ, Grad Sch Environm Sci, Div Environm Sci Dev, Kita Ku, North 10 West 5, Sapporo, Hokkaido 0600810, Japan.	shunitz@ees.hokudai.ac.jp					Amina A., 2008, DYES PIGMENTS, V76, P282; Hale SE, 2011, ENVIRON SCI TECHNOL, V45, P10445, DOI 10.1021/es202970x; Albuquerque MGE, 2005, ENZYME MICROB TECH, V36, P790, DOI 10.1016/j.enzmictec.2005.01.005; Ravikumar K, 2005, J HAZARD MATER, V122, P75, DOI 10.1016/j.jhazmat.2005.03.008; Saichek RE, 2005, CRIT REV ENV SCI TEC, V35, P115, DOI 10.1080/10643380590900237; Kavitha D, 2007, BIORESOURCE TECHNOL, V98, P14, DOI 10.1016/j.biortech.2005.12.008; Sarahney H, 2005, ENVIRON ENG SCI, V22, P642, DOI 10.1089/ees.2005.22.642; Yeung AT, 2006, ENVIRON ENG SCI, V23, P202, DOI 10.1089/ees.2006.23.202; Pazos M, 2008, ENVIRON ENG SCI, V25, P419, DOI 10.1089/ees.2007.0068; Zille A, 2003, BIOTECHNOL LETT, V25, P1473, DOI 10.1023/A:1025032323517; Khodadoust AP, 2004, ENVIRON ENG SCI, V21, P691, DOI 10.1089/ees.2004.21.691; Muruganandham M, 2006, DYES PIGMENTS, V68, P133, DOI 10.1016/j.dyepig.2005.01.004; Maas R, 2005, PROCESS BIOCHEM, V40, P699, DOI 10.1016/j.procbio.2004.01.038; Jensen PE, 2007, ENVIRON ENG SCI, V24, P234, DOI 10.1089/ees.2005-0122; Cox L, 2004, J AGR FOOD CHEM, V52, P5635, DOI 10.1021/jf0306035; Putra RS, 2011, SEP PURIF TECHNOL, V79, P208, DOI 10.1016/j.seppur.2011.02.015; LAKSHMI S, 1995, J PHOTOCH PHOTOBIO A, V88, P163, DOI 10.1016/1010-6030(94)04030-6; Pazos M, 2007, ELECTROCHIM ACTA, V52, P3393, DOI 10.1016/j.electacta.2006.04.067; ACAR YB, 1993, ENVIRON SCI TECHNOL, V27, P2638, DOI 10.1021/es00049a002; Page MM, 2002, J ENVIRON ENG-ASCE, V128, P208, DOI 10.1061/(ASCE)0733-9372(2002)128:3(208); Muthuraman G, 2009, J HAZARD MATER, V163, P363, DOI 10.1016/j.jhazmat.2008.06.122; HICKS RE, 1994, ENVIRON SCI TECHNOL, V28, P2203, DOI 10.1021/es00061a032; Altin A, 2005, SCI TOTAL ENVIRON, V337, P1, DOI 10.1016/j.scitotenv.2004.06.017; Borchert M, 2001, BIOTECHNOL BIOENG, V75, P313, DOI 10.1002/bit.10026; Breese Randall R., 1986, JAIC, V25, P39; Couto SR, 2002, CHEMOSPHERE, V46, P83; Hatzinger Paul B., ENV SCI TECHNOL, V29; Moldes D, 2003, CHEMOSPHERE, V51, P295, DOI 10.1016/S0045-6535(02)00406-X; Pamukcu S., 2007, ELECT J GEOTECH ENG, V2; Pianizza M., 2007, SEP PURIF TECHNOL, V54, P382; Sanroman A., 2004, CHEMOSPHERE, V57, P233; Vyrkutyte J, 2002, SCI TOTAL ENVIRON, V289, P97; Zollinger H., 2003, COLOUR CHEM SYNTHESI	33	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0013-4686	1873-3859		ELECTROCHIM ACTA	Electrochim. Acta	NOV 1	2015	181						130	138		10.1016/j.electacta.2015.06.153		9	Electrochemistry	Electrochemistry	CU4CR	WOS:000363474500017		
J	Shimamura, S; Yoshikawa, E; Yoshida, S; Ushio, T; Matayoshi, N				Shimamura, Shigeharu; Yoshikawa, Eiichi; Yoshida, Satoru; Ushio, Tomoo; Matayoshi, Naoki			Preliminary Study on Low-Level Turbulence Advisory System with Ku-Band Broadband Radar at Shonai Airport, Yamagata Prefecture	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						radar; meteorology; rain; tornado; downburst; airport	SINGLE-DOPPLER RADAR	During winter, at Shonai Airport located at the northern part of Japan, some low-level turbulence caused by tornadoes and downbursts often interrupts takeoffs and landings. This is a primary source of economic loss. It is well-known that a weather radar system is one of the most useful devices for observing various weather phenomena. However, it is difficult for conventional radar systems with a range resolution of several hundred meters and a temporal resolution of about 5 min to detect small-scale phenomena with a horizontal scale of several hundred meters and duration of several minutes. We have been developing a meteorological Ku-band broadband radar (BBR) that can detect small-scale phenomena with high resolution (a range resolution of several meters and a temporal resolution of about 1 min). We constructed an advisory system with the BBR in order to support aircraft operation at this airport, and performed a comparison between BBR data and flight data recorder (FDR) data. (C) 2015Wiley Periodicals, Inc.	[Shimamura, Shigeharu; Ushio, Tomoo] Osaka Univ, Suita, Osaka 565, Japan; [Yoshikawa, Eiichi; Matayoshi, Naoki] JAXA, Chofu, Tokyo, Japan; [Yoshida, Satoru] Meteorol Res Inst, Yokohama, Kanagawa, Japan	Shimamura, S (reprint author), Osaka Univ, Suita, Osaka 565, Japan.						Air Traffic Service Research Institute, 2009, REP INV EFF ADV WEAT; Mega T, 2007, IEEE GEOSCI REMOTE S, V4, P392, DOI 10.1109/LGRS.2007.895705; WALDTEUFEL P, 1979, J APPL METEOROL, V18, P532, DOI 10.1175/1520-0450(1979)018<0532:OTAOSD>2.0.CO;2; Browning K. A., 1968, J APPL METEOROL, V7, P105, DOI 10.1175/1520-0450(1968)007<0105:TDOKPO>2.0.CO;2; Committee on Investigation of Air and Rail Accidents, 2008, REP RAILW ACC INV E; Ishihara M., 2001, NOTES ATMOSPHERIC RE, P12; Ishihara M, 2001, NOTES ATMOSPHERIC RE, P39; KOSCIELNY AJ, 1982, J APPL METEOROL, V21, P197, DOI 10.1175/1520-0450(1982)021<0197:SCITEO>2.0.CO;2; Kusunoki K, 2009, METEOROLOGICAL SOC B, P163; Matayoshi N, 2010, 41 REG M JAP SOC AER; Matayoshi N, 2011, 49 AIRCR S MET SOC J; Monden K, 2006, J IEICE B, VJ89-B, P278; Tsuzuki Y, 2000, ELECT MEASUREMENTS	13	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2015	98	11					1	8		10.1002/ecj.11745		8	Engineering, Electrical & Electronic	Engineering	CU2BR	WOS:000363327100001		
J	Kosuge, T; Itakura, N; Mito, K				Kosuge, Tomohiro; Itakura, Naoaki; Mito, Kazuyuki			Conducting Wave Investigation by Multichannel Surface EMG	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						surface EMG; MFCV	VELOCITY	Muscular activity is investigated by analyzing the action potential generated by motor units. The multichannel surface electromyogram (EMG) is used to analyze the conduction of muscle potential, which is recorded as the interference electric potential generated by motor units. The multichannel surface EMG includes waveforms that conduct in several channels (conducting waves). We believe that it may be possible to analyze the changes in surface muscle potential caused by muscular activity so as to examine the composition of conducting waves in the multichannel surface EMG. Thus, in this paper, we propose a new method of analyzing the multichannel surface EMG. The proposed method involves quantitatively searching for all conducting waves that appear in the multichannel surface EMG in order to calculate the similarity of the waveforms. Using this method, which is referred to as the multichannel method for conducting waves (m-ch method), various types of data for each wave, including the conduction velocity and amplitude, across channels can be examined. Using the m-ch method, we analyzed the multichannel surface EMG in subjects holding a load. We also examined the changes in the composition of the conducting waves. We believe that muscular activity can be analyzed based on conducting waves from a surface EMG. (C) 2015 Wiley Periodicals, Inc.	[Kosuge, Tomohiro] Univ Electrocommun, Grad Sch Engn, Doctoral Program Elect & Commun Engn, Chofu, Tokyo 182, Japan; [Itakura, Naoaki] Univ Electrocommun, Dept Elect & Informat, Chofu, Tokyo 182, Japan; [Mito, Kazuyuki] Univ Electrocommun, Grad Sch Elect Commun, Doctoral Program, Chofu, Tokyo 182, Japan	Kosuge, T (reprint author), Univ Electrocommun, Grad Sch Informat & Engn, Doctoral Program, Chofu, Tokyo 182, Japan.						Akaboshi K, 1999, JPN J REHABIL MED, V36, P669; Denslow JS, 1943, AM J PHYSIOL, V139, P0652; MASUDA T, 1982, IEEE T BIO-MED ENG, V29, P673, DOI 10.1109/TBME.1982.324859; Yamada H, 2003, JPN J PHYS FIT SPORT, V52, P29; Farina D, 2004, IEEE T BIO-MED ENG, V51, P1383, DOI [10.1109/TBME.2004.827556, 10.1109/TMBE.2004.827556]; Aoki K, TECH REPORT IEICE, V103, P51; Hara Y, 2004, IEEE J T EIS, V124, P431, DOI 10.1541/ieejeiss.124.431; Kai Y, 2009, RIGAKURYOHO KAGAKU, V24, P605; Kikukawa J, 1997, P 37 GEN C JAP SOC P, P75; Li Weiqiang, 1996, Applied Human Science, V15, P41, DOI 10.2114/jpa.15.41; Matsunaga Satoshi, 1993, Annals of Physiological Anthropology, V12, P251; Nagata A, 1982, J SOC BIOMECHANISMS, V6, P109; Nishihara K, 2003, SPEC REHABIL, V2, P42; NISHIZONO H, 1979, ELECTROEN CLIN NEURO, V46, P659, DOI 10.1016/0013-4694(79)90103-2; Oka H, 1994, IEICE MBE, V94, P37; Okitsu T, 2009, JPN J REHABIL MED, V46, P649; Okuno R, 1998, TECH REPORT IEICE MB, V97, P117; Willison RG, 1964, NEUROL NEUROSURG PSY, V27, P386	18	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2015	98	11					9	18		10.1002/ecj.11751		10	Engineering, Electrical & Electronic	Engineering	CU2BR	WOS:000363327100002		
J	Wada, M; Watabe, K; Okubo, S; Suzuyama, T; Hong, F; Amemiya, M				Wada, Masato; Watabe, Ken-Ichi; Okubo, Sho; Suzuyama, Tomonari; Hong, Feng-Lei; Amemiya, Masaki			A Precise Frequency Comparison System Using an Optical Carrier	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						frequency standard; optical fiber; precise frequency comparison; optical carrier transfer; frequency stability; phase compensation	DISTRIBUTED CAVITY PHASE; FIBER NETWORK; LATTICE CLOCK; LINK; DISSEMINATION; UNCERTAINTY; STANDARDS; METROLOGY; ACCURACY; SHIFTS	We have investigated the performance of an optical carrier transfer system for remote comparison of optical clocks. In the frequency transfer system, technical problems and fundamental principles limit coherent transfer on a long-haul optical fiber. They contribute to noise processes that come from the propagation delay in the fiber, the design of the interferometer, burst length fluctuations of the fiber, asymmetrical propagation characteristics, and so on. The feasibility of a full optical link with high stability is discussed. Phase detection with a high degree of precision and cancelation of the fiber-induced noise on the round-trip light are achieved with a well-known standard technique using an all-fiber-based interferometer. We report the characteristics of these noise processes with results on a spooled fiber. The Allan deviation of the compensated link which is extended to 90 km reaches 5 x 10(-18), close to the theoretical limit imposed by the delay-unsuppressed fiber noise at an averaging time of 103 s. (C) 2015 Wiley Periodicals, Inc.	[Wada, Masato; Watabe, Ken-Ichi; Okubo, Sho; Suzuyama, Tomonari; Hong, Feng-Lei; Amemiya, Masaki] Natl Inst Adv Ind Sci & Technol, NMIJ, Tsukuba, Ibaraki, Japan	Wada, M (reprint author), Natl Inst Adv Ind Sci & Technol, NMIJ, Tsukuba, Ibaraki, Japan.						Nicholson TL, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.230801; Lopez O, 2010, OPT EXPRESS, V18, P16849, DOI 10.1364/OE.18.016849; Predehl K, 2012, SCIENCE, V336, P441, DOI 10.1126/science.1218442; Chou CW, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.070802; Hinkley N, 2013, SCIENCE, V341, P1215, DOI 10.1126/science.1240420; Terra O, 2009, APPL PHYS B-LASERS O, V97, P541, DOI 10.1007/s00340-009-3653-2; Williams PA, 2008, J OPT SOC AM B, V25, P1284, DOI 10.1364/JOSAB.25.001284; Bauch A, 2006, METROLOGIA, V43, P109, DOI 10.1088/0026-1394/43/1/016; Chou CW, 2010, SCIENCE, V329, P1630, DOI 10.1126/science.1192720; Grosche G, 2009, OPT LETT, V34, P2270, DOI 10.1364/OL.34.002270; Yasuda M, 2012, APPL PHYS EXPRESS, V5, DOI 10.1143/APEX.5.102401; Musha M, 2008, OPT EXPRESS, V16, P16459, DOI 10.1364/OE.16.016459; Huntemann N, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.090801; Yamaguchi A, 2011, APPL PHYS EXPRESS, V4, DOI 10.1143/APEX.4.082203; Lopez O, 2012, OPT EXPRESS, V20, P23518, DOI 10.1364/OE.20.023518; Li RX, 2011, METROLOGIA, V48, P283, DOI 10.1088/0026-1394/48/5/007; Parker TE, 2010, METROLOGIA, V47, P1, DOI 10.1088/0026-1394/47/1/001; Narbonneau F, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2205155; Ludlow AD, 2008, SCIENCE, V319, P1805, DOI 10.1126/science.1153341; Guena J, 2012, IEEE T ULTRASON FERR, V59, P391, DOI 10.1109/TUFFC.2012.2208; Katori H, 2011, NAT PHOTONICS, V5, P203, DOI [10.1038/nphoton.2011.45, 10.1038/NPHOTON.2011.45]; Imaoka A, 1998, IEEE T INSTRUM MEAS, V47, P537, DOI 10.1109/19.744202; Lopez O, 2010, APPL PHYS B-LASERS O, V98, P723, DOI 10.1007/s00340-009-3832-1; Hong FL, 2009, OPT LETT, V34, P692, DOI 10.1364/OL.34.000692; Sherman JA, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.153002; KERSEY AD, 1991, ELECTRON LETT, V27, P518, DOI 10.1049/el:19910325; Weyers S, 2012, METROLOGIA, V49, P82, DOI 10.1088/0026-1394/49/1/012; Matveev A, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.230801; Blatt S, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.140801; Targat R. L., 2013, NAT COMMUN, V4, P2109	30	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2015	98	11					19	27		10.1002/ecj.11754		9	Engineering, Electrical & Electronic	Engineering	CU2BR	WOS:000363327100003		
J	Matsugasaki, N; Shinyama, K; Fujita, S				Matsugasaki, Naru; Shinyama, Katsuyoshi; Fujita, Shigetaka			Dielectric Breakdown Properties of Polylactic Acid with Spherulite Growth	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						bioplastics; polylactic acid; breakdown properties; mechanical properties; spherulites		Polylactic acid (PLA) is a bioplastic and a biomass material that is made from corn starch, and so on. Having studied the potential of PLA as an electrical insulation material, the authors have demonstrated that PLA has high resistivity, high dielectric breakdown strength, and other outstanding electrical insulation properties, equivalent to those of low-density polyethylene (LDPE) and other petroleum-based plastics, within a temperature range from room temperature to approximately 70 degrees C. The degree of crystallinity of PLA was increased by heat treatment, and the dielectric breakdown strength (EB) and mechanical properties of the obtained PLA with different spherulite sizes were studied. PLA heat-treated at a temperature of 120 degrees C or higher showed rapid increases in spherulite size. At both measurement temperatures of 25 degrees C and 80 degrees C, the EB showed rapid falls when the heat treatment temperature was 120 degrees C or higher. At a measurement temperature of 25 degrees C, the tensile strength at break and breaking elongation showed rapid falls when the heat treatment temperature was 120 degrees C or higher. (C) 2015 Wiley Periodicals, Inc.	[Matsugasaki, Naru; Shinyama, Katsuyoshi; Fujita, Shigetaka] Hachinohe Inst Technol, Hachinohe, Aomori, Japan	Matsugasaki, N (reprint author), Hachinohe Inst Technol, Hachinohe, Aomori, Japan.						Fujita S, 1985, T IEE JPN D, V105-A, P45; Hikosaka S, 2009, IEEJ T FUNDAM MAT, V129, P217; Kawanami H, 2006, IEEJ T FM, V126, P363; Mitsuta R, 2007, SEIKEI KAKOU, V19, P730; Oi T, 2011, IEEJ T FM, V131, P395; Shinyama K, 2010, IEEJ T FM, V130, P369; Shinyama K., 2006, IEEJ T FM, V126-A, P31, DOI 10.1541/ieejfms.126.31; Tsuji H, 2008, POLYLACTIC ACID, V78, P153; Tsuji H, 1998, POLYLACTIC ACID MED, P78; Yamakita T, 1992, T IEE JPN D, V112, P145	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2015	98	11					28	34		10.1002/ecj.11758		7	Engineering, Electrical & Electronic	Engineering	CU2BR	WOS:000363327100004		
J	Haruyama, Y; Okada, M; Nakai, Y; Ishida, T; Matsui, S				Haruyama, Yuichi; Okada, Makoto; Nakai, Yasuki; Ishida, Takao; Matsui, Shinji			Evaluation of Fluorinated Self-Assembled Monolayer by Photoelectron and Near Edge X-Ray Absorption Fine Structure Spectroscopy	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						fluorinated self-assembled monolayer; F-SAM; FAS; photoelectron spectroscopy; NEXAFS	SYNCHROTRON-RADIATION; POLARIZED XANES	The electronic structure of fluorinated self-assembled monolayers (F-SAMs) with different chain lengths was investigated by photoelectron and near edge X-ray absorption fine structure (NEXAFS) spectroscopy. From the measurements of the photoelectron spectra in the wide region and in the C 1s core-level region, the chemical compositions and components of the F-SAMs with different chain length were clarified. In the C K-edge NEXAFS spectra of the F-SAMs, the several spectral features were observed and the intensity of the features at 292 eV and 299 eV decreased with increasing incidence angle of the excitation photons. Based on the results of the photoelectron and NEXAFS spectral measurements, the electronic structure of four F-SAMs with different chain length is discussed. (C) 2015 Wiley Periodicals, Inc.	[Haruyama, Yuichi; Okada, Makoto; Nakai, Yasuki; Matsui, Shinji] Univ Hyogo, Kobe, Hyogo 6500044, Japan; [Haruyama, Yuichi; Okada, Makoto; Nakai, Yasuki; Matsui, Shinji] Japan Sci & Technol Agcy, CREST, Tokyo, Japan; [Ishida, Takao] Natl Inst Adv Ind Sci & Technol, Tokyo, Japan	Haruyama, Y (reprint author), Univ Hyogo, Kobe, Hyogo 6500044, Japan.				Kawanishi Memorial ShinMaywa Education Foundation; JSPS [13240361]	This study was supported in part by the Kawanishi Memorial ShinMaywa Education Foundation, and by a JSPS Grant-in-Aid for Scientific Research(13240361).	Nakai Y, 2010, J PHOTOPOLYM SCI TEC, V23, P55, DOI 10.2494/photopolymer.23.55; Katoh T, 1996, APPL PHYS LETT, V68, P865, DOI 10.1063/1.116526; NAGAYAMA K, 1995, PHYSICA B, V208, P419, DOI 10.1016/0921-4526(94)00716-9; OHTA T, 1990, PHYS SCRIPTA, V41, P150, DOI 10.1088/0031-8949/41/1/036; ZHANG Y, 1995, APPL PHYS LETT, V67, P872, DOI 10.1063/1.115533; CHOU SY, 1995, APPL PHYS LETT, V67, P3114, DOI 10.1063/1.114851; Hozumi A, 1999, LANGMUIR, V15, P7600, DOI 10.1021/la9809067; Nakamatsu K, 2005, J VAC SCI TECHNOL B, V23, P507, DOI 10.1116/1.1868695; Chinen M., 2012, THESIS U HYOGO, P38; Okada M., 2011, THESIS U HYOGO, P20	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2015	98	11					35	40		10.1002/ecj.11759		6	Engineering, Electrical & Electronic	Engineering	CU2BR	WOS:000363327100005		
J	Takahashi, K; Okamura, S; Sato, M				Takahashi, Kazunori; Okamura, Saika; Sato, Motoyuki			A Fundamental Study of Polarimetric GB-SAR for Nondestructive Inspection of Internal Damage in Concrete Walls	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						nondestructive inspection (NDI); synthetic aperture radar (SAR); radar polarimetry; ground-based synthetic aperture radar (GB-SAR)		Damages on the surfaces of concrete buildings can easily be detected by visual inspection and can be repaired. However, damages inside walls need nondestructive inspection techniques to be detected, located, and identified. There has been a great demand for such techniques particularly after the 3.11 Great East Japan Earthquake. Ground-based synthetic aperture radar (GB-SAR) is a technique that can be potentially used for inspection of concrete walls in a nondestructive and noncontacting manner. The paper reports a fundamental experiment with a polarimetric GB-SAR system to detect internal damage in a concrete specimen caused by horizontal loading simulating earthquakes. The results show that the system does not have enough resolution to visualize individual defects, and that the effect of steel rebars installed inside the concrete is so strong that it masks weak responses. However, polarimetric analysis demonstrated the capability to minimize the effect of rebars by rearranging polarization basis and to extract weak responses. In particular, internal damages could be detected by observing the volume scattering component in this experiment. (C) 2015 Wiley Periodicals, Inc.	[Takahashi, Kazunori] Tohoku Univ, Doctoral Program Environm Sci, Sendai, Miyagi 980, Japan; [Okamura, Saika] Tohoku Univ, Dept Mech & Aerosp Engn, Sendai, Miyagi 980, Japan; [Sato, Motoyuki] Tohoku Univ, Grad Sch Engn, Doctoral Program, Sendai, Miyagi 980, Japan	Takahashi, K (reprint author), Tohoku Univ, Doctoral Program Environm Sci, Sendai, Miyagi 980, Japan.						Cloude S. R., 2009, POLARIZATION APPL RE; Iisaka K., 1998, HDB IMAGES SYNTHETIC; Ito M, 2013, CONCRETE TE IN PRESS, P35; Lee JS, 2009, OPT SCI ENG-CRC, P1; Okamoto K., 1999, GLOBAL ENV MEASUREME; Okamura S, 2013, P 128 SEGI C, P121; Uomoto T, 1990, NONDESTRUCTIVE INSPE; Yamaguchi Y., 2007, FUNDAMENTALS APPL RA	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2015	98	11					41	49		10.1002/ecj.11762		9	Engineering, Electrical & Electronic	Engineering	CU2BR	WOS:000363327100006		
J	Yang, JF; Yoshida, Y; Shibata, H				Yang, Jinfeng; Yoshida, Yoichi; Shibata, Hiromi			Femtosecond Time-Resolved Electron Microscopy	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						time-resolved electron microscopy; TEM; femtosecond electron imaging; radio-frequency electron gun	GUN	The revealing and understanding of ultrafast structural-change induced dynamics not only are essential in physics, chemistry, and biology, but also are indispensable for the development of new materials, new devices, and applications. A new radio-frequency electron gun-based ultrafast relativistic electron microscopy (UEM) is being developed at Osaka University to for direct probing structural changes at the atomic scale with sub-100 fs temporal resolution in materials. The first prototype femtosecond time-resolved relativistic-energy UEM was constructed at end of October 2012. Both relativistic-energy electron diffraction and image measurements have been successfully performed using a femtosecond electron beam. In this paper, the development of the UEM prototype and the first experiments on relativistic-energy electron imaging are reported. (C) 2015 Wiley Periodicals, Inc.	[Yang, Jinfeng; Yoshida, Yoichi; Shibata, Hiromi] Osaka Univ, ISIR, Suita, Osaka 565, Japan	Yang, JF (reprint author), Osaka Univ, ISIR, Suita, Osaka 565, Japan.						Siwick BJ, 2002, J APPL PHYS, V92, P1643, DOI 10.1063/1.1487437; Yang J, 2002, J APPL PHYS, V92, P1608, DOI 10.1063/1.1487457; Yang JF, 2009, RADIAT PHYS CHEM, V78, P1106, DOI 10.1016/j.radphyschem.2009.05.009; Gahlmann A, 2008, PHYS CHEM CHEM PHYS, V10, P2894, DOI 10.1039/b802136h; Yang JF, 2011, NUCL INSTRUM METH A, V637, pS24, DOI 10.1016/j.nima.2010.02.014; Campbell GH, 2010, J ELECTRON MICROSC, V59, pS67, DOI 10.1093/jmicro/dfq032; Barwick B, 2008, SCIENCE, V322, P1227, DOI 10.1126/science.1164000; Kan K, 2011, NUCL INSTRUM METH A, V659, P44, DOI 10.1016/j.nima.2011.08.016; LaGrange T, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2236263; King WE, 2005, J APPL PHYS, V97, DOI 10.1063/1.1927699; Muro'oka Y, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3602314; Naruse N, 2010, J PARTICLE ACCELERAT, V7, P261; Yang J, 2012, J VAC SOC JPN, V55, P42; Zewail AH, 2010, SCIENCE, V328	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2015	98	11					50	57		10.1002/ecj.11763		8	Engineering, Electrical & Electronic	Engineering	CU2BR	WOS:000363327100007		
J	Ooka, R; Ikeda, S				Ooka, Ryozo; Ikeda, Shintaro			A review on optimization techniques for active thermal energy storage control	ENERGY AND BUILDINGS			English	Review						Thermal energy storage; Smart energy systems; Optimization control; Mixed-integer linear programming; Metaheuristic methods	PARTICLE SWARM OPTIMIZATION; AIR-CONDITIONING SYSTEM; ICE-STORAGE; THERMOECONOMIC OPTIMIZATION; FUNCTION MINIMIZATION; PROGRAMMING-PROBLEMS; CONTROL STRATEGIES; PREDICTIVE CONTROL; POWER-SYSTEM; MANAGEMENT	The increasing popularity of smart energy systems has led to a gradual increase in the importance of thermal energy storage (TES) technology. Thus, the control strategy employed to efficiently take advantage of TES is expected to be very important. In other words, the time schedule, the particular components to be activated, and the amount of charging/discharging have to be appropriately determined. To date, a number of studies have investigated the optimization of TES operations by using optimization techniques. Current methods being used to achieve optimal TES operation are reviewed in this paper. (C) 2015 Elsevier B.V. All rights reserved.	[Ooka, Ryozo] Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan; [Ikeda, Shintaro] Univ Tokyo, Dept Architecture, Meguro Ku, Tokyo 1538505, Japan	Ooka, R (reprint author), Univ Tokyo, Inst Ind Sci, Meguro Ku, 4-6-1 Komaba, Tokyo 1538505, Japan.	ooka@iis.u-tokyo.ac.jp					Akimoto Y., 2009, P 11 ANN C GEN EV CO, P739, DOI 10.1145/1569901.1570004; Salvador M, 2012, ENERG BUILDINGS, V47, P659, DOI 10.1016/j.enbuild.2012.01.006; Sanaye S, 2011, ENERGY, V36, P1057, DOI 10.1016/j.energy.2010.12.002; Liu YF, 2002, ENERG CONVERS MANAGE, V43, P2357; LAND AH, 1960, ECONOMETRICA, V28, P497, DOI 10.2307/1910129; Henze GP, 2003, J SOL ENERG-T ASME, V125, P2, DOI 10.1115/1.1530629; Fazlollahi S, 2014, COMPUT CHEM ENG, V71, P648, DOI 10.1016/j.compchemeng.2013.10.016; Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/ICNN.1995.488968; Motevasel M, 2013, ENERGY, V51, P123, DOI 10.1016/j.energy.2012.11.035; Wakui T, 2010, ENERGY, V35, P740, DOI 10.1016/j.energy.2009.09.029; Ashouri A, 2013, ENERGY, V59, P365, DOI 10.1016/j.energy.2013.06.053; Vetterli J, 2012, ENERG BUILDINGS, V49, P226, DOI 10.1016/j.enbuild.2012.02.012; NELDER JA, 1965, COMPUT J, V7, P308; Rivarolo M, 2013, ENERG CONVERS MANAGE, V65, P75, DOI 10.1016/j.enconman.2012.09.005; FLETCHER R, 1970, COMPUT J, V13, P317, DOI 10.1093/comjnl/13.3.317; Sun YJ, 2013, ENERG CONVERS MANAGE, V71, P101, DOI 10.1016/j.enconman.2013.03.026; Byrd RH, 1996, SIAM J OPTIMIZ, V6, P1025, DOI 10.1137/S1052623493252985; Buoro D, 2014, APPL ENERG, V124, P298, DOI 10.1016/j.apenergy.2014.02.062; Chen HJ, 2005, APPL THERM ENG, V25, P461, DOI 10.1016/j.applthermaleng.2003.12.006; Lee WS, 2009, APPL ENERG, V86, P1589, DOI 10.1016/j.apenergy.2008.12.025; Barbieri ES, 2012, APPL ENERG, V97, P714, DOI 10.1016/j.apenergy.2012.01.001; Hajiah A, 2012, ENERG CONVERS MANAGE, V64, P509, DOI 10.1016/j.enconman.2012.02.020; Andersen ED, 1995, MATH PROGRAM, V71, P221, DOI 10.1007/BF01586000; Hajiah A, 2012, ENERG CONVERS MANAGE, V64, P499, DOI 10.1016/j.enconman.2012.02.016; Kim SH, 2013, BUILD ENVIRON, V67, P111, DOI 10.1016/j.buildenv.2013.05.005; Ashok S, 2003, ENERGY, V28, P115, DOI 10.1016/S0360-5442(02)00109-3; BERNDT EK, 1974, ANN ECON SOC MEAS, V3, P653; Uemura K, 2013, 2013 IEEE CONGRESS ON EVOLUTIONARY COMPUTATION (CEC), P2887; Sanaye S, 2013, ENERG BUILDINGS, V60, P100, DOI 10.1016/j.enbuild.2012.12.040; Takahashi T, 2013, PHYSCS PROC, V46, P239, DOI 10.1016/j.phpro.2013.07.060; Wang SW, 2008, HVAC&R RES, V14, P3, DOI 10.1080/10789669.2008.10390991; Facci AL, 2014, ENRGY PROCED, V45, P1295, DOI 10.1016/j.egypro.2014.01.135; Wang JJ, 2010, APPL ENERG, V87, P3668, DOI 10.1016/j.apenergy.2010.06.021; Stacey A, 2003, IEEE C EVOL COMPUTAT, P1425; Shaikh PH, 2014, RENEW SUST ENERG REV, V34, P409, DOI 10.1016/j.rser.2014.03.027; Wakui T, 2014, ENERGY, V68, P29, DOI 10.1016/j.energy.2014.01.110; Lemort V, 2006, ENERG CONVERS MANAGE, V47, P3619, DOI 10.1016/j.enconman.2006.01.015; Palacio SN, 2014, APPL ENERG, V129, P228, DOI 10.1016/j.apenergy.2014.04.089; Candanedo JA, 2013, APPL ENERG, V111, P1032, DOI 10.1016/j.apenergy.2013.05.081; Zhou Z, 2013, APPL THERM ENG, V53, P387, DOI 10.1016/j.applthermaleng.2012.01.067; Ferrari ML, 2014, APPL ENERG, V130, P670, DOI 10.1016/j.apenergy.2014.02.025; Bellman R., 1957, DYNAMIC PROGRAMMING; Bradley S.P., 1977, APPL MATH PROGRAMMIN, P320; Braun JE, 2003, J SOL ENERG-T ASME, V125, P292, DOI 10.1115/1.1592184; Broyden C.G., 1970, IMA J APPL MATH, P76; Cornuejols G., 2007, MATH PROGRAM, V112, P3, DOI 10.1007/s10107-006-0086-0; DAKIN RJ, 1965, COMPUT J, V8, P250, DOI 10.1093/comjnl/8.3.250; DURAN MA, 1986, MATH PROGRAM, V36, P307, DOI 10.1007/BF02592064; Geoffrion A. M., 1972, Journal of Optimization Theory and Applications, V10, DOI 10.1007/BF00934810; GOLDFARB D, 1970, MATH COMPUT, V24, P23, DOI 10.2307/2004873; Henze G. P., 1997, HVAC&R RES, V3, P233, DOI 10.1080/10789669.1997.10391376; Henze GP, 2004, INT J THERM SCI, V43, P173, DOI DOI 10.1016/J.IJTHERMALSCI.2003.06.001; Higashi N., 2003, P 2003 IEEE SWARM IN, p[72, 79]; Holland J. H., 1992, ADAPTATION NATURAL A; Ikegami T., 2012, POW SYST TECHN POWER; Lee J, 2012, IMA VOL MATH APPL, V154, P1, DOI 10.1007/978-1-4614-1927-3; Ma Y., 2009, DEC CONTR 2009 HELD; Mcdowall R., 2007, FUNDAMENTALS OF HVAC; Miranda V, 2002, P IEEE C EV COMP, V2, P1080, DOI 10.1109/CEC.2002.1004393; SHANNO DF, 1970, MATH COMPUT, V24, P647, DOI 10.2307/2004840; Shi YH, 1998, IEEE C EVOL COMPUTAT, P69, DOI 10.1109/ICEC.1998.699146; Yang X.S., 2010, NATURE INSPIRED META, P4; Yun HT, 2011, ENRGY PROCED, V12, DOI 10.1016/j.egypro.2011.10.126	63	0	0	ELSEVIER SCIENCE SA	LAUSANNE	PO BOX 564, 1001 LAUSANNE, SWITZERLAND	0378-7788	1872-6178		ENERG BUILDINGS	Energy Build.	NOV 1	2015	106				SI		225	233		10.1016/j.enbuild.2015.07.031		9	Construction & Building Technology; Energy & Fuels; Engineering, Civil	Construction & Building Technology; Energy & Fuels; Engineering	CU2IB	WOS:000363346100022		
J	Ariyanti, NA; Hoa, VQ; Khrustaleva, LI; Hirata, S; Abdelrahman, M; Ito, S; Yamauchi, N; Shigyo, M				Ariyanti, Nur Aeni; Vu Quynh Hoa; Khrustaleva, Ludmila I.; Hirata, Sho; Abdelrahman, Mostafa; Ito, Shin-ichi; Yamauchi, Naoki; Shigyo, Masayoshi			Production and characterization of alien chromosome addition lines in Allium fistulosum carrying extra chromosomes of Allium roylei using molecular and cytogenetic analyses	EUPHYTICA			English	Article						Allium fistulosum; Allium roylei; Alien addition lines; Antifungal activity; Biochemical variation	L. AGGREGATUM GROUP; CEPA L; GENE LOCI; ONION; INTROGRESSION; LOCATIONS; RESISTANCE; NOMENCLATURE; POLYMORPHISM; ASSIGNMENT	Allium roylei was employed for the production of alien chromosome addition lines in A. fistulosum. Interspecific hybridization between A. fistulosum and A. roylei successfully produced F-1 hybrids. Chromosome doubling of an F-1 hybrid was carried out to produce amphidiploids. After two times backcrossing of the amphidiploids with A. fistulosum, a BC2 generation was obtained with chromosome numbers (2n) ranging from 16 to 23. Alien monosomic addition lines (AMAL, FF + nR, 2n = 17) appeared with the highest frequency. Furthermore, multiple addition lines (MAL, 2n = 18-23) were also observed with lower frequencies. Five AMALs (FF + 1R, +3R, +4R, +5R, and +8R) and ten MALs (2n = 18-23) were characterized using isozyme and DNA markers. The extra chromosomes from A. roylei clearly altered the biochemical characteristics of the MALs. Variations in sugar, cysteine sulfoxide, and flavonoid contents were observed among the MALs in various amounts. Allium fistulosum-A. roylei allotriploids (2n = 24, FFR) showed significantly higher saponin content and antifungal activities of saponin extracts against isolates of Fusarium oxysporum f. sp. cepae in comparison with A. fistulosum. This first report of A. fistulosum-A. roylei addition lines opens the possibility of developing novel A. fistulosum cultivars with enhanced nutritional value and disease resistance.	[Ariyanti, Nur Aeni; Hirata, Sho; Abdelrahman, Mostafa; Ito, Shin-ichi; Yamauchi, Naoki; Shigyo, Masayoshi] Tottori Univ, United Grad Sch Agr Sci, Tottori 6808553, Japan; [Vu Quynh Hoa] Hanoi Univ Agr, Fac Agron, Dept Vegetable Flower Fruit Crop Sci, Hanoi, Vietnam; [Khrustaleva, Ludmila I.] Russian State Agr Univ, Moscow Timiryazev Agr Acad, Moscow, Russia; [Ito, Shin-ichi; Yamauchi, Naoki; Shigyo, Masayoshi] Yamaguchi Univ, Fac Agr, Yamaguchi 7538515, Japan	Shigyo, M (reprint author), Yamaguchi Univ, Fac Agr, 1677-1 Yoshida, Yamaguchi 7538515, Japan.	shigyo@yamaguchi-u.ac.jp					SHIGYO M, 1995, JPN J GENET, V70, P399, DOI 10.1266/jjg.70.399; Yaguchi S, 2009, GENES GENET SYST, V84, P43, DOI 10.1266/ggs.84.43; Shigyo M, 1997, GENES GENET SYST, V72, P149, DOI 10.1266/ggs.72.149; Scholten OE, 2007, EUPHYTICA, V156, P345, DOI 10.1007/s10681-007-9383-9; Tsukazaki H, 2008, THEOR APPL GENET, V117, P1213, DOI 10.1007/s00122-008-0849-5; Masuzaki S, 2006, GENES GENET SYST, V81, P255, DOI 10.1266/ggs.81.255; Hang TTM, 2004, GENES GENET SYST, V79, P263, DOI 10.1266/ggs.79.263; Khrustaleva LI, 2000, THEOR APPL GENET, V100, P17, DOI 10.1007/s001220050003; KALKMAN ER, 1984, GENETICA, V65, P141, DOI 10.1007/BF00135278; Vu HQ, 2012, THEOR APPL GENET, V124, P1241, DOI 10.1007/s00122-011-1783-5; MCCOLLUM GD, 1982, BOT GAZ, V143, P238; Masuzaki S, 2006, HORTSCIENCE, V41, P315; Shigyo M, 1997, GENES GENET SYST, V72, P181, DOI 10.1266/ggs.72.181; Dissanayake MLMC, 2009, J GEN PLANT PATHOL, V75, P37, DOI 10.1007/s10327-008-0135-z; SHIGYO M, 1994, JPN J GENET, V69, P417, DOI 10.1266/jjg.69.417; van Heusden AW, 2000, THEOR APPL GENET, V100, P480, DOI 10.1007/s001220050062; van Heusden AW, 2000, THEOR APPL GENET, V100, P118, DOI 10.1007/s001220050017; Khrustaleva LI, 1998, THEOR APPL GENET, V96, P8, DOI 10.1007/s001220050702; DEVRIES JN, 1992, EUPHYTICA, V62, P127; DEVRIES JN, 1990, EUPHYTICA, V49, P1; Yaguchi S, 2008, PLANT CELL PHYSIOL, V49, P730, DOI 10.1093/pcp/pcn048; Galvan GA, 2008, EUR J PLANT PATHOL, V121, P499, DOI 10.1007/s10658-008-9270-9; McCallum J, 2007, THEOR APPL GENET, V114, P815, DOI 10.1007/s00122-006-0479-8; Vu HQ, 2011, PLANT BREEDING, V130, P469, DOI 10.1111/j.1439-0523.2011.01855.x; Block E, 2010, GARLIC AND OTHER ALLIUMS: THE LORE AND THE SCIENCE, P1; Ebrahimzadeh H, 1998, INDIAN DRUGS, V35, P379; Inden H, 1990, ONIONS ALLIED CROPS, V3, P159; Kik C., 2002, P81, DOI 10.1079/9780851995106.0081; Maude R.B., 1990, ONIONS ALLIED CROPS, VII, P173; [Anonymous], 1962, PHYSIOL PLANTARUM, DOI DOI 10.1111/J.1399-3054.1962.TB08052.X; Singh R.J., 2003, PLANT CYTOGENETICS; Vu HQ, 2013, GENET RESOUR CROP EV, DOI [10.1007/s10722-012-9920-9, DOI 10.1007/S10722-012-9920-9]	32	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	NOV	2015	206	2					343	355		10.1007/s10681-015-1476-2		13	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CU5CD	WOS:000363548400006		
J	Onodera, Y; Arakawa, T; Yui-Kurino, R; Yamamoto, MP; Kitazaki, K; Ebe, S; Matsunaga, M; Taguchi, K; Kuroda, Y; Yamashita, S; Sakai, T; Kinoshita, T; Mikami, T; Kubo, T				Onodera, Yasuyuki; Arakawa, Takumi; Yui-Kurino, Rika; Yamamoto, Masayuki P.; Kitazaki, Kazuyoshi; Ebe, Shigehiko; Matsunaga, Muneyuki; Taguchi, Kazunori; Kuroda, Yosuke; Yamashita, Shiko; Sakai, Tomoyuki; Kinoshita, Toshiro; Mikami, Tetsuo; Kubo, Tomohiko			Two male sterility-inducing cytoplasms of beet (Beta vulgaris) are genetically distinct but have closely related mitochondrial genomes: implication of a substoichiometric mitochondrial DNA molecule in their evolution	EUPHYTICA			English	Article						F-1 hybrid; Mitochondrial evolution; Mitochondrial gene; Nuclear-cytoplasmic interaction; Plant mitochondria; Substoichiometric DNA	SUGAR-BEET; FERTILITY RESTORATION; WILD BEETS; GENE; MAIZE; DIVERSITY; L.; SEQUENCE; PLANTS; RICE	I-12CMS(2) and I-12CMS(3) are sugar beet lines with different sources of cytoplasmic male sterility (CMS) derived from wild beets in Turkey and Pakistan, respectively. We established that I-12CMS(2) has a genetically distinct cytoplasm, but its mitochondrial genome is very similar to I-12CMS(3). Male fertility was assessed in F-1 hybrids produced with a common pollen parent. Fertility in the F-1's carrying the I-12CMS(3) cytoplasm exceeded that of the F-1's with the I-12CMS(2) cytoplasm. Organization of the I-12CMS(2) and I-12CMS(3) mitochondrial genomes were compared based on their physical maps. Mitochondrial genomes of the two strains were largely collinear, except for a large deletion in the noncoding region of I-12CMS(2). Because a mitochondrial orf129 in the I-12CMS(3) cytoplasm is associated with a male sterility phenotype and preservation of orf129 was evident in I-12CMS(2), I-12CMS(2) orf129 was investigated in detail. I-12CMS(2) plants contained three to five times more ORF129 protein than did I-12CMS(3) plants. A single nucleotide substitution, present in the putative promoter region of orf129, appeared to be responsible for the differential accumulation of orf129 transcript. A long N-terminal extension of atp6 is a common feature of some beet CMSs and is found in I-12CMS(2), but the amino acid sequence is unique. I-12CMS(3) mitochondria, but not I-12CMS(2) mitochondria, were found to be heteroplasmic. This heteroplasmy is characterized by a substoichiometric DNA molecule(s) that has at least two I-12CMS(2)-type mitochondrial loci, suggesting the possibility that the I-12CMS(2) mitochondrial genome might have evolved from such a substoichiometric DNA molecule in I-12CMS(3) mitochondria.	[Onodera, Yasuyuki; Arakawa, Takumi; Yui-Kurino, Rika; Yamamoto, Masayuki P.; Kitazaki, Kazuyoshi; Matsunaga, Muneyuki; Yamashita, Shiko; Sakai, Tomoyuki; Mikami, Tetsuo; Kubo, Tomohiko] Hokkaido Univ, Genet Engn Lab, Res Fac Agr, Sapporo, Hokkaido 0608589, Japan; [Ebe, Shigehiko; Kinoshita, Toshiro] Hokkaido Univ, Plant Breeding Inst, Res Fac Agr, Sapporo, Hokkaido 0608589, Japan; [Taguchi, Kazunori; Kuroda, Yosuke] Natl Agr & Food Res Org, Hokkaido Agr Res Ctr, Memuro, Hokkaido 0820081, Japan	Kubo, T (reprint author), Hokkaido Univ, Genet Engn Lab, Res Fac Agr, Sapporo, Hokkaido 0608589, Japan.	tomohiko@abs.agr.hokudai.ac.jp	Kubo, Tomohiko/B-7738-2012		JSPS KAKENHI [25292001]	Part of this work was conducted at the Center for Genome Dynamics, Faculty of Science, Hokkaido University. This work was supported in part by JSPS KAKENHI Grant Number 25292001.	Muller K, 2013, PLANT MOL BIOL, V81, P495, DOI 10.1007/s11103-013-0018-3; MIKAMI T, 1985, THEOR APPL GENET, V71, P166, DOI 10.1007/BF00252051; Dohm JC, 2014, NATURE, V505, P546, DOI 10.1038/nature12817; Darracq A, 2011, GENOME BIOL EVOL, V3, P723, DOI 10.1093/gbe/evr042; Bosemark N. O., 2006, Sugar beet, P50, DOI 10.1002/9780470751114.ch4; LEVINGS CS, 1993, PLANT CELL, V5, P1285; SMALL ID, 1987, EMBO J, V6, P865; LAUGHNAN JR, 1983, ANNU REV GENET, V17, P27, DOI 10.1146/annurev.ge.17.120183.000331; Lange H, 2009, TRENDS PLANT SCI, V14, P497, DOI 10.1016/j.tplants.2009.06.007; Matsunaga M, 2011, PLANT CELL REP, V30, P231, DOI 10.1007/s00299-010-0912-y; KUBO T, 1995, CURR GENET, V28, P235, DOI 10.1007/BF00309782; Yamamoto MP, 2008, PLANT J, V54, P1027, DOI 10.1111/j.1365-313X.2008.03473.x; Janska H, 1998, PLANT CELL, V10, P1163; Cheng DY, 2009, EUPHYTICA, V165, P345, DOI 10.1007/s10681-008-9796-0; Kubo T, 2011, CRIT REV PLANT SCI, V30, P378, DOI 10.1080/07352689.2011.587727; Kawanishi Y, 2010, GENOME, V53, P251, DOI [10.1139/g10-003, 10.1139/G10-003]; LASER KD, 1972, BOT REV, V38, P425, DOI 10.1007/BF02860010; Cheng DY, 2011, GENET RESOUR CROP EV, V58, P553, DOI 10.1007/s10722-010-9598-9; Hagihara E, 2005, THEOR APPL GENET, V111, P250, DOI 10.1007/s00122-005-2010-z; Moritani M, 2013, MOL BREEDING, V32, P91, DOI 10.1007/s11032-013-9854-8; Kubo T, 2000, NUCLEIC ACIDS RES, V28, P2571, DOI 10.1093/nar/28.13.2571; Nishizawa S, 2007, GENETICS, V177, P1703, DOI 10.1534/genetics.107.076380; HALLDEN C, 1992, THEOR APPL GENET, V85, P139, DOI 10.1007/BF00222851; Chen LT, 2014, ANNU REV PLANT BIOL, V65, P579, DOI 10.1146/annurev-arplant-050213-040119; Hanson MR, 2004, PLANT CELL, V16, pS154, DOI 10.1105/tpc.015966; Kubo T, 2008, MITOCHONDRION, V8, P5, DOI 10.1016/j.mito.2007.10.006; Schnable PS, 1998, TRENDS PLANT SCI, V3, P175, DOI 10.1016/S1360-1385(98)01235-7; Itabashi E, 2009, PLANT CELL REP, V28, P233, DOI 10.1007/s00299-008-0625-7; Allen JO, 2007, GENETICS, V177, P1173, DOI 10.1534/genetics.107.073312; Onodera Y, 1999, J PLANT PHYSIOL, V155, P656; LHomme Y, 1997, CURR GENET, V31, P325, DOI 10.1007/s002940050212; Yamamoto MP, 2005, MOL GENET GENOMICS, V273, P342, DOI 10.1007/s00438-005-1140-y; Kuhn J, 2002, NUCLEIC ACIDS RES, V30, P439, DOI 10.1093/nar/30.2.439; Bosemark NO, 1979, P C BROAD GEN BAS CR, P29; Budar F, 2006, FLOWERING ITS MANIPU, P147, DOI 10.1002/9780470988602.ch7; Christensen CA, 2014, GENOME BIOL EVOL, V6, P1448; Doyle J.J., 1990, FOCUS, V12, P13; DUVICK DONALD N., 1965, ADVANCE GENET, V13, P1, DOI 10.1016/S0065-2660(08)60046-2; Fenart S, 2006, P R SOC B, V273, P1391, DOI 10.1098/rspb.2005.3464; Fujii S, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-209; Gagliardi D, 2007, PLANT MITOCHONDRIA, P50, DOI 10.1002/9780470986592.ch3; OWEN F. V., 1942, American Journal of Botany, V29, pp; Sambrook J, 1989, SPRING; Touzet P, 2012, ADV BOT RES, V63, P71, DOI 10.1016/B978-0-12-394279-1.00004-1	44	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0014-2336	1573-5060		EUPHYTICA	Euphytica	NOV	2015	206	2					365	379		10.1007/s10681-015-1484-2		15	Agronomy; Plant Sciences; Horticulture	Agriculture; Plant Sciences	CU5CD	WOS:000363548400008		
J	Leicht, CA; Kouda, K; Umemoto, Y; Banno, M; Kinoshita, T; Moriki, T; Nakamura, T; Bishop, NC; Goosey-Tolfrey, VL; Tajima, F				Leicht, C. A.; Kouda, K.; Umemoto, Y.; Banno, M.; Kinoshita, T.; Moriki, T.; Nakamura, T.; Bishop, N. C.; Goosey-Tolfrey, V. L.; Tajima, F.			Hot water immersion induces an acute cytokine response in cervical spinal cord injury	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY			English	Article						Cytokines; Immune function; Tetraplegia; Non-exercise intervention	CRANK ERGOMETER EXERCISE; KILLER-CELL ACTIVITY; PLASMA INTERLEUKIN-6; ADHESION MOLECULES; STRENUOUS EXERCISE; ENDOCRINE ORGAN; SKELETAL-MUSCLE; IMMUNE FUNCTION; HYPERTHERMIA; REDISTRIBUTION	The dysfunctional sympathetic nervous system in individuals with cervical spinal cord injury (CSCI) impairs adrenergic responses and may, therefore, contribute to the blunted post-exercise cytokine response. The purpose of this study was to investigate an alternative way to exercise to induce an acute cytokine response by passive core temperature elevation in CSCI. Seven male participants with a motor complete CSCI and 8 male able-bodied controls were immersed for 60 min in water set at a temperature 2 A degrees C above the individuals' resting oesophageal temperature. Blood was collected pre, post, and every hour up to 4 h post-immersion. Hot water immersion resulted in an IL-6 plasma concentration mean increase of 133 +/- A 144 % in both groups (P = 0.001). On a group level, IL-6 plasma concentrations were 68 +/- A 38 % higher in CSCI (P = 0.06). In both groups, IL-8 increased by 14 +/- A 11 % (P = 0.02) and IL-1ra by 18 +/- A 17 % (P = 0.05). Catecholamine plasma concentrations were significantly reduced in CSCI (P < 0.05) and did not increase following immersion. Passive elevation of core temperature acutely elevates IL-6, IL-8 and IL-1ra in CSCI despite a blunted adrenergic response, which is in contrast to earlier exercise interventions in CSCI. The present study lays the foundation for future studies to explore water immersion as an alternative to exercise to induce an acute cytokine response in CSCI.	[Kouda, K.; Umemoto, Y.; Banno, M.; Kinoshita, T.; Moriki, T.; Nakamura, T.; Tajima, F.] Wakayama Med Univ, Dept Rehabil Med, Wakayama, Japan; [Leicht, C. A.; Bishop, N. C.; Goosey-Tolfrey, V. L.] Univ Loughborough, Peter Harrison Ctr Disabil Sport, Sch Sport Exercise & Hlth Sci, Loughborough, Leics, England	Leicht, CA (reprint author), Univ Loughborough, Peter Harrison Ctr Disabil Sport, Sch Sport Exercise & Hlth Sci, Loughborough, Leics, England.	c.a.leicht@lboro.ac.uk			Joint Usage/Research Center of Sports for Persons with Impairments (Tokyo, Japan); Research Center of Sports Medicine and Balneology (Natchi-Katsuura, Japan)	We thank all participants for their willingness to take part in this study. Appreciation is extended to the physiotherapy and medical teams in Nachi-Katsuura and Wakayama for their contribution during laboratory testing. This study was supported by grants from the Joint Usage/Research Center of Sports for Persons with Impairments (Tokyo, Japan), and the Research Center of Sports Medicine and Balneology (Natchi-Katsuura, Japan).	Gibson AE, 2008, SPINAL CORD, V46, P616, DOI 10.1038/sc.2008.32; MCCARTHY DA, 1988, SPORTS MED, V6, P333; Gass EM, 2002, SPINAL CORD, V40, P474, DOI 10.1038/sj.sc.3101341; Laing SJ, 2008, J APPL PHYSIOL, V104, P20, DOI 10.1152/japplphysiol.00792.2007; DILL DB, 1974, J APPL PHYSIOL, V37, P247; Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189; Banno M, 2012, SPINAL CORD, V50, P533, DOI 10.1038/sc.2011.188; Starkie RL, 2001, AM J PHYSIOL-CELL PH, V281, pC1233; Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041; Welc SS, 2013, EXP PHYSIOL, V98, P359, DOI 10.1113/expphysiol.2012.068189; Zhang HG, 2008, CANCER LETT, V271, P191, DOI 10.1016/j.canlet.2008.05.026; Kruger K, 2008, BRAIN BEHAV IMMUN, V22, P324, DOI 10.1016/j.bbi.2007.08.008; Walsh NP, 2006, SPORTS MED, V36, P941, DOI 10.2165/00007256-200636110-00003; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Steensberg A, 2003, AM J PHYSIOL-ENDOC M, V285, pE433, DOI 10.1152/ajpendo.00074.2003; Cardenas DD, 2004, ARCH PHYS MED REHAB, V85, P1757, DOI 10.1016/j.apmr.2004.03.016; Paulson TAW, 2013, MED SCI SPORT EXER, V45, P1649, DOI 10.1249/MSS.0b013e31828f9bbb; Brenner IKM, 1999, J APPL PHYSIOL, V87, P699; Steensberg A, 2001, AM J PHYSIOL-CELL PH, V281, pC1001; Kliesch WF, 1996, PARAPLEGIA, V34, P82; Kappel M, 1998, EUR J APPL PHYSIOL O, V77, P149; Chen Q, 2006, NAT IMMUNOL, V7, P1299, DOI 10.1038/ni1406; Shephard RJ, 2003, SPORTS MED, V33, P261, DOI 10.2165/00007256-200333040-00002; KAPPEL M, 1991, CLIN EXP IMMUNOL, V84, P175; Yamanaka M, 2010, SPINAL CORD, V48, P734, DOI 10.1038/sc.2010.13; Rhind SG, 1999, J APPL PHYSIOL, V87, P1178; Segal JL, 1997, ARCH PHYS MED REHAB, V78, P44, DOI 10.1016/S0003-9993(97)90008-3; Pedersen BK, 2008, PHYSIOL REV, V88, P1379, DOI 10.1152/physrev.90100.2007; Davies AL, 2007, ARCH PHYS MED REHAB, V88, P1384, DOI 10.1016/j.apmr.2007.08.004; Kesiktas N, 2004, NEUROREHAB NEURAL RE, V18, P268, DOI 10.1177/1545968304270002; Bhambhani Y, 2002, SPORTS MED, V32, P23, DOI 10.2165/00007256-200232010-00002; Kouda K, 2012, EUR J APPL PHYSIOL, V112, P597, DOI 10.1007/s00421-011-2004-2; FOSTER NK, 1986, J APPL PHYSIOL, V61, P2218; Welc SS, 2012, AM J PHYSIOL-CELL PH, V303, pC455, DOI 10.1152/ajpcell.00028.2012; Leicht CA, 2013, EXERC IMMUNOL REV, V19, P146; Nagao F, 2000, AM J PHYSIOL-REG I, V279, pR1251	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-6319	1439-6327		EUR J APPL PHYSIOL	Eur. J. Appl. Physiol.	NOV	2015	115	11					2243	2252		10.1007/s00421-015-3206-9		10	Physiology; Sport Sciences	Physiology; Sport Sciences	CT8HZ	WOS:000363057400001		
J	Shimizu, H; Saitoh, T; Machida, S; Kako, S; Doki, N; Mori, T; Sakura, T; Kanda, Y; Kanamori, H; Miyawaki, S; Okamoto, S				Shimizu, Hiroaki; Saitoh, Takayuki; Machida, Shinichiro; Kako, Shinichi; Doki, Noriko; Mori, Takehiko; Sakura, Toru; Kanda, Yoshinobu; Kanamori, Heiwa; Miyawaki, Shuichi; Okamoto, Shinichiro		KSGCT	Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis	EUROPEAN JOURNAL OF HAEMATOLOGY			English	Article						mixed phenotype acute leukemia; allogeneic hematopoietic stem cell transplantation; outcomes; matched-pair analysis; Philadelphia chromosome	BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; PRIMARY INDUCTION FAILURE; COMPLETE REMISSION; CLASSIFICATION; CHILDREN; IMATINIB; THERAPY	Adult patients with mixed phenotype acute leukemia (MPAL) have a poor prognosis, and the therapeutic role of allogeneic stem cell transplantation (allo-SCT) for MPAL remains to be elucidated. Thus, we retrospectively assessed the efficacy of allo-SCT for MPAL. Eighteen patients with MPAL were identified from the transplant outcome database of Kanto Study Group for Cell Therapy (KSGCT). We also selected 215 patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) as control cohorts using an optimal matching method. The 5-yr overall survival (OS) rate of patients with MPAL was 48.1%, and patients in remission at the time of transplant showed significantly better survival than those not in remission (5-yr OS: 71.8% vs. 0%, P=0.001). No significant differences were seen in OS when stratifying patients according to immunophenotype, cytogenetic abnormalities, or the type of induction therapy. The 5-yr OS rate of patients with MPAL was not significantly different compared with AML control patients (48.1% vs. 48.1%; P=0.855) or ALL control patients (48.1% vs. 37.8%; P=0.426). These results suggested that allo-SCT is an effective treatment for MPAL, especially early in the disease course, and innovative transplant approaches are warranted to improve the transplant outcome of patients with MPAL who are not in remission.	[Shimizu, Hiroaki; Saitoh, Takayuki] Gunma Univ, Dept Med & Clin Sci, Maebashi, Gunma 3718511, Japan; [Machida, Shinichiro] Tokai Univ, Sch Med, Dept Hematol & Oncol, Yokohama, Kanagawa 2591100, Japan; [Kako, Shinichi; Kanda, Yoshinobu] Jichi Med Univ, Saitama Med Ctr, Div Hematol, Saitama, Japan; [Doki, Noriko] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Div Hematol, Tokyo, Japan; [Mori, Takehiko; Okamoto, Shinichiro] Keio Univ, Sch Med, Dept Med, Div Hematol, Tokyo 160, Japan; [Sakura, Toru] Saiseikai Maebashi Hosp, Leukemia Res Ctr, Gunma, Japan; [Kanamori, Heiwa] Kanagawa Canc Ctr, Dept Hematol, Yokohama, Kanagawa, Japan; [Miyawaki, Shuichi] Tokyo Metropolitan Otsuka Hosp, Dept Internal Med, Tokyo, Japan	Shimizu, H (reprint author), Gunma Univ, Dept Med & Clin Sci, 3-39-22 Showa, Maebashi, Gunma 3718511, Japan.	hiroakis@ked.biglobe.ne.jp					SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; Hansen BB, 2006, J COMPUT GRAPH STAT, V15, P609, DOI 10.1198/106186006X137047; BENE MC, 1995, LEUKEMIA, V9, P1783; Yanada M, 2006, J CLIN ONCOL, V24, P460, DOI 10.1200/JCO.2005.03.2177; Thomas DA, 2004, BLOOD, V103, P4396, DOI 10.1182/blood-2003-08-2958; Mejstrikova E, 2010, HAEMATOL-HEMATOL J, V95, P928, DOI 10.3324/haematol.2009.014506; Bornhauser M, 2012, LANCET ONCOL, V13, P1035, DOI 10.1016/S1470-2045(12)70349-2; FORMAN SJ, 1991, J CLIN ONCOL, V9, P1570; Gluckman E, 2009, BRIT J HAEMATOL, V147, P192, DOI 10.1111/j.1365-2141.2009.07780.x; Matutes E, 2011, BLOOD, V117, P3163, DOI 10.1182/blood-2010-10-314682; Slavin S, 1998, BLOOD, V91, P756; Zhang HR, 2012, BIOL BLOOD MARROW TR, V18, P1164, DOI 10.1016/j.bbmt.2012.01.015; Duval M, 2010, J CLIN ONCOL, V28, P3730, DOI 10.1200/JCO.2010.28.8852; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Wang Y, 2011, INT J HEMATOL, V94, P552, DOI 10.1007/s12185-011-0953-1; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Weinberg OK, 2010, LEUKEMIA, V24, P1844, DOI 10.1038/leu.2010.202; Rubnitz JE, 2009, BLOOD, V113, P5083, DOI 10.1182/blood-2008-10-187351; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Swerdlow SH, 2008, WHO CLASSIFICATION T; Yan LZ, 2012, HAEMATOL-HEMATOL J, V97, P1708, DOI 10.3324/haematol.2012.064485	21	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0902-4441	1600-0609		EUR J HAEMATOL	Eur. J. Haematol.	NOV	2015	95	5					455	460		10.1111/ejh.12516		6	Hematology	Hematology	CU2CD	WOS:000363328800011		
J	Yamamoto, H; Natsume, J; Kidokoro, H; Ishihara, N; Suzuki, M; Tsuji, T; Kubota, T; Yamada, A; Ozeki, M; Kato, Z; Kawamura, Y; Yoshikawa, T; Okumura, A; Ando, N; Saitoh, S; Takahashi, Y; Watanabe, K; Kojima, S				Yamamoto, Hiroyuki; Natsume, Jun; Kidokoro, Hiroyuki; Ishihara, Naoko; Suzuki, Motomasa; Tsuji, Takeshi; Kubota, Tetsuo; Yamada, Akio; Ozeki, Michio; Kato, Zenichiro; Kawamura, Yoshiki; Yoshikawa, Tetsushi; Okumura, Akihisa; Ando, Naoki; Saitoh, Shinji; Takahashi, Yoshiyuki; Watanabe, Kazuyoshi; Kojima, Seiji			Clinical and neuroimaging findings in children with posterior reversible encephalopathy syndrome	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article						Posterior reversible encephalopathy syndrome; Diffusion-weighted MRI; ADC; Epilepsy	LEUKOENCEPHALOPATHY SYNDROME; HYPERTENSIVE ENCEPHALOPATHY	Objective: To clarity the clinical and radiological spectrum of posterior reversible encephalopathy syndrome (PRES) in children, and to identify the prognostic factors. Methods: The records of 40 children with PRES were reviewed. Acute clinical symptoms, MRI including apparent diffusion coefficient (ADC) maps in the acute and follow-up periods and neurological sequelae, including epilepsy, were noted. Results: Age at onset ranged from 2 to 16 years. Underlying disorders were hematological or neoplastic disorders (n = 20), renal diseases (n = 14) and others (n = 6). In the acute period, 31 patients had seizures, 25 had altered consciousness, 11 had visual disturbances and 10 had headache. Of 29 patients who had ADC maps in the acute period, 13 had reduced diffusivity as shown by ADC within PRES lesions. Of 26 patients with follow-up MAI, 13 had focal gliosis or cortical atrophy. No patients had motor impairment, and four patients had focal epilepsy. No clinical variables were associated with focal gliosis or cortical atrophy on follow-up MRI, but lesional ADC reduction in the acute period was prognostic for focal gliosis or cortical atrophy on follow-up MRI (p = 0.005). Conclusions: To the best of our knowledge, this is the largest cohort study to date involving PRES in children. Acute symptoms in pediatric patients are similar to those reported in adults, but altered consciousness was more frequent in children. Lesional ADC reduction in the acute period was common and was a good predictor of later, irreversible MRI lesions. (C) 2015 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	[Yamamoto, Hiroyuki; Natsume, Jun; Kidokoro, Hiroyuki; Ishihara, Naoko; Takahashi, Yoshiyuki; Watanabe, Kazuyoshi; Kojima, Seiji] Nagoya Univ, Grad Sch Med, Dept Pediat, Nagoya, Aichi 4668550, Japan; [Suzuki, Motomasa] Aichi Childrens Hlth & Med Ctr, Dept Neurol, Obu, Japan; [Tsuji, Takeshi] Okazaki City Hosp, Dept Pediat, Okazaki, Aichi, Japan; [Kubota, Tetsuo] Anjo Kosei Hosp, Dept Pediat, Anjo, Japan; [Yamada, Akio] Social Insurance Chukyo Hosp, Dept Pediat, Nagoya, Aichi, Japan; [Ozeki, Michio; Kato, Zenichiro] Gifu Univ, Dept Pediat, Grad Sch Med, Gifu, Japan; [Kawamura, Yoshiki; Yoshikawa, Tetsushi] Fujita Hlth Univ, Sch Med, Dept Pediat, Toyoake, Aichi 47011, Japan; [Okumura, Akihisa] Aichi Med Univ, Dept Pediat, Nagakute, Aichi 48011, Japan; [Okumura, Akihisa] Juntendo Univ, Sch Med, Dept Pediat, Tokyo 113, Japan; [Ando, Naoki; Saitoh, Shinji] Nagoya City Univ, Grad Sch Med Sci, Dept Pediat & Neonatol, Nagoya, Aichi, Japan	Yamamoto, H (reprint author), Nagoya Univ, Grad Sch Med, Dept Pediat, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	h-yamamoto@med.nagoya-u.ac.jp					Covarrubias DJ, 2002, AM J NEURORADIOL, V23, P1038; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; Sharma A, 2010, NEURORADIOLOGY, V52, P855, DOI 10.1007/s00234-009-0632-6; Ishikura K, 2011, CLIN EXP NEPHROL, V15, P275, DOI 10.1007/s10157-010-0380-2; Kastrup O, 2012, J NEUROL, V259, P1383, DOI 10.1007/s00415-011-6362-9; Hefzy HM, 2009, AM J NEURORADIOL, V30, P1371, DOI 10.3174/ajnr.A1588; Yamada A, 2012, PEDIATR NEPHROL, V27, P277, DOI 10.1007/s00467-011-1974-y; Liman TG, 2012, EUR J NEUROL, V19, P935, DOI 10.1111/j.1468-1331.2011.03629.x; McKinney AM, 2012, AM J NEURORADIOL, V33, P896, DOI 10.3174/ajnr.A2886; Zhang HL, 2010, LANCET NEUROL, V9, P1046, DOI 10.1016/S1474-4422(10)70262-3; Schwartz RB, 1998, AM J NEURORADIOL, V19, P859; Lee VH, 2008, ARCH NEUROL-CHICAGO, V65, P205, DOI 10.1001/archneurol.2007.46; Mukherjee P, 2001, RADIOLOGY, V219, P756; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Ni J, 2011, J NEUROIMAGING, V21, P219, DOI 10.1111/j.1552-6569.2010.00497.x; Vaughan CJ, 2000, LANCET, V356, P411, DOI 10.1016/S0140-6736(00)02539-3; Siebert E, 2013, EUR J PAEDIATR NEURO, V17, P169, DOI 10.1016/j.ejpn.2012.08.003; Bartynski WS, 2007, AM J NEURORADIOL, V28, P1320, DOI 10.3174/ajnr.A0549; McKinney AM, 2007, AM J ROENTGENOL, V189, P904, DOI 10.2214/AJR.07.2024; Stevens CJ, 2012, BRIT J RADIOL, V85, P1566, DOI 10.1259/bjr/25273221; Prasad N, 2003, PEDIATR NEPHROL, V18, P1161, DOI 10.1007/s00467-003-1243-9; Benziada-Boudour A, 2009, J NEURORADIOLOGY, V36, P102, DOI 10.1016/j.neurad.2008.08.003; Bo Gao, 2012, Acta Neurol Belg, V112, P281, DOI 10.1007/s13760-012-0060-y; Legriel S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044534; Li R, 2013, J CLIN NEUROSCI, V20, P242, DOI 10.1016/j.jocn.2012.02.023; Liman TG, 2011, J NEUROL, V259, P155; National High Blood Pressure Education Program Working Group on High Blood Pressure in C Adolescents, 2004, PEDIATRICS, V114, P555, DOI DOI 10.1542/PEDS.114.2.S2.555; Ohta T, 1974, No Shinkei Geka, V2, P623; Pavlakis SG, 1999, J CHILD NEUROL, V14, P277, DOI 10.1177/088307389901400502	29	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	NOV	2015	19	6					672	678		10.1016/j.ejpn.2015.07.005		7	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CU2IE	WOS:000363346400009		
J	Hyodo, R; Suzuki, K; Ogawa, H; Komada, T; Naganawa, S				Hyodo, Ryota; Suzuki, Kojiro; Ogawa, Hiroshi; Komada, Tomohiro; Naganawa, Shinji			Pancreatic neuroendocrine tumors containing areas of iso- or hypoattenuation in dynamic contrast-enhanced computed tomography: Spectrum of imaging findings and pathological grading	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Pancreas; Neuroendocrine tumor; Dynamic contrast-enhanced CT; Pathological grading	PROGNOSTIC-FACTORS; ENDOCRINE TUMORS; AUTOIMMUNE PANCREATITIS; HELICAL CT; FEATURES; DIFFERENTIATION; CLASSIFICATION; EPIDEMIOLOGY; MALIGNANCY; CARCINOMA	Purpose: To evaluate dynamic contrast-enhanced computed tomography (CT) features of pancreatic neuroendocrine tumors (PNETs) containing areas of iso- or hypoattenuation and the relationship with pathological grading. Materials and Methods: Between June 2006 and March 2014,61 PNETs in 58 consecutive patients (29 male, 29 female; median-age 55 years), which were surgically diagnosed, underwent preoperative dynamic contrast-enhanced CT. PNETs were classified based on contrast enhancement patterns in the pancreatic phase: iso/hypo-PNETs were defined as tumors containing areas of iso- or hypoattenuation except for cystic components, and hyper-PNETs were tumors showing hyperattenuation over the whole area. CT findings and contrast-enhancement patterns of the tumors were evaluated retrospectively by two radiologists and compared with the pathological grading. Results: Iso/hypo-PNETs comprised 26 tumors, and hyper-PNETs comprised 35 tumors. Not only hyperPNETs but also most iso/hypo-PNETs showed peak enhancement in the pancreatic phase and a washout from the portal venous phase to the delayed phase. Iso/hypo-PNETs showed larger tumor size than the hyper-PNETs (mean, 3.7 cm vs. 1.6 cm; P< 0.001), and were significantly correlated with unclear tumor margins (n= 4 vs. n= 0; P = 0.029), the existence of cystic components (n=10 vs. n= 3; P = 0.006), intratumoral blood vessels in the early arterial phase (n= 13 vs. n= 3; P< 0.001), and a smooth rim enhancement in the delayed phase (n= 12 vs. n= 6; P= 0.019). Iso/hypo-PNETs also showed significantly higher pathological grading (WHO 2010 classification; iso/hypo, G1 = 14, G2 = 11, G3 = 1; hyper, G1 =34, G2 = 1; P< 0.001). Conclusion: PNETs containing iso/hypo-areas showed a rapid enhancement pattern as well as hyperPNETs, various radiological features and higher malignant potential. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Hyodo, Ryota; Suzuki, Kojiro; Ogawa, Hiroshi; Komada, Tomohiro; Naganawa, Shinji] Nagoya Univ, Grad Sch Med, Dept Radiol, Showa Ku, Nagoya, Aichi 4668550, Japan	Hyodo, R (reprint author), Nagoya Univ, Grad Sch Med, Dept Radiol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	ryouta771@med.naogoya-u.ac.jp; Kojiro@med.naogoya-u.ac.jp; ogawa.hiroshi@h.mbox.nagoya-u.ac.jp; tidai@med.nagoya-u.ac.jp; naganawa@med.nagoya-u.ac.jp	Naganawa, Shinji/I-1572-2012; 	Naganawa, Shinji/0000-0002-0214-613X; Komada, Tomihiro/0000-0001-9241-1429			Graziani R, 2010, RADIOL MED, V115, P1047, DOI 10.1007/s11547-010-0540-1; Rodallec M, 2006, PANCREATOLOGY, V6, P77, DOI 10.1159/000090026; Raman SP, 2012, AM J ROENTGENOL, V199, P309, DOI 10.2214/AJR.12.8627; Hattori Y, 2010, PANCREAS, V39, P1263, DOI 10.1097/MPA.0b013e3181dbc583; Gallotti A, 2013, AM J ROENTGENOL, V200, P355, DOI 10.2214/AJR.11.8037; Tatsumoto S, 2013, ABDOM IMAGING, V38, P358, DOI 10.1007/s00261-012-9953-8; Kuo EJ, 2013, ANN SURG ONCOL, V20, P2815, DOI 10.1245/s10434-013-3005-7; Klimstra DS, 2010, PANCREAS, V39, P707, DOI 10.1097/MPA.0b013e3181ec124e; Kartalis N, 2015, ANN GASTROENTEROL, V28, P193; Foti G, 2013, RADIOL MED, V118, P1082, DOI 10.1007/s11547-013-0956-5; Lewis RB, 2010, RADIOGRAPHICS, V30, P1445, DOI 10.1148/rg.306105523; Fraenkel M, 2012, BEST PRACT RES CL GA, V26, P691, DOI 10.1016/j.bpg.2013.01.006; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Hayashi D, 2011, JPN J RADIOL, V29, P85, DOI 10.1007/s11604-010-0522-1; Sugiyama Y, 2012, JPN J RADIOL, V30, P296, DOI 10.1007/s11604-011-0047-2; d'Assignies G, 2009, RADIOLOGY, V250, P407, DOI 10.1148/radiol.2501080291; Baur A. D., 2015, ACTA RADIOL; Bosnian FT, 2010, WHO CLASSIFICATION T; Cappelli C, 2015, EUR RADIOL, V25, P751, DOI 10.1007/s00330-014-3485-2; Fidler JL, 2003, AM J ROENTGENOL, V181, P775; Furuhashi N, 2015, EUR RADIOL, V25, P1366, DOI 10.1007/s00330-014-3512-3; Kasajima A., 2015, J HEPATOBILIARY PANC; Kim DW, 2015, EUR RADIOL, V25, P1375, DOI 10.1007/s00330-014-3532-z; Luo YJ, 2014, EUR RADIOL, V24, P2945, DOI 10.1007/s00330-014-3317-4; Sundin A, 2012, BEST PRACT RES CL GA, V26, P803, DOI 10.1016/j.bpg.2012.12.004; Worhunsky DJ, 2014, HPB, V16, P304, DOI 10.1111/hpb.12139	26	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	NOV	2015	84	11					2103	2109		10.1016/j.ejrad.2015.08.014		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1FN	WOS:000363265600009		
J	Fujima, N; Kameda, H; Tsukahara, A; Yoshida, D; Sakashita, T; Homma, A; Tha, KK; Kudo, K; Shirato, H				Fujima, Noriyuki; Kameda, Hiroyuki; Tsukahara, Akiko; Yoshida, Daisuke; Sakashita, Tomohiro; Homma, Akihiro; Tha, Khin Khin; Kudo, Kohsuke; Shirato, Hiroki			Diagnostic value of tumor blood flow and its histogram analysis obtained with pCASL to differentiate sinonasal malignant lymphoma from squamous cell carcinoma	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Tumor blood flow; Pseudo-continuous arterial spin labeling; Squamous cell carcinoma; Malignant lymphoma	APPARENT DIFFUSION-COEFFICIENTS; NECK-CANCER; HEAD; MRI; FEATURES; REGIONS	Objectives: To investigate the diagnostic value of tumor blood flow (TBF) obtained with pseudocontinuous arterial spin labeling (pCASL) for the differentiation of squamous cell carcinoma (SCC) and malignant lymphoma (ML) in the nasal or sinonasal cavity. Methods: Thirty-three patients with SCC and 6 patients with ML in the nasal or sinonasal cavity were retrospectively analyzed. Quantitative TBF values were obtained using whole-tumor region of interest (ROI) from pCASL data. The histogram analysis of TBF values within the tumor ROI was also performed by calculating the coefficient of variation (CV), kurtosis, and skewness. The mean TBF value, histogram CV, kurtosis and skewness of the patients with SCC were compared with those of the ML patients. The diagnostic accuracy to differentiate SCC from ML was also calculated by receiver operating characteristic (ROC) curve analysis. In addition, multiple logistic regression models were also performed to determine their independent predictive value, and diagnostic accuracy with the combined use of these parameters. Results: Between the SCC and ML groups, significant differences were observed in mean TBF, CV, and kurtosis, but not in skewness. In ROC curve analysis, the diagnostic accuracy values for the differentiation of SCC from ML in mean TBF, CV, and kurtosis were all 0.87, respectively. Multiple logistic regression models revealed TBF and CV were respectively independent predictive value. With the combination of these parameters, the diagnostic accuracy was elevated to 0.97. Conclusions: The TBF value and its histogram analysis obtained with pCASL can help differentiate SCC and ML. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Fujima, Noriyuki; Kameda, Hiroyuki; Tsukahara, Akiko; Yoshida, Daisuke; Kudo, Kohsuke] Hokkaido Univ Hosp, Dept Diagnost & Intervent Radiol, Sapporo, Hokkaido 0608638, Japan; [Sakashita, Tomohiro; Homma, Akihiro] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido, Japan; [Tha, Khin Khin; Shirato, Hiroki] Hokkaido Univ, Grad Sch Med, Dept Radiat Med, Sapporo, Hokkaido, Japan; [Tha, Khin Khin; Shirato, Hiroki] Global Inst Collaborat Res & Educ, Global Stn Quantum Med Sci & Engn, Sapporo, Hokkaido, Japan	Fujima, N (reprint author), Hokkaido Univ Hosp, Dept Diagnost & Intervent Radiol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	Noriyuki.Fujima@mb9.seikyou.ne.jp					Matsuzaki H, 2012, OR SURG OR MED OR PA, V113, P126, DOI 10.1016/j.tripleo.2011.07.038; Liu XW, 2012, EUR J RADIOL, V81, P1146, DOI 10.1016/j.ejrad.2011.03.066; Asaumi J, 2004, ORAL ONCOL, V40, P579, DOI 10.1016/j.oraloncology.2003.12.002; WHEELER RH, 1986, CANCER RES, V46, P4200; Sumi M, 2009, EUR RADIOL, V19, P975, DOI 10.1007/s00330-008-1217-1; Wang Z, 2008, MAGN RESON IMAGING, V26, P261, DOI 10.1016/j.mri.2007.07.003; King AD, 2013, RADIOLOGY, V266, P531, DOI 10.1148/radiol.12120167; Ichikawa Y, 2012, AM J NEURORADIOL, V33, P761, DOI 10.3174/ajnr.A2834; Vidal RW, 1999, ANN OTO RHINOL LARYN, V108, P411; Razek AAKA, 2010, J COMPUT ASSIST TOMO, V34, P808, DOI 10.1097/RCT.0b013e3181f01796; NEGENDANK WG, 1990, RADIOLOGY, V177, P209; Sumi M, 2007, EUR RADIOL, V17, P2631, DOI 10.1007/s00330-007-0588-z; Lee FKH, 2012, EUR J RADIOL, V81, P784, DOI 10.1016/j.ejrad.2011.01.089; Sanghvi S, 2014, LARYNGOSCOPE, V124, P76, DOI 10.1002/lary.24264; Logsdon MD, 1997, CANCER, V80, P477, DOI 10.1002/(SICI)1097-0142(19970801)80:3<477::AID-CNCR16>3.3.CO;2-V; Pal I, 2010, INDIAN J OTOLARYNGOL, V62, P92, DOI 10.1007/s12070-010-0003-y; Golay X, 2005, MAGNET RESON MED, V53, P15, DOI 10.1002/mrm.20338; Fujima N., 2014, J MAGN RESON IMAGING; Fujima N, 2014, J MAGN RESON IMAGING, V40, P920, DOI 10.1002/jmri.24421; Jegoux F, 2013, EUR ANN OTORHINOLARY, V130, P327, DOI 10.1016/j.anorl.2012.07.007; Telischak N. A., 2014, J MAGN RESON IMAGING; Zyłka Stanisław, 2008, Otolaryngol Pol, V62, P436, DOI 10.1016/S0030-6657(08)70287-7	22	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	NOV	2015	84	11					2187	2193		10.1016/j.ejrad.2015.07.026		7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1FN	WOS:000363265600021		
J	Masaoka, Y; Hiraki, T; Gobara, H; Iguchi, T; Fujiwara, H; Matsui, Y; Toyooka, S; Soh, J; Kiura, K; Kanazawa, S				Masaoka, Yoshihisa; Hiraki, Takao; Gobara, Hideo; Iguchi, Toshihiro; Fujiwara, Hiroyasu; Matsui, Yusuke; Toyooka, Shinichi; Soh, Junichi; Kiura, Katsuyuki; Kanazawa, Susumu			Fever after lung radiofrequency ablation: Prospective evaluation of its incidence and associated factors	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Lung; Radiofrequency ablation; Fever; Pulmonary infiltration	PERCUTANEOUS RADIOFREQUENCY; INTERSTITIAL PNEUMONIA; CENTER EXPERIENCE; LIVER METASTASES; THERMAL ABLATION; HEPATIC-TUMORS; CANCER; COMPLICATIONS; ELECTRODE; NEEDLE	Purpose: To prospectively investigate the incidence of post-lung radiofrequency (RF) ablation fever as well as its associated factors, according to the grade of fever. Materials and Methods: A total of 56 patients who underwent 67 lung RF sessions were analyzed. Postablation fever (>= 37.0 degrees C) was graded according to the common toxicity criteria of adverse events v. 4.0. Fever >= 37.0 degrees C and <38.0 C was defined as grade 0 fever. The 67 RF sessions were divided into two groups according to the presence of post-ablation fever, and the factors associated with fever were determined using univariate and multivariate analyses. Subsequently, the RF sessions accompanied by post-ablation fever were further divided into two groups according to the grade of fever (grade 0 vs. grade >= 1), and the factors associated with the grade of fever were determined. Results: Grade 0, 1, and 2 fever accompanied 36 (54%), 11(16%), and 2 (3%) sessions, respectively. Post-ablation fever was significantly associated with larger ablated parenchymal volume (P=0.001) and development of pulmonary infiltration (P=0.004). Additionally, development of pulmonary infiltration (P=0.048) was also significantly and independently associated with higher grade of fever in the multivariate analysis. Conclusions: The incidences of grade 0, 1, and 2 post-ablation fever were 54%, 16%, and 3%, respectively. Larger ablated parenchymal volume and development of pulmonary infiltration were found to be associated with the development of post-ablation fever, with the latter being an independent factor associated with higher grade of fever. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Masaoka, Yoshihisa; Hiraki, Takao; Gobara, Hideo; Iguchi, Toshihiro; Fujiwara, Hiroyasu; Matsui, Yusuke; Kanazawa, Susumu] Okayama Univ, Sch Med, Dept Radiol, Okayama 7008558, Japan; [Toyooka, Shinichi; Soh, Junichi] Okayama Univ, Sch Med, Dept Thorac Surg, Okayama 7008558, Japan; [Kiura, Katsuyuki] Okayama Univ, Sch Med, Dept Resp Med, Okayama 7008558, Japan	Hiraki, T (reprint author), Okayama Univ, Sch Med, Dept Radiol, 2-5-1 Kita Ku Shikata Cho, Okayama 7008558, Japan.	ymsok88222@gmail.com; takaoh@tc4.so-net.ne.jp; gobara@cc.okayama-u.ac.jp; iguchi@ba2.so-net.ne.jp; hirofujiwar@gmail.com; wckyh140@yahoo.co.jp; toyooka@md.okayama-u.ac.jp; soh-j@cc.okayama-u.ac.jp; kkiura@md.okayama-u.ac.jp; susumu@cc.okayama-u.ac.jp					Fernando HC, 2005, J THORAC CARDIOV SUR, V129, P639, DOI 10.1016/j.jtevs.2004.10.019; Hiraki T, 2012, J VASC INTERV RADIOL, V23, P126, DOI 10.1016/j.jvir.2011.09.011; Hiraki T, 2011, ACTA MED OKAYAMA, V65, P287; GOLDBERG SN, 1995, ACAD RADIOL, V2, P776, DOI 10.1016/S1076-6332(05)80852-9; Sano Y, 2007, CANCER, V109, P1397, DOI 10.1002/cncr.22541; van Tilborg AAJM, 2011, BRIT J RADIOL, V84, P556, DOI 10.1259/bjr/78268814; KOBAYASHI J, 1995, CHEST, V108, P311, DOI 10.1378/chest.108.2.311; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rossi S, 2006, EUR RESPIR J, V27, P556, DOI 10.1183/09031936.06.00052905; Rossi S, 1998, AM J ROENTGENOL, V170, P1015; Soga N, 2009, BJU INT, V104, P790, DOI 10.1111/j.1464-410X.2009.08459.x; Nomura M, 2008, BRIT J RADIOL, V81, P244, DOI 10.1259/bjr/84269673; Lencioni R, 1998, EUR RADIOL, V8, P1205, DOI 10.1007/s003300050536; Okuma T, 2009, ANN THORAC SURG, V87, P948, DOI 10.1016/j.athoracsur.2008.07.069; Lee JM, 2004, RADIOLOGY, V230, P125, DOI 10.1148/radiol.2301020934; Yasui K, 2004, RADIOLOGY, V231, P850, DOI 10.1148/radiol.2313030347; HONDA Y, 1995, AM J RESP CRIT CARE, V152, P1860; Yamamoto A, 2005, AM J ROENTGENOL, V185, P1299, DOI 10.2214/AJR.04.0968; Dodd GD, 2005, AM J ROENTGENOL, V185, P51; Carrafiello G, 2007, AUSTRALAS RADIOL, V51, P550, DOI 10.1111/j.1440-1673.2007.01871.x; Wah TM, 2005, RADIOLOGY, V237, P1097, DOI 10.1148/radiol.2373042008; Kang Shijun, 2004, World J Surg Oncol, V2, P30, DOI 10.1186/1477-7819-2-30	22	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	NOV	2015	84	11					2202	2209		10.1016/j.ejrad.2015.07.009		8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1FN	WOS:000363265600023		
J	Yoneyama, H; Kondo, C; Yamasaki, A; Nakanishi, T; Sakai, S				Yoneyama, Hiroko; Kondo, Chisato; Yamasaki, Aki; Nakanishi, Toshio; Sakai, Shuji			Comparison of situs ambiguous patterns between heterotaxy syndromes with polysplenia and asplenia	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Polysplenia; Asplenia; Heterotaxy syndrome; Situs ambiguus viscerum; Renal vein; Multidetector Computed Tomography	INFERIOR VENA-CAVA; CT FEATURES; ABNORMALITIES; PANCREAS; DISEASE; SPLEEN; ADULTS; HEART	Objectives: To compare the differences of visceral anomalies shown by computed tomography (CT) in patients with polysplenia syndrome (PS) or asplenia syndrome (AS). Methods: This retrospective study was approved by the institutional review board, and informed consent was waived. Thirty-one patients with PS and 29 patients with AS underwent chest-abdominal CT. The evaluated CT findings were as follows: the orientation of stomach, liver and gallbladder; short pancreas; azygous/hemiazygous continuation; ipsilateral position of the inferior vena cava and aorta; preduodenal portal vein; abnormal confluence of renal vein (defined as renal vein drains to the inferior vena cava or azygous/hemiazygous vein at the upper level of celiac trunk origin); gastrointestinal malrotation; and tracheobronchial tree. Results: Azygous/hemiazygous continuation was seen in 74% (20 of 27)10% (0 of 28) of PS/AS (P< 0.0001), bilateral hyparterial bronchi in 75% (24 of 32)15% (1 of 22), bilateral eparterial bronchi in 9% (3 of 32)195% (21 of 22), ipsilateral position of the inferior vena cava and aorta in 59% (16 of 27)189% (25 of 28), and abnormal confluence of renal vein in 7% (2 of 27)157% (16 of 28), respectively. No significant differences were found in the other anomalies. Conclusion: Significant differences in anomalous systemic venous connections and tracheobronchial anomaly were observed between PS and AS. Abnormal confluence of renal vein is relatively rare anomalous venous connections, but frequently observed in AS. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Yoneyama, Hiroko; Kondo, Chisato; Yamasaki, Aki; Sakai, Shuji] Tokyo Womens Med Univ, Dept Diagnost Imaging & Nucl Med, Shinjuku Ku, Tokyo 1628666, Japan; [Nakanishi, Toshio] Tokyo Womens Med Univ, Dept Pediat Cardiol, Shinjuku Ku, Tokyo 1628666, Japan	Kondo, C (reprint author), Tokyo Womens Med Univ, Dept Diagnost Imaging & Nucl Med, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.	pkondou@pop02.odn.ne.jp					Anderson R. H., 1978, PAEDIAT CARDIOLOGY; PEOPLES WM, 1983, PEDIATR CARDIOL, V4, P129, DOI 10.1007/BF02076338; SOLER R, 1992, J COMPUT ASSIST TOMO, V16, P921, DOI 10.1097/00004728-199211000-00017; TSUDA Y, 1991, J COMPUT ASSIST TOMO, V15, P585, DOI 10.1097/00004728-199107000-00011; WINERMURAM HT, 1991, J THORAC IMAG, V6, P69, DOI 10.1097/00005382-199104000-00015; Fulcher AS, 2002, RADIOGRAPHICS, V22, P1439, DOI 10.1148/rg.226025016; Applegate KE, 1999, RADIOGRAPHICS, V19, P837; Karadeniz A, 2010, VASC ENDOVASC SURG, V44, P381, DOI 10.1177/1538574410370789; Wallihan DB, 2013, PEDIATR RADIOL, V43, P330, DOI 10.1007/s00247-012-2531-y; Gayer G, 1999, ABDOM IMAGING, V24, P178, DOI 10.1007/s002619900471; McElhinney DB, 2011, CONGENIT HEART DIS, V6, P28, DOI 10.1111/j.1747-0803.2010.00478.x; Bartram U, 2008, PEDIATR DEVEL PATHOL, V11, P266, DOI 10.2350/07-01-0207.1; FUJIWARA T, 1995, J COMPUT ASSIST TOMO, V19, P84, DOI 10.1097/00004728-199501000-00016; FREEDOM RM, 1973, RADIOLOGY, V107, P387; MOLLER JH, 1967, CIRCULATION, V36, P789; Newman B, 2014, PEDIATR RADIOL, V44, P542, DOI 10.1007/s00247-013-2861-4; HADAR H, 1991, ACTA RADIOL, V32, P299; HAUSER GJ, 1982, CLIN NUCL MED, V7, P543, DOI 10.1097/00003072-198212000-00003; Mortele KJ, 2004, AM J ROENTGENOL, V183, P1653; PHOON CK, 1994, AM J CARDIOL, V73, P581; Lee NK, 2010, RADIOGRAPHICS, V30, P1489, DOI 10.1148/rg.306105504; Bass J E, 2000, Radiographics, V20, P639; C Louise alder a, 2011, PEDIAT CARDIOL, V32, P875; FREEDOM RM, 1972, J PEDIATR-US, V81, P1130, DOI 10.1016/S0022-3476(72)80244-0; Kellman G M, 1988, Radiographics, V8, P533; Winer-Muran HT, 1995, J THORAC IMAG, V10, P43, DOI 10.1097/00005382-199501010-00004	26	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	NOV	2015	84	11					2301	2306		10.1016/j.ejrad.2015.08.004		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1FN	WOS:000363265600037		
J	Ohno, Y; Koyama, H; Yoshikawa, T; Takenaka, D; Kassai, Y; Yui, M; Matsumoto, S; Sugimura, K				Ohno, Yoshiharu; Koyama, Hisanobu; Yoshikawa, Takeshi; Takenaka, Daisuke; Kassai, Yoshimori; Yui, Masao; Matsumoto, Sumiaki; Sugimura, Kazuro			Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						Lung; MR imaging; PET/CT; Diffusion; Lung cancer; Staging	TURBO SPIN-ECHO; POSITRON-EMISSION-TOMOGRAPHY; QUALITATIVE ASSESSMENT; LYMPH-NODES; BODY; METASTASES; PROSTATE	Purpose: To prospectively compare the diagnostic capability of diffusion-weighted MR imaging obtained with fast advantage spin-echo sequence (FASE-DWI) and echo planar imaging sequence (EPI-DWI), short inversion time inversion recovery fast advanced spin-echo (STIR FASE) imaging and FDG PET/CT for N-stage assessment of non-small cell carcinoma (NSCLC) patients. Materials and methods: 95 consecutive operable NSCLC patients underwent STIR FASE imaging, FASE-DWI and EPI-DWI with a 3T system, integrated PET/CT, surgical treatment and pathological and follow-up examinations. Probability of lymph node metastasis was visually assessed using a 5-point visual scoring system. ROC analyses were used to compare diagnostic capability of all methods, while their diagnostic performance was also compared by means of McNemar's test on a per node basis. Finally, McNemar's test was also used for statistical comparison of accuracy of N-stage assessment. Results: Areas under the curve (Azs) for STIR FASE imaging (Az = 0.95) and FASE-DWI (Az = 0.92) were significantly larger than those for EPI-DWI (Az = 0.78; p <0.0001 for STIR FSE imaging and FASE-DWI) and PET/CT (Az = 0.85; p = 0.0001 for STIR FSE imaging, p = 0.03 for FASE-DWI) on a per node basis analysis. Accuracy of N-stage assessment using STIR FASE imaging (84.2% [80195]) and FASE-DWI (83.2% [79195]) was significantly higher than that using EPI-DWI (76.8% [73195]; p = 0.02 for STIR FASE imaging, p = 0.03 for FASE-DWI) and PET/CT (73.7% [70195]; p = 0.002 for STIR FSE imaging, p = 0.004 for FASE-DWI). Conclusion: Qualitative N-stage assessments of NSCLC patients obtained with FASE-DWI as well as STIR FASE imaging are more sensitive and/or accurate than those obtained with EPI-DWI and FDG PET/CT. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Ohno, Yoshiharu; Yoshikawa, Takeshi; Matsumoto, Sumiaki] Kobe Univ, Grad Sch Med, Adv Biomed Imaging Res Ctr, Kobe, Hyogo 6500017, Japan; [Ohno, Yoshiharu; Yoshikawa, Takeshi; Matsumoto, Sumiaki] Kobe Univ, Grad Sch Med, Dept Radiol, Div Funct & Diagnost Imaging Res, Kobe, Hyogo 6500017, Japan; [Koyama, Hisanobu; Sugimura, Kazuro] Kobe Univ, Grad Sch Med, Dept Radiol, Div Radiol, Kobe, Hyogo 6500017, Japan; [Takenaka, Daisuke] Hyogo Canc Ctr, Dept Radiol, Akashi, Hyogo, Japan; [Kassai, Yoshimori; Yui, Masao] Toshiba Med Syst Corp, Otawara, Tochigi, Japan	Ohno, Y (reprint author), Kobe Univ, Grad Sch Med, Dept Radiol, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	yoshiharuohno@aol.com			Toshiba Medical Systems Corporation	This work was supported by Toshiba Medical Systems Corporation.	Baltzer PAT, 2009, EUR RADIOL, V19, P1612, DOI 10.1007/s00330-009-1326-5; Shimizu H, 2013, EUR J RADIOL, V82, P453, DOI 10.1016/j.ejrad.2012.10.020; Usuda K, 2013, ANN SURG ONCOL, V20, P1676, DOI 10.1245/s10434-012-2799-z; Shim SS, 2005, RADIOLOGY, V236, P1011, DOI 10.1148/radiol.2363041310; Ohno Y, 2004, RADIOLOGY, V231, P872, DOI 10.1148/radiol.2313030103; Tsuchiya K, 2003, NEURORADIOLOGY, V45, P90, DOI 10.1007/s00234-002-0898-4; Ohno Y, 2011, RADIOLOGY, V261, P605, DOI 10.1148/radiol.11110281; Federau C, 2014, J MAGN RESON IMAGING, V39, P624, DOI 10.1002/jmri.24195; Babourina-Brooks B, 2012, MAGN RESON IMAGING, V30, P189, DOI 10.1016/j.mri.2011.09.024; Schmidt H, 2013, INVEST RADIOL, V48, P247, DOI 10.1097/RLI.0b013e31828d56a1; Koh DM, 2007, AM J ROENTGENOL, V188, P1622, DOI 10.2214/AJR.06.1403; Takenaka D, 2002, EUR J RADIOL, V44, P216, DOI 10.1016/S0720-048X(02)00271-1; Chen Q, 1999, EUR J RADIOL, V29, P90, DOI 10.1016/S0720-048X(98)00172-7; Marom EM, 1999, RADIOLOGY, V212, P803; Antoch G, 2003, RADIOLOGY, V229, P526, DOI 10.1148/radiol.2292021598; Verhappen MH, 2012, AM J NEURORADIOL, V33, P1239, DOI 10.3174/ajnr.A2949; SVANHOLM H, 1989, APMIS, V97, P689; Rusch VW, 2009, J THORAC ONCOL, V4, P568, DOI 10.1097/JTO.0b013e3181a0d82e; Nomori H, 2008, J THORAC CARDIOV SUR, V135, P816, DOI 10.1016/j.jtcvs.2007.10.035; Raya JG, 2006, J MAGN RESON IMAGING, V24, P1207, DOI 10.1002/jmri.20748; Schwenzer NF, 2012, RADIOLOGY, V264, P551, DOI 10.1148/radiol.12111942; Ohno Y, 2007, J MAGN RESON IMAGING, V26, P1071, DOI 10.1002/jmri.21106; Ueno Y, 2013, EUR RADIOL, V23, P3509, DOI 10.1007/s00330-013-2958-z; Kim SK, 2009, EUR J CANCER, V45, P2103, DOI 10.1016/j.ejca.2009.04.006; Cai J, 2001, Gastric Cancer, V4, P66, DOI 10.1007/PL00011726; Kiefer B, 1994, MAGN RESON IMAGING, V4, P86; Koyama H, 2015, EUR J RADIOL, V84, P509, DOI 10.1016/j.ejrad.2014.11.024; Silvestri GA, 2007, CHEST, V132, p178S, DOI 10.1378/chest.07-1360	28	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X	1872-7727		EUR J RADIOL	Eur. J. Radiol.	NOV	2015	84	11					2321	2331		10.1016/j.ejrad.2015.07.019		11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1FN	WOS:000363265600040		
J	Bokhorst, LP; Alberts, AR; Rannikko, A; Valdagni, R; Pickles, T; Kakehi, Y; Bangma, CH; Roobol, MJ				Bokhorst, Leonard P.; Alberts, Arnout R.; Rannikko, Antti; Valdagni, Riccardo; Pickles, Tom; Kakehi, Yoshiyuki; Bangma, Chris H.; Roobol, Monique J.		PRIAS Study Grp	Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers	EUROPEAN UROLOGY			English	Article						Prostatic neoplasms; Active surveillance; Prostate-specific antigen; Prostate biopsy; Compliance; Disease progression	FOLLOW-UP; RADICAL PROSTATECTOMY; JOHNS-HOPKINS; PROGRAM; INTERVENTION; BIOPSY; COHORT; MEN	Background: Men with prostate cancer on active surveillance (AS) are advised to follow strict follow-up schedules and switch to definitive treatment on risk reclassification. However, some men might not adhere to these strict protocols. Objective: To determine the number of noncompliers and disease reclassification rates in men not complying with the follow-up protocol of the Prostate Cancer Research International Active Surveillance (PRIAS) study. Design, setting, and participants: A total of 4547 men with low-risk prostate cancer were included and prospectively followed on AS. Men were regularly examined using prostate-specific antigen (PSA), digital rectal examination, and repeat biopsies, and were advised to switch to definitive treatment on disease reclassification (>cT2c, Gleason score > 3 + 3, >2 cores positive, or PSA doubling time [PSA-DT] 0-3 yr). Outcome measurements and statistical analysis: Rates of men not complying with follow-up visits or a recommendation to discontinue AS are reported. Biopsy outcome (Gleason >= 7 or > 2 cores positive) was compared between compliers and noncompliers using Cox proportional hazards analysis. Results and limitations: The compliance rate for PSA visits was 91%. By contrast, the compliance rate for standard repeat biopsies decreased over time (81%, 60%, 53%, and 33% at 1, 4, 7, and 10 yr after diagnosis, respectively). Yearly repeat biopsies in men with faster rising PSA (PSA-DT 3-10 yr) was low at < 30%, although these men had higher upgrading rates at repeat biopsy (25-30% vs 16%). PSA-DT of 0-3 yr was the most common recommendation for discontinuation, but 71% continued on AS. Men with PSADT of 0-3 yr were at higher risk of upgrading on repeat biopsy (hazard ratio 2.02, 95% confidence interval 1.36-3.00) compared to men without fast rising PSA. Conclusion: Some men and their physicians do not comply with AS follow-up protocols. In particular, yearly repeat biopsies in men with fast rising PSA are often ignored, as is the recommendation to discontinue AS because of very fast rising PSA. Although these men are at greater risk of higher Gleason scores on repeat biopsy, the majority still exhibit favorable tumor characteristics. Fast rising PSA should therefore not trigger a recommendation to receive active treatment, but should rather serve as a criterion for stricter follow-up. In addition, we should aim to find ways of safely reducing the number of biopsies to increase adherence to AS protocols. Patient summary: Welooked at compliance with an active surveillance protocol for low-risk prostate cancer in a large active surveillance study. We observed reluctance to undergo yearly biopsies because of fast rising prostate-specific antigen, despite a higher risk of disease progression. Further research should aim to safely reduce the number of repeat biopsies in men on active surveillance to increase protocol adherence. (C) 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.	[Bokhorst, Leonard P.; Alberts, Arnout R.; Bangma, Chris H.; Roobol, Monique J.] Erasmus Univ, Med Ctr, Dept Urol, NL-3000 CA Rotterdam, Netherlands; [Rannikko, Antti] Univ Helsinki, Cent Hosp, Dept Urol, Helsinki, Finland; [Valdagni, Riccardo] Fdn IRCSS Ist Nazl Tumori, Prostate Canc Program & Radiat Oncol 1, Milan, Italy; [Pickles, Tom] British Columbia Canc Agcy, Dept Radiat Oncol, Vancouver, BC V5Z 4E6, Canada; [Kakehi, Yoshiyuki] Kagawa Univ, Fac Med, Dept Urol, Takamatsu, Kagawa, Japan	Bokhorst, LP (reprint author), Erasmus Univ, Med Ctr, Dept Urol, Room NA 1710,POB 2040, NL-3000 CA Rotterdam, Netherlands.	l.bokhorst@erasmusmc.nl			Prostate Cancer Research Foundation Rotterdam	The PRIAS study is supported by grants from the Prostate Cancer Research Foundation Rotterdam. The sponsor played no role in the study.	Loeb S, 2013, EUR UROL, V64, P876, DOI 10.1016/j.eururo.2013.05.049; Tosoian JJ, 2011, J CLIN ONCOL, V29, P2185, DOI 10.1200/JCO.2010.32.8112; Cooperberg MR, 2011, J CLIN ONCOL, V29, P228, DOI 10.1200/JCO.2010.31.4252; Bul M, 2012, EUR UROL, V62, P195, DOI 10.1016/j.eururo.2012.02.002; Ross HM, 2012, AM J SURG PATHOL, V36, P1346, DOI 10.1097/PAS.0b013e3182556dcd; van den Bergh RCN, 2007, EUR UROL, V52, P1560, DOI 10.1016/j.eururo.2007.05.011; Soloway MS, 2010, EUR UROL, V58, P831, DOI 10.1016/j.eururo.2010.08.027; Selvadurai ED, 2013, EUR UROL, V64, P981, DOI 10.1016/j.eururo.2013.02.020; Kweldam CF, 2015, BJU INT, V116, P230, DOI 10.1111/bju.12879; Ross AE, 2010, J CLIN ONCOL, V28, P2810, DOI 10.1200/JCO.2009.25.7311; Bul M, 2012, EUR UROL, V61, P370, DOI 10.1016/j.eururo.2011.06.027; Bokhorst L, 2015, J UROLOGY, V193, pE755; Bul M, 2012, EUR UROL, V63, P597; Kates M, 2015, BJU INT, V115, P216, DOI 10.1111/bju.12828; Klotz L, 2015, J CLIN ONCOL, V33, P272, DOI 10.1200/JCO.2014.55.1192; Makinen T, 2002, UROLOGY, V60, P846; Schoots IG, 2015, EUR UROL, V67, P627, DOI 10.1016/j.eururo.2014.10.050; Welty CJ, 2015, J UROLOGY, V193, P807, DOI 10.1016/j.juro.2014.09.094	18	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0302-2838	1873-7560		EUR UROL	Eur. Urol.	NOV	2015	68	5					814	821		10.1016/j.eururo.2015.06.012		8	Urology & Nephrology	Urology & Nephrology	CU4DC	WOS:000363475800024		
J	Yamaguchi, M; Smith, A; Ohtsubo, Y				Yamaguchi, Mana; Smith, Adam; Ohtsubo, Yohsuke			Commitment signals in friendship and romantic relationships	EVOLUTION AND HUMAN BEHAVIOR			English	Article						Romantic relationships; Friendship; Commitment signals; Commitment problem	CLOSE RELATIONSHIPS; ATTRACTIVE ALTERNATIVES; SACRIFICE; GIFTS; LOVE; WILLINGNESS; MAINTENANCE; PERCEPTION; EVOLUTION; ATTENTION	Due to the ever-present allure of potentially more appealing or attractive partners, people in mutually committed relationships face a commitment problem (i.e., uncertainty about partner fidelity). This problem exists for both friendship and romantic relationships. In an exploratory pilot study, participants described real-life commitment-confirming incidents in either friendship or romantic relationships. The results revealed that the same types of pro-relationship acts (e.g., throwing a surprise party) were used to communicate commitment to one's partner in both types of relationship. Using signaling theory, we predicted that costly commitment signals would be more effective than non-costly commitment signals (Hypothesis 1). Also, we predicted that failure to engage in such behaviors would communicate non-commitment, and that such failures would have a more detrimental effect on romantic relationships than friendship (Hypothesis 2). Two scenario experiments (study 1 in Japan and study 2 in the U.S.) were conducted to test these hypotheses. The results showed that costly commitment signals were more effective than non-costly commitment signals in both Japan and the U.S. In addition, the absence of situationally appropriate commitment signals (e.g., forgetting a special occasion) was substantially more damaging to romantic relationships than to friendship. (C) 2015 Elsevier Inc. All rights reserved.	[Yamaguchi, Mana; Smith, Adam; Ohtsubo, Yohsuke] Kobe Univ, Grad Sch Humanities, Dept Psychol, Nada Ku, Kobe, Hyogo 6578501, Japan	Ohtsubo, Y (reprint author), Kobe Univ, Grad Sch Humanities, Dept Psychol, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.	yohtsubo@lit.kobe-u.ac.jp			Japan Society for the Promotion of Science [21683006]	We thank Hitomi Kuranaga, Daisuke Nakanishi and Kunihiro Yokota for their generous support in the data collection. We are also grateful to Miho Iwasaki, Hitomi Sakaue, Shiori Tamada, Kanako Tanaka and Fumiaki Tanimoto for their help in data coding. Our gratitude is also extended to Daniel Nettle, Aaron Goetz, and an anonymous reviewer for their insightful comments on earlier versions of this article. This research was supported by the Japan Society for the Promotion of Science (Grant no. 21683006).	Brown SL, 2008, PERS SOC PSYCHOL B, V34, P849, DOI 10.1177/0146167208314972; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Sutcliffe A, 2012, BRIT J PSYCHOL, V103, P149, DOI 10.1111/j.2044-8295.2011.02061.x; Ohtsubo Y, 2014, EVOL HUM BEHAV, V35, P237, DOI 10.1016/j.evolhumbehav.2014.02.004; Miller RS, 1997, J PERS SOC PSYCHOL, V73, P758, DOI 10.1037/0022-3514.73.4.758; VanLange PAM, 1997, J PERS SOC PSYCHOL, V72, P1373, DOI 10.1037/0022-3514.72.6.1373; MILARDO RM, 1983, J PERS SOC PSYCHOL, V44, P964; Reis HT, 2010, J PERS SOC PSYCHOL, V99, P311, DOI 10.1037/a0018344; Stanley SM, 2006, FAM PROCESS, V45, P289, DOI 10.1111/j.1545-5300.2006.00171.x; Powell C, 2003, EUR J SOC PSYCHOL, V33, P403, DOI 10.1002/ejsp.154; Karremans JC, 2011, SOC PSYCHOL PERS SCI, V2, P443, DOI 10.1177/1948550610396957; Perry S, 2011, PHILOS T R SOC B, V366, P988, DOI 10.1098/rstb.2010.0317; Ohtsubo Y, 2009, EVOL HUM BEHAV, V30, P114, DOI 10.1016/j.evolhumbehav.2008.09.004; Gonzaga GC, 2006, EMOTION, V6, P163, DOI 10.1037/1528-3542.6.2.163; Gonzaga GC, 2001, J PERS SOC PSYCHOL, V81, P247, DOI 10.1037//0022-3514.81.2.247; Maner JK, 2009, J EXP SOC PSYCHOL, V45, P174, DOI 10.1016/j.jesp.2008.08.002; Finkel EJ, 2002, J PERS SOC PSYCHOL, V82, P956, DOI 10.1037//0022-3514.82.6.956; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1126/science.3399889; Bolle F, 2001, THEOR DECIS, V50, P1, DOI 10.1023/A:1005261400484; Lydon JE, 1999, PERS SOC PSYCHOL B, V25, P152, DOI 10.1177/0146167299025002002; Dunbar RIM, 2010, BEHAVIOUR, V147, P775, DOI 10.1163/000579510X501151; JOHNSON DJ, 1989, J PERS SOC PSYCHOL, V57, P967, DOI 10.1037/0022-3514.57.6.967; Mason W, 2012, BEHAV RES METHODS, V44, P1, DOI 10.3758/s13428-011-0124-6; ROBBEN HSJ, 1994, J ECON PSYCHOL, V15, P333, DOI 10.1016/0167-4870(94)90008-6; Sozou PD, 2005, P ROY SOC B-BIOL SCI, V272, P1877, DOI 10.1098/rspb.2005.3152; Ohtsubo Y, 2015, EVOL HUM BEHAV, V36, P232, DOI 10.1016/j.evolhumbehav.2014.11.008; Algoe SB, 2008, EMOTION, V8, P425, DOI 10.1037/1528-3542.8.3.425; ZAHAVI A, 1977, ANIM BEHAV, V25, P246, DOI 10.1016/0003-3472(77)90089-6; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; SIMPSON JA, 1990, J PERS SOC PSYCHOL, V59, P1192, DOI 10.1037/0022-3514.59.6.1192; Gonzaga GC, 2008, EVOL HUM BEHAV, V29, P119, DOI 10.1016/j.evolhumbehav.2007.11.003; Buss DM, 2000, AM PSYCHOL, V55, P15, DOI 10.1037//0003-066X.55.1.15; Argyle M., 1987, PSYCHOL HAPPINESS; Argyle M., 1984, J SOCIAL PERSONAL RE, V1, P211, DOI [10.1177/0265407584012005, DOI 10.1177/0265407584012005]; Buhrmester M, 2011, PERSPECT PSYCHOL SCI, V6, P3, DOI 10.1177/1745691610393980; Cacioppo J. T., 2008, LONELINESS HUMAN NAT; CAMERER C, 1988, AM J SOCIOL, V94, pS180, DOI 10.1086/228946; Campbell L., 2005, HDB EVOLUTIONARY PSY, P419; Derlega V. J., 1993, SELF DISCLOSURE; FARRELL J, 1987, RAND J ECON, V18, P34, DOI 10.2307/2555533; Frank R. H., 1988, PASSIONS REASON STRA; Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316; House JS, 1985, SOCIAL SUPPORT HLTH, P83; Hruschka D. J., 2010, FRIENDSHIP DEV ECOLO; Jaremka LM, 2014, WILEY-BL HB BEHAV SC, P487; Kelley H. H., 1983, CLOSE RELATIONSHIPS, P265; Maestripieri D, 2012, GAMES PRIMATES PLAY; Maynard Smith J., 2003, ANIMAL SIGNALS; MYERS DG, 1995, PSYCHOL SCI, V6, P10, DOI 10.1111/j.1467-9280.1995.tb00298.x; Nesse R. M., 2001, EVOLUTION CAPACITY C; Pentland A. S., 2008, HONEST SIGNALS THEY; Rasmusen E, 2007, GAMES INFORM INTRO G; Rose S. M., 1984, J SOCIAL PERSONAL RE, V1, P267, DOI 10.1177/0265407584013001; Schelling Thomas C., 1960, STRATEGY CONFLICT; Zahavi A., 1997, HANDICAP PRINCIPLE M	55	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1090-5138	1879-0607		EVOL HUM BEHAV	Evol. Hum. Behav.	NOV	2015	36	6					467	474		10.1016/j.evolhumbehav.2015.05.002		8	Psychology, Biological; Behavioral Sciences; Social Sciences, Biomedical	Psychology; Behavioral Sciences; Biomedical Social Sciences	CU2MZ	WOS:000363358900006		
J	Mahajan, A; Haessler, J; Okada, Y; Stilp, A; Whitfield, J; Laurie, C; Franceschini, N; Morris, AP				Mahajan, Anubha; Haessler, Jeffrey; Okada, Yukinori; Stilp, Adrienne; Whitfield, John; Laurie, Cathy; Franceschini, Nora; Morris, Andrew P.			Trans-ethnic meta-analysis reveals novel loci and effector genes for kidney function in diverse populations	GENETIC EPIDEMIOLOGY			English	Meeting Abstract	Annual Meeting of the International-Genetic-Epidemiology-Society (IGES)	OCT 04-06, 2015	Baltimore, MD	Int Genet Epidemiol Soc					[Mahajan, Anubha; Morris, Andrew P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Haessler, Jeffrey] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA; [Okada, Yukinori] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Tokyo, Japan; [Stilp, Adrienne; Laurie, Cathy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Whitfield, John] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Franceschini, Nora] Univ N Carolina, Chapel Hill, NC USA; [Morris, Andrew P.] Univ Liverpool, Dept Biostat, Liverpool L69 3BX, Merseyside, England								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0741-0395	1098-2272		GENET EPIDEMIOL	Genet. Epidemiol.	NOV	2015	39	7				102	567	567				1	Genetics & Heredity; Public, Environmental & Occupational Health	Genetics & Heredity; Public, Environmental & Occupational Health	CU2FZ	WOS:000363340500106		
J	Lam, LG; Bergado, DT; Hino, T				Lam, Le Gia; Bergado, Dennes T.; Hino, Takenori			PVD improvement of soft Bangkok clay with and without vacuum preloading using analytical and numerical analyses	GEOTEXTILES AND GEOMEMBRANES			English	Article						Vacuum PVD; Vacuum preloading; PVD improvement; Bangkok clay improvement; Embankment preloading	PREFABRICATED VERTICAL DRAINS; LATERAL DISPLACEMENT; GROUND DEFORMATION; FIELD PERFORMANCE; CONSOLIDATION; SURCHARGE; DEPOSIT; SOIL; PRESSURE; EMBANKMENTS	This paper presents the performance of improved soft Bangkok clay with prefabricated vertical drains (PVDs) combined with embankment preloading (conventional PVD method) and vacuum preloading (vacuum PVD method). The performance was evaluated in terms of settlements and flow parameters using analytical methods and numerical simulations in the ABAQUS software. The horizontal coefficient of consolidation (C-h), the ratio (k(h)/k(s)) between the horizontal hydraulic conductivity in the undisturbed zone (k(h)) and the horizontal hydraulic conductivity in the smeared zone (k(s)), and the final settlement (S-f) were back-calculated using the measured data. The sensitivity analysis was performed by varying the values of kh/ks. The vacuum PVD method was confirmed to have a higher rate of settlement than the conventional method. In particular, C-y increased from 4C(v) to 5C(v), k(h)/k(s) decreased from 8 to 7, and the consolidation time required to obtain a settlement of 1.30 m decreased from 300 days to 100 days. In addition, the calculated results from both the analytical method and FEM simulations for the conventional PVD agreed with the measured data. However, the results from the vacuum PVD method demonstrated that the FEM simulations yielded more reasonable results compared with the corresponding results obtained from the analytical methods. (C) 2015 Elsevier Ltd. All rights reserved.	[Lam, Le Gia; Bergado, Dennes T.; Hino, Takenori] Saga Univ, Inst Lowland & Marine Res, Saga 8408502, Japan; [Bergado, Dennes T.] Asian Inst Technol, Pathum Thani 12120, Thailand; [Lam, Le Gia] Can Tho Univ, Can Tho, Vietnam	Lam, LG (reprint author), Saga Univ, Inst Lowland & Marine Res, Honjo Machi 1, Saga 8408502, Japan.	lglam@ctu.edu.vn; dbergado@gmail.com			Royal Thai Government (RTG); Maruyama Industry Co., Ltd.	The authors would like to acknowledge the Royal Thai Government (RTG) and Maruyama Industry Co., Ltd. for their financial support in this research.	Chai JC, 2001, J GEOTECH GEOENVIRON, V127, P965, DOI 10.1061/(ASCE)1090-0241(2001)127:11(965); Chai JC, 2010, GEOTEXT GEOMEMBRANES, V28, P525, DOI 10.1016/j.geotexmem.2010.01.003; Artidteang S, 2011, GEOSYNTH INT, V18, P35, DOI 10.1680/gein.2011.18.1.35; Indraratna B, 2005, CAN GEOTECH J, V42, P994, DOI 10.1139/T05-029; Chai JC, 2008, GEOTEXT GEOMEMBRANES, V26, P220, DOI 10.1016/j.geotexmem.2007.10.004; Chung SG, 2014, GEOTEXT GEOMEMBRANES, V42, P405, DOI 10.1016/j.geotexmem.2014.06.005; Saowapakpiboon J, 2010, GEOTEXT GEOMEMBRANES, V28, P1, DOI 10.1016/j.geotexmem.2009.08.002; Rujikiatkamjorn C, 2008, INT J GEOMECH, V8, P144, DOI 10.1061/(ASCE)1532-3641(2008)8:2(144); Abuel-Naga HM, 2012, GEOTEXT GEOMEMBRANES, V32, P1, DOI 10.1016/j.geotexmem.2011.10.007; Rowe RK, 2008, GEOTEXT GEOMEMBRANES, V26, P239, DOI 10.1016/j.geotexmem.2007.10.001; Deng YB, 2013, GEOTEXT GEOMEMBRANES, V36, P20, DOI 10.1016/j.geotexmem.2012.10.003; Indraratna B, 2012, GEOTEXT GEOMEMBRANES, V30, P16, DOI 10.1016/j.geotexmem.2011.01.004; Chai JC, 2006, CAN GEOTECH J, V43, P985, DOI 10.1139/T06-056; Chai JC, 2005, J GEOTECH GEOENVIRON, V131, P1552, DOI 10.1061/(ASCE)1090-0241(2005)131:12(1552); Saowapakpiboon J, 2011, GEOTEXT GEOMEMBRANES, V29, P74, DOI 10.1016/j.geotexmem.2010.06.008; Tang M, 2000, GEOTECHNIQUE, V50, P613; Shen SL, 2005, GEOTEXT GEOMEMBRANES, V23, P463, DOI 10.1016/j.geotexmem.2005.05.002; Cascone E, 2013, GEOTEXT GEOMEMBRANES, V38, P51, DOI 10.1016/j.geotexmem.2013.05.002; Bergado DT, 2002, CAN GEOTECH J, V39, P304, DOI 10.1139/T01-100; Ong CY, 2012, GEOTEXT GEOMEMBRANES, V34, P19, DOI 10.1016/j.geotexmem.2012.02.008; Indraratna B, 2004, CAN GEOTECH J, V41, P1098, DOI 10.1139/T04-054; Mohamedelhassan E, 2002, CAN GEOTECH J, V39, P1126, DOI 10.1139/T02-052; Rujikiatkamjorn C, 2007, CAN GEOTECH J, V44, P326, DOI 10.1139/T06-124; Chai J, 2013, GEOTECHNIQUE, V63, P842, DOI [10.1680/geot.12.P060, 10.1680/geot.12.P.060]; Xue JF, 2014, GEOTEXT GEOMEMBRANES, V42, P302, DOI 10.1016/j.geotexmem.2014.05.003; Asaoka A., 1978, SOILS FOUND, V18, P87; Bari MW, 2014, GEOTEXT GEOMEMBRANES, V42, P1, DOI 10.1016/j.geotexmem.2013.11.001; Bergado D. T., 1999, LOWLAND TECH INT, V1, P55; Bergado D. T., 2006, P 6 S SOFT GROUND IM, P18; Bergado D.T., 1996, GEOTECH ENG J, V27, P1; Bergado D. T., 1996, Geosynthetics International, V3, P63; Bergado D.T., 1998, J GEOTECH ENG SE ASI, V29, P95; Carillo N., 1942, J MATH PHYS, V21, P1; Chai J. C., 2007, P 3 CHIN JAP JOINT G; Chai J. C., 2006, P 21 GEOS S AOM JAP; Chai J. C., 2000, P INT SEM GEOT KOCH, P161; Chai J. C., 2005, P 16 INT C SOIL MECH; Chai J.C., 2003, P 18 GEOS S JAP BRAN, V18, P231; Chai J.C., 2013, GROUND IMPROV, V166, P65; CHOA V, 1989, PROCEEDINGS OF THE TWELFTH INTERNATIONAL CONFERENCE ON SOIL MECHANICS AND FOUNDATION ENGINEERING, VOL 2, P1347; Chu J., 2005, INT J GEOMECH, V5, P158, DOI DOI 10.1061/(ASCE)1532-3641(2005); COFRA (Thailand), 1996, DES PROP EX TEST FIE; Cognon J.M., 1994, ASCE SPECIAL PUBLICA, V40, P1237; Hanbo S., 1979, GROUND ENG, V12, P16; Hansbo S., 1981, P 10 INT C SOIL MECH, V3, P677; Hibbitt, 2006, ABAQUS STAND US MAN; Holtz R.D., 1975, TRANSPORT RES REC, V548, P26; Indraratna B., 2010, GROUND IMPROV, V163, P31; Indraratna B., 2009, P 17 INT C SOIL MECH, P2204; Kjellman W., 1952, P C SOIL STAB MIT BO, P258; Lam L.G., 2014, P 9 INT S LOWL TECHN, P313; Liu JC, 2014, GEOTEXT GEOMEMBRANES, V42, P267, DOI 10.1016/j.geotexmem.2014.04.001; Saowapakpiboon J., 2010, LOWL TECHNOL INT J, V13, P2; Saowapakpiboon J., 2008, LOWLAND TECHNOLOGY I, V10, P42; Saowapakpiboon J., 2008, P 4 AS REG C GEOS SH, P18; Shahiduzzaman M., 2010, LOWL TECHNOL INT J, V12, P23; Voottipruex P, 2014, GEOTEXT GEOMEMBRANES, V42, P457, DOI 10.1016/j.geotexmem.2014.07.004; Wu Y.J., 2013, LOWL TECHNOL INT J, V15, P23; Xu F, 2014, GEOSYNTH INT, V21, P286, DOI 10.1680/gein.14.00016; Yan S. W., 2006, LOWL TECHNOL INT J, V8, P1	60	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0266-1144	1879-3584		GEOTEXT GEOMEMBRANES	Geotext. Geomembr.	NOV	2015	43	6			SI		547	557		10.1016/j.geotexmem.2015.07.013		11	Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	CT8NO	WOS:000363073500010		
J	Chai, JC; Rondonuwu, SG				Chai, Jinchun; Rondonuwu, Steeva Gaily			Surcharge loading rate for minimizing lateral displacement of PVD improved deposit with vacuum pressure	GEOTEXTILES AND GEOMEMBRANES			English	Article						Preloading; Consolidation; Vacuum pressure; Lateral displacement; Loading rate	PRELOADING METHOD; SOIL IMPROVEMENT; CONSOLIDATION	A series of laboratory radial drainage odometer and triaxial tests were conducted to investigate the deformation behaviour of clayey soils under combined vacuum pressure and surcharge loads. Based on the test results, a method for determining the optimum surcharge loading rate (SLR) which will result in minimum lateral displacement of a deposit under combined loads has been proposed. The method using a dimensionless parameter, a, defined as the ratio of SLR and the parameters controlling the rate of consolidation of a deposit improved by prefabricated vertical drains (PVDs). The ratio between surcharge load (Delta sigma(s)) to the vacuum pressure (Delta sigma(vac)) is designated as (LR = Delta sigma(s)/vertical bar Delta sigma(vac)vertical bar). Values for the optimum SLR increase with increasing of initial effective stress in the soil and with reducing LR. It is suggested that the method can be used for design the preloading project with combined vacuum and surcharge loads. (C) 2015 Elsevier Ltd. All rights reserved.	[Chai, Jinchun; Rondonuwu, Steeva Gaily] Saga Univ, Dept Civil Engn & Architecture, Saga 8408502, Japan	Chai, JC (reprint author), Saga Univ, Dept Civil Engn & Architecture, 1 Honjo, Saga 8408502, Japan.	chai@cc.saga-u.ac.jp; 12634008@edu.cc.saga-u.ac.jp					Shang JQ, 1998, CAN GEOTECH J, V35, P740, DOI 10.1139/cgj-35-5-740; Artidteang S, 2011, GEOSYNTH INT, V18, P35, DOI 10.1680/gein.2011.18.1.35; Indraratna B, 2011, J GEOTECH GEOENVIRON, V137, P1009, DOI 10.1061/(ASCE)GT.1943-5606.0000519; Chu J, 2000, GEOTECHNIQUE, V50, P625; Indraratna B, 2012, GEOTEXT GEOMEMBRANES, V30, P16, DOI 10.1016/j.geotexmem.2011.01.004; Chai JC, 2005, J GEOTECH GEOENVIRON, V131, P1552, DOI 10.1061/(ASCE)1090-0241(2005)131:12(1552); Chai J, 2013, GEOTECHNIQUE, V63, P842, DOI [10.1680/geot.12.P060, 10.1680/geot.12.P.060]; Yan SW, 2005, CAN GEOTECH J, V42, P1094, DOI 10.1139/T05-042; Bergado D.T., 1998, J GEOTECH ENG SE ASI, V29, P95; Chai J.-C., 2011, P 14 AS REG C SOIL M; Chai J.-C., 2012, GEOTECH TEST J ASTM, V35, P1; Chai J.C., 2013, GEOTECH ENG J SEAGS, V44, P1; Hansbo S., 1981, P 10 INT C SOIL MECH, V3, P677; Kelly R.B., 2009, AUST GEOMECH, V44, P55; Long P.V., 2013, GEOTECH ENG J SEAGS, V44, P37; Miura N., 1998, INDIAN GEOTECH J, V28, P121; Ohtsubo K., 1995, GEOTECHNIQUE, V45, P509; Ong C. Y., 2011, FRONTIERS ARCHITECTU, V5, P239, DOI DOI 10.1007/S11709-011-0110-1; Xu F, 2014, GEOSYNTH INT, V21, P286, DOI 10.1680/gein.14.00016	19	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0266-1144	1879-3584		GEOTEXT GEOMEMBRANES	Geotext. Geomembr.	NOV	2015	43	6			SI		558	566		10.1016/j.geotexmem.2015.07.012		9	Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	CT8NO	WOS:000363073500011		
J	Tanaka, K; Tamiya-Koizumi, K; Yamada, M; Murate, T; Kannagi, R; Kyogashima, M				Tanaka, Kouji; Tamiya-Koizumi, Keiko; Yamada, Masaki; Murate, Takashi; Kannagi, Reiji; Kyogashima, Mamoru			Hypoxia remodels the composition of the constituent ceramide species of HexCer and Hex2Cer with phytosphingosine and hydroxy fatty acids in human colon cancer LS174T cells	GLYCOCONJUGATE JOURNAL			English	Article						Ceramides; Glycosphingolipids; Hypoxia; Sphingolipid-species; Phytosphingosine; Hydroxy-fatty acid	ESCHERICHIA-COLI; DIHYDROCERAMIDE; TRANSPORT; GLYCOSPHINGOLIPIDS; SPHINGOMYELIN; METABOLISM; IDENTIFICATION; SPHINGANINE; DESATURASE; INTESTINE	Oxygen-requiring enzymes, such as Delta 4-desaturase (dihydroceramide desaturase), sphingolipid Delta 4-desaturase/C-4-hydroxylase, and fatty acid 2-hydroxylase are involved in ceramide synthesis. We prepared free ceramides, sphingomyelins and glycosphingolipids (GSLs) from cancer cells cultivated under conditions of normoxia and hypoxia, and analyzed these compounds using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Human colon cancer LS174T cells were employed because these cells highly express hydroxyl fatty acids and phytosphingosine (t18:0) which are expected to be greatly influenced by changes in oxygen levels. As expected, the populations of dihydro-species of free ceramide and sphingomyelin with C16:0 non-hydroxy fatty acid were elevated, and the populations of HexCers and Hex2Cers, composed of C16:0 or C16:0 hydroxy fatty acid (C16:0h), and sphingosine (d18:1) or t18:0, were decreased under hypoxia. However, appreciable populations of HexCer and Hex2Cer species of C24:0 or C24:0h and t18:0 remained. These results suggest that the individual species of GSLs with fatty acids possessing different alkyl chain lengths, either non-hydroxy fatty acids or hydroxyl fatty acids, may be metabolized individually.	[Tanaka, Kouji; Tamiya-Koizumi, Keiko; Murate, Takashi] Nagoya Univ, Grad Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; [Yamada, Masaki] Shimadzu Co Ltd, Nakagyo Ku, Kyoto 6048511, Japan; [Kannagi, Reiji] Aichi Med Univ, Res Complex Med Frontiers, Nagakute, Aichi 4801195, Japan; [Kyogashima, Mamoru] Nihon Pharmaceut Univ, Dept Microbiol & Mol Cell Biol, Ina, Saitama 3620806, Japan	Kyogashima, M (reprint author), Nihon Pharmaceut Univ, Dept Microbiol & Mol Cell Biol, Komuro 10281, Ina, Saitama 3620806, Japan.	mkyogashi@nichiyaku.ac.jp					DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Alderson NL, 2004, J BIOL CHEM, V279, P48562, DOI 10.1074/jbc.M406649200; Airley RE, 2007, CHEMOTHERAPY, V53, P233, DOI 10.1159/000104457; KYOGASHIMA M, 1986, JPN J EXP MED, V56, P113; Yamaji T, 2015, TRAFFIC, V16, P101, DOI 10.1111/tra.12239; Hanada K, 2010, P JPN ACAD B-PHYS, V86, P426, DOI 10.2183/pjab.86.426; Tidhar R, 2013, BBA-MOL CELL RES, V1833, P2511, DOI 10.1016/j.bbamcr.2013.04.010; NISHIMURA K, 1987, COMP BIOCHEM PHYS B, V86, P149, DOI 10.1016/0305-0491(87)90190-8; Mizutani Y, 2008, J LIPID RES, V49, P2356, DOI 10.1194/jlr.M800158-JLR200; Yoneshige A, 2010, J NUTR BIOCHEM, V21, P214, DOI 10.1016/j.jnutbio.2008.12.009; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Dyatlovitskaya EV, 2001, BIOCHEMISTRY-MOSCOW+, V66, P502, DOI 10.1023/A:1010250600604; Tanaka K, 2011, GLYCOCONJUGATE J, V28, P67, DOI 10.1007/s10719-011-9325-6; Rylova SN, 1999, BIOCHEMISTRY-MOSCOW+, V64, P437; Hakomori SI, 2008, BBA-GEN SUBJECTS, V1780, P325, DOI 10.1016/j.bbagen.2007.08.015; Kyogashima M, 2006, GLYCOBIOLOGY, V16, P719, DOI 10.1093/glycob/cwj122; KANNAGI R, 1983, CANCER RES, V43, P4997; Kyogashima M, 2008, J BIOCHEM, V144, P95, DOI 10.1093/jb/mvn050; SAITO T, 1971, J LIPID RES, V12, P257; Ishibashi Y, 2013, BBA-MOL CELL BIOL L, V1831, P1475, DOI 10.1016/j.bbalip.2013.06.001; Giussani P, 2008, BBA-MOL CELL BIOL L, V1781, P40, DOI 10.1016/j.bbalip.2007.11.002; Taniguchi M, 2014, BBA-MOL CELL BIOL L, V1841, P692, DOI 10.1016/j.bbalip.2013.12.003; Fabrias G, 2012, PROG LIPID RES, V51, P82, DOI 10.1016/j.plipres.2011.12.002; Tanaka K, 2014, GLYCOCONJUGATE J, V31, P209, DOI 10.1007/s10719-013-9511-9; Mizutani Y, 2004, FEBS LETT, V563, P93, DOI 10.1016/S0014-5793(04)00274-1; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; KYOGASHIMA M, 1989, ARCH BIOCHEM BIOPHYS, V270, P391, DOI 10.1016/0003-9861(89)90042-8; Enomoto A, 2006, BIOCHEM J, V397, P289, DOI 10.1042/BJ20051938; Karlsson KA, 2001, ADV EXP MED BIOL, V491, P431; Devlin CM, 2011, J BIOL CHEM, V286, P38069, DOI 10.1074/jbc.M111.297994; Kota Venkatesh, 2014, Advances in Biological Regulation, V54, P223, DOI 10.1016/j.jbior.2013.09.012; D'Angelo G, 2013, NATURE, V501, DOI 10.1038/nature12423; Honke K, 2014, HDB GLYCOSYLTRANSFER, P131; Johansson MM, 2014, MICROB PATHOGENESIS, V76, P51, DOI 10.1016/j.micpath.2014.09.009	34	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0282-0080	1573-4986		GLYCOCONJUGATE J	Glycoconjugate J.	NOV	2015	32	8					615	623		10.1007/s10719-015-9607-5		9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CU4HK	WOS:000363488300004		
J	Bhanu, LSM; Amano, M; Nishimura, SI; Aparna, HS				Bhanu, L. S. Mamatha; Amano, M.; Nishimura, S. -I.; Aparna, H. S.			Glycome characterization of immunoglobulin G from buffalo (Bubalus bubalis) colostrum	GLYCOCONJUGATE JOURNAL			English	Article						Bubalus bubalis; Colostrum; Glycoblotting; Immunoglobulin G; MALDI-TOF MS	MONOCLONAL-ANTIBODY; MILK; BINDING; SERUM; SITE; OLIGOSACCHARIDES; GLYCOSYLATION; GLYCAN	Immunoglobulin G (IgG) is a major glycoprotein in ruminant colostrum. First day buffalo colostrum protein was purified on Sephadex G-100 and its mass was determined by MALDI-TOF as 147.848 KDa. The PMF data of protein subunits revealed its homology to IgG, which was supported by the identification of peptide sequences LLIYGATSR and VYNEYLPAPIVR corresponding to light and heavy chains of IgG by CID MS/MS analysis. The N-glycan microheterogeneity was established based on chemoselective glycoblotting technique with the identification of high mannose, neutral complex/hybrid and sialylated complex/hybrid glycans. A complete structural assignment of 54 N-linked oligosaccharides were identified and the ratio of sialyl oligosaccharides was found to be higher compared to neutral saccharides. The fucosylation observed in more than 20 oligosaccharides, high mannose and trisialyl oligosaccharides were present in diminutive amount. The high non-fucosyl and sialyl oligosaccharides in buffalo colostrum IgG provide ample scope for its utilization in targeted therapies to elicit effective ADCC and anti-inflammatory responses.	[Bhanu, L. S. Mamatha; Aparna, H. S.] Univ Mysore, Dept Biotechnol, Mysore 570006, Karnataka, India; [Amano, M.; Nishimura, S. -I.] Hokkaido Univ, Fac Adv Life Sci, Sapporo, Hokkaido 0010021, Japan	Aparna, HS (reprint author), Univ Mysore, Dept Biotechnol, Mysore 570006, Karnataka, India.	ls.mamatha@gmail.com			Indian National Science Academy (INSA); Japan Society for the Promotion of Science (JSPS)	This work was supported by the Indian National Science Academy (INSA) and the Japan Society for the Promotion of Science (JSPS) fund.	Alain O., 1999, J DAIRY RES, V66, P421; Gapper LW, 2007, ANAL BIOANAL CHEM, V389, P93, DOI 10.1007/s00216-007-1391-z; Nwosu CC, 2012, J PROTEOME RES, V11, P2912, DOI 10.1021/pr300008u; Furukawa JI, 2008, ANAL CHEM, V80, P1094, DOI 10.1021/ac702124d; Mesmin C, 2012, RAPID COMMUN MASS SP, V26, P163, DOI 10.1002/rcm.5326; Hodoniczky J, 2005, BIOTECHNOL PROGR, V21, P1644, DOI 10.1021/bp050228w; Ezan E, 2009, BIOANALYSIS, V1, P1375, DOI [10.4155/bio.09.121, 10.4155/BIO.09.121]; Suckau D, 2003, ANAL BIOANAL CHEM, V376, P952, DOI 10.1007/s00216-003-2057-0; Menon S, 2009, P NATL ACAD SCI USA, V106, P11524, DOI 10.1073/pnas.0901783106; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Aparna HS, 2001, J FOOD SCI TECH MYS, V38, P450; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Menegatti S, 2013, BIOTECHNOL BIOENG, V110, P857, DOI 10.1002/bit.24760; Colarow L, 2003, BBA-MOL CELL BIOL L, V1631, P94, DOI 10.1016/S1388-1981(02)00360-8; SATO T, 1995, J BIOCHEM-TOKYO, V117, P147; Martinez-Ferez A, 2006, INT DAIRY J, V16, P173, DOI 10.1016/j.idairyj.2005.02.003; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; Junttila TT, 2010, CANCER RES, V70, P4481, DOI 10.1158/0008-5472.CAN-09-3704; Takimori S, 2011, FEBS J, V278, P3769, DOI 10.1111/j.1742-4658.2011.08299.x; Wei Z, 2000, J DAIRY SCI, V83, P683; Kanade SR, 2009, GLYCOCONJUGATE J, V26, P535, DOI 10.1007/s10719-008-9205-x; Kita Y, 2007, MOL CELL PROTEOMICS, V6, P1437, DOI 10.1074/mcp.T600063-MCP200; Zeitlin L, 2011, P NATL ACAD SCI USA, V108, P20690, DOI 10.1073/pnas.1108360108; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Urashima T, 2013, BIOSCI BIOTECH BIOCH, V77, P455, DOI 10.1271/bbb.120810; Antonius M., 2000, BR J NUTR, V84, P127; Aparna H.S., 2011, J BIOCH, V150, P279; Arnold N., 2007, ANNU REV IMMUNOL, V25, P21; Aurelia P., 2009, Journal of Central European Agriculture, V10, P201; Bulter J.E., 1983, VET IMMUNOL IMMUNOP, V4, P43; Dang A.K., 2008, TROP ANIM HLTH PRO, V41, P1213; Elke S., 2008, MALARIAL J, V7, P129; Gill H.S., 2000, BR J NUTR, V84, P69; Goodman W., 1987, BASIC CLIN IMMUNOL, P27; Korhonen H, 2000, BR J NUTR, V84, P75; KULKARNI BA, 1981, INDIAN J BIOCHEM BIO, V18, P28; Nongluk S., 2012, OPEN GLYSOSCI, V5, P41; Premysl K., 1994, J CHROMATOGR A, V673, P45; Robert A., 2012, ANN NY ACAD SCI, V1253, P170; Robert M.A., 2013, ANTIBODIES, V2, P392; Tong F., 2012, J CHROMATOGR A, V1244, P116; Uruakpa O., 2002, NUTR RES, V22, P755; Wu H., 2011, PLOS ONE, V6	43	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0282-0080	1573-4986		GLYCOCONJUGATE J	Glycoconjugate J.	NOV	2015	32	8					625	634		10.1007/s10719-015-9608-4		10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CU4HK	WOS:000363488300005		
J	Shiba, C; Shiba, T; Takahashi, M; Hori, Y; Maeno, T				Shiba, Chieko; Shiba, Tomoaki; Takahashi, Mao; Hori, Yuichi; Maeno, Takatoshi			Relationships among serum lipoprotein lipase mass, visceral fat, and retinal nerve fiber layer thickness	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						Lipoprotein lipase mass; Retinal nerve layer fiber thickness; Visceral fat; Subcutaneous fat; Optical coherence tomography	GLAUCOMA; METABOLISM	The purpose of the study was to determine whether there were significant correlations among the serum lipoprotein lipase mass, visceral fat, and the retinal nerve fiber layer (RNFL) thickness. We studied 118 consecutive subjects. Optical coherence tomography (OCT) was used to measure the RNFL thickness. The Pearson correlation coefficient was used to determine the relationships among lipoprotein lipase (LPL) mass, visceral fat area by computed tomography, OCT, and other parameters. We performed a multiple regression analysis to identify independent factors for the RNFL sectors that were the most strongly correlated with the LPL mass and visceral fat area. The LPL mass was significantly correlated with the nasal RNFL thickness in both eyes (right eye: r = 0.24, p = 0.008, left eye: 0.32, 0.0008) and inferior RNFL thickness in the left eye ( r = 0.23, p = 0.01). The visceral fat area was significantly correlated with the nasal RNFL thickness in both eyes (right eye: r = -0.19, p = 0.04, left eye: -0.30, 0.0008) and the inferior RNFL thickness in the left eye ( r = -0.23, p = 0.01). The subcutaneous fat area was not significantly correlated with any OCT parameters. The multiple regression analysis revealed that age, LPL mass, and visceral fat area were independent contributors to the nasal RNFL thickness in the left eye (age, standard regression coefficient = -0.34 , p = 0.0004; LPL mass, 0.26, 2.49, 0.01; visceral fat area, -0.21, 0.03). A reduction of lipoprotein lipase and accumulation of visceral fat might produce retinal neurodegenerative disorders that decrease the RNFL thickness, especially on the nasal side.	[Shiba, Chieko; Shiba, Tomoaki; Maeno, Takatoshi] Toho Univ, Sakura Med Ctr, Dept Ophthalmol, Sakura, Chiba 2858741, Japan; [Takahashi, Mao] Toho Univ, Sakura Med Ctr, Ctr Cardiovasc, Sakura, Chiba 2858741, Japan; [Hori, Yuichi] Toho Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan	Shiba, T (reprint author), Toho Univ, Sakura Med Ctr, Dept Ophthalmol, 564-1 Shimoshizu, Sakura, Chiba 2858741, Japan.	tomoaki-s@sakura.med.toho-u.ac.jp					FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; Saiki A, 2005, J ATHEROSCLER THROMB, V12, P163; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; Jaffe GJ, 2004, AM J OPHTHALMOL, V137, P156, DOI 10.1016/S0002-9394(03)00792-X; QUIGLEY HA, 1989, AM J OPHTHALMOL, V107, P453; Lee VWH, 1999, OPHTHALMOLOGY, V106, P1006, DOI 10.1016/S0161-6420(99)00524-2; NILSSONEHLE P, 1980, ANNU REV BIOCHEM, V49, P667, DOI 10.1146/annurev.bi.49.070180.003315; Kwon YH, 2000, J GLAUCOMA, V9, P281; Leung DYL, 2010, OPHTHALMOLOGY, V117, P471, DOI 10.1016/j.ophtha.2009.08.016; Watanabe H, 1999, ATHEROSCLEROSIS, V145, P45, DOI 10.1016/S0021-9150(99)00012-X; BRUNZELL JD, 2001, METABOLIC MOL BASES, P2789; Endo Kei, 2004, J Atheroscler Thromb, V11, P341; Kim M, 2014, ACTA OPHTHALMOL, DOI [10.1111/aos.12434.2014.05.19, DOI 10.1111/AOS.12434.2014.05.19]; Kobayashi Junji, 2004, J Atheroscler Thromb, V11, P1; Quigley HA, 1996, NUMBER, V80, P389	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	NOV	2015	253	11					1883	1888		10.1007/s00417-014-2898-6		6	Ophthalmology	Ophthalmology	CT8IE	WOS:000363057900007		
J	Ohtake-Matsumoto, A; Keino, H; Koto, T; Okada, AA				Ohtake-Matsumoto, Anna; Keino, Hiroshi; Koto, Takashi; Okada, Annabelle A.			Spectral domain and swept source optical coherence tomography findings in acute retinal necrosis	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Letter									[Ohtake-Matsumoto, Anna; Keino, Hiroshi; Koto, Takashi; Okada, Annabelle A.] Kyorin Univ, Dept Ophthalmol, Sch Med, Mitaka, Tokyo 1818611, Japan	Okada, AA (reprint author), Kyorin Univ, Dept Ophthalmol, Sch Med, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	aokada@eye-center.org					Suzuki J, 2006, OCUL IMMUNOL INFLAMM, V14, P165, DOI 10.1080/09273940600672198; CULBERTSON WW, 1982, OPHTHALMOLOGY, V89, P1317; HOLLAND GN, 1994, AM J OPHTHALMOL, V117, P663; Kurup SP, 2014, RETINA-J RET VIT DIS, V34, P2233, DOI 10.1097/IAE.0000000000000218; Urayama A, 1971, JPN J CLIN OPHTHAL, V25, P607	5	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	NOV	2015	253	11					2049	2051		10.1007/s00417-015-3051-x		3	Ophthalmology	Ophthalmology	CT8IE	WOS:000363057900030		
J	Yanagisawa, S; Soyano, A; Igarashi, H; Ura, M; Nakamura, Y				Yanagisawa, Satoko; Soyano, Ayako; Igarashi, Hisato; Ura, Midori; Nakamura, Yasuhide			Effect of a maternal and child health handbook on maternal knowledge and behaviour: a community-based controlled trial in rural Cambodia	HEALTH POLICY AND PLANNING			English	Article						Antenatal care; difference-in-differences analysis; home-based record; maternal and child health (MCH) handbook; maternal outcome; skilled birth attendant	RECORD; MANAGEMENT; INDONESIA; PROGRAM; MOTHERS	Maternal and child health (MCH) handbooks are comprehensive home-based booklets designed to integrate MCH records. Although empirical evidence suggests the handbooks are more effective than current card-type records, this has not been scientifically demonstrated. The objectives of this study were to evaluate the impact of the MCH handbook on maternal knowledge and behaviour as measured by antenatal care (ANC) attendance, delivery with skilled birth attendants (SBAs) and delivery at a health facility. The Cambodian version of the MCH handbook was developed and introduced in two health centres, and two other health centres served as controls. Pre-intervention and post-intervention surveys were conducted with 320 women from the intervention areas and 320 women from the control areas who had given birth within 1 year before the survey. We evaluated the impact of the handbook by using difference-in-differences (DID) analysis and calculated adjusted odds ratios for pre-post changes in key indicators by using logistic regression. In addition, we interviewed multiparous women, health staff and health volunteers to assess the acceptance and cultural appropriateness of the handbook. Content analysis was performed with the English-translated transcriptions. The DID analyses revealed that all key indicators increased in the intervention group against counterfactual assumptions. The intervention also increased maternal knowledge of all topics addressed except for the risk of severe bleeding after delivery; this may be attributable to the influence of cultural belief. Logistic regression showed that the intervention increased ANC attendance, delivery with SBAs and delivery at a health facility, even after adjusting for maternal age, education and economic conditions. The qualitative data indicated that the handbook was well received and culturally appropriate. Thus, the MCH handbook is a reasonable and superior alternative to current card-type maternal records.	[Yanagisawa, Satoko] Aichi Prefectural Univ, Sch Nursing & Hlth, Nagoya, Aichi 4638502, Japan; [Soyano, Ayako] Saku Univ, Sch Nursing, Saku, Nagano 3850022, Japan; [Igarashi, Hisato] Shinshu Univ, Sch Hlth Sci, Matsumoto, Nagano 390, Japan; [Ura, Midori] Shinshu Univ Hosp, Dept Lab Med, Matsumoto, Nagano 3908621, Japan; [Nakamura, Yasuhide] Osaka Univ, Grad Sch Human Sci, Suita, Osaka 5650871, Japan	Yanagisawa, S (reprint author), Aichi Prefectural Univ, Moriyama Ku, Nagoya, Aichi 4638502, Japan.	sayanagi@nrs.aichi-pu.ac.jp			Ministry of Education, Culture, Sports, Science and Technology in Japan [C 18390599]	This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan (grant number: C 18390599).	Aihara Y, 2006, J INT HLTH, V21, P123; De Clercq PA, 2003, MED INFORM INTERNET, V28, P117, DOI 10.1080/14639230310001600506; Mahomed K, 2000, TROP DOCT, V30, P155; McMaster P, 1996, J ROY SOC MED, V89, P202; Osaki K, 2009, T ROY SOC TROP MED H, V103, P846, DOI 10.1016/j.trstmh.2009.03.011; SHAH PM, 1993, B WORLD HEALTH ORGAN, V71, P535; ESSEN B, 1994, J TROP PEDIATRICS, V40, P130; Osaki K, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.20429; Thompson ME, 2009, HEALTH POLICY PLANN, V24, P101, DOI 10.1093/heapol/czn048; Hagiwara A, 2013, J PUBLIC HEALTH POL, V34, P31, DOI 10.1057/jphp.2012.56; Baequni Nakamura Y, 2012, J INT HLTH, V27, P121; Bhuiyan SU, 2006, J PUBLIC HLTH DEV, V4, P45; Brown HC, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002856.pub2, DOI 10.1002/14651858.CD002856.PUB2]; Gertler PJ, 2011, IMPACT EVALUATION IN PRACTICE, P1, DOI 10.1596/978-0-8213-8541-8; Isaranurag S., 2009, J INT HLTH, V24, P61; Kusumayati A, 2007, J INT HLTH, V22, P143; Murira N., 1996, Central African Journal of Medicine, V42, P297; National Institute of Public Health National Institute of Statistics (CAMBODIA) ORC Macro., 2006, CAMB DEM HLTH SURV; National Institute of Statistics, 2009, GEN POP CENS CAMB 20; Østerlund Carsten S, 2005, AMIA Annu Symp Proc, P580; Pandara VE, 2006, UTILIZATION MCH HDB; World Health Organization, 1994, HOM BAS MAT REC GUID; World Health Organization Regional Office for Africa, 2012, KEN 8 INT C MCH HDB	23	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1080	1460-2237		HEALTH POLICY PLANN	Health Policy Plan.	NOV	2015	30	9					1184	1192		10.1093/heapol/czu133		9	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	CT7QA	WOS:000363008400009		
J	Sugi, K; Nakano, S; Fukasawa, Y; Maruyama, R; Tanno, J; Senbonmatsu, T; Nishimura, S				Sugi, Keiki; Nakano, Shintaro; Fukasawa, Yusuke; Maruyama, Ryugen; Tanno, Jun; Senbonmatsu, Takaaki; Nishimura, Shigeyuki			Percutaneous Coronary Intervention for Septic Emboli in the Left Main Trunk as a Complication of Infective Endocarditis	HEART LUNG AND CIRCULATION			English	Article						Myocardial infarction; Percutaneous coronary intervention; Infective endocarditis; Coronary emboli; Left main coronary artery		Infective endocarditis (IE) complicated by acute myocardial infarction (AMI) is frequently fatal and may require emergent interventions. However, the optimal treatment of this rare condition remains controversial as it lacks established guidelines. We successfully treated a patient with IE complicated by AMI during the acute phase using percutaneous coronary intervention (PCI) followed by surgery. A 73-year-old man was diagnosed with IE of the mitral and aortic valves caused by Streptococcus oralis. Four weeks after the initiation of antibiotics sensitive to the causative bacteria, he suddenly developed AMI manifested by chest pain and dyspnoea with cardiovascular collapse. Emergent coronary angiography revealed that the myocardial infarction was secondary to septic emboli in the left main trunk. Emergent PCI comprising aspiration and stent deployment, was successfully performed, and his vital signs were immediately stabilised. He subsequently underwent mitral and aortic valve replacement and debridement without major post-operative complications. Although the optimal treatment strategy for haemodynamically unstable AMI secondary to IE requires further discussion, the present case indicates the importance of early diagnosis and the potential effectiveness of aggressive PCI as a bridge to the following surgery.	[Sugi, Keiki; Nakano, Shintaro; Fukasawa, Yusuke; Maruyama, Ryugen; Tanno, Jun; Senbonmatsu, Takaaki; Nishimura, Shigeyuki] Saitama Med Univ, Int Med Ctr, Div Cardiol, Hidaka, Saitama 3501298, Japan	Sugi, K (reprint author), Saitama Med Univ, Int Med Ctr, Div Cardiol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan.	keiki_s@saitama-med.ac.jp					DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; Seo GW, 2014, INTERNAL MED, V53, P713, DOI 10.2169/internalmedicine.53.1415; Roxas CJ, 2011, J EMERG MED, V40, P509, DOI 10.1016/j.jemermed.2007.12.041; Bor DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060033; Rischin AP, 2015, HEART LUNG CIRC, V24, pE1, DOI 10.1016/j.hlc.2014.07.070; Singh M, 2015, CATHETER CARDIOVASC	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1443-9506	1444-2892		HEART LUNG CIRC	Heart Lung Circ.	NOV	2015	24	11					E176	E179		10.1016/j.hlc.2015.06.819		4	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU4GZ	WOS:000363487100003		
J	Kamada, Y; Ono, M; Hyogo, H; Fujii, H; Sumida, Y; Mori, K; Tanaka, S; Yamada, M; Akita, M; Mizutani, K; Fujii, H; Yamamoto, A; Takamatsu, S; Yoshida, Y; Itoh, Y; Kawada, N; Chayama, K; Saibara, T; Takehara, T; Miyoshi, E				Kamada, Yoshihiro; Ono, Masafumi; Hyogo, Hideyuki; Fujii, Hideki; Sumida, Yoshio; Mori, Kojiroh; Tanaka, Saiyu; Yamada, Makoto; Akita, Maaya; Mizutani, Kayo; Fujii, Hironobu; Yamamoto, Akiko; Takamatsu, Shinji; Yoshida, Yuichi; Itoh, Yoshito; Kawada, Norifumi; Chayama, Kazuaki; Saibara, Toshiji; Takehara, Tetsuo; Miyoshi, Eiji			A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers	HEPATOLOGY			English	Article							FATTY LIVER-DISEASE; FUCOSYLATED HAPTOGLOBIN; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; NATURAL-HISTORY; SEVERELY OBESE; SCORING SYSTEM; CELL-LINES; N-GLYCANS; FIBROSIS	Nonalcoholic fatty liver disease (NAFLD) is a growing medical problem; thus, discriminating nonalcoholic steatohepatitis (NASH) from NAFLD is of great clinical significance. For the diagnosis of NASH, liver biopsy-proven histological examination is the current gold standard, and noninvasive and reliable biomarkers are greatly needed. Recently, we found that two glycobiomarkers, fucosylated haptoglobin (Fuc-Hpt) and Mac-2 binding protein (Mac2bp), are useful independently for NASH diagnosis. In this study, we confirmed that serum Fuc-Hpt is suitable for the prediction of ballooning hepatocytes and that serum Mac2bp is suitable for the prediction of liver fibrosis severity in 124 biopsy-proven NAFLD patients (training cohort). In addition, we found that the combination of serum Fuc-Hpt and Mac2bp levels was an excellent tool for NASH diagnosis. Using receiver operating characteristic analyses, the area under the receiver operating characteristic curve, sensitivity, and specificity of the combination of these two glycobiomarkers were 0.854, 81.1%, and 79.3%, respectively. We established a prediction model for NASH diagnosis using logistic regression analysis: logit (p)=-2.700+0.00242 x Fuc-Hpt+1.225 x Mac2bp. To validate the prediction model, another 382 biopsy-proven NAFLD patients were enrolled (validation cohort). In the validation cohort, the area under the receiver operating characteristic curve of this model for NASH diagnosis was 0.844, with 71.4% and 82.3% sensitivity and specificity, respectively. In addition, we investigated the significance of our developed NASH diagnosis model in ultrasound-diagnosed NAFLD subjects who received medical health checkups (n=803). Our model also could predict NAFLD disease severity in this larger population. Conclusion: The combination of serum Fuc-Hpt and Mac2bp can distinguish NASH from NAFLD patients. Our noninvasive model using two serum glycobiomarkers contributes to a novel NASH diagnostic methodology that could replace liver biopsy. (Hepatology 2015;62:1433-1443)	[Kamada, Yoshihiro; Akita, Maaya; Mizutani, Kayo; Fujii, Hironobu; Yamamoto, Akiko; Takamatsu, Shinji; Miyoshi, Eiji] Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Osaka, Japan; [Kamada, Yoshihiro; Yoshida, Yuichi; Takehara, Tetsuo] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Osaka, Japan; [Ono, Masafumi; Saibara, Toshiji] Kochi Med Sch, Dept Gastroenterol & Hepatol, Kochi, Japan; [Hyogo, Hideyuki; Chayama, Kazuaki] Hiroshima Univ, Dept Gastroenterol & Metab, Hiroshima, Japan; [Fujii, Hideki; Kawada, Norifumi] Osaka City Univ, Grad Sch Med, Dept Hepatol, Osaka 558, Japan; [Fujii, Hideki] Osaka City Juso Hosp, Dept Gastroenterol, Osaka, Japan; [Sumida, Yoshio; Itoh, Yoshito] Kyoto Prefectural Univ Med, Dept Gastroenterol & Hepatol, Kyoto, Japan; [Mori, Kojiroh; Tanaka, Saiyu] Nara City Hosp, Ctr Digest & Liver Dis, Nara, Japan; [Yamada, Makoto] aMs New Otani Clin, Osaka, Japan	Miyoshi, E (reprint author), Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, 1-7 Yamada Oka, Suita, Osaka 5650871, Japan.	emiyoshi@sahs.med.oska-u.ac.jp			Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science [24590972, 15H04810]; Kurozumi Medical Foundation; Shimadzu Science Foundation; Kondou kinen Medical Foundation; Japanese Society of Laboratory Medicine Fund for the Promotion of Scientific Research	Supported as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan, and by Grants-in-Aid for Scientific Research (C, 24590972; B, 15H04810) from the Japan Society for the Promotion of Science, Kurozumi Medical Foundation, Shimadzu Science Foundation, Kondou kinen Medical Foundation, and Japanese Society of Laboratory Medicine Fund for the Promotion of Scientific Research.	Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Brunt EM, 2010, WORLD J GASTROENTERO, V16, P5286, DOI 10.3748/wjg.v16.i42.5286; Wieckowska A, 2006, HEPATOLOGY, V44, P27, DOI 10.1002/hep.21223; Okuyama N, 2006, INT J CANCER, V118, P2803, DOI 10.1002/ijc.21728; Kaneda H, 2006, J GASTROEN HEPATOL, V21, P1459, DOI 10.1111/j.1440-1746.2006.04447.x; Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168; Angulo P, 2007, HEPATOLOGY, V45, P846, DOI 10.1002/hep.21496; Shah AG, 2009, CLIN GASTROENTEROL H, V7, P1104, DOI 10.1016/j.cgh.2009.05.033; Ito K, 2012, HEPATOLOGY, V56, P1448, DOI 10.1002/hep.25815; Liou I, 2006, J CLIN GASTROENTEROL, V40, pS11; Callewaert N, 2004, NAT MED, V10, P429, DOI 10.1038/nm1006; Yoon Y, 1998, AM J PHYSIOL-GASTR L, V274, pG757; Ananth CV, 1997, INT J EPIDEMIOL, V26, P1323, DOI 10.1093/ije/26.6.1323; Wang MJ, 2009, CANCER EPIDEM BIOMAR, V18, P1914, DOI 10.1158/1055-9965.EPI-08-0980; Narisada M, 2008, BIOCHEM BIOPH RES CO, V377, P792, DOI 10.1016/j.bbrc.2008.10.061; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178; Artini M, 1996, J HEPATOL, V25, P212, DOI 10.1016/S0168-8278(96)80076-6; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Harrison SA, 2008, GUT, V57, P1441, DOI 10.1136/gut.2007.146019; Nakagawa T, 2006, J BIOL CHEM, V281, P29797, DOI 10.1074/jbc.M605697200; Kamada Y, 2013, PROTEOM CLIN APPL, V7, P648, DOI 10.1002/prca.201200137; Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466; Kajihara M, 2007, J GASTROEN HEPATOL, V22, P112, DOI 10.1111/j.1440-1746.2006.04359.x; Younossi ZM, 2011, HEPATOLOGY, V53, P1874, DOI 10.1002/hep.24268; Cheung KJ, 2009, J VIRAL HEPATITIS, V16, P418, DOI 10.1111/j.1365-2893.2009.01083.x; Miyoshi E, 2008, J BIOCHEM, V143, P725, DOI 10.1093/jb/mvn011; Kamada Y, 2013, CLIN CHIM ACTA, V417, P48, DOI 10.1016/j.cca.2012.12.014; Feldstein AE, 2009, HEPATOLOGY, V50, P1072, DOI 10.1002/hep.23050; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Przybylo M, 2007, BBA-GEN SUBJECTS, V1770, P1427, DOI 10.1016/j.bbagen.2007.05.006; Yoneda M, 2011, J GASTROENTEROL, V46, P1300, DOI 10.1007/s00535-011-0436-4; Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540; Gholam PM, 2007, AM J GASTROENTEROL, V102, P399, DOI 10.1111/j.1572-0241.2006.01041.x; Nakagawa T, 2012, J PROTEOME RES, V11, P2798, DOI 10.1021/pr201154k; Grassadonia Antonino, 2004, Glycoconjugate Journal, V19, P551; Kamada Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066328; Kuno A, 2013, SCI REP-UK, V3, DOI 10.1038/srep01065; Sumida Y, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-2; WANLESS IR, 1990, HEPATOLOGY, V12, P1106, DOI 10.1002/hep.1840120505	41	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2015	62	5					1433	1443		10.1002/hep.28002		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU1EZ	WOS:000363264100014		
J	Siddique, HR; Feldman, DE; Chen, CL; Punj, V; Tokumitsu, H; Machida, K				Siddique, Hifzur R.; Feldman, Douglas E.; Chen, Chia-Lin; Punj, Vasu; Tokumitsu, Hiroshi; Machida, Keigo			NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer	HEPATOLOGY			English	Article							TGF-BETA; MIGRATION; NETWORKS; LINKING; GENES	Stem cell populations are maintained through self-renewing divisions in which one daughter cell commits to a particular fate whereas the other retains the multipotent characteristics of its parent. The NUMB, a tumor suppressor, in conjunction with another tumor-suppressor protein, p53, preserves this property and acts as a barrier against deregulated expansion of tumor-associated stem cells. In this context, NUMB-p53 interaction plays a crucial role to maintain the proper homeostasis of both stem cells, as well as differentiated cells. Because the molecular mechanism governing the assembly and stability of the NUMB-p53 interaction/complex are poorly understood, we tried to identify the molecule(s) that govern this process. Using cancer cell lines, tumor-initiating cells (TICs) of liver, the mouse model, and clinical samples, we identified that phosphorylations of NUMB destabilize p53 and promote self-renewal of TICs in a pluripotency-associated transcription factor NANOG-dependent manner. NANOG phosphorylates NUMB by atypical protein kinase C zeta (aPKC), through the direct induction of Aurora A kinase (AURKA) and the repression of an aPKC inhibitor, lethal (2) giant larvae. By radioactivity-based kinase activity assays, we showed that NANOG enhances kinase activities of both AURKA and aPKC, an important upstream process for NUMB phosphorylation. Phosphorylation of NUMB by aPKC destabilizes the NUMB-p53 interaction and p53 proteolysis and deregulates self-renewal in TICs. Conclusion: Post-translational modification of NUMB by the NANOG-AURKA-aPKC pathway is an important event in TIC self-renewal and tumorigenesis. Hence, the NANOG-NUMB-p53 signaling axis is an important regulatory pathway for TIC events in TIC self-renewal and liver tumorigenesis, suggesting a therapeutic strategy by targeting NUMB phosphorylation. Further in-depth in vivo and clinical studies are warranted to verify this suggestion. (Hepatology 2015;62:1466-1479)	[Siddique, Hifzur R.; Feldman, Douglas E.; Chen, Chia-Lin; Machida, Keigo] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; [Punj, Vasu] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Tokumitsu, Hiroshi] Okayama Univ, Grad Sch Nat Sci & Technol, Div Med Bioengn, Okayama 7008530, Japan; [Machida, Keigo] Southern Calif Res Ctr Alcohol Liver & Pancreat D, Los Angeles, CA USA	Machida, K (reprint author), Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Hoffman Med Res Bldg,Room 503C,2011 Zonal Ave, Los Angeles, CA 90033 USA.	keigo.machida@med.usc.edu			Cell and Tissue Imaging Core of the USC Research Center for Liver Diseases; National Institutes of Health (NIH) [P30 DK048522, S10 RR022508]	Tissue pathological slide preparation was performed by Ms. Moli Chen of Norris Comprehensive Cancer Center. The authors also thank Prof. Dennis Strand (Johannes Gutenberg University, Mainz, Germany) and Prof. Yoshiaki Ishigatsubo (Yokohama City University, Yokohama, Japan) for generously providing the reporter plasmids for LGL2 and AURKA promoter, respectively. Fluorescence-activated cell sorting analysis was performed by the Flow Cytometry Core at University of Southern California (USC) Keck Medical Center and Cell Isolation Core, Research Center for Liver Diseases. Statistical analysis was performed by Dr. Susan Groshen and Ms. Lingyun Ji in Norris Comprehensive Cancer Center Biostatistics Core. Confocal microscopy services were provided by the Cell and Tissue Imaging Core of the USC Research Center for Liver Diseases and National Institutes of Health (NIH) grants P30 DK048522 and S10 RR022508.	Wirtz-Peitz F, 2008, CELL, V135, P161, DOI 10.1016/j.cell.2008.07.049; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Bric A, 2009, CANCER CELL, V16, P324, DOI 10.1016/j.ccr.2009.08.015; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Colaluca IN, 2008, NATURE, V451, P76, DOI 10.1038/nature06412; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kepp O, 2015, SEMIN CANCER BIOL, V33, P86, DOI 10.1016/j.semcancer.2015.02.004; March HN, 2011, NAT GENET, V43, P1202, DOI 10.1038/ng.990; Guntur VP, 2010, ANTICANCER RES, V30, P3557; Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546; Brooks CL, 2011, FEBS LETT, V585, P2803, DOI 10.1016/j.febslet.2011.05.022; Chen CL, 2013, J CLIN INVEST, V123, P2832, DOI 10.1172/JCI65859; Cohen P, 2006, NAT REV MOL CELL BIO, V7, P867, DOI 10.1038/nrm2043; Dhami GK, 2013, MOL CELL, V50, P565, DOI 10.1016/j.molcel.2013.04.028; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; CARLSSON G, 1983, J CANCER RES CLIN, V105, P20, DOI 10.1007/BF00391826; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Aparicio S, 2009, CELL, V138, P1060, DOI 10.1016/j.cell.2009.09.004; BOULIKAS T, 1995, INT J ONCOL, V6, P271; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Carter S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-221; Cuesta N, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001687; Li YX, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3174; Machida K, 2015, ADV EXP MED BIOL, V815, P131, DOI 10.1007/978-3-319-09614-8_8; Mu Y, 2015, BRIT J CANCER, V112, P1223, DOI 10.1038/bjc.2015.71; StataCorp, 2009, STAT STAT SOFTW REL	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2015	62	5					1466	1479		10.1002/hep.27987		14	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU1EZ	WOS:000363264100017		
J	Beuers, U; Gershwin, ME; Gish, RG; Invernizzi, P; Jones, DEJ; Lindor, K; Ma, X; Mackay, IR; Pares, A; Tanaka, A; Vierling, JM; Poupon, R				Beuers, Ulrich; Gershwin, M. Eric; Gish, Robert G.; Invernizzi, Pietro; Jones, David E. J.; Lindor, Keith; Ma, Xiong; Mackay, Ian R.; Pares, Albert; Tanaka, Atsushi; Vierling, John M.; Poupon, Raoul			Changing nomenclature for PBC: From "cirrhosis' to "cholangitis'	HEPATOLOGY			English	Article						Cholestasis; Cholangiopathy; Primary biliary cirrhosis	PRIMARY BILIARY-CIRRHOSIS; HCO3-UMBRELLA; CHOLANGIOCYTES; EXPRESSION		[Beuers, Ulrich] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; [Beuers, Ulrich] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands; [Gershwin, M. Eric] Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; [Gish, Robert G.] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA; [Invernizzi, Pietro] Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Milan, Italy; [Jones, David E. J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Lindor, Keith] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ USA; [Ma, Xiong] Shanghai Jiao Tong Univ, Shanghai Inst Digest Dis, Div Gastroenterol & Hepatol, Renji Hosp,Sch Med, Shanghai 200030, Peoples R China; [Mackay, Ian R.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia; [Pares, Albert] Univ Barcelona, CIBERehd, IDIBAPS, Hosp Clin Barcelona,Liver Unit, Barcelona, Spain; [Tanaka, Atsushi] Teikyo Univ, Sch Med, Dept Med, Tokyo 173, Japan; [Vierling, John M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Vierling, John M.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; [Poupon, Raoul] St Antoine Hosp, Serv Hepatol, Reference Ctr Inflammatory Biliary Dis, Paris, France	Beuers, U (reprint author), Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, Dept Gastroenterol & Hepatol, Meibergdreef 9, NL-1100 DE Amsterdam, Netherlands.	u.h.beuers@amc.uva.nl					Addison T, 1851, GUYS HOSP REP, V7, P265; AHRENS EH, 1950, MEDICINE, V29, P299; Sasaki M, 2013, LIVER INT, V33, P312, DOI 10.1111/liv.12049; Beuers U, 2010, HEPATOLOGY, V52, P1489, DOI 10.1002/hep.23810; Banales JM, 2012, HEPATOLOGY, V56, P687, DOI 10.1002/hep.25691; RUBIN E, 1965, AM J PATHOL, V46, P387; Odin JA, 2001, J CLIN INVEST, V108, P223, DOI 10.1172/JCI10716; Hohenester S, 2012, HEPATOLOGY, V55, P173, DOI 10.1002/hep.24691; Lindor KD, 2009, HEPATOLOGY, V50, P291, DOI 10.1002/hep.22906; Gershwin ME, 2008, HEPATOLOGY, V47, P737, DOI 10.1002/hep.22042; SHERLOCK S, 1959, GASTROENTEROLOGY, V37, P574; MACMAHON HE, 1949, ANN INTERN MED, V30, P121; Bianchi I, 2014, SEMIN LIVER DIS, V34, P255, DOI 10.1055/s-0034-1383725; Lleo A, 2010, HEPATOLOGY, V52, P987, DOI 10.1002/hep.23783; Lleo A, 2014, SEMIN LIVER DIS, V34, P273, DOI 10.1055/s-0034-1383727; Beuers U, 2015, J HEPATOL, V62, pS25, DOI 10.1016/j.jhep.2015.02.023; Dyson JK, 2015, NAT REV GASTRO HEPAT, V12, P147, DOI 10.1038/nrgastro.2015.12; European Association for the Study of the Liver, 2009, J HEPATOL, V51, P237, DOI DOI 10.1016/J.JHEP.2009.04.009; Hanot V., 1876, STUDY FORM HYPERTROP; Hirschfield GM, 2013, ANNU REV PATHOL-MECH, V8, P303, DOI 10.1146/annurev-pathol-020712-164014; Sherlock S., 1968, DIS LIVER BILIARY SY	21	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2015	62	5					1620	1622		10.1002/hep.28140		3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU1EZ	WOS:000363264100030		
J	Hagiwara, S; Nishida, N; Park, AM; Sakurai, T; Kawada, A; Kudo, M				Hagiwara, Satoru; Nishida, Naoshi; Park, Ah-Mee; Sakurai, Toshiharu; Kawada, Akira; Kudo, Masatoshi			Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria	HEPATOLOGY			English	Article									[Hagiwara, Satoru; Nishida, Naoshi; Sakurai, Toshiharu; Kudo, Masatoshi] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka, Osaka 5898511, Japan; [Park, Ah-Mee] Kinki Univ, Sch Med, Dept Microbiol, Osaka, Osaka 5898511, Japan; [Kawada, Akira] Kinki Univ, Sch Med, Dept Dermatol, Osaka, Osaka 5898511, Japan	Nishida, N (reprint author), Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan.	naoshi@med.kindai.ac.jp					Bloomer J, 2005, J CLIN GASTROENTEROL, V39, pS167, DOI 10.1097/01.mcg.0000155518.96629.ea; Kobuchi H, PLOS ONE, V7; TODD DJ, 1994, BRIT J DERMATOL, V131, P751, DOI 10.1111/j.1365-2133.1994.tb08577.x	3	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2015	62	5					1638	1639		10.1002/hep.27871		2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU1EZ	WOS:000363264100034		
J	Kawamura, K; Cheng, Y; Sun, YP; Zhai, J; Diaz-Garcia, C; Simon, C; Pellicer, A; Hsueh, AJ				Kawamura, Kazuhiro; Cheng, Yuan; Sun, Ying-Pu; Zhai, Jun; Diaz-Garcia, Cesar; Simon, Carlos; Pellicer, Antonio; Hsueh, Aaron J.			Ovary transplantation: to activate or not to activate	HUMAN REPRODUCTION			English	Editorial Material							FERTILITY PRESERVATION; TISSUE; VITRIFICATION; PREGNANCY		[Kawamura, Kazuhiro; Cheng, Yuan] St Mariana Univ, Dept Ob Gyn, Kawasaki, Kanagawa, Japan; [Sun, Ying-Pu; Zhai, Jun] Zhengzhou Univ, Affiliated Hosp 1, Reprod Med Ctr, Zhengzhou 450052, Peoples R China; [Diaz-Garcia, Cesar; Simon, Carlos; Pellicer, Antonio] Univ Valencia, FIVI, Paterna, Spain; [Diaz-Garcia, Cesar; Simon, Carlos; Pellicer, Antonio] Inst Univ IVI INCLIVA, La Fe Univ Hosp, Paterna, Spain; [Simon, Carlos; Hsueh, Aaron J.] Stanford Univ, Sch Med, Dept Ob Gyn, Stanford, CA 94305 USA	Kawamura, K (reprint author), St Mariana Univ, Dept Ob Gyn, Kawasaki, Kanagawa, Japan.	kazuhironanami@gmail.com; aaron.hsueh@stanford.edu					Adhikari D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039034; Donnez J, 2015, CURR OPIN OBSTET GYN, V27, P222, DOI 10.1097/GCO.0000000000000171; Donnez J, 2013, NAT REV ENDOCRINOL, V9, P735, DOI 10.1038/nrendo.2013.205; Donnez J, 2013, FERTIL STERIL, V99, P1503, DOI 10.1016/j.fertnstert.2013.03.030; Meirow D, 2001, HUM REPROD, V16, P632, DOI 10.1093/humrep/16.4.632; Kawamura K, 2013, P NATL ACAD SCI USA, V110, P17474, DOI 10.1073/pnas.1312830110; Skory RM, 2015, HUM REPROD, V30, P1386, DOI 10.1093/humrep/dev052; Gosden RG, 2008, REPRODUCTION, V136, P671, DOI 10.1530/REP-08-0099; Magelssen H, 2008, HUM REPROD, V23, P178, DOI 10.1093/humrep/dem362; Hsueh AJW, 2015, ENDOCR REV, V36, P1, DOI 10.1210/er.2014-1020; Kuwayama M, 2005, REPROD BIOMED ONLINE, V11, P300; Macklon KT, 2014, J ASSIST REPROD GEN, V31, P1557, DOI 10.1007/s10815-014-0331-z; Meirow D, 2015, HUM REPROD, V30, P2453, DOI 10.1093/humrep/dev210; Suzuki N, 2015, HUM REPROD, V30, P608, DOI 10.1093/humrep/deu353	14	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1161	1460-2350		HUM REPROD	Hum. Reprod.	NOV	2015	30	11					2457	2460		10.1093/humrep/dev211		4	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	CT8GQ	WOS:000363053400002		
J	Suzuki, N				Suzuki, Nao			Ovarian tissue cryopreservation using vitrification and/or in vitro activated technology	HUMAN REPRODUCTION			English	Editorial Material							FERTILITY PRESERVATION; BREAST-CANCER; LYMPHOMA; WOMEN		St Marianna Univ, Sch Med, Dept Obstet & Gynecol, Kawasaki, Kanagawa, Japan	Suzuki, N (reprint author), St Marianna Univ, Sch Med, Dept Obstet & Gynecol, Kawasaki, Kanagawa, Japan.	nao@marianna-u.ac.jp					Kim SS, 2012, J ASSIST REPROD GEN, V29, P465, DOI 10.1007/s10815-012-9786-y; Suzuki N, 2012, HUM REPROD, V27, P2420, DOI 10.1093/humrep/des178; Kawamura K, 2013, P NATL ACAD SCI USA, V110, P17474, DOI 10.1073/pnas.1312830110; Wallace WHB, 2014, LANCET ONCOL, V15, P1129, DOI 10.1016/S1470-2045(14)70334-1; Hashimoto S, 2010, REPROD BIOMED ONLINE, V21, P501, DOI 10.1016/j.rbmo.2010.04.029; Donnez J, 2004, LANCET, V364, P1405, DOI 10.1016/S0140-6736(04)17222-X; von Wolff M, 2011, ARCH GYNECOL OBSTET, V284, P427, DOI 10.1007/s00404-011-1874-1; Meirow D, 2015, HUM REPROD, V30, P2453, DOI 10.1093/humrep/dev210; Suzuki N, 2015, HUM REPROD, V30, P608, DOI 10.1093/humrep/deu353	9	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0268-1161	1460-2350		HUM REPROD	Hum. Reprod.	NOV	2015	30	11					2461	2462		10.1093/humrep/dev212		2	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	CT8GQ	WOS:000363053400003		
J	Umbert, M; Bonada, J; Goto, M; Nakano, T; Sundberg, J				Umbert, Marti; Bonada, Jordi; Goto, Masataka; Nakano, Tomoyasu; Sundberg, Johan			Expression Control in Singing Voice Synthesis	IEEE SIGNAL PROCESSING MAGAZINE			English	Article							MUSIC PERFORMANCE; SIGNALS; FUTURE; MODELS; AI	In the context of singing voice synthesis, expression control manipulates a set of voice features related to a particular emotion, style, or singer. Also known as performance modeling, it has been approached from different perspectives and for different purposes, and different projects have shown a wide extent of applicability. The aim of this article is to provide an overview of approaches to expression control in singing voice synthesis. We introduce some musical applications that use singing voice synthesis techniques to justify the need for an accurate control of expression. Then, expression is defined and related to speech and instrument performance modeling. Next, we present the commonly studied set of voice parameters that can change perceptual aspects of synthesized voices. After that, we provide an up-to-date classification, comparison, and description of a selection of approaches to expression control. Then, we describe how these approaches are currently evaluated and discuss the benefits of building a common evaluation framework and adopting perceptually-motivated objective measures. Finally, we discuss the challenges that we currently foresee.	[Umbert, Marti] Univ Politecn Cataluna, Telecommun, E-08028 Barcelona, Spain; [Bonada, Jordi] UPF, Comp Sci & Digital Commun, Barcelona, Spain; [Goto, Masataka] Waseda Univ, Tokyo, Japan; [Nakano, Tomoyasu] Univ Tsukuba, Tsukuba, Ibaraki 305, Japan; [Sundberg, Johan] Uppsala Univ, Musicol, Uppsala, Sweden	Umbert, M (reprint author), UPF, Mus Technol Grp, Barcelona, Spain.	marti.umbert@upf.edu; jordi.bonada@upf.edu; m.goto@aist.go.jp; t.nakano@aist.go.jp; jsu@csc.kth.se			Core Research for Evolutional Science and Technology	We would like to thank Alastair Porter for proofreading and Merlijn Blaauw for reviewing the article. Some works presented in the article were supported in part by the Core Research for Evolutional Science and Technology funding program provided by the Japan Science and Technology Agency.	Alonso M., 2005, THESIS U POMPEU FABR; Mori M, 2012, IEEE ROBOT AUTOM MAG, V19, P98, DOI 10.1109/MRA.2012.2192811; Sundberg J, 2007, J VOICE, V21, P285, DOI 10.1016/j.jvoice.2006.01.003; Canazza S, 2004, P IEEE, V92, P686, DOI 10.1109/JPROC.2004.825889; [Anonymous], 2009, P ICASSP 2009; Goto M, 2012, 2012 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH AND SIGNAL PROCESSING (ICASSP), P5393; Widmer G, 2001, AI COMMUN, V14, P149; Cook PR, 1996, COMPUT MUSIC J, V20, P38, DOI 10.2307/3680822; Plack CJ, 2005, SPR HDB AUD, V24, P1; Nakano T, 2011, INT CONF ACOUST SPEE, P453; Juslin PN, 2003, PSYCHOL BULL, V129, P770, DOI 10.1037/0033-2909.129.5.770; Scheirer ED, 1998, J ACOUST SOC AM, V103, P588, DOI 10.1121/1.421129; Campbell D, 2009, SIGNAL PROCESS, V89, P1489, DOI 10.1016/j.sigpro.2009.02.015; Kob M, 2004, ACTA ACUST UNITED AC, V90, P649; Salamon J, 2014, IEEE SIGNAL PROC MAG, V31, P118, DOI 10.1109/MSP.2013.2271648; Saino K, 2010, 11TH ANNUAL CONFERENCE OF THE INTERNATIONAL SPEECH COMMUNICATION ASSOCIATION 2010 (INTERSPEECH 2010), VOLS 3 AND 4, P2894; Katayose H, 2012, J NEW MUSIC RES, V41, P299, DOI 10.1080/09298215.2012.745579; de Mantaras RL, 2002, AI MAG, V23, P43; Schroder M, 2009, AFFECTIVE INFORMATION PROCESSING, P111, DOI 10.1007/978-1-84800-306-4_7; Widmer G, 2004, J NEW MUSIC RES, V33, P203, DOI 10.1080/0929821042000317804; Bresin R, 2000, COMPUT MUSIC J, V24, P44, DOI 10.1162/014892600559515; Bonada J, 2007, IEEE SIGNAL PROC MAG, V24, P67, DOI 10.1109/MSP.2007.323266; [Anonymous], 2010, P 11 ANN C INT SPEEC; Bonada J., 2008, THESIS U POMPEU FABR; Chu M., 2001, P 7 EUR C SPEECH COM, P2087; Doi H., 2012, APSIPA ASC, P1; Friberg A, 2006, ADV COGNITIVE PSYCHO, V2, P145, DOI DOI 10.2478/V10053-008-0052-X; Goto Masataka, 2012, MULTIMODAL MUSIC PRO, V3, P217; Janer J., 2006, P 9 INT C DIG AUD EF, V6, P42; Juslin P. N., 2003, PSYCHOL MUSIC, V31, P273, DOI [10.1177/03057356030313003, DOI 10.1177/03057356030313003]; Kenmochi H., 2007, P INTERSPEECH, P4009; Kirke A., 2013, GUIDE COMPUTING EXPR; Lesaffre M., 2005, THESIS GHENT U; Loscos A., 2004, P INT C DIG AUD EFF, P49; Marinescu M. C., 2011, P INT C COMP COMP IN, V31, P311; Meron Y., 1999, THESIS U TOKYO; Nakano T., 2009, P SMC 2009, P343; Oura K., 2010, P 7 ISCA TUT RES WOR, P211; Rodet X., 2002, P 1 IEEE BEN WORKSH, P99; Saino K., 2006, P INTERSPEECH, P1141; Saitou T., 2007, P IEEE WORKSH APPL S, P215; Sundberg J., 2006, ADV COGNITIVE PSYCHO, V2, P131; Sundberg J., 1981, P S VEN, P145; Sundberg J., 1987, SCI SINGING VOICE; Ternstrom S., 2002, P 143 AC SOC AM ASA; Thalén M, 2001, Logoped Phoniatr Vocol, V26, P82; Umbert M., 2013, P STOCKH MUS AC C SM, P315; Umbert M., 2013, P INT SPEECH COMM AS, P213; Yoshimura T., 1999, P EUROSPEECH, V5, P2347	49	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1053-5888	1558-0792		IEEE SIGNAL PROC MAG	IEEE Signal Process. Mag.	NOV	2015	32	6					55	73		10.1109/MSP.2015.2424572		19	Engineering, Electrical & Electronic	Engineering	CU0WI	WOS:000363239200006		
J	Kikuuwe, R; Kanaoka, K; Kumon, T; Yamamoto, M				Kikuuwe, Ryo; Kanaoka, Katsuya; Kumon, Tomohiro; Yamamoto, Motoji			Phase-Lead Stabilization of Force-Projecting Master-Slave Systems With a New Sliding Mode Filter	IEEE TRANSACTIONS ON CONTROL SYSTEMS TECHNOLOGY			English	Article						Force control; master-slave (MS) system; noise filter; sliding mode; teleoperation	BILATERAL TELEOPERATION; TIME-DELAY; CONTROLLER; STABILITY; ARCHITECTURES; TRANSPARENCY; PERFORMANCE; REFLECTION; DESIGN; MOTION	The force-projecting master-slave (MS) control scheme is the reversed implementation of the conventional force-reflecting scheme. This paper presents a method to stabilize force projecting MS systems using a linear phase-lead compensator and a new nonlinear filter. The nonlinear filter is a modified version of Jin et al.'s parabolic sliding mode filter, which produces a relatively small phase lag. Some numerical properties of the new filter are presented. The filter is then applied to an experimental MS system composed of two industrial manipulators. A force scaling factor of 25 was achieved with maintaining the stability.	[Kikuuwe, Ryo; Kumon, Tomohiro; Yamamoto, Motoji] Kyushu Univ, Dept Mech Engn, Fukuoka 8190395, Japan; [Kanaoka, Katsuya] Ritsumeikan Univ, Adv Robot Res Ctr, Kusatsu 5258577, Japan; [Kanaoka, Katsuya] Man Machine Synergy Effectors Inc, Kusatsu 5258577, Japan	Kikuuwe, R (reprint author), Kyushu Univ, Dept Mech Engn, Fukuoka 8190395, Japan.	kikuuwe@mech.kyushu-u.ac.jp; kanaoka@fc.ritsumei.ac.jp; kumon@ctrl.mech.kyushu-u.ac.jp; yama@mech.kyushu-u.ac.jp			Japan Society for the Promotion of Science [24360098]	This work was supported by the Grant-in-Aid for Scientific Research through the Japan Society for the Promotion of Science under Grant 24360098. Recommended by Associate Editor M. Fujita.	KIM WS, 1992, 1992 IEEE INTERNATIONAL CONF ON ROBOTICS AND AUTOMATION : PROCEEDINGS, VOLS 1-3, P1412; QIAN HP, 1992, 1992 IEEE INTERNATIONAL CONF ON ROBOTICS AND AUTOMATION : PROCEEDINGS, VOLS 1-3, P1374; Kim J, 2013, IEEE T CONTR SYST T, V21, P40, DOI 10.1109/TCST.2011.2172945; Polushin IG, 2007, IEEE-ASME T MECH, V12, P361, DOI 10.1109/TMECH.2007.897285; SHEVITZ D, 1994, IEEE T AUTOMAT CONTR, V39, P1910, DOI 10.1109/9.317122; Hashtrudi-Zaad K, 2001, INT J ROBOT RES, V20, P419, DOI 10.1177/02783640122067471; YOKOKOHJI Y, 1994, IEEE T ROBOTIC AUTOM, V10, P605, DOI 10.1109/70.326566; Levant A, 2007, AUTOMATICA, V43, P576, DOI 10.1016/j.automatica.2006.10.008; XU Y, 1995, IEEE CONTR SYST MAG, V15, P15, DOI 10.1109/37.341859; Lau HYK, 2005, ROBOT CIM-INT MANUF, V21, P145, DOI 10.1016/j.rcim.2004.06.005; Wang H, 2008, ROBOTICA, V26, P781, DOI 10.1017/S0263574708004372; Artigas J, 2010, PRESENCE-TELEOP VIRT, V19, P482, DOI 10.1162/pres_a_00013; Jin SH, 2014, ADV ROBOTICS, V28, P943, DOI 10.1080/01691864.2014.899161; Willaert B, 2011, INT J ROBOT RES, V30, P444, DOI 10.1177/0278364910378334; Boukhnifer M, 2007, IEEE T CONTR SYST T, V15, P891, DOI 10.1109/TCST.2007.902951; Emaru T, 2003, IEEE T ROBOTIC AUTOM, V19, P391, DOI 10.1109/TRA.2003.810243; Daniel RW, 1998, INT J ROBOT RES, V17, P811, DOI 10.1177/027836499801700801; Vander Poorten EB, 2006, ADV ROBOTICS, V20, P681, DOI 10.1163/156855306777361640; Sun D, 2014, ANNU REV CONTROL, V38, P12, DOI 10.1016/j.arcontrol.2014.03.002; Kikuuwe R, 2014, IEEE-ASME T MECH, V19, P1489, DOI 10.1109/TMECH.2013.2286411; Natale C, 2000, IEEE-ASME T MECH, V5, P122, DOI 10.1109/3516.847085; Tobergte A, 2012, 2012 IEEE INTERNATIONAL CONFERENCE ON ROBOTICS AND AUTOMATION (ICRA), P4280, DOI 10.1109/ICRA.2012.6224617; MANN KA, 1989, J ORTHOPAED RES, V7, P304, DOI 10.1002/jor.1100070219; Imaida T, 2004, IEEE T ROBOTIC AUTOM, V20, P499, DOI 10.1109/TRA.2004.825271; Peer A, 2008, IEEE-ASME T MECH, V13, P416, DOI 10.1109/TMECH.2008.2001690; HANNAFORD B, 1991, IEEE T SYST MAN CYB, V21, P620, DOI 10.1109/21.97455; Jin SH, 2012, ADV ROBOTICS, V26, P877, DOI 10.1163/156855312X633011; Abbott JJ, 2007, INT J ROBOT RES, V26, P865, DOI 10.1177/0278364907080425; Bacciotti A., 1999, ESAIM. Control, Optimisation and Calculus of Variations, V4, DOI 10.1051/cocv:1999113; Brooks T. L., 1990, P IEEE INT C SYST MA, P113; Cortes J., 2008, CONTROL SYSTEMS IEEE, V28, P36, DOI DOI 10.1109/MCS.2008.919306; Filippov A. F., 1988, DIFFERENTIAL EQUATIO; Han J., 1994, J SYST SCI MATH SCI, V14, P177; HOLLERBACH JM, 1981, BIOL CYBERN, V39, P139, DOI 10.1007/BF00336740; Jin S., 2012, J CONTROL SCI ENG, V2012; Kanaoka K., 2011, WO Patent, Patent No. [2 011 115 287, 2011115287]; Kanaoka K., 2009, P 13 ANN C ROB SOC J; KIM WS, 1992, IEEE T ROBOTIC AUTOM, V8, P176, DOI 10.1109/70.134272; Kuchenbecker K. J., 2006, T ASME J DYN SYST ME, V128, P808; Lawrence D. A., IEEE T ROBOT AUTOM, V9, P624; Mahvash M., 2007, P 2 JOINT EUROHAPTIC, P470; Naerum E., 2009, P IEEE INT C ROB AUT, P4344; Park J, 2006, INT J ROBOT RES, V25, P575, DOI 10.1177/0278364906065385; Peer A., 2005, P IEEE RSJ INT C INT, P3493; Shull P., 2008, P ASME DYN SYST CONT, P607; Slotine J.E., 1990, APPL NONLINEAR CONTR; Smirnov G., 2002, INTRO THEORY DIFFERE	47	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1063-6536	1558-0865		IEEE T CONTR SYST T	IEEE Trans. Control Syst. Technol.	NOV	2015	23	6					2182	2194		10.1109/TCST.2015.2404893		13	Automation & Control Systems; Engineering, Electrical & Electronic	Automation & Control Systems; Engineering	CU1BF	WOS:000363253300009		
J	Lu, S; Hou, W; Cheng, J				Lu, Shan; Hou, Wei; Cheng, Jun			A Family of (k+1)-Ary Signature Codes for Noisy Multiple-Access Adder Channel	IEEE TRANSACTIONS ON INFORMATION THEORY			English	Article						Signature code; error-correcting code; multiuser code; multiple-access adder channel; Hadamard matrix	SUM-DISTINCT SETS; SUPERIMPOSED CODES; INTEGRAL VECTORS	A coding scheme of (k + 1)-ary error-correcting signature codes for a noisy multiple-access adder channel is proposed. Given a signature matrix A and a difference matrix D = D+ - D- a priori, a larger signature matrix is obtained by replacing each element in the Hadamard matrix with A, or D+, or D- depending on the values of the elements and their locations in the Hadamard matrix. The set of rows in the proposed matrix gives an error-correcting signature code. Introducing a difference matrix makes it possible to construct an error-correcting signature code whose sum rate is increased with an increase in the order of the Hadamard matrix. Either binary or non-binary signature codes are constructed when the pairs of matrices A and D are given.	[Lu, Shan; Hou, Wei; Cheng, Jun] Doshisha Univ, Dept Intelligent Informat Engn & Sci, Kyoto 6100321, Japan	Lu, S (reprint author), Doshisha Univ, Kyoto 6100321, Japan.	shanluxd@gmail.com; hou.ita@outlook.com; jcheng@ieee.org			Japan Society for the Promotion of Science [24300030]	Manuscript received December 3, 2013; accepted August 31, 2015. Date of publication September 16, 2015; date of current version October 16, 2015. This work was supported by the Grants-in-Aid for Scientific Research through the Japan Society for the Promotion of Science under Grant 24300030. This paper was presented at the 2007 IEEE International Symposium on Information Theory and the 2013 IEEE International Symposium on Information Theory.	FAN PZ, 1995, IEEE T INFORM THEORY, V41, P1178, DOI 10.1109/18.391266; Khachatrian GH, 1998, IEEE T INFORM THEORY, V44, P1953, DOI 10.1109/18.705572; Hughes BL, 1996, IEEE T INFORM THEORY, V42, P387, DOI 10.1109/18.485711; WILSON JH, 1988, IEEE T INFORM THEORY, V34, P888, DOI 10.1109/18.9792; CHANG S, 1979, IEEE T INFORM THEORY, V25, P684; Cheng J, 2006, IEEE T INFORM THEORY, V52, P5524, DOI 10.1109/TIT.2006.885470; CANTOR DG, 1966, CANADIAN J MATH, V18, P42, DOI 10.4153/CJM-1966-007-2; ERICSON T, 1988, IEEE T INFORM THEORY, V34, P877, DOI 10.1109/18.9789; Jevtic DB, 1997, ARS COMBINATORIA, V45, P87; JEVTIC DB, 1995, SIAM J DISCRETE MATH, V8, P652; JEVTIC DB, 1992, IEEE T INFORM THEORY, V38, P1142, DOI 10.1109/18.135657; Mow WH, 2009, IEEE T INFORM THEORY, V55, P93, DOI 10.1109/TIT.2008.2008139; Chang S. C., 1984, IEEE Transactions on Information Theory, VIT-30; Cheng J, 2001, IEEE T INFORM THEORY, V47, P2603, DOI 10.1109/18.945276; FERGUSON TJ, 1982, IEEE T INFORM THEORY, V28, P775, DOI 10.1109/TIT.1982.1056549; Macwilliams F. J., 1977, THEORY ERROR CORRECT; Martirosyan S. S., 1989, Problems of Information Transmission, V25	17	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9448	1557-9654		IEEE T INFORM THEORY	IEEE Trans. Inf. Theory	NOV	2015	61	11					5848	5853		10.1109/TIT.2015.2479219		6	Computer Science, Information Systems; Engineering, Electrical & Electronic	Computer Science; Engineering	CU1CI	WOS:000363256500010		
J	Hikawa, H; Maeda, Y				Hikawa, Hiroomi; Maeda, Yutaka			Improved Learning Performance of Hardware Self-Organizing Map Using a Novel Neighborhood Function	IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS			English	Article						Field-programmable gate array (FPGA); hardware; neighborhood function; self-organizing map (SOM)	NEURAL-NETWORK; IP CORE; IMPLEMENTATION; PARALLEL; ARCHITECTURE; FPGA; CHIP	Many self-organizing maps (SOMs) implemented on hardware restrict their neighborhood function values to negative powers of two. In this paper, we propose a novel hardware friendly neighborhood function that is aimed to improve the vector quantization performance of hardware SOM. The quantization performance of the hardware SOM with the proposed neighborhood function is examined by simulations. Simulation results show that the proposed function can improve the hardware SOM's vector quantization capability even though the function value is restricted to negative powers of two. Then, the hardware SOM is implemented on field-programmable gate array to find out the hardware cost and performance speed of the proposed neighborhood function. Experimental results show that the proposed neighborhood function can improve SOM's quantization performance without additional hardware cost or slowing down the operating speed. Due to fully parallel operation, the proposed SOM with 16 x 16 neurons achieves a performance of 25 344 million connections updates per second.	[Hikawa, Hiroomi; Maeda, Yutaka] Kansai Univ, Dept Engn, Osaka 5648680, Japan	Hikawa, H (reprint author), Kansai Univ, Dept Engn, Osaka 5648680, Japan.	hikawa@kansai-u.ac.jp; maedayut@kansai-u.ac.jp					Dlugosz R, 2011, IEEE T NEURAL NETWOR, V22, P2091, DOI 10.1109/TNN.2011.2169809; Appiah K, 2012, IEEE T CIRC SYST VID, V22, P1150, DOI 10.1109/TCSVT.2012.2197077; Hendry DC, 2004, NEUROCOMPUTING, V62, P389, DOI 10.1016/j.neucom.2004.05.002; Ienne P, 1997, IEEE T NEURAL NETWOR, V8, P315, DOI 10.1109/72.557669; Manolakos I, 2007, INT CONF ACOUST SPEE, P61; Dlugosz R, 2010, IEEE T NEURAL NETWOR, V21, P961, DOI 10.1109/TNN.2010.2046497; Asanovic K, 1997, LECT NOTES COMPUT SC, V1240, P792; Porrmann M, 2003, IEEE T NEURAL NETWOR, V14, P1110, DOI 10.1109/TNN.2003.816368; Hikawa H, 2005, NEURAL NETWORKS, V18, P514, DOI 10.1016/j.neunet.2005.06.012; Kolasa M, 2012, NEURAL NETWORKS, V25, P146, DOI 10.1016/j.neunet.2011.09.002; Mailachalam B, 2002, MICROPROCESS MICROSY, V26, P399, DOI 10.1016/S0141-9331(02)00065-0; Hendry DC, 2003, IEEE T NEURAL NETWOR, V14, P1085, DOI 10.1109/TNN.2003.816353; Ramirez-Agundis A, 2008, MICROPROCESS MICROSY, V32, P33, DOI 10.1016/j.micpro.2007.06.004; Tamukoh H, 2004, IEEE IJCNN, P2683; Shi C, 2014, IEEE J SOLID-ST CIRC, V49, P2067, DOI 10.1109/JSSC.2014.2332134; Appiah Kofi, 2009, Proceedings 2009 International Joint Conference on Neural Networks (IJCNN 2009 - Atlanta), DOI 10.1109/IJCNN.2009.5179001; Ben K. Khalifa, 2004, P ICM, P709, DOI DOI 10.1109/ICM.2004.1434765; Dlugosz R., 2011, P INT C MIX DES INT, P258; Kohonen T., 2001, SPRINGER SERIES INFO, V30; Kung S. Y., 1987, VLSI ARRAY PROCESSOR; Pena J., 2006, P IEEE INT C REC COM, P1; Pohl C., 2004, Proceedings. 2004 IEEE International Conference on Field- Programmable Technology (IEEE Cat. No.04EX921), DOI 10.1109/FPT.2004.1393256; Porrmann M., 2002, P EUR S ART NEUR NET, P337; Siemon H., 1990, P IJCNN1990, V2, P643; Yamakawa T., 2002, P 9 INT C NEUR INF P, P1330	25	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2162-237X	2162-2388		IEEE T NEUR NET LEAR	IEEE Trans. Neural Netw. Learn. Syst.	NOV	2015	26	11					2861	2873		10.1109/TNNLS.2015.2398932		13	Computer Science, Artificial Intelligence; Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	CU0XQ	WOS:000363242800019		
J	Ubagai, T; Nakano, R; Nakano, A; Kamoshida, G; Ono, Y				Ubagai, Tsuneyuki; Nakano, Ryuichi; Nakano, Akiyo; Kamoshida, Go; Ono, Yasuo			Gene expression analysis in human polymorphonuclear leukocytes stimulated by LPSs from nosocomial opportunistic pathogens	INNATE IMMUNITY			English	Article						LPS; polymorphonuclear leukocyte; MDRA; MDRP; RT-PCR	ACINETOBACTER-BAUMANNII RESISTANT; CATIONIC ANTIMICROBIAL PEPTIDES; 2-COMPONENT REGULATORY SYSTEM; POLYMYXIN-B RESISTANCE; PSEUDOMONAS-AERUGINOSA; COLISTIN-RESISTANT; PHOSPHOETHANOLAMINE MODIFICATION; ANTIBIOTIC-RESISTANCE; MEMBRANE-VESICLES; INNATE IMMUNITY	Innate immunity coordinates LPS detection via TLR4 on polymorphonuclear leukocytes (PMNs) to elicit responses to many Gram-negative bacteria. In this study, we describe the effects of five subtypes of LPS [isolated from Escherichia coli B4, Pseudomonas aeruginosa PAO1, multidrug-resistant P. aeruginosa (MDRP), Acinetobacter baumannii and multidrug-resistant A. baumannii (MDRA)] on gene expression in PMNs. LPS isolated from B4, PAO1, and A. baumannii did not significantly alter TLR2 expression. However, LPS from MDRP and MDRA caused a 0.6-fold decrease and 2.7-fold increase, respectively, in TLR2 expression. Similarly, TLR4 expression was not significantly altered by LPS isolated from B4, PAO1 and A. baumannii but was down-regulated by LPS isolated from MDRP and MDRA by 0.1- and 0.6-fold, respectively. All LPS subtypes, excluding PAO1, down-regulated CD14 expression in PMNs. However, all five LPS subtypes up-regulated TNFA, IL1B, IL6, IL10 and TREM1 expression in a concentration-dependent manner, with the most substantial responses observed following exposure to LPS from MDRP and MDRA. These different effects on the gene expression in PMNs may depend on variation in LPS structural modifications related to acquired drug resistance, such as acylation and/or glycosylation.	[Ubagai, Tsuneyuki; Nakano, Ryuichi; Nakano, Akiyo; Kamoshida, Go; Ono, Yasuo] Teikyo Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 1738605, Japan	Ubagai, T (reprint author), Teikyo Univ, Sch Med, Dept Microbiol & Immunol, Itabashi Ku, Kaga 2-11-1, Tokyo 1738605, Japan.	ubat@med.teikyo-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24591490]	Financial support for this study was provided by a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan (24591490).	Gooderham WJ, 2008, J BACTERIOL, V190, P5624, DOI 10.1128/JB.00594-08; Gioannini TL, 2007, IMMUNOL RES, V39, P249, DOI 10.1007/s12026-007-0069-0; Moskowitz SM, 2012, ANTIMICROB AGENTS CH, V56, P1019, DOI 10.1128/AAC.05829-11; Pelletier MR, 2013, ANTIMICROB AGENTS CH, V57, P4831, DOI 10.1128/AAC.00865-13; Lee JY, 2014, DIAGN MICR INFEC DIS, V78, P271, DOI 10.1016/j.diagmicrobio.2013.11.027; Macfarlane ELA, 1999, MOL MICROBIOL, V34, P305, DOI 10.1046/j.1365-2958.1999.01600.x; Ubagai T, 2009, J INFECT CHEMOTHER, V15, P374, DOI 10.1007/s10156-009-0728-2; Fernandez L, 2013, ANTIMICROB AGENTS CH, V57, P110, DOI 10.1128/AAC.01583-12; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Barbe V, 2004, NUCLEIC ACIDS RES, V32, P5766, DOI 10.1093/nar/gkh910; Sabra W, 2003, MICROBIOL-SGM, V149, P2789, DOI 10.1099/mic.0.26443-0; Medzhitov R, 2009, IMMUNITY, V30, P766, DOI 10.1016/j.immuni.2009.06.004; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Barrow K, 2009, ANTIMICROB AGENTS CH, V53, P5150, DOI 10.1128/AAC.00893-09; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Arroyo LA, 2011, ANTIMICROB AGENTS CH, V55, P3743, DOI 10.1128/AAC.00256-11; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Raetz CRH, 2007, ANNU REV BIOCHEM, V76, P295, DOI 10.1146/annurev.biochem.76.010307.145803; Lopez-Rojas R, 2011, J INFECT DIS, V204, P1147, DOI 10.1093/infdis/jir476; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Opal SM, 2007, INT J MED MICROBIOL, V297, P365, DOI 10.1016/j.ijmm.2007.03.006; West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973; Henry R, 2012, ANTIMICROB AGENTS CH, V56, P59, DOI 10.1128/AAC.05191-11; Munford RS, 2008, INFECT IMMUN, V76, P454, DOI 10.1128/IAI.00939-07; Kitchens RL, 1998, J IMMUNOL, V160, P1920; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Beceiro A, 2011, ANTIMICROB AGENTS CH, V55, P3370, DOI 10.1128/AAC.00079-11; Gunn JS, 2001, J ENDOTOXIN RES, V7, P57, DOI 10.1179/096805101101532558; Ubagai T, 2014, INT J MED SCI, V11, P215, DOI 10.7150/ijms.7231; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; McPhee JB, 2003, MOL MICROBIOL, V50, P205, DOI 10.1046/j.1365-2958.2003.03673.x; Rolain JM, 2013, ANTIMICROB AGENTS CH, V57, P592, DOI 10.1128/AAC.01314-12; Gomez MJ, 2006, ANTIMICROB AGENTS CH, V50, P3562, DOI 10.1128/AAC.00579-06; Abraham N, 2009, FEMS MICROBIOL LETT, V298, P249, DOI 10.1111/j.1574-6968.2009.01720.x; Rolain JM, 2011, J INFECT DIS, V204, P1146, DOI 10.1093/infdis/jir475; Beceiro A, 2013, CLIN MICROBIOL REV, V26, P185, DOI 10.1128/CMR.00059-12; Moffatt JH, 2010, ANTIMICROB AGENTS CH, V54, P4971, DOI 10.1128/AAC.00834-10; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Adams MD, 2009, ANTIMICROB AGENTS CH, V53, P3628, DOI 10.1128/AAC.00284-09; Kobayashi SD, 2003, P NATL ACAD SCI USA, V100, P10948, DOI 10.1073/pnas.1833375100; Martin-Loeches I, 2014, CURR OPIN CRIT CARE, V20, P516, DOI 10.1097/MCC.0000000000000124; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985; Ernest RK, 1999, SCIENCE, V286, P1561; Molloy Eleanor J, 2009, Recent Pat Antiinfect Drug Discov, V4, P51; Morrison DC, 1972, METHOD ENZYMOL, V28, P254; Nachtigall I, 2013, J INT MED RES, V42, P93	47	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1753-4259	1753-4267		INNATE IMMUN-LONDON	Innate Immun.	NOV	2015	21	8					802	812		10.1177/1753425915605892		11	Biochemistry & Molecular Biology; Immunology; Medicine, Research & Experimental; Microbiology	Biochemistry & Molecular Biology; Immunology; Research & Experimental Medicine; Microbiology	CU0NW	WOS:000363215100002		
J	Sakuma, T; Kimura, K; Hayama, K; Mitsuya, J; Asami, T; Kashimura, T; Saitoh, N; Terui, T				Sakuma, Tomo; Kimura, Kumiko; Hayama, Koremasa; Mitsuya, Juniku; Asami, Takashi; Kashimura, Tsutomu; Saitoh, Norio; Terui, Tadashi			Verrucous nevoid melanoma with satellite lesions on the scalp of a young man	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Article									[Sakuma, Tomo; Kimura, Kumiko; Hayama, Koremasa; Mitsuya, Juniku; Terui, Tadashi] Nihon Univ, Sch Med, Dept Dermatol, Div Cutaneous Sci, Tokyo 1738610, Japan; [Asami, Takashi; Kashimura, Tsutomu] Nihon Univ, Sch Med, Dept Plast & Reconstruct Surg, Div Plast & Reconstruct Surg, Tokyo 1738610, Japan; [Saitoh, Norio] Saitoh Dermatol Clin, Tokyo, Japan	Kimura, K (reprint author), Nihon Univ, Sch Med, Itabashi Ku, 30-1 Oyaguchi Kamicho, Tokyo 1738610, Japan.	kimura.kumiko@nihon-u.ac.jp					SCHMOECKEL C, 1985, ARCH DERMATOL RES, V277, P362, DOI 10.1007/BF00509234; Jakobiec FA, 2010, ARCH OPHTHALMOL-CHIC, V128, P174, DOI 10.1001/archophthalmol.2009.394; BARNHILL RL, 1995, CANCER, V76, P1833, DOI 10.1002/1097-0142(19951115)76:10<1833::AID-CNCR2820761024>3.0.CO;2-L; Zembowicz A, 2001, AM J DERMATOPATH, V23, P167, DOI 10.1097/00000372-200106000-00001; Magro CM, 2006, MODERN PATHOL, V19, P41	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	NOV	2015	54	11					1291	1293		10.1111/ijd.12269		3	Dermatology	Dermatology	CU3CU	WOS:000363402100033		
J	Imafuku, K; Hata, H; Kitamura, S; Iwata, H; Shimizu, H				Imafuku, Keisuke; Hata, Hiroo; Kitamura, Shinya; Iwata, Hiroaki; Shimizu, Hiroshi			In-transit metastasis of advanced eccrine porocarcinoma	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Letter									[Imafuku, Keisuke; Hata, Hiroo; Kitamura, Shinya; Iwata, Hiroaki; Shimizu, Hiroshi] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan	Imafuku, K (reprint author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido, Japan.	hata07jp@yahoo.co.jp					KISH J, 1982, CANCER TREAT REP, V66, P471; Robson A, 2001, AM J SURG PATHOL, V25, P710, DOI 10.1097/00000478-200106000-00002; Bhat W, 2011, ANN PLAS SURG, V66, P344, DOI 10.1097/SAP.0b013e3181e35c8d; Grotz TE, 2011, ONCOLOGY-NY, V25, P1340; Shinohara J, 2007, J DERMATOL, V34, P516	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	NOV	2015	54	11					E503	E505		10.1111/ijd.12928		3	Dermatology	Dermatology	CU3CU	WOS:000363402100017		
J	Kuniyuki, S; Maekawa, N				Kuniyuki, Shuichi; Maekawa, Naoki			Ectopic extramammary Paget's disease on the head: case report and literature review	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Article							RECEPTORS; MAMMARY		[Kuniyuki, Shuichi; Maekawa, Naoki] Osaka City Gen Hosp, Dept Dermatol, Osaka, Japan	Kuniyuki, S (reprint author), Osaka City Gen Hosp, Dept Dermatol, Osaka, Japan.	ga28547@wa2.so-net.ne.jp					Viacava P, 1998, VIRCHOWS ARCH, V432, P255, DOI 10.1007/s004280050163; Liegl B, 2005, MODERN PATHOL, V18, P1283, DOI 10.1038/modpathol.3800437; Iwenofu OH, 2008, J CUTAN PATHOL, V35, P761, DOI 10.1111/j.1600-0560.2007.00897.x; Lloyd J, 2000, J CLIN PATHOL, V53, P742, DOI 10.1136/jcp.53.10.742; Onishi Y, 1996, BRIT J DERMATOL, V134, P958; Robson A, 2008, AM J SURG PATHOL, V32, P682, DOI 10.1097/PAS.0b013e3181590ba4; de Leon ED, 2000, AM J CLIN PATHOL, V113, P572; Sawada Y, 2010, ACTA DERM-VENEREOL, V90, P502, DOI 10.2340/00015555-0892; Córdoba A, 2013, Actas Dermosifiliogr, V104, P355, DOI 10.1016/j.adengl.2013.03.006; Inada S, 1985, JPN J CLIN DERMATOL, V39, P685; Jones R E Jr, 1979, Am J Dermatopathol, V1, P101; Sai Y, 1994, JPN J CLIN DERMATOL, V48, P359; SAIDA T, 1987, Journal of the American Academy of Dermatology, V17, P910, DOI 10.1016/S0190-9622(87)70279-5	13	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	NOV	2015	54	11					E483	E486		10.1111/ijd.13018		4	Dermatology	Dermatology	CU3CU	WOS:000363402100009		
J	Shirakawa, T; Miyahara, Y; Tanimura, K; Morita, H; Kawakami, F; Itoh, T; Yamada, H				Shirakawa, Tokuro; Miyahara, Yoshiya; Tanimura, Kenji; Morita, Hiroki; Kawakami, Fumi; Itoh, Tomoo; Yamada, Hideto			Expression of Epithelial-Mesenchymal Transition-related Factors in Adherent Placenta	INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY			English	Article						Adherent placenta; E-cadherin; Snail; TGF-beta	SOLUBLE E-CADHERIN; CLINICAL-SIGNIFICANCE; CANCER; TROPHOBLAST; METASTASES; RECURRENCE; CARCINOMA; BREAST; CRETA	Epithelial-mesenchymal transition is a key process influencing cancer progression and metastasis. The purpose of this study was to investigate the expression of epithelial-mesenchymal transition-related factors in chorionic villi and decidual cells in adherent placenta. The current study included 19 patients diagnosed with adherent placenta after hysterectomy. The expression of E-cadherin, Vimentin, Snail, and transforming growth factor- in placental tissues was analyzed by immunohistochemical staining. Immunostaining intensity was semiquantitatively evaluated using the HSCORE algorithm. In the chorionic villi of the invasive part (placenta with invasion into myometrium), E-cadherin expression was significantly lower than that in the noninvasive part (placenta with no invasion). In the decidual cells of the invasive part, expression of transforming growth factor- and Snail significantly increased. These results suggest that epithelial-mesenchymal transition may contribute to excessive trophoblast invasion into the myometrium in adherent placenta.	[Shirakawa, Tokuro; Miyahara, Yoshiya; Tanimura, Kenji; Morita, Hiroki; Yamada, Hideto] Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Kobe, Hyogo 6500017, Japan; [Kawakami, Fumi; Itoh, Tomoo] Kobe Univ Hosp, Dept Diagnost Pathol, Kobe, Hyogo, Japan	Yamada, H (reprint author), Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	yhideto@med.kobe-u.ac.jp			Japan Society for the Promotion of Science [23592403, 26462489]	This work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science (No. 23592403 and 26462489).	Shih IM, 2002, PLACENTA, V23, P706, DOI 10.1053/plac.2002.0864; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Lim KH, 1997, AM J PATHOL, V151, P1809; Charalabopoulos K., 2006, Experimental Oncology, V28, P83; Matsumoto K, 2003, J UROLOGY, V170, P2248, DOI 10.1097/01.ju.0000094189.93805.17; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; De Wever O, 2007, CLIN EXP METASTAS, V24, P685, DOI 10.1007/s10585-007-9104-8; Chan ACO, 2003, J CLIN ONCOL, V21, P2288, DOI 10.1200/JCO.2003.08.078; Syrigos KN, 2004, ANTICANCER RES, V24, P2027; Griffiths TRL, 1996, BRIT J CANCER, V74, P579, DOI 10.1038/bjc.1996.404; Lockwood CJ, 2012, AM J PATHOL, V181, P2138, DOI [10.1016/j.ajpath.2012.08.036, 10.1016/j.ajpath.2012.08036]; Rothberg BEG, 2006, BREAST CANCER RES TR, V100, P139, DOI 10.1007/s10549-006-9248-2; Soyama A, 2008, HEPATO-GASTROENTEROL, V55, P1390; Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651; Wu S, 2005, AM J OBSTET GYNECOL, V192, P1458, DOI 10.1016/j.ajog.2004.12.074; Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; DORUDI S, 1993, AM J PATHOL, V142, P981; Tantbirojn P, 2008, PLACENTA, V29, P639, DOI 10.1016/j.placenta.2008.04.008; Chan AOO, 2005, CANCER, V104, P740, DOI 10.1002/cncr.21260; Gielchinsky Y, 2002, PLACENTA, V23, P210, DOI 10.1053/plac.2001.0764; KHONG TY, 1987, PLACENTA, V8, P399, DOI 10.1016/0143-4004(87)90067-1; Baergen RN, 2005, MANUAL BENIRSCHKE KA; Larisa F, 2012, REPROD BIOL ENDOCRIN, V10, P15, DOI [10.1186/1477-7827-10-15, DOI 10.1186/1477-7827-10-15]	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-1691	1538-7151		INT J GYNECOL PATHOL	Int. J. Gynecol. Pathol.	NOV	2015	34	6					584	589		10.1097/PGP.0000000000000190		6	Obstetrics & Gynecology; Pathology	Obstetrics & Gynecology; Pathology	CU1VB	WOS:000363308600012		
J	Yamamuro, S; Sano, E; Okamoto, Y; Ochiai, Y; Ohta, T; Ogino, A; Natsume, A; Wakabayashi, T; Ueda, T; Hara, H; Nakayama, T; Yoshino, A; Katayama, Y				Yamamuro, Shun; Sano, Emiko; Okamoto, Yutaka; Ochiai, Yushi; Ohta, Takashi; Ogino, Akiyoshi; Natsume, Atsushi; Wakabayashi, Toshihiko; Ueda, Takuya; Hara, Hiroyuki; Nakayama, Tomohiro; Yoshino, Atsuo; Katayama, Yoichi			Antitumorigenic effect of interferon-beta by inhibition of undifferentiated glioblastoma cells	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						glioblastoma; glioma stem-like cells; interferon; differentiation; undifferentiation	STEM-CELLS; ADJUVANT TEMOZOLOMIDE; INITIATING CELLS; GLIOMA-CELLS; CANCER-CELLS; IFN-BETA; GENE; EXPRESSION; EZH2; RADIOTHERAPY	Glioma stem-like cells (GSCs) are undifferentiated cells that are considered to be an origin of glioblastomas. Furthermore, they may contribute to treatment resistance and recurrence in glioblastomas. GSCs differentiate into differentiated glioma cells (non-glioma stem-like cells: non-GSCs), and interconversion might occur between GSCs and non-GSCs. We investigated whether interferon-beta (IFN-beta) could exert any efficacy towards GSCs or such interconversion processes. The neural stem cell marker CD133 and pluripotency marker Nanog in GSCs were analyzed to evaluate their differentiation levels. GSCs were considered to undergo differentiation into non-GSCs upon serum exposure, since the expression of CD133 and Nanog in the GSCs was negatively affected. Furthermore, the cells regained their undifferentiated features upon removal of the serum. However, we verified that IFN-beta reduced cell proliferation and tumor sphere formation in GSCs, and induced suppression of the restoration of such undifferentiated features. In addition, we also confirmed that IFN-beta suppressed the acquisition process of undifferentiated features in human malignant glioma cell lines. Our data thus suggest that IFN-beta could be an effective agent not only through its cell growth inhibitory effect on GSCs but also as a means of targeting the interconversion between GSCs and non-GSCs, indicating the possibility of IFN-beta being used to prevent treatment resistance and recurrence in glioblastomas, via the inhibition of undifferentiated features.	[Yamamuro, Shun; Ochiai, Yushi; Ohta, Takashi; Ogino, Akiyoshi; Yoshino, Atsuo; Katayama, Yoichi] Nihon Univ, Sch Med, Dept Neurol Surg, Tokyo 1738610, Japan; [Hara, Hiroyuki] Nihon Univ, Sch Med, Dept Funct Morphol, Tokyo 1738610, Japan; [Nakayama, Tomohiro] Nihon Univ, Sch Med, Dept Pathol Microbiol, Div Compan Diagnost, Tokyo 1738610, Japan; [Sano, Emiko; Ueda, Takuya] Univ Tokyo, Grad Sch Frontier Sci, Chiba, Japan; [Okamoto, Yutaka] Japan Agcy Med Res & Dev, Dept Res Promot, Nagoya, Aichi, Japan; [Natsume, Atsushi; Wakabayashi, Toshihiko] Nagoya Univ, Sch Med, Dept Neurosurg, Nagoya, Aichi 466, Japan	Yoshino, A (reprint author), Nihon Univ, Sch Med, Dept Neurol Surg, Itabashi Ku, 30-1 Oyaguchi Kamimachi, Tokyo 1738610, Japan.	yoshino.atsuo@nihon-u.ac.jp			Health Sciences Research Institute, Inc., Yokohama, Japan; Medtronic Japan Co., Ltd.	This study was supported in part by a grant from the Health Sciences Research Institute, Inc., Yokohama, Japan, to the Division of Companion Diagnostics, Department of Pathology of Microbiology, Nihon University School of Medicine. The authors are grateful to Hiroyuki Satake and Nobuo Miyazaki, bray Industries Inc. (Tokyo, Japan), for their invaluable discussions and supply of natural type IFN-beta. Some parts of this study have been submitted for the Japanese-language thesis of Shun Yamamuro's Ph.D. degree at Nihon University School of Medicine. Toshihiko Wakabayashi received funds for other research projects not related to this study from Eisai Co., Ltd, Chugai Pharmaceutical Co., Ltd., MSD K.K., Mizuho Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Toray Industries Inc. Takuya Ueda received funds for other research projects not related to this study from the Ministry of Education, Culture, Sports, Science and Technology, Japan, Minister of Economy, Trade and Industry, Japan and Human Frontier Science Program. Yoichi Katayama received research funds for another research project from Medtronic Japan Co., Ltd.	Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Singh SK, 2003, CANCER RES, V63, P5821; Natsume A, 2005, CANCER RES, V65, P7573, DOI 10.1158/0008-5472.CAN-05-0036; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrcd1991; Cebria F, 2002, NATURE, V419, P620, DOI 10.1038/nature01042; Raaphorst FM, 2003, NEOPLASIA, V5, P481; Wakabayashi T, 2008, JPN J CLIN ONCOL, V38, P715, DOI 10.1093/jjco/hyn095; Bracken AP, 2009, NAT REV CANCER, V9, P773, DOI 10.1038/nrc2736; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Poltavtseva RA, 2002, DEV BRAIN RES, V134, P149, DOI 10.1016/S0165-3806(02)00274-2; Smith TJ, 2000, J CLIN ONCOL, V18, P3441; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Saito R, 2004, J NEURO-ONCOL, V67, P273, DOI 10.1023/B:NEON.0000024217.68738.11; Gupta PB, 2009, NAT MED, V15, P1010, DOI [10.1038/nm0909-1010, 10.1038/nm.2032]; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159; Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Natsume A, 2013, CANCER RES, V73, P4559, DOI 10.1158/0008-5472.CAN-13-0109; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Wakabayashi T, 2011, J NEURO-ONCOL, V104, P573, DOI 10.1007/s11060-011-0529-1; Wilson RJ, 2004, NATURE, V432, P393, DOI 10.1038/nature03031; Yoshino A, 2005, J NEURO-ONCOL, V74, P249, DOI 10.1007/s11060-004-7316-1; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Yuki K, 2009, CANCER LETT, V284, P71, DOI 10.1016/j.canlet.2009.04.020; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Vannucchi S, 2007, CURR MED CHEM, V14, P667, DOI 10.2174/092986707780059616; Yoshino A, 2011, INT J ONCOL, V39, P529, DOI 10.3892/ijo.2011.1068; Park JA, 2006, ONCOL REP, V16, P1253; Qiang L, 2009, CANCER LETT, V279, P13, DOI 10.1016/j.canlet.2009.01.016; Hatano S, 2005, MECH DEVELOP, V122, P67, DOI 10.1016/j.mod.2004.08.008; PEGG AE, 1990, CANCER RES, V50, P6119; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Griguer CE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003655; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262	42	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	NOV	2015	47	5					1647	1654		10.3892/ijo.2015.3165		8	Oncology	Oncology	CU2LV	WOS:000363355900004		
J	Hattori, N; Yamada, S; Torii, K; Takeda, S; Nakamura, K; Tanaka, H; Kajiyama, H; Kanda, M; Fujii, T; Nakayama, G; Sugimoto, H; Koike, M; Nomoto, S; Fujiwara, M; Mizuno, M; Hori, M; Kodera, Y				Hattori, Norifumi; Yamada, Suguru; Torii, Koji; Takeda, Shigeomi; Nakamura, Kae; Tanaka, Hiromasa; Kajiyama, Hiroaki; Kanda, Mitsuro; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Koike, Masahiko; Nomoto, Shuji; Fujiwara, Michitaka; Mizuno, Masaaki; Hori, Masaru; Kodera, Yasuhiro			Effectiveness of plasma treatment on pancreatic cancer cells	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						apoptosis; non-thermal atmospheric pressure plasma; pancreatic cancer; reactive oxygen species; xenograft model antitumor assays	LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; NONTHERMAL PLASMA; GASTRIC-CANCER; METASTASIS; APOPTOSIS; RESECTION; JETS; CURE	Non-equilibrium atmospheric pressure plasma (NEAPP) has attracted attention in cancer therapy. We explored the indirect effect of NEAPP through plasma-activated medium (PAM) on pancreatic cancer cells in vitro and in vivo. In this study, four pancreatic cancer cell lines were used and the antitumor effects of PAM treatment were evaluated using a cell proliferation assay. To explore functional mechanisms, morphological change and caspase-3/7 activation in cells were also assessed. Furthermore, reactive oxygen species (ROS) generation in cells was examined and N-acetyl cysteine (NAC), an intracellular ROS scavenger, was tested. Finally, the antitumor effect of local injection of PAM was investigated in a mouse xenograft model. We found that PAM treatment had lethal effect on pancreatic cancer cells. Typical morphological findings suggestive of apoptosis such as vacuolization of cell membranes, small and round cells and aggregation of cell nuclei, were observed in the PAM treated cells. Caspase-3/7 activation was detected in accordance with the observed morphological changes. Additionally, ROS uptake was observed in all cell lines tested, while the antitumor effects of PAM were completely inhibited with NAC. In the mouse xenograft model, the calculated tumor volume on day 28 in the PAM treatment group was significantly smaller compared with the control group [28 +/- 22 vs. 89 +/- 38 (mm(3) +/- SD), p=0.0031]. These results show that PAM treatment of pancreatic cancer might be a promising therapeutic strategy.	[Hattori, Norifumi; Yamada, Suguru; Torii, Koji; Takeda, Shigeomi; Kanda, Mitsuro; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Koike, Masahiko; Nomoto, Shuji; Fujiwara, Michitaka; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi 4668550, Japan; [Nakamura, Kae; Kajiyama, Hiroaki] Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol, Nagoya, Aichi 4668550, Japan; [Tanaka, Hiromasa; Mizuno, Masaaki] Nagoya Univ, Grad Sch Med, Ctr Adv Med & Clin Res, Nagoya, Aichi 4668550, Japan; [Hori, Masaru] Nagoya Univ, Plasma Nanotechnol Res Ctr, Nagoya, Aichi 4648603, Japan	Yamada, S (reprint author), Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	suguru@med.nagoya-u.ac.jp					Fridman G, 2007, PLASMA CHEM PLASMA P, V27, P163, DOI 10.1007/s11090-007-9048-4; Schnelldorfer T, 2008, ANN SURG, V247, P456, DOI 10.1097/SLA.0b013e3181613142; Furuse J, 2013, JPN J CLIN ONCOL, V43, P2, DOI 10.1093/jjco/hys177; Ferrone CR, 2012, SURGERY, V152, pS43, DOI 10.1016/j.surg.2012.05.020; Nicco C, 2005, BIOMED PHARMACOTHER, V59, P169, DOI 10.1016/j.biopha.2005.03.009; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Keidar M, 2011, BRIT J CANCER, V105, P1295, DOI 10.1038/bjc.2011.386; Yamazaki H, 2011, DENT MATER J, V30, P384, DOI 10.4012/dmj.2010-190; Sensenig R, 2011, ANN BIOMED ENG, V39, P674, DOI 10.1007/s10439-010-0197-x; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Jia FD, 2011, APPL PHYS EXPRESS, V4, DOI 10.1143/APEX.4.026101; Ishigami H, 2010, ANN ONCOL, V21, P67, DOI 10.1093/annonc/mdp260; Aruoma OI, 1998, J AM OIL CHEM SOC, V75, P199, DOI 10.1007/s11746-998-0032-9; Ninomiya K, 2013, J PHYS D APPL PHYS, V46, DOI 10.1088/0022-3727/46/42/425401; Conlon KC, 1996, ANN SURG, V223, P273, DOI 10.1097/00000658-199603000-00007; Iwasaki M, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2885084; Nishikawa M, 2008, CANCER LETT, V266, P53, DOI 10.1016/j.canlet.2008.02.031; Stoffels E, 2003, J PHYS D APPL PHYS, V36, P2908, DOI 10.1088/0022-3727/36/23/007; Kim CH, 2010, J BIOTECHNOL, V150, P530, DOI 10.1016/j.jbiotec.2010.10.003; Winter JM, 2012, ANN SURG ONCOL, V19, P169, DOI 10.1245/s10434-011-1900-3; Kalghatgi S, 2010, ANN BIOMED ENG, V38, P748, DOI 10.1007/s10439-009-9868-x; Wray CJ, 2005, GASTROENTEROLOGY, V128, P1626, DOI 10.1053/j.gastro.2005.03.035; Malvezzi M, 2012, ANN ONCOL, V23, P1044, DOI 10.1093/annonc/mds024; Torii K, 2015, GASTRIC CANCER, V18, P635, DOI 10.1007/s10120-014-0395-6; Georgescu N, 2010, IEEE T PLASMA SCI, V38, P1949, DOI 10.1109/TPS.2010.2041075; Vandamme M, 2010, PLASMA PROCESS POLYM, V7, P264, DOI 10.1002/ppap.200900080; Iseki S, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3694928; Arjunan KP, 2012, J R SOC INTERFACE, V9, P147; Barrera G., 2012, ISRN ONCOL, DOI [10.5402/2012/137289, DOI 10.5402/2012/137289]; Brulle L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052653; Kalghatgi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016270; Kim GJ, 2010, APPL PHYS LETT, V96, DOI 10.1063/1.3292206; Ma Y, 2014, PLOS ONE, V9; Takahara Naminatsu, 2014, J Gastrointest Cancer, V45, P307, DOI 10.1007/s12029-014-9603-1; Tanaka H, 2011, PLASMA MED, V1, P265; Utsumi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081576	36	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	NOV	2015	47	5					1655	1662		10.3892/ijo.2015.3149		8	Oncology	Oncology	CU2LV	WOS:000363355900005		
J	Wen, CY; Huang, LL; Chen, JX; Lin, MM; Li, W; Lu, BY; Rutnam, ZJ; Iwamoto, A; Wang, ZY; Yang, XL; Liu, HL				Wen, Chuangyu; Huang, Lanlan; Chen, Junxiong; Lin, Mengmeng; Li, Wen; Lu, Biyan; Rutnam, Zina Jeyapalan; Iwamoto, Aikichi; Wang, Zhongyang; Yang, Xiangling; Liu, Huanliang			Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						gambogic acid; colorectal cancer; 5-FU resistance; apoptosis; JNK signaling pathway	C-JUN; TRANSCRIPTION FACTOR; P-GLYCOPROTEIN; BREAST-CANCER; CYCLE ARREST; IN-VITRO; KINASE; MITOCHONDRIA; CHEMOTHERAPY; BCL-2	The emergence of chemoresistance is a major limitation of colorectal cancer (CRC) therapies and novel biologically based therapies are urgently needed. Natural products represent a novel potential anticancer therapy. Gambogic acid (GA), a small molecule derived from Garcinia hanburyi Hook. f., has been demonstrated to be highly cytotoxic to several types of cancer cells and have low toxicity to the hematopoietic system. However, the potential role of GA in colorectal cancer and its ability to overcome the chemotherapeutic resistance in CRC cells have not been well studied. In the present study, we showed that GA directly inhibited proliferation and induced apoptosis in both 5-fluorouracil (5-FU) sensitive and 5-FU resistant colorectal cancer cells; induced apoptosis via activating JNK signaling pathway. The data, therefore, suggested an alternative strategy to overcome 5-FU resistance in CRC and that GA could be a promising medicinal compound for colorectal cancer therapy.	[Wen, Chuangyu; Huang, Lanlan; Chen, Junxiong; Lin, Mengmeng; Wang, Zhongyang; Yang, Xiangling; Liu, Huanliang] Sun Yat Sen Univ, Guangdong Inst Gastroenterol, Guangzhou 510655, Guangdong, Peoples R China; [Wen, Chuangyu; Huang, Lanlan; Chen, Junxiong; Lin, Mengmeng; Wang, Zhongyang; Yang, Xiangling; Liu, Huanliang] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou 510655, Guangdong, Peoples R China; [Wen, Chuangyu; Huang, Lanlan; Chen, Junxiong; Lin, Mengmeng; Yang, Xiangling; Liu, Huanliang] Sun Yat Sen Univ, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou 510655, Guangdong, Peoples R China; [Wen, Chuangyu; Huang, Lanlan; Chen, Junxiong; Lin, Mengmeng; Yang, Xiangling; Liu, Huanliang] Sun Yat Sen Univ, Minist Educ, Inst Human Virol, Guangzhou 510080, Guangdong, Peoples R China; [Wen, Chuangyu; Huang, Lanlan; Chen, Junxiong; Lin, Mengmeng; Yang, Xiangling; Liu, Huanliang] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510080, Guangdong, Peoples R China; [Li, Wen] Guangzhou Med Univ, Guangdong Prov Key Lab Allergy & Immunol, Guangzhou 510260, Guangdong, Peoples R China; [Lu, Biyan] Dongguan Hlth Sch, Dongguan 523186, Guangdong, Peoples R China; [Rutnam, Zina Jeyapalan] Univ Washington, Ctr Translat Med Womens Hlth, Tumor Vaccine Grp, Seattle, WA 98195 USA; [Iwamoto, Aikichi] Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Tokyo 1088639, Japan	Yang, XL (reprint author), Sun Yat Sen Univ, Guangdong Inst Gastroenterol, 260 Yuancun Er Heng Rd, Guangzhou 510655, Guangdong, Peoples R China.	morningyang100@gmail.com; liuhuanl@mail.sysu.edu.cn			Guangdong Provincial Department of Science and Technology [2012B050500004, 2011B090400559]; Guangdong Innovative Research Team Program [2009010058]; ScienceandInformationTechnology Bureau of Guangzhou, Guangdong [2011J5200009]; Overseas Excellent Professor Project, Ministry of Education, China; Japan Ministry of Education, Culture, Sports, Science and Technology (MEXT) for Program of Japan Initiative for Global Research Network on Infectious Diseases (J-GRID)	This study was supported by the Guangdong Provincial Department of Science and Technology (2012B050500004; 2011B090400559); the Guangdong Innovative Research Team Program (2009010058); the ScienceandInformationTechnology Bureau of Guangzhou, Guangdong (2011J5200009); the Overseas Excellent Professor Project, Ministry of Education, China; and the Japan Ministry of Education, Culture, Sports, Science and Technology (MEXT) for Program of Japan Initiative for Global Research Network on Infectious Diseases (J-GRID).	Akasaka T, 2015, INT J ONCOL, V46, P63, DOI 10.3892/ijo.2014.2693; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Nie FF, 2009, TOXICOLOGY, V260, P60, DOI 10.1016/j.tox.2009.03.010; Wang XD, 2001, GENE DEV, V15, P2922; Lee PNH, 2013, ONCOL REP, V29, P1744, DOI 10.3892/or.2013.2291; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Wang LH, 2014, CURR CANCER DRUG TAR, V14, P91; Wang SP, 2015, CHEM-BIOL INTERACT, V235, P76, DOI 10.1016/j.cbi.2015.03.017; Chen J, 2008, LIFE SCI, V83, P103, DOI 10.1016/j.lfs.2008.05.003; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Chi YHBL, 2013, CHINESE MED J-PEKING, V126, P1642, DOI 10.3760/cma.j.issn.0366-6999.20122582; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Qi Q, 2008, J ETHNOPHARMACOL, V117, P433, DOI 10.1016/j.jep.2008.02.027; Marquez F, 2012, CRIT REV FOOD SCI, V52, P585, DOI 10.1080/10408398.2010.500551; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Temraz S, 2014, CRIT REV ONCOL HEMAT, V89, P217, DOI 10.1016/j.critrevonc.2013.08.015; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Yi T, 2008, CANCER RES, V68, P1843, DOI 10.1158/0008-5472.CAN-07-5944; Chuah LO, 2012, EVID-BASED COMPL ALT, DOI 10.1155/2012/197920; Zhao W, 2013, MOL CELL BIOCHEM, V382, P243, DOI 10.1007/s11010-013-1740-5; Zhao W, 2011, ONCOL REP, V25, P1289, DOI 10.3892/or.2011.1189; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Li XF, 2013, CELL REP, V3, P211, DOI 10.1016/j.celrep.2012.11.023; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Xu JY, 2013, CHINESE J CANCER RES, V25, P183, DOI 10.3978/j.issn.1000-9604.2013.02.06; Li CL, 2012, BIOCHEM CELL BIOL, V90, P718, DOI [10.1139/o2012-030, 10.1139/O2012-030]; Shi XP, 2014, CLIN CANCER RES, V20, P151, DOI 10.1158/1078-0432.CCR-13-1063; Gandhi S, 2015, CURR ONCOL, V22, pS82, DOI 10.3747/co.22.2321; Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002; Krajarng A, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0544-4; Song MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065821; Thota R, 2014, ONCOLOGY-NY, V28, P70	36	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	NOV	2015	47	5					1663	1671		10.3892/ijo.2015.3166		9	Oncology	Oncology	CU2LV	WOS:000363355900006		
J	Kurokawa, T; Murata, S; Zheng, YW; Iwasaki, K; Kohno, K; Fukunaga, K; Ohkohchi, N				Kurokawa, Tomohiro; Murata, Soichiro; Zheng, Yun-Wen; Iwasaki, Kenichi; Kohno, Keisuke; Fukunaga, Kiyoshi; Ohkohchi, Nobuhiro			The Eltrombopag antitumor effect on hepatocellular carcinoma	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						hepatocellular carcinoma; eltrombopag; deferoxamine cell cycle; iron chelate; thrombopoietin; Huh7; thrombocytopenia; cirrhosis; liver cirrhosis; liver cancer; sorafenib	CELL-CYCLE PROGRESSION; RIBONUCLEOTIDE REDUCTASE-ACTIVITY; THROMBOPOIETIN RECEPTOR AGONIST; CHRONIC HEPATITIS-C; IRON CHELATORS; PLATELET PRODUCTION; ANTINEUROBLASTOMA ACTIVITY; MEGAKARYOCYTE DEVELOPMENT; SELECTIVE-INHIBITION; MULTIPLE-MYELOMA	Currently, sorafenib is the only available chemotherapeutic agent for advanced hepatocellular carcinoma (HCC), but it cannot be used in patients with liver cirrhosis (LC) or thrombocytopenia. In these cases, sorafenib is likely effective if given in combination with treatments that increase the number of platelets, such as thrombopoietin (TPO) receptor agonists. Increasing the platelet count via TPO treatment resulted in reduction of LC. Eltrombopag (EP), a TPO receptor agonist, has been reported to have antitumor effects against certain cancers, despite their lack of TPO receptor expression. We hypothesized that EP may possess antitumor activity against HCC in addition to its ability to suppress hepatic fibrosis by increasing the platelet count. In the present study, the antitumor activity of EP was examined by assessing the inhibition of cell proliferation and then ascertaining the ability of iron supplementation to reverse these effects in HepG2, Hep3B and Huh7 cells. In addition, a cell cycle assay was performed using flow cytometry, and signal transduction was evaluated by analyzing cell cycle-related protein expression. The results of EP were compared with those of the most common iron chelator, deferoxamine (DFO). The combined effect of EP and sorafenib was also assessed. The. results revealed that EP exerts antitumor activity in HCC that is mediated by the modulation of intracellular iron content. EP suppressed the expression of the cell cycle-related protein cyclin D1 and elicited cell cycle arrest in the G0/G1 phase. The activity of EP was comparable to that of DFO in HCC, and EP did not compete with sorafenib at low concentrations. In conclusion, our findings suggest that EP is a good candidate chemotherapeutic agent for the treatment of HCC in patients with LC and thrombocytopenia.	[Kurokawa, Tomohiro; Murata, Soichiro; Zheng, Yun-Wen; Iwasaki, Kenichi; Kohno, Keisuke; Fukunaga, Kiyoshi; Ohkohchi, Nobuhiro] Univ Tsukuba, Fac Med, Dept Surg, Div Gastroenterol & Hepatobiliary Surg & Organ Tr, Tsukuba, Ibaraki 3058575, Japan	Ohkohchi, N (reprint author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Surg, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	nokochi3@md.tsukuba.ac.jp			Ministry of Education, Culture, Sports, and Science and Technology of Japan (MEXT)	The present study was supported in part by grants from the Ministry of Education, Culture, Sports, and Science and Technology of Japan (MEXT).	Andrews NC, 1999, NEW ENGL J MED, V341, P1986, DOI 10.1056/NEJM199912233412607; deSauvage FJ, 1996, J EXP MED, V183, P651, DOI 10.1084/jem.183.2.651; Duffy KJ, 2002, J MED CHEM, V45, P3573, DOI 10.1021/jm025535c; Erickson-Miller CL, 2005, EXP HEMATOL, V33, P85, DOI 10.1016/j.expharm.2004.09.006; Deutsch VR, 2006, BRIT J HAEMATOL, V134, P453, DOI 10.1111/j.1365-2141.2006.06215.x; Louandre C, 2013, INT J CANCER, V133, P1732, DOI 10.1002/ijc.28159; ELFORD HL, 1970, J BIOL CHEM, V245, P5228; LUCAS JJ, 1995, BLOOD, V86, P2268; Rao VA, 2009, CANCER RES, V69, P948, DOI 10.1158/0008-5472.CAN-08-1437; Mark TM, 2013, BIOL BLOOD MARROW TR, V19, P831, DOI 10.1016/j.bbmt.2013.02.013; Will B, 2009, BLOOD, V114, P3899, DOI 10.1182/blood-2009-04-219493; ESTROV Z, 1987, BLOOD, V69, P757; Williams DD, 2009, CLIN THER, V31, P764, DOI 10.1016/j.clinthera.2009.04.010; Nozaki R, 2013, HEPATOL RES, V43, P610, DOI 10.1111/hepr.12006; RICHARDSON DR, 1990, BIOCHIM BIOPHYS ACTA, V1053, P1, DOI 10.1016/0167-4889(90)90018-9; TAKEDA E, 1981, LIFE SCI, V28, P1007, DOI 10.1016/0024-3205(81)90746-3; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Musto P, 2008, EXPERT REV ANTICANC, V8, P1569, DOI 10.1586/14737140.8.10.1569; Bussel JB, 2007, NEW ENGL J MED, V357, P2237, DOI 10.1056/NEJMoa073275; Kwok JC, 2002, CRIT REV ONCOL HEMAT, V42, P65, DOI 10.1016/S1040-8428(01)00213-X; Erickson-Miller CL, 2010, LEUKEMIA RES, V34, P1224, DOI 10.1016/j.leukres.2010.02.005; Cardier JE, 1998, BLOOD, V91, P923; Gao J, 2001, BLOOD, V98, P842, DOI 10.1182/blood.V98.3.842; Wolber EM, 2002, NEWS PHYSIOL SCI, V17, P6; Le NTV, 2004, BLOOD, V104, P2967, DOI 10.1182/blood-2004-05-1866; Whitnall M, 2006, P NATL ACAD SCI USA, V103, P14901, DOI 10.1073/pnas.0604979103; Tanaka H, 2008, BRIT J CANCER, V98, P580, DOI 10.1038/sj.bjc.6604204; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; Yamasaki T, 2011, NEW ENGL J MED, V365, P576, DOI 10.1056/NEJMc1105726; BLATT J, 1988, J LAB CLIN MED, V112, P433; Matthys G, 2011, J CLIN PHARMACOL, V51, P301, DOI 10.1177/0091270010368677; Fu D, 2007, BLOOD, V110, P752, DOI 10.1182/blood-2007-03-076737; GANGAIDZO IT, 1995, GUT, V37, P727, DOI 10.1136/gut.37.5.727; [Anonymous], 2010, PHARM MED; KAPLINSKY C, 1987, LEUKEMIA, V1, P437; DONFRANCESCO A, 1990, CANCER RES, V50, P4929; Kalinowski DS, 2005, PHARMACOL REV, V57, P547, DOI 10.1124/pr.57.4.2; Rakba N, 2000, CARCINOGENESIS, V21, P943, DOI 10.1093/carcin/21.5.943; Kaushansky K, 2002, ONCOGENE, V21, P3359, DOI 10.1038/j/onc/1205323; Schmelzer E, 2008, EUR J GASTROEN HEPAT, V20, P209, DOI 10.1097/MEG.0b013e3282f246e6; LARRICK JW, 1979, J SUPRAMOL STR CELL, V11, P579, DOI 10.1002/jss.400110415; Witt L, 1978, Adv Enzyme Regul, V17, P157; Roth M, 2012, BLOOD, V120, P386, DOI 10.1182/blood-2011-12-399667; Erickson-Miller CL, 2009, STEM CELLS, V27, P424, DOI 10.1634/stemcells.2008-0366; Ba Q, 2011, CLIN CANCER RES, V17, P7625, DOI 10.1158/1078-0432.CCR-10-3099; Kato J, 2001, CANCER RES, V61, P8697; Peeters K, 2008, DRUG DISCOV TODAY, V13, P798, DOI 10.1016/j.drudis.2008.06.002; Kawaguchi T, 2014, ONCOL LETT, V7, P2130, DOI 10.3892/ol.2014.1976; Kawaguchi T, 2012, J GASTROENTEROL, V47, P1342, DOI 10.1007/s00535-012-0600-5; Safonov IG, 2006, BIOORG MED CHEM LETT, V16, P1212, DOI 10.1016/j.bmcl.2005.11.096; BLATT J, 1987, CANCER RES, V47, P1749; Duffy KJ, 2002, J MED CHEM, V45, P3576, DOI 10.1021/jm0255365; RICHARDSON DR, 1992, BIOCHIM BIOPHYS ACTA, V1103, P275, DOI 10.1016/0005-2736(92)90097-6; Le NTV, 2002, BBA-REV CANCER, V1603, P31, DOI 10.1016/S0304-419X(02)00068-9; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Buss JL, 2004, CURR TOP MED CHEM, V4, P1623, DOI 10.2174/1568026043387269; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006; BRODIE C, 1993, CANCER RES, V53, P3968; Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Erickson-Miller C, 2004, BLOOD, V104, P2912; Erickson-Miller CL, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-405; HERSHKO C, 1994, BAILLIERE CLIN HAEM, V7, P965, DOI 10.1016/S0950-3536(05)80133-7; Kalota A, 2004, BLOOD, V104, p796A; Luengo JI, 2004, BLOOD, V104, P2910; McHutchison JG, 2007, NEW ENGL J MED, V357, P2227, DOI 10.1056/NEJMoa073255; Montalto G, 2002, ANN NY ACAD SCI, V963, P13; Nurtjahja-Tjendraputra E, 2007, BLOOD, V109, P4045, DOI 10.1182/blood-2006-10-047753	69	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	NOV	2015	47	5					1696	1702		10.3892/ijo.2015.3180		7	Oncology	Oncology	CU2LV	WOS:000363355900009		
J	Tanaka, H; Kanda, M; Koike, M; Iwata, N; Shimizu, D; Ezaka, K; Sueoka, S; Tanaka, Y; Takami, H; Hashimoto, R; Tanaka, C; Yamada, S; Fujii, T; Nakayama, G; Sugimoto, H; Fujiwara, M; Kodera, Y				Tanaka, Haruyoshi; Kanda, Mitsuro; Koike, Masahiko; Iwata, Naoki; Shimizu, Dai; Ezaka, Kazuhiro; Sueoka, Satoshi; Tanaka, Yuri; Takami, Hideki; Hashimoto, Ryoji; Tanaka, Chie; Yamada, Suguru; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Fujiwara, Michitaka; Kodera, Yasuhiro			Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						esophageal cancer; AJAP1; methylation; recurrence; biomarker	DIHYDROPYRIMIDINASE-LIKE 3; HEPATOCELLULAR-CARCINOMA; GASTRIC-CANCER; PROMOTER HYPERMETHYLATION; DECREASED EXPRESSION; TUMOR-SUPPRESSOR; EZRIN; METASTASIS; ADHESION; INVASION	Esophageal squamous cell carcinoma (ESCC), the most common esophageal cancer in East Asia, is among the six cancers with the highest fatality rates worldwide. Unfortunately, multidisciplinary treatment strategies have not achieved satisfactory outcomes. Therefore, novel insights into the molecular biology of ESCC are required to improve treatment. The gene encoding the transmembrane adherens junctions-associated protein-1 (AJAP1) expressed by epithelial cells resides in chromosome 1p36, which is frequently lost or epigenetically silenced in several malignancies. Here, we investigated the expression levels and regulatory mechanism of AJAP1 transcription. We determined the levels of AJAP1 mRNA and the genes encoding potentially interacting proteins expressed by ESCC cell lines, as well as the chromosomal copy number of AJAP1 and the methylation status of its promoter region. AJAP1 mRNA levels of 78 pairs of surgically resected specimens were determined to evaluate the association of AJAP1 expression and clinicopathological factors. Nine ESCC cell lines differentially expressed AJAP1 mRNA, and demethylation of hypermethylated AJAP1 genomic DNA reactivated AJAP1 mRNA expression. The copy number of sequences upstream or downstream of the AJAP1 transcriptional start site was not detectably altered. AJAP1 mRNA levels correlated inversely with those of ezrin (EZR) and were significantly lower in ESCC tissues compared with adjacent normal tissues. AJAP1 mRNA levels decreased gradually with increasing tumor stage. Patients with downregulated AJAP1 transcription were more likely to experience shorter overall and disease-free survival. Multivariate analysis of disease-free survival identified downregulated AJAP1 transcription as an independent prognostic factor. These results suggest that in ESCC, AJAP1 acts as a putative tumor suppressor and that AJAP1 transcription is regulated by promoter hypermethylation. These findings indicate that downregulated AJAP1 transcription may serve as a novel tumor biomarker to predict recurrence of ESCC after esophagectomy.	[Tanaka, Haruyoshi; Kanda, Mitsuro; Koike, Masahiko; Iwata, Naoki; Shimizu, Dai; Ezaka, Kazuhiro; Sueoka, Satoshi; Tanaka, Yuri; Takami, Hideki; Hashimoto, Ryoji; Tanaka, Chie; Yamada, Suguru; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Fujiwara, Michitaka; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Showa Ku, Nagoya, Aichi 4668550, Japan	Kanda, M (reprint author), Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	m-kanda@med.nagoya-u.ac.jp					Lin NJ, 2012, MOL CANCER RES, V10, P208, DOI 10.1158/1541-7786.MCR-10-0109; Wang X, 2014, GENET MOL RES, V13, P8002, DOI 10.4238/2014.September.29.13; Kanda M, 2015, INT J ONCOL, V46, P641, DOI 10.3892/ijo.2014.2762; Wang Y, 2014, BRIT J CANCER, V110, P695, DOI 10.1038/bjc.2013.770; Kanda M, 2014, INT J ONCOL, V45, P2005, DOI 10.3892/ijo.2014.2637; Kamangar F, 2009, GASTROENTEROL CLIN N, V38, P27, DOI 10.1016/j.gtc.2009.01.004; McDonald JM, 2006, CANCER BIOL THER, V5, P300; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Zeng L, 2014, INT J ONCOL, V44, P1243, DOI 10.3892/ijo.2014.2277; Oya H, 2015, J GASTROENTEROL, V50, P590, DOI 10.1007/s00535-014-0993-4; Han L, 2014, CNS NEUROSCI THER, V20, P429, DOI 10.1111/cns.12232; Tang JCO, 2001, CLIN CANCER RES, V7, P1539; Zeng L, 2014, INT J ONCOL, V45, P13, DOI 10.3892/ijo.2014.2425; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.E04-08-0721; Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.01059.x; Kanda M, 2014, INT J ONCOL, V44, P44, DOI 10.3892/ijo.2013.2165; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010; Xie JJ, 2009, INT J CANCER, V124, P2549, DOI 10.1002/ijc.24216; Tanaka Y, 2015, INT J ONCOL, V46, P2546, DOI 10.3892/ijo.2015.2965; Long MJ, 2013, ALCOHOL, V47, P473, DOI 10.1016/j.alcohol.2013.06.003; Kanda M, 2014, J SURG ONCOL, V110, P136, DOI 10.1002/jso.23614; Schreiner A, 2007, MOL BIOL CELL, V18, P1272, DOI 10.1091/mbc.E06-07-0637; Hibino S, 2014, ONCOL REP, V31, P693, DOI 10.3892/or.2013.2901; Zhang HX, 2010, NAT GENET, V42, P755, DOI 10.1038/ng.638; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Cogdell David, 2011, Chin J Cancer, V30, P247; Ghaffari A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0438-2; Jin TF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-191; Kanda M, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0066-9; Kanda M, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0088-3; Kanda M, 2014, DIGEST DIS SCI, V60, P1256; Kanda M, 2015, GASTRIC CANCER, V18, P288, DOI 10.1007/s10120-014-0372-0; Kong JN, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-520; Lee HW, 2015, DIS ESOPHAGUS, DOI [10.1111/dote.12359., DOI 10.1111/DOTE.12359]; Mayne ST, 2002, J NUTR, V132, P3467; Oya H, 2015, DIS ESOPHAGUS   0508, DOI [10.1111/dote.12373., DOI 10.1111/DOTE.12373]; Oya H, 2015, DIS ESOPHAGUS, V28, P188, DOI 10.1111/dote.12156; Shim HJ, 2015, CANCER RES TREAT, DOI [10.4143/crt.2015.018., DOI 10.4143/CRT.2015.018]; Takai Daiya, 2003, In Silico Biology, V3, P235; Xin M, 2015, BIOMED PHARMACOTHER, V69, P179, DOI 10.1016/j.biopha.2014.11.024	41	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	NOV	2015	47	5					1811	1818		10.3892/ijo.2015.3167		8	Oncology	Oncology	CU2LV	WOS:000363355900021		
J	Dong, M; Hiwasa, T; Cong, B; Shi, QW; Wang, SM; Kita, K; Sugaya, S; Suzuki, N				Dong, Mei; Hiwasa, Takaki; Cong, Bin; Shi, Qing-Wen; Wang, Si-Ming; Kita, Kazuko; Sugaya, Shigeru; Suzuki, Nobuo			Protein kinase C alpha-mediated cytotoxic activity of ineupatorolide B from Inula cappa DC. in HeLa cells	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						sesquiterpene; ineupatorolide B; nuclear factor of activated T-cell; apoptosis; protein kinase C	APOPTOSIS-INDUCIBLE ACTIVITY; DOWN-REGULATION; GENE; P53; SESQUITERPENE; ACTIVATION; EXPRESSION; CANCER; DEATH	There is an ongoing search for plant-derived sesquiterpenes, particularly for those with anticancer activity against human cancer cells. The sesquiterpene ineupatorolide B (InB), isolated from the Inula cappa, showed potent growth-inhibitory activity against He La cells but less activity against MM1-CB melanoma cells. Staining by terminal deoxynucleotidyl transferase dUTP nick-end labeling method revealed that this activity was, at least in part, due to the induction of apoptosis. The activities of major transcription factors were examined by using a luciferase reporter assay. The results showed that the transactivation ability of nuclear factor of activated T-cell (NFAT) was enhanced. The activation of NFAT by InB was largely suppressed by preincubation with protein kinase C (PKC) inhibitors such as staurosporine and K252a. Western blot analysis revealed that the the levels of phosphorylated PKC alpha, but not other subtypes, increased after treatment with InB. Knockdown of PKC alpha using siRNA attenuated the cytotoxic activity of Inb. Thus, InB may exhibit growth-inhibitory activity through the activation of PKC alpha, followed by an increase in NFAT transactivation ability.	[Dong, Mei; Cong, Bin; Shi, Qing-Wen; Wang, Si-Ming] Hebei Med Univ, Sch Pharmaceut Sci, Dept Forens Med, Shijiazhuang 050017, Hebei, Peoples R China; [Dong, Mei; Kita, Kazuko; Sugaya, Shigeru; Suzuki, Nobuo] Chiba Univ, Grad Sch Med, Dept Environm Biochem, Chiba 2608670, Japan; [Hiwasa, Takaki] Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chiba 2608670, Japan	Hiwasa, T (reprint author), Chiba Univ, Grad Sch Med, Dept Biochem & Genet, Chuo Ku, Inohana 1-8-1, Chiba 2608670, Japan.	hiwasa_takaki@faculty.chiba-u.jp; nobuo@faculty.chiba-u.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan China Medical Association; Goho Life Sciences International Fund	The present study was supported, in part, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan as well as grants from the Japan China Medical Association and Goho Life Sciences International Fund. The authors thank Drs. Bert Vogelstein (Howard Hughes Medical Institute), Mian Wu (University of Science and Technology of China) and Nobuyuki Tanaka (Nippon Medical School) for providing reporter plasmids. We also thank Professor Masaki Takiguchi (Department of Biochemistry and Genetics, Graduate School of Medicine, Chiba University) for valuable discussion.	Shinmen N, 2009, FEBS LETT, V583, P1916, DOI 10.1016/j.febslet.2009.04.041; Wano C, 2004, EXP CELL RES, V298, P584, DOI 10.1016/j.yexcr.2004.04.048; Kumazawa T, 2007, INT J MOL MED, V19, P765; DANIEWSKI WM, 1993, PHYTOCHEMISTRY, V34, P1639, DOI 10.1016/S0031-9422(00)90862-8; Hasegawa R, 2003, J LAB CLIN MED, V141, P168, DOI 10.1067/mlc.2003.16; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Seca AML, 2014, J ETHNOPHARMACOL, V154, P286, DOI 10.1016/j.jep.2014.04.010; Howat S, 2014, NEW BIOTECHNOL, V31, P242, DOI 10.1016/j.nbt.2014.02.010; Dong M, 2009, INT J ONCOL, V34, P201, DOI 10.3892/ijo_00000142; Al-Howiriny TA, 2005, INDIAN J CHEM B, V44, P2538; Xie HG, 2007, CHEM PHARM BULL, V55, P1258, DOI 10.1248/cpb.55.1258; Zhai L, 2005, EXP CELL RES, V305, P244, DOI 10.1016/j.yexcr.2005.01.002; BARUAH RN, 1980, J ORG CHEM, V45, P4838, DOI 10.1021/jo01312a007; MIYASHITA T, 1995, CELL, V80, P293; Ohno S, 2002, J BIOCHEM, V132, P509; KOJIMA T, 1990, INT J CANCER, V46, P853, DOI 10.1002/ijc.2910460517; Chen SP, 2010, MOL MED REP, V3, P673, DOI 10.3892/mmr_00000315; Shimada H, 2001, SURG TODAY, V31, P597; Hiwasa T, 2003, FEBS LETT, V552, P177, DOI 10.1016/S0014-5793(03)00918-9; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Lee J, 2010, ONCOL REP, V23, P229, DOI 10.3892/or_00000628; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Mojsa B, 2015, CELL DEATH DIFFER, V22, P274, DOI 10.1038/cdd.2014.141; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Shimada H, 2015, J CANC SCI THER, V7, P60; Yao J, 2015, J CELL PHYSIOL, V230, P1235, DOI 10.1002/jcp.24858	27	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	NOV	2015	47	5					1839	1844		10.3892/ijo.2015.3172		6	Oncology	Oncology	CU2LV	WOS:000363355900024		
J	Funamizu, N; Lacy, CR; Kamada, M; Yanaga, K; Manome, Y				Funamizu, Naotake; Lacy, Curtis R.; Kamada, Minori; Yanaga, Katsuhiko; Manome, Yoshinobu			MicroRNA-203 induces apoptosis by upregulating Puma expression in colon and lung cancer cells	INTERNATIONAL JOURNAL OF ONCOLOGY			English	Article						microRNA-203; Puma; gemcitabine sensitivity	PANCREATIC-CARCINOMA CELLS; REPRESSING DELTA-NP63; TUMOR-SUPPRESSOR; P53; PROLIFERATION; MIGRATION; MIR-203; STEMNESS; ADENOCARCINOMA; GEMCITABINE	The present study investigated the relationship between microRNA-203 (miR-203) and the p53 upregulated modulator of apoptosis (Puma) in colon (HCT116) and lung cancer (A549) cells. Colon and lung cancer cell lines were selected for this study since a relationship between p53/miR-203 and p53/Puma has been established in both cancers. In the present study, adriamycin and nutlin-3 were used to activate p53, which induced both miR-203 and Puma expression in HCT116 cells. In contrast, HCT 116 cells with downregulated p53 showed decreased miR-203 and Puma expression. Importantly, we found that overexpressed miR-203 in HCT116 cells resulted in significantly increased Puma expression (P<0.05). Based on these findings, we hypothesized that another limb of the p53/Puma axis depends on miR-203 expression. To further validate this relationship, we used lung cancer cells (A549) and found that activated p53 increased both miR-203 and Puma expression. In addition, we found that Puma expression remained elevated in cells with overexpressed miR-203 in the presence of p53 downregulation. Cumulatively, our data purport that p53 not only increased Puma expression directly, but that it may also do so through miR-203. Additionally, functional studies revealed that miR-203 overexpression induced apoptosis and inhibited cell invasiveness.	[Funamizu, Naotake; Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Tokyo 1058461, Japan; [Lacy, Curtis R.] Howard Univ, Sch Med, Washington, DC 20059 USA; [Kamada, Minori; Manome, Yoshinobu] Jikei Univ, Sch Med, Dept Mol Cell Biol, Tokyo 1058461, Japan	Funamizu, N (reprint author), Jikei Univ, Sch Med, Dept Surg, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	funamizujikei@yahoo.co.jp					Yang A, 1999, NATURE, V398, P714; Yuan M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.15; Tian LL, 2014, TUMOR BIOL, V35, P5953, DOI 10.1007/s13277-014-1790-7; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Funamizu N, 2012, PANCREAS, V41, P107, DOI 10.1097/MPA.0b013e318224b5fb; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Ikenaga N, 2010, ANN SURG ONCOL, V17, P3120, DOI 10.1245/s10434-010-1188-8; Liu YL, 2014, INT J ONCOL, V44, P203, DOI 10.3892/ijo.2013.2168; Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Rinne T, 2007, CELL CYCLE, V6, P262, DOI 10.4161/cc.6.3.3796; Okumura T, 2014, INT J ONCOL, V44, P1923, DOI 10.3892/ijo.2014.2365; Li C, 2012, CLIN EXP PHARMACOL P, V39, P739, DOI 10.1111/j.1440-1681.2012.05700.x; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687; Takeshita N, 2012, INT J ONCOL, V41, P1653, DOI 10.3892/ijo.2012.1614; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Li JA, 2011, CANCER LETT, V304, P52, DOI 10.1016/j.canlet.2011.02.003; Funamizu N, 2013, INT J CANCER, V132, P785, DOI 10.1002/ijc.27736; Nikitina E. G., 2012, Experimental Oncology, V34, P2; McKenna DJ, 2010, J VIROL, V84, P10644, DOI 10.1128/JVI.00703-10; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Feber A, 2008, J THORAC CARDIOV SUR, V135, P255, DOI 10.1016/j.jtcvs.2007.08.055; He JH, 2013, EXP THER MED, V5, P1315, DOI 10.3892/etm.2013.981; Funamizu N, 2010, ONCOL REP, V23, P471, DOI 10.3892/or_00000657; Funamizu N, 2014, INT J ONCOL, V44, P725, DOI 10.3892/ijo.2014.2243; Miao LF, 2014, ONCOL LETT, V7, P658, DOI 10.3892/ol.2014.1807; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Bu PY, 2014, EXP THER MED, V8, P309, DOI 10.3892/etm.2014.1708; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Funamizu N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037424; Li JR, 2014, ONCOL REP, V32, P2511, DOI 10.3892/or.2014.3519; Piepoli A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033663; Ru Peng, 2011, Genes Cancer, V2, P720, DOI 10.1177/1947601911425832; Wang C, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-58; Wei Wang, 2013, Cell Biochem Funct, V31, P82, DOI 10.1002/cbf.2863; Wu Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029043; Yuan Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-57; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743	46	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1019-6439	1791-2423		INT J ONCOL	Int. J. Oncol.	NOV	2015	47	5					1981	1988		10.3892/ijo.2015.3178		8	Oncology	Oncology	CU2LV	WOS:000363355900039		
J	Ang, JSK; Shimada, T; Quek, SA; Lim, E				Ang, James S. K.; Shimada, Tomoaki; Quek, Ser-Aik; Lim, Eugene			Manufacturing strategy and competitive performance - An ACE analysis	INTERNATIONAL JOURNAL OF PRODUCTION ECONOMICS			English	Article						Manufacturing strategy; Competitive performance; Established countries and emerging countries; Nonlinear statistical approach; ACE algorithm	BUSINESS STRATEGY; TRANSFORMATIONS; TECHNOLOGY; REGRESSION; ENVIRONMENT; INTEGRATION; CAPABILITY; KNOWLEDGE; CONTEXT; POLICY	In this study, we investigate the relationships between competitive dimensions of manufacturing strategy and competitive performance in two clusters. One consists of plants in countries known for their manufacturing excellence (i.e., "JUG" referring to Japan, the United States and Germany); and the other of plants in emerging manufacturing countries (i.e., "BC" referring to Brazil and China). Data from the third round of the High Performance Manufacturing (HPM) project, which is a worldwide plant-level questionnaire survey project, were used in this study. The Alternating Conditional Expectations (ACE) algorithm, which is a nonlinear statistical tool, was applied to capture nonlinear relationships among the factors. Specifically, the possession of proprietary resources and the use of manufacturing as a competitive resource exhibit negative relationships with competitive performance for BC, but positive relationships for JUG. The achievement of functional integration varies negatively with competitive performance for JUG, but positively for BC. These relationships plateau over the mid-ranges. A proactive IT posture demonstrates the most statistically significant positive relationship with competitive performance for both JUG and BC. Based on our findings in an exploratory approach, managerial implications are also discussed. (C) 2015 Elsevier B.V. All rights reserved.	[Ang, James S. K.] Natl Univ Singapore, Logist Inst Asia Pacific, Singapore 119613, Singapore; [Shimada, Tomoaki] Kobe Univ, Grad Sch Business Adm, Kobe, Hyogo, Japan; [Quek, Ser-Aik; Lim, Eugene] Natl Univ Singapore, Sch Business, Singapore 119613, Singapore	Ang, JSK (reprint author), Natl Univ Singapore, Logist Inst Asia Pacific, 21 Heng Mui Keng Terrace 04-01, Singapore 119613, Singapore.	bizangsk@nus.edu.sg; shimada@b.kobe-u.ac.jp; seraik@nus.edu.sg; eugene.lim@nus.edu.sg	QUEK, Ser Aik/P-4764-2015	QUEK, Ser Aik/0000-0003-4826-9888			Ahmad Sohel, 2011, Journal of Manufacturing Technology Management, V22, DOI 10.1108/17410381111099789; Grant RM, 1996, ORGAN SCI, V7, P375, DOI 10.1287/orsc.7.4.375; SWAMIDASS PM, 1987, MANAGE SCI, V33, P509, DOI 10.1287/mnsc.33.4.509; DEVEAUX RD, 1989, SOCIOL METHOD RES, V18, P327, DOI 10.1177/0049124189018002005; Corbett LM, 2002, INT J PROD RES, V40, P109, DOI 10.1080/00207540110073091; Safizadeh MH, 2000, PROD OPER MANAG, V9, P111; Swink M, 1995, INT J OPER PROD MAN, V15, P4, DOI 10.1108/01443579510090381; BREIMAN L, 1985, J AM STAT ASSOC, V80, P580, DOI 10.2307/2288473; Zhao MY, 2006, MANAGE SCI, V52, P1185, DOI 10.1287/mnsc.1060.0516; VICKERY SK, 1993, DECISION SCI, V24, P435, DOI 10.1111/j.1540-5915.1993.tb00482.x; LEONG GK, 1990, OMEGA-INT J MANAGE S, V18, P109, DOI 10.1016/0305-0483(90)90058-H; ARGOTE L, 1990, MANAGE SCI, V36, P140, DOI 10.1287/mnsc.36.2.140; DEVEAUX RD, 1989, TECHNOMETRICS, V31, P91, DOI 10.2307/1270368; Jimenez CHO, 2011, INT J PROD ECON, V133, P508, DOI 10.1016/j.ijpe.2011.04.011; Schroeder RG, 2002, STRATEGIC MANAGE J, V23, P105, DOI 10.1002/smj.213; Yang J, 2009, INT J PROD RES, V47, P1055, DOI 10.1080/00207540701376358; Sum CC, 2002, DECISION SCI, V33, P347, DOI 10.1111/j.1540-5915.2002.tb01648.x; Platts KW, 1998, INT J PROD ECON, V56-7, P517, DOI 10.1016/S0925-5273(97)00134-5; Ketokivi MA, 2004, J OPER MANAG, V22, P247, DOI 10.1016/j.jom.2002.07.001; Flynn BB, 2010, J OPER MANAG, V28, P58, DOI 10.1016/j.jom.2009.06.001; Ward PT, 2000, J OPER MANAG, V18, P123, DOI 10.1016/S0272-6963(99)00021-2; Coeurderoy R, 2004, J BUS RES, V57, P583, DOI 10.1016/S0148-2963(02)00423-X; Kotha S, 2000, J OPER MANAG, V18, P257, DOI 10.1016/S0272-6963(99)00025-X; Dangayach GS, 2001, INT J OPER PROD MAN, V21, P884, DOI 10.1108/01443570110393414; Yang J, 2009, IND MANAGE DATA SYST, V109, P1197, DOI 10.1108/02635570911002270; SKINNER W, 1969, HARVARD BUS REV, V47, P136; Chen H., 2007, INT J LOGIST MANAG, V18, P5, DOI DOI 10.1108/09574090710748144; Clarke B., 2011, PRINCIPLES THEORY DA; Duhigg Charles, 2012, NY TIMES; Ferdows K., 1990, J OPERATIONS MANAGEM, V9, P168, DOI 10.1016/0272-6963(90)90094-T; Hayes R.H., 1984, RESTORING OUR COMPET; Hebbs D.O., 1949, ORG BEHAV; Hill T., 2009, MANUFACTURING OPERAT; Hofer C.W., 1978, STRATEGY FORMULATION; Jackson E., 2011, FORBES          1214; LEVITT B, 1988, ANNU REV SOCIOL, V14, P319, DOI 10.1146/annurev.so.14.080188.001535; Nakane J., 1986, MANUFACTURING FUTURE; Noble MA, 1995, DECISION SCI, V26, P693, DOI 10.1111/j.1540-5915.1995.tb01446.x; Paul R., 2011, CRITICAL THINKING TO; Porter M.E., 1985, COMPETITIVE ADVANTAG; Rodriguez R, 1985, P COMP SCI STAT S IN, P159; Schroeder R. G., 2001, HIGH PERFORMANCE MAN; Sum C.C., 1995, J OPERATIONS MANAGEM, V13, P35, DOI 10.1016/0272-6963(95)00005-D; TEECE DJ, 1986, RES POLICY, V15, P285, DOI 10.1016/0048-7333(86)90027-2; TIBSHIRANI R, 1988, J AM STAT ASSOC, V83, P394, DOI 10.2307/2288855; U.S. Chamber of Commerce, 2012, MEAS MOM GIPC INT IP; Venables W. N., 2002, MODERN APPL STAT S; Wang D. L., 2004, J DATA SCI, V2, P329; Ward PT, 1996, J MANAGE, V22, P597; World Economic Forum, 2012, GLOB COMP REP 2012 2; ZAHRA SA, 1993, STRATEGIC MANAGE J, V14, P451, DOI 10.1002/smj.4250140605	51	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-5273	1873-7579		INT J PROD ECON	Int. J. Prod. Econ.	NOV	2015	169						240	252		10.1016/j.ijpe.2015.03.031		13	Engineering, Industrial; Engineering, Manufacturing; Operations Research & Management Science	Engineering; Operations Research & Management Science	CU2KQ	WOS:000363352800022		
J	Nagata, T; Hirose, J; Nakamura, T; Tokunaga, T; Uehara, Y; Mizuta, H				Nagata, Takehiro; Hirose, Jun; Nakamura, Takayuki; Tokunaga, Takuya; Uehara, Yusuke; Mizuta, Hiroshi			Evaluation of the utility of the Estimation of Physiologic Ability and Surgical Stress score for predicting post-operative morbidity after orthopaedic surgery	INTERNATIONAL ORTHOPAEDICS			English	Article						Post-operative morbidity; Orthopaedic surgery; Surgical risk score	E-PASS; HIP FRACTURE; SYSTEM; COMPLICATIONS; MORTALITY; RISK	The purpose of this study was to investigate the utility of the Estimation of Physiologic Ability and Surgical Stress (E-PASS) scoring system for predicting post-operative morbidity. We included 1,883 patients (mean age, 52.1 years) who underwent orthopaedic surgery. The post-operative complications were classified as surgical site and non-surgical site complications, and the relationship between the E-PASS scores and post-operative morbidity was investigated. The incidence of post-operative complications (n = 274) significantly increased with an increase in E-PASS scores (p < 0.001). The areas under the curve for the comprehensive risk score of the E-PASS scoring system for overall and non-surgical site complications were 0.777 and 0.794, respectively. The E-PASS scoring system showed some utility in predicting post-operative morbidity after general orthopaedic surgery. However, creating a new risk score that is more suitable for orthopaedic surgery will be challenging.	[Nagata, Takehiro; Hirose, Jun; Nakamura, Takayuki; Tokunaga, Takuya; Uehara, Yusuke; Mizuta, Hiroshi] Kumamoto Univ, Fac Life Sci, Dept Orthopaed Surg, Chuo Ku, Kumamoto 8608556, Japan; [Hirose, Jun] Kumamoto Univ Hosp, Dept Med Informat Sci & Adm Planning, Chuo Ku, Kumamoto 8608556, Japan	Hirose, J (reprint author), Kumamoto Univ, Fac Life Sci, Dept Orthopaed Surg, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.	sr400na@gmail.com; hirojun-mk@umin.ac.jp; korokoro_0829@yahoo.co.jp; ttokunaga@fc.kuh.kumamoto-u.ac.jp; ue1nen@yahoo.co.jp; mizuta@kumamoto-u.ac.jp					YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Tang T, 2007, AM J SURG, V194, P176, DOI 10.1016/j.amjsurg.2006.10.032; Koushi K, 2011, SURG TODAY, V41, P1481, DOI 10.1007/s00595-010-4538-z; Haga Y, 1999, SURG TODAY, V29, P842; Lawrence VA, 2002, ARCH INTERN MED, V162, P2053, DOI 10.1001/archinte.162.18.2053; Yamashita S, 2004, EUR SURG RES, V36, P249, DOI 10.1159/000078860; Hirose J, 2008, CLIN ORTHOP RELAT R, V466, P2833, DOI 10.1007/s11999-008-0377-2; Kotera A, 2011, J ANESTH, V25, P481, DOI 10.1007/s00540-011-1162-z; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Hirose J, 2010, ARCH PHYS MED REHAB, V91, P67, DOI 10.1016/j.apmr.2009.09.018; Gawande AA, 2007, J AM COLL SURGEONS, V204, P201, DOI 10.1016/j.jamcollsurg.2006.11.011; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Haga Y, 1999, SURG TODAY, V29, P219; Haga Y, 2004, SURGERY, V135, P586, DOI 10.1016/j.surg.2003.11.012; Copeland G P, 1991, Br J Surg, V78, P355, DOI 10.1002/bjs.1800780327; Dolgin M, 1994, NOMENCLATURE CRITERI; Hirose J, 2013, J SPINAL DISORD TECH	18	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0341-2695	1432-5195		INT ORTHOP	Int. Orthop.	NOV	2015	39	11					2167	2172		10.1007/s00264-015-2993-2		6	Orthopedics	Orthopedics	CU0ZP	WOS:000363248700011		
J	Sakamoto, T; Naito, M; Nakamura, Y				Sakamoto, Tetsuya; Naito, Masatoshi; Nakamura, Yoshinari			Outcome of peri-acetabular osteotomy for hip dysplasia in teenagers	INTERNATIONAL ORTHOPAEDICS			English	Article						Curved peri-acetabular osteotomy; Hip dysplasia; Teenagers; Non-union	BERNESE PERIACETABULAR OSTEOTOMY; COMPLICATIONS; PREDICTORS	Peri-acetabular osteotomy, especially curved peri-acetabular osteotomy, is an effective surgical procedure for re-orientating the acetabulum. However, there have been few reports on this procedure in teenagers. The purpose of this study was to investigate the treatment outcomes of curved peri-acetabular osteotomy in teenagers. We retrospectively reviewed 33 hips in 27 teenage patients with acetabular dysplasia who underwent curved peri-acetabular osteotomy between 1995 and 2012. The mean age was 17.0 years (range, 14-19 years). The mean follow-up duration at the most recent physical examination was 33.3 months (range, 24-96 months). All hips were evaluated in terms of the Harris hip score, radiographic measurements, and complications. The mean Harris hip score improved from 80.1 points pre-operatively to 95.4 points post-operatively (p < 0.001). There were significant differences in all of the radiographic measurements between the pre-operative and post-operative values (p < 0.001). One major complication occurred (symptomatic ischial nonunion) and required subsequent surgery. Nine hips had minor complications, including nonunion of the superior ramus osteotomy (four hips), superficial stitch abscess (two hips), and transient lateral femoral cutaneous nerve palsy (three hips). Satisfactory results can be obtained clinically and radiographically after curved peri-acetabular osteotomy in adolescents. Osteotomy for acetabular dysplasia is effective in teenagers.	[Sakamoto, Tetsuya; Naito, Masatoshi; Nakamura, Yoshinari] Fukuoka Univ, Sch Med, Dept Orthopaed Surg, Fukuoka 81401, Japan	Sakamoto, T (reprint author), Fukuoka Univ, Sch Med, Dept Orthopaed Surg, Fukuoka 81401, Japan.	tetsusakamotoplayer@yahoo.co.jp					Jacobsen S, 2005, J BONE JOINT SURG BR, V87B, P471, DOI 10.1302/0301-620X.87B4; WEDGE JH, 1979, J BONE JOINT SURG BR, V61, P334; Biedermann R, 2008, INT ORTHOP, V32, P611, DOI 10.1007/s00264-007-0372-3; Siebenrock KA, 1999, CLIN ORTHOP RELAT R, P9; Schoenecker PL, 2011, J AM ACAD ORTHOP SUR, V19, P275; Murphy S, 2002, CLIN ORTHOP RELAT R, P168, DOI 10.1097/01.blo.0000038466.05771.d9; Naal FD, 2009, CLIN ORTHOP RELAT R, V467, P958, DOI 10.1007/s11999-008-0358-5; Naito M, 2005, CLIN ORTHOP RELAT R, P129, DOI 10.1097/01.blo.0000153281.75265.1d; Teratani T, 2010, J BONE JOINT SURG AM, V92A, P31, DOI 10.2106/JBJS.H.01556; Thawrani D, 2010, J BONE JOINT SURG AM, V92A, P1707, DOI 10.2106/JBJS.I.00829; Espinosa N, 2008, CLIN ORTHOP RELAT R, V466, P1645, DOI 10.1007/s11999-008-0280-x; HEYMAN CH, 1950, J BONE JOINT SURG AM, V32-A, P767; NINOMIYA S, 1984, J BONE JOINT SURG AM, V66A, P430; Clohisy JC, 2005, J BONE JOINT SURG AM, V87A, P254, DOI 10.2106/JBJS.D.02093; Karashima H, 2011, CLIN ORTHOP RELAT R, V469, P1436, DOI 10.1007/s11999-010-1616-x; Davey JP, 1999, CLIN ORTHOP RELAT R, P33; Matta JM, 1999, CLIN ORTHOP RELAT R, P21; Maeyama A, 2009, J BONE JOINT SURG BR, V91B, P1438, DOI 10.1302/0301-620X.91B11.21796; Tonnis D, 1999, J BONE JOINT SURG AM, V81A, P1747; SHARP IK, 1961, J BONE JOINT SURG BR, V43, P268; MASSIE WK, 1950, J BONE JOINT SURG AM, V32-A, P519; LEQUESNE M, 1961, Rev Rhum Mal Osteoartic, V28, P643; GANZ R, 1988, CLIN ORTHOP RELAT R, P26; Hussell JG, 1999, CLIN ORTHOP RELAT R, P64; Matheney T, 2010, J BONE JOINT SURG AM, V92A, P115, DOI 10.2106/JBJS.J.00646	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0341-2695	1432-5195		INT ORTHOP	Int. Orthop.	NOV	2015	39	11					2281	2286		10.1007/s00264-015-2973-6		6	Orthopedics	Orthopedics	CU0ZP	WOS:000363248700026		
J	Higashi, Y				Higashi, Yasuhiko			Simple HPLC-fluorescence determination of eugenol in clove oil after pre-column derivatization with 4-(N-chloroformylmethyl-Nmethylamino)-7-nitro-2,1,3-benzoxadiazole	JOURNAL OF ANALYTICAL CHEMISTRY			English	Article						eugenol; HPLC; 4-(N-chloroformylmethyl-N-methylamino)-7-nitro-2,1,3-benzoxadiazole; derivatization; fluorescence	MASS-SPECTROMETRY; UV ANALYSIS; RAT PLASMA; IN-VIVO; 4-FLUORO-7-NITRO-2,1,3-BENZOXADIAZOLE; COLUMN; SERUM; SMOKE; JUICE	Eugenol is a phenolic flavor constituent of various plants, including clove and cinnamon. Eugenol content in clove oil has been analyzed by HPLC-UV after pre-column derivatization with 4-fluoro-7-nitro- 2,1,3-benzoxadiazole (NBD-F). Here, we present a simple, more sensitive HPLC-fluorescence method for determination of eugenol in clove oil by pre-column derivatization with 4-(N-chloroformylmethyl-N-methylamino)-7-nitro-2,1,3-benzoxadiazole (NBD-COCl). The retention time of NBD-CO-eugenol was 14.9 min. A standard curve, obtained after derivatization with NBD-COCl in borate buffer (pH 9.0) at room temperature for 1 min, was linear in the range of 0.025 to 0.4 mu g/mL with r (2) value of 0.9992. The limit of detection was 0.006 mu g/mL (signal-to-noise ratio of 3: 1). This is 6.7-fold lower in terms of concentration and about 45-fold lower in terms of absolute amount, compared with the previous method using NBD-F. The coefficients of variation were less than 9.4%. The content of eugenol in clove oil (1.00 g) was 0.73 +/- 0.05 g (range 0.65 to 0.79 g). Recovery tests were satisfactory (86 +/- 5%; range 80 to 92%).	Hokuriku Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Kanazawa, Ishikawa 9201181, Japan	Higashi, Y (reprint author), Hokuriku Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Ho-3 Kanagawa Machi, Kanazawa, Ishikawa 9201181, Japan.	y-higashi@hokuriku-u.ac.jp					Magalhaes CB, 2010, J APPL PHYSIOL, V108, P845, DOI 10.1152/japplphysiol.00560.2009; Park CK, 2006, J DENT RES, V85, P900; Villa C, 2007, J PHARMACEUT BIOMED, V44, P755, DOI 10.1016/j.jpba.2007.03.020; Yalcin H, 2007, J MED FOOD, V10, P715, DOI 10.1089/jmf.2007.404; Schulz K, 2008, J CHROMATOGR A, V1211, P113, DOI 10.1016/j.chroma.2008.09.068; Higashi Y, 2007, J LIQ CHROMATOGR R T, V30, P2747, DOI 10.1080/10826070701560850; Nagababu E, 2010, METHODS MOL BIOL, V610, P165, DOI 10.1007/978-1-60327-029-8_10; Myint S, 1996, J CHROMATOGR B, V679, P193, DOI 10.1016/0378-4347(96)00008-4; Polzin GM, 2007, FOOD CHEM TOXICOL, V45, P1948, DOI 10.1016/j.fct.2007.04.012; Wang HF, 2008, J COSMET SCI, V59, P509; Kennison KR, 2008, J AGR FOOD CHEM, V56, P7379, DOI 10.1021/jf800927e; Flamini R, 2007, J MASS SPECTROM, V42, P641, DOI 10.1002/jms.1193; Kim HM, 1997, PHARMACOL RES, V36, P475, DOI 10.1006/phrs.1997.0256; Higashi Y, 2009, J LIQ CHROMATOGR R T, V32, P2372, DOI 10.1080/10826070903188013; Toyo'oka T, 2003, BIOMED CHROMATOGR, V17, P133, DOI 10.1002/bmc.223; Imai K, 2003, YAKUGAKU ZASSHI, V123, P901, DOI 10.1248/yakushi.123.901; Gopu CL, 2008, PHYTOCHEM ANALYSIS, V19, P116, DOI 10.1002/pca.1022; Higashi Y, 2006, BIOMED CHROMATOGR, V20, P423, DOI 10.1002/bmc.577; Fukushima T, 2004, BIOMED CHROMATOGR, V18, P813, DOI 10.1002/bmc.394; Higashi Y, 2009, J LIQ CHROMATOGR R T, V32, P1141, DOI 10.1080/10826070902841844; Beaudry F, 2006, BIOMED CHROMATOGR, V20, P1216, DOI 10.1002/bmc.687; Higashi Y, 2011, J LIQ CHROMATOGR R T, V34, P18, DOI 10.1080/10826076.2011.534689; Higashi Y, 2015, J ANAL CHEM+, V70, P346, DOI 10.1134/S1061934815030235; Nishijima H., 1998, SMOOTH MUSCLE RES, V34, P123; Pino Benitez N., 2009, J CHROMATOGR SCI, V47, P800; Slamenova D, 2009, MUTAT RES-GEN TOX EN, V677, P46, DOI 10.1016/j.mrgentox.2009.05.016	26	0	0	MAIK NAUKA/INTERPERIODICA/SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013-1578 USA	1061-9348	1608-3199		J ANAL CHEM+	J. Anal. Chem.	NOV	2015	70	11					1401	1405		10.1134/S1061934815110179		5	Chemistry, Analytical	Chemistry	CU1FA	WOS:000363264200016		
J	Nakata, H; Wakayama, T; Sonomura, T; Honma, S; Hatta, T; Iseki, S				Nakata, Hiroki; Wakayama, Tomohiko; Sonomura, Takahiro; Honma, Satoru; Hatta, Toshihisa; Iseki, Shoichi			Three-dimensional structure of seminiferous tubules in the adult mouse	JOURNAL OF ANATOMY			English	Article						mouse; seminiferous tubules; testis; three-dimensional reconstruction	MICE; RATS	Seminiferous tubules develop from sex cords, which are embryonic structures with simple C-shaped arches. Histologically, the epithelium of adult mouse seminiferous tubules has been divided into 12 stages based on the associations of spermatogenic cells in four cycles of spermatogenesis. However, the gross characteristics of the seminiferous tubules themselves, including their number, length, run, and mutual relationships remain largely unknown. In the present study, we analyzed all seminiferous tubules in a single adult mouse testis with high resolution using serial paraffin sections and high-perfomance three-dimensional reconstruction software. There were 11 seminiferous tubules with an average length of 140mm. Each tubule ran along circular paths within the testis while making convolutions with cranial and caudal hairpin turns. The cranial turns of all tubules were in contact with the tunica albuginea, whereas the caudal turns were not, resulting in funnel-shaped networks of these tubules with tapered caudal portions. The caudally located networks surrounded the preceding cranially located networks from the bottom and outside, similar to stacked paper cups. Five out of the 11 seminiferous tubules were continuous from one end to the other both connected with the rete testis (10 connection points). Nine branching points, one blind end, and 18 more connection points with the rete testis were detected in the remaining six seminiferous tubules, making the paths of these tubules complicated to various degrees. The present study revealed that the 3D structures of seminiferous tubules were highly regular as a whole in the adult mouse testis.	[Nakata, Hiroki; Wakayama, Tomohiko; Iseki, Shoichi] Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, Kanazawa, Ishikawa 9208640, Japan; [Sonomura, Takahiro; Honma, Satoru] Kanazawa Med Univ, Sch Med, Dept Anat 2, Uchinada, Ishikawa 92002, Japan; [Hatta, Toshihisa] Kanazawa Med Univ, Dept Anat, Uchinada, Ishikawa 92002, Japan	Iseki, S (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Histol & Embryol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan.	siseki@med.kanazawa-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [25460241]	We thank Mr. Itsuro Kamimura for his advice on using the AMIRA software. We also thank Mr. Shuichi Yamazaki for his technical assistance making paraffin sections. This study was supported in part by a Grant-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan to TW (#25460241).	Ahmed EA, 2009, METHODS MOL BIOL, V558, P263, DOI 10.1007/978-1-60761-103-5_16; Yeung JC, 2011, ANAT SCI EDUC, V4, P92, DOI 10.1002/ase.190; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; CLERMONT Y, 1953, AM J ANAT, V93, P475, DOI 10.1002/aja.1000930308; Silvan U, 2012, REPRODUCTION, V144, P385, DOI 10.1530/REP-12-0043; Martin CM, 2013, ANAT SCI EDUC, V6, P393, DOI 10.1002/ase.1367; CLERMONT Y, 1961, AM J ANAT, V108, P79, DOI 10.1002/aja.1001080106; JOST A, 1981, HUM GENET, V58, P59; Combes AN, 2009, DEV DYNAM, V238, P1033, DOI 10.1002/dvdy.21925; Drumond AL, 2011, REPRODUCTION, V142, P145, DOI 10.1530/REP-10-0431; Nel-Themaat L, 2009, DEV DYNAM, V238, P1100, DOI 10.1002/dvdy.21954; CLERMONT Y, 1957, AM J ANAT, V100, P241, DOI 10.1002/aja.1001000205; Nakata H, 2015, J HISTOCHEM CYTOCHEM, V63, P99, DOI 10.1369/0022155414562045; Meistrich Marvin L, 2013, Methods Mol Biol, V927, P299	14	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-8782	1469-7580		J ANAT	J. Anat.	NOV	2015	227	5					686	694		10.1111/joa.12375		9	Anatomy & Morphology	Anatomy & Morphology	CU0ME	WOS:000363210100009		
J	Fukagawa, M				Fukagawa, Masafumi			Not only for the risk of bone fracture	JOURNAL OF BONE AND MINERAL METABOLISM			English	Editorial Material						FRAX; Chronic kidney disease; Fracture; Survival; Cardiovasucular event	CHRONIC KIDNEY-DISEASE; PARATHYROID-HORMONE; SKELETAL RESISTANCE; MINERAL DENSITY; METABOLISM; CKD; HEMODIALYSIS; DYSFUNCTION; REGULATOR; PHOSPHATE		Tokai Univ, Div Nephrol Endocrinol & Metab, Sch Med, Isehara, Kanagawa 2591193, Japan	Fukagawa, M (reprint author), Tokai Univ, Div Nephrol Endocrinol & Metab, Sch Med, 143 Shimo Kasuya, Isehara, Kanagawa 2591193, Japan.	fukagawa@tokai-u.jp					Andrukhova O, 2014, EMBO MOL MED, V5, P744; Tanaka H, 2013, BONE, V56, P347, DOI 10.1016/j.bone.2013.07.002; Isakova T, 2011, KIDNEY INT, V79, P1370, DOI 10.1038/ki.2011.47; Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414; London GM, 2008, J AM SOC NEPHROL, V19, P1827, DOI 10.1681/ASN.2007050622; Scialla JJ, 2014, J AM SOC NEPHROL, V25, P349, DOI 10.1681/ASN.2013050465; Iwasaki Y, 2013, BONE, V57, P477, DOI 10.1016/j.bone.2013.07.037; Iwasaki-Ishizuka Y, 2005, NEPHROL DIAL TRANSPL, V20, P1904, DOI 10.1093/ndt/gfh876; Wakasugi M, 2013, J BONE MINER METAB, V31, P315, DOI 10.1007/s00774-012-0411-z; Fujiwara S, 2008, OSTEOPOROSIS INT, V19, P429, DOI 10.1007/s00198-007-0544-4; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Komaba H, 2012, NAT REV NEPHROL, V8, P484, DOI 10.1038/nrneph.2012.116; Fukagawa M, 2006, J BONE MINER METAB, V24, P434, DOI 10.1007/s00774-006-0719-7; Kazama JJ, 2015, J BONE MINER METAB, V33, P245, DOI 10.1007/s00774-014-0639-x; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; Faul C, 2011, J CLIN INVEST, V121, P4393, DOI 10.1172/JCI46122; Iimori S, 2012, NEPHROL DIAL TRANSPL, V27, P345, DOI 10.1093/ndt/gfr317; West SL, 2015, J BONE MINER RES, V30, P913, DOI 10.1002/jbmr.2406; Komaba H, 2011, CLIN EXP NEPHROL, V15, P797, DOI 10.1007/s10157-011-0502-5; Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sk.ki.5001754; Gutierrez OM, 2008, NEW ENGL J MED, V359, P584, DOI 10.1056/NEJMoa0706130; Coe LM, 2014, J BIOL CHEM, V289, P9795, DOI 10.1074/jbc.M113.527150; Nii-Kono T, 2007, KIDNEY INT, V71, P738, DOI 10.1038/sj.ki.5002097; Shimada T, 2004, J BONE MINER RES, V19, P429, DOI 10.1359/JBMR.0301264; Hayashi T, 2015, J BONE MINER METAB, V33, P674, DOI 10.1007/s00774-014-0631-5; Jamal SA, 2014, OSTEOPOROSIS INT, V25, P71, DOI 10.1007/s00198-013-2524-1; Kazama JJ, 2013, KIDNEY INT S, V3, P29; Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, KIDNEY INT S113, V76, pS1; Noylor KL, 2014, TRANSPLANTATION, V97, P940; Yokoyama K, 2013, KIDNEY INT S, V3, P34	30	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0914-8779	1435-5604		J BONE MINER METAB	J. Bone Miner. Metab.	NOV	2015	33	6					603	604		10.1007/s00774-015-0661-7		2	Endocrinology & Metabolism; Medicine, Research & Experimental	Endocrinology & Metabolism; Research & Experimental Medicine	CU4HN	WOS:000363488600002		
J	Uemura, Y; Miyakawa, N; Orimo, H; Shiraki, M; Nakamura, T; Mori, S				Uemura, Yukari; Miyakawa, Nobuaki; Orimo, Hajime; Shiraki, Masataka; Nakamura, Toshitaka; Mori, Satoshi			Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan	JOURNAL OF BONE AND MINERAL METABOLISM			English	Article						Osteoporosis; Semiquantitative method; Spinal fracture index; Vertebral fracture	DEFORMITY INDEX SDI; POSTMENOPAUSAL OSTEOPOROSIS; PREVALENT; TRIAL; WOMEN; RISK	Assessment of vertebral fracture is critically important for the diagnosis and treatment of osteoporosis. This study aimed to clarify the effectiveness of the semiquantitative (SQ) method in the assessment of vertebral fractures in Japanese clinical practice. Forty-four physicians (seven experts and 37 nonexperts) assessed the spinal radiographs of 40 patients participating in the Adequate Treatment of Osteoporosis (A-TOP) Japanese Osteoporosis Intervention Trial (JOINT)-02 at the baseline, 12 months, and 24 months using the SQ method. The proportion of diagnosed fracture cases per spine was higher in the nonexpert group than in the expert group at each time point, and was especially high in the upper thoracic spine (T4-T6). The least mean squares spinal fracture index was significantly higher in the nonexpert group than in the expert group for all time points. The kappa statistics were also higher in the expert group than in the nonexpert group for all vertebral levels at all time points. Assessment of vertebral fractures using the SQ method tended to be overestimated by nonexpert physicians compared with the experts, with poor nonexpert interobserver reliability and well-matched expert interobserver reliability. Conscious efforts to avoid overestimation and to obtain higher reliability with the SQ method should be made to achieve more precise diagnoses and treatment of osteoporosis in Japanese clinical practice.	[Uemura, Yukari] Univ Tokyo, Dept Biostat, Sch Publ Hlth, Tokyo, Japan; [Miyakawa, Nobuaki] Publ Hlth Res Fdn, Tokyo, Japan; [Orimo, Hajime] Japan Osteoporosis Fdn, Tokyo, Japan; [Shiraki, Masataka] Res Inst & Practice Involut Dis, Dept Internal Med, Nagano, Japan; [Nakamura, Toshitaka] Natl Ctr Global Hlth & Med, Tokyo, Japan; [Mori, Satoshi] Seirei Hamamatsu Gen Hosp, Bone & Joint Surg, Naka Ku, Hamamatsu, Shizuoka 4308558, Japan	Mori, S (reprint author), Seirei Hamamatsu Gen Hosp, Bone & Joint Surg, Naka Ku, 2-12-12 Sumiyoshi, Hamamatsu, Shizuoka 4308558, Japan.	stmori@sis.seirei.or.jp					Delmas PD, 2005, J BONE MINER RES, V20, P557, DOI 10.1359/JBMR.041214; Orimo H, 2011, CURR MED RES OPIN, V27, P1273, DOI 10.1185/03007995.2011.580341; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Crans GG, 2005, BONE, V37, P175, DOI 10.1016/j.bone.2005.04.003; MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P113, DOI 10.1007/BF01623271; Genant HK, 1996, J BONE MINER RES, V11, P984; MINNE HW, 1988, BONE MINER, V3, P335; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; Shiraki M, 2011, J BONE MINER METAB, V29, P37, DOI 10.1007/s00774-010-0188-x; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; SAUER P, 1991, J BONE MINER RES, V6, P227; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; EASTELL R, 1991, J BONE MINER RES, V6, P207; Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325; GENANT HK, 1993, J BONE MINER RES, V8, P1137; Grados F, 2001, OSTEOPOROSIS INT, V12, P716, DOI 10.1007/s001980170046; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; WU CY, 1995, OSTEOPOROSIS INT, V5, P354, DOI 10.1007/BF01622258	18	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0914-8779	1435-5604		J BONE MINER METAB	J. Bone Miner. Metab.	NOV	2015	33	6					642	650		10.1007/s00774-014-0625-3		9	Endocrinology & Metabolism; Medicine, Research & Experimental	Endocrinology & Metabolism; Research & Experimental Medicine	CU4HN	WOS:000363488600006		
J	Hayashi, T; Joki, N; Tanaka, Y; Iwasaki, M; Kubo, S; Asakawa, T; Matsukane, A; Takahashi, Y; Imamura, Y; Hirahata, K; Hase, H				Hayashi, Toshihide; Joki, Nobuhiko; Tanaka, Yuri; Iwasaki, Masaki; Kubo, Shun; Asakawa, Takasuke; Matsukane, Ai; Takahashi, Yasunori; Imamura, Yoshihiko; Hirahata, Koichi; Hase, Hiroki			The FRAX((R)) as a predictor of mortality in Japanese incident hemodialysis patients: an observational, follow-up study	JOURNAL OF BONE AND MINERAL METABOLISM			English	Article						CKD; FRAX; Hemodialysis; Mortality	CHRONIC KIDNEY-DISEASE; FRACTURE RISK-ASSESSMENT; BONE-MINERAL DENSITY; AORTIC CALCIFICATION; VASCULAR CALCIFICATION; POSTMENOPAUSAL WOMEN; CLINICAL-PRACTICE; OSTEOPOROSIS; HIP; ASSOCIATION	The World Health Organization Fracture Risk Assessment Tool (FRAX((R))) was recently developed to estimate the 10-year absolute risk of osteoporotic fracture among the general population. However, the evidence for its use in chronic kidney disease patients has been lacking, and the association between the FRAX((R)) and mortality is unknown. Therefore, a hospital-based, prospective, cohort study was conducted to evaluate the predictive ability of the FRAX((R)) for mortality in hemodialysis patients. A total of 252 patients who had been started on maintenance hemodialysis, 171 men and 81 women, with a mean age of 67 +/- A 14 years, was studied. The endpoint was defined as all-cause death. The Cox proportional hazards model was used to calculate hazard ratios and 95 % confidence intervals. During the mean follow-up period of 3.4 +/- A 2.7 years, 61 deaths occurred. The median (interquartile range) of the FRAX((R)) for major osteoporotic fracture was 6.9 (4.6-12.0) % in men and 19.0 (7.6-33.0) % in women. Cumulative survival rates at 5 years after starting dialysis, with the FRAX((R)) levels above and below the median, were 51.9 and 87.9 %, respectively, in men and 67.4 and 83.7 %, respectively, in women. Overall, in men, the multivariate Cox regression analyses revealed that the log-transformed FRAX((R)) remained an independent predictor of death after adjusting by confounding variables. However, in women, the significant association between the FRAX((R)) value and the outcome was eliminated if age was put into these models. Among Japanese hemodialysis patients, the FRAX((R)) seems to be useful for predicting death, especially in men.	[Hayashi, Toshihide; Joki, Nobuhiko; Tanaka, Yuri; Iwasaki, Masaki; Kubo, Shun; Asakawa, Takasuke; Matsukane, Ai; Takahashi, Yasunori; Hase, Hiroki] Toho Univ, Div Nephrol, Ohashi Med Ctr, Meguro Ku, Tokyo 1538515, Japan; [Imamura, Yoshihiko] Nissan Tamagawa Hosp, Div Dialysis, Tokyo, Japan; [Hirahata, Koichi] Hirahata Clin, Tokyo, Japan	Joki, N (reprint author), Toho Univ, Div Nephrol, Ohashi Med Ctr, Meguro Ku, 2-17-6 Ohashi, Tokyo 1538515, Japan.	thayashi0803@gmail.com; jokinobuhiko@gmail.com					Kiel DP, 2001, CALCIFIED TISSUE INT, V68, P271, DOI 10.1007/BF02390833; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Dawson-Hughes B, 2008, OSTEOPOROSIS INT, V19, P449, DOI 10.1007/s00198-008-0559-5; [Anonymous], 1996, ARCH INTERN MED; Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295; KEENE GS, 1993, BRIT MED J, V307, P1248; Doren M, 2003, HUM REPROD, V18, P1737, DOI 10.1093/humrep/deg315; Hak AE, 2000, ARTERIOSCL THROM VAS, V20, P1926; Braun J, 1996, AM J KIDNEY DIS, V27, P394, DOI 10.1016/S0272-6386(96)90363-7; Ball AM, 2002, JAMA-J AM MED ASSOC, V288, P3014, DOI 10.1001/jama.288.23.3014; Kanis JA, 2011, OSTEOPOROSIS INT, V22, P2395, DOI 10.1007/s00198-011-1713-z; Tentori F, 2014, KIDNEY INT, V85, P166, DOI 10.1038/ki.2013.279; Wexler L, 1996, CIRCULATION, V94, P1175; Fujiwara S, 2008, OSTEOPOROSIS INT, V19, P429, DOI 10.1007/s00198-007-0544-4; BOUKHRIS R, 1972, J AMER MED ASSOC, V219, P1307, DOI 10.1001/jama.219.10.1307; Fukagawa M, 2013, THER APHER DIAL, V17, P247, DOI 10.1111/1744-9987.12058; Moroi M, 2013, AM J KIDNEY DIS, V61, P466, DOI 10.1053/j.ajkd.2012.09.017; WHITE BL, 1987, J BONE JOINT SURG AM, V69A, P1335; Alem AM, 2000, KIDNEY INT, V58, P396, DOI 10.1046/j.1523-1755.2000.00178.x; Silva HC, 2013, BONE, V52, P562, DOI 10.1016/j.bone.2012.11.004; Gal-Moscovici A, 2007, SEMIN DIALYSIS, V20, P423, DOI 10.1111/j.1525-139X.2007.00319.x; Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198-007-0543-5; BANKS LM, 1994, EUR J CLIN INVEST, V24, P813, DOI 10.1111/j.1365-2362.1994.tb02024.x; Jadoul M, 2006, KIDNEY INT, V70, P1358, DOI 10.1038/sk.ki.5001754; GARRAWAY WM, 1979, MAYO CLIN PROC, V54, P701; Stompor T, 2013, POL ARCH MED WEWN, V123, P314; Jamal SA, 2014, OSTEOPOROSIS INT, V25, P71, DOI 10.1007/s00198-013-2524-1; Moe SM, 2006, EUR J CLIN INVEST, V36, P51, DOI 10.1111/j.1365-2362.2006.01665.x; RIGGS BL, 1992, NEW ENGL J MED, V327, P620; Joki Nobuhiko, 2005, Clin Calcium, V15, P131; Toussain ND, 2008, NEPHROL DIAL TRANSPL, V23, P586, DOI 10.1093/ndt/gfm660	31	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0914-8779	1435-5604		J BONE MINER METAB	J. Bone Miner. Metab.	NOV	2015	33	6					674	683		10.1007/s00774-014-0631-5		10	Endocrinology & Metabolism; Medicine, Research & Experimental	Endocrinology & Metabolism; Research & Experimental Medicine	CU4HN	WOS:000363488600010		
J	Zhou, HY; Mori, S; Tanaka, M; Sawabe, M; Arai, T; Muramatsu, M; Mieno, MN; Shinkai, S; Yamada, Y; Miyachi, M; Murakami, H; Sanada, K; Ito, H				Zhou, Heying; Mori, Seijiro; Tanaka, Masashi; Sawabe, Motoji; Arai, Tomio; Muramatsu, Masaaki; Mieno, Makiko Naka; Shinkai, Shoji; Yamada, Yoshiji; Miyachi, Motohiko; Murakami, Haruka; Sanada, Kiyoshi; Ito, Hideki			A missense single nucleotide polymorphism, V114I of the Werner syndrome gene, is associated with risk of osteoporosis and femoral fracture in the Japanese population	JOURNAL OF BONE AND MINERAL METABOLISM			English	Article						Femoral fracture; Osteoporosis; Single nucleotide polymorphism; Werner syndrome	NON-HODGKIN-LYMPHOMA; DNA-REPAIR; OSTEOBLAST DIFFERENTIATION; TELOMERE DYSFUNCTION; HELICASE GENE; WRN GENE; BONE; VARIANT; MAINTENANCE; MUTATION	Werner syndrome is a rare autosomal recessive disorder caused by mutations in the human WRN gene and characterized by the early onset of normal aging symptoms. Given that patients with this disease exhibit osteoporosis, the present study aimed to determine whether the WRN gene contributes to the etiology of osteoporosis. A genetic association study of eight non-synonymous polymorphisms in the WRN gene and the incidence of femoral fracture was undertaken in 1,632 consecutive Japanese autopsies in which 140 patients had experienced the fracture during their lifetime. The results were validated in 251 unrelated postmenopausal Japanese women with osteoporosis and 269 non-institutionalized, community-dwelling Japanese adults. A statistically significant association was observed between rs2230009 (c.340G > A)-which results in a Val to Ile substitution-and fracture risk; the incidence of femoral fracture increased dose-dependently with the number of A alleles (p = 0.0120). Femoral neck bone and whole bone densities were lower among postmenopausal women with osteoporosis and community-dwelling adults, respectively, if they were of the AG instead of the GG genotype. The results suggest that Japanese subjects bearing at least one A allele of rs2230009 of the WRN gene are at a significantly higher risk of femoral fracture, possibly due to decreased bone density.	[Zhou, Heying; Mori, Seijiro] Tokyo Metropolitan Geriatr Hosp, Ctr Promot Clin Invest, Tokyo 1730015, Japan; [Tanaka, Masashi] Tokyo Metropolitan Inst Gerontol, Dept Genom Longev & Hlth, Tokyo, Japan; [Sawabe, Motoji] Tokyo Med & Dent Univ, Sect Mol Pathol, Grad Sch Hlth Care Sci, Tokyo, Japan; [Arai, Tomio] Tokyo Metropolitan Geriatr Hosp, Dept Pathol, Tokyo 1730015, Japan; [Muramatsu, Masaaki] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Epidemiol, Tokyo, Japan; [Mieno, Makiko Naka] Jichi Med Univ, Dept Med Informat, Ctr Informat, Shimotsuke, Tochigi, Japan; [Shinkai, Shoji] Tokyo Metropolitan Inst Gerontol, Res Team Social Participat & Community Hlth, Tokyo, Japan; [Yamada, Yoshiji] Mie Univ, Dept Human Funct Genom, Ctr Sci Res, Tsu, Mie 514, Japan; [Miyachi, Motohiko; Murakami, Haruka] Natl Inst Hlth & Nutr, Dept Hlth Promot & Exercise, Tokyo 162, Japan; [Sanada, Kiyoshi] Ritsumeikan Univ, Fac Sport & Hlth Sci, Shiga, Japan; [Ito, Hideki] Tokyo Metropolitan Geriatr Hosp, Local Independent Adm Agcy, Tokyo 1730015, Japan; [Ito, Hideki] Inst Gerontol, Tokyo, Japan	Mori, S (reprint author), Tokyo Metropolitan Geriatr Hosp, Ctr Promot Clin Invest, 35-2 Sakae, Tokyo 1730015, Japan.	mori_seijiro@tmghig.jp			Leading Project for Personalized Medicine of the Ministry of Education, Culture, Sports, Science and Technology of Japan [09042037]; Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare of Japan [H23-016, H23-119, H24-005]; Mitsui Sumitomo Insurance Welfare Foundation; Pfizer Academic Contribution Fund; Takeda Science Foundation; Smoking Research Foundation; Mie Medical Valley Project;  [22240072];  [21390459];  [21590411];  [18209023];  [18018021];  [19659149];  [24590746];  [23240089]	This work was supported by a grant (no. 09042037) from the Leading Project for Personalized Medicine of the Ministry of Education, Culture, Sports, Science and Technology of Japan (to S.M.); Grants-in-Aid for Scientific Research (nos. 22240072, 21390459, and 21590411 [to M.T.], 18209023, 18018021, 19659149, and 24590746 [to YY], and 23240089 [to MM]); a Grant-in-Aid for the Global COE (Sport Sciences for the Promotion of Active Life to Waseda University) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to MT); a Grant-in-Aid for Scientific Research (to MM) and Grants-in-Aid (H23-016, H23-119, and H24-005) for Research on Intractable Diseases (Mitochondrial Disease) (to MT) from the Ministry of Health, Labour and Welfare of Japan; grants for scientific research from Mitsui Sumitomo Insurance Welfare Foundation (to SM); the Pfizer Academic Contribution Fund (to SM); Takeda Science Foundation (to MT); the Smoking Research Foundation (to TA and MS); and the Mie Medical Valley Project (to YY).	Wang HT, 2012, AGING CELL, V11, P704, DOI 10.1111/j.1474-9726.2012.00838.x; JACOBSON HG, 1960, RADIOLOGY, V74, P373; MURATA K, 1982, J AM GERIATR SOC, V30, P303; Rossi ML, 2010, DNA REPAIR, V9, P331, DOI 10.1016/j.dnarep.2009.12.011; Crabbe L, 2007, P NATL ACAD SCI USA, V104, P2205, DOI 10.1073/pnas.0609410104; Mori S, 2010, J BONE MINER METAB, V28, P446, DOI 10.1007/s00774-009-0147-6; Yoshida T, 2009, HYPERTENS RES, V32, P411, DOI 10.1038/hr.2009.22; Estrada K, 2012, NAT GENET, V44, P491, DOI 10.1038/ng.2249; Takemoto M, 2013, GERIATR GERONTOL INT, V13, P475, DOI 10.1111/j.1447-0594.2012.00913.x; Tadokoro T, 2013, DNA REPAIR, V12, P414, DOI 10.1016/j.dnarep.2013.03.004; Morita H, 1999, THROMB HAEMOSTASIS, V82, P160; Wirtenberger M, 2006, CARCINOGENESIS, V27, P1655, DOI 10.1093/carcin/bgi374; Ogata N, 2001, J BONE MINER METAB, V19, P296, DOI 10.1007/s007740170013; Ye L, 1997, AM J MED GENET, V68, P494, DOI 10.1002/(SICI)1096-8628(19970211)68:4<494::AID-AJMG30>3.0.CO;2-L; Nakayama R, 2008, CANCER SCI, V99, P333, DOI 10.1111/j.1349-7006.2007.00692.x; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; Fuku N, 2012, GERIATR GERONTOL INT, V12, P292, DOI 10.1111/j.1447-0594.2011.00768.x; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Lan Q, 2009, CARCINOGENESIS, V30, P50, DOI 10.1093/carcin/bgn249; Walton NP, 2000, J BONE JOINT SURG BR, V82B, P885, DOI 10.1302/0301-620X.82B6.10457; RUBIN CD, 1992, J AM GERIATR SOC, V40, P1161; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Wang ZW, 2009, BREAST CANCER RES TR, V118, P169, DOI 10.1007/s10549-009-0327-z; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268; Pignolo RJ, 2008, AGING CELL, V7, P23, DOI 10.1111/j.1474-9726.2007.00350.x; Hill DA, 2006, BLOOD, V108, P3161, DOI 10.1182/blood-2005-01-026690; EPSTEIN CJ, 1966, MEDICINE, V45, P177; Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001; Laroche M, 1997, REV RHUM, V64, P843; Shen M, 2006, HUM GENET, V119, P659, DOI 10.1007/s00439-006-0177-2; Grove ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068095; Shiraki M, 1988, ENDOCR J, V45, P505	33	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0914-8779	1435-5604		J BONE MINER METAB	J. Bone Miner. Metab.	NOV	2015	33	6					694	700		10.1007/s00774-014-0636-0		7	Endocrinology & Metabolism; Medicine, Research & Experimental	Endocrinology & Metabolism; Research & Experimental Medicine	CU4HN	WOS:000363488600012		
J	Dong, BZ; Endo, I; Ohnishi, Y; Kondo, T; Hasegawa, T; Amizuka, N; Kiyonari, H; Shioi, G; Abe, M; Fukumoto, S; Matsumoto, T				Dong, Bingzi; Endo, Itsuro; Ohnishi, Yukiyo; Kondo, Takeshi; Hasegawa, Tomoka; Amizuka, Norio; Kiyonari, Hiroshi; Shioi, Go; Abe, Masahiro; Fukumoto, Seiji; Matsumoto, Toshio			Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH)	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						DISORDERS OF CALCIUM; PHOSPHATE METABOLISM; GENETIC ANIMAL MODELS; PTH; VITAMIN D; FGF23; HORMONE REPLACEMENT; RECEPTOR MODULATORS; BONE MODELING AND REMODELING	NEGATIVE ALLOSTERIC MODULATORS; PARATHYROID-HORMONE 1-34; OF-FUNCTION MUTATIONS; CA2+-SENSING RECEPTOR; FUNCTIONAL-CHARACTERIZATION; TRANSMEMBRANE DOMAIN; ACTIVATING MUTATIONS; REPLACEMENT THERAPY; BONE-FORMATION; BINDING-SITES	Activating mutations of calcium-sensing receptor (CaSR) cause autosomal dominant hypocalcemia (ADH). ADH patients develop hypocalcemia, hyperphosphatemia, and hypercalciuria, similar to the clinical features of hypoparathyroidism. The current treatment of ADH is similar to the other forms of hypoparathyroidism, using active vitamin D-3 or parathyroid hormone (PTH). However, these treatments aggravate hypercalciuria and renal calcification. Thus, new therapeutic strategies for ADH are needed. Calcilytics are allosteric antagonists of CaSR, and may be effective for the treatment of ADH caused by activating mutations of CaSR. In order to examine the effect of calcilytic JTT-305/MK-5442 on CaSR harboring activating mutations in the extracellular and transmembrane domains in vitro, we first transfected a mutated CaSR gene into HEK cells. JTT-305/MK-5442 suppressed the hypersensitivity to extracellular Ca2+ of HEK cells transfected with the CaSR gene with activating mutations in the extracellular and transmembrane domains. We then selected two activating mutations locating in the extracellular (C129S) and transmembrane (A843E) domains, and generated two strains of CaSR knock-in mice to build an ADH mouse model. Both mutant mice mimicked almost all the clinical features of human ADH. JTT-305/MK-5442 treatment in vivo increased urinary cAMP excretion, improved serum and urinary calcium and phosphate levels by stimulating endogenous PTH secretion, and prevented renal calcification. In contrast, PTH(1-34) treatment normalized serum calcium and phosphate but could not reduce hypercalciuria or renal calcification. CaSR knock-in mice exhibited low bone turnover due to the deficiency of PTH, and JTT-305/MK-5442 as well as PTH(1-34) increased bone turnover and bone mineral density (BMD) in these mice. These results demonstrate that calcilytics can reverse almost all the phenotypes of ADH including hypercalciuria and renal calcification, and suggest that calcilytics can become a novel therapeutic agent for ADH. (c) 2015 American Society for Bone and Mineral Research.	[Dong, Bingzi; Endo, Itsuro; Ohnishi, Yukiyo; Kondo, Takeshi; Abe, Masahiro] Univ Tokushima, Dept Med & Bioregulatory Sci, Grad Sch Med Sci, Tokushima 7708503, Japan; [Hasegawa, Tomoka; Amizuka, Norio] Hokkaido Univ, Dept Dev Biol Hard Tissue, Grad Sch Dent Med, Sapporo, Hokkaido, Japan; [Kiyonari, Hiroshi] RIKEN, Anim Resource Dev Unit, Ctr Life Sci Technol, Kobe, Hyogo, Japan; [Shioi, Go] RIKEN, Genet Engn Team, Ctr Life Sci Technol, Kobe, Hyogo, Japan; [Fukumoto, Seiji; Matsumoto, Toshio] Univ Tokushima, Fujii Mem Inst Med Sci, Tokushima 7708503, Japan	Fukumoto, S (reprint author), Univ Tokushima, Fujii Mem Inst Med Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	fukumoto-tky@umin.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [25293215]	This work was supported in part by Grants-in-Aid for Scientific Research (25293215) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. Calcilytic JTT-305/MK-5442 was kindly provided by Japan Tobacco Inc., Tokyo, Japan.	Alvarez-Hernandez D, 2003, J MOL ENDOCRINOL, V31, P255, DOI 10.1677/jme.0.0310255; Shinagawa Y, 2011, ACS MED CHEM LETT, V2, P238, DOI 10.1021/ml100268k; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Raue F, 2011, CLIN ENDOCRINOL, V75, P760, DOI 10.1111/j.1365-2265.2011.04142.x; Saidak Z, 2009, MOL PHARMACOL, V76, P1131, DOI 10.1124/mol.109.058784; Lambert AS, 2014, J CLIN ENDOCR METAB, V99, pE469, DOI 10.1210/jc.2013-3136; Baron J, 1996, HUM MOL GENET, V5, P601, DOI 10.1093/hmg/5.5.601; Brown EM, 2001, PHYSIOL REV, V81, P239; Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; Winer KK, 2010, J CLIN ENDOCR METAB, V95, P2680, DOI 10.1210/jc.2009-2464; Hirai H, 2001, J HUM GENET, V46, P41, DOI 10.1007/s100380170124; Kimura S, 2011, EUR J PHARMACOL, V668, P331, DOI 10.1016/j.ejphar.2011.07.015; Fukumoto S, 1998, MOL CELL ENDOCRINOL, V141, P41, DOI 10.1016/S0303-7207(98)00092-6; Gafni RI, 2012, J BONE MINER RES, V27, P1811, DOI 10.1002/jbmr.1627; Nakamura A, 2013, J CLIN ENDOCR METAB, V98, pE1692, DOI 10.1210/jc.2013-1974; Hannan FM, 2012, HUM MOL GENET, V21, P2768, DOI 10.1093/hmg/dds105; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Lienhardt A, 2001, J CLIN ENDOCR METAB, V86, P5313, DOI 10.1210/jc.86.11.5313; Amrein K, 2011, OSTEOPOROSIS INT, V22, P2903, DOI 10.1007/s00198-010-1441-9; Yamamoto M, 2000, J CLIN ENDOCR METAB, V85, P4583, DOI 10.1210/jc.85.12.4583; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; Nagase T, 2002, J CLIN ENDOCR METAB, V87, P2681, DOI 10.1210/jc.87.6.2681; Yamamoto T, 2012, J ELECTRON MICROSC, V61, P113, DOI 10.1093/jmicro/dfs033; Miao DS, 2004, ENDOCRINOLOGY, V145, P3554, DOI 10.1210/en.2003-1695; Sanda S, 2008, J PEDIATR ENDOCR MET, V21, P385; Davey AE, 2012, ENDOCRINOLOGY, V153, P1232, DOI 10.1210/en.2011-1426; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Isshiki M, 2002, J BIOL CHEM, V277, P43389, DOI 10.1074/jbc.M205411200; Rubin MR, 2010, OSTEOPOROSIS INT, V21, P1927, DOI 10.1007/s00198-009-1149-x; Kinoshita Y, 2014, J CLIN ENDOCR METAB, V99, pE363, DOI 10.1210/jc.2013-3430; Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213-8587(13)70106-2; Theman TA, 2009, J BONE MINER RES, V24, P964, DOI [10.1359/jbmr.081233, 10.1359/JBMR.081233]; Hough TA, 2004, P NATL ACAD SCI USA, V101, P13566, DOI 10.1073/pnas.0405516101; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Magno AL, 2011, ENDOCR REV, V32, P3, DOI 10.1210/er.2009-0043; Nesbit MA, 2013, NAT GENET, V45, P93, DOI 10.1038/ng.2492; Pearce SHS, 1995, J CLIN INVEST, V96, P2683, DOI 10.1172/JCI118335; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Rubin MR, 2010, BONE, V46, P190, DOI 10.1016/j.bone.2009.09.020; Guarnieri V, 2012, MOL GENET METAB, V107, P548, DOI 10.1016/j.ymgme.2012.06.012; Cabal A, 2013, J BONE MINER RES, V28, P1830, DOI 10.1002/jbmr.1900; Vargas-Poussou R, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025781.16723.68; Rubin MR, 2011, J BONE MINER RES, V26, P2727, DOI 10.1002/jbmr.452; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; Alfadda TI, 2014, AM J PHYSIOL-CELL PH, V307, pC221, DOI 10.1152/ajpcell.00139.2014; Sakai K, 1997, BIOCHEM BIOPH RES CO, V237, P318, DOI 10.1006/bbrc.1997.7111; Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI [10.1359/jbmr.080803, 10.1359/JBMR.080803]; Halse J, 2014, J CLIN ENDOCR METAB, V99, pE2207, DOI 10.1210/jc.2013-4009; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Kumar S, 2010, BONE, V46, P534, DOI 10.1016/j.bone.2009.09.028; Li D, 2014, J CLIN ENDOCR METAB, V99, pE1774, DOI 10.1210/jc.2014-1029; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470; Okazaki Ryo, 1999, Journal of Clinical Endocrinology and Metabolism, V84, P363, DOI 10.1210/jc.84.1.363; Rogers A, 2014, J CLIN ENDOCR METAB, V99, pE1300, DOI 10.1210/jc.2013-3909	58	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0884-0431	1523-4681		J BONE MINER RES	J. Bone Miner. Res.	NOV	2015	30	11					1980	1993		10.1002/jbmr.2551		14	Endocrinology & Metabolism	Endocrinology & Metabolism	CU1MV	WOS:000363286900005		
J	Kamiya, N; Shen, JL; Noda, K; Kitami, M; Feng, GS; Chen, D; Komatsu, Y				Kamiya, Nobuhiro; Shen, Jingling; Noda, Kazuo; Kitami, Megumi; Feng, Gen-Sheng; Chen, Di; Komatsu, Yoshihiro			SHP2-Deficiency in Chondrocytes Deforms Orofacial Cartilage and Ciliogenesis in Mice	JOURNAL OF BONE AND MINERAL RESEARCH			English	Article						CHONDROCYTE; CILIOGENESIS; CONDYLE; SHP2; INTRAFLAGELLAR TRANSPORTS	TYROSINE-PHOSPHATASE; CRANIOFACIAL ANOMALIES; PRIMARY CILIUM; SHP-2; DELETION; BONE	Congenital orofacial abnormalities are clinically seen in human syndromes with SHP2 germline mutations such as LEOPARD and Noonan syndrome. Recent studies demonstrate that SHP2-deficiency leads to skeletal abnormalities including scoliosis and cartilaginous benign tumor metachondromatosis, suggesting that growth plate cartilage is a key tissue regulated by SHP2. The role and cellular mechanism of SHP2 in the orofacial cartilage, however, remains unknown. Here, we investigated the postnatal craniofacial development by inducible disruption of Shp2 in chondrocytes. Shp2 conditional knockout (cKO) mice displayed severe deformity of the mandibular condyle accompanied by disorganized, expanded cartilage in the trabecular bone region, enhanced type X collagen, and reduced Erk production. Interestingly, the length of primary cilia, an antenna like organelle sensing environmental signaling, was significantly shortened, and the number of primary cilia was reduced in the cKO mice. The expression levels of intraflagellar transports (IFTs), essential molecules in the assembly and function of primary cilia, were significantly decreased. Taken together, lack of Shp2 in orofacial cartilage led to severe defects of ciliogenesis through IFT reduction, resulting in mandibular condyle malformation and cartilaginous expansion. Our study provides new insights into the molecular pathogenesis of SHP2-deficiency in cartilage and helps to understand orofacial and skeletal manifestations seen in patients with SHP2 mutations. (c) 2015 American Society for Bone and Mineral Research.	[Kamiya, Nobuhiro] Texas Scottish Rite Hosp Children, Ctr Excellence Hip Disorders, Dallas, TX 75219 USA; [Kamiya, Nobuhiro] Univ Texas SW Med Ctr Dallas, Dept Orthopaed Surg, Dallas, TX 75390 USA; [Kamiya, Nobuhiro] Tenri Univ, Sports Med, Tenri, Nara, Japan; [Shen, Jingling; Noda, Kazuo; Kitami, Megumi; Komatsu, Yoshihiro] Univ Texas Houston, Dept Pediat, Med Sch Houston, Houston, TX 77030 USA; [Shen, Jingling] Harbin Med Univ, Dept Histol & Embryol, Harbin, Peoples R China; [Feng, Gen-Sheng] Univ Calif San Diego, Dept Pathol, Div Biol Sci, La Jolla, CA 92093 USA; [Chen, Di] Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA; [Komatsu, Yoshihiro] Univ Texas Houston, Grad Program Genes & Dev, Grad Sch Biomed Sci Houston, Houston, TX 77030 USA	Komatsu, Y (reprint author), Univ Texas Houston, Dept Pediat, Med Sch Houston, 6431 Fannin St, Houston, TX 77030 USA.	Yoshihiro.Komatsu@uth.tmc.edu			NIDCR/NIH [R00DE021054]; Texas Scottish Rite Hospital for Children; Heilongjiang Province fellowship grant; Uehara Memorial Foundation fellowship grant	This work was supported by NIDCR/NIH research grant R00DE021054 (to YK); intramural grant at Texas Scottish Rite Hospital for Children (to NK); Heilongjiang Province fellowship grant (to JS); and the Uehara Memorial Foundation fellowship grant (to KN). We thank Drs. Junichi Iwata and Eric Swindell for critical reading of the manuscript; Drs. Yuji Mishina and Honghao Zhang for advice about primary chondrocyte culture; Dr. Akiko Suzuki for fruitful discussion; and Dr. Harry Kim for generous support.	Khonsari RH, 2013, HUM MOL GENET, V22, P1873, DOI 10.1093/hmg/ddt041; Lapinski PE, 2013, DIS MODEL MECH, V6, P1448, DOI 10.1242/dmm.012849; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101; Chen M, 2007, GENESIS, V45, P44, DOI 10.1002/dvg.20261; Muhammad H, 2012, CELL MOL LIFE SCI, V69, P2101, DOI 10.1007/s00018-011-0911-3; Ruhlen R, 2014, OSTEOARTHR CARTILAGE, V22, P1071, DOI 10.1016/j.joca.2014.05.011; Eggenschwiler JT, 2007, ANNU REV CELL DEV BI, V23, P345, DOI 10.1146/annurev.cellbio.23.090506.123249; Bauler TJ, 2011, DIS MODEL MECH, V4, P228, DOI 10.1242/dmm.006130; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Kim HKW, 2014, J BONE MINER RES, V29, P761, DOI 10.1002/jbmr.2062; Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95; Zaghloul NA, 2011, GENESIS, V49, P231, DOI 10.1002/dvg.20728; Yam AA, 2001, ORAL DIS, V7, P200, DOI 10.1034/j.1601-0825.2001.0070311.x; Kim HKW, 2013, SPINE, V38, pE1307, DOI 10.1097/BRS.0b013e3182a3d370; Yang WT, 2013, NATURE, V499, P491, DOI 10.1038/nature12396; Bhambhani V, 2014, AM FAM PHYSICIAN, V89, P37; Bowen ME, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004364; Kamiya N, 2014, BONE, V69, P55, DOI 10.1016/j.bone.2014.08.015; Sobreira NLM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000991	20	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0884-0431	1523-4681		J BONE MINER RES	J. Bone Miner. Res.	NOV	2015	30	11					2028	2032		10.1002/jbmr.2541		5	Endocrinology & Metabolism	Endocrinology & Metabolism	CU1MV	WOS:000363286900009		
J	Nagata, N; Sakamoto, K; Arai, T; Niikura, R; Shimbo, T; Shinozaki, M; Aoki, T; Sekine, K; Okubo, H; Watanabe, K; Sakurai, T; Yokoi, C; Akiyama, J; Yanase, M; Noda, M; Itoh, T; Mizokami, M; Uemura, N				Nagata, Naoyoshi; Sakamoto, Kayo; Arai, Tomohiro; Niikura, Ryota; Shimbo, Takuro; Shinozaki, Masafumi; Aoki, Tomonori; Sekine, Katsunori; Okubo, Hidetaka; Watanabe, Kazuhiro; Sakurai, Toshiyuki; Yokoi, Chizu; Akiyama, Junichi; Yanase, Mikio; Noda, Mitsuhiko; Itoh, Toshiyuki; Mizokami, Masashi; Uemura, Naomi			Visceral Abdominal Obesity Measured by Computed Tomography is Associated With Increased Risk of Colonic Diverticulosis	JOURNAL OF CLINICAL GASTROENTEROLOGY			English	Article						abdominal visceral fat; visceral adiposity; metabolic syndrome; asymptomatic colonic diverticulosis; colonic diverticular disease	IRRITABLE-BOWEL-SYNDROME; FIBER DIET; BODY-FAT; DISEASE; POPULATION; BACTERIA; METHANE	Goals:To investigate whether visceral obesity measured by computed tomography (CT) is a risk factor for colonic diverticulosis.Background:The association between colonoscopy-proven diverticulosis and visceral obesity has not been studied.Study:A cohort of 1445 participants (1117 nondiverticulosis and 328 diverticulosis) undergoing colonoscopy and CT was prospectively analyzed. Diverticulosis was diagnosed by high-resolution colonoscopy. The associations between body mass index (BMI), visceral adipose tissue (VAT) area, subcutaneous adipose tissue (SAT) area, and diverticulosis were estimated using odds ratios (ORs) adjusted for age, sex, alcohol, smoking, medications, and comorbidities.Results:In multivariate analysis, diverticulosis was significantly associated with VAT area and SAT area for both categorical data and trend (P for trend <0.001), but not BMI.Diverticulosis had a positive association with VAT area and SAT area for both categorical data and trend (P for trend <0.001) in men, but none of these associations were noted in women. In the subanalysis of normal-weight patients (BMI<25), diverticulosis was independently associated with VAT area and SAT area (P for trend <0.001). The adjusted ORs for VAT area 100 cm(2) was significantly increased in right-sided (OR, 1.8), left-sided (OR, 2.3), and bilateral (OR, 3.0) diverticula (P for trend <0.001).Conclusions:Abdominal obesity measured by CT, not BMI, is associated with colonic diverticulosis, even when body weight was normal. These findings suggest an important role for visceral fat accumulation in diverticulosis development. A high visceral fat was positively associated with the distribution of diverticula.	[Nagata, Naoyoshi; Niikura, Ryota; Aoki, Tomonori; Sekine, Katsunori; Okubo, Hidetaka; Watanabe, Kazuhiro; Sakurai, Toshiyuki; Yokoi, Chizu; Akiyama, Junichi; Yanase, Mikio] Natl Ctr Global Hlth & Med, Dept Gastroenterol & Hepatol, Tokyo 1628655, Japan; [Sakamoto, Kayo; Arai, Tomohiro; Shinozaki, Masafumi] Natl Ctr Global Hlth & Med, Dept Diagnost Radiol, Tokyo 1628655, Japan; [Shimbo, Takuro] Natl Ctr Global Hlth & Med, Int Clin Res Ctr Res Inst, Clin Res & Informat, Tokyo 1628655, Japan; [Noda, Mitsuhiko] Natl Ctr Global Hlth & Med, Diabet Res, Diabet Res Ctr, Tokyo 1628655, Japan; [Itoh, Toshiyuki] Natl Ctr Global Hlth & Med, Clin Res Ctr Clin Sci, Tokyo 1628655, Japan; [Mizokami, Masashi] Kohnodai Hosp, Natl Ctr Global Hlth & Med, Res Ctr Hepatitis & Immunol, Chiba, Japan; [Uemura, Naomi] Kohnodai Hosp, Dept Gastroenterol & Hepatol, Natl Ctr Global Hlth & Med, Chiba, Japan	Nagata, N (reprint author), Natl Ctr Global Hlth & Med, Dept Gastroenterol & Hepatol, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	nnagata_ncgm@yahoo.co.jp			National Center for Global Health and Medicine [26A-201]	Supported in part by a National Center for Global Health and Medicine (26A-201).	Rafferty J, 2006, DIS COLON RECTUM, V49, P939, DOI 10.1007/s10350-006-0578-2; Wells JCK, 2012, INT J OBESITY, V36, P148, DOI 10.1038/ijo.2011.51; Song Jung Hoon, 2010, Korean Journal of Internal Medicine, V25, P140, DOI 10.3904/kjim.2010.25.2.140; Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607; Nakaji S, 2002, INT J COLORECTAL DIS, V17, P365, DOI 10.1007/s00384-002-0403-x; Delvaux M, 2003, ALIMENT PHARM THERAP, V18, P71, DOI 10.1046/j.0953-0673.2003.01720.x; Peery AF, 2013, CLIN GASTROENTEROL H, V11, P1622, DOI 10.1016/j.cgh.2013.06.033; WEAVER GA, 1986, GUT, V27, P698, DOI 10.1136/gut.27.6.698; Shaheen NJ, 2006, AM J GASTROENTEROL, V101, P2128, DOI 10.1111/j.1572-0241.2006.00723.x; Peery AF, 2012, GASTROENTEROLOGY, V142, P266, DOI 10.1053/j.gastro.2011.10.035; Strate LL, 2009, GASTROENTEROLOGY, V136, P115, DOI 10.1053/j.gastro.2008.09.025; Mathur R, 2013, J CLIN ENDOCR METAB, V98, pE698, DOI 10.1210/jc.2012-3144; Pimentel M, 2006, AM J PHYSIOL-GASTR L, V290, pG1089, DOI 10.1152/ajpgi.00574.2004; Jung HK, 2010, AM J GASTROENTEROL, V105, P652, DOI 10.1038/ajg.2009.621; Strate LL, 2012, DIGEST DIS, V30, P35, DOI 10.1159/000335707; Goodpaster BH, 2002, CURR OPIN CLIN NUTR, V5, P481, DOI 10.1097/00075197-200209000-00005; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059; Burkitt D, 1973, Trans Med Soc Lond, V89, P81; El-Serag HB, 2014, GUT, V63, P220, DOI 10.1136/gutjnl-2012-304189; Nagata N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081137; Nagata N, 2013, INT J COLORECTAL DIS, V29, P379; Nam SY, 2010, GASTROENTEROLOGY, V139; Sharara AI, 2012, J CLIN GASTROENTEROL, V47, P420; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0192-0790	1539-2031		J CLIN GASTROENTEROL	J. Clin. Gastroenterol.	NOV-DEC	2015	49	10					816	822		10.1097/MCG.0000000000000267		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU1SB	WOS:000363300500004		
J	Uda, T; Morino, M; Minami, N; Matsumoto, T; Uchida, T; Kamei, T				Uda, Takehiro; Morino, Michiharu; Minami, Noriaki; Matsumoto, Takahiro; Uchida, Tatsuya; Kamei, Takamasa			Abnormal discharges from the temporal neocortex after selective amygdalohippocampectomy and seizure outcomes	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Electrocorticography; Residual spike; Mesial temporal lobe epilepsy; Seizure outcomes; Selective amygdalohippocampectomy	LOBE EPILEPSY; SURGICAL-TREATMENT; CLINICAL ARTICLE; HIPPOCAMPAL SCLEROSIS; PREDICTIVE-VALUE; LOBECTOMY; ELECTROCORTICOGRAPHY; STANDARD; SURGERY; METAANALYSIS	The present study examined the relationship between residual discharges from the temporal neocortex postoperatively and seizure outcomes, in mesial temporal lobe epilepsy (MTLE) patients with hippocampal sclerosis (HS) who were treated with selective amygdalohippocampectomy (SelAH). Abnormal discharges from the temporal neocortex are often observed and remain postoperatively. However, no recommendations have been made regarding whether additional procedures to eliminate these discharges should be performed for seizure relief. We retrospectively analyzed 28 patients with unilateral MTLE and HS, who underwent transsylvian SelAH. The mean follow-up period was 29 months (range: 16-49). In the pre- and postresection states, electrocorticography (ECoG) was recorded for the temporal base and lateral temporal cortex. The extent of resection was not influenced by the results of the preresection ECoG. Even if residual abnormal discharges were identified on the temporal neocortex, no additional procedures were undertaken to eliminate these abnormalities. The postresection spike counts were examined to determine the postresective alterations in spike count, and the frequency of residual spike count. The seizure outcomes were evaluated in all patients using the Engel classification. The postoperative seizure-free rate was 92.9%. No significant correlations were seen between a decreasing spike count and seizure outcomes (p = 0.9259), or between the absence of residual spikes and seizure outcomes (p = 1.000). Residual spikes at the temporal neocortex do not appear to influence seizure outcomes. Only mesial temporal structures should be removed, and additional procedures to eliminate residual spikes are not required. (C) 2015 Elsevier Ltd. All rights reserved.	[Uda, Takehiro] Osaka City Univ, Grad Sch Med, Dept Neurosurg, Abeno Ku, Osaka 5458585, Japan; [Uda, Takehiro; Morino, Michiharu; Minami, Noriaki; Matsumoto, Takahiro; Uchida, Tatsuya; Kamei, Takamasa] Tokyo Metropolitan Neurol Hosp, Dept Neurosurg, Tokyo, Japan	Uda, T (reprint author), Osaka City Univ, Grad Sch Med, Dept Neurosurg, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	uda@med.osaka-cu.ac.jp					Tripathi M, 2010, EPILEPSY RES, V89, P133, DOI 10.1016/j.eplepsyres.2009.12.007; Gelinas JN, 2011, CHILD NERV SYST, V27, P381, DOI 10.1007/s00381-010-1279-7; MORRELL F, 1989, J NEUROSURG, V70, P231, DOI 10.3171/jns.1989.70.2.0231; Morino M, 2009, J NEUROSURG, V110, P1164, DOI 10.3171/2008.9.JNS08247; Wray CD, 2012, J NEUROSURG-PEDIATR, V9, P546, DOI 10.3171/2012.1.PEDS11441; CENDES F, 1993, EPILEPSY RES, V16, P195, DOI 10.1016/0920-1211(93)90080-Q; RASMUSSEN T, 1983, EPILEPSIA, V24, P482, DOI 10.1111/j.1528-1157.1983.tb04919.x; HORI T, 1993, NEUROSURGERY, V33, P50; MCBRIDE MC, 1991, ANN NEUROL, V30, P526, DOI 10.1002/ana.410300404; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501; WIESER HG, 1982, SURG NEUROL, V17, P445, DOI 10.1016/S0090-3019(82)80016-5; Schwartz TH, 1998, J NEUROSURG, V89, P962, DOI 10.3171/jns.1998.89.6.0962; Kuang YQ, 2014, BRIT J NEUROSURG, V28, P374, DOI 10.3109/02688697.2013.841854; Chen X, 2006, NEUROSURG REV, V29, P108, DOI 10.1007/s10143-005-0002-8; Mengesha T, 2009, J NEURO-OPHTHALMOL, V29, P208, DOI 10.1097/WNO.0b013e3181b41262; Josephson CB, 2013, NEUROLOGY, V80, P1669, DOI 10.1212/WNL.0b013e3182904f82; FIOL ME, 1991, NEUROLOGY, V41, P512; Park TS, 1996, J NEUROSURG, V85, P1172, DOI 10.3171/jns.1996.85.6.1172; WYLLIE E, 1987, NEUROLOGY, V37, P1634; Morino M, 2006, EPILEPSY BEHAV, V9, P95, DOI 10.1016/j.yebeh.2006.04.017; Bujarski KA, 2013, J NEUROSURG, V119, P16, DOI 10.3171/2013.3.JNS12714; SO N, 1989, ANN NEUROL, V25, P432, DOI 10.1002/ana.410250503; Hu WH, 2013, J NEUROSURG, V119, P1089, DOI 10.3171/2013.8.JNS121854; KANNER AM, 1995, ARCH NEUROL-CHICAGO, V52, P173; Engel J., 1993, SURG TREATMENT EPILE; FALCONER M A, 1955, Lancet, V268, P827; Hori T, 1993, NEUROSURGERY, V33, P56; Olivier A, 2000, CAN J NEUROL SCI, V27, pS68; Olivier A, 2000, CAN J NEUROL SCI S1, V27, pS92; Rosenow Felix, 1998, Epilepsia, V39, P850, DOI 10.1111/j.1528-1157.1998.tb01179.x; Spencer DD, 1991, SURG EPILEPSY, P129; Wheatley BM, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/9/E4; Wieser HG, 1988, EPILEPSIA S2, V29, P100; Yaşargil M G, 1985, Adv Tech Stand Neurosurg, V12, P93	34	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	NOV	2015	22	11					1797	1801		10.1016/j.jocn.2015.03.063		5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU2JZ	WOS:000363351100016		
J	Momohara, Y; Yoshida, M; Nagayama, T				Momohara, Yuto; Yoshida, Misaki; Nagayama, Toshiki			Serotonergic modulation of social status-dependent behavioural plasticity of the crayfish avoidance reaction	JOURNAL OF COMPARATIVE PHYSIOLOGY A-NEUROETHOLOGY SENSORY NEURAL AND BEHAVIORAL PHYSIOLOGY			English	Article						Neural switch; Dart; Turn; Aminergic modulation; Nonspiking neurones	TERMINAL ABDOMINAL-GANGLION; NONSPIKING LOCAL INTERNEURONS; DOMINANCE HIERARCHY FORMATION; ORGANIZATION UNDERLYING CONTROL; INDUCED SYNAPTIC ENHANCEMENT; PROCAMBARUS-CLARKII GIRARD; POSITIONING INTERNEURONS; ANTAGONISTIC MUSCLES; DESCENDING CONTROL; JUVENILE CRAYFISH	Small crayfish usually showed escape-like dart responses to mechanical stimulation of the tailfan. Following agonistic bouts with conspecifics, dominant crayfish showed a defensive-like turn response to the same sensory stimulus. During the dart response, both uropods closed and animals walked forwards with the abdomen extended, while during the turn response the uropod on the stimulated side opened and animals turned towards the stimulus source with the abdomen frequently flexed. Using an isolated nerve cord preparation, we found that the spike activities of both the abdominal postural and uropod motor neurones in response to sensory stimulation of the exopodite reversed in dominant animals. In naive and subordinate animals, extensor motor neurones were excited and antagonistic flexor motor neurones inhibited in response to sensory stimulation. Furthermore, the spike frequency of uropod closer motor neurones increased while that of the antagonistic opener motor neurones decreased. By contrast, in more than half of the dominant animals, flexor and opener motor neurones showed excitatory responses while extensor and closer motor neurones showed inhibitory responses to the same sensory stimulation. This reverse of activity of the abdominal postural and uropod motor neurones was also observed when serotonin of more than 12.5 mu M in concentration was applied.	[Momohara, Yuto; Yoshida, Misaki] Yamagata Univ, Grad Sch Sci & Engn, Div Biol, Yamagata 9908560, Japan; [Nagayama, Toshiki] Yamagata Univ, Fac Sci, Dept Biol, Yamagata 9908560, Japan	Nagayama, T (reprint author), Yamagata Univ, Fac Sci, Dept Biol, Yamagata 9908560, Japan.	nagayama@sci.kj.yamagata-u.ac.jp			Ministry of Education, Science, Sport and Culture [25440165]	This work was supported by Grants-in-Aid from the Ministry of Education, Science, Sport and Culture to TN (25440165). We thank Dr. N. Fujiyama for support for statistical analyses. All experiments were carried out in accordance with the Guide for the care and use of Laboratory animals of Yamagata University (Japan).	von Holst D, 1999, NATURWISSENSCHAFTEN, V86, P388, DOI 10.1007/s001140050638; Weiger WA, 1997, BIOL REV, V72, P61, DOI 10.1017/S0006323196004975; Dyakonova VE, 1999, NATURWISSENSCHAFTEN, V86, P435, DOI 10.1007/s001140050647; Herberholz J, 2003, J COMP PHYSIOL A, V189, P321, DOI 10.1007/s00359-003-0409-z; Namba H, 2004, J COMP PHYSIOL A, V190, P615, DOI 10.1007/s00359-004-0516-5; Hofmann HA, 1999, P NATL ACAD SCI USA, V96, P14171, DOI 10.1073/pnas.96.24.14171; NAGAYAMA T, 1983, J COMP PHYSIOL, V152, P335; Araki M, 2012, J COMP PHYSIOL A, V198, P607, DOI 10.1007/s00359-012-0733-2; Fujimoto S, 2011, J EXP BIOL, V214, P2718, DOI 10.1242/jeb.057752; Tierney AJ, 2001, J COMP PHYSIOL A, V187, P757; Song CK, 2006, J EXP BIOL, V209, P1355, DOI 10.1242/jeb.02126; LIVINGSTONE MS, 1980, SCIENCE, V208, P76, DOI 10.1126/science.208.4439.76; LARIMER JL, 1983, J EXP ZOOL, V226, P341, DOI 10.1002/jez.1402260303; Araki M, 2013, J EXP BIOL, V216, P681, DOI 10.1242/jeb.075689; Gill MD, 1996, J NEUROPHYSIOL, V76, P3535; LARIMER JL, 1984, J EXP ZOOL, V230, P1, DOI 10.1002/jez.1402300102; EVOY WH, 1967, J EXP ZOOL, V165, P223, DOI 10.1002/jez.1401650207; Nagayama T, 2002, J EXP BIOL, V205, P3067; Huber R, 1997, P NATL ACAD SCI USA, V94, P5939, DOI 10.1073/pnas.94.11.5939; Namba H, 1997, J COMP PHYSIOL A, V180, P463, DOI 10.1007/s003590050063; MA PM, 1992, J NEUROPHYSIOL, V68, P36; Yeh SR, 1997, J NEUROSCI, V17, P697; NAGAYAMA T, 1986, EXP BIOL, V46, P75; Araki M, 2005, J NEUROPHYSIOL, V94, P2644, DOI 10.1152/jn.00502.2005; NAGAYAMA T, 1994, HISTOL HISTOPATHOL, V9, P791; NAGAYAMA T, 1987, J COMP NEUROL, V257, P347, DOI 10.1002/cne.902570304; BOVBJERG RV, 1953, PHYSIOL ZOOL, V26, P173; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; Huber R, 1998, J COMP PHYSIOL A, V182, P573, DOI 10.1007/s003590050204; Cattaert D, 2010, J NEUROSCI, V30, P5603, DOI 10.1523/JNEUROSCI.0367-10.2010; NAGAYAMA T, 1984, J COMP PHYSIOL, V154, P499, DOI 10.1007/BF00610164; HARRISWARRICK RM, 1985, J COMP PHYSIOL A, V156, P875, DOI 10.1007/BF00610838; Daws AG, 2002, MAR FRESHW BEHAV PHY, V35, P139, DOI 10.1080/1023624021000014725; Namba H, 2015, J COMP PHYSIOL A, V201, P773, DOI 10.1007/s00359-015-1017-4; LANG F, 1977, SCIENCE, V197, P682, DOI 10.1126/science.197.4304.682; NAMBA H, 1994, J NEUROPHYSIOL, V72, P235; Ueno R, 2012, J EXP BIOL, V215, P2841, DOI 10.1242/jeb.072520; KENNEDY D, 1967, J EXP ZOOL, V165, P239, DOI 10.1002/jez.1401650208; JELLIES J, 1986, J EXP BIOL, V120, P173; Issa FA, 1999, J EXP BIOL, V202, P3497; Sato D, 2012, J EXP BIOL, V215, P1210, DOI 10.1242/jeb.066191; AONUMA H, 1994, ZOOL SCI, V11, P191; HARRISWARRICK RM, 1984, J NEUROSCI, V4, P1976; Issa FA, 2012, J NEUROSCI, V32, P5638, DOI 10.1523/JNEUROSCI.5668-11.2012; BOVBJERG RICHARD V., 1956, PHYSIOL ZOOL, V29, P127; GLANZMAN DL, 1983, J NEUROSCI, V3, P2263; HOLM S, 1979, SCAND J STAT, V6, P65; Momohara Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074489; Nagayama T, 1999, J EXP ZOOL, V279, P29	49	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-7594	1432-1351		J COMP PHYSIOL A	J. Comp. Physiol. A -Neuroethol. Sens. Neural Behav. Physiol.	NOV	2015	201	11					1063	1074		10.1007/s00359-015-1038-z		12	Behavioral Sciences; Neurosciences; Physiology; Zoology	Behavioral Sciences; Neurosciences & Neurology; Physiology; Zoology	CU1BO	WOS:000363254200003		
J	Sato, C; Nicolae, VV; Ramalingam, B; Shields, M; Tanaka, H				Sato, Chikashi; Nicolae, Verona Veturia; Ramalingam, Bharath; Shields, Malcolm; Tanaka, Hiroaki			Inactivation of E. coli Using Flow-Through Ultrasound and Ultraviolet Light Reactors in Series	JOURNAL OF ENVIRONMENTAL ENGINEERING			English	Article						Water disinfection; Ultrasound; Ultraviolet light; Reactor model; Escherichia coli	ESCHERICHIA-COLI; WASTE-WATER; PHOTOCATALYTIC DISINFECTION; HYDRODYNAMIC CAVITATION; FREQUENCY ULTRASOUND; POTENTIAL USES; VISIBLE-LIGHT; DEGRADATION; IRRADIATION; TIO2	Water disinfection processes with sequential arrangements of ultrasound (US) and ultraviolet light (UV) reactors were investigated using Escherichia coli (E. coli) in a solution of 0.9% salinity. Experimental runs were carried out with reactor setups that provided sequential treatments of US followed by UVand UV followed by US. Using a mathematical model developed for three continuously stirred tank reactors in series (3-CSTR), a nonlinear regression analysis was conducted to determine the inactivation rate constants for E. coli and the formation rate constants for hydroxyl radicals. The additive, antagonistic, and synergistic effects of US (frequency 20 kHz, power density 275 mW= mL) and UV (irradiance 2.25 mW= cm(2)) were evaluated using kinetic constants and reactor efficiencies. Results showed that the sequential irradiation of US followed by UV yielded a synergistic effect on the inactivation of E. coli and that UV followed by US produced weak synergism. (C) 2015 American Society of Civil Engineers.	[Sato, Chikashi; Nicolae, Verona Veturia; Ramalingam, Bharath] Idaho State Univ, Dept Civil & Environm Engn, Pocatello, ID 83209 USA; [Shields, Malcolm] Idaho State Univ, Dept Biol Sci, Pocatello, ID 83209 USA; [Tanaka, Hiroaki] Kyoto Univ, Res Ctr Environm Qual Management, Grad Sch Engn, Otsu, Shiga 5200811, Japan	Sato, C (reprint author), Idaho State Univ, Dept Civil & Environm Engn, 921S 8th Ave,Stop 8060, Pocatello, ID 83209 USA.	satochik@isu.edu; nicovero@isu.edu; krbharath@gmail.com; shiemalc@isu.edu; htanaka@biwa.eqc.kyoto-u.ac.jp			Kyoto University	The authors would like to thank Teri Peterson for her help with the statistical analysis. The draft and final versions of the manuscript were prepared during the visiting scholar program under the auspices of Kyoto University.	Phull SS, 1997, ULTRASON SONOCHEM, V4, P157, DOI 10.1016/S1350-4177(97)00029-1; Vasilyak LM, 2010, SURF ENG APPL ELECT+, V46, P489, DOI 10.3103/S1068375510050133; Cho M, 2005, APPL ENVIRON MICROB, V71, P270, DOI 10.1128/AEM.71.1.270-275.2005; Yong HN, 2009, WATER ENVIRON RES, V81, P695, DOI 10.2175/106143008X390753; Joyce E, 2003, ULTRASON SONOCHEM, V10, P315, DOI 10.1016/S1350-4177(03)00101-9; Hartmann J, 2008, CHEMOSPHERE, V70, P453, DOI 10.1016/j.chemosphere.2007.06.063; Drosou C, 2010, J CHEM TECHNOL BIOT, V85, P1049, DOI 10.1002/jctb.2396; Rajan R, 1998, ENVIRON SCI TECHNOL, V32, P1128, DOI 10.1021/es970272a; Sato CK, 2001, J ENVIRON ENG-ASCE, V127, P620, DOI 10.1061/(ASCE)0733-9372(2001)127:7(620); Sato C, 2006, J ENVIRON ENG-ASCE, V132, P32, DOI 10.1061/(ASCE)0733-9372(2006)132:1(32); Shimizu N, 2010, BIOCHEM ENG J, V48, P416, DOI 10.1016/j.bej.2009.10.009; Rahman MM, 2010, ULTRASON SONOCHEM, V17, P738, DOI 10.1016/j.ultsonch.2009.12.001; PARLITZ U, 1995, CHAOS SOLITON FRACT, V5, P1881, DOI 10.1016/0960-0779(94)00192-S; Lifka J, 2003, ENG LIFE SCI, V3, P253, DOI 10.1002/elsc.200390040; Antoniadis A, 2007, J HAZARD MATER, V146, P492, DOI 10.1016/j.jhazmat.2007.04.065; Viten'ko TN, 2011, J WATER CHEM TECHNO+, V33, P301, DOI 10.3103/S1063455X11050055; Joyce EM, 2006, INT J ENVIRON POLLUT, V27, P222; SUSLICK KS, 1990, SCIENCE, V247, P1439, DOI 10.1126/science.247.4949.1439; Hulsmans A, 2010, ULTRASON SONOCHEM, V17, P1004, DOI 10.1016/j.ultsonch.2009.10.013; Ince NH, 2001, APPL CATAL B-ENVIRON, V29, P167, DOI 10.1016/S0926-3373(00)00224-1; An TC, 2003, J CHEM TECHNOL BIOT, V78, P1142, DOI 10.1002/jctb.915; Hua I, 2000, WATER RES, V34, P3888, DOI 10.1016/S0043-1354(00)00121-4; Drakopoulou S, 2009, ULTRASON SONOCHEM, V16, P629, DOI 10.1016/j.ultsonch.2008.11.011; Mason TJ, 2003, ULTRASON SONOCHEM, V10, P319, DOI 10.1016/S1350-4177(03)00102-0; Vollmer AC, 1998, APPL ENVIRON MICROB, V64, P3927; Hua I, 1997, ENVIRON SCI TECHNOL, V31, P2237, DOI 10.1021/es960717f; Mrowetz M, 2003, ULTRASON SONOCHEM, V10, P247, DOI 10.1016/S1350-4177(03)00090-7; Weavers LK, 2005, WATER ENVIRON RES, V77, P259, DOI 10.2175/106143005X41834; Salcedo I, 2007, APPL ENVIRON MICROB, V73, P1594, DOI 10.1128/AEM.02145-06; Morison KR, 2009, ULTRASON SONOCHEM, V16, P176, DOI 10.1016/j.ultsonch.2008.07.001; Davydov L, 2001, APPL CATAL B-ENVIRON, V32, P95, DOI 10.1016/S0926-3373(01)00126-6; Sato C, 2003, J ENVIRON ENG-ASCE, V129, P136, DOI 10.1061/(ASCE)0733-9372(2003)129:2(136); Vidal A, 1999, CATAL TODAY, V54, P283, DOI 10.1016/S0920-5861(99)00189-3; Ayyildiz O, 2011, ULTRASON SONOCHEM, V18, P683, DOI 10.1016/j.ultsonch.2010.08.008; Entezari MH, 1996, ULTRASON SONOCHEM, V3, P19, DOI 10.1016/1350-4177(95)00037-2; WEISSLER A, 1959, J AM CHEM SOC, V81, P1077, DOI 10.1021/ja01514a015; Blume T, 2004, ULTRASON SONOCHEM, V11, P333, DOI 10.1016/S1350-4177(03)00156-1; Furuta M, 2004, ULTRASON SONOCHEM, V11, P57, DOI 10.1016/S1350-4177(03)00136-6; Wu ZL, 2005, ULTRASON SONOCHEM, V12, P127, DOI 10.1016/j.ultsonch.2004.05.014; Gomez-Diaz JJ, 2011, J FOOD PROTECT, V74, P1751, DOI 10.4315/0362-028X.JFP-10-522; Hoffmann MR, 1996, ULTRASON SONOCHEM, V3, pS163, DOI 10.1016/S1350-4177(96)00022-3; Chrysikopoulos CV, 2013, COLLOID SURFACE B, V107, P174, DOI 10.1016/j.colsurfb.2013.01.038; Naddeo V, 2009, J HAZARD MATER, V168, P925, DOI 10.1016/j.jhazmat.2009.02.128; Jyoti KK, 2003, ULTRASON SONOCHEM, V10, P255, DOI 10.1016/S1350-4177(03)00095-6; Jin X, 2013, ULTRASON SONOCHEM, V20, P1384, DOI 10.1016/j.ultsonch.2013.03.010; Nair RG, 2011, COLLOID SURFACE B, V86, P7, DOI 10.1016/j.colsurfb.2011.03.011; Arnaude C., 2007, CHEM ENG NEWS, P8; Bolton R. J., 2003, J ENV ENG, DOI [10.1061/(ASCE)0733-9372(2003)129:3(209), 209-215, DOI 10.1061/(ASCE)0733-9372(2003)129:3(209)]; Brock D. T., 1991, BIOL MICROORGANISMS; Campbell N. A., 2002, BIOLOGY; Dehghani M. H., 2005, American Journal of Environmental Sciences, V1; Ensminger D., 1973, ULTRASONICS LOW HIGH; Kidak R, 2006, ULTRASON SONOCHEM, V13, P195, DOI 10.1016/j.ultsonch.2005.11.004; Manson T. J., 1988, SONOCHEMISTRY THEORY; Naidu P. D. V., 1994, CHEM ENG SCI, V49, P877; Neis U., 2003, Water Science and Technology: Water Supply, V3, P261; Pennell G. K., 2008, J ENV ENG, P513, DOI [10.1061/(ASCE)0733-9372(2008)134:7(513), DOI 10.1061/(ASCE)0733-9372(2008)134:7(513)]; U.S. EPA (Environmental Protection Agency), 2006, 815D03007 US EPA	58	0	0	ASCE-AMER SOC CIVIL ENGINEERS	RESTON	1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA	0733-9372	1943-7870		J ENVIRON ENG	J. Environ. Eng.-ASCE	NOV	2015	141	11							04015034	10.1061/(ASCE)EE.1943-7870.0000973		11	Engineering, Environmental; Engineering, Civil; Environmental Sciences	Engineering; Environmental Sciences & Ecology	CT8TE	WOS:000363088600009		
J	Rovira, L; Trobajo, R; Sato, S; Ibanez, C; Mann, DG				Rovira, Laia; Trobajo, Rosa; Sato, Shinya; Ibanez, Carles; Mann, David G.			Genetic and Physiological Diversity in the Diatom Nitzschia inconspicua	JOURNAL OF EUKARYOTIC MICROBIOLOGY			English	Article						Automixis; cryptic species; diatoms; ecophysiological responses; LSU rDNA; molecular phylogeny; rbcL; taxonomy	RIBOSOMAL-RNA GENE; COMPLEX BACILLARIOPHYCEAE; SEXUAL REPRODUCTION; SPECIES IDENTIFICATION; MOLECULAR PHYLOGENY; CRYPTIC DIVERSITY; ESTUARINE DIATOMS; ECOLOGICAL STATUS; VEGETATIVE CELL; RDNA SEQUENCES	Nitzschia inconspicua is an ecologically important diatom species, which is believed to have a widespread distribution and to be tolerant to salinity and to organic or nutrient pollution. However, its identification is not straightforward and there is no information on genetic and ecophysiological diversity within the species. We used morphological, molecular (rbcL and LSU D1-D3), ecophysiological and reproductive data to investigate whether N. inconspicua constitutes a single species with a broad ecological tolerance or two or more cryptic species with shared or different ecological preferences. Molecular genetic data for clones from upstream and deltaic sites in the Ebro River basin (Catalonia, Spain) revealed seven N. inconspicua rbcL+LSU genotypes grouped into three major clades. Two of the clades were related to other Nitzschia and Denticula species, making N. inconspicua paraphyletic and suggesting the need for taxonomic revision. Most clones were observed to be automictic, exhibiting paedogamy, and so the biological species concept cannot be used to establish species boundaries. Although there were morphological differences among clones, we found no consistent differences among genotypes belonging to different clades, which are definable only through sequence data. Nevertheless, separating the genotypes could be important for ecological purposes because two different ecophysiological responses were encountered among them.	[Rovira, Laia; Trobajo, Rosa; Ibanez, Carles; Mann, David G.] Inst Food & Agr Res & Technol IRTA, Aquat Ecosyst, San Carlos de la Rapita 43540, Catalonia, Spain; [Sato, Shinya] Fukui Prefectural Univ, Lab Marine Biosci, Obama, Fukui 9170003, Japan; [Mann, David G.] Royal Bot Garden Edinburgh, Edinburgh EH3 5LR, Midlothian, Scotland	Mann, DG (reprint author), Royal Bot Garden Edinburgh, 20A Inverleith Row, Edinburgh EH3 5LR, Midlothian, Scotland.	d.mann@rbge.ac.uk	Ibanez, Carles/D-2777-2009; Trobajo, Rosa/B-2900-2013	Ibanez, Carles/0000-0002-7091-5527; Trobajo, Rosa/0000-0001-9498-3797	European Distributed Institute of Taxonomy (EDIT) WP2 Research Grant - EU FP6; SYNTHESYS project - EU FP7 under the "Capacities" Programme; Government of Catalonia (Catalan Water Agency, ACA)	This study was financially supported by (i) European Distributed Institute of Taxonomy (EDIT) WP2 Research Grant (funded by EU FP6), which made possible the visits of Rosa Trobajo to the Natural History Museum London and Laia Rovira to the Royal Botanic Garden Edinburgh (RBGE) in 2010; (ii) SYNTHESYS project (funded by EU FP7 under the "Capacities" Programme) which made possible the visit of Rosa Trobajo to RBGE in 2011; and (iii) the Government of Catalonia (Catalan Water Agency, ACA) which supported Laia Rovira's Ph.D. fellowship. The authors thank Lluis Jornet, David Mateu and Rosa Valmana (IRTA) for sampling support; Alex Ball (NHM) and Frieda Christie (RBGE) for help with SEM; Michelle Hollingsworth and Ruth McGregor (RBGE) for their assistance and training in molecular work; Sarah Hamsher and Gary Saunders for supplying material of clone CCMP 1532; and two anonymous reviewers for constructive comments.	Beszteri B, 2007, EUR J PHYCOL, V42, P47, DOI 10.1080/09670260601044068; GEITLER L, 1969, OSTERR BOT Z, V117, P404, DOI 10.1007/BF01377798; Rovira L, 2012, MAR POLLUT BULL, V64, P500, DOI 10.1016/j.marpolbul.2012.01.005; Kaczmarska I, 2014, AM J BOT, V101, P267, DOI 10.3732/ajb.1300306; Kermarrec L, 2013, PROTIST, V164, P686, DOI 10.1016/j.protis.2013.07.005; Mann DG, 2010, CRYPTOGAMIE ALGOL, V31, P557; Holtermann KE, 2010, J PHYCOL, V46, P41, DOI 10.1111/j.1529-8817.2009.00792.x; Hamsher SE, 2014, EUR J PHYCOL, V49, P47, DOI 10.1080/09670262.2014.885582; Rimet F, 2014, PROTIST, V165, P245, DOI 10.1016/j.protis.2014.03.005; Rovira L, 2012, ESTUAR COAST SHELF S, V101, P1, DOI 10.1016/j.ecss.2011.12.033; Yoccoz NG, 2012, MOL ECOL, V21, P2031, DOI 10.1111/j.1365-294X.2012.05505.x; Goma J, 2005, HYDROBIOLOGIA, V551, P209, DOI 10.1007/s10750-005-4462-1; Daugbjerg N, 1997, J PHYCOL, V33, P1031, DOI 10.1111/j.0022-3646.1997.01031.x; Kaeriyama H, 2011, EUR J PHYCOL, V46, P113, DOI 10.1080/09670262.2011.565128; Kooistra WHCF, 2008, PROTIST, V159, P177, DOI 10.1016/j.protis.2007.09.004; De Queiroz K, 2007, SYST BIOL, V56, P879, DOI 10.1080/10635150701701083; Licursi M, 2010, MAR ECOL PROG SER, V418, P105, DOI 10.3354/meps08865; Sato S, 2008, PHYCOLOGIA, V47, P12, DOI 10.2216/07-34.1; Trobajo R, 2004, ARCH HYDROBIOL, V160, P375, DOI 10.1127/0003-9136/2004/0160-0375; Mann DG, 2013, J EUKARYOT MICROBIOL, V60, P414, DOI 10.1111/jeu.12047; Ruck EC, 2011, PROTIST, V162, P723, DOI 10.1016/j.protis.2011.02.003; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; WOLFE KH, 1987, P NATL ACAD SCI USA, V84, P9054, DOI 10.1073/pnas.84.24.9054; Huseby S, 2012, EUR J PHYCOL, V47, P480, DOI 10.1080/09670262.2012.741714; Vanormelingen P, 2013, EUR J PHYCOL, V48, P93, DOI 10.1080/09670262.2013.772242; Lundholm N, 2002, EUR J PHYCOL, V37, P115, DOI 10.1017/S096702620100347X; Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083; Nanjappa D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103810; Kooistra WHCF, 2010, PHYCOLOGIA, V49, P471, DOI 10.2216/09-59.1; Zimmermann J, 2011, ORG DIVERS EVOL, V11, P173, DOI 10.1007/s13127-011-0050-6; Fawzi B, 2002, LIMNOLOGICA, V32, P54, DOI 10.1016/S0075-9511(02)80017-2; LANGEBERTALOT H, 1977, NOVA HEDWIGIA, V28, P253; Evans KM, 2007, PROTIST, V158, P349, DOI 10.1016/j.protis.2007.04.001; SCHOLIN CA, 1994, J PHYCOL, V30, P999, DOI 10.1111/j.0022-3646.1994.00999.x; BOUSQUET J, 1992, P NATL ACAD SCI USA, V89, P7844, DOI 10.1073/pnas.89.16.7844; Trobajo R, 2004, NOVA HEDWIGIA, V79, P433, DOI 10.1127/0029-5035/2004/0079-0433; Balzano S, 2011, J PLANKTON RES, V33, P937, DOI 10.1093/plankt/fbq150; Kaczmarska I, 2009, PHYCOLOGIA, V48, P391, DOI 10.2216/08-74.1; Nunn GB, 1996, J MOL EVOL, V42, P211, DOI 10.1007/BF02198847; Saravanan V, 2010, EUR J PHYCOL, V45, P177, DOI 10.1080/09670260903445146; Delgado C, 2012, ECOL INDIC, V15, P131, DOI 10.1016/j.ecolind.2011.09.037; ADMIRAAL W, 1977, MAR BIOL, V39, P11, DOI 10.1007/BF00395587; Rovira L, 2009, ACTA BOT CROAT, V68, P285; Mann DG, 2013, PHYCOLOGIA, V52, P204, DOI 10.2216/12-077.1; Trobajo R, 2009, PHYCOLOGIA, V48, P443, DOI 10.2216/08-69.1; Potapova MG, 2004, HYDROBIOLOGIA, V517, P25, DOI 10.1023/B:HYDR.0000027335.73651.ea; Vanelslander B, 2009, J PHYCOL, V45, P1278, DOI 10.1111/j.1529-8817.2009.00762.x; Trobajo R, 2006, J PHYCOL, V42, P1353, DOI 10.1111/j.1529-8817.2006.00291.x; Sorhannus U, 1999, J MOL EVOL, V48, P209, DOI 10.1007/PL00006459; GUILLARD RR, 1972, J PHYCOL, V8, P10, DOI 10.1111/j.0022-3646.1972.00010.x; Naymik J, 2005, J N AM BENTHOL SOC, V24, P569, DOI 10.1899/0887-3593(2005)024\[0569:DAAIOT\]2.0.CO;2; Vanormelingen P, 2008, PROTIST, V159, P73, DOI 10.1016/j.protis.2007.08.004; VANLANDINGHAM SL, 1991, NOVA HEDWIGIA, V53, P349; Capesius I, 1997, J PLANT PHYSIOL, V151, P239; Trobajo R, 2011, PHYCOL RES, V59, P83, DOI 10.1111/j.1440-1835.2010.00603.x; Amato A, 2007, PROTIST, V158, P193, DOI 10.1016/j.protis.2006.10.001; Quijano-Scheggia S, 2009, J PHYCOL, V45, P100, DOI 10.1111/j.1529-8817.2008.00636.x; Trobajo R, 2013, DIATOM RES, V28, P37, DOI 10.1080/0269249X.2012.734531; MANN DG, 1982, PLANT SYST EVOL, V141, P143, DOI 10.1007/BF00986414; Kelly M, 2008, FRESHWATER BIOL, V53, P403, DOI 10.1111/j.1365-2427.2007.01903.x; Ulanova A, 2009, J PHYCOL, V45, P54, DOI 10.1111/j.1529-8817.2008.00628.x; Nagai S, 1995, PHYCOLOGIA, V34, P533, DOI 10.2216/i0031-8884-34-6-533.1; Beszteri B, 2005, PROTIST, V156, P317, DOI 10.1016/j.protis.2005.07.002; Vesela J, 2012, PHYCOLOGIA, V51, P552, DOI 10.2116/11-101.1; GUILLARD RR, 1962, CAN J MICROBIOL, V8, P229; Guo LL, 2015, INT J SYST EVOL MICR, V65, P1369, DOI 10.1099/ijs.0.000076; Vanormelingen P, 2013, FOTTEA, V13, P133; Chepurnov VA, 1997, EUR J PHYCOL, V32, P147; Hamsher SE, 2011, PROTIST, V162, P405, DOI 10.1016/j.protis.2010.09.005; Rimet F, 2011, DIATOM RES, V26, P273, DOI 10.1080/0269249X.2011.597988; Gaut BS, 1996, P NATL ACAD SCI USA, V93, P10274, DOI 10.1073/pnas.93.19.10274; Trobajo R, 2010, EUR J PHYCOL, V45, P413, DOI 10.1080/09670262.2010.498586; Fontaneto D, 2007, PLOS BIOL, V5, P914, DOI 10.1371/journal.pbio.0050087; Theriot EC, 2010, PLANT ECOL EVOL, V143, P278, DOI 10.5091/plecevo.2010.418; Creach V, 2006, J PHYCOL, V42, P1142, DOI 10.1111/j.1529-8817.2006.00268.x; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Tang CQ, 2014, EVOLUTION, V68, P2901, DOI 10.1111/evo.12483; Charlesworth D., 2010, ELEMENTS EVOLUTIONAR, P1; Chepurnov VA, 2004, INT REV CYTOL, V237, P91, DOI 10.1016/S0074-7696(04)37003-8; Chepurnov V. A., 1992, ALGOLOGIA, V2, P26; Cox EJ, 1995, PROCEEDINGS OF THE THIRTEENTH INTERNATIONAL DIATOM SYMPOSIUM, P335; Geitler L, 1953, OSTERR BOT Z, V100, P331, DOI 10.1007/BF01805777; Grunow A., 1880, K SVENSKA VETENSK AK, V17, P1; Hajibabei M., 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017497, DOI 10.1371/JOURNAL.PONE.0017497.]; Hajos M., 1986, GEOL HUNG SER PALAEO, V49, P1; Hara H, 1985, ORIGIN EVOLUTION DIV, P304; Hustedt F., 1937, BERICHTE DTSCH BOT G, V55, P465; Kelly M. G., 2014, DIATOM RES, V30, P27; Krammer K., 1988, SUSSWASSERFLORA MITT; Lange-Bertalot H., 1993, BIBLIOTHECA DIATOMOL, V27, P1; LANGE-BERTALOT H, 1978, Bacillaria, V1, P11; MANN DG, 1994, LINNEAN SOC, P17; Mann D. G., 1986, P 8 INT DIAT S, P215; MANN D. G., 2007, UNRAVELLING ALGAE PR, P231; Mann D. G., 1981, P 6 S REC FOSS DIAT, P279; Poulickova A, 2010, PROTIST, V161, P353, DOI 10.1016/j.protis.2009.12.003; Roshchin A. M., 1994, ZHIZNENNYE TSIKLY DI, P1; Sarno D, 2010, DEEP-SEA RES PT II, V57, P248, DOI 10.1016/j.dsr2.2009.09.012; Sato S, 2013, PHYCOLOGIA, V52, P225, DOI 10.2216/12-072.1; Souffreau C., 2012, PROTIST, V164, P101; Stein J. R., 1973, PHYCOLOGICAL METHODS, P7; Trobajo R., 2006, P 18 INT DIAT S, P431; Underwood A. J., 1997, EXPT ECOLOGY THEIR L, P1; Van Dam Herman, 1994, Netherlands Journal of Aquatic Ecology, V28, P117; Van Landingham S. L., 1967, NOVA HEDWIGIA S, V26, P1; Van Landingham S. L., 1964, NOVA HEDWIGIA S, V14, P1; von Stosch HA, 1965, PHYCOLOGIA, V5, P21; Werner D, 1977, BIOL DIATOMS, P24; WILLIAMS RICHARD B., 1964, ECOLOGY, V45, P877, DOI 10.2307/1934940; Wood A. M., 2005, ALGAL CULTURING TECH, P269; Zimmermann J., 2014, MOL ECOL, DOI [10.1111/1755-0998.12336, DOI 10.1111/1755-0998.12336.]	111	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5234	1550-7408		J EUKARYOT MICROBIOL	J. Eukaryot. Microbiol.	NOV-DEC	2015	62	6					815	832		10.1111/jeu.12240		18	Microbiology	Microbiology	CU4SD	WOS:000363519400011		
J	Yamada, A; Kodo, Y; Murakami, M; Kuroda, M; Aoki, T; Fujimoto, T; Arai, K				Yamada, Aya; Kodo, Yukihiro; Murakami, Masaru; Kuroda, Masamichi; Aoki, Takao; Fujimoto, Takafumi; Arai, Katsutoshi			Hybrid Origin of Gynogenetic Clones and the Introgression of Their Mitochondrial Genome Into Sexual Diploids Through Meiotic Hybridogenesis in the Loach, Misgurnus anguillicuadatus	JOURNAL OF EXPERIMENTAL ZOOLOGY PART A-ECOLOGICAL GENETICS AND PHYSIOLOGY			English	Article							ANGUILLICAUDATUS TELEOSTEI; INTERSPECIFIC HYBRIDIZATION; PREMEIOTIC ENDOMITOSIS; MOLECULAR PHYLOGENY; MAXIMUM-LIKELIHOOD; DNA-SEQUENCES; FISH; COBITIDAE; SPERMATOZOA; DIVERSITY	In a few Japanese populations of the loach Misgurnus anguillicaudatus (Teleostei: Cobitidae), clonal diploid lineages produce unreduced diploid eggs that normally undergo gynogenetic reproduction; however the origin of these clones remains elusive. Here, we show the presence of two diverse clades, A and B, within this loach species from sequence analyses of two nuclear genes RAG1 (recombination activating gene 1) and IRBP2 (interphotoreceptor retinoid-binding protein, 2) and then demonstrate heterozygous genotypes fixed at the two loci as the evidence of the hybrid nature of clonal lineages. All the clonal individuals were identified by clone-specific mitochondrial DNA haplotypes, microsatellite genotypes, and random amplified polymorphic DNA fingerprints; they commonly showed two alleles, one from clade A and another from clade B, whereas other wild-type diploids possessed alleles from either clade A or B. However, we also found wild-type diploids with clone-specific mitochondrial DNA and nuclear genes from clade B. One possible explanation is an introgression of a clone-specific mitochondrial genome from clonal to these wild-type loaches. These individuals likely arose by a cross between haploid sperm from bisexual B clade males and haploid eggs with clone-specific mtDNA and clade B nuclear genome, produced by meiotic hybridogenesis (elimination of unmatched A genome followed by meiosis after preferential pairing between two matched B genomes) in clone-origin triploid individual (ABB). (C) 2015 Wiley Periodicals, Inc.	[Yamada, Aya; Kuroda, Masamichi; Aoki, Takao; Fujimoto, Takafumi; Arai, Katsutoshi] Hokkaido Univ, Fac & Grad Sch Fisheries Sci, Hakodate, Hokkaido 0418611, Japan; [Kodo, Yukihiro; Murakami, Masaru] Azabu Univ, Fac Vet Med, Sagamihara, Kanagawa, Japan	Arai, K (reprint author), Hokkaido Univ, Fac & Grad Sch Fisheries Sci, 3-1-1 Minato, Hakodate, Hokkaido 0418611, Japan.	araikt@fish.hokudai.ac.jp			JSPS-KAKENHI [21380114]	Grant sponsor: JSPS-KAKENHI; grant number: 21380114.	Sinclair EA, 2010, EVOLUTION, V64, P1346, DOI 10.1111/j.1558-5646.2009.00893.x; Morishima K, 2008, HEREDITY, V100, P581, DOI 10.1038/hdy.2008.17; VRIJENHOEK RC, 1994, ANNU REV ECOL SYST, V25, P71, DOI 10.1146/annurev.es.25.110194.000443; Saitoh K, 2010, MOL PHYLOGENET EVOL, V56, P1001, DOI 10.1016/j.ympev.2010.04.021; Fujimoto T, 2008, J APPL ICHTHYOL, V24, P430, DOI 10.1111/j.1439-0426.2008.01131.x; Koizumi Noriyuki, 2009, Transactions of the Japanese Society of Irrigation Drainage and Rural Engineering, V77, P7; DAWLEY RM, 1985, J HERED, V76, P251; Asahida T, 1996, FISHERIES SCI, V62, P727; KUSUNOKI T, 1994, FISHERIES SCI, V60, P415; Choleva L, 2012, EVOLUTION, V66, P2191, DOI 10.1111/j.1558-5646.2012.01589.x; JOHNSON KR, 1986, AQUACULTURE, V57, P345, DOI 10.1016/0044-8486(86)90213-9; Perdices A, 2012, ICHTHYOL RES, V59, P113, DOI 10.1007/s10228-011-0259-6; Morishima K, 2008, GENETICA, V132, P159, DOI 10.1007/s10709-007-9158-1; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Arias-Rodriguez L, 2009, GENETICA, V136, P49, DOI 10.1007/s10709-008-9299-x; Arai K, 2013, CYTOGENET GENOME RES, V140, P226, DOI 10.1159/000353301; Collares-Pereira MJ, 2013, CYTOGENET GENOME RES, V140, P97, DOI 10.1159/000351729; Morishima K, 2002, ZOOL SCI, V19, P565, DOI 10.2108/zsj.19.565; Chen WJ, 2008, GENE, V423, P125, DOI 10.1016/j.gene.2008.07.016; Khan MR, 2000, FISHERIES SCI, V66, P211, DOI 10.1046/j.1444-2906.2000.00037.x; Liu SJ, 2001, AQUACULTURE, V192, P171, DOI 10.1016/S0044-8486(00)00451-8; CHEVASSUS B, 1983, AQUACULTURE, V33, P245, DOI 10.1016/0044-8486(83)90405-2; Yoshikawa H, 2009, BIOL REPROD, V80, P973, DOI 10.1095/biolreprod.108.075150; Itono M, 2007, J EXP ZOOL PART A, V307A, P35, DOI 10.1002/jez.e.344; Itono M, 2006, J EXP ZOOL PART A, V305A, P513, DOI 10.1002/jez.a.283; Slechtova V, 2008, MOL PHYLOGENET EVOL, V47, P812, DOI 10.1016/j.ympev.2007.12.018; Quenouille B, 2004, MOL PHYLOGENET EVOL, V31, P66, DOI 10.1016/s1055-7903(03)00278-1; Shimizu Y, 2000, ZOOL SCI, V17, P951, DOI 10.2108/zsj.17.951; Arias-Rodriguez L, 2010, J APPL ICHTHYOL, V26, P653, DOI 10.1111/j.1439-0426.2010.01534.x; Morishima K, 2008, GENETICA, V132, P227, DOI 10.1007/s10709-007-9165-2; Gui JF, 2010, SCI CHINA LIFE SCI, V53, P409, DOI 10.1007/s11427-010-0092-6; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Arias-Rodriguez L, 2007, MOL ECOL NOTES, V7, P82, DOI 10.1111/j.1471-8286.2006.01536.x; Dawley R.M., 1989, EVOLUTION ECOLOGY UN, V466, P1; Janko K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045384; Kitagawa T, 2011, FOLIA ZOOL, V60, P340; Minamori S., 1953, J SCI HIROSHIMA U B, V1, P125; Minamori S., 1957, J SCI HIROSHIMA U B, V1, P55; Morishima K, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.093302; Saitoh K, 1989, FRESHWATER FISHES JA, P382; Vrijenhoek R. C., 1989, B NEW YORK STATE MUS, V466, P19; YANG ZH, 1994, J MOL EVOL, V39, P306, DOI 10.1007/BF00160154; Zhou XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092033	43	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-5223	1932-5231		J EXP ZOOL PART A	J. Exp. Zool. Part A	NOV 1	2015	323	9					593	606		10.1002/jez.1950		14	Zoology	Zoology	CT8BG	WOS:000363039400001		
J	Gao, B; He, X; Liu, W; Zhang, HH; Saito, N; Tsuda, S				Gao, Bei; He, Xin; Liu, Wei; Zhang, Huanhuan; Saito, Norimitsu; Tsuda, Shuji			Distribution of perfluoroalkyl compounds in rats: Indication for using hair as bioindicator of exposure	JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY			English	Article						perfluoroalkyl acids; hair; serum; tissue; urine; feces	PERFLUORINATED COMPOUNDS; PERFLUOROOCTANOIC ACID; POLYFLUOROALKYL SUBSTANCES; DRINKING-WATER; SHORT-CHAIN; CHILDREN; SERUM; SULFONATE; BINDING; ADULTS	Hair analysis is potentially advantageous in exposure assessment of perfluoroalkyl acids (PFAAs) as a non-invasive method, combined with the ability to reflect long-term exposure. The present study aims to assess the feasibility of using hair as an indicator of PFAA exposure. Adult male and female rats were subchronically exposed to selected PFAAs, including perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorooctanesulfonate (PFOS), for 90 days. Hair, serum, and other tissues, including liver, kidney, spleen, lung, brain and heart, as well as the urine and feces excretions, were analyzed for PFAA levels. PFOA/PFNA/PFOS were detected in rat hair in a dose-dependent manner, in the order of PFOS > PFNA > PFOA. Hair PFAA concentrations were higher in male rats than the female rats, except for PFOS at low dose. Moreover, significant positive correlations as well as similar PFAA profiles were observed between hair, serum, and other tissues. Besides, hair PFAAs were negatively correlated with the urinary excretion rate. Although the influencing factors in humans still need further investigation, the results suggested that hair is capable of reflecting PFAA exposure, and could be employed as an alternative exposure bioindicator of PFAAs.	[Gao, Bei; He, Xin; Liu, Wei; Zhang, Huanhuan] Dalian Univ Technol, Sch Environm Sci & Technol, Key Lab Ind Ecol & Environm Engn, MOE, Dalian 116024, Peoples R China; [Saito, Norimitsu; Tsuda, Shuji] Res Inst Environm Sci & Publ Hlth Iwate Prefectur, Morioka, Iwate, Japan	Liu, W (reprint author), Dalian Univ Technol, Sch Environm Sci & Technol, Key Lab Ind Ecol & Environm Engn, MOE, Dalian 116024, Peoples R China.	liu_wei@dlut.edu.cn			National Nature Science Foundation of China [81102096, 21177020]; Fundamental Research Funds for the Central Universities [DUT12LK13]; Geping Green Finance [CEPF2011-123-2-14]	The paper is to commemorate late Professor Dr Yihe Jin (1959-2013) who devoted his whole life to the scientific research and who contributed greatly to the present research. This study is financially supported by National Nature Science Foundation of China (81102096, 21177020) and the Fundamental Research Funds for the Central Universities (DUT12LK13). We also appreciate the 123 Project of Liaoning environment education research supported by Geping Green Finance (CEPF2011-123-2-14).	Ye XB, 2008, ENVIRON INT, V34, P932, DOI 10.1016/j.envint.2008.02.003; Zhang T, 2010, ENVIRON SCI TECHNOL, V44, P4341, DOI 10.1021/es1002132; Egeghy PP, 2011, J EXPO SCI ENV EPID, V21, P150, DOI 10.1038/jes.2009.73; Buist SCN, 2004, DRUG METAB DISPOS, V32, P620, DOI 10.1124/dmd.32.6.620; Kannan K, 2011, ENVIRON CHEM, V8, P333, DOI 10.1071/EN11053; Altshul L, 2004, ENVIRON HEALTH PERSP, V112, P1193, DOI 10.1289/ehp.6916; VANCE DE, 1988, BIOL TRACE ELEM RES, V17, P109, DOI 10.1007/BF02795450; Kudo N, 2002, CHEM-BIOL INTERACT, V139, P301, DOI 10.1016/S0009-2797(02)00006-6; Sukumar A, 2005, REV ENVIRON CONTAM T, V185, P141; Lindstrom AB, 2011, ENVIRON SCI TECHNOL, V45, P7954, DOI 10.1021/es2011622; Kato K, 2011, ENVIRON SCI TECHNOL, V45, P8037, DOI 10.1021/es1043613; Ohmori K, 2003, TOXICOLOGY, V184, P135, DOI 10.1016/S0300-483X(02)00573-5; Nakao T, 2002, CHEMOSPHERE, V48, P885, DOI 10.1016/S0045-6535(02)00156-X; Jones PD, 2003, ENVIRON TOXICOL CHEM, V22, P2639, DOI 10.1897/02-553; Pirali B, 2009, THYROID, V19, P1407, DOI 10.1089/thy.2009.0174; Wielgomas B, 2012, CHEMOSPHERE, V89, P975, DOI 10.1016/j.chemosphere.2012.06.056; Post GB, 2013, ENVIRON SCI TECHNOL, V47, P13266, DOI 10.1021/es402884x; Toms LML, 2009, ENVIRON SCI TECHNOL, V43, P4194, DOI 10.1021/es900272u; Taniyasu S, 2005, J CHROMATOGR A, V1093, P89, DOI 10.1016/j.chroma.2005.07.053; Holzer J, 2008, ENVIRON HEALTH PERSP, V116, P651, DOI 10.1289/ehp.11064; Shi YL, 2010, ENVIRON INT, V36, P46, DOI 10.1016/j.envint.2009.09.005; Haug LS, 2010, ENVIRON INT, V36, P772, DOI 10.1016/j.envint.2010.05.016; Bischel HN, 2011, ENVIRON TOXICOL CHEM, V30, P2423, DOI 10.1002/etc.647; Han X, 2003, CHEM RES TOXICOL, V16, P775, DOI 10.1021/tx034005w; Granum B, 2013, J IMMUNOTOXICOL, V10, P373, DOI 10.3109/1547691X.2012.755580; Liu W, 2011, ENVIRON SCI TECHNOL, V45, P8144, DOI 10.1021/es1036207; Meyer J, 2009, SCI TOTAL ENVIRON, V407, P5894, DOI 10.1016/j.scitotenv.2009.07.032; Houde M, 2006, ENVIRON SCI TECHNOL, V40, P3463, DOI 10.1021/es052580b; Miekeley N, 2001, J TRACE ELEM MED BIO, V15, P46, DOI 10.1016/S0946-672X(01)80026-2; Li JG, 2013, ENVIRON INT, V53, P47, DOI 10.1016/j.envint.2012.12.002; Lau C, 2007, TOXICOL SCI, V99, P366, DOI 10.1093/toxsci/kfm128; Kovarova J, 2008, NEUROENDOCRINOL LETT, V29, P599; Melzer D, 2010, ENVIRON HEALTH PERSP, V118, P686, DOI 10.1289/ehp.0901584; Eriksson U, 2013, ENVIRON SCI POLLUT R, V20, P7940, DOI 10.1007/s11356-013-1700-3; Olsen GW, 2003, AIHA J, V64, P651, DOI 10.1080/15428110308984859; Tatum-Gibbs K, 2011, TOXICOLOGY, V281, P48, DOI 10.1016/j.tox.2011.01.003; Grandjean P, 2012, JAMA-J AM MED ASSOC, V307, P391, DOI 10.1001/jama.2011.2034; Hermann F, 2009, INT J HYG ENVIR HEAL, V212, P239; Lau Christopher, 2012, EXS, V101, P47, DOI 10.1007/978-3-7643-8340-4_3; VANDENHEUVEL JP, 1992, J BIOCHEM TOXICOL, V7, P31, DOI 10.1002/jbt.2570070107; Vestergren V, 2012, ENVIRON INT, V49, P120; Wang JS, 2012, ENVIRON SCI TECHNOL, V46, P9274	42	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1559-0631	1559-064X		J EXPO SCI ENV EPID	J. Expo. Sci. Environ. Epidemiol.	NOV-DEC	2015	25	6					632	638		10.1038/jes.2014.54		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	CU0QX	WOS:000363224900013		
J	Takeishi, K; Kawahara, G; Wakabayashi, H; Uhlmann, M; Pinelli, A				Takeishi, Keisuke; Kawahara, Genta; Wakabayashi, Hiroki; Uhlmann, Markus; Pinelli, Alfredo			Localized turbulence structures in transitional rectangular-duct flow	JOURNAL OF FLUID MECHANICS			English	Article						instability; transition to turbulence; turbulent flows	PLANE POISEUILLE FLOW; NEAR-WALL TURBULENCE; PIPE-FLOW; SQUARE DUCT; PUFFS; SLUGS	Direct numerical simulations of transitional flow in a rectangular duct of cross-sectional aspect ratio A equivalent to s/h = 1-9 (s and h being the duct half-span and half-height, respectively) have been performed in the Reynolds number range Re equivalent to u(b)h/nu = 650-1500 (u(b) and nu being the bulk velocity and the kinematic viscosity, respectively) in order to investigate the dependence on the aspect ratio of spatially localized turbulence structures. It was observed that the lowest Reynolds number Re-T, estimated in a specific way, for localized (transiently sustaining) turbulence decreases monotonically from Re-T = 730 for A = 1 (square duct) with increasing aspect ratio, and for A = 5 it nearly attains a minimal value Re-T approximate to 670 that is consistent with the onset Reynolds number of turbulent spots in a plane channel (A = infinity). Turbulent states consist of localized structures that undergo a fundamental change around A = 4. At Re = Re-T turbulence for A = 1-3 is streamwise-localized similar to turbulent puffs in pipe flow, while for A = 5-9 turbulence at Re = Re-T is also localized in the spanwise direction, similar to turbulent spots in plane channel flow. This structural change in turbulent states at Re = Re-T is attributed to the exclusion of turbulence from the vicinity of the duct sidewalls in the case of a wide duct with A greater than or similar to 4: here the friction length on the sidewalls is so long that the size (around 100 times the friction length) of a self-sustaining minimal flow unit of streamwise vortices and streaks is larger than the duct height and, therefore, it cannot be accommodated.	[Takeishi, Keisuke; Kawahara, Genta; Wakabayashi, Hiroki] Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan; [Uhlmann, Markus] Karlsruhe Inst Technol, Inst Hydromech, D-76131 Karlsruhe, Germany; [Pinelli, Alfredo] City Univ London, Sch Math Comp Sci & Engn, London EC1V 0HB, England	Kawahara, G (reprint author), Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan.	kawahara@me.es.osaka-u.ac.jp			Japanese Society for the Promotion of Science [25249014, 26630055]	This work was partially supported by a Grant-in-Aid for Scientific Research (grant nos 25249014, 26630055) from the Japanese Society for the Promotion of Science.	LAI YC, 1995, PHYS REV LETT, V74, P5208, DOI 10.1103/PhysRevLett.74.5208; TATSUMI T, 1990, J FLUID MECH, V212, P437, DOI 10.1017/S002211209000204X; CARLSON DR, 1982, J FLUID MECH, V121, P487, DOI 10.1017/S0022112082002006; Kawahara G, 2012, ANNU REV FLUID MECH, V44, P203, DOI 10.1146/annurev-fluid-120710-101228; Uhlmann M, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3466661; Nishi M, 2008, J FLUID MECH, V614, P425, DOI 10.1017/S0022112008003315; Hashimoto S, 2009, TURBULENCE, HEAT AND MASS TRANSFER 6, P193; Peixinho J, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.094501; KANTZ H, 1985, PHYSICA D, V17, P75, DOI 10.1016/0167-2789(85)90135-6; Mullin T, 2011, ANNU REV FLUID MECH, V43, P1, DOI 10.1146/annurev-fluid-122109-160652; Pinelli A, 2010, J FLUID MECH, V644, P107, DOI 10.1017/S0022112009992242; Avila M, 2010, J FLUID MECH, V646, P127, DOI 10.1017/S0022112009993296; Uhlmann M, 2007, J FLUID MECH, V588, P153, DOI 10.1017/S0O022112007007604; JIMENEZ J, 1991, J FLUID MECH, V225, P213, DOI 10.1017/S0022112091002033; BROSA U, 1989, J STAT PHYS, V55, P1303, DOI 10.1007/BF01041090; HAMILTON JM, 1995, J FLUID MECH, V287, P317, DOI 10.1017/S0022112095000978; De Lozar A, 2009, PHILOS T R SOC A, V367, P589, DOI 10.1098/rsta.2008.0199; Hof B, 2006, NATURE, V443, P59, DOI 10.1038/nature05089; Aida H, 2010, PROCEEDINGS OF THE ASME FLUIDS ENGINEERING DIVISION SUMMER CONFERENCE - 2010 - VOL 1, PTS A-C, P2125; Avila M, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.224502; Brand E, 2014, J FLUID MECH, V750, DOI 10.1017/jfm.2014.285; Dean R. B., 1978, Transactions of the ASME. Journal of Fluids Engineering, V100; Lemoult G, 2013, J FLUID MECH, V731, DOI 10.1017/jfm.2013.388; Avila K, 2011, SCIENCE, V333, P192, DOI 10.1126/science.1203223; WYGNANSK.IJ, 1973, J FLUID MECH, V59, P281, DOI 10.1017/S0022112073001576; Zammert S, 2014, J FLUID MECH, V761, DOI 10.1017/jfm.2014.633	26	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0022-1120	1469-7645		J FLUID MECH	J. Fluid Mech.	NOV	2015	782						368	379		10.1017/jfm.2015.546		12	Mechanics; Physics, Fluids & Plasmas	Mechanics; Physics	CU1MQ	WOS:000363286400018		
J	Nio, K; Yamashita, T; Okada, H; Kondo, M; Hayashi, T; Hara, Y; Nomura, Y; Zeng, SS; Yoshida, M; Hayashi, T; Sunagozaka, H; Oishi, N; Honda, M; Kaneko, S				Nio, Kouki; Yamashita, Taro; Okada, Hikari; Kondo, Mitsumasa; Hayashi, Takehiro; Hara, Yasumasa; Nomura, Yoshimoto; Zeng, Sha Sha; Yoshida, Mariko; Hayashi, Tomoyuki; Sunagozaka, Hajime; Oishi, Naoki; Honda, Masao; Kaneko, Shuichi			Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma	JOURNAL OF HEPATOLOGY			English	Article						Chromodomain-helicase-DNA-binding protein 4; Liver cancer stem cells; Histone deacetylase; Poly (ADP-ribose) polymerase; Chemoresistance	TUMOR-INITIATING CELLS; DNA-DAMAGE; SOMATIC MUTATIONS; SALL4 INTERACTS; COMPLEX; PLURIPOTENCY; REPAIR; NURD; INHIBITION; ACTIVATION	Background & Aims: Hepatocellular carcinoma is composed of a subset of cells with enhanced tumorigenicity and chemoresistance that are called cancer stem (or stem-like) cells. We explored the role of chromodomain-helicase-DNA-binding protein 4, which is encoded by the CHD4 gene and is known to epigenetically control gene regulation and DNA damage responses in EpCAM(+) liver cancer stem cells. Methods: Gene and protein expression profiles were determined by microarray and immunohistochemistry in 245 and 144 hepatocellular carcinoma patients, respectively. The relationship between gene/protein expression and prognosis was examined. The functional role of CHD4 was evaluated in primary hepatocellular carcinoma cells and in cell lines in vitro and in vivo. Results: CHD4 was abundantly expressed in EpCAM(+) hepatocellular carcinoma with expression of hepatic stem cell markers and poor prognosis in two independent cohorts. In cell lines, CHD4 knockdown increased chemosensitivity and CHD4 overexpression induced epirubicin chemoresistance. To inhibit the functions of CHD4 that are mediated through histone deacetylase and poly (ADP-ribose) polymerase, we evaluated the effect of the histone deacetylase inhibitor suberohydroxamic acid and the poly (ADP-ribose) polymerase inhibitor AG-014699. Treatment with either suberohydroxamic acid or AG-014699 reduced the number of EpCAM(+) liver cancer stem cells in vitro, and suberohydroxamic acid and AG-014699 in combination successfully inhibited tumor growth in a mouse xenograft model. Conclusions: CHD4 plays a pivotal role in chemoresistance and the maintenance of stemness in liver cancer stem cells and is therefore a good target for the eradication of hepatocellular carcinoma. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.	[Nio, Kouki; Yamashita, Taro; Okada, Hikari; Kondo, Mitsumasa; Hayashi, Takehiro; Hara, Yasumasa; Nomura, Yoshimoto; Zeng, Sha Sha; Yoshida, Mariko; Hayashi, Tomoyuki; Sunagozaka, Hajime; Oishi, Naoki; Honda, Masao; Kaneko, Shuichi] Kanazawa Univ, Grad Sch Med Sci, Dept Gastroenterol, Kanazawa, Ishikawa 9208641, Japan	Yamashita, T (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Gen Med Gastroenterol, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.	taroy@m-kanazawa.jp			Ministry of Education, Culture, Sports, Science and Technology [23590967, 26460994]; Ministry of Health, Labour and Welfare; National Cancer Center Research and Development Fund [23-B-5]; Project for Development of Innovative Research on Cancer Therapeutics	This study was supported by Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology (No. 23590967 and 26460994), a grant from the Ministry of Health, Labour and Welfare, a grant from the National Cancer Center Research and Development Fund (23-B-5), and a grant from the Project for Development of Innovative Research on Cancer Therapeutics.	Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Yang JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI 10.1073/pnas.0809321105; Larsen DH, 2010, J CELL BIOL, V190, P731, DOI 10.1083/jcb.200912135; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Rao S, 2010, MOL CELL BIOL, V30, P5364, DOI 10.1128/MCB.00419-10; Tanimura N, 2013, J BIOL CHEM, V288, P5027, DOI 10.1074/jbc.M112.411173; Yamashita T, 2013, HEPATOLOGY, V57, P1484, DOI 10.1002/hep.26168; Zeng SS, 2014, J HEPATOL, V60, P127, DOI 10.1016/j.jhep.2013.08.024; Yamashita T, 2010, CANCER RES, V70, P4687, DOI 10.1158/0008-5472.CAN-09-4210; Yamashita T, 2009, J HEPATOL, V50, P100, DOI 10.1016/j.jhep.2008.07.036; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Lee YH, 2014, CANCER RES, V74, P4752, DOI 10.1158/0008-5472.CAN-13-3531; Kim H, 2013, J HEPATOL, V59, P746, DOI 10.1016/j.jhep.2013.05.011; Smeenk G, 2010, J CELL BIOL, V190, P741, DOI 10.1083/jcb.201001048; Marquardt JU, 2013, NEW ENGL J MED, V368, P2316, DOI 10.1056/NEJMe1303026; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Polo SE, 2010, EMBO J, V29, P3130, DOI 10.1038/emboj.2010.188; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Chou DM, 2010, P NATL ACAD SCI USA, V107, P18475, DOI 10.1073/pnas.1012946107; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908; Oikawa T, 2013, HEPATOLOGY, V57, P1469, DOI 10.1002/hep.26159; Zhang JX, 2012, HEPATOLOGY, V55, P1840, DOI 10.1002/hep.25566; de Lope CR, 2012, J HEPATOL, V56, pS75, DOI 10.1016/S0168-8278(12)60009-9; Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Pan MR, 2012, J BIOL CHEM, V287, P6764, DOI 10.1074/jbc.M111.287037; Raggi C, 2014, HEPATOLOGY, V59, P2251, DOI 10.1002/hep.27026; Roessler S, 2012, GASTROENTEROLOGY, V142, pe912; Shibata T, 2014, NAT REV GASTRO HEPAT, V11, DOI 10.1038/nrgastro.2014.6; Yamashita T, 2014, HEPATOLOGY, V60, P1674, DOI 10.1002/hep.27093; Yang JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010766	39	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-8278	1600-0641		J HEPATOL	J. Hepatol.	NOV	2015	63	5					1164	1172		10.1016/j.jhep.2015.06.009		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU1US	WOS:000363307600017		
J	Beuers, U; Gershwin, ME; Gish, RG; Invernizzi, P; Jones, DEJ; Lindor, K; Ma, X; Mackay, IR; Pares, A; Tanaka, A; Vierling, JM; Poupon, R				Beuers, Ulrich; Gershwin, M. Eric; Gish, Robert G.; Invernizzi, Pietro; Jones, David E. J.; Lindor, Keith; Ma, Xiong; Mackay, Ian R.; Pares, Albert; Tanaka, Atsushi; Vierling, John M.; Poupon, Raoul			Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'	JOURNAL OF HEPATOLOGY			English	Article						Cholestasis; Cholangiopathy; Primary biliary cirrhosis	PRIMARY BILIARY-CIRRHOSIS; HCO3-UMBRELLA; CHOLANGIOCYTES; EXPRESSION		[Beuers, Ulrich] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands; [Beuers, Ulrich] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands; [Gershwin, M. Eric] Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA; [Gish, Robert G.] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Stanford, CA 94305 USA; [Invernizzi, Pietro] Humanitas Clin & Res Ctr, Ctr Autoimmune Liver Dis, Milan, Italy; [Jones, David E. J.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Lindor, Keith] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ USA; [Ma, Xiong] Shanghai Jiao Tong Univ, Shanghai Inst Digest Dis, Sch Med, Div Gastroenterol & Hepatol,Renji Hosp, Shanghai 200030, Peoples R China; [Mackay, Ian R.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; [Pares, Albert] Univ Barcelona, CIBERehd, IDIBAPS, Liver Unit,Hosp Clin, Barcelona, Spain; [Tanaka, Atsushi] Teikyo Univ, Sch Med, Dept Med, Tokyo 173, Japan; [Vierling, John M.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Vierling, John M.] Baylor Coll Med, Dept Surg, Houston, TX 77030 USA; [Poupon, Raoul] Hop St Antoine, Serv Hepatol, Reference Ctr Inflammatory Biliary Dis, F-75571 Paris, France	Beuers, U (reprint author), Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, Dept Gastroenterol & Hepatol, Meibergdreef 9, NL-1100 DE Amsterdam, Netherlands.	u.h.beuers@amc.uva.nl					Addison T, 1851, GUYS HOSP REP, V7, P265; AHRENS EH, 1950, MEDICINE, V29, P299; Sasaki M, 2013, LIVER INT, V33, P312, DOI 10.1111/liv.12049; Beuers U, 2010, HEPATOLOGY, V52, P1489, DOI 10.1002/hep.23810; Banales JM, 2012, HEPATOLOGY, V56, P687, DOI 10.1002/hep.25691; RUBIN E, 1965, AM J PATHOL, V46, P387; Odin JA, 2001, J CLIN INVEST, V108, P223, DOI 10.1172/JCI10716; Hohenester S, 2012, HEPATOLOGY, V55, P173, DOI 10.1002/hep.24691; Lindor KD, 2009, HEPATOLOGY, V50, P291, DOI 10.1002/hep.22906; Gershwin ME, 2008, HEPATOLOGY, V47, P737, DOI 10.1002/hep.22042; SHERLOCK S, 1959, GASTROENTEROLOGY, V37, P574; MACMAHON HE, 1949, ANN INTERN MED, V30, P121; Bianchi I, 2014, SEMIN LIVER DIS, V34, P255, DOI 10.1055/s-0034-1383725; Lleo A, 2010, HEPATOLOGY, V52, P987, DOI 10.1002/hep.23783; Lleo A, 2014, SEMIN LIVER DIS, V34, P273, DOI 10.1055/s-0034-1383727; Beuers U, 2015, J HEPATOL, V62, pS25, DOI 10.1016/j.jhep.2015.02.023; Dyson JK, 2015, NAT REV GASTRO HEPAT, V12, P147, DOI 10.1038/nrgastro.2015.12; EASL, 2009, J HEPATOL, V51, P237; Hanot V, 1876, ETUDE FORME CIRRHOSE; Hirschfield GM, 2013, ANNU REV PATHOL-MECH, V8, P303, DOI 10.1146/annurev-pathol-020712-164014; Sherlock S, 1968, DIS LIVER BILIARY SY, P305	21	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0168-8278	1600-0641		J HEPATOL	J. Hepatol.	NOV	2015	63	5					1285	1287				3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU1US	WOS:000363307600029		
J	Motosugi, U; Hernando, D; Bannas, P; Holmes, JH; Wang, K; Shimakawa, A; Iwadate, Y; Taviani, V; Rehm, JL; Reeder, SB				Motosugi, Utaroh; Hernando, Diego; Bannas, Peter; Holmes, James H.; Wang, Kang; Shimakawa, Ann; Iwadate, Yuji; Taviani, Valentina; Rehm, Jennifer L.; Reeder, Scott B.			Quantification of liver fat with respiratory-gated quantitative chemical shift encoded MRI	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						liver; fat quantification; navigator echo; respiratory monitoring; magnetic resonance imaging	GRADIENT-ECHO SEQUENCE; HEPATIC STEATOSIS; NONALCOHOLIC STEATOHEPATITIS; SAMPLING VARIABILITY; COMPUTED-TOMOGRAPHY; DISEASE; RECONSTRUCTION; SPECTROSCOPY; VALIDATION; SEPARATION	PurposeTo evaluate free-breathing chemical shift-encoded (CSE) magnetic resonance imaging (MRI) for quantification of hepatic proton density fat-fraction (PDFF). A secondary purpose was to evaluate hepatic R2* values measured using free-breathing quantitative CSE-MRI. Materials and MethodsFifty patients (mean age, 56 years) were prospectively recruited and underwent the following four acquisitions to measure PDFF and R2*; 1) conventional breath-hold CSE-MRI (BH-CSE); 2) respiratory-gated CSE-MRI using respiratory bellows (BL-CSE); 3) respiratory-gated CSE-MRI using navigator echoes (NV-CSE); and 4) single voxel MR spectroscopy (MRS) as the reference standard for PDFF. Image quality was evaluated by two radiologists. MRI-PDFF measured from the three CSE-MRI methods were compared with MRS-PDFF using linear regression. The PDFF and R2* values were compared using two one-sided t-test to evaluate statistical equivalence. ResultsThere was no significant difference in the image quality scores among the three CSE-MRI methods for either PDFF (P=1.000) or R2* maps (P=0.359-1.000). Correlation coefficients (95% confidence interval [CI]) for the PDFF comparisons were 0.98 (0.96-0.99) for BH-, 0.99 (0.97-0.99) for BL-, and 0.99 (0.98-0.99) for NV-CSE. The statistical equivalence test revealed that the mean difference in PDFF and R2* between any two of the three CSE-MRI methods was less than 1 percentage point (pp) and +/- 5 s(-1), respectively (P<0.046). ConclusionRespiratory-gated CSE-MRI with respiratory bellows or navigator echo are feasible methods to quantify liver PDFF and R2* and are as valid as the standard breath-hold technique. J. Magn. Reson. Imaging 2015;42:1241-1248.	[Motosugi, Utaroh; Hernando, Diego; Bannas, Peter; Reeder, Scott B.] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA; [Motosugi, Utaroh] Univ Yamanashi, Dept Radiol, Yamanashi, Japan; [Bannas, Peter] Univ Hosp Hamburg Eppendorf, Dept Radiol, Hamburg, Germany; [Holmes, James H.; Wang, Kang] GE Healthcare, Global MR Applicat & Workflow, Madison, WI USA; [Shimakawa, Ann] GE Healthcare, Global MR Applicat & Workflow, Menlo Pk, CA USA; [Iwadate, Yuji] GE Healthcare, Global MR Applicat & Workflow, Hino, Tokyo, Japan; [Taviani, Valentina] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; [Rehm, Jennifer L.] Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; [Reeder, Scott B.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA; [Reeder, Scott B.] Univ Wisconsin, Dept Biomed Engn & Med, Madison, WI 53706 USA; [Reeder, Scott B.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Reeder, Scott B.] Univ Wisconsin, Dept Emergency Med, Madison, WI 53706 USA	Motosugi, U (reprint author), Univ Wisconsin, Dept Radiol, Ctr Clin Sci, 600 Highland Ave, Madison, WI 53706 USA.	umotosugi@uwhealth.org					Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Yu HZ, 2007, J MAGN RESON IMAGING, V26, P1153, DOI 10.1002/jmri.21090; Reeder SB, 2011, J MAGN RESON IMAGING, V34, P729, DOI 10.1002/jmri.22580; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; Yokoo T, 2009, RADIOLOGY, V251, P67, DOI 10.1148/radiol.2511080666; Brau ACS, 2008, MAGN RESON MED, V59, P382, DOI 10.1002/mrm.21481; Kodama Y, 2007, AM J ROENTGENOL, V188, P1307, DOI 10.2214/AJR.06.0992; Yokoo T, 2011, RADIOLOGY, V258, P749, DOI 10.1148/radiol.10100659; Reiner CS, 2013, EUR RADIOL, V23, P3087, DOI 10.1007/s00330-013-2910-2; Reeder SB, 2012, J MAGN RESON IMAGING, V36, P1011, DOI 10.1002/jmri.23741; Marks B, 1997, JMRI-J MAGN RESON IM, V7, P595, DOI 10.1002/jmri.1880070323; Hernando D, 2013, MAGN RESON MED, V70, P1319, DOI 10.1002/mrm.24593; Liu CY, 2007, MAGN RESON MED, V58, P354, DOI 10.1002/mrm.21301; Kuhn JP, 2014, J MAGN RESON IMAGING, V39, P1494, DOI 10.1002/jmri.24289; Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604; Ratziu V, 2005, GASTROENTEROLOGY, V128, P1898, DOI 10.1053/j.gastro.2005.03.084; Yu HZ, 2008, MAGN RESON MED, V60, P1122, DOI 10.1002/mrm.21737; Chandarana H, 2011, INVEST RADIOL, V46, P648, DOI 10.1097/RLI.0b013e31821eea45; Chandarana H, 2014, EUR RADIOL, V24, P320, DOI 10.1007/s00330-013-3026-4; Reeder SB, 2013, HEPATOLOGY, V58, P1877, DOI 10.1002/hep.26543; Mishra P, 2007, AM J GASTROENTEROL, V102, P2716, DOI 10.1111/j.1572-0241.2007.01520.x; Artz NS, 2012, INVEST RADIOL, V47, P603, DOI 10.1097/RLI.0b013e318261fad0; Asbach P, 2008, INVEST RADIOL, V43, P809, DOI 10.1097/RLI.0b013e318186242b; Azevedo RM, 2011, AM J ROENTGENOL, V197, P650, DOI 10.2214/AJR.10.5881; Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008; GAY SB, 1994, INVEST RADIOL, V29, P848, DOI 10.1097/00004424-199409000-00009; Yu HZ, 2011, MAGN RESON MED, V66, P199, DOI 10.1002/mrm.22840; Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022; Hernando D, 2014, P 22 ANN M ISMRM MIL; Kew Michael C, 2014, Liver Cancer, V3, P31, DOI 10.1159/000343856; Szczepaniak LS, 2005, AM J PHYSIOL-ENDOC M, V288, pE462, DOI 10.1152/ajpendo.00064.2004	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	NOV	2015	42	5					1241	1248		10.1002/jmri.24896		8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1KN	WOS:000363280300009		
J	Yasokawa, K; Ito, K; Tamada, T; Yamamoto, A; Hayashida, M; Tanimoto, D; Higaki, A; Noda, Y; Kido, A				Yasokawa, Kazuya; Ito, Katsuyoshi; Tamada, Tsutomu; Yamamoto, Akira; Hayashida, Minoru; Tanimoto, Daigo; Higaki, Atsushi; Noda, Yasufumi; Kido, Ayumu			Noninvasive investigation of exocrine pancreatic function: Feasibility of cine dynamic MRCP with a spatially selective inversion-recovery pulse	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						cine dynamic MRCP; pancreas; MR imaging; chronic pancreatitis; pancreatic exocrine function	SECRETIN-STIMULATED MRCP; DUCT VISUALIZATION; DIAGNOSIS; JUICE; PANCREATOGRAPHY; QUANTIFICATION; PEPTIDE; FLOW; MRI	PurposeTo investigate the feasibility of noncontrast-enhanced cine dynamic magnetic resonance cholangiopancreatography (MRCP) with a spatially selective inversion-recovery (IR) pulse for evaluating exocrine pancreatic function in comparison with the N-benzoyl-L-tyrosyl-p-aminobenzoic acid (BT-PABA) test as a pancreatic exocrine function test. Materials and MethodsTwenty subjects with or without chronic pancreatitis were included. MRCP with a spatially selective IR pulse was repeated every 15 seconds for 5 minutes to acquire a total of 20 images (cine-dynamic MRCP). The median and mean frequency of the observation (the number of times) and the moving distance (mean secretion grading scores) of pancreatic juice inflow on cine-dynamic MRCP were compared with a BT-PABA test. ResultsThe urinary PABA excretion rate (%) had significant positive correlations with both the mean secretion grade (r=0.66, P=0.002) and frequency of secretory inflow (r=0.62, P=0.004) in cine dynamic MRCP. Both the mean frequency of observations of pancreatic secretory inflow (1.41.6 times vs. 14.3 +/- 4.2 times, P<0.001) and the mean secretion grade (grade=0.16 +/- 0.24 vs. grade=1.81 +/- 0.81, P<0.001) was significantly lower in the chronic pancreatitis group than in the normal subject group. ConclusionCine dynamic MRCP with a spatially selective IR pulse may have potential for estimating the pancreatic exocrine function noninvasively as a substitute for the BT-PABA test. J. Magn. Reson. Imaging 2015;42:1266-1271.	[Yasokawa, Kazuya; Ito, Katsuyoshi; Tamada, Tsutomu; Yamamoto, Akira; Hayashida, Minoru; Tanimoto, Daigo; Higaki, Atsushi; Noda, Yasufumi; Kido, Ayumu] Kawasaki Med Univ, Dept Diagnost Radiol, Kurashiki, Okayama 7010192, Japan	Yasokawa, K (reprint author), Kawasaki Med Univ, Dept Diagnost Radiol, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.	relax_yacchin_1006@yahoo.co.jp					HARADA H, 1979, AM J GASTROENTEROL, V71, P45; Stein J, 1996, CLIN CHEM, V42, P222; Shimosegawa T, 2010, J GASTROENTEROL, V45, P584, DOI 10.1007/s00535-010-0242-4; Ito K, 2011, RADIOLOGY, V261, P582, DOI 10.1148/radiol.11110162; GYR K, 1976, GUT, V17, P27, DOI 10.1136/gut.17.1.27; Punwani S, 2003, EUR RADIOL, V13, P273, DOI 10.1007/s00330-002-1605-x; Heverhagen JT, 2001, RADIOLOGY, V218, P61; AMMANN RW, 1981, DIGESTION, V21, P281; Torigoe T, 2014, AM J ROENTGENOL, V202, P1022, DOI 10.2214/AJR.13.10852; Cappeliez O, 2000, RADIOLOGY, V215, P358; Manfredi R, 2000, RADIOLOGY, V214, P849; Matos C, 1997, RADIOLOGY, V203, P435; Mensel B, 2014, AM J ROENTGENOL, V202, P102, DOI 10.2214/AJR.12.10271; LANKISCH PG, 1993, INT J PANCREATOL, V14, P9; Balci C, 2011, DIAGN INTERV RADIOL, V17, P249, DOI 10.4261/1305-3825.DIR.3889-10.0; Balci NC, 2010, J MAGN RESON IMAGING, V31, P601, DOI 10.1002/jmri.22085; Ochi K, 1997, DIGEST DIS SCI, V42, P492, DOI 10.1023/A:1018878505670; Wada K, 1998, PANCREAS, V16, P124, DOI 10.1097/00006676-199803000-00003; Ishii Y, 2007, PANCREAS, V35, P313; Kataoka K, 1999, DIGESTION, V60, P86, DOI 10.1159/000051461; NIEDERAU C, 1985, GASTROENTEROLOGY, V88, P1973; Manikkavasakar S, 2014, WORLD J GASTROENTERO, V20, P14760, DOI 10.3748/wjg.v20.i40.14760	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	NOV	2015	42	5					1266	1271		10.1002/jmri.24906		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1KN	WOS:000363280300012		
J	Sofue, K; Mileto, A; Dale, BM; Zhong, XD; Bashir, MR				Sofue, Keitaro; Mileto, Achille; Dale, Brian M.; Zhong, Xiaodong; Bashir, Mustafa R.			Interexamination repeatability and spatial heterogeneity of liver iron and fat quantification using MRI-based multistep adaptive fitting algorithm	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						magnetic resonance imaging; liver iron; liver fat; repeatability; heterogeneity	NEEDLE-BIOPSY SPECIMENS; HEPATIC IRON; NONALCOHOLIC STEATOHEPATITIS; FRACTION ESTIMATION; FLIP-ANGLE; ACCURACY; SPECTRUM; DISEASE; VARIABILITY; STEATOSIS	PurposeTo assess the interexamination repeatability and spatial heterogeneity of liver iron and fat measurements using a magnetic resonance imaging (MRI)-based multistep adaptive fitting algorithm. Materials and MethodsThis prospective observational study was Institutional Review Board-approved and Health Insurance Portability and Accountability Act-compliant. Written informed consent was waived. In all, 150 subjects were imaged on 3T MRI systems. A whole-liver volume acquisition was performed twice using a six-echo 3D spoiled gradient echo sequence during two immediately adjacent examinations. Colocalized regions of interest (ROIs) in three different hepatic segments were placed for R-2* and proton density fat fraction (PDFF) measurements by two readers independently. Mean R-2* and PDFF values between readers and acquisitions were compared using the Wilcoxon signed-rank test, intraclass correlation coefficients (ICCs), linear regression, Bland-Altman analysis, and analysis of variance (ANOVA). ResultsThe mean R-2* and PDFF values across all ROIs and measurements were 51.225.2 s(-1) and 6.9 +/- 6.4%, respectively. Mean R-2* and PDFF values showed no significant differences between the two acquisitions (P=0.05-0.87). Between the two acquisitions, R-2* and PDFF values demonstrated almost perfect agreement (ICCs=0.979-0.994) and excellent correlation (R-2=0.958-0.989). Bland-Altman analysis also demonstrated excellent agreement. In the ANOVA, the individual patient and ROI location were significant effects for both R-2* and PDFF values (P<0.05). ConclusionMRI-based R-2* and PDFF measurements are repeatable between examinations. Between-measurement changes in R-2* of more than 10.1 s(-1) and in PDFF of more than 1.7% are likely due to actual tissue changes. Liver iron and fat content are variable between hepatic segments. J. Magn. Reson. Imaging 2015;42:1281-1290.	[Sofue, Keitaro; Mileto, Achille; Bashir, Mustafa R.] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA; [Sofue, Keitaro] Kobe Univ, Grad Sch Med, Dept Radiol, Kobe, Hyogo 657, Japan; [Dale, Brian M.] Siemens Healthcare, Morrisville, NC USA; [Zhong, Xiaodong] Siemens Healthcare, Atlanta, GA USA; [Bashir, Mustafa R.] Duke Univ, Med Ctr, Ctr Adv Magnet Resonance Dev, Durham, NC 27710 USA	Bashir, MR (reprint author), Duke Univ, Med Ctr, Box 3808, Durham, NC 27710 USA.	mustafa.bashir@duke.edu	Bashir, Mustafa/P-3428-2015		Siemens Healthcare	K.S. and A.M. have no relevant disclosures. X.Z. and B.M.D. are employees of Siemens Healthcare. M.R.B.'s institution receives research support from Siemens Healthcare.	Reeder SB, 2011, J MAGN RESON IMAGING, V34, P729, DOI 10.1002/jmri.22580; O'Regan DP, 2008, RADIOLOGY, V247, P550, DOI 10.1148/radiol.2472070880; Bonekamp S, 2014, J MAGN RESON IMAGING, V39, P1525, DOI 10.1002/jmri.24321; Yokoo T, 2009, RADIOLOGY, V251, P67, DOI 10.1148/radiol.2511080666; Villeneuve JP, 1996, J HEPATOL, V25, P172, DOI 10.1016/S0168-8278(96)80070-5; Mashhood A, 2013, J MAGN RESON IMAGING, V37, P1359, DOI 10.1002/jmri.23928; Chebrolu VV, 2010, MAGN RESON MED, V63, P849, DOI 10.1002/mrm.22300; Yokoo T, 2011, RADIOLOGY, V258, P749, DOI 10.1148/radiol.10100659; Levin YS, 2014, J MAGN RESON IMAGING, V39, P567, DOI 10.1002/jmri.24193; Positano V, 2007, P ANN INT IEEE EMBS, P2895, DOI 10.1109/IEMBS.2007.4352934; Butensky E, 2005, AM J CLIN PATHOL, V123, P146, DOI 10.1309/PUUXEGXDLH26NXA2; Sumida Y, 2009, HEPATOL RES, V39, P213, DOI 10.1111/j.1872-034X.2008.00442.x; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Meisamy S, 2011, RADIOLOGY, V258, P767, DOI 10.1148/radiol.10100708; Ren JM, 2008, J LIPID RES, V49, P2055, DOI 10.1194/jlr.D800010-JLR200; Hernando D, 2013, MAGN RESON MED, V70, P1319, DOI 10.1002/mrm.24593; George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2; Hines CDG, 2011, J MAGN RESON IMAGING, V33, P873, DOI 10.1002/jmri.22514; Browning JD, 2004, HEPATOLOGY, V40, P1387, DOI 10.1002/hep.20466; Ratziu V, 2005, GASTROENTEROLOGY, V128, P1898, DOI 10.1053/j.gastro.2005.03.084; Yu HZ, 2008, MAGN RESON MED, V60, P1122, DOI 10.1002/mrm.21737; Breuer FA, 2006, MAGN RESON MED, V55, P549, DOI 10.1002/mrm.20787; Kuhn JP, 2012, RADIOLOGY, V265, P133, DOI 10.1148/radiol.12112520; Bydder M, 2008, MAGN RESON IMAGING, V26, P347, DOI 10.1016/j.mri.2007.08.012; Piperno A, 1998, HEPATOLOGY, V28, P1105, DOI 10.1002/hep.510280427; Negrete LM, 2014, J MAGN RESON IMAGING, V39, P1265, DOI 10.1002/jmri.24284; Lambrecht RW, 2011, GASTROENTEROLOGY, V140, P1490, DOI 10.1053/j.gastro.2011.01.053; Dongiovanni P, 2011, J HEPATOL, V55, P920, DOI 10.1016/j.jhep.2011.05.008; Kang GH, 2011, J MAGN RESON IMAGING, V34, P928, DOI 10.1002/jmri.22701; Kew MC, 2009, CANCER LETT, V286, P38, DOI 10.1016/j.canlet.2008.11.001; Bashir MR, 2015, AM J ROENTGENOL, V204, P297, DOI 10.2214/AJR.14.12457; Henninger Benjamin, 2013, Eur Radiol, V23, P1643, DOI 10.1007/s00330-012-2745-2; Hernando D, 2014, J MAGN RESON IMAGING, V40, P1003, DOI 10.1002/jmri.24584; Johnson BL, 2014, J MAGN RESON IMAGING, V39, P440, DOI 10.1002/jmri.24153; Manco M, 2011, HEPATOLOGY, V53, P1057, DOI 10.1002/hep.24142; Manco M, 2011, HEPATOLOGY, V53, P1058; Mavrogeni S, 2013, INT J CARDIOVASC IMA; Zhong X, 2013, MAGN RESON MED, V72, P1353	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	NOV	2015	42	5					1281	1290		10.1002/jmri.24922		10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1KN	WOS:000363280300014		
J	Togao, O; Hiwatashi, A; Keupp, J; Yamashita, K; Kikuchi, K; Yoshiura, T; Suzuki, Y; Kruiskamp, MJ; Sagiyama, K; Takahashi, M; Honda, H				Togao, Osamu; Hiwatashi, Akio; Keupp, Jochen; Yamashita, Koji; Kikuchi, Kazufumi; Yoshiura, Takashi; Suzuki, Yuriko; Kruiskamp, Marijn J.; Sagiyama, Koji; Takahashi, Masaya; Honda, Hiroshi			Scan-rescan reproducibility of parallel transmission based amide proton transfer imaging of brain tumors	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						glioma; amide proton transfer (APT) imaging; chemical exchange saturation transfer (CEST); reproducibility; scan; rescan test	IN-VIVO; GLIOBLASTOMA; PEPTIDES; PROTEINS; CONTRAST; GLIOMA	PurposeTo evaluate the reproducibility of amide proton transfer (APT) imaging of brain tumors using a parallel transmission-based technique. Materials and MethodsThirteen patients with brain tumors (four low-grade gliomas, three glioblastoma multiforme, five meningiomas, and one malignant lymphoma) were included in the study. APT imaging was conducted at 3T using a 2-channel parallel transmission scheme with a saturation time of 2 seconds and B-1 amplitude of 2 T. A 2D fast spin-echo sequence with driven-equilibrium refocusing was used for imaging. Z-spectra were obtained at 25 frequency offsets from -6 to +6 ppm (step 0.5 ppm). A point-by-point B-0 correction was performed with a B-0 map. A scan-rescan reproducibility test was performed in two sessions on separate days for each patient. The interval between the two sessions was 4.83.5 days. Regions-of-interest (ROIs) were placed to include the whole tumor for each case. A mean and 90-percentile value of APT signal for the whole tumor histogram was calculated for each session. The between-session and within-session reproducibility was evaluated using linear regression analysis, intraclass correlation coefficient (ICC), and a Bland-Altman plot. ResultsThe mean and 90-percentile values of the APT signal for whole tumor ROI showed excellent agreements between the two sessions, with R-2 of 0.91 and 0.96 in the linear regression analysis and ICC of 0.95 and 0.97, respectively. ConclusionParallel transmission-based APT imaging of brain tumors showed good reproducibility. J. Magn. Reson. Imaging 2015;42:1346-1353.	[Togao, Osamu; Hiwatashi, Akio; Yamashita, Koji; Kikuchi, Kazufumi; Yoshiura, Takashi; Sagiyama, Koji; Honda, Hiroshi] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka 8128582, Japan; [Keupp, Jochen; Kruiskamp, Marijn J.] Philips Res Europe, Hamburg, Germany; [Suzuki, Yuriko] Philips Elect Japan, Tokyo, Japan; [Sagiyama, Koji; Takahashi, Masaya] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA	Togao, O (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	togao@radiol.med.kyushu-u.ac.jp			Japanese Society of Neuroradiology; Japanese Radiological Society; Philips Electronics Japan; Bayer Healthcare Japan; Fukuoka Foundation for Sound Health Cancer Research Fund;  [26461827];  [22591340]	Contract grant sponsor: Japanese Society of Neuroradiology; Contract grant sponsor: Japanese Radiological Society; Contract grant sponsor: Philips Electronics Japan; Contract grant sponsor: Bayer Healthcare Japan; Contract grant sponsor: Fukuoka Foundation for Sound Health Cancer Research Fund; Contract grant numbers: Grant-in-Aid for Scientific Research numbers 26461827 and 22591340.	Zhou JY, 2003, MAGNET RESON MED, V50, P1120, DOI 10.1002/mrm.10651; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Wen ZB, 2010, NEUROIMAGE, V51, P616, DOI 10.1016/j.neuroimage.2010.02.050; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037//0033-2909.86.2.420; Zhou JY, 2011, NAT MED, V17, P130, DOI 10.1038/nm.2268; Zhou JY, 2013, MAGN RESON MED, V70, P320, DOI 10.1002/mrm.24784; Sagiyama K, 2014, P NATL ACAD SCI USA, V111, P4542, DOI 10.1073/pnas.1323855111; Ling W, 2008, P NATL ACAD SCI USA, V105, P2266, DOI 10.1073/pnas.0707666105; Salhotra A, 2008, NMR BIOMED, V21, P489, DOI 10.1002/nbm.1216; Petersen ET, 2010, NEUROIMAGE, V49, P104, DOI 10.1016/j.neuroimage.2009.07.068; Kim M, 2009, MAGN RESON MED, V61, P1441, DOI 10.1002/mrm.21873; Zhou JY, 2003, NAT MED, V9, P1085, DOI 10.1038/nm907; Zhou JY, 2008, MAGN RESON MED, V60, P842, DOI 10.1002/mrm.21712; Keupp J, 2010, P 18 ANN M ISMRM STO; Keupp J, 2011, P 19 ANN M ISMRM MON; BLAND JM, 1986, LANCET, V1, P307; Togao O, 2014, NEURO-ONCOLOGY, V16, P441, DOI 10.1093/neuonc/not158; Togao O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077019; vansZijl PC, 2007, P NATL ACAD SCI USA, V104, P4359	19	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	NOV	2015	42	5					1346	1353		10.1002/jmri.24895		8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CU1KN	WOS:000363280300022		
J	Gong, FY; Zhang, DW; Ueda, T; Sicat, E				Gong, Fuyuan; Zhang, Dawei; Ueda, Tamon; Sicat, Evdon			Closure to "Empirical Estimation of Pore Size Distribution in Cement, Mortar, and Concrete" by Fuyuan Gong, Dawei Zhang, Evdon Sicat, and Tamon Ueda	JOURNAL OF MATERIALS IN CIVIL ENGINEERING			English	Editorial Material							ADSORPTION		[Gong, Fuyuan; Ueda, Tamon; Sicat, Evdon] Hokkaido Univ, Coll Engn, Lab Engn Maintenance Syst, Sapporo, Hokkaido 0600808, Japan; [Zhang, Dawei] Zhejiang Univ, Coll Architecture & Civil Engn, Inst Struct Engn, Hangzhou 310058, Zhejiang, Peoples R China	Zhang, DW (reprint author), Zhejiang Univ, Coll Architecture & Civil Engn, Inst Struct Engn, Hangzhou 310058, Zhejiang, Peoples R China.	dwzhang@zju.edu.cn					Promentilla MAB, 2009, CEMENT CONCRETE RES, V39, P548, DOI 10.1016/j.cemconres.2009.03.005; HAGYMASS.J, 1969, J COLLOID INTERF SCI, V29, P485, DOI 10.1016/0021-9797(69)90132-5; Scherer G. W., 2005, MAT SCI CONCRETE, V7; Shimomura T., 1992, P JCI, V14, P631; Takewaka K., 2003, J ADV CONCR TECHNOL, V1, P139, DOI 10.3151/jact.1.139; Uchikawa H., 1991, MORTAR CONCRETE, V88, P67; XI YP, 1994, ADV CEM BASED MATER, V1, P248, DOI 10.1016/1065-7355(94)90033-7; Zeng Q., 2014, J MATER CIVIL ENG, V26	8	0	0	ASCE-AMER SOC CIVIL ENGINEERS	RESTON	1801 ALEXANDER BELL DR, RESTON, VA 20191-4400 USA	0899-1561	1943-5533		J MATER CIVIL ENG	J. Mater. Civ. Eng.	NOV	2015	27	11							07015008	10.1061/(ASCE)MT.1943-5533.0001297		2	Construction & Building Technology; Engineering, Civil; Materials Science, Multidisciplinary	Construction & Building Technology; Engineering; Materials Science	CT8TP	WOS:000363089700027		
J	Hirano, T; Saito, T; Chiba, S				Hirano, Takahiro; Saito, Takumi; Chiba, Satoshi			Phylogeny of freshwater viviparid snails in Japan	JOURNAL OF MOLLUSCAN STUDIES			English	Article							PACHYCHILIDAE; CERITHIOIDEA; GASTROPODA; GENETICS; MODELS; POPULATIONS; LIKELIHOOD; DIVERSITY; RATCHET; RIVER	We document extensive incongruence between molecular phylogeny and the current taxonomy of the freshwater gastropod family Viviparidae in Japan. A phylogeny based on the mitochondrial cytochrome oxidase subunit I and 16S rRNA genes for East Asian viviparids comprises three major clades, the two largest of which are composed primarily of paraphyletic or highly polyphyletic taxonomic species. Sinotaia quadrata histrica includes several lineages whose geographical distribution and shell morphology are largely incongruent with their phylogenetic relationships. Several individuals identified as Heterogen longispira are nested within a clade of Cipangopaludina japonica. In contrast, Cipangopaludina chinensis laeta and C. c. chinensis from China are both monophyletic, but the two are not supported as sister taxa. The observed incongruence between phylogeny and taxonomy may be due to incomplete lineage sorting, introgressive hybridization and/ or phenotypic plasticity. Further molecular phylogenetic analyses are needed to clarify the significance of the observed patterns and to verify the systematic relationships.	[Hirano, Takahiro; Saito, Takumi; Chiba, Satoshi] Tohoku Univ, Grad Sch, Aoba Ku, Sendai, Miyagi 9808578, Japan	Hirano, T (reprint author), Tohoku Univ, Grad Sch, Aoba Ku, 41 Kawauchi, Sendai, Miyagi 9808578, Japan.	hirano0223t@yahoo.co.jp			Research Institute of Marine Invertebrates; JSPS [15H03743]	We thank H. Fukuda, T. Haga, K. Hirano, N. Hirano, M. Ishida, Y. Kameda, N. Kimura, H. Kubo, Y. Morii, K. Nakai, Okayama Prefectural Nature Conservation Center, W. Otani, L. Prozorova, R. Sato and S. Uchida for sample collection. This study was supported by a research grant from the Research Institute of Marine Invertebrates and JSPS Grant-in-Aid for Scientific Research (No 15H03743). Finally, we are grateful to F. Kohler, E. E. Strong and an anonymous referee for constructive comments on the manuscript.	Tanabe AS, 2011, MOL ECOL RESOUR, V11, P914, DOI 10.1111/j.1755-0998.2011.03021.x; Du L, 2013, CHINESE SCI BULL, V58, P2154, DOI 10.1007/s11434-012-5632-y; Castresana J, 2000, MOL BIOL EVOL, V17, P540; Inoue K, 2013, ECOL EVOL, V3, P2670, DOI 10.1002/ece3.649; Kohler F, 2004, EVOLUTION, V58, P2215; Minton RL, 2003, MOL ECOL, V12, P75, DOI 10.1046/j.1365-294X.2003.01719.x; Kohler F, 2010, EVOLUTION IN ACTION: CASE STUDIES IN ADAPTIVE RADIATION, SPECIATION AND THE ORIGIN OF BIODIVERSITY, P513, DOI 10.1007/978-3-642-12425-9_24; Ricciardi A, 1999, CONSERV BIOL, V13, P1220, DOI 10.1046/j.1523-1739.1999.98380.x; Lv S, 2013, DIVERS DISTRIB, V19, P147, DOI 10.1111/j.1472-4642.2012.00924.x; Hayes KA, 2008, DIVERS DISTRIB, V14, P701, DOI 10.1111/j.1472-4642.2008.00483.x; Deans AR, 2012, TRENDS ECOL EVOL, V27, P78, DOI 10.1016/j.tree.2011.11.007; Miura O, 2013, J MOLLUS STUD, V79, P86, DOI 10.1093/mollus/eys036; Vos RA, 2003, SYST BIOL, V52, P368, DOI 10.1080/10635150390196993; Glaubrecht M, 2008, HYDROBIOLOGIA, V615, P181, DOI 10.1007/s10750-008-9568-9; Kohler F, 2006, MALACOLOGIA, V48, P159; Dillon RT, 2013, HYDROBIOLOGIA, V709, P117, DOI 10.1007/s10750-012-1441-1; Shirai Akihisa, 2010, Venus (Tokyo), V68, P151; Dillon RT, 2009, J N AM BENTHOL SOC, V28, P1, DOI 10.1899/08-034.1; Strong EE, 2008, HYDROBIOLOGIA, V595, P149, DOI 10.1007/s10750-007-9012-6; Nixon KC, 1999, CLADISTICS, V15, P407, DOI 10.1006/clad.1999.0121; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Glaubrecht M, 2004, BIOL J LINN SOC, V82, P275, DOI 10.1111/j.1095-8312.2004.00361.x; Sengupta ME, 2009, MOL PHYLOGENET EVOL, V52, P797, DOI 10.1016/j.ympev.2009.05.007; Hornbach DJ, 2010, AM MIDL NAT, V164, P22; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Bronmark C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021773; Bronmark C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030467; Brown D.S., 1994, FRESHWATER SNAILS AF; Folmer O., 1994, Molecular Marine Biology and Biotechnology, V3, P294; FRANKE H., 2007, WORLD C MAL ANTW BEL; Graf Daniel L., 1998, American Conchologist, V26, P20; HABE T., 1990, HITACHIOBI, V54, P3; JOBB G., 2008, TREEFINDER VERSION O; KIHIRA H., 2004, ILLUSTRATED BOOK JAP; Kim Woo-Jin, 2010, Korean Journal of Malacology, V26, P275; Koehler Frank, 2010, Zoosystematics and Evolution, V86, P301, DOI 10.1002/zoos.201000013; KUROZUMI T., 1996, RES REPORT ANIMALS P, P623; KUROZUMI T., 2001, BERDER, V15, P30; MATSUOKA K., 1985, T P PALAEONTOLOGICAL, V139, P180; MATSUOKA K, 1987, Journal of Earth Sciences Nagoya University, V35, P23; MIN D. H., 2004, MOLLUSKS KOREA; ORTMANN A. E., 1920, P AM PHILOS SOC, V59, P268; Palumbi S., 1991, SIMPLE FOOLS GUIDE P; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Sokolov P. E., 2000, J MOLLUS STUD, V66, P573, DOI 10.1093/mollus/66.4.573; TANABE A. S., 2012, PHYLOGEARS VERSION 2; YAMAGUCHI PREFECTURE, 2003, RED DAT BOOK YAM	47	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0260-1230	1464-3766		J MOLLUS STUD	J. Molluscan Stud.	NOV	2015	81		4				435	441		10.1093/mollus/eyv019		7	Marine & Freshwater Biology; Zoology	Marine & Freshwater Biology; Zoology	CU4RR	WOS:000363518100002		
J	Kitaguchi, N; Hasegawa, M; Ito, S; Kawaguchi, K; Hiki, Y; Nakai, S; Suzuki, N; Shimano, Y; Ishida, O; Kushimoto, H; Kato, M; Koide, S; Kanayama, K; Kato, T; Ito, K; Takahashi, H; Mutoh, T; Sugiyama, S; Yuzawa, Y				Kitaguchi, Nobuya; Hasegawa, Midori; Ito, Shinji; Kawaguchi, Kazunori; Hiki, Yoshiyuki; Nakai, Sigeru; Suzuki, Nobuo; Shimano, Yasunobu; Ishida, Osamu; Kushimoto, Hiroko; Kato, Masao; Koide, Sigehisa; Kanayama, Kyoko; Kato, Takashi; Ito, Kengo; Takahashi, Hiroshi; Mutoh, Tatsuro; Sugiyama, Satoshi; Yuzawa, Yukio			A prospective study on blood A beta levels and the cognitive function of patients with hemodialysis: a potential therapeutic strategy for Alzheimer's disease	JOURNAL OF NEURAL TRANSMISSION			English	Article						Alzheimer's disease; Amyloid-beta (A beta); Blood purification; Prospective study; Hemodialysis; Cognitive function	AMYLOID-BETA; CEREBROSPINAL-FLUID; PLASMA; CLEARANCE; MOUSE; DEPOSITION; OLIGOMERS; PEPTIDE; DECLINE; PROTEIN	To obtain the proof of concept of a novel therapy for Alzheimer's disease (AD), we conducted two prospective studies with hemodialysis patients who had amyloid beta protein (A beta) removed from their blood three times a week. One major pathological change in the brain associated with AD is A beta deposition, mainly 40 amino acids A beta(1-40) and 42 amino acids A beta(1-42). Impaired A beta clearance is proposed to be one cause of increased A beta in the AD brain. Thus, we hypothesized that an extracorporeal removal system of A beta from the blood may remove brain A beta and be a useful therapeutic strategy for AD. In the first prospective study, plasma A beta levels and the cognitive function of 30 hemodialysis patients (65-76 years old) were evaluated at baseline as well as 18 or 36 months after. Although plasma A beta(1-40) levels either decreased or remained unchanged, levels of A beta(1-42) either remained unchanged or increased at the second time point. Mini-Mental State Examination scores of most subjects increased or were maintained at the second time point. A beta(1-40) influx into the blood correlated with MMSE at the second time point. In the second prospective study, five patients (51-84 years old) with renal failure were evaluated before and after the initiation of hemodialysis. Plasma A beta levels decreased, while cognitive function improved after initiating blood A beta removal. Therefore, long-term hemodialysis, which effectively removes blood A beta, might alter A beta influx and help maintain cognitive function.	[Kitaguchi, Nobuya; Kawaguchi, Kazunori; Hiki, Yoshiyuki; Nakai, Sigeru] Fujita Hlth Univ, Sch Hlth Sci, Fac Clin Engn, Toyoake, Aichi 4701192, Japan; [Hasegawa, Midori; Kato, Masao; Koide, Sigehisa; Kanayama, Kyoko; Yuzawa, Yukio] Fujita Hlth Univ, Sch Med, Dept Nephrol, Toyoake, Aichi 4701192, Japan; [Ito, Shinji; Mutoh, Tatsuro] Fujita Hlth Univ, Sch Med, Dept Neurol, Toyoake, Aichi 4701192, Japan; [Suzuki, Nobuo] Chiryu Clin, Chiryu, Aichi, Japan; [Shimano, Yasunobu] Gojohgawa Rehabil Hosp, Kiyosu, Aichi, Japan; [Ishida, Osamu] Kawana Hosp, Nagoya, Aichi, Japan; [Kushimoto, Hiroko] Nishichita Gen Hosp, Chita City Hosp, Chita, Aichi, Japan; [Kato, Takashi; Ito, Kengo] Natl Ctr Geriatr & Gerontol, Obu, Japan; [Takahashi, Hiroshi] Fujita Hlth Univ, Div Med Stat, Toyoake, Aichi 4701192, Japan; [Sugiyama, Satoshi] Kanayama Clin, Nagoya, Aichi, Japan	Kitaguchi, N (reprint author), Fujita Hlth Univ, Sch Hlth Sci, Fac Clin Engn, 1-98 Kutsukake Cho, Toyoake, Aichi 4701192, Japan.	nkitaguc@fujita-hu.ac.jp			KAKENHI [20509008, 23500531, 26282126]; Smoking Research Foundation; Suzuken Memorial Foundation	The authors sincerely thank Ms. Miwa Sakata for her technical assistance and Ms. Michiyo Hata for discussion regarding the cognitive function of Group B. This work was partly supported by KAKENHI (20509008, 23500531 and 26282126), Smoking Research Foundation, and Suzuken Memorial Foundation.	Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Hung LW, 2008, J NEUROSCI, V28, P11950, DOI 10.1523/JNEUROSCI.3916-08.2008; Schoonenboom NS, 2005, ANN NEUROL, V58, P139, DOI 10.1002/ana.20508; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Kawaguchi K, 2010, J ARTIF ORGANS, V13, P31, DOI 10.1007/s10047-010-0482-3; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P98, DOI 10.1097/NEN.0b013e3181c8ad2f; Yaffe K, 2010, J AM GERIATR SOC, V58, P338, DOI 10.1111/j.1532-5415.2009.02670.x; Donahue JE, 2006, ACTA NEUROPATHOL, V112, P405, DOI 10.1007/s00401-006-0115-3; Matsuoka Y, 2003, J NEUROSCI, V23, P29; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Lopez OL, 2008, NEUROLOGY, V70, P1664, DOI 10.1212/01.wnl.0000306696.82017.66; Wiltfang J, 2002, J NEUROCHEM, V81, P481, DOI 10.1046/j.1471-4159.2002.00818.x; Kitaguchi N, 2011, BLOOD PURIFICAT, V32, P57, DOI 10.1159/000322624; Kaneko N, 2014, P JPN ACAD B-PHYS, V90, P353, DOI 10.2183/pjab.90.353; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Bell RD, 2007, J CEREBR BLOOD F MET, V27, P909, DOI 10.1038/sj.jcbfm.9600419; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Kato M, 2012, J NEURAL TRANSM, V119, P1533, DOI 10.1007/s00702-012-0844-5; Boada M, 2009, DRUG NEWS PERSPECT, V22, P325, DOI 10.1358/dnp.2009.22.6.1395256; Rembach A, 2014, J ALZHEIMERS DIS, V40, P95, DOI 10.3233/JAD-131802; Hellstrom-Lindahl E, 2004, NEUROBIOL DIS, V15, P351, DOI 10.1016/j.nbd.2003.11.024; Koumi H, 2010, B FAC SOC WELFARE HA, V18, P91; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Megson GM, 1996, J CLIN MICROBIOL, V34, P218; Morris AWJ, 2014, FRONT AGING NEUROSCI, V6, P1	27	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	NOV	2015	122	11					1593	1607		10.1007/s00702-015-1431-3		15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU1IL	WOS:000363274200011		
J	Jitoku, D; Yamamoto, N; Iwayama, Y; Toyota, T; Miyagi, M; Enokida, T; Tasaka, Y; Umino, M; Umino, A; Uezato, A; Iwata, Y; Suzuki, K; Kikuchi, M; Hashimoto, T; Kanahara, N; Kurumaji, A; Yoshikawa, T; Nishikawa, T				Jitoku, Daisuke; Yamamoto, Naoki; Iwayama, Yoshimi; Toyota, Tomoko; Miyagi, Momo; Enokida, Takeshi; Tasaka, Yuri; Umino, Masakazu; Umino, Asami; Uezato, Akihito; Iwata, Yasuhide; Suzuki, Katsuaki; Kikuchi, Mitsuru; Hashimoto, Tasuku; Kanahara, Nobuhisa; Kurumaji, Akeo; Yoshikawa, Takeo; Nishikawa, Toru			Association study of H2AFZ with schizophrenia in a Japanese case-control sample (vol 122, pg 915, 2015)	JOURNAL OF NEURAL TRANSMISSION			English	Correction									[Jitoku, Daisuke; Yamamoto, Naoki; Miyagi, Momo; Enokida, Takeshi; Tasaka, Yuri; Umino, Masakazu; Umino, Asami; Uezato, Akihito; Kurumaji, Akeo; Yoshikawa, Takeo; Nishikawa, Toru] Tokyo Med & Dent Univ, Grad Sch, Dept Psychiat & Behav Sci, Tokyo 1130034, Japan; [Iwayama, Yoshimi; Toyota, Tomoko; Yoshikawa, Takeo] RIKEN, Brain Sci Inst, Lab Mol Psychiat, Wako, Saitama, Japan; [Iwata, Yasuhide; Suzuki, Katsuaki] Hamamatsu Univ Sch Med, Dept Psychiat & Neurol, Shizuoka, Japan; [Kikuchi, Mitsuru] Kanazawa Univ, Grad Sch Med, Dept Psychiat & Neurobiol, Kanazawa, Ishikawa, Japan; [Hashimoto, Tasuku; Kanahara, Nobuhisa] Chiba Univ, Dept Psychiat, Grad Sch Med, Chiba, Japan	Nishikawa, T (reprint author), Tokyo Med & Dent Univ, Grad Sch, Dept Psychiat & Behav Sci, Tokyo 1130034, Japan.	tnis.psyc@tmd.ac.jp					Jitoku D, 2015, J NEURAL TRANSM, V122, P915, DOI 10.1007/s00702-014-1332-x	1	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	NOV	2015	122	11					1619	1620		10.1007/s00702-015-1429-x		2	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CU1IL	WOS:000363274200013		
J	He, DH; Chen, H; Muramatsu, H; Lasek, AW				He, Donghong; Chen, Hu; Muramatsu, Hisako; Lasek, Amy W.			Ethanol activates midkine and anaplastic lymphoma kinase signaling in neuroblastoma cells and in the brain	JOURNAL OF NEUROCHEMISTRY			English	Article						addiction; alcohol; ALK; ERK; midkine; STAT3	RECEPTOR TYROSINE KINASE; HUMAN PREFRONTAL CORTEX; GROWTH-FACTOR MIDKINE; ADULT C57BL/6J MICE; NUCLEUS-ACCUMBENS; ALCOHOL-DRINKING; PROTEIN-KINASE; NEURONAL DIFFERENTIATION; ERK-PHOSPHORYLATION; NEURITE OUTGROWTH	Alcohol engages signaling pathways in the brain. Midkine (MDK) is a neurotrophic factor that is over-expressed in the prefrontal cortex of alcoholics. MDK and one of its receptors, anaplastic lymphoma kinase (ALK), also regulate behavioral responses to ethanol in mice. The goal of this study was to determine whether MDK and ALK expression and signaling are activated by ethanol. We found that ethanol treatment of neuroblastoma cells increased MDK and ALK expression. We also assessed activation of ALK by ethanol in cells and found that ALK and ALK-dependent extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) phosphorylation increased rapidly with ethanol exposure. Similarly, treatment of cells with recombinant MDK protein increased ALK, ERK and STAT3 phosphorylation, suggesting that ethanol may utilize MDK to activate ALK signaling. In support of this, transfection of cells with MDK siRNAs attenuated ALK signaling in response to ethanol. Ethanol also activates ERK signaling in the brain. We found that inhibition of ALK or knockout of MDK attenuated ethanol-induced ERK phosphorylation in mouse amygdala. These results demonstrate that ethanol engages MDK and ALK signaling, which has important consequences for alcohol-induced neurotoxicity and the regulation of behaviors related to alcohol abuse.	[He, Donghong; Chen, Hu; Lasek, Amy W.] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA; [Muramatsu, Hisako] Aichi Gakuin Univ, Fac Psychol & Phys Sci, Nisshin, Aichi, Japan	Lasek, AW (reprint author), Univ Illinois, Dept Psychiat, 1601 West Taylor St,M-C 912, Chicago, IL 60612 USA.	alasek@psych.uic.edu			National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism [AA020912, AA016654]	This study was supported by the National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism (AA020912 and AA016654). We thank Roberta Franks of the UIC Transgenic Production Service for assistance in re-deriving the MDK<SUP>KO</SUP> mice from frozen embryos. The authors declare no conflicts of interest.	Agoglia AE, 2015, ALCOHOL CLIN EXP RES, V39, P463, DOI 10.1111/acer.12645; Miyashiro M, 1998, CURR EYE RES, V17, P9, DOI 10.1076/ceyr.17.1.9.5257; Mochizuki R, 1998, EXP NEUROL, V149, P73, DOI 10.1006/exnr.1997.6687; MICHIKAWA M, 1993, J NEUROSCI RES, V35, P530, DOI 10.1002/jnr.490350509; MARUTA H, 1993, GROWTH FACTORS, V8, P119, DOI 10.3109/08977199309046932; Nakamura E, 1998, GENES CELLS, V3, P811, DOI 10.1046/j.1365-2443.1998.00231.x; Ezquerra L, 2007, EUR J PHARMACOL, V557, P147, DOI 10.1016/j.ejphar.2006.11.024; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Owada K, 1999, J NEUROCHEM, V73, P2084; Kuo AH, 2007, ONCOGENE, V26, P859, DOI 10.1038/sj.onc.1209840; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; Sanna PP, 2002, BRAIN RES, V948, P186, DOI 10.1016/S0006-8993(02)03191-8; Mazot P, 2011, ONCOGENE, V30, P2017, DOI 10.1038/onc.2010.595; Lorente M, 2011, CELL DEATH DIFFER, V18, P959, DOI 10.1038/cdd.2010.170; Neasta J, 2011, BIOL PSYCHIAT, V70, P575, DOI 10.1016/j.biopsych.2011.03.019; Bachtell RK, 2002, J PHARMACOL EXP THER, V302, P516, DOI 10.1124/jpet.102.036046; Mulligan MK, 2011, ALCOHOL CLIN EXP RES, V35, P659, DOI 10.1111/j.1530-0277.2010.01384.x; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; Muramoto A, 2013, NEUROSCI LETT, V550, P150, DOI 10.1016/j.neulet.2013.06.025; Lasek AW, 2011, J NEUROSCI, V31, P14134, DOI 10.1523/JNEUROSCI.3415-11.2011; Mulligan MK, 2006, P NATL ACAD SCI USA, V103, P6368, DOI 10.1073/pnas.0510188103; Sattu K, 2013, FEBS J, V280, P5269, DOI 10.1111/febs.12453; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; Gramage E, 2011, NEUROSCIENCE, V190, P307, DOI 10.1016/j.neuroscience.2011.06.014; Flatscher-Bader T, 2008, ALCOHOL CLIN EXP RES, V32, P1849, DOI 10.1111/j.1530-0277.2008.00754.x; Spanos M, 2012, BEHAV BRAIN RES, V230, P158, DOI 10.1016/j.bbr.2012.02.010; Kadomatsu K, 2013, J BIOCHEM, V153, P511, DOI 10.1093/jb/mvt035; Peana AT, 2013, ALCOHOL CLIN EXP RES, V37, pE329, DOI 10.1111/j.1530-0277.2012.01877.x; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; Seiler AEM, 2001, J NEUROCHEM, V76, P573, DOI 10.1046/j.1471-4159.2001.00025.x; Thorsell A, 2013, J NEUROSCI, V33, P10132, DOI 10.1523/JNEUROSCI.4742-12.2013; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Zhao GF, 2012, MOL ENDOCRINOL, V26, P1304, DOI 10.1210/me.2012-1028; KIKUCHI S, 1993, NEUROSCI LETT, V160, P9, DOI 10.1016/0304-3940(93)90904-Y; Girault JA, 2007, CURR OPIN PHARMACOL, V7, P77, DOI 10.1016/j.coph.2006.08.012; Reiff T, 2011, DEVELOPMENT, V138, P4699, DOI 10.1242/dev.072157; Wada M, 2002, J NEUROL SCI, V200, P67, DOI 10.1016/S0022-510X(02)00134-X; Stylianou DC, 2009, ONCOGENE, V28, P3296, DOI 10.1038/onc.2009.184; Gouzi JY, 2005, J CELL SCI, V118, P5811, DOI 10.1242/jcs.02695; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Stacey D, 2012, P NATL ACAD SCI USA, V109, P21128, DOI 10.1073/pnas.1211844110; Weckbach LT, 2011, THESCIENTIFICWORLDJO, V11, P2491, DOI 10.1100/2011/517152; Jeanblanc J, 2013, EUR J NEUROSCI, V37, P607, DOI 10.1111/ejn.12067; Faccidomo S, 2009, PSYCHOPHARMACOLOGY, V204, P135, DOI 10.1007/s00213-008-1444-9; Flatscher-Bader T, 2005, J NEUROCHEM, V93, P359, DOI 10.1111/j.1471-4159.2005.03021.x; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Flatscher-Bader T, 2006, ALCOHOL CLIN EXP RES, V30, P908, DOI 10.1111/j.1530-0277.2006.00106.x; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Gao B, 2012, J GASTROEN HEPATOL, V27, P89, DOI 10.1111/j.1440-1746.2011.07003.x; Kalluri HSG, 2003, NEUROCHEM RES, V28, P765, DOI 10.1023/A:1022822119560; Perez-Pinera P, 2007, J BIOL CHEM, V282, P28683, DOI 10.1074/jbc.M704505200; YOSHIDA Y, 1995, DEV BRAIN RES, V85, P25, DOI 10.1016/0165-3806(94)00183-Z; Ibba F, 2009, ALCOHOL CLIN EXP RES, V33, P858, DOI 10.1111/j.1530-0277.2009.00907.x; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Garcia-Perez D, 2014, J NEUROIMMUNOL, V274, P244, DOI 10.1016/j.jneuroim.2014.07.017; Hao HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071093; Herradon G, 2014, BRIT J PHARMACOL, V171, P837, DOI 10.1111/bph.12312; Korecka JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063862; Lasek AW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022636; Muramatsu T, 2014, BRIT J PHARMACOL, V171, P814, DOI 10.1111/bph.12353; Owada K, 1999, J Med Dent Sci, V46, P45; Roberto M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012195; Vicente-Rodriguez M, 2014, BEHAV BRAIN RES, V274, P258, DOI 10.1016/j.bbr.2014.08.023; Zhu YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054930	65	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2015	135	3					508	521		10.1111/jnc.13252		14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CU1EE	WOS:000363261700007		
J	Iijima, K; Kurachi, M; Shibasaki, K; Naruse, M; Puentes, S; Imai, H; Yoshimoto, Y; Mikuni, M; Ishizaki, Y				Iijima, Keiya; Kurachi, Masashi; Shibasaki, Koji; Naruse, Masae; Puentes, Sandra; Imai, Hideaki; Yoshimoto, Yuhei; Mikuni, Masahiko; Ishizaki, Yasuki			Transplanted microvascular endothelial cells promote oligodendrocyte precursor cell survival in ischemic demyelinating lesions	JOURNAL OF NEUROCHEMISTRY			English	Article						cell survival; cerebral microvascular endothelial cells; cerebral small vessel disease; oligodendrocyte; precursor cell; remyelination	SMALL VESSEL DISEASE; ANGIOGENESIS; BRAIN; STROKE; INJURY; DAMAGE; THROMBOLYSIS; NEUROGENESIS; MYELINATION; MACROPHAGES	We previously showed that transplantation of brain microvascular endothelial cells (MVECs) greatly stimulated remyelination in the white matter infarct of the internal capsule (IC) induced by endothelin-1 injection and improved the behavioral outcome. In the present study, we examined the effect of MVEC transplantation on the infarct volume using intermittent magnetic resonance image and on the behavior of oligodendrocyte lineage cells histochemically. Our results invivo show that MVEC transplantation reduced the infarct volume in IC and apoptotic death of oligodendrocyte precursor cells (OPCs). These results indicate that MVECs have a survival effect on OPCs, and this effect might contribute to the recovery of the white matter infarct. The conditioned-medium from cultured MVECs reduced apoptosis of cultured OPCs, while the conditioned medium from cultured fibroblasts did not show such effect. These results suggest a possibility that transplanted MVECs increased the number of OPCs through the release of humoral factors that prevent their apoptotic death. Identification of such humoral factors may lead to the new therapeutic strategy against ischemic demyelinating diseases.	[Iijima, Keiya; Puentes, Sandra; Yoshimoto, Yuhei] Gunma Univ, Dept Neurosurg, Grad Sch Med, Maebashi, Gumma 3718511, Japan; [Kurachi, Masashi; Shibasaki, Koji; Naruse, Masae; Ishizaki, Yasuki] Gunma Univ, Dept Mol & Cellular Neurobiol, Grad Sch Med, Maebashi, Gumma 3718511, Japan; [Imai, Hideaki] Univ Tokyo, Dept Neurosurg, Grad Sch Med, Bunkyo Ku, Tokyo 113, Japan; [Mikuni, Masahiko] Gunma Univ, Dept Psychiat & Neurosci, Grad Sch Med, Maebashi, Gumma 3718511, Japan	Ishizaki, Y (reprint author), Gunma Univ, Dept Mol & Cellular Neurobiol, Grad Sch Med, 3-39-22 Showa Machi, Maebashi, Gumma 3718511, Japan.	yasukiishizaki@gunma-u.ac.jp			Japan Society for the Promotion of Science [25122704]	We thank Dr. H. Ono (Department of Neurosurgery, Tokyo University Graduate School of Medicine) for advice on surgical techniques, and Dr. N. Yamane (Department of Neurosurgery, Gunma University Graduate School of Medicine), Ms. Y. Arai (Department of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Gifu, Japan), and Ms. K. Abe (Department of Molecular and Cellular Neurobiology, Gunma University Graduate School of Medicine) for technical assistance. This work was partly supported by a Grant-in-Aid for Scientific Research (No. 25122704) from the Japan Society for the Promotion of Science to Y. Ishizaki. A part of this study is the result of 'Integrated Research on Neuropsychiatric Disorders' carried out under the Strategic Research program for Brain Sciences (SRPBS) by the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) and Japan Agency for Medical Research and Development (AMED). The authors declare no conflicts of interest.	BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Ishikawa H, 2013, STROKE, V44, P3473, DOI 10.1161/STROKEAHA.113.001943; Uemura M, 2012, CURR VASC PHARMACOL, V10, P285; Yuen TJ, 2014, CELL, V158, P383, DOI 10.1016/j.cell.2014.04.052; Schmid A, 2013, MOL IMAGING BIOL, V15, P155, DOI 10.1007/s11307-012-0577-8; Shin HY, 2008, J NEUROSCI RES, V86, P356, DOI 10.1002/jnr.21494; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Gadea A, 2009, J NEUROSCI, V29, P10047, DOI 10.1523/JNEUROSCI.0822-09.2009; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887; Puentes S, 2012, BRAIN RES, V1469, P43, DOI 10.1016/j.brainres.2012.06.042; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Khalilzada M, 2011, STROKE, V42, P2071, DOI 10.1161/STROKEAHA.110.611574; Wardlaw JM, 2013, LANCET NEUROL, V12, P822, DOI 10.1016/S1474-4422(13)70124-8; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; Ivanova A, 2003, J NEUROSCI RES, V73, P581, DOI 10.1002/jnr.10717; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Muramatsu R, 2012, NAT MED, V18, P1658, DOI 10.1038/nm.2943; Sun JQ, 2010, BIOCHEM BIOPH RES CO, V394, P146, DOI 10.1016/j.bbrc.2010.02.132; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Nitkunan A, 2008, STROKE, V39, P1999, DOI 10.1161/STROKEAHA.107.507475; Conijn MMA, 2011, STROKE, V42, P3105, DOI 10.1161/STROKEAHA.110.594853; Lecrux C, 2008, STROKE, V39, P448, DOI 10.1161/STROKEAHA.107.492934; Arbab AS, 2005, NMR BIOMED, V18, P553, DOI 10.1002/nbm.991; Arai K, 2009, J NEUROSCI, V29, P4351, DOI 10.1523/JNEUROSCI.0035-09.2009; Miron VE, 2011, BBA-MOL BASIS DIS, V1812, P184, DOI 10.1016/j.bbadis.2010.09.010; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Schonberg DL, 2007, J NEUROPATH EXP NEUR, V66, P1124, DOI 10.1097/nen.0b013e31815c2530; Shibasaki K, 2007, J NEUROSCI, V27, P1566, DOI 10.1523/JNEUROSCI.4284-06.2007; Rhodes KE, 2006, NEUROSCIENCE, V140, P87, DOI 10.1016/j.neuroscience.2006.01.055; Jones LL, 2002, J NEUROSCI, V22, P2792; Payne SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065710; Porambo M, 2015, GLIA, V63, P452, DOI 10.1002/glia.22764; Szabó C A, 1997, Neurobiology (Bp), V5, P1	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2015	135	3					539	550		10.1111/jnc.13262		12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CU1EE	WOS:000363261700009		
J	Nakada, T				Nakada, Tsutomu			The Molecular Mechanisms of Neural Flow Coupling: A New Concept	JOURNAL OF NEUROIMAGING			English	Article						neuro flow coupling; aquaporin 4; interstitial flow; protons; neural activation	CARBONIC-ANHYDRASE-IV; VIRCHOW-ROBIN SPACE; CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID; INTERSTITIAL FLUID; ENDOTHELIAL-CELLS; WATER INFLUX; BRAIN; AQUAPORIN-4; PH	The phenomenon known as neural flow coupling (NFC) occurs at the capillary level where there are no known pressure controlling structures. Recent developments in advanced magnetic resonance imaging technologies have made possible in vivo direct investigations of water physiology that have shed new insight on the water dynamics of the cortical pericapillary space and their complex functionality in relation to NFC. Neural activities initiate a chain of events that ultimately affect NFC. First, neural activities generate extracellular acidification. Extracellular acidosis in turn produces inhibition of aquaporin-4 (AQP-4) located at the end feet of pericapillary astrocytes, the water channel which regulates water influx into the pericapillary space and, hence, interstitial flow. Reduction of pericapillary water pressure results in a negative balance between pericapillary and intraluminal capillary pressure, allowing for capillary caliber expansion. Proton permeability through the tight junctions of the blood brain barrier is significantly high owing to the Grotthuss proton tunneling mechanism and, therefore, carbonic anhydrase (CA) type IV (CA-IV) anchored to the luminal surface of brain capillaries functions as scavenger of extracellular protons. CA-IV inhibition by acetazolamide or carbon dioxide results in the accumulation of extracellular protons, causing AQP-4 inhibition and a secondary increase in rCBF.	Niigata Univ, Brain Res Inst, Ctr Integrated Human Brain Sci, Niigata 9518585, Japan	Nakada, T (reprint author), Niigata Univ, Brain Res Inst, Ctr Integrated Human Brain Sci, 1-757 Asahimachi, Niigata 9518585, Japan.	tnakada@bri.niigata-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology (Japan)	The work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology (Japan).	Haj-Yasein NN, 2012, GLIA, V60, P867, DOI 10.1002/glia.22319; Igarashi H, 2014, NEUROREPORT, V25, P39, DOI 10.1097/WNR.0000000000000042; Parihar MS, 2010, J ALZHEIMERS DIS, V22, P741, DOI 10.3233/JAD-2010-101020; WELLER RO, 1992, BRAIN PATHOL, V2, P277, DOI 10.1111/j.1750-3639.1992.tb00704.x; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Talman WT, 2007, BRAIN RES, V1139, P126, DOI 10.1016/j.brainres.2007.01.008; ESIRI MM, 1990, J NEUROL SCI, V100, P3, DOI 10.1016/0022-510X(90)90004-7; Magnotta VA, 2012, P NATL ACAD SCI USA, V109, P8270, DOI 10.1073/pnas.1205902109; Dolman D, 2005, J NEUROCHEM, V93, P825, DOI 10.1111/j.1471-4159.2005.03111.x; Osol G, 2002, AM J PHYSIOL-HEART C, V283, pH2260, DOI 10.1152/ajpheart.00634.2002; VORSTRUP S, 1984, J CLIN INVEST, V74, P1634, DOI 10.1172/JCI111579; Tong CK, 2000, J NEUROSCI, V20, P8247; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831; Kitaura H, 2009, NEUROSCI RES, V64, P208, DOI 10.1016/j.neures.2009.03.002; CHESLER M, 1989, J NEUROSCI, V9, P2011; Johnston M, 2002, NEWS PHYSIOL SCI, V17, P227, DOI 10.1152/nips.01400.2002; GHANDOUR MS, 1992, P NATL ACAD SCI USA, V89, P6823, DOI 10.1073/pnas.89.15.6823; Angelow S, 2006, J PHYSIOL-LONDON, V571, P15, DOI 10.1113/jphysiol.2005.099135; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Huber VJ, 2012, MOL ASPECTS MED, V33, P691, DOI 10.1016/j.mam.2012.01.002; Weller RO, 1998, J NEUROPATH EXP NEUR, V57, P885, DOI 10.1097/00005072-199810000-00001; Alvarez BV, 2003, BIOCHEMISTRY-US, V42, P12321, DOI 10.1021/bi0353124; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; URBANICS R, 1978, PFLUG ARCH EUR J PHY, V378, P47, DOI 10.1007/BF00581957; Frick A, 2013, FEBS LETT, V587, P989, DOI 10.1016/j.febslet.2013.02.038; Weller RO, 2009, ACTA NEUROPATHOL, V117, P1, DOI 10.1007/s00401-008-0457-0; Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Igarashi H, 2013, NEUROREPORT, V24, P324, DOI 10.1097/WNR.0b013e32835fc827; Busija EW, 1984, REV PHYSL BIOCH PHAR, V101, P161; Faber T E, 1995, FLUID DYNAMICS PHYS; Fujiwara Y, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1823; Heistad DD, 1979, HDB PHYSL, VIII, P137; Igarashi H, 2014, NEUROL RES, V36, P1094, DOI 10.1179/1743132814Y.0000000434; Iliff JJ, 2012, SCI TRANSL MED, V15, P147, DOI DOI 10.1126/SCITRANSLMED.3003748; Li X, 2011, NEURODEGENERATION, V6, P79; Lulu X, 2013, SCIENCE, V342, P373, DOI [10.1126/science.1241224, DOI 10.1126/SCIENCE.1241224]; MELLANDER S, 1989, J HYPERTENS, V7, pS21; Nakada T, 2014, CROAT MED J, V55, P328, DOI 10.3325/cmj.2014.55.328; Nakada T, 2014, AM ACAD NEUROLOGY AN; Orekovi D, 2010, BRAIN RES REV, V64, P241; Robin C, 1859, J PHYSL HOMME ANIMAU, V2, P537; Silver IA, 2008, CIB FDN S 56 CER VAS; Virchow R., 1851, ARCH PATH ANAT, V3, P427	43	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1051-2284	1552-6569		J NEUROIMAGING	J. Neuroimaging	NOV-DEC	2015	25	6					861	865		10.1111/jon.12219		5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CU2DW	WOS:000363334100002		
J	Ueda, T; Ishida, E; Kojima, Y; Yoshikawa, S; Yonemoto, H				Ueda, Takeshi; Ishida, Eri; Kojima, Yusuke; Yoshikawa, Satoshi; Yonemoto, Hitoshi			Sonographic Optic Nerve Sheath Diameter: A Simple and Rapid Tool to Assess the Neurologic Prognosis After Cardiac Arrest	JOURNAL OF NEUROIMAGING			English	Article						Ultrasonography; optic nerve sheath diameter; hypoxic encephalopathy; cardiac arrest; prognosis	INTRACRANIAL HYPERTENSION; COMPUTED-TOMOGRAPHY; EARLY PREDICTOR; WHITE-MATTER; ULTRASOUND; FUNDAMENTALS; EXPANSION; PRESSURE; RATIO	BACKGROUND AND PURPOSEThe early prediction of hypoxic encephalopathy after cardiac arrest is challenging. Measurement of the optic nerve sheath diameter (ONSD) by using sonography is a straightforward, noninvasive technique to detect an increased intracranial pressure, which can even be conducted at the bedside. However, it remains unknown whether or not sonographic ONSD measurement is valuable as a prognostic indicator of hypoxic encephalopathy. METHODSSeventeen patients after cardiac arrest were retrospectively enrolled in this study. ONSD measurements 3mm behind the papilla were recorded. A Glasgow Outcome Scale score of 4 or above was considered to indicate a favorable prognosis. RESULTSThe mean ONSD associated with a favorable prognosis was 5.0 mm (4.4-6.1mm). The ONSD associated with a poor prognosis was 6.1 mm (5.4-7.2mm). ONSD less than or equal to 5.4 mm was an indicator of a favorable prognosis, with a sensitivity of 83%, specificity of 73%, positive likelihood ratio of 3.1, and negative likelihood ratio of .23. CONCLUSIONSSonographic ONSD measurement is a simple, rapid technique to assess the neurological prognosis after cardiac arrest.	[Ueda, Takeshi; Ishida, Eri; Kojima, Yusuke; Yoshikawa, Satoshi; Yonemoto, Hitoshi] Rakuwakai Marutamachi Hosp, Emergency & Gen Internal Med, Kyoto, Kyoto 6048401, Japan	Ueda, T (reprint author), Rakuwakai Marutamachi Hosp, Emergency & Gen Internal Med, Nakagyo Ku, 9-7 Jyurakumawari Matsushita Cho Marutamachi, Kyoto, Kyoto 6048401, Japan.	maruta-GIM_ER-ueda@live.jp					Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Choi SP, 2008, EMERG MED J, V25, P666, DOI 10.1136/emj.2007.053306; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; Seo H, 2013, TRANSPL P, V45, P2272, DOI 10.1016/j.transproceed.2012.12.032; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; Gentsch A, 2015, CLIN NEURORADIOL, V25, P49, DOI 10.1007/s00062-013-0281-3; Helmke K, 1996, PEDIATR RADIOL, V26, P706, DOI 10.1007/BF01383384; Bauerle J, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-187; Driessen C, 2012, PLAST RECONSTR SURG, V130, p448E, DOI 10.1097/PRS.0b013e31825dc1f1; Kim SH, 2011, SCAND J TRAUMA RESUS, V21, P57; Kim Young-Kug, 2013, Korean J Anesthesiol, V64, P451, DOI 10.4097/kjae.2013.64.5.451; Lochner Piergiorgio, 2014, J Ultrasound, V17, P225, DOI 10.1007/s40477-014-0069-6; Yamamura H, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-37	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1051-2284	1552-6569		J NEUROIMAGING	J. Neuroimaging	NOV-DEC	2015	25	6					927	930		10.1111/jon.12246		4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CU2DW	WOS:000363334100012		
J	Horie, N; Morofuji, Y; Morikawa, M; Tateishi, Y; Lzumo, T; Hayashi, K; Tsujino, A; Nagata, L				Horie, Nobutaka; Morofuji, Yoichi; Morikawa, Minoru; Tateishi, Yohei; Lzumo, Tsuyoshi; Hayashi, Kentaro; Tsujino, Akira; Nagata, Lzumi			Communication of inwardly projecting neovessels with the lumen contributes to symptomatic intraplaque hemorrhage in carotid artery stenosis	JOURNAL OF NEUROSURGERY			English	Article						carotid plaque; intraplaque hemorrhage; neovascularization; inflammation; vascular disorders	PLAQUE VULNERABILITY; VASA VASORUM; ATHEROSCLEROTIC PLAQUES; NEOVASCULARIZATION; ENHANCEMENT; INFLAMMATION; ANGIOGRAPHY; MECHANISMS; STROKE; CT	OBJECT Recent studies have demonstrated that plaque morphology can contribute to identification of patients at high risk of carotid artery atherosclerosis as well as the degree of stenosis in those with carotid atherosclerosis. Neovascularization of carotid plaques is associated with plaque vulnerability. However, the mechanism of neovascularization in intra-plaque hemorrhage (IPH) and its clinical contribution remain undetermined. In this study, the-authors aimed to clarify the characteristics of neovessel appearance with a focus on inwardly projecting neovessels, which are reportedly important in plaque advancement. METHODS Consecutive patients with moderate to severe carotid atherosclerosis who underwent carotid endarterectomy were prospectively analyzed from 2010 to 2014. The neovessel appearance was categorized into 3 groups based on intraoperative indocyanine green (ICG) videoangiography: early appearance of neovessels from the endothelium (NVe), late appearance of neovessels from the vase vasorum (NVv), and no appearance of vessels. Each neovessel pattern was evaluated with respect to clinical, radiological, and pathological findings including IPH, neovascularization, hemosiderin spots, and inflammation. RESULTS Of 57 patients, 13 exhibited NVe, 33 exhibited NVv, and 11 exhibited no neovessels. Overall, the interobserver and intraobserver reproducibilities of neovessel appearance were substantial for ICG videoangiography (kappa = 0.76) and at 7 days postoperatively (kappa = 0.76). There were no significant differences in baseline characteristics among The 3 groups, with the exception of a higher percentage of symptomatic presentations in patients with NVe (artery-to-artery embolic infarction in 61.5% and transient ischemic attack in 23.1%). Moreover, patients with NVe exhibited larger infarctions than did those with NVv (9675.0 +/- 5601.9 mm(3) vs 2306.6 +/- 856.9 mm(3), respectively; p = 0.04). Pathologically, patients with NVe had more severe IPH (47.2 +/- 8.3 mm(2) vs 19.8 +/- 5.2 mm(2), respectively; p < 0.01), hemosiderin spots (0.5 +/- 0.2 mm(2) vs 0.2 +/- 0.1 mm(2), respectively; p = 0.04), neovessels (0.4 +/- 0.7 mm(2) vs 0.1 +/- 0.4 mm(2), respectively; p = 0.11), and inflammation (1.0 +/- 1.1 mm(2) vs 0.6 +/- 0.9 mm(2), respectively; p = 0.26) around the endothelium than did patients with NVv, and all of these parameters were correlated with hyperintensity on time-of-flight MRI. However, the neovessel and inflammation differences were nonsignificant. Interestingly, inflammation was significantly correlated with neovessel formation (r = 0.43, p = 0.0008), hemosiderin spots (r = 0.62, p < 0.0001), and IPH (r = 0.349, p = 0.0097), suggesting that inflammation may be a key factor in plaque vulnerability. CONCLUSIONS Communication of inwardly projecting neovessels with the lumen and inflammation synergistically contribute to IPH and symptomatic presentations in patients with carotid stenosis and are more specific than the vase vasorum. This condition could be a new therapeutic target, and regression of lumina] neovessel sprouting and inflammation may help to prevent IPH development and a symptomatic presentation.	[Horie, Nobutaka; Morofuji, Yoichi; Lzumo, Tsuyoshi; Hayashi, Kentaro; Nagata, Lzumi] Nagasaki Univ, Sch Med, Dept Neurosurg, Nagasaki 8528501, Japan; [Morikawa, Minoru] Nagasaki Univ, Sch Med, Dept Radiol, Nagasaki 8528501, Japan; [Tateishi, Yohei; Tsujino, Akira] Nagasaki Univ, Sch Med, Dept Neurol & Strokol, Nagasaki 8528501, Japan	Horie, N (reprint author), Nagasaki Univ, Sch Med, Dept Neurosurg, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	nobstanford@gmail.com			Japan Society for the Promotion of Science [21591847]	This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science to Dr. Nagata (no. 21591847).	Staub D, 2010, STROKE, V41, P41, DOI 10.1161/STROKEAHA.109.560342; Finn AV, 2010, JACC-CARDIOVASC IMAG, V3, P41, DOI 10.1016/j.jcmg.2009.11.001; Cicha I, 2011, STROKE, V42, P3502, DOI 10.1161/STROKEAHA.111.627265; Michel JB, 2014, ATHEROSCLEROSIS, V234, P311, DOI 10.1016/j.atherosclerosis.2014.03.020; Millon A, 2012, STROKE, V43, P3023, DOI 10.1161/STROKEAHA.112.662692; Hone N, 2012, STROKE, V43, P393, DOI 10.1161/STROKEAHA.111.635953; Saba L, 2014, AM J NEURORADIOL, V35, P754, DOI 10.3174/ajnr.A3759; Chalela JA, 2009, CEREBROVASC DIS, V27, P19, DOI 10.1159/000200438; Doyle B, 2007, J AM COLL CARDIOL, V49, P2073, DOI 10.1016/j.jacc.2007.01.089; Kawahara I, 2007, SURG NEUROL, V68, P60, DOI 10.1016/j.surneu.2006.09.037; Truijman MTB, 2013, STROKE, V44, P3568, DOI 10.1161/STROKEAHA.113.003140; Yoshimura S, 2011, STROKE, V42, P3132, DOI 10.1161/STROKEAHA.111.615708; Marnane M, 2014, STROKE, V45, P801, DOI 10.1161/STROKEAHA.113.003657; KUMAMOTO M, 1995, HUM PATHOL, V26, P450, DOI 10.1016/0046-8177(95)90148-5; Sluimer JC, 2008, J AM COLL CARDIOL, V51, P1258, DOI 10.1016/j.jacc.2007.12.025; Hoogi A, 2011, AM J ROENTGENOL, V196, P431, DOI 10.2214/AJR.10.4522; Moreno PR, 2006, CIRCULATION, V113, P2245, DOI 10.1161/CIRCULATIONAHA.105.578955; Granada JF, 2008, NAT CLIN PRACT CARD, V5, pS18, DOI 10.1038/ncpcardio1157; Szabo K, 2007, INT J STROKE, V2, P97, DOI 10.1111/j.1747-4949.2007.00103.x; Kernan WN, 2014, STROKE, V45, P2160, DOI 10.1161/STR.0000000000000024; Kerwin WS, 2008, MAGN RESON MED, V59, P507, DOI 10.1002/mrm.21532; BARGER AC, 1984, NEW ENGL J MED, V310, P175, DOI 10.1056/NEJM198401193100307; European Carotid Surgery Trialists' Collaborative Group, 1998, LANCET, V351, P1379; Nakaoka T, 2008, NEUROL SURG TOKYO, V36, P991; Saba L, EUR RADIOL, V22, P2237; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445	26	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2015	123	5					1125	1132		10.3171/2014.12.JNS14237.1		8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QL	WOS:000363439800003		
J	Takanari, K; Araki, Y; Okamoto, S; Sato, H; Yagi, S; Toriyama, K; Yokoyama, K; Murotani, K; Matsui, S; Wakabayashi, T; Kamei, Y				Takanari, Keisuke; Araki, Yoshio; Okamoto, Sho; Sato, Hideyoshi; Yagi, Shunjiro; Toriyama, Kazuhiro; Yokoyama, Kinya; Murotani, Kenta; Matsui, Shigeyuki; Wakabayashi, Toshihiko; Kamei, Yuzuru			Operative wound-related complications after cranial revascularization surgeries	JOURNAL OF NEUROSURGERY			English	Article						cranial revascularization surgery; extracranial to intracranial bypass; infection; skin necrosis; superficial temporal artery-to-middle cerebral artery anastomosis; wound-related complication; vascular disorders	SUPERFICIAL TEMPORAL ARTERY; SCALP RECONSTRUCTION; MOYAMOYA-DISEASE; CEREBRAL REVASCULARIZATION; MICROSURGICAL ANATOMY; SURGICAL-MANAGEMENT; FLAP; CRANIOTOMY; CIRCULATION; INFECTION	OBJECT Intracranial revascularization surgeries are an effective treatment for moyamoya disease and other intracranial vascular obliterative diseases. However, in some cases, wound-related complications develop after surgery. Although the incidence of wound complication is supposed to be higher than that with a usual craniotomy, this complication has rarely been the focus of studies in the literature that report the outcomes of revascularization surgeries. Here, the relationship between intracranial revascularization surgeries and their complications is statistically assessed. METHODS Between October 2004 and February 2010, 71 patients were treated using cerebral revascularization surgeries on 98 sides of the head. The relationship between wound complications and operative technique was retrospectively assessed. Multivariate logistic regression analysis was performed to identify the risk factors of wound complication, including operative technique, age, sex, diabetes mellitus (DM), hypertension, hyperlipidemia, and smoking history. RESULTS In total, there were 21(21.4%) operative wound complications. Of these 21 complications, there were 14 (66.7%) minor complications and 7 (33.3%) major complications. No statistically significant relationship was found between wound complications and any surgical procedure. A trend toward severer complications was demonstrated for the procedures that used both STA branches ("double" procedures) in comparison with the procedures that used only 1 STA branch ("single" procedures, p = 0.016, Cochran-Armitage trend test). Multivariate logistic regression analysis also revealed that double procedures demonstrated a significantly higher incidence of wound complications than single procedures (OR 3.087, p = 0.048). DM was found to be a risk factor for wound complication (OR 9.42, p = 0.02), but age, sex, hypertension, and hyperlipidemia were not associated with the incidence of complications. Even though the blood supply to the scalp is abundant due to 5 arteriovenous systems, sometimes cutaneous necrosis develops after intracranial revascularization surgeries. The galeal blood supply is thought to be crucial for preventing wound-related complications. Special care is also thought to be required for DM patients. CONCLUSIONS Revascularization surgeries seemed to demonstrate a higher risk of wound-related complications. Double-type procedures, which use both branches of the STA, and a history of DM were found to be risk factors for wound-related complications. Attention should be paid to the design of the galeal incision and vessel harvest line. Also, special attention should be paid to patiehts with DM.	[Takanari, Keisuke; Sato, Hideyoshi; Yagi, Shunjiro; Toriyama, Kazuhiro] Nagoya Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Nagoya, Aichi 4648560, Japan; [Araki, Yoshio; Okamoto, Sho; Yokoyama, Kinya; Wakabayashi, Toshihiko; Kamei, Yuzuru] Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi 4648560, Japan; [Matsui, Shigeyuki] Nagoya Univ, Grad Sch Med, Dept Biostat, Nagoya, Aichi 4648560, Japan; [Murotani, Kenta] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan	Takanari, K (reprint author), Nagoya Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4648560, Japan.	takanari@med.nagoya-u.ac.jp					Newman MI, 2004, ANN PLAS SURG, V52, P501, DOI 10.1097/01.sap.0000123346.58418.e6; Iblher N, 2010, PLAST RECONSTR SURG, V126, P450, DOI 10.1097/PRS.0b013e3181e09515; Smith SF, 2005, J CLIN NEUROSCI, V12, P915, DOI 10.1016/j.jocn.2005.03.016; ABULHASSAN HS, 1986, PLAST RECONSTR SURG, V77, P17; STOCK AL, 1980, HEAD NECK SURG, V2, P466, DOI 10.1002/hed.2890020604; Houkin K, 1997, CLIN NEUROL NEUROSUR, V99, pS142; Pinar YA, 2006, SURG RADIOL ANAT, V28, P248, DOI 10.1007/s00276-006-0094-z; Asai S, 2004, ANN PLAS SURG, V52, P144, DOI 10.1097/01.sap.0000100898.68014.6f; Delgado-Lopez PD, 2009, NEUROCIRUGIA, V20, P124; Kleintjes WG, 2007, J PLAST RECONSTR AES, V60, P593, DOI 10.1016/j.bjps.2006.12.006; Kawashima M, 2005, J NEUROSURG, V102, P132, DOI 10.3171/jns.2005.102.1.0132; Kubo S, 2003, NEUROSURGERY, V52, P982, DOI 10.1227/01.NEU.0000053151.65510.8D; Mehrara BJ, 2006, J SURG ONCOL, V94, P504, DOI 10.1002/jso.20487; Patel HC, 2010, BRIT J NEUROSURG, V24, P179, DOI 10.3109/02688690903536603; Seery GE, 2002, DERMATOL SURG, V28, P581, DOI 10.1046/j.1524-4725.2002.12015.x; OISHI SN, 1995, CLIN PLAST SURG, V22, P51; Kwon H, 2008, J CRANIOFAC SURG, V19, P1075, DOI 10.1097/SCS.0b013e31817bd820; Aydin K, 2006, MINIM INVAS NEUROSUR, V49, P189, DOI 10.1055/s-2006-948300; Kawashima M, 2005, J NEUROSURG, V102, P116, DOI 10.3171/jns.2005.102.1.0116; Katsuta T, 2001, NEUROSURGERY, V49, P879, DOI 10.1097/00006123-200110000-00019; Beheiry EE, 2007, PLAST RECONSTR SURG, V119, P136, DOI 10.1097/01.prs.0000245068.04942.a8; Baaj AA, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.01.FOCUS08293; Dashti SR, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/6/E10; Leedy JE, 2005, PLAST RECONSTR SURG, V116, p54E, DOI 10.1097/01.prs.0000179188.25019.6c; Origitano TC, 2006, NEUROSURGERY S2, V58; Senyuva C, 1996, J CRANIOFAC SURG, V7, P317	26	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2015	123	5					1145	1150		10.3171/2014.12.JNS132602		6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QL	WOS:000363439800005		
J	Sadahiro, H; Nomura, S; Goto, H; Sugimoto, K; Inamura, A; Fujiyama, Y; Yamane, A; Oku, T; Shinoyama, M; Suzuki, M				Sadahiro, Hirokazu; Nomura, Sadahiro; Goto, Hisaharu; Sugimoto, Kazutaka; Inamura, Akinori; Fujiyama, Yuichi; Yamane, Akiko; Oku, Takayuki; Shinoyama, Mizuya; Suzuki, Michiyasu			Real-time ultrasound-guided endoscopic surgery for putaminal hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						intracerebral hemorrhage; ultrasound; endoscopic surgery; real-time; bur hole; surgical technique; vascular disorders	THALAMIC HEMORRHAGE; HEMATOMA EVACUATION	OBJECT Endoscopic surgery plays a significant role in the treatment of intracerebral hemorrhage. However, the residual hematoma cannot be measured intraoperatively from the endoscopic view, and it is difficult to determine the precise location of the endoscope within the hematoma cavity. The authors attempted to develop real-time ultrasound-guided endoscopic surgery using a bur-hole-type probe. METHODS From November 2012 to March 2014, patients with hypertensive putaminal hemorrhage who underwent endoscopic hematoma removal were enrolled in this study. Real-time ultrasound guidance was performed with a bur-hole-type probe that was advanced via a second bur hole, which was placed in the temporal region. Ultrasound was used to guide insertion of the endoscope sheath as well as to provide information regarding the location of the hematoma during surgical evacuation. Finally, the cavity was irrigated with artificial cerebrospinal fluid and was observed as a low-echoic space, which facilitated detection of residual hematoma. RESULTS Ten patients with putaminal hemorrhage > 30 cm(3), were included in this study. Their mean age (+/- SD) was 60.9 +/- 8.6 years, and the mean preoperative hematoma volume was 65.2 +/- 37.1 cm(3): The mean percentage of hematoma that was evacuated was 96% +/- 3%. None of the patients exhibited rebleeding after surgery. CONCLUSIONS This navigation method was effective in demonstrating both the real-time location of the endoscope and real-time viewing of the residual hematoma. Use of ultrasound guidance minimized the occurrence of brain injury due to hematoma evacuation.	[Sadahiro, Hirokazu; Nomura, Sadahiro; Goto, Hisaharu; Sugimoto, Kazutaka; Inamura, Akinori; Fujiyama, Yuichi; Yamane, Akiko; Oku, Takayuki; Shinoyama, Mizuya; Suzuki, Michiyasu] Yamanashi Univ, Sch Med, Dept Neurosurg & Clin Neurosci, Ube, Yamaguchi, Japan	Sadahiro, H (reprint author), Yamanashi Univ, Sch Med, Dept Neurosurg & Clin Neurosci, 1-1-1 Minami Kogushi, Ube, Yamaguchi, Japan.	sadapiro@yamaguchi-u.ac.jp					Chen CC, 2007, SURG NEUROL, V68, P438, DOI 10.1016/j.sumeu.2006.11.054; Kubben PL, 2011, LANCET ONCOL, V12, P1062, DOI 10.1016/S1470-2045(11)70130-9; Senft C, 2010, J SURG ONCOL, V101, P436, DOI 10.1002/jso.21508; Chen CC, 2005, J CLIN NEUROSCI, V12, P937, DOI 10.1016/j.jocn.2005.04.006; KWAK R, 1983, STROKE, V14, P493; Senft C, 2010, CLIN NEUROL NEUROSUR, V112, P237, DOI 10.1016/j.clineuro.2009.12.003; Chen CC, 2011, WORLD NEUROSURG, V75, P264, DOI 10.1016/j.wneu.2010.07.041; Nishihara T, 2005, NEUROCRIT CARE, V2, P67, DOI 10.1385/NCC:2:1:067; Hsieh PC, 2005, SURG NEUROL, V64, P147, DOI 10.1016/j.surneu.2004.11.028; Kuo LT, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS10313	10	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2015	123	5					1151	1155		10.3171/2014.11.JNS141508		5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QL	WOS:000363439800006		
J	Ito, H; Morino, M; Niimura, M; Takamizawa, S; Shimizu, Y				Ito, Hirotaka; Morino, Michiharu; Niimura, Manabu; Takamizawa, Sachiko; Shimizu, Yoshie			Posterior callosotomy using a parietooccipital interhemispheric approach in the semi-prone park-bench position	JOURNAL OF NEUROSURGERY			English	Article						posterior corpus callosotomy; surgical approach; epilepsy surgery; surgical technique	VAGUS NERVE-STIMULATION; CORPUS CALLOSOTOMY; GENERALIZED EPILEPSY; LENNOX-GASTAUT; SEIZURE; ANTERIOR; CHILDREN	A 2-stage corpus callosotomy is accepted as a palliative procedure for patients older than 16 years with, in particular, medically intractable generalized epilepsy and drop attack seizures and is preferable for a lower risk of disconnection syndrome. Although the methods by which a previously performed craniotomy can be reopened for posterior callosotomy have already been reported, posterior corpus callosotomy using a parietooccipital interhemispheric approach with the patient in a semi-prone park-bench position has not been described in the literature. Here, the authors present a surgical technique for posterior callosotomy using a parietooccipital interhemispheric approach with a semi-prone park-bench position as a second surgery. Although this procedure requires an additional skin incision in the parietooccipital region, it makes the 2-stage callosotomy safer and easier to perform because of reduced intracranial adhesion, less bleeding, and an easier approach to the splenium of the corpus callosum.	[Ito, Hirotaka; Morino, Michiharu; Niimura, Manabu; Takamizawa, Sachiko; Shimizu, Yoshie] Tokyo Metropolitan Neurol Hosp, Dept Neurosurg, Fuchu, Tokyo, Japan	Ito, H (reprint author), Tokyo Metropolitan Neurol Hosp, Dept Neurosurg, Musashidai 2-6-1, Fuchu, Tokyo, Japan.	xb9r715@hotmail.com					Chi JH, 2006, NEUROSURGERY, V59, P41, DOI 10.1227/01.NEU.0000219880.66309.85; WILSON DH, 1982, NEUROLOGY, V32, P687; NORDGREN RE, 1991, ARCH NEUROL-CHICAGO, V48, P364; Lancman G, 2013, SEIZURE-EUR J EPILEP, V22, P3, DOI 10.1016/j.seizure.2012.09.014; Kim DS, 2004, YONSEI MED J, V45, P233; Cukiert A, 2013, SEIZURE-EUR J EPILEP, V22, P396, DOI 10.1016/j.seizure.2013.02.009; SPENCER SS, 1993, EPILEPSIA, V34, P561, DOI 10.1111/j.1528-1157.1993.tb02596.x; Shim KW, 2008, J NEUROS-PEDIATR, V2, P29, DOI [10.3171/PED/2008/2/7/029, 10.3171/PED/2008/22/7/029]; FUIKS KS, 1991, J NEUROSURG, V74, P573, DOI 10.3171/jns.1991.74.4.0573; Jalilian L, 2010, J NEUROSURG-PEDIATR, V6, P257, DOI 10.3171/2010.5.PEDS1029; REUTENS DC, 1993, EPILEPSIA, V34, P904, DOI 10.1111/j.1528-1157.1993.tb02110.x; CENDES F, 1993, EPILEPSIA, V34, P910, DOI 10.1111/j.1528-1157.1993.tb02111.x; Rosenfeld WE, 2009, EPILEPSIA, V50, P25, DOI 10.1111/j.1528-1167.2009.02232.x; Roberts D W, 1993, Neurosurg Clin N Am, V4, P293; Yaşargil M Gazi, 2005, Neurosurg Focus, V18, pE1	15	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2015	123	5					1322	1325		10.3171/2014.12.JNS141732		4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QL	WOS:000363439800031		
J	Morishita, T; Tsuboi, Y; Higuchi, M; Inoue, T				Morishita, Takashi; Tsuboi, Yoshio; Higuchi, Masa-aki; Inoue, Tooru			Is one large target better than two?	JOURNAL OF NEUROSURGERY			English	Letter							DEEP BRAIN-STIMULATION; TREMOR		[Morishita, Takashi; Tsuboi, Yoshio; Higuchi, Masa-aki; Inoue, Tooru] Fukuoka Univ, Fac Med, Fukuoka 81401, Japan	Morishita, T (reprint author), Fukuoka Univ, Fac Med, Fukuoka 81401, Japan.						Yamamoto T, 2001, J NEUROSURG, V95, P1075, DOI 10.3171/jns.2001.95.6.1075; HIRAI T, 1983, BRAIN, V106, P1001, DOI 10.1093/brain/106.4.1001; Kilbane C, 2015, J NEUROSURG, V122, P1306, DOI 10.3171/2015.2.JNS141098; Morishita T, 2010, STEREOT FUNCT NEUROS, V88, P98, DOI 10.1159/000289354; Foote KD, 2006, NEUROSURGERY, V58, P280, DOI 10.1227/01.NEU.0000192692.95455.FD	5	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2015	123	5					1349	1349		10.3171/2015.4.JNS15850		1	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QL	WOS:000363439800038		
J	Kimiwada, T; Hayashi, T; Narisawa, A; Shirane, R; Tominaga, T				Kimiwada, Tomomi; Hayashi, Toshiaki; Narisawa, Ayumi; Shirane, Reizo; Tominaga, Teiji			Shunt placement after cyst fenestration for middle cranial fossa arachnoid cysts in children	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						middle fosse arachnoid cyst; shunt placement; fenestration; macrocephaly; congenital	CLINICAL ARTICLE; POSTOPERATIVE IMPROVEMENT; CYSTOPERITONEAL SHUNT; INFANTS	OBJECT Some pediatric patients with middle cranial fossa arachnoid cysts present with symptoms of increased intracranial pressure (ICP) and require shunt placement after a cyst fenestration. However, factors concerning increased ICP after fenestration followed by shunt placement have not been elucidated. This study evaluated factors that are associated with shunt placement following cyst fenestration in pediatric patients with middle cranial fossa arachnoid cysts. METHODS Twenty-six pediatric patients with middle cranial fossa arachnoid cysts who were surgically treated at a single institution between 2004 and 2013 were retrospectively identified. The surgical indications for middle cranial fossa arachnoid cysts were as follows: 1) arachnoid cysts associated with symptoms such as headache and abnormally enlarging head circumference; 2) progressively expanding arachnoid cysts; and 3) large arachnoid cysts such as Galassi Type III. A cyst fenestration was performed as a first-line treatment, and shunt placement was required if symptoms associated with increased ICP were found following fenestration. The risk factors evaluated included age; sex, presenting symptoms, the presence of head enlargement, progressive cyst expansion, and subdural hematoma/hygroma. RESULTS Four patients (15.4%) required shunt placement after cyst fenestration. Younger age, abnormal head enlargement, and progressive cyst expansion before fenestration were significantly associated with the need for shunt placement following fenestration. Arachnoid cysts decreased in size in 22 patients (84.6%) after fenestration and/or shunt placement. The presence of symptoms was not associated with postoperative cyst size in this study. CONCLUSIONS In this study, younger age, abnormal head enlargement, and progressive cyst expansion were risk factors for shunt placement after cyst fenestration in pediatric patients with middle cranial fossa arachnoid cysts. It is important to consider that cyst fenestration may not be effective because of a latent derangement of CSF circulation in patients with these risk factors.	[Kimiwada, Tomomi; Shirane, Reizo] Miyagi Childrens Hosp, Dept Neurosurg, Sendai, Miyagi 9893126, Japan; [Hayashi, Toshiaki; Narisawa, Ayumi] Sendai City Hosp, Dept Neurosurg, Sendai, Miyagi, Japan; [Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 980, Japan	Kimiwada, T (reprint author), Miyagi Childrens Hosp, Dept Neurosurg, Aoba Ku, 4-3-17 Ochiai, Sendai, Miyagi 9893126, Japan.	tomomi@nsg.med.tohoku.acjp					AICARDI J, 1975, J NEUROL NEUROSUR PS, V38, P57, DOI 10.1136/jnnp.38.1.57; WESTER K, 1995, J NEUROL NEUROSUR PS, V59, P293, DOI 10.1136/jnnp.59.3.293; Choi Jin-Kyung, 2015, Animal Systematics Evolution and Diversity, V31, P77, DOI 10.5635/ASED.2015.31.2.077; Zhang B, 2012, J NEUROSURG-PEDIATR, V10, P302, DOI 10.3171/2012.7.PEDS11540; Di Rocco C, 2003, SURG NEUROL, V60, P211, DOI 10.1016/S0090-3019(02)00064-8; Cress M, 2013, NEUROSURGERY, V72, P716, DOI 10.1227/NEU.0b013e318285b3a4; Lee JY, 2012, CHILD NERV SYST, V28, P1203, DOI 10.1007/s00381-012-1722-z; Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464; Levy ML, 2004, J NEUROSURG, V101, P25; Gangemi M, 2011, J NEUROSURG-PEDIATR, V8, P158, DOI 10.3171/2011.5.PEDS1152; PEYSER E, 1961, J NEUROSURG, V18, P551, DOI 10.3171/jns.1961.18.4.0551; Levy ML, 2003, NEUROSURGERY, V53, P1138, DOI 10.1227/01.NEU.0000089060.65702.03; RAFFEL C, 1988, NEUROSURGERY, V23, P338; El-Ghandour NMF, 2012, J NEUROSURG-PEDIATR, V9, P231, DOI 10.3171/2011.12.PEDS11298; Li CD, 2014, CHILD NERV SYST, V30, P471, DOI 10.1007/s00381-013-2248-8; Gjerde PB, 2013, J NEURODEV DISORD, V5, DOI 10.1186/1866-1955-5-21; Kaliaperumal C, 2013, WORLD NEUROSURG, V80; Silav G, 2015, CHILD NERV SYST, V31, P87, DOI 10.1007/s00381-014-2530-4	18	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2015	16	5					533	539		10.3171/2015.3.PEDS14573		7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CU3QK	WOS:000363439700011		
J	Naito, K; Yamagata, T; Arima, H; Abe, J; Tsuyuguchi, N; Ohata, K; Takami, T				Naito, Kentaro; Yamagata, Toru; Arima, Hironori; Abe, Junya; Tsuyuguchi, Naohiro; Ohata, Kenji; Takami, Toshihiro			Qualitative analysis of spinal intramedullary lesions using PET/CT	JOURNAL OF NEUROSURGERY-SPINE			English	Article						astrocytoma; cavernous malformation; ependymoma; positron emission tomography; spinal intramedullary tumor; technique	POSITRON-EMISSION-TOMOGRAPHY; RADIATION NECROSIS; STEREOTACTIC RADIOSURGERY; C-11-METHIONINE PET; C-11 METHIONINE; CORD METASTASES; BRAIN-TUMORS; LUNG-CANCER; F-18 FDG; DIFFERENTIATION	OBJECT Although the usefulness of PET for brain lesions has been established, few reports have examined the use of PET for spinal intramedullary lesions. This study investigated the diagnostic utility of PET/CT for spinal intramedullary lesions. METHODS L-[methyl-C-11]-methionine (MET)- or [F-18]-fluorodeoxyglucose (FDG) PET/CT was performed in 26 patients with spinal intramedullary lesions. The region of interest (ROI) within the spinal cord parenchyma was placed manually in the axial plane. Maximum pixel counts in the ROIs were normalized to the maximum standardized uptake value (SUVmax) using subject body weight. For FDG-PET the SUVmax was corrected for lean body mass (SULmax) to exclude any influence of the patient's body shape. Each SUV was analyzed based on histopathological results after surgery. The diagnostic validity of the SUV was further compared with the tumor proliferation index using the MIB-1 monoclonal antibody (MIB-1 index). RESULTS A total of 16 patients underwent both FOG-PET and MET-PET, and the remaining 10 patients underwent either FOG-PET or MET-PET. Pathological diagnoses included high-grade malignancy such as glioblastoma multiforme, anaplastic astrocytoma, or anaplastic ependymoma in 5 patients; low-grade malignancy such as hemangioblastoma, diffuse astrocytoma, or ependymoma in 12 patients; and nonneoplastic lesion including cavernous malformation in 9 patients. Both FOG and MET accumulated significantly in high-grade malignancy, and the SULmax and SUVmax correlated with the tumor proliferation index. Therapeutic response after chemotherapy or radiation in high-grade malignancy was well monitored. However, a significant difference in SULmax and SUVmax for FOG-PET and MET-PET was not evident between low-grade malignancy and nonneoplastic lesions. CONCLUSIONS Spinal PET/CT using FOG or MET for spinal intramedullary lesions appears useful and practical, particularly for tumors with high-grade malignancy. Differentiation of tumors with low-grade malignancy from nonneoplastic lesions may still prove difficult. Further technological refinement, including the selection of radiotracer or analysis evaluation methods, is needed.	[Naito, Kentaro; Abe, Junya; Tsuyuguchi, Naohiro; Ohata, Kenji; Takami, Toshihiro] Osaka City Univ, Grad Sch Med, Dept Neurosurg, Osaka 558, Japan; [Yamagata, Toru] Osaka City Gen Hosp, Dept Neurosurg, Osaka, Japan	Takami, T (reprint author), Osaka City Univ, Grad Sch Med, Dept Neurosurg, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	ttakami@med.osaka-cu.ac.jp					Jayasundera MV, 1997, EUR J CANCER, V33, P508, DOI 10.1016/S0959-8049(96)00408-X; DERLON JM, 1989, NEUROSURGERY, V25, P720; Wilmshurst JM, 2000, J CHILD NEUROL, V15, P465, DOI 10.1177/088307380001500708; Sasajima T, 1996, NEURORADIOLOGY, V38, P53; Gwak HS, 2006, MINIM INVAS NEUROSUR, V49, P127, DOI 10.1055/s-2006-932181; Ikeda H, 2013, ANN NUCL MED, V27, P772, DOI 10.1007/s12149-013-0747-z; Shimizu T, 2004, SURG NEUROL, V61, P77, DOI 10.1016/S0090-3019(03)00397-5; HIGANO S, 1990, J COMPUT ASSIST TOMO, V14, P297, DOI 10.1097/00004728-199003000-00027; Nakamoto Y, 2005, RADIOLOGY, V234, P879, DOI 10.1148/radiol.2343030301; Terakawa Y, 2008, J NUCL MED, V49, P694, DOI 10.2967/jnumed.107.048082; DICHIRO G, 1983, J COMPUT ASSIST TOMO, V7, P937; Ceyssens S, 2006, AM J NEURORADIOL, V27, P1432; Sugawara Y, 1999, RADIOLOGY, V213, P521; Kamoto Y, 1998, J COMPUT ASSIST TOMO, V22, P487, DOI 10.1097/00004728-199805000-00023; Meltzer CC, 1998, J NUCL MED, V39, P1207; Poggi MM, 2001, CLIN NUCL MED, V26, P837, DOI 10.1097/00003072-200110000-00006; McCarville MB, 2009, ACAD RADIOL, V16, P881, DOI 10.1016/j.acra.2009.01.022; Kato T, 2008, AM J NEURORADIOL, V29, P1867, DOI 10.3174/ajnr.A1242; Tsuyuguchi N, 2004, ANN NUCL MED, V18, P291, DOI 10.1007/BF02984466; Tsuyuguchi N, 2003, J NEUROSURG, V98, P1056, DOI 10.3171/jns.2003.98.5.1056; Komori T, 2001, CLIN NUCL MED, V26, P905, DOI 10.1097/00003072-200111000-00001; Nguyen NC, 2008, CLIN NUCL MED, V33, P356, DOI 10.1097/RLU.0b013e31816a784c; Do BH, 1976, SPINE PHILAPA 1976, V36, pE1395; Tomura N, 2013, AM J NEURORADIOL, V34, P1278, DOI 10.3174/ajnr.A3374; Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307	25	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	NOV	2015	23	5					613	619		10.3171/2015.2.SPINE141254		7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QJ	WOS:000363439600011		
J	Yamaguchi, S; Takeda, M; Takahashi, T; Yamahata, H; Mitsuhara, T; Niiro, T; Hanakita, J; Hida, K; Arita, K; Kurisu, K				Yamaguchi, Satoshi; Takeda, Masaaki; Takahashi, Toshiyuki; Yamahata, Hitoshi; Mitsuhara, Takafumi; Niiro, Tadaaki; Hanakita, Junya; Hida, Kazutoshi; Arita, Kazunori; Kurisu, Kaoru			Ginkgo leaf sign: a highly predictive imaging feature of spinal meningioma	JOURNAL OF NEUROSURGERY-SPINE			English	Article						spinal meningioma; magnetic resonance imaging; dentate ligament; oncology	SCHWANNOMAS; NEURINOMAS; TUMORS; MRI	OBJECT Spinal meningioma and schwannoma are the most common spinal intradural extramedullary tumors, and the differentiation of these 2 tumors by CT and MRI has been a matter of debate. The purpose of this article is to present a case series of spinal meningiomas showing unique imaging features: a combination of a fan-shaped spinal cord and a streak in the tumor. The authors termed the former imaging feature "ginkgo leaf sign" and evaluated its diagnostic value. METHODS The authors'present 7 cases of spinal meningioma having the ginkgo leaf sign. Thirty spinal extramedullary tumors arising lateral or ventrolateral to the spinal cord were studied to evaluate the diagnostic value of the ginkgo leaf sign for spinal meningiomas. Among 30 cases, 12 tumors were spinal meningiomas and 18 tumors from the control group were all schwannomas. RESULTS Seven of the 12 spinal meningiomas were positive for the ginkgo leaf sign. The sign was not present in the control group tumors. The overall ability to use the ginkgo leaf sign to detect meningioma indicated a sensitivity of 58%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 78%. CONCLUSIONS The ginkgo leaf sign is highly specific to spinal meningiomas arising lateral or ventrolateral to the spinal cord. In the present series, the ginkgo leaf sign was perfectly predictive for spinal meningioma.	[Yamaguchi, Satoshi; Takeda, Masaaki; Mitsuhara, Takafumi; Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Minami Ku, Hiroshima, Hiroshima 7348551, Japan; [Takahashi, Toshiyuki; Hanakita, Junya] Fujieda Heisei Mem Hosp, Fujieda, Shizuoka, Japan; [Yamahata, Hitoshi; Niiro, Tadaaki; Arita, Kazunori] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurosurg, Kagoshima 890, Japan; [Hida, Kazutoshi] Sapporo Azabu Neurosurg Hosp, Sapporo, Hokkaido, Japan	Yamaguchi, S (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Minami Ku, 1-2-3 Kasumi, Hiroshima, Hiroshima 7348551, Japan.	satoya@hiroshima-u.ac.jp					Tubbs RS, 2001, J NEUROSURG, V94, P271, DOI 10.3171/spi.2001.94.2.0271; Chamberlain MC, 2011, CURR NEUROL NEUROSCI, V11, P320, DOI 10.1007/s11910-011-0190-2; SCHROTH G, 1987, J NEUROSURG, V66, P695, DOI 10.3171/jns.1987.66.5.0695; Wein S, 2013, POSTGRAD MED J, V89, P457, DOI 10.1136/postgradmedj-2012-131503; Hu YF, 2009, ACTA OTO-LARYNGOL, V129, P161, DOI 10.1080/00016480802126553; Abul-Kasim K, 2008, NEURORADIOLOGY, V50, P301, DOI 10.1007/s00234-007-0345-7; MATSUMOTO S, 1993, CLIN IMAG, V17, P46, DOI 10.1016/0899-7071(93)90013-D; Liu WC, 2009, EUR RADIOL, V19, P2707, DOI 10.1007/s00330-009-1466-7; de Verdelhan O, 2005, J NEURORADIOLOGY, V32, P42, DOI 10.1016/S0150-9861(05)83021-4; Kulwin CG, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12177; Setzer Matthias, 2007, Neurosurg Focus, V23, pE14, DOI 10.3171/FOC-07/10/E14; Yamahata Hitoshi, 2013, Asian Spine J, V7, P339, DOI 10.4184/asj.2013.7.4.339	12	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	NOV	2015	23	5					642	646		10.3171/2015.3.SPINE1598		5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QJ	WOS:000363439600015		
J	Yokomichi, N; Morita, T; Nitto, A; Takahashi, N; Miyamoto, S; Nishie, H; Matsuoka, J; Sakurai, H; Ishihara, T; Mori, M; Tarumi, Y; Ogawa, A				Yokomichi, Naosuke; Morita, Tatsuya; Nitto, Akihiro; Takahashi, Naoko; Miyamoto, Shingo; Nishie, Hiroyuki; Matsuoka, Junji; Sakurai, Hiroki; Ishihara, Tatsuhiko; Mori, Masanori; Tarumi, Yoko; Ogawa, Asao			Validation of the Japanese Version of the Edmonton Symptom Assessment System-Revised	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Edmonton Symptom Assessment System; Edmonton Symptom Assessment System-revised; symptom assessment; validity; reliability; validation	RANDOMIZED CONTROLLED-TRIAL; EARLY PALLIATIVE CARE; ADVANCED CANCER; ASSESSMENT SCALE; EUROPEAN-ORGANIZATION; EORTC QLQ-C30; DOUBLE-BLIND; LUNG-CANCER; DISTRESS; ESAS	Context. The Edmonton Symptom Assessment System-revised (ESAS-r) is a brief and widely used symptom measurement tool. Objectives. To validate the Japanese version of the ESAS-r in Japanese patients with cancer. Methods. We assessed the internal consistency, test-retest reliability, concurrent validity, and known-group validity in 292 Japanese adult patients with cancer. They completed Japanese versions of the ESAS-r, M. D. Anderson Symptom Inventory, and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. Results. Cronbach's alpha coefficient of the Japanese version of the ESAS-r was 0.87. The intraclass correlation coefficient in the test-retest examination ranged from 0.82 to 0.91 for each symptom score and was 0.90 for the total score. Pearson correlation coefficients of each ESAS-r symptom score with corresponding M. D. Anderson Symptom Inventory and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 items ranged from 0.45 to 0.80. The total score of the ESAS-r was significantly higher in patients with an Eastern Cooperative Oncology Group performance status of 2-4 than in those with a performance status of 0 and 1 (P < 0.0001). Conclusion. The Japanese version of the ESAS-r is a reliable and valid tool for measuring symptoms in Japanese adult patients with cancer. (C) 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Yokomichi, Naosuke; Morita, Tatsuya] Seirei Mikatahara Gen Hosp, Seirei Hosp, Shizuoka, Japan; [Morita, Tatsuya] Seirei Mikatahara Gen Hosp, Dept Palliat & Support Care, Seirei Hosp, Shizuoka, Japan; [Morita, Tatsuya] Seirei Mikatahara Gen Hosp, Palliat Care Team, Seirei Hosp, Shizuoka, Japan; [Nitto, Akihiro; Ogawa, Asao] Natl Canc Ctr Hosp East, Psychooncol Div, Kashiwa, Chiba 2778577, Japan; [Takahashi, Naoko] Japanese Red Cross Med Ctr, Dept Palliat Care, Tokyo, Japan; [Miyamoto, Shingo] Japanese Red Cross Med Ctr, Dept Oncol, Tokyo, Japan; [Nishie, Hiroyuki] Okayama Univ Hosp, Dept Anesthesiol & Resuscitol, Okayama, Japan; [Matsuoka, Junji] Okayama Univ Hosp, Dept Palliat Care, Okayama, Japan; [Sakurai, Hiroki] St Lukes Int Hosp, Dept Palliat Care, Tokyo, Japan; [Ishihara, Tatsuhiko] Okayama Saiseikai Gen Hosp, Dept Palliat Care, Okayama, Japan; [Mori, Masanori] Seirei Hamamatsu Gen Hosp, Dept Palliat Med, Shizuoka, Japan; [Tarumi, Yoko] Univ Alberta, Dept Oncol, Div Palliat Care Med, Edmonton, AB, Canada	Ogawa, A (reprint author), Natl Canc Ctr Hosp East, Psychooncol Div, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.	asogawa@east.ncc.go.jp					AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Chang VT, 2000, CANCER, V88, P2164, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5; Watanabe S, 2009, SUPPORT CARE CANCER, V17, P675, DOI 10.1007/s00520-008-0522-1; Cleeland CS, 2000, CANCER, V89, P1634, DOI 10.1002/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V; Chinda M, 2011, J PAIN SYMPTOM MANAG, V42, P954, DOI 10.1016/j.jpainsymman.2011.02.020; Carlson LE, 2012, J CLIN ONCOL, V30, P1160, DOI 10.1200/JCO.2011.39.5509; Hui D, 2014, J CLIN ONCOL, V32, P1640, DOI 10.1200/JCO.2013.52.2508; Nekolaichuk C, 2008, PALLIATIVE MED, V22, P111, DOI 10.1177/0269216307087659; Bruera E, 2013, J CLIN ONCOL, V31, P111, DOI 10.1200/JCO.2012.44.6518; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Yennurajalingam S, 2013, J CLIN ONCOL, V31, P3076, DOI 10.1200/JCO.2012.44.4661; Kwon JH, 2013, J PAIN SYMPTOM MANAG, V46, P947, DOI 10.1016/j.jpainsymman.2013.01.012; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Moro C, 2006, SUPPORT CARE CANCER, V14, P30, DOI 10.1007/s00520-005-0834-3; Carlson LE, 2010, J CLIN ONCOL, V28, P4884, DOI 10.1200/JCO.2009.27.3698; Okuyama T, 2003, J PAIN SYMPTOM MANAG, V26, P1093, DOI 10.1016/j.jpainsymman.2003.05.003; Zimmermann C, 2014, LANCET, V383, P1721, DOI 10.1016/S0140-6736(13)62416-2; Watanabe SM, 2012, PSYCHO-ONCOLOGY, V21, P977, DOI 10.1002/pon.1996; Bjordal K, 2000, EUR J CANCER, V36, P1796, DOI 10.1016/S0959-8049(00)00186-6; Barbera L, 2012, J CLIN ONCOL, V30, P1095, DOI 10.1200/JCO.2011.37.3068; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Carvajal A, 2011, EUR J CANCER, V47, P1863, DOI 10.1016/j.ejca.2011.03.027; Pautex S, 2003, CRIT REV ONCOL HEMAT, V47, P281, DOI 10.1016/S1040-8428(03)00043-X; Kobayashi K, 1998, EUR J CANCER, V34, P810, DOI 10.1016/S0959-8049(97)00395-X; Garyali A, 2006, J PALLIAT MED, V9, P1059, DOI 10.1089/jpm.2006.9.1059; Carvajal A, 2013, J PAIN SYMPTOM MANAG, V45, P129, DOI 10.1016/j.jpainsymman.2012.01.014; Bruera E, 1991, J Palliat Care, V7, P6; Delgado-Guay MO, 2015, TXB PALLIATIVE MED S, P323; [Anonymous], 1975, J PSYCHIATR RES, DOI DOI 10.1016/0022-3956(75)90026-6; Watanabe Sharon, 2006, Int J Palliat Nurs, V12, P111; Watanabe SM, 2011, J PAIN SYMPTOM MANAG, V41, P456, DOI 10.1016/j.jpainsymman.2010.04.020; World Health Organization, 2002, NAT CANC CONTR PROGR	32	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	NOV	2015	50	5					718	723		10.1016/j.jpainsymman.2015.05.014		6	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	CU3NX	WOS:000363433200017		
J	Wakamoto, H; Sano, N; Yano, Y; Sakai, S; Kikuchi, T; Fukuda, M; Morimoto, T; Ishii, E				Wakamoto, Hiroyuki; Sano, Nozomi; Yano, Yoshiaki; Sakai, Shinya; Kikuchi, Takanori; Fukuda, Mitsumasa; Morimoto, Takehiko; Ishii, Eiichi			Clinical Usefulness of Serum Krebs von den Lungen-6 for Detecting Chronic Aspiration in Children with Severe Motor and Intellectual Disabilities	JOURNAL OF PEDIATRICS			English	Article							SILENT ASPIRATION; CEREBRAL-PALSY; KL-6; PNEUMONIA; RELIABILITY; INTERJUDGE; DISEASE	Objective To determine whether the serum level of Krebs von den Lungen-6 (KL-6), a circulating high-molecular weight glycoprotein and a diagnostic biomarker of interstitial lung diseases, is a clinically useful biomarker for detecting chronic aspiration in children with severe motor and intellectual disabilities (SMIDS). Study design Children with SMIDS undergoing videofluorography for assessment of dysphagia were prospectively evaluated. Based on the videofluorography results, the participants were classified into aspiration and non-aspiration groups. Age, sex, white blood cell count, and serum levels of C-reactive protein, lactate dehydrogenase, albumin, and KL-6were compared between the 2 groups. Binary logistic regression was performed to identify factors independently associated with the presence of aspiration. Results A total of 66 patients participated in this study, 37 who were classified as the aspiration group and 29 as the non-aspiration group. The serum KL-6 level in the aspiration group was significantly higher than that in the nonaspiration group (median, 344 U/mL vs 207 U/mL, P < .01). Logistic regression modeling showed that the number of prescribed antiepileptic drugs (OR, 1.978; 95% CI, 1.217, 3.214; P < .01) and serum KL-6 level (OR, 1.012; 95% CI, 1.005, 1.019; P < .01) were independent predictors of aspiration. Conclusions The study demonstrated that the KL-6 level is significantly higher in children with SMIDS who aspirate than in those who do not. KL-6 shows promise as a biomarker for chronic lung disease due to aspiration in these children.	[Wakamoto, Hiroyuki; Morimoto, Takehiko] Ehime Rehabil Ctr Children, Dept Pediat, Toon, Ehime 7910212, Japan; [Sano, Nozomi] Natl Hosp Org Minami Kyushu Hosp, Dept Pediat, Kagoshima, Japan; [Yano, Yoshiaki] Natl Hosp Org Ehime Med Ctr, Dept Pediat, Matsue, Shimane, Japan; [Sakai, Shinya] Natl Hosp Org Shikoku Med Ctr, Dept Radiol, Matsuyama, Ehime, Japan; [Kikuchi, Takanori] Ehime Prefectural Cent Hosp, Dept Radiol, Matsuyama, Ehime, Japan; [Fukuda, Mitsumasa; Ishii, Eiichi] Ehime Univ, Dept Pediat, Grad Sch Med, Matsuyama, Ehime 790, Japan	Wakamoto, H (reprint author), Ehime Rehabil Ctr Children, Dept Pediat, Tanokubo 2135, Toon, Ehime 7910212, Japan.	wakamoto-hiroyuki@pref.ehime.jp					Jahromi SR, 2011, SEIZURE-EUR J EPILEP, V20, P343, DOI 10.1016/j.seizure.2010.12.011; Mukhopadhyay S, 2007, AM J SURG PATHOL, V31, P752, DOI 10.1097/01.pas.0000213418.08009.f9; Lee JS, 2010, AM J MED, V123, P304, DOI 10.1016/j.amjmed.2009.07.033; Imai T, 2002, PEDIATR PULM, V33, P135, DOI 10.1002/ppul.10044; Epler GR, 2011, EXPERT REV RESP MED, V5, P353, DOI [10.1586/ers.11.19, 10.1586/ERS.11.19]; Wilcox F, 1996, J SPEECH HEAR RES, V39, P144; Komiya K, 2013, GERIATR GERONTOL INT, V13, P580, DOI 10.1111/j.1447-0594.2012.00940.x; Ramsey D, 2005, DYSPHAGIA, V20, P218, DOI 10.1007/s00455-005-0018-9; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214; KOBAYASHI J, 1995, CHEST, V108, P311, DOI 10.1378/chest.108.2.311; Barnes TW, 2006, MAYO CLIN PROC, V81, P172; Reilly S, 1996, J PEDIATR-US, V129, P877, DOI 10.1016/S0022-3476(96)70032-X; ARVEDSON J, 1994, INT J PEDIATR OTORHI, V28, P173, DOI 10.1016/0165-5876(94)90009-4; McCullough GH, 2001, DYSPHAGIA, V16, P110, DOI 10.1007/s004550010004; Marom EM, 1999, AM J ROENTGENOL, V172, P121; Ohnishi H, 2002, AM J RESP CRIT CARE, V165, P378; Ochi F, 2015, PEDIATR INT, V57, P439, DOI 10.1111/ped.12537; KOHNO N, 1989, CHEST, V96, P68, DOI 10.1378/chest.96.1.68; Ishikawa Nobuhisa, 2012, Respir Investig, V50, P3, DOI 10.1016/j.resinv.2012.02.001; Langmore Susan E, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P485, DOI 10.1097/00020840-200312000-00014; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Mirrett Penny L., 1994, Dysphagia, V9, P174, DOI 10.1007/BF00341262; Reyas AI, 1993, CHILD CARE HLTH DEV, V19, P109	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	NOV	2015	167	5					1136	1142		10.1016/j.jpeds.2015.08.030		7	Pediatrics	Pediatrics	CU5CW	WOS:000363550300035		
J	Uda, K; Hataya, H				Uda, Kazuhiro; Hataya, Hiroshi			Ulceration at Bacillus Calmette-Guerin Inoculation Site in a Patient with Kawasaki Disease	JOURNAL OF PEDIATRICS			English	Editorial Material									[Uda, Kazuhiro; Hataya, Hiroshi] Tokyo Metropolitan Childrens Med Ctr, Dept Gen Pediat, Fuchu, Tokyo, Japan	Uda, K (reprint author), Tokyo Metropolitan Childrens Med Ctr, Dept Gen Pediat, Fuchu, Tokyo, Japan.						Kuniyuki S, 1997, J AM ACAD DERMATOL, V37, P303, DOI 10.1016/S0190-9622(97)80376-3; Yamamoto S, 2007, JPN J INFECT DIS, V60, P331; Gyldenlove M, 2012, HUM VACC IMMUNOTHER, V8, P423, DOI 10.4161/hv.19067; Uehara R, 2010, PEDIATR INFECT DIS J, V29, P430, DOI 10.1097/INF.0b013e3181cacede	4	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	NOV	2015	167	5					1167	+		10.1016/j.jpeds.2015.08.018		2	Pediatrics	Pediatrics	CU5CW	WOS:000363550300048		
J	Hattori, Y; Sato, M; Otsuka, M				Hattori, Yusuke; Sato, Maiko; Otsuka, Makoto			Initial dissolution kinetics of cocrystal of carbamazepine with nicotinamide	JOURNAL OF PHARMACY AND PHARMACOLOGY			English	Article						carbamazepine; classical least squares regression; cocrystal; dissolution kinetics; nicotinamide	ORGANIC MEDICINALS; PHASE; CALORIMETRY; BEHAVIOR; SOLIDS; STATE	ObjectivesObjectives of this study are investigating the initial dissolution kinetics of the cocrystal of carbamazepine (CBZ) with nicotinamide (NIC) and understanding its initial dissolution process. MethodsCocrystal solids of CBZ with NIC were prepared by co-milling and solvent evaporation methods. The formation of cocrystal solid was verified via X-ray diffraction measurement. Dissolution tests of the solids were performed using an original flow cell and ultraviolet-visible spectroscopic detector. The spectra monitored in situ were analyzed to determine the dissolved compounds separately using the classical least squares regression method. The initial dissolution profiles were interpreted using simultaneous model of dissolution and phase changes. Key findingsIn the initial dissolution, CBZ in the cocrystal structure dissolved in water and it was suggested that CBZ reached a metastable intermediate state simultaneously with dissolution. The cocrystal solid prepared by solvent evaporation provided a higher rate constant of the phase change than that prepared by co-milling. Our results thus support the use of evaporation as the method of choice to produce ordered cocrystal structures. ConclusionWe suggest that CBZ forms dihydrate during the dissolution process; however, during the initial phase of dissolution, CBZ changes to a metastable intermediate phase.	[Hattori, Yusuke; Sato, Maiko; Otsuka, Makoto] Musashino Univ, Fac Pharm, Pharmaceut Sci Res Inst, Nishitokyo, Tokyo 2028585, Japan	Otsuka, M (reprint author), Musashino Univ, Fac Pharm, Pharmaceut Sci Res Inst, 1-1-20 Shin Machi, Nishitokyo, Tokyo 2028585, Japan.	motsuka@musashino-u.ac.jp					Basavoju S, 2006, CRYST GROWTH DES, V6, P2699, DOI 10.1021/cg060327x; KANENIWA N, 1984, YAKUGAKU ZASSHI, V104, P184; Porter WW, 2008, CRYST GROWTH DES, V8, P14, DOI 10.1021/cg701022e; Good DJ, 2009, CRYST GROWTH DES, V9, P2252, DOI 10.1021/cg801039j; JOHARI GP, 1990, J NON-CRYST SOLIDS, V116, P282, DOI 10.1016/0022-3093(90)90703-O; WEEBER AW, 1988, PHYSICA B, V153, P93, DOI 10.1016/0921-4526(88)90038-5; [Anonymous], 2007, PHARM RES, DOI DOI 10.1007/S11095-007-9394-1; Rager T, 2010, CRYST GROWTH DES, V10, P3237, DOI 10.1021/cg100361y; Nehm SJ, 2006, CRYST GROWTH DES, V6, P592, DOI 10.1021/cg0503346; Gupta MK, 2003, J PHARM SCI, V92, P536, DOI 10.1002/jps.10308; Otsuka M, 2000, COLLOID SURFACE B, V17, P145, DOI 10.1016/S0927-7765(99)00111-3; Jayasankar A, 2006, PHARM RES, V23, P2381, DOI 10.1007/s11095-006-9110-6; Maggio RM, 2013, J PHARMACEUT BIOMED, V72, P51, DOI 10.1016/j.jpba.2012.09.022; Fleischman SG, 2003, CRYST GROWTH DES, V3, P909, DOI 10.1021/cg034035x; NOGAMI H, 1969, CHEM PHARM BULL, V17, P499; Qiao N, 2013, EUR J PHARM BIOPHARM, V83, P415, DOI 10.1016/j.ejpb.2012.10.005; Jayasankar A, 2007, MOL PHARM, V4, P360, DOI 10.1021/mp0700099; Chieng N, 2009, CRYST GROWTH DES, V9, P2377, DOI 10.1021/cg801253f; Lefort R, 2004, INT J PHARMACEUT, V280, P209, DOI 10.1016/j.ijpharm.2004.05.012; Seefeldt K, 2007, J PHARM SCI-US, V96, P1147, DOI 10.1002/jps.20945; SEKIGUCH.K, 1965, CHEM PHARM BULL, V13, P405; Watanabe H, 1960, YAKUGAKU ZASSHI, V80, P119	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3573	2042-7158		J PHARM PHARMACOL	J. Pharm. Pharmacol.	NOV	2015	67	11					1512	1518		10.1111/jphp.12461		7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CU2BB	WOS:000363325100005		
J	Takeba, J; Takahashi, T; Watanabe, S; Imai, H; Kikuchi, S; Umakoshi, K; Matsumoto, H; Ohshita, M; Miura, H; Aibiki, M				Takeba, Jun; Takahashi, Toshiaki; Watanabe, Seiji; Imai, Hiroshi; Kikuchi, Satoshi; Umakoshi, Kensuke; Matsumoto, Hironori; Ohshita, Muneaki; Miura, Hiromasa; Aibiki, Mayuki			Short-term clinical results of arthroscopic osteochondral fixation for elbow osteochondritis dissecans in teenaged baseball players	JOURNAL OF SHOULDER AND ELBOW SURGERY			English	Article						Osteochondritis dissecans (OCD); elbow; arthroscopic surgery; osteochondral fixation; baseball	HUMERAL CAPITELLUM; FOLLOW-UP; AUTOGRAFT TRANSPLANTATION; SKELETALLY IMMATURE; FRAGMENT FIXATION; LESIONS; MOSAICPLASTY; DEBRIDEMENT; JOINT; CLASSIFICATION	Background: Reports regarding arthroscopic fixation of the osteochondral fragments for elbow osteochondritis dissecans (OCD) are few. This study assessed the clinical outcomes of arthroscopic fixation of unstable osteochondral fragments by using absorbable pins over a postoperative period of at least 1 year. Methods: The patients were 13 adolescent baseball players with a mean age of 14 years (range, 1216 years) who underwent OCD of primary lesions at International Cartilage Repair Society grades III and IV. The patients were evaluated by using validated outcome measures at a mean follow-up period of 24 months (range, 12-50 months). Results: The mean (standard deviation) score in the disability/symptom section of the Disabilities of the Arm, Shoulder, and Hand improved from 12.4 (6.0) before the surgery to 0.5 (1.2) after the surgery, and the sports section improved from 74.5 (25.4) to 1.4 (5.2). The mean (standard deviation) extension improved from -11 degrees (10.8) to -2 degrees (3.9; P < .001). The mean (SD) flexion improved from 129 degrees (11.6) to 137 degrees (5.6; P = .040). All patients were able to resume playing baseball, and 9 (69%) resumed playing at the same position as before their injuries. Conclusions: The clinical results of arthroscopic osteochondral fragment fixation in the teenaged baseball players with elbow OCD, albeit obtained over only a short period, were favorable. This arthroscopic treatment enables repair of lesions and is considered appropriate for unstable OCD during the adolescent growth spurt. (C) 2015 Journal of Shoulder and Elbow Surgery Board of Trustees.	[Takeba, Jun; Kikuchi, Satoshi; Umakoshi, Kensuke; Matsumoto, Hironori; Ohshita, Muneaki; Aibiki, Mayuki] Ehime Univ, Dept Emergency Med, Toon, Ehime, Japan; [Takahashi, Toshiaki; Watanabe, Seiji; Imai, Hiroshi; Miura, Hiromasa] Ehime Univ, Dept Orthoped Surg, Toon, Ehime, Japan	Takahashi, T (reprint author), Ehime Univ, Dept Orthoped Surg, Toon, Ehime, Japan.	takahast@m.ehime-u.ac.jp		Takahashi, Toshiaki/0000-0002-4450-0547			Ruchelsman DE, 2010, J AM ACAD ORTHOP SUR, V18, P557; van den Ende KIM, 2011, ARTHROSCOPY, V27, P122, DOI 10.1016/j.arthro.2010.08.008; Byram IR, 2013, AM J SPORT MED, V41, P2191, DOI 10.1177/0363546513482106; Miyake J, 2011, J HAND SURG-AM, V36A, P1333, DOI 10.1016/j.jhsa.2011.05.024; Tsuda E, 2005, ARTHROSCOPY, V21, P1270, DOI 10.1016/j.arthro.2005.06.006; Kim SJ, 2000, CLIN ORTHOP RELAT R, P140; Schoch B, 2010, ARTHROSCOPY, V26, P1469, DOI 10.1016/j.arthro.2010.03.008; Shi LL, 2012, J PEDIATR ORTHOPED, V32, P221, DOI 10.1097/BPO.0b013e31824afecf; Takahara M, 2007, J BONE JOINT SURG AM, V89A, P1205, DOI 10.2106/JBJS.F.00622; Lyman S, 2002, AM J SPORT MED, V30, P463; Yeoh KM, 2012, ARTHROSCOPY, V28, P272, DOI 10.1016/j.arthro.2011.10.007; Rahusen FTG, 2006, BRIT J SPORT MED, V40, P966, DOI 10.1136/bjsm.2006.030056; Baker CL, 2010, AM J SPORT MED, V38, P1917, DOI 10.1177/0363546509354969; Jones KJ, 2010, J PEDIATR ORTHOPED, V30, P8, DOI 10.1097/BPO.0b013e3181c3be83; Gudas R, 2005, ARTHROSCOPY, V21, P1066, DOI 10.1016/j.arthro.2005.06.018; Tis JE, 2012, J PEDIATR ORTHOPED, V32, P226, DOI 10.1097/BPO.0b013e31824afeb8; Takeda H, 2002, AM J SPORT MED, V30, P713; Janarv PM, 1997, J PEDIATR ORTHOPED, V17, P311, DOI 10.1097/00004694-199705000-00008; Uchida S, 2015, AM J SPORT MED, V43, P1057, DOI 10.1177/0363546515570871; Byrd JWT, 2002, AM J SPORT MED, V30, P474; Shimada K, 2005, CLIN ORTHOP RELAT R, P140, DOI 10.1097/01.blo.0000160025.14363.f9; Harada M, 2002, J SHOULDER ELB SURG, V11, P368, DOI 10.1067/mse.2002.123900; Krijnen MR, 2003, ARTHROSCOPY, V19, P210, DOI 10.1053/jars.2003.50052; Ruch DS, 1998, ARTHROSCOPY, V14, P797, DOI 10.1016/S0749-8063(98)70013-1; Matsuura T, 2008, AM J SPORT MED, V36, P868, DOI 10.1177/0363546507312168; Iwasaki N, 2010, J BONE JOINT SURG AM, V92A, P208, DOI 10.2106/JBJS.J.00214; Baumgarten TE, 1998, AM J SPORT MED, V26, P520; Yamamoto Y, 2006, AM J SPORT MED, V34, P714, DOI 10.1177/0363546505282620; Ansah P, 2007, J BONE JOINT SURG AM, V89A, P2188, DOI 10.2106/JBJS.F.00299; Brownlow HC, 2006, KNEE SURG SPORT TR A, V14, P198, DOI 10.1007/s00167-005-0623-z; Mihara K, 2010, J SHOULDER ELB SURG, V19, P31, DOI 10.1016/j.jse.2009.04.007; Davis JT, 2007, ARTHROSCOPY, V23, P723, DOI 10.1016/j.arthro.2007.01.029; Iwasaki N, 2006, AM J SPORT MED, V34, P1233, DOI 10.1177/0363546506286343; Iwasaki N, 2007, AM J SPORT MED, V35, P2096, DOI 10.1177/0363546507306465; Takeba J, 2010, KNEE SURG SPORT TR A, V18, P831, DOI 10.1007/s00167-009-0945-3; Mihara K, 2009, AM J SPORT MED, V37, P298, DOI 10.1177/0363546508324970; de Graaff Frank, 2011, Arthroscopy, V27, P986, DOI 10.1016/j.arthro.2011.01.002; Hennrikus William P, 2015, J Pediatr Orthop, V35, P467, DOI 10.1097/BPO.0000000000000308	38	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	1058-2746			J SHOULDER ELB SURG	J. Shoulder Elbow Surg.	NOV	2015	24	11					1749	1756		10.1016/j.jse.2015.07.009		8	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CU1FE	WOS:000363264600016		
J	Kijima, T; Matsuki, K; Ochiai, N; Yamaguchi, T; Sasaki, Y; Hashimoto, E; Sasaki, Y; Yamazaki, H; Kenmoku, T; Yamaguchi, S; Masuda, Y; Umekita, H; Banks, SA; Takahashi, K				Kijima, Takehiro; Matsuki, Keisuke; Ochiai, Nobuyasu; Yamaguchi, Takeshi; Sasaki, Yu; Hashimoto, Eiko; Sasaki, Yasuhito; Yamazaki, Hironori; Kenmoku, Tomonori; Yamaguchi, Satoshi; Masuda, Yoshitada; Umekita, Hideo; Banks, Scott A.; Takahashi, Kazuhisa			In vivo 3-dimensional analysis of scapular and glenohumeral kinematics: comparison of symptomatic or asymptomatic shoulders with rotator cuff tears and healthy shoulders	JOURNAL OF SHOULDER AND ELBOW SURGERY			English	Article						Shoulder; scapular kinematics; 3-dimensional kinematics; rotator cuff tear; asymptomatic; 3D/2D registration techniques	JOINT KINEMATICS; FLUOROSCOPY; REGISTRATION; IMPINGEMENT; MODELS; MOTION	Background: Alteration in shoulder kinematics has been suggested as one cause of symptoms in shoulders with rotator cuff tears (RCTs). However, only a few studies comparing symptomatic and asymptomatic RCTs using kinematic analysis have been performed. The purpose of this study was to compare 3-dimensional (3D) scapular and glenohumeral kinematics during scapular-plane abduction among symptomatic RCTs, asymptomatic RCTs, and healthy shoulders. Methods: This study included 7 healthy shoulders in subjects with a mean age of 62 years, 5 symptomatic RCTs in subjects with a mean age of 70 years, and 7 asymptomatic RCTs in subjects with a mean age of 67 years. All shoulders with RCTs had medium-sized tears (1-3 cm in the coronal plane) that were confirmed with magnetic resonance imaging. Biplane fluoroscopic images during scapular-plane abduction were recorded, and computed tomography-derived 3D bone models were matched with the silhouettes of the bones on the fluoroscopic images using 3D/2-dimensional model-image registration techniques. Angular values of the scapula and glenohumeral kinematics were compared among the 3 groups. Results: Posterior tilt of the scapula was significantly smaller in the symptomatic RCTs (3.1 degrees +/- 1.8 degrees) than in healthy shoulders (10.4 degrees +/- 0.8 degrees) (P = .049). The humerus of the symptomatic shoulders was less externally rotated relative to the scapula throughout the activity than the healthy shoulders and asymptomatic RCTs (P = .006 and P = .028 respectively). However, there were no kinematic differences between the asymptomatic RCTs and healthy shoulders. Conclusion: Kinematic changes in symptomatic RCTs might be associated with development of symptoms. Improvement of these kinematic changes may be a key to successful conservative treatment for symptomatic RCTs. (C) 2015 Journal of Shoulder and Elbow Surgery Board of Trustees.	[Kijima, Takehiro; Ochiai, Nobuyasu; Yamaguchi, Takeshi; Sasaki, Yu; Hashimoto, Eiko; Sasaki, Yasuhito; Yamaguchi, Satoshi; Takahashi, Kazuhisa] Chiba Univ, Dept Orthoped Surg, Grad Sch Med, Chiba 2608670, Japan; [Matsuki, Keisuke] Funabashi Orthoped Hosp, Shoulder & Elbow Ctr, Chiba, Japan; [Yamazaki, Hironori] Chiba Med Ctr, Dept Orthoped Surg, Chiba, Japan; [Kenmoku, Tomonori] Kitasato Univ, Dept Orthoped Surg, Sagamihara, Kanagawa, Japan; [Masuda, Yoshitada; Umekita, Hideo] Chiba Univ, Dept Radiol, Chiba 2608670, Japan; [Banks, Scott A.] Univ Florida, Dept Mech & Aerosp Engn, Gainesville, FL USA	Kijima, T (reprint author), Chiba Univ, Dept Orthoped Surg, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	kijima0602@yahoo.co.jp	Banks, Scott/B-6345-2008	Banks, Scott/0000-0003-0404-6826			Kelly BT, 2005, J SHOULDER ELB SURG, V14, P165, DOI 10.1016/j.jse.2004.06.010; Mahfouz MR, 2003, IEEE T MED IMAGING, V22, P1561, DOI 10.1109/TMI.2003.820027; Ludewig PM, 2000, PHYS THER, V80, P276; Hebert LJ, 2002, ARCH PHYS MED REHAB, V83, P60, DOI 10.1053/apmr.2002.27471; Keener JD, 2009, J BONE JOINT SURG AM, V91A, P1405, DOI 10.2106/JBJS.H.00854; Shinozaki N, 2014, J SHOULDER ELB SURG, V23, pE61, DOI 10.1016/j.jse.2013.06.009; Moro-Oka T, 2007, J ORTHOP RES, V25, P867, DOI 10.1002/jor.20355; Mahfouz M, 2005, J BONE JOINT SURG AM, V87A, P107, DOI 10.2106/JBJS.E.00483; Matsuki K, 2012, J ORTHOP SPORT PHYS, V42, P96, DOI 10.2519/jospt.2012.3584; Matsuki K, 2011, J SHOULDER ELB SURG, V20, P659, DOI 10.1016/j.jse.2010.09.012; Nishinaka N, 2008, J SHOULDER ELB SURG, V17, P319, DOI 10.1016/j.jse.2007.05.018; MILGROM C, 1995, J BONE JOINT SURG BR, V77B, P296; Uhl TL, 2009, ARTHROSCOPY, V25, P1240, DOI 10.1016/j.arthro.2009.06.007; Yamaguchi K, 2000, J SHOULDER ELB SURG, V9, P6, DOI 10.1016/S1058-2746(00)90002-8; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; McClure PW, 2001, J SHOULDER ELB SURG, V10, P269, DOI 10.1067/mse.2001.112954; Banks SA, 1996, IEEE T BIO-MED ENG, V43, P638, DOI 10.1109/10.495283; Kon Y, 2008, J SHOULDER ELB SURG, V17, P943, DOI 10.1016/j.jse.2008.05.047; Paletta GA, 1997, J SHOULDER ELB SURG, V6, P516, DOI 10.1016/S1058-2746(97)90084-7; Bey MJ, 2006, J BIOMECH ENG-T ASME, V128, P604, DOI 10.1115/1.2206199; Bey MJ, 2008, J BIOMECH, V41, P711, DOI 10.1016/j.jbiomech.2007.09.029; Yamaguchi K, 2001, J SHOULDER ELB SURG, V10, P199, DOI 10.1067/mse.2001.113086; Matsuki K, 2012, JPN J CLIN BIOMECH, V33, P151	23	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	1058-2746			J SHOULDER ELB SURG	J. Shoulder Elbow Surg.	NOV	2015	24	11					1817	1826		10.1016/j.jse.2015.06.003		10	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CU1FE	WOS:000363264600024		
J	Naganuma, T; Singh, H; Nakabayashi, S				Naganuma, Tomoya; Singh, Harpartap; Nakabayashi, Seiichiro			Feedback effect on pitting corrosion dynamics	JOURNAL OF SOLID STATE ELECTROCHEMISTRY			English	Article						Electrochemical system; Halide environment; Metallic feedback	SULFURIC-ACID-SOLUTIONS; POINT-DEFECT MODEL; CURRENT OSCILLATIONS; LOCALIZED CORROSION; STOCHASTIC-PROCESS; IRON; TRANSITION; ELECTRODISSOLUTION; PASSIVATION; STATES	We have investigated the feedback effect on the pitting dynamics in the chloride -Fe | 0.75 M H2SO4 system by the introduction of copper plate. This copper plate is placed directly below the reacting surface area of the Fe (working) electrode without any electrical connection. It has been observed that the feedback reduces the pitting induced dynamics such as current offset, frequency, amplitude, and complexity of the waveforms. The feedback effect could be attributed to the reduction of pitting tendency of the Cl- ions in the presence of negative electric field which is induced by the bursting of Fe2+ ions (iron electro-dissolution). This negative electric field acts as the negative feedback dynamics via copper plate. In addition, the electric feedback is found to be more pronounced when electrochemical cell is working in the passive regions, since in these conditions the pitting dynamics are more sensitive towards the Cl- ions concentration than the change in pH (in case of well buffered solution). Furthermore, an acrylic plate has also been employed to verify that the present effect is due to the feedback of electrode's electrical behavior rather than the mass transfer.	[Naganuma, Tomoya; Singh, Harpartap; Nakabayashi, Seiichiro] Saitama Univ, Dept Chem, Fac Sci, Saitama 3388570, Japan	Singh, H (reprint author), Saitama Univ, Dept Chem, Fac Sci, Saitama 3388570, Japan.	harpartap@mail.saitama-u.ac.jp			Saitama University Japan	Financial support from Saitama University Japan is acknowledged.	Pagitsas M, 2003, CHAOS SOLITON FRACT, V17, P263, DOI 10.1016/S0960-0779(02)00351-X; Shibata T, 1996, CORROSION, V52, P813; Valor A, 2007, CORROS SCI, V49, P559, DOI 10.1016/j.corsci.2006.05.049; Zaid B, 2008, CORROS SCI, V50, P1841, DOI 10.1016/j.corsci.2008.03.006; MACDONALD DD, 1992, J ELECTROCHEM SOC, V139, P3434, DOI 10.1149/1.2069096; Ulrich C, 2009, ANAL CHEM, V81, P453, DOI 10.1021/ac801871c; Frankel GS, 1998, J ELECTROCHEM SOC, V145, P2186, DOI 10.1149/1.1838615; KOPER MTM, 1993, J ELECTROANAL CHEM, V347, P31, DOI 10.1016/0022-0728(93)80079-W; Hong HP, 1999, CORROSION, V55, P10; Pagitsas M, 1999, J ELECTROANAL CHEM, V471, P132, DOI 10.1016/S0022-0728(99)00268-5; Sazou D, 2012, J ELECTROANAL CHEM, V675, P54, DOI 10.1016/j.jelechem.2012.04.012; Koutsaftis D, 2007, J PHYS CHEM C, V111, P13579, DOI 10.1021/jp074344o; Sazou D, 2000, J ELECTROANAL CHEM, V489, P1, DOI 10.1016/S0022-0728(00)00218-7; PROVAN JW, 1989, CORROSION, V45, P178; Sazou D, 2014, ELECTROCHIM ACTA, V119, P175, DOI 10.1016/j.electacta.2013.12.029; SHIBATA T, 1976, NATURE, V260, P315, DOI 10.1038/260315a0; SAZOU D, 1992, ELECTROCHIM ACTA, V37, P2067, DOI 10.1016/0013-4686(92)87123-H; Aziz PM, 1956, CORROSION, V12, P35; Chaofang D, 2011, J WUHAN UNIV TECHNOL, V26, P641; Gracia E, 2003, CORROSION, V59, P50; Sazou D, 2003, CHAOS SOLITON FRACT, V17, P505, DOI 10.1016/S0960-0779(02)00394-6	21	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1432-8488	1433-0768		J SOLID STATE ELECTR	J. Solid State Electrochem.	NOV	2015	19	11					3219	3228		10.1007/s10008-015-2991-8		10	Electrochemistry	Electrochemistry	CU1IN	WOS:000363274400003		
J	Mukouyama, Y; Kawasaki, H; Hara, D; Nakanishi, S				Mukouyama, Yoshiharu; Kawasaki, Hirokazu; Hara, Daisuke; Nakanishi, Shuji			Transient chaotic behavior during simultaneous occurrence of two electrochemical oscillations	JOURNAL OF SOLID STATE ELECTROCHEMISTRY			English	Article						Electrochemical oscillation; N-NDR oscillator; Chaos; Mixed-mode oscillation; Hydrogen peroxide reduction; Peroxodisulfate reduction	MIXED-MODE OSCILLATIONS; H2O2 REDUCTION; POTENTIAL OSCILLATIONS; HYDROGEN-PEROXIDE; ACID-SOLUTIONS; HALIDE-IONS; SYSTEM; ELECTRODES; OXIDATION; ELECTRODISSOLUTION	We have found that a chaotic oscillation transiently appears when two kinds of current oscillations, named oscillation A and oscillation alpha, occur simultaneously. Oscillations A and alpha appear during the reduction of H2O2 and S2O8 (2-) respectively on the Pt electrode. When the electrode potential is stepped from the rest potential to a potential where both the oscillations appear, a period-1 oscillation first appears, and then a period-doubling bifurcation cascade occurs. After that, the transient chaos appears, which is followed by a sequence of mixed-mode oscillations (MMOs). The appearance of the chaotic behavior and the MMOs can be explained on the basis of the reported mechanisms for oscillations A and alpha. Both the oscillations are caused by an N-shaped negative differential resistance (N-NDR) due to the formation of under-potential deposited H (upd-H), indicating that a positive feedback mechanism works during the simultaneous occurrence of oscillations A and alpha. On the other hand, negative feedback mechanisms for oscillations A and alpha include the surface concentration of H2O2 and S2O8 (2-), respectively. We can, then, conclude that the combination of the positive feedback mechanism and the two negative feedback mechanisms of different time scales gives rise to the chaotic behavior and the MMOs, which has been verified by numerical simulations.	[Mukouyama, Yoshiharu; Kawasaki, Hirokazu; Hara, Daisuke] Tokyo Denki Univ, Div Sci, Coll Sci & Engn, Hatoyama, Saitama 3500394, Japan; [Nakanishi, Shuji] Univ Tokyo, Dept Appl Chem, Bunkyo Ku, Tokyo 1138656, Japan	Mukouyama, Y (reprint author), Tokyo Denki Univ, Div Sci, Coll Sci & Engn, Hatoyama, Saitama 3500394, Japan.	mukoyama@mail.dendai.ac.jp					ALBAHADILY FN, 1989, J CHEM PHYS, V90, P813, DOI 10.1063/1.456106; Nakanishi S, 2000, J PHYS CHEM B, V104, P4181, DOI 10.1021/jp993961c; HUDSON JL, 1994, CHEM ENG SCI, V49, P1493, DOI 10.1016/0009-2509(94)85063-1; BASSETT MR, 1987, CHEM ENG COMMUN, V60, P145, DOI 10.1080/00986448708912014; Mukouyama Y, 2005, J SOLID STATE ELECTR, V9, P290, DOI 10.1007/s10008-004-0609-7; Okamoto H, 1998, J PHYS CHEM A, V102, P7343, DOI 10.1021/jp981292h; Nakanishi S, 2002, J PHYS CHEM B, V106, P2287, DOI 10.1021/jp013275p; Mukouyama Y, 2001, J PHYS CHEM B, V105, P10905, DOI 10.1021/jp012461s; BASSETT MR, 1990, J ELECTROCHEM SOC, V137, P1815, DOI 10.1149/1.2086810; Sazou D, 1997, ELECTROCHIM ACTA, V42, P627, DOI 10.1016/S0013-4686(96)00208-3; Matsuda T, 1997, J ELECTROCHEM SOC, V144, P1988, DOI 10.1149/1.1837733; Mukouyama Y, 2000, J PHYS CHEM B, V104, P11186, DOI 10.1021/jp0017011; Strasser P, 1999, J ELECTROANAL CHEM, V478, P50, DOI 10.1016/S0022-0728(99)00412-X; Nakanishi S, 2003, J ELECTROCHEM SOC, V150, pE47, DOI 10.1149/1.1526112; Mukouyama Y, 2014, ECS TRANSACTIONS, V58, P99, DOI 10.1149/05825.0099ecst; Koper MTM, 1996, J ELECTROANAL CHEM, V409, P175, DOI 10.1016/0022-0728(95)04391-8; Okamoto H, 1998, J PHYS CHEM A, V102, P7353, DOI 10.1021/jp981293+; Mukouyama Y, 1999, J ELECTROANAL CHEM, V473, P156, DOI 10.1016/S0022-0728(99)00169-2; Strasser P, 1997, J CHEM PHYS, V107, P991, DOI 10.1063/1.474451; KRISCHER K, 1993, PHYSICA D, V62, P123, DOI 10.1016/0167-2789(93)90277-8; Mukouyama Y, 1999, B CHEM SOC JPN, V72, P2573, DOI 10.1246/bcsj.72.2573; Bi WY, 2014, ELECTROCHIM ACTA, V133, P308, DOI 10.1016/j.electacta.2014.04.055; Mukouyama Y, 2001, J PHYS CHEM B, V105, P7246, DOI 10.1021/jp0104381; SCHELL M, 1989, J CHEM PHYS, V90, P822, DOI 10.1063/1.456107; Okamoto H, 1997, J PHYS CHEM A, V101, P8480, DOI 10.1021/jp971858m; Kiss IZ, 2011, SOLID STATE ELECTRON, P125; Koper M.T.M, 1996, ADV CHEM PHYS, V92, P161, DOI DOI 10.1002/9780470141519.CH2; Krischer K., 1999, MOD ASPECT ELECTROC, V32, P1; Krischer K., 2003, ADV ELECTROCHEMICAL, V8, P89; Orlik M., 2012, SELF ORG ELECTROCHEM; Scott SK, 1991, CHEM CHAOS	31	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1432-8488	1433-0768		J SOLID STATE ELECTR	J. Solid State Electrochem.	NOV	2015	19	11					3253	3263		10.1007/s10008-015-2813-z		11	Electrochemistry	Electrochemistry	CU1IN	WOS:000363274400006		
J	Fu, YS; Liu, YY; Li, YN; Li, J; Qiao, JL; Zhang, JJ				Fu, Yishu; Liu, Yuyu; Li, Yanan; Li, Jing; Qiao, Jinli; Zhang, Jiujun			Synergistic electrocatalysis of N,NE1-bis(salicylidene)-ethylenediamine-cobalt(II) and conductive carbon black (BP) for high efficient CO2 electroreduction	JOURNAL OF SOLID STATE ELECTROCHEMISTRY			English	Article						Electrochemical reduction of CO2; Gas diffusion electrode; Catalytic activity; Onset potential; Formic acid	SCHIFF-BASE COMPLEXES; ELECTROCHEMICAL REDUCTION; DIOXIDE; ELECTRODES; NANOTUBES; PORPHYRIN; COBALT; CELL	Gas diffusion electrodes (GDEs) modified with N,NE1-Bis(salicylidene)-ethylenediamine-cobalt(II) (Cosalen) and conductive carbon black (BP) have been prepared. It is demonstrated that modified BP-Cosalen/GDE electrode is able to catalyze CO2 reduction in a more efficient and selective manner than that of bulk Cosalen/GDE in 0.5 M KHCO3 solution. In the presence of 60 wt% of BP, the as-prepared BP-Cosalen/GDE electrode exhibits the highest activity for catalyzing CO2 reduction reaction, wherever increase or decrease the amount of BP do not benefit to CO2 reduction. Compared to other BP-Cosalen/GDE electrodes, the BP-Cosalen/GDE60 shows the most positive onset potential, and the maximum current density reaches 21 mA cm(-2). The improved catalytic activity is largely due to the excellent electrical conductivity and the developed pore structure of BP which provides more active phases for the electrochemical reduction of CO2. Further analysis of reduction product reveals that the product on BP-Cosalen/GDE60 electrode is formate in 0.5 M KHCO3 electrolyte. The highest faradaic efficiency reached 27 % along with the production rate of formate as much as 0.44 mM.	[Fu, Yishu; Li, Yanan; Li, Jing; Qiao, Jinli] Donghua Univ, Coll Environm Sci & Engn, Shanghai 201620, Peoples R China; [Liu, Yuyu] Tohoku Univ, Grad Sch Environm Studies, Multidisciplinary Res Circulat Waste Resources, Aoba Ku, Sendai, Miyagi 9808579, Japan; [Zhang, Jiujun] Donghua Univ, Res Inst, Shanghai 201620, Peoples R China; [Zhang, Jiujun] Natl Res Council Canada, NRC Energy Min & Environm, Vancouver, BC V6T 1W5, Canada	Liu, YY (reprint author), Tohoku Univ, Grad Sch Environm Studies, Multidisciplinary Res Circulat Waste Resources, Aoba Ku, Aza Aoba 6-6-11, Sendai, Miyagi 9808579, Japan.	liu@mail.kankyo.tohoku.ac.jp; qiaojl@dhu.edu.cn			National Natural Science Foundation of China [21173039]; International Academic Cooperation and Exchange Program of Shanghai Science and Technology Committee [14520721900]; project of Introducing Overseas Intelligence High Education of China; College of Environmental Science and Engineering, State Environmental Protection Engineering Center for Pollution Treatment and Control in Textile Industry, Donghua University	This work is supported by the National Natural Science Foundation of China (21173039), the International Academic Cooperation and Exchange Program of Shanghai Science and Technology Committee (14520721900), the project of Introducing Overseas Intelligence High Education of China (2015), and the College of Environmental Science and Engineering, State Environmental Protection Engineering Center for Pollution Treatment and Control in Textile Industry, Donghua University. All the financial supports are gratefully acknowledged.	Qiao JL, 2014, CHEM SOC REV, V43, P631, DOI 10.1039/c3cs60323g; Jia FL, 2014, J POWER SOURCES, V252, P85, DOI 10.1016/j.jpowsour.2013.12.002; Zhou XJ, 2014, J POWER SOURCES, V260, P349, DOI 10.1016/j.jpowsour.2014.03.017; Hayashi T, 1999, J ORGANOMET CHEM, V576, P195, DOI 10.1016/S0022-328X(98)01058-4; Lee J, 2009, CHEM-ASIAN J, V4, P1516, DOI 10.1002/asia.200900055; Lee KR, 1999, KOREAN J CHEM ENG, V16, P829, DOI 10.1007/BF02698360; FISHER B, 1980, J AM CHEM SOC, V102, P7361, DOI 10.1021/ja00544a035; KAPUSTA S, 1984, J ELECTROCHEM SOC, V131, P1511, DOI 10.1149/1.2115882; CHRISTENSEN PA, 1988, J ELECTROANAL CHEM, V241, P361, DOI 10.1016/0022-0728(88)85139-8; Zhao HZ, 2012, ENVIRON SCI TECHNOL, V46, P5198, DOI 10.1021/es300186f; Machunda RL, 2011, CURR APPL PHYS, V11, P986, DOI 10.1016/j.cap.2011.01.003; Choi A, 2008, ELECTROCHIM ACTA, V53, P2579, DOI 10.1016/j.electacta.2007.10.029; Kianfar AH, 2015, SPECTROCHIM ACTA A, V136, P1582, DOI 10.1016/j.saa.2014.10.051; Li GC, 2013, J POWER SOURCES, V240, P598, DOI 10.1016/j.jpowsour.2013.02.095; Zhao HZ, 2013, J SOLID STATE ELECTR, V17, P1657, DOI 10.1007/s10008-013-2027-1; LOSADA J, 1995, J ELECTROANAL CHEM, V398, P89, DOI 10.1016/0022-0728(95)04155-6; Chang TY, 2009, MATER LETT, V63, P1001, DOI 10.1016/j.matlet.2009.01.067; Xu P, 2015, RSC ADV, V5, P6195, DOI 10.1039/c4ra11643g; Antony R, 2013, J MOL STRUCT, V1050, P53, DOI 10.1016/j.molstruc.2013.07.006; Tang L, 2011, NEW CARBON MATER, V26, P237, DOI 10.1016/S1872-5805(11)60079-6; Delacourt C, 2008, J ELECTROCHEM SOC, V155, pB42, DOI 10.1149/1.2801871; Sanchez-Sanchez CM, 2001, PURE APPL CHEM, V73, P1917, DOI 10.1351/pac200173121917; Kumar B, 2013, NAT COMMUN, V4, P94; Lv WX, 2014, J POWER SOURCES, V253, P276	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1432-8488	1433-0768		J SOLID STATE ELECTR	J. Solid State Electrochem.	NOV	2015	19	11					3355	3363		10.1007/s10008-015-2955-z		9	Electrochemistry	Electrochemistry	CU1IN	WOS:000363274400017		
J	Hattori, M; Takata, S				Hattori, Masanari; Takata, Shigeru			Second-Order Knudsen-Layer Analysis for the Generalized Slip-Flow Theory II: Curvature Effects	JOURNAL OF STATISTICAL PHYSICS			English	Article						Boltzmann equation; Kinetic theory; Slip flow; Curvature effect; Divergence singularity; Knudsen number; Rarefied gas	LINEARIZED BOLTZMANN-EQUATION; HARD-SPHERE MOLECULES; RAREFIED-GAS; NUMERICAL-ANALYSIS; ASYMPTOTIC THEORY; SOLID BOUNDARY; STOKES-FOURIER; PLANE WALL; BEHAVIOR; LIMITS	Numerical analyses of the second-order Knudsen layer are carried out on the basis of the linearized Boltzmann equation for hard-sphere molecules under the diffuse reflection boundary condition. The effects of the boundary curvature have been clarified in details, thereby completing the numerical data required up to the second order of the Knudsen number for the asymptotic theory of the Boltzmann equation (the generalized slip-flow theory). A local singularity appears as a result of the expansion at the level of the velocity distribution function, when the curvature exists.	[Hattori, Masanari] Kyoto Univ, Dept Mech Engn & Sci, Kyoto, Kyoto 6158540, Japan; [Takata, Shigeru] Kyoto Univ, Dept Aeronaut & Astronaut, Kyoto, Kyoto 6158540, Japan; [Takata, Shigeru] Kyoto Univ, Adv Engn Res Ctr, Kyoto, Kyoto 6158540, Japan	Takata, S (reprint author), Kyoto Univ, Dept Aeronaut & Astronaut, Kyoto, Kyoto 6158540, Japan.	takata.shigeru.4a@kyoto-u.ac.jp	Takata, Shigeru/G-2933-2011	Takata, Shigeru/0000-0001-6787-6777	KAKENHI from JSPS [23360083, 13J01011]	The present work is supported in part by KAKENHI from JSPS (Nos. 23360083 and 13J01011). The authors thank Professor Kazuo Aoki, Kyoto University, for his interest and encouragement.	Yu SH, 2005, COMMUN PUR APPL MATH, V58, P409, DOI 10.1002/cpa.20027; Nassios J, 2012, J FLUID MECH, V708, P197, DOI 10.1017/jfm.2012.302; OHWADA T, 1992, EUR J MECH B-FLUID, V11, P389; SONE Y, 1989, PHYS FLUIDS A-FLUID, V1, P363, DOI 10.1063/1.857457; SONE Y, 1973, PHYS FLUIDS, V16, P1422, DOI 10.1063/1.1694535; Jiang N, 2010, COMMUN PART DIFF EQ, V35, P1590, DOI 10.1080/03605302.2010.496096; Golse F, 2013, COMPUT MATH APPL, V65, P815, DOI 10.1016/j.camwa.2012.02.009; Takata S, 2011, J FLUID MECH, V669, P242, DOI 10.1017/S0022112010005021; Inaba M, 2012, FLUID DYN RES, V44, DOI 10.1088/0169-5983/44/2/025506; GRAD H, 1963, PHYS FLUIDS, V6, P147, DOI 10.1063/1.1706716; BHATNAGAR PL, 1954, PHYS REV, V94, P511, DOI 10.1103/PhysRev.94.511; Hilbert D, 1912, MATH ANN, V72, P562, DOI 10.1007/BF01456676; WELANDER P, 1954, ARK FYS, V7, P507; Golse F, 2004, INVENT MATH, V155, P81, DOI 10.1007/s00222-003-0316-5; Takata S, 2009, J STAT PHYS, V136, P751, DOI 10.1007/s10955-009-9793-2; Takata S, 2012, J STAT PHYS, V147, P1182, DOI 10.1007/s10955-012-0512-z; Takata S, 2013, J FLUID MECH, V717, P30, DOI 10.1017/jfm.2012.559; Golse F, 2002, COMMUN PUR APPL MATH, V55, P336, DOI 10.1002/cpa.3011; Takata S, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.3691262; BARDOS C, 1986, COMMUN PUR APPL MATH, V39, P323, DOI 10.1002/cpa.3160390304; OHWADA T, 1989, PHYS FLUIDS A-FLUID, V1, P1588, DOI 10.1063/1.857304; Chapman S., 1991, MATH THEORY NONUNIFO; Hattori M., 2015, B I MATH ACAD SIN, V10, P423; Kennard E. H., 1938, KINETIC THEORY GASES; Masmoudi N, 2003, COMMUN PUR APPL MATH, V56, P1263, DOI 10.1002/cpa.10095; Sone Y., 1971, RAREFIED GAS DYN, VII, P737; Sone Y., 1992, Transport Theory and Statistical Physics, V21, DOI 10.1080/00411459208203796; Sone Y., 2007, SUPPLEMENTARY NOTES; Sone Y., 1969, RAREFIED GAS DYN, VI, P243	29	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0022-4715	1572-9613		J STAT PHYS	J. Stat. Phys.	NOV	2015	161	4					1010	1036		10.1007/s10955-015-1364-0		27	Physics, Mathematical	Physics	CU1CS	WOS:000363257600012		
J	Suenaga, M; Yamada, S; Fuchs, BC; Fujii, T; Kanda, M; Tanaka, C; Kobayashi, D; Fujiwara, M; Tanabe, KK; Kodera, Y				Suenaga, Masaya; Yamada, Suguru; Fuchs, Bryan C.; Fujii, Tsutomu; Kanda, Mitsuro; Tanaka, Chie; Kobayashi, Daisuke; Fujiwara, Michitaka; Tanabe, Kenneth K.; Kodera, Yasuhiro			CD44 single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence	JOURNAL OF SURGICAL ONCOLOGY			English	Article						CD44; single nucleotide polymorphism; gastric cancer; isoform switching; disease recurrence	COLORECTAL-CANCER; PERIPHERAL-BLOOD; CELLS; EXPRESSION; CARCINOMA; MARKER; ADENOCARCINOMA; METAANALYSIS; ASSOCIATION; CONCORDANCE	Background and ObjectivesThe clinical implications of single nucleotide polymorphisms (SNPs) in CD44 remain unclear. This study examined the relationships of CD44 SNPs with clinicopathological parameters and prognosis in Japanese gastric cancer patients. MethodsThe CD44 SNPs were analyzed in 11 gastric cancer cell lines and 517 clinical specimens. The expression of CD44 standard (CD44s) and CD44 variant 9 isoform (CD44v9) transcripts were measured by quantitative real-time polymerase chain reaction. ResultsThe CD44 rs187116 A/A, A/G, and G/G genotypes were present in 10.3%, 45.1%, and 44.7% of patients, respectively. The presence of CD44 rs187116 A/G or G/G genotypes was significantly associated with positive peritoneal washing cytology (P=0.012). Disease-free survival of patients with these genotypes was significantly worse than in those with the A/A genotype (P=0.039). Multivariate analysis showed that the CD44 rs187116 was independently prognostic of disease-free survival (P=0.047). The CD44s/CD44v9 ratio was significantly lower in patients with the CD44 rs187116 A/A genotype than in those with the A/G (P=0.046) and G/G (P=0.047) genotypes. ConclusionsThe CD44 rs187116 genotype could predict disease recurrence in Japanese gastric cancer patients, and the SNP was associated with CD44 isoform switching. J. Surg. Oncol. 2015;112:622-628. (c) 2015 Wiley Periodicals, Inc.	[Suenaga, Masaya; Yamada, Suguru; Fujii, Tsutomu; Kanda, Mitsuro; Tanaka, Chie; Kobayashi, Daisuke; Fujiwara, Michitaka; Kodera, Yasuhiro] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi 4668550, Japan; [Fuchs, Bryan C.; Tanabe, Kenneth K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Surg Oncol,Canc Ctr, Boston, MA USA	Yamada, S (reprint author), Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	suguru@med.nagoya-u.ac.jp					Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Suenaga M, 2013, ONCOTARGETS THER, V6, P1805, DOI 10.2147/OTT.S53625; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Yoon C, 2014, CLIN CANCER RES, V20, P3974, DOI 10.1158/1078-0432.CCR-14-0011; Ozmen F, 2011, WORLD J GASTROENTERO, V17, P3220, DOI 10.3748/wjg.v17.i27.3220; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Zhang LN, 2013, J MOL DIAGN, V15, P600, DOI 10.1016/j.jmoldx.2013.04.005; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Vazquez A, 2010, CANCER RES, V70, P172, DOI 10.1158/0008-5472.CAN-09-2218; Winder T, 2011, INT J CANCER, V129, P1096, DOI 10.1002/ijc.25787; Sasako M, 2010, JPN J CLIN ONCOL, V40, pi28, DOI 10.1093/jjco/hyq124; Mima K, 2012, CANCER RES, V72, P3414, DOI 10.1158/0008-5472.CAN-12-0299; Jung WY, 2013, HISTOPATHOLOGY, V63, P474, DOI 10.1111/his.12202; Okugawa Y, 2012, J SURG ONCOL, V106, P280, DOI 10.1002/jso.22142; Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x; Marisi G, 2014, INT J MOL SCI, V15, P13333, DOI 10.3390/ijms150813333; Ghaffarzadehgan K, 2008, WORLD J GASTROENTERO, V14, P6376, DOI 10.3748/wjg.14.6376; Ni J, 2014, PROSTATE, V74, P602, DOI 10.1002/pros.22775; van Huis-Tanja L, 2013, PHARMACOGENOMICS, V14, P2005, DOI [10.2217/pgs.13.169, 10.2217/PGS.13.169]; D'Angelica M, 2004, ANN SURG, V240, P808, DOI 10.1097/01.sla.0000143245.28656.15; Zhou JH, 2010, ANTICANCER RES, V30, P1263; Doventas A, 2012, HEPATO-GASTROENTEROL, V59, P2196, DOI 10.5754/hge10498; Lau WM, 2014, CANCER RES, V74, P2630, DOI 10.1158/0008-5472.CAN-13-2309; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Marsh S, 2005, PHARMACOGENOMICS, V6, P873, DOI 10.2217/14622416.6.8.873; Hirata K, 2013, BRIT J CANCER, V109, P379, DOI 10.1038/bjc.2013.314; TANABE KK, 1993, MOL CARCINOGEN, V7, P212, DOI 10.1002/mc.2940070403; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Chou YE, 2014, BIOMED RES INT, DOI 10.1155/2014/231474; Li M, 2014, BIOMED RES INT, DOI 10.1155/2014/981261; Yang J, 2012, CLIN RES HEPATOL GAS, V36, P169, DOI 10.1016/j.clinre.2011.11.007; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023; Dong S, 2014, TUMOR BIOL, V35, P8913, DOI 10.1007/s13277-014-2082-y; Biddle A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057314; Chou YE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093692; Gong WF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060108; Mashita N, 2014, J SURG ONCOL, V110, P745, DOI 10.1002/jso.23705; Park MJ, 2014, MOL BIOL REP, V42, P119; Peng QL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082773; Tulsyan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071073	42	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-4790	1096-9098		J SURG ONCOL	J. Surg. Oncol.	NOV 1	2015	112	6					622	628		10.1002/jso.24056		7	Oncology; Surgery	Oncology; Surgery	CU5RD	WOS:000363588800010		
J	da Silva, JAT; Dobranszki, J				da Silva, Jaime A. Teixeira; Dobranszki, Judit			Do open access data files represent an academic Risk?	JOURNAL OF THE ASSOCIATION FOR INFORMATION SCIENCE AND TECHNOLOGY			English	Letter									[Dobranszki, Judit] Univ Debrecen, Res Inst Nyiregyhaza, H-4400 Nyiregyhaza, Hungary	da Silva, JAT (reprint author), POB 7,Miki Cho Post Off,Ikenobe 3011-2, Takamatsu, Kagawa 7610799, Japan.	jaimetex@yahoo.com; dobranszki@freemail.hu					Zhang QF, 2014, J PHYS CHEM LETT, V5, P370, DOI 10.1021/jz402795x; Blasco J, 2015, J SYST SOFTWARE, V101, P147, DOI 10.1016/j.jss.2014.11.050; Oaten A., 2014, LIFE SCI CYBERTHEFT; Sahoo Pratap K., 2014, Materials Research Express, V1, DOI 10.1088/2053-1591/1/3/035018; Tuffani M., 2015, BRAZILIAN GRADUATE P	5	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2330-1635	2330-1643		J ASSOC INF SCI TECH		NOV	2015	66	11					2390	2391		10.1002/asi.23557		2	Computer Science, Information Systems; Information Science & Library Science	Computer Science; Information Science & Library Science	CU0NC	WOS:000363213000019		
J	Eberhardt, WEE; Mitchell, A; Crowley, J; Kondo, H; Kim, YT; Turrisi, A; Goldstraw, P; Rami-Porta, R				Eberhardt, Wilfried E. E.; Mitchell, Alan; Crowley, John; Kondo, Haruhiko; Kim, Young Tae; Turrisi, Andrew, III; Goldstraw, Peter; Rami-Porta, Ramon		Int Assoc Study Lung Canc; Staging Prognostic Factors Comm	The IASLC Lung Cancer Staging Project Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer	JOURNAL OF THORACIC ONCOLOGY			English	Review						Lung cancer; Staging; Metastases	ESMO CONSENSUS CONFERENCE; FORTHCOMING 7TH EDITION; TNM CLASSIFICATION; RADIATION-THERAPY; RADICAL TREATMENT; BRAIN METASTASES; OLIGOMETASTASES; PROPOSALS; CARCINOMA; SURVIVAL	Introduction: The aim of this study is to analyze all metastatic (M) categories of the current tumor, node, and metastasis (TNM) classification of lung cancer with the objective of providing suggestions for modifications of the M component in the next edition of the TNM classification for lung cancer. Methods: The new International Association for the Study of Lung Cancer lung cancer database was created from 94,708 patients diagnosed as having lung cancer between 1999 and 2010. Including further patients submitted through the electronic data capture system to Cancer Research and Biostatistics until 2012, all together 1059 non-small-cell lung cancer cases were available for a detailed analysis of the clinical M categories. Overall survival was calculated using the Kaplan-Meier method, and prognosis was assessed using a Cox proportional hazards regression analysis. Results: No significant differences were found among the M1a (metastases within the chest cavity) descriptors. However, when M1b (distant metastases outside the chest cavity) were assessed according to the number of metastases, tumors with a single metastasis in a single organ had significantly better prognosis than those with multiple metastases in one or several organs. Conclusions: In this revision of the TNM classification, cases with pleural/pericardial effusions, contralateral/bilateral lung nodules, contralateral/bilateral pleural nodules, or a combination of multiple of these parameters should continue to be grouped as M1a category. Single metastatic lesions in a single distant organ should be newly designated to the M1b category. Multiple lesions in a single organ or multiple lesions in multiple organs should be reclassified as M1c category. This new division can serve as a first step into providing rational definitions for an oligometastatic disease stage in non-small-cell lung cancer in the future.	[Eberhardt, Wilfried E. E.] Univ Duisburg Essen, Univ Hosp Essen, Dept Med Oncol, Ruhrlandklin,West German Canc Ctr, D-45122 Essen, Germany; [Mitchell, Alan; Crowley, John] Canc Res & Biostat, Seattle, WA USA; [Kondo, Haruhiko] Kyorin Univ Hosp, Tokyo, Japan; [Kim, Young Tae] Seoul Natl Univ Hosp, Canc Res Inst, Dept Thorac & Cardiovasc Surg, Seoul 110744, South Korea; [Turrisi, Andrew, III] Sinai Grace Hosp, Detroit, MI USA; [Goldstraw, Peter] Royal Brompton Hosp, London SW3 6LY, England; [Goldstraw, Peter] Univ London Imperial Coll Sci Technol & Med, London, England; [Rami-Porta, Ramon] Hosp Univ Mutua Terrassa, Dept Thorac Surg, Barcelona, Spain; [Rami-Porta, Ramon] CIBERES Lung Canc Grp, Barcelona, Spain	Eberhardt, WEE (reprint author), Univ Duisburg Essen, Univ Hosp Essen, Dept Med Oncol, Ruhrlandklin,West German Canc Ctr, Hufelandstr 55, D-45122 Essen, Germany.	wilfried.eberhardt@uni-duisburg-essen.de			International Association for the Study of Lung Cancer (IASLC); IASLC	Disclosure: Wilfried Ernst Erich Eberhardt has declared to have received honoraria for advisory board function and educational lectures from Eli Lilly. His institution has received a research grant for an Investigator Initiated Trial from Eli Lilly. John Crowley has declared that his work is funded by the International Association for the Study of Lung Cancer (IASLC) and has received grants and support to travel from the IASLC. Alan Mitchell has declared that his work is funded by the International Association for the Study of Lung Cancer (IASLC) and has received grants and support to travel from the IASLC.	De Wever W, 2007, EUR RESPIR J, V29, P995, DOI 10.1183/09031936.00119106; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Tonnies M, 2014, ANN THORAC SURG, V98, P249, DOI 10.1016/j.athoracsur.2014.03.028; Geiger GA, 2014, CLIN LUNG CANCER, V15, P79, DOI 10.1016/j.cllc.2013.08.004; Bonnette P, 2001, CHEST, V119, P1469, DOI 10.1378/chest.119.5.1469; Vansteenkiste J, 2014, ANN ONCOL, V25, P1462, DOI 10.1093/annonc/mdu089; Salama JK, 2015, CANCER METAST REV, V34, P183, DOI 10.1007/s10555-015-9559-z; Rami-Porta R, 2015, J THORAC ONCOL, V10, P990, DOI 10.1097/JTO.0000000000000559; Eberhardt WEE, 2015, ANN ONCOL, V26, P1573, DOI 10.1093/annonc/mdv187; Postmus PE, 2007, J THORAC ONCOL, V2, P686, DOI 10.1097/JTO.0b013e31811f4703; Gray PJ, 2014, LUNG CANCER, V85, P239, DOI 10.1016/j.lungcan.2014.06.001; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Shaw MG, 2013, CURR TREAT OPTION ON, V14, P553, DOI 10.1007/s11864-013-0258-0; De Leyn P, 2014, EUR J CARDIO-THORAC, V45, P787, DOI 10.1093/ejcts/ezu028; De Ruysscher D, 2012, J THORAC ONCOL, V7, P1547, DOI 10.1097/JTO.0b013e318262caf6; COX DR, 1972, J R STAT SOC B, V34, P187; Tanvetyanon T, 2008, J CLIN ONCOL, V26, P1142, DOI 10.1200/JCO.2007.14.2091; Paz-Ares LG, 2013, J CLIN ONCOL, V31, P2895, DOI 10.1200/JCO.2012.47.1102; Congedo MT, 2012, J THORAC CARDIOV SUR, V144, P444, DOI 10.1016/j.jtcvs.2012.05.051; Griffioen GHMJ, 2013, LUNG CANCER, V82, P95, DOI 10.1016/j.lungcan.2013.07.023; Ryu JS, 2014, J CLIN ONCOL, V32, P960, DOI 10.1200/JCO.2013.50.5453; Kavanagh BD, 2006, SEMIN RADIAT ONCOL, V16, P77, DOI 10.1016/j.semradonc.2005.12.003; Asamura H, 2015, J THORAC ONCOL, V10, P990; Besse B, 2014, ANN ONCOL, V25, P1475, DOI 10.1093/annonc/mdu123; Falcoz PE, 2015, EUR J CARDIOTHORAC S; He YY, 2014, CLIN LUNG CANCER, V15, P441, DOI 10.1016/j.cllc.2014.06.006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Rami-Porta R, 2014, J THORAC ONCOL, V9, P1618, DOI 10.1097/JTO.0000000000000334; SAS User Guide, 2009, SAS US GUID SAS VERS; Toufektzian L, 2014, LUNG CANCER, V83, P14, DOI 10.1016/j.lungcan.2013.10.012	30	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	NOV	2015	10	11					1515	1522		10.1097/JTO.0000000000000673		8	Oncology; Respiratory System	Oncology; Respiratory System	CU1WL	WOS:000363312700002		
J	Hata, A; Katakami, N; Yoshioka, H; Kaji, R; Masago, K; Fujita, S; Imai, Y; Nishiyama, A; Ishida, T; Nishimura, Y; Yatabe, Y				Hata, Akito; Katakami, Nobuyuki; Yoshioka, Hiroshige; Kaji, Reiko; Masago, Katsuhiro; Fujita, Shiro; Imai, Yukihiro; Nishiyama, Akihiro; Ishida, Tadashi; Nishimura, Yoshihiro; Yatabe, Yasushi			Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI	JOURNAL OF THORACIC ONCOLOGY			English	Article						Epidermal growth factor receptor mutation; T790M; Epidermal growth factor receptor-tyrosine kinase inhibitor; Acquired resistance; Rebiopsy	GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; RANDOMIZED PHASE-3 TRIAL; 1ST-LINE TREATMENT; OPEN-LABEL; LEPTOMENINGEAL METASTASES; GEFITINIB RESISTANCE; ACTIVATING MUTATIONS; ERLOTINIB; ADENOCARCINOMA	Introduction: Epidermal growth factor receptor (EGFR) mutation T790M accounts for approximately half of acquired resistances to EGFR-tyrosine kinase inhibitor (TKI). Because T790M is mediated by TKI exposure, its penetration and on-off may affect T790M status. Methods: We retrospectively reviewed T790M status and clinical course of patients who had undergone multiple rebiopsies after acquired resistance to EGFR-TKI. Results: Of 145 patients with EGFR-mutant NSCLC receiving rebiopsy after acquired resistance, 30 underwent multiple site rebiopsies, and 24 received repeated rebiopsies at the same lesion. In 22 patients who underwent rebiopsies from both central nervous system (CNS; 20 cerebrospinal fluids [CSF] and 2 brain tumoral tissues) and thoracic lesions (7 lung tissues, 14 pleural effusions, and 1 lymph node), 12 were thoracic-T790M-positive. Of these 12 patients, 10 were CNS-T790M-negative, despite exhibiting thoracic-T790M-positive. All 10 thoracic-T790M-negatives were CNS-T790M-negative. Three patients revealed a spatial heterogeneous T790M status among their thoracic lesions. In 24 patients receiving repeated rebiopsies at the same lesion (12 lung tissues, 6 CSFs, and 6 pleural effusions), T790M status of lung lesions varied in five patients after TKI-free interval. In all five patients whose T790M status changed from positive to negative, EGFR-TKI rechallenge was effective. In three of these five patients, after further TKI exposure, T790M status changed from negative to positive again. There was also a patient whose CSF T790M status changed from negative to positive after high-dose erlotinib therapy. Conclusions: T790M status in an individual patient can be spatiotemporally heterogeneous because of selective pressure from EGFR-TKI.	[Hata, Akito; Katakami, Nobuyuki; Kaji, Reiko; Masago, Katsuhiro; Fujita, Shiro; Imai, Yukihiro] Inst Biomed Res & Innovat, Div Integrated Oncol, Kobe, Hyogo 6500047, Japan; [Yoshioka, Hiroshige; Nishiyama, Akihiro; Ishida, Tadashi] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan; [Nishimura, Yoshihiro] Kobe Univ, Sch Med, Dept Resp Med, Kobe, Hyogo 650, Japan; [Yatabe, Yasushi] Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 464, Japan	Hata, A (reprint author), Inst Biomed Res & Innovat, Div Integrated Oncol, Chuo Ku, 2-2 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	a-hata@fbri.org			Shinryokukai General Incorporated Association	The study was partially supported by research assistance funds from Shinryokukai General Incorporated Association.	Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Jackman D, 2010, J CLIN ONCOL, V28, P357, DOI 10.1200/JCO.2009.24.7049; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Asahina H, 2010, ONCOLOGY-BASEL, V79, P423, DOI 10.1159/000326488; Su KY, 2012, J CLIN ONCOL, V30, P433, DOI 10.1200/JCO.2011.38.3224; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Oxnard GR, 2011, CLIN CANCER RES, V17, P1616, DOI 10.1158/1078-0432.CCR-10-2692; Inukai M, 2006, CANCER RES, V66, P7854, DOI 10.1158/0008-5472.CAN-06-1951; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Hata A, 2014, J THORAC ONCOL, V9, pE64, DOI 10.1097/JTO.0000000000000255; Rosell R, 2011, CLIN CANCER RES, V17, P1160, DOI 10.1158/1078-0432.CCR-10-2158; Hata A, 2015, ANTICANCER RES, V35, P1025; Hata A, 2011, J THORAC ONCOL, V6, P653, DOI 10.1097/JTO.0b013e3181d899bb; Goto K, 2012, ANN ONCOL, V23, P2914, DOI 10.1093/annonc/mds121; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Toyooka S, 2005, NEW ENGL J MED, V352, P2136; Kuiper JL, 2014, LUNG CANCER, V85, P19, DOI 10.1016/j.lungcan.2014.03.016; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Hata A, 2011, LUNG CANCER, V74, P268, DOI 10.1016/j.lungcan.2011.03.010; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Jackman DM, 2006, J CLIN ONCOL, V24, P4517, DOI 10.1200/JCO.2006.06.6126; Grommes C, 2011, NEURO-ONCOLOGY, V13, P1364, DOI 10.1093/neuonc/nor121; Chmielecki J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002356; Graziano P, 2014, J CLIN ONCOL; Hata A, 2013, CANCER-AM CANCER SOC, V119, P4325, DOI 10.1002/cncr.28364; Heon S, 2012, J CLIN ONCOL, P30; Janne PA, 2014, J CLIN ONCOL, V32; Pao W, 2005, PLOS MED, V2, pe73; Sequist LV, 2014, J CLIN ONCOL, V32; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Wu YL, 2014, LANCET ONCOL, V15, P213, DOI 10.1016/S1470-2045(13)70604-1	42	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	NOV	2015	10	11					1553	1559		10.1097/JTO.0000000000000647		7	Oncology; Respiratory System	Oncology; Respiratory System	CU1WL	WOS:000363312700007		
J	Mahar, AL; Compton, C; McShane, LM; Halabi, S; Asamura, H; Rami-Porta, R; Groome, PA				Mahar, Alyson L.; Compton, Carolyn; McShane, Lisa M.; Halabi, Susan; Asamura, Hisao; Rami-Porta, Ramon; Groome, Patti A.		Amer Joint Comm Canc	Refining Prognosis in Lung Cancer A Report on the Quality and Relevance of Clinical Prognostic Tools	JOURNAL OF THORACIC ONCOLOGY			English	Article						Lung cancer; Prognosis; Clinical prediction tools; Prediction models; Prognostic model	MULTIVARIABLE PREDICTION MODEL; TNM CLASSIFICATION; STAGING PROJECT; EXTERNAL VALIDATION; LABORATORY PARAMETERS; INDIVIDUAL PROGNOSIS; SALVAGE TREATMENT; MALIGNANT-TUMORS; DIAGNOSIS TRIPOD; 7TH EDITION	Introduction: Accurate, individualized prognostication for lung cancer patients requires the integration of standard patient and pathologic factors, biological, genetic, and other molecular characteristics of the tumor. Clinical prognostic tools aim to aggregate information on an individual patient to predict disease outcomes such as overall survival, but little is known about their clinical utility and accuracy in lung cancer. Methods: A systematic search of the scientific literature for clinical prognostic tools in lung cancer published from January 1, 1996 to January 27, 2015 was performed. In addition, web-based resources were searched. A priori criteria determined by the Molecular Modellers Working Group of the American Joint Committee on Cancer were used to investigate the quality and usefulness of tools. Criteria included clinical presentation, model development approaches, validation strategies, and performance metrics. Results: Thirty-two prognostic tools were identified. Patients with metastases were the most frequently considered population in non-small-cell lung cancer. All tools for small-cell lung cancer covered that entire patient population. Included prognostic factors varied considerably across tools. Internal validity was not formally evaluated for most tools and only 11 were evaluated for external validity. Two key considerations were highlighted for tool development: identification of an explicit purpose related to a relevant clinical population and clear decision points and prioritized inclusion of established prognostic factors over emerging factors. Conclusions: Prognostic tools will contribute more meaningfully to the practice of personalized medicine if better study design and analysis approaches are used in their development and validation.	[Mahar, Alyson L.; Groome, Patti A.] Queens Univ, Div Canc Care & Epidemiol, Canc Res Inst, Kingston, ON K7L 3N6, Canada; [Compton, Carolyn] Arizona State Univ, Phoenix, AZ USA; [Compton, Carolyn] Mayo Clin, Sch Med, Lab Med & Pathol, Rochester, MN USA; [McShane, Lisa M.] NCI, Biometr Res Branch, Div Canc Treatment & Diag, Bethesda, MD 20892 USA; [Halabi, Susan] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA; [Halabi, Susan] Alliance Stat & Data Ctr, Durham, NC USA; [Asamura, Hisao] Natl Canc Ctr, Div Thorac Surg, Tokyo, Japan; [Rami-Porta, Ramon] Hosp Univ Mutua Terrassa, Dept Thorac Surg, Barcelona, Spain	Groome, PA (reprint author), Queens Canc Res Inst, Canc Res Inst, Div Canc Care & Epidemiol, Level 2,10 Stuart St, Kingston, ON K7L 3N6, Canada.	groomep@queensu.ca					American Joint Committee on Cancer, 2014, AJCC UPD; Hoang T, 2012, J THORAC ONCOL, V7, P1361, DOI 10.1097/JTO.0b013e318260e106; Kim ST, 2010, ONCOLOGY-BASEL, V79, P78, DOI 10.1159/000320190; Dehing-Oberije C, 2011, INT J RADIAT ONCOL, V81, P360, DOI 10.1016/j.ijrobp.2010.06.011; Dehing-Oberije C, 2009, INT J RADIAT ONCOL, V74, P355, DOI 10.1016/j.ijrobp.2008.08.052; Goldstraw P, 2007, J THORAC ONCOL, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a; Wang FH, 2011, MED ONCOL, V28, P331, DOI 10.1007/s12032-010-9451-1; Wigren T, 1997, J CANCER RES CLIN, V123, P259, DOI 10.1007/BF01208636; Florescu M, 2008, J THORAC ONCOL, V3, P590, DOI 10.1097/JTO.0b013e3181729299; Wigren T, 1997, RADIOTHER ONCOL, V44, P9, DOI 10.1016/S0167-8140(97)00087-X; Mandrekar SJ, 2006, CANCER, V107, P781, DOI 10.1002/cncr.22049; Sobin LH, 2001, CANCER, V91, P1589, DOI 10.1002/1097-0142(20010415)91:8+<1589::AID-CNCR1170>3.0.CO;2-K; Yilmaz A, 2011, EUR J CARDIO-THORAC, V40, P664, DOI 10.1016/j.ejcts.2010.12.059; Moons KGM, 2012, HEART, V98, P683, DOI 10.1136/heartjnl-2011-301246; Matsumura Y, 2014, J THORAC ONCOL, V9, P337, DOI 10.1097/JTO.0000000000000073; VINCENT MD, 1987, EUR J CANCER CLIN ON, V23, P1589, DOI 10.1016/0277-5379(87)90436-6; SOUHAMI RL, 1985, CANCER RES, V45, P2878; Shimada Y, 2012, J THORAC ONCOL, V7, P1263, DOI 10.1097/JTO.0b013e31825cca6e; de Jong WK, 2007, CLIN LUNG CANCER, V8, P376, DOI 10.3816/CLC.2007.n.018; Di Maio M, 2010, EUR J CANCER, V46, P735, DOI 10.1016/j.ejca.2009.12.013; Gagnon B, 2013, BRIT J CANCER, V109, P2066, DOI 10.1038/bjc.2013.515; Di Maio M, 2012, LUNG CANCER, V77, P116, DOI 10.1016/j.lungcan.2012.01.013; Greene FL, 2009, J SURG ONCOL, V99, P269, DOI 10.1002/jso.21237; Moons KGM, 2012, HEART, V98, P691, DOI 10.1136/heartjnl-2011-301247; Wojas-Krawczyk K, 2011, RESPIRATION, V82, P341, DOI 10.1159/000322843; Lopez-Encuentra A, 2011, EUR RESPIR J, V37, P136, DOI 10.1183/09031936.00028610; Blanchon F, 2006, LANCET ONCOL, V7, P829, DOI 10.1016/S1470-2045(06)70868-3; Park MJ, 2009, CANCER, V115, P1518, DOI 10.1002/cncr.24151; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI 10.7326/M14-0697; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Padilla J, 2002, LUNG CANCER-J IASLC, V36, P43, DOI 10.1016/S0169-5002(01)00450-0; Gospodarowicz MK, 2004, CANCER, V100, P1, DOI 10.1002/cncr.11898; Williams BA, 2006, ANN THORAC SURG, V81, P1021, DOI 10.1016/j.athoracsur.2005.09.020; Hoang T, 2005, J CLIN ONCOL, V23, P175, DOI 10.1200/JCO.2005.04.177; Hong S, 2010, ONCOLOGY-BASEL, V79, P293, DOI 10.1159/000323333; Giroux DJ, 2009, J THORAC ONCOL, V4, P679, DOI 10.1097/JTO.0b013e3181a52370; Vickers AJ, 2011, CA-CANCER J CLIN, V61, P315, DOI 10.3322/caac.20118; Hermanek P, 1996, CANCER, V77, P815, DOI 10.1002/(SICI)1097-0142(19960301)77:5<815::AID-CNCR1>3.0.CO;2-D; McShane LM, 2005, J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237; Sculier JP, 2008, J THORAC ONCOL, V3, P457, DOI 10.1097/JTO.0b013e31816de2b8; [Anonymous], 2008, WILL YOUR PATIENT BE; [Anonymous], 2011, ADJUVANT LUNG CANC N; Maestu I, 1997, ANN ONCOL, V8, P547, DOI 10.1023/A:1008212826956; Tibaldi C, 2008, J CANCER RES CLIN, V134, P1143, DOI 10.1007/s00432-008-0378-2; Chansky K, 2009, J THORAC ONCOL, V4, P792, DOI 10.1097/JTO.0b013e3181a7716e; Bouwmeester Walter, 2012, PLoS Med, V9, P1, DOI 10.1371/journal.pmed.1001221; CERNY T, 1987, INT J CANCER, V39, P146, DOI 10.1002/ijc.2910390204; Edge SB, 2010, AJCC CANC STAG MAN; Goldstraw P., 2009, IASLC STAGING MANUAL; Harrell FE, 2001, REGRESSION MODELING; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hemingway H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e5595; Hingorani AD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e5793; Kawahara M, 1997, JPN J CLIN ONCOL, V27, P158, DOI 10.1093/jjco/27.3.158; Mahar AL, 2013, J CLIN ONCOL, V31; Mallett S, 2010, BMC MED, V8; Mallett S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-21; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Moons KGM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001744; Mou WJ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0059-8; Oberije C, 2014, RADIOTHER ONCOL, V112, P37, DOI 10.1016/j.radonc.2014.04.012; Putila J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017493; Putila J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100994; Rami-Porta R, 2014, J THORAC ONCOL, V9, P1618, DOI 10.1097/JTO.0000000000000334; Riley RD, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001380; Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381; Steyerberg EW, 2009, CLIN PREDICTION MODE; Ulas A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114471; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Zhang KJ, 2015, INT J CANCER, V136, P382, DOI 10.1002/ijc.28995	71	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	NOV	2015	10	11					1576	1589		10.1097/JTO.0000000000000652		14	Oncology; Respiratory System	Oncology; Respiratory System	CU1WL	WOS:000363312700010		
J	Inoue, Y; Matsuura, S; Kurabe, N; Kahyo, T; Mori, H; Kawase, A; Karayama, M; Inui, N; Funai, K; Shinmura, K; Suda, T; Sugimura, H				Inoue, Yusuke; Matsuura, Shun; Kurabe, Nobuya; Kahyo, Tomoaki; Mori, Hiroki; Kawase, Akikazu; Karayama, Masato; Inui, Naoki; Funai, Kazuhito; Shinmura, Kazuya; Suda, Takafumi; Sugimura, Haruhiko			Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification	JOURNAL OF THORACIC ONCOLOGY			English	Article						Non-small-cell lung cancer; Gene amplification; Coamplification; NKX2-1; SETDB1	IN-SITU HYBRIDIZATION; INDEPENDENT PROGNOSTIC-FACTOR; COPY NUMBER; PROTEIN EXPRESSION; GEFITINIB THERAPY; 3Q AMPLIFICATION; ADENOCARCINOMA; RESISTANCE; CARCINOMAS; ONCOGENE	Introduction: Gene amplification is an important genetic change in cancer cells. We investigated the prevalence, clinicopathological characteristics, and prognostic value of NKX2-1 (also known as TTF-1), SETDB1, MET, HER2, SOX2, FGFR1, and PIK3CA amplification in Japanese patients with non-small-cell lung cancer (NSCLC). Methods: The copy numbers of the seven above-mentioned genes were assessed using fluorescence in situ hybridization in a tissue microarray containing 282 surgically resected NSCLC specimens (164 adenocarcinoma [AC], 99 squamous cell carcinoma [SCC], and 19 others). Clinicopathological information were obtained from the medical records. Results:NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, and PIK3CA gene amplification were observed in 30 of 277 (10.8%), 16 of 280 (5.7%), 38 of 278 (13.7%), 8 of 270 (3.0%), 34 of 278 (12.2%), 18 of 282 (6.4%), and 53 of 278 (19.1%) cases, respectively. Coamplification was detected in 16 of 156 (10.3%) AC patients and 35 of 93 (37.6%) SCC patients (p < 0.0001). NKX2-1 amplification was significantly related to an AC histology (p = 0.004), whereas SOX2, FGFR1, and PIK3CA amplifications were related to a SCC histology (p < 0.0001). Within the ACs, NKX2-1 and SETDB1 amplifications were markers of a shorter survival period. A multivariate Cox proportional hazards model revealed that NKX2-1 amplification was an independent predictor of poor survival (hazard ratio, 2.938; 95% confidence interval, 1.434-6.022; p = 0.003). Coamplification had impact on patient outcome in AC but not in entire NSCLC and SCC. Conclusions: The amplification status differed among the histological types of NSCLC. NKX2-1 amplification was an independent and the most practically important predictor of a poor prognosis among Japanese patients with AC.	[Inoue, Yusuke; Matsuura, Shun; Kurabe, Nobuya; Kahyo, Tomoaki; Shinmura, Kazuya; Sugimura, Haruhiko] Hamamatsu Univ Sch Med, Dept Tumor Pathol, Hamamatsu, Shizuoka 4313192, Japan; [Inoue, Yusuke; Matsuura, Shun; Karayama, Masato; Inui, Naoki; Suda, Takafumi] Hamamatsu Univ Sch Med, Dept Internal Med, Div 2, Hamamatsu, Shizuoka 4313192, Japan; [Mori, Hiroki] Hamamatsu Med Ctr, Dept Pathol, Hamamatsu, Shizuoka, Japan; [Kawase, Akikazu; Funai, Kazuhito] Hamamatsu Univ Sch Med, Dept Surg 1, Hamamatsu, Shizuoka 4313192, Japan; [Karayama, Masato] Hamamatsu Univ Sch Med, Clin Oncol, Hamamatsu, Shizuoka 4313192, Japan; [Inui, Naoki] Hamamatsu Univ Sch Med, Clin Pharmacol & Therapeut, Hamamatsu, Shizuoka 4313192, Japan	Sugimura, H (reprint author), Hamamatsu Univ Sch Med, Dept Tumor Pathol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	hsugimur@hama-med.ac.jp	Shinmura, Kazuya /K-8940-2012	Shinmura, Kazuya /0000-0003-4963-746X	Ministry of Health, Labour and Welfare [19-19, 10103838]; Japan Society for the Promotion of Science [22590356, 23790396]; Ministry of Education, Culture, Sports, Science and Technology [S-001]; National Cancer Center Research and Development Fund [25-A-1]; Ministry of Health, Labor and Welfare	This work was supported by grants from the Ministry of Health, Labour and Welfare (19-19, 10103838), the Japan Society for the Promotion of Science (22590356, 23790396), the Ministry of Education, Culture, Sports, Science and Technology (S-001), the National Cancer Center Research and Development Fund (25-A-1), and Research on global health issues from Ministry of Health, Labor and Welfare.	Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Tran TN, 2013, LUNG CANCER, V81, P462, DOI 10.1016/j.lungcan.2013.05.015; Watanabe Y, 2004, GENOMICS, V84, P796, DOI 10.1016/j.ygeno.2004.08.001; Wilbertz T, 2011, MODERN PATHOL, V24, P944, DOI 10.1038/modpathol.2011.49; Pelosi G, 2007, CLIN CANCER RES, V13, P1995, DOI 10.1158/1078-0432.CCR-06-2483; Cappuzzo F, 2009, ANN ONCOL, V20, P298, DOI 10.1093/annonc/mdn635; Dziadziuszko R, 2012, J THORAC ONCOL, V7, P340, DOI 10.1097/JTO.0b013e318240ca0d; Beau-Faller M, 2008, J THORAC ONCOL, V3, P331, DOI 10.1097/JTO.0b013e318168d9d4; Cappuzzo F, 2005, J CLIN ONCOL, V23, P5007, DOI 10.1200/JCO.2005.09.111; Barletta JA, 2009, J CELL MOL MED, V13, P1977, DOI 10.1111/j.1582-4934.2008.00594.x; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Kawano O, 2007, LUNG CANCER, V58, P159, DOI 10.1016/j.lungcan.2007.06.020; Kim HR, 2013, J CLIN ONCOL, V31, P731, DOI 10.1200/JCO.2012.43.8622; Pellegrini C, 2003, CLIN CANCER RES, V9, P3645; Tang XM, 2011, CLIN CANCER RES, V17, P2434, DOI 10.1158/1078-0432.CCR-10-1412; Sano T, 2006, PATHOL INT, V56, P117, DOI 10.1111/j.1440-1827.2006.01940.x; Toschi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095303; Okudela K, 2007, PATHOL INT, V57, P664, DOI 10.1111/j.1440-1827.2007.02155.x; Harte PJ, 1999, CYTOGENET CELL GENET, V84, P83, DOI 10.1159/000015220; Kiyose S, 2012, PATHOL INT, V62, P477, DOI 10.1111/j.1440-1827.2012.02832.x; Saito RA, 2009, CANCER RES, V69, P2783, DOI 10.1158/0008-5472.CAN-08-3490; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Heinmoller P, 2003, CLIN CANCER RES, V9, P5238; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Anagnostou VK, 2009, J CLIN ONCOL, V27, P271, DOI 10.1200/JCO.2008.17.0043; Lee JS, 2013, ANN SURG ONCOL, V20, P3015, DOI 10.1245/s10434-013-2937-2; Cappuzzo F, 2009, J CLIN ONCOL, V27, P1667, DOI 10.1200/JCO.2008.19.1635; Sugimura H, 2008, CARCINOGENESIS, V29, P681, DOI 10.1093/carcin/bgn046; Massion PP, 2002, CANCER RES, V62, P3636; Gomez-Martin C, 2013, J CLIN ONCOL, V31, P4445, DOI 10.1200/JCO.2013.48.9070; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Hirsch FR, 2002, BRIT J CANCER, V86, P1449, DOI 10.1038/sj/bjc/6600286; Hussenet T, 2010, CELL CYCLE, V9, P1480, DOI 10.4161/cc.9.8.11203; Cihoric N, 2014, BRIT J CANCER, V110, P2914, DOI 10.1038/bjc.2014.229; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Kendall J, 2007, P NATL ACAD SCI USA, V104, P16663, DOI 10.1073/pnas.0708286104; McCaughan F, 2010, AM J RESP CRIT CARE, V182, P83, DOI 10.1164/rccm.201001-0005OC; Perner S, 2009, J PATHOL, V217, P65, DOI 10.1002/path.2443; Qian J, 2008, J THORAC ONCOL, V3, P212, DOI 10.1097/JTO.0b013e3181663544; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Dutt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020351; Jiang T, 2015, LUNG CANCER, V87, P1, DOI 10.1016/j.lungcan.2014.11.009; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022; Mass Robert D, 2005, Clin Breast Cancer, V6, P240, DOI 10.3816/CBC.2005.n.026; Matsuura S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03012; Rodriguez-Paredes M, 2014, ONCOGENE, V22, P2807; Suzuki M, 2015, LUNG CANCER, V87, P14, DOI 10.1016/j.lungcan.2014.10.014; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451	50	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	NOV	2015	10	11					1590	1600		10.1097/JTO.0000000000000685		11	Oncology; Respiratory System	Oncology; Respiratory System	CU1WL	WOS:000363312700011		
J	Hamaji, M; Chen, FS; Matsuo, Y; Ueki, N; Hiraoka, M; Date, H				Hamaji, Masatsugu; Chen, Fengshi; Matsuo, Yukinori; Ueki, Nami; Hiraoka, Masahiro; Date, Hiroshi			Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Importance of Salvage Surgery	JOURNAL OF THORACIC ONCOLOGY			English	Article						Non-small-cell lung cancer; Surgery; Radiotherapy; Chemotherapy	POSITRON-EMISSION-TOMOGRAPHY; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; THORACOSCOPIC LOBECTOMY; TUMOR RECURRENCE; F-18-FDG PET/CT; HIGH-RISK; RESECTION; FAILURE; OUTCOMES	Introduction: Many efforts have been made to detect local relapse (LR) in the follow-up after stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC) although limited data are available on its treatment and prognosis. We aimed to characterize treatment options and clarify long-term outcomes of isolated LR after SBRT for patients with clinical stage I NSCLC. Methods: We reviewed our institutional database in search of patients with isolated LR after SBRT for clinical stage I NSCLC at our institution between 1999 and 2013. Patient characteristics were compared with Mann-Whitney U test, (2) test, or Fisher's exact test as appropriate. Survival outcomes were estimated with Kaplan-Meier method. Potential prognostic factors were investigated using Cox proportional hazard model. Results: Of 308 patients undergoing SBRT for clinical stage I NSCLC, 49 patients were identified to have isolated LR. Twelve patients underwent salvage surgery, none underwent radiotherapy, and eight patients received chemotherapy, whereas 29 patients received best supportive care. No patient characteristic except operability was significantly related with patient selection for LR treatments. Five-year overall survival (OS) rate of the whole cohort was 47.9% from SBRT and 25.7% from LR. Salvage surgery was associated with improved OS after LR (p = 0.014), and 5-year OS for patients undergoing salvage surgery was 79.5% from LR. Conclusions: It was confirmed that our patient selection for salvage surgery for isolated LR was associated with favorable survival outcomes. Operability based on multidisciplinary conferences, rather than measurable patient characteristics, is essential for appropriate patient selection for salvage surgery.	[Hamaji, Masatsugu; Chen, Fengshi; Date, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto 6068507, Japan; [Matsuo, Yukinori; Ueki, Nami; Hiraoka, Masahiro] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan	Date, H (reprint author), Kyoto Univ Hosp, Dept Thorac Surg, Sakyo Ku, 54 Kawaharacho, Kyoto 6068507, Japan.	hdate@kuhp.kyoto-u.ac					Ricardi U, 2014, LUNG CANCER, V84, P248, DOI 10.1016/j.lungcan.2014.02.015; Senthi S, 2012, LANCET ONCOL, V13, P802, DOI 10.1016/S1470-2045(12)70242-5; Satoh Y, 2012, EUR J RADIOL, V81, P3530, DOI 10.1016/j.ejrad.2011.11.047; Ebright MI, 2013, J THORAC CARDIOV SUR, V145, P709, DOI 10.1016/j.jtcvs.2012.12.024; Bollineni VR, 2012, INT J RADIAT ONCOL, V83, pE551, DOI 10.1016/j.ijrobp.2012.01.012; Hamaji M, 2015, ANN THORAC SURG, V99, P1122, DOI 10.1016/j.athoracsur.2014.11.009; Seder CW, 2013, ANN THORAC SURG, V95, P1708, DOI 10.1016/j.athoracsur.2013.02.041; Bradley JD, 2010, INT J RADIAT ONCOL, V77, P1146, DOI 10.1016/j.ijrobp.2009.06.017; Essler M, 2013, STRAHLENTHER ONKOL, V189, P495, DOI 10.1007/s00066-013-0310-9; Huang K, 2012, RADIOTHER ONCOL, V102, P335, DOI 10.1016/j.radonc.2011.12.018; Ng T, 2010, ANN SURG ONCOL, V17, P476, DOI 10.1245/s10434-009-0810-0; Zhang X, 2012, INT J RADIAT ONCOL, V83, P1558, DOI 10.1016/j.ijrobp.2011.10.035; Imai H, 2013, ANTICANCER RES, V33, P3279; Chen FS, 2010, J THORAC ONCOL, V5, P1999, DOI 10.1097/JTO.0b013e3181f260f9; Senan S, 2013, LANCET ONCOL, V14, pE270, DOI 10.1016/S1470-2045(12)70592-2; Meijneke TR, 2013, RADIOTHER ONCOL, V107, P423, DOI 10.1016/j.radonc.2013.03.015; Peulen H, 2011, RADIOTHER ONCOL, V101, P260, DOI 10.1016/j.radonc.2011.09.012; Fakiris AJ, 2009, INT J RADIAT ONCOL, V75, P677, DOI 10.1016/j.ijrobp.2008.11.042; Allibhai Z, 2012, EUR RESPIR J, V39, P1039, DOI 10.1183/09031936.00075811; Hearn JWD, 2014, INT J RADIAT ONCOL, V90, P402, DOI 10.1016/j.ijrobp.2014.05.048; Allibhai Z, 2013, INT J RADIAT ONCOL, V87, P1064, DOI 10.1016/j.ijrobp.2013.08.020; Takeda A, 2013, LUNG CANCER, V79, P248, DOI 10.1016/j.lungcan.2012.11.008; Kopek N, 2009, RADIOTHER ONCOL, V93, P402, DOI 10.1016/j.radonc.2009.06.002; Dunlap NE, 2010, J THORAC CARDIOV SUR, V140, P583, DOI 10.1016/j.jtcvs.2010.01.046; Robinson CG, 2013, J THORAC ONCOL, V8, P192, DOI 10.1097/JTO.0b013e31827ce361; Dunlap NE, 2012, INT J RADIAT ONCOL, V84, P1071, DOI 10.1016/j.ijrobp.2012.01.088; Neri S, 2010, J THORAC ONCOL, V5, P2003, DOI 10.1097/JTO.0b013e3181f8a785; Nwogu CE, 2015, ANN THORAC SURG, V99, P399, DOI 10.1016/j.athoracsur.2014.09.018; Crabtree TD, 2010, J THORAC CARDIOV SUR, V140, P377, DOI 10.1016/j.jtcvs.2009.12.054; CHARLSON ME, 1987, J CHRON DIS, V40, P31, DOI 10.1016/0021-9681(87)90094-4; Song ZB, 2014, J CLIN NEUROSCI, V21, P591, DOI 10.1016/j.jocn.2013.05.022; Nakajima N, 2013, ANN NUCL MED, V27, P261, DOI 10.1007/s12149-012-0682-4; Chen YS, 2008, RADIOTHER ONCOL, V88, P351, DOI 10.1016/j.radonc.2008.07.013; Huang K, 2013, RADIOTHER ONCOL, V109, P51, DOI 10.1016/j.radonc.2013.06.047; Taira N, 2014, ANN THORAC SURG, V97, P2167, DOI 10.1016/j.athoracsur.2013.07.123; Burt BM, 2014, J THORAC CARDIOV SUR, V148, P19, DOI 10.1016/j.jtcvs.2014.03.007; Sonobe M, 2014, ANN SURG ONCOL, V21, P2546, DOI 10.1245/s10434-014-3630-9; Valakh V, 2013, J CANCER RES THER, V9, P680, DOI 10.4103/0973-1482.126481; Grills IS, 2010, J CLIN ONCOL, V28, P928, DOI 10.1200/JCO.2009.25.0928; Chang JY, 2015, LANCET ONCOL, V16, P630, DOI 10.1016/S1470-2045(15)70168-3; Birim O, 2003, EUR J CARDIO-THORAC, V23, P30, DOI 10.1016/S1010-7940(02)00721-2; Hamaji M, 2013, ASIAN CARDIOVASC THO, V22, P700; Ishikura Satoshi, 2012, Gen Thorac Cardiovasc Surg, V60, P127, DOI 10.1007/s11748-011-0832-y; Matsuo Y, 2014, EUR J CANCER, V50, P2932, DOI 10.1016/j.ejca.2014.09.006; Yamashita Shin-Ichi, 2014, Gen Thorac Cardiovasc Surg, V62, P701, DOI 10.1007/s11748-014-0467-x; Yano Tokujiro, 2014, World J Clin Oncol, V5, P1048, DOI 10.5306/wjco.v5.i5.1048	46	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1556-0864	1556-1380		J THORAC ONCOL	J. Thorac. Oncol.	NOV	2015	10	11					1616	1624		10.1097/JTO.0000000000000662		9	Oncology; Respiratory System	Oncology; Respiratory System	CU1WL	WOS:000363312700014		
J	Zhao, DM; Fukuyama, S; Yamada, S; Lopes, TJS; Maemura, T; Katsura, H; Ozawa, M; Watanabe, S; Neumann, G; Kawaoka, Y				Zhao, Dongming; Fukuyama, Satoshi; Yamada, Shinya; Lopes, Tiago J. S.; Maemura, Tadashi; Katsura, Hiroaki; Ozawa, Makoto; Watanabe, Shinji; Neumann, Gabriele; Kawaoka, Yoshihiro			Molecular Determinants of Virulence and Stability of a Reporter-Expressing H5N1 Influenza A Virus	JOURNAL OF VIROLOGY			English	Article							IN-VIVO; RNA-POLYMERASE; GENETIC COMPATIBILITY; INFECTION; MICE; PROTEIN; REPLICATION; CONTRIBUTE; HOST; PA	We previously reported that an H5N1 virus carrying the Venus reporter gene, which was inserted into the NS gene segment from the A/Puerto Rico/8/1934(H1N1) virus (Venus-H5N1 virus), became more lethal to mice, and the reporter gene was stably maintained after mouse adaptation compared with the wild-type Venus-H5N1 (WT-Venus-H5N1) virus. However, the basis for this difference in virulence and Venus stability was unclear. Here, we investigated the molecular determinants behind this virulence and reporter stability by comparing WT-Venus-H5N1 virus with a mouse-adapted Venus-H5N1 (MA-Venus-H5N1) virus. To determine the genetic basis for these differences, we used reverse genetics to generate a series of reassortants of these two viruses. We found that reassortants with PB2 from MA-Venus-H5N1 (MA-PB2), MA-PA, or MA-NS expressed Venus more stably than did WT-Venus-H5N1 virus. We also found that a single mutation in PB2 (V25A) or in PA (R443K) increased the virulence of the WT-Venus-H5N1 virus in mice and that the presence of both of these mutations substantially enhanced the pathogenicity of the virus. Our results suggest roles for PB2 and PA in the stable maintenance of a foreign protein as an NS1 fusion protein in influenza A virus. IMPORTANCE The ability to visualize influenza viruses has far-reaching benefits in influenza virus research. Previously, we reported that an H5N1 virus bearing the Venus reporter gene became more pathogenic to mice and that its reporter gene was more highly expressed and more stably maintained after mouse adaptation. Here, we investigated the molecular determinants behind this enhanced virulence and reporter stability. We found that mutations in PB2 (V25A) and PA (R443K) play crucial roles in the stable maintenance of a foreign protein as an NS1 fusion protein in influenza A virus and in the virulence of influenza virus in mice. Our findings further our knowledge of the pathogenicity of influenza virus in mammals and will help advance influenza virus-related live-imaging studies in vitro and in vivo.	[Zhao, Dongming; Fukuyama, Satoshi; Lopes, Tiago J. S.; Watanabe, Shinji; Kawaoka, Yoshihiro] Japan Sci & Technol Agcy, Exploratory Res Adv Technol Infect Induced Host R, Saitama, Japan; [Zhao, Dongming; Fukuyama, Satoshi; Yamada, Shinya; Maemura, Tadashi; Katsura, Hiroaki; Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Div Virol, Dept Microbiol & Immunol, Tokyo, Japan; [Ozawa, Makoto] Kagoshima Univ, Lab Anim Hyg, Joint Fac Vet Med, Kagoshima 890, Japan; [Ozawa, Makoto] Kagoshima Univ, Transboundary Anim Distance Ctr, Joint Fac Vet Med, Kagoshima 890, Japan; [Watanabe, Shinji] Miyazaki Univ, Dept Vet Sci, Microbiol, Miyazaki, Japan; [Neumann, Gabriele; Kawaoka, Yoshihiro] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA; [Kawaoka, Yoshihiro] Univ Tokyo, Inst Med Sci, Dept Special Pathogens, Int Res Ctr Infect Dis, Tokyo, Japan	Kawaoka, Y (reprint author), Japan Sci & Technol Agcy, Exploratory Res Adv Technol Infect Induced Host R, Saitama, Japan.	kawaoka@ims.u-tokyo.ac.jp			Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Ministry of Health, Labor and Welfare, Japan; ERATO; Strategic Basic Research Programs of the Japan Science and Technology Agency; Advanced Research & Development Programs for Medical Innovation from the Japan Agency for Medical Research and Development (AMED); NIAID-funded Center for Research on Influenza Pathogenesis (CRIP) grant [HHSN266200700010C]; JSPS	This work was supported by the Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science and Technology, Japan; by grants-in-aid from the Ministry of Health, Labor and Welfare, Japan; by ERATO and the Strategic Basic Research Programs of the Japan Science and Technology Agency; by the Advanced Research & Development Programs for Medical Innovation from the Japan Agency for Medical Research and Development (AMED); and by an NIAID-funded Center for Research on Influenza Pathogenesis (CRIP) grant (HHSN266200700010C). H. Katsura is supported by JSPS research fellowships for young scientists.	Hu J, 2013, J VIROL, V87, P2660, DOI 10.1128/JVI.02891-12; Regan JF, 2006, J VIROL, V80, P252, DOI 10.1128/JVI.80.1.252-261.2006; Chua MA, 2013, CELL REP, V3, P23, DOI 10.1016/j.celrep.2012.12.010; Song JS, 2011, J VIROL, V85, P2180, DOI 10.1128/JVI.01975-10; Fan SF, 2009, VIROLOGY, V384, P28, DOI 10.1016/j.virol.2008.11.044; Yamayoshi S, 2014, J VIROL, V88, P3127, DOI 10.1128/JVI.03155-13; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Sugiyama K, 2009, EMBO J, V28, P1803, DOI 10.1038/emboj.2009.138; Neumann G, 2010, CELL RES, V20, P51, DOI 10.1038/cr.2009.124; Chen HY, 2014, LANCET, V383, P714, DOI 10.1016/S0140-6736(14)60111-2; Looney MR, 2011, NAT METHODS, V8, P91, DOI [10.1038/nmeth.1543, 10.1038/NMETH.1543]; Leung BW, 2010, VIROLOGY, V401, P96, DOI 10.1016/j.virol.2010.01.036; Suguitan AL, 2012, J VIROL, V86, P2706, DOI 10.1128/JVI.05546-11; Manicassamy B, 2010, P NATL ACAD SCI USA, V107, P11531, DOI 10.1073/pnas.0914994107; Li CJ, 2008, J VIROL, V82, P11880, DOI 10.1128/JVI.01445-08; Murakami S, 2008, J VIROL, V82, P1605, DOI 10.1128/JVI.01876-07; Naffakh N, 2008, ANNU REV MICROBIOL, V62, P403, DOI 10.1146/annurev.micro.62.081307.162746; Shinya K, 2004, J VIROL, V78, P3083, DOI 10.1128/JVI.78.6.3083-3088.2004; Robb NC, 2009, J GEN VIROL, V90, P1398, DOI 10.1099/vir.0.009639-0; Ozawa M, 2007, J VIROL, V81, P30, DOI 10.1128/JVI.01434-06; Zhao DM, 2012, PROTEOMICS, V12, P1970, DOI 10.1002/pmic.201100619; KAWAOKA Y, 1988, P NATL ACAD SCI USA, V85, P324, DOI 10.1073/pnas.85.2.324; Zhang H, 2014, J GEN VIROL, V95, P779, DOI 10.1099/vir.0.061721-0; Gabriel G, 2005, P NATL ACAD SCI USA, V102, P18590, DOI 10.1073/pnas.0507415102; Salomon R, 2006, J EXP MED, V203, P689, DOI 10.1084/jem.20051938; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Sun YP, 2011, P NATL ACAD SCI USA, V108, P4164, DOI 10.1073/pnas.1019109108; Kittel C, 2004, VIROLOGY, V324, P67, DOI 10.1016/j.virol.2004.03.035; Zhang Y, 2013, SCIENCE, V340, P1459, DOI 10.1126/science.1229455; Li ZJ, 2006, J VIROL, V80, P11115, DOI 10.1128/JVI.00993-06; He XJ, 2008, NATURE, V454, P1123, DOI 10.1038/nature07120; Octaviani CP, 2010, J VIROL, V84, P10918, DOI 10.1128/JVI.01140-10; Kreisel D, 2010, P NATL ACAD SCI USA, V107, P18073, DOI 10.1073/pnas.1008737107; Helft J, 2012, J CLIN INVEST, V122, P4037, DOI 10.1172/JCI60659; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Heaton NS, 2013, J VIROL, V87, P8272, DOI 10.1128/JVI.00969-13; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Li YB, 2010, J VIROL, V84, P8389, DOI 10.1128/JVI.00413-10; Obayashi E, 2008, NATURE, V454, P1127, DOI 10.1038/nature07225; Fournier G, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004164; Fukuyama S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7600; HOLM S, 1979, SCAND J STAT, V6, P65; Li Q, 2014, NEW ENGL J MED, V370, P520, DOI 10.1056/NEJMoa1304617; Pan WQ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3369; REED L. J., 1938, AMER JOUR HYG, V27, P493; Schmolke M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002186	47	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	NOV	2015	89	22					11337	11346		10.1128/JVI.01886-15		10	Virology	Virology	CU4AC	WOS:000363467200015		
J	Oda, K; Matoba, Y; Irie, T; Kawabata, R; Fukushi, M; Sugiyama, M; Sakaguchi, T				Oda, Kosuke; Matoba, Yasuyuki; Irie, Takashi; Kawabata, Ryoko; Fukushi, Masaya; Sugiyama, Masanori; Sakaguchi, Takemasa			Structural Basis of the Inhibition of STAT1 Activity by Sendai Virus C Protein	JOURNAL OF VIROLOGY			English	Article							VIRAL-RNA SYNTHESIS; INTERFERON RESPONSE; ANTIVIRAL ACTION; ACTIVATION; EXPRESSION; DEPHOSPHORYLATION; PHOSPHORYLATION; IMPAIRS; ABILITY; GENOME	Sendai virus (SeV) C protein inhibits the signal transduction pathways of interferon alpha/beta (IFN-alpha/beta) and IFN-gamma by binding to the N-terminal domain of STAT1 (STAT1ND), thereby allowing SeV to escape from host innate immunity. Here we determined the crystal structure of STAT1ND associated with the C-terminal half of the C protein (Y3 [amino acids 99 to 204]) at a resolution of 2.0 angstrom. This showed that two molecules of Y3 symmetrically bind to each niche created between two molecules of the STAT1ND dimer. Molecular modeling suggested that an antiparallel form of the full-length STAT1 dimer can bind only one Y3 molecule and that a parallel form can bind two Y3 molecules. Affinity analysis demonstrated anticooperative binding of two Y3 molecules with the STAT1 dimer, which is consistent with the hypothetical model that the second Y3 molecule can only target the STAT1 dimer in a parallel form. STAT1 with excess amounts of Y3 was prone to inhibit the dephosphorylation at Tyr(701) by a phosphatase. In an electrophoretic mobility shift assay, tyrosine-phosphorylated STAT1 (pY-STAT1) with Y3 associated with the gamma-activated sequence, probably as high-molecular-weight complexes (HMWCs), which may account for partial inhibition of a reporter assay from IFN-gamma by Y3. Our study suggests that the full-length C protein interferes with the domain arrangement of the STAT1 dimer, leading to the accumulation of pY-STAT1 and the formation of HMWCs. In addition, we discuss the mechanism by which phosphorylation of STAT2 is inhibited in the presence of the C protein after stimulation by IFN-alpha/beta. IMPORTANCE Sendai virus, a paramyxovirus that causes respiratory diseases in rodents, possesses the C protein, which inhibits the signal transduction pathways of interferon alpha/beta (IFN-alpha/beta) and IFN-alpha by binding to the transcription factor STAT1. In virusinfected cells, phosphorylation of STAT1 at the Tyr701 residue is potently enhanced, although transcription by STAT1 is inert. Here, we determined the crystal structure of the N-terminal domain of STAT1 associated with the C-terminal half of the C protein. Molecular modeling and experiments suggested that the two C proteins bind to and stabilize the parallel form of the STAT1 dimer, which are likely to be phosphorylated at Tyr701, further inducing high-molecular-weight complex formation and inhibition of transcription by IFN-gamma. We also discuss the possible mechanism of inhibition of the IFN-alpha/beta pathways by the C protein. This is the first structural report of the C protein, suggesting a mechanism of evasion of the paramyxovirus from innate immunity.	[Oda, Kosuke; Irie, Takashi; Kawabata, Ryoko; Fukushi, Masaya; Sakaguchi, Takemasa] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Virol, Hiroshima, Japan; [Matoba, Yasuyuki; Sugiyama, Masanori] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Mol Microbiol & Biotechnol, Hiroshima, Japan	Sakaguchi, T (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Virol, Hiroshima, Japan.	tsaka@hiroshima-u.ac.jp			Inamori Foundation; Glaxo-SmithCline Japan; Takeda Science Foundation; Japan Society for the Promotion of Science	This study was funded by the Inamori Foundation (to K.O.), Glaxo-SmithCline Japan (to K.O.), the Takeda Science Foundation (to K.O.), and the Japan Society for the Promotion of Science (to T.S. and K.O.).	Sakaguchi T, 2011, NEUROSCI LETT, V505, P279, DOI 10.1016/j.neulet.2011.10.040; Wenta N, 2008, P NATL ACAD SCI USA, V105, P9238, DOI 10.1073/pnas.0802130105; NIWA H, 1991, GENE, V108, P193; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Kato A, 2001, J VIROL, V75, P3802, DOI 10.1128/JVI.75.8.3802-3810.2001; Takeuchi K, 2001, GENES CELLS, V6, P545, DOI 10.1046/j.1365-2443.2001.00442.x; Kato A, 2002, J VIROL, V76, P7114, DOI 10.1128/JVI.76.14.7114-7124.2002; Gotoh B, 2003, J VIROL, V77, P3360, DOI 10.1128/JVI.77.6.3360-3370.2003; Young DF, 2000, VIROLOGY, V269, P383, DOI 10.1006/viro.2000.0240; Sugahara F, 2004, VIROLOGY, V325, P1, DOI 10.1016/j.virol.2004.04.019; Schaap M, 2013, PROTEIN SCI, V22, P1812, DOI 10.1002/pro.2384; Garcin D, 1999, J VIROL, V73, P6559; Gotoh B, 2004, FEBS LETT, V567, P291, DOI 10.1016/j.febslet.2004.05.001; Irie T, 2008, VIROLOGY, V374, P495, DOI 10.1016/j.virol.2008.01.004; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Garcin D, 2002, VIROLOGY, V295, P256, DOI 10.1006/viro.2001.1342; Hasan MK, 2000, J VIROL, V74, P5619, DOI 10.1128/JVI.74.12.5619-5628.2000; Takeuchi K, 2008, J VIROL, V82, P10102, DOI 10.1128/JVI.00599-08; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102; Komatsu T, 2002, FEBS LETT, V511, P139, DOI 10.1016/S0014-5793(01)03301-4; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Irie T, 2014, J VIROL, V88, P690, DOI 10.1128/JVI.02798-13; Kurotani A, 1998, GENES CELLS, V3, P111, DOI 10.1046/j.1365-2443.1998.00170.x; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gotoh B, 1999, FEBS LETT, V459, P205, DOI 10.1016/S0014-5793(99)01241-7; Nagai Y, 2011, BIOLOGY OF PARAMYXOVIRUSES, P115; Mertens C, 2006, GENE DEV, V20, P3372, DOI 10.1101/gad.1485406; Komatsu T, 2004, VIROLOGY, V325, P137, DOI 10.1016/j.virol.2004.04.025; *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DELANO WL, 2002, PYMOL MOL GRAPHICS S; Gotoh Bin, 2003, Virology, V316, P29, DOI 10.1016/S0042-6822(03)00590-7; Irie T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073740; Irie T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010719; Lamb RA, 2013, FIELDS VIROLOGY, V1, P957; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reich N. C., 2013, JAK STAT, V2, DOI DOI 10.4161/JKST.27080	38	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0022-538X	1098-5514		J VIROL	J. Virol.	NOV	2015	89	22					11487	11499		10.1128/JVI.01887-15		13	Virology	Virology	CU4AC	WOS:000363467200026		
J	Iriuchishima, T; Ryu, K; Aizawa, S; Fu, FH				Iriuchishima, Takanori; Ryu, Keinosuke; Aizawa, Shin; Fu, Freddie H.			Proportional evaluation of anterior cruciate ligament footprint size and knee bony morphology	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Anterior cruciate ligament; Anatomy; Double bundle; Prediction	ANATOMIC DOUBLE-BUNDLE; INTERCONDYLAR NOTCH WIDTH; PATELLAR TENDON-BONE; POSTEROLATERAL BUNDLES; TUNNEL PLACEMENT; TIBIAL INSERTIONS; SINGLE-BUNDLE; RECONSTRUCTION; GRAFT; ACL	The purpose of this study was to reveal the correlation in size between the native anterior cruciate ligament (ACL) footprint and the femoral intercondylar notch and the tibia plateau, and to calculate the proportion in size between the ACL footprint and knee bony morphology. Twenty-six non-paired human cadaver knees were used. All soft tissues around the knee were resected except the ACL. The ACL was cut in the middle, and the femoral bone was cut at the most proximal point of the femoral notch. The ACL was carefully dissected, and the periphery of the ACL insertion site was outlined on both the femoral and tibial sides. An accurate lateral view of the femoral condyle and an axial view of the tibial plateau were photographed with a digital camera, and the images were downloaded to a personal computer. The size of the femoral and tibial ACL footprints and the area of the lateral wall of the intercondylar notch and the tibia plateau were measured with Image J software (National Institution of Health). The sizes of the native femoral and tibial ACL footprints were 69.8 +/- A 25 and 133.8 +/- A 31.3 mm(2), respectively. The areas of the lateral wall of the intercondylar notch and the tibia plateau were 390.5 +/- A 70.5 and 2,281.7 +/- A 377.3 mm(2), respectively. The femoral ACL footprint area and the area of the lateral wall of the femoral intercondylar notch (Pearson's correlation coefficient = 0.603, p = 0.001), and the tibial ACL footprint area and the area of the tibia plateau (Pearson's correlation coefficient = 0.452, p = 0.02) both showed significant correlation. The femoral ACL footprint was 17.8 +/- A 4.9 %, the size of the lateral wall of the femoral intercondylar notch, and the tibial ACL footprint was 5.9 +/- A 1.3 %, the size of the tibia plateau. For clinical relevance, the femoral ACL footprint is approximately 18 %, the size of the intercondylar notch, and the tibial ACL footprint is approximately 6 %, the size of the tibia plateau. It might be possible to predict the size of the ACL measuring these parameters preoperatively.	[Iriuchishima, Takanori] Kamimoku Hot Springs Hosp, Dept Orthopaed Surg, Minakami, Japan; [Iriuchishima, Takanori; Aizawa, Shin] Nihon Univ, Sch Med, Dept Funct Morphol, Tokyo, Japan; [Ryu, Keinosuke] Surugadai Nihon Univ Hosp, Dept Orthopaed Surg, Tokyo, Japan; [Fu, Freddie H.] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA	Iriuchishima, T (reprint author), Kamimoku Hot Springs Hosp, Dept Orthopaed Surg, Minakami, Japan.	sekaiwoseisu@yahoo.co.jp					Ferretti M, 2007, ARTHROSCOPY, V23, P1218, DOI 10.1016/j.arthro.2007.09.008; Harner CD, 1999, ARTHROSCOPY, V15, P741, DOI 10.1016/S0749-8063(99)70006-X; Siebold R, 2008, ARTHROSCOPY, V24, P154, DOI 10.1016/j.arthro.2007.08.006; Shin SH, 2010, J HAND SURG-AM, V35A, P1120, DOI 10.1016/j.jhsa.2010.04.002; van Eck CF, 2011, ARTHROSCOPY, V27, P1235, DOI 10.1016/j.arthro.2011.03.085; van Eck CF, 2010, KNEE SURG SPORT TR A, V18, P1257, DOI [10.1007/s00167-010-1135-z, 10.1007/s00167-009-1038-z]; Davis TJ, 1999, KNEE SURG SPORT TR A, V7, P209, DOI 10.1007/s001670050150; Yasuda K, 2011, AM J SPORT MED, V39, P1789, DOI 10.1177/0363546511402659; Siebold R, 2008, ARTHROSCOPY, V24, P585, DOI 10.1016/j.arthro.2007.12.008; Fu FH, 2011, ORTHOPEDICS, V34, P281, DOI 10.3928/01477447-20110228-15; Muneta T, 2007, ARTHROSCOPY, V23, P618, DOI 10.1016/j.arthro.2007.04.010; Okada E, 2011, EUR SPINE J, V20, P1567, DOI 10.1007/s00586-011-1774-x; Iriuchishima T, 2009, KNEE SURG SPORT TR A, V17, P590, DOI 10.1007/s00167-008-0691-y; Darcy SP, 2006, J BIOMECH, V39, P2371, DOI 10.1016/j.jbiomech.2005.08.009; Kondo E, 2008, AM J SPORT MED, V36, P1675, DOI 10.1177/0363546508317123; Muneta T, 1997, AM J SPORT MED, V25, P69, DOI 10.1177/036354659702500113; Iriuchishima T, 2013, KNEE SURG SPORT TR A, V21, P789, DOI 10.1007/s00167-012-2044-0; Kopf S, 2009, KNEE SURG SPORT TR A, V17, P213, DOI 10.1007/s00167-008-0709-5; Kopf S, 2011, AM J SPORT MED, V39, P108, DOI 10.1177/0363546510377399; Yagi M, 2002, AM J SPORT MED, V30, P660; Steiner ME, 2008, AM J SPORT MED, V36, P176, DOI 10.1177/0363546507311690; Zantop T, 2008, AM J SPORT MED, V36, P65, DOI 10.1177/0363546507308361; Niki Y, 2011, ARTHROSCOPY, V27, P1242, DOI 10.1016/j.arthro.2011.03.086; Dargel J, 2006, SURG RADIOL ANAT, V28, P398, DOI 10.1007/s00276-006-0107-y; Luites JWH, 2007, KNEE SURG SPORT TR A, V15, P1422, DOI 10.1007/s00167-007-0402-0; Yasuda K, 2006, ARTHROSCOPY, V22, P240, DOI 10.1016/j.arthro.2005.12.017; Takahashi M, 2006, AM J SPORT MED, V34, P787, DOI 10.1177/0363546505282625; Iriuchishima T, 2011, ARCH ORTHOP TRAUM SU, V131, P1085, DOI 10.1007/s00402-011-1308-3; Stijak L, 2009, KNEE SURG SPORT TR A, V17, P812, DOI 10.1007/s00167-009-0807-z; Brophy RH, 2006, ARTHROSCOPY, V22, DOI 10.1016/j.arthro.2005.08.051; Loh JC, 2003, ARTHROSCOPY, V19, P297, DOI 10.1053/jars.2003.50084; Wolters F, 2011, KNEE SURG SPORT TR A, V19, pS17, DOI 10.1007/s00167-011-1503-3; Iriuchishima T, 2010, KNEE SURG SPORT TR A, V18, P1226, DOI 10.1007/s00167-010-1128-y; Shino K, 2008, ARTHROSCOPY, V24, P1178, DOI 10.1016/j.arthro.2008.06.010; Maeyama A, 2011, KNEE SURG SPORT TR A, V19, P1233, DOI 10.1007/s00167-010-1382-z; Karlsson J, 2011, AM J SPORT MED, V39, P2016, DOI 10.1177/0363546511402660; Iriuchishima T, 2015, KNEE SURG SPORT TR A, V23, P1147, DOI 10.1007/s00167-014-2927-3; Tompkins Marc, 2011, J Bone Joint Surg Am, V93, P789, DOI 10.2106/JBJS.J.01723; Wu Eileen, 2011, J Knee Surg, V24, P39	39	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	NOV	2015	23	11					3157	3162		10.1007/s00167-014-3139-6		6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CU1CW	WOS:000363258000005		
J	Orita, N; Deie, M; Shimada, N; Iwaki, D; Asaeda, M; Hirata, K; Ochi, M				Orita, Naoya; Deie, Masataka; Shimada, Noboru; Iwaki, Daisuke; Asaeda, Makoto; Hirata, Kazuhiko; Ochi, Mitsuo			Posterior tibial displacement in the PCL-deficient knee is reduced compared to the normal knee during gait	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Isolated posterior cruciate ligament injury; Point cluster technique; Gait analysis; Dynamic condition; Posterior tibial displacement	CRUCIATE LIGAMENT INJURIES; STAIR DESCENT; INSTABILITY; TRANSLATION; ADAPTATIONS; LAXITY	Most individuals with an isolated posterior cruciate ligament (PCL) injury do not complain of disability even if posterior instability is objectively revealed by a static physical examination, such as the posterior drawer test. This suggests it is insufficient to only evaluate posterior instability under static conditions. Therefore, we have investigated the effect of isolated PCL injury on the detailed kinematics of the knee in a dynamic environment such as during gait. Eight unilateral PCL-deficient males and eight healthy control volunteers participated in this study. Isolated PCL injury was diagnosed by clinical examination. Stress X-ray imaging showed an average side-to-side difference of 12.7 +/- A 3.5 mm. Knee kinematics including anteroposterior tibial displacement were analysed during walking using the point cluster technique. Posterior tibial displacement from initial contact was significantly smaller during 9-22 % of the gait cycle by an average of 0.4 cm in the PCL group, compared to controls. In the PCL-deficient knee, the external rotational angle increased by an average of 3.3A degrees at the loading response during 3-11 % of the gait cycle and the varus angle from initial contact increased by an average of 2.0A degrees during 28-52 % of the gait cycle, compared to controls. Dynamic changes in the rotation and posterior translation patterns were seen after isolated PCL injury, suggesting the kinematics of PCL-deficient knees might be different to normal knees. These factors may contribute to long-term osteoarthritic change. Consequently, when choosing conservative treatment for PCL injury, these changes should be considered to prevent osteoarthritic change. III.	[Orita, Naoya; Deie, Masataka; Asaeda, Makoto] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima 7348551, Japan; [Orita, Naoya; Shimada, Noboru; Iwaki, Daisuke; Hirata, Kazuhiko] Hiroshima Univ Hosp, Div Clin Support, Hiroshima, Japan; [Ochi, Mitsuo] Hiroshima Univ, Dept Orthopaed Surg, Hiroshima 7348551, Japan	Deie, M (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, 1-2-3 Kasumi Minami Ku, Hiroshima 7348551, Japan.	snm3@hiroshima-u.ac.jp					CAIN TE, 1981, AM J SPORT MED, V9, P203, DOI 10.1177/036354658100900402; Liu MF, 2010, CLIN BIOMECH, V25, P909, DOI 10.1016/j.clinbiomech.2010.06.014; Zabala ME, 2013, J BIOMECH, V46, P515, DOI 10.1016/j.jbiomech.2012.10.010; Strobel MJ, 2003, ARTHROSCOPY, V19, P262, DOI 10.1053/jars.2003.50037; Iwata S, 2007, KNEE SURG SPORT TR A, V15, P335, DOI 10.1007/s00167-006-0198-3; Andriacchi TP, 1998, J BIOMECH ENG-T ASME, V120, P743, DOI 10.1115/1.2834888; Bergfeld JA, 2001, J BONE JOINT SURG AM, V83A, P1339; Yoon KH, 2011, AM J SPORT MED, V39, P474, DOI 10.1177/0363546510382206; Iwata S, 2007, KNEE SURG SPORT TR A, V15, P705, DOI 10.1007/s00167-006-0270-z; Beynnon BD, 2005, AM J SPORT MED, V33, P1579, DOI 10.1177/0363546505279913; CROSS MJ, 1984, AM J SPORT MED, V12, P292, DOI 10.1177/036354658401200409; DANDY DJ, 1982, J BONE JOINT SURG BR, V64, P92; Adachi N, 2003, ACTA ORTHOP SCAND, V74, P683, DOI 10.1080/00016470310018207; Reider B, 2003, ARTHROSCOPY, V19, P2, DOI 10.1053/jars.2003.50006; Hooper DM, 2002, CLIN BIOMECH, V17, P227, DOI 10.1016/S0268-0033(02)00002-5; Shelbourne KD, 2005, ARTHROSCOPY, V21, P457, DOI 10.1016/j.arthro.2004.11.013; TIBONE JE, 1988, AM J SPORT MED, V16, P217, DOI 10.1177/036354658801600303; Fontbote CA, 2005, AM J SPORT MED, V33, P982, DOI 10.1177/0363546504271966; Harner CD, 1998, AM J SPORT MED, V26, P471; Shelbourne KD, 1999, AM J SPORT MED, V27, P276; Grassmayr MJ, 2008, J SCI MED SPORT, V11, P433, DOI 10.1016/j.jsams.2007.07.007; Kuroyanagi Y, 2012, KNEE, V19, P130, DOI 10.1016/j.knee.2010.12.007; Fanelli Gregory C, 2010, J Knee Surg, V23, P61; FOWLER PJ, 1987, AM J SPORT MED, V15, P553, DOI 10.1177/036354658701500606; KELLER PM, 1993, AM J SPORT MED, V21, P132, DOI 10.1177/036354659302100122; Orita N, 2012, THESIS HIROSHIMA U J	26	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	NOV	2015	23	11					3251	3258		10.1007/s00167-014-3162-7		8	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CU1CW	WOS:000363258000018		
J	Terashima, T; Onodera, T; Sawaguchi, N; Kasahara, Y; Majima, T				Terashima, Takashi; Onodera, Tomohiro; Sawaguchi, Naohiro; Kasahara, Yasuhiko; Majima, Tokifumi			External rotation of the femoral component decreases patellofemoral contact stress in total knee arthroplasty	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Total knee arthroplasty; Patellofemoral joint; Patellofemoral contact stress; Rotational alignment of the femoral component	IN-VITRO MEASUREMENT; PATELLAR TRACKING; MOBILE-BEARING; ALIGNMENT; KINEMATICS; JOINT; COMPLICATIONS; REPLACEMENT; PROSTHESIS; SYSTEM	The purpose of this study was to investigate the relationship between patellofemoral (PF) contact stress in vivo and the alignment of the femoral component in patients after total knee arthroplasty (TKA). Thirty knees with medial compartment osteoarthritis that underwent mobile-bearing TKA with modified gap technique were evaluated. Surgery was performed using a subvastus approach to eliminate the effect of the approach to muscle balance, with a computed tomography-based navigation system (Vector Vision 1.61; Brain Lab, Heimstetten, Germany). PF contact stress was measured by a Flexiforce pressure sensor (Nitta Co., Ltd., Osaka, Japan) intraoperatively, and the results were compared with the alignment of the femoral component after TKA. The PF contact stress was not correlated with sagittal and coronal alignment of the femoral component and patellar tracking, whereas rotational alignment of the femoral component was negatively correlated with PF contact stress (r = -0.718, p < 0.01). Regarding the alignment of the femoral component, only the rotational alignment of the femoral component was correlated with PF contact stress. PF contact stress decreased more as the femoral component rotated more externally. Case control study, Level III.	[Terashima, Takashi; Onodera, Tomohiro; Sawaguchi, Naohiro; Kasahara, Yasuhiko] Hokkaido Univ, Grad Sch Med, Dept Orthopaed Surg, Kita Ku, Sapporo, Hokkaido 0608638, Japan; [Majima, Tokifumi] Int Univ Hlth & Welf Hosp, Dept Orthoped Surg, Nasushiobara 3292763, Japan	Majima, T (reprint author), Int Univ Hlth & Welf Hosp, Dept Orthoped Surg, 537-8 Iguchi, Nasushiobara 3292763, Japan.	tkmajima@iuhw.ac.jp			Northern Advancement Center for Science and Technology of Hokkaido, Japan	This research was supported in part by Grants-in-aid for a Regional R&D Proposal-Based Program from the Northern Advancement Center for Science and Technology of Hokkaido, Japan.	Akagi M, 1999, CLIN ORTHOP RELAT R, P155; Berger RA, 1998, CLIN ORTHOP RELAT R, P144; Zhang XL, 2012, CHINESE MED J-PEKING, V125, P236, DOI 10.3760/cma.j.issn.0366-6999.2012.02.014; EWALD FC, 1989, CLIN ORTHOP RELAT R, P9; Howell SM, 2013, KNEE SURG SPORT TR A, V21, P2281, DOI 10.1007/s00167-012-2220-2; Olcott CW, 1999, CLIN ORTHOP RELAT R, P39; Wolterbeek N, 2012, KNEE SURG SPORT TR A, V20, P2487, DOI 10.1007/s00167-012-1936-3; Fehring TK, 2001, CLIN ORTHOP RELAT R, P315; Eisenhuth SA, 2006, CLIN ORTHOP RELAT R, P149, DOI 10.1097/01.blo.0000214415.83593.db; Merican AM, 2011, KNEE SURG SPORT TR A, V19, P1479, DOI 10.1007/s00167-011-1499-8; JEFFERY RS, 1991, J BONE JOINT SURG BR, V73, P709; Sawaguchi N, 2010, J ARTHROPLASTY, V25, P920, DOI 10.1016/j.arth.2009.07.024; Futai K, 2011, KNEE SURG SPORT TR A, V19, P914, DOI 10.1007/s00167-010-1262-6; HEALY WL, 1995, J ARTHROPLASTY, V10, P197, DOI 10.1016/S0883-5403(05)80127-5; Kanekasu K, 2005, CLIN ORTHOP RELAT R, P193, DOI 10.1097/01.blo.0000156819.24866.8b; Skwara A, 2009, ARCH ORTHOP TRAUM SU, V129, P901, DOI 10.1007/s00402-008-0757-9; Hsu HC, 1996, J ARTHROPLASTY, V11, P69, DOI 10.1016/S0883-5403(96)80163-X; Takahashi A, 2012, KNEE SURG SPORT TR A, V20, P1787, DOI 10.1007/s00167-011-1768-6; Rees JL, 2005, CLIN ORTHOP RELAT R, P204, DOI 10.1097/01.blo.0000150372.92398.ba; INSALL J, 1971, RADIOLOGY, V101, P101; Matsuda S, 1997, J ARTHROPLASTY, V12, P790, DOI 10.1016/S0883-5403(97)90010-3; Pierson JL, 2007, J BONE JOINT SURG AM, V89A, P2195, DOI 10.2106/JBJS.E.01223; Sodha S, 2004, J ARTHROPLASTY, V19, P459, DOI 10.1016/j.arth.2003.12.072; [Anonymous], 2000, CLIN ORTHOPAEDICS, DOI 10.1097/00003086-200011000-00010; Mullaji AB, 2013, J ARTHROPLASTY, V28, P20, DOI 10.1016/j.arth.2012.04.014; Sharkey PF, 2002, CLIN ORTHOP RELAT R, P7, DOI 10.1097/01.blo.0000036002.13841.32; BRICK GW, 1988, CLIN ORTHOP RELAT R, P163; Lombardi AVJ, 2003, ADULT KNEE, V2, P1223; Lynch A F, 1987, J Arthroplasty, V2, P135, DOI 10.1016/S0883-5403(87)80020-7; Majima T, 2012, J BONE JOINT SUR S25, V94, P135; Miller MC, 2001, CLIN ORTHOP RELAT R, P38; Pagnano MW, 2004, CLIN ORTHOP RELAT R, P221, DOI 10.1097/01.blo.0000148892.31464.81; RANAWAT CS, 1986, CLIN ORTHOP RELAT R, P93; RITTER MA, 1994, CLIN ORTHOP RELAT R, P153; Scuderi G, 1987, J Arthroplasty, V2, P209, DOI 10.1016/S0883-5403(87)80039-6; Steinbruck A, 2013, BIOMED ENG ONLINE, V12, DOI 10.1186/1475-925X-12-58; WRIGHT J, 1990, J BONE JOINT SURG AM, V72A, P1003	37	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	NOV	2015	23	11					3266	3272		10.1007/s00167-014-3103-5		7	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CU1CW	WOS:000363258000020		
J	Izumi, M; Ikeuchi, M; Aso, K; Sugimura, N; Kamimoto, Y; Mitani, T; Ueta, T; Sato, T; Yokoyama, M; Sugiura, T; Tani, T				Izumi, Masashi; Ikeuchi, Masahiko; Aso, Koji; Sugimura, Natsuki; Kamimoto, Yuko; Mitani, Tetsuya; Ueta, Tadashi; Sato, Takayuki; Yokoyama, Masataka; Sugiura, Tetsuro; Tani, Toshikazu			Less deep vein thrombosis due to transcutaneous fibular nerve stimulation in total knee arthroplasty: a randomized controlled trial	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Venous thromboembolism (VTE); Deep vein thrombosis (DVT); Pulmonary thromboembolism (PTE); Transcutaneous electrical nerve stimulation (TENS); Total knee arthroplasty (TKA); Prevention	INTERMITTENT PNEUMATIC COMPRESSION; TOTAL JOINT ARTHROPLASTY; TOTAL HIP-ARTHROPLASTY; THROMBOEMBOLIC DISEASE; VENOUS THROMBOEMBOLISM; D-DIMER; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; SOLUBLE FIBRIN; REPLACEMENT; TOURNIQUET	It has been known for years that deep vein thrombi (DVT) start to develop during total joint arthroplasty. Previously, we reported effective prevention of venous stasis by transcutaneous electrical nerve stimulation (TENS). It is hypothesized that TENS might be a thromboprophylactic tool for the limb undergoing surgery. The purpose of this study is to clarify the clinical efficacy and safety of TENS in patients during total knee arthroplasty (TKA). Ninety patients undergoing primary TKA were involved and randomly allocated to the TENS or control group. In the TENS group, electrical stimulation of the common fibular nerve, which produced a brisk dorsiflexion of the ankle, was performed for the operated leg during surgery. In the control group, no electrical stimulation was applied. Serum D-dimer and soluble fibrin monomer complex (SFMC) levels were measured before surgery, immediately after surgery, and post-operative day (POD) 1. Ultrasonography was performed on POD 1. Immediately after surgery, D-dimer and SFMC levels of each group were significantly lower in the TENS group compared with control (p < 0.05). The incidence of DVT was 11 % (five cases) in the TENS group while 31 % (14 cases) in control (p = 0.02). There were no adverse effects related to TENS. TENS during TKA showed significant effects on preventing DVT. Sustaining muscle pump activation during surgery prevented not only venous stasis, but also hypercoagulability of blood. Intraoperative TENS is a safe and novel strategy against early post-operative thromboembolism, which is difficult to be completed through existing prophylaxis after total joint arthroplasty. Randomized controlled trial, Level I.	[Izumi, Masashi; Ikeuchi, Masahiko; Aso, Koji; Sugimura, Natsuki; Tani, Toshikazu] Kochi Univ, Dept Orthopaed Surg, Nankoku, Kochi 7838505, Japan; [Kamimoto, Yuko; Yokoyama, Masataka] Kochi Univ, Dept Anesthesiol, Nankoku, Kochi 7838505, Japan; [Mitani, Tetsuya; Ueta, Tadashi; Sugiura, Tetsuro] Kochi Univ, Dept Anesthesiol, Nankoku, Kochi 7838505, Japan; [Sato, Takayuki] Kochi Univ, Dept Cardiovasc Control, Nankoku, Kochi 7838505, Japan	Ikeuchi, M (reprint author), Kochi Univ, Dept Orthopaed Surg, Oko Cho Kohasu, Nankoku, Kochi 7838505, Japan.	ikeuchim@kochi-u.ac.jp					Lurie F, 2003, J VASC SURG, V37, P137, DOI 10.1067/mva.2002.24; Wada H, 2006, J THROMB HAEMOST, V4, P1253, DOI 10.1111/j.1538-7836.2006.01942.x; Mont MA, 2011, J AM ACAD ORTHOP SUR, V19, P777; SHARROCK NE, 1995, J ARTHROPLASTY, V10, P523, DOI 10.1016/S0883-5403(05)80155-X; Clayton RAE, 2009, KNEE, V16, P18, DOI 10.1016/j.knee.2008.09.007; Berman AT, 1998, J BONE JOINT SURG AM, V80A, P389; Howie C, 2005, J BONE JOINT SURG BR, V87B, P1675, DOI 10.1302/0301-620X.87B12.16298; Patel VP, 2007, J BONE JOINT SURG AM, V89A, P33, DOI 10.2106/JBJS.F.00163; Izumi M, 2010, EUR J VASC ENDOVASC, V39, P642, DOI 10.1016/j.ejvs.2009.11.035; Yamaguchi T, 2010, THROMB RES, V126, pE323, DOI 10.1016/j.thromres.2010.03.018; Nassif JM, 2000, J ARTHROPLASTY, V15, P16, DOI 10.1016/S0883-5403(00)91025-8; Schellong SM, 2007, J THROMB HAEMOST, V5, P1431, DOI 10.1111/j.1538-7836.2007.02570.x; Lee AYY, 2004, J THROMB HAEMOST, V2, P1752, DOI 10.1111/j.1538-7836.2004.00915.x; DiGiovanni CW, 2000, CLIN ORTHOP RELAT R, P178; Pedersen BK, 2011, BRAIN BEHAV IMMUN, V25, P811, DOI 10.1016/j.bbi.2011.02.010; MAYNARD MJ, 1991, CLIN ORTHOP RELAT R, P125; Reitman RD, 2003, J ARTHROPLASTY, V18, P161, DOI 10.1054/arth.2003.50026; Silbersack Y, 2004, J BONE JOINT SURG BR, V86B, P809, DOI 10.1302/0301-620X.86B6.13958; BOUNAMEAUX H, 1991, LANCET, V337, P196, DOI 10.1016/0140-6736(91)92158-X; Chen AH, 2001, EUR J VASC ENDOVASC, V21, P383, DOI 10.1053/ejvs.2001.1348; Aksu K, 2012, CURR PHARM DESIGN, V18, P1478; Dorr LD, 2007, J BONE JOINT SURG AM, V89A, P2648, DOI 10.2106/JBJS.F00235; Jezovnik MK, 2010, INT ANGIOL, V29, P226; Anderson FA, 2003, CIRCULATION, V107, pI9, DOI 10.1161/01.CIR.0000078469.07362.E6; Pedersen BK, 2008, PHYSIOL REV, V88, P1379, DOI 10.1152/physrev.90100.2007; Katsumata S, 2005, ACTA ANAESTH SCAND, V49, P510, DOI 10.1111/j.1399-6576.2004.00621.x; Misaki T, 2008, J ORTHOP SCI, V13, P419, DOI 10.1007/s00776-008-1266-y; Righini M, 2008, J THROMB HAEMOST, V6, P1059, DOI 10.1111/j.1538-7836.2008.02981.x; Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje; Kato N, 2002, ANESTHESIOLOGY, V97, P1123, DOI 10.1097/00000542-200211000-00014; Pour AE, 2013, J ARTHROPLASTY, V28, P410, DOI 10.1016/j.arth.2012.08.003; Saleh K, 2002, J ORTHOPAED RES, V20, P506, DOI 10.1016/S0736-0266(01)00153-X; Falck-Ytter Yngve, 2012, Chest, V141, pe278S, DOI 10.1378/chest.11-2404; Hartford J M, 1998, Am J Orthop (Belle Mead NJ), V27, P123; Kim Kang-Il, 2013, Knee Surg Relat Res, V25, P43, DOI 10.5792/ksrr.2013.25.2.43; Sharrock NE, 1997, BRIT J ANAESTH, V79, P29; SHARROCK NE, 1995, CLIN ORTHOP RELAT R, P16	37	3	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	NOV	2015	23	11					3317	3323		10.1007/s00167-014-3141-z		7	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CU1CW	WOS:000363258000026		
J	Kanamoto, T; Tanaka, Y; Yonetani, Y; Kita, K; Amano, H; Kusano, M; Hirabayashi, S; Horibe, S				Kanamoto, Takashi; Tanaka, Yoshinari; Yonetani, Yasukazu; Kita, Keisuke; Amano, Hiroshi; Kusano, Masashi; Hirabayashi, Shinji; Horibe, Shuji			Anterior knee symptoms after double-bundle ACL reconstruction with hamstring tendon autografts: an ultrasonographic and power Doppler investigation	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Anterior knee problems/symptoms; ACL reconstruction; Ultrasound; Infrapatellar fat pad; Increased blood flow	CRUCIATE LIGAMENT RECONSTRUCTION; INFRAPATELLAR FAT PAD; PATELLAR TENDON; SEMITENDINOSUS; GRACILIS; BONE; DISORDERS; RESECTION; GRAFTS; PAIN	Anterior knee pain related to the donor site is a frequent complication of anterior cruciate ligament reconstruction (ACLR) with bone-patellar tendon-bone autograft tissue. Even when hamstring tendon (HT) grafts are used instead, symptoms such as mild pain and discomfort can still occur. The purpose of this study was to elucidate the pathophysiology of anterior knee symptoms after ACLR with HT autografts. Fifty-seven patients (22 men and 35 women; mean age, 24.7 years) who underwent anatomic double-bundle ACLR with HT autografts were examined 6 months post-operatively. The presence of anterior knee symptoms, anterior knee laxity, range of motion, and muscle strength were assessed. Changes in patellar tendon and infrapatellar fat pad (IFP) morphology and blood flow were also evaluated using ultrasound. Potential variables affecting the presence of anterior knee symptoms were subjected to univariate analysis and multivariate logistic regression analysis to identify independent risk factors. Six months post-operatively, the total incidence of anterior knee symptoms was 56.1 % (32/57). According to univariate analysis, age, quadriceps strength, and increased blood flow in the IFP were significantly associated with the presence of anterior knee symptoms. Multivariate logistic regression analysis revealed that increased blood flow in the IFP was an independent factor for the presence of anterior knee symptoms (odds ratio 5.0; 95 % confidence interval 1.3-19.9). There were no significant findings inside the patellar tendon. Increased blood flow in the IFP was identified as an independent factor for the presence of anterior knee symptoms 6 months after ACLR with HT autografts. The ultrasound evaluation can help to define precisely the origin of anterior knee symptoms after ACLR with HT autografts. Case series with no comparison groups, Level IV.	[Kanamoto, Takashi; Hirabayashi, Shinji] Osaka Rosai Hosp, Dept Rehabil, Kita Ku, Sakai, Osaka 5978025, Japan; [Tanaka, Yoshinari; Kita, Keisuke; Amano, Hiroshi] Osaka Rosai Hosp, Dept Orthopaed Surg, Sakai, Osaka 5978025, Japan; [Yonetani, Yasukazu] Osaka Univ, Grad Sch Med, Dept Orthopaed Surg, Osaka, Japan; [Kusano, Masashi] Kansai Rosai Hosp, Dept Orthopaed Surg, Sakai, Osaka, Japan; [Horibe, Shuji] Osaka Prefecture Univ, Fac Comprehens Rehabil, Habikino, Osaka, Japan	Kanamoto, T (reprint author), Osaka Rosai Hosp, Dept Rehabil, Kita Ku, 1179-3 Nagasone Cho, Sakai, Osaka 5978025, Japan.	takanamoto2@gmail.com					AGLIETTI P, 1994, AM J SPORT MED, V22, P211, DOI 10.1177/036354659402200210; Eriksson K, 2001, J BONE JOINT SURG BR, V83B, P348, DOI 10.1302/0301-620X.83B3.11685; Muneta T, 1998, SCAND J MED SCI SPOR, V8, P283, DOI 10.1111/j.1600-0838.1998.tb00484.x; Ibrahim SAR, 2005, ARTHROSCOPY, V21, P412, DOI 10.1016/j.arthro.2004.12.002; Cook JL, 2005, BRIT J SPORT MED, V39, P700, DOI 10.1136/bjsm.2004.016410; Shelbourne KD, 1997, AM J SPORT MED, V25, P41, DOI 10.1177/036354659702500108; Bayar A, 2008, KNEE SURG SPORT TR A, V16, P1114, DOI 10.1007/s00167-008-0612-0; Bohnsack M, 2004, AM J SPORT MED, V32, P1873, DOI 10.1177/0363546504263946; Vedung T, 2011, J HAND SURG-AM, V36A, P1974, DOI 10.1016/j.jhsa.2011.08.028; Clockaerts S, 2010, OSTEOARTHR CARTILAGE, V18, P876, DOI 10.1016/j.joca.2010.03.014; Skiadas V, 2013, KNEE SURG SPORT TR A, V21, P294, DOI 10.1007/s00167-012-1976-8; Hoksrud A, 2008, AM J SPORT MED, V36, P1813, DOI 10.1177/0363546508319897; Risberg MA, 1999, J ORTHOP SPORT PHYS, V29, P400; Niki Y, 2011, ARTHROSCOPY, V27, P1242, DOI 10.1016/j.arthro.2011.03.086; Niki Y, 2012, KNEE SURG SPORT TR A, V20, P1543, DOI 10.1007/s00167-011-1746-z; Distel E, 2009, ARTHRITIS RHEUM-US, V60, P3374, DOI 10.1002/art.24881; OGILVIEHARRIS DJ, 1994, ARTHROSCOPY, V10, P184, DOI 10.1016/S0749-8063(05)80091-X; Tsuda E, 2001, AM J SPORT MED, V29, P450; Kartus J, 2001, ARTHROSCOPY, V17, P971, DOI 10.1053/jars.2001.28979; Dragoo JL, 2003, J BONE JOINT SURG BR, V85B, P740, DOI 10.1302/0301-620X.85B5.13587; Dragoo JL, 2012, SPORTS MED, V42, P51, DOI 10.2165/11595680-000000000-00000; KUJALA UM, 1993, ARTHROSCOPY, V9, P159, DOI 10.1016/S0749-8063(05)80366-4; Mohtadi N, 2011, COCHRANE DB SYST REV, V9; Sandon A, 2014, KNEE SURG SPORTS TRA; Singer Barby, 2009, Aust J Physiother, V55, P140; Sonnery-Cottet B, 2011, Orthop Traumatol Surg Res, V97, P870, DOI 10.1016/j.otsr.2011.08.007; Tanaka Y, 2013, KNEE SURG SPORT TR A, V22, P1541; Witonski Dariusz, 2005, Polish Journal of Pathology, V56, P203	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	NOV	2015	23	11					3324	3329		10.1007/s00167-014-3142-y		6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CU1CW	WOS:000363258000027		
J	Kuroda, Y; Ishida, K; Matsumoto, T; Sasaki, H; Matsuzaki, T; Oka, S; Takayama, K; Tei, K; Matsushita, T; Tsumura, N; Kuroda, R; Kurosaka, M				Kuroda, Yuichi; Ishida, Kazunari; Matsumoto, Tomoyuki; Sasaki, Hiroshi; Matsuzaki, Tokio; Oka, Shinya; Takayama, Koji; Tei, Katsumasa; Matsushita, Takehiko; Tsumura, Nobuhiro; Kuroda, Ryosuke; Kurosaka, Masahiro			Fibular axes are not a reliable landmark for tibial mechanical axes of osteoarthritic knees that underwent total knee arthroplasty	KNEE SURGERY SPORTS TRAUMATOLOGY ARTHROSCOPY			English	Article						Total knee arthroplasty; Fibula axis; Surgical technique; Anatomical landmark; Tibial slope	ANATOMICAL REFERENCES; ROTATIONAL ALIGNMENT; SAGITTAL ALIGNMENT; SLOPE; COMPONENT; INTRAMEDULLARY	The sagittal fibular axis serves as an intra-operative landmark during conventional total knee arthroplasty (TKA); however, only a few relevant anatomical studies have been published regarding its use as an extramedullary guide. Furthermore, the correlation between the coronal fibular and tibial mechanical axes in osteoarthritic knees has been only reported once. Here, the hypothesis of this study is that the fibula can be a reliable intra-operative landmark, in the sagittal and coronal planes, among patients with osteoarthritis who have undergone TKA. Osteoarthritic knees (n = 62) after TKA were evaluated using three-dimensional image-matching software. The angles between the tibial mechanical axis and the fibular shaft axis were measured in the sagittal and coronal planes. Moreover, correlations between the angles and patient-specific factors were evaluated. The mean angle between the tibial mechanical and fibular shaft axes was 2.6A degrees A A +/- A 2.3A degrees for posterior inclination in the sagittal plane and 0.9A degrees A A +/- A 2.0A degrees for varus inclination in the coronal plane. The percentage of subjects with the fibular shaft axis within 2A degrees of the tibial mechanical axis was 17.7 and 69.3 % in the sagittal and coronal planes, respectively. No patient-specific factors were correlated with the angle between the tibial mechanical and fibular shaft axes. The angle between the tibial mechanical and fibular shaft axes differed among patients, independent of patient-specific factors, and did not appear to be a reliable intra-operative landmark. Surgeons should use values from individual pre-operative evaluations of the axis as reference for conventional TKA. Case series with no comparison group, Level IV.	[Kuroda, Yuichi; Tsumura, Nobuhiro] Hyogo Rehabil Ctr Hosp, Dept Orthopaed Surg, Kobe, Hyogo, Japan; [Ishida, Kazunari; Sasaki, Hiroshi] Kobe Kaisei Hosp, Dept Orthopaed Surg, Nada Ku, Kobe, Hyogo 6570068, Japan; [Matsumoto, Tomoyuki; Matsuzaki, Tokio; Oka, Shinya; Takayama, Koji; Matsushita, Takehiko; Kuroda, Ryosuke; Kurosaka, Masahiro] Kobe Univ, Dept Orthopaed Surg, Grad Sch Med, Kobe, Hyogo 657, Japan; [Tei, Katsumasa] Chibune Gen Hosp, Dept Orthopaed Surg, Osaka, Japan	Ishida, K (reprint author), Kobe Kaisei Hosp, Dept Orthopaed Surg, Nada Ku, 3-11-15 Shinohara Kita, Kobe, Hyogo 6570068, Japan.	wavedreamer17@yahoo.co.jp					Akagi M, 2004, CLIN ORTHOP RELAT R, P213, DOI 10.1097/01.blo.0000118442.93383.16; Hernigou P, 2004, J BONE JOINT SURG AM, V86A, P506; Han HS, 2008, KNEE SURG SPORT TR A, V16, P373, DOI 10.1007/s00167-008-0486-1; Schneider M, 2007, J ARTHROPLASTY, V22, P219, DOI 10.1016/j.arth.2006.04.023; Jojima H, 2004, CLIN ORTHOP RELAT R, P194, DOI 10.1097/01.blo.0000138960.57680.60; Cashman JP, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749-799X-6-44; Kim YH, 2014, INT ORTHOP, V38, P379, DOI 10.1007/s00264-013-2097-9; Laskin RS, 2003, J ARTHROPLASTY, V18, P18, DOI 10.1054/arth.2003.50066; Sahin N, 2012, KNEE SURG SPORT TR A, V20, P565, DOI 10.1007/s00167-011-1606-x; Waelchli B, 2001, KNEE SURG SPORT TR A, V9, P296; Bellemans J, 2005, KNEE SURG SPORT TR A, V13, P193, DOI 10.1007/s00167-004-0557-x; Dennis D A, 1993, J Arthroplasty, V8, P43, DOI 10.1016/S0883-5403(06)80106-3; Bai B, 2000, J ARTHROPLASTY, V15, P916, DOI 10.1054/arth.2000.9058; Kim D, 2012, KNEE SURG SPORT TR A, V20, P337, DOI 10.1007/s00167-011-1750-3; Shao JJ, 2013, CHINESE MED J-PEKING, V126, P3840, DOI 10.3760/cma.j.issn.0366-6999.20131796; Paley D, 2000, ORTHOPADE, V29, P18; Mizu-Uchi H, 2006, J BONE JOINT SURG AM, V88A, P2632, DOI 10.2106/JBJS.E.01288; Chinzei N, 2013, INT ORTHOP, V38, P509; Rajadhyaksha Amar D, 2009, Am J Orthop (Belle Mead NJ), V38, pE68; Sugimura N, 2014, KNEE SURG SPORT TR A, V22, P2618, DOI 10.1007/s00167-013-2461-8; Tei Katsumasa, 2012, Orthopedics, V35, pe1711, DOI 10.3928/01477447-20121120-14; Tsukeoka T, 2012, KNEE, V21, P283	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0942-2056	1433-7347		KNEE SURG SPORT TR A	Knee Surg. Sports Traumatol. Arthrosc.	NOV	2015	23	11					3362	3367		10.1007/s00167-014-3170-7		6	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	CU1CW	WOS:000363258000032		
J	Shah, P; Ando, AW				Shah, Payal; Ando, Amy W.			Downside versus Symmetric Measures of Uncertainty in Natural Resource Portfolio Design to Manage Climate Change Uncertainty	LAND ECONOMICS			English	Article							LOWER PARTIAL MOMENT; MARINE RESERVES; MIGRATORY BIRDS; CONSERVATION; RISK; OPTIMIZATION; BIODIVERSITY; DIVERSITY; FISHERIES; SHORTFALL	Recent work uses Markowitz's mean-variance framework to identify efficient allocations of conservation activity across subregions of a planning landscape to minimize climate change induced uncertainty in future conservation benefits. We replace variance with a downside measure of uncertainty and compare the resulting portfolios of conservation activity and uncertainty expected value results against those generated by the mean-variance approach. Results illustrate that conservation agents can manage climate changed induced uncertainty in future conservation outcomes more efficiently using our framework when they are particularly averse to downside uncertainty and when predicted future conservation outcomes within subregions across their planning horizon exhibit skewed distributions.	[Shah, Payal] Grad Univ, Okinawa Inst Sci & Technol, Okinawa, Japan; [Ando, Amy W.] Univ Illinois, Dept Agr & Consumer Econ, Urbana, IL 61801 USA; [Ando, Amy W.] Resources Future Inc, Washington, DC USA	Shah, P (reprint author), Grad Univ, Okinawa Inst Sci & Technol, Okinawa, Japan.				USDA-NIFA Hatch project [ILLU-470-316]; U.S. Geological Survey [G12AC20056]; National Science Foundation [1339944]	We are grateful to Phil Garcia, Mindy Mallory, Paul Ferraro, Kathy Baylis, Alex Winter-Nelson, two anonymous referees, and members of the UIUC Program in Environmental and Resource Economics seminar group for helpful comments. Part of the work for this paper was done by Payal Shah while a Ph.D. student at the University of Illinois at Urbana-Champaign. This paper was based in part on work supported by USDA-NIFA Hatch project #ILLU-470-316, by Cooperative Agreement Number G12AC20056 from the U.S. Geological Survey, and by the National Science Foundation under Grant #1339944. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the USDA, USGS, or NSF.	Ando AW, 2012, P NATL ACAD SCI USA, V109, pE2305, DOI 10.1073/pnas.1210404109; Harwood J, 2003, TRENDS ECOL EVOL, V18, P617, DOI 10.1016/j.tree.2003.08.001; Matthews SN, 2011, ECOGRAPHY, V34, P933, DOI 10.1111/j.1600-0587.2011.06803.x; Regan HM, 2005, ECOL APPL, V15, P1471, DOI 10.1890/03-5419; Jonzen N, 2006, SCIENCE, V312, P1959, DOI 10.1126/science.1126119; Lempert R, 2004, CLIMATIC CHANGE, V65, P1, DOI 10.1023/B:CLIM.0000037561.75281.b3; FISHBURN PC, 1977, AM ECON REV, V67, P116; Wilson KA, 2006, NATURE, V440, P337, DOI 10.1038/nature04366; BAWA VS, 1977, J FINANC ECON, V5, P189, DOI 10.1016/0304-405X(77)90017-4; Moloney PD, 2011, NAT RESOUR MODEL, V24, P102, DOI 10.1111/j.1939-7445.2010.00084.x; Moore JW, 2010, CONSERV LETT, V3, P340, DOI 10.1111/j.1755-263X.2010.00119.x; Beaumont LJ, 2006, GLOBAL CHANGE BIOL, V12, P1339, DOI 10.1111/j.1365-2486.2006.01171.x; TSIANG SC, 1974, AM ECON REV, V64, P442; NAWROCKI DN, 1991, APPL ECON, V23, P465, DOI 10.1080/00036849100000021; Naidoo R, 2006, TRENDS ECOL EVOL, V21, P681, DOI 10.1016/j.tree.2006.10.003; Richardson DM, 2009, P NATL ACAD SCI USA, V106, P9721, DOI 10.1073/pnas.0902327106; Waite TA, 2006, P R SOC B, V273, P2809, DOI 10.1098/rspb.2006.3667; Ando AW, 2012, P NATL ACAD SCI USA, V109, P6484, DOI 10.1073/pnas.1114653109; Doyen L, 2003, J ENVIRON MANAGE, V69, P1, DOI 10.1016/S0301-4797(03)00004-5; Parmesan C, 2006, ANNU REV ECOL EVOL S, V37, P637, DOI 10.1146/annurev.ecolsys.37.091305.110100; Both C, 2006, NATURE, V441, P81, DOI 10.1038/nature04539; Schlenker W, 2005, AM ECON REV, V95, P395, DOI 10.1257/0002828053828455; Figge F, 2004, BIODIVERS CONSERV, V13, P827, DOI 10.1023/B:BIOC.0000011729.93889.34; Schindler DE, 2010, NATURE, V465, P609, DOI 10.1038/nature09060; Crowe KA, 2008, CLIMATIC CHANGE, V89, P355, DOI 10.1007/s10584-007-9373-x; Yemshanov D, 2014, ECOL ECON, V104, P61, DOI 10.1016/j.ecolecon.2014.04.024; Grafton RQ, 2005, B MATH BIOL, V67, P957, DOI 10.1016/j.bulm.2004.11.006; Koellner T, 2006, BIOSCIENCE, V56, P977, DOI 10.1641/0006-3568(2006)56[977:BEFAIR]2.0.CO;2; MARDIA KV, 1970, BIOMETRIKA, V57, P519, DOI 10.2307/2334770; Mohd WRW, 2013, AIP CONF PROC, V1522, P1086, DOI 10.1063/1.4801251; BAWA VS, 1978, J FINANC QUANT ANAL, V13, P255, DOI 10.2307/2330386; Bawa V.S., 1975, J FINANC ECON, V2, P95, DOI 10.1016/0304-405X(75)90025-2; Bertsimas D, 2004, J ECON DYN CONTROL, V28, P1353, DOI 10.1016/S0165-1889(03)00109-X; Dawson Terence P., 2011, SCIENCE, V33, P53; Dowd K, 1998, VALUE RISK NEW SCI R; Duffle D., 1997, J DERIV, P47, DOI 10.3905/jod.1997.407971; Dunkel J, 2012, P NATL ACAD SCI USA, V109, pE2304, DOI 10.1073/pnas.1207485109; Estrada, 2007, INT REV ECON FINANC, V16, P169; Hallegatte Stephane, 2012, INVESTMENT DECISION; Harlow W.V., 1991, FINANCIAL ANAL J, V47, P28, DOI 10.2469/faj.v47.n5.28; Heal Geoffrey, 2013, 18929 NBER; Jorion P, 1997, VALUE RISK NEW BENCH; Joy O. Maurice, 1974, J FINANCE QUANTITATI, V9, P25; Kennedy Elizabeth T., 2009, NEW DIRECTIONS EVALU, V122, P41; Lande R., 2003, STOCHASTIC POPULATIO; Mallory ML, 2014, RESOUR ENERGY ECON, V38, P1, DOI 10.1016/j.reseneeco.2014.05.001; Matthews S. N., 2007, CLIMATE CHANGE BIRD; McCarthy James, 2005, ARCTIC CLIMATE IMPAC, P945; Nawrocki David N., 1992, INT REV FINANCIAL AN, V1, P195, DOI 10.1016/1057-5219(92)90004-N; Nawrocki D.N., 1999, J INVESTING, V8, P9, DOI 10.3905/joi.1999.319365; Porter R. Burr, 1972, AM ECON REV, V62, P438; Regan HM, 2002, HUM ECOL RISK ASSESS, V8, P1757, DOI 10.1080/20028091057592; Rom Brian M., 1993, J INVESTING, V2, P27, DOI 10.3905/joi.2.4.27; Roy A.D., 1952, ECONOMETRICA, V20, P431, DOI DOI 10.2307/1907413; Scherer Bernd, 2007, PORTFOLIO CONSTRUCTI; Schloss CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028788; SOLOW A, 1993, J ENVIRON ECON MANAG, V24, P60, DOI 10.1006/jeem.1993.1004; WEITZMAN ML, 1992, Q J ECON, V107, P363, DOI 10.2307/2118476; Xepapadeas Athanasios, 2013, 1332 DEOS ATH U EC B	59	0	0	UNIV WISCONSIN PRESS	MADISON	JOURNAL DIVISION, 1930 MONROE ST, 3RD FL, MADISON, WI 53711 USA	0023-7639	1543-8325		LAND ECON	Land Econ.	NOV	2015	91	4					664	687				24	Economics; Environmental Studies	Business & Economics; Environmental Sciences & Ecology	CT8OA	WOS:000363074700004		
J	Fukumoto, K; Matsuo, A				Fukumoto, Kentaro; Matsuo, Akitaka			The Effects of Election Proximity on Participatory Shirking: The Staggered-Term Chamber as a Laboratory	LEGISLATIVE STUDIES QUARTERLY			English	Article							UNITED-STATES-SENATE; HOUSE-OF-REPRESENTATIVES; ELECTORAL CONNECTION; POLITICAL SHIRKING; VOTING-BEHAVIOR; US SENATE; TALK; INCENTIVES; REELECTION; SPEECHES	This study discusses a downside of electoral pressure. As elections approach, legislators reduce their effort in legislative activities, albeit while increasing their efficiency. To show this, we propose a new, natural experimental design exploiting staggered legislative election calendars to identify the effect of approaching elections. Two-way natural blocking improves the balance of pretreatments and an instrumental variable approach addresses noncompliance by retirees. Our analysis of the Japanese House of Councillors demonstrates that legislators up for election show up in the chamber less often than those not facing election; however, when they do show up and speak, they tend to speak longer.	[Fukumoto, Kentaro] Gakushuin Univ, Polit Sci, Tokyo 171, Japan; [Matsuo, Akitaka] Univ Oxford Nuffield Coll, Oxford OX1 1NF, England	Fukumoto, K (reprint author), Washington Univ, St Louis, MO 63130 USA.	kentaro.fukumoto@gakushuin.ac.jp; akitaka.matsuo@nuffield.ox.ac.uk			Japan Society for the Promotion of Science [20330023, 21330031, 21653011]; Joint Usage/Research Center (Ministry of Education, Culture, Sports, Science and Technology, Japan)	Earlier versions of this article were presented at the 2010 Annual Summer Meetings of the Society for Political Methodology (University of Iowa) and the American Political Science Association (Washington, D.C.). We appreciate Will Bullock, Adam Glynn, Kosuke Imai, Henry Kim, Matt Loftis, Kenneth Shepsle, and Andrew R. Wood for comments. Fukumoto thanks Kota Nozaki for research assistance. Fukumoto also acknowledges the financial assistance of the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research (B) 20330023 and 21330031 and Challenging Exploratory Research 21653011) and the Joint Usage/Research Center (2008-2012; Ministry of Education, Culture, Sports, Science and Technology, Japan). Our data and R code for replication as well as the online appendix are uploaded at http://www-cc.gakushuin.ac.jp/similar to e982440/research/replication/.	AHUJA S, 1994, AM POLIT QUART, V22, P104, DOI 10.1177/1532673X9402200107; Angrist JD, 2009, MOSTLY HARMLESS ECONOMETRICS: AN EMPIRICISTS COMPANION, P1; Besley T, 2011, PUBLIC CHOICE, V146, P291, DOI 10.1007/s11127-009-9591-z; Rothenberg LS, 2000, AM J POLIT SCI, V44, P316, DOI 10.2307/2669313; Albouy D, 2011, ELECT STUD, V30, P162, DOI 10.1016/j.electstud.2010.11.016; AMACHER RC, 1978, PUBLIC CHOICE, V33, P5, DOI 10.1007/BF00154680; Lindstadt R, 2011, PUBLIC CHOICE, V148, P119, DOI 10.1007/s11127-010-9649-y; Carey JM, 1995, ELECT STUD, V14, P417, DOI 10.1016/0261-3794(94)00035-2; ELLING RC, 1982, LEGIS STUD QUART, V7, P75, DOI 10.2307/439692; Martin LW, 2008, POLIT RES QUART, V61, P502, DOI 10.1177/1065912907308348; Quinn KM, 2010, AM J POLIT SCI, V54, P209; Morris JS, 2001, LEGIS STUD QUART, V26, P101, DOI 10.2307/440405; WRIGHT GC, 1986, AM POLIT SCI REV, V80, P567, DOI 10.2307/1958274; Harris DB, 2005, LEGIS STUD QUART, V30, P127, DOI 10.3162/036298005X201482; LOTT JR, 1992, PUBLIC CHOICE, V74, P461; Rocca MS, 2007, AM POLIT RES, V35, P489, DOI 10.1177/1532673X07300233; ZUPAN MA, 1990, PUBLIC CHOICE, V65, P167, DOI 10.1007/BF00123797; Bender B, 1996, PUBLIC CHOICE, V87, P67, DOI 10.1007/BF00151730; Hill KQ, 2002, J POLIT, V64, P219; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; LOTT JR, 1990, ECON INQ, V28, P133; Ingall RE, 2001, LEGIS STUD QUART, V26, P487, DOI 10.2307/440333; Huber GA, 2012, AM POLIT SCI REV, V106, P720, DOI 10.1017/S0003055412000391; Bernstein Jr Robert A., 1988, AM POLIT SCI REV, V82, P237, DOI 10.2307/1958067; Cameron A. Colin, 2011, HDB EMPIRICAL EC FIN, P1; Carey JM, 2009, CAMB STUD COMPAR, P1; Crisp BF, 2004, J POLIT, V66, P136, DOI 10.1046/j.1468-2508.2004.00145.x; Dubin Michael J, 2007, PARTY AFFILIATIONS S; Dunning T, 2012, NATURAL EXPT SOCIAL; Fenno Jr Richard. F., 1982, US STATE SENATE BICA; Fenno R. F., 1978, HOME STYLE HOUSE MEM; Hall Richard L., 1996, PARTICIPATION C; HERRICK R, 1994, J POLIT, V56, P214, DOI 10.2307/2132354; KALT JP, 1990, J LAW ECON, V33, P103, DOI 10.1086/467201; Kellermann Michael, 2013, POLITICAL SCI RES ME, V1, P263; MacManus Susan, 1999, AM STATE LOCAL POLIT, P166; Maltzman F, 1996, J POLIT, V58, P819, DOI 10.2307/2960448; Mayhew David R., 1974, C ELECTORAL CONNECTI; POOLE KT, 1981, AM J POLIT SCI, V25, P49, DOI 10.2307/2110912; Proksch SO, 2012, AM J POLIT SCI, V56, P520, DOI 10.1111/j.1540-5907.2011.00565.x; Rosenbaum P. R., 2002, OBSERVATIONAL STUDIE; Schiller Wendy J., 2000, PARTNERS RIVALS REPR; Senate Parliament of the Czech Republic, 2014, AR SEN EL; Shepsle KA, 2009, AM J POLIT SCI, V53, P343, DOI 10.1111/j.1540-5907.2009.00374.x; Stratmann T., 2000, AM POLIT SCI REV, V94, P665, DOI 10.2307/2585838; THOMAS M, 1985, AM J POLIT SCI, V29, P96, DOI 10.2307/2111213; Todai Ho Dai 5 Ki Kabashima Ikuo Zemi, 2005, SANGIIN NO KENKYU; Yamauchi Yurika, 2005, SANGIIN NO KENKYU, V2, P362	48	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0362-9805	1939-9162		LEGIS STUD QUART	Legis. Stud. Q.	NOV	2015	40	4					599	625		10.1111/lsq.12090		27	Political Science	Government & Law	CU4RH	WOS:000363516800005		
J	Pinato, DJ; Karamanakos, G; Ishizuka, M; Smirne, C; Pirisi, M; Kubota, K; Sharma, R				Pinato, David J.; Karamanakos, Georgios; Ishizuka, Mitsuru; Smirne, Carlo; Pirisi, Mario; Kubota, Keiichi; Sharma, Rohini			The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application	LIVER INTERNATIONAL			English	Article						aspartate aminotransferase; hepatocellular carcinoma; international normalized ratio; Kings Score; platelet count; prognosis	CHRONIC HEPATITIS-C; VENOUS-PRESSURE GRADIENT; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER-TRANSPLANTATION; CIRRHOSIS; SURVIVAL; INDEX; RESECTION; CANCER	Background & AimsThere are a number of prognostic scores in hepatocellular carcinoma (HCC), none of which is optimal in predicting overall survival (OS) in the individual patient, particularly in intermediate stage disease, where patients are not surgically treatable but may qualify for a wide range of palliative interventions. We evaluated the prognostic role of a biochemical algorithm, the Kings Score (KS), in the palliative setting of care. MethodsWe used the algorithm [age x AST x INR]/platelet count to derive the KS. Full clinical data including Barcelona Clinic Liver Cancer (BCLC) stage were studied in a training set of 97 patients from the UK. Independent predictors of survival identified in multivariate analysis were validated in an independent cohort of 766 patients from Japan and Italy. ResultsIn both training and validation sets, KS was confirmed as an independent predictor of OS (P<0.01). Ad-hoc subgroup analysis revealed the KS to be prognostic in the palliative setting, being able to subclassify patients presenting with intermediate and advanced disease according to BCLC criteria (P<0.001). ConclusionThe KS integrates into the BCLC system to improve prognostic substratification in the palliative setting of care. The KS may help reducing disease heterogeneity and refine treatment allocation in intermediate-advanced HCC.	[Pinato, David J.; Karamanakos, Georgios; Sharma, Rohini] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Expt Med, London, England; [Ishizuka, Mitsuru; Kubota, Keiichi] Dokkyo Med Univ, Dept Surg Gastroenterol, Mibu, Tochigi, Japan; [Smirne, Carlo; Pirisi, Mario] Univ Piemonte Orientale, Dept Translat Med, Novara, Italy; [Pirisi, Mario] Univ Piemonte Orientale, Interdisciplinary Res Ctr Autoimmune Dis, Novara, Italy	Sharma, R (reprint author), Univ London Imperial Coll Sci Technol & Med, Oncol & Clin Pharmacol, Hammersmith Campus,Cane Rd, London W12 0HS, England.	r.sharma@imperial.ac.uk					Boleslawski E, 2012, BRIT J SURG, V99, P855, DOI 10.1002/bjs.8753; Masuzaki R, 2010, J HEPATO-BIL-PAN SCI, V17, P440, DOI 10.1007/s00534-009-0240-1; Cross TJS, 2010, J VIRAL HEPATITIS, V17, P546, DOI 10.1111/j.1365-2893.2009.01210.x; Camma C, 2009, LIVER INT, V29, P478, DOI 10.1111/j.1478-3231.2009.01994.x; Miraglia R, 2007, WORLD J GASTROENTERO, V13, P6022, DOI 10.3748/wjg.13.6022; Chang HC, 2013, ANTICANCER RES, V33, P5171; Carr BI, 2014, SEMIN ONCOL, V41, P415, DOI 10.1053/j.seminoncol.2014.04.001; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep20933; Pinato DJ, 2012, TRANSL RES, V160, P146, DOI 10.1016/j.trsl.2012.01.011; Snowdon V, 2011, GUT, V60, pA247, DOI 10.1136/gut.2011.239301.524; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Felga G, 2014, TRANSPL P, V46, P1764, DOI 10.1016/j.transproceed.2014.05.004; Kikuchi L, 2014, WORLD J GASTROENTERO, V20, P1585, DOI 10.3748/wjg.v20.i6.1585; Cross TJS, 2010, J VIRAL HEPATITIS, V17, P640, DOI 10.1111/j.1365-2893.2009.01222.x; Pinato DJ, 2012, J HEPATOL, V57, P1013, DOI 10.1016/j.jhep.2012.06.022; Sieghart W, 2013, HEPATOLOGY, V57, P2261, DOI 10.1002/hep.26256; Cucchetti A, 2015, HEPATOLOGY, V61, P905, DOI 10.1002/hep.27321; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Kim HY, 2013, J GASTROEN HEPATOL, V28, P1756, DOI 10.1111/jgh.12310; Ripoll C, 2009, J HEPATOL, V50, P923, DOI 10.1016/j.jhep.2009.01.014; Changchien CS, 2008, J GASTROENTEROL, V43, P159, DOI [10.1007/s00535-007-2134-9, 10.1007/s00535-007-21.34-9]; Llovet JM, 2008, J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Bolondi L, 2012, SEMIN LIVER DIS, V32, P348, DOI 10.1055/s-0032-1329906; Cross TJS, 2009, EUR J GASTROEN HEPAT, V21, P730, DOI 10.1097/MEG.0b013e32830dfcb3; Kadalayil L, 2013, ANN ONCOL, V24, P2565, DOI 10.1093/annonc/mdt247; Kim Hyung Joon, 2013, Clin Mol Hepatol, V19, P105, DOI 10.3350/cmh.2013.19.2.105; Morimoto Y, 2014, HEPATOL RES, V44, pE353, DOI 10.1111/hepr.12315; Motoyama H, 2015, AM J SURG, V209, P733, DOI 10.1016/j.amjsurg.2014.05.026; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Pinato DJ, 2014, ALIMENT PHARM THER, V40, P1270, DOI 10.1111/apt.12992; Shen SL, 2014, ANN SURG ONCOL, V21, P3802, DOI 10.1245/s10434-014-3771-x; Zhang JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088182	32	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1478-3223	1478-3231		LIVER INT	Liver Int.	NOV	2015	35	11					2458	2465		10.1111/liv.12841		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU3GI	WOS:000363411900015		
J	Guo, HX; Ishida, M				Guo, Hongxin; Ishida, Masashi			Harnack estimates for nonlinear heat equations with potentials in geometric flows	MANUSCRIPTA MATHEMATICA			English	Article							HARMONIC MAP FLOW; RICCI FLOW; POSITIVE SOLUTIONS	Let M be a closed Riemannian manifold with a family of Riemannian metrics evolving by geometric flow partial derivative(t)g(ij) = -2S(ij), where S-ij(t)is a family of smooth symmetric two-tensors on M. In this paper we derive differential Harnack estimates for positive solutions to the nonlinear heat equation with potential: partial derivative f/partial derivative t = Delta f + gamma(t) f log f + aSf, where gamma(t) is a continuous function on t, a is a constant and S = g(ij)S(ij) is the trace of S-ij. Our Harnack estimates include many known results as special cases, and moreover lead to new Harnack inequalities for a variety geometric flows.	[Guo, Hongxin] Wenzhou Univ, Sch Math & Informat Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Ishida, Masashi] Osaka Univ, Grad Sch Sci, Dept Math, Toyonaka, Osaka 5600043, Japan	Ishida, M (reprint author), Osaka Univ, Grad Sch Sci, Dept Math, 1-1 Machikaneyama, Toyonaka, Osaka 5600043, Japan.	guo@wzu.edu.cn; ishida@math.sci.osaka-u.ac.jp			NSFC [11001203, 11171143]; Zhejiang Provincial Natural Science Foundation of China [LY13A010009]; Japan Society for the Promotion of Science [25400074]	The first author was supported by NSFC (Grant Nos. 11001203 and 11171143) and Zhejiang Provincial Natural Science Foundation of China (Project No. LY13A010009). The second author was partially supported by the Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, No. 25400074.	Cao XD, 2008, J FUNCT ANAL, V255, P1024, DOI 10.1016/j.jfa.2008.05.009; Wu JY, 2012, PAC J MATH, V257, P199; HAMILTON RS, 1993, J DIFFER GEOM, V37, P225; [Anonymous], 2006, INT MATH RES NOTICES, DOI DOI 10.1155/IMRN/2006/92314; Cao XD, 2011, SPRINGER PROC MATH, V8, P87, DOI 10.1007/978-3-642-20300-8_5; Guo HX, 2013, PAC J MATH, V264, P61, DOI 10.2140/pjm.2013.264.61; Cao XD, 2009, GEOM FUNCT ANAL, V19, P989, DOI 10.1007/s00039-009-0024-4; Liu SP, 2009, PAC J MATH, V243, P165; Kuang SL, 2008, J FUNCT ANAL, V255, P1008, DOI 10.1016/j.jfa.2008.05.014; Muller R, 2012, ANN SCI ECOLE NORM S, V45, P101; [Anonymous], 2005, THESIS AEI POTSDAM; Sun J, 2011, PAC J MATH, V253, P489; Muller R, 2010, J REINE ANGEW MATH, V643, P39, DOI 10.1515/CRELLE.2010.044; Guo HX, 2014, GEOMETRIAE DEDICATA, V169, P411, DOI 10.1007/s10711-013-9864-z; Bailesteanu M, 2010, J FUNCT ANAL, V258, P3517, DOI 10.1016/j.jfa.2009.12.003; Guenther C. M., 2002, J GEOM ANAL, V12, P425; Guo HX, 2014, J FUNCT ANAL, V267, P2638, DOI 10.1016/j.jfa.2014.08.006; HAMILTON RS, 1982, J DIFFER GEOM, V17, P255; Ishida M, 2014, ANN GLOB ANAL GEOM, V45, P287, DOI 10.1007/s10455-013-9401-1; LI P, 1986, ACTA MATH-DJURSHOLM, V156, P153, DOI 10.1007/BF02399203; Ni L., 2008, SURV DIFFER GEOM, V12, P251; Perelman G., 2002, ENTROPY FORMULA RICC	22	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0025-2611	1432-1785		MANUSCRIPTA MATH	Manuscr. Math.	NOV	2015	148	3-4					471	484		10.1007/s00229-015-0757-3		14	Mathematics	Mathematics	CU1GJ	WOS:000363268100011		
J	Toda, Y				Toda, Yukinobu			Non-commutative width and Gopakumar-Vafa invariants	MANUSCRIPTA MATHEMATICA			English	Article							CATEGORIES; FLOPS; THREEFOLDS; CURVES	We show that the non-commutative widths for flopping curves on smooth three-folds introduced by Donovan-Wemyss are described by Katz's genus zero Gopakumar-Vafa invariants.	Univ Tokyo, Kavli Inst Phys & Math Universe, Kashiwa, Chiba 2778583, Japan	Toda, Y (reprint author), Univ Tokyo, Kavli Inst Phys & Math Universe, 5-1-5 Kashiwanoha, Kashiwa, Chiba 2778583, Japan.	yukinobu.toda@ipmu.jp			World Premier International Research Center Initiative (WPI initiative), MEXT, Japan; Ministry of Education, Culture, Sports, Science and Technology, Japan [26287002]	I would like to thank Michael Wemyss and Will Donovan for valuable comments on the manuscript. I would also like to thank Tom Bridgeland for checking a misprint of his paper [2], and allowing me to correct it in "Appendix B". I would like to thank the referee for the careful check of the manuscript, and several comments. This work is supported by World Premier International Research Center Initiative (WPI initiative), MEXT, Japan. This work is also supported by Grant-in Aid for Scientific Research grant (No. 26287002) from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Katz S, 2008, J DIFFER GEOM, V79, P185; Toda Y, 2008, T AM MATH SOC, V360, P6149, DOI 10.1090/S0002-9947-08-04509-1; Seidel P, 2001, DUKE MATH J, V108, P37; Chen JC, 2002, J DIFFER GEOM, V61, P227; Bridgeland T, 2002, INVENT MATH, V147, P613, DOI 10.1007/s002220100185; Van den Bergh M, 2004, DUKE MATH J, V122, P423, DOI 10.1215/S0012-7094-04-12231-6; Bryan J, 2001, J ALGEBRAIC GEOM, V10, P549; Donovan W., ARXIV13090698; Huybrechts D, 2006, OXFORD MATH MONOGRAP; Katz S., 1992, J ALGEBRAIC GEOM, V1, P449; Orlov D. O., 1997, J MATH SCI NEW YORK, V84, P1361, DOI 10.1007/BF02399195; Reid M., ADV STUD PURE MATH, V1, P131; Toda Y., 2007, B SMF, V135, P97	13	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0025-2611	1432-1785		MANUSCRIPTA MATH	Manuscr. Math.	NOV	2015	148	3-4					521	533		10.1007/s00229-015-0760-8		13	Mathematics	Mathematics	CU1GJ	WOS:000363268100015		
J	King, DR; Sun, TL; Huang, YW; Kurokawa, T; Nonoyama, T; Crosby, AJ; Gong, JP				King, Daniel R.; Sun, Tao Lin; Huang, Yiwan; Kurokawa, Takayuki; Nonoyama, Takayuki; Crosby, Alfred J.; Gong, Jian Ping			Extremely tough composites from fabric reinforced polyampholyte hydrogels	MATERIALS HORIZONS			English	Article							ANTERIOR CRUCIATE LIGAMENT; DOUBLE-NETWORK HYDROGELS; DETERMINING TEAR RESISTANCE; FLEXIBLE CARBON-FIBER; MECHANISTIC ROLE; WOVEN CLOTH; TONGUE TEAR; REPLACEMENT; STRENGTH; FRICTION	Ligaments are unique wet biological tissues with high tensile modulus and fracture stress, combined with high bending flexibility. Developing synthetic materials with these properties is a significant challenge. Hydrogel composites made from high stiffness fabrics is a strategy to develop such unique materials; however, the ability to produce these materials has proven difficult, since common hydrogels swell in water and interact poorly with solid components, limiting the transfer of force from the fabric to the hydrogel matrix. In this work, for the first time, we successfully produce extraordinarily tough hydrogel composites by strategically selecting a recently developed tough hydrogel that de-swells in water. The new composites, consisting of polyampholyte hydrogels and glass fiber woven fabrics, exhibit extremely high effective toughness (250 000 J m(-2)), high tear strength (similar to 65 N mm(-1)), high tensile modulus (606 MPa), and low bending modulus (4.7 MPa). Even though these composites are composed of water-containing, biocompatible materials, their mechanical properties are comparable to high toughness Kevlar/polyurethane blends and fiber-reinforced polymers. Importantly, the mechanical properties of these composites greatly outperform the properties of either individual component. A mechanism is proposed based on established fabric tearing theory, which will enable the development of a new generation of mechanically robust composites based on fabrics. These results will be important towards developing soft biological prosthetics, and more generally for commercial applications such as tear-resistant gloves and bulletproof vests.	[King, Daniel R.; Crosby, Alfred J.] Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA; [Sun, Tao Lin; Kurokawa, Takayuki; Nonoyama, Takayuki; Gong, Jian Ping] Hokkaido Univ, Fac Adv Life Sci, Sapporo, Hokkaido 0600810, Japan; [Huang, Yiwan] Hokkaido Univ, Grad Sch Life Sci, Sapporo, Hokkaido 0600810, Japan	Crosby, AJ (reprint author), Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA.	crosby@mail.pse.umass.edu; gong@mail.sci.hokudai.ac.jp	Gong, Jian Ping/B-7019-2009	Gong, Jian Ping/0000-0003-2228-2750	Japan Society for the Promotion of Science (JSPS) [124225006]; Human Frontiers Science Program	D.R.K. would like to acknowledge H. Yin and T. Ouchi for help with sample preparation, and A. Ihsan and T. Sullivan for experimental support. This research was financially supported by a Grant-in-Aid for Scientific Research (S) (No. 124225006) from Japan Society for the Promotion of Science (JSPS), and the Human Frontiers Science Program.	Bin Ihsan A, 2013, J MATER CHEM B, V1, P4555, DOI 10.1039/c3tb20790k; SCHARLING M, 1981, ACTA ORTHOP SCAND, V52, P575, DOI 10.3109/17453678108992149; Ramakrishna S, 2001, COMPOS SCI TECHNOL, V61, P1189, DOI 10.1016/S0266-3538(00)00241-4; Rose S, 2014, NATURE, V505, P382, DOI 10.1038/nature12806; Lin ST, 2014, SOFT MATTER, V10, P7519, DOI 10.1039/c4sm01039f; SCELZO WA, 1994, TEXT RES J, V64, P291, DOI 10.1177/004051759406400506; Gong JP, 2006, SOFT MATTER, V2, P544, DOI 10.1039/b603209p; Tanaka Y, 2005, J PHYS CHEM B, V109, P11559, DOI 10.1021/jp0500790; RIVLIN RS, 1953, J POLYM SCI, V10, P291, DOI 10.1002/pol.1953.120100303; Keller MW, 2007, ADV FUNCT MATER, V17, P2399, DOI 10.1002/adfm.200700086; Yasuda K, 2005, BIOMATERIALS, V26, P4468, DOI 10.1016/j.biomaterials.2004.11.021; Tominaga T, 2008, SOFT MATTER, V4, P1033, DOI 10.1039/b716465c; Altman GH, 2002, BIOMATERIALS, V23, P4131, DOI 10.1016/S0142-9612(02)00156-4; Freeman JW, 2011, J BIOMECH, V44, P694, DOI 10.1016/j.jbiomech.2010.10.043; Durselen L, 1996, BIOMATERIALS, V17, P977, DOI 10.1016/0142-9612(96)84671-0; Gong JP, 2010, SOFT MATTER, V6, P2583, DOI 10.1039/b924290b; Cui J, 2012, BIOMACROMOLECULES, V13, P584, DOI 10.1021/bm300015s; Osada Y, 1998, ADV MATER, V10, P827, DOI 10.1002/(SICI)1521-4095(199808)10:11<827::AID-ADMA827>3.0.CO;2-L; Sun JY, 2012, NATURE, V489, P133, DOI 10.1038/nature11409; Agrawal A, 2013, ACTA BIOMATER, V9, P5313, DOI 10.1016/j.actbio.2012.10.011; ROTH JH, 1985, AM J SPORT MED, V13, P321, DOI 10.1177/036354658501300507; Pendergraph SA, 2012, ACS APPL MATER INTER, V4, P6640, DOI [10.1021/am3017812, 10.1021/am3012812]; Gong JP, 2001, J AM CHEM SOC, V123, P5582, DOI 10.1021/ja003794q; Wenger MPE, 2007, BIOPHYS J, V93, P1255, DOI 10.1529/biophysj.106.103192; KUTTY SKN, 1991, J APPL POLYM SCI, V43, P1913, DOI 10.1002/app.1991.070431016; MENDES DG, 1986, J BIOMED MATER RES, V20, P699, DOI 10.1002/jbm.820200604; AMIS AA, 1988, J BONE JOINT SURG BR, V70, P628; DeKosky BJ, 2010, TISSUE ENG PART C-ME, V16, P1533, DOI 10.1089/ten.tec.2009.0761; MOYEN B, 1994, J BONE JOINT SURG BR, V76B, P173; JENKINS DHR, 1980, J BONE JOINT SURG BR, V62, P497; Myung D, 2008, POLYM ADVAN TECHNOL, V19, P647, DOI 10.1002/pat.1134; SCELZO WA, 1994, TEXT RES J, V64, P321, DOI 10.1177/004051759406400603; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Brown HR, 2007, MACROMOLECULES, V40, P3815, DOI 10.1021/ma062642y; GENT AN, 1982, J POLYM SCI POL PHYS, V20, P2051, DOI 10.1002/pol.1982.180201107; Strasser S, 2007, BIOCHEM BIOPH RES CO, V354, P27, DOI 10.1016/j.bbrc.2006.12.114; Liao IC, 2013, ADV FUNCT MATER, V23, P5833, DOI 10.1002/adfm.201300483; Corner E M, 1914, Proc R Soc Med, V7, P120; JENKINS DHR, 1978, J BONE JOINT SURG BR, V60, P520; Mascarenhas Randy, 2008, Mcgill J Med, V11, P29; Miller K., 2011, COMPREHENSIVE BIOMAT, P257; Sun T. L., 2013, NAT MATER, V12, P1; Visser J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7933; Woo S. L., 2005, BASIC ORTHOPAEDIC BI, P301; Woo SLY, 2003, FUNCTIONAL TISSUE ENGINEERING, P17, DOI 10.1007/0-387-21547-6_2	45	0	0	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2051-6347	2051-6355		MATER HORIZ	Mater. Horizons	NOV	2015	2	6					584	591		10.1039/c5mh00127g		8	Chemistry, Multidisciplinary; Materials Science, Multidisciplinary	Chemistry; Materials Science	CU0TG	WOS:000363231000004		
J	He, ZC; Liu, F; Wang, C; Chen, JH; He, LL; Nordlund, D; Wu, HB; Russell, TP; Cao, Y				He, Zhicai; Liu, Feng; Wang, Cheng; Chen, Jihua; He, Lilin; Nordlund, Dennis; Wu, Hongbin; Russell, Thomas P.; Cao, Yong			Simultaneous spin-coating and solvent annealing: manipulating the active layer morphology to a power conversion efficiency of 9.6% in polymer solar cells	MATERIALS HORIZONS			English	Article							SMALL-ANGLE; PHASE	We developed a simultaneous spin-coating/solvent-annealing process and demonstrated morphology optimization for PTB7 based organic photovoltaics. This novel processing method enhances the edge-on crystalline content in thin films and induces the formation of weak PCBM aggregates. As a result, the efficiency of polymer solar cells increased from 9.2% to a certified high efficiency of 9.61%, owing to an enhanced short-circuit current (J(sc), 18.4 mA cm(-2) vs. 17. 5 mA cm(-2)) and an improved fill factor.	[He, Zhicai; Wu, Hongbin; Cao, Yong] S China Univ Technol, Inst Polymer Optoelect Mat & Devices, State Key Lab Luminescent Mat & Devices, Guangzhou 510640, Guangdong, Peoples R China; [Liu, Feng; Russell, Thomas P.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA; [Liu, Feng; Russell, Thomas P.] Univ Massachusetts, Dept Polymer Sci & Engn, Amherst, MA 01003 USA; [Wang, Cheng] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Adv Light Source, Berkeley, CA 94720 USA; [Chen, Jihua] Oak Ridge Natl Lab, Ctr Nanophase Mat Sci, Oak Ridge, TN 37831 USA; [He, Lilin] Oak Ridge Natl Lab, Biol & Soft Matter Div, Neutron Sci Directorate, Oak Ridge, TN 37831 USA; [Nordlund, Dennis] SLAC Natl Accelerator Lab, Stanford Synchrotron Radiat Lightsource, Menlo Pk, CA 94025 USA; [Russell, Thomas P.] Tohoku Univ, WPI Adv Inst Mat Res, Aoba Ku, Sendai, Miyagi 9808577, Japan	Wu, HB (reprint author), S China Univ Technol, Inst Polymer Optoelect Mat & Devices, State Key Lab Luminescent Mat & Devices, Guangzhou 510640, Guangdong, Peoples R China.	iamfengliu@gmail.com; hbwu@scut.edu.cn; russell@mail.pse.umass.edu			National Natural Science Foundation of China [91333206, 51403066, 51225301, 61177022, 5141101251]; Fundamental Research Funds for the Central Universities [2014ZM001]; Innovation Program of Guangdong Province Universities and Colleges [2012KJCX0009]; Polymer-Based Materials for Harvesting Solar Energy (PHaSE), an Energy Frontier Research Centre - US Department of Energy, Office of Basic Energy Sciences [DE-SC0001087]; DOE, Office of Science, and Office of Basic Energy Sciences; US Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-76SF00515]; Division of Scientific User Facilities, Office of Basic Energy Sciences, US Department of Energy; Scientific User Facilities Division, Office of Basic Energy Sciences, US Department of Energy	H.W. and Z.H. acknowledge financial support from the National Natural Science Foundation of China (no. 91333206, 51403066, 51225301, 61177022 and 5141101251), Fundamental Research Funds for the Central Universities (2014ZM001) and Innovation Program of Guangdong Province Universities and Colleges (2012KJCX0009), and thank M. Yun and X. Wang of CPVT for device performance verification. F.L. and T.P.R. were supported by Polymer-Based Materials for Harvesting Solar Energy (PHaSE), an Energy Frontier Research Centre funded by the US Department of Energy, Office of Basic Energy Sciences under award number DE-SC0001087. Portions of this research were carried out at beamline 7.3.3 and 11.0.1.2 at the Advanced Light Source, and Molecular Foundry, Lawrence Berkeley National Laboratory, which was supported by the DOE, Office of Science, and Office of Basic Energy Sciences. Use of the Stanford Synchrotron Radiation Light source, SLAC National Accelerator Laboratory, was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515. Energy filtered TEM was conducted at the Center for Nanophase Materials Sciences, which was sponsored at Oak Ridge National Laboratory by the Division of Scientific User Facilities, Office of Basic Energy Sciences, US Department of Energy. Research conducted at ORNL's High Flux Isotope Reactor was sponsored by the Scientific User Facilities Division, Office of Basic Energy Sciences, US Department of Energy.	Hammond MR, 2011, ACS NANO, V5, P8248, DOI 10.1021/nn202951e; Chen DA, 2011, NANO LETT, V11, P561, DOI 10.1021/nl103482n; Chang H, 2013, SYNTHETIC MET, V184, P1, DOI 10.1016/j.synthmet.2013.09.031; Bian LY, 2012, PROG POLYM SCI, V37, P1292, DOI 10.1016/j.progpolymsci.2012.03.001; Collins BA, 2013, ADV ENERGY MATER, V3, P65, DOI 10.1002/aenm.201200377; Liang YY, 2009, J AM CHEM SOC, V131, P7792, DOI 10.1021/ja901545q; Liu F, 2012, J POLYM SCI POL PHYS, V50, P1018, DOI 10.1002/polb.23063; Gann E, 2012, REV SCI INSTRUM, V83, DOI 10.1063/1.3701831; Li G, 2005, NAT MATER, V4, P864, DOI 10.1038/nmat1500; Li G, 2007, ADV FUNCT MATER, V17, P1636, DOI 10.1002/adfm.200600624; He ZC, 2012, NAT PHOTONICS, V6, P591, DOI 10.1038/NPHOTON.2012.190; Chiu MY, 2008, ADV MATER, V20, P2573, DOI 10.1002/adma.200703097; Chen HY, 2009, NAT PHOTONICS, V3, P649, DOI 10.1038/NPHOTON.2009.192; Liu F, 2013, PROG POLYM SCI, V38, P1990, DOI 10.1016/j.progpolymsci.2013.07.010; Chen W, 2011, NANO LETT, V11, P3707, DOI 10.1021/nl201715q; Son HJ, 2011, J AM CHEM SOC, V133, P1885, DOI 10.1021/ja108601g; Park J, 2008, ADV MATER, V20, P2491, DOI 10.1002/adma.200702995; Drummy LF, 2011, CHEM MATER, V23, P907, DOI 10.1021/cm102463t; Clark J, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.206406; Liang YY, 2010, ADV MATER, V22, pE135, DOI 10.1002/adma.200903528; Yao B, 2013, ORG ELECTRON, V14, P897, DOI 10.1016/j.orgel.2013.01.016; Beaucage G, 1996, J APPL CRYSTALLOGR, V29, P134, DOI 10.1107/S0021889895011605; Beaucage G., 1995, J APPL CRYSTALLOGR, P1; Kim Y, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1861123; Liu F, 2014, ADV ENERGY MATER, V4, DOI 10.1002/aenm.201301377; Schmidt K., 2013, ADV MATER, V26, P300; van Franeker J. J., 2015, NAT COMMUN, V6, P1; You JB, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2411	28	0	0	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2051-6347	2051-6355		MATER HORIZ	Mater. Horizons	NOV	2015	2	6					592	597		10.1039/c5mh00076a		6	Chemistry, Multidisciplinary; Materials Science, Multidisciplinary	Chemistry; Materials Science	CU0TG	WOS:000363231000005		
J	Chen, YZ; Liang, LF; Yang, QH; Hong, MC; Xu, Q; Yu, SH; Jiang, HL				Chen, Yu-Zhen; Liang, Linfeng; Yang, Qihao; Hong, Maochun; Xu, Qiang; Yu, Shu-Hong; Jiang, Hai-Long			A seed-mediated approach to the general and mild synthesis of non-noble metal nanoparticles stabilized by a metal-organic framework for highly efficient catalysis	MATERIALS HORIZONS			English	Article							CHEMICAL HYDROGEN STORAGE; CORE-SHELL NANOPARTICLES; POROUS COORDINATION POLYMERS; AMMONIA-BORANE; HYDROLYTIC DEHYDROGENATION; NANOCLUSTERS CATALYST; NICKEL NANOPARTICLES; CARBON-DIOXIDE; WATER; PERFORMANCE	A novel and facile in situ seed-mediated synthetic approach has been developed to reduce non-noble metal precursors (Ni2+, Co2+, Fe2+, etc.) at room temperature, by taking advantage of a trace amount of noble metal cations (Ag+, Pd2+, Pt2+, Au3+, etc.) as a seed/initiator and NH3BH3 as a moderate reducing agent. The obtained noble metal-seed-mediated (NMSM) non-noble metal nanoparticles (NPs), stabilized by a metal-organic framework, are low-cost and display superior catalytic activity in the hydrolytic dehydrogenation of NH3BH3 under ambient conditions. As a representative catalyst, Ag-doped Ni/MIL-101 (with a Ag/Ni molar ratio as low as 1/200), exhibited a much higher activity than any of the other corresponding counterparts.	[Chen, Yu-Zhen; Liang, Linfeng; Yang, Qihao; Yu, Shu-Hong; Jiang, Hai-Long] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Key Lab Soft Matter Chem,Chinese Acad Sci,Dept Ch, Hefei 230026, Anhui, Peoples R China; [Liang, Linfeng; Hong, Maochun; Jiang, Hai-Long] Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou 350002, Fujian, Peoples R China; [Xu, Qiang] Natl Inst Adv Ind Sci & Technol, Ikeda, Osaka 5638577, Japan	Jiang, HL (reprint author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Key Lab Soft Matter Chem,Chinese Acad Sci,Dept Ch, Hefei 230026, Anhui, Peoples R China.	jianglab@ustc.edu.cn	Jiang, Hai-Long/B-2995-2011; Yu, Shu-Hong/A-1903-2010	Jiang, Hai-Long/0000-0002-2975-7977; Yu, Shu-Hong/0000-0003-3732-1011	NSFC [21371162, 51301159]; 973 program [2014CB931803]; NSF of Anhui Province [1408085MB23]; Research Fund for the Doctoral Program of Higher Education of China [20133402120020]; Recruitment Program of Global Youth Experts; Fundamental Research Funds for the Central Universities [WK2060190026]	We gratefully thank the reviewers for their valuable suggestions. This work is supported by the NSFC (21371162 and 51301159), the 973 program (2014CB931803), NSF of Anhui Province (1408085MB23), Research Fund for the Doctoral Program of Higher Education of China (20133402120020), the Recruitment Program of Global Youth Experts and the Fundamental Research Funds for the Central Universities (WK2060190026).	Wang ZQ, 2009, CHEM SOC REV, V38, P1315, DOI 10.1039/b802258p; Yamada Y, 2012, ENERG ENVIRON SCI, V5, P5356, DOI 10.1039/c1ee02639a; Moon HR, 2013, CHEM SOC REV, V42, P1807, DOI 10.1039/c2cs35320b; Jiang HL, 2009, J AM CHEM SOC, V131, P11302, DOI 10.1021/ja9047653; Chen P, 2002, NATURE, V420, P302, DOI 10.1038/nature01210; Zahmakiran M, 2009, APPL CATAL B-ENVIRON, V89, P104, DOI 10.1016/j.apcatb.2008.12.004; Zhang T, 2014, CHEM SOC REV, V43, P5982, DOI 10.1039/c4cs00103f; Grochala W, 2004, CHEM REV, V104, P1283, DOI 10.1021/cr030691s; Gutowska A, 2005, ANGEW CHEM INT EDIT, V44, P3578, DOI 10.1002/anie.200462602; Zhou HC, 2012, CHEM REV, V112, P673, DOI 10.1021/cr300014x; Fu HR, 2015, CHEM MATER, V27, P205, DOI 10.1021/cm503767r; Jiang HL, 2011, CATAL TODAY, V170, P56, DOI 10.1016/j.cattod.2010.09.019; Zhou HC, 2014, CHEM SOC REV, V43, P5415, DOI 10.1039/c4cs90059f; Li XH, 2013, CHEM SOC REV, V42, P6593, DOI 10.1039/c3cs60067j; Chen YZ, 2015, SMALL, V11, P71, DOI 10.1002/smll.201401875; Jiang HL, 2011, CHEM COMMUN, V47, P10999, DOI 10.1039/c1cc13989d; Bluhm ME, 2006, J AM CHEM SOC, V128, P7748, DOI 10.1021/ja062085v; Li JR, 2012, CHEM REV, V112, P869, DOI 10.1021/cr200190s; Chen YZ, 2015, ACS CATAL, V5, P2062, DOI 10.1021/cs501953d; Hermes S, 2005, ANGEW CHEM INT EDIT, V44, P6237, DOI 10.1002/anie.200462515; Wang DS, 2010, J AM CHEM SOC, V132, P6280, DOI 10.1021/ja100845v; Yan JM, 2010, J AM CHEM SOC, V132, P5326, DOI 10.1021/ja910513h; Sun DH, 2011, ACS NANO, V5, P6458, DOI 10.1021/nn2016666; Chandra M, 2006, J POWER SOURCES, V156, P190, DOI 10.1016/j.jpowsour.2005.05.043; Zheng NF, 2006, J AM CHEM SOC, V128, P14278, DOI 10.1021/ja0659929; Guo LT, 2015, ACS CATAL, V5, P388, DOI 10.1021/cs501692n; Li PZ, 2012, ANGEW CHEM INT EDIT, V51, P6753, DOI 10.1002/anie.201202055; Li CM, 2013, CHEM MATER, V25, P3888, DOI 10.1021/cm4021832; Cheng FY, 2007, INORG CHEM, V46, P788, DOI 10.1021/ic061712e; Keaton RJ, 2007, J AM CHEM SOC, V129, P1844, DOI 10.1021/ja066860i; Demirci UB, 2010, J POWER SOURCES, V195, P4030, DOI 10.1016/j.jpowsour.2010.01.002; Hannauer J, 2011, ENERG ENVIRON SCI, V4, P3355, DOI 10.1039/c1ee01886h; Yang L, 2013, ACS APPL MATER INTER, V5, P8231, DOI 10.1021/am402373p; Cao CY, 2010, CHEMSUSCHEM, V3, P1241, DOI 10.1002/cssc.201000229; Kitchin JR, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.156801; Hwang YK, 2008, ANGEW CHEM INT EDIT, V47, P4144, DOI 10.1002/anie.200705998; Lu G, 2012, NAT CHEM, V4, P310, DOI 10.1038/nchem.1272; Jiang HL, 2011, CHEM COMMUN, V47, P3351, DOI 10.1039/c0cc05419d; Jiang HL, 2010, CHEMSUSCHEM, V3, P541, DOI 10.1002/cssc.201000023; Ferey G, 2005, SCIENCE, V309, P2040, DOI 10.1126/science.1116275; Kalidindi SB, 2008, PHYS CHEM CHEM PHYS, V10, P5870, DOI 10.1039/b805726e; Yuan BZ, 2010, ANGEW CHEM INT EDIT, V49, P4054, DOI 10.1002/anie.201000576; Chen BL, 2010, ACCOUNTS CHEM RES, V43, P1115, DOI 10.1021/ar100023y; Metin O, 2010, J AM CHEM SOC, V132, P1468, DOI 10.1021/ja909243z; Liu XH, 2015, ANGEW CHEM INT EDIT, V54, P988, DOI 10.1002/anie.201409103; Hamilton CW, 2009, CHEM SOC REV, V38, P279, DOI 10.1039/b800312m; Karahan S, 2012, CHEM COMMUN, V48, P1180, DOI 10.1039/c1cc15864c; Yan JM, 2012, J MATER CHEM, V22, P10990, DOI 10.1039/c2jm31042b; Zhao MT, 2014, J AM CHEM SOC, V136, P1738, DOI 10.1021/ja411468e; Cao A, 2010, PHYS CHEM CHEM PHYS, V12, P13499, DOI 10.1039/c0cp00729c; Ishida T, 2008, CHEM-EUR J, V14, P8456, DOI 10.1002/chem.200800980; Shimizu K, 2013, ACS CATAL, V3, P998, DOI 10.1021/cs4001267; Alayoglu S, 2008, NAT MATER, V7, P333, DOI 10.1038/nmat2156; Farrusseng D, 2009, ANGEW CHEM INT EDIT, V48, P7502, DOI 10.1002/anie.200806063; Lee YW, 2008, J PHYS CHEM C, V112, P6717, DOI 10.1021/jp710933d; Lin WW, 2012, J CATAL, V291, P149, DOI 10.1016/j.jcat.2012.04.020; Metin O, 2011, INT J HYDROGEN ENERG, V36, P1424, DOI 10.1016/j.ijhydene.2010.10.070; Wang C, 2012, J AM CHEM SOC, V134, P7211, DOI 10.1021/ja300539p; Zheng N, 2006, J AM CHEM SOC, V128, P6550, DOI 10.1021/ja0604717; Yan JM, 2008, ANGEW CHEM INT EDIT, V47, P2287, DOI 10.1002/anie.200704943; Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229; Astruc D., 2008, NANOPARTICLES CATALY, V2, P1; Dhakshinamoorthy A, 2012, CHEM SOC REV, V41, P5262, DOI 10.1039/c2cs35047e; Hermannsdorfer J, 2012, ANGEW CHEM INT EDIT, V51, P11473, DOI 10.1002/anie.201205078; Hu P, 2014, ACS CATAL, V4, P4409, DOI 10.1021/cs5012662; Hu ZG, 2014, CHEMSUSCHEM, V7, P2791, DOI 10.1002/cssc.201402378; Metin O, 2009, ENERG FUEL, V23, P3517, DOI 10.1021/ef900171t; Tao F., 2014, METAL NANOPARTICLES; Yadav M, 2012, ENERG ENVIRON SCI, V5, P9698, DOI 10.1039/c2ee22937d	69	0	0	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2051-6347	2051-6355		MATER HORIZ	Mater. Horizons	NOV	2015	2	6					606	612		10.1039/c5mh00125k		7	Chemistry, Multidisciplinary; Materials Science, Multidisciplinary	Chemistry; Materials Science	CU0TG	WOS:000363231000007		
J	Wakumoto-Nakashima, K; Yamada, N; Morino, S; Yamamoto, O				Wakumoto-Nakashima, Keiko; Yamada, Nanako; Morino, Shinichi; Yamamoto, Osamu			Novel in vivo observations on double acting points of luliconazole on Trichophyton rubrum: an ultrastructural study	MEDICAL MYCOLOGY			English	Article						luliconazole; T. rubrum; in vivo effect; scanning electron microscopy; transmission electron microscopy	EPIDERMOPHYTON-FLOCCOSUM; CELL-WALL; ANTIFUNGAL ACTIVITY; CHITIN SYNTHETASE; GLUCAN SYNTHASE; PLASMA-MEMBRANE; MENTAGROPHYTES; VITRO; BIFONAZOLE; IMIDAZOLE	Scales from lesional skin of 12 patients with tinea pedis were investigated by scanning electron microscopy (SEM) and transmission electron microscopy (TEM) to gain an insight into the spatial and morphological changes of dermatophytes after application of a clinical dosage of topical luliconazole 1% cream (Lulicon (R) cream 1%). In all cases, Trichophyton rubrum was identified. The scales from the lesions collected before and after topical luliconazole application were fixed with glutaraldehyde and subjected to SEM and TEM. For SEM, fixed specimens were first placed in 1N-KOH and then post-fixed and observed. SEM showed a swollen appearance of fungal hyphae as an early change, and then shrinkage of them showing a flattened and twisted appearance as a later change. TEM showed cell wall alterations with initial development of and accumulation of a granular structure in the outermost layer and subsequent amorphous and electron-lucent change of the thickened inner part of the cell wall. This is the first report of dramatic morphological changes of T. rubrum before and after topical luliconazole application in vivo demonstrated by SEM and TEM. We hypothesize that luliconazole has double acting points, on the plasma membrane and cell wall, of dermatophyte hyphae.	[Wakumoto-Nakashima, Keiko; Yamada, Nanako; Yamamoto, Osamu] Tottori Univ, Fac Med, Dept Med Sensory & Motor Organs, Div Dermatol, Yonago, Tottori 6838504, Japan; [Morino, Shinichi] Tottori Univ, Electron Microscopy Lab, Yonago, Tottori 6838504, Japan	Yamada, N (reprint author), Tottori Univ, Fac Med, Dept Med Sensory & Motor Organs, Div Dermatol, 36-1 Nishicho, Yonago, Tottori 6838504, Japan.	nayamada@grape.med.tottori-u.ac.jp					Niwano Y, 1998, ANTIMICROB AGENTS CH, V42, P967; Koga Hiroyasu, 2006, Journal of Infection and Chemotherapy, V12, P163, DOI 10.1007/s10156-006-0440-4; Romagnoli C, 2002, MYCOPATHOLOGIA, V153, P129, DOI 10.1023/A:1014593416665; NOZAWA Y, 1973, BIOCHIM BIOPHYS ACTA, V307, P92, DOI 10.1016/0005-2736(73)90028-X; CAPUTO R, 1977, J ULTRA MOL STRUCT R, V59, P149, DOI 10.1016/S0022-5320(77)80075-0; RASHID A, 1995, J MED VET MYCOL, V33, P229; DURAN A, 1975, P NATL ACAD SCI USA, V72, P3952, DOI 10.1073/pnas.72.10.3952; KITAJIMA Y, 1975, BIOCHIM BIOPHYS ACTA, V394, P558, DOI 10.1016/0005-2736(75)90141-8; NISHIYAMA Y, 1992, CLIN EXP DERMATOL, V17, P13, DOI 10.1111/j.1365-2230.1992.tb00271.x; NOGUCHI T, 1971, ARCH BIOCHEM BIOPHYS, V146, P506, DOI 10.1016/0003-9861(71)90155-X; OSUMI M, 1984, DERMATOLOGICA, V169, P19; Beauvais A, 2001, J BACTERIOL, V183, P2273, DOI 10.1128/JB.183.7.2273-2279.2001; WUYUAN CD, 1977, J BACTERIOL, V129, P1584; HASHIMOTO T, 1976, J BACTERIOL, V127, P1543; Koga H, 2009, MED MYCOL, V47, P640, DOI 10.1080/13693780802541518; OSUMI M, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1484; DURAN A, 1978, J BIOL CHEM, V253, P4419; Kitajma Y, 2000, Nihon Ishinkin Gakkai Zasshi, V41, P211; KITAZIMA Y, 1972, ARCH BIOCHEM BIOPHYS, V152, P811, DOI 10.1016/0003-9861(72)90277-9; Kitajima Y., 1984, Japanese Journal of Medical Mycology, V25, P94; Kurtz MB, 1997, J MED VET MYCOL, V35, P79; Nishiyama Y., 1991, Japanese Journal of Medical Mycology, V32, P165; Ohmi T., 1992, Japanese Journal of Medical Mycology, V33, P339; Taki A., 1991, Japanese Journal of Medical Mycology, V32, P31; Tameike A., 1996, Japanese Journal of Medical Mycology, V37, P251; Uchida Katsuhisa, 2004, Journal of Infection and Chemotherapy, V10, P216; Yamada N., 1986, Japanese Journal of Medical Mycology, V27, P256; Yamaguchi H, 1985, JPN J CHEMOTHER, V33, P227	28	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1369-3786	1460-2709		MED MYCOL	Med. Mycol.	NOV	2015	53	8					860	867		10.1093/mmy/myv058		8	Infectious Diseases; Mycology; Veterinary Sciences	Infectious Diseases; Mycology; Veterinary Sciences	CT7ZN	WOS:000363034600009		
J	Matsuo, Y; Tanaka, M; Yamakage, H; Sasaki, Y; Muranaka, K; Hata, H; Ikai, I; Shimatsu, A; Inoue, M; Chun, TH; Satoh-Asahara, N				Matsuo, Yoshiyuki; Tanaka, Masashi; Yamakage, Hajime; Sasaki, Yousuke; Muranaka, Kazuya; Hata, Hiroaki; Ikai, Iwao; Shimatsu, Akira; Inoue, Mayumi; Chun, Tae-Hwa; Satoh-Asahara, Noriko			Thrombospondin 1 as a novel biological marker of obesity and metabolic syndrome	METABOLISM-CLINICAL AND EXPERIMENTAL			English	Article						Thrombospondin 1; Biological marker; Obesity; Diabetes; Metabolic syndrome	ADIPOSE-TISSUE EXPANDABILITY; BODY-FAT DISTRIBUTION; INSULIN-RESISTANCE; TGF-BETA; ENDOTHELIAL-CELLS; SEXUAL-DIMORPHISM; VISCERAL FAT; ACTIVATION; PROTEIN; WEIGHT	Context. Thrombospondin 1 (THBS1 or TSP-1) is an adipose-derived matricellular protein, which has recently been highlighted as a potential mediator of insulin resistance and adipose inflammation in obesity. Objective. In this study, we aimed to determine the clinical significance of THBS1 as a novel biological marker of visceral obesity, metabolic syndrome, and diabetes. Methods. The THBS1 mRNA level was quantified with real-time PCR in human adipose tissues obtained from 16 non-obese subjects. The relationships between serum THBS1 level and obesity/diabetes traits as well as the diagnostic components of metabolic syndrome were assessed in 164 normal-weight or overweight/obese subjects (78 males and 86 females; mean age, 50.4; mean BMI, 29.8) with analysis of covariance (ANCOVA) and regression analyses. Results. THBS1 was predominantly expressed in visceral adipose tissues relative to subcutaneous adipose tissues (P < 0.001). The visceral THBS1 expression was positively associated with the body mass index (BMI; gamma(s) = 0.54, P = 0.033). ANCOVA demonstrated that the THBS1 level is associated with abdominal obesity (P < 0.001), hyperglycemia (P = 0.02), and hypertension (P = 0.04). Multivariable regression analysis suggested an association between serum THBS1 and fasting plasma glucose levels. The associations between serum THBS1 levels and obesity/diabetes traits were found preferentially in women (BMI, gamma(s) = 0.30, P = 0.05; FPG, gamma(s) = 0.26, P = 0.016). Subanalyses demonstrated that the association with obesity traits was predominantly found in premenopausal women (BMI, gamma(s) = 0.41, P = 0.007), whereas the association with diabetes traits was predominant in postmenopausal women (HbA1c, gamma(s) = 0.38, P = 0.01). During medical weight reduction treatment, the change in the serum THBS1 level was associated with the change in BMI and HbA1c in pre- and postmenopausal women, respectively. Conclusions. Serum THBS1 is a useful biological marker of obesity and metabolic syndrome in Japanese subjects, particularly in women. THBS1 may act as a critical circulating factor that couples obesity with metabolic syndrome and diabetes in humans. (C) 2015 Elsevier Inc. All rights reserved.	[Matsuo, Yoshiyuki; Tanaka, Masashi; Yamakage, Hajime; Sasaki, Yousuke; Muranaka, Kazuya; Shimatsu, Akira; Satoh-Asahara, Noriko] Kyoto Med Ctr, Natl Hosp Org, Clin Res Inst, Div Diabet Res,Fushimi Ku, Kyoto 6128555, Japan; [Hata, Hiroaki; Ikai, Iwao] Kyoto Med Ctr, Natl Hosp Org, Dept Surg, Fushimi Ku, Kyoto 6128555, Japan; [Chun, Tae-Hwa] Univ Michigan, Sch Med, Dept Internal Med, Div Metab Endocrinol & Diabet MEND, Ann Arbor, MI 48109 USA; [Chun, Tae-Hwa] Univ Michigan, Biointerfaces Inst, Ann Arbor, MI 48109 USA	Chun, TH (reprint author), Univ Michigan, Sch Med, Dept Internal Med, Div Metab Endocrinol & Diabet MEND, NCRC Bldg 10-A186,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	taehwa@med.umich.edu; nsatoh@kuhp.kyoto-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan, JSPS KAKENHI [24590719, 15K08634]; Danone Institute of Japan Foundation; JSPS KAKENHI [26893335]; Michigan Center of Diabetes Translational Research (MCDTR) Methods and Measurement Core [P30DK092926]	This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, JSPS KAKENHI, Grant Number 24590719 and 15K08634 and Danone Institute of Japan Foundation for a financial support of the 2015 DIJF to NS-A, JSPS KAKENHI Grant Number 26893335 to YM, and grant P30DK092926 to Michigan Center of Diabetes Translational Research (MCDTR) Methods and Measurement Core.	LAWLER JW, 1978, J BIOL CHEM, V253, P8609; Satoh N, 2008, HYPERTENS RES, V31, P1921, DOI 10.1291/hypres.31.1921; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Tan CY, 2008, BIOCHEM SOC T, V36, P935, DOI 10.1042/BST0360935; Inoue M, 2013, ENDOCRINOLOGY, V154, P4548, DOI 10.1210/en.2013-1587; Guo W, 2007, AM J PHYSIOL-ENDOC M, V292, pE1041, DOI 10.1152/ajpendo.00557.2006; Ramis JM, 2002, CELL MOL LIFE SCI, V59, P1960, DOI 10.1007/PL00012518; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; KOTANI K, 1994, INT J OBESITY, V18, P207; Yamakage H, 2014, ENDOCR J, V61, P807, DOI 10.1507/endocrj.EJ14-0092; Varma V, 2008, DIABETES, V57, P432, DOI 10.2337/db07-0840; Stenina OI, 2004, INT J BIOCHEM CELL B, V36, P1013, DOI 10.1016/j.biocel.2004.01.005; JAFFE EA, 1985, BLOOD, V65, P79; Bruun JM, 2005, J CLIN ENDOCR METAB, V90, P2282, DOI 10.1210/jc.2004-1696; Rosenquist KJ, 2015, J CLIN ENDOCR METAB, V100, P227, DOI 10.1210/jc.2013-4296; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; He Q, 2002, J CLIN ENDOCR METAB, V87, P2164, DOI 10.1210/jc.87.5.2164; Kong P, 2013, AM J PHYSIOL-ENDOC M, V305, pE439, DOI 10.1152/ajpendo.00006.2013; Gao AG, 1996, J BIOL CHEM, V271, P21; Winton HL, 2014, INVEST OPHTH VIS SCI, V55, P2115, DOI 10.1167/iovs.13-13681; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Gray SL, 2007, NUTR REV, V65, pS7, DOI 10.1301/nr.2007.jun.S7-S12; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; Sweetwyne MT, 2012, MATRIX BIOL, V31, P178, DOI 10.1016/j.matbio.2012.01.006; Saad MF, 1997, J CLIN ENDOCR METAB, V82, P579, DOI 10.1210/jc.82.2.579; LEY CJ, 1992, AM J CLIN NUTR, V55, P950; Banerji MA, 1999, J CLIN ENDOCR METAB, V84, P137, DOI 10.1210/jc.84.1.137; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; BAENZIGE.NL, 1972, J BIOL CHEM, V247, P2723; Li Y, 2011, AQUAC RES, V22, P1, DOI DOI 10.1155/2011/341520; Tardif N, 2014, AGING CELL, V13, P1001, DOI 10.1111/acel.12263	34	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0026-0495	1532-8600		METABOLISM	Metab.-Clin. Exp.	NOV	2015	64	11					1490	1499		10.1016/j.metabol.2015.07.016		10	Endocrinology & Metabolism	Endocrinology & Metabolism	CU3PJ	WOS:000363437000014		
J	Morard, R; Darling, KF; Mahe, F; Audic, S; Ujiie, Y; Weiner, AKM; Andre, A; Seears, HA; Wade, CM; Quillevere, F; Douady, CJ; Escarguel, G; de Garidel-Thoron, T; Siccha, M; Kucera, M; de Vargas, C				Morard, Raphael; Darling, Kate F.; Mahe, Frederic; Audic, Stephane; Ujiie, Yurika; Weiner, Agnes K. M.; Andre, Aurore; Seears, Heidi A.; Wade, Christopher M.; Quillevere, Frederic; Douady, Christophe J.; Escarguel, Gilles; de Garidel-Thoron, Thibault; Siccha, Michael; Kucera, Michal; de Vargas, Colomban			PFR2: a curated database of planktonic foraminifera 18S ribosomal DNA as a resource for studies of plankton ecology, biogeography and evolution	MOLECULAR ECOLOGY RESOURCES			English	Article						18S ribosomal DNA; genetic diversity; molecular ecology; molecular taxonomy; planktonic foraminifera; sequence database	MOLECULAR EVIDENCE; SPECIES IDENTIFICATION; SEQUENCE ALIGNMENT; RNA GENOTYPES; DIVERSITY; PROTIST; SEA; DIFFERENTIATION; POPULATIONS; EUKARYOTES	Planktonic foraminifera (Rhizaria) are ubiquitous marine pelagic protists producing calcareous shells with conspicuous morphology. They play an important role in the marine carbon cycle, and their exceptional fossil record serves as the basis for biochronostratigraphy and past climate reconstructions. A major worldwide sampling effort over the last two decades has resulted in the establishment of multiple large collections of cryopreserved individual planktonic foraminifera samples. Thousands of 18S rDNA partial sequences have been generated, representing all major known morphological taxa across their worldwide oceanic range. This comprehensive data coverage provides an opportunity to assess patterns of molecular ecology and evolution in a holistic way for an entire group of planktonic protists. We combined all available published and unpublished genetic data to build PFR2, the Planktonic foraminifera Ribosomal Reference database. The first version of the database includes 3322 reference 18S rDNA sequences belonging to 32 of the 47 known morphospecies of extant planktonic foraminifera, collected from 460 oceanic stations. All sequences have been rigorously taxonomically curated using a six-rank annotation system fully resolved to the morphological species level and linked to a series of metadata. The PFR2 website, available at , allows downloading the entire database or specific sections, as well as the identification of new planktonic foraminiferal sequences. Its novel, fully documented curation process integrates advances in morphological and molecular taxonomy. It allows for an increase in its taxonomic resolution and assures that integrity is maintained by including a complete contingency tracking of annotations and assuring that the annotations remain internally consistent.	[Morard, Raphael; Audic, Stephane; de Vargas, Colomban] CNRS, UMR 7144, EPEP, Stn Biol Roscoff, F-29680 Roscoff, France; [Morard, Raphael; Audic, Stephane; de Vargas, Colomban] Univ Paris 06, Univ Paris 04, UMR 7144, Stn Biol Roscoff, F-29680 Roscoff, France; [Morard, Raphael; Weiner, Agnes K. M.; de Garidel-Thoron, Thibault; Siccha, Michael; Kucera, Michal] Univ Bremen, MARUM Ctr Marine Environm Sci, D-28359 Bremen, Germany; [Darling, Kate F.] Univ Edinburgh, Sch GeoSci, Edinburgh EH9 3JW, Midlothian, Scotland; [Darling, Kate F.] Univ St Andrews, Sch Geog & GeoSci, St Andrews KY16 9AL, Fife, Scotland; [Mahe, Frederic] Tech Univ Kaiserslautern, Dept Ecol, D-67663 Kaiserslautern, Germany; [Ujiie, Yurika] Shinshu Univ, Dept Biol, Matsumoto, Nagano 3908621, Japan; [Andre, Aurore; Quillevere, Frederic; Escarguel, Gilles] Univ Lyon 1, CNRS UMR 5276, Lab Geol Lyon Terre, Planetes,Environm, F-69622 Villeurbanne, France; [Andre, Aurore] Univ Reims, UFR Sci Exactes & Nat, F-51100 Reims, France; [Seears, Heidi A.; Wade, Christopher M.] Univ Nottingham, Sch Life Sci, Nottingham NG7 2RD, England; [Seears, Heidi A.] Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18105 USA; [Douady, Christophe J.] Univ Lyon 1, Ecol Hydrosyst Nat & Anthropises UMR5023, ENTPE, CNRS, F-69622 Villeurbanne, France; [Douady, Christophe J.] Inst Univ France, F-75005 Paris, France; [de Garidel-Thoron, Thibault] Aix Marseille Univ, CNRS, CEREGE UM34, F-13545 Aix En Provence, France	Morard, R (reprint author), CNRS, UMR 7144, EPEP, Stn Biol Roscoff, F-29680 Roscoff, France.	rmorard@marum.de		Audic, Stephane/0000-0001-6193-4374	Natural Environment Research Council of the United Kingdom [NER/J/S2000/00860, NE/D009707/1]; Leverhulme Trust; Carnegie Trust for the Universities of Scotland; DFG-Research Center/Cluster of Excellence 'The Ocean in the Earth System'; Deutsche Forschungsgemeinschaft [KU2259/19, DU1319/1-1];  [ANR-11-BTBR-0008 OCEANOMICS];  [ANR-09-BLAN-0348 POSEIDON];  [ANR-JCJC06-0142-PALEO-CTD]	We thank all crew members and scientist for their help in the collection of planktonic foraminifera that were used to generate the database. We thank Erica de Leau for her help in compiling the data and Dominique Boeuf and ABIMS for their help in designing and hosting the PFR<SUP>2</SUP> website. This work was supported by grants from ANR-11-BTBR-0008 OCEANOMICS, ANR-09-BLAN-0348 POSEIDON, ANR-JCJC06-0142-PALEO-CTD, from Natural Environment Research Council of the United Kingdom (NER/J/S2000/00860 and NE/D009707/1), the Leverhulme Trust and the Carnegie Trust for the Universities of Scotland, from DFG-Research Center/Cluster of Excellence 'The Ocean in the Earth System' and from the Deutsche Forschungsgemeinschaft KU2259/19 and DU1319/1-1. This study is a contribution to the effort of the SCOR/IGBP Working Group 138 'Modern planktonic foraminifera and ocean changes'.	Andre A, 2014, PLOS ONE, V9, P1; Darling KF, 2007, P NATL ACAD SCI USA, V104, P5002, DOI 10.1073/pnas.0700520104; Saunders GW, 2005, PHILOS T ROY SOC B, V360, P1879, DOI 10.1098/rstb.2005.1719; Weber AAT, 2014, PROTIST, V165, P645, DOI 10.1016/j.protis.2014.07.006; Darling KF, 1999, PALEOCEANOGRAPHY, V14, P3, DOI 10.1029/1998PA900002; Weiner A, 2012, MOL ECOL, V21, P4063, DOI 10.1111/j.1365-294X.2012.05686.x; Stewart IA, 2001, MAR MICROPALEONTOL, V43, P143, DOI 10.1016/S0377-8398(01)00024-X; Guillou L, 2013, NUCLEIC ACIDS RES, V41, pD597, DOI 10.1093/nar/gks1160; Darling KF, 1996, J FORAMIN RES, V26, P324; Darling KF, 1997, MAR MICROPALEONTOL, V30, P251, DOI 10.1016/S0377-8398(96)00057-6; Sogin ML, 2006, P NATL ACAD SCI USA, V103, P12115, DOI 10.1073/pnas.0605127103; Morard R, 2013, PALAEOGEOGR PALAEOCL, V391, P13, DOI 10.1016/j.palaeo.2013.05.011; Holzmann M, 1996, J FORAMIN RES, V26, P264; Ujiie Y, 2008, MAR MICROPALEONTOL, V69, P334, DOI 10.1016/j.marmicro.2008.09.003; Hollingsworth PM, 2009, P NATL ACAD SCI USA, V106, P12794, DOI 10.1073/pnas.0905845106; Aurahs R, 2009, MOL ECOL, V18, P1692, DOI 10.1111/j.1365-294X.2009.04136.x; Darling KF, 2004, P NATL ACAD SCI USA, V101, P7657, DOI 10.1073/pnas.0402401101; Kucera M, 2002, PHILOS T ROY SOC A, V360, P695, DOI 10.1098/rsta.2001.0962; Pawlowski J, 2010, J EUKARYOT MICROBIOL, V57, P197, DOI 10.1111/j.1550-7408.2009.00468.x; Pawlowski J, 2014, BIOL BULL-US, V227, P93; Logares R, 2014, CURR BIOL, V24, P813, DOI 10.1016/j.cub.2014.02.050; Zaric S, 2005, MAR MICROPALEONTOL, V55, P75, DOI 10.1016/j.marmicro.2005.01.002; Morard R, 2009, MAR MICROPALEONTOL, V71, P148, DOI 10.1016/j.marmicro.2009.03.001; Gouy M, 2010, MOL BIOL EVOL, V27, P221, DOI 10.1093/molbev/msp259; Kucera M, 2005, QUATERNARY SCI REV, V24, P951, DOI 10.1016/j.quascirev.2004.07.014; Aze T, 2011, BIOL REV, V86, P900, DOI 10.1111/j.1469-185X.2011.00178.x; Weiner AKM, 2015, MAR MICROPALEONTOL, V114, P19, DOI 10.1016/j.marmicro.2014.10.003; Ujiie Y, 2009, J FORAMIN RES, V39, P145; Ujiie Y, 2012, ECOL EVOL, V2, P1725, DOI 10.1002/ece3.286; Schoch CL, 2012, P NATL ACAD SCI USA, V109, P6241, DOI 10.1073/pnas.1117018109; Quillevere F, 2013, PALAEOGEOGR PALAEOCL, V391, P2, DOI 10.1016/j.palaeo.2011.03.013; Wade CM, 1996, J MOL EVOL, V43, P672, DOI 10.1007/BF02202115; SPENCERCERVATO C, 1994, PALEOCEANOGRAPHY, V9, P739, DOI 10.1029/94PA01456; Nikolaev SI, 2004, P NATL ACAD SCI USA, V101, P8066, DOI 10.1073/pnas.0308602101; Darling KF, 2006, PALEOCEANOGRAPHY, V21, DOI 10.1029/2005PA001189; Nassonova E, 2010, PROTIST, V161, P102, DOI 10.1016/j.protis.2009.07.003; Darling KF, 2008, MAR MICROPALEONTOL, V67, P216, DOI 10.1016/j.marmicro.2008.01.009; Darling KF, 2000, NATURE, V405, P43, DOI 10.1038/35011002; Aurahs R, 2011, MAR MICROPALEONTOL, V79, P1, DOI 10.1016/j.marmicro.2010.12.001; Sherwood AR, 2007, J PHYCOL, V43, P605, DOI 10.1111/j.1529-8817.2007.00341.x; Darling KF, 2009, P NATL ACAD SCI USA, V106, P12629, DOI 10.1073/pnas.0902827106; Andre A, 2013, PALEOBIOLOGY, V39, P21, DOI 10.1666/0094-8373-39.1.21; Hamsher SE, 2011, PROTIST, V162, P405, DOI 10.1016/j.protis.2010.09.005; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; BRUMMER GJA, 1986, NATURE, V319, P50, DOI 10.1038/319050a0; Aurahs R, 2009, BIOINFORMATICS BIOLO, V2009, P155; Be A.W.H., 1971, MICROPALEONTOLOGY OC, P105; Darling KF, 2003, PALEOCEANOGRAPHY, V18, P1; desVargas C., 2001, PALEOBIOLOGY, V27, P104; desVargas C, 1999, P NATL ACAD SCI USA, V96, P2864; desVargas C, 2002, MAR MICROPALEONTOL, V45, P101; desVargas C, 1997, J MOL EVOL, V45, P285; Guillou L, 2012, NUCLEIC ACIDS RES, V41, pD597, DOI DOI 10.1093/NAR/GKS1160.HTTP://SSU-RNA.0RG; Hemleben C., 1989, MODERN PLANKTONIC FO, P363; Be A. W. H, 1977, Micropaleontology, V23, P369, DOI 10.2307/1485406; Morard R, 2011, PLOS ONE, V6, P1; NEEDLEMA.SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Pawlowski J, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001419; Pawlowski J, 1998, MOL PHYLOGENET EVOL, V9, P463; Pawlowski J, 2014, J FORAMIN RES, V44, P62; R Development Core Team, 2014, R LANG ENV STAT COMP; Rice P., 2000, TRENDS GENET, V16, P2; Rognes T, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-221; Seears HA, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-54; Stern RF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013991; Mora C, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000606; Weiner AKM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092148; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Yilmaz P., 2013, NUCLEIC ACIDS RES, V42, pD643, DOI DOI 10.1093/NAR/GKT1209; Zimmermann J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108793	70	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-098X	1755-0998		MOL ECOL RESOUR	Mol. Ecol. Resour.	NOV	2015	15	6					1472	1485		10.1111/1755-0998.12410		14	Biochemistry & Molecular Biology; Ecology; Evolutionary Biology	Biochemistry & Molecular Biology; Environmental Sciences & Ecology; Evolutionary Biology	CT5GZ	WOS:000362838300020		
J	Kondo, M; Nakamura, Y; Ishida, Y; Shimada, S				Kondo, M.; Nakamura, Y.; Ishida, Y.; Shimada, S.			The 5-HT3 receptor is essential for exercise-induced hippocampal neurogenesis and antidepressant effects	MOLECULAR PSYCHIATRY			English	Article							LONG-TERM POTENTIATION; ADULT-RAT HIPPOCAMPUS; DENTATE GYRUS; VOLUNTARY EXERCISE; SYNAPTIC PLASTICITY; PHYSICAL-EXERCISE; ENVIRONMENTAL ENRICHMENT; VENTRAL HIPPOCAMPUS; PARKINSONS-DISEASE; SEROTONIN RECEPTOR	Exercise has a variety of beneficial effects on brain structure and function, such as hippocampal neurogenesis, mood and memory. Previous studies have shown that exercise enhances hippocampal neurogenesis, induces antidepressant effects and improves learning behavior. Brain serotonin (5-hydroxytryptamine, 5-HT) levels increase following exercise, and the 5-HT system has been suggested to have an important role in these exercise-induced neuronal effects. However, the precise mechanism remains unclear. In this study, analysis of the 5-HT type 3A receptor subunit-deficient (htr3a(-/-)) mice revealed that lack of the 5-HT type 3 (5-HT3) receptor resulted in loss of exercise-induced hippocampal neurogenesis and antidepressant effects, but not of learning enhancement. Furthermore, stimulation of the 5-HT3 receptor promoted neurogenesis. These findings demonstrate that the 5-HT3 receptor is the critical target of 5-HT action in the brain following exercise, and is indispensable for hippocampal neurogenesis and antidepressant effects induced by exercise. This is the first report of a pivotal 5-HT receptor subtype that has a fundamental role in exercise-induced morphological changes and psychological effects.	[Kondo, M.; Nakamura, Y.; Ishida, Y.; Shimada, S.] Osaka Univ, Grad Sch Med, Dept Neurosci & Cell Biol, Suita, Osaka 5650871, Japan	Kondo, M (reprint author), Osaka Univ, Grad Sch Med, Dept Neurosci & Cell Biol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mkondo@anat1.med.osaka-u.ac.jp			JSPS KAKENHI grant [26860926]; Uehara Memorial Foundation; Japan Prize Foundation; Brain Science Foundation; Sakamoto Research Foundation of Psychiatric Diseases; Takeda Science Foundation; Ichiro Kanehara Foundation; Kanae Foundation; Suzuken Memorial Foundation; Meiji Yasuda Life Foundation	This work was supported by JSPS KAKENHI grant number 26860926, and grants from the Uehara Memorial Foundation, the Japan Prize Foundation, Brain Science Foundation, the Sakamoto Research Foundation of Psychiatric Diseases, Takeda Science Foundation, the Ichiro Kanehara Foundation, Kanae Foundation, Suzuken Memorial Foundation and Meiji Yasuda Life Foundation. We thank Shingo Miyata (Kinki University) for technical assistance.	Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Ernst C, 2006, J PSYCHIATR NEUROSCI, V31, P84; MOORE RY, 1975, J COMP NEUROL, V164, P171, DOI 10.1002/cne.901640203; Greenwood BN, 2003, J NEUROSCI, V23, P2889; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Banasr M, 2004, NEUROPSYCHOPHARMACOL, V29, P450, DOI 10.1038/sj.npp.1300320; Zeitz KP, 2002, J NEUROSCI, V22, P1010; Malberg JE, 2000, J NEUROSCI, V20, P9104; Bequet F, 2001, ACTA PHYSIOL SCAND, V173, P223, DOI 10.1046/j.1365-201X.2001.00859.x; van Praag H, 1999, NAT NEUROSCI, V2, P266; Strawbridge WJ, 2002, AM J EPIDEMIOL, V156, P328, DOI 10.1093/aje/kwf047; Goodwin VA, 2008, MOVEMENT DISORD, V23, P631, DOI 10.1002/mds.21922; Gomez-Merino D, 2001, NEUROSCI LETT, V301, P143, DOI 10.1016/S0304-3940(01)01626-3; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Crizzle AM, 2006, CLIN J SPORT MED, V16, P422, DOI 10.1097/01.jsm.0000244612.55550.7d; Airan RD, 2007, SCIENCE, V317, P819, DOI 10.1126/science.1144400; Redila VA, 2006, NEUROSCIENCE, V137, P1299, DOI 10.1016/j.neuroscience.2005.10.050; van Praag H, 2009, TRENDS NEUROSCI, V32, P283, DOI 10.1016/j.tins.2008.12.007; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; DERKACH V, 1989, NATURE, V339, P706, DOI 10.1038/339706a0; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Tanti A, 2013, NEUROSCIENCE, V252, P234, DOI 10.1016/j.neuroscience.2013.08.017; Wilson WM, 1996, BEHAV PHARMACOL, V7, P101; Schloesser RJ, 2010, MOL PSYCHIATR, V15, P1152, DOI 10.1038/mp.2010.34; Sahay A, 2011, NATURE, V472, P466, DOI 10.1038/nature09817; Anderson BJ, 2000, PHYSIOL BEHAV, V70, P425, DOI 10.1016/S0031-9384(00)00282-1; Kondo M, 2012, NEURON, V73, P743, DOI 10.1016/j.neuron.2011.12.020; Carro E, 2001, J NEUROSCI, V21, P5678; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Bednarczyk MR, 2009, HIPPOCAMPUS, V19, P913, DOI 10.1002/hipo.20621; Duman CH, 2008, BRAIN RES, V1199, P148, DOI 10.1016/j.brainres.2007.12.047; GAGE FH, 1980, BRAIN RES BULL, V5, P771, DOI 10.1016/0361-9230(80)90220-8; Meeusen R, 1996, BRAIN RES, V740, P245, DOI 10.1016/S0006-8993(96)00872-4; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Wang JW, 2008, J NEUROSCI, V28, P1374, DOI 10.1523/JNEUROSCI.3632-07.2008; BACHY A, 1993, EUR J PHARMACOL, V237, P299, DOI 10.1016/0014-2999(93)90282-M; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Greenwood BN, 2009, HIPPOCAMPUS, V19, P988, DOI 10.1002/hipo.20534; Klempin F, 2013, J NEUROSCI, V33, P8270, DOI 10.1523/JNEUROSCI.5855-12.2013; Kheirbek MA, 2011, NEUROPSYCHOPHARMACOL, V36, P373, DOI 10.1038/npp.2010.148; Baruch DE, 2004, BEHAV NEUROSCI, V118, P1123, DOI 10.1037/0735-7044.118.5.1123; Dietrich MO, 2008, J NEUROSCI, V28, P10766, DOI 10.1523/JNEUROSCI.2744-08.2008; Morales M, 1997, J NEUROSCI, V17, P3157; BLISS TVP, 1983, J PHYSIOL-LONDON, V334, P475; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Trejo JL, 2001, J NEUROSCI, V21, P1628; Morales M, 1996, MOL BRAIN RES, V36, P251, DOI 10.1016/0169-328X(96)88406-3; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05-2005; OLESKEVICH S, 1990, NEUROSCIENCE, V34, P19, DOI 10.1016/0306-4522(90)90301-J; Barnes NM, 1999, NEUROPHARMACOLOGY, V38, P1083, DOI 10.1016/S0028-3908(99)00010-6; STAUBLI U, 1995, J NEUROSCI, V15, P2445; Banasr M, 2006, BIOL PSYCHIAT, V59, P1087, DOI 10.1016/j.biopsych.2005.11.025; Liu JB, 2013, J PINEAL RES, V54, P222, DOI 10.1111/jpi.12023; Teri L, 2003, JAMA-J AM MED ASSOC, V290, P2015, DOI 10.1001/jama.290.15.2015; Rainer Q, 2012, INT J NEUROPSYCHOPH, V15, P321, DOI 10.1017/S1461145711000356; Boldrini M, 2009, NEUROPSYCHOPHARMACOL, V34, P2376, DOI 10.1038/npp.2009.75; Schmidt-Hieber C, 2004, NATURE, V429, P184, DOI 10.1038/nature02553; Eadie BD, 2005, J COMP NEUROL, V486, P39, DOI 10.1002/cne.20493; Bjarkam CR, 2003, HIPPOCAMPUS, V13, P21, DOI 10.1002/hipo.10042; Moon HY, 2012, P NATL ACAD SCI USA, V109, P13094, DOI 10.1073/pnas.1205535109; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Meshi D, 2006, NAT NEUROSCI, V9, P729, DOI 10.1038/nn1696; Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1046/j.1460-9568.2003.03041.x; Brunton L.L, 2006, GOODMAN GILMANS PHAR; Castagne V., 2011, CURR PROTOC NEUROSCI, P55, DOI DOI 10.1002/0471142301.NS0810AS55; David JD, 2009, NEURON, V62, P479; During Matthew J., 2006, Current Alzheimer Research, V3, P29, DOI 10.2174/156720506775697133; Franklin K, 2007, MOUSE BRAIN STEREOTA; Gould E, 1999, NEUROPSYCHOPHARMACOL, V21, pS46, DOI 10.1038/sj.npp.1395369; Kelley SP, 2003, EUR J PHARMACOL, V461, P19, DOI 10.1016/S0014-2999(02)02960-6; Klempin F, 2010, FRONT MOL NEUROSCI, V3, P1; Kondo M, 2014, LEARN MEMORY, V21, P740; Nabkasorn C, 2006, EUR J PUBLIC HEALTH, V16, P179, DOI 10.1093/eurpub/cki159; PONCELET M, 1995, J NEURAL TRANSM-GEN, V102, P83, DOI 10.1007/BF01276504	82	3	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	NOV	2015	20	11					1428	1437		10.1038/mp.2014.153		10	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	CU3ZK	WOS:000363465300017		
J	Xu, H; Gao, J; Jiang, DL				Xu, Hong; Gao, Jia; Jiang, Donglin			Stable, crystalline, porous, covalent organic frameworks as a platform for chiral organocatalysts	NATURE CHEMISTRY			English	Article							PROLINE; MICHAEL; CONSTRUCTION; STABILITY; CATALYSIS; POLYMER; ALDOL	The periodic layers and ordered nanochannels of covalent organic frameworks (COFs) make these materials viable open catalytic nanoreactors, but their low stability has precluded their practical implementation. Here we report the synthesis of a crystalline porous COF that is stable against water, strong acids and strong bases, and we demonstrate its utility as a material platform for structural design and functional development. We endowed a crystalline and porous imine-based COF with stability by incorporating methoxy groups into its pore walls to reinforce interlayer interactions. We subsequently converted the resulting achiral material into two distinct chiral organocatalysts, with the high crystallinity and porosity retained, by appending chiral centres and catalytically active sites on its channel walls. The COFs thus prepared combine catalytic activity, enantioselectivity and recyclability, which are attractive in heterogeneous organocatalysis, and were shown to promote asymmetric C-C bond formation in water under ambient conditions.	[Xu, Hong; Gao, Jia; Jiang, Donglin] Natl Inst Nat Sci, Inst Mol Sci, Dept Mat Mol Sci, Okazaki, Aichi 4448787, Japan	Jiang, DL (reprint author), Natl Inst Nat Sci, Inst Mol Sci, Dept Mat Mol Sci, 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan.	jiang@ims.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) [24245030]	D.J. acknowledges the support of a Grant-in-Aid for Scientific Research (A) (24245030) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT).	Wan S, 2008, ANGEW CHEM INT EDIT, V47, P8826, DOI 10.1002/anie.200803826; Spitler EL, 2010, NAT CHEM, V2, P672, DOI [10.1038/nchem.695, 10.1038/NCHEM.695]; Chandra S, 2014, J AM CHEM SOC, V136, P6570, DOI 10.1021/ja502212v; Xu H, 2014, CHEM COMMUN, V50, P1292, DOI 10.1039/c3cc48813f; Banerjee M, 2009, J AM CHEM SOC, V131, P7524, DOI 10.1021/ja901440g; Luo SZ, 2008, CHEM-EUR J, V14, P1273, DOI 10.1002/chem.200701129; Wan S, 2011, CHEM MATER, V23, P4094, DOI 10.1021/cm201140r; Kandambeth S, 2012, J AM CHEM SOC, V134, P19524, DOI 10.1021/ja308278w; Feng X, 2012, CHEM SOC REV, V41, P6010, DOI 10.1039/c2cs35157a; Ding SY, 2013, CHEM SOC REV, V42, P548, DOI 10.1039/c2cs35072f; Tilford RW, 2006, CHEM MATER, V18, P5296, DOI 10.1021/cm061177g; Belowich ME, 2012, CHEM SOC REV, V41, P2003, DOI 10.1039/c2cs15305j; Cote AP, 2007, J AM CHEM SOC, V129, P12914, DOI 10.1021/ja0751781; Lee J, 2009, CHEM SOC REV, V38, P1450, DOI 10.1039/b807080f; Ding SY, 2011, J AM CHEM SOC, V133, P19816, DOI 10.1021/ja206846p; Bock DA, 2010, P NATL ACAD SCI USA, V107, P20636, DOI 10.1073/pnas.1006509107; Tilford RW, 2008, ADV MATER, V20, P2741, DOI 10.1002/adma.200800030; Campbell NL, 2009, CHEM MATER, V21, P204, DOI 10.1021/cm802981m; Benaglia M, 2003, CHEM REV, V103, P3401, DOI 10.1021/cr010440o; Yoon M, 2012, CHEM REV, V112, P1196, DOI 10.1021/cr2003147; Rabbani MG, 2013, CHEM-EUR J, V19, P3324, DOI 10.1002/chem.201203753; Lun DJ, 2011, J AM CHEM SOC, V133, P5806, DOI 10.1021/ja202223d; Kuhn P, 2008, ANGEW CHEM INT EDIT, V47, P3450, DOI 10.1002/anie.200705710; Dang DB, 2010, J AM CHEM SOC, V132, P14321, DOI 10.1021/ja101208s; Dogru M, 2011, CHEM COMMUN, V47, P1707, DOI 10.1039/c0cc03792c; Lukose B, 2011, CHEM-EUR J, V17, P2388, DOI 10.1002/chem.201001290; Wang CA, 2012, CHEM-EUR J, V18, P6718, DOI 10.1002/chem.201200753; Wan S, 2009, ANGEW CHEM INT EDIT, V48, P5439, DOI 10.1002/anie.200900881; Du Y, 2012, CHEM COMMUN, V48, P4606, DOI 10.1039/c2cc30781b; Chen X, 2013, J AM CHEM SOC, V135, P546, DOI 10.1021/ja3100319; Kandambeth S, 2013, ANGEW CHEM INT EDIT, V52, P13052, DOI 10.1002/anie.201306775; Uribe-Romo FJ, 2011, J AM CHEM SOC, V133, P11478, DOI 10.1021/ja204728y; Dalapati S, 2013, J AM CHEM SOC, V135, P17310, DOI 10.1021/ja4103293; Biswal BP, 2013, J AM CHEM SOC, V135, P5328, DOI 10.1021/ja4017842; Notz W, 2004, ACCOUNTS CHEM RES, V37, P580, DOI 10.1021/ar0300468; Cote AP, 2005, SCIENCE, V310, P1166, DOI 10.1126/science.1120411; MacMillan DWC, 2008, NATURE, V455, P304, DOI 10.1038/nature07367; Berner OM, 2002, EUR J ORG CHEM, P1877; Guo J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3736; List B, 2002, TETRAHEDRON, V58, P5573, DOI 10.1016/S0040-4020(02)00516-1; Nagai A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1542; Xiang ZH, 2015, POLYM CHEM-UK, V6, P1896, DOI 10.1039/c4py01383b	42	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1755-4330	1755-4349		NAT CHEM	Nat. Chem.	NOV	2015	7	11					905	912		10.1038/NCHEM.2352		8	Chemistry, Multidisciplinary	Chemistry	CU4AO	WOS:000363468600012		
J	Kezsmarki, I; Bordacs, S; Milde, P; Neuber, E; Eng, LM; White, JS; Ronnow, HM; Dewhurst, CD; Mochizuki, M; Yanai, K; Nakamura, H; Ehlers, D; Tsurkan, V; Loidl, A				Kezsmarki, I.; Bordacs, S.; Milde, P.; Neuber, E.; Eng, L. M.; White, J. S.; Ronnow, H. M.; Dewhurst, C. D.; Mochizuki, M.; Yanai, K.; Nakamura, H.; Ehlers, D.; Tsurkan, V.; Loidl, A.			Neel-type skyrmion lattice with confined orientation in the polar magnetic semiconductor GaV4S8	NATURE MATERIALS			English	Article							REAL-SPACE OBSERVATION; PHASE-TRANSITIONS; MIXED-STATE; MNSI; FIELD; CRYSTALS; MOTION	Following the early prediction of the skyrmion lattice (SkL)-a periodic array of spin vortices-it has been observed recently in various magnetic crystals mostly with chiral structure. Although non-chiral but polar crystals with C-nv symmetry were identified as ideal SkL hosts in pioneering theoretical studies, this archetype of SkL has remained experimentally unexplored. Here, we report the discovery of a SkL in the polar magnetic semiconductor GaV4S8 with rhombohedral (C-3v) symmetry and easy axis anisotropy. The SkL exists over an unusually broad temperature range compared with other bulk crystals and the orientation of the vortices is not controlled by the external magnetic field, but instead confined to the magnetic easy axis. Supporting theory attributes these unique features to a new Neel-type of SkL describable as a superposition of spin cycloids in contrast to the Bloch-type SkL in chiral magnets described in terms of spin helices.	[Kezsmarki, I.; Bordacs, S.] Budapest Univ Technol & Econ, Dept Phys, H-1111 Budapest, Hungary; [Kezsmarki, I.; Bordacs, S.] MTA BME Lendulet Magneto Opt Spect Res Grp, H-1111 Budapest, Hungary; [Kezsmarki, I.; Ehlers, D.; Tsurkan, V.; Loidl, A.] Univ Augsburg, Expt Phys 5, Ctr Elect Correlat & Magnetism, D-86135 Augsburg, Germany; [Milde, P.; Neuber, E.; Eng, L. M.] Tech Univ Dresden, Inst Angew Photophys, D-01069 Dresden, Germany; [White, J. S.] Paul Scherrer Inst, Lab Neutron Scattering & Imaging, CH-5232 Villigen, Switzerland; [Ronnow, H. M.] Ecole Polytech Fed Lausanne, Lab Quantum Magnetism, CH-1015 Lausanne, Switzerland; [Dewhurst, C. D.] Inst Laue Langevin, F-38042 Grenoble, France; [Mochizuki, M.; Yanai, K.] Aoyama Gakuin Univ, Dept Math & Phys, Sagamihara, Kanagawa 2298558, Japan; [Mochizuki, M.] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; [Nakamura, H.] Kyoto Univ, Dept Mat Sci & Engn, Kyoto 6068501, Japan; [Tsurkan, V.] Moldavian Acad Sci, Inst Appl Phys, MD-2028 Kishinev, Moldova	Kezsmarki, I (reprint author), Budapest Univ Technol & Econ, Dept Phys, H-1111 Budapest, Hungary.	kezsmark@mail.bme.hu	White, Jonathan/G-2742-2010	White, Jonathan/0000-0001-7738-0150	Hungarian Research Funds [OTKA K 108918, OTKA PD 111756, Bolyai 00565/14/11]; European Research Council; Swiss NSF [153451, 146870, 141962]; DFG [SFB 1143]; Transregional Research Collaboration From Electronic Correlations [TRR 80]; JSPS KAKENHI from MEXT Japan [25870169, 25287088]	We thank H. A. K. V. Nidda and T. Feher for useful discussions. This work was supported by the Hungarian Research Funds OTKA K 108918, OTKA PD 111756 and Bolyai 00565/14/11, by the European Research Council Project CONQUEST, by the Swiss NSF Grant Nos. 153451, 146870 and 141962, by the DFG under Grant No. SFB 1143 and via the Transregional Research Collaboration TRR 80 From Electronic Correlations to Functionality (Augsburg/Munich/Stuttgart) and by JSPS KAKENHI under Grant Nos. 25870169 and 25287088 from MEXT Japan.	Yadav CS, 2008, PHYSICA B, V403, P1474, DOI 10.1016/j.physb.2007.10.172; Sampaio J, 2013, NAT NANOTECHNOL, V8, P839, DOI [10.1038/nnano.2013.210, 10.1038/nnano.2013.233, 10.1038/NNANO.2013.210]; Adams T, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.217206; Mochizuki M, 2014, NAT MATER, V13, P241, DOI [10.1038/nmat3862, 10.1038/NMAT3862]; Yu XZ, 2011, NAT MATER, V10, P106, DOI 10.1038/nmat2916; Pfleiderer C, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/16/164207; Adams T, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.237204; Dorolti E, 2010, J AM CHEM SOC, V132, P5704, DOI 10.1021/ja908128b; Muhlbauer S, 2009, SCIENCE, V323, P915, DOI 10.1126/science.1166767; Lamago D, 2006, PHYSICA B, V385, P385, DOI 10.1016/j.physb.2006.05.079; Abd-Elmeguid MM, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.126403; Nakamura H, 2009, J PHYS CONF SER, V145, DOI 10.1088/1742-6596/145/1/012077; Wilhelm H, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.127203; Thessieu C, 1997, J PHYS-CONDENS MAT, V9, P6677, DOI 10.1088/0953-8984/9/31/019; Okamoto Y, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.097203; BOGDANOV A, 1994, J MAGN MAGN MATER, V138, P255, DOI 10.1016/0304-8853(94)90046-9; Seki S, 2012, SCIENCE, V336, P198, DOI 10.1126/science.1214143; Pocha R, 2000, CHEM MATER, V12, P2882, DOI 10.1021/cm001099b; Heinze S, 2011, NAT PHYS, V7, P713, DOI [10.1038/nphys2045, 10.1038/NPHYS2045]; Yu XZ, 2010, NATURE, V465, P901, DOI 10.1038/nature09124; Shibata K, 2013, NAT NANOTECHNOL, V8, P723, DOI 10.1038/nnano.2013.174; BOGDANOV A, 1994, PHYS STATUS SOLIDI B, V186, P527, DOI 10.1002/pssb.2221860223; Singh K, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.137602; White JS, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.107203; Romming N, 2015, PHYS REV LETT, V114, DOI 10.1103/PhysRevLett.114.177203; Tonomura A, 2012, NANO LETT, V12, P1673, DOI 10.1021/nl300073m; Wilson MN, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.144420; Romming N, 2013, SCIENCE, V341, P636, DOI 10.1126/science.1240573; Fert A, 2013, NAT NANOTECHNOL, V8, P152, DOI 10.1038/nnano.2013.29; Milde P, 2013, SCIENCE, V340, P1076, DOI 10.1126/science.1234657; BOGDANOV AN, 1989, ZH EKSP TEOR FIZ+, V96, P253; BOGDANOV AN, 1989, ZH EKSP TEOR FIZ+, V95, P178; Dzyloshinskii I. E., 1964, SOV PHYS JETP, V19, P960; Guiot V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2735; BAK P, 1980, J PHYS C SOLID STATE, V13, pL881, DOI 10.1088/0022-3719/13/31/002; Kim HS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4988; Kimura K, 2014, PHYS REV B, V90, DOI 10.1103/PhysRevB.90.060414; Leonov A., 2014, THESIS; Munzer W, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.041203; Park Hyun Soon, 2014, Nat Nanotechnol, V9, P337, DOI 10.1038/nnano.2014.52; Rossler UK, 2006, NATURE, V442, P797, DOI 10.1038/nature05056; Ruff E., 2015, PREPRINT; Ta Phouc V., 2013, PHYS REV LETT, V110; Wilson MN, 2014, PHYS REV B, V89, DOI 10.1103/PhysRevB.89.094411	44	3	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1476-1122	1476-4660		NAT MATER	Nat. Mater.	NOV	2015	14	11					1116	+		10.1038/NMAT4402		8	Chemistry, Physical; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Chemistry; Materials Science; Physics	CU4BU	WOS:000363471900019		
J	Lyon, AR; Akashi, YJ				Lyon, Alexander R.; Akashi, Yoshihiro J.			Use of cardiac MRI to diagnose Takotsubo syndrome	NATURE REVIEWS CARDIOLOGY			English	Letter							TAKO-TSUBO CARDIOMYOPATHY; INTRAVASCULAR ULTRASOUND		[Lyon, Alexander R.] Royal Brompton Hosp, NIHR Cardiovasc Biomed Res Unit, London SW3 6NP, England; [Lyon, Alexander R.] Univ London Imperial Coll Sci Technol & Med, London SW3 6NP, England; [Akashi, Yoshihiro J.] St Marianna Univ, Sch Med, Dept Internal Med, Div Cardiol,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan	Akashi, YJ (reprint author), St Marianna Univ, Sch Med, Dept Internal Med, Div Cardiol,Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.	yoakashi-circ@umin.ac.jp	Akashi, Yoshihiro/E-5227-2011	Akashi, Yoshihiro/0000-0001-7670-7326			Akashi YJ, 2015, NAT REV CARDIOL, V12, P387, DOI 10.1038/nrcardio.2015.39; Schneider B, 2014, INT J CARDIOL, V176, P199, DOI 10.1016/j.ijcard.2014.07.002; Ibanez B, 2005, HEART, V91, P102, DOI 10.1136/hrt.2004.035709; Delgado GA, 2011, AM J CARDIOL, V108, P888, DOI 10.1016/j.amjcard.2011.05.012; Pant S, 2013, INT J CARDIOL, V170, P64, DOI 10.1016/j.ijcard.2013.10.041; Haghi D, 2010, CLIN CARDIOL, V33, P307, DOI 10.1002/clc.20747; Citro R, 2014, JACC-CARDIOVASC IMAG, V7, P119, DOI 10.1016/j.jcmg.2013.09.020; Garg P., NAT REV CARDIOL	8	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-5002	1759-5010		NAT REV CARDIOL	Nat. Rev. Cardiol.	NOV	2015	12	11								10.1038/nrcardio.2015.155		1	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CU4CN	WOS:000363474000009		
J	Muraki, Y				Muraki, Yukiko			Comparative functional selectivity of imidafenacin and propiverine, antimuscarinic agents, for the urinary bladder over colon in conscious rats	NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY			English	Article						Bladder selectivity; Imidafenacin; Antimuscarinics; Colonic transit; Overactive bladder; Conscious rat	MUSCARINIC RECEPTOR ANTAGONISTS; OVERACTIVE BLADDER; HUMAN UROTHELIUM; SMOOTH-MUSCLE; CONTRACTIONS; PHARMACOKINETICS; EXPRESSION; DETRUSOR; CAPACITY; BINDING	Antimuscarinics are the first-line choice of treatment for overactive bladder (OAB). Imidafenacin distributes in the bladder more selectively than in the submaxillary gland and colon, and hence, this drug is considered more useful for OAB than other antimuscarinics. However, the examination of imidafenacin selectivity to bladder over colon using in vivo models is limited. Thus, the author examined whether imidafenacin could induce more selective blockade of the bladder over colon in conscious rats using two pharmacological indices (colonic transit and neostigmine-induced fecal pellet output) and compared its bladder selectivity with propiverine. In the bladder study, the inhibitory doses of antimuscarinics were calculated using the area under the curve of the distension-induced rhythmic contraction in conscious rats. The relative bladder selectivity of imidafenacin to propiverine was 50-fold and 61-fold, respectively, in a dye marker colonic transit model and in a neostigmine-induced fecal pellet output model. This comparative study shows that the functional bladder selectivity of imidafenacin is higher than that of propiverine tested under the present conditions in conscious rats.	Kyorin Pharmaceut Co Ltd, Watarase Res Ctr, Nogi, Tochigi 3290114, Japan	Muraki, Y (reprint author), Kyorin Pharmaceut Co Ltd, Watarase Res Ctr, 1848 Nogi, Nogi, Tochigi 3290114, Japan.	yukiko.muraki@mb.kyorin-pharm.co.jp					Bschleipfer T, 2007, LIFE SCI, V80, P2303, DOI 10.1016/j.lfs.2007.01.053; CHEN HI, 1990, BRIT J PHARMACOL, V101, P212; Sawyer GW, 1998, J PHARMACOL EXP THER, V284, P269; Sui GP, 2014, AM J PHYSIOL-RENAL, V306, pF286, DOI 10.1152/ajprenal.00291.2013; Hanna-Mitchell AT, 2007, LIFE SCI, V80, P2298, DOI 10.1016/j.lfs.2007.02.010; KIRKPATRICK CT, 1982, CLIN EXP PHARMACOL P, V9, P603, DOI 10.1111/j.1440-1681.1982.tb00831.x; Hegde SS, 2006, BRIT J PHARMACOL, V147, pS80, DOI 10.1038/sj.bjp.0706560; Eglen RM, 2001, TRENDS PHARMACOL SCI, V22, P409, DOI 10.1016/S0165-6147(00)01737-5; Kim Y, 2006, BJU INT, V97, P400, DOI 10.1111/j.1464-410X.2005.05913.x; Yamada S, 2010, DRUG METAB DISPOS, V38, P1314, DOI 10.1124/dmd.110.033233; Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Andersson KE, 2013, J UROLOGY, V190, P1173, DOI 10.1016/j.juro.2013.02.104; Yamada S, 2011, J PHARMACOL EXP THER, V336, P365, DOI 10.1124/jpet.110.172288; HATA F, 1990, BRIT J PHARMACOL, V101, P1011; Gonzalez A, 2001, AM J PHYSIOL-GASTR L, V281, pG275; Ehlert FJ, 2005, J PHARMACOL EXP THER, V313, P368, DOI 10.1124/jpet.104.077909; Kullmann FA, 2008, AM J PHYSIOL-RENAL, V294, pF971, DOI 10.1152/ajprenal.00313.2007; Grider JR, 2003, AM J PHYSIOL-GASTR L, V284, pG768, DOI 10.1152/ajpgi.00384.1998; Kennedy C, 2007, J NEUROSCI, V27, P845, DOI 10.1523/JNEUROSCI.3115-06.2007; Abrams P, 2007, BJU INT, V100, P987, DOI 10.1111/j.1464-410X.2007.07205.x; Kim Y, 2005, UROLOGY, V65, P238, DOI 10.1016/j.urology.2004.11.021; KISHIBAYASHI N, 1995, JPN J PHARMACOL, V67, P45, DOI 10.1254/jjp.67.45; Ono S, 2005, BIOMED RES-TOKYO, V26, P173, DOI 10.2220/biomedres.26.173; Tyagi S, 2006, J UROLOGY, V176, P1673, DOI 10.1016/j.juro.2006.06.088; Chapple CR, 2000, UROLOGY, V55, P33, DOI 10.1016/S0090-4295(99)00492-6; Nakamura T, 2002, INT J UROL, V9, P689, DOI 10.1046/j.1442-2042.2002.00548.x; Meek PD, 2011, DIGEST DIS SCI, V56, P7, DOI 10.1007/s10620-010-1313-3; Yoshida M, 2006, UROLOGY, V67, P425, DOI 10.1016/j.urology.2005.08.014; Kondo T, 2011, EUR J PHARMACOL, V670, P236, DOI 10.1016/j.ejphar.2011.08.034; Kobayashi F, 2007, ARZNEIMITTEL-FORSCH, V57, P147; Abrams P, 2006, BRIT J PHARMACOL, V148, P565, DOI 10.1038/sj.bjp.0706780; Moro C., 2012, Autonomic & Autacoid Pharmacology, V32, P53, DOI 10.1111/aap.12000; Yamazaki T, 2011, N-S ARCH PHARMACOL, V384, P319, DOI 10.1007/s00210-011-0675-1; MEINI S, 1994, BRIT J PHARMACOL, V112, P1123; Campbell-Dittmeyer K, 2009, NEUROGASTROENT MOTIL, V21, P1197, DOI 10.1111/j.1365-2982.2008.01238.x; Chess-Williams Z, 2002, AUTON AUTACOID PHARM, V22, P133; Kugimiya T, 1990, JPN J CLIN PHARM THE, V21, P555; Mansfield KJ, 2010, CLIN MED INSIGHT THE, V2, P471; Moro C., 2011, UROLOGY, V78, P1442; Nile CJ, 2012, UROLOGY, V79, P240; Ohno T, 2007, BR J CLIN PHARM, V65, P197	41	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-1298	1432-1912		N-S ARCH PHARMACOL	Naunyn-Schmiedebergs Arch. Pharmacol.	NOV	2015	388	11					1171	1178		10.1007/s00210-015-1155-9		8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CU4SW	WOS:000363521300006		
J	Pasqualotto, E; Matuz, T; Federici, S; Ruf, CA; Bartl, M; Belardinelli, MO; Birbaumer, N; Halder, S				Pasqualotto, Emanuele; Matuz, Tamara; Federici, Stefano; Ruf, Carolin A.; Bartl, Mathias; Belardinelli, Marta Olivetti; Birbaumer, Niels; Halder, Sebastian			Usability and Workload of Access Technology for People With Severe Motor Impairment: A Comparison of Brain-Computer Interfacing and Eye Tracking	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						BCI; brain-computer interface; eye tracking; usability; cognitive workload; assistive technology; ALS	AMYOTROPHIC-LATERAL-SCLEROSIS; P300 SPELLING SYSTEM; LOCKED-IN STATE; ALS PATIENTS; COMMUNICATION; DESIGN; PARALYSIS; DEVICES; SCALE; USERS	Background. Eye trackers are widely used among people with amyotrophic lateral sclerosis, and their benefits to quality of life have been previously shown. On the contrary, Brain-computer interfaces (BCIs) are still quite a novel technology, which also serves as an access technology for people with severe motor impairment. Objective. To compare a visual P300-based BCI and an eye tracker in terms of information transfer rate (ITR), usability, and cognitive workload in users with motor impairments. Methods. Each participant performed 3 spelling tasks, over 4 total sessions, using an Internet browser, which was controlled by a spelling interface that was suitable for use with either the BCI or the eye tracker. At the end of each session, participants evaluated usability and cognitive workload of the system. Results. ITR and System Usability Scale (SUS) score were higher for the eye tracker (Wilcoxon signed-rank test: ITR T = 9, P = .016; SUS T = 12.50, P = .035). Cognitive workload was higher for the BCI (T = 4; P = .003). Conclusions. Although BCIs could be potentially useful for people with severe physical disabilities, we showed that the usability of BCIs based on the visual P300 remains inferior to eye tracking. We suggest that future research on visual BCIs should use eye tracking-based control as a comparison to evaluate performance or focus on nonvisual paradigms for persons who have lost gaze control.	[Pasqualotto, Emanuele] Catholic Univ Louvain, Louvain La Neuve, Belgium; [Matuz, Tamara; Ruf, Carolin A.; Bartl, Mathias; Birbaumer, Niels] Univ Tubingen, Tubingen, Germany; [Federici, Stefano] Univ Perugia, I-06100 Perugia, Italy; [Federici, Stefano; Belardinelli, Marta Olivetti] Univ Roma La Sapienza, I-00185 Rome, Italy; [Birbaumer, Niels] Ist Ricovero & Cura Carattere Sci IRCCS, Venezia Lido, Italy; [Halder, Sebastian] Univ Wurzburg, D-97070 Wurzburg, Germany; [Halder, Sebastian] Natl Rehabil Ctr Persons Disabil, Tokorozawa, Saitama, Japan	Pasqualotto, E (reprint author), Catholic Univ Louvain, Ave Hippocrate 54,Bte B1-54-09, B-1200 Brussels, Belgium.	emanuele.pasqualotto@uclouvain.be	Federici, Stefano/D-2125-2011	Federici, Stefano/0000-0001-5681-0633	Inter-University Centre for Research on Cognitive Processing in Natural and Artificial Systems (ECONA); Werner Reichardt Centre for Integrative Neuroscience (CIN) pool project; Deutsche Forschungsgemeinschaft (DFG); European ICT Program Project [FP7-288566]; Japan Society for the Promotion of Science (JSPS); Alexander von Humboldt Foundation	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was partially funded by the Inter-University Centre for Research on Cognitive Processing in Natural and Artificial Systems (ECONA), the Werner Reichardt Centre for Integrative Neuroscience (CIN) pool project 2009-10, the Deutsche Forschungsgemeinschaft (DFG), and the European ICT Program Project FP7-288566. SH received funding as international research fellow from the Japan Society for the Promotion of Science (JSPS) and the Alexander von Humboldt Foundation.	Ahani A, 2014, BRAIN COMPUT INTERFA, V1, P192; Amiri Setare, 2013, Advances in Human-Computing Interaction, DOI 10.1155/2013/187024; Piccione F, 2006, CLIN NEUROPHYSIOL, V117, P531, DOI 10.1016/j.clinph.2005.07.024; Kubler A, 2008, CLIN NEUROPHYSIOL, V119, P2658, DOI 10.1016/j.clinph.2008.06.019; Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5; Lim JH, 2013, J NEURAL ENG, V10, DOI 10.1088/1741-2560/10/2/026021; Furdea A, 2009, PSYCHOPHYSIOLOGY, V46, P617, DOI 10.1111/j.1469-8986.2008.00783.x; Kubler A, 2009, ANN NY ACAD SCI, V1157, P90, DOI 10.1111/j.1749-6632.2008.04122.x; Nijboer F, 2008, CLIN NEUROPHYSIOL, V119, P1909, DOI 10.1016/j.clinph.2008.03.034; Iturrate I, 2009, IEEE T ROBOT, V25, P614, DOI 10.1109/TRO.2009.2020347; Kathner I, 2014, BIOL PSYCHOL, V102, P118, DOI 10.1016/j.biopsycho.2014.07.014; FARWELL LA, 1988, ELECTROEN CLIN NEURO, V70, P510, DOI 10.1016/0013-4694(88)90149-6; Zickler C, 2013, ARTIF INTELL MED, V59, P99, DOI 10.1016/j.artmed.2013.08.003; Schalk G, 2004, IEEE T BIO-MED ENG, V51, P1034, DOI 10.1109/TBME.2004.827072; Sharma R, 2011, ARCH NEUROL-CHICAGO, V68, P857, DOI 10.1001/archneurol.2011.130; Kleih SC, 2010, CLIN NEUROPHYSIOL, V121, P1023, DOI 10.1016/j.clinph.2010.01.034; Halder S, 2010, CLIN NEUROPHYSIOL, V121, P516, DOI 10.1016/j.clinph.2009.11.087; Marchetti M, 2013, NEUROREHAB NEURAL RE, V27, P430, DOI 10.1177/1545968312471903; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Riccio A, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/2/025028; Kathner I, 2013, CLIN NEUROPHYSIOL, V124, P327, DOI 10.1016/j.clinph.2012.08.006; Bayliss JD, 2003, IEEE T NEUR SYS REH, V11, P113, DOI 10.1109/TNSRE.2003.814438; Bangor A, 2008, INT J HUM-COMPUT INT, V24, P574, DOI 10.1080/10447310802205776; Mugler EM, 2010, IEEE T NEUR SYS REH, V18, P599, DOI 10.1109/TNSRE.2010.2068059; Liberati G, 2012, J ALZHEIMERS DIS, V31, pS211, DOI 10.3233/JAD-2012-112129; Duncan CC, 2009, CLIN NEUROPHYSIOL, V120, P1883, DOI 10.1016/j.clinph.2009.07.045; Moss HE, 2012, J NEUROL SCI, V314, P97, DOI 10.1016/j.jns.2011.10.016; Ball LJ, 2010, J MED SPEECH-LANG PA, V18, P11; Sellers EW, 2006, CLIN NEUROPHYSIOL, V117, P538, DOI 10.1016/j.clinph.2005.06.027; Birbaumer N, 2006, PSYCHOPHYSIOLOGY, V43, P517, DOI 10.1111/j.1469-8986.2006.00456.x; Murguialday AR, 2011, CLIN NEUROPHYSIOL, V122, P925, DOI 10.1016/j.clinph.2010.08.019; Lule D, 2010, J NEUROL NEUROSUR PS, V81, P899, DOI 10.1136/jnnp.2009.192260; Huggins JE, 2011, AMYOTROPH LATERAL SC, V12, P318, DOI 10.3109/17482968.2011.572978; Furdea A, 2012, J NEUROSCI METH, V203, P233, DOI 10.1016/j.jneumeth.2011.09.013; Calvo A, 2008, LECT NOTES COMPUT SC, V5105, P70, DOI 10.1007/978-3-540-70540-6_9; Scherer MJ, 2011, DISABIL REHABIL, V33, P811, DOI 10.3109/09638288.2010.511418; Ball L., 2004, AUGMENTATIVE ALTERNA, V20, P113, DOI 10.1080/0743461042000216596; Brooke J., 1996, USABILITY EVAL IND, V189, P189; Brouwer Anne-Marie, 2010, Front Neurosci, V4, P19, DOI 10.3389/fnins.2010.00019; Brunner P, 2010, J NEURAL ENG, V7; Federici S., 2011, EVERYDAY TECHNOLOGY, V29, P979, DOI DOI 10.3233/978-1-60750-814-4-979; Gibbons C, 2010, PERSPECTIVES AUGMENT, V19, P64; HART S G, 1988, P139; Hill NJ, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00181; Kaufmann T, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00129; Majaranta P., 2002, Proceedings ETRA 2002. Eye Tracking Research and Applications Symposium; Münßinger Jana I, 2010, Front Neurosci, V4, P182, DOI 10.3389/fnins.2010.00182; Nijboer F., 2010, FRONT NEUROSCI, V4, P55, DOI [10.3389/fnins.2010.00055, DOI 10.3389/FNINS.2010.00055]; Pannasch S, 2008, J EYE MOVEMENT RES, V2; Pasqualotto E, 2011, ASSIST TECHNOL, V29, P481; Pasqualotto E, 2011, INT J BIOELECTROMAGN, V13, P121; Pasqualotto Emanuele, 2012, Disabil Rehabil Assist Technol, V7, P89, DOI 10.3109/17483107.2011.589486; Pierce J. R., 1980, INTRO INFORM THEORY; Ringelstein Marius, 2014, Ann Clin Transl Neurol, V1, P290, DOI 10.1002/acn3.46; Schreuder M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009813; Silvoni Stefano, 2009, Front Neurosci, V3, P60, DOI 10.3389/neuro.20.001.2009; Simon N, 2015, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.01039; STAMPE DM, 1995, STUD VIS INFORM PROC, V6, P467; van der Heiden L, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00247; Zander TO, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00053	60	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	NOV-DEC	2015	29	10					950	957		10.1177/1545968315575611		8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CU2BP	WOS:000363326800004		
J	Choi, D; Fox, Z; Albert, T; Arts, M; Balabaud, L; Bunger, C; Buchowski, JM; Coppes, MH; Depreitere, B; Fehlings, MG; Harrop, J; Kawahara, N; Martin-Benlloch, JA; Massicotte, EM; Mazel, C; Oner, FC; Peul, W; Quraishi, N; Tokuhashi, Y; Tomita, K; Verlaan, JJ; Wang, M; Crockard, HA				Choi, David; Fox, Zoe; Albert, Todd; Arts, Mark; Balabaud, Laurent; Bunger, Cody; Buchowski, Jacob M.; Coppes, Maarten H.; Depreitere, Bart; Fehlings, Michael G.; Harrop, James; Kawahara, Norio; Martin-Benlloch, Juan A.; Massicotte, Eric M.; Mazel, Christian; Oner, Fetullah C.; Peul, Wilco; Quraishi, Nasir; Tokuhashi, Yasuaki; Tomita, Katsuro; Verlaan, Jorit Jan; Wang, Michael; Crockard, H. Alan			Prediction of Quality of Life and Survival After Surgery for Symptomatic Spinal Metastases: A Multicenter Cohort Study to Determine Suitability for Surgical Treatment	NEUROSURGERY			English	Article						Prognosis; Quality of life; Spinal metastases; Surgery; Survival	CORD COMPRESSION; PREOPERATIVE EVALUATION; SCORING SYSTEM; PROGNOSTIC-FACTORS; RANDOMIZED-TRIAL; TOKUHASHI SCORE; TUMOR PROGNOSIS; DISEASE; CANCER; STRATEGY	BACKGROUND:Surgery for symptomatic spinal metastases aims to improve quality of life, pain, function, and stability. Complications in the postoperative period are not uncommon; therefore, it is important to select appropriate patients who are likely to benefit the greatest from surgery. Previous studies have focused on predicting survival rather than quality of life after surgery.OBJECTIVE:To determine preoperative patient characteristics that predict postoperative quality of life and survival in patients who undergo surgery for spinal metastases.METHODS:In a prospective cohort study of 922 patients with spinal metastases who underwent surgery, we performed preoperative and postoperative assessment of EuroQol EQ-5D quality of life, visual analog score for pain, Karnofsky physical functioning score, complication rates, and survival.RESULTS:The primary tumor type, number of spinal metastases, and presence of visceral metastases were independent predictors of survival. Predictors of quality of life after surgery included preoperative EQ-5D (P = .002), Frankel score (P < .001), and Karnofsky Performance Status (P < .001).CONCLUSION:Data from the largest prospective surgical series of patients with symptomatic spinal metastases revealed that tumor type, the number of spinal metastases, and the presence of visceral metastases are the most useful predictors of survival and that quality of life is best predicted by preoperative Karnofsky, Frankel, and EQ-5D scores. The Karnofsky score predicts quality of life and survival and is easy to determine at the bedside, unlike the EQ-5D index. Karnofsky score, tumor type, and spinal and visceral metastases should be considered the 4 most important prognostic variables that influence patient management.ABBREVIATIONS:ASA, American Society of AnesthesiologistsCI, confidence intervalQoL, quality of life	[Choi, David; Fox, Zoe; Crockard, H. Alan] UCL, Natl Hosp Neurol & Neurosurg, Dept Neurosurg, London, England; [Albert, Todd; Harrop, James] Thomas Jefferson Univ & Hosp, Dept Neurosurg, Philadelphia, PA USA; [Albert, Todd; Harrop, James] Thomas Jefferson Univ & Hosp, Dept Orthoped Surg, Philadelphia, PA USA; [Arts, Mark] Med Ctr Haaglanden, Dept Neurosurg, Haaglanden, Netherlands; [Balabaud, Laurent] Inst Mutualiste Montsouris, Dept Orthoped Surg, Paris, France; [Bunger, Cody] Aarhus Univ Hosp, Dept Orthoped Surg, DK-8000 Aarhus, Denmark; [Buchowski, Jacob M.] Washington Univ, Dept Orthoped, St Louis, MO USA; [Buchowski, Jacob M.] Washington Univ, Dept Neurol Surg, St Louis, MO USA; [Coppes, Maarten H.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurosurg, Groningen, Netherlands; [Depreitere, Bart] Univ Hosp Leuven, Div Neurosurg, Leuven, Belgium; [Fehlings, Michael G.; Massicotte, Eric M.] Univ Toronto, Div Neurosurg, Toronto, ON, Canada; [Fehlings, Michael G.; Massicotte, Eric M.] Univ Toronto, Spinal Program, Toronto, ON, Canada; [Fehlings, Michael G.; Massicotte, Eric M.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; [Kawahara, Norio] Kanazawa Med Univ Hosp, Dept Orthoped Surg, Kanazawa, Ishikawa, Japan; [Martin-Benlloch, Juan A.] Hosp Univ Dr Peset, Spinal Unit, Valencia, Spain; [Oner, Fetullah C.; Verlaan, Jorit Jan] Univ Med Ctr Utrecht, Dept Orthoped Surg, Utrecht, Netherlands; [Peul, Wilco] Leiden Univ, Med Ctr, Dept Neurosurg, Leiden, Netherlands; [Quraishi, Nasir] Queens Med Ctr, Ctr Spine Studies & Surg, Nottingham NG7 2UH, England; [Tokuhashi, Yasuaki] Nihon Univ, Sch Med, Dept Orthopaed Surg, Tokyo 102, Japan; [Tomita, Katsuro] Kanazawa Univ, Dept Orthoped Surg, Kanazawa, Ishikawa, Japan; [Wang, Michael] Univ Miami, Jackson Mem Hosp, Dept Neurosurg, Miami, FL 33136 USA	Choi, D (reprint author), Natl Hosp Neurol & Neurosurg, Queen Sq, London WC1N 3BG, England.	david.choi@uclh.nhs.uk			Global Spine Tumour Study Group, a registered charity of England and Wales, Charity Commission [1134934]; DePuy Synthes; National Institute for Health Research, UK; European Research Council; Inspine; Biomet; Silony; Amedica; CSSG/K2M Inc.	This work was funded by the Global Spine Tumour Study Group, a registered charity of England and Wales, Charity Commission No. 1134934, and DePuy Synthes. This study was performed in part at University College London Biomedical Research Centre, which receives funding from the National Institute for Health Research, UK. Dr Choi reports research funding from European Research Council. Dr Albert reports royalties and consultant fees from DePuy Synthes, royalties from Biomet Spine, and holding stock in Paradigm Spine. Dr Arts reports research funding and consulting fees from Inspine, Biomet, Silony, and Amedica. Dr Buchowski is a consultant for advance medica, Corelink Inc, Globus Medical, K2M, Medtronic, and Stryker; has teaching arrangements with Broadwater/Vertical Health, DePuy Synthes, and Orthofix; has received royalties from Wolters Kluwer Health (textbook) and Globus Medical (for spine instrumentation); and has received research grant/institutional support from CSSG/K2M Inc. Dr Harrop has been a consultant for DePuy Spine and on the advisory board for bioventus. Dr Massicotte has received honoraria from AO Spine North America. Dr Wang has been a consultant for DePuy Spine and Aesulap Spine and has received royalties from DePuy Spine. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.	Wang M, 2014, SPINE, V39, P1620, DOI 10.1097/BRS.0000000000000473; Quraishi NA, 2013, EUR SPINE J, V22, pS21, DOI 10.1007/s00586-012-2649-5; BAUER HCF, 1995, ACTA ORTHOP SCAND, V66, P143, DOI 10.3109/17453679508995508; Tomita K, 2001, SPINE, V26, P298, DOI 10.1097/00007632-200102010-00016; de Ruiter GCW, 2014, SPINE J, V14, P2085, DOI 10.1016/j.spinee.2013.12.029; van der Linden YM, 2005, CANCER, V103, P320, DOI 10.1002/cncr.20756; Pointillart V, 2011, J CANCER RES CLIN, V137, P849, DOI 10.1007/s00432-010-0946-0; Tabouret E, 2015, SPINE J, V15, P944, DOI 10.1016/j.spinee.2013.06.036; Sciubba DM, 2007, EUR SPINE J, V16, P1659, DOI 10.1007/s00586-007-0380-4; Falicov A, 2006, SPINE, V31, P2849, DOI 10.1097/01.brs.0000245838.37817.40; Balain B, 2013, BONE JOINT J, V95B, P210, DOI 10.1302/0301-620X.95B2.29323; Kim JM, 2012, SPINE, V37, P78, DOI 10.1097/BRS.0b013e318223b9b6; Paton GR, 2011, CAN J NEUROL SCI, V38, P396; Choi D, 2010, EUR SPINE J, V19, P215, DOI 10.1007/s00586-009-1252-x; Leithner A, 2008, EUR SPINE J, V17, P1488, DOI 10.1007/s00586-008-0763-1; Lee BH, 2013, ANN SURG ONCOL, V20, P40, DOI 10.1245/s10434-012-2644-4; Yamashita T, 2011, SPINE, V36, P910, DOI 10.1097/BRS.0b013e3181e56ec1; Tokuhashi Y, 2009, ORTHOP CLIN N AM, V40, P37, DOI 10.1016/j.ocl.2008.09.002; Chong S, 2012, SPINE J, V12, P1083, DOI 10.1016/j.spinee.2012.10.015; Hessler C, 2011, SPINE, V36, P983, DOI 10.1097/BRS.0b013e3181e8f7f8; Rades D, 2008, INT J RADIAT ONCOL, V72, P905, DOI 10.1016/j.ijrobp.2008.02.018; Gasbarrini A, 2012, J SPINAL DISORD TECH, V25, pE7, DOI 10.1097/BSD.0b013e31823d3699; Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140-6736(05)66954-1; Tokuhashi Y, 2009, SPINE, V34, P69, DOI 10.1097/BRS.0b013e3181913f19; Tokuhashi Y, 2005, SPINE, V30, P2186, DOI 10.1097/01.brs.0000180401.06919.a5; Kim CH, 2013, J SURG ONCOL, V108, P499, DOI 10.1002/jso.23418; Bartels RHMA, 2007, CANCER, V110, P2042, DOI 10.1002/cncr.23002; Wibmer C, 2011, SPINE, V36, P1977, DOI 10.1097/BRS.0b013e3182011f84; TOKUHASHI Y, 1990, SPINE, V15, P1110, DOI 10.1097/00007632-199011010-00005; Ulmar B, 2007, EJSO-EUR J SURG ONC, V33, P914, DOI 10.1016/j.ejso.2006.11.018; Chen HJ, 2010, SPINE, V35, pE1339, DOI 10.1097/BRS.0b013e3181e574f5; Chen YJ, 2007, SPINE, V32, pE413, DOI 10.1097/BRS.0b013e318074d6c7; Hernandez-Fernandez A, 2012, J CANCER RES CLIN, V138, P1493, DOI 10.1007/s00432-012-1222-2; Tokuhashi Yasuaki, 2014, World J Orthop, V5, P262, DOI 10.5312/wjo.v5.i3.262; Wu JA, 2010, CANCER-AM CANCER SOC, V116, P3875, DOI 10.1002/cncr.25126; Yoshihara H, 2013, SPINE J, V14, P1844	36	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0148-396X			NEUROSURGERY	Neurosurgery	NOV	2015	77	5					698	708		10.1227/NEU.0000000000000907		11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU1NQ	WOS:000363289000006		
J	Akaiwa, K; Nakamura, Y; Iwasaki, M; Tsutsumi, H; Kondo, K				Akaiwa, Kanae; Nakamura, Yoshimasa; Iwasaki, Masashi; Tsutsumi, Hisayoshi; Kondo, Koichi			A finite-step construction of totally nonnegative matrices with specified eigenvalues	NUMERICAL ALGORITHMS			English	Article						Finite-step construction; Totally nonnegative; Inverse eigenvalue problem; Discrete hungry Toda equation	POSITIVE MATRICES; TODA EQUATION; ALGORITHM; SYSTEMS	Matrices where all minors are nonnegative are said to be totally nonnegative (TN) matrices. In the case of banded TN matrices, which can be expressed by products of several bidiagonal TN matrices, Fukuda et al. (Annal. Mat. Pura Appl. 192, 423-445, 2013) discussed the eigenvalue problem from the viewpoint of the discrete hungry Toda (dhToda) equation. The dhToda equation is a discrete integrable system associated with box and ball systems. In this paper, we consider an inverse eigenvalue problem for such banded TN matrices by examining the properties of the dhToda equation. This problem is a real-valued nonnegative inverse eigenvalue problem. First, we show the determinant solution to the dhToda equation with suitable boundary conditions. Next, we clarify the relationship between the characteristic polynomials of the banded TN matrices and the determinant solution. Finally, taking this relationship into account, we design a finite-step procedure for constructing banded TN matrices with specified eigenvalues. We also present an example to demonstrate this procedure.	[Akaiwa, Kanae; Nakamura, Yoshimasa] Kyoto Univ, Grad Sch Informat, Sakyo Ku, Kyoto 6068501, Japan; [Iwasaki, Masashi] Kyoto Prefectural Univ, Dept Informat & Environm Sci, Sakyo Ku, Kyoto 6068522, Japan; [Tsutsumi, Hisayoshi; Kondo, Koichi] Doshisha Univ, Grad Sch Sci & Engn, Kyotanabe, Kyoto 6100394, Japan	Akaiwa, K (reprint author), Kyoto Univ, Grad Sch Informat, Sakyo Ku, Kyoto 6068501, Japan.	akaiwa.kanae.83w@st.kyoto-u.ac.jp			Japan Society for the Promotion of Science [26400208, 26.6045]	The authors thank the reviewer for his/her careful reading and insightful suggestions. This work is supported by the Grant-in-Aid for Scientific Research (C) No. 26400208 and the Grant-in-Aid for JSPS Fellows No. 26.6045 from the Japan Society for the Promotion of Science.	Akaiwa K., 2014, PACIFIC J MATH IND, V6; Fallat SM, 2001, AM MATH MON, V108, P697, DOI 10.2307/2695613; ANDO T, 1987, LINEAR ALGEBRA APPL, V90, P165, DOI 10.1016/0024-3795(87)90313-2; GRAGG WB, 1984, NUMER MATH, V44, P317, DOI 10.1007/BF01405565; Fukuda A, 2012, NUMER ALGORITHMS, V61, P243, DOI 10.1007/s11075-012-9606-6; Gladwell GML, 2004, LINEAR ALGEBRA APPL, V393, P179, DOI 10.1016/j.laa.2004.04.008; Fukuda A, 2013, MONATSH MATH, V170, P11, DOI 10.1007/s00605-012-0404-y; CRYER CW, 1976, LINEAR ALGEBRA APPL, V15, P1, DOI 10.1016/0024-3795(76)90076-8; Fukuda A, 2013, ANN MAT PUR APPL, V192, P423, DOI 10.1007/s10231-011-0231-0; Tokihiro T, 1999, INVERSE PROBL, V15, P1639, DOI 10.1088/0266-5611/15/6/314; Chu M.T., 2005, INVERSE EIGENVALUE P; de Boor C., 1978, Linear Algebra and Its Applications, V21, DOI 10.1016/0024-3795(78)90086-1; Fallat S.M., 2011, TOTALLY NONNEGATIVE; Gasca M., 1996, MATH APPL, V359; Henrici P., 1974, APPL COMPUTATIONAL C, VI; HIROTA R, 1977, J PHYS SOC JPN, V43, P2074, DOI 10.1143/JPSJ.43.2074; Karlin S., 1968, TOTAL POSITIVITY, V1; Pinkus A., 2009, TOTALLY POSITIVE MAT; Press W. H., 1992, NUMERICAL RECIPES C; SYMES WW, 1982, PHYSICA D, V4, P275, DOI 10.1016/0167-2789(82)90069-0	20	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1017-1398	1572-9265		NUMER ALGORITHMS	Numer. Algorithms	NOV	2015	70	3					469	484		10.1007/s11075-015-9957-x		16	Mathematics, Applied	Mathematics	CU1GQ	WOS:000363268900002		
J	Brown, L; Poudyal, H; Panchal, SK				Brown, L.; Poudyal, H.; Panchal, S. K.			Functional foods as potential therapeutic options for metabolic syndrome	OBESITY REVIEWS			English	Review						Flavonoids; functional food; obesity; prebiotics	HIGH-FAT-DIET; CONJUGATED LINOLEIC-ACID; BROWN ADIPOSE-TISSUE; INDUCED OBESE RATS; RANDOMIZED CONTROLLED-TRIALS; HEPATIC LIPID-ACCUMULATION; CONTROLLED CLINICAL-TRIAL; MEDIUM-CHAIN TRIGLYCERIDE; TYPE-2 DIABETES-MELLITUS; PURIFIED EICOSAPENTAENOIC ACID	Obesity as part of metabolic syndrome is a major lifestyle disorder throughout the world. Current drug treatments for obesity produce small and usually unsustainable decreases in body weight with the risk of major adverse effects. Surgery has been the only treatment producing successful long-term weight loss. As a different but complementary approach, lifestyle modification including the use of functional foods could produce a reliable decrease in obesity with decreased comorbidities. Functional foods may include fruits such as berries, vegetables, fibre-enriched grains and beverages such as tea and coffee. Although health improvements continue to be reported for these functional foods in rodent studies, further evidence showing the translation of these results into humans is required. Thus, the concept that these fruits and vegetables will act as functional foods in humans to reduce obesity and thereby improve health remains intuitive and possible rather than proven.	[Brown, L.; Panchal, S. K.] Univ So Queensland, Inst Agr & Environm, Toowoomba, Qld 4350, Australia; [Brown, L.] Univ So Queensland, Sch Hlth & Wellbeing, Toowoomba, Qld 4350, Australia; [Poudyal, H.] Kyoto Univ, Dept Diabet Endocrinol & Nutr, Hakubi Ctr Adv Res, Kyoto, Japan	Panchal, SK (reprint author), Univ So Queensland, Inst Agr & Environm, Toowoomba, Qld 4350, Australia.	Sunil.Panchal@usq.edu.au					Abenavoli Ludovico, 2014, Rev Recent Clin Trials, V9, P134; Alissa EM, 2012, J NUTR METAB, V2012, DOI DOI 10.1155/2012/569486; Amara Nisserine Ben, 2014, Genes Nutr, V9, P410, DOI 10.1007/s12263-014-0410-x; An HM, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-116; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1056/NEJMra011775; Cao K, 2014, FREE RADICAL BIO MED, V67, P396, DOI 10.1016/j.freeradbiomed.2013.11.029; Lim J, 2013, FASEB J, V27, P822, DOI 10.1096/fj.12-220582; Poudyal H, 2013, J NUTR BIOCHEM, V24, P1381, DOI 10.1016/j.jnutbio.2012.11.006; Moussavi N, 2008, OBESITY, V16, P7, DOI 10.1038/oby.2007.14; Stull AJ, 2010, J NUTR, V140, P1764, DOI 10.3945/jn.110.125336; Jimenez-Gomez Y, 2013, CELL METAB, V18, P533, DOI 10.1016/j.cmet.2013.09.004; Baranowski M, 2012, CYTOKINE, V59, P382, DOI 10.1016/j.cyto.2012.04.004; Musso G, 2011, ANNU REV MED, V62, P361, DOI 10.1146/annurev-med-012510-175505; Malaguarnera M, 2012, DIGEST DIS SCI, V57, P545, DOI 10.1007/s10620-011-1887-4; Russo GL, 2009, BIOCHEM PHARMACOL, V77, P937, DOI 10.1016/j.bcp.2008.10.020; DOUGLAS JG, 1982, PHARMACOL THERAPEUT, V18, P351, DOI 10.1016/0163-7258(82)90037-7; Assuncao ML, 2009, LIPIDS, V44, P593, DOI 10.1007/s11745-009-3306-6; Genta S, 2009, CLIN NUTR, V28, P182, DOI 10.1016/j.clnu.2009.01.013; Sharma N, 2008, J HYPERTENS, V26, P1402, DOI 10.1097/HJH.0b013e3283007dda; Katan MB, 2012, BENEF MICROBES, V3, P85, DOI 10.3920/BM2012.0008; Sinha RA, 2014, HEPATOLOGY, V59, P1366, DOI 10.1002/hep.26667; Wang S, 2015, INT J OBESITY, V39, P967, DOI 10.1038/ijo.2015.23; Wang HY, 2011, FOOD CHEM, V128, P573, DOI 10.1016/j.foodchem.2011.03.075; Jurgonski A, 2015, EUR J NUTR, V54, P991, DOI 10.1007/s00394-014-0775-z; St-Onge MP, 2003, INT J OBESITY, V27, P95, DOI [10.1038/sj.ijo.0802169, 10.1038/sj.ijo.08032169]; Greenberg JA, 2006, AM J CLIN NUTR, V84, P682; Zhu Y, 2013, NUTR METAB CARDIOVAS, V23, P843, DOI 10.1016/j.numecd.2012.06.005; Xue CY, 2009, BIOSCI BIOTECH BIOCH, V73, P1711, DOI 10.1271/bbb.80827; Vandenplas Y, 2015, J PEDIAT-BRAZIL, V91, P6, DOI 10.1016/j.jped.2014.08.005; Ilich JZ, 2014, ARH HIG RADA TOKSIKO, V65, P139, DOI 10.2478/10004-1254-65-2014-2541; Jeukendrup AE, 2011, OBES REV, V12, P841, DOI 10.1111/j.1467-789X.2011.00908.x; Chan EW, 2013, OBES REV, V14, P383, DOI 10.1111/obr.12015; Ibrugger S, 2012, APPETITE, V58, P490, DOI 10.1016/j.appet.2011.12.024; Sae-tan S, 2014, MOL NUTR FOOD RES, V58, P1156, DOI 10.1002/mnfr.201300621; Takami H, 2013, J EPIDEMIOL, V23, P12, DOI 10.2188/jea.JE20120053; Parnell JA, 2012, BRIT J NUTR, V107, P601, DOI 10.1017/S0007114511003163; van der Lans AAJJ, 2013, J CLIN INVEST, V123, P3395, DOI 10.1172/JCI68993; Glade MJ, 2010, NUTRITION, V26, P932, DOI 10.1016/j.nut.2010.08.004; Bray GA, 2014, BEST PRACT RES CL GA, V28, P665, DOI 10.1016/j.bpg.2014.07.015; Marseglia L, 2015, INT J MOL SCI, V16, P378, DOI 10.3390/ijms16010378; Astell KJ, 2013, COMPLEMENT THER MED, V21, P180, DOI 10.1016/j.ctim.2013.01.004; Makino-Wakagi Y, 2012, BIOCHEM BIOPH RES CO, V417, P880, DOI 10.1016/j.bbrc.2011.12.067; Lou-Bonafonte JM, 2012, CURR VASC PHARMACOL, V10, P392; Perez-Vizcaino F, 2009, PHARMACOL REP, V61, P67; Lei F, 2007, INT J OBESITY, V31, P1023, DOI 10.1038/sj.ijo.0803502; Wu J, 2015, TRENDS GENET, V31, P232, DOI 10.1016/j.tig.2015.03.003; Murkovic M, 2004, J BIOCHEM BIOPH METH, V61, P155, DOI 10.1016/j.jbbm.2004.04.002; Santos S, 2013, NUTR RES, V33, P687, DOI 10.1016/j.nutres.2013.07.002; Malnick SDH, 2006, QJM-INT J MED, V99, P565, DOI 10.1093/qjmed/hcl085; Gao MM, 2013, PHARM RES-DORDR, V30, P2940, DOI 10.1007/s11095-013-1125-1; Chen JJ, 2012, BRIT J NUTR, V107, P1429, DOI 10.1017/S0007114511004491; Jensen MG, 2013, OBES REV, V14, P129, DOI 10.1111/j.1467-789X.2012.01056.x; Fiamoncini J, 2013, OBESITY, V21, P1200, DOI 10.1002/oby.20132; Karlsen A, 2007, J NUTR, V137, P1951; Conde SV, 2012, BRIT J NUTR, V107, P86, DOI 10.1017/S0007114511002406; Fabbrini E, 2010, HEPATOLOGY, V51, P679, DOI 10.1002/hep.23280; Hellmann J, 2013, J IMMUNOL, V191, P1383, DOI 10.4049/jimmunol.1203369; Dilzer A, 2012, CRIT REV FOOD SCI, V52, P488, DOI 10.1080/10408398.2010.501409; Rhee EJ, 2011, AM J MED, V124, P69, DOI 10.1016/j.amjmed.2010.08.012; Mason C, 2014, AM J CLIN NUTR, V99, P1015, DOI 10.3945/ajcn.113.073734; Wu T, 2013, FOOD CHEM, V141, P482, DOI 10.1016/j.foodchem.2013.03.046; Bachmann K, 1996, ENVIRON HEALTH PERSP, V104, P400, DOI 10.2307/3432684; Liu YX, 2009, INDIAN J MED RES, V129, P150; Motard-Belanger A, 2008, AM J CLIN NUTR, V87, P593; Gulvady AA, 2013, J NUTR BIOCHEM, V24, P1625, DOI 10.1016/j.jnutbio.2013.02.003; Agatston AS, 2005, CLEV CLIN J MED, V72, P946; Bes-Rastrollo M, 2010, OLIVES AND OLIVE OIL IN HEALTH AND DISEASE PREVENTION, P895, DOI 10.1016/B978-0-12-374420-3.00096-6; Passariello A, 2014, CURR MED RES OPIN, V30, P1055, DOI 10.1185/03007995.2014.898138; Song SJ, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/718379; Binnendijk KH, 2013, BENEF MICROBES, V4, P223, DOI 10.3920/BM2013.0019; Dulloo AG, 1996, EUR J CLIN NUTR, V50, P152; Cardona F, 2013, J NUTR BIOCHEM, V24, P1415, DOI 10.1016/j.jnutbio.2013.05.001; Iyer A, 2012, DIABETES, V61, P2320, DOI 10.2337/db11-1179; Han JR, 2007, METABOLISM, V56, P985, DOI 10.1016/j.metabol.2007.03.005; Aguirre L, 2014, MOLECULES, V19, P18632, DOI 10.3390/molecules191118632; Kim S, 2011, BIOCHEM PHARMACOL, V81, P1343, DOI 10.1016/j.bcp.2011.03.012; Zhu YN, 2011, CLIN CHEM, V57, P1524, DOI 10.1373/clinchem.2011.167361; Li ZP, 2005, ANN INTERN MED, V142, P532; Mohankumar SK, 2013, BRIT J NUTR, V109, P1628, DOI 10.1017/S000711451200339X; Patel S, 2012, 3 BIOTECH, V2, P115, DOI 10.1007/s13205-012-0044-x; Poulsen MM, 2013, DIABETES, V62, P1186, DOI 10.2337/db12-0975; Gillingham LG, 2011, LIPIDS, V46, P209, DOI 10.1007/s11745-010-3524-y; Pagidipati NJ, 2013, CIRCULATION, V127, P749, DOI 10.1161/CIRCULATIONAHA.112.128413; Wright ORL, 2013, CAN J PHYSIOL PHARM, V91, P480, DOI 10.1139/cjpp-2012-0349; Sioen I, 2009, LIPIDS, V44, P603, DOI 10.1007/s11745-009-3307-5; Oliva ME, 2013, PROSTAG LEUKOTR ESS, V89, P279, DOI 10.1016/j.plefa.2013.09.010; Chachay VS, 2014, CLIN GASTROENTEROL H, V12, P2092, DOI 10.1016/j.cgh.2014.02.024; Tan HW, 2008, ACTA PHARMACOL SIN, V29, P1051, DOI 10.1111/j.1745-7254.2008.00843.x; Fleming JW, 2013, ANN PHARMACOTHER, V47, P1007, DOI 10.1345/aph.1R779; Poudyal H, 2013, ENDOCR METAB IMMUNE, V13, P105; Norris LE, 2009, AM J CLIN NUTR, V90, P468, DOI 10.3945/ajcn.2008.27371; Wu T, 2013, FOOD FUNCT, V4, P1654, DOI 10.1039/c3fo60251f; Lim JX, 2013, FASEB J, V27, P4757, DOI 10.1096/fj.13-232702; Okada T, 2005, AM J CLIN NUTR, V82, P747; Adan RAH, 2008, TRENDS PHARMACOL SCI, V29, P208, DOI 10.1016/j.tips.2008.01.008; Yu W, 2012, J CELL BIOCHEM, V113, P752, DOI 10.1002/jcb.23431; Moon J, 2013, FOOD CHEM TOXICOL, V58, P347, DOI 10.1016/j.fct.2013.05.006; Chechi K, 2010, BRIT J NUTR, V104, P1313, DOI 10.1017/S0007114510002187; Mumme K, 2015, J ACAD NUTR DIET, V115, P249, DOI 10.1016/j.jand.2014.10.022; Kunesova M, 2012, PHYSIOL RES, V61, P597; Medjakovic S, 2013, FOOD FUNCT, V4, P19, DOI 10.1039/c2fo30034f; Konings E, 2014, INT J OBESITY, V38, P470, DOI 10.1038/ijo.2013.155; Bagul PK, 2012, PHARMACOL RES, V66, P260, DOI 10.1016/j.phrs.2012.05.003; [Anonymous], 2012, AM J GASTROENTEROL S, DOI DOI 10.1038/AJGSUP.2012.5; Qin Y, 2009, AM J CLIN NUTR, V90, P485, DOI 10.3945/ajcn.2009.27814; Beserra BTS, 2015, CLIN NUTR, V34, P845, DOI 10.1016/j.clnu.2014.10.004; Oleszczuk J, 2012, POL J VET SCI, V15, P403, DOI 10.2478/v10181-012-0063-x; Speakman J, 2008, LAB ANIM-UK, V42, P413, DOI 10.1258/la.2007.006067; Moy GA, 2013, PHYSIOL BEHAV, V109, P69, DOI 10.1016/j.physbeh.2012.11.008; Stahl A, 1999, MOL CELL, V4, P299, DOI 10.1016/S1097-2765(00)80332-9; Bonita JS, 2007, PHARMACOL RES, V55, P187, DOI 10.1016/j.phrs.2007.01.006; Dewulf EM, 2013, GUT, V62, P1112, DOI 10.1136/gutjnl-2012-303304; Gong JA, 2011, AM J CLIN NUTR, V93, P186, DOI 10.3945/ajcn.110.006502; Tsuji H, 2001, J NUTR, V131, P2853; Chen JJ, 2011, EXP BIOL MED, V236, P823, DOI 10.1258/ebm.2011.010399; Hartmann-Boyce J, 2014, OBES REV, V15, P598, DOI 10.1111/obr.12165; Thavanesan N, 2011, BRIT J NUTR, V106, P1297, DOI 10.1017/S0007114511003849; Maric G, 2014, ACTA PHYSIOL HUNG, V101, P395, DOI 10.1556/APhysiol.101.2014.4.1; Perez-Jimenez F, 2007, MOL NUTR FOOD RES, V51, P1199, DOI 10.1002/mnfr.200600273; Nakamura K, 2011, J PHYSIOL-LONDON, V589, P3641, DOI 10.1113/jphysiol.2011.210047; Yin YN, 2010, WORLD J GASTROENTERO, V16, P3394, DOI 10.3748/wjg.v16.i27.3394; Poudyal H, 2012, J NUTR BIOCHEM, V23, P153, DOI 10.1016/j.jnutbio.2010.11.011; Parker-Barnes JM, 2000, P NATL ACAD SCI USA, V97, P8284, DOI 10.1073/pnas.97.15.8284; Segula D, 2014, MALAWI MED J, V26, P20; Kennedy A, 2010, J NUTR BIOCHEM, V21, P171, DOI 10.1016/j.jnutbio.2009.08.003; Gregor MF, 2011, ANNU REV IMMUNOL, V29, P415, DOI 10.1146/annurev-immunol-031210-101322; Parnell JA, 2009, AM J CLIN NUTR, V89, P1751, DOI 10.3945/ajcn.2009.27465; Panchal SK, 2013, EUR J NUTR, V52, P559, DOI 10.1007/s00394-012-0358-9; Sang SM, 2011, PHARMACOL RES, V64, P87, DOI 10.1016/j.phrs.2011.02.007; Zhao YY, 2012, HYPERTENS RES, V35, P370, DOI 10.1038/hr.2011.195; Wadikar DD, 2012, CRIT REV FOOD SCI, V52, P949, DOI 10.1080/10408398.2010.514757; Hassanali Z, 2010, DIABETES OBES METAB, V12, P139, DOI 10.1111/j.1463-1326.2009.01130.x; Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002; Lee JH, 2009, NAT REV CARDIOL, V6, P753, DOI 10.1038/nrcardio.2009.188; Cohen DE, 2013, SEMIN LIVER DIS, V33, P380, DOI 10.1055/s-0033-1358519; Poudyal H, 2011, PROG LIPID RES, V50, P372, DOI 10.1016/j.plipres.2011.06.003; Lee K, 2007, J APPL MICROBIOL, V103, P1140, DOI 10.1111/j.1365-2672.2007.03336.x; Qiao Y, 2014, FOOD FUNCT, V5, P1241, DOI 10.1039/c3fo60630a; Prior RL, 2010, J AGR FOOD CHEM, V58, P3970, DOI 10.1021/jf902852d; Panchal SK, 2012, J NUTR, V142, P690, DOI 10.3945/jn.111.153577; Pieterse Z, 2005, NUTRITION, V21, P67, DOI 10.1016/j.nut.2004.09.010; Wein S, 2009, DIABETES-METAB RES, V25, P185, DOI 10.1002/dmrr.925; Ascacio-Valdes JA, 2011, J MED PLANTS RES, V5, P4696; Schwingshackl L, 2011, ANN NUTR METAB, V59, P176, DOI 10.1159/000334071; Buettner R, 2007, OBESITY, V15, P798, DOI 10.1038/oby.2007.608; Buettner R, 2006, J MOL ENDOCRINOL, V36, P485, DOI 10.1677/jme.1.01909; Gebauer SK, 2011, ADV NUTR, V2, P332, DOI [10.3945/​an.111.000521, 10.3945/an.111.000521]; Bender N, 2014, OBES REV, V15, P657, DOI 10.1111/obr.12189; St-Onge MP, 2003, INT J OBESITY, V27, P1565, DOI 10.1038/sj.ijo.0802467; Santure M, 2002, BRIT J PHARMACOL, V137, P185, DOI 10.1038/sj.bjp.0704864; Ziaee A, 2009, BASIC CLIN PHARMACOL, V104, P253, DOI 10.1111/j.1742-7843.2008.00368.x; Poudyal H, 2010, BRIT J NUTR, V104, P1322, DOI 10.1017/S0007114510002308; Gomez-Zorita S, 2013, NUTRITION, V29, P1374, DOI 10.1016/j.nut.2013.04.014; Roberfroid M, 2010, BRIT J NUTR, V104, pS1, DOI 10.1017/S0007114510003363; Delzenne NM, 2011, NAT REV ENDOCRINOL, V7, P639, DOI 10.1038/nrendo.2011.126; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Mori Y, 1999, METABOLISM, V48, P1089, DOI 10.1016/S0026-0495(99)90120-8; O'Reilly GA, 2014, OBES REV, V15, P453, DOI 10.1111/obr.12156; Barnes AS, 2012, TEX HEART I J, V39, P224; Brunerova L, 2007, DIABETIC MED, V24, P533, DOI 10.1111/j.1464-5491.2007.02104.x; Lai YHL, 2013, CLIN NUTR, V32, P966, DOI 10.1016/j.clnu.2013.05.002; Boeing H, 2012, EUR J NUTR, V51, P637, DOI 10.1007/s00394-012-0380-y; Fiori JL, 2013, DIABETES, V62, P3500, DOI 10.2337/db13-0266; Hsu CL, 2007, J AGR FOOD CHEM, V55, P8404, DOI 10.1021/jf071695r; Lacroix E, 2012, AM J CLIN NUTR, V95, P318, DOI 10.3945/ajcn.111.023408; Silveira MB, 2007, PUBLIC HEALTH NUTR, V10, P1181, DOI 10.1017/S1368980007000687; Hruby A, 2015, PHARMACOECONOMICS, V33, P673, DOI 10.1007/s40273-014-0243-x; Kaume L, 2012, J FUNCT FOODS, V4, P480, DOI 10.1016/j.jff.2012.02.008; Lorente-Cebrian S, 2013, J PHYSIOL BIOCHEM, V69, P633, DOI 10.1007/s13105-013-0265-4; Whigham LD, 2007, AM J CLIN NUTR, V85, P1203; Woodman RJ, 2002, AM J CLIN NUTR, V76, P1007; Panchal SK, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/351982; Kang JH, 2010, J MICROBIOL, V48, P712, DOI 10.1007/s12275-010-0363-8; Arai T, 2009, J ATHEROSCLER THROMB, V16, P674; Zhu YN, 2014, J CLIN ENDOCR METAB, V99, P561, DOI 10.1210/jc.2013-2845; Patel J, 2009, INDIAN J BIOCHEM BIO, V46, P66; Covas MI, 2006, NUTR REV, V64, pS20, DOI 10.1301/nr.2006.oct.S20-S30; Jeyakumar SM, 2006, OBESITY, V14, P52, DOI 10.1038/oby.2006.7; Hsu CL, 2009, J AGR FOOD CHEM, V57, P425, DOI [10.1021/jf802715t, 10.1021/if802715t]; Marineli RD, 2015, NUTRITION, V31, P740, DOI 10.1016/j.nut.2014.11.009; Cani PD, 2007, DIABETOLOGIA, V50, P2374, DOI 10.1007/s00125-007-0791-0; Do GM, 2012, MOL NUTR FOOD RES, V56, P1282, DOI 10.1002/mnfr.201200067; Zhang YH, 2010, LIPIDS, V45, P501, DOI 10.1007/s11745-010-3418-z; Aasheim ET, 2008, AM J CLIN NUTR, V87, P362; Mozaffarian D, 2010, ANN INTERN MED, V153, P790, DOI 10.7326/0003-4819-153-12-201012210-00005; Parkinson L, 2014, INT J MOL SCI, V15, P12323, DOI 10.3390/ijms150712323; Larsen TM, 2003, J LIPID RES, V44, P2234, DOI 10.1194/jlr.R300011-JLR200; Grimsgaard S, 1997, AM J CLIN NUTR, V66, P649; Franco JG, 2013, J NUTR BIOCHEM, V24, P960, DOI 10.1016/j.jnutbio.2012.06.019; Adiels M, 2008, CURR DIABETES REP, V8, P60, DOI 10.1007/s11892-008-0011-4; Aureli P, 2011, PHARMACOL RES, V63, P366, DOI 10.1016/j.phrs.2011.02.006; Mubarak A, 2013, J AGR FOOD CHEM, V61, P4371, DOI 10.1021/jf400920x; Pandey MM, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/376327; Samane S, 2009, METABOLISM, V58, P909, DOI 10.1016/j.metabol.2009.02.013; Krishna KM, 2005, CAN J PHYSIOL PHARM, V83, P343, DOI 10.1139/Y05-009; Cowan TE, 2014, J NUTR BIOCHEM, V25, P489, DOI 10.1016/j.jnutbio.2013.12.009; Alligier M, 2014, OBESITY, V22, P1653, DOI 10.1002/oby.20733; McCrorie TA, 2011, NUTR RES REV, V24, P206, DOI 10.1017/S0954422411000114; Kam PCA, 2002, ANAESTHESIA, V57, P1083, DOI 10.1046/j.1365-2044.2002.02823.x; Qin BL, 2012, BRIT J NUTR, V108, P581, DOI 10.1017/S000711451100599X; Jacome-Sosa MM, 2014, J NUTR BIOCHEM, V25, P692, DOI 10.1016/j.jnutbio.2014.02.011; Panchal SK, 2012, NUTRITION, V28, P1055, DOI 10.1016/j.nut.2012.02.013; Coelho MS, 2010, REGUL PEPTIDES, V162, P61, DOI 10.1016/j.regpep.2010.03.008; Poudyal H, 2013, J NUTR BIOCHEM, V24, P1041, DOI 10.1016/j.jnutbio.2012.07.014; Halford JCG, 2006, APPETITE, V46, P6, DOI 10.1016/j.appet.2005.07.010; Mamikutty N, 2014, BIOMED RES INT, DOI 10.1155/2014/263897; Gomez-Zorita S, 2014, J AGR FOOD CHEM, V62, P8371, DOI 10.1021/jf501318b; Nimptsch K, 2010, PUBLIC HEALTH NUTR, V13, P1636, DOI 10.1017/S1368980009993041; Seeley RJ, 2015, CELL METAB, V21, P369, DOI 10.1016/j.cmet.2015.01.001; Poudyal H, 2012, AM J PHYSIOL-ENDOC M, V302, pE1472, DOI 10.1152/ajpendo.00102.2012; Preuss HG, 2004, DIABETES OBES METAB, V6, P171, DOI 10.1111/j.1462-8902.2004.00328.x; Wach A, 2007, FOOD CHEM, V100, P699, DOI 10.1016/j.foodchem.2005.10.028; Lopez-Miranda J, 2010, NUTR METAB CARDIOVAS, V20, P284, DOI 10.1016/j.numecd.2009.12.007; Wendland E, 2006, HEART, V92, P166, DOI 10.1136/hrt.2004.053538; Han JR, 2003, OBES RES, V11, P734, DOI 10.1038/oby.2003.103; Bjermo H, 2012, AM J CLIN NUTR, V95, P1003, DOI 10.3945/ajcn.111.030114; Andrade JMO, 2014, NUTRITION, V30, P915, DOI 10.1016/j.nut.2013.11.016; St-Onge MP, 2008, J AM COLL NUTR, V27, P547; Williams CM, 1999, PSYCHOPHARMACOLOGY, V143, P315, DOI 10.1007/s002130050953; Zhang Y, 2011, NUTR METAB CARDIOVAS, V21, P418, DOI 10.1016/j.numecd.2009.10.020; Xue C, 2009, EUR J CLIN NUTR, V63, P879, DOI 10.1038/ejcn.2008.76; Pojer E, 2013, COMPR REV FOOD SCI F, V12, P483, DOI 10.1111/1541-4337.12024; Yamamoto Y, 2006, BIOSCI BIOTECH BIOCH, V70, P933, DOI 10.1271/bbb.70.933; Panchal SK, 2011, J CARDIOVASC PHARM, V57, P51, DOI 10.1097/FJC.0b013e31821b1379; Nagao K, 2010, PHARMACOL RES, V61, P208, DOI 10.1016/j.phrs.2009.11.007; Gomez-Zorita S, 2012, BRIT J NUTR, V107, P202, DOI 10.1017/S0007114511002753; St-Onge MP, 2008, AM J CLIN NUTR, V87, P621; Paivarinta E, 2006, NUTR CANCER, V54, P79, DOI 10.1207/s15327914nc5401_9; Heber D, 2014, J NUTR, V144, P1385, DOI 10.3945/jn.114.191007; Moreira ASP, 2012, FOOD FUNCT, V3, P903, DOI 10.1039/c2fo30048f; Li SY, 2008, OBESITY, V16, P811, DOI 10.1038/oby.2007.116; Scoditti E, 2012, ARCH BIOCHEM BIOPHYS, V527, P81, DOI 10.1016/j.abb.2012.05.003; Faintuch J, 2007, OBES SURG, V17, P341, DOI 10.1007/s11695-007-9062-x; Panchal SK, 2011, J NUTR, V141, P1062, DOI 10.3945/jn.111.137877; Poudyal H, 2010, J NUTR, V140, P946, DOI 10.3945/jn.109.117812; Martin CK, 2015, OBESITY, V23, P935, DOI 10.1002/oby.21063; Cordain L, 2005, AM J CLIN NUTR, V81, P341; Moreno-Luna R, 2012, AM J HYPERTENS, V25, P1299, DOI 10.1038/ajh.2012.128; Visioli F, 2011, CURR PHARM DESIGN, V17, P786, DOI 10.2174/138161211795428885; Lee P, 2014, INT J OBESITY, V38, P170, DOI 10.1038/ijo.2013.82; HORROBIN DF, 1992, PROG LIPID RES, V31, P163, DOI 10.1016/0163-7827(92)90008-7; Yuliana ND, 2014, CRIT REV FOOD SCI, V54, P373, DOI 10.1080/10408398.2011.586739; Kim HY, 2015, MOLECULES, V20, P3107, DOI 10.3390/molecules20023107; Salazar N, 2015, CLIN NUTR, V34, P501, DOI 10.1016/j.clnu.2014.06.001; PINDER RM, 1975, DRUGS, V10, P241, DOI 10.2165/00003495-197510040-00001; Lin PH, 2012, OBESITY, V20, P571, DOI 10.1038/oby.2011.17; Blankson H, 2000, J NUTR, V130, P2943; Million M, 2012, MICROB PATHOGENESIS, V53, P100, DOI 10.1016/j.micpath.2012.05.007; Vyas U, 2012, GASTROENT RES PRACT, DOI 10.1155/2012/872716; Morales FJ, 2012, AMINO ACIDS, V42, P1097, DOI 10.1007/s00726-010-0774-1; Ozen AE, 2012, NUTR REV, V70, P472, DOI 10.1111/j.1753-4887.2012.00492.x; Jakobsen MU, 2013, BRIT J NUTR, V109, P353, DOI 10.1017/S0007114512001079; Panickar KS, 2013, MOL NUTR FOOD RES, V57, P34, DOI 10.1002/mnfr.201200431; Hussein N, 2005, J LIPID RES, V46, P269, DOI 10.1194/jlr.M400225-JLR200; Kwon JY, 2012, J BIOL CHEM, V287, P11566, DOI 10.1074/jbc.M111.259721; Jourdes M, 2011, ANAL BIOANAL CHEM, V401, P1531, DOI 10.1007/s00216-011-4949-8; WEINTRAUB M, 1991, CLIN PHARMACOL THER, V50, P330; Riviere C, 2012, NAT PROD REP, V29, P1317, DOI 10.1039/c2np20049j; Rusconi RE, 2015, INT J FOOD SCI NUTR, V66, P132, DOI 10.3109/09637486.2014.959902; Rodgers RJ, 2012, DIS MODEL MECH, V5, P621, DOI 10.1242/dmm.009621; Fernandes AAH, 2010, BIOMED PHARMACOTHER, V64, P214, DOI 10.1016/j.biopha.2009.08.007; Rothmeier AS, 2012, SEMIN IMMUNOPATHOL, V34, P133, DOI 10.1007/s00281-011-0289-1; Panchal SK, 2012, J NUTR, V142, P1026, DOI 10.3945/jn.111.157263; Alberdi G, 2013, FOOD CHEM, V141, P1530, DOI 10.1016/j.foodchem.2013.03.085; Borrelli RC, 2005, MOL NUTR FOOD RES, V49, P673, DOI 10.1002/mnfr.200500011; Nedergaard J, 2010, ANN NY ACAD SCI, V1212, pE20, DOI 10.1111/j.1749-6632.2010.05905.x; Bray GA, 2002, J NUTR, V132, P2488; Wortsman J, 2000, AM J CLIN NUTR, V72, P690; Al-Sheraji SH, 2013, J FUNCT FOODS, V5, P1542, DOI 10.1016/j.jff.2013.08.009; Wang B, 2014, FOOD FUNCT, V5, P1452, DOI 10.1039/c3fo60714c; DeWeerdt S, 2014, NATURE, V508, pS61, DOI 10.1038/508S61a; Arias N, 2014, GENES NUTR, V9, DOI 10.1007/s12263-013-0361-7; Arnaud M. J., 2011, HDB EXPT PHARM, V200, P33; Azizi-Soleiman Fatemeh, 2013, Int J Prev Med, V4, P922; Baddini FA, 2009, NUTR HOSP, V24, P422; Baek SH, 2014, SCI REP-UK, V4, DOI 10.1038/srep03879; Barre Douglas Edward, 2007, J Oleo Sci, V56, P319; Bellesia A, 2015, INT J FOOD SCI NUTR, V66, P85, DOI 10.3109/09637486.2014.953455; Broeders E, 2015, ANN MED, V47, P123, DOI 10.3109/07853890.2013.874663; CARLOTTI M, 1993, ANN NY ACAD SCI, V683, P349; Chajes V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118206; Chandler PD, 2015, NUTR DIABETES, V5, DOI 10.1038/nutd.2014.44; Chen ZY, 2014, CAN J PHYSIOL PHARM, V92, P797, DOI 10.1139/cjpp-2014-0169; Cheung Bernard Man Yung, 2013, Ther Adv Drug Saf, V4, P171, DOI 10.1177/2042098613489721; Chondronikola M, 2014, DIABETES, V63, P4089, DOI 10.2337/db14-0746; Crane JD, 2015, NAT MED, V21, P166, DOI 10.1038/nm.3766; Crescenzo R, 2014, EXP PHYSIOL, V99, P1203, DOI 10.1113/expphysiol.2014.079632; Daniel Deepu, 2015, J Community Hosp Intern Med Perspect, V5, P26069, DOI 10.3402/jchimp.v5.26069; Das UN, 2006, CURRENT PHARM BIOTEC, V7, P467; dasCosta CA, 2013, HORM METAB RES, V45, P652; dasSilva ST, 2013, NUTR HOSP, V28, P1039; desLigt M, 2015, BIOCHIM BIOPHYS ACTA, V1852, P1137; desLuis DA, 2011, NUTR HOSP, V26, P827; desMelo CL, 2010, CHEM-BIOL INTERACT, V185, P59; desRoos B, 1999, CURR OPIN LIPIDOL, V10, P41; desWit N, 2012, AM J PHYSIOL-GASTR L, V303, pG589; Diaz MB, 2014, METABOLISM, V63, P1238, DOI 10.1016/j.metabol.2014.07.002; Dombrowski SU, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2646; Ebaid GMX, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-46; European Food Safety Authority Panel on Food Additives and Nutrient Sources added to food (ANS), 2013, EFSA J, V11, P3145; Franco JG, 2015, EUR J NUTR, DOI [10.1007/s00394-00015-00880-00397, DOI 10.1007/S00394-00015-00880-00397]; Glanville J, 2015, NUTR J, V14, DOI 10.1186/s12937-015-0004-5; Guo HH, 2012, J NUTR BIOCHEM, V23, P349, DOI 10.1016/j.jnutbio.2010.12.013; Guo HH, 2015, REV ENDOCR METAB DIS, V16, P1, DOI 10.1007/s11154-014-9302-z; Hartmann-Boyce J, 2014, OBES REV, V15, P920, DOI 10.1111/obr.12220; Henagan T M, 2015, Genes Nutr, V10, P451, DOI 10.1007/s12263-014-0451-1; Huang J, 2014, EUR J CLIN NUTR, V68, P1075, DOI 10.1038/ejcn.2014.143; Iepsen EW, 2014, EXPERT OPIN PHARMACO, V15, P2487, DOI 10.1517/14656566.2014.965678; Ivanova Z, 2014, EUR J NUTR, DOI [10.1007/s00394-00014-00782-00390, DOI 10.1007/S00394-00014-00782-00390]; Jia HJ, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0389-3; Juwiak S, 2005, PHARM REP, V57, P604; Kechagia M, 2013, ISRN NUTR, V2013, DOI DOI 10.5402/2013/481651; Kim HJ, 2014, DIABETES RES CLIN PR, V106, P145, DOI 10.1016/j.diabres.2014.07.007; Kim KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047713; Lai M, 2014, NUTR DIABETES, V4, DOI 10.1038/nutd.2014.30; Le NH, 2014, MEDIAT INFLAMM, V2014; Lee LS, 2015, MOL NUTR FOOD RES, V59, P784, DOI 10.1002/mnfr.201400470; Lee P, 2014, DIABETES, V63, P3686, DOI 10.2337/db14-0513; Li Kwok, 2014, ARCH BIOCHEM BIOPHYS, V559, P46; Liberato MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036297; Liu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091163; Luo J, 2000, J NUTR, V130, P1572; Ma YJ, 2015, PHARM RES-DORDR, V32, P1200, DOI 10.1007/s11095-014-1526-9; Mahmoud AAA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106993; Martinez-Victoria E, 2012, BRIT J NUTR, V107, pS107, DOI 10.1017/S000711451200150X; Masquio DCL, 2015, BRIT J NUTR, V113, P1920, DOI 10.1017/S0007114515001129; McGill Anne-Thea, 2014, Arch Public Health, V72, P30, DOI 10.1186/2049-3258-72-30; Mielgo-Ayuso J, 2014, BRIT J NUTR, V111, P1263, DOI 10.1017/S0007114513003784; Moreno MF, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-84; Moroti C, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-29; Morrison SF, 2012, FRONT ENDOCRINOL LAU, V3, P5, DOI DOI 10.3389/FENDO.2012.00005; Mozaffarian D, 2006, NEW ENGL J MED, V354, P1601, DOI 10.1056/NEJMra054035; Munzberg H, 2015, OBES REV, V16, P77, DOI 10.1111/obr.12258; Mykkanen OT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114790; Nagao K, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-8; Nakamura YK, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-60; Nikolopoulou Angeliki, 2012, Expert Rev Cardiovasc Ther, V10, P933, DOI 10.1586/erc.12.74; Nunez IN, 2014, NUTRITION, V30, P1423, DOI 10.1016/j.nut.2014.03.025; O'Neill S, 2015, OBES REV, V16, P1, DOI 10.1111/obr.12229; Onakpoya IJ, 2015, J HUM HYPERTENS, V29, P77, DOI 10.1038/jhh.2014.46; Pala L, 2012, J NUTR METAB, V2012; Peirson Leslea, 2014, CMAJ Open, V2, pE268, DOI 10.9778/cmajo.20140019; Pena F, 2014, J FOOD NUTR RES, V2, P491; Perez-Matute P, 2007, BRIT J NUTR, V97, P389, DOI 10.1017/S0007114507207627; Salehpour A, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-78; Shen Y, 2014, EVID-BASED COMPL ALT, V2014; Thirunavukkarasu V, 2004, NUTR METAB CARDIOVAS, V14, P351, DOI 10.1016/S0939-4753(04)80025-5; Tong XL, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-98; Uchiyama-Tanaka Y, 2014, J ALTERN COMPLEM MED, V20, P800, DOI 10.1089/acm.2013.0245; Valenti L., 2013, OXID MED CELL LONGEV, V2013; Vijay-Kumar M, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-2; Voigt JP, 2015, BEHAV BRAIN RES, V277, P14, DOI 10.1016/j.bbr.2014.08.065; Wang X, 2014, J HUM NUTR DIET, V27, P501, DOI 10.1111/jhn.12181; Williams LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106159; Williamson G., 2000, J NUTR, V130, P2073; Wu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077585; Xu Y, 2015, FOOD FUNCT, V6, P297, DOI 10.1039/c4fo00970c; Yang ZH, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-120; Yoshimura Y, 2013, BIOCHEM BIOPH RES CO, V434, P486, DOI 10.1016/j.bbrc.2013.03.100; Zarfeshany Aida, 2014, Adv Biomed Res, V3, P100, DOI 10.4103/2277-9175.129371; Zheng GD, 2014, BRIT J NUTR, V112, P1034, DOI 10.1017/S0007114514001652	361	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-7881	1467-789X		OBES REV	Obes. Rev.	NOV	2015	16	11					914	941		10.1111/obr.12313		28	Endocrinology & Metabolism	Endocrinology & Metabolism	CU3KQ	WOS:000363424300002		
J	Veronese, N; Cereda, E; Solmi, M; Fowler, SA; Manzato, E; Maggi, S; Manu, P; Abe, E; Hayashi, K; Allard, JP; Arendt, BM; Beck, A; Chan, M; Audrey, YJP; Lin, WY; Hsu, HS; Lin, CC; Diekmann, R; Kimyagarov, S; Miller, M; Cameron, ID; Pitkala, KH; Lee, J; Woo, J; Nakamura, K; Smiley, D; Umpierrez, G; Rondanelli, M; Sund-Levander, M; Valentini, L; Schindler, K; Torma, J; Volpato, S; Zuliani, G; Wong, M; Lok, K; Kane, JM; Sergi, G; Correll, CU				Veronese, N.; Cereda, E.; Solmi, M.; Fowler, S. A.; Manzato, E.; Maggi, S.; Manu, P.; Abe, E.; Hayashi, K.; Allard, J. P.; Arendt, B. M.; Beck, A.; Chan, M.; Audrey, Y. J. P.; Lin, W. -Y.; Hsu, H. -S.; Lin, C. -C.; Diekmann, R.; Kimyagarov, S.; Miller, M.; Cameron, I. D.; Pitkala, K. H.; Lee, J.; Woo, J.; Nakamura, K.; Smiley, D.; Umpierrez, G.; Rondanelli, M.; Sund-Levander, M.; Valentini, L.; Schindler, K.; Torma, J.; Volpato, S.; Zuliani, G.; Wong, M.; Lok, K.; Kane, J. M.; Sergi, G.; Correll, C. U.			Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects	OBESITY REVIEWS			English	Review						Body mass index; elderly; mortality; nursing home	ALL-CAUSE MORTALITY; LONG-TERM-CARE; OBESITY PARADOX; FOLLOW-UP; CARDIOVASCULAR-DISEASE; WAIST CIRCUMFERENCE; RISK-FACTORS; ASSOCIATION; ADULTS; SURVIVAL	Body mass index (BMI) and mortality in old adults from the general population have been related in a U-shaped or J-shaped curve. However, limited information is available for elderly nursing home populations, particularly about specific cause of death. A systematic PubMed/EMBASE/CINAHL/SCOPUS search until 31 May 2014 without language restrictions was conducted. As no published study reported mortality in standard BMI groups (<18.5, 18.5-24.9, 25-29.9, 30kg/m(2)), the most adjusted hazard ratios (HRs) according to a pre-defined list of covariates were obtained from authors and pooled by random-effect model across each BMI category. Out of 342 hits, 20 studies including 19,538 older nursing home residents with 5,223 deaths during a median of 2 years of follow-up were meta-analysed. Compared with normal weight, all-cause mortality HRs were 1.41 (95% CI=1.26-1.58) for underweight, 0.85 (95% CI=0.73-0.99) for overweight and 0.74 (95% CI=0.57-0.96) for obesity. Underweight was a risk factor for higher mortality caused by infections (HR=1.65 [95% CI=1.13-2.40]). RR results corroborated primary HR results, with additionally lower infection-related mortality in overweight and obese than in normal-weight individuals. Like in the general population, underweight is a risk factor for mortality in old nursing home residents. However, uniquely, not only overweight but also obesity is protective, which has relevant nutritional goal implications in this population/setting.	[Veronese, N.; Manzato, E.; Sergi, G.] Univ Padua, Geriatr Sect, Dept Med DIMED, Padua, Italy; [Cereda, E.] Fdn IRCCS Policlin San Matteo, Nutr & Dietet Serv, Pavia, Italy; [Solmi, M.] Univ Padua, Dept Neurosci, Padua, Italy; [Fowler, S. A.] Washington Univ, Becker Med Lib, St Louis, MO USA; [Manzato, E.; Maggi, S.] Inst Neurosci, Natl Res Council, Padua, Italy; [Manu, P.; Kane, J. M.; Correll, C. U.] Zucker Hillside Hosp, North Shore Long Island Jewish Hlth Syst, Psychiat Res, Glen Oaks, NY USA; [Manu, P.; Kane, J. M.; Correll, C. U.] Hofstra North Shore LIJ Sch Med, Hempstead, NY USA; [Manu, P.; Kane, J. M.; Correll, C. U.] Feinstein Inst Med Res, Manhasset, NY USA; [Manu, P.; Kane, J. M.; Correll, C. U.] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Abe, E.; Hayashi, K.] Gunma Univ, Grad Sch Hlth Sci, Maebashi, Gumma 371, Japan; [Allard, J. P.; Arendt, B. M.] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada; [Allard, J. P.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Beck, A.] Herlev Univ Hosp, Res Unit Nutr EFFECT, DK-2730 Herlev, Denmark; [Chan, M.; Audrey, Y. J. P.] Tan Tock Seng Hosp, Dept Geriatr Med, Singapore, Singapore; [Lin, W. -Y.; Hsu, H. -S.; Lin, C. -C.] China Med Univ Hosp, Dept Family Med, Taichung, Taiwan; [Lin, W. -Y.; Hsu, H. -S.; Lin, C. -C.] China Med Univ, Sch Med, Taichung, Taiwan; [Diekmann, R.] Univ Erlangen Nurnberg, Inst Biomed Aging, Nurnberg, Germany; [Kimyagarov, S.] Gilad Geriatr Ctr, Ramat Gan, Israel; [Miller, M.] Flinders Univ S Australia, Nutr & Dietet, Adelaide, SA 5001, Australia; [Cameron, I. D.] Univ Sydney, Walsh Ctr Rehabil Res, Sydney, NSW 2006, Australia; [Pitkala, K. H.] Univ Helsinki, Cent Hosp, Dept Gen Practice, Unit Primary Hlth Care, Helsinki, Finland; [Lee, J.; Woo, J.] Chinese Univ Hong Kong, SH Ho Ctr Gerontol & Geriatr, Hong Kong, Hong Kong, Peoples R China; [Lee, J.; Woo, J.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Nakamura, K.] Niigata Univ, Grad Sch Med & Dent Sci, Div Prevent Med, Niigata, Niigata, Japan; [Smiley, D.; Umpierrez, G.] Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Atlanta, GA 30322 USA; [Rondanelli, M.] Univ Pavia, Dept Publ Hlth Expt & Forens Med, Sect Human Nutr, Endocrinol & Nutr Unit, Pavia, Italy; [Sund-Levander, M.] Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden; [Valentini, L.] Univ Appl Sci, Sect Dietet, Dept Agr & Food Sci, Neubrandenburg, Germany; [Schindler, K.] Med Univ Vienna, Div Endocrinol & Metab, Dept Internal Med 3, Vienna, Austria; [Torma, J.] Uppsala Univ, Dept Publ Hlth & Caring Sci, Clin Nutr & Metab, Uppsala, Sweden; [Volpato, S.; Zuliani, G.] Univ Ferrara, Dept Med Sci, I-44100 Ferrara, Italy; [Wong, M.; Lok, K.] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China	Correll, CU (reprint author), Zucker Hillside Hosp, Dept Psychiat, 75-59 263rd St, Glen Oaks, NY 11004 USA.	ccorrell@lij.edu	Woo, Jean/K-2625-2014	Woo, Jean/0000-0001-7593-3081	Baxter; Abbott; Fresenius-Kabi; Pfizeer; Nestle; Sanofi; Novo Nordisk; Boehringer Ingelheim; Merck; BMS; Feinstein Institute for Medical Research; Janssen/JJ; National Institute of Mental Health (NIMH); National Alliance for Research in Schizophrenia and Depression (NARSAD); Otsuka; Takeda	Dr. Allard is a consultant/speaker for Abbott and Baxter Corp and received honararia. In addition, she received unrestricted grants from Baxter, Abbott, Fresenius-Kabi, Pfizeer and Nestle.; Dr. Umpierrez has received research grant support (to Emory University) from Sanofi, Novo Nordisk, Boehringer Ingelheim and Merck, and has been a consultant for Sanofi, Novo Nordisk, Merck, Boehringer Ingelheim, and Regeneron.; Dr. Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Actelion, Alexza; American Academy of Child and Adolescent Psychiatry, Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, GersonLehrman Group, IntraCellular Therapies, Lundbeck, Medavante, Medscape, Merck, National Institute of Mental Health, Janssen/J&J, Otsuka, Pfizer, ProPhase, Reviva, Roche, Sunovion, Takeda, Teva and Vanda. He has received grant support from BMS, Feinstein Institute for Medical Research, Janssen/J&J, National Institute of Mental Health (NIMH), National Alliance for Research in Schizophrenia and Depression (NARSAD), Otsuka and Takeda.	Abe E, 2011, KITAKANTO MED J, V61, P471; Fontaine KR, 2012, INT J OBESITY, V36, P1121, DOI 10.1038/ijo.2011.194; Katz PR, 2011, J AM MED DIR ASSOC, V12, P487, DOI 10.1016/j.jamda.2011.01.017; Kuk JL, 2009, J AM GERIATR SOC, V57, P2077, DOI 10.1111/j.1532-5415.2009.02486.x; Sullivan DH, 2004, J GERONTOL A-BIOL, V59, P633; Taylor DH, 2001, J AM GERIATR SOC, V49, P1319, DOI 10.1046/j.1532-5415.2001.49259.x; Pickkers P, 2013, CRIT CARE MED, V41, P1878, DOI 10.1097/CCM.0b013e31828a2aa1; Chan M, 2010, J NUTR HEALTH AGING, V14, P23, DOI 10.1007/s12603-010-0005-1; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.2009.2014; Grabowski DC, 2005, J GERONTOL A-BIOL, V60, P1184; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Iozzo P, 2013, INT J CARDIOL, V168, P112, DOI 10.1016/j.ijcard.2012.09.061; Strandberg TE, 2009, EUR HEART J, V30, P1720, DOI 10.1093/eurheartj/ehp162; Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905; Bradway C, 2008, J AM GERIATR SOC, V56, P1528, DOI 10.1111/j.1532-5415.2008.01821.x; Valentini L, 2009, CLIN NUTR, V28, P109, DOI 10.1016/j.clnu.2009.01.021; Nakazawa A, 2013, ENVIRON HEALTH PREV, V18, P502, DOI 10.1007/s12199-013-0351-9; Bouillanne O, 2009, AM J CLIN NUTR, V90, P505, DOI 10.3945/ajcn.2009.27819; Beck AM, 2008, J NUTR HEALTH AGING, V12, P675; Avraham Y, 2002, NUTR NEUROSCI, V5, P327, DOI 10.1080/1028415021000033794; Thomas DR, 2000, J GERONTOL A-BIOL, V55, pM725; Romero-Corral A, 2006, LANCET, V368, P666, DOI 10.1016/S0140-6736(06)69251-9; [Anonymous], 2000, WHO TECH REP SER, Vi-xii, P1; Hsu HS, 2013, NUTRITION, V29, P737, DOI 10.1016/j.nut.2012.10.015; [Anonymous], 2000, WHO TECH REP SER, V894, P1; Allard JP, 2004, J AM GERIATR SOC, V52, P59, DOI 10.1111/j.1532-5415.2004.52011.x; Greenberg JA, 2013, AM J CLIN NUTR, V97, P1195, DOI 10.3945/ajcn.112.045815; Miller MD, 2009, BRIT J NUTR, V101, P1300, DOI 10.1017/S0007114508076289; Stein PD, 2011, THROMB RES, V128, P518, DOI 10.1016/j.thromres.2011.10.019; Cereda E, 2011, J AM MED DIR ASSOC, V12, P174, DOI 10.1016/j.jamda.2010.11.013; Dixon JB, 2013, ATHEROSCLEROSIS, V226, P47, DOI 10.1016/j.atherosclerosis.2012.11.005; Kuikka LK, 2009, J AM MED DIR ASSOC, V10, P348, DOI 10.1016/j.jamda.2009.02.007; Chapman IM, 2010, INTERD TOP GERONTOL, V37, P20, DOI 10.1159/000319992; Volpato S, 2004, J AM GERIATR SOC, V52, P886, DOI 10.1111/j.1532-5415.2004.52254.x; Afram B, 2014, J AM MED DIR ASSOC, V15, P108, DOI 10.1016/j.jamda.2013.09.012; Lee JSW, 2014, J AM MED DIR ASSOC, V15, P342, DOI 10.1016/j.jamda.2013.12.081; Lancefield T, 2010, JACC-CARDIOVASC INTE, V3, P660, DOI 10.1016/j.jcin.2010.03.018; Zanandrea V, 2013, CLIN NUTR, V32, P679, DOI 10.1016/j.clnu.2013.05.008; Ma JM, 2013, PREV MED, V56, P178, DOI 10.1016/j.ypmed.2012.12.012; MATTILA K, 1986, BRIT MED J, V292, P867; Tsai ACH, 2012, ARCH GERONTOL GERIAT, V55, P217, DOI 10.1016/j.archger.2011.08.006; Lin WY, 2010, J AM GERIATR SOC, V58, P2092, DOI 10.1111/j.1532-5415.2010.03148.x; de Hollander EL, 2012, INT J EPIDEMIOL, V41, P805, DOI 10.1093/ije/dys008; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; Sund-Levander M, 2007, SCAND J CARING SCI, V21, P18, DOI 10.1111/j.1471-6712.2007.00431.x; Muscaritoli M, 2010, CLIN NUTR, V29, P154, DOI 10.1016/j.clnu.2009.12.004; Genton L, 2013, AGE AGEING, V42, P33, DOI 10.1093/ageing/afs091; Norman K, 2008, CLIN NUTR, V27, P5, DOI 10.1016/j.clnu.2007.10.007; Sergi G, 2005, J GERONTOL A-BIOL, V60, P866; Venihaki M, 2001, J CLIN INVEST, V108, P1159, DOI 10.1172/JCI12869; Kaiser R, 2010, J AM MED DIR ASSOC, V11, P428, DOI 10.1016/j.jamda.2009.10.004; Yeh SS, 1999, AM J CLIN NUTR, V70, P183; Allison DB, 1997, AM J EPIDEMIOL, V146, P339; Lim WS, 2001, EUR RESPIR J, V18, P362, DOI 10.1183/09031936.01.00204401; Dahl AK, 2013, J AM GERIATR SOC, V61, P512, DOI 10.1111/jgs.12158; Lok K, 2009, J NUTR HEALTH AGING, V13, P96, DOI 10.1007/s12603-009-0014-0; Torma J, 2013, CLIN NUTR, V32, P562, DOI 10.1016/j.clnu.2012.10.007; Thomsen M, 2014, JAMA INTERN MED, V174, P15, DOI 10.1001/jamainternmed.2013.10522; Veronese N, 2013, J AM MED DIR ASSOC, V14, P53, DOI 10.1016/j.jamda.2012.09.014; Oreopoulos A, 2009, CLIN GERIATR MED, V25, P643, DOI 10.1016/j.cger.2009.07.005; Dyer AR, 2004, ANN EPIDEMIOL, V14, P101, DOI 10.1016/S1047-2797(03)00121-2; Kimyagarov S, 2010, ARCH GERONTOL GERIAT, V51, P227, DOI 10.1016/j.archger.2009.10.013; KATZ S, 1970, GERONTOLOGIST, V10, P20; Ayaz Syed Imran, 2014, Int J Emerg Med, V7, P19, DOI 10.1186/1865-1380-7-19; de Gonzalez AB, 2010, NEW ENGL J MED, V363, P2211, DOI 10.1056/NEJMoa1000367; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Kiely D K, 2000, J Am Med Dir Assoc, V1, P8; Kiely Dan K, 2002, J Am Med Dir Assoc, V3, P302, DOI 10.1097/00130535-200209000-00004; Kitahara CM, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001673; Kramer CK, 2011, REV ASSOC MED BRAS, V159, P758; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; MAHONEY F I, 1965, Md State Med J, V14, P61; Oreopoulos A, 2009, CLIN GERIATR MED, V25, pviii; Smiley D, 2012, DIABETES, V61, pA289; Song X, 2015, NUTR METAB CARDIOVAS, V25, P295, DOI 10.1016/j.numecd.2014.09.004; Tobias DK, 2014, NEW ENGL J MED, V370, P233, DOI 10.1056/NEJMoa1304501; Wells G, 2014, NEWCASTLE OTTAWA SCA; Winter JE, 2014, AM J CLIN NUTR, V99, P875, DOI 10.3945/ajcn.113.068122; World Health Organization, LIF EXP DAT COUNTR; Wu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102589; Yi Z, 2012, NEPHRON CLIN PRACT, V121, pc102	83	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-7881	1467-789X		OBES REV	Obes. Rev.	NOV	2015	16	11					1001	1015		10.1111/obr.12309		15	Endocrinology & Metabolism	Endocrinology & Metabolism	CU3KQ	WOS:000363424300007		
J	Day, AH; Babarit, A; Fontaine, A; He, YP; Kraskowski, M; Murai, M; Penesis, I; Salvatore, F; Shin, HK				Day, A. H.; Babarit, A.; Fontaine, A.; He, Y. -P.; Kraskowski, M.; Murai, M.; Penesis, I.; Salvatore, F.; Shin, H. -K.			Hydrodynamic modelling of marine renewable energy devices: A state of the art review	OCEAN ENGINEERING			English	Article						Hydrodynamic modelling; Marine renewable energy	POWER TAKE-OFF; WAVE-POWER; CURRENT TURBINES; CONTROL STRATEGIES; TIDAL TURBINES; NUMERICAL-SIMULATION; LATCHING CONTROL; STREAM TURBINES; FLOW CONDITIONS; POINT ABSORBER	This paper reviews key issues in the physical and numerical modelling of marine renewable energy systems, including wave energy devices, current turbines, and offshore wind turbines. The paper starts with an overview of the types of devices considered, and introduces some key studies in marine renewable energy modelling research. The development of new International Towing Tank Conference (ITTC) guidelines for model testing these devices is placed in the context of guidelines developed or under development by other international bodies as well as via research projects. Some particular challenges are introduced in the experimental and numerical modelling and testing of these devices, including the simulation of Power-Take-Off systems (PTOs) for physical models of all devices, approaches for numerical modelling of devices, and the correct modelling of wind load on offshore wind turbines. Finally, issues related to the uncertainty in performance prediction from model test results are discussed. The paper is based on the report of the International Towing Tank Conference specialist committee on Hydrodynamic Modelling of Marine Renewable Energy Devices to the 27th ITTC held in Copenhagen, Denmark in 2014 (ITTC Specialist Committee on Hydrodynamic Modelling of Marine Renewable Energy Devices, 2014a. Final Report and Recommendations to the 27th FITC Proc. 27th International Towing Tank Conference, Copehagen, Denmark, vol. 2, pp. 680-725). (C) 2015 Published by Elsevier Ltd.	[Day, A. H.] Univ Strathclyde, Glasgow, Lanark, Scotland; [Babarit, A.] Ecole Cent Nantes, CNRS, Nantes, France; [Fontaine, A.] Penn State Univ, State Coll, PA USA; [He, Y. -P.] Shanghai Jiao Tong Univ, Shanghai 200030, Peoples R China; [Kraskowski, M.] CTO, Gdansk, Poland; [Murai, M.] Yokohama Natl Univ, Yokohama, Kanagawa 240, Japan; [Penesis, I.] Australian Maritime Coll, Launceston, Tas, Australia; [Salvatore, F.] CNR, INSEAN, Rome, Italy; [Shin, H. -K.] Univ Ulsan, Ulsan 680749, South Korea	Day, AH (reprint author), Univ Strathclyde, Glasgow, Lanark, Scotland.	sandy.day@strath.ac.uk					SALTER SH, 1974, NATURE, V249, P720, DOI 10.1038/249720a0; Babarit A, 2013, RENEW ENERG, V58, P68, DOI 10.1016/j.renene.2013.03.008; Ahmadian R, 2012, RENEW ENERG, V38, P107, DOI 10.1016/j.renene.2011.07.005; Li Y, 2011, OCEAN ENG, V38, P550, DOI 10.1016/j.oceaneng.2010.11.025; Falcao AFD, 2010, RENEW SUST ENERG REV, V14, P899, DOI 10.1016/j.rser.2009.11.003; Payne GS, 2008, OCEAN ENG, V35, P342, DOI 10.1016/j.oceaneng.2007.10.008; Myers LE, 2012, RENEW ENERG, V37, P28, DOI 10.1016/j.renene.2011.03.043; Babarit A, 2009, OCEAN ENG, V36, P1015, DOI 10.1016/j.oceaneng.2009.05.006; Pinon G, 2012, RENEW ENERG, V46, P111, DOI 10.1016/j.renene.2012.03.037; Fusco F, 2012, IEEE T SUSTAIN ENERG, V3, P176, DOI 10.1109/TSTE.2011.2170226; Khan MJ, 2009, APPL ENERG, V86, P1823, DOI 10.1016/j.apenergy.2009.02.017; Falcao AFDO, 2007, OCEAN ENG, V34, P2021, DOI 10.1016/j.oceaneng.2007.02.006; Milne IA, 2013, OCEAN ENG, V60, P163, DOI 10.1016/j.oceaneng.2012.12.027; Maitre T, 2013, RENEW ENERG, V51, P497, DOI 10.1016/j.renene.2012.09.030; Birjandi AH, 2012, RENEW ENERG, V48, P183, DOI 10.1016/j.renene.2012.04.045; Mason-Jones A, 2013, RENEW ENERG, V52, P23, DOI 10.1016/j.renene.2012.10.022; [Anonymous], 2014, 750207039 ITTC; Xiao Q, 2012, RENEW ENERG, V37, P61, DOI 10.1016/j.renene.2011.05.029; [Anonymous], 2014, 750207037 ITTC; Vicente PC, 2009, APPL OCEAN RES, V31, P267, DOI 10.1016/j.apor.2009.09.002; [Anonymous], 2014, 750207038 ITTC; Saulnier JB, 2011, OCEAN ENG, V38, P130, DOI 10.1016/j.oceaneng.2010.10.002; Bahaj AS, 2007, RENEW ENERG, V32, P407, DOI 10.1016/j.renene.2006.01.012; Neill SP, 2012, RENEW ENERG, V37, P387, DOI 10.1016/j.renene.2011.07.003; Folley M, 2009, RENEW ENERG, V34, P1709, DOI 10.1016/j.renene.2009.01.003; Gebreslassie MG, 2013, RENEW ENERG, V50, P994, DOI 10.1016/j.renene.2012.08.065; Lovas S, 2010, APPL OCEAN RES, V32, P267, DOI 10.1016/j.apor.2010.06.004; Wang D, 2007, P I MECH ENG A-J POW, V221, P219, DOI 10.1243/09576509JPE310; Guerber E, 2012, ENG ANAL BOUND ELEM, V36, P1151, DOI 10.1016/j.enganabound.2012.02.005; MALMO O, 1985, J FLUID MECH, V158, P153, DOI 10.1017/S0022112085002592; Falcao AFO, 2012, RENEW ENERG, V48, P369, DOI 10.1016/j.renene.2012.05.009; Maganga F, 2010, IET RENEW POWER GEN, V4, P498, DOI 10.1049/iet-rpg.2009.0205; Antheaume S, 2008, RENEW ENERG, V33, P2186, DOI 10.1016/j.renene.2007.12.022; [Anonymous], 2014, 75010303 ITTC; Falnes J, 2007, MAR STRUCT, V20, P185, DOI 10.1016/j.marstruc.2007.09.001; Amelio M, 2012, APPL ENERG, V97, P944, DOI 10.1016/j.apenergy.2011.11.044; Jo CH, 2012, RENEW ENERG, V42, P195, DOI 10.1016/j.renene.2011.08.017; Babarit A, 2012, RENEW ENERG, V41, P44, DOI 10.1016/j.renene.2011.10.002; Whelan JI, 2009, J FLUID MECH, V624, P281, DOI 10.1017/S0022112009005916; Yang B, 2011, RENEW ENERG, V36, P3355, DOI 10.1016/j.renene.2011.05.014; Neill SP, 2009, RENEW ENERG, V34, P2803, DOI 10.1016/j.renene.2009.06.015; Ruellan M, 2010, IEEE T ENERGY CONVER, V25, P760, DOI 10.1109/TEC.2010.2046808; [Anonymous], 2014, 750207021 ITTC; [Anonymous], 2014, 750203022 ITTC; Henderson R, 2006, RENEW ENERG, V31, P271, DOI 10.1016/j.renene.2005.08.021; Li Y, 2010, RENEW ENERG, V35, P2325, DOI 10.1016/j.renene.2010.03.002; Li Y, 2010, OCEAN ENG, V37, P627, DOI 10.1016/j.oceaneng.2010.01.006; GREENHOW M, 1984, APPL OCEAN RES, V6, P197, DOI 10.1016/0141-1187(84)90058-0; Hwang IS, 2009, APPL ENERG, V86, P1532, DOI 10.1016/j.apenergy.2008.11.009; Renzi E, 2012, J FLUID MECH, V701, P482, DOI 10.1017/jfm.2012.194; Gaurier B, 2013, RENEW ENERG, V59, P1, DOI 10.1016/j.renene.2013.02.026; Ferreira CS, 2009, EXP FLUIDS, V46, P97, DOI 10.1007/s00348-008-0543-z; Nicholls-Lee RF, 2013, RENEW ENERG, V50, P541, DOI 10.1016/j.renene.2012.06.043; Urbina R, 2013, RENEW ENERG, V50, P662, DOI 10.1016/j.renene.2012.08.011; EVANS DV, 1976, J FLUID MECH, V77, P1, DOI 10.1017/S0022112076001109; Xiao Q, 2013, RENEW ENERG, V51, P141, DOI 10.1016/j.renene.2012.09.021; Mycek P, 2014, RENEW ENERG, V68, P876, DOI 10.1016/j.renene.2013.12.048; Bahaj AS, 2007, RENEW ENERG, V32, P2479, DOI 10.1016/j.renene.2007.10.001; Baltazar J, 2008, PROCEEDINGS OF THE 27TH INTERNATIONAL CONFERENCE ON OFFSHORE MECHANICS AND ARCTIC ENGINEERING - 2008, VOL 6, P883; Tedeschi E, 2011, IEEE T ENERGY CONVER, V26, P1088, DOI 10.1109/TEC.2011.2164798; [Anonymous], 614003 IEC; Stratigaki V, 2014, ENERGIES, V7, P701, DOI 10.3390/en7020701; Paillard B, 2013, RENEW ENERG, V52, P209, DOI 10.1016/j.renene.2012.10.018; Oskamp JA, 2012, RENEW ENERG, V45, P72, DOI 10.1016/j.renene.2012.02.004; Clement AH, 2012, PHILOS T R SOC A, V370, P288, DOI 10.1098/rsta.2011.0132; Parmeggiani S, 2013, ENERGIES, V6, P1961, DOI 10.3390/en6041961; Folley M, 2007, OCEAN ENG, V34, P1265, DOI 10.1016/j.oceaneng.2006.05.015; Hu Z, 2012, RENEW ENERG, V48, P251, DOI 10.1016/j.renene.2012.05.002; Bjarte-Larsson T, 2006, OCEAN ENG, V33, P847, DOI 10.1016/j.oceaneng.2005.07.007; Babarit A, 2004, APPL OCEAN RES, V26, P227, DOI 10.1016/j.apor.2005.05.003; Alam MR, 2012, P ROY SOC A-MATH PHY, V468, P3153, DOI 10.1098/rspa.2012.0193; BUDAL K, 1977, J SHIP RES, V21, P248; Babarit A., 2006, APPL OCEAN RES, V128, P56; Babarit A., 2013, P 32 INT C OFFSH MEC; Babarit A., 2005, P 24 INT C OFFSH MEC; Babarit A., 2009, P 28 INT C OFFSH MEC; Banks D., 2013, P 32 INT C OC OFFSH; Bayati I., 2014, ENERGY PROCEDIA, V53, P313; Bellamy N.W., 1986, P 3 INT S WAV TID OT; Berge H., 1982, WAV EN UT P 2 INT S; Bhinder M. A., 2011, P 9 EUR WAV TID EN C; Borgarino B., 2007, 35 DCE AALB U; Brito, 2012, OCEAN ENERGY SYSTEMS; BUDAR K, 1975, NATURE, V256, P478, DOI 10.1038/256478a0; Cermelli C., 2009, P 28 INT C OC OFFSH; Chujo T., 2011, P 30 INT C OC OFFSH; Cretel J.A.M., 2011, P 18 IFAC WORLD C MI; Cretel J.A.M., 2010, PROC IFAC CONF CONTR, P267; Cruz J, 2008, GREEN ENERGY TECHNOL, P1, DOI 10.1007/978-3-540-74895-3; De Ridder E., 2011, P 30 INT C OC OFFSH; De Ridder E.-J., 2013, P EWEA OFFSH 2013 FR; Durand M., 2007, P 7 EUR WAV TID EN C; Ersdal S., 2013, P 32 INT C OC OFFSH; Evans D.V., 1979, P 1 S WAV EN UT GOTH; Evans D.V., 1985, P IUTAM S LISB PORT; Falcao de Campos J.A.C., 2007, P 17 INT OFFSH POL E, V1, P307; Falnes J, 1980, APPL OCEAN RES, V2, P75, DOI DOI 10.1016/0141-1187(80)90032-2); Falnes J., 2002, OCEAN WAVES OSCILLAT; Farley F.J.M., 2011, PHILOS T R SOC A, V370, P381; Fleming A., 2013, J OFFSHORE MECH ARCT, V135; Folley M., 2007, P 7 EUR WAV TID EN C; Folley M., 2012, P 31 INT C OFFSH MEC; Forestier J. M., 2007, P 7 EUR WAV TID EN C; Fraenkel P.L., 2010, P 3 INT C OC EN ICOE; Gaden L.F., 2010, RENEW ENERG, V35, P1152; Gilloteaux J.C., 2007, P 26 INT C OFFSH MEC; Girard Pere et fils, 1799, BREVET INVENTION QUI; Gomes R.P.F., 2011, P 9 EUR WAV TID EN C; Goupee A. J., 2012, P 31 INT C OC OFFSH; Hals J., 2002, P 21 INT C OFFSH MEC; Hansen RH, 2011, P 9 EUR WAV TID EN C; ITTC Specialist Committee on Hydrodynamic Modelling of Marine Renewable Energy Devices, 2014, 27 ITTC P 27 INT TOW, V2, P680; ITTC Specialist Committee on Surface Treatment Final Report and Recommendations to the 26th ITTC, 2011, 26 ITTC P 26 INT TOW, V2, P419; Jonkman J., 2010, TECHNICAL REPORT; Josset C., 2007, Proceedings of the Institution of Mechanical Engineers, Part M (Journal of Engineering for the Maritime Environment), V221, DOI 10.1243/14750902JEME48; Kerbiriou M.A., 2007, P 26 INT C OFFSH MEC; Kraskowski M., 2012, P 18 AUSTR FLUID MEC; Kurniawan A., 2011, P 30 INT C OC OFFSH; Lamont-Kane P., 2013, P 10 EUR WAV TID EN; Li Y., 2012, COMPUT FLUIDS, V73, P104; Liu W., 2013, BIOINSPIRATION BIOMI, V8; Luquet R., 2013, INT J MAR ENERGY, V2, P61; Lust EE, 2013, INT J MAR ENERGY, V3-4, P27; Mankins J.C., 1995, NASA OFFICE SPACE AC; Martin H. R., 2012, P 31 INT C OC OFFSH; McCormick M.E., 1981, OCEAN WAVE ENERGY CO; Meyer N.I., 2002, TECHNICAL REPORT; Muthanna C., 2013, P 32 INT C OC OFFSH; Mycek A.B., 2013, INT J MAR ENERGY, V1, P70; Obhrai C, 2012, P 22 INT OFFSH POL E; Pizer D., 1992, TECHNICAL REPORT; Ponta F.L., 2008, RENEW ENERG, V33, P665; Popko W., 2012, 22 INT OFFSH POL ENG; Previsic M., 2004, WP004USREV1 E2I EPRI; Robertson A., 2014, P 33 INT C OC OFFSH; Robertson A., 2013, P EWEA OFFSH 2013 FR; Salvatore F., 2008, RINA C MAR REN EN NO; Sheng W., 2013, P 32 INT C OC OFFSH; Shin H., 2013, P 32 INT C OC OFFSH; Siegel S.G., 2013, P 10 EUR WAV TID EN; Signorelli C., 2011, P 9 EUR WAV TID EN C; Soulard T., 2012, P 31 INT C OFFSH MEC; van Bussel GJW, 2007, J PHYS CONF SER, V75, P12010, DOI 10.1088/1742-6596/75/1/012010; Weber J., 2007, P 7 EUR WAV TID EN C; Yang L., 2010, OCEAN ENG, V337, P1089; Zamora-Rodriguez R., 2014, P 33 INT C OC OFFSH	146	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0029-8018			OCEAN ENG	Ocean Eng.	NOV 1	2015	108						46	69		10.1016/j.oceaneng.2015.05.036		24	Engineering, Marine; Engineering, Civil; Engineering, Ocean; Oceanography	Engineering; Oceanography	CU2HY	WOS:000363345800005		
J	Kagemoto, H				Kagemoto, Hiroshi			Revisiting the complete wave transmission and reflection due to an array of 2-D surface-piercing truncated vertical plates fixed in regular incident waves (part 2)	OCEAN ENGINEERING			English	Article						Two dimensional hydrodynamic interaction; Wave transmission; Complete wave transmission; Transparent structure; Viscous energy dissipation	BARRIERS	As the second paper under the same title of the first one, we revisit a rather classic problem, complete wave transmission and reflection due to an array of 2-D bodies. In this second paper, wave interaction mechanism resulting in complete transmission is further examined. The analysis is extended to more than 2 bodies and the possibility of complete wave transmission through an array composed of more than two bodies is theoretically examined. Effect of viscous energy dissipation on wave transmission is also discussed through the comparison between non-viscous theoretical results and experimental results. (C) 2015 Elsevier Ltd. All rights reserved.	Univ Tokyo, Grad Sch Frontier Sci, Kashiwa, Chiba 2778561, Japan	Kagemoto, H (reprint author), Univ Tokyo, Grad Sch Frontier Sci, 5-1-5 Kashiwanoha, Kashiwa, Chiba 2778561, Japan.	kagemoto@k.u-tokyo.ac.jp					PORTER R, 1995, J FLUID MECH, V294, P155, DOI 10.1017/S0022112095002849; Kagemoto H, 2011, OCEAN ENG, V38, P976, DOI 10.1016/j.oceaneng.2011.03.007; NEWMAN JN, 1974, J FLUID MECH, V66, P97, DOI 10.1017/S0022112074000085; De S, 2009, J ENG MATH, V65, P75, DOI 10.1007/s10665-009-9265-3; Isaacson M, 1999, APPL OCEAN RES, V21, P81, DOI 10.1016/S0141-1187(98)00039-X; Evans D. V., 1972, Journal of the Institute of Mathematics and Its Applications, V10; Jarvis R. J., 1971, Journal of the Institute of Mathematics and Its Applications, V7; Kagemoto H., 2005, INTERNAL REPORT; Kriebel D. L., 1996, COASTAL ENG 1996, P2470	9	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0029-8018			OCEAN ENG	Ocean Eng.	NOV 1	2015	108						173	180		10.1016/j.oceaneng.2015.08.002		8	Engineering, Marine; Engineering, Civil; Engineering, Ocean; Oceanography	Engineering; Oceanography	CU2HY	WOS:000363345800015		
J	Sugimoto, Y; Mochizuki, H; Ohkubo, S; Higashide, T; Sugiyama, K; Kiuchi, Y				Sugimoto, Yosuke; Mochizuki, Hideki; Ohkubo, Shinji; Higashide, Tomomi; Sugiyama, Kazuhisa; Kiuchi, Yoshiaki			Intraocular Pressure Outcomes and Risk Factors for Failure in the Collaborative Bleb-Related Infection Incidence and Treatment Study	OPHTHALMOLOGY			English	Article							OPEN-ANGLE GLAUCOMA; NORMAL-TENSION GLAUCOMA; MITOMYCIN-C; FOLLOW-UP; TRABECULECTOMY TVT; PROGNOSTIC-FACTORS; AQUEOUS-HUMOR; COMPLICATIONS; EYES; FLUOROURACIL	Purpose: To evaluate the efficacy and safety of trabeculectomy for patients with glaucoma who were enrolled in the Collaborative Bleb-related Infection Incidence and Treatment Study (CBIITS). Design: Multicenter, prospective, cohort study. Participants: A total of 829 eyes in 829 patients with glaucoma who had undergone trabeculectomy alone or trabeculectomy combined with phacoemulsification at 34 clinical centers were examined in this study. Main Outcome Measures: Intraocular pressures (IOPs, in millimeters of mercury), risk factors for surgical failure, and surgical complications. Methods: The enrollment period was 2 years, and follow-up was conducted every 6 months for up to 5 years. Outcomes were measured at 6-month intervals. Four levels of success were defined by achievement of the following IOP: (A) 4 < IOP < 22, (B) 4 < IOP < 19, (C) 4 < IOP < 16, and (D) 4 < IOP < 13. The primary outcome was the qualified success rate according to the defined criteria. The secondary outcomes included IOP, risk factors for surgical failure, and surgical complications. Results: Mean IOP and preoperative antiglaucoma medications were significantly decreased from 24.9 +/- 9.0 to 12.6 +/- 5.2 mmHg (P < 0.0001) and from 2.8 +/- 1.0 to 1.2 +/- 1.3 mmHg (P < 0.0001), respectively, 5 years after surgery. For criteria A, B, C, and D, the qualified success rates were 90.1%, 88.9%, 77.6%, and 57.7% at 1 year, respectively, and 71.9%, 66.7%, 50.1%, and 29.9% at 5 years, respectively. The third or subsequent trabeculectomy was less effective than the first and second trabeculectomies. Preoperative lens status and preoperative higher IOP were risk factors for trabeculectomy failure. The needling procedure and cataract surgery were associated with the risk of failure. The rates of postoperative hyphema, shallow anterior chamber, bleb leak, and choroidal detachment were 2.7%, 3.1%, 1.9%, and 7.2%, respectively, in our series. Conclusions: Trabeculectomy with mitomycin C is an effective and safe procedure for reducing IOP in the CBIITS. The number of previous glaucoma surgeries, preoperative lens status and IOP, the needling procedure, and cataract surgery after trabeculectomy influenced the success rate, as determined by the target IOP. (C) 2015 by the American Academy of Ophthalmology.	[Sugimoto, Yosuke; Mochizuki, Hideki; Kiuchi, Yoshiaki] Hiroshima Univ, Dept Ophthalmol & Visual Sci, Grad Sch Biomed Sci, Hiroshima 7348551, Japan; [Ohkubo, Shinji; Higashide, Tomomi; Sugiyama, Kazuhisa] Kanazawa Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Kanazawa, Ishikawa, Japan	Sugimoto, Y (reprint author), Hiroshima Univ, Dept Ophthalmol & Visual Sci, Grad Sch Biomed Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	sugimoto@hiroshima-u.ac.jp			Nidek; Ministry of Education, Culture, Science, and Technology, Japan	The author(s) have made the following disclosure(s): S.O.: Personal fees - Nidek, outside the submitted work.; Y.K.: Grant - Ministry of Education, Culture, Science, and Technology, Japan.	Allingham RR, 2011, SHIELDS TXB GLAUCOMA, P578; Jampel HD, 2005, AM J OPHTHALMOL, V140, P16, DOI 10.1016/j.ajo.2005.02.013; Yamamoto T, 2011, OPHTHALMOLOGY, V118, P453, DOI 10.1016/j.ophtha.2010.07.002; KITAZAWA Y, 1991, ARCH OPHTHALMOL-CHIC, V109, P1693; Alward WLM, 1996, AM J OPHTHALMOL, V121, P349; Fontana H, 2006, OPHTHALMOLOGY, V113, P930, DOI 10.1016/j.ophtha.2006.01.062; Gedde SJ, 2012, AM J OPHTHALMOL, V153, P789, DOI 10.1016/j.ajo.2011.10.026; Fontana H, 2006, AM J OPHTHALMOL, V141, P652, DOI 10.1016/j.ajo.2005.11.039; Yamamoto T, 2014, OPHTHALMOLOGY, V121, P1001, DOI 10.1016/j.ophtha.2013.11.025; Iwao K, 2014, J GLAUCOMA, V23, P88, DOI 10.1097/IJG.0b013e3182685167; Zahid S, 2013, AM J OPHTHALMOL, V155, P674, DOI 10.1016/j.ajo.2012.10.017; Kawana K, 2009, OPHTHALMOLOGY, V116, P848, DOI 10.1016/j.ophtha.2008.11.019; Yamamoto T, 2005, OPHTHALMOLOGY, V112, P1661, DOI 10.1016/j.ophtha.2005.05.012; Alward WL, 1998, AM J OPHTHALMOL, V126, P498; Awai-Kasaoka N, 2013, JPN J OPHTHALMOL, V57, P514, DOI 10.1007/s10384-013-0257-5; Law SK, 2009, AM J OPHTHALMOL, V148, P685, DOI 10.1016/j.ajo.2009.05.032; Oyakhire JO, 2004, AM J OPHTHALMOL, V137, P953, DOI 10.1016/j.ajo.2003.11.019; Mandal AK, 1997, OPHTHALMOLOGY, V104, P996; Buys YM, 2013, CURR OPIN OPHTHALMOL, V24, P111, DOI 10.1097/ICU.0b013e32835907a6; Inoue T, 2014, CLIN EXP OPHTHALMOL, V42, P334, DOI 10.1111/ceo.12204; Kiuchi Y, 2006, OPHTHALMOLOGICA, V220, P383, DOI 10.1159/000095865; Inoue T, 2012, J CATARACT REFR SURG, V38, P1389, DOI 10.1016/j.jcrs.2012.04.028; Gedde SJ, 2009, AM J OPHTHALMOL, V148, P670, DOI 10.1016/j.ajo.2009.06.018; Gedde SJ, 2012, AM J OPHTHALMOL, V153, P804, DOI 10.1016/j.ajo.2011.10.024; Beck AD, 2003, AM J OPHTHALMOL, V136, P994, DOI 10.1016/S0002-9394(03)00714-1; Sidoti PA, 2000, OPHTHALMOLOGY, V107, P422, DOI 10.1016/S0161-6420(99)00130-X; Kirwan JF, 2013, OPHTHALMOLOGY, V120, P2532, DOI 10.1016/j.ophtha.2013.07.049; DeBry PW, 2002, ARCH OPHTHALMOL-CHIC, V120, P297; Budenz DL, 2015, OPHTHALMOLOGY, V122, P308, DOI 10.1016/j.ophtha.2014.08.043; Schulzer M, 1998, AM J OPHTHALMOL, V126, P487; Heuer DK, 2009, GUIDELINES DESIGN RE, P15; Lochhead J, 2003, BRIT J OPHTHALMOL, V87, P850, DOI 10.1136/bjo.87.7.850; Mac Ivan, 2003, Curr Opin Ophthalmol, V14, P91, DOI 10.1097/00055735-200304000-00007; Ogata-Iwao M, 2013, ACTA OPHTHALMOL, V91, P500; Pathania D, 2014, INDIAN J OPHTHALMOL, V62, P224, DOI 10.4103/0301-4738.101074; Stewart W C, 1995, J Glaucoma, V4, P164; Suzanna R, 1995, J GLAUCOMA, V4, P151; Takihara Y, 2014, JAMA OPHTHALMOL, V132, P69, DOI [10.1001/jamaophthalmol.2013.5605, 10.1001/jamaophthalmo1.2013.5605]; Wang W, 2011, PLOS ONE, V8; Wellik SR, 2015, CLIN OPHTHALMOL, V9, P677, DOI 10.2147/OPTH.S57217	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	NOV	2015	122	11					2223	2233		10.1016/j.ophtha.2015.06.038		11	Ophthalmology	Ophthalmology	CU4IQ	WOS:000363491800024		
J	Akagi-Kurashige, Y; Yamashiro, K; Gotoh, N; Miyake, M; Morooka, S; Yoshikawa, M; Nakata, I; Kumagai, K; Tsujikawa, A; Yamada, R; Matsuda, F; Saito, M; Iida, T; Sugahara, M; Kurimoto, Y; Cheng, CY; Khor, CC; Wong, TY; Yoshimura, N				Akagi-Kurashige, Yumiko; Yamashiro, Kenji; Gotoh, Norimoto; Miyake, Masahiro; Morooka, Satoshi; Yoshikawa, Munemitsu; Nakata, Isao; Kumagai, Kyoko; Tsujikawa, Akitaka; Yamada, Ryo; Matsuda, Fumihiko; Saito, Masaaki; Iida, Tomohiro; Sugahara, Masako; Kurimoto, Yasuo; Cheng, Ching-Yu; Khor, Chiea-Chuen; Wong, Tien-Yin; Yoshimura, Nagahisa		Nagahama Cohort Res Grp	MMP20 and ARMS2/HTRA1 Are Associated with Neovascular Lesion Size in Age-Related Macular Degeneration	OPHTHALMOLOGY			English	Article							COMPLEMENT-FACTOR-H; POLYPOIDAL CHOROIDAL VASCULOPATHY; CHLAMYDIA-PNEUMONIAE INFECTION; RETINAL-PIGMENT EPITHELIUM; MATRIX METALLOPROTEINASES; PHOTODYNAMIC THERAPY; JAPANESE POPULATION; SUBGROUP ANALYSIS; RANIBIZUMAB; POLYMORPHISM	Purpose: Age-related macular degeneration (AMD) is the leading cause of severe visual impairment. Despite treatment, a central scotoma often remains. The size of the scotoma depends on the lesion size of the choroidal neovascular membrane and significantly affects the patient's quality of life, and the lesion size of neovascularization also affects response to treatments. The aim of this study was to identify genes associated with the neovascular lesion size in neovascular AMD. Design: A genome-wide association study (GWAS). Participants: We included 1146 Japanese patients with neovascular AMD. Methods: We performed a 2-stage GWAS for the lesion size of AMD as a quantitative trait among 1146 (first stage: 727, second stage: 419) Japanese patients with neovascular AMD. Lesion size was determined by the greatest linear dimension measured with fluorescein angiography examination before treatment. We examined the association between the genotypic distribution of each single nucleotide polymorphism (SNP) and the trait using an additive model adjusted for age and sex. To evaluate the associations between AMD development and SNPs associated with lesion size, we also performed a case-control study by using the genotype data from these 1146 Japanese patients as case subjects and the fixed dataset from the Nagahama Study as control subjects. Main Outcome Measures: Genes associated with the lesion size in neovascular AMD. Results: In the discovery stage, rs10895322 in MMP20 showed a genome-wide significant P value of 6.95x10(-8), and rs2284665 in ARMS2/HTRA1 showed a P value of 1.55x10(-7). The associations of these 2 SNPs were successfully replicated in the replication stage, and a meta-analysis of both stages showed genome-wide significant P values (2.80x10(-9) and 4.41x10(-9), respectively). In a case-control study using 3248 Japanese subjects as controls, we could not find contribution of MMP20 rs10895322 for AMD development. Although MMP20 has been thought to be expressed only in dental tissues, we confirmed MMP20 expression in the human retina and retinal pigment epithelium/choroid with polymerase chain reaction. Conclusions: The growth of choroidal neovascularization in AMD would be affected by 2 genes: MMP20, a newly confirmed gene expressed in the retina, and ARMS2/HTRA1, a well-known susceptibility gene for AMD. (C) 2015 by the American Academy of Ophthalmology.	[Akagi-Kurashige, Yumiko; Yamashiro, Kenji; Gotoh, Norimoto; Miyake, Masahiro; Morooka, Satoshi; Yoshikawa, Munemitsu; Nakata, Isao; Kumagai, Kyoko; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol, Kyoto 6068507, Japan; [Akagi-Kurashige, Yumiko; Gotoh, Norimoto; Miyake, Masahiro; Yoshikawa, Munemitsu; Nakata, Isao; Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med, Kyoto 6068507, Japan; [Saito, Masaaki] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima, Japan; [Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan; [Sugahara, Masako; Kurimoto, Yasuo] Kobe City Med Ctr Gen Hosp, Dept Ophthalmol, Kobe, Hyogo, Japan; [Cheng, Ching-Yu; Khor, Chiea-Chuen; Wong, Tien-Yin] Singapore Eye Res Inst, Singapore, Singapore; [Cheng, Ching-Yu; Wong, Tien-Yin] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore; [Cheng, Ching-Yu; Wong, Tien-Yin] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore; [Cheng, Ching-Yu; Wong, Tien-Yin] Natl Univ Hlth Syst, Singapore, Singapore; [Cheng, Ching-Yu; Wong, Tien-Yin] Singapore Natl Eye Ctr, Singapore, Singapore; [Khor, Chiea-Chuen] Genome Inst Singapore, Div Human Genet, Singapore, Singapore; [Khor, Chiea-Chuen] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore; [Khor, Chiea-Chuen] Natl Univ Hlth Syst, Singapore, Singapore	Yamashiro, K (reprint author), Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.	yamashro@kuhp.kyoto-u.ac.jp			Japan Society for the Promotion of Science, Tokyo, Japan [22791653, 21249084]; Japan National Society for the Prevention of Blindness, Tokyo, Japan	Supported by Grants-in-Aid for Scientific Research (grant nos. 22791653 and 21249084 to N.Y.) from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Japan National Society for the Prevention of Blindness, Tokyo, Japan. The funding organizations had no role in the design or conduct of this research.	Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018; Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464; Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578; Sakurada Y, 2008, AM J OPHTHALMOL, V145, P1058, DOI 10.1016/j.ajo.2008.02.007; Chowers I, 2008, MOL VIS, V14, P1829; Tamura H, 2012, AM J OPHTHALMOL, V154, P542, DOI 10.1016/j.ajo.2012.03.042; Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x; Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045; Grant GM, 1999, MATRIX BIOL, V18, P145, DOI 10.1016/S0945-053X(99)00003-7; Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047; Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x; Baird PN, 2008, HUM MOL GENET, V17, P1299, DOI 10.1093/hmg/ddn018; Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Llano E, 1997, BIOCHEMISTRY-US, V36, P15101, DOI 10.1021/bi972120y; Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008; Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130; Bessho H, 2011, MOL VIS, V17, P977; Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807; Sakurada Y, 2011, OPHTHALMOLOGY, V118, P1402, DOI 10.1016/j.ophtha.2010.12.010; Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007; Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353; Chowers I, 2008, MOL VIS, V14, P2263; Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017; Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y; Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052; Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012; Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329; Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383; Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478; Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037; Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194; Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063; Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396; Steinbugler WFC, ARCH OPHTHALMOL; Wheeler HE, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000685; Wolf-Schnurrbusch Ute E K, 2013, Ocul Immunol Inflamm, V21, P36, DOI 10.3109/09273948.2012.726393	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	NOV	2015	122	11					2295	+		10.1016/j.ophtha.2015.07.032		10	Ophthalmology	Ophthalmology	CU4IQ	WOS:000363491800032		
J	Kuroda, Y; Yamashiro, K; Miyake, M; Yoshikawa, M; Nakanishi, H; Oishi, A; Tamura, H; Ooto, S; Tsujikawa, A; Yoshimura, N				Kuroda, Yoshimasa; Yamashiro, Kenji; Miyake, Masahiro; Yoshikawa, Munemitsu; Nakanishi, Hideo; Oishi, Akio; Tamura, Hiroshi; Ooto, Sotaro; Tsujikawa, Akitaka; Yoshimura, Nagahisa			Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment	OPHTHALMOLOGY			English	Article							POLYPOIDAL CHOROIDAL VASCULOPATHY; INTRAVITREAL RANIBIZUMAB; NEOVASCULAR MEMBRANES; PHOTODYNAMIC THERAPY; CLINICAL CHARACTERISTICS; JAPANESE PATIENTS; DOSING REGIMEN; VERTEPORFIN; POPULATION; EFFICACY	Purpose: To investigate the predictive factors associated with recurrence after anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD). Design: Retrospective cohort study. Participants: A total of 343 eyes of 326 patients with subfoveal neovascular AMD who were treated with an as-needed regimen after 3 monthly loading doses of intravitreal ranibizumab. Methods: Patients were followed up by an as-needed regimen for more than 1 year after the first injection. Baseline data and CFH I62V and ARMS2 A69S polymorphisms were analyzed for their association with recurrence after anti-VEGF treatment. Regression analysis was used to identify independent predictors of visual acuity (VA) prognosis. Main Outcome Measures: The primary end point was the presence or absence of recurrence. The secondary end point was VA improvement. Results: In total, 236 eyes (68.8%) showed complete resolution of retinal exudative change after the 3 loading injections, and 81 eyes (34.3%) experienced no recurrence during the first year. Of the 236 eyes, 139 (58.9%) were followed for more than 2 years and 35 (25.2%) showed no recurrent retinal exudation during 24 months. Visual acuity improvement was significantly better in eyes without recurrence than in eyes with recurrence during the 2-year period. Baseline characteristics and genotypes had no influence on response to ranibizumab loading treatment. Stepwise analysis revealed that age (P < 0.001), subtype of AMD (P = 0.041), and VA at baseline (P < 0.001) were associated with VA at 24 months. Older patients (P = 0.006) and male patients (P = 0.018) tended to require re-treatment for recurrence during the first year, yet the statistical significance disappeared when evaluated in 2 years. The subtypes of neovascular AMD were solely associated with the interval to the recurrence, which was shorter in eyes with polypoidal choroidal vasculopathy (PCV) than in eyes with typical AMD (P = 0.015). Conclusions: Older age and male sex may predict recurrence after 3 monthly ranibizumab injections, and PCV may be associated with shorter interval to recurrence. Predicting the risk of recurrence would help us to choose the most appropriate follow-up treatment strategy for patients with AMD. (C) 2015 by the American Academy of Ophthalmology.	[Kuroda, Yoshimasa; Yamashiro, Kenji; Miyake, Masahiro; Yoshikawa, Munemitsu; Nakanishi, Hideo; Oishi, Akio; Tamura, Hiroshi; Ooto, Sotaro; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan; [Tsujikawa, Akitaka] Kagawa Univ, Fac Med, Dept Ophthalmol, Kagawa, Japan	Yamashiro, K (reprint author), Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara, Kyoto 6068507, Japan.	yamashro@kuhp.kyoto-u.ac.jp			Japan Society for the Promotion of Science, Tokyo, Japan [24592624]; Japan National Society for the Prevention of Blindness, Tokyo, Japan	Supported in part by grants-in-aid for scientific research (No. 24592624) from the Japan Society for the Promotion of Science, Tokyo, Japan, and the Japan National Society for the Prevention of Blindness, Tokyo, Japan. The funding organizations had no role in the design or conduct of this research.	Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018; Hikichi T, 2012, AM J OPHTHALMOL, V154, P117, DOI 10.1016/j.ajo.2011.12.019; Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032; Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9; Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855; Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047; Abedi F, 2013, OPHTHALMOLOGY, V120, P1641, DOI 10.1016/j.ophtha.2013.01.014; Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037; Tian J, 2012, PHARMACOGENOMICS, V13, P779, DOI [10.2217/pgs.12.53, 10.2217/PGS.12.53]; Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453; Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004; Frank RN, 1996, AM J OPHTHALMOL, V122, P393; Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c; Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8; Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019; Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564; Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004; Teper SJ, 2010, MOL VIS, V16, P2598; Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430; Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609; Koizumi H, 2011, BRIT J OPHTHALMOL, V95, P1555, DOI 10.1136/bjophthalmol-2011-300285; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46; Yamashiro K, 2008, JPN J OPHTHALMOL, V52, P457, DOI 10.1007/s10384-008-0582-2; Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046; Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029; Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024; Lalwani Geeta A, 2009, Am J Ophthalmol, V148, P43, DOI 10.1016/j.ajo.2009.01.024; Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407; Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260; Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003; Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028; Hata M, 2015, GRAEF ARCH CLIN EXP, V253, P221, DOI 10.1007/s00417-014-2688-1; Holladay JT, 1997, J REFRACT SURG, V13, P388; Kang Haeng Ku, 2012, Korean J Ophthalmol, V26, P414, DOI 10.3341/kjo.2012.26.6.414; Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080; Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053; Menghini M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042014	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	NOV	2015	122	11					2303	2310		10.1016/j.ophtha.2015.06.053		8	Ophthalmology	Ophthalmology	CU4IQ	WOS:000363491800033		
J	Ueno, Y; Hiraoka, T; Miyazaki, M; Ito, M; Oshika, T				Ueno, Yuta; Hiraoka, Takahiro; Miyazaki, Maki; Ito, Mutsuko; Oshika, Tetsuro			Re: Ueno et al.: Corneal thickness profile and posterior corneal astigmatism in normal corneas (Ophthalmology 2015;122:1072-8) REPLY	OPHTHALMOLOGY			English	Letter									[Ueno, Yuta; Miyazaki, Maki] Univ Tsukuba Hosp, Dept Ophthalmol, Tsukuba, Ibaraki 3058576, Japan; [Hiraoka, Takahiro; Oshika, Tetsuro] Univ Tsukuba, Fac Med, Dept Ophthalmol, Ibaraki, Japan; [Ito, Mutsuko] Ito Eye Clin, Ibaraki, Japan	Ueno, Y (reprint author), Univ Tsukuba Hosp, Dept Ophthalmol, 2-1-1 Amakubo, Tsukuba, Ibaraki 3058576, Japan.	yu_ueno71@yahoo.co.jp					Koch DD, 2012, J CATARACT REFR SURG, V38, P2080, DOI 10.1016/j.jcrs.2012.08.036; Ueno Y, 2014, J REFRACT SURG, V30, P192, DOI 10.3928/1081597X-20140218-01; Tonn B, 2014, INVEST OPHTH VIS SCI, V56, P291; Ueno Y, 2015, OPHTHALMOLOGY, V122, P1072, DOI 10.1016/j.ophtha.2015.01.021	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	NOV	2015	122	11					E66	E67				4	Ophthalmology	Ophthalmology	CU4IQ	WOS:000363491800005		
J	Kuribayashi, Y; Tsushima, F; Morita, K; Matsumoto, K; Sakurai, J; Uesugi, A; Sato, K; Oda, S; Sakamoto, K; Harada, H				Kuribayashi, Yuri; Tsushima, Fumihiko; Morita, Kei-ichi; Matsumoto, Kanako; Sakurai, Jinkyo; Uesugi, Atsushi; Sato, Kiyoshi; Oda, Seiichiro; Sakamoto, Kei; Harada, Hiroyuki			Long-term outcome of non-surgical treatment in patients with oral leukoplakia	ORAL ONCOLOGY			English	Article						Oral leukoplakia; Epithelial dysplasia; Malignant transformation	POTENTIALLY MALIGNANT DISORDERS; PREMALIGNANT LESIONS; FOLLOW-UP; RECURRENCE PATTERNS; MUCOSAL DISORDERS; TRANSFORMATION; CAVITY; RISK; POPULATION; MICROARRAY	The standard treatments for oral leukoplakia range from careful observation to complete resection. No surgical intervention is chosen for several supposable reasons. Surgical treatment and no surgical treatment for oral leukoplakia have no defined basis for comparisons, and few studies have reported on the long-term outcomes of oral leukoplakia without surgery. Objectives: This study aimed to identify the important factors using a long-term wait-and-see policy in patients with oral leukoplakia. Materials and methods: In total, 237 lesions from 218 patients selected for non-surgical therapy between 2001 and 2010 were analyzed. On the basis of long-term follow-up data, lesions were classified as unchanged, reduced, disappeared, expanded, and malignantly transformed. Results: In total, 135 (57.0%) lesions remained unchanged, 30 (12.7%) lesions were characterized by a reduction in size or clinical severity, and 44 (18.6%) lesions had disappeared. Another 17 (7.2%) lesions resulted in spread or clinical deterioration, and 11 (4.6%) lesions developed oral squamous cell carcinoma. Conclusions: We demonstrated a cumulative malignant transformation rate of 11.6% in 10 years without resection. The lesions that were nonhomogeneous, and higher degree of epithelial dysplasia, located on the tongue were likely to progress into cancer. In addition, 32.5% of lesions without surgical treatment were reduced or disappeared. There is a possibility that removal of considerable irritation for a long time contributes to the treatment of this disease. The development of appropriate treatments for oral leukoplakia is required, which will enable successful differentiation between surgical and observation cases. (C) 2015 Elsevier Ltd. All rights reserved.	[Kuribayashi, Yuri; Tsushima, Fumihiko; Morita, Kei-ichi; Matsumoto, Kanako; Sakurai, Jinkyo; Uesugi, Atsushi; Sato, Kiyoshi; Oda, Seiichiro; Harada, Hiroyuki] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Hlth Sci, Oral & Maxillofacial Surg,Bunkyo Ku, Tokyo 1138549, Japan; [Sakamoto, Kei] Tokyo Med & Dent Univ, Sect Oral Pathol, Bunkyo Ku, Tokyo 1138549, Japan	Kuribayashi, Y (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Hlth Sci, Oral & Maxillofacial Surg,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	kuriosur@tmd.ac.jp; ft.osur@tmd.ac.jp					Abdulmajeed AA1, 2013, CLIN MED INSIGHTS ON, V31, P279; Kumar A, 2013, BRIT J ORAL MAX SURG, V51, P377, DOI 10.1016/j.bjoms.2012.10.018; Zhang L, 2001, ORAL ONCOL, V37, P505, DOI 10.1016/S1368-8375(00)00140-8; Weber RG, 1998, AM J PATHOL, V153, P295, DOI 10.1016/S0002-9440(10)65571-X; Roosaar A, 2007, J ORAL PATHOL MED, V36, P78; Schepman KP, 1998, ORAL ONCOL, V34, P270, DOI 10.1016/S1368-8375(98)80007-9; Liu WW, 2011, ONCOL REP, V26, P265, DOI 10.3892/or.2011.1281; Napier SS, 2008, J ORAL PATHOL MED, V37, P1, DOI 10.1111/j.1600-0714.2007.00579.x; Holmstrup P, 2007, J ORAL PATHOL MED, V36, P262, DOI 10.1111/j.1600-0714.2007.00513.x; SILVERMAN S, 1984, CANCER, V53, P563; Gainza-Cirauqui ML, 2013, J ORAL PATHOL MED, V42, P243, DOI 10.1111/j.1600-0714.2012.01203.x; Arnaoutakis D, 2013, ORAL ONCOL, V49, P814, DOI 10.1016/j.oraloncology.2013.04.008; Ho MW, 2012, ORAL ONCOL, V48, P969, DOI 10.1016/j.oraloncology.2012.04.002; Balasundaram I, 2014, J ORAL PATHOL MED, V43, P239, DOI 10.1111/jop.12088; Chandran R, 2013, ORAL DIS, V19, P592, DOI 10.1111/odi.12040; Kuribayashi Y, 2012, J ORAL PATHOL MED, V41, P682, DOI 10.1111/j.1600-0714.2012.01167.x; Warnakulasuriya S, 2011, J ORAL PATHOL MED, V40, P677, DOI 10.1111/j.1600-0714.2011.01054.x; Ishii J, 2003, ORAL ONCOL, V39, P759, DOI 10.1016/S1368-8375(03)00043-5; Kuribayashi Y, 2009, J ORAL PATHOL MED, V38, P356, DOI 10.1111/j.1600-0714.2008.00731.x; Brouns EREA, 2014, ORAL DIS, V20, pe19, DOI 10.1111/odi.12095; Holmstrup P, 2006, ORAL ONCOL, V42, P461, DOI 10.1016/j.oraloncology.2005.08.011; Pentenero M, 2012, J ORAL PATHOL MED, V41, P119, DOI 10.1111/j.1600-0714.2011.01085.x; van der Waal I, 2002, ORAL ONCOL, V38, P521, DOI 10.1016/S1368-8375(01)00125-7; GUPTA PC, 1989, CANCER, V63, P2247, DOI 10.1002/1097-0142(19890601)63:11<2247::AID-CNCR2820631132>3.0.CO;2-D; Amagasa T, 2011, INT J CLIN ONCOL, V16, P5, DOI 10.1007/s10147-010-0157-3; Giaretti W, 2012, CELL ONCOL, V35, P43, DOI 10.1007/s13402-011-0064-2; Barnes L, 2005, WHO CLASSIFICATION T; Dionne KR, 2015, INT J CANCER, V136, P503, DOI 10.1002/ijc.28754; Liu Wei, 2012, PLOS ONE, V17; Lodi Giovanni, 2002, J Dent Educ, V66, P896; Maeda K, 2009, INT J ORAL MAXILLOF, V39, P486; Pragati BH, 2013, J ORAL SCI, V55, P157; Ribeiro AS, 2010, INT J DENTISITRY; Sieders TJH, 2013, ORAL ONCOL, V49, P1121; Singh Siddharth Kumar, 2014, J Clin Diagn Res, V8, pZC31, DOI 10.7860/JCDR/2014/9872.4956; Wang YY, 2014, BMC ORAL HEALTH, V14, DOI 10.1186/1472-6831-14-99	36	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1368-8375	1879-0593		ORAL ONCOL	Oral Oncol.	NOV	2015	51	11					1020	1025		10.1016/j.oraloncology.2015.09.004		6	Oncology; Dentistry, Oral Surgery & Medicine	Oncology; Dentistry, Oral Surgery & Medicine	CU4GG	WOS:000363484800014		
J	Afghani, E; Pandol, SJ; Shimosegawa, T; Sutton, R; Wu, BCU; Vege, SS; Gorelick, F; Hirota, M; Windsor, J; Lo, SK; Freeman, ML; Lerch, MM; Tsuji, Y; Melmed, GY; Wassef, W; Mayerle, J				Afghani, Elham; Pandol, Stephen J.; Shimosegawa, Tooru; Sutton, Robert; Wu, Bechien U.; Vege, Santhi Swaroop; Gorelick, Fred; Hirota, Morihisa; Windsor, John; Lo, Simon K.; Freeman, Martin L.; Lerch, Markus M.; Tsuji, Yoshihisa; Melmed, Gil Y.; Wassef, Wahid; Mayerle, Julia			Acute Pancreatitis-Progress and Challenges A Report on an International Symposium	PANCREAS			English	Article						acute pancreatitis; post-ERCP pancreatitis; treatment; CRAI; quality indicators	MAGNETIC-RESONANCE ELASTOGRAPHY; ALCOHOLIC CHRONIC-PANCREATITIS; ENDOSCOPIC ULTRASOUND; INTEROBSERVER AGREEMENT; PROSTATE-CANCER; DIAGNOSTIC PERFORMANCE; DIABETES-MELLITUS; EUS ELASTOGRAPHY; NATURAL-HISTORY; CELLS	An international symposium entitled "Acute pancreatitis: progress and challenges" was held on November 5, 2014 at the Hapuna Beach Hotel, Big Island, Hawaii, as part of the 45th Anniversary Meeting of the American Pancreatic Association and the Japanese Pancreas Society. The course was organized and directed by Drs. Stephen Pandol, Tooru Shimosegawa, Robert Sutton, Bechien Wu, and Santhi Swaroop Vege. The symposium objectives were to: (1) highlight current issues in management of acute pancreatitis, (2) discuss promising treatments, (3) consider development of quality indicators and improved measures of disease activity, and (4) present a framework for international collaboration for development of new therapies. This article represents a compilation and adaptation of brief summaries prepared by speakers at the symposium with the purpose of broadly disseminating information and initiatives.	[Afghani, Elham; Pandol, Stephen J.; Lo, Simon K.; Melmed, Gil Y.] Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA; [Shimosegawa, Tooru; Hirota, Morihisa] Tohoku Univ Hosp, Div Gastroenterol, Sendai, Miyagi, Japan; [Sutton, Robert] Royal Liverpool Univ Hosp, Natl Inst Hlth Res, Liverpool Pancreas Biomed Res Unit, Liverpool, Merseyside, England; [Wu, Bechien U.] Kaiser Permanente Los Angeles Med Ctr, Div Gastroenterol, Los Angeles, CA USA; [Vege, Santhi Swaroop] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA; [Gorelick, Fred] Yale Univ, Sect Digest Dis, Dept Internal Med, New Haven, CT USA; [Windsor, John] Univ Auckland, Dept Surg, Auckland 1, New Zealand; [Freeman, Martin L.] Univ Minnesota, Div Gastroenterol, Minneapolis, MN USA; [Lerch, Markus M.; Mayerle, Julia] Univ Med Greifswald, Dept Med, Greifswald, Germany; [Tsuji, Yoshihisa] Kyoto Univ Hosp, Div Gastroenterol, Kyoto 606, Japan; [Wassef, Wahid] Univ Massachusetts, Div Gastroenterol, Worcester, MA 01605 USA	Afghani, E (reprint author), 8700 Beverly Blvd,Suite 7511, Los Angeles, CA 90048 USA.	Elham.afghani@cshs.org			National Institutes of Health, Department of Veterans Affair; National Institutes for Health Research UK, RCUR; Astra-Zeneca; Novartis; Metanomics-Health; Pfizer; Prometheus Labs; Alcresta	S.P. is a consultant at Calcimedica and received a grant support from the National Institutes of Health, Department of Veterans Affair. S.S.V. is a consultant in Calcimedica and received UpToDate royalties for chapters on acute pancreatitis. R.S. is part of Novartis, Glaxo Smith Kline and received a grant support from the National Institutes for Health Research UK, RCUR. F.G. is part of Astra Zeneca and received a grant support from the National Institutes of Health, Department of Veterans Affair. M.L.F. is part of the Boston scientific and XLumena. M.M.L. is part of the advisory board for Astra-Zeneca, Abbott, Abvie; Speakers list fur Falk Foundation, Bayer healthcare; Eli Lilly, Roche; Recordati, Abbott and received an unrestricted grant support from Astra-Zeneca, Novartis, Metanomics-Health. G.Y.M. is part of Abbvie, Celgene, Given Imaging, Janssen, Luitpold, Genentech, Takeda, UCB Pharma and received a grant support from Pfizer, Prometheus Labs. W.W. received a grant support from Alcresta. J.M. is part of the Speakers list falk foundation, Astra Zeneca, unrestricted grant support from Astra-Zeneca as well as Novartis.	Abu Dayyeh BK, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2014.23; LeBlanc JK, 2014, PANCREAS, V43, P440, DOI 10.1097/MPA.0000000000000047; Franklin RB, 2007, ARCH BIOCHEM BIOPHYS, V463, P211, DOI 10.1016/j.abb.2007.02.033; Yadav D, 2012, AM J GASTROENTEROL, V107, P1096, DOI 10.1038/ajg.2012.126; Eggers JP, 2011, CLIN CANCER RES, V17, P6140, DOI 10.1158/1078-0432.CCR-10-2288; Dimastromatteo J, 2015, CANCER J, V21, P188, DOI 10.1097/PPO.0000000000000109; Vitale GC, 2009, AM SURGEON, V75, P649; Xu W, 2013, EUR J GASTROEN HEPAT, V25, P218, DOI 10.1097/MEG.0b013e32835a7f7c; Kenner BJ, 2015, PANCREAS, V44, P686, DOI 10.1097/MPA.0000000000000369; Korc M, 2015, CLIN CANCER RES, V21, P1508, DOI 10.1158/1078-0432.CCR-14-2990; Varadarajulu S, 2007, GASTROINTEST ENDOSC, V66, P501, DOI 10.1016/j.gie.2006.12.043; Wallace MB, 2001, GASTROINTEST ENDOSC, V53, P294, DOI 10.1067/mge.2001.112191; Janssen J, 2014, ULTRASCHALL MED, V35, P253, DOI 10.1055/s-0033-1355767; Canto MI, 2013, GUT, V62, P339, DOI 10.1136/gutjnl-2012-303108; AMMANN RW, 1987, PANCREAS, V2, P368, DOI 10.1097/00006676-198707000-00002; Sanyal R, 1997, MUTAGENESIS, V12, P297, DOI 10.1093/mutage/12.4.297; Costello LC, 1998, PROSTATE, V35, P285, DOI 10.1002/(SICI)1097-0045(19980601)35:4<285::AID-PROS8>3.0.CO;2-F; Foygel K, 2013, GASTROENTEROLOGY, V145, P885, DOI 10.1053/j.gastro.2013.06.011; Aggarwal G, 2012, GASTROENTEROLOGY, V143, P1510, DOI 10.1053/j.gastro.2012.08.044; Bali MA, 2011, RADIOLOGY, V261, P456, DOI 10.1148/radiol.11103515; Tauro BJ, 2012, METHODS, V56, P293, DOI 10.1016/j.ymeth.2012.01.002; Esqueda AC, 2009, J AM CHEM SOC, V131, P11387, DOI 10.1021/ja901875v; Pannala R, 2008, GASTROENTEROLOGY, V134, P981, DOI 10.1053/j.gastro.2008.01.039; Albashir S, 2010, AM J GASTROENTEROL, V105, P2498, DOI 10.1038/ajg.2010.274; Ketwaroo G, 2013, AM J GASTROENTEROL, V108, P1360, DOI 10.1038/ajg.2013.148; Swanson BJ, 2007, CANCER RES, V67, P10222, DOI 10.1158/0008-5472.CAN-06-2483; Wu BC, 2009, AM J GASTROENTEROL, V104, P2381, DOI 10.1038/ajg.2008.181; Oiva J, 2013, PANCREATOLOGY, V13, P118, DOI 10.1016/j.pan.2013.01.010; Gibbons C, 2007, MOL ENDOCRINOL, V21, P783, DOI 10.1210/me.2006-0156; Janssen J, 2007, GASTROINTEST ENDOSC, V65, P971, DOI 10.1016/j.gie.2006.12.057; Gardner TB, 2011, J CLIN GASTROENTEROL, V45, P542, DOI 10.1097/MCG.0b013e3181f42d69; Paulo JA, 2012, J PROTEOME RES, V11, P1897, DOI 10.1021/pr2011022; Del Pozo D, 2012, PANCREATOLOGY, V12, P284, DOI 10.1016/j.pan.2012.03.054; Yusoff IF, 2004, CLIN GASTROENTEROL H, V2, P405, DOI 10.1053/S1542-3565(04)00126-0; Pannala R, 2009, LANCET ONCOL, V10, P88, DOI 10.1016/S1470-2045(08)70337-1; Kelleher SL, 2011, ADV NUTR, V2, P101, DOI 10.3945/an.110.000232; Emmrich J, 1998, DIGESTION, V59, P192, DOI 10.1159/000007488; LANKISCH PG, 1993, DIGESTION, V54, P148; Stevens T, 2010, GASTROINTEST ENDOSC, V71, P519, DOI 10.1016/j.gie.2009.10.043; Stevens T, 2008, GASTROINTEST ENDOSC, V67, P458, DOI 10.1016/j.gie.2007.07.028; Catalano MF, 2009, GASTROINTEST ENDOSC, V69, P1251, DOI 10.1016/j.gie.2008.07.043; Akisik MF, 2010, RADIOLOGY, V256, P441, DOI 10.1148/radiol.10091733; Pysz MA, 2015, RADIOLOGY, V274, P790, DOI 10.1148/radiol.14140568; Al-Haddad M, 2009, PANCREAS, V38, P672, DOI 10.1097/MPA.0b013e3181a9d5af; van Geenen EJM, 2011, AM J GASTROENTEROL, V106, P1161, DOI 10.1038/ajg.2011.43; Viola-Villegas NT, 2014, P NATL ACAD SCI USA, V111, P7254, DOI 10.1073/pnas.1405240111; Hart PA, 2011, PANCREAS, V40, P768, DOI 10.1097/MPA.0b013e318220816a; Zhang H, 2013, J CLIN INVEST, V123, P1019, DOI 10.1172/JCI64931; Venkatesh SK, 2013, J MAGN RESON IMAGING, V37, P544, DOI 10.1002/jmri.23731; LAYER P, 1994, GASTROENTEROLOGY, V107, P1481; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Bhutani MS, 2009, PANCREAS, V38, P820, DOI 10.1097/MPA.0b013e3181b2bc1a; Huang W, 2008, P NATL ACAD SCI USA, V105, P17943, DOI 10.1073/pnas.0711226105; Chong AKH, 2007, GASTROINTEST ENDOSC, V65, P808, DOI 10.1016/j.gie.2006.09.026; Obuz F, 2001, EUR RADIOL, V11, P1642, DOI 10.1007/s003300000799; Apte MV, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00344; Lubag AJM, 2011, P NATL ACAD SCI USA, V108, P18400, DOI 10.1073/pnas.1109649108; Fink DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112737; Garai E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123185; Jacobs I, 2015, MAGN RESON MED; Kadiyala Vivek, 2013, JOP, V14, P31, DOI 10.6092/1590-8577/1195; LaRusch J, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004376; Reynolds F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022471; Rhim AD, 2014, GASTROENTEROLOGY, V146, P647, DOI 10.1053/j.gastro.2013.12.007; Rogalla S, 2015, CANCER J, V21, P179, DOI 10.1097/PPO.0000000000000122; Schmitz-Winnenthal H, 2010, GASTROENTEROLOGY, V138, P1178, DOI 10.1053/j.gastro.2009.11.011; Shi Y, 2015, J MAGN RESON IMAGING, V41, P369, DOI 10.1002/jmri.24572; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Singh S, 2015, CLIN GASTROENTEROL H, V13, P440, DOI 10.1016/j.cgh.2014.09.046; Wilcox CM, 2015, CLIN GASTROENTEROL H, V13, P552, DOI 10.1016/j.cgh.2014.10.015; Xue J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8158; Yao XZ, 2012, EUR J RADIOL, V81, pE917, DOI 10.1016/j.ejrad.2012.05.011	72	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1195	1210		10.1097/MPA.0000000000000500		16	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000007		
J	Kondo, N; Murakami, Y; Uemura, K; Hashimoto, Y; Nakagawa, N; Sasaki, H; Sueda, T				Kondo, Naru; Murakami, Yoshiaki; Uemura, Kenichiro; Hashimoto, Yasushi; Nakagawa, Naoya; Sasaki, Hayato; Sueda, Taijiro			An Increased Number of Perineural Invasions Is Independently Associated With Poor Survival of Patients With Resectable Pancreatic Ductal Adenocarcinoma	PANCREAS			English	Article						perineural invasion; pancreatic cancer; disease-free survival; overall survival; surgery; recurrence site	HELICOBACTER-PYLORI INFECTION; CANCER-RISK; SEROPOSITIVITY; DISEASES	Objectives: The aim of this study was to investigate the impact of the number of perineural invasions (PNIs) in resected specimens on the survival of patients with pancreatic ductal adenocarcinoma (PDAC). Methods: A retrospective cohort study of 209 patients underwent surgical resection for PDAC between 1999 and 2013 was performed. The severity of PNI was evaluated by counting the number of PNIs in all sections with PDAC. The relationships of the number of PNIs with disease-free survival (DFS) and overall survival (OS) were analyzed. Results: At least 1 PNI was observed in 197 (94%) of 209 patients. Significant differences in DFS and OS were found between groups when analyzed by the median number of PNIs (>= 25 vs < 25) (DFS: P < 0.0001; OS: P < 0.0001) and among tertiles greater than 40 versus 40 to 14 versus less than 14 (DFS: P < 0.0001, OS: P < 0.0001). By multivariate analysis, an increased number of PNIs (> 40 vs 40-14 vs < 14) was identified as an independent risk factor for poor DFS (P < 0.0001) and OS (P < 0.0001). Conclusions: The severity of PNI evaluated by counting the number of PNIs in resected specimens was useful for predicting the prognosis of patients with resectable PDAC.	[Kondo, Naru; Murakami, Yoshiaki; Uemura, Kenichiro; Hashimoto, Yasushi; Nakagawa, Naoya; Sasaki, Hayato; Sueda, Taijiro] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Surg, Hiroshima 7348551, Japan	Kondo, N (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Surg, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	k-naru-surg@hiroshima-u.ac.jp					Risch HA, 2014, CANCER EPIDEM BIOMAR, V23, P172, DOI 10.1158/1055-9965.EPI-13-0447; de Martel C, 2008, CANCER EPIDEM BIOMAR, V17, P1188, DOI 10.1158/1055-9965.EPI-08-0185; Yu GQ, 2013, CANCER EPIDEM BIOMAR, V22, P2416, DOI 10.1158/1055-9965.EPI-13-0680; Raderer M, 1998, ONCOLOGY-BASEL, V55, P16, DOI 10.1159/000011830; Kosunen TU, 2011, INT J CANCER, V128, P433, DOI 10.1002/ijc.25337; Ai FL, 2015, CELL BIOCHEM BIOPHYS, V71, P397, DOI 10.1007/s12013-014-0211-2; Wang Y, 2014, ASIAN PAC J CANCER P, V15, P4449, DOI 10.7314/APJCP.2014.15.11.4449; Franceschi F, 2014, HELICOBACTER, V19, P52, DOI 10.1111/hel.12159; Franceschi F, 2014, NAT REV GASTRO HEPAT, V11, P234, DOI 10.1038/nrgastro.2013.243; Shimoyama T, 2010, J GASTROEN HEPATOL, V25, pS86, DOI 10.1111/j.1440-1746.2010.06224.x; Risch HA, 2010, J NATL CANCER I, V102, P502, DOI 10.1093/jnci/djq007; CORREA P, 1992, CANCER RES, V52, P6735; Ferlay J, 2013, IARC CANCERBASE; Gawin Alicja, 2012, Pol Merkur Lekarski, V32, P103; Hsu WY, 2014, EUR J INTERN MED, V25, P235, DOI 10.1016/j.ejim.2014.01.009; Kosunen TU, 2004, HELICOBACTER, V9, P534; Lindkvist B, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-321; Stolzenberg-Solomon RZ, 2001, J NATL CANCER I, V93, P937, DOI 10.1093/jnci/93.12.937; Trikudanathan Guru, 2011, JOP, V12, P26; Wadstrom T., 2004, HELICOBACTER, V9, P538; Xiao MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075559	21	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1345	1351		10.1097/MPA.0000000000000413		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000025		
J	Nakamura, Y; Itoh, A; Kawashima, H; Ohno, E; Itoh, Y; Hiramatsu, T; Sugimoto, H; Sumi, H; Hayashi, D; Kuwahara, T; Funasaka, K; Nakamura, M; Miyahara, R; Ohmiya, N; Katano, Y; Ishigami, M; Shimoyama, Y; Nakamura, S; Goto, H; Hirooka, Y				Nakamura, Yosuke; Itoh, Akihiro; Kawashima, Hiroki; Ohno, Eizaburo; Itoh, Yuya; Hiramatsu, Takeshi; Sugimoto, Hiroyuki; Sumi, Hajime; Hayashi, Daijuro; Kuwahara, Takamichi; Funasaka, Kohei; Nakamura, Masanao; Miyahara, Ryoji; Ohmiya, Naoki; Katano, Yoshiaki; Ishigami, Masatoshi; Shimoyama, Yoshie; Nakamura, Shigeo; Goto, Hidemi; Hirooka, Yoshiki			Investigation of Morphological and Functional Changes in the Small Intestine With Pancreatic Disease	PANCREAS			English	Article						chronic pancreatitis; small intestine; gastric inhibitory polypeptide; glucagon-like peptide 1	RANDOMIZED CONTROLLED-TRIAL; PERINEURAL INVASION; DUCTAL ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; PROGNOSTIC IMPACT; PLEXUS INVASION; NEURAL INVASION; NERVE PLEXUS; PHASE-II; CANCER	Objectives: The aim of this study was to investigate the relationship between pancreas and small intestine evaluating the endoscopic and histopathologic findings of the proximal small intestine in pancreatic diseases. Methods: Fifty patients (18 patients with chronic pancreatitis, 17 patients with pancreatic cancer, 15 control subjects) underwent enteroscopy using a prototype enteroscope. The villous height of the jejunum on bioptic specimens was measured, and the mean values of the villi were compared among the 3 groups. Exocrine function was calculated by the pancreatic function diagnostic test, and the correlation between the recovery rate of p-aminobenzoic acid and the villous height was assessed. Finally, the distribution of the K cells secreting glucose-dependent insulinotropic polypeptide and the L cells secreting glucagon-like peptide 1 in the duodenum and jejunum was investigated using immunohistochemistry for glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1. Results: The mean villous height in chronic pancreatitis (328 +/- 67 mu m) was significantly lower than that in pancreatic cancer (413 +/- 57 mu m) and control subjects (461 +/- 97 mu m) (P = 0.004 and P < 0.0001, respectively). A positive correlation was found between the recovery rate of p-aminobenzoic acid and the villous height (r = 0.52, P = 0.0001). The presence of K and L cells was verified in the duodenum and the jejunum. Conclusions: Close relationship between pancreas and small intestine was demonstrated.	[Nakamura, Yosuke; Funasaka, Kohei; Goto, Hidemi; Hirooka, Yoshiki] Nagoya Univ Hosp, Dept Endoscopy, Nagoya, Aichi 4668550, Japan; [Itoh, Akihiro; Kawashima, Hiroki; Ohno, Eizaburo; Itoh, Yuya; Hiramatsu, Takeshi; Sugimoto, Hiroyuki; Sumi, Hajime; Hayashi, Daijuro; Kuwahara, Takamichi; Nakamura, Masanao; Miyahara, Ryoji; Ohmiya, Naoki; Katano, Yoshiaki; Ishigami, Masatoshi; Goto, Hidemi] Nagoya Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Nagoya, Aichi 4648601, Japan; [Shimoyama, Yoshie; Nakamura, Shigeo] Nagoya Univ Hosp, Dept Pathol, Nagoya, Aichi 4668550, Japan; [Shimoyama, Yoshie; Nakamura, Shigeo] Nagoya Univ Hosp, Clin Labs, Nagoya, Aichi 4668550, Japan	Hirooka, Y (reprint author), Nagoya Univ Hosp, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.	hirooka@med.nagoya-u.ac.jp	KAWASHIMA, Hiroki/I-7285-2014				Murakami Y, 2008, AM J SURG, V195, P757, DOI 10.1016/j.amjsurg.2007.04.018; Liebig C, 2009, CANCER, V115, P3379, DOI 10.1002/cncr.24396; NAGAKAWA T, 1991, INT J PANCREATOL, V10, P113; Chen JWC, 2010, HPB, V12, P101, DOI 10.1111/j.1477-2574.2009.00140.x; Takahashi T, 1997, J SURG ONCOL, V65, P164, DOI 10.1002/(SICI)1096-9098(199707)65:3<164::AID-JSO4>3.0.CO;2-4; Konner JA, 2011, J CLIN ONCOL, V29, P4662, DOI 10.1200/JCO.2011.36.1352; Robinson SM, 2012, EJSO-EUR J SURG ONC, V38, P333, DOI 10.1016/j.ejso.2011.12.020; Kazanjian KK, 2008, ARCH SURG-CHICAGO, V143, P1166, DOI 10.1001/archsurg.143.12.1166; Kanda M, 2011, PANCREAS, V40, P951, DOI 10.1097/MPA.0b013e3182148342; Takahashi H, 2012, ANN SURG, V255, P95, DOI 10.1097/SLA.0b013e31823d813c; Ishigami H, 2010, ANN ONCOL, V21, P67, DOI 10.1093/annonc/mdp260; Kondo N, 2010, ANN SURG ONCOL, V17, P2321, DOI 10.1245/s10434-010-1033-0; BHUIYA MMR, 1992, ANN SURG, V215, P344; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Chatterjee D, 2012, AM J SURG PATHOL, V36, P409, DOI 10.1097/PAS.0b013e31824104c5; Pour PM, 2003, PANCREAS, V26, P322, DOI 10.1097/00006676-200305000-00002; Kayahara M, 2007, PANCREAS, V35, P218; Mitsunaga S, 2007, AM J SURG PATHOL, V31, P1636; OLSSON Y, 1990, CRIT REV NEUROBIOL, V5, P265; Shimada K, 2011, PANCREAS, V40, P464, DOI 10.1097/MPA.0b013e31820b5d37; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Hirai I, 2002, PANCREAS, V24, P15, DOI 10.1097/00006676-200201000-00003; Shirai K, 2008, WORLD J SURG, V32, P2395, DOI 10.1007/s00268-008-9726-2; Noto M, 2005, AM J SURG PATHOL, V29, P1056; Nakao A, 1996, PANCREAS, V12, P357, DOI 10.1097/00006676-199605000-00006; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Matsuno S, 2004, PANCREAS, V28, P219, DOI 10.1097/00006676-200404000-00002; BATSAKIS JG, 1985, ANN OTO RHINOL LARYN, V94, P426; Liu Bin, 2002, Hepatobiliary Pancreat Dis Int, V1, P469; Sahin IH, 2012, CANCER MED-US, V1, P357, DOI 10.1002/cam4.43; Sobin LH, 2010, TMN CLASSIFICATION M; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Takahara Naminatsu, 2014, J Gastrointest Cancer, V45, P307, DOI 10.1007/s12029-014-9603-1; Veness M J, 2000, Australas Radiol, V44, P296, DOI 10.1046/j.1440-1673.2000.00817.x	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1352	1357		10.1097/MPA.0000000000000426		6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000026		
J	Abe, T; Ohuchida, K; Nakamura, M				Abe, T.; Ohuchida, K.; Nakamura, M.			Comparison of Surgical Outcome of Radical Antegrade Modular Pancreatosplenectomy With Standard Retrograde Pancreatosplenectomy and Evaluation of the Prognostic Factors in Left Side Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Abe, T.; Ohuchida, K.; Nakamura, M.] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 812, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1358	1358				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000028		
J	Aikawa, M; Miyazawa, M; Ishida, S; Okada, K; Watanabe, Y; Okamota, K; Koyama, I; Taguchi, T				Aikawa, M.; Miyazawa, M.; Ishida, S.; Okada, K.; Watanabe, Y.; Okamota, K.; Koyama, I.; Taguchi, T.			Development of a Novel Biocompatible Bond for the Prevention of Pancreatic Fistulas	PANCREAS			English	Meeting Abstract									[Aikawa, M.; Miyazawa, M.; Ishida, S.; Okada, K.; Watanabe, Y.; Okamota, K.; Koyama, I.; Taguchi, T.] Saitama Med Univ, Int Med Ctr, Saitama, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1358	1359				2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000031		
J	Akao, J; Shimizu, K; Ajihara, T; Nagao, K; Tahara, J; Takayama, Y; Shiratori, K; Yamamoto, M; Furukawa, T				Akao, J.; Shimizu, K.; Ajihara, T.; Nagao, K.; Tahara, J.; Takayama, Y.; Shiratori, K.; Yamamoto, M.; Furukawa, T.			Verification of the Utility of International Consensus Guidelines 2012 for the Management of IPMN and MCN of the Pancreas	PANCREAS			English	Meeting Abstract									[Akao, J.; Shimizu, K.; Ajihara, T.; Nagao, K.; Tahara, J.; Takayama, Y.; Shiratori, K.] Tokyo Womens Med Univ, Dept Gastroenterol, Tokyo, Japan; [Yamamoto, M.] Tokyo Womens Med Univ, Gastroenterol Surg, Tokyo, Japan; [Furukawa, T.] Tokyo Womens Med Univ, Inst Integrated Med Sci, Tokyo, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1359	1359				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000032		
J	Asari, S; Toyama, H; Goto, T; Terai, S; Ajiki, T; Matsumoto, T; Shinozaki, K; Kido, M; Takebe, A; Tanaka, M; Kuramitsu, K; Kinoshita, H; Fukumoto, T; Ku, Y				Asari, S.; Toyama, H.; Goto, T.; Terai, S.; Ajiki, T.; Matsumoto, T.; Shinozaki, K.; Kido, M.; Takebe, A.; Tanaka, M.; Kuramitsu, K.; Kinoshita, H.; Fukumoto, T.; Ku, Y.			Preoperative Independent Prognostic Factors in Patients With "Resectable" Pancreatic Ductal Adenocarcinoma Following Curative Resection: Neutrophil-lymphocyte Ratio and Platelet-Lymphocyte Ratio	PANCREAS			English	Meeting Abstract									[Asari, S.; Toyama, H.; Goto, T.; Terai, S.; Ajiki, T.; Matsumoto, T.; Shinozaki, K.; Kido, M.; Takebe, A.; Tanaka, M.; Kuramitsu, K.; Kinoshita, H.; Fukumoto, T.; Ku, Y.] Kobe Univ, Div Hepatobiliary Pancreat Surg, Dept Surg, Grad Sch Med, Kobe, Hyogo 657, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1360	1360				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000036		
J	Date, K; Ohtsuka, T; Fujimoto, T; Gotoh, Y; Nakashima, Y; Kimura, H; Matsunaga, T; Mochidome, N; Miyazaki, T; Oda, Y; Tanaka, M; Nakamura, M				Date, K.; Ohtsuka, T.; Fujimoto, T.; Gotoh, Y.; Nakashima, Y.; Kimura, H.; Matsunaga, T.; Mochidome, N.; Miyazaki, T.; Oda, Y.; Tanaka, M.; Nakamura, M.			Molecular Evidence for Monoclonal Skip Progression in Main Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas	PANCREAS			English	Meeting Abstract									[Date, K.; Ohtsuka, T.; Fujimoto, T.; Gotoh, Y.; Nakashima, Y.; Kimura, H.; Matsunaga, T.; Tanaka, M.; Nakamura, M.] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 812, Japan; [Mochidome, N.; Miyazaki, T.; Oda, Y.] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 812, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1368	1368				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000072		
J	Gaddam, RR; Badiei, A; Chambers, ST; Ishii, I; Bhatia, M				Gaddam, R. R.; Badiei, A.; Chambers, S. T.; Ishii, I.; Bhatia, M.			The Effect of Cystathionine-Gamma-Lyase Gene Deletion on the Renin-Angiotensin System in Cerulein-Induced Acute Pancreatitis in Mice	PANCREAS			English	Meeting Abstract									[Gaddam, R. R.; Badiei, A.; Chambers, S. T.; Bhatia, M.] Univ Otago, Dept Pathol, Christchurch, New Zealand; [Ishii, I.] Keio Univ, Grad Sch Pharmaceut Sci, Dept Biochem, Tokyo, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1373	1373				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000092		
J	Gyoten, K; Mizuno, S; Kato, H; Tanemura, A; Murata, Y; Kuriyama, N; Azumi, Y; Kishiwada, M; Usui, M; Sakurai, H; Isaji, S				Gyoten, K.; Mizuno, S.; Kato, H.; Tanemura, A.; Murata, Y.; Kuriyama, N.; Azumi, Y.; Kishiwada, M.; Usui, M.; Sakurai, H.; Isaji, S.			Left-Sided Portal Hypertension following Pancreatoduodenectomy With Resection of the Superior Mesenteric-Portal Vein Confluence for Locally Advanced Pancreatic Ductal Adenocarcinoma: Benefit of Concomitant Resection of the Splenic Artery	PANCREAS			English	Meeting Abstract									[Gyoten, K.; Mizuno, S.; Kato, H.; Tanemura, A.; Murata, Y.; Kuriyama, N.; Azumi, Y.; Kishiwada, M.; Usui, M.; Sakurai, H.; Isaji, S.] Mie Univ, Sch Med, Dept Hepatobiliary Pancreat & Transplant Surg, Tsu, Mie, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1377	1377				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000106		
J	Hayasaki, A; Murata, Y; Usui, M; Kishiwada, M; Mizuno, S; Sakurai, H; Yoshida, T; Isaji, S				Hayasaki, A.; Murata, Y.; Usui, M.; Kishiwada, M.; Mizuno, S.; Sakurai, H.; Yoshida, T.; Isaji, S.			Intratumoral Expression of Tenascin C is a Potential Surrogate Marker for Histological Effect of Chemoradiotherapy in Locally Advanced Pancreatic Cancer Patients	PANCREAS			English	Meeting Abstract									[Hayasaki, A.; Murata, Y.; Usui, M.; Kishiwada, M.; Mizuno, S.; Sakurai, H.; Isaji, S.] Mie Univ, Div Hepatobiliary Pancreat & Transplant Surg, Tsu, Mie 514, Japan; [Yoshida, T.] Mie Univ, Div Matrix Biol, Tsu, Mie 514, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1378	1378				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000111		
J	Horioka, K; Ohuchida, K; Sada, M; Zheng, B; Ohtsuka, T; Ueki, T; Nagai, E; Mizumoto, K; Oda, Y; Nakamura, M				Horioka, K.; Ohuchida, K.; Sada, M.; Zheng, B.; Ohtsuka, T.; Ueki, T.; Nagai, E.; Mizumoto, K.; Oda, Y.; Nakamura, M.			Suppression of CD51 in Pancreatic Stellate Cells Inhibits Tumor Growth by Reducing Stroma and Altering Tumor-Stromal Interaction in Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Horioka, K.; Ohuchida, K.; Sada, M.; Zheng, B.; Ohtsuka, T.; Ueki, T.; Nagai, E.; Mizumoto, K.; Oda, Y.; Nakamura, M.] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 812, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1379	1379				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000115		
J	Iizawa, Y; Kato, H; Tanemura, A; Murata, Y; Yoshinori, A; Kuriyama, N; Kishiwada, M; Mizuno, S; Usui, M; Sakurai, H; Isaji, S				Iizawa, Y.; Kato, H.; Tanemura, A.; Murata, Y.; Yoshinori, A.; Kuriyama, N.; Kishiwada, M.; Mizuno, S.; Usui, M.; Sakurai, H.; Isaji, S.			The Impact of Early Initiation of High-Dose Pancreatic Enzyme Supplementation for Prevention of Nonalcoholic Fatty Liver Disease After Pancreaticoduodenectomy	PANCREAS			English	Meeting Abstract									[Iizawa, Y.; Kato, H.; Tanemura, A.; Murata, Y.; Yoshinori, A.; Kuriyama, N.; Kishiwada, M.; Mizuno, S.; Usui, M.; Sakurai, H.; Isaji, S.] Mie Univ, Div Hepatobiliary Pancreat & Transplant Surg, Tsu, Mie 514, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1380	1381				2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000121		
J	Itakura, J; Watanabe, M; Hosomura, N; Amemiya, H; Kawaida, H; Okamoto, H; Kohno, H				Itakura, J.; Watanabe, M.; Hosomura, N.; Amemiya, H.; Kawaida, H.; Okamoto, H.; Kohno, H.			Treatment Strategy for Locally Invasive Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Itakura, J.; Watanabe, M.; Hosomura, N.; Amemiya, H.; Kawaida, H.; Okamoto, H.; Kohno, H.] Univ Yamanashi, Dept Surg, Cyuo, Yamanashi, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1382	1382				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000126		
J	Ito, T; Hamano, M; Kawai, T; Ishimi, A; Tokuda, Y; Hibino, C; Kato, M; Saiki, H; Yamamoto, K; Naito, M; Miyoshi, E				Ito, T.; Hamano, M.; Kawai, T.; Ishimi, A.; Tokuda, Y.; Hibino, C.; Kato, M.; Saiki, H.; Yamamoto, K.; Naito, M.; Miyoshi, E.			Clinical Analysis of Agalactosyl Immunoglobulin-G (IgG) in Chronic Pancreatitis (CP) Patients	PANCREAS			English	Meeting Abstract									[Ito, T.; Hamano, M.; Kawai, T.; Ishimi, A.; Tokuda, Y.; Hibino, C.; Kato, M.; Saiki, H.; Yamamoto, K.; Naito, M.] Osaka Hosp, Japan Community Healthcare Org, Osaka, Japan; [Miyoshi, E.] Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Suita, Osaka, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1382	1382				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000127		
J	Ito, T; Sugiura, T; Okamura, Y; Yamamoto, Y; Ashida, R; Uesaka, K				Ito, T.; Sugiura, T.; Okamura, Y.; Yamamoto, Y.; Ashida, R.; Uesaka, K.			Surgical Resection for Adenosquamous Carcinoma of the Pancreas	PANCREAS			English	Meeting Abstract									[Ito, T.; Sugiura, T.; Okamura, Y.; Yamamoto, Y.; Ashida, R.; Uesaka, K.] Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, Shizuoka, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1382	1382				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000128		
J	Kagawa, S; Yoshitomi, H; Shimizu, H; Ohtsuka, M; Kato, A; Furukawa, K; Takayashiki, T; Takano, S; Kuboki, S; Suzuki, D; Sakai, N; Miyazaki, M				Kagawa, S.; Yoshitomi, H.; Shimizu, H.; Ohtsuka, M.; Kato, A.; Furukawa, K.; Takayashiki, T.; Takano, S.; Kuboki, S.; Suzuki, D.; Sakai, N.; Miyazaki, M.			The Role of nab-Paclitaxel Plus Gemcitabine Therapy for Recurrent Pancreatic Cancer Refractory to Gemcitabine and S-1	PANCREAS			English	Meeting Abstract									[Kagawa, S.; Yoshitomi, H.; Shimizu, H.; Ohtsuka, M.; Kato, A.; Furukawa, K.; Takayashiki, T.; Takano, S.; Kuboki, S.; Suzuki, D.; Sakai, N.; Miyazaki, M.] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chiba, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1385	1385				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000139		
J	Karasaki, H; Mizukami, Y; Kono, T; Maejima, T; Fukahori, S; Mukai, N; Kasai, S; Matsubara, Y; Amizuka, H; Nagashima, K				Karasaki, H.; Mizukami, Y.; Kono, T.; Maejima, T.; Fukahori, S.; Mukai, N.; Kasai, S.; Matsubara, Y.; Amizuka, H.; Nagashima, K.			A Surgical Approach to Extrahepatic Bile Duct Carcinoma With Intestinal Non-Rotation Presenting With Pre-Duodenal Portal Vein	PANCREAS			English	Meeting Abstract									[Karasaki, H.; Kono, T.; Maejima, T.; Fukahori, S.; Mukai, N.; Kasai, S.] Sapporo Higashi Tokushukai Hosp, Dept Surg, Sapporo, Hokkaido, Japan; [Karasaki, H.; Mizukami, Y.; Kono, T.] Sapporo Higashi Tokushukai Hosp, Ctr Clin & Biomed Res, Sapporo, Hokkaido, Japan; [Matsubara, Y.; Amizuka, H.] Sapporo Higashi Tokushukai Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan; [Nagashima, K.] Sapporo Higashi Tokushukai Hosp, Dept Pathol, Sapporo, Hokkaido, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1385	1386				2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000141		
J	Kawabata, Y; Tajima, Y				Kawabata, Y.; Tajima, Y.			Pancreatectomy With Artery-First Approach for Borderline Resectable Pancreatic Cancer: Surgical Technique to Secure Negative Tangential Margins and its Outcome	PANCREAS			English	Meeting Abstract									[Kawabata, Y.; Tajima, Y.] Shimane Univ, Fac Med, Dept Digest & Gen Surg, Matsue, Shimane, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1386	1386				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000142		
J	Kimura, K; Amano, R; Yamazoe, S; Ohira, G; Miura, K; Nishio, K; Sakurai, K; Toyokawa, T; Ohira, M; Hirakawa, K				Kimura, K.; Amano, R.; Yamazoe, S.; Ohira, G.; Miura, K.; Nishio, K.; Sakurai, K.; Toyokawa, T.; Ohira, M.; Hirakawa, K.			Evaluation of the Prognostic Significance of 'High-risk Stigmata' in the International Consensus Guidelines 2012 for Intraductal Papillary Mucinous Neoplasm	PANCREAS			English	Meeting Abstract									[Kimura, K.; Amano, R.; Yamazoe, S.; Ohira, G.; Miura, K.; Nishio, K.; Sakurai, K.; Toyokawa, T.; Ohira, M.; Hirakawa, K.] Osaka City Univ, Dept Surg Oncol, Grad Sch Med, Osaka 558, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1387	1387				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000146		
J	Koikawa, K; Ohuchida, K; Sada, M; Abe, T; Endo, S; Horioka, K; Moriyama, T; Miyasaka, Y; Ohtuka, T; Ohuchida, R; Ueki, T; Nagai, E; Mizumoto, K; Nakamura, M				Koikawa, K.; Ohuchida, K.; Sada, M.; Abe, T.; Endo, S.; Horioka, K.; Moriyama, T.; Miyasaka, Y.; Ohtuka, T.; Ohuchida, R.; Ueki, T.; Nagai, E.; Mizumoto, K.; Nakamura, M.			Pancreatic Stellate Cells Lead and Promote the Local Invasion of Cancer Cells, by Physically Remodeling the Extracellular Matrix With a Collagen Fiber Alignment in Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Koikawa, K.; Ohuchida, K.; Sada, M.; Abe, T.; Endo, S.; Horioka, K.; Moriyama, T.; Miyasaka, Y.; Ohtuka, T.; Ueki, T.; Nagai, E.; Mizumoto, K.; Nakamura, M.] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka, Japan; [Ohuchida, R.] Kyushu Univ, Sect Fixed Prosthodont, Div Oral Rehabil, Fac Dent Sci, Fukuoka 812, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1387	1387				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000148		
J	Koizumi, M; Sata, N; Taguchi, M; Miki, A; Endo, H; Sasanuma, H; Sakuma, Y; Horie, H; Hosoya, Y; Lefor, AK				Koizumi, M.; Sata, N.; Taguchi, M.; Miki, A.; Endo, H.; Sasanuma, H.; Sakuma, Y.; Horie, H.; Hosoya, Y.; Lefor, A. K.			Management of Pancreatic Anastomotic Leakage by Measuring Drainage Amylase and Volume After Pylorus Preserving Pancreatoduodenectomy	PANCREAS			English	Meeting Abstract									[Koizumi, M.; Sata, N.; Taguchi, M.; Miki, A.; Endo, H.; Sasanuma, H.; Sakuma, Y.; Horie, H.; Hosoya, Y.; Lefor, A. K.] Jichi Med Univ, Dept Surg, Shimotsuke, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1387	1388				2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000149		
J	Kumar, S; Rachagani, S; Joshi, S; Gupta, S; Varney, M; Cannon, AC; Mallya, K; Kaur, S; Jain, M; Akira, S; Singh, RK; Batra, SK				Kumar, S.; Rachagani, S.; Joshi, S.; Gupta, S.; Varney, M.; Cannon, A. C.; Mallya, K.; Kaur, S.; Jain, M.; Akira, S.; Singh, R. K.; Batra, S. K.			Deficiency of Lipocalin-2 Protect Against Cerulein-Induced Severe Acute Pancreatitis	PANCREAS			English	Meeting Abstract									[Kumar, S.; Rachagani, S.; Joshi, S.; Gupta, S.; Cannon, A. C.; Mallya, K.; Kaur, S.; Jain, M.; Batra, S. K.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE USA; [Varney, M.; Singh, R. K.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Akira, S.] Osaka Univ, Immunol Frontier Res Ctr IFReC, Suita, Osaka, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1389	1389				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000156		
J	Lee, L; Ito, T; Igarashi, H; Kawabe, K; Oda, Y; Jensen, RT				Lee, L.; Ito, T.; Igarashi, H.; Kawabe, K.; Oda, Y.; Jensen, R. T.			Long-Term Outcomes and Prognostic Factors in 78 Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study	PANCREAS			English	Meeting Abstract									[Lee, L.; Ito, T.; Igarashi, H.; Kawabe, K.] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan; [Oda, Y.] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 812, Japan; [Jensen, R. T.] Natl Inst Diabet Digest & Kidney Dis, Digest Dis Branch, NIH, Bethesda, MD USA								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1391	1391				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000162		
J	Malla, SR; Qin, Y; Mareninova, OA; Elperin, JM; Lotshaw, EM; Ohmuraya, M; French, SW; Gukovskaya, AS; Gukovsky, I				Malla, S. R.; Qin, Y.; Mareninova, O. A.; Elperin, J. M.; Lotshaw, E. M.; Ohmuraya, M.; French, S. W.; Gukovskaya, A. S.; Gukovsky, I.			Atg5 Deficiency Worsens Cerulein Pancreatitis	PANCREAS			English	Meeting Abstract									[Malla, S. R.; Qin, Y.; Mareninova, O. A.; Elperin, J. M.; Lotshaw, E. M.; Gukovskaya, A. S.; Gukovsky, I.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Malla, S. R.; Qin, Y.; Mareninova, O. A.; Elperin, J. M.; Lotshaw, E. M.; Gukovskaya, A. S.; Gukovsky, I.] Univ Calif Los Angeles, Los Angeles, CA USA; [Ohmuraya, M.] Kumamoto Univ, Kumamoto 860, Japan; [French, S. W.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1395	1395				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000181		
J	Miki, A; Sakuma, Y; Sasanuma, H; Koizumi, M; Endo, K; Sata, N				Miki, A.; Sakuma, Y.; Sasanuma, H.; Koizumi, M.; Endo, K.; Sata, N.			The Impact of Curative Resection for Pancreatic Adenocarcinoma With Lymph Node Metastasis Status	PANCREAS			English	Meeting Abstract									[Miki, A.; Sakuma, Y.; Sasanuma, H.; Koizumi, M.; Endo, K.; Sata, N.] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1398	1398				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000192		
J	Miura, K; Kimura, K; Amano, R; Yamazoe, S; Ohira, G; Nishio, K; Shibutani, M; Sakurai, K; Nagahara, H; Toyokawa, T; Kubo, N; Tanaka, H; Muguruma, K; Otani, H; Yashiro, M; Maeda, K; Ohira, M; Hirakawa, K				Miura, K.; Kimura, K.; Amano, R.; Yamazoe, S.; Ohira, G.; Nishio, K.; Shibutani, M.; Sakurai, K.; Nagahara, H.; Toyokawa, T.; Kubo, N.; Tanaka, H.; Muguruma, K.; Otani, H.; Yashiro, M.; Maeda, K.; Ohira, M.; Hirakawa, K.			Is Anaplastic Pancreatic Cancer Originated from Invasive Ductal Carcinoma of Pancreas?	PANCREAS			English	Meeting Abstract									[Miura, K.; Kimura, K.; Amano, R.; Yamazoe, S.; Ohira, G.; Nishio, K.; Shibutani, M.; Sakurai, K.; Nagahara, H.; Toyokawa, T.; Kubo, N.; Tanaka, H.; Muguruma, K.; Otani, H.; Yashiro, M.; Maeda, K.; Ohira, M.; Hirakawa, K.] Osaka City Univ, Dept Surg Oncol, Grad Sch Med, Osaka 558, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1398	1398				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000193		
J	Miyasaka, Y; Nakamura, M; Tanaka, M; Morikawa, T; Unno, M; Wakabayashi, G; Beppu, T; Takahara, T; Yamaue, H; Miyazaki, M; Takada, T				Miyasaka, Y.; Nakamura, M.; Tanaka, M.; Morikawa, T.; Unno, M.; Wakabayashi, G.; Beppu, T.; Takahara, T.; Yamaue, H.; Miyazaki, M.; Takada, T.			Multicenter Comparative Study of Laparoscopic and Open Distal Pancreatectomy Using Propensity Score-Matching	PANCREAS			English	Meeting Abstract									[Miyasaka, Y.; Nakamura, M.; Tanaka, M.] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 812, Japan; [Morikawa, T.; Unno, M.] Tohoku Univ, Dept Surg, Grad Sch Med, Sendai, Miyagi 980, Japan; [Wakabayashi, G.] Ageo Cent Gen Hosp, Dept Surg, Ageo, Japan; [Beppu, T.] Kumamoto Univ, Grad Sch Life Sci, Dept Surg Gastroenterol, Kumamoto, Japan; [Takahara, T.] Iwate Med Univ, Sch Med, Dept Surg, Morioka, Iwate 020, Japan; [Yamaue, H.] Wakayama Med Univ, Sch Med, Dept Surg 2, Wakayama, Japan; [Miyazaki, M.] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chiba, Japan; [Takada, T.] Teikyo Univ, Sch Med, Dept Surg, Tokyo 173, Japan; [Miyasaka, Y.; Nakamura, M.; Tanaka, M.; Morikawa, T.; Unno, M.; Wakabayashi, G.; Beppu, T.; Takahara, T.; Yamaue, H.; Miyazaki, M.; Takada, T.] Japanese Soc Hepatobiliary Pancreat Surg, Tokyo, Japan; [Miyasaka, Y.; Nakamura, M.; Tanaka, M.; Morikawa, T.; Unno, M.; Wakabayashi, G.; Beppu, T.; Takahara, T.; Yamaue, H.; Miyazaki, M.; Takada, T.] Japanese Soc Endoscop Pancreat Surg, Tokyo, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1398	1398				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000194		
J	Miyazaki, T; Ohishi, Y; Miyasaka, Y; Ozono, K; Abe, A; Mochidome, N; Saeki, K; Nagai, E; Oda, Y; Nakamura, M				Miyazaki, T.; Ohishi, Y.; Miyasaka, Y.; Ozono, K.; Abe, A.; Mochidome, N.; Saeki, K.; Nagai, E.; Oda, Y.; Nakamura, M.			Pancreatic Ductal Adenocarcioma Without High-Grade Pancreatic Intraepithelial Neoplasia (PanIN) May Develop via a Pathway Other Than PanIN-Carcinoma Sequence	PANCREAS			English	Meeting Abstract									[Miyazaki, T.; Ohishi, Y.; Ozono, K.; Abe, A.; Mochidome, N.; Saeki, K.; Oda, Y.] Kyushu Univ, Dept Anat Pathol, Fukuoka 812, Japan; [Miyazaki, T.; Miyasaka, Y.; Ozono, K.; Abe, A.; Mochidome, N.; Saeki, K.; Nagai, E.; Nakamura, M.] Kyushu Univ, Dept Surg & Oncol, Fukuoka 812, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1398	1399				2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000195		
J	Mizukami, Y; Ono, Y; Karasaki, H; Ogata, M; Kono, T; Nagashima, K				Mizukami, Y.; Ono, Y.; Karasaki, H.; Ogata, M.; Kono, T.; Nagashima, K.			Plasma DNA Genotyping Using Digital PCR for Early Detection of Pancreatic Neoplasm	PANCREAS			English	Meeting Abstract									[Mizukami, Y.; Ono, Y.; Karasaki, H.; Ogata, M.; Kono, T.; Nagashima, K.] Sapporo Higashi Tokushukai Hosp, Ctr Clin & Biomed Res, Sapporo, Hokkaido, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1399	1399				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000196		
J	Moriyasu, F; Sofuni, A; Sano, T; Fujita, M; Itoi, T				Moriyasu, F.; Sofuni, A.; Sano, T.; Fujita, M.; Itoi, T.			High-Intensity Focused Ultrasound (HIFU) Therapy Combined With Chemotherapy has an Effect of Survival Time Elongation for the Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Moriyasu, F.; Sofuni, A.; Sano, T.; Fujita, M.; Itoi, T.] Tokyo Med Univ, Dept Gastroenterol & Hepatol, Shinjuku Ku, Tokyo 1608402, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1400	1400				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000202		
J	Murata, Y; Kishiwada, M; Kuriyama, N; Azumi, Y; Mizuno, S; Usui, M; Sakurai, H; Isaji, S				Murata, Y.; Kishiwada, M.; Kuriyama, N.; Azumi, Y.; Mizuno, S.; Usui, M.; Sakurai, H.; Isaji, S.			Histological Effect of Chemoradiotherapy Contributes to Securing a Surgical Margin and Improving Prognosis in Patients With Locally Advanced Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Murata, Y.; Kishiwada, M.; Kuriyama, N.; Azumi, Y.; Mizuno, S.; Usui, M.; Sakurai, H.; Isaji, S.] Mie Univ, Div Hepatobiliary Pancreat & Transplant Surg, Tsu, Mie 514, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1401	1401				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000206		
J	Nishio, K; Kimura, K; Amano, R; Miura, K; Ohira, G; Yamazoe, S; Ohira, M; Hirakawa, K				Nishio, K.; Kimura, K.; Amano, R.; Miura, K.; Ohira, G.; Yamazoe, S.; Ohira, M.; Hirakawa, K.			Analysis of Clinicopathological Features of Early Recurrence After Curative Resection for Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Nishio, K.; Kimura, K.; Amano, R.; Miura, K.; Ohira, G.; Yamazoe, S.; Ohira, M.; Hirakawa, K.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Osaka 558, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1403	1403				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000214		
J	Ohgi, K; Okamura, Y; Yamamoto, Y; Sugiura, T; Ito, T; Ashida, R; Uesaka, K				Ohgi, K.; Okamura, Y.; Yamamoto, Y.; Sugiura, T.; Ito, T.; Ashida, R.; Uesaka, K.			Preoperative CT Assessments of the Pancreas Predict Fatty Liver After Pancreaticoduodenectomy	PANCREAS			English	Meeting Abstract									[Ohgi, K.; Okamura, Y.; Yamamoto, Y.; Sugiura, T.; Ito, T.; Ashida, R.; Uesaka, K.] Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, Shizuoka, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1404	1404				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000218		
J	Okamoto, H; Itakura, J; Fujii, H				Okamoto, H.; Itakura, J.; Fujii, H.			Therapeutic Management of Disconnected Pancreatic Duct Syndrome (DPDS)	PANCREAS			English	Meeting Abstract									[Okamoto, H.] Tsuru Municipal Hosital, Dept Surg, Kofu, Yamanashi, Japan; [Okamoto, H.; Itakura, J.; Fujii, H.] Univ Yamanashi, Dept Gastrointestinal Surg, Kofu, Yamanashi, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1404	1404				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000219		
J	Shindo, Y; Ueno, T; Suzuki, N; Matsui, H; Nakajima, M; Matsukuma, S; Tokumitsu, Y; Tokuhisa, Y; Sakamoto, K; Tamesa, T; Takeda, S; Yoshino, S; Hazama, S; Nagano, H				Shindo, Y.; Ueno, T.; Suzuki, N.; Matsui, H.; Nakajima, M.; Matsukuma, S.; Tokumitsu, Y.; Tokuhisa, Y.; Sakamoto, K.; Tamesa, T.; Takeda, S.; Yoshino, S.; Hazama, S.; Nagano, H.			Pancreas Transection With Linear Stapler and Bipolar Cautery Forceps in Distal Pancreatectomy	PANCREAS			English	Meeting Abstract									[Shindo, Y.; Ueno, T.; Suzuki, N.; Matsui, H.; Nakajima, M.; Matsukuma, S.; Tokumitsu, Y.; Tokuhisa, Y.; Sakamoto, K.; Tamesa, T.; Takeda, S.; Yoshino, S.; Hazama, S.; Nagano, H.] Yamaguchi Univ, Dept Digest Surg & Surg Oncol, Grad Sch Med, Ube, Yamaguchi 755, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1415	1415				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000263		
J	Sugiura, T; Okamura, Y; Ito, T; Yamamoto, Y; Ashida, R; Uesaka, K				Sugiura, T.; Okamura, Y.; Ito, T.; Yamamoto, Y.; Ashida, R.; Uesaka, K.			Prognostic Scoring System for Patients Who Present With Gastric Outlet Obstruction Due to Advanced Pancreatic Adenocarcinoma	PANCREAS			English	Meeting Abstract									[Sugiura, T.; Okamura, Y.; Ito, T.; Yamamoto, Y.; Ashida, R.; Uesaka, K.] Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, Shizuoka, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1417	1417				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000271		
J	Sunahara, M; Ueki, S; Ono, Y; Sakamoto, Y; Sawano, T; Sato, T; Kasajima, H; Kurushima, M; Suzuki, S; Kimura, J				Sunahara, M.; Ueki, S.; Ono, Y.; Sakamoto, Y.; Sawano, T.; Sato, T.; Kasajima, H.; Kurushima, M.; Suzuki, S.; Kimura, J.			Undifferentiated Pancreatic Carcinoma With Osteoclast-like Giant Cells Showing Tumor Thrombus Into the Main Pancreatic Duct: Report of a Case With Osteoid Formation	PANCREAS			English	Meeting Abstract									[Sunahara, M.; Ueki, S.; Ono, Y.; Sakamoto, Y.; Sawano, T.; Sato, T.; Kasajima, H.; Kurushima, M.; Suzuki, S.; Kimura, J.] Hakodate Municipal Hosp, Inst Gastroenterol, Dept Surg, Hakodate, Hokkaido, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1417	1417				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000272		
J	Takano, S; Sogawa, K; Yoshitomi, H; Kagawa, S; Shimizu, H; Ohtsuka, M; Kato, A; Furukawa, K; Takayashiki, T; Kuboki, S; Suzuki, D; Sakai, N; Nomura, F; Miyazaki, M				Takano, S.; Sogawa, K.; Yoshitomi, H.; Kagawa, S.; Shimizu, H.; Ohtsuka, M.; Kato, A.; Furukawa, K.; Takayashiki, T.; Kuboki, S.; Suzuki, D.; Sakai, N.; Nomura, F.; Miyazaki, M.			Circulating Annexin II Predicts Rapid Recurrence After Surgery in Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Takano, S.; Yoshitomi, H.; Kagawa, S.; Shimizu, H.; Ohtsuka, M.; Kato, A.; Furukawa, K.; Takayashiki, T.; Kuboki, S.; Suzuki, D.; Sakai, N.; Miyazaki, M.] Chiba Univ, Dept Gen Surg, Chiba, Japan; [Sogawa, K.; Nomura, F.] Chiba Univ, Dept Mol Diag, Chiba, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1418	1418				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000276		
J	Takayama, Y; Shimizu, K; Yamamoto, M; Furukawa, T				Takayama, Y.; Shimizu, K.; Yamamoto, M.; Furukawa, T.			Problems in the Diagnosis of Pancreatic Neuroendocrine Tumors (PNETs) in Clinical Practice	PANCREAS			English	Meeting Abstract									[Takayama, Y.; Shimizu, K.] Tokyo Womens Med Univ, Dept Internal Med, Inst Gastroenterol, Tokyo, Japan; [Yamamoto, M.] Tokyo Womens Med Univ, Dept Surg, Inst Gastroenterol, Tokyo, Japan; [Furukawa, T.] Tokyo Womens Med Univ, Inst Integrated Med Sci, Tokyo, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1419	1419				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000277		
J	Toyoki, Y; Ishido, K; Kudo, D; Wakiya, T; Wakasa, Y; Kasai, D; Hakamada, K				Toyoki, Y.; Ishido, K.; Kudo, D.; Wakiya, T.; Wakasa, Y.; Kasai, D.; Hakamada, K.			Preoperative Neutrophil to Lymphocyte Ratio Predict Overall Survival After Macroscopic Curative Resection for Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Toyoki, Y.; Ishido, K.; Kudo, D.; Wakiya, T.; Wakasa, Y.; Kasai, D.; Hakamada, K.] Hirosaki Univ, Grad Sch Med, Dept Surg Gastroenterol, Hirosaki, Aomori, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1419	1420				2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000281		
J	Uchida, K; Mitsuyama, T; Yanagawa, M; Miyoshi, H; Ikeura, T; Shimatani, M; Fukui, T; Takaoka, M; Nishio, A; Mizuno, N; Notohara, K; Zamboni, G; Frulloni, L; Shimosegawa, T; Okazaki, K				Uchida, K.; Mitsuyama, T.; Yanagawa, M.; Miyoshi, H.; Ikeura, T.; Shimatani, M.; Fukui, T.; Takaoka, M.; Nishio, A.; Mizuno, N.; Notohara, K.; Zamboni, G.; Frulloni, L.; Shimosegawa, T.; Okazaki, K.			The Difference in Mechanisms of Neutrophil Infiltration between Type 1 and Type2 Autoimmune Pancreatitis	PANCREAS			English	Meeting Abstract									[Uchida, K.; Mitsuyama, T.; Yanagawa, M.; Miyoshi, H.; Ikeura, T.; Shimatani, M.; Fukui, T.; Takaoka, M.; Nishio, A.; Okazaki, K.] Kansai Med Univ, Dept Gastroenterol & Hepatol, Hirakata, Osaka, Japan; [Mizuno, N.] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi 464, Japan; [Notohara, K.] Kurashiki Cent Hosp, Dept Pathol, Kurashiki, Okayama, Japan; [Zamboni, G.] Univ Verona, Dept Pathol, I-37100 Verona, Italy; [Frulloni, L.] Univ Verona, Dept Med, I-37100 Verona, Italy; [Shimosegawa, T.] Tohoku Univ, Sch Med, Div Gastroenterol, Sendai, Miyagi 980, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1421	1421				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000287		
J	Ueda, K; Lee, L; Fujiyama, T; Tachibana, Y; Masami, M; Yasunaga, K; Kawabe, K; Honda, H; Nakamura, M; Oda, Y; Ito, T				Ueda, K.; Lee, L.; Fujiyama, T.; Tachibana, Y.; Masami, M.; Yasunaga, K.; Kawabe, K.; Honda, H.; Nakamura, M.; Oda, Y.; Ito, T.			Selective Arterial Secretagogue Injection Test (SASI Test) in 15 Insulinoma Patients	PANCREAS			English	Meeting Abstract									[Ueda, K.; Lee, L.; Fujiyama, T.; Tachibana, Y.; Masami, M.; Yasunaga, K.; Kawabe, K.; Ito, T.] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan; [Honda, H.] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka 812, Japan; [Nakamura, M.] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 812, Japan; [Oda, Y.] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 812, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1421	1421				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000288		
J	Yamazoe, S; Amano, R; Kimura, K; Ohira, G; Nishio, K; Miura, K; Ohira, M; Hirakawa, K				Yamazoe, S.; Amano, R.; Kimura, K.; Ohira, G.; Nishio, K.; Miura, K.; Ohira, M.; Hirakawa, K.			Adverse Effect of Re-elevation of Postoperative Inflammatory Reaction on Recurrence Free Survival Time of Patients Undergoing Potentially Curative Resection for Distal Pancreatic Cancer	PANCREAS			English	Meeting Abstract									[Yamazoe, S.; Amano, R.; Kimura, K.; Ohira, G.; Nishio, K.; Miura, K.; Ohira, M.; Hirakawa, K.] Osaka City Univ, Grad Sch Med, Dept Surg 1, Dept Surg Oncol, Osaka 558, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1427	1427				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000310		
J	Yoshida, E; Kudo, D; Nagase, H; Suto, A; Wakiya, T; Ishido, K; Toyoki, Y; Hakamada, K				Yoshida, E.; Kudo, D.; Nagase, H.; Suto, A.; Wakiya, T.; Ishido, K.; Toyoki, Y.; Hakamada, K.			Extracellular Matrix Modulation Therapy of Pancreatic Cancer by 4-methylumbelliferone and 5-fluorouracil	PANCREAS			English	Meeting Abstract									[Yoshida, E.; Kudo, D.; Nagase, H.; Suto, A.; Wakiya, T.; Ishido, K.; Toyoki, Y.; Hakamada, K.] Hirosaki Univ, Grad Sch Med, Gastroenterol Surg, Hirosaki, Aomori, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1427	1427				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000312		
J	Yoshitomi, H; Sakai, N; Shimizu, H; Ohtsuka, M; Kato, A; Furukawa, K; Takayashiki, T; Takano, S; Kuboki, S; Suzuki, D; Kagawa, S; Miyazaki, M				Yoshitomi, H.; Sakai, N.; Shimizu, H.; Ohtsuka, M.; Kato, A.; Furukawa, K.; Takayashiki, T.; Takano, S.; Kuboki, S.; Suzuki, D.; Kagawa, S.; Miyazaki, M.			Arterial Resection Without Reconstruction Following Preoperative Arterial Embolization for Locally Advanced Pancreatic Head Cancer With Arterial Invasion	PANCREAS			English	Meeting Abstract									[Yoshitomi, H.; Sakai, N.; Shimizu, H.; Ohtsuka, M.; Kato, A.; Furukawa, K.; Takayashiki, T.; Takano, S.; Kuboki, S.; Suzuki, D.; Kagawa, S.; Miyazaki, M.] Chiba Univ, Dept Gen Surg, Chiba, Japan								0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-3177	1536-4828		PANCREAS	Pancreas	NOV	2015	44	8					1428	1428				1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CU2AQ	WOS:000363324000313		
J	Harada, A; Ishigami, S; Kijima, Y; Nakajo, A; Arigami, T; Kurahara, H; Kita, Y; Yoshinaka, H; Natsugoe, S				Harada, Aya; Ishigami, Sumiya; Kijima, Yuko; Nakajo, Akihiro; Arigami, Takaaki; Kurahara, Hiroshi; Kita, Yoshiaki; Yoshinaka, Heiji; Natsugoe, Shoji			Clinical implication of human leukocyte antigen (HLA)-F expression in breast cancer	PATHOLOGY INTERNATIONAL			English	Article						breast cancer; clinical stage; HLA-F; tumor infiltrating cells	HLA-F; CELL; TUMOR; LYMPHOCYTES; METASTASIS; RECEPTORS; CARCINOMA; SURVIVAL; MODEL	Human leukocyte antigen (HLA)-F is one of the non-classical HLA class I molecules that protects the fetus in pregnancy. HLA-F expression was immunohistochemically examined and the association between clinical parameters and HLA-F expression was analyzed. Cancerous HLA-F and stromal HLA-F-positive infiltrating cells were detected in 91 (40.0%) and 186 (81.6%) cases, respectively. HLA-F positivity in cancer cells was significantly associated with tumor size (P<0.05). There was a weak correlation between HLA-F positivity of cancer cells and HLA-F positive infiltrative cells (P<0.01, r=0.11). HLA-F positivity did not affect patients' survival in 209 breast cancer. However, confined to stage II breast cancer, the HLA-F positive group showed significantly poorer outcomes than the HLA-F negative group (P<0.05). The present study provides the first evidence that HLA-F positivity in breast carcinoma affects clinicopathological factors and could be selected as a prognostic marker for limited clinical stage.	[Harada, Aya; Ishigami, Sumiya; Kijima, Yuko; Nakajo, Akihiro; Arigami, Takaaki; Kurahara, Hiroshi; Kita, Yoshiaki; Yoshinaka, Heiji; Natsugoe, Shoji] Kagoshima Univ, Sch Med, Dept Digest Surg & Breast & Thyroid Surg, Kagoshima 8908520, Japan	Ishigami, S (reprint author), Kagoshima Univ, Sch Med, Dept Digest Surg & Breast & Thyroid Surg, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	ishiga@m.kufm.kagoshima-u.ac.jp					American Joint Committee on Cancer, 2002, AM JOINT COMMITTEE C; Lin AF, 2012, INT J CANCER, V131, P150, DOI 10.1002/ijc.26375; Yan WH, 2011, CANCER LETT, V311, P123, DOI 10.1016/j.canlet.2011.07.019; Lin AF, 2011, LUNG CANCER, V74, P504, DOI 10.1016/j.lungcan.2011.04.006; Nakamura R, 2009, EUR J CANCER, V45, P2123, DOI 10.1016/j.ejca.2009.03.024; Benson JR, 2009, LANCET, V373, P1463, DOI 10.1016/S0140-6736(09)60316-0; Llanes-Fernandez L, 2009, J CANCER RES CLIN, V135, P255, DOI 10.1007/s00432-008-0446-7; Gooden M, 2011, P NATL ACAD SCI USA, V108, P10656, DOI 10.1073/pnas.1100354108; King A, 2000, EUR J IMMUNOL, V30, P1623, DOI 10.1002/1521-4141(200006)30:6<1623::AID-IMMU1623>3.0.CO;2-M; Yu B, 2011, CELL BIOL INT, V35, P165, DOI 10.1042/CBI20100346; Lee N, 2010, EUR J IMMUNOL, V40, P2308, DOI 10.1002/eji.201040348; Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2; Wischhusen J, 2005, J NEUROPATH EXP NEUR, V64, P523; Lepin EJM, 2000, EUR J IMMUNOL, V30, P3552, DOI 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L; MCINTYRE JA, 1992, AM J REPROD IMMUNOL, V28, P127; Zhang X, 2013, INT J CANCER, V132, P82, DOI 10.1002/ijc.27621; Ishigami S, 2013, J SURG RES, V184, P802, DOI 10.1016/j.jss.2013.04.003; Paez D, 2012, CLIN CANCER RES, V18, P645, DOI 10.1158/1078-0432.CCR-11-2186; Lee N, 2003, J IMMUNOL, V171, P5264; Benevolo M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-184; Cavallo Federica, 2009, Expert Rev Vaccines, V8, P25, DOI 10.1586/14760584.8.1.25; desKruijf EM, 2010, J IMMUNOL, V185, P7452; Kaneko K, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-454; Le Bouteiller P, 1997, Rev Reprod, V2, P7; MILLER FR, 1993, CRIT REV ONCOGENESIS, V4, P293; Stebbing Justin, 2012, Br J Nurs, V21, pS18	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					569	574		10.1111/pin.12343		6	Pathology	Pathology	CU3WF	WOS:000363456000001		
J	Uesugi, N; Shimazu, Y; Aoba, T; Kikuchi, K; Nagata, M				Uesugi, Noriko; Shimazu, Yoshihito; Aoba, Takaaki; Kikuchi, Kazunori; Nagata, Michio			High-resolution three-dimensional digital imaging of the human renal microcirculation: An aid to evaluating microvascular alterations in chronic kidney disease in humans	PATHOLOGY INTERNATIONAL			English	Article						human renal microcirculation; immunohistochemistry; paraffin-embedded sections; three-dimensional imaging; virtual microscopy	RECONSTRUCTION; 3D; VISUALIZATION; TOMOGRAPHY; CARCINOMA; INVASION	We have developed a new virtual microscopy method, with two- and three-dimensional (2D, 3D) synchronization, that enables visualization of the human renal microvasculature. The method was used to evaluate 120-150 serially cut sections of paraffin-embedded human renal tissue from nephrectomized samples. Virtual microscopy images of sections double-immunostained with antibodies against CD34 (an endothelium marker) and smooth muscle actin (an arterial media marker) and stained with periodic acid-Schiff were processed using digital imaging analysis software. Image registration was conducted to generate 3D displays with red-green-blue color segmentation. The reconstructed images of the microvasculature, including the interlobular arteries and the glomeruli, allowed visualization of 3D structures and direct glomerular connections. Synchronizing these 3D images with the corresponding 2D images revealed the relationships between arteriosclerotic lesions and downstream glomeruli. Thus, interlobular arteries with moderate intimal thickening and afferent arterioles with segmental hyalinosis/sclerosis, as seen on the 2D images, exhibited wall irregularities on the corresponding 3D images. However, these lesions were not directly influenced by lesions in downstream glomeruli, such as sclerotic lesions. Our virtual-slide method based on 2D and 3D image synchronization provides a comprehensive view of the renal microcirculation and therefore novel insights into the pathogenesis of vascular-associated renal diseases.	[Uesugi, Noriko; Nagata, Michio] Univ Tsukuba, Fac Med, Dept Kidney & Vasc Pathol, Tsukuba, Ibaraki 3053878, Japan; [Kikuchi, Kazunori] Tsukuba Med Ctr, Div Pathol, Tsukuba, Ibaraki, Japan; [Shimazu, Yoshihito] Azabu Univ, Lab Food & Physiol Sci, Sagamihara, Kanagawa, Japan; [Shimazu, Yoshihito; Aoba, Takaaki] Nippon Dent Univ, Sch Life Dent Tokyo, Dept Pathol, Chiyoda Ku, Niigata, Japan	Uesugi, N (reprint author), Univ Tsukuba, Fac Med, Dept Kidney & Vasc Pathol, 1-1 Tennodai, Tsukuba, Ibaraki 3053878, Japan.	nouesugi@md.tsukuba.ac.jp			Japan Society for the Promotion of Science [C 23591179, C26461211]	This study was supported by Japanese Grants-in-Aid for Scientific Research of the Japan Society for the Promotion of Science (C 23591179, C26461211).	Advani A, 2011, PLOS ONE, V7; Alpers CE, 2013, ROBBINS BASIC PATHOL, P539; Wentzensen N, 2007, CYTOM PART A, V71A, P327, DOI 10.1002/cyto.a.20385; Roberts N, 2012, AM J PATHOL, V180, P1835, DOI 10.1016/j.ajpath.2012.01.033; Asioli S, 2008, VIRCHOWS ARCH, V453, P401, DOI 10.1007/s00428-008-0657-y; Maruyama S, 2014, J ORAL PATHOL MED, V43, P627, DOI 10.1111/jop.12184; Kurata M, 2014, J STROKE CEREBROVASC, V23, P1440, DOI 10.1016/j.jstrokecerebrovasdis.2013.12.003; Wierwille J, 2011, LAB INVEST, V91, P1596, DOI 10.1038/labinvest.2011.112; Scruggs BS, 2011, AM J PATHOL, V178, P1891, DOI 10.1016/j.ajpath.2010.12.029; Wu MLC, 2005, ARCH PATHOL LAB MED, V129, P507; LJUNGQVIST A, 1962, J ANAT, V96, P285; Rule AD, 2010, ANN INTERN MED, V152, P561, DOI 10.7326/0003-4819-152-9-201005040-00006; Bentley MD, 2007, ANAT REC, V290, P277, DOI 10.1002/ar.20422; Clendenon SG, 2013, KIDNEY INT, V83, P757, DOI 10.1038/ki.2012.464; MIN W, 1993, VIRCHOWS ARCH A, V423, P201, DOI 10.1007/BF01614771; Xu YH, 2004, COMPUT METH PROG BIO, V76, P143, DOI 10.1016/j.cmpb.2004.04.002; Bentley MD, 2002, KIDNEY INT, V61, P1056, DOI 10.1046/j.1523-1755.2002.00211.x; Hill GS, 2006, KIDNEY INT, V69, P823, DOI 10.1038/sj.ki.5000163; Ren H, 2014, AM J PHYSIOL-RENAL, V306, pF321, DOI 10.1152/ajprenal.00429.2013; Garcia-Sanz A, 1988, HYPERTENSION, V31, P440; Giuvărăşteanu Ileana, 2007, Rom J Morphol Embryol, V48, P257; Kudo T, 2013, INT J DENT, V13, P424; Matsumoto T, 1982, Acta Pathol Jpn, V32 Suppl 2, P285; Varik BJ, 2012, FRONT GENET, V3, P290	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					575	584		10.1111/pin.12339		10	Pathology	Pathology	CU3WF	WOS:000363456000002		
J	Takahashi, M; Masuda, H; Yoshida, M; Ito, Y; Nanjo, H; Sugiyama, T; Maeda, D; Goto, A				Takahashi, Masato; Masuda, Hirotake; Yoshida, Makoto; Ito, Yukinobu; Nanjo, Hiroshi; Sugiyama, Tatsuo; Maeda, Daichi; Goto, Akiteru			Clusters of proliferating endothelial cells and smooth muscle cells in rabbit carotid arteries	PATHOLOGY INTERNATIONAL			English	Article						carotid artery; endothelial cells; Ki67; rabbit; serial section; smooth muscle cells	PROGENITOR CELLS; AORTIC ENDOTHELIUM; STEM-CELLS; WALL; RAT; ANGIOGENESIS; REPLICATION; ENLARGEMENT; PEROXIDASE; ADVENTITIA	Schwarz and Benditt found clustering of replicating cells in aortic endothelium in 1976 and discussed how homeostasis of the arterial wall is maintained through this nonrandom distribution of replicating cells. However, it is still unclear how cells of vascular walls turnover. In order to address this issue, we evaluated distribution of the cells in mitotic cycle, labeled by Ki67-immunostaining, in serial histological sections of twelve carotid arteries of six adult male Japanese rabbits. As a result, a total of 1713 Ki67-positive endothelial cells (ECs) and 1247 Ki67-positive smooth muscle cells (SMCs) were identified. The Ki67-positivity rate in ECs and SMCs were about 0.048% and 0.0027%, respectively. Many of the Ki67-positive cells clustered in two (EC, 37%; SMC, 33%), three to four (EC, 8%; SMC, 28%), and five to eight cells (EC, 5%; SMC, 10%). Clusters having more than eight cells were not found. Thus, it can be speculated that the cell division of proliferating ECs and SMCs occur four times at most. These novel findings offer great insights for better understanding of the mechanism that underlies cell number regulation of the blood vessel.	[Takahashi, Masato] Akita Kosei Med Ctr, Dept Diagnost Pathol, Akita, Akita 0110948, Japan; [Yoshida, Makoto; Ito, Yukinobu; Maeda, Daichi; Goto, Akiteru] Akita Univ, Grad Sch Med, Dept Cellular & Organ Pathol, Akita 010, Japan; [Nanjo, Hiroshi] Akita Univ Hosp, Dept Surg Pathol, Akita, Japan; [Masuda, Hirotake] Ogachi Cent Gen Hosp, Dept Clin Lab, Yuzawa, Japan; [Sugiyama, Tatsuo] Akita Karyol & Histol Res Ctr, Diagnost Pathol, Yurihonjo, Akita, Japan	Takahashi, M (reprint author), Akita Kosei Med Ctr, Dept Diagnost Pathol, 1-1-1 Nishibukuro, Akita, Akita 0110948, Japan.	takahashi_masato@akikumihsp.com					Campagnolo P, 2010, CIRCULATION, V121, P1735, DOI 10.1161/CIRCULATIONAHA.109.899252; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5; Grundmann S, 2005, AM J PHYSIOL-HEART C, V289, pH1497, DOI 10.1152/ajpheart.00959.2004; Majesky MW, 2011, ARTERIOSCL THROM VAS, V31, P1530, DOI 10.1161/ATVBAHA.110.221549; [Anonymous], 2010, ARTERIOSCLER THROMB, V30, P1094; Hamamdzic D, 2010, AM J PHYSIOL-HEART C, V299, pH699, DOI 10.1152/ajpheart.00071.2010; Naito H, 2012, EMBO J, V31, P842, DOI 10.1038/emboj.2011.465; Passman JN, 2008, P NATL ACAD SCI USA, V105, P9349, DOI 10.1073/pnas.0711382105; REIDY MA, 1990, ARTERIOSCLEROSIS, V10, P298; Masuda H, 1999, ARTERIOSCL THROM VAS, V19, P2298; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Charruyer A, 2009, J INVEST DERMATOL, V129, P2574, DOI 10.1038/jid.2009.127; Hirschi KK, 2010, ARTERIOSCL THROM VAS, V30, P1078, DOI 10.1161/ATVBAHA.110.208041; Abedin M, 2004, CIRC RES, V95, P671, DOI 10.1161/01.RES.0000143421.27684.12; Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e; DAEMEN MJAP, 1991, CIRC RES, V68, P450; Ingram DA, 2005, BLOOD, V105, P2783, DOI 10.1182/blood-2004-08-3057; SCHWARTZ SM, 1977, CIRC RES, V41, P248; Op den Buijs J, 2004, AM J PHYSIOL-HEART C, V287, pH2651, DOI 10.1152/ajpheart.00332.2004; Chen YL, 1997, ATHEROSCLEROSIS, V133, P7, DOI 10.1016/S0021-9150(97)06111-X; MASUDA H, 1989, ARTERIOSCLEROSIS, V9, P812; Nakagawa T, 2010, SCIENCE, V328, P62, DOI 10.1126/science.1182868; Tanaka R, 2011, J HISTOCHEM CYTOCHEM, V59, P791, DOI 10.1369/0022155411411090; LOMBARDI DM, 1991, AM J PATHOL, V138, P441; SCHWARTZ SM, 1976, P NATL ACAD SCI USA, V73, P651, DOI 10.1073/pnas.73.2.651; WRIGHT HP, 1972, ATHEROSCLEROSIS, V15, P93; Diaz-Flores L, 2006, HISTOL HISTOPATHOL, V21, P995; Dajnowiec D, 2007, HYPERTENSION, V50, P255, DOI 10.1161/HYPERTENSIONAHA.107.089730; Caplan EA, 1973, ATHEROSCLEROSIS, V17; Klein D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020540; Li S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078564; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Rasband W.S., 1997, IMAGEJ; van den Esschert JW, 2011, SURGERY, V149, P378, DOI 10.1016/j.surg.2010.07.045	35	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					585	594		10.1111/pin.12348		10	Pathology	Pathology	CU3WF	WOS:000363456000003		
J	Yoshimoto, T; Matsubara, D; Nakano, T; Tamura, T; Endo, S; Sugiyama, Y; Niki, T				Yoshimoto, Taichiro; Matsubara, Daisuke; Nakano, Tomoyuki; Tamura, Tomoko; Endo, Shunsuke; Sugiyama, Yukihiko; Niki, Toshiro			Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung	PATHOLOGY INTERNATIONAL			English	Article						immunohistochemistry; lung cancer; SWI; SNF complex	INACTIVATING MUTATIONS; CANCER; ARID1A; ADENOCARCINOMA; PROGNOSIS; SURVIVAL; BRG1/BRM; THERAPY; TUMORS; LINES	The switch/sucrose non-fermenting (SWI/SNF) complex has recently emerged as a novel tumor suppressor in various human cancers. In the present study, we analyzed the expression of multiple SWI/SNF subunits in primary non-small cell lung cancer (NSCLC). A total of 133 NSCLC, consisting of 25 squamous cell carcinomas (SCC), 70 adenocarcinomas (AD), 16 large cell carcinomas (LC), and 22 pleomorphic carcinomas (PL), were immunohistochemically examined for the expression of BRG1, BRM, BAF47, ARID1A, and ARID1B. The frequency at which reductions in the expression of BRG1 were observed was significantly higher in the LC-PL group (13/38, 34.2%) than in the SCC-AD group (7/95, 7.4%). Similarly, the frequency at which reductions in the expression of BRM were observed was significantly higher in the LC-PL group (17/38, 44.7%) than in the SCC-AD group (14/95, 14.7%). The loss of the expression of ARID1A, ARID1B, and BAF47 was observed only in a fraction of NSCLC cases. Furthermore, the frequency at which the concurrent loss of multiple subunits of the SWI/SNF complex was observed was significantly higher in the LC-PL group (10/38, 26.3%) than in the SCC-AD group (8/95, 8.4%). Collectively, these results indicate that the loss of the SWI/SNF complex was related to dedifferentiation in NSCLC.	[Yoshimoto, Taichiro; Matsubara, Daisuke; Tamura, Tomoko; Niki, Toshiro] Jichi Med Univ, Dept Integrat Pathol, Shimotsuke, Tochigi 3290498, Japan; [Nakano, Tomoyuki; Endo, Shunsuke] Jichi Med Univ, Div Gen Thorac Surg, Shimotsuke, Tochigi 3290498, Japan; [Sugiyama, Yukihiko] Jichi Med Univ, Div Pulm Med, Shimotsuke, Tochigi 3290498, Japan; [Matsubara, Daisuke] Univ Tokyo, Inst Med Sci, Mol Pathol Lab, Tokyo, Japan	Niki, T (reprint author), Jichi Med Univ, Dept Integrat Pathol, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	tniki@jichi.ac.jp			JSPS KAKENHI [25860275, 25460432, 26293080]; Grants for Research on Human Genome Tailor from the Ministry of Health, Labor, and Welfare of Japan; Smoking Research Foundation; Foundation for the Development of the Community	This study was supported in part by JSPS KAKENHI Grant Number 25860275, JSPS KAKENHI Grant Number 25460432, JSPS KAKENHI Grant Number 26293080, Grants for Research on Human Genome Tailor-made from the Ministry of Health, Labor, and Welfare of Japan, the Smoking Research Foundation, and the Foundation for the Development of the Community.	Reisman DN, 2003, CANCER RES, V63, P560; Schoeps A, 2014, GENET EPIDEMIOL, V38, P84, DOI 10.1002/gepi.21771; Yang Ping, 2009, V471, P469, DOI 10.1007/978-1-59745-416-2_24; Tsuta K, 2006, J PATHOL, V209, P78, DOI 10.1002/path.1947; Cajuso T, 2014, INT J CANCER, V135, P611, DOI 10.1002/ijc.28705; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Helming KC, 2014, CANCER CELL, V26, P309, DOI 10.1016/j.ccr.2014.07.018; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Oike T, 2014, CANCER RES, V74, P4948, DOI 10.1158/0008-5472.CAN-14-0674; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911; Ahuja N, 2014, J CLIN INVEST, V124, P56, DOI 10.1172/JCI69736; Nissenblatt M, 2011, NEW ENGL J MED, V364, P482, DOI 10.1056/NEJMc1012780#SA1; Matsubara D, 2013, CANCER SCI, V104, P266, DOI 10.1111/cas.12065; Wu JN, 2013, CANCER DISCOV, V3, P35, DOI 10.1158/2159-8290.CD-12-0361; Katagiri A, 2012, MODERN PATHOL, V25, P282, DOI 10.1038/modpathol.2011.161; Biegel JA, 2014, AM J MED GENET C, V166, P350, DOI 10.1002/ajmg.c.31410; Giulio R, 2004, AM J CLIN PATHOL, V122, P884; Li L, 2014, HUM PATHOL, V45, P2247, DOI 10.1016/j.humpath.2014.06.027; Margol AS, 2014, CANCER GENET-NY, V207, P358, DOI 10.1016/j.cancergen.2014.07.004; Miyahara S, 2015, LUNG CANCER, V87, P39, DOI 10.1016/j.lungcan.2014.11.007; Oike T, 2013, JPN J CLIN ONCOL, V43, P849, DOI 10.1093/jjco/hyt101; Rao Q, 2014, HISTOPATHOLOGY, V67, P121; Travis W, 2015, WHO CLASSIFICATION T; Valentina M, 2009, MODERN PATHOL, V22, P709	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					595	602		10.1111/pin.12350		8	Pathology	Pathology	CU3WF	WOS:000363456000004		
J	Matsuda, K; Yamaryo, T; Akazawa, Y; Kawakami, K; Nakashima, M				Matsuda, Katsuya; Yamaryo, Takeshi; Akazawa, Yuko; Kawakami, Kenji; Nakashima, Masahiro			Primary pleural angiosarcoma associated with pneumoconiosis: An autopsy case	PATHOLOGY INTERNATIONAL			English	Article						autopsy; pleural angiosarcoma; pneumoconiosis	EPITHELIOID ANGIOSARCOMA; LUNG	We report a case of pleural angiosarcoma in an adult male patient confirmed by autopsy and possibly associated with pneumoconiosis. The lesion was characterized by thickened pleura of both lungs with nodular tumors. Histologically, the tumor was composed of spindle-to-polygonal epithelioid cells that were positive for CD31, CD34, vimentin, and cytokeratin on immunohistochemical staining but were negative for calretinin. Further examination revealed mix-dust pathological findings consistent with the existence of pneumoconiosis; dystrophic ossification, anthracosis, and fractal small dust particles were observed in the lung parenchyma and a hilar lymph node. The current case suggests that pneumoconiosis-associated pathologies may be risk factors for the development of angiosarcoma in the pleura.	[Matsuda, Katsuya; Akazawa, Yuko; Nakashima, Masahiro] Atom Bomb Dis Inst, Dept Tumor & Diagnost Pathol, Nagasaki, Japan; [Akazawa, Yuko] Nagasaki Univ Hosp, Dept Gastroenterol & Hepatol, Nagasaki, Japan; [Yamaryo, Takeshi; Kawakami, Kenji] Natl Hosp Org, Surg, Nagasaki Kawatana Med Ctr, Nagasaki, Japan	Akazawa, Y (reprint author), Nagasaki Univ, Dept Tumor & Diagnost Pathol, Atom Bomb Dis Inst, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	akazaway@nagasaki-u.ac.jp					Abu-Zaid A, 2013, CASE REP PULMONOL, V2013; Alexiou C, 1998, EUR J CARDIO-THORAC, V14, P523, DOI 10.1016/S1010-7940(98)00211-5; Honma K, 2004, HUM PATHOL, V35, P1515, DOI 10.1016/j.humpath.2004.09.008; NAKA N, 1995, CANCER, V75, P989, DOI 10.1002/1097-0142(19950215)75:4<989::AID-CNCR2820750414>3.0.CO;2-K; Kotromanovic Z, 2012, COLLEGIUM ANTROPOL, V36, P185; Falconieri G, 1997, HISTOPATHOLOGY, V30, P419, DOI 10.1046/j.1365-2559.1997.5370782.x; Knaapen AM, 2004, INT J CANCER, V109, P799, DOI 10.1002/ijc.11708; Dainese E, 2010, PATHOL RES PRACT, V206, P415, DOI 10.1016/j.prp.2009.11.008; Zhang PJ, 2000, HUM PATHOL, V31, P29, DOI 10.1016/S0046-8177(00)80194-X; Young RJ, 2010, LANCET ONCOL, V11, P983, DOI 10.1016/S1470-2045(10)70023-1; Olawaiye AB, 2008, ARCH GYNECOL OBSTET, V278, P401, DOI 10.1007/s00404-008-0727-z; PATEL AM, 1993, CHEST, V103, P1531, DOI 10.1378/chest.103.5.1531; Al-Shraim M, 2005, J CLIN PATHOL, V58, P107, DOI 10.1136/jcp.2004.018937; Roh MS, 2001, J KOREAN MED SCI, V16, P792; Kimura M, 2003, PATHOL INT, V53, P547, DOI 10.1046/j.1440-1827.2003.01510.x; Goh Seng Geok Nicholas, 2003, Arch Pathol Lab Med, V127, pE70; Kurtz Jean-Emmanuel, 2004, Sarcoma, V8, P103, DOI 10.1080/1357-7140400003596; Stout A P, 1943, Ann Surg, V118, P445, DOI 10.1097/00000658-194309000-00014	18	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					603	607		10.1111/pin.12347		5	Pathology	Pathology	CU3WF	WOS:000363456000005		
J	Oyama, T; Okamoto, K; Nakamura, R; Tajiri, R; Ikeda, H; Ninomiya, I; Ooi, A				Oyama, Takeru; Okamoto, Koichi; Nakamura, Ritsuko; Tajiri, Ryosuke; Ikeda, Hiroko; Ninomiya, Itasu; Ooi, Akishi			Overexpression and gene amplification of both ERBB2 and EGFR in an esophageal squamous cell carcinoma revealed by fluorescence in situ hybridization, multiplex ligation-dependent probe amplification and immunohistochemistry	PATHOLOGY INTERNATIONAL			English	Article						CCND1; EGFR; ERBB2; esophageal cancer; FISH; gene amplification; MLPA	GROWTH-FACTOR RECEPTOR; PROTEIN OVEREXPRESSION; CYCLIN D1; CANCER; COAMPLIFICATION; ADENOCARCINOMA; MYC	EGFR and ERBB2 belong to the EGFR gene family. In esophageal squamous cell carcinomas (SCCs), amplification of EGFR or ERBB2 is usually mutually exclusive. EGFR amplification occurs in approximately 15% of SCCs, ERBB2 occurs in less than 5%. Here, we report the co-amplification of EGFR and ERBB2 in an ulcerative and infiltrating-type SCC that measured approximately 4.2 x 2.7 x 1.2cm with a superficial lesion occurring in the thoracic esophagus of a 72-year-old man. Multiplex ligation-dependent probe amplification using representative tumor sections showed gain of CCND1 and coincident amplification of ERBB2 or EGFR or neither. Immunohistochemistry and fluorescence in situ hybridization revealed that the tumor comprised three cancer-cell populations: well-differentiated SCC with high-level ERBB2 amplification and ERBB2 overexpression, more infiltrative poorly-differentiated SCC with high-level EGFR amplification and EGFR overexpression, and poorly-differentiated SCC lacking any ERBB2 or EGFR abnormality. These three populations each had low-level CCND1 amplification and nuclear cyclin D1 overexpression. This histological topology and gene amplification combinations suggested that genetic instability first produced CCND1 amplification, and then ERBB2 or EGFR gene amplification occurred. It is further speculated that during cancer progression and clonal selection indecisive predominance of either clone caused the rare co-amplification of ERBB2 and EGFR in a single chimeric tumor.	[Oyama, Takeru; Nakamura, Ritsuko; Tajiri, Ryosuke; Ooi, Akishi] Kanazawa Univ, Univ Hosp, Dept Mol & Cellular Pathol, Ishikawa 9208641, Japan; [Okamoto, Koichi; Ninomiya, Itasu] Kanazawa Univ, Univ Hosp, Dept Gastroenterol Surg, Grad Sch Med Sci, Ishikawa 9208641, Japan; [Ikeda, Hiroko; Ooi, Akishi] Kanazawa Univ, Univ Hosp, Pathol Sect, Ishikawa 9208641, Japan	Ooi, A (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Mol & Cellular Pathol, Ishikawa 9208641, Japan.	aooi@med.kanazawa-u.ac.jp			Japanese Ministry of Education, Sports, Science and Culture [C25460452, 25860266, 26860235]	This work was financially supported by the Japanese Ministry of Education, Sports, Science and Culture (C25460452 (AO), and Young Scientists (B) (25860266) (TO) and (26860235) (RN)).	Tajiri R, 2014, HUM PATHOL, V45, P725, DOI 10.1016/j.humpath.2013.11.004; Kobayashi M, 2002, HUM PATHOL, V33, P21, DOI 10.1053/hupa.2002.30185; Ooi A, 2015, MODERN PATHOL, V28, P861, DOI 10.1038/modpathol.2015.33; Ooi A, 2009, ANTICANCER RES, V29, P19; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Kono K, 2012, ANN THORAC CARDIOVAS, V18, P506, DOI 10.5761/atcs.ra.12.01995; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Mitsui F, 2007, MODERN PATHOL, V20, P622, DOI 10.1038/modpathol.3800777; Sunpaweravong P, 2005, J CANCER RES CLIN, V131, P111, DOI 10.1007/s00432-004-0610-7; Dragnev KH, 2011, CANCER PREV RES, V4, P818, DOI 10.1158/1940-6207.CAPR-10-0376; Ooi A, 2012, J PATHOL, V227, P8, DOI 10.1002/path.3974; Reichelt U, 2007, MODERN PATHOL, V20, P120, DOI 10.1038/modpathol.3800712; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Kalish LH, 2004, CLIN CANCER RES, V10, P7764, DOI 10.1158/1078-0432.CCR-04-0012; Zhang YW, 2013, WORLD J GASTROENTERO, V19, P5598, DOI 10.3748/wjg.v19.i34.5598; Moelans CB, 2009, CELL ONCOL, V31, P1, DOI 10.3233/CLO-2009-0461; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Flemming ID, 1997, CANC STAGING MANUAL, P65; Ying JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039797	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					608	613		10.1111/pin.12344		6	Pathology	Pathology	CU3WF	WOS:000363456000006		
J	Taniguchi, J; Kaidoh, T; Okazaki, K; Nakane, H; Naguro, T; Mukuda, T; Koyama, Y; Kameie, T; Inaga, S				Taniguchi, Jumpei; Kaidoh, Toshiyuki; Okazaki, Kenji; Nakane, Hironobu; Naguro, Tomonori; Mukuda, Takao; Koyama, Yuka; Kameie, Toshio; Inaga, Sumire			Thoracic insufficiency syndrome in an elderly patient: An autopsy case	PATHOLOGY INTERNATIONAL			English	Letter							SCOLIOSIS		[Taniguchi, Jumpei; Kaidoh, Toshiyuki; Okazaki, Kenji; Nakane, Hironobu; Naguro, Tomonori; Mukuda, Takao; Koyama, Yuka; Kameie, Toshio; Inaga, Sumire] Tottori Univ, Fac Med, Dept Anat, Yonago, Tottori 683, Japan	Taniguchi, J (reprint author), Tottori Univ, Fac Med, Dept Anat, Yonago, Tottori 683, Japan.						Campbell RM, 2007, J BONE JOINT SURG AM, V89A, P108, DOI 10.2106/JBJS.F.00270; Aoyama H, 2005, INT J DEV BIOL, V49, P325, DOI 10.1387/ijdb.041932ha; Campbell RM, 2003, J BONE JOINT SURG AM, V85A, P399; Mayer OH, 2009, CURR OPIN PEDIATR, V21, P333, DOI 10.1097/MOP.0b013e328329a500; Sawabe M, 2006, PATHOL INT, V56, P315, DOI 10.1111/j.1440-1827.2006.01966.x; Vitale MG, 2008, J PEDIATR ORTHOPED, V28, P239, DOI 10.1097/BPO.0b013e31816521bb; Campbell RM, 2013, EUR SPINE J, V22, pS106, DOI 10.1007/s00586-013-2671-2; DiMeglio A, 1990, RACHIS ENCROISSANCE; Murray JF, 1986, NORMAL LUNG BASIS DI, P46	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					614	616		10.1111/pin.12311		3	Pathology	Pathology	CU3WF	WOS:000363456000007		
J	Fujino, A; Hao, H; Kawakami, R; Fujii, K; Imanaka, T; Ishihara, M; Tsuchida, Y; Hirota, S				Fujino, Akiko; Hao, Hiroyuki; Kawakami, Rika; Fujii, Kenichi; Imanaka, Takahiro; Ishihara, Masaharu; Tsuchida, Yasu-aki; Hirota, Seiichi			Is optical frequency domain imaging a promising modality for diagnosis of erosion?	PATHOLOGY INTERNATIONAL			English	Letter							COHERENCE TOMOGRAPHY; PLAQUE EROSION		[Fujino, Akiko; Hao, Hiroyuki; Kawakami, Rika; Tsuchida, Yasu-aki; Hirota, Seiichi] Hyogo Coll Med, Dept Surg Pathol, Nishinomiya, Hyogo 6638501, Japan; [Fujii, Kenichi; Imanaka, Takahiro; Ishihara, Masaharu] Hyogo Coll Med, Div Coronary Heart Dis, Dept Internal Med, Nishinomiya, Hyogo 6638501, Japan	Fujino, A (reprint author), Hyogo Coll Med, Dept Surg Pathol, Nishinomiya, Hyogo 6638501, Japan.						Jia HB, 2013, J AM COLL CARDIOL, V62, P1748, DOI 10.1016/j.jacc.2013.05.071; Alfonso F, 2014, J AM COLL CARDIOL, V63, P1458, DOI 10.1016/j.jacc.2013.08.1653; Kubo T, 2007, J AM COLL CARDIOL, V50, P933, DOI 10.1016/j.jacc.2007.04.082; Virmani R, 2000, ARTERIOSCL THROM VAS, V20, P1262	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					617	618		10.1111/pin.12310		2	Pathology	Pathology	CU3WF	WOS:000363456000008		
J	Kajimoto, N; Hao, H; Kawakami, R; Takagi, Y; Fujino, A; Sugahara, M; Masuyama, T; Hirota, S				Kajimoto, Noriko; Hao, Hiroyuki; Kawakami, Rika; Takagi, Yaemi; Fujino, Akiko; Sugahara, Masataka; Masuyama, Tohru; Hirota, Seiichi			Cardiac sarcoidosis predominantly involved in right ventricle: An autopsy case	PATHOLOGY INTERNATIONAL			English	Letter							DYSPLASIA; FEATURES		[Kajimoto, Noriko; Hao, Hiroyuki; Kawakami, Rika; Takagi, Yaemi; Fujino, Akiko; Hirota, Seiichi] Hyogo Coll Med, Dept Surg Pathol, Nishinomiya, Hyogo 6638501, Japan; [Sugahara, Masataka; Masuyama, Tohru] Hyogo Coll Med, Div Cardiol, Dept Internal Med, Nishinomiya, Hyogo 6638501, Japan	Kajimoto, N (reprint author), Hyogo Coll Med, Dept Surg Pathol, Nishinomiya, Hyogo 6638501, Japan.						Noda T, 2004, PACE, V27, P561, DOI 10.1111/j.1540-8159.2004.00485.x; Ott P, 2003, PACE, V26, P1498, DOI 10.1046/j.1460-9592.2003.t01-1-00217.x; Tavora F, 2009, AM J CARDIOL, V104, P571, DOI 10.1016/j.amjcard.2009.03.068; Vasaiwala SC, 2009, J CARDIOVASC ELECTR, V20, P473, DOI 10.1111/j.1540-8167.2008.01351.x; Philips B, 2014, CIRC-ARRHYTHMIA ELEC, V7, P230, DOI 10.1161/CIRCEP.113.000932; Shiraishi J, 2003, CIRC J, V67, P169, DOI 10.1253/circj.67.169; Lagana SM, 2010, ARCH PATHOL LAB MED, V134, P1039, DOI 10.1043/2009-0274-RA.1; Isobe M, 2014, INT J CARDIOL C, V182C, P132; IWAI K, 1993, ACTA PATHOL JAPON, V43, P372	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	NOV	2015	65	11					619	621		10.1111/pin.12313		3	Pathology	Pathology	CU3WF	WOS:000363456000009		
J	Baba, H; Takahara, J; Yamashita, F; Hashida, M				Baba, Hiromi; Takahara, Jun-ichi; Yamashita, Fumiyoshi; Hashida, Mitsuru			Modeling and Prediction of Solvent Effect on Human Skin Permeability using Support Vector Regression and Random Forest	PHARMACEUTICAL RESEARCH			English	Article						in silico prediction; quantitative structure-property relationship; skin permeability; solvent effect; support vector regression	STRUCTURE-PERMEATION RELATIONSHIPS; DIFFERENT VALIDATION CRITERIA; REAL EXTERNAL PREDICTIVITY; COMPLEX CHEMICAL-MIXTURES; LEAST-SQUARES REGRESSION; IN-VITRO DATA; PERCUTANEOUS-ABSORPTION; TRANSDERMAL DELIVERY; CROSS-VALIDATION; DRUG-DELIVERY	The solvent effect on skin permeability is important for assessing the effectiveness and toxicological risk of new dermatological formulations in pharmaceuticals and cosmetics development. The solvent effect occurs by diverse mechanisms, which could be elucidated by efficient and reliable prediction models. However, such prediction models have been hampered by the small variety of permeants and mixture components archived in databases and by low predictive performance. Here, we propose a solution to both problems. We first compiled a novel large database of 412 samples from 261 structurally diverse permeants and 31 solvents reported in the literature. The data were carefully screened to ensure their collection under consistent experimental conditions. To construct a high-performance predictive model, we then applied support vector regression (SVR) and random forest (RF) with greedy stepwise descriptor selection to our database. The models were internally and externally validated. The SVR achieved higher performance statistics than RF. The (externally validated) determination coefficient, root mean square error, and mean absolute error of SVR were 0.899, 0.351, and 0.268, respectively. Moreover, because all descriptors are fully computational, our method can predict as-yet unsynthesized compounds. Our high-performance prediction model offers an attractive alternative to permeability experiments for pharmaceutical and cosmetic candidate screening and optimizing skin-permeable topical formulations.	[Baba, Hiromi; Takahara, Jun-ichi; Yamashita, Fumiyoshi; Hashida, Mitsuru] Maruho Co Ltd, Kyoto R&D Ctr, Shimogyo Ku, Kyoto 6008815, Japan	Baba, H (reprint author), Maruho Co Ltd, Kyoto R&D Ctr, Shimogyo Ku, 93 Awata Cho, Kyoto 6008815, Japan.	baba_dfq@mii.maruho.co.jp					Neely BJ, 2009, J PHARM SCI-US, V98, P4069, DOI 10.1002/jps.21678; GOLDBERGCETTINA M, 1995, INT J PHARM, V114, P237, DOI 10.1016/0378-5173(94)00253-2; SATHYAN G, 1995, INT J PHARM, V114, P75, DOI 10.1016/0378-5173(94)00214-P; Smola AJ, 2004, STAT COMPUT, V14, P199, DOI 10.1023/B:STCO.0000035301.49549.88; Ghafourian T, 2010, INT J PHARMACEUT, V398, P28, DOI 10.1016/j.ijpharm.2010.07.014; El-Sebakhy EA, 2009, J PETROL SCI ENG, V64, P25, DOI 10.1016/j.petrol.2008.12.006; VERHAAR HJM, 1992, CHEMOSPHERE, V25, P471, DOI 10.1016/0045-6535(92)90280-5; Lim CW, 2002, BIOL PHARM BULL, V25, P361, DOI 10.1248/bpb.25.361; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Barry BW, 2004, NAT BIOTECHNOL, V22, P165, DOI 10.1038/nbt0204-165; MICHAELS AS, 1975, AICHE J, V21, P985, DOI 10.1002/aic.690210522; Monte-Moreno E, 2011, ARTIF INTELL MED, V53, P127, DOI 10.1016/j.artmed.2011.05.001; Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304; Geinoz S, 2004, PHARM RES, V21, P83, DOI 10.1023/B:PHAM.0000012155.27488.2b; Chirico N, 2011, J CHEM INF MODEL, V51, P2320, DOI 10.1021/ci200211n; Karadzovska D, 2013, EUR J PHARM SCI, V50, P569, DOI 10.1016/j.ejps.2013.02.020; ROY SD, 1995, J PHARM SCI, V84, P1190, DOI 10.1002/jps.2600841010; Buchwald P, 2001, J PHARM PHARMACOL, V53, P1087, DOI 10.1211/0022357011776478; Watkinson RM, 2009, SKIN PHARMACOL PHYS, V22, P225, DOI 10.1159/000231528; Cronin MTD, 1999, EUR J PHARM SCI, V7, P325, DOI 10.1016/S0928-0987(98)00041-4; Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155; Abraham MH, 2004, J PHARM SCI-US, V93, P1508, DOI 10.1002/jps.20070; Shahlaei M, 2013, CHEM REV, V113, P8093, DOI 10.1021/cr3004339; Yap CW, 2006, J MOL GRAPH MODEL, V24, P383, DOI 10.1016/j.jmgm.2005.10.004; Zhang Q, 2009, PHARM RES-DORD, V26, P1974, DOI 10.1007/s11095-009-9912-4; Stewart JJP, 2013, J MOL MODEL, V19, P1, DOI 10.1007/s00894-012-1667-x; Riviere JE, 2011, TOXICOL SCI, V119, P224, DOI 10.1093/toxsci/kfq317; PARDO A, 1990, J PHARM SCI, V79, P573, DOI 10.1002/jps.2600790705; Roy K, 2012, J CHEM INF MODEL, V52, P396, DOI 10.1021/ci200520g; Ghafourian T, 2010, EUR J PHARM SCI, V41, P612, DOI 10.1016/j.ejps.2010.08.014; BURMAN P, 1989, BIOMETRIKA, V76, P503, DOI 10.1093/biomet/76.3.503; YANO T, 1986, LIFE SCI, V39, P1043, DOI 10.1016/0024-3205(86)90195-5; Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g; SHAO J, 1993, J AM STAT ASSOC, V88, P486, DOI 10.2307/2290328; POTTS RO, 1992, PHARMACEUT RES, V9, P663, DOI 10.1023/A:1015810312465; Chirico N, 2012, J CHEM INF MODEL, V52, P2044, DOI 10.1021/ci300084j; Riviere JE, 2007, SAR QSAR ENVIRON RES, V18, P31, DOI 10.1080/10629360601033598; FRANZ TJ, 1975, J INVEST DERMATOL, V64, P190, DOI 10.1111/1523-1747.ep12533356; Consonni V, 2009, J CHEM INF MODEL, V49, P1669, DOI 10.1021/ci900115y; BLANK IH, 1985, J INVEST DERMATOL, V85, P522, DOI 10.1111/1523-1747.ep12277325; Chauhan P, 2010, SAR QSAR ENVIRON RES, V21, P481, DOI 10.1080/1062936X.2010.501819; Neumann D, 2006, J CHEM INF MODEL, V46, P424, DOI 10.1021/ci050332t; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; Moss GP, 2009, J PHARM PHARMACOL, V61, P1147, DOI 10.1211/jpp/61.09.0003; Roy PP, 2008, QSAR COMB SCI, V27, P302, DOI 10.1002/qsar.200710043; Golbraikh A, 2002, J MOL GRAPH MODEL, V20, P269, DOI 10.1016/S1093-3263(01)00123-1; Khajeh A, 2014, SAR QSAR ENVIRON RES, V25, P35, DOI 10.1080/1062936X.2013.826275; Takeuchi H, 2012, BIOL PHARM BULL, V35, P192; BARTEK MJ, 1972, J INVEST DERMATOL, V58, P114, DOI 10.1111/1523-1747.ep12538909; Katritzky AR, 2006, J MED CHEM, V49, P3305, DOI 10.1021/jm051031d; Ojha PK, 2011, CHEMOMETR INTELL LAB, V107, P194, DOI 10.1016/j.chemolab.2011.03.011; Baert B, 2007, BIOORGAN MED CHEM, V15, P6943, DOI 10.1016/j.bmc.2007.07.050; Baba H, 2015, PHARM RES-DORDR, V32, P2360, DOI 10.1007/s11095-015-1629-y; Bharathidason S, 2014, INT J COMPUT APPL, V101, P26; Boonen J, 2014, J PHARM ANA, V4, P303, DOI DOI 10.1016/j.jpha.2013.12.006; BURKERT U, 1982, ACS MONOGRAPH, V177; Fornberg B, 1994, ACTA NUMER, V3, P203, DOI 10.1017/S0962492900002440; Funar-Timofei S, 2014, STRUCT CHEM, V25, P1847, DOI 10.1007/s11224-014-0474-7; Inselberg A., 2009, PARALLEL COORDINATES; KASTING G B, 1987, P138; Lane ME, 2013, INT J PHARMACEUT, V447, P12, DOI 10.1016/j.ijpharm.2013.02.040; Law V, 2014, NUCLEIC ACIDS RES, V42, pD1091, DOI 10.1093/nar/gkt1068; Liaw A, 2002, R NEWS, V2, P18, DOI DOI 10.1016/J.MEMSCI.2010.02.036; Meyer D., 2014, E1071 MISC FUNCTIONS; Patel Jigneshkumar, 2013, Curr Drug Discov Technol, V10, P2; Smith EW, 2005, PERCUTANEOUS PENETRA; ZHANG P, 1993, ANN STAT, V21, P299, DOI 10.1214/aos/1176349027	67	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741	1573-904X		PHARM RES-DORDR	Pharm. Res.	NOV	2015	32	11					3604	3617		10.1007/s11095-015-1720-4		14	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	CT3EB	WOS:000362688900014		
J	Kato, T; Yui, M; Deo, VK; Park, EY				Kato, Tatsuya; Yui, Megumi; Deo, Vipin Kumar; Park, Enoch Y.			Development of Rous sarcoma Virus-like Particles Displaying hCC49 scFv for Specific Targeted Drug Delivery to Human Colon Carcinoma Cells	PHARMACEUTICAL RESEARCH			English	Article						drug delivery; colon carcinoma; Rous sarcoma virus-like particles; silkworm; doxorubicin	HVJ ENVELOPE VECTOR; RECEPTOR-BINDING; MAMMALIAN-CELLS; SILKWORM LARVAE; CANCER-THERAPY; STRATEGIES; PROTEINS; VACCINES; RELEASE; FUSION	Virus-like particles (VLPs) have been used as drug carriers for drug delivery systems. In this study, hCC49 single chain fragment variable (scFv)-displaying Rous sarcoma virus-like particles (RSV VLPs) were produced in silkworm larvae to be a specific carrier of an anti-cancer drug. RSV VLPs displaying hCC49 scFv were created by the fusion of the transmembrane and cytoplasmic domains of hemagglutinin from influenza A (H1N1) virus and produced in silkworm larvae. The display of hCC49 scFv on the surface of RSV VLPs was confirmed by enzyme-linked immunosorbent assay using tumor-associated glycoprotein-72 (TAG-72), fluorescent microscopy, and immunoelectron microscopy. Fluorescein isothiocyanate (FITC) or doxorubicin (DOX) was incorporated into hCC49 scFv-displaying RSV VLPs by electroporation and specific targeting of these VLPs was investigated by fluorescent microscopy and cytotoxicity assay using LS174T cells. FITC was delivered to LS174T human colon adenocarcinoma cells by hCC49 scFv-displaying RSV VLPs, but not by RSV VLPs. This indicated that hCC49 scFv allowed FITC-loaded RSV VLPs to be delivered to LS174T cells. DOX, which is an anti-cancer drug with intrinsic red fluorescence, was also loaded into hCC49 scFv-displaying RSV VLPs by electroporation; the DOX-loaded hCC49 scFv-displaying RSV VLPs killed LS174T cells via the specific delivery of DOX that was mediated by hCC49 scFv. HEK293 cells were alive even though in the presence of DOX-loaded hCC49 scFv-displaying RSV VLPs. These results showed that hCC49 scFv-displaying RSV VLPs from silkworm larvae offered specific drug delivery to colon carcinoma cells in vitro. This scFv-displaying enveloped VLP system could be applied to drug and gene delivery to other target cells.	[Kato, Tatsuya; Yui, Megumi; Park, Enoch Y.] Shizuoka Univ, Fac Agr, Dept Appl Biol Chem, Biotechnol Lab, Shizuoka 4228529, Japan; [Kato, Tatsuya; Deo, Vipin Kumar; Park, Enoch Y.] Shizuoka Univ, Grad Sch Sci & Technol, Shizuoka 4228529, Japan; [Kato, Tatsuya; Park, Enoch Y.] Shizuoka Univ, Res Inst Green Sci & Technol, Suruga Ku, Shizuoka 4228529, Japan	Park, EY (reprint author), Shizuoka Univ, Fac Agr, Dept Appl Biol Chem, Biotechnol Lab, 836 Ohya, Shizuoka 4228529, Japan.	park.enoch@shizuoka.ac.jp	Kato, Tatsuya/E-3095-2010		Promotion of Nanobio-Technology Research to Support Aging and Welfare Society from the Ministry of Education, Culture, Sports, Science and Technology, Japan;  [22248009]	We thank Professor Hiroshi Ueda (Tokyo Institute of Technology, Japan) for the contribution of the plasmid carrying scFv cDNA. This work was supported by Grant-in-Aid for Scientific Research (A) Grant No. 22248009 and by Promotion of Nanobio-Technology Research to Support Aging and Welfare Society from the Ministry of Education, Culture, Sports, Science and Technology, Japan. No additional external funding was received for this study.	COLCHER D, 1988, CANCER RES, V48, P4597; Smith MT, 2013, CURR OPIN BIOTECH, V24, P620, DOI 10.1016/j.copbio.2013.01.011; Brasch M, 2013, FARADAY DISCUSS, V166, P47, DOI 10.1039/c3fd00088e; Hefferon KL, 1999, VIROLOGY, V258, P455, DOI 10.1006/viro.1999.9758; Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159; THOR A, 1986, CANCER RES, V46, P3118; Kim YS, 2010, MOL THER, V18, P1310, DOI 10.1038/mt.2010.48; Shimbo T, 2007, BIOCHEM BIOPH RES CO, V364, P423, DOI 10.1016/j.bbrc.2007.09.135; Pan YS, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/506363; Deo VK, 2014, PHARM RES-DORDR, V31, P2166, DOI 10.1007/s11095-014-1316-4; Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154; Tsuji Y, 2011, J BIOTECHNOL, V155, P185, DOI 10.1016/j.jbiotec.2011.07.008; Zhao QJ, 2012, NANOMED-NANOTECHNOL, V8, P1182, DOI 10.1016/j.nano.2012.01.007; Motohashi T, 2005, BIOCHEM BIOPH RES CO, V326, P564, DOI 10.1016/j.bbrc.2004.11.060; Tani H, 2001, VIROLOGY, V279, P343, DOI 10.1006/viro.2000.0699; Mima H, 2006, MOL CANCER THER, V5, P1021, DOI 10.1158/1535-7163.MCT-05-0352; Arhel N, 2010, BBA-MOL BASIS DIS, V1802, P313, DOI 10.1016/j.bbadis.2009.12.003; Zhang QX, 2008, BIOCHEM BIOPH RES CO, V373, P345, DOI 10.1016/j.bbrc.2008.06.055; Boyce FM, 1996, P NATL ACAD SCI USA, V93, P2348, DOI 10.1073/pnas.93.6.2348; Deo VK, 2011, J VIROL METHODS, V177, P147, DOI 10.1016/j.jviromet.2011.07.012; Kaneda Y, 2012, ADV DRUG DELIVER REV, V64, P730, DOI 10.1016/j.addr.2011.03.007; Dong SC, 2010, J VIROL, V84, P5351, DOI 10.1128/JVI.02517-09; Niikura K, 2013, MOL BIOSYST, V9, P501, DOI 10.1039/c2mb25420d; Wei HJ, 2011, VACCINE, V29, P7163, DOI 10.1016/j.vaccine.2011.05.077; Fay F, 2011, IMMUNOTHERAPY-UK, V3, P381, DOI [10.2217/imt.11.5, 10.2217/IMT.11.5]; Zeltins A, 2013, MOL BIOTECHNOL, V53, P92, DOI 10.1007/s12033-012-9598-4; Xiang Y, 1997, J VIROL, V71, P2083; Deo VK, 2015, MOL PHARM IN PRESS; Divig CR, 1994, NUCL MED BIOL, V21, P9; Kim Chang Wook, 2013, Clin Mol Hepatol, V19, P17, DOI 10.3350/cmh.2013.19.1.17; Luz-Madrigal A, 2013, J VIROL, V87, P11849; Wu S, 2012, J VIROL, V86, P484	32	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741	1573-904X		PHARM RES-DORDR	Pharm. Res.	NOV	2015	32	11					3699	3707		10.1007/s11095-015-1730-2		9	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	CT3EB	WOS:000362688900021		
J	Kato, Y; Zhu, WL; Backer, MV; Neoh, CC; Hapuarachchige, S; Sarkar, SK; Backer, JM; Artemov, D				Kato, Yoshinori; Zhu, Wenlian; Backer, Marina V.; Neoh, Christopher C.; Hapuarachchige, Sudath; Sarkar, Susanta K.; Backer, Joseph M.; Artemov, Dmitri			Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice	PHARMACEUTICAL RESEARCH			English	Article						liposomes; magnetic resonance imaging (MRI); passive targeting; single-chain vascular endothelial growth factor (scVEGF); superparamagnetic iron oxide nanoparticles (SPIONs)	CANCER-CHEMOTHERAPY; CONTRAST AGENTS; IN-VIVO; ANGIOGENESIS; NANOCARRIERS; BARRIERS; RELEASE	Magnetic resonance imaging (MRI) is widely used for diagnostic imaging in preclinical studies and in clinical settings. Considering the intrinsic low sensitivity and poor specificity of standard MRI contrast agents, the enhanced delivery of MRI tracers into tumors is an important challenge to be addressed. This study was intended to investigate whether delivery of superparamagnetic iron oxide nanoparticles (SPIONs) can be enhanced by liposomal SPION formulations for either "passive" delivery into tumor via the enhanced permeability and retention (EPR) effect or "active" targeted delivery to tumor endothelium via the receptors for vascular endothelial growth factor (VEGFRs). In vivo MRI of orthotopic MDA-MB-231 tumors was performed on a preclinical 9.4 T MRI scanner following intravenous administration of either free/non-targeted or targeted liposomal SPIONs. In vivo MRI study revealed that only the non-targeted liposomal formulation provided a statistically significant accumulation of SPIONs in the tumor at four hours post-injection. The EPR effect contributes to improved accumulation of liposomal SPIONs in tumors compared to the presumably more transient retention during the targeting of the tumor vasculature via VEGFRs. A non-targeted liposomal formulation of SPIONs could be the optimal option for MRI detection of breast tumors and for the development of therapeutic liposomes for MRI-guided therapy.	[Kato, Yoshinori; Zhu, Wenlian; Neoh, Christopher C.; Hapuarachchige, Sudath; Artemov, Dmitri] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Div Canc Imaging Res, Baltimore, MD 21205 USA; [Kato, Yoshinori; Artemov, Dmitri] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21205 USA; [Kato, Yoshinori] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Life Sci Tokyo Adv Res Ctr L StaR, Shinagawa Ku, Tokyo 142, Japan; [Backer, Marina V.; Backer, Joseph M.] SibTech Inc, Brookfield, CT 06804 USA; [Sarkar, Susanta K.] CadenzaMed LLC, Wayne, PA 19087 USA	Artemov, D (reprint author), Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Div Canc Imaging Res, 720 Rutland Ave, Baltimore, MD 21205 USA.	dartemo2@jhmi.edu		Kato, Yoshinori/0000-0002-6218-8710	National Institutes of Health [CA154738]	This study was supported by the National Institutes of Health, CA154738 (DA, JMB, and SKS). We are grateful to Ms. Mary McAllister for editing the manuscript.	Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216; Chauhan VP, 2012, NAT NANOTECHNOL, V7, P383, DOI [10.1038/nnano.2012.45, 10.1038/NNANO.2012.45]; Anderson CR, 2010, INVEST RADIOL, V45, P579, DOI 10.1097/RLI.0b013e3181efd581; CHAMBON C, 1993, MAGN RESON IMAGING, V11, P509, DOI 10.1016/0730-725X(93)90470-X; Kato Y, 2002, J PHARM PHARMACOL, V54, P529, DOI 10.1211/0022357021778646; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; JAIN RK, 1994, SCI AM, V271, P58; Winter PM, 2003, CANCER RES, V63, P5838; Backer MV, 2007, NAT MED, V13, P504, DOI 10.1038/nm1522; Onuki Y, 2010, BIOMATERIALS, V31, P7132, DOI 10.1016/j.biomaterials.2010.06.008; Zanganeh S, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.126014; Moreira JN, 2002, PHARMACEUT RES, V19, P265, DOI 10.1023/A:1014434732752; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Thirumamagal BTS, 2006, BIOCONJUGATE CHEM, V17, P1141, DOI 10.1021/bc060075d; Imoukhuede PI, 2014, CANCER MED-US, V3, P225, DOI 10.1002/cam4.188; DUNCAN R, 1992, J CONTROL RELEASE, V19, P331, DOI 10.1016/0168-3659(92)90088-9; Kato Y, 2009, MAGN RESON MED, V61, P1059, DOI 10.1002/mrm.21939; BAO L, 1994, BRIT J CANCER, V70, P228, DOI 10.1038/bjc.1994.284; JAIN RK, 1990, CANCER METAST REV, V9, P253, DOI 10.1007/BF00046364; Kato Y, 2011, PAN ST SER BIOM NANO, V2, P1	20	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741	1573-904X		PHARM RES-DORDR	Pharm. Res.	NOV	2015	32	11					3746	3755		10.1007/s11095-015-1736-9		10	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	CT3EB	WOS:000362688900025		
J	Del Bino, S; Ito, S; Sok, J; Nakanishi, Y; Bastien, P; Wakamatsu, K; Bernerd, F				Del Bino, Sandra; Ito, Shosuke; Sok, Juliette; Nakanishi, Yukiko; Bastien, Philippe; Wakamatsu, Kazumasa; Bernerd, Francoise			Chemical analysis of constitutive pigmentation of human epidermis reveals constant eumelanin to pheomelanin ratio	PIGMENT CELL & MELANOMA RESEARCH			English	Article						skin constitutive pigmentation; melanin; eumelanin; pheomelanin	METASTASIS SUPPRESSOR GENE; ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; TUMOR ANGIOGENESIS; MELANOMA ANGIOGENESIS; TRANSMEMBRANE-4 SUPERFAMILY; BREAST-CARCINOMA; PROSTATIC-CANCER; FACTOR RECEPTOR; CELL-MIGRATION	The skin constitutive pigmentation is given by the amount of melanin pigment, its relative composition (eu/pheomelanin) and distribution within the epidermis, and is largely responsible for the sensitivity to UV exposure. Nevertheless, a precise knowledge of melanins in human skin is lacking. We characterized the melanin content of human breast skin samples with variable pigmentations rigorously classified through the Individual Typology Angle (ITA) by image analysis, spectrophotometry after solubilization with Soluene-350 and high-performance liquid chromatography (HPLC) after chemical degradation. ITA and total melanin content were found correlated, ITA and PTCA (degradation product of DHICA melanin), and TTCA (degradation product of benzothiazole-type pheomelanin) as well but not 4-AHP (degradation product of benzothiazine-type pheomelanin). Results revealed that human epidermis comprises approximately 74% of eumelanin and 26% pheomelanin, regardless of the degree of pigmentation. They also confirm the low content of photoprotective eumelanin among lighter skins thereby explaining the higher sensitivity toward UV exposure.	[Del Bino, Sandra; Sok, Juliette; Bastien, Philippe; Bernerd, Francoise] LOreal Res & Innovat, Aulnay Sous Bois, France; [Ito, Shosuke; Nakanishi, Yukiko; Wakamatsu, Kazumasa] Fujita Hlth Univ, Sch Hlth Sci, Dept Chem, Toyoake, Aichi, Japan	Del Bino, S (reprint author), LOreal Res & Innovat, Aulnay Sous Bois, France.	sdelbino@rd.loreal.com					American Cancer Society, 2012, J CONSUM HLTH INTERN, V16, P366; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Nakamura K, 2000, J BIOL CHEM, V275, P18284, DOI 10.1074/jbc.M907971199; Odintsova E, 2013, J BIOL CHEM, V288, P26323, DOI 10.1074/jbc.M112.439380; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Tang Y, 2014, CARCINOGENESIS, V35, P86, DOI 10.1093/carcin/bgt346; Marquez-Rodas I, 2011, CLIN TRANSL ONCOL, V13, P787, DOI [1007/s12094-011-0734-6, 10.1007/s12094-011-0734-6]; Hatakeyama M, 2007, HEART VESSELS, V22, P123, DOI 10.1007/s00380-006-0942-0; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340; Tzeng HE, 2013, BIOCHEM PHARMACOL, V85, P531, DOI 10.1016/j.bcp.2012.11.021; Karst AM, 2009, INT J CANCER, V124, P494, DOI 10.1002/ijc.23973; WEIDNER N, 1995, BREAST CANCER RES TR, V36, P169, DOI 10.1007/BF00666038; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; ICHIKAWA T, 1991, CANCER RES, V51, P3788; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Tsao H, 2005, DERMATOL CLIN, V23, P323, DOI 10.1016/j.det.2004.09.005; Wani AA, 2011, ONCOGENE, V30, P2778, DOI 10.1038/onc.2010.644; Cohen T, 1996, J BIOL CHEM, V271, P736; BYERS HR, 1991, AM J PATHOL, V139, P423; Dimmeler S, 2000, CIRC RES, V86, P4; Liu YF, 2012, J INFRARED MILLIM W, V31, P1; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Tang JF, 2014, ANTI-CANCER AGENT ME, V14, P673; Wang J, 2006, CANCER RES, V66, P1906, DOI 10.1158/0008-5472.CAN-05-3444; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Bai D, 2009, INT J CANCER, V125, P2863, DOI 10.1002/ijc.24748; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Mamou F, 2006, ANTICANCER RES, V26, P1753; Mannion BA, 1996, J IMMUNOL, V157, P2039; FOLKMAN J, 1974, CANCER RES, V34, P2109; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Guo C, 2009, HEPATOB PANCREAT DIS, V8, P389; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Balch CM, 2001, J CLIN ONCOL, V19, P3635; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Li J, 2010, CANCER RES, V70, P10445, DOI 10.1158/0008-5472.CAN-10-3040; Liu FS, 2001, AM J PATHOL, V159, P1629, DOI 10.1016/S0002-9440(10)63009-X; Lu J, 2007, MOL CANCER RES, V5, P1342, DOI 10.1158/1541-7786.MCR-07-0115; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Qin L, 2012, ADV CANCER RES, V113, P191, DOI 10.1016/B978-0-12-394280-7.00006-3; ICHIKAWA T, 1992, CANCER RES, V52, P3486; Ono M, 1999, CANCER RES, V59, P2335; Galbaugh T, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-34; Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4	50	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-1471	1755-148X		PIGM CELL MELANOMA R	Pigment Cell Melanoma Res.	NOV	2015	28	6					707	717		10.1111/pcmr.12410		11	Oncology; Cell Biology; Dermatology	Oncology; Cell Biology; Dermatology	CU3DL	WOS:000363404000011		
J	Inaguma, Y				Inaguma, Yoshiharu			Friction of outer rotor affecting friction torque characteristics in an internal gear pump	PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART C-JOURNAL OF MECHANICAL ENGINEERING SCIENCE			English	Article						Fluid power system; hydraulic pump; internal gear pump; outer rotor; friction torque; pressure distribution	HYDRAULIC PUMPS	This article presents the friction torque in an internal gear pump and the friction force between an outer circumference of an outer rotor and a body, which causes a significant loss, has been investigated. When in use at a high pressure, the pump has a large friction torque due to the friction force acting on the outer rotor circumference. This friction force is caused by imbalanced force acting on the outer rotor. As well as by a positioning suction and a delivery port, the force can be reduced by setting a suction pressure recess in a section of the outer rotor circumference. In this study, through the measurement of the friction torque in an actual pump and the pressure distribution on the outer circumference of the outer rotor, it is investigated how the suction pressure recess can change the force acting on the outer rotor. The actual internal gear pump without the suction pressure recess has a large friction torque, and it corresponds to a large force on the outer rotor, which is calculated from the pressure distributions on the inside and outside of the outer rotor. In addition, on the basis of the measured friction torque of the test pump and the force acting on the outer rotor, calculated using the results of the pressure distribution, the coefficient of friction between the outer rotor circumference and the body can be estimated.	JTEKT Corp, Hydraul Syst Engn Dept, Hydraul Pump Engn Off, Aichi 4441323, Japan	Inaguma, Y (reprint author), JTEKT Corp, Hydraul Syst Engn Dept, Hydraul Pump Engn Off, 1-5-3 Tado Cho, Aichi 4441323, Japan.	yoshiharu_inaguma@jtekt.co.jp					Inaguma Y, 2013, P I MECH ENG C-J MEC, V227, P980, DOI 10.1177/0954406212456933; Inaguma Y, 2012, P I MECH ENG C-J MEC, V226, P2267, DOI 10.1177/0954406211430572; Inaguma Y, 2011, P I MECH ENG C-J MEC, V225, P1523, DOI 10.1177/0954406211399659; Englisch A, 2001, P GLOB POW C 2001 AD; Fujiwara H, 2002, Patent application, Patent No. [P2002-48074 A, 200248074]; Furtner H, 1989, OLHYDRAULIK PNEUMATI, V33, P890; Gosele R., 1979, Oelhydraulik und Pneumatik, V23; Hattori M, 2003, P 2003 JASE ANN C 21, P13; Japan Society of Lubrication Engineers, 1980, JUNK LUBR HDB, P681; Kanada T, 1999, 1999010749 SAE; Kaufmann W, 1973, FLUID MECH, P307; Kluger MA, 1996, 960424 SAE; Kluger MA, 1999, 1999011259 SAE; Kunii H, 2002, P 2002 JASE ANN C 23, P1; Manco S, 1989, 982689 SAE; Nishigaya M, 2001, 2001010872 SAE; Oshidari T, 1999, J JPN HYDRAUL PNEUMA, V30, P99; Rosch R, 1995, ATZ, V97, P536	18	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0954-4062	2041-2983		P I MECH ENG C-J MEC	Proc. Inst. Mech. Eng. Part C-J. Eng. Mech. Eng. Sci.	NOV	2015	229	16					3013	3026		10.1177/0954406214565804		14	Engineering, Mechanical	Engineering	CU1WJ	WOS:000363312500013		
J	Liem, PH; Naito, Y				Liem, Peng Hong; Naito, Yoshitaka			TRACY and SILENE Benchmark Phase II evaluation by TRACE code	PROGRESS IN NUCLEAR ENERGY			English	Article						Criticality excursion; TRACY; SILENE; TRACE code; LEO and HEU uranyl nitrate solution		Following the Benchmark Phase I on the criticality excursion organized by the OECD NEA Working Party on the Nuclear Criticality Safety (Expert Group on Criticality Excursion), the Phase II of the benchmark was launched by selecting three experiments (R159, R76, R61) conducted at Japanese TRACY facility and one (LE1-641) from French SILENE facility. The main features of the Phase II of the benchmark are the ramp reactivity insertion generated by pumping fuel solution into the core tank (TRACY) or slow withdrawal of central transient rod (SILENE), and the use of both low enriched uranium (10 w/o, TRACY) and high enriched uranium (93 w/o, SILENE) for the uranyl nitrate fuel solution. As in the Phase I, TRACE code was used for the Phase II and the benchmark evaluated results were presented and discussed. The kinetic parameters, reactivity temperature and void coefficients for the benchmark were prepared using SRAC code system (PIJ, ANISN, CITATION and TWOTRAN modules) with JENDL-3.3 library. In general, the code benchmark results for the TRACY cases show excellent agreement with the measured data. However, for the SILENE case, overestimation of the power profile was observed. (C) 2015 Elsevier Ltd. All rights reserved.	[Liem, Peng Hong; Naito, Yoshitaka] Nippon Adv Information Serv NAIS Co Inc, Tokai, Ibaraki 3191112, Japan	Liem, PH (reprint author), Nippon Adv Information Serv NAIS Co Inc, 416 Muramatsu, Tokai, Ibaraki 3191112, Japan.	liemph@nais.ne.jp	Liem, Peng Hong/N-4155-2015	Liem, Peng Hong/0000-0002-0285-4507			Shibata K, 2002, J NUCL SCI TECHNOL, V39, P1125, DOI 10.3327/jnst.39.1125; Barbry F., 1989, 8908 SRSC; Liem P.H., 2005, TRACY SILENE BENCHMA; Mather D.J., 1994, CSR1007R AEA; McLaughlin, 2000, LA13638; Mitake S., 2003, P 7 INT C NUCL CRIT; Miyoshi Y., 2009, BENCHMARK PHASE 1 PU, V6285; Nakajima K., 2002, TRACY TRANSIENT EXPT, V1; Pain C.C., 2002, JAERICONF2002004; Tani H., 1999, NUCL CRITICALITY SAF, P1340; Yamane Y., 2004, OECD NEA WPCNS M PRA; Yamane Y., 2000, P SPRING ANN M JAP A	12	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	NOV	2015	85						71	82		10.1016/j.pnucene.2015.06.007		12	Nuclear Science & Technology	Nuclear Science & Technology	CU2JF	WOS:000363349100007		
J	Tanaka, K; Ueno, J; Adachi, M; Chiba, S				Tanaka, Ken-ichi; Ueno, Jun; Adachi, Masataka; Chiba, Satoshi			Improvement of a calculation procedure of neutron-flux distribution for radioactivity inventory estimation for decommissioning of nuclear power plants	PROGRESS IN NUCLEAR ENERGY			English	Article						Decommissioning; BWR; Radioactivity; Calculation; Measurement; Radiological characterization; Neutron flux; Neutron spectrum; DORT; TORT		We improved a calculation procedure of neutron-flux distribution in the Primary Containment Vessel (PCV) to get reliable estimation of radioactivity inventory, which is crucial for specification of a decommissioning plan of nuclear power plants. We calculated two-dimensional (2D) distribution of neutron-flux in cylindrical coordinate (r-z) with a 2D discrete ordinate (Sn) code DORT by utilizing knowledge of the characteristics of neutron-flux distribution in the PCV of Tsuruga Nuclear Power Plant unit 1 (TS-1). The knowledge was obtained from measurements and three-dimensional (3D) calculation of neutron-flux distribution in cylindrical coordinate (r-theta-z) with a 3D Sn code TORT. The measurements were performed by using activation foils at 30 locations where the distribution characteristics could be observed in the PCV. The 3D calculation provided us better qualitative understandings about the characteristics of neutron-flux distribution in the PCV. An improved model of 2D calculation of neutronflux distribution was generated by utilizing the knowledge from the measurements and the 3D calculation in the PCV. The reliability of 2D calculation was confirmed by comparing calculated fluxes with measured ones at locations where measurements were performed. The comparison between them showed that neutron-flux distribution calculated by the improved 2D model has met our criteria of the reliability. Therefore, the improved procedure provided a reliable 20 distribution of neutron-flux. (C) 2015 Elsevier Ltd. All rights reserved.	[Tanaka, Ken-ichi] Japan Atom Power Co, Chiyoda Ku, Tokyo 1050004, Japan; [Ueno, Jun; Adachi, Masataka] Genden Informat Syst Co, Chiyoda Ku, Tokyo 1050004, Japan; [Tanaka, Ken-ichi; Chiba, Satoshi] Tokyo Inst Technol, Meguro Ku, Tokyo 1528550, Japan	Tanaka, K (reprint author), Inst Appl Energy, Minato Ku, 1-14 Nishi Shinbashi 1 Chome, Tokyo 1050003, Japan.	k-tanaka@iae.or.jp					IAEA, 1998, IAEA TECHNICAL REPOR, V389; IAEA,, 1989, IAEA SAF SER, V100; Murakami Y., 1989, RAD DATA BOOK; NEA, 2013, NEARWMWPDD20132; ORNL, 1998, DOORS3 2 ON 2 3 DIM; Roberto O, 2002, FISP127001 ENEA BOL; Sukegawa T., 1993, INDCJPN164 INT AT EN; Tanaka K., 2007, P 2007 FALL M AESJ J; Tanaka K., 2011, P ICONE19 2011 OCT 2; Tanaka K., 2007, P ISRSM 2007 OCT 200, P132; Tanaka K., 2010, ICEM201040045; Tsoulfanidis N, 1986, MEASUREMENT DETECTIO; Tsukiyama T., 2002, P 11 INT S REACT DOS; Wall S.J., 1996, P 1996 TOP M RAD PRO; White E.J., 1996, DLC185BUGLE96 OAK RI; White J.R., 1996, P 1998 TOP M RAD PRO	16	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	NOV	2015	85						254	270		10.1016/j.pnucene.2015.05.009		17	Nuclear Science & Technology	Nuclear Science & Technology	CU2JF	WOS:000363349100022		
J	Matsumoto, T; Arima, T; Inagaki, Y; Idemitsu, K; Kato, M; Uchida, T				Matsumoto, Taku; Arima, Tatsumi; Inagaki, Yaohiro; Idemitsu, Kazuya; Kato, Masato; Uchida, Teppei			Molecular dynamics calculations of heat conduction in actinide oxides under thermal gradient	PROGRESS IN NUCLEAR ENERGY			English	Article						Non-equilibrium molecular dynamics simulations; UO2; PuO2; MOX; Thermal conductivity	SOLID-SOLUTIONS; MIXED-OXIDE; 2000 K; SIMULATION; FUEL; UO2; (U	Thermal conductivities of UO2, PuO2 and (U-0.8,Pu-0.(2))O-2 have been investigated by non-equilibrium molecular dynamics (NEMD) simulation between 300 K and 2000 K. The thermal conductivity was directly calculated by the temperature gradient on the system according to Fourier's law in NEMD simulation. The thermal conductivity obtained from the NEMD simulation decreases with a decrease of the supercell size, which means the phonon scattering occurs at the system boundaries in the microsystem. In addition, the present NEMD simulation, as well as previous EMD simulation studies, clearly shows that the Umklapp process causes the decrease of thermal conductivity at high temperatures. When comparison is made with literature data, the calculated results obtained from the relatively small supercell are in good agreement with the measured ones for the above actinide dioxides. (C) 2015 Elsevier Ltd. All rights reserved.	[Matsumoto, Taku; Arima, Tatsumi; Inagaki, Yaohiro; Idemitsu, Kazuya] Kyushu Univ, Fac Engn, Dept Appl Quantum Phys & Nucl Engn, Fukuoka 8190395, Japan; [Kato, Masato; Uchida, Teppei] Japan Atom Energy Agcy, Nucl Fuel Cycle Engn Labs, Tokai, Ibaraki 3191194, Japan	Matsumoto, T (reprint author), Kyushu Univ, Fac Engn, Dept Appl Quantum Phys & Nucl Engn, 744 Motooka, Fukuoka 8190395, Japan.	t-matsumoto@nucl.kyushu-u.ac.jp					Arima T, 2010, IOP CONF SER-MAT SCI, V9, DOI 10.1088/1757-899X/9/1/012003; Uchida T, 2010, J NUCL MATER, V400, P3, DOI 10.1016/j.jnucmat.2010.02.001; Nichenko S, 2013, J NUCL MATER, V439, P93, DOI 10.1016/j.jnucmat.2013.03.075; Inaba H, 1999, SOLID STATE IONICS, V122, P95, DOI 10.1016/S0167-2738(99)00036-3; Inoue M, 2000, J NUCL MATER, V282, P186, DOI 10.1016/S0022-3115(00)00407-4; Duriez C, 2000, J NUCL MATER, V277, P143, DOI 10.1016/S0022-3115(99)00205-6; Cozzo C, 2011, J NUCL MATER, V416, P135, DOI 10.1016/j.jnucmat.2011.01.109; FUKUSHIMA S, 1983, J NUCL MATER, V116, P287, DOI 10.1016/0022-3115(83)90114-9; Fink JK, 2000, J NUCL MATER, V279, P1, DOI 10.1016/S0022-3115(99)00273-1; Arima T, 2009, J NUCL MATER, V389, P149, DOI 10.1016/j.jnucmat.2009.01.020; Arima T, 2006, J ALLOY COMPD, V415, P43, DOI 10.1016/j.jallcom.2005.08.003; Arima T, 2005, J ALLOY COMPD, V400, P43, DOI 10.1016/j.jallcom.2005.04.003; BRANDT R, 1976, J NON-EQUIL THERMODY, V1, P3, DOI 10.1515/jnet.1976.1.1.3; Degueldre C, 2003, J NUCL MATER, V319, P6, DOI 10.1016/S0022-3115(03)00127-2; GIBBY RL, 1971, J NUCL MATER, V38, P163, DOI 10.1016/0022-3115(71)90040-7; Draghi C.N., 2003, MOL PHYS, V101, P2302; Evans D. J., 1990, STAT MECH NONEQUILIB; Hirao K., 1994, MAT DESIGN USING PER; Olander D.R., 1976, FUNDAMENTAL ASPECTS; Plathe F., 1997, J CHEM PHYS, V106, P6082	20	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	NOV	2015	85						271	276		10.1016/j.pnucene.2015.06.012		6	Nuclear Science & Technology	Nuclear Science & Technology	CU2JF	WOS:000363349100023		
J	Aritomo, Y; Chiba, S; Nishio, K				Aritomo, Yoshihiro; Chiba, Satoshi; Nishio, Katsuhisa			Independent fission yields studied based on Langevin equation	PROGRESS IN NUCLEAR ENERGY			English	Article						Fission; Mass distribution of fission fragments; Langevin equation; Shell correction energy	ONE-BODY DISSIPATION; NEUTRONS; DYNAMICS; URANIUM; FUSION	Mass distributions of fission fragments of U and Pu isotopes at low excitation energies are studied using a dynamical model based on the fluctuation-dissipation theorem formulated as Langevin equations. Though the Langevin approaches have been applied successfully to the fission process at high excitation energy, it is the first time to obtain the mass distribution of fission fragments for the neutron-induced fission of U-233'235 and Pu-239. It was found that the shell effect of the potential energy landscape has the dominant role in determining the mass distribution. The calculation results show the asymmetric fission and the good agreement with the experimental data without any parameter adjustments. Using this approach, we obtain the independent protons and neutrons fission yields of n + U-233. The present approach can serve as a basis for more refined analysis being planned in the future aiming at a realistic description of the whole process of fission, starting from the compound nuclei at various excitation energies reaching to the fission products populated after g-decay. (C) 2015 Elsevier Ltd. All rights reserved.	[Aritomo, Yoshihiro; Chiba, Satoshi] Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, Tokyo 1528550, Japan; [Nishio, Katsuhisa] Japan Atom Energy Agcy, Adv Sci Res Ctr, Tokai, Ibaraki 3191195, Japan	Aritomo, Y (reprint author), Tokyo Inst Technol, Nucl Reactors Res Lab, Meguro Ku, 2-12-1 Ookayama, Tokyo 1528550, Japan.	aritomo.yoshihiro@nr.titech.ac.jp					Bohr N, 1939, PHYS REV, V56, P426, DOI 10.1103/PhysRev.56.426; Aritomo Y, 2004, NUCL PHYS A, V744, P3, DOI 10.1016/j.nuclphysa.2004.08.009; DAVIES KTR, 1976, PHYS REV C, V13, P2385, DOI 10.1103/PhysRevC.13.2385; FELDMEIER H, 1987, REP PROG PHYS, V50, P915, DOI 10.1088/0034-4885/50/8/001; Meitner L, 1939, NATURE, V143, P239, DOI 10.1038/143239a0; IGNATYUK AV, 1975, SOV J NUCL PHYS+, V21, P255; MARUHN J, 1972, Z PHYS, V251, P431, DOI 10.1007/BF01391737; BLOCKI J, 1978, ANN PHYS-NEW YORK, V113, P330, DOI 10.1016/0003-4916(78)90208-7; KRAPPE HJ, 1979, PHYS REV C, V20, P992, DOI 10.1103/PhysRevC.20.992; Hahn O, 1939, NATURWISSENSCHAFTEN, V27, P11; Zagrebaev V, 2008, J PHYS G NUCL PARTIC, V35, DOI 10.1088/0954-3899/35/12/125103; Aritomo Y, 2013, PHYS REV C, V88, DOI 10.1103/PhysRevC.88.044614; Asano T., 2004, J NUCL RADIOCHEM SCI, V5, P1; Katakura J., 2012, JENDL FP DECAY DATA; NIX JR, 1984, NUCL PHYS A, V428, pC161; SATO K, 1978, Z PHYS A-HADRON NUCL, V288, P383, DOI 10.1007/BF01417722; Vandenbosh R., 1973, NUCL FISSION; WADA T, 1993, PHYS REV LETT, V70, P3538, DOI 10.1103/PhysRevLett.70.3538	18	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-1970			PROG NUCL ENERG	Prog. Nucl. Energy	NOV	2015	85						568	572		10.1016/j.pnucene.2015.08.004		5	Nuclear Science & Technology	Nuclear Science & Technology	CU2JF	WOS:000363349100051		
J	Holmstrom, F; Shimizu, S; Shimizu, T; Higashi, Y; Martin, DT; Honda, M; Saito, M				Holmstroem, Felix; Shimizu, Shogo; Shimizu, Takahiro; Higashi, Youichirou; Martin, Darryl T.; Honda, Masashi; Saito, Motoaki			Protective Effect of Hydroxyfasudil, a Rho Kinase Inhibitor, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat	PROSTATE			English	Article						hydroxyfasudil; spontaneously hypertensive rat; prostate; growth factor	URINARY-TRACT SYMPTOMS; SMOOTH-MUSCLE-CELLS; RHOA/RHO-KINASE; GROWTH-FACTORS; STROMAL CELLS; BPH; PROLIFERATION; INFLAMMATION; SENSITIZATION; CONTRACTION	BACKGROUND. Rho kinase (ROCK) pathway is associated with various cellular functions, such as smooth muscle contraction, inflammatory response, and cell proliferation. The spontaneously hypertensive rat (SHR) is commonly used genetically hypertensive rat model which develops hyperplastic morphological abnormalities in the ventral prostate. We investigated whether administration of hydroxyfasudil, a ROCK inhibitor, could reduce the levels of growth factors, inflammatory markers, and morphological abnormalities in the ventral prostate of the SHR. METHODS. Twelve-week-old SHRs were treated with hydroxyfasudil (1 mg/kg/day, i.p.) or vehicle once daily for another 6 weeks. Wistar Kyoto (WKY) rats treated with vehicle were used as normotensive controls. At 18 weeks of age, blood pressure and heart rate were measured by the tail cuff method. Then the rats were sacrificed, and the ventral prostates were removed. The levels of ROCK activity, growth factors (TGF-beta 1 and bFGF), a smooth muscle differentiation marker (alpha-SMA) and an inflammatory cytokine (IL-6) in the ventral prostate were measured by ELISA and western blot. A histological evaluation in each group was also performed. RESULTS. There were significant increases in blood pressure, prostate weight, prostate body weight ratio, and tissue levels of ROCK activity, TGF-beta 1, bFGF, alpha-SMA, and IL-6 in the SHR compared to the WKY rat. Histological examination of the ventral prostate showed morphological abnormalities such as a higher degree of proliferation in the glandular epithelial and stromal area in the SHR compared to the WKY rat. Treatment with hydroxyfasudil reduced the elevated ROCK activity, TGF-beta 1, bFGF, alpha-SMA, and IL-6 found in the ventral prostate of the SHR. Moreover, treatment with hydroxyfasudil decreased the morphological abnormalies in the SHR ventral prostate. CONCLUSIONS. Treatment with hydroxyfasudil decreased the growth factors, an inflammatory cytokine, and morphological abnormalies in the SHR ventral prostate. These results suggest that chronic treatment with hydroxyfasudil may inhibit the progression of prostatic hyperplasia in the SHR. (C) 2015 Wiley Periodicals, Inc.	[Holmstroem, Felix; Shimizu, Shogo; Shimizu, Takahiro; Higashi, Youichirou; Saito, Motoaki] Kochi Univ, Kochi Med Sch, Dept Pharmacol, Nankoku, Kochi 7838505, Japan; [Martin, Darryl T.] Yale Univ, Sch Med, Dept Urol, New Haven, CT USA; [Honda, Masashi] Tottori Univ, Sch Med, Dept Surg, Div Urol, Yonago, Tottori 683, Japan	Shimizu, S (reprint author), Kochi Univ, Kochi Med Sch, Dept Pharmacol, Nankoku, Kochi 7838505, Japan.	shimizu-sh@kochi-u.ac.jp			JSPS KAKENHI [24592431, 20591880]	Grant sponsor: JSPS KAKENHI; Grant numbers: #24592431; 20591880.	GUICHENEY P, 1991, J HYPERTENS, V9, P23; Shimizu S, 2014, INT J UROL, V21, P856, DOI 10.1111/iju.12501; Yamashita M, 2003, UROLOGY, V61, P484, DOI 10.1016/S0090-4295(02)0216702; Kramer G, 2007, EUR UROL, V51, P1202, DOI 10.1016/j.eururo.2006.12.011; Wilson JD, 1999, J CLIN ENDOCR METAB, V84, P4324, DOI 10.1210/jc.84.12.4324; Colli E, 2006, EUR UROL, V49, P82, DOI 10.1016/j.eururo.2005.08.014; Lam M, 2013, J UROLOGY, V189, P1147, DOI 10.1016/j.juro.2012.08.220; Penna G, 2009, PROSTATE, V69, P480, DOI 10.1002/pros.20896; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Tsounapi P, 2012, EUR J PHARMACOL, V691, P182, DOI 10.1016/j.ejphar.2012.07.016; MORI H, 1990, PROSTATE, V16, P71, DOI 10.1002/pros.2990160108; Matityahou A, 2003, J ANDROL, V24, P263; Wolak T, 2014, J HYPERTENS, V32, P1132, DOI 10.1097/HJH.0000000000000119; De Nunzio C, 2011, EUR UROL, V60, P106, DOI 10.1016/j.eururo.2011.03.055; Penna G, 2007, EUR UROL, V51, P524, DOI 10.1016/j.eururo.2006.07.016; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; GOLOMB E, 1994, AM J HYPERTENS, V7, P69; Takahashi R, 2007, NEUROUROL URODYNAM, V26, P547, DOI 10.1002/nau.20365; Zhou H, 2011, ACTA PHARMACOL SIN, V32, P999, DOI 10.1038/aps.2011.54; Rees RW, 2003, J UROLOGY, V170, P2517, DOI 10.1097/01.ju.0000085024.47406.6c; Adorini L, 2010, ANN NY ACAD SCI, V1193, P146, DOI 10.1111/j.1749-6632.2009.05299.x; Schenk JM, 2010, AM J EPIDEMIOL, V171, P571, DOI 10.1093/aje/kwp406; Quiles MT, 2010, PROSTATE, V70, P1044, DOI 10.1002/pros.21138; Satoh K, 2011, AM J PHYSIOL-HEART C, V301, pH287, DOI 10.1152/ajpheart.00327.2011; Kyprianou N, 1998, J UROLOGY, V159, P1810, DOI 10.1016/S0022-5347(01)63162-8; Untergasser G, 2005, EXP GERONTOL, V40, P121, DOI 10.1016/j.exeger.2004.12.008; CAINE M, 1988, UROLOGY, V32, P16; Golomb E, 2000, J ANDROL, V21, P58; Wibberley A, 2003, BRIT J PHARMACOL, V138, P757, DOI 10.1038/sj.bjp.0705109; Saito M, 2011, MOL CELL BIOCHEM, V358, P207, DOI 10.1007/s11010-011-0936-9; MULLER WJ, 1990, EMBO J, V9, P907; Ficarra V, 2014, CURR UROL REP, V15, DOI 10.1007/s11934-014-0463-9; Hennenberg M, 2015, LIFE SCI, V123, P18, DOI 10.1016/j.lfs.2014.12.006; Inoue S, 2012, UROLOGY, V79; Mukai Yasushi, 2001, FASEB Journal, V15, P1062; Saito M, 2014, SCI REP-UK, V4, DOI 10.1038/srep03822; Wolak T, 2014, J HYPERTENS, V32, P1137; Zarifpour M, 2015, PROSTATE, V75, P233, DOI 10.1002/pros.22909	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-4137	1097-0045		PROSTATE	Prostate	NOV 1	2015	75	15					1774	1782		10.1002/pros.23063		9	Endocrinology & Metabolism; Urology & Nephrology	Endocrinology & Metabolism; Urology & Nephrology	CU0PJ	WOS:000363219200011		
J	Kuribayashi, R; Nittono, H				Kuribayashi, Ryuma; Nittono, Hiroshi			Speeding up the tempo of background sounds accelerates the pace of behavior	PSYCHOLOGY OF MUSIC			English	Article						background music; cognition; order; speed of performance; tempo	CLOCK SPEED; MUSIC; AROUSAL; ADULTS; RHYTHM; LEVEL; TIME; MOOD	Hearing fast-tempo music in the background is shown to affect the pace of motor behavior. However, the mechanism underlying this phenomenon remains unclear. We investigated how tempo influences behavioral pace in a simple perceptual-motor task in which participants heard background sound sequences (30, 60, 120, 180, and 240 bpm) while performing a line-tracing task. The order of the tempo conditions (ascending vs. descending series of tempo) was manipulated. When sound sequences changed from slower to faster tempi (that is, ascending series), behavioral pace accelerated. However, the pace did not change in the descending series. The subjective arousal level increased under faster tempo sounds regardless of tempo series. The results indicated that the ongoing tempo of background sounds did not determine the behavioral pace directly through increased arousal or perceptual-motor synchronization. Not only the ongoing tempo but also the preceding tempo of background sounds is shown to be an important factor for behavioral pace change.	[Kuribayashi, Ryuma; Nittono, Hiroshi] Hiroshima Univ, Higashihiroshima 7398521, Japan	Kuribayashi, R (reprint author), Hiroshima Univ, Grad Sch Integrated Arts & Sci, 1-7-1 Kagamiyama, Higashihiroshima 7398521, Japan.	ryuma.kuribayashi@gmail.com	Nittono, Hiroshi/C-4043-2009	Nittono, Hiroshi/0000-0001-5671-609X			Kallinen K, 2002, COMPUT HUM BEHAV, V18, P537, DOI 10.1016/S0747-5632(02)00005-5; Ozel S, 2004, CAN J EXP PSYCHOL, V58, P196, DOI 10.1037/h0087444; ROBALLEY TC, 1985, B PSYCHONOMIC SOC, V23, P221; HELSON H, 1964, AM PSYCHOL, V19, P26, DOI 10.1037/h0040013; Patton D, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2825; Dickstein R, 2012, PERCEPT MOTOR SKILL, V114, P21, DOI 10.2466/15.25.PMS.114.1.21-28; McAuley JD, 2012, ANN NY ACAD SCI, V1252, P77, DOI 10.1111/j.1749-6632.2011.06433.x; Neuhoff JG, 2002, J EXP PSYCHOL-APPL, V8, P17, DOI 10.1037//1076-898X.8.1.17; Pronin E, 2008, PERSPECT PSYCHOL SCI, V3, P461, DOI 10.1111/j.1745-6924.2008.00091.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Gil S, 2012, COGNITION EMOTION, V26, P847, DOI 10.1080/02699931.2011.625401; Phillips-Silver J, 2010, MUSIC PERCEPT, V28, P3, DOI 10.1525/MP.2010.28.1.3; McConnell MM, 2011, COGNITION EMOTION, V25, P1184, DOI 10.1080/02699931.2010.524396; Wittwer JE, 2013, GAIT POSTURE, V37, P219, DOI 10.1016/j.gaitpost.2012.07.006; McAuley JD, 2010, SPRINGER HANDB AUDIT, V36, P165, DOI 10.1007/978-1-4419-6114-3_6; MILLIMAN RE, 1982, J MARKETING, V46, P86, DOI 10.2307/1251706; Szabo A, 1999, J SPORT MED PHYS FIT, V39, P220; Edworthy J, 2006, ERGONOMICS, V49, P1597, DOI 10.1080/00140130600899104; Husain G, 2002, MUSIC PERCEPT, V20, P151, DOI 10.1525/mp.2002.20.2.151; Lake JI, 2013, NEUROPSYCHOLOGIA, V51, P284, DOI 10.1016/j.neuropsychologia.2012.09.014; Kampfe J, 2011, PSYCHOL MUSIC, V39, P424, DOI 10.1177/0305735610376261; Nittono H, 2000, PERCEPT MOTOR SKILL, V90, P1122, DOI 10.2466/PMS.90.3.1122-1122; Neuhoff JG, 1998, NATURE, V395, P123, DOI 10.1038/25862; MCELREA H, 1992, PERCEPT MOTOR SKILL, V75, P362, DOI 10.2466/PMS.75.5.362-362; Madison G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008151; Bolton T. L., 1894, AM J PSYCHOL, V6, P145; Fraisse P, 1982, PSYCHOL MUSIC, P149; Liu Y. P., 2012, SENTIENCE, V6, P1; Powell W, 2010, STUD HEALTH TECHNOL, V154, P202, DOI 10.3233/978-1-60750-561-7-202; RUSSELL JA, 1989, J PERS SOC PSYCHOL, V57, P493, DOI 10.1037/0022-3514.57.3.493; Schellenberg E. G., 2007, PSYCHOL MUSIC, V35, p5?19, DOI DOI 10.1177/0305735607068885; Terrier P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047171	32	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0305-7356	1741-3087		PSYCHOL MUSIC	Psychol. Music	NOV	2015	43	6					808	817		10.1177/0305735614543216		10	Psychology, Educational; Psychology, Applied; Music; Psychology, Experimental	Psychology; Music	CU1KI	WOS:000363279700004		
J	Shigeno, S				Shigeno, Sumi			Effects of background music on young Japanese adults' impressions of opposite-sex conversation partners	PSYCHOLOGY OF MUSIC			English	Article						background music; cognition; communication; speech; youth culture		This study examines whether background music gives young Japanese adults a more favorable impression of conversation partners of the opposite sex for the first meeting during conversation for konkatsu. A total of 32 students in their teens and twenties (16 males and 16 females) participated in the experiment. The two conditions were as follows: the with-music' condition, where BGM was played during a 20-minute conversation, and the no-music' condition, where BGM was absent. The participants were divided into eight small groups, consisting of two males and two females each. Four other students (two males and two females) participated in pairs (two couples) in each group as the target conversation partners (called guests' here). The participants rated their impressions of the guests of the opposite sex before and after the conversation. The guests were instructed to keep the conversation smooth and amicable. The results showed that irrespective of the presence of background music, face-to-face conversation between young males and females led to a change in their impression of their partner and created intimacy between them. The biggest difference between the no-music and with-music conditions is the point that music facilitated the feelings of love for the partner of the opposite sex.	[Shigeno, Sumi] Aoyama Gakuin Univ, Dept Psychol, Tokyo 150, Japan	Shigeno, S (reprint author), Aoyama Gakuin Univ, Dept Psychol, Shibuya Ku, 4-4-25 Shibuya, Tokyo 1508366, Japan.	sshigeno@ephs.aoyama.ac.jp			VECTOR INC.; Sony Corporation	This research was supported by VECTOR INC. and Sony Corporation.	Panksepp J, 2002, BEHAV PROCESS, V60, P133, DOI 10.1016/S0376-6357(02)00080-3; Brown S, 2004, NEUROREPORT, V15, P2033, DOI 10.1097/00001756-200409150-00008; North AC, 1999, J APPL PSYCHOL, V84, P271, DOI 10.1037/0021-9010.84.2.271; Rentfrow PJ, 2006, PSYCHOL SCI, V17, P236, DOI 10.1111/j.1467-9280.2006.01691.x; FRIED R, 1979, J APPL SOC PSYCHOL, V9, P199, DOI 10.1111/j.1559-1816.1979.tb02706.x; Gueguen N, 2010, PSYCHOL MUSIC, V38, P303, DOI 10.1177/0305735609360428; Gueguen N., 2007, EUROPEAN J SCI RES, V16, P268; Hayashi F., 1976, B FACULTY ED NAGOYA, V23, P27; Juslin P. N., 2001, MUSIC EMOTION THEORY; Levitin D. J., 2006, THIS IS YOUR BRAIN M; Ogawa K., 2000, B GRADUATE SCH ED HU, V47, P173; Shirakawa M., 2008, ERA MARRIAGE HUNTING; Vastfjall D, 2002, MUSIC SCI S, V5, P173, DOI DOI 10.1177/10298649020050S107	13	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0305-7356	1741-3087		PSYCHOL MUSIC	Psychol. Music	NOV	2015	43	6					898	908		10.1177/0305735614561816		11	Psychology, Educational; Psychology, Applied; Music; Psychology, Experimental	Psychology; Music	CU1KI	WOS:000363279700010		
J	Kubo, Y; Yamamoto, T; Motomura, G; Tsukamoto, N; Karasuyama, K; Sonoda, K; Hatanaka, H; Utsunomiya, T; Iwamoto, Y				Kubo, Yusuke; Yamamoto, Takuaki; Motomura, Goro; Tsukamoto, Nobuaki; Karasuyama, Kazuyuki; Sonoda, Kazuhiko; Hatanaka, Hiroyuki; Utsunomiya, Takeshi; Iwamoto, Yukihide			MRI-detected bone marrow changes within 3 weeks after initiation of high-dose corticosteroid therapy: a possible change preceding the subsequent appearance of low-intensity band in femoral head osteonecrosis	RHEUMATOLOGY INTERNATIONAL			English	Review						Osteonecrosis of the femoral head; Corticosteroid treatment; Short-tau inversion recovery (STIR) sequence image; Hemophagocytic syndrome	STEROID-INDUCED OSTEONECROSIS; NONTRAUMATIC OSTEONECROSIS; IDIOPATHIC OSTEONECROSIS; AVASCULAR NECROSIS; ALCOHOL INTAKE; RABBITS; RISK; PREVENTION; PREDICTION; COLLAPSE	Osteonecrosis of the femoral head is considered to occur early during the course of corticosteroid treatment. However, it remains unclear exactly how early it can develop after initiation of corticosteroid treatment. We report a case of osteonecrosis of the femoral head in which abnormal findings were observed on short-tau inversion recovery (STIR) sequence image performed 2 weeks and 4 days after initiation of high-dose corticosteroid therapy. A 45-year-old man with hemophagocytic syndrome was started on prednisolone, with a maximum dose of 40 mg/day. On day 13 after initiation of this corticosteroid therapy, he transiently experienced left hip pain with no apparent cause. STIR sequence image 5 days after the onset of pain revealed high-intensity bone marrow lesions at the femoral neck of both hips. At 3 months after initiation of corticosteroid therapy, T1-weighted magnetic resonance imaging revealed concave-shaped low-intensity bands, which corresponded to the preceding high-intensity lesions on both hips. Because of the subsequent progression to collapse of the left femoral head, he underwent prosthetic replacement surgery. The high-intensity lesions on STIR sequence image indicate the possibility that osteonecrosis can occur within 3 weeks after initiation of high-dose corticosteroid therapy.	[Kubo, Yusuke; Yamamoto, Takuaki; Motomura, Goro; Karasuyama, Kazuyuki; Sonoda, Kazuhiko; Hatanaka, Hiroyuki; Utsunomiya, Takeshi; Iwamoto, Yukihide] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan; [Tsukamoto, Nobuaki] Saga Prefectural Med Ctr Koseikan, Dept Orthopaed Surg, Saga 8408571, Japan	Yamamoto, T (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yamataku@ortho.med.kyushu-u.ac.jp			Grant for Intractable Diseases from Japan Agency for Medical Research and Development, AMED [H26-Itaku(Nan)-Ippan-031]	This work was partially supported by a Research Grant for Intractable Diseases from Japan Agency for Medical Research and Development, AMED (H26-Itaku(Nan)-Ippan-031).	Fukushima W, 2010, CLIN ORTHOP RELAT R, V468, P2715, DOI 10.1007/s11999-010-1292-x; Yamamoto T, 1999, J BONE JOINT SURG BR, V81B, P328; FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3; Fukushima W, 2013, BONE JOINT J, V95B, P320, DOI 10.1302/0301-620X.95B3.30856; Motomura G, 2004, ARTHRITIS RHEUM, V50, P3387, DOI 10.1002/art.20517; Nishida K, 2008, CLIN ORTHOP RELAT R, V466, P1054, DOI 10.1007/s11999-008-0189-4; Kubo T, 1997, MAGN RESON IMAGING, V15, P1017, DOI 10.1016/S0730-725X(97)00159-8; Ikemura S, 2013, BONE, V53, P329, DOI 10.1016/j.bone.2012.12.050; SHIMIZU K, 1994, J BONE JOINT SURG AM, V76A, P215; Oinuma K, 2001, ANN RHEUM DIS, V60, P1145, DOI 10.1136/ard.60.12.1145; TAKATORI Y, 1993, J BONE JOINT SURG BR, V75, P217; Sakai T, 1999, J ORTHOPAED RES, V17, P784, DOI 10.1002/jor.1100170525; Fujioka M, 2001, MAGN RESON IMAGING, V19, P985, DOI 10.1016/S0730-725X(01)00424-6; HIROTA Y, 1993, AM J EPIDEMIOL, V137, P530; Yamaguchi R, 2012, RHEUMATOLOGY, V51, P789, DOI 10.1093/rheumatology/ker197; JONES JP, 1993, CLIN ORTHOP RELAT R, P294; Sugano N, 1999, J BONE JOINT SURG BR, V81B, P590, DOI 10.1302/0301-620X.81B4.9393; KOKUBO T, 1992, CLIN ORTHOP RELAT R, P54; Seamon J, 2012, ARTHRITIS, DOI [10.1155/2012/601763, DOI 10.1155/2012/601763]	19	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0172-8172	1437-160X		RHEUMATOL INT	Rheumatol. Int.	NOV	2015	35	11					1909	1912		10.1007/s00296-015-3346-6		4	Rheumatology	Rheumatology	CU1DU	WOS:000363260600015		
J	Tamba, T; Nguyen, TM; Takeya, K; Harasaki, T; Iwakawa, A; Sasoh, A				Tamba, T.; Nguyen, T. M.; Takeya, K.; Harasaki, T.; Iwakawa, A.; Sasoh, A.			Counter-driver shock tube	SHOCK WAVES			English	Article						Shock tube; Shock wave interaction	DRAG REDUCTION; OPENING TIME; WAVE; DIAPHRAGM; REFLECTION	A "counter-driver" shock tube was developed. In this device, two counter drivers are actuated with an appropriate delay time to generate the interaction between a shock wave and a flow in the opposite direction which is induced by another shock wave. The conditions for the counter drivers can be set independently. Each driver is activated by a separate electrically controlled diaphragm rupture device, in which a pneumatic piston drives a rupture needle with a temporal jitter of better than 1.1 ms. Operation demonstrations were conducted to evaluate the practical performance.	[Tamba, T.; Nguyen, T. M.; Iwakawa, A.; Sasoh, A.] Nagoya Univ, Dept Aerosp Engn, Chikusa Ku, Nagoya, Aichi 4648603, Japan; [Takeya, K.] Komatsu Ltd, Hirakata, Osaka 5731175, Japan; [Harasaki, T.] IHI Corp, Soma, Fukushima 9760016, Japan	Tamba, T (reprint author), Nagoya Univ, Dept Aerosp Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.	tamba@fuji.nuae.nagoya-u.ac.jp			Japan Society for the Promotion of Science (JSPS) "KAKENHI" [22226014, 25630390]	The authors acknowledge the valuable technical support provided by Mr. Akira Saito from the Technical Division, Nagoya University. This work was supported by Japan Society for the Promotion of Science (JSPS) "KAKENHI" through a Grant-in-Aid for Scientific Research, (S) 22226014, and that for Challenging Exploratory Research No. 25630390.	Sasoh A, 2010, AIAA J, V48, P2811, DOI 10.2514/1.J050174; Sasoh A, 2006, AIAA J, V44, P1110, DOI 10.2514/1.10047; Agui JH, 2005, J FLUID MECH, V524, P143, DOI 10.1017/S0022112004002514; Kim JH, 2011, AIAA J, V49, P2076, DOI 10.2514/1.J051145; SIMPSON CJS, 1967, PHYS FLUIDS, V10, P1894, DOI 10.1063/1.1762384; WHITE DR, 1958, J FLUID MECH, V4, P585, DOI 10.1017/S0022112058000677; HICKMAN RS, 1975, PHYS FLUIDS, V18, P1249, DOI 10.1063/1.861010; Barbosa FJ, 2002, J FLUID MECH, V472, P263, DOI 10.1017/S0022112902002343; MILLER CG, 1977, AIAA J, V15, P1045, DOI 10.2514/3.7395; Yang J, 1996, SHOCK WAVES, V6, P267, DOI 10.1007/BF02535740; Glass Irvine I., 1994, NONSTATIONARY FLOWS, P88; Ikui T., 1969, Bulletin of the Japan Society of Mechanical Engineers, V12; Landau L., 1987, FLUID MECH, V6; Oertel H., 1966, STOSSROHRE, P670; Oguchi H., 1991, Shock Waves, V1, DOI 10.1007/BF01413798; Oguchi H., 1976, NEW TYPE SHOCK VALVE; Yang J., 1994, JSME INT J B-FLUID T, V60, P473	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-1287	1432-2153		SHOCK WAVES	Shock Waves	NOV	2015	25	6					667	674		10.1007/s00193-015-0594-z		8	Mechanics	Mechanics	CT8IY	WOS:000363060300008		
J	Moriya, S; Tahara, Y; Sasaki, H; Ishigooka, J; Shibata, S				Moriya, Shunpei; Tahara, Yu; Sasaki, Hiroyuki; Ishigooka, Jun; Shibata, Shigenobu			Phase-delay in the light-dark cycle impairs clock gene expression and levels of serotonin, norepinephrine, and their metabolites in the mouse hippocampus and amygdala	SLEEP MEDICINE			English	Article						Monoamine; Amygdala; Circadian rhythm; Phase delay; Locomotor activity	DISCRETE BRAIN-REGIONS; MONOAMINE CONTENTS; CIRCADIAN-RHYTHMS; MICE; MICRODIALYSIS; RESPONSES; SHIFT; ACID	Objective: A number of animal studies have implicated circadian clock genes in the regulation of mood, anxiety, and reward. However, the effect of misalignment of the environmental light-dark and internal circadian clock on the monoamine system is not fully understood. In the present study, we examined whether an abnormal light-dark schedule would affect behavior-, circadian clock-, and monoamine-related gene expressions, along with monoamine contents in the amygdala and hippocampus of mice. Methods: Mice were subjected to an 8-hour phase delay in the light-dark cycle (Shift) every two days for four weeks, and locomotor activity was continuously measured. We examined the circadian expression of clock genes (Per1, Per2, and Bmal1) and genes of the NE/5HT uptake transporters (Net and Sert). In addition, the levels of NE/5HT and their metabolites MHPG/5HIAA were analyzed in the amygdala and hippocampus. Results: Locomotor activity showed a free-running phenotype with a longer period (>24 hours) and showed misalignment between the light-dark and inactive-active cycles. The amplitude of the day-night fluctuation of Bmal1 expression was reduced in the amygdala and hippocampus of light-dark-shifted mice. Net gene expression in the Shift group showed different profiles compared with the Control group. In addition, NE and 5HT levels in the amygdala of the Shift group increased during the active period. Conclusions: The present results suggest that misalignment of the internal and external clocks by continuous shifting of the light-dark cycle affects the circadian clocks and monoamine metabolism in the amygdala and hippocampus of mice. (C) 2015 Elsevier B.V. All rights reserved.	[Moriya, Shunpei; Tahara, Yu; Sasaki, Hiroyuki; Shibata, Shigenobu] Waseda Univ, Sch Adv Sci & Engn, Lab Physiol & Pharmacol, Shinjuku Ku, Tokyo 1628480, Japan; [Moriya, Shunpei; Ishigooka, Jun] Tokyo Womens Med Univ, Sch Med, Dept Psychiat, Shinjuku Ku, Tokyo, Japan	Shibata, S (reprint author), Waseda Univ, Sch Adv Sci & Engn, Lab Physiol & Pharmacol, Shinjuku Ku, Tokyo 1628480, Japan.	shibatas@waseda.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [26220201]	This study was partially supported by a Grant-in-Aid for Scientific Research (S) (26220201) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (S.S.).	Akerstedt T, 2009, SLEEP MED CLIN, V4, P257, DOI DOI 10.1016/J.JSMC.2009.03.001; Corthell JT, 2013, NEUROSCIENCE, V247, P234, DOI 10.1016/j.neuroscience.2013.05.040; Nagano M, 2003, J NEUROSCI, V23, P6141; Hansen MB, 2008, PHYSIOL RES, V57, P63; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Hampp G, 2008, CURR BIOL, V18, P678, DOI 10.1016/j.cub.2008.04.012; MATSUMOTO M, 1981, J NEUROCHEM, V37, P792; Ridder S, 2005, J NEUROSCI, V25, P6243, DOI 10.1523/JNEUROSCI.0736-05.2005; MOORE RY, 1976, NEUROENDOCRINOLOGY, V20, P250, DOI 10.1159/000122489; Nakayama K, 2002, PROG NEURO-PSYCHOPH, V26, P1383, DOI 10.1016/S0278-5846(02)00304-4; ALDEGUNDE M, 1984, INT J NEUROSCI, V24, P233, DOI 10.3109/00207458409089811; Ushijima K, 2012, MOL PHARMACOL, V82, P264, DOI 10.1124/mol.112.079079; DASZUTA A, 1982, BRAIN RES BULL, V8, P477, DOI 10.1016/0361-9230(82)90004-1; Bara AC, 2009, SCAND J WORK ENV HEA, V35, P361; CAGAMPANG FRA, 1994, NEUROSCI LETT, V173, P185, DOI 10.1016/0304-3940(94)90179-1; Otsuka T, 2014, PSYCHONEUROENDOCRINO, V40, P37, DOI 10.1016/j.psyneuen.2013.10.013; Prendergast BJ, 2005, PSYCHONEUROENDOCRINO, V30, P438, DOI 10.1016/j.psyneuen.2004.08.008; Nebigil CG, 2001, TRENDS CARDIOVAS MED, V11, P329, DOI 10.1016/S1050-1738(01)00135-9; Driesen K, 2011, SCAND J WORK ENV HEA, V37, P402, DOI 10.5271/sjweh.3158; Davidson AJ, 2006, CURR BIOL, V16, pR914, DOI 10.1016/j.cub.2006.09.058; Rueter LE, 1996, BRAIN RES, V739, P57, DOI 10.1016/S0006-8993(96)00809-8; LANDFIELD PW, 1981, SCIENCE, V214, P581, DOI 10.1126/science.6270791; Lamant EW, 2005, P NATL ACAD SCI USA, V102, P4180; McClung CA, 2011, EUR NEUROPSYCHOPHARM, V4, pS683; Niu SF, 2011, J NURS RES, V19, P69; Virtanen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030719	26	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	NOV	2015	16	11					1352	1359		10.1016/j.sleep.2015.06.020		8	Clinical Neurology	Neurosciences & Neurology	CU4CL	WOS:000363473700008		
J	Uemura, SI; Kanbayashi, T; Wakasa, M; Satake, M; Ito, W; Shimizu, K; Shioya, T; Shimizu, T; Nishino, S				Uemura, Sachiko Ito; Kanbayashi, Takashi; Wakasa, Masahiko; Satake, Masahiro; Ito, Wakako; Shimizu, Kazumi; Shioya, Takanobu; Shimizu, Tetsuo; Nishino, Seiji			Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study	SLEEP MEDICINE			English	Article						Zolpidem; Triazolam; Rilmazafone; Elderly; Residual effects; Randomized study	RISK-INCREASING DRUGS; JAPANESE GENERAL-POPULATION; PHYSICAL PERFORMANCE; INSOMNIA; FALLS; WITHDRAWAL; HYPNOTICS; ZALEPLON; SLEEP; PHARMACOLOGY	With current hypnotic agents, next-day residual effects are a common problem. The purpose of the present study was to evaluate the residual effects of the commercially available hypnotics - zolpidem, triazolam, and rilmazafone - on the physical and cognitive functions of healthy elderly people in the early morning and the day following drug administration. In this study, the next-day residual effects of zolpidem, triazolam, and rilmazafone, following bedtime dosing in elderly subjects, were evaluated. Women (n = 11) and men (n = 2) aged 60-70 years received a single dose (at 23:00) of one of these, zolpidem 5 mg, triazolam 0.125 mg, rilmazafone 1mg and placebo in a randomized, double-blind, crossover design. Measures of objective parameters and psychomotor performances (Timed up and Go test, Functional Reach Test, body sway test, critical flicker fusion test, simple discrimination reaction test, short-term memory test) and subjective ratings were obtained at 04:00, 07:00, and the next time of the day. All hypnotics were generally well tolerated; there were no serious adverse side effects and no subjects discontinued the evaluations. Compared to placebo, zolpidem and rilmazafone had good results on the Functional Reach Test. Although subjective assessments tended to be poor in the early morning, rilmazafone significantly improved the body sway test in the other hypnotics. A single dose of zolpidem 5 mg and triazolam 0.125 mg did not have any next-day residual effects on healthy elderly subjects. Residual effects appeared to be related to the compound's half-life and the dose used. Rilmazafone 1mg exhibited steadiness in static and dynamic balance and seemed to be more favorable for the elderly with early morning awakening. (C) 2015 Elsevier B.V. All rights reserved.	[Uemura, Sachiko Ito; Wakasa, Masahiko; Satake, Masahiro; Shioya, Takanobu] Akita Univ, Grad Sch Hlth Sci, Dept Phys Therapy, Akita 0108543, Japan; [Kanbayashi, Takashi; Ito, Wakako; Shimizu, Kazumi; Shimizu, Tetsuo] Akita Univ, Grad Sch Med, Dept Psychiat, Akita 0108543, Japan; [Kanbayashi, Takashi; Shimizu, Tetsuo] Univ Tsukuba, Int Inst Integrat Sleep Med WPI IIIS, Tsukuba, Ibaraki, Japan; [Nishino, Seiji] Stanford Univ, Sch Med, Stanford Sleep Res Ctr, Sleep & Circadian Neurobiol Lab, Palo Alto, CA 94304 USA	Uemura, SI (reprint author), Akita Univ, Grad Sch Hlth Sci, Dept Phys Therapy, 1-1-1 Hondo, Akita 0108543, Japan.	uemura@hs.akita-u.ac.jp			 [20500838]	This study was funded by Grants-and-Aid for Scientific Research 'Scientific Research (C) (General)' (20500838).	Kim K, 2000, SLEEP, V23, P41; Terzano MG, 2003, DRUG SAFETY, V26, P261, DOI 10.2165/00002018-200326040-00004; Sterke CS, 2012, J CLIN PHARMACOL, V52, P947, DOI 10.1177/0091270011405665; Vermeeren A, 2004, CNS DRUGS, V18, P297, DOI 10.2165/00023210-200418050-00003; Sullivan SS, 2010, MED CLIN N AM, V94, P563, DOI 10.1016/j.mcna.2010.02.012; Ito W, 2010, SLEEP, V33, pA309; Dundar Y, 2004, HUM PSYCHOPHARM CLIN, V19, P305, DOI 10.1002/hup.594; Van der Velde N, 2007, BRIT J CLIN PHARMACO, V63, P232, DOI 10.1111/j.1365-2125.2006.02736.x; Roy AN, 2010, SLEEP MED, V11, P462, DOI 10.1016/j.sleep.2009.09.012; Mintzer MZ, 2000, MEM COGNITION, V28, P1357, DOI 10.3758/BF03211836; WATANABE S, 1986, FOLIA PHARMACOL JPN, V88, P19, DOI 10.1254/fpj.88.19; Allain H, 2005, DRUG AGING, V22, P749, DOI 10.2165/00002512-200522090-00004; Kaneita Y, 2007, SLEEP MED, V8, P723, DOI 10.1016/j.sleep.2006.10.009; Allain H, 2003, EUR J CLIN PHARMACOL, V59, P179, DOI 10.1007/s00228-003-0591-5; Akishita M, 2011, GERIATR GERONTOL INT, V11, P3, DOI 10.1111/j.1447-0594.2010.00631.x; Lader M, 2014, BRIT J CLIN PHARMACO, V77, P295, DOI 10.1111/j.1365-2125.2012.04418.x; Bauer TK, 2012, PHARMACOEPIDEM DR S, V21, P1321, DOI 10.1002/pds.3357; Yamada M, 2012, GERIATR GERONTOL INT, V12, P238, DOI 10.1111/j.1447-0594.2011.00757.x; Ito SU, 2007, NEUROSCI RES, V59, P309, DOI 10.1016/j.neures.2007.07.009; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; Demura SI, 2007, TOHOKU J EXP MED, V213, P105, DOI 10.1620/tjem.213.105; van der Velde N, 2008, DRUG AGING, V25, P521; Landi F, 2005, J GERONTOL A-BIOL, V60, P622; PERRAULT G, 1990, EUR J PHARMACOL, V187, P487, DOI 10.1016/0014-2999(90)90375-G; YAMAGUCHI T, 1987, FOLIA PHARMACOL JPN, V90, P239, DOI 10.1254/fpj.90.239; van der Velde N, 2007, DRUG AGING, V24, P691, DOI 10.2165/00002512-200724080-00006; Danjou P, 1999, BRIT J CLIN PHARMACO, V48, P367; Doi Y, 2000, J Epidemiol, V10, P79; Duncan PW, 1990, J GERONTOL, V45, P192; Hindmarch I., 2004, BR J CLIN PHARM, V58, pS41; Hindmarch I, 2004, BRIT J CLIN PHARMACO, V58, pS720, DOI 10.1111/j.1365-2125.2004.02279.x; Inomata S, 2011, AKITA J MED, V38, P63; Izumi Kiyoko, 2002, Nurs Health Sci, V4, P141, DOI 10.1046/j.1442-2018.2002.00119.x; Nakajima M, 2010, JPN J PHARM HLTH CAR, V36, P863; Plati C, 1992, Scand J Caring Sci, V6, P113; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142; Sada Kouji, 2010, Int J Older People Nurs, V5, P34, DOI 10.1111/j.1748-3743.2009.00187.x; Stone KL, 2008, SLEEP MED, V9, pS18, DOI 10.1016/S1389-9457(08)70012-1; Uchiyama Makoto, 2012, Nihon Rinsho, V70, P52; Uchiyama Makoto, 2012, Nihon Rinsho, V70, P1241; Yasui Mitsuru, 2005, Nihon Shinkei Seishin Yakurigaku Zasshi, V25, P143	41	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	NOV	2015	16	11					1395	1402		10.1016/j.sleep.2015.05.021		8	Clinical Neurology	Neurosciences & Neurology	CU4CL	WOS:000363473700015		
J	Matsuoka, R; Nakamuro, M; Inui, T				Matsuoka, Ryoji; Nakamuro, Makiko; Inui, Tomohiko			Emerging inequality in effort: A longitudinal investigation of parental involvement and early elementary school-aged children's learning time in Japan	SOCIAL SCIENCE RESEARCH			English	Article						Learning time; Effort; Parental education; Parental involvement; Shadow education; Extracurricular activities	SOCIAL-CLASS; ACHIEVEMENT; RACE	While studies on effort (e.g., Carbonaro, 2005; Kariya, 2000, 2013) have revealed relationships among students' effort (e.g., self-reported learning time), socioeconomic status, and school-related factors (e.g., tracking) through secondary education data, whether and how the effort gap emerges and widens in the early years of compulsory education have not been researched. This study investigates the beginning of inequality in effort by using four waves (from first- to fourth-grade students) of the Longitudinal Survey of Babies in the 21st Century, collected in Japan. The results indicate that college-educated parents tend to employ parenting practices that directly and indirectly shape children's learning time; inequality in effort exists, and it becomes exacerbated partly because of parenting differences in a society with a relatively equal elementary education system. (C) 2015 Elsevier Inc. All rights reserved.	[Matsuoka, Ryoji] Waseda Univ, Waseda Inst Adv Study, Tokyo, Tokyo, Japan; [Nakamuro, Makiko] Keio Univ, Fac Policy Management, Tokyo 108, Japan; [Inui, Tomohiko] Gakushuin Univ, Fac Int Social Sci, Preparatory Off, Tokyo 171, Japan	Matsuoka, R (reprint author), Waseda Inst Adv Study, Shinjuku Ku, 1-6-1 Nishi Waseda, Tokyo 1698050, Japan.	ryojim@aoni.waseda.jp			JSPS KAKENHI [23243044, 26780488]	This work was supported by JSPS KAKENHI Grant Numbers 23243044 and 26780488.	Allison P.D., 2009, FIXED EFFECTS REGRES; Bodovski K, 2010, BRIT J SOCIOL EDUC, V31, P139, DOI 10.1080/01425690903539024; Carbonaro W, 2005, SOCIOL EDUC, V78, P27; Ma YY, 2009, SOCIOL PERSPECT, V52, P211, DOI 10.1525/sop.2009.52.2.211; Burkam DT, 2004, SOCIOL EDUC, V77, P1; Miwa S, 2012, SOCIOL THEOR METHOD, V27, P63; Heinrich CJ, 2013, AM EDUC RES J, V50, P856, DOI 10.3102/0002831213486334; Nakazawa W, 2012, SOCIOL THEOR METHOD, V27, P23; Bennett PR, 2012, SOCIOL EDUC, V85, P131, DOI 10.1177/0038040711431585; El Nokali NE, 2010, CHILD DEV, V81, P988, DOI 10.1111/j.1467-8624.2010.01447.x; Yamamoto Y, 2010, SOCIOL EDUC, V83, P67, DOI 10.1177/0038040709356567; Cheadle JE, 2009, SOC SCI RES, V38, P477, DOI 10.1016/j.ssresearch.2008.12.002; McNeal RB, 1999, SOC FORCES, V78, P117; Bodovski K, 2008, SOC SCI RES, V37, P903, DOI 10.1016/j.ssresearch.2008.02.007; Domina T, 2005, SOCIOL EDUC, V78, P233; Cheadle JE, 2011, J FAM ISSUES, V32, P679, DOI 10.1177/0192513X10386305; Hill NE, 2009, DEV PSYCHOL, V45, P740, DOI 10.1037/a0015362; Fan WH, 2010, EDUC PSYCHOL-UK, V30, P53, DOI 10.1080/01443410903353302; Park H, 2011, SOCIOL EDUC, V84, P3, DOI 10.1177/0038040710392719; Aramaki S., 2002, KYOIKU SHAKAIGAKU KE, V71, P5; Beaton A. E., 1996, MATH ACHIEVEMENT MID; Cummings W. K., 1980, ED EQUALITY JAPAN; Gecas V., 1979, CONT THEORIES FAMILY, V1, P365; Hirasawa K., 2008, KYOIKU SHAKAIGAKU KE, V82, P43; Holloway S. D., 2008, EARLY CHILDHOOD RES, P10; Honda Y., 2008, KATEI KYOIKU NO AIRO; Hox JJ, 2010, MULTILEVEL ANAL TECH; Kaneko M., 2004, GAKURYOKU NO SHAKAIG, P153; Kariya T., 2009, KYOIKU TO BYODO TAIS; Kariya T., 2013, ED REFORM SOCIAL CLA; Kariya T., 2000, KYOIKU SHAKAIGAKU KE, V66, P213; Kataoka E., 2009, JAPANESE J FAMILY SO, V21, P30; Kataoka E, 2001, KYAIKUGAKU KENKYD, V68, P259; Kikkawa T., 2009, GAKUREKI BUNDAN SHAK; Kitamura Y., 2013, GLOBAL COE HI STAT D; Koyama O., 2011, KENKYU SHOHO, V60, P92; Lareau A, 2011, UNEQUAL CHILDHOODS: CLASS, RACE, AND FAMILY LIFE, 2ND EDITION, P1; Lareau A., 2003, UNEQUAL CHILDHOODS C; LeTendre G., 1996, RES SOCIOL EDUC, V11, P203; Matsuoka R, 2015, BRIT J SOCIOL EDUC, V36, P270, DOI 10.1080/01425692.2013.820125; Matsuoka R., 2013, RIRON TO HOHO, V28, P87; Ministry of Education Culture Sports Science and Technology (MEXT), SHOCH NO JUGY NI KAN; Ministry of Health Labour and Welfare, NIJ SHUSS JUD CHOS C; Mullis I. V., 1997, MATH ACHIEVEMENT PRI; Muthen B. O., 1998, MPLUS USERS GUIDE; National Institute for Educational Policy Research (NIER), KYOIK KAT KENK SENT; Ochanomizu University, 2014, HEIS 25 NEND ZENK GA; OECD, 2011, QUAL TIM STUD LEARN; Origuchi T., 2008, KYOIKUGAKU ZASSHI, V43, P97; Otawa N., 2008, HEISEI 19 NENDO ZENK, P41; Rosenbaum J. E., 2003, HDB LIFE COURSE, P51, DOI 10.1007/978-0-306-48247-2_3; Shinogaya K., 2012, OYAKOKANKEI TO KAKEI, P81; Sugihara N., 2011, KAKUSA SHAKAI O IKIR, P19; Takata Y., 2000, KYOIKUKI NO KOSODATE; USEEM EL, 1992, SOCIOL EDUC, V65, P263, DOI 10.2307/2112770; Uzuki Y., 2004, JOSEI NO SHUGYO TO O, P114; Young M. D, 1958, RISE MERITOCRACY 187	57	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0049-089X	1096-0317		SOC SCI RES	Soc. Sci. Res.	NOV	2015	54						159	176		10.1016/j.ssresearch.2015.06.009		18	Sociology	Sociology	CT8UQ	WOS:000363092600011		
J	Zhou, FY; Wen, XZ; Fukuwa, NB; Zhu, HP				Zhou, Fangyuan; Wen, Xuezhang; Fukuwa, Nobuo; Zhu, Hongping			A simplified method of calculating the impedance and foundation input motion of foundations with a large number of piles	SOIL DYNAMICS AND EARTHQUAKE ENGINEERING			English	Article						Impedance; Foundation input motion; Neighboring piles; Single equivalent pile; Soil-structure interaction	DYNAMIC BEHAVIOR; SOIL	A new simplified method is developed for the analysis of the impedance and foundation input motion of foundations with a large number of piles. In this proposed method, the neighboring piles are replaced by a single equivalent pile. This process of replacement reduces the number of degrees of freedom, computer memory requirement, and calculation time. To validate the simplified method, the impedance and foundation input motion of a raft foundation and an embedded foundation supported by piles groups are calculated through both the simplified method and the rigorous numerical method. Results show that the proposed simplified method for the impedance and foundation input motion of a foundation with a large number of piles has sufficient accuracy and good computational efficiency. (C) 2015 Elsevier Ltd. All rights reserved.	[Zhou, Fangyuan; Zhu, Hongping] Huazhong Univ Sci & Technol, Sch Civil Engn & Mech, Wuhan 430074, Hubei, Peoples R China; [Wen, Xuezhang] Hunan Univ, Coll Civil Engn, Changsha 410082, Hunan, Peoples R China; [Fukuwa, Nobuo] Nagoya Univ, Grad Sch Environm Studies, Nagoya, Aichi 4648601, Japan	Wen, XZ (reprint author), Hunan Univ, Coll Civil Engn, Changsha 410082, Hunan, Peoples R China.	fangyuanzhou@hust.edu.cn; wenxuezhang630@gmail.com; fukuwa@sharaku.nuac.nagoya-u.ac.jp; hpzhu@mail.hust.edu.cn			National Natural Science Foundation of China [51308243]; National Basic Research Program (973) of China [2011CB013800]	The authors would like to gratefully acknowledge the financial support for this research provide by the National Natural Science Foundation of China (Grant no. 51308243) and the National Basic Research Program (973) of China (Grant no. 2011CB013800).	MAMOON SM, 1990, J ENG MECH-ASCE, V116, P2237, DOI 10.1061/(ASCE)0733-9399(1990)116:10(2237); GAZETAS G, 1991, J GEOTECH ENG-ASCE, V117, P1531, DOI 10.1061/(ASCE)0733-9410(1991)117:10(1531); DOBRY R, 1988, GEOTECHNIQUE, V38, P557; DAVIES TG, 1985, J GEOTECH ENG-ASCE, V111, P1365; GAZETAS G, 1991, EARTHQUAKE ENG STRUC, V20, P115, DOI 10.1002/eqe.4290200203; Hiroshi Asega, 1999, J STRUCT CONSTR ENG, V525, P49; Hisashi Nozoe, 1999, J STRUCT CONSTR ENG, V525, P49; Kaynia A. M., 1991, SOIL DYN EARTHQ ENG, V10, P386, DOI 10.1016/0267-7261(91)90053-3; Kaynia AM, 1982, P 2 INT C NUM METH O, P509; KAYNIA AM, 1992, EARTHQUAKE ENG STRUC, V21, P303, DOI 10.1002/eqe.4290210403; Lysmer J, UCBGT8102; MAKRIS N, 1992, EARTHQUAKE ENG STRUC, V21, P145, DOI 10.1002/eqe.4290210204; MIURA K, 1994, EARTHQUAKE ENG STRUC, V23, P183, DOI 10.1002/eqe.4290230206; NOGAMI T, 1985, EARTHQUAKE ENG STRUC, V13, P321, DOI 10.1002/eqe.4290130306; Shimizu N, 1977, T AIJ, V253, P31; Takano S, 1992, P 10 WCEE, V3, P1767; Wass G, 1972, S7114 U CAL	17	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0267-7261	1879-341X		SOIL DYN EARTHQ ENG	Soil Dyn. Earthq. Eng.	NOV	2015	78						175	188		10.1016/j.soildyn.2015.08.003		14	Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	CT8OC	WOS:000363074900014		
J	Nishiyama, M; Nita, A; Yumimoto, K; Nakayama, KI				Nishiyama, Masaaki; Nita, Akihiro; Yumimoto, Kanae; Nakayama, Keiichi I.			FBXL12-Mediated Degradation of ALDH3 Is Essential for Trophoblast Differentiation During Placental Development	STEM CELLS			English	Article						Trophoblast; Placenta; Differentiation; Targeted gene disruption; Developmental biology	ALDEHYDE DEHYDROGENASE-ACTIVITY; HEMATOPOIETIC STEM-CELLS; METABOLIZING-ENZYMES; LIPID-PEROXIDATION; MOUSE PLACENTA; MICE LACKING; TUMOR-CELLS; CANCER; MARKER; RAT	How stem cells maintain their stemness or initiate exit from the stem cell state for differentiation remains largely unknown. Aldehyde dehydrogenase ( ALDH) activity is a hallmark of stem cells-including embryonic, adult tissue, and cancer stem cells-and is essential for their maintenance. The mechanisms by which ALDH activity is regulated in stem cells have remained poorly understood, however. We now show that the ubiquitin-dependent degradation of ALDH3 mediated by FBXL12 (F box and leucine-rich repeat protein 12) is essential for execution of the differentiation program of trophoblast stem cells (TSCs). FBXL12 is present only in eutherian mammals, and its expression is largely restricted to the placenta during mouse embryogenesis. FBXL12 was found to interact specifically with members of the ALDH3 family and to mediate their polyubiquitylation. Most mice deficient in FBXL12 died during the embryonic or perinatal period probably as a result of abnormal development of the placenta, characterized by impaired formation of the junctional zone. ALDH3 accumulated in the FBXL12-deficient placenta, and forced expression of ALDH3 in wild-type TSCs phenocopied the differentiation defect of FBXL12-deficient TSCs. Conversely, inhibition of ALDH3 activity by gossypol rescued the phenotype of FBXL12 deficiency. Our results suggest that FBXL12 plays a key role in the downregulation of ALDH3 activity in TSCs and thereby initiates trophoblast differentiation during placental development.	[Nishiyama, Masaaki; Nita, Akihiro; Yumimoto, Kanae; Nakayama, Keiichi I.] Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Higashi Ku, Fukuoka, Fukuoka 8128582, Japan	Nakayama, KI (reprint author), Kyushu Univ, Dept Mol & Cellular Biol, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp			KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology in Japan [25221303, 26640080]	We thank S. Matsumura for HTR-8/SVneo cells; M. J. Soares for Rcho-1 cells; S. Tanaka for mouse TSCs; T. Kitamura for pMX-puro; H. Miyoshi for CSII-CMV-MCS and CSII-EF-MCS; J. M. Cunningham and K. Hanada for the mCAT-1 plasmid; D. Bohmann for pMT107 His<INF>6</INF>-Ub; H. Takeda, C. Mitai, K. Tsunematsu, Y. Yamada, K. Takeda, M. Oda, E. Koba, and N. Kinoshita for technical assistance; and N. Wake, K. Asanoma, R. Tsunematsu, C. Meno, and members of our laboratory for discussion. This study was performed as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan. This study was also supported in part by KAKENHI (25221303 and 26640080) from the Ministry of Education, Culture, Sports, Science and Technology in Japan.	Gasparetto M, 2012, EXP HEMATOL, V40, P318, DOI 10.1016/j.exphem.2011.12.006; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Moneypenny CG, 2005, BIOCHEM PHARMACOL, V69, P105, DOI 10.1016/j.bcp.2004.09.001; Soares MJ, 1996, PLACENTA, V17, P277, DOI 10.1016/S0143-4004(96)90051-X; Simmons DG, 2005, DEV BIOL, V284, P12, DOI 10.1016/j.ydbio.2005.05.010; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Nishiyama M, 2004, MOL CELL BIOL, V24, P8386, DOI 10.1128/MCB.24.19.8386-8394.2004; Jean E, 2011, J CELL MOL MED, V15, P119, DOI 10.1111/j.1582-4934.2009.00942.x; Sreerama L, 1997, CLIN CANCER RES, V3, P1901; VERSTUYF A, 1990, INT J CANCER, V45, P752, DOI 10.1002/ijc.2910450430; Rekha GK, 1997, ADV EXP MED BIOL, V414, P133; Tsunematsu R, 2006, MOL CELL BIOL, V26, P6157, DOI 10.1128/MCB.00595-06; Lugli A, 2010, BRIT J CANCER, V103, P382, DOI 10.1038/sj.bjc.6605762; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486; Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418; Lingala S, 2010, EXP MOL PATHOL, V89, P27, DOI 10.1016/j.yexmp.2010.05.005; Storms RW, 1999, P NATL ACAD SCI USA, V96, P9118, DOI 10.1073/pnas.96.16.9118; Sladek NE, 1999, CURR PHARM DESIGN, V5, P607; Cerbone A, 2007, FREE RADICAL BIO MED, V42, P1661, DOI 10.1016/j.freeradbiomed.2007.02.009; CANUTO RA, 1994, CARCINOGENESIS, V15, P1359, DOI 10.1093/carcin/15.7.1359; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Su Y, 2010, CANCER EPIDEM BIOMAR, V19, P327, DOI 10.1158/1055-9965.EPI-09-0865; Yan JL, 2001, DEV BIOL, V235, P422, DOI 10.1006/dbio.2001.0300; Rasheed ZA, 2010, J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Trombetta A, 2007, CHEM-BIOL INTERACT, V165, P239, DOI 10.1016/j.cbi.2006.12.014; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Christ O, 2007, HAEMATOL-HEMATOL J, V92, P1165, DOI 10.3324/haematol.11366; FARIA TN, 1991, ENDOCRINOLOGY, V129, P2895; Adamson SL, 2002, DEV BIOL, V250, P358, DOI [10.1006/dbio.2002.0773, 10.1016/S0012-1606(02)90773-6]; Corti S, 2006, STEM CELLS, V24, P975, DOI 10.1634/stemcells.2005-0217; Muzio G, 2012, FREE RADICAL BIO MED, V52, P735, DOI 10.1016/j.freeradbiomed.2011.11.033; Ullah Z, 2008, GENE DEV, V22, P3024, DOI 10.1101/gad.1718108; KASTAN MB, 1990, BLOOD, V75, P1947; Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI [10.1517/17425255.4.6.697 , 10.1517/17425250802102627]; Burger PE, 2009, STEM CELLS, V27, P2220, DOI 10.1002/stem.135; BENEDETTI A, 1980, BIOCHIM BIOPHYS ACTA, V620, P281, DOI 10.1016/0005-2760(80)90209-X; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Cai JL, 2004, J NEUROCHEM, V88, P212, DOI 10.1046/j.1471-4159.2003.02184.x; Ain R, 2003, DEV BIOL, V260, P176, DOI 10.1016/S0012-1606(03)00210-0; Muzio G, 2006, FREE RADICAL BIO MED, V40, P1929, DOI 10.1016/j.freeradbiomed.2006.01.020; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Rossant J, 2001, NAT REV GENET, V2, P538, DOI 10.1038/35080570; Yumimoto K, 2012, J PROTEOME RES, V11, P3175, DOI 10.1021/pr201216u; Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304; Noda T, 2012, DEV BIOL, V362, P83, DOI 10.1016/j.ydbio.2011.11.019; Buckley SM, 2012, CELL STEM CELL, V11, P783, DOI 10.1016/j.stem.2012.09.011; Estes Bradley T, 2006, J Cell Physiol, V209, P987, DOI 10.1002/jcp.20808; GARDNER RL, 1988, J CELL SCI, P11; JONES RJ, 1995, BLOOD, V85, P2742; Townley-Tilson WHD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089451	51	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	NOV	2015	33	11					3327	3340		10.1002/stem.2088		14	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	CU1FP	WOS:000363265900016		
J	Nakamura, H; Takagi, M				Nakamura, Haruhiko; Takagi, Masayuki			Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons	SURGERY TODAY			English	Review						Lung cancer; Adenocarcinoma; Subtype; Chest surgery; Prognosis	GROUND-GLASS OPACITY; RESPIRATORY SOCIETY CLASSIFICATION; PREDOMINANT HISTOLOGIC SUBTYPE; RAS ONCOGENE ACTIVATION; LIMITED-RESECTION TRIAL; EGFR GENE-MUTATIONS; STAGE-I DISEASE; INTERNATIONAL-ASSOCIATION; PROGNOSTIC VALUE; DRIVER MUTATIONS	In 2011, a new pathological classification of lung adenocarcinoma was proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society and the European Respiratory Society. The new criteria classify adenocarcinomas into eight subtypes according to their histological features. The criteria introduce a new concept of early stage lung cancer, consisting of adenocarcinoma in situ and minimally invasive adenocarcinoma, and categorize invasive adenocarcinomas by the predominant histological pattern. In addition to morphological differences among subtypes, the classification also considers the tumor behavior based on the genetic background within each subtype. We herein review the clinical impact of this new classification for chest surgeons based on the data from several recent validation studies from various institutions.	[Nakamura, Haruhiko] St Marianna Univ, Dept Chest Surg, Sch Med, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan; [Takagi, Masayuki] St Marianna Univ, Sch Med, Dept Pathol, Kawasaki, Kanagawa 2168511, Japan	Nakamura, H (reprint author), St Marianna Univ, Dept Chest Surg, Sch Med, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168511, Japan.	h-nakamura@marianna-u.ac.jp					Kadota K, 2012, ANN SURG ONCOL, V19, P3598, DOI 10.1245/s10434-012-2414-3; Nakata M, 2005, J THORAC CARDIOV SUR, V129, P1226, DOI 10.1016/j.jtcvs.2004.10.032; Nakamura H, 2014, SURG TODAY, V44, P1004, DOI 10.1007/s00595-013-0636-z; Russell PA, 2013, J THORAC ONCOL, V8, P461, DOI 10.1097/JTO.0b013e3182828fb8; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; RODENHUIS S, 1988, CANCER RES, V48, P5738; Tsuta K, 2013, LUNG CANCER, V81, P371, DOI 10.1016/j.lungcan.2013.06.012; Lee HJ, 2013, RADIOLOGY, V268, P254, DOI 10.1148/radiol.13112553; Nakamura H, 2004, LUNG CANCER-J IASLC, V44, P61, DOI 10.1016/j.lungcan.2003.09.025; Zell JA, 2005, J CLIN ONCOL, V23, P8396, DOI 10.1200/JCO.2005.03.0312; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Inoue A, 2013, ANN ONCOL, V24, P54, DOI 10.1093/annonc/mds214; Wang R, 2014, J THORAC ONCOL, V9, P760, DOI 10.1097/JTO.0b013e3182a406d1; Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Serizawa M, 2014, CANCER-AM CANCER SOC, V120, P1471, DOI 10.1002/cncr.28604; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Hung JJ, 2013, ANN SURG, V258, P1079, DOI 10.1097/SLA.0b013e31828920c0; Uramoto H, 2014, SURG TODAY, V44, P2249, DOI 10.1007/s00595-014-0861-0; Mansuet-Lupo A, 2014, CHEST, V146, P633, DOI 10.1378/chest.13-2499; Nakamura K, 2010, JPN J CLIN ONCOL, V40, P271, DOI 10.1093/jjco/hyp156; Gu J, 2013, J SURG ONCOL, V107, P474, DOI 10.1002/jso.23259; Nakao M, 2012, J THORAC ONCOL, V7, P1563, DOI 10.1097/JTO.0b013e3182641b5c; Warth A, 2012, VIRCHOWS ARCH, V461, P185, DOI 10.1007/s00428-012-1263-6; Woo T, 2012, PATHOL INT, V62, P785, DOI 10.1111/pin.12016; Yasuda M, 2014, SURG TODAY, V44, P1626, DOI 10.1007/s00595-013-0719-x; Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270; Shaw AT, 2014, NEW ENGL J MED, V370, P1189, DOI 10.1056/NEJMoa1311107; Yoshino I, 2014, SURG TODAY, V44, P302, DOI 10.1007/s00595-013-0509-5; Li H, 2013, LUNG CANCER, V79, P8, DOI 10.1016/j.lungcan.2012.09.018; Kawaguchi T, 2010, J THORAC ONCOL, V5, P1001, DOI 10.1097/JTO.0b013e3181e2f607; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Yoshida T, 2013, J CANCER RES CLIN, V139, P1691, DOI 10.1007/s00432-013-1495-0; Campos-Parra AD, 2014, EUR RESPIR J, V43, P1439, DOI 10.1183/09031936.00138813; Godoy MCB, 2012, J THORAC IMAG, V27, P240, DOI 10.1097/RTI.0b013e31825d515b; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Araki K, 2014, ANTICANCER RES, V34, P3153; NOGUCHI M, 1995, CANCER, V75, P2844, DOI 10.1002/1097-0142(19950615)75:12<2844::AID-CNCR2820751209>3.0.CO;2-#; Song Z, 2013, EJSO-EUR J SURG ONC, V39, P1262, DOI 10.1016/j.ejso.2013.08.026; Westaway DD, 2013, PATHOLOGY, V45, P553, DOI 10.1097/PAT.0b013e32836532ae; Asamura H, 2008, J THORAC ONCOL, V3, P46, DOI 10.1097/JTO.0b013e31815e8577; Kadota K, 2014, MODERN PATHOL, V27, P690, DOI 10.1038/modpathol.2013.188; Shames DS, 2014, J PATHOL, V232, P121, DOI 10.1002/path.4275; Meng DQ, 2013, LUNG CANCER, V81, P1, DOI 10.1016/j.lungcan.2013.03.019; Oxnard GR, 2013, J CLIN ONCOL, V31, P1097, DOI 10.1200/JCO.2012.42.9829; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P668, DOI 10.5858/arpa.2012-0263-RA; Yoshizawa A, 2011, MODERN PATHOL, V24, P653, DOI 10.1038/modpathol.2010.232; Yanagawa N, 2014, ANN THORAC SURG, V98, P453, DOI 10.1016/j.athoracsur.2014.04.108; Darling GE, 2011, J THORAC CARDIOV SUR, V141, P662, DOI 10.1016/j.jtcvs.2010.11.008; Shapiro M, 2013, CHEST, V144, P1615, DOI 10.1378/chest.12-3069; Izar B, 2013, ANN THORAC SURG, V96, P962, DOI 10.1016/j.athoracsur.2013.05.091; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Goss GD, 2013, J CLIN ONCOL, V31, P3320, DOI 10.1200/JCO.2013.51.1816; D'Angelo SP, 2012, J THORAC ONCOL, V7, P1815, DOI 10.1097/JTO.0b013e31826bb7b2; Warth A, 2012, J CLIN ONCOL, V30, P1438, DOI 10.1200/JCO.2011.37.2185; Yoshida J, 2005, J THORAC CARDIOV SUR, V129, P991, DOI 10.1016/j.jtcvs.2004.07.038; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Zhang Y, 2012, CLIN CANCER RES, V18, P1947, DOI 10.1158/1078-0432.CCR-11-2511; Nitadori J, 2013, JNCI-J NATL CANCER I, V105, P1212, DOI 10.1093/jnci/djt166; Sonobe M, 2012, ANN SURG ONCOL, V19, pS347, DOI 10.1245/s10434-011-1799-8; Cha MJ, 2014, J THORAC CARDIOV SUR, V147, P921, DOI 10.1016/j.jtcvs.2013.09.045; Colby TV, 2004, PATHOLOGY GENETICS T, P35; Honda T, 2013, CLIN RADIOL, V68, pE21, DOI 10.1016/j.crad.2012.09.002; Hu HD, 2013, J THORAC DIS, V5, P841, DOI 10.3978/j.issn.2072-1439.2013.12.16; Hwang DH, 2013, ARCH PATHOL LAB MED, V138, P626; Kadota K, 2014, AM J SURG PATHOL, V38, P448, DOI 10.1097/PAS.0000000000000134; Kim H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076999; Nakamura Haruhiko, 2008, Gen Thorac Cardiovasc Surg, V56, P421, DOI 10.1007/s11748-008-0262-7; Sim HJ, 2014, EUR J CARDIOTHORAC S; Song ZB, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0645-1; Yoshizawa A, 2013, J THORAC ONCOL, V8, P52, DOI 10.1097/JTO.0b013e3182769aa8	70	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1341	1351		10.1007/s00595-014-1089-8		11	Surgery	Surgery	CT8DE	WOS:000363044400001		
J	Hayashi, S; Fujii, M; Takayama, T				Hayashi, Shigeoki; Fujii, Masashi; Takayama, Tadatoshi			Prevention of postoperative small bowel obstruction in gastric cancer	SURGERY TODAY			English	Review						Small bowel obstruction; Gastric cancer; Laparoscopic gastrectomy; Hyaluronic acid/carboxymethylcellulose	ICODEXTRIN 4-PERCENT SOLUTION; OPEN DISTAL GASTRECTOMY; SOLUBLE CONTRAST AGENT; INTESTINAL-OBSTRUCTION; ADHESION FORMATION; BIORESORBABLE MEMBRANE; RANDOMIZED TRIAL; GLOVE POWDER; SURGERY; METAANALYSIS	Postoperative adhesion is a frequent problem in patients undergoing surgery. In particular, gastrectomy is associated with a high risk of bowel obstruction. However, there are few reports of small bowel obstruction (SBO) after gastrectomy in the English-language literature. We reviewed the literature to assess the effectiveness of various techniques for preventing adhesion in patients treated with gastrectomy. We assumed that strategies used to prevent postoperative adhesion associated with colorectal surgery, cholecystectomy, appendectomy and gynecologic procedures are similar to those used in gastrectomy. We therefore reviewed reports on the prevention of postoperative SBO in any abdominal surgical procedure, focusing especially on gastrectomy. General intraoperative preventive techniques, such as the use of starch-free gloves, saline irrigation at a temperature below 37 A degrees C and laparoscopic techniques whenever possible, may reduce the incidence of SBO in patients with gastric cancer who undergo gastrectomy. If preserving the omentum is unrelated to the survival rate of patients with gastric cancer, this technique should be recommended for preventing postoperative SBO. The use of hyaluronic acid/carboxymethylcellulose bioabsorbable membranes should also be considered in patients undergoing gastrectomy. However, demonstrating the advantages of bioabsorbable membranes would require larger randomized studies with a longer follow-up period.	[Hayashi, Shigeoki; Fujii, Masashi; Takayama, Tadatoshi] Nihon Univ, Dept Digest Surg, Sch Med, Itabashi Ku, Tokyo 1738610, Japan	Hayashi, S (reprint author), Nihon Univ, Dept Digest Surg, Sch Med, Itabashi Ku, 30-1 Ooyaguchikamimachi, Tokyo 1738610, Japan.	hayashi.shigeoki@nihon-u.ac.jp					ASSALIA A, 1994, SURGERY, V115, P433; Catena F, 2012, J GASTROINTEST SURG, V16, P382, DOI 10.1007/s11605-011-1736-y; Brown CB, 2007, FERTIL STERIL, V88, P1413, DOI 10.1016/j.fertnstert.2006.12.084; Saravelos H, 1996, HUM REPROD, V11, P992; Lee WS, 2013, SURG TODAY, V43, P995, DOI 10.1007/s00595-013-0490-z; Lee JH, 2009, SURG ENDOSC, V23, P1759, DOI 10.1007/s00464-008-0198-0; Mochiki E, 2002, WORLD J SURG, V26, P1145, DOI 10.1007/s00268-002-6286-8; Mohri Y, 2013, INT SURG, V98, P271, DOI 10.9738/INTSURG-D-13-00025.1; van den Tol MP, 2001, BRIT J SURG, V88, P1258, DOI 10.1046/j.0007-1323.2001.01846.x; COOKE SAR, 1977, BRIT J SURG, V64, P410, DOI 10.1002/bjs.1800640610; CADE D, 1976, EUR SURG RES, V8, P471, DOI 10.1159/000127891; Mohri Y, 2005, AM SURGEON, V71, P861; Inoue M, 2013, J PEDIATR SURG, V48, P1528, DOI 10.1016/j.jpedsurg.2013.01.028; Abbas SM, 2007, BRIT J SURG, V94, P404, DOI 10.1002/bjs.5775; Korenaga D, 2001, HEPATO-GASTROENTEROL, V48, P1389; Sugimachi K, 2008, HEPATO-GASTROENTEROL, V55, P496; KAMFFER WJ, 1992, S AFR MED J, V81, P158; Hasegawa S, 2013, JPN J CLIN ONCOL, V43, P214, DOI 10.1093/jjco/hys208; KAPPAS AM, 1988, BRIT J SURG, V75, P854, DOI 10.1002/bjs.1800750908; Hayashi S, 2008, ANN SURG, V247, P766, DOI 10.1097/SLA.0b013e3181656d4e; MAIS V, 1995, OBSTET GYNECOL, V86, P512, DOI 10.1016/S0029-7844(95)80007-7; Branco BC, 2010, BRIT J SURG, V97, P470, DOI 10.1002/bjs.7019; Fazio VW, 2006, DIS COLON RECTUM, V49, P1, DOI 10.1007/s10350-005-0268-5; Yasunaga H, 2013, ANN SURG, V257, P640, DOI 10.1097/SLA.0b013e31826fd541; Hosono S, 2006, WORLD J GASTROENTERO, V12, P7676; Markogiannakis H, 2007, WORLD J GASTROENTERO, V13, P432; Zielinski MD, 2010, WORLD J SURG, V34, P910, DOI 10.1007/s00268-010-0479-3; Moran BJ, 2007, COLORECTAL DIS, V9, P39, DOI 10.1111/j.1463-1318.2007.01347.x; Kawamura H, 2010, SURG TODAY, V40, P223, DOI 10.1007/s00595-008-4059-1; Beck DE, 2003, DIS COLON RECTUM, V46, P1310; Fujita J, 2003, JPN J GASTROENTEROL, V36, P1151; Inaba Tsuyoshi, 2004, Gastric Cancer, V7, P167; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Lee FJ, 2004, ANN COLL SURG H K, V8, P120; MENZIES D, 1990, ANN ROY COLL SURG, V72, P60; Shimizu K, 2003, JPN J CLIN SURG, V64, P801	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1352	1359		10.1007/s00595-014-1106-y		8	Surgery	Surgery	CT8DE	WOS:000363044400002		
J	Akutsu, Y; Matsubara, H				Akutsu, Yasunori; Matsubara, Hisahiro			Chemoradiotherapy and surgery for T4 esophageal cancer in Japan	SURGERY TODAY			English	Review						Esophageal cancer; T4; Chemoradiotherapy; Surgery; Japan	SQUAMOUS-CELL CARCINOMA; DEFINITIVE CHEMORADIOTHERAPY; RADIATION-THERAPY; PREOPERATIVE CHEMORADIOTHERAPY; NEOADJUVANT CHEMORADIOTHERAPY; CONCURRENT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; ADJACENT ORGANS; NECK-CANCER; CISPLATIN	Esophageal cancer is thought to be the most malignant neoplasm due to its biological aggressiveness. The most effective treatment modality for esophageal cancer, particularly T4 esophageal cancer, is chemoradiotherapy (CRT). Some T4 patients show long-term survival after receiving CRT, suggesting that even T4 esophageal cancer can be cured with this modality. Although surgery is performed after CRT in some T4 cases, its prognostic benefit is controversial. In this paper, we review the status of CRT and conversion surgery as well as the development of new regimens and discuss the future prospects of CRT in the treatment of T4 esophageal cancer in Japan.	[Akutsu, Yasunori; Matsubara, Hisahiro] Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chuo Ku, Chiba 2608670, Japan	Akutsu, Y (reprint author), Chiba Univ, Grad Sch Med, Dept Frontier Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	yakutsu@faculty.chiba-u.jp					Akutsu Y, 2014, WORLD J SURG, V38, P2891, DOI 10.1007/s00268-014-2668-y; Ohtsu A, 1999, J CLIN ONCOL, V17, P2915; Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118; Minsky BD, 2002, J CLIN ONCOL, V20, P1167, DOI 10.1200/JCO.20.5.1167; Yoneda M, 2013, ANTICANCER RES, V33, P2699; CHAK A, 1995, GASTROINTEST ENDOSC, V42, P501, DOI 10.1016/S0016-5107(95)70001-3; Wakamatsu T, 2006, RESPIRATION, V73, P651, DOI 10.1159/000093160; Fujita H, 2005, J SURG ONCOL, V90, P209, DOI 10.1002/jso.20259; Kuroda J, 2012, J GASTROEN HEPATOL, V27, P88, DOI 10.1111/j.1440-1746.2012.07078.x; Ikeda K, 2001, DIS ESOPHAGUS, V14, P197, DOI 10.1046/j.1442-2050.2001.00184.x; Zhang JX, 2013, INT J CANCER, V132, P2567, DOI 10.1002/ijc.27930; Ohtsu A, 1995, JPN J CLIN ONCOL, V25, P261; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Pimiento JM, 2013, ANN SURG ONCOL, V20, P2706, DOI 10.1245/s10434-013-2885-x; Akutsu Y, 2012, J SURG ONCOL, V105, P750, DOI 10.1002/jso.22127; Noguchi T, 2003, DIS ESOPHAGUS, V16, P94, DOI 10.1046/j.1442-2050.2003.00304.x; Seto Y, 2007, CANCER SCI, V98, P937, DOI 10.1111/j.1349-7006.2007.00479.x; Makuuchi Y, 2013, CANCER SCI, V104, P1045, DOI 10.1111/cas.12187; Crosby TDL, 2004, BRIT J CANCER, V90, P70, DOI 10.1038/sj.bjc.6601461; Kim TJ, 2009, RADIOGRAPHICS, V29, P403, DOI 10.1148/rg.292085106; Wayman J, 2001, POSTGRAD MED J, V77, P181, DOI 10.1136/pmj.77.905.181; Yusup G, 2014, INT J ONCOL, V44, P1146, DOI 10.3892/ijo.2014.2300; Yamada I, 2006, J MAGN RESON IMAGING, V24, P1326, DOI 10.1002/jmri.20741; Ishida K, 2004, JPN J CLIN ONCOL, V34, P615, DOI 10.1093/jjco/hyh107; Imanishi S, 2013, DIGEST SURG, V30, P240, DOI 10.1159/000351435; Shimada H, 2008, J AM COLL SURGEONS, V206, P48, DOI 10.1016/j.jamcollsurg.2007.06.013; Nishimura Y, 2002, INT J RADIAT ONCOL, V53, P134, DOI 10.1016/S0360-3016(01)02813-9; Yano M, 1999, J SURG ONCOL, V70, P25, DOI 10.1002/(SICI)1096-9098(199901)70:1<25::AID-JSO5>3.0.CO;2-M; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; VanRaemdonck D, 1997, EUR J CARDIO-THORAC, V11, P828, DOI 10.1016/S1010-7940(97)01194-9; Ito B, 2005, EUR J RADIOL, V54, P377, DOI 10.1016/j.ejrad.2004.09.006; Shimoji H, 2013, WORLD J SURG, V37, P2180, DOI 10.1007/s00268-013-2074-x; Higuchi K, 2008, RADIOTHER ONCOL, V87, P398, DOI 10.1016/j.radonc.2008.03.006; Akutsu Y, 2011, ANN SURG ONCOL, V18, P2946, DOI 10.1245/s10434-011-1645-z; Yokota T, 2011, ANTICANCER RES, V31, P3535; Miyata H, 2012, J SURG ONCOL, V106, P441, DOI 10.1002/jso.23081; Makino T, 2011, ANN THORAC CARDIOVAS, V17, P221, DOI 10.5761/atcs.ra.11.01676; Fujita H, 2005, WORLD J SURG, V29, P25, DOI 10.1007/s00268-004-7590-2; Fujita H, 2005, WORLD J SURG, V29, P30; Higuchi K, 2014, INT J RAD ONCOL BIOL; Hironaka S, 2014, CANCER SCI, V105, P1189, DOI 10.1111/cas.12486; Japan Esophageal Society, 2012, GUID DIAGN TREATM CA; Karimata H, 2014, SURG TODAY; Shinoda M, 2010, ASCO ANN M P S15, V28, P4053; Tachimori Y, 2014, ESOPHAGUS-TOKYO, V11, P21, DOI 10.1007/s10388-013-0393-5	45	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1360	1365		10.1007/s00595-015-1116-4		6	Surgery	Surgery	CT8DE	WOS:000363044400003		
J	Maeda, K; Nagahara, H; Shibutani, M; Otani, H; Sakurai, K; Toyokawa, T; Tanaka, H; Kubo, N; Muguruma, K; Kamata, N; Yamagami, H; Hirakawa, K				Maeda, Kiyoshi; Nagahara, Hisashi; Shibutani, Masatsune; Otani, Hiroshi; Sakurai, Katsunobu; Toyokawa, Takahiro; Tanaka, Hiroaki; Kubo, Naoshi; Muguruma, Kazuya; Kamata, Noriko; Yamagami, Hirokazu; Hirakawa, Kosei			A preoperative low nutritional prognostic index correlates with the incidence of incisional surgical site infections after bowel resection in patients with Crohn's disease	SURGERY TODAY			English	Article						Crohn's disease; Incisional surgical site infection; Nutritional prognostic index	INTRAABDOMINAL SEPTIC COMPLICATIONS; C-REACTIVE PROTEIN; RISK-FACTORS; ULCERATIVE-COLITIS; COLORECTAL-CANCER; ACCENT-I; INFLIXIMAB; SURGERY; TRIAL; MAINTENANCE	The incidence of incisional surgical site infections (SSIs) is reported to be higher among patients with Crohn's disease (CD) than among those with colorectal cancer. It has also been reported that the preoperative nutritional and inflammatory status is associated with the frequency of postoperative complications. Onodera's prognostic nutritional index (OPNI) is a simple and useful parameter for determining the nutritional and inflammatory status. In the present study, we retrospectively investigated the correlation between the OPNI and the incidence of incisional SSI in patients with CD who had undergone bowel resection. A total of 177 CD patients who underwent abdominal surgery were enrolled. Various clinical factors and the OPNI values were evaluated to identify risk factors for incisional SSIs. The incidence of incisional SSIs was 19.8 %. A multivariate analysis indicated that the OPNI was an independent risk factor for incisional SSIs. The results of this retrospective study suggest that the OPNI is an independent risk factor for incisional SSIs in patients with a history of bowel resection for CD.	[Maeda, Kiyoshi; Nagahara, Hisashi; Shibutani, Masatsune; Otani, Hiroshi; Sakurai, Katsunobu; Toyokawa, Takahiro; Tanaka, Hiroaki; Kubo, Naoshi; Muguruma, Kazuya; Hirakawa, Kosei] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka 558, Japan; [Kamata, Noriko; Yamagami, Hirokazu] Osaka City Univ, Grad Sch Med, Dept Gastroenterol, Osaka 558, Japan	Maeda, K (reprint author), Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, 1-4-3 Asahimachi, Osaka 558, Japan.	m1378386@med.osaka-cu.ac.jp					Alp E, 2014, SURG TODAY, V44, P685, DOI 10.1007/s00595-013-0705-3; Beattie AH, 2000, GUT, V46, P813, DOI 10.1136/gut.46.6.813; Oh CA, 2012, WORLD J GASTROENTERO, V18, P673, DOI 10.3748/wjg.v18.i7.673; Kanazawa A, 2012, DIS COLON RECTUM, V55, P957, DOI 10.1097/DCR.0b013e3182617716; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Moyes LH, 2009, BRIT J CANCER, V100, P1236, DOI 10.1038/sj.bjc.6604997; Shinkawa H, 2013, SURG TODAY, V43, P276, DOI 10.1007/s00595-012-0350-2; Braga M, 1998, NUTRITION, V14, P831, DOI 10.1016/S0899-9007(98)00103-8; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2007.11.041; Iesalnieks I, 2008, INT J COLORECTAL DIS, V23, P1167, DOI 10.1007/s00384-008-0534-9; Watanabe M, 2012, WORLD J SURG, V36, P1632, DOI 10.1007/s00268-012-1526-z; Yamamoto T, 2000, DIS COLON RECTUM, V43, P1141, DOI 10.1007/BF02236563; Appau KA, 2008, J GASTROINTEST SURG, V12, P1738, DOI 10.1007/s11605-008-0646-0; CRUSE PJE, 1980, SURG CLIN N AM, V60, P27; Burden ST, 2010, J HUM NUTR DIET, V23, P402, DOI 10.1111/j.1365-277X.2010.01070.x; Lohsiriwat V, 2008, WORLD J GASTROENTERO, V14, P1248, DOI 10.3748/wjg.14.1248; Alves A, 2007, DIS COLON RECTUM, V50, P331, DOI 10.1007/s10350-006-0782-0; Ordas I, 2011, GUT, V60, P1754, DOI 10.1136/gutjnl-2011-300934; Uchino M, 2009, WORLD J SURG, V33, P1042, DOI 10.1007/s00268-009-9934-4; Reinisch W, 2012, ALIMENT PHARM THER, V35, P568, DOI 10.1111/j.1365-2036.2011.04987.x; Ferrante M, 2009, INFLAMM BOWEL DIS, V15, P1062, DOI 10.1002/ibd.20863; Araki T, 2014, SURG TODAY, V44, P1072, DOI 10.1007/s00595-013-0809-9; Kopylov U, 2012, INFLAMM BOWEL DIS, V18, P2404, DOI 10.1002/ibd.22954; Ali T, 2012, WORLD J GASTROENTERO, V18, P197, DOI 10.3748/wjg.v18.i3.197; Beleo-Tome C, 2012, BR J NUTR, V108, P343; Culver DH, 1991, AM J MED S3B, V91, P152; Gasche C, 2000, INFLAMM BOWEL DIS, V6, P8; Hnauer SB, 2006, GASTROENTEROLOGY, V130, P323; Kamat A A, 2000, Infect Dis Obstet Gynecol, V8, P230, DOI 10.1155/S1064744900000338; Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0; Matthiessen P, 2008, COLORECTAL DIS, V10, P75, DOI 10.1111/j.1463-1318.2007.01300.x; Oh CA, 2010, J KOREAN GASTRIC CAN, V10, P5; Onodera T, 1984, Nihon Geka Gakkai Zasshi, V85, P1001; The examination Comiitee of Criteria for 'Obesity Disease' in Japan Japan Society for the Study of Obesity, 2002, CIR J, V66, P987, DOI DOI 10.1253/CIRCJ.66.987; Weisch T, 2007, INT J COLORECTAL DIS, V22, P1499	35	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1366	1372		10.1007/s00595-014-1044-8		7	Surgery	Surgery	CT8DE	WOS:000363044400004		
J	Maeda, T; Ito, T; Kurimoto, Y; Watanabe, T; Kuroda, Y; Kawaharada, N; Higami, T				Maeda, Toshiyuki; Ito, Toshiro; Kurimoto, Yoshihiko; Watanabe, Toshitaka; Kuroda, Yohsuke; Kawaharada, Nobuyoshi; Higami, Tetsuya			Risk factors for a persistent type 2 endoleak after endovascular aneurysm repair	SURGERY TODAY			English	Article						Abdominal aortic aneurysm; Endovascular surgery; Type 2 endoleak	ABDOMINAL AORTIC-ANEURYSM; II ENDOLEAKS; SELECTIVE INTERVENTION; COIL EMBOLIZATION; SAC; EXPERIENCE; BENIGN; SAFE	To investigate the natural course of type 2 endoleaks (T2Es) and to identify the risk factors associated with a persistent T2E after endovascular aneurysm repair (EVAR). The medical records of patients who underwent EVAR for the treatment of an atherosclerotic abdominal aortic aneurysm between October 2006 and December 2011 at our institute were reviewed. T2Es were diagnosed by contrast-enhanced computed tomography within 4 weeks of EVAR, and patients were followed up at 6 and 12 months. In cases where a T2E was detected, the blood vessels responsible for the T2E were identified and statistically analyzed for their association with a persistent T2E. We identified T2Es in 111 of 469 patients within 4 weeks of undergoing EVAR. During the follow-up, 41 patients (36.9 %) showed spontaneous resolution of their T2E. The percentage of patients with a T2E was 75.4, 69.2 and 58.0 % at 6, 12 and 24 months, respectively. T2E caused by defects in multiple vessels and T2E associated with the fourth lumbar artery were identified as risk factors associated with a persistent T2E in the univariate analysis. In the multivariate analysis, T2E caused by multiple vessels was identified as the only independent risk factor for a persistent T2E. We identified T2E caused by multiple vessel failure as an independent risk factor for persistent T2E.	[Maeda, Toshiyuki; Ito, Toshiro; Kurimoto, Yoshihiko; Watanabe, Toshitaka; Kuroda, Yohsuke; Kawaharada, Nobuyoshi; Higami, Tetsuya] Sapporo Med Univ, Dept Cardiovasc Surg, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Ito, T (reprint author), Sapporo Med Univ, Dept Cardiovasc Surg, Chuo Ku, South 1 West 16, Sapporo, Hokkaido 0608543, Japan.	t.ito@sapmed.ac.jp					Timaran CH, 2004, J VASC SURG, V39, P1157, DOI 10.1016/j.jvs.2003.12.033; Solis MM, 2002, J VASC SURG, V36, P485, DOI 10.1067/mva.2002.126542; Silverberg D, 2006, J VASC SURG, V44, P453, DOI 10.1016/j.jvs.2006.04.058; Kasirajan K, 2003, J VASC SURG, V38, P61, DOI 10.1016/S0741-5214(02)75467-0; Arko FR, 2001, J ENDOVASC THER, V8, P503, DOI 10.1583/1545-1550(2001)008<0503:TIEFEA>2.0.CO;2; Nolz R, 2012, J ENDOVASC THER, V19, P193, DOI 10.1583/11-3803.1; Bobadilla JL, 2010, J VASC SURG, V52, P267, DOI 10.1016/j.jvs.2010.02.290; Jones JE, 2007, J VASC SURG, V46, P1, DOI 10.1016/j.jvs.2007.02.073; El Batti S, 2013, J VASC SURG, V57, P1291, DOI 10.1016/j.jvs.2012.10.118; Kodama A, 2011, CIRC J, V75, P550, DOI 10.1253/circj.CJ-09-0576; Abularrage CJ, 2012, J VASC SURG, V56, P630, DOI 10.1016/j.jvs.2012.02.038; Beeman BR, 2010, J VASC SURG, V52, P1147, DOI 10.1016/j.jvs.2010.06.099; Tuerff SN, 2002, ANN VASC SURG, V16, P50, DOI 10.1007/s10016-001-0126-4; Abularrage CJ, 2010, J VASC SURG, V52, P19, DOI 10.1016/j.jvs.2010.02.023; Steinmetz E, 2004, J VASC SURG, V39, P306, DOI 10.1016/j.jvs.2003.10.026; AbuRahma AF, 2011, J VASC SURG, V53, P1534, DOI 10.1016/j.jvs.2011.02.016; Schermerhorn ML, 2008, NEW ENGL J MED, V358, P464, DOI 10.1056/NEJMoa0707348; Marchiori A, 2011, J ENDOVASC THER, V18, P299, DOI 10.1583/10-3116.1; Harris PL, 2000, J VASC SURG, V32, P739, DOI 10.1067/mva.2000.109990; Koyanagi T, 2010, ECHOCARDIOGR-J CARD, V27, P17, DOI 10.1111/j.1540-8175.2009.00970.x	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1373	1377		10.1007/s00595-014-1070-6		5	Surgery	Surgery	CT8DE	WOS:000363044400005		
J	Hanada, M; Furuya, T; Sugito, K; Ohashi, K; Ikeda, T; Koshinaga, T; Kawashima, H; Inoue, M; Hosoda, T; Goto, H				Hanada, Manabu; Furuya, Takeshi; Sugito, Kiminobu; Ohashi, Kensuke; Ikeda, Taro; Koshinaga, Tsugumichi; Kawashima, Hiroyuki; Inoue, Mikiya; Hosoda, Toshifumi; Goto, Hiroshi			Evaluation of the efficacy of incision and drainage versus hainosankyuto treatment for perianal abscess in infants: a multicenter study	SURGERY TODAY			English	Article						Perianal abscess; Incision and drainage; Hainosankyuto; Infant	FISTULA-IN-ANO; NONOPERATIVE MANAGEMENT; ETIOLOGY; CHILDREN; SETON	We retrospectively compared the short-term outcomes between incision and drainage (ID) and hainosankyuto (TJ-122, Tsumura & Co, Tokyo, Japan) treatment for perianal abscess (PA) in infants. We retrospectively examined 48 consecutive patients (median age 129 days; range 19-330 days) who presented with PA over a 3 year period. Group 1 comprised 26 patients who were treated with ID at presentation, and Group 2 comprised 22 patients who were treated with oral TJ-122 at presentation; oral treatment was continued until the disappearance of purulent discharge and resolution of induration at the abscess site. PAs were identified in all 48 patients at presentation. The median duration of follow-up was 26 months (range 13-40 months). At presentation, there were no differences in the gender, age, birth weight, duration of symptoms, skin erosion or prevalence of diarrhea between the two groups. Purulent discharge resolved within a median period of 26 days (range 7-42 days) in Group 2, but persisted for 40 days (range 4-196 days) in Group 1. The induration resolved within a median period of 39 days (range 7-91 days) in Group 2, but persisted for 70 days (range 4-308 days) in Group 1 (p = 0.04). TJ-122 treatment was more beneficial than ID in treating PA in infants.	[Hanada, Manabu; Furuya, Takeshi; Sugito, Kiminobu; Ohashi, Kensuke; Ikeda, Taro; Koshinaga, Tsugumichi] Nihon Univ, Sch Med, Dept Pediat Surg, Itabashi Ku, Tokyo 1738610, Japan; [Kawashima, Hiroyuki] Kawagoe Mitsui Hosp, Dept Surg, Kawagoe, Saitama, Japan; [Inoue, Mikiya] Teikyo Univ, Sch Med, Dept Pediat Surg, Itabashi Ku, Tokyo, Japan; [Hosoda, Toshifumi] Numazu City Hosp, Dept Surg, Numazu, Japan; [Goto, Hiroshi] Tokyo Metropolitan Otsuka Hosp, Dept Pediat Surg, Toshima Ku, Tokyo, Japan	Sugito, K (reprint author), Nihon Univ, Sch Med, Dept Pediat Surg, Itabashi Ku, 30-1 Ohyaguchikami Cho, Tokyo 1738610, Japan.	sugitou.kiminobu@nihon-u.ac.jp					Kawahara H, 2011, PEDIATR INT, V53, P892, DOI 10.1111/j.1442-200X.2011.03395.x; Christison-Lagay ER, 2007, PEDIATRICS, V120, pE548, DOI 10.1542/peds.2006-3092; Ezer SS, 2010, J PAEDIATR CHILD H, V46, P92, DOI 10.1111/j.1440-1754.2009.01644.x; Kubota M, 2010, PEDIATR SURG INT, V26, P1037, DOI 10.1007/s00383-010-2664-8; POENARU D, 1993, J PEDIATR SURG, V28, P1194; Festen C, 1998, J PEDIATR SURG, V33, P711, DOI 10.1016/S0022-3468(98)90193-2; Watanabe Y, 1998, PEDIATR SURG INT, V13, P274, DOI 10.1007/s003830050315; Rosen NG, 2000, J PEDIATR SURG, V35, P938, DOI 10.1053/jpsu.2000.6931; Novotny NM, 2008, PEDIATR SURG INT, V24, P1197, DOI 10.1007/s00383-008-2236-3; Ikeda T, 2007, J PEDIATR SURG, V42, P1095, DOI 10.1016/j.jpedsurg.2007.01.062; Inoue M, 2014, J GASTROINTEST SURG, V18, P580, DOI 10.1007/s11605-013-2351-x; Macdonald A, 2003, BRIT J SURG, V90, P220, DOI 10.1002/bjs.4017; Minami M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022188; Nishida Shigehito, 2003, Journal of Infection and Chemotherapy, V9, P58, DOI 10.1007/s10156-002-0211-9; Shimizu S, 1997, NIHON TOYO IGAKU ZAS, V48, P369; Stites Thomas, 2007, Semin Pediatr Surg, V16, P71, DOI 10.1053/j.sempedsurg.2006.10.010	16	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1385	1389		10.1007/s00595-014-1058-2		5	Surgery	Surgery	CT8DE	WOS:000363044400007		
J	Ueno, H; Hattori, A; Matsunaga, T; Takamochi, K; Oh, S; Suzuki, K				Ueno, Hiroyasu; Hattori, Aritoshi; Matsunaga, Takeshi; Takamochi, Kazuya; Oh, Shiaki; Suzuki, Kenji			Is lower zone mediastinal nodal dissection always mandatory for lung cancer in the lower lobe?	SURGERY TODAY			English	Article						Lung cancer; Lower zone lymph node; Lymph node dissection; Predictive factor	SECTION COMPUTED-TOMOGRAPHY; GROUND-GLASS OPACITY; RANDOMIZED-TRIAL; N2 DISEASE; AMERICAN-COLLEGE; SKIP METASTASIS; LYMPH-NODES; NONSMALL; SURVIVAL; ADENOCARCINOMA	Dissection of the lower zone mediastinal nodes is mandatory during systematic nodal dissection for lung cancer. However, the significance of lower zone lymph node metastasis (LZM) in lung cancer remains unclear. Therefore, we aimed to identify the predictive factors for LZM in patients with lower lobe lung cancer. A retrospective study was conducted on 257 patients with lower lobe lung cancer, in whom pulmonary resection and mediastinal nodal dissection were performed between 2009 and 2013. The radiological factors on thin-section computed tomography scans (TSCT) and several conventional clinical factors were evaluated as possible predictors of LZM. Twenty (7.8 %) patients exhibited LZM. The majority of the tumors were especially located in segment 10 (50 %). All patients showed a solid appearance on TSCT. In a univariate analysis, the tumor location, a solid appearance and the clinical T factor significantly predicted LZM (p = 0.011, 0.005, 0.018). Furthermore, based on a multivariate analysis, the tumor location in segment 10 significantly predicted LZM in patients with lower lobe solid lung cancer (p = 0.031). The appropriate surgical strategy for lower zone lymph node dissection should be selected based on the tumor location and the findings of TSCT, due to the high frequency of LZM (19.6 %), especially in patients with pure solid lung cancer in segment 10.	[Ueno, Hiroyasu; Hattori, Aritoshi; Matsunaga, Takeshi; Takamochi, Kazuya; Oh, Shiaki; Suzuki, Kenji] Juntendo Univ, Sch Med, Dept Gen Thorac Surg, Bunkyo Ku, Tokyo 1138431, Japan	Suzuki, K (reprint author), Juntendo Univ, Sch Med, Dept Gen Thorac Surg, Bunkyo Ku, 1-3,Hongo 3 Chome, Tokyo 1138431, Japan.	h-ueno@juntendo.ac.jp; kjsuzuki@juntendo.ac.jp			Ministry of Health, Labour and Welfare of Japan; Smoking Research Foundation	This study was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare of Japan and the Smoking Research Foundation.	Riquet M, 2005, ANN THORAC SURG, V79, P225, DOI 10.1016/j.athoracsur.2004.06.081; Keller SM, 2000, ANN THORAC SURG, V70, P358, DOI 10.1016/S0003-4975(00)01673-8; Suzuki K, 2011, J THORAC ONCOL, V6, P751, DOI 10.1097/JTO.0b013e31821038ab; Takamochi K, 2010, THORAC CARDIOV SURG, V58, P345, DOI 10.1055/s-0030-1249944; Suzuki K, 2006, ANN THORAC SURG, V81, P413, DOI 10.1016/j.athoracsur.2005.07.058; Matsuguma H, 2002, J THORAC CARDIOV SUR, V124, P278, DOI 10.1067/mtc.122298; Rusch VW, 2007, J THORAC ONCOL, V2, P603, DOI 10.1097/JTO.0b013e31807ec803; Nomori H, 2011, SURG TODAY, V41, P889, DOI 10.1007/s00595-010-4528-1; Imai K, 2014, SURG TODAY, V44, P1197, DOI 10.1007/s00595-013-0660-z; Izbicki JR, 1998, ANN SURG, V227, P138, DOI 10.1097/00000658-199801000-00020; Keller SM, 2004, J THORAC CARDIOV SUR, V128, P130, DOI 10.1016/j.jtcvs.2003.11.061; Aoki T, 2001, RADIOLOGY, V220, P803, DOI 10.1148/radiol.2203001701; Takamochi K, 2001, J THORAC CARDIOV SUR, V122, P325, DOI 10.1067/mtc.2001.114355; Detterbeck FC, 2013, CHEST, V143, pE191, DOI 10.1378/chest.12-2354; Prenzel KL, 2004, CANCER, V100, P1909, DOI 10.1002/cncr.20165; Suzuki K, 2002, ANN THORAC SURG, V74, P1635, DOI 10.1016/S0003-4975(02)03895-X; Misthos P, 2008, ANN THORAC SURG, V86, P1626, DOI 10.1016/j.athoracsur.2008.07.076; Imai K, 2013, SURG TODAY, V43, P249, DOI 10.1007/s00595-012-0237-2; Tsubota N, 1996, SURG TODAY, V26, P169; Maeyashiki T, 2013, EUR J CARDIO-THORAC, V43, P915, DOI 10.1093/ejcts/ezs516; Darling GE, 2011, J THORAC CARDIOV SUR, V141, P662, DOI 10.1016/j.jtcvs.2010.11.008; Lardinois D, 2005, ANN THORAC SURG, V80, P268, DOI 10.1016/j.athoracsur.2005.02.005; Hattori A, 2012, ANN THORAC SURG, V94, P212, DOI 10.1016/j.athoracsur.2012.03.033; Fukui T, 2006, J THORAC ONCOL, V1, P120, DOI 10.1097/01243894-200602000-00004; Wu YL, 2002, LUNG CANCER-J IASLC, V36, P1, DOI 10.1016/S0169-5002(01)00445-7; Hattori A, 2014, EUR J CARDIO-THORAC, V45, P699, DOI 10.1093/ejcts/ezt467; Miyoshi S, 2014, SURG TODAY, V44, P2028, DOI 10.1007/s00595-013-0772-5; Shields TW, 2009, GEN THORACIC SURG, P87	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1390	1395		10.1007/s00595-014-1105-z		6	Surgery	Surgery	CT8DE	WOS:000363044400008		
J	Adachi, T; Hinoi, T; Hattori, M; Egi, H; Shimomura, M; Saito, Y; Sawada, H; Miguchi, M; Niitsu, H; Mukai, S; Yano, T; Ohdan, H				Adachi, Tomohiro; Hinoi, Takao; Hattori, Minoru; Egi, Hiroyuki; Shimomura, Manabu; Saito, Yasufumi; Sawada, Hiroyuki; Miguchi, Masashi; Niitsu, Hiroaki; Mukai, Shoichiro; Yano, Takuya; Ohdan, Hideki			The modified Glasgow prognostic score for early mortality in patients with synchronous peritoneal carcinomatosis from colorectal cancer	SURGERY TODAY			English	Article						Colorectal cancer; Peritoneal carcinomatosis; Synchronous; The modified glasgow prognostic score (mGPS); Early mortality	HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; SYSTEMIC INFLAMMATORY RESPONSE; CELL LUNG-CANCER; CYTOREDUCTIVE SURGERY; PERFORMANCE STATUS; CURATIVE SURGERY; TUMOR SITE; SURVIVAL; MANAGEMENT; METASTASIS	Few studies have investigated the risk factors in patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) who die within 3 months of undergoing surgical intervention and systemic chemotherapy. This study aimed to identify the risk factors associated with the post-treatment 3-month mortality rate. Retrospectively collected data from Hiroshima University were analyzed for patients presenting with synchronous PC from CRC between 1992 and 2012. The clinical, histological and survival data were evaluated and correlated with the overall survival rate at 3 months after surgical intervention. In patients who underwent surgical intervention with systemic chemotherapy for synchronous PC from CRC (N = 65), a Kaplan-Meier analysis and the log-rank test revealed that systemic chemotherapy (P = 0.023) and the modified Glasgow Prognostic Score (mGPS) (P = 0.00001) were associated with the 3-month mortality rate. Multivariate analyses using these two factors revealed that the mGPS (0/1, 2) (odds ratio 8.087; 95 % CI 1.512-43.25; P = 0.015) was an independent risk factor for the 3-month mortality rate. The mGPS is an important independent predictor of the 3-month mortality rate in patients who undergo surgical intervention with systemic chemotherapy for synchronous PC from CRC. The mGPS could aid surgeons in choosing the appropriate treatment strategy and best care for patients.	[Adachi, Tomohiro; Hinoi, Takao; Egi, Hiroyuki; Shimomura, Manabu; Ohdan, Hideki] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Transplant Surg Appl Life Sc, Minami Ku, Hiroshima 7348551, Japan; [Hattori, Minoru; Saito, Yasufumi; Sawada, Hiroyuki; Miguchi, Masashi] Hiroshima Univ, Dept Surg, Div Frontier Med Sci, Programs Biomed Res,Grad Sch Biomed Sci,Minami Ku, Hiroshima 7348551, Japan; [Niitsu, Hiroaki; Mukai, Shoichiro; Yano, Takuya] Hiroshima Univ, Dept Gastroenterol & Transplant Surg, Grad Sch Biomed & Hlth Sci,Div Med, Program Med,Biomed Sci Major,Kasumi Minami Ku, Hiroshima 7348551, Japan	Adachi, T (reprint author), Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Transplant Surg Appl Life Sc, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	adachitomohiro@hotmail.com; thinoi@hiroshima-u.ac.jp; m-hattori@hiroshima-u.ac.jp; hiroegi@yahoo.co.jp; manabus761215@gmail.com; ngywc515@ybb.ne.jp; dannte5426@yahoo.co.jp; edajimaheihachi_1@yahoo.co.jp; hiroaki_niitsu@yahoo.co.jp; silentman1087@yahoo.co.jp; yano-tuk@umin.ac.jp; hohdan@hiroshima-u.ac.jp					Sadeghi B, 2000, CANCER, V88, P358, DOI 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O; Teo MCC, 2013, ANN SURG ONCOL, V20, P2968, DOI 10.1245/s10434-013-2947-0; Powell AGMT, 2012, COLORECTAL DIS, V14, P1493, DOI 10.1111/j.1463-1318.2012.03048.x; JACQUET P, 1993, CANCER, V72, P1631, DOI 10.1002/1097-0142(19930901)72:5<1631::AID-CNCR2820720523>3.0.CO;2-I; Park IJ, 2009, ANN SURG, V249, P960, DOI 10.1097/SLA.0b013e3181a57c8f; Verwaal VJ, 2003, J CLIN ONCOL, V21, P3737, DOI 10.1200/JCO.2003.04.187; Proctor MJ, 2011, EUR J CANCER, V47, P2633, DOI 10.1016/j.ejca.2011.03.028; Chua TC, 2010, ANN SURG ONCOL, V17, P1330, DOI 10.1245/s10434-009-0866-x; Crozier JEM, 2009, AM J SURG, V197, P544, DOI 10.1016/j.amjsurg.2007.12.052; Forrest LM, 2005, BRIT J CANCER, V92, P1834, DOI 10.1038/sj.bjc.6602591; Kerscher AG, 2013, BRIT J CANCER, V108, P1432, DOI 10.1038/bjc.2013.82; Leitch EF, 2007, BRIT J CANCER, V97, P1266, DOI 10.1038/sj.bjc.6604027; Nakamura M, 2014, SURG TODAY, V44, P875, DOI 10.1007/s00595-013-0628-z; Glehen O, 2004, J CLIN ONCOL, V22, P3284, DOI 10.1200/JCO.2004.10.012; Lemmens VE, 2011, INT J CANCER, V128, P2717, DOI 10.1002/ijc.25596; Jayne DG, 2002, BRIT J SURG, V89, P1545, DOI 10.1046/j.1365-2168.2002.02274.x; Elias D, 2001, CANCER, V92, P71, DOI 10.1002/1097-0142(20010701)92:1<71::AID-CNCR1293>3.0.CO;2-9; Forrest LM, 2004, BRIT J CANCER, V90, P1704, DOI 10.1038/sj.bjc.6601789; Leung EYL, 2008, INT J CANCER, V123, P2460, DOI 10.1002/ijc.23811; Cashin PH, 2012, ANN SURG, V256, P1078, DOI 10.1097/SLA.0b013e318254f281; Klaver YLB, 2013, EJSO-EUR J SURG ONC, V39, P734, DOI 10.1016/j.ejso.2013.03.003; CHU DZJ, 1989, CANCER, V63, P364, DOI 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V; Honore C, 2013, ANN SURG ONCOL, V20, P183, DOI 10.1245/s10434-012-2473-5; Elias D, 2009, J CLIN ONCOL, V27, P681, DOI 10.1200/JCO.2008.19.7160; Yan TD, 2006, J CLIN ONCOL, V24, P4011, DOI 10.1200/JCO.2006.07.1142; Proctor MJ, 2011, BRIT J CANCER, V104, P726, DOI 10.1038/sj.bjc.6606087; Goere D, 2013, ANN SURG, V257, P1065, DOI 10.1097/SLA.0b013e31827e9289; Verwaal VJ, 2004, BRIT J SURG, V91, P739, DOI 10.1002/bjs.4516; Carmignani CP, 2004, EJSO, V30, P391, DOI 10.1016/j.ejso.2004.01.017; Mori Takeo, 2003, Nihon Rinsho, V61 Suppl 7, P255	30	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1396	1403		10.1007/s00595-014-1080-4		8	Surgery	Surgery	CT8DE	WOS:000363044400009		
J	Shimizu, T; Ishizuka, M; Kubota, K				Shimizu, Takayuki; Ishizuka, Mitsuru; Kubota, Keiichi			The preoperative serum C-reactive protein level is a useful predictor of surgical site infections in patients undergoing appendectomy	SURGERY TODAY			English	Article						Appendectomy; C-reactive protein; Surgical site infection	PROSPECTIVE RANDOMIZED TRIAL; CELL LUNG-CANCER; ACUTE APPENDICITIS; COLORECTAL-CANCER; RISK-FACTORS; SYSTEMIC INFLAMMATION; PERFORMANCE STATUS; WOUND-INFECTION; SCORE GPS; SURGERY	Although surgical site infections (SSI) are a major postoperative complication of appendectomy, few studies have focused on the risk factors for SSI. In this study, we investigated the risk factors for SSI in patients who had undergone appendectomy. Three hundred patients who had undergone open appendectomy were enrolled. The patients were divided into two groups based on the presence or absence of SSI. A statistical analysis was performed to assess the clinical features associated with SSI after appendectomy. A multivariate analysis using the results of univariate analyses revealed that the serum C-reactive protein (CRP) level (a parts per thousand currency sign65/> 65, mg/l), length of the operation (a parts per thousand currency sign80/> 80, min) and pathology (catarrhal, phlegmonous/gangrenous) were associated with SSI. Among these three clinical features, only the CRP level was found to predict the risk of SSI prior to appendectomy (odds ratio 3.797; 95 % confidence intervals 1.305-11.04; P = 0.014). Preoperative elevation of the serum CRP level (> 65 mg/l) is a valuable predictor of SSI in patients undergoing appendectomy.	[Shimizu, Takayuki; Ishizuka, Mitsuru; Kubota, Keiichi] Dokkyo Med Univ, Dept Surg 2, Mibu, Tochigi 3210293, Japan	Shimizu, T (reprint author), Dokkyo Med Univ, Dept Surg 2, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	stratstrat1213@gmail.com					Alp E, 2014, SURG TODAY, V44, P685, DOI 10.1007/s00595-013-0705-3; Andersen B, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001439.pub2; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; FRAZEE RC, 1994, ANN SURG, V219, P725, DOI 10.1097/00000658-199406000-00017; Moyes LH, 2009, BRIT J CANCER, V100, P1236, DOI 10.1038/sj.bjc.6604997; Andersson RE, 2000, WORLD J SURG, V24, P479; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Angele MK, 2005, LANGENBECK ARCH SURG, V390, P333, DOI 10.1007/s00423-005-0557-4; Macarulla E, 1997, SURG LAPAROSC ENDOSC, V7, P335, DOI 10.1097/00019509-199708000-00016; Forrest LM, 2005, BRIT J CANCER, V92, P1834, DOI 10.1038/sj.bjc.6602591; Walsh Sr, 2005, J SURG ONCOL, V91, P181, DOI 10.1002/jso.20329; Bennett-Guerrero E, 2010, NEW ENGL J MED, V363, P1038, DOI 10.1056/NEJMoa1000837; KRUKOWSKI ZH, 1988, BRIT J SURG, V75, P1023, DOI 10.1002/bjs.1800751023; Itatsu K, 2014, SURG TODAY, V44, P1242, DOI 10.1007/s00595-013-0677-3; Shiozaki A, 2012, ONCOL LETT, V3, P907, DOI 10.3892/ol.2012.589; Fujii T, 2011, HEPATO-GASTROENTEROL, V58, P752; Asfar S, 2000, J ROY COLL SURG EDIN, V45, P21; Forrest LM, 2004, BRIT J CANCER, V90, P1704, DOI 10.1038/sj.bjc.6601789; Dutta S, 2011, WORLD J SURG, V35, P1017, DOI 10.1007/s00268-011-1002-1; Kazemier G, 1997, SURG ENDOSC-ULTRAS, V11, P336, DOI 10.1007/s004649900358; Lee P, 2009, ARCH SURG-CHICAGO, V144, P872, DOI 10.1001/archsurg.2009.151; Humes DJ, 2006, BRIT MED J, V333, P530, DOI 10.1136/bmj.38940.664363.AE; Teixeira PG, 2012, ANN SURG, V256, P538, DOI 10.1097/SLA.0b013e318265ea13; Chamisa I, 2009, ANN ROY COLL SURG, V91, P688, DOI 10.1308/003588409X12486167521677; Reddy RC, 2001, IMMUNOL RES, V24, P273, DOI 10.1385/IR:24:3:273; Araki T, 2014, SURG TODAY, V44, P1072, DOI 10.1007/s00595-013-0809-9; Giraudo G, 2013, SURG TODAY, V43, P392, DOI 10.1007/s00595-012-0250-5; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; Ni Choileain N, 2006, Surgeon, V4, P23; Wang ZX, 2013, BRIT J SURG, V100, P465, DOI 10.1002/bjs.9062	30	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1404	1410		10.1007/s00595-014-1086-y		7	Surgery	Surgery	CT8DE	WOS:000363044400010		
J	Matsutani, N; Dejima, H; Takahashi, Y; Kawamura, M				Matsutani, Noriyuki; Dejima, Hitoshi; Takahashi, Yusuke; Kawamura, Masafumi			Pregabalin reduces post-surgical pain after thoracotomy: a prospective, randomized, controlled trial	SURGERY TODAY			English	Article						Intercostal pain; Postoperative pain; Thoracotomy; Pregabalin	PLACEBO-CONTROLLED TRIAL; POSTOPERATIVE PAIN; LAPAROSCOPIC CHOLECYSTECTOMY; POSTHERPETIC NEURALGIA; ORAL PREGABALIN; CLINICAL-TRIAL; GABAPENTIN; ARTHROPLASTY; ATTENUATION; MANAGEMENT	A new perioperative management method was explored by assessing the safety and the efficacy of pregabalin for the treatment of intercostal neuralgia after thoracotomy. The study was conducted on 68 adult patients scheduled to undergo thoracotomy. Patients were randomly divided into two groups; a NSAIDs group, where 34 patients were orally administered loxoprofen three times daily and a pregabalin group, where 34 patients were orally administered 75 mg of pregabalin twice daily, starting on the day of surgery and continuing for 2 weeks. The pain scores, sleep interference and the incidence of neuropathic pain were evaluated on days 1, 3 and 7, and at weeks 4, 8 and 12 after surgery. The frequency of pain medication use in the first week after surgery and the adverse effects in each group were also examined. The pain scores, sleep interference and incidence of neuropathic pain were significantly lower (p < 0.001) at all time points in the pregabalin group. The use of additional pain medication during the first week after surgery was not significantly different between the groups. The only significant adverse effect was a stomach ache in the NSAIDs group, while mild drowsiness was reported in the pregabalin group. Pregabalin is considered to be an effective and safe drug for the treatment of pain after thoracotomy.	[Matsutani, Noriyuki; Dejima, Hitoshi; Takahashi, Yusuke; Kawamura, Masafumi] Teikyo Univ, Sch Med, Dept Surg, Itabashi Ku, Tokyo 1738605, Japan	Matsutani, N (reprint author), Teikyo Univ, Sch Med, Dept Surg, Itabashi Ku, 2-11-1 Kaga, Tokyo 1738605, Japan.	matsutani1970@yahoo.co.jp			Pfizer	Noriyuki Matsutani has received a research grant from Pfizer. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. For the remaining authors, no potential conflicts of interest were declared.	Ben-Menachem E, 2004, EPILEPSIA, V45, P13, DOI 10.1111/j.0013-9580.2004.455003.x; Dworkin RH, 2003, NEUROLOGY, V60, P1274; Sabatowski R, 2004, PAIN, V109, P26, DOI 10.1016/j.pain.2004.01.001; SABANATHAN S, 1995, ANN ROY COLL SURG, V77, P202; Bennett MI, 2005, J PAIN, V6, P149, DOI 10.1016/j.jpain.2004.11.007; Hill CM, 2001, EUR J PAIN-LONDON, V5, P119, DOI 10.1053/eujp.2001.0235; Agarwal A, 2008, BRIT J ANAESTH, V101, P700, DOI 10.1093/bja/aen244; Dooley DJ, 2002, SYNAPSE, V45, P171, DOI 10.1002/syn.10094; Buvanendran A, 2003, JAMA-J AM MED ASSOC, V290, P2411, DOI 10.1001/jama.290.18.2411; Tolle T, 2008, EUR J PAIN, V12, P203, DOI 10.1016/j.ejpain.2007.05.003; Dahl JB, 2004, ACTA ANAESTH SCAND, V48, P1130, DOI 10.1111/j.1399-6576.2004.00484.x; Buvanendran A, 2010, ANESTH ANALG, V110, P199, DOI 10.1213/ANE.0b013e3181c4273a; Williams EH, 2008, ANN THORAC SURG, V85, P1766, DOI 10.1016/j.athoracsur.2007.11.058; Mathiesen O, 2008, BRIT J ANAESTH, V101, P535, DOI 10.1093/bja/aen215; Steegers MAH, 2008, J PAIN, V9, P955, DOI 10.1016/j.jpain.2008.05.009; White PF, 2009, ANESTH ANALG, V108, P1140, DOI 10.1213/ane.0b013e31818d40ce; Alar T, 2014, SURG TODAY, V44, P264, DOI 10.1007/s00595-013-0586-5; Matsutani N, 2013, SURG TODAY, V43, P915, DOI 10.1007/s00595-012-0287-5; Rogers ML, 2002, EUR J CARDIO-THORAC, V21, P298, DOI 10.1016/S1010-7940(01)01104-6; Chang SH, 2009, ANESTH ANALG, V109, P1284, DOI 10.1213/ane.0b013e3181b4874d; Kinney MAO, 2012, PAIN PRACT, V12, P175, DOI 10.1111/j.1533-2500.2011.00480.x; Paech MF, 2007, ANESTH ANALG, V105, P1449, DOI 10.1213/01.ane.0000286227.13306.d7; Frampton JE, 2004, DRUGS, V64, P2813, DOI 10.2165/00003495-200464240-00006; Kobayashi R, 2013, SURG TODAY, V43, P963, DOI 10.1007/s00595-012-0485-1; Matsutani N, 2014, SURG TODAY, V44, P712, DOI 10.1007/s00595-013-0743-x	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1411	1416		10.1007/s00595-014-1088-9		6	Surgery	Surgery	CT8DE	WOS:000363044400011		
J	Toma, H; Eguchi, T; Toyoda, S; Okabe, Y; Kobarai, T; Naritomi, G; Ogawa, T; Hirota, I				Toma, Hiroki; Eguchi, Toru; Toyoda, Shuichi; Okabe, Yasuhiro; Kobarai, Tomonari; Naritomi, Gen; Ogawa, Takahiro; Hirota, Ichio			A 10-year experience of totally extraperitoneal endoscopic repair for adult inguinal hernia	SURGERY TODAY			English	Article						Inguinal hernia; Laparoscopic surgery; TEP	RANDOMIZED-CONTROLLED-TRIAL; CLINICAL-TRIAL; CHRONIC PAIN; MESH REPAIR; LICHTENSTEIN; TEP	Laparoscopic surgery is fast becoming the treatment of choice for inguinal hernia. By reviewing our 10-year experience of performing totally extraperitoneal repair (TEP), we sought to establish its clinical significance in the treatment of adult inguinal hernia. We reviewed retrospectively the clinical records of patients who underwent TEP for adult inguinal hernia between January 2003 and December 2012. None of the 303 patients with adult primary or recurrent inguinal hernia in our study needed TEP converted to other procedures or suffered serious complications during the procedure. A significant difference was noted in the operation time between direct (n = 32) vs indirect (n = 128) hernias in the primary unilateral inguinal hernia group (91 +/- A 27 vs 80 +/- A 32 min, p = 0.033) and between direct/direct (n = 31) vs indirect/indirect (n = 24) hernias (136 +/- A 58 vs 89 +/- A 24 min, p = 0.01) in the primary bilateral inguinal hernia group. The only postoperative complications recorded were four cases of hernia recurrence (1.3 %) and one case of chronic pain (0.3 %). The results obtained for TEP over 10 years support this as a promising procedure for the treatment of adult inguinal hernia.	[Toma, Hiroki; Eguchi, Toru; Toyoda, Shuichi; Okabe, Yasuhiro; Kobarai, Tomonari; Naritomi, Gen; Ogawa, Takahiro; Hirota, Ichio] Harasanshin Hosp, Dept Surg, Fukuoka, Japan	Toma, H (reprint author), Harasanshin Hosp, Dept Surg, Taihakucho,1-10 Hakataku, Fukuoka, Japan.	toma@surg1.med.kyushu-u.ac.jp					Kumar S, 2002, BRIT J SURG, V89, P1476, DOI 10.1046/j.1365-2168.2002.02260.x; Lau H, 2003, J LAPAROENDOSC ADV A, V13, P153, DOI 10.1089/109264203766207663; Kald A, 2002, EUR J SURG, V168, P150, DOI 10.1080/110241502320127757; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Eklund AS, 2009, ANN SURG, V249, P33, DOI 10.1097/SLA.0b013e31819255d0; Simons MP, 2009, HERNIA, V13, P343, DOI 10.1007/s10029-009-0529-7; Langeveld HR, 2010, ANN SURG, V251, P819, DOI 10.1097/SLA.0b013e3181d96c32; Belyansky I, 2011, ANN SURG, V254, P709, DOI 10.1097/SLA.0b013e3182359d07; Beldi G, 2008, SURG ENDOSC, V22, P129, DOI 10.1007/s00464-007-9388-4; Zendejas B, 2011, ANN SURG, V254, P502, DOI 10.1097/SLA.0b013e31822c6994; Edwards CC, 2000, SURG LAPARO ENDO PER, V10, P149, DOI 10.1097/00019509-200006000-00010; Neumayer L, 2004, NEW ENGL J MED, V350, P1819, DOI 10.1056/NEJMoa040093; Lau H, 2005, ANN SURG, V242, P670, DOI 10.1097/01.sla.0000186440.02977.de; Eklund A, 2010, BRIT J SURG, V97, P600, DOI 10.1002/bjs.6904; Bringman S, 2006, BRIT J SURG, V93, P1056, DOI 10.1002/bjs.5403; Eklund A, 2006, BRIT J SURG, V93, P1060, DOI 10.1002/bjs.5405; Liem MSL, 1997, NEW ENGL J MED, V336, P1541, DOI 10.1056/NEJM199705293362201	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1417	1420		10.1007/s00595-014-1101-3		4	Surgery	Surgery	CT8DE	WOS:000363044400012		
J	Saito, H; Yamada, Y; Takaya, S; Osaki, T; Ikeguchi, M				Saito, Hiroaki; Yamada, Yoshinori; Takaya, Seigo; Osaki, Tomohiro; Ikeguchi, Masahide			Clinical relevance of the number of interleukin-17-producing CD 8+T cells in patients with gastric cancer	SURGERY TODAY			English	Article						CD 8+T cells; Gastric cancer; Interleukin-17	HELICOBACTER-PYLORI INFECTION; TH17 CELLS; POOR-PROGNOSIS; TRANSFORMING GROWTH-FACTOR-BETA-1; PROINFLAMMATORY CYTOKINES; IL-17-PRODUCING CELLS; PROMOTES ANGIOGENESIS; COLORECTAL-CARCINOMA; MULTIPLE-MYELOMA; TUMOR-GROWTH	There is accumulating evidence that inflammation is linked to cancer development and progression. Interleukin-17 (IL-17), an inflammatory cytokine, is produced by CD 8+ T cells (Tc17 cells); however, the specific role of Tc17 cells in tumor immunity against gastric cancer remains unclear. The prevalence of Tc17 cells in both peripheral blood mononuclear cells and gastric tissue was evaluated by multicolor flow cytometry and the concentration of IL-17 in sera was quantitated by an enzyme-linked immunosorbent assay. Circulating Tc17 cells were significantly more numerous in gastric cancer patients than in controls, and significantly more numerous before surgery than after surgery. IL-17 concentrations in gastric cancer patients and healthy controls were 0.51 +/- A 0.54 and 0.084 +/- A 0.084 pg/mL, respectively, with this difference being significant. The percentage of Tc17 cells was significantly related to serum IL-17 concentration. Tc17 cells were significantly more numerous than peripheral blood mononuclear cells in gastric cancer tissue. Furthermore, Tc17 cells were more numerous in cancerous gastric tissue than in normal gastric tissue. Tc17 cells may be the main source of IL-17 in gastric cancer patients and thus involved in the progression of gastric cancer.	[Saito, Hiroaki; Yamada, Yoshinori; Takaya, Seigo; Osaki, Tomohiro; Ikeguchi, Masahide] Tottori Univ, Sch Med, Dept Surg, Div Surg Oncol, Yonago, Tottori 6838504, Japan	Saito, H (reprint author), Tottori Univ, Sch Med, Dept Surg, Div Surg Oncol, 36-1 Nishi Cho, Yonago, Tottori 6838504, Japan.	sai10@med.tottori-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan	This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Prabhala RH, 2010, BLOOD, V115, P5385, DOI 10.1182/blood-2009-10-246660; Deans DAC, 2006, BRIT J CANCER, V95, P1568, DOI 10.1038/sj.bjc.6603446; Aarvak T, 1999, J IMMUNOL, V162, P1246; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249; Zhuang Y, 2012, GASTROENTEROLOGY, V143, P951, DOI 10.1053/j.gastro.2012.06.010; Saito H, 2000, ANTICANCER RES, V20, P4489; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Liu JK, 2011, BIOCHEM BIOPH RES CO, V407, P348, DOI 10.1016/j.bbrc.2011.03.021; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; KLEIN B, 1992, HEMATOL ONCOL CLIN N, V6, P273; Saito H, 1999, CANCER, V86, P1455, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1455::AID-CNCR11>3.0.CO;2-L; Iida T, 2011, ONCOL REP, V25, P1271, DOI 10.3892/or.2011.1201; CARNEIRO F, 1995, PATHOL RES PRACT, V191, P571; Kai H, 2005, ANTICANCER RES, V25, P709; Zhang B, 2008, BIOCHEM BIOPH RES CO, V374, P533, DOI 10.1016/j.bbrc.2008.07.060; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Ikeguchi M, 2009, GASTRIC CANCER, V12, P95, DOI 10.1007/s10120-009-0509-8; McGeachy MJ, 2008, IMMUNITY, V28, P445, DOI 10.1016/j.immuni.2008.03.001; Yamada Y, 2012, J SURG RES, V178, P685, DOI 10.1016/j.jss.2012.07.055; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Shimoyama T, 1998, GUT, V43, pS2; Kesselring R, 2010, BRIT J CANCER, V103, P1245, DOI 10.1038/sj.bjc.6605891; PUNNONEN J, 1991, J CANCER RES CLIN, V117, P587, DOI 10.1007/BF01613293; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Miyahara Y, 2008, P NATL ACAD SCI USA, V105, P15505, DOI 10.1073/pnas.0710686105; Blaser MJ, 1998, BRIT MED J, V316, P1507; CORREA P, 1992, CANCER RES, V52, P6735; Dixon M F, 1994, Scand J Gastroenterol Suppl, V201, P7; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Miki C, 2004, DIGEST DIS SCI, V49, P970, DOI 10.1023/B:DDAS.0000034556.48527.6e; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Sipponen P, 1994, Scand J Gastroenterol Suppl, V201, P24; Solcia E, 1996, AM J SURG PATHOL, V20, pS8; Wu JX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050035; Yao Zhengbin, 1995, Journal of Immunology, V155, P5483; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033	40	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1429	1435		10.1007/s00595-015-1165-8		7	Surgery	Surgery	CT8DE	WOS:000363044400014		
J	Kikuchi, S; Watanabe, Y; Sato, K; Matsumoto, H; Umakoshi, K; Aibiki, M				Kikuchi, Satoshi; Watanabe, Yuji; Sato, Koichi; Matsumoto, Hironori; Umakoshi, Kensuke; Aibiki, Mayuki			Minimally invasive necrosectomy using resectoscope for intractable necrotic abscess after severe acute pancreatitis: report of a case	SURGERY TODAY			English	Article						Pancreatitis; Minimum invasion; Surgical therapy	ENTERAL NUTRITION; COMPLICATIONS; INFECTION; MORTALITY; NECROSIS	A 43-year-old male was admitted to a regional hospital after being diagnosed with severe acute pancreatitis. The patient developed a pancreatic abscess with multiple organ failure. He was transferred to our hospital in critical condition. Computed tomography scans revealed enormous pancreatic abscesses expanding from the pancreatic body to the pelvic area. Pigtail catheters were inserted for percutaneous drainage. Even after the drainage, the abscesses did not improve. Percutaneous necrosectomy was performed using a resectoscope through a fistulous tract. After two necrosectomies, the CT scans showed remarkable decreases in the size of the cystic abscesses, and finally, no abscesses were detectable on the 117th hospital day. We herein present the first description of a minimally invasive technique, using resectoscopy, for treating intractable pancreatic abscesses. Future studies are warranted to examine the efficacy and safety of this procedure for difficult cases, as presented in this report.	[Kikuchi, Satoshi; Watanabe, Yuji; Sato, Koichi; Matsumoto, Hironori; Umakoshi, Kensuke; Aibiki, Mayuki] Ehime Univ, Grad Sch Med, Dept Emergency Med, Div Gastrointestinal Surg & Surg Oncol, Toon, Ehime 7910295, Japan	Kikuchi, S (reprint author), Ehime Univ, Grad Sch Med, Dept Emergency Med, Div Gastrointestinal Surg & Surg Oncol, Toon, Ehime 7910295, Japan.	kiku@m.ehime-u.ac.jp					Connor S, 2005, SURGERY, V137, P499, DOI 10.1016/j.surg.2005.01.003; van Santvoort HC, 2010, NEW ENGL J MED, V362, P1491, DOI 10.1056/NEJMoa0908821; Yasuda T, 2006, J SURG RES, V135, P18, DOI 10.1016/j.jss.2006.02.050; Besselink MGH, 2007, ARCH SURG-CHICAGO, V142, P1194, DOI 10.1001/archsurg.142.12.1194; Yasuda T, 2007, J SURG RES, V138, P300, DOI 10.1016/j.jss.2006.09.022; Perez A, 2002, PANCREAS, V25, P229, DOI 10.1097/00006676-200210000-00003; Nathens AB, 2004, CRIT CARE MED, V32, P2524, DOI 10.1097/01.CCM.0000148222.09869.92; Heinrich S, 2006, ANN SURG, V243, P154, DOI 10.1097/01.sla.0000197334.58374.70; Banks PA, 1995, INT J PANCREATOL, V18, P265; Horvath KD, 2001, SURG ENDOSC-ULTRAS, V15, P1221, DOI 10.1007/s004640080166; Marik PE, 2004, BRIT MED J, V328, P1407, DOI 10.1136/bmj.38118.593900.55; Lankisch PG, 2002, PANCREAS, V24, P217, DOI 10.1097/00006676-200204000-00002; Petrov MS, 2006, DIGEST SURG, V23, P336, DOI 10.1159/000097949; [Anonymous], 2003, SCAND J GASTROENTE S; Gullo L, 2002, PANCREAS, V24, P223, DOI 10.1097/00006676-200204000-00003; Buchler MW, 2000, ANN SURG, V232, P619; BEGER HG, 1988, BRIT J SURG, V75, P207, DOI 10.1002/bjs.1800750306; Cater CR, 2000, ANN SURG, V232, P175; Gagner M, 1996, SEMIN LAPAROSC SURG, V3, P10; Parekh D, 2006, ARCH SURG-CHICAGO, V141, P895, DOI 10.1001/archsurg.141.9.895; Villatoro E, 2003, COCHRANE DB SYST REV, V4; Watanabe Y, 1993, J Laparoendosc Surg, V3, P489, DOI 10.1089/lps.1993.3.489	22	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1442	1445		10.1007/s00595-014-1063-5		4	Surgery	Surgery	CT8DE	WOS:000363044400016		
J	Yamamoto, Y; Yoshioka, M; Watanabe, G; Uchinami, H				Yamamoto, Yuzo; Yoshioka, Masato; Watanabe, Go; Uchinami, Hiroshi			Opportunistic use of a Foley catheter to provide a common electrocautery with a water-irrigating channel for hepatic parenchymal transection	SURGERY TODAY			English	Editorial Material						Electrocautery; Hepatic parenchymal transection; Water irrigation channel	RESECTION; LIVER; MODEL	High-tech surgical energy devices that are used during a single surgery have increased in number and the expense for such disposable units is by no means negligible. We developed a handmade water-irrigating monopolar electrocautery using a Foley catheter to perform liver parenchymal transection. A commonly used 20-24 Fr Foley catheter was cut at a length of about 8 cm. The shaft of the 5 mm ball electrode measuring 13.5 cm in length was then inlaid into the urine drainage channel. The target tissues were cauterized without making an eschar, thereby preventing the adhesion of the electrode to the tissues. A ball electrode with our handmade water irrigation sheath can be made in only a few minutes at a very low cost, using common medical supplies and yielding satisfactory effects comparable to the use of specialized high-tech devices.	[Yamamoto, Yuzo; Yoshioka, Masato; Watanabe, Go; Uchinami, Hiroshi] Akita Univ, Grad Sch Med, Dept Surg Gastroenterol, Akita 0108543, Japan	Yamamoto, Y (reprint author), Akita Univ, Grad Sch Med, Dept Surg Gastroenterol, 1-1-1 Hondo, Akita 0108543, Japan.	yamamoto-kyt@umin.ac.jp					Poon RT, 2005, J AM COLL SURGEONS, V200, P308, DOI 10.1016/j.jamcollsurg.2004.10.008; Yamamoto Y, 1999, WORLD J SURG, V23, P1032; Mizuguchi T, 2014, SURG TODAY, V44, P1, DOI 10.1007/s00595-013-0534-4; YAMAOKA Y, 1995, TRANSPLANTATION, V59, P224, DOI 10.1097/00007890-199501270-00012; Yamamoto Y, 2001, CHIRURG, V72, P784, DOI 10.1007/s001040170106; Di Carlo I, 2004, J GASTROINTEST SURG, V8, P596, DOI 10.1016/j.gassur.2003.12.010; Munro MG, 2012, SAGES MANUAL ON THE FUNDAMENTAL USE OF SURGICAL ENERGY (FUSE), P15, DOI 10.1007/978-1-4614-2074-3_2; Sugo H, 2000, SURG TODAY, V30, P959; Patrlj L, 2010, J AM COLL SURGEONS, V210, P39, DOI 10.1016/j.jamcollsurg.2009.09.035; Fioole B, 2005, BRIT J SURG, V92, P1409, DOI 10.1002/bjs.5170; Hammond J, 2012, HPB, V14, P828, DOI 10.1111/j.1477-2574.2012.00547.x; Romano Fabrizio, 2007, HPB (Oxford), V9, P339, DOI 10.1080/13651820701504181	12	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1457	1462		10.1007/s00595-015-1156-9		6	Surgery	Surgery	CT8DE	WOS:000363044400019		
J	Watanabe, M; Murakami, M; Ozawa, Y; Uchida, M; Yamazaki, K; Fujimori, A; Otsuka, K; Aoki, T				Watanabe, Makoto; Murakami, Masahiko; Ozawa, Yoshiaki; Uchida, Marie; Yamazaki, Kimiyasu; Fujimori, Akira; Otsuka, Koji; Aoki, Takeshi			The modified Altemeier procedure for a loop colostomy prolapse	SURGERY TODAY			English	Editorial Material						Loop colostomy prolapse; Stomal prolapse; Modified Altemeier procedure	RECTAL PROLAPSE; DISTAL LIMB; EXCISION; REPAIR	Loop colostomy prolapse is associated with an impaired quality of life. Surgical treatment may sometimes be required for cases that cannot be closed by colon colostomy because of high-risk morbidities or advanced disease. We applied the Altimeter operation for patients with transverse loop colostomy. The Altemeier operation is therefore indicated for rectal prolapse. This technique involves a simple operation, which includes a circumferential incision through the full thickness of the outer and inner cylinder of the prolapsed limb, without incising the abdominal wall, and anastomosis with sutures using absorbable thread. We performed the Altemeier operation for three cases of loop stomal prolapse. Those patients demonstrated no postoperative complications (including obstruction, prolapse recurrence, or hernia). Our findings suggest that this procedure is useful as an optional surgical treatment for cases of transverse loop colostomy prolapse as a permanent measure in patients with high-risk morbidities or advanced disease.	[Watanabe, Makoto; Murakami, Masahiko; Ozawa, Yoshiaki; Uchida, Marie; Yamazaki, Kimiyasu; Fujimori, Akira; Otsuka, Koji; Aoki, Takeshi] Showa Univ, Sch Med, Dept Gen & Gastroenterol Surg, Shinagawa Ku, Tokyo 1428666, Japan	Watanabe, M (reprint author), Showa Univ, Sch Med, Dept Gen & Gastroenterol Surg, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan.	m-watanabe@med.showa-u.ac.jp					ALTEMEIE.WA, 1971, ANN SURG, V173, P993, DOI 10.1097/00000658-197106010-00018; Law WL, 2002, BRIT J SURG, V89, P704, DOI 10.1046/j.1365-2168.2002.02082.x; Funahashi K, 2014, SURG TODAY, V44, P1465, DOI 10.1007/s00595-013-0721-3; Ono C, 2012, TECH COLOPROCTOL, V16, P255, DOI 10.1007/s10151-012-0829-2; Seamon LG, 2008, GYNECOL ONCOL, V111, P549, DOI 10.1016/j.ygyno.2008.01.029; Masumori K, 2012, TECH COLOPROCTOL, V16, P143, DOI 10.1007/s10151-011-0785-2; Hammond Kerry, 2007, Ochsner J, V7, P24; COHEN BE, 1987, PLAST RECONSTR SURG, V79, P610, DOI 10.1097/00006534-198704000-00016; Cirocco WC, 2010, DIS COLON RECTUM, V53, P1618, DOI 10.1007/DCR.0b013e3181f22cef; Harris DA, 2005, ANN ROY COLL SURG, V87, P427, DOI 10.1308/003588405X60713; Maeda K, 2003, Tech Coloproctol, V7, P108, DOI 10.1007/s10151-003-0020-x; Maeda K, 2004, Tech Coloproctol, V8, P45, DOI 10.1007/s10151-004-0051-y; Marrosu Antonio, 2012, Ann Ital Chir, V83, P567; Rashid OM, 2013, AM SURGEON, V79, P167; Takahashi H, 2012, SURG LAPARO ENDO PER, V22, P263; Tepetes K, 2005, Tech Coloproctol, V9, P156, DOI 10.1007/s10151-005-0217-2; Theodoropoulos GE, 2013, AM SURGEON, V79, P121	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	NOV	2015	45	11					1463	1466		10.1007/s00595-015-1194-3		4	Surgery	Surgery	CT8DE	WOS:000363044400020		
J	Uchino, A; Saito, N; Okano, N; Kakehi, Y				Uchino, Akira; Saito, Naoko; Okano, Nanami; Kakehi, Yoshiaki			Aberrant internal carotid artery associated with occipital artery arising from the internal carotid artery	SURGICAL AND RADIOLOGIC ANATOMY			English	Article						Cerebral arterial variation; Computed tomography angiography; Internal carotid artery; Magnetic resonance angiography; Occipital artery	PERSISTENT STAPEDIAL ARTERIES; OBJECTIVE PULSATILE TINNITUS; ANTERIOR CEREBRAL-ARTERY	We present an extremely rare case of an aberrant course of the petrous internal carotid artery (ICA) associated with the ipsilateral occipital artery arising from the cervical ICA, a combination not previously reported by magnetic resonance (MR) angiography. The patient was a 53-year-old woman with no symptoms related to the anomalous ICA. Source images and partial maximum-intensity-projection images of MR angiography are useful in diagnosing these variations. Source images and curved multiplanar reconstruction images of computed tomography angiography are important for the accurate evaluation of reduced arterial diameter and the relationship between the anomalous artery and petrous bone.	[Uchino, Akira; Saito, Naoko; Okano, Nanami] Saitama Med Univ, Int Med Ctr, Dept Diagnost Radiol, Saitama 3501298, Japan; [Kakehi, Yoshiaki] Saitama Med Univ, Int Med Ctr, Dept Intravasc Neurosurg, Saitama 3501298, Japan	Uchino, A (reprint author), Saitama Med Univ, Int Med Ctr, Dept Diagnost Radiol, 1397-1 Yamane, Saitama 3501298, Japan.	auchino@saitama-med.ac.jp					LASJAUNIAS P, 1977, NEURORADIOLOGY, V13, P267; Saini J, 2008, SURG RADIOL ANAT, V30, P453, DOI 10.1007/s00276-008-0341-6; LASJAUNIAS P, 1978, NEURORADIOLOGY, V15, P31; Roll JD, 2003, AM J NEURORADIOL, V24, P762; Endo K, 2006, AURIS NASUS LARYNX, V33, P447, DOI 10.1016/j.anl.2006.03.007; Celebi I, 2012, SURG RADIOL ANAT, V34, P665, DOI 10.1007/s00276-011-0912-9; Song YS, 2012, ACTA OTO-LARYNGOL, V132, P1126, DOI 10.3109/00016489.2012.684400; Hitier M, 2013, SURG RADIOL ANAT, V35, P883, DOI 10.1007/s00276-013-1127-z; Shimizu S, 2009, AURIS NASUS LARYNX, V36, P359, DOI 10.1016/j.anl.2008.08.008; Uchino A, 2011, NEURORADIOLOGY, V53, P853, DOI 10.1007/s00234-010-0825-z; Uchino A, 2011, AM J NEURORADIOL, V32, P1119, DOI 10.3174/ajnr.A2462; Sauvaget E, 2006, ARCH OTOLARYNGOL, V132, P86, DOI 10.1001/archotol.132.1.86; Srinivasan S, 2013, SURG RADIOL ANAT, V35, P449, DOI 10.1007/s00276-012-1047-3; Hatipoglu Hatice Gul, 2011, Ear Nose Throat J, V90, pE17; Lasjaunias P, 2001, SURG NEUROANGIOGRAPH, P285	15	0	0	SPRINGER FRANCE	PARIS	22 RUE DE PALESTRO, PARIS, 75002, FRANCE	0930-1038	1279-8517		SURG RADIOL ANAT	Surg. Radiol. Anat.	NOV	2015	37	9					1137	1140		10.1007/s00276-015-1451-6		4	Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery	Anatomy & Morphology; Radiology, Nuclear Medicine & Medical Imaging; Surgery	CU1GV	WOS:000363269500018		
J	Talukdar, R; Inoue, H; Reddy, DN				Talukdar, Rupjyoti; Inoue, Haruhiro; Reddy, D. Nageshwar			Efficacy of peroral endoscopic myotomy (POEM) in the treatment of achalasia: a systematic review and meta-analysis	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Review						Peroral endoscopic myotomy; Achalasia; Systematic review; Meta-analysis; Heller's myotomy; Efficacy; Adverse events	PROSPECTIVE SINGLE-CENTER; ESOPHAGEAL ACHALASIA; HELLER MYOTOMY	Peroral endoscopic myotomy (POEM) is an evolving therapeutic modality for achalasia. We aim to determine efficacy of POEM for the treatment of achalasia and compare it with laparoscopic Heller's myotomy (LHM). Systematic review and meta-analyses was conducted on 19 studies using POEM for achalasia. Pubmed, Medline, Cochrane, and Ovid databases, were searched using the terms 'achalasia', 'POEM', 'peroral endoscopic myotomy', 'per oral endoscopic myotomy', and 'per-oral endoscopic myotomy'. Reduction in Eckhart's score and lower esophageal sphincter (LES) pressure were the main outcome measures. A total of 1,045 patients underwent POEM in 29 studies. Ninety patients undergoing POEM was compared with 160 undergoing LHM in five studies. Nineteen and 14 studies, respectively, evaluated for Eckhart's score and LES pressure. There was significant reduction in Eckhart's score and LES pressure with effect sizes of -7.95 (p < 0.0001) and -7.28 (p < 0.0001), respectively. There was significant heterogeneity among the studies [(Q = 83.06; I (2) = 78.33 %; p < 0.0001) for Eckhart's score and (Q = 61.44; I (2) = 75.68 %; p < 0.0001) for LES pressure]. There were no differences between POEM and LHM in reduction in Eckhart's score, post-operative pain scores and analgesic requirements, length of hospital stay, adverse events, and symptomatic gastroesophageal reflux/reflux esophagitis. Operative time was significantly lower for POEM. POEM is effective for achalasia and has similar outcomes as LHM. Multicenter randomized trials need to be conducted to further compare the efficacy and safety of POEM between treatment na < ve achalasia patients and those who failed treatment.	[Talukdar, Rupjyoti; Reddy, D. Nageshwar] Asian Inst Gastroenterol, Hyderabad 500082, Andhra Pradesh, India; [Talukdar, Rupjyoti] Asian Healthcare Fdn, Hyderabad, Andhra Pradesh, India; [Inoue, Haruhiro] Showa Univ, Ctr Digest Dis, Yokohama, Kanagawa, Japan	Talukdar, R (reprint author), Asian Inst Gastroenterol, 6-3-661 Somajiguda, Hyderabad 500082, Andhra Pradesh, India.	rup_talukdar@yahoo.com; aigindia@yahoo.co.in					Kurian AA, 2013, GASTROINTEST ENDOSC, V77, P719, DOI 10.1016/j.gie.2012.12.006; Cai MY, 2014, SURG ENDOSC, V28, P1158, DOI 10.1007/s00464-013-3300-1; Swanstrom LL, 2012, ANN SURG, V256, P659, DOI 10.1097/SLA.0b013e31826b5212; Onimaru M, 2013, J AM COLL SURGEONS, V217, P598, DOI 10.1016/j.jamcollsurg.2013.05.025; von Renteln D, 2012, AM J GASTROENTEROL, V107, P411, DOI 10.1038/ajg.2011.388; Inoue H, 2010, ENDOSCOPY, V42, P265, DOI 10.1055/s-0029-1244080; Ujiki MB, 2013, SURGERY, V154, P893, DOI 10.1016/j.surg.2013.04.042; von Renteln D, 2013, GASTROENTEROLOGY, V145, P309, DOI 10.1053/j.gastro.2013.04.057; Swanstrom LL, 2011, J AM COLL SURGEONS, V213, P751, DOI 10.1016/j.jamcollsurg.2011.09.001; Ren Z, 2012, SURG ENDOSC, V26, P3267, DOI 10.1007/s00464-012-2336-y; Verlaan T, 2013, GASTROINTEST ENDOSC, V78, P39, DOI 10.1016/j.gie.2013.01.006; Sharata A, 2013, J GASTROINTEST SURG, V17, P1188, DOI 10.1007/s11605-013-2193-6; Pasricha PJ, 2007, ENDOSCOPY, V39, P761, DOI 10.1055/s-2007-966764; Chiu PWY, 2013, GASTROINTEST ENDOSC, V77, P29, DOI 10.1016/j.gie.2012.08.018; Minami H, 2014, DIGEST ENDOSC, V26, P43, DOI 10.1111/den.12086; Vigneswaran Y, 2014, J GASTROINTEST SURG, V18, P1071, DOI 10.1007/s11605-014-2496-2; Li QL, 2013, J AM COLL SURGEONS, V217, P442, DOI 10.1016/j.jamcollsurg.2013.04.033; Bhayani NH, 2014, ANN SURG, V259, P1098, DOI 10.1097/SLA.0000000000000268; Hungness ES, 2013, J GASTROINTEST SURG, V17, P228, DOI 10.1007/s11605-012-2030-3; ORTEGA JA, 1980, GASTROINTEST ENDOSC, V26, P8, DOI 10.1016/S0016-5107(80)73249-2; Zhou PH, 2013, ENDOSCOPY, V45, P161, DOI 10.1055/s-0032-1326203; Costamagna G, 2012, DIGEST LIVER DIS, V44, P827, DOI 10.1016/j.dld.2012.04.003; Bredenoord AJ, 2014, NEUROGASTROENT MOTIL, V26, P3, DOI 10.1111/nmo.12257; Familiari P, 2003, J PEDIAT GASTROENTER, V57, P794; Higgins J. P. T., 2006, COCHRANE HDB SYSTEMA; Higgins JPT, 2011, COCHRANE HDB SYSTEMA; Khashab MA, 2014, ENDOSCOPY, V46, P298, DOI 10.1055/s-0033-1359024; Lee Byung Hoo, 2013, Clin Endosc, V46, P161, DOI 10.5946/ce.2013.46.2.161; Ling T, 2014, J GASTROEN HEPATOL, DOI [10.1111/jgh.12570.Mar14, DOI 10.1111/JGH.12570.MAR14]; Mantel N, 1959, JNCI-J NATL CANCER I, V22, P48; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Rahden BH, 2014, CHIRURG, V85, P420; Teitelbaum EN, 2014, SURG ENDOSC; Tietelbaum EN, 2013, SURGERY, V154, P885; Zhai Yaqi, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P1399; ZHOU Ping-hong, 2011, Zhonghua Wei Chang Wai Ke Za Zhi, V14, P705	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	NOV	2015	29	11					3030	3046		10.1007/s00464-014-4040-6		17	Surgery	Surgery	CT8JC	WOS:000363060700002		
J	Pioche, M; Rivory, J; Aguero-Garcete, G; Guillaud, O; O'Brien, M; Lafon, C; Reversat, N; Uraoka, T; Yahagi, N; Ponchon, T				Pioche, Mathieu; Rivory, Jerome; Aguero-Garcete, Guillermo; Guillaud, Olivier; O'Brien, Marc; Lafon, Cyril; Reversat, Nicolas; Uraoka, Toshio; Yahagi, Naohisa; Ponchon, Thierry			New isolated bovine colon model dedicated to colonic ESD hands-on training: development and first evaluation	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						ESD; Training; Colon neoplasia; Animal model	ENDOSCOPIC SUBMUCOSAL DISSECTION; LEARNING-CURVE; SYSTEM	ESD is the reference method to achieve en bloc resections for large digestive lesions. Nevertheless, it is a difficult and risky technique. Animal models exist to teach the initial skills, particularly in Japan, where pigs' stomachs are dedicated models to gastric ESD. In Europe, we have to develop different strategies of teaching with dedicated colon models. A pig colon is a good model but thinner and narrower than a human's. In this present work, we evaluated a bovine colon model to perform rectal ESD in retroflexion. First, we prepared six bowels to precise the preparation protocol. Then, two endoscopists unexperienced in ESD performed 64 procedures on eight models. Learning curves and factors of variation were studied. A precise protocol to prepare the colon was defined. The two students achieved en bloc resection in 89.1 % of cases with a rate of 6.2 % of perforations. A large heterogeneity appeared between the speed and the success rate depending mainly on the age of the animal bowel. Using calf colons, the failure rates were higher (p = 0.002) and the speed was lower (p < 0.001) than for adult bovine ones. A learning curve appeared with, respectively, 0.49 and 0.59 cm(2)/min throughout the study. No significant difference appeared between measured and calculated specimen areas. Bovine colon is a new model to teach ESD in colorectal conditions. The bovine age is important to homogenize the model. A learning curve existed with a time procedure decreasing throughout the study. Further studies are needed to evaluate the precise learning curve with more students. A bovine colon model is a suitable model to teach colorectal ESD. Nevertheless, an adult bovine colon model is more homogeneous than a calf one.	[Pioche, Mathieu; Rivory, Jerome; Aguero-Garcete, Guillermo; Guillaud, Olivier; O'Brien, Marc; Ponchon, Thierry] Hop Edouard Herriot, Gastroenterol & Endoscopy Unit, Digest Dis Dept, F-69437 Lyon, France; [Pioche, Mathieu; Uraoka, Toshio; Yahagi, Naohisa] Keio Univ, Ctr Canc, Endoscopy Unit, Tokyo, Japan; [Pioche, Mathieu; Lafon, Cyril; Ponchon, Thierry] INSERM, U1032, F-69008 Lyon, France; [Reversat, Nicolas] Rhone Vet Author, Lyon, France	Pioche, M (reprint author), Hop Edouard Herriot, Gastroenterol & Endoscopy Unit, Digest Dis Dept, H Pavillon, F-69437 Lyon, France.	mathieu.pioche@chu-lyon.fr					Farhat S, 2011, ENDOSCOPY, V43, P664, DOI 10.1055/s-0030-1256413; Sakamoto T, 2011, DIS COLON RECTUM, V54, P1307, DOI 10.1097/DCR.0b013e3182282ab0; Ohata K, 2012, DIGEST ENDOSC, V24, P84, DOI 10.1111/j.1443-1661.2012.01272.x; Berr F, 2011, DIGEST ENDOSC, V23, P281, DOI 10.1111/j.1443-1661.2011.01129.x; Kakushima N, 2012, DIGEST ENDOSC, V24, P133, DOI 10.1111/j.1443-1661.2012.01257.x; Rahmi G, 2014, ENDOSCOPY, V46, P670, DOI 10.1055/s-0034-1365810; Parra-Blanco A, 2013, ENDOSCOPY, V45, P478, DOI 10.1055/s-0033-1344153; Iacopini F, 2012, GASTROINTEST ENDOSC, V76, P1188, DOI 10.1016/j.gie.2012.08.024; Parra-Blanco A, 2010, WORLD J GASTROENTERO, V16, P2895, DOI 10.3748/wjg.v16.i23.2895; Tanaka S, 2012, SURG ENDOSC, V26, P1579, DOI 10.1007/s00464-011-2074-6; Goda K, 2012, DIGEST ENDOSC, V24, P136, DOI 10.1111/j.1443-1661.2012.01274.x; Martinek J, 2011, GASTROINTEST ENDOSC, V74, P367, DOI 10.1016/j.gie.2011.04.042; Pioche M, 2014, SURG ENDOSC, V28, P1742, DOI 10.1007/s00464-013-3378-5; Yahagi N, 2009, ENDOSCOPY, V41, P340, DOI 10.1055/s-0029-1214473; Berr F, 2014, DIGESTION, V89, P184, DOI 10.1159/000357805; Ciocirlan M, 2014, ENDOSCOPY, V46, P139, DOI 10.1055/s-0033-1344892; Parra-Blanco Adolfo, 2012, Clin Endosc, V45, P350, DOI 10.5946/ce.2012.45.4.350; Spychalski M, 2015, DIGEST ENDOSC, V27, P368, DOI 10.1111/den.12353	18	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	NOV	2015	29	11					3209	3215		10.1007/s00464-014-4062-0		7	Surgery	Surgery	CT8JC	WOS:000363060700024		
J	Lee, J; Kim, YM; Woo, Y; Obama, K; Noh, SH; Hyung, WJ				Lee, Juhan; Kim, Yoo-Min; Woo, Yanghee; Obama, Kazutaka; Noh, Sung Hoon; Hyung, Woo Jin			Robotic distal subtotal gastrectomy with D2 lymphadenectomy for gastric cancer patients with high body mass index: comparison with conventional laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Gastric cancer; Gastrectomy; D2 lymphadenectomy; Robot; Laparoscopy	LYMPH-NODE DISSECTION; MORBIDLY OBESE-PATIENTS; ASSISTED GASTRECTOMY; PHASE-II; SURVIVAL; SURGERY; MULTICENTER; INFECTION; OUTCOMES; IMPACT	Minimally invasive surgery (MIS) has emerged as a treatment of choice for early-stage gastric cancer. However, applying MIS to gastric patients with high body mass index (BMI) is technically challenging, especially when performing D2 lymphadenectomy. Recently, robotic systems have been adopted to overcome the technical limitations of conventional laparoscopic surgery. Nevertheless, studies on the impact of the use of robotic systems to perform D2 lymphadenectomy in high BMI patients are lacking. Accordingly, this study was designed to compare the quality of lymphadenectomy, together with surgical outcomes, by robotic distal subtotal gastrectomy with D2 lymphadenectomy (RDGD2) to those by laparoscopic distal subtotal gastrectomy with D2 lymphadenectomy (LDGD2) in patients of different BMI status. Retrospective review of a prospectively collected database identified 400 gastric cancer patients who underwent either RDGD2 (n = 133) or LDGD2 (n = 267) between 2003 and 2010. Patients were categorized according to surgical approach and BMI. We compared clinicopathologic characteristics, as well as short-term and long-term outcomes, between surgery and BMI groups. Regardless of BMI, RDGD2 required significantly longer operation time than LDGD2 (p = 0.001); meanwhile, RDGD2 showed significantly less blood loss than LDGD2 (p = 0.005). Between BMI groups, RDGD2 showed no significant difference in the rate of retrieving more than 25 lymph nodes (p = 0.181); however, LDGD2 was associated with a significantly lower rate of retrieving more than 25 lymph nodes in high BMI patients (p = 0.006). In high BMI patients, complications did not significantly differ between surgical approaches. As well, RDGD2 and LDGD2 demonstrated no statistically significant survival difference according to BMI status. The benefits of a robotic approach were more evident in high BMI patients than in normal BMI patients when performing distal subtotal gastrectomy with D2 lymphadenectomy, particularly in terms of blood loss and consistent quality of lymphadenectomy. Robotic surgery could be an effective alternative to conventional laparoscopic surgery in treating gastric cancer patients with high BMI.	[Lee, Juhan; Noh, Sung Hoon; Hyung, Woo Jin] Yonsei Univ, Coll Med, Dept Surg, Seoul 120752, South Korea; [Kim, Yoo-Min] CHA Univ, CHA Bundang Med Ctr, Dept Surg, Songnam, Gyeonggi Do, South Korea; [Woo, Yanghee] Columbia Univ Coll Phys & Surg, Dept Surg, New York, NY 10032 USA; [Obama, Kazutaka] Kyoto Univ, Dept Surg Gastroenterol, Kyoto, Japan; [Noh, Sung Hoon; Hyung, Woo Jin] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Gastr Canc Ctr, Seoul, South Korea; [Hyung, Woo Jin] Yonsei Univ Hlth Syst, Severance Hosp, Robot & MIS Ctr, Seoul, South Korea	Hyung, WJ (reprint author), Yonsei Univ, Coll Med, Dept Surg, 50-1 Yonsei Ro, Seoul 120752, South Korea.	wjhyung@yuhs.ac			ETRI R&D Program - Government of Korea [14ZC1400]	This work was supported by ETRI R&D Program [14ZC1400, the Development of a Realistic Surgery Rehearsal System based on Patient Specific Surgical Planning] funded by the Government of Korea. The authors would like to thank Anthony Thomas Milliken (Editing Synthase, Seoul, Korea) for his help with the editing of this manuscript. We also acknowledge the assistance of BioScience Writers, LLC (Houston, TX, USA), in copyediting of the manuscript and corrections of English language usage.	Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Kitano S, 2002, SURG LAPARO ENDO PER, V12, P204, DOI 10.1097/01.SLE.0000017663.43677.6E; Degiuli M, 2004, BRIT J CANCER, V90, P1727, DOI 10.1038/sj.bjc.6601761; Hyung WJ, 2002, ANN SURG ONCOL, V9, P5, DOI 10.1245/aso.2002.9.1.5; Lanfranco AR, 2004, ANN SURG, V239, P14, DOI 10.1094/01.sla.0000103020.19595.7d; Park SS, 2012, SURG ENDOSC, V26, P60, DOI 10.1007/s00464-011-1828-5; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Woo Y, 2011, ARCH SURG-CHICAGO, V146, P1086, DOI 10.1001/archsurg.2011.114; Park JY, 2012, BRIT J SURG, V99, P1554, DOI 10.1002/bjs.8887; Shen JY, 2007, CANCER, V110, P745, DOI 10.1002/cncr.22837; Dixon E, 2009, J SURG ONCOL, V99, P508, DOI 10.1002/jso.21187; Ajani JA, 2010, J NATL COMPR CANC NE, V8, P378; Songun I, 2010, LANCET ONCOL, V11, P439, DOI 10.1016/S1470-2045(10)70070-X; Kim MG, 2011, SURG LAPARO ENDO PER, V21, P151, DOI 10.1097/SLE.0b013e318219a57d; Ohno T, 2010, SURG ENDOSC, V24, P2770, DOI 10.1007/s00464-010-1044-8; Dhar DK, 2000, ONCOLOGY-BASEL, V59, P18, DOI 10.1159/000012131; Patriti A, 2008, SURG ENDOSC, V22, P2753, DOI 10.1007/s00464-008-0129-0; Hyung WJ, 2007, EJSO-EUR J SURG ONC, V33, P314, DOI 10.1016/j.ejso.2006.11.010; Hwang SI, 2009, SURG ENDOSC, V23, P1252, DOI 10.1007/s00464-008-0140-5; Song J, 2009, ANN SURG, V249, P927, DOI 10.1097/01.sla.0000351688.64999.73; Lo CH, 2008, AM J SURG, V196, P741, DOI 10.1016/j.amjsurg.2007.11.031; Gallo T, 2012, JSLS-J SOC LAPAROEND, V16, P421, DOI 10.4293/108680812X13462882735890; Leung WK, 2008, LANCET ONCOL, V9, P279, DOI 10.1016/S1470-2045(08)70072-X; Hermsen ED, 2010, INFECT CONT HOSP EP, V31, P822, DOI 10.1086/654006; Jung KW, 2013, CANCER RES TREAT, V45, P1, DOI 10.4143/crt.2013.45.1.1; Park B, 2012, CANCER RES TREAT, V44, P113, DOI 10.4143/crt.2012.44.2.113; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Lee JH, 2005, SURG ENDOSC, V19, P168, DOI 10.1007/s00464-004-8808-y; Han TS, 2011, ANN SURG ONCOL, V18, P2818, DOI 10.1245/s10434-011-1620-8; Lee HJ, 2009, SURG ENDOSC, V23, P2473, DOI 10.1007/s00464-009-0419-1; Lee JH, 2007, ANN SURG ONCOL, V14, P3148, DOI 10.1245/s10434-007-9446-0; Vinuela EF, 2012, ANN SURG, V255, P446, DOI 10.1097/SLA.0b013e31824682f4; Smith DD, 2005, J CLIN ONCOL, V23, P7114, DOI 10.1200/JCO.2005.14.621; Kim HH, 2010, ANN SURG, V251, P417, DOI 10.1097/SLA.0b013e3181cc8f6b; Markar SR, 2011, INT J MED ROBOT COMP, V7, P393, DOI 10.1002/rcs.414; Cadiere GB, 2001, WORLD J SURG, V25, P1467; Deurenberg P, 2002, Obes Rev, V3, P141, DOI 10.1046/j.1467-789X.2002.00065.x; Ferlay J, 2012, IARC CANCERBASE; Japanese Gastric Cancer Association, 2011, GASTRIC CANCER, V14, P113, DOI [10.1007/s10120-011-0042-4, DOI 10.1007/S10120-011-0042-4]]; Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI DOI 10.1007/S101209800016]; Jeong Oh, 2011, J Gastric Cancer, V11, P69, DOI 10.5230/jgc.2011.11.2.69; Kim Ki-Han, 2006, Gastric Cancer, V9, P303, DOI 10.1007/s10120-006-0395-2; WAGNER PK, 1991, BRIT J SURG, V78, P825, DOI 10.1002/bjs.1800780719	43	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	NOV	2015	29	11					3251	3260		10.1007/s00464-015-4069-1		10	Surgery	Surgery	CT8JC	WOS:000363060700030		
J	Man-i, M; Suda, K; Kikuchi, K; Tanaka, T; Furuta, S; Nakauchi, M; Ishikawa, K; Ishida, Y; Uyama, I				Man-i, Mariko; Suda, Koichi; Kikuchi, Kenji; Tanaka, Tsuyoshi; Furuta, Shimpei; Nakauchi, Masaya; Ishikawa, Ken; Ishida, Yoshinori; Uyama, Ichiro			Totally intracorporeal delta-shaped B-I anastomosis following laparoscopic distal gastrectomy using the Tri-Staple (TM) reloads on the manual Ultra handle: a prospective cohort study with historical controls	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Stomach neoplasms; Laparoscopic distal gastrectomy; Delta-shaped anastomosis; Complication; Staple-line bleeding; Endo GIA Tri-Staple	ADVANCED GASTRIC-CANCER; LYMPH-NODE DISSECTION; COMPLICATIONS; MULTICENTER; ANESTHESIA; MORBIDITY; MORTALITY; SURGERY	A delta-shaped anastomosis in totally laparoscopic Billroth I gastrectomy could be performed easily and sufficiently using only laparoscopic linear staplers. However, the restricted maneuverability and severe blurring of these staplers along with their limited hemostability induced strain. In this study, we determined the feasibility and safety of performing delta-shaped anastomosis using the Endo GIA (TM) Reloads with Tri-Staple (TM) Technology combined with Endo GIA (TM) Ultra Universal stapler (Tri-Staple) with a particular focus on short-term surgical outcomes. We performed a single-institutional prospective interventional study (UMIN 000008014). The Tri-Staple was prospectively used on 23 consecutive patients who underwent a curative totally laparoscopic Billroth I gastrectomy with delta-shaped anastomosis. These patients were matched with the 19 patients previously treated using the ENDOPATH(A (R)) ETS Articulating Linear Cutters (ETS) on clinical and demographic characteristics. There were no differences between the groups in anastomosis-related local complications, morbidity, non-anastomosis-related local complications, total systemic complications, and short-term outcomes with the exception of significantly reduced blood loss in the Tri-Staple group (ETS vs. Tri-Staple: 37 [10-306] vs. 15 [5-210] mL, p = 0.02). Intraoperative bleeding from the staple line was significantly reduced in the Tri-Staple group. The postoperative drain indwelling period (ETS vs. Tri-Staple, 6 [4-10] vs. 4 [2-43] days, p = 0.032), fasting period (5 [3-7] vs. 3 [3-24] days, p = 0.022), and hospital stay (14 [10-47] vs. 11 [6-58] days, p = 0.025) were significantly shorter in the Tri-Staple group. There was no mortality in this series. Acceleration assessed as indices of blurring of stapler tip might have a significant adverse influence on staple-line bleeding at stapling sites. Totally laparoscopic Billroth I distal gastrectomy using Tri-Staple was feasible and safe with favorable short-term surgical outcomes. Reduced blurring while stapling may be a novel endpoint which newly developed stapling devices should target.	[Man-i, Mariko; Suda, Koichi; Kikuchi, Kenji; Tanaka, Tsuyoshi; Furuta, Shimpei; Nakauchi, Masaya; Ishikawa, Ken; Ishida, Yoshinori; Uyama, Ichiro] Fujita Hlth Univ, Div Upper GI, Dept Surg, Toyoake, Aichi 4701192, Japan	Suda, K (reprint author), Fujita Hlth Univ, Div Upper GI, Dept Surg, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan.	mariko-m@bc5.so-net.ne.jp; ko-suda@nifty.com			Covidien Surgical Devices Investigator Sponsored Research Grants	Our "Feasibility Study of Delta-Shaped Anastomosis in Totally Laparoscopic Billroth I Gastrectomy using Tri-Staple" was funded by Covidien Surgical Devices Investigator Sponsored Research Grants (2,100,000JPY), and Koichi Suda and Ichiro Uyama have conflicts of interest and financial ties to disclose. Mariko Man-i, Kenji Kikuchi, Tsuyoshi Tanaka, Shimpei Furuta, Masaya Nakauchi, Ken Ishikawa, and Yoshinori Ishida have no conflicts of interest or financial ties to disclose.	Abel M, 2011, GEN SURG NEWS, V38, P6; Shinohara T, 2013, SURG ENDOSC, V27, P286, DOI 10.1007/s00464-012-2442-x; Huscher CGS, 2007, AM J SURG, V194, P839, DOI 10.1016/j.amjsurg.2007.08.037; Tanimura S, 2005, SURG ENDOSC, V19, P1177, DOI 10.1007/s00464-004-8936-4; Adachi Y, 2000, ARCH SURG-CHICAGO, V135, P806, DOI 10.1001/archsurg.135.7.806; Kim MC, 2007, EJSO-EUR J SURG ONC, V33, P700, DOI 10.1016/j.ejso.2007.02.018; Kanaya S, 2002, J AM COLL SURGEONS, V195, P284, DOI 10.1016/S1072-7515(02)01239-5; WARNER MA, 1993, JAMA-J AM MED ASSOC, V270, P1437, DOI 10.1001/jama.270.12.1437; Guzman EA, 2009, ANN SURG ONCOL, V16, P2218, DOI 10.1245/s10434-009-0508-3; Ikeda O, 2009, SURG ENDOSC, V23, P2374, DOI 10.1007/s00464-009-0360-3; McCulloch P, 2003, BMJ-BRIT MED J, V327, P1192, DOI 10.1136/bmj.327.7425.1192; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Song KY, 2008, J GASTROINTEST SURG, V12, P1015, DOI 10.1007/s11605-008-0484-0; Kanaya S, 2011, SURG ENDOSC, V25, P3928, DOI 10.1007/s00464-011-1792-0; PEDERSEN T, 1986, EUR J ANAESTH, V3, P225; Cottam D, 2011, GEN SURG NEWS, V38, P8; Hansen H, 2011, GEN SURG NEWS, V38, P22; Hori Seiji, 2004, Gastric Cancer, V7, P24, DOI 10.1007/s10120-003-0263-2; Japan Clinical Oncology Group, POST COMPL CRIT ACC; Japanese Gastric Cancer Association, 2011, GASTRIC CANCER, V14, P113, DOI [10.1007/s10120-011-0042-4, DOI 10.1007/S10120-011-0042-4]]; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Kitano S, 2002, SURGERY, V131, pS306, DOI 10.1067/msy.2002.120115; Satoh Yukitoshi, 2009, Gen Thorac Cardiovasc Surg, V57, P402, DOI 10.1007/s11748-009-0407-3; Uyama Ichiro, 2013, J Gastric Cancer, V13, P19, DOI 10.5230/jgc.2013.13.1.19	24	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	NOV	2015	29	11					3304	3312		10.1007/s00464-015-4085-1		9	Surgery	Surgery	CT8JC	WOS:000363060700037		
J	Dobashi, A; Goda, K; Sumiyama, K; Kobayashi, M; Ohya, TR; Kato, M; Toyoizumi, H; Kato, T; Matsushima, M; Tajiri, H				Dobashi, Akira; Goda, Kenichi; Sumiyama, Kazuki; Kobayashi, Masakuni; Ohya, Tomohiko R.; Kato, Masayuki; Toyoizumi, Hirobumi; Kato, Tomohiro; Matsushima, Masato; Tajiri, Hisao			A feasibility study of chemically assisted endoscopic submucosal mechanical dissection using mesna for superficial esophageal squamous cell carcinomas	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Endoscopic resection; Endoscopic submucosal dissection; Mechanical submucosal dissection; Mesna; Superficial esophageal squamous cell carcinoma	MUCOSAL RESECTION; PORCINE MODEL; NEOPLASMS; CANCER; INJECTION; TISSUES; KNIFE	Injection of mesna into submucosal layers was recently reported to chemically soften connective tissue and facilitate the gastric endoscopic submucosal dissection (ESD) procedure. This study aimed to evaluate the safety and feasibility of similarly using mesna for esophageal ESD (mesna ESD). We performed mesna ESD in 20 consecutive patients with superficial esophageal squamous cell carcinomas (SESCCs). To do this, a submucosal fluid cushion was initially formed using sodium hyaluronate, and the esophageal lesion was circumferentially isolated with a short blade needle-knife. Mesna solution was then injected into the submucosal layer, which was dissected mechanically by cleavage using the tip of a cap-fitted endoscope. The number of electrosurgical incisions was recorded by computer software in real time. The data from 20 conventional ESD procedures without mesna (consecutive 10 SESCCs pre and post the 20 consecutive mesna ESD) were used for comparison to evaluate the mesna ESD. The mesna ESDs achieved en bloc and R0 resection success rates of 100 and 95 %, respectively. There was no perforation or uncontrollable hemorrhage during and after mesna ESD, and the median procedural time of submucosal dissection was significantly less with mesna ESD than with conventional ESD (median; 8 vs. 15 min, P < 0.05). There were also significantly fewer electrosurgical incisions made during the mesna ESD than with conventional ESDs (median; 65 vs. 183 times, P < 0.01). Mesna ESD for SESCCs is a safe procedure with the potential to facilitate esophageal ESD.	[Dobashi, Akira; Goda, Kenichi; Sumiyama, Kazuki; Kobayashi, Masakuni; Ohya, Tomohiko R.; Kato, Masayuki; Toyoizumi, Hirobumi; Kato, Tomohiro; Tajiri, Hisao] Jikei Univ, Sch Med, Dept Endoscopy, Minato Ku, Tokyo 1058461, Japan; [Matsushima, Masato] Jikei Univ, Sch Med, Dept Epidemiol, Minato Ku, Tokyo 1058461, Japan; [Tajiri, Hisao] Jikei Univ, Sch Med, Dept Internal Med,Div Gastroenterol & Hepatol, Minato Ku, Tokyo 1058461, Japan	Dobashi, A (reprint author), Jikei Univ, Sch Med, Dept Endoscopy, Minato Ku, 3-25-8 Nishi Shimbashi, Tokyo 1058461, Japan.	akira.dobashi@nifty.com					Farhat S, 2011, ENDOSCOPY, V43, P664, DOI 10.1055/s-0030-1256413; Cao Y, 2009, ENDOSCOPY, V41, P751, DOI 10.1055/s-0029-1215053; BOMBECK CT, 1966, ANN SURG, V164, P643; Benassi L, 2000, J AM COLL SURGEONS, V191, P65, DOI 10.1016/S1072-7515(00)00296-9; Reinhart WH, 1999, EUR J HAEMATOL, V62, P223; Sumiyama K, 2010, ENDOSCOPY, V42, P627, DOI 10.1055/s-0029-1244223; Dobashi A, 2013, ENDOSCOPY, V45, P661, DOI 10.1055/s-0033-1344126; Kawahara Y, 2013, ENDOSCOPY, V45, P869, DOI 10.1055/s-0033-1344229; Akahoshi K, 2013, ENDOSCOPY, V45, P1035, DOI 10.1055/s-0033-1344863; Sumiyama K, 2014, GASTROINTEST ENDOSC, V79, P756, DOI 10.1016/j.gie.2013.09.027; Sumiyama K, 2008, GASTROINTEST ENDOSC, V67, P534, DOI 10.1016/j.gie.2007.10.041; Fujishiro M, 2009, DIGEST ENDOSC, V21, P109, DOI 10.1111/j.1443-1661.2009.00837.x; Isomoto H, 2013, DIGEST ENDOSC, V25, P29, DOI 10.1111/j.1443-1661.2012.01388.x; Neuhaus H, 2009, GASTROINTEST ENDOSC, V70, P112, DOI 10.1016/j.gie.2008.10.042; Willingham FF, 2009, GASTROINTEST ENDOSC, V69, P147, DOI 10.1016/j.gie.2008.09.010; Goda K, 2012, DIGEST ENDOSC, V24, P136, DOI 10.1111/j.1443-1661.2012.01274.x; Higuchi K, 2013, GASTROINTEST ENDOSC, V78, P704, DOI 10.1016/j.gie.2013.04.182; Ono H, 2001, GUT, V48, P225, DOI 10.1136/gut.48.2.225; Gostout CJ, 2012, GASTROINTEST ENDOSC, V76, P829, DOI 10.1016/j.gie.2012.05.037; Ajmal N, 2003, PLAST RECONSTR SURG, V112, P1449, DOI 10.1097/01.PRS.0000081069.87802.98; Ono S, 2009, GASTROINTEST ENDOSC, V70, P860, DOI 10.1016/j.gie.2009.04.044; Goda K, 2009, DIS ESOPHAGUS, V22, P453, DOI 10.1111/j.1442-2050.2009.00942.x; Fujinami H, 2014, DIS ESOPHAGUS, V27, P50, DOI 10.1111/dote.12039; Fujishiro M, 2008, Endoscopy, V40 Suppl 2, pE81, DOI 10.1055/s-2007-995538; Inoue H, 1997, DIGEST ENDOSC, V9/1, P16, DOI 10.1111/j.1443-1661.1997.tb00453.x; Oyama Tsuneo, 2005, Clin Gastroenterol Hepatol, V3, pS67, DOI 10.1016/S1542-3565(05)00291-0; Sato H, 2014, DIS ESOPHAGUS, V27, P617, DOI 10.1111/dote.12125; The Japan Esophageal Society, 2008, JAP CLASS ES CANC	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	NOV	2015	29	11					3373	3381		10.1007/s00464-014-4031-7		9	Surgery	Surgery	CT8JC	WOS:000363060700048		
J	Matsuda, T; Iwasaki, T; Mitsutsuji, M; Hirata, K; Maekawa, Y; Tsugawa, D; Sugita, Y; Shimada, E; Kakeji, Y				Matsuda, Takeru; Iwasaki, Takeshi; Mitsutsuji, Masaaki; Hirata, Kenro; Maekawa, Yoko; Tsugawa, Daisuke; Sugita, Yutaka; Shimada, Etsuji; Kakeji, Yoshihiro			Surgical outcomes of intracorporeal circular-stapled esophagojejunostomy using modified over-and-over suture technique in laparoscopic total gastrectomy	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Esophagojejunostomy; Laparoscopy; Gastric cancer	BILLROTH-I GASTRECTOMY; LYMPH-NODE DISSECTION; PURSE-STRING SUTURE; GASTRIC-CANCER; DISTAL GASTRECTOMY; ANASTOMOSIS; STENOSIS; PHASE	Esophagojejunostomy in laparoscopic total gastrectomy (LTG) is a technically demanding procedure. Although several methods have been reported to date, none is considered consistently reliable. We developed a simple method for intracorporeal circular-stapled esophagojejunostomy using a modified over-and-over suture technique. The surgical outcomes of our technique were evaluated in comparison with those of open total gastrectomy (OTG). From April 2012 to August 2014, reconstruction using this method in LTG was performed for 21 consecutive patients with gastric cancer (LTG group). Their surgical outcomes were compared with those of 27 patients with gastric cancer who underwent OTG without splenectomy (OTG group) between January 2011 and April 2014. Estimated blood loss was significantly lower, and the postoperative hospital stay was significantly shorter in the LTG group than in the OTG group. The operating time and the number of harvested lymph nodes were similar between the two groups. The incidence of overall complications did not differ significantly between the two groups. Anastomotic leakage developed in one of the 21 patients in the LTG group and in two of the 27 patients in the OTG group. Anastomotic stenosis was observed in one patient in the LTG group. We consider this method as simple and feasible for most laparoscopic surgeons with basic laparoscopic suturing skills. This method might help LTG to become an accepted standard surgical option for treatment of patients with gastric cancer.	[Matsuda, Takeru; Iwasaki, Takeshi; Mitsutsuji, Masaaki; Hirata, Kenro; Maekawa, Yoko; Tsugawa, Daisuke; Sugita, Yutaka; Shimada, Etsuji] Natl Hosp Org Kobe Med Ctr, Dept Surg, Suma Ku, Kobe, Hyogo 6540155, Japan; [Kakeji, Yoshihiro] Kobe Univ, Dept Surg, Grad Sch Med, Div Gastrointestinal Surg, Kobe, Hyogo 657, Japan	Matsuda, T (reprint author), Natl Hosp Org Kobe Med Ctr, Dept Surg, Suma Ku, 3-1-1 Nishi Ochiai, Kobe, Hyogo 6540155, Japan.	takerumatsuda@nifty.com					Zuiki T, 2013, SURG ENDOSC, V27, P3683, DOI 10.1007/s00464-013-2945-0; Huscher CGS, 2007, AM J SURG, V194, P839, DOI 10.1016/j.amjsurg.2007.08.037; Takiguchi S, 2005, SURG TODAY, V35, P896, DOI 10.1007/s00595-005-3030-7; Kodera Y, 2010, J AM COLL SURGEONS, V211, P677, DOI 10.1016/j.jamcollsurg.2010.07.013; Bannura GC, 2004, WORLD J SURG, V28, P921, DOI 10.1007/s00268-004-7375-7; Kanaya S, 2002, J AM COLL SURGEONS, V195, P284, DOI 10.1016/S1072-7515(02)01239-5; Inaba K, 2010, J AM COLL SURGEONS, V211, pE25, DOI 10.1016/j.jamcollsurg.2010.09.005; Kanaji S, 2014, SURG ENDOSC, V28, P1250, DOI 10.1007/s00464-013-3315-7; Kinoshita T, 2010, SURG ENDOSC, V24, P2908, DOI 10.1007/s00464-010-1041-y; Lee JH, 2005, SURG ENDOSC, V19, P168, DOI 10.1007/s00464-004-8808-y; Hiki N, 2007, GASTRIC CANCER, V10, P181, DOI 10.1007/s10120-007-0433-8; Usui S, 2008, GASTRIC CANCER, V11, P233, DOI 10.1007/s10120-008-0481-8; Tanimura S, 2007, BRIT J SURG, V94, P204, DOI 10.1002/bjs.5542; Kim HH, 2010, ANN SURG, V251, P417, DOI 10.1097/SLA.0b013e3181cc8f6b; Jeong O, 2009, SURG ENDOSC, V23, P2624, DOI 10.1007/s00464-009-0461-z; KITANO S, 1994, SURG LAPAROSC ENDOSC, V4, P146; Omori Takeshi, 2009, Am J Surg, V197, pe13, DOI 10.1016/j.amjsurg.2008.04.019	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	NOV	2015	29	11					3386	3391		10.1007/s00464-015-4073-5		6	Surgery	Surgery	CT8JC	WOS:000363060700050		
J	Krug, PJ; Vendetti, JE; Ellingson, RA; Trowbridge, CD; Hirano, YM; Trathen, DY; Rodriguez, AK; Swennen, C; Wilson, NG; Valdes, AA				Krug, Patrick J.; Vendetti, Jann E.; Ellingson, Ryan A.; Trowbridge, Cynthia D.; Hirano, Yayoi M.; Trathen, Danielle Y.; Rodriguez, Albert K.; Swennen, Cornelis; Wilson, Nerida G.; Valdes, Angel A.			Species Selection Favors Dispersive Life Histories in Sea Slugs, but Higher Per-Offspring Investment Drives Shifts to Short-Lived Larvae	SYSTEMATIC BIOLOGY			English	Article						Development mode; gastropod; lecithotrophy; macroevolution; planktotrophy; Sacoglossa; species selection	POPULATION GENETIC-STRUCTURE; PHYLOGENETIC ANALYSIS; SACOGLOSSA MOLLUSCA; EGG SIZE; MARINE-INVERTEBRATES; CATEGORICAL CHARACTERS; MOLECULAR SYSTEMATICS; DEVELOPMENT PATTERNS; EXPLOSIVE RADIATION; SUBSTITUTION MODELS	For 40 years, paleontological studies of marine gastropods have suggested that species selection favors lineages with short-lived (lecithotrophic) larvae, which are less dispersive than long-lived (planktotrophic) larvae. Although lecithotrophs appeared to speciate more often and accumulate over time in some groups, lecithotrophy also increased extinction rates, and tests for state-dependent diversification were never performed. Molecular phylogenies of diverse groups instead suggested lecithotrophs accumulate without diversifying due to frequent, unidirectional character change. Although lecithotrophy has repeatedly originated in most phyla, no adult trait has been correlated with shifts in larval type. Thus, both the evolutionary origins of lecithotrophy and its consequences for patterns of species richness remain poorly understood. Here, we test hypothesized links between development mode and evolutionary rates using likelihood-based methods and a phylogeny of 202 species of gastropod molluscs in Sacoglossa, a clade of herbivorous sea slugs. Evolutionary quantitative genetics modeling and stochastic character mapping supported 27 origins of lecithotrophy. Tests for correlated evolution revealed lecithotrophy evolved more often in lineages investing in extra-embryonic yolk, the first adult trait associated with shifts in development mode across a group. However, contrary to predictions from paleontological studies, species selection actually favored planktotrophy; most extant lecithotrophs originated through recent character change, and did not subsequently diversify. Increased offspring provisioning in planktotrophs thus favored shifts to short-lived larvae, which led to short-lived lineages over macroevolutionary time scales. These findings challenge long-standing assumptions about the effects of alternative life histories in the sea. Species selection can explain the long-term persistence of planktotrophy, the ancestral state in most clades, despite frequent transitions to lecithotrophy.	[Krug, Patrick J.; Vendetti, Jann E.; Ellingson, Ryan A.; Trathen, Danielle Y.; Rodriguez, Albert K.] Calif State Univ Los Angeles, Dept Biol Sci, Los Angeles, CA 90032 USA; [Trowbridge, Cynthia D.] Univ Oregon, Oregon Inst Marine Biol, Charleston, OR 97420 USA; [Hirano, Yayoi M.] Nat Hist Museum & Inst, Coastal Branch, Chiba, Katsuura 2995242, Japan; [Swennen, Cornelis] Prince Songkla Univ, Fac Sci & Technol, Pattani 94000, Thailand; [Wilson, Nerida G.] Western Australian Museum, Perth, WA 6106, Australia; [Valdes, Angel A.] Calif State Polytech Univ Pomona, Dept Biol Sci, Pomona, CA 91768 USA	Krug, PJ (reprint author), Calif State Univ Los Angeles, Dept Biol Sci, Los Angeles, CA 90032 USA.	pkrug@calstatela.edu			US National Science Foundation [DEB-0817084, DEB-1355190, OCE 11-30072, DEB-1355177]; US National Institutes of Health [GM-61331]; American Association for the Advancement of Science; US National Science Foundation; Australian Museum	This work was supported by awards from the US National Science Foundation [DEB-0817084, DEB-1355190, and OCE 11-30072 to PJK; DEB-1355177 to AAV], the US National Institutes of Health [grant number GM-61331 supporting AKR and DYT], and Women-In-Science Collaboration funds from the American Association for the Advancement of Science and the US National Science Foundation to CDT and YMH. The Australian Museum provided support for NGW and fieldwork on Lord Howe Island.	Paradis E, 2004, BIOINFORMATICS, V20, P289, DOI 10.1093/bioinformatics/btg412; Huelsenbeck JP, 2004, SYST BIOL, V53, P904, DOI 10.1080/1063515049522629; Lanfear R, 2012, MOL BIOL EVOL, V29, P1695, DOI 10.1093/molbev/mss020; Marshall DJ, 2008, ECOLOGY, V89, P2506, DOI 10.1890/07-0267.1; HANSEN TA, 1980, PALEOBIOLOGY, V6, P193; Foltz DW, 2004, GENETICA, V122, P115, DOI 10.1023/B:GENE.0000041002.97173.1e; Mayrose I, 2011, MOL BIOL EVOL, V28, P759, DOI 10.1093/molbev/msq263; Hart MW, 1997, EVOLUTION, V51, P1848, DOI 10.2307/2411007; Jeffery CH, 2003, MOL PHYLOGENET EVOL, V28, P99, DOI 10.1016/S1055-7903(03)00030-7; Miles CM, 2002, J MOLLUS STUD, V68, P101, DOI 10.1093/mollus/68.2.101; Duda TF, 2005, MOL ECOL, V14, P267, DOI 10.1111/j.1365-294X.2004.02397.x; McDonald KA, 2014, INVERTEBR BIOL, V133, P213, DOI 10.1111/ivb.12057; Krug PJ, 2008, J MOLLUS STUD, V74, P267, DOI 10.1093/mollus/eyn018; Hart M, 2000, SEMIN CELL DEV BIOL, V11, P411, DOI 10.1006/scdb.2000.0194; Castresana J, 2000, MOL BIOL EVOL, V17, P540; Alfaro ME, 2009, P NATL ACAD SCI USA, V106, P13410, DOI 10.1073/pnas.0811087106; Lydeard C, 2000, MOL PHYLOGENET EVOL, V15, P83, DOI 10.1006/mpev.1999.0719; Botello G, 2006, MAR ECOL PROG SER, V312, P149, DOI 10.3354/meps312149; Pechenik JA, 1999, MAR ECOL PROG SER, V177, P269, DOI 10.3354/meps177269; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Strathmann RR, 2002, EVOLUTION, V56, P708; Magnuson-Ford K, 2012, AM NAT, V180, P225, DOI 10.1086/666649; Krug PJ, 2013, MOL PHYLOGENET EVOL, V69, P1101, DOI 10.1016/j.ympev.2013.07.009; JABLONSKI D, 1986, B MAR SCI, V39, P565; Rouse GW, 2000, EVOL DEV, V2, P222, DOI 10.1046/j.1525-142x.2000.00063.x; Oliphant A, 2013, MAR ECOL PROG SER, V493, P207, DOI 10.3354/meps10496; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Hadfield JD, 2010, J EVOLUTION BIOL, V23, P494, DOI 10.1111/j.1420-9101.2009.01915.x; Wilson NG, 2009, MOL ECOL, V18, P965, DOI 10.1111/j.1365-294X.2008.04071.x; Meyer CP, 2003, BIOL J LINN SOC, V79, P401, DOI 10.1046/j.1095-8312.2003.00197.x; Cunha RL, 2005, SYST BIOL, V54, P634, DOI 10.1080/106341591007471; Mallatt J, 2010, MOL PHYLOGENET EVOL, V55, P1, DOI 10.1016/j.ympev.2009.09.028; Krug PJ, 2011, AM MALACOL BULL, V29, P169; Keever CC, 2008, EVOL DEV, V10, P62, DOI 10.1111/j.1525-142X.2008.00214.x; Allen RM, 2009, MAR ECOL PROG SER, V389, P127, DOI 10.3354/meps08157; LIEBERMAN BS, 1993, PALEOBIOLOGY, V19, P205; Kocot KM, 2013, MOL PHYLOGENET EVOL, V69, P764, DOI 10.1016/j.ympev.2013.07.001; VERMEIJ GJ, 1982, NATURE, V299, P349, DOI 10.1038/299349a0; Waeschenbach A, 2012, MOL PHYLOGENET EVOL, V62, P718, DOI 10.1016/j.ympev.2011.11.011; Ellingson RA, 2014, MOL PHYLOGENET EVOL, V70, P464, DOI 10.1016/j.ympev.2013.10.009; Foltz DW, 2003, J MOL EVOL, V57, P607, DOI 10.1007/s00239-003-2495-5; Goldberg EE, 2010, SCIENCE, V330, P493, DOI 10.1126/science.1194513; Raff EC, 2003, EVOL DEV, V5, P478, DOI 10.1046/j.1525-142X.2003.03054.x; SHUTO T, 1974, LETHAIA, V7, P239, DOI 10.1111/j.1502-3931.1974.tb00899.x; Pagel M, 2004, SYST BIOL, V53, P571, DOI 10.1080/10635150490468675; STRATHMANN RR, 1985, ANNU REV ECOL SYST, V16, P339, DOI 10.1146/annurev.es.16.110185.002011; Collin R, 2007, BIOL BULL-US, V212, P83; Nutzel A, 2014, PALAEONTOLOGY, V57, P479, DOI 10.1111/pala.12104; Selkoe KA, 2011, MAR ECOL PROG SER, V436, P291, DOI 10.3354/meps09238; STANLEY SM, 1975, P NATL ACAD SCI USA, V72, P646, DOI 10.1073/pnas.72.2.646; Medina M, 2000, MOL PHYLOGENET EVOL, V15, P41, DOI 10.1006/mpev.1999.0736; Maddison WP, 2007, SYSTEMATIC BIOL, V56, P701, DOI 10.1080/10635150701607033; JABLONSKI D, 1983, BIOL REV, V58, P21, DOI 10.1111/j.1469-185X.1983.tb00380.x; Levitan DR, 2000, AM NAT, V156, P175, DOI 10.1086/303376; Krug PJ, 2009, BIOL BULL-US, V216, P355; Cooke S, 2014, ZOOL SCR, V43, P351, DOI 10.1111/zsc.12063; Paradis E, 2013, MOL PHYLOGENET EVOL, V67, P436, DOI 10.1016/j.ympev.2013.02.008; Jablonski D, 2008, ANNU REV ECOL EVOL S, V39, P501, DOI 10.1146/annurev.ecolsys.39.110707.173510; CLARK KB, 1981, INT J INVER REP DEV, V3, P57; Mikkelsen PM, 1998, ZOOL SCR, V27, P49, DOI 10.1111/j.1463-6409.1998.tb00428.x; Jensen Kathe R., 2007, Bonner Zoologische Beitraege, V55, P255; Jensen KR, 1997, EVOL ECOL, V11, P301, DOI 10.1023/A:1018468420368; Collin R, 2004, EVOLUTION, V58, P1488; Vendetti JE, 2012, INTEGR COMP BIOL, V52, P138, DOI 10.1093/icb/ics077; HANSEN TA, 1982, PALEOBIOLOGY, V8, P367; Marshall DJ, 2012, ANNU REV ECOL EVOL S, V43, P97, DOI 10.1146/annurev-ecolsys-102710-145004; FitzJohn RG, 2012, METHODS ECOL EVOL, V3, P1084, DOI 10.1111/j.2041-210X.2012.00234.x; Duda TF, 1999, P NATL ACAD SCI USA, V96, P10272, DOI 10.1073/pnas.96.18.10272; Rabosky DL, 2010, EVOLUTION, V64, P1816, DOI 10.1111/j.1558-5646.2009.00926.x; Allen JD, 2007, J EXP MAR BIOL ECOL, V347, P77, DOI 10.1016/j.jembe.2007.03.010; Maddison WP, 2015, SYST BIOL, V64, P127, DOI 10.1093/sysbio/syu070; Marshall DJ, 2011, CURR BIOL, V21, pR718, DOI 10.1016/j.cub.2011.08.022; Bradbury IR, 2008, P ROY SOC B-BIOL SCI, V275, P1803, DOI 10.1098/rspb.2008.0216; Lee HJE, 2009, MOL ECOL, V18, P2165, DOI 10.1111/j.1365-294X.2009.04169.x; Akimoto A, 2014, MAR BIOL, V161, P1095, DOI 10.1007/s00227-014-2402-1; JABLONSKI D, 1986, SCIENCE, V231, P129, DOI 10.1126/science.231.4734.129; Jensen KR, 1996, PHILOS T ROY SOC B, V351, P91, DOI 10.1098/rstb.1996.0006; Hart MW, 2005, MOL PHYLOGENET EVOL, V34, P438, DOI 10.1016/j.ympev.2004.09.011; THORSON G, 1950, BIOL REV, V25, P1, DOI 10.1111/j.1469-185X.1950.tb00585.x; Pagel M, 2006, AM NAT, V167, P808, DOI 10.1086/503444; Pringle JM, 2014, ECOLOGY, V95, P1022, DOI 10.1890/13-0970.1; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; CLARK KB, 1978, J MOLLUS STUD, V44, P283; Maliska ME, 2013, BIOL LETTERS, V9, DOI 10.1098/rsbl.2013.0068; Berger C., 2012, EVOLUTION, P1; Christa G., 2014, ORG DIVERS EVOL, V15, P123; Gould S.J., 1982, P83; Handeler K, 2009, FRONT ZOOL, V6, DOI 10.1186/1742-9994-6-28; Hansen T.A., 1978, SCIENCE, V199, P886; Jablonski D., 1982, P257; JENSEN KR, 1980, J MOLLUS STUD, V46, P282; Levin L.A., 1995, MARINE INVERTEBRATE, P1; Miller M. A., 2010, GAT COMP ENV WORKSH, P1, DOI DOI 10.1109/GCE.2010.5676129; Pappalardo P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094104; Rabosky DL, 2015, SYST BIOL, V64, P340, DOI 10.1093/sysbio/syu131; Rabosky DL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089543; Rabosky D.L., 2009, TRENDS ECOL EVOL, V25, P68; RADWIN G E, 1973, Transactions of the San Diego Society of Natural History, V17, P107; Rafftery A.A., 1996, MARKOV CHAIN MONTE C, P163; Revell LJ, 2012, METHODS ECOL EVOL, V3, P217, DOI 10.1111/j.2041-210X.2011.00169.x; REVELL LJ, 2013, EVOLUTION, V0068; Ridley M., 2004, EVOLUTION, P1; Scheltema R., 1978, MARINE ORGANISMS GEN, P303; SCHELTEM.RS, 1971, BIOL BULL, V140, P284, DOI 10.2307/1540075; Strathmann R.R., 1978, EVOLUTION, V32, P899; Wilson NG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080277; Wray Gregory A., 1995, P413	107	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1063-5157	1076-836X		SYST BIOL	Syst. Biol.	NOV	2015	64	6					983	999		10.1093/sysbio/syv046		17	Evolutionary Biology	Evolutionary Biology	CT9WU	WOS:000363168100008		
J	Mohammad, AF; Zaki, SA; Hagishima, A; Ali, MSM				Mohammad, A. F.; Zaki, S. A.; Hagishima, A.; Ali, M. S. M.			Determination of aerodynamic parameters of urban surfaces: methods and results revisited	THEORETICAL AND APPLIED CLIMATOLOGY			English	Article							WALL BOUNDARY-LAYERS; CUBE ARRAYS; MOMENTUM ABSORPTION; ROUGHNESS ELEMENTS; VELOCITY PROFILE; BUILDING ARRAYS; STREET CANYONS; CHANNEL FLOW; WIND; SIMULATION	Estimates of aerodynamic parameters, in particular roughness length z (0) and displacement height d, are important for the analysis of the roughness of an urban surface, which affects processes that occur within the urban boundary layer such as pollutant dispersion and urban ventilation. Findings regarding the aerodynamic effects of various configurations of urban arrays were compiled from various studies. Several experimental, numerical and semi-empirical studies to estimate z (0) and d were reviewed and compared with each other. The results can be summarized as follows: (1) the influence of the frontal area index (lambda (f) ) on z (0) is significant and their relationship has been confirmed by both experimental and numerical data; (2) compared to one-parameter and two-parameter fitting methods, the three-parameter fitting method is the least accurate; (3) the physical meaning of d remains vague because its definition as the height where surface drag acts may not be accurate for sharp-edged roughness blocks and (4) the peak values of z (0) for uniform and heterogeneous block heights indicate presence of skimming or wake-interference flow effects, which may influence surface roughness. Finally, the semi-empirical models were found to be limited to cases derived from available experimental data, which normally involve uniform arrays of cubes.	[Mohammad, A. F.; Zaki, S. A.; Ali, M. S. M.] Univ Teknol Malaysia Kuala Lumpur, Malaysia Japan Int Inst Technol, Kuala Lumpur 54100, Malaysia; [Hagishima, A.] Kyushu Univ, Interdisciplinary Grad Sch Engn Sci, Kasuga, Fukuoka 8168580, Japan	Zaki, SA (reprint author), Univ Teknol Malaysia Kuala Lumpur, Malaysia Japan Int Inst Technol, Jalan Semarak, Kuala Lumpur 54100, Malaysia.	sheikh.ahmadzaki@gmail.com			Malaysian Ministry of Higher Education (MOHE) under the Fundamental Research Grant Scheme project of Universiti Teknologi Malaysia [4 F350]	This research was financially supported by the Malaysian Ministry of Higher Education (MOHE) under the Fundamental Research Grant Scheme (4 F350) project of Universiti Teknologi Malaysia.	Cheng H, 2002, BOUND-LAY METEOROL, V104, P229, DOI 10.1023/A:1016060103448; Iyengar AKS, 2001, J WIND ENG IND AEROD, V89, P1059, DOI 10.1016/S0167-6105(01)00099-X; Claus J, 2012, BOUND-LAY METEOROL, V142, P265, DOI 10.1007/s10546-011-9667-4; Cao MC, 2014, J APPL MATH, DOI 10.1155/2014/267683; JACKSON PS, 1981, J FLUID MECH, V111, P15, DOI 10.1017/S0022112081002279; Zaki SA, 2012, J WIND ENG IND AEROD, V103, P31, DOI 10.1016/j.jweia.2012.02.008; Vardoulakis S, 2003, ATMOS ENVIRON, V37, P155, DOI 10.1016/S1352-2310(02)00857-9; Kanda M, 2004, BOUND-LAY METEOROL, V112, P343, DOI 10.1023/B:BOUN.0000027909.40439.7c; MacDonald RW, 1998, ATMOS ENVIRON, V32, P1857, DOI 10.1016/S1352-2310(97)00403-2; Bottema M, 1996, J WIND ENG IND AEROD, V64, P249, DOI 10.1016/S0167-6105(96)00062-1; Di Sabatino S, 2008, BOUND-LAY METEOROL, V127, P131, DOI 10.1007/s10546-007-9250-1; Kanda M, 2009, BOUND-LAY METEOROL, V131, P385, DOI 10.1007/s10546-009-9381-7; Raupach MR, 2006, BOUND-LAY METEOROL, V120, P201, DOI 10.1007/s10546-006-9058-4; Zaki SA, 2011, BOUND-LAY METEOROL, V138, P99, DOI 10.1007/s10546-010-9551-7; Tominaga Y, 2012, J VISUAL-JAPAN, V15, P269, DOI 10.1007/s12650-012-0128-z; Uehara K, 2000, ATMOS ENVIRON, V34, P1553, DOI 10.1016/S1352-2310(99)00410-0; Solazzo E, 2010, BOUND-LAY METEOROL, V137, P441, DOI 10.1007/s10546-010-9536-6; Leonardi S, 2010, J FLUID MECH, V651, P519, DOI 10.1017/S002211200999423X; Farell C, 1999, J WIND ENG IND AEROD, V79, P11, DOI 10.1016/S0167-6105(98)00117-2; Leonardi S, 2003, J FLUID MECH, V491, P229, DOI 10.1017/S0020112003005500; Macdonald RW, 2000, BOUND-LAY METEOROL, V97, P25, DOI 10.1023/A:1002785830512; COUNIHAN J, 1971, ATMOS ENVIRON, V5, P637, DOI 10.1016/0004-6981(71)90120-X; Boppana VBL, 2010, BOUND-LAY METEOROL, V135, P433, DOI 10.1007/s10546-010-9489-9; Kanda M, 2013, BOUND-LAY METEOROL, V148, P357, DOI 10.1007/s10546-013-9818-x; AKINS RE, 1977, J IND AERODYNAM, V2, P195, DOI 10.1016/0167-6105(77)90022-8; Millward-Hopkins JT, 2011, BOUND-LAY METEOROL, V141, P443, DOI 10.1007/s10546-011-9640-2; Xie ZT, 2006, FLOW TURBUL COMBUST, V76, P291, DOI 10.1007/s10494-006-9018-6; Snyder WH, 2002, J WIND ENG IND AEROD, V90, P41, DOI 10.1016/S0167-6105(01)00114-3; Cheng H, 2007, J WIND ENG IND AEROD, V95, P715, DOI 10.1016/j.jweia.2007.01.004; THEURER W, 1992, J WIND ENG IND AEROD, V41, P437, DOI 10.1016/0167-6105(92)90443-E; Jiang DH, 2008, WIND STRUCT, V11, P275; Coceal O, 2006, BOUND-LAY METEOROL, V121, P491, DOI 10.1007/s10546-006-9076-2; Hagishima A, 2009, BOUND-LAY METEOROL, V132, P315, DOI 10.1007/s10546-009-9403-5; Santiago JL, 2008, BOUND-LAY METEOROL, V128, P445, DOI 10.1007/s10546-008-9294-x; Bao JW, 2002, AMS MON WEATHER REV, V130; Bottema M, 1995, ENV T ECOL, V6, P2; Clauser F. H., 1956, ADVANCES APPLIED MEC, V4, P1, DOI DOI 10.1016/S0065-2156(08)70370-3; Coceal O, 2014, J WIND ENG IND AEROD, V125, P52, DOI 10.1016/j.jweia.2013.11.013; ESDU, 1980, MEAN FLUID FORC MOM; COLES D, 1956, J FLUID MECH, V1, P191, DOI 10.1017/S0022112056000135; Garrat JR, 1992, ATMOSPHERIC BOUNDARY; Hama FR, 1954, T SOC NAVAL ARCHITEC, V62, P333; Huq P, 2013, BOUND-LAY METEOROL, V147, P103, DOI 10.1007/s10546-012-9780-z; Jiang X, 2009, NUMERICAL TECHNIQUES; Kutzbach J, 1961, ANN REP 1961 U WISCO, P71; Lettau H, 1969, J APPL METEOROL, V8, P828, DOI DOI 10.1175/1520-0450(1969)0082.0.CO;2; Millward-Hopkins JT, 2012, BOUND-LAY METEOROL, V146, P447, DOI [10.1007/s10546-012-9761-2, DOI 10.1007/S10546-012-9761-2]; Oke T. R., 1987, BOUNDARY LAYER CLIMA; Padhra A, 2010, THESIS U READING; RAUPACH MR, 1992, BOUND-LAY METEOROL, V60, P375, DOI 10.1007/BF00155203; Abd Razak A, 2013, BUILD ENVIRON, V59, P56, DOI 10.1016/j.buildenv.2012.08.007; Salizzoni P, 2009, ATMOS ENVIRON, V43, P5056, DOI 10.1016/j.atmosenv.2009.06.045; Stull RB, 1988, INTRO BOUNDARY LAYER; THOM AS, 1971, Q J ROY METEOR SOC, V97, P414, DOI 10.1256/smsqj.41403; Zaki SA, 2014, J ENG SCI TECHNOL, V9, P176	55	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0177-798X	1434-4483		THEOR APPL CLIMATOL	Theor. Appl. Climatol.	NOV	2015	122	3-4					635	649		10.1007/s00704-014-1323-8		15	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CT8JM	WOS:000363061900017		
J	Yan, HF; Zhang, C; Oue, H; Wang, GQ; He, B				Yan, Haofang; Zhang, Chuan; Oue, Hiroki; Wang, Guoqing; He, Bin			Study of evapotranspiration and evaporation beneath the canopy in a buckwheat field	THEORETICAL AND APPLIED CLIMATOLOGY			English	Article							CROP COEFFICIENT METHOD; IRRIGATED MAIZE FIELD; WINTER-WHEAT; SURFACE EVAPORATION; REGION; CHINA; RICE; SOIL; TRANSPIRATION; LYSIMETER	The determination of evaporation and transpiration separately is very important in improving water use efficiency and developing exact irrigation scheduling. Hourly crop evapotranspiration (ET (c)) and soil evaporation (E (g)) beneath the buckwheat canopy were measured using Bowen ratio energy balance method and micro-lysimeters, respectively. The total ET (c) and E (g) in the whole growth season of buckwheat were 187.4 and 72.1 mm, respectively. Crop coefficient of buckwheat plant was simulated by days after sowing (DAS) and leaf area index (LAI), the average values for four growth stages were 0.58, 0.59, 1.10, and 0.74; and soil evaporation coefficient (the ratio of soil evaporation to reference evapotranspiration) was modeled by soil water content at 5-cm depth by dividing the LAI into two stages. The relationship between the ratio of soil evaporation to actual evapotranspiration (E (g)/ET (c)) and LAI was decided. It was found that E (g)/ET (c) decreased from 1 to 0.3 with the increase in LAI.	[Yan, Haofang] Jiangsu Univ, Res Ctr Fluid Machinery Engn & Technol, Zhenjiang 212013, Jiangsu, Peoples R China; [Zhang, Chuan] Jiangsu Univ, Inst Agr Engn, Zhenjiang 212013, Jiangsu, Peoples R China; [Oue, Hiroki] Ehime Univ, United Grad Sch Agr Sci, Matsuyama, Ehime 7908566, Japan; [Wang, Guoqing] Nanjing Hydraul Res Inst, State Key Lab Hydrol Water Resources & Hydraul En, Nanjing 210029, Jiangsu, Peoples R China; [He, Bin] Chinese Acad Sci, Nanjing Inst Geog & Limnol, State Key Lab Lake Sci & Environm, Nanjing 210029, Jiangsu, Peoples R China	Yan, HF (reprint author), Jiangsu Univ, Res Ctr Fluid Machinery Engn & Technol, Zhenjiang 212013, Jiangsu, Peoples R China.	yanhaofang@yahoo.com; chuan_z@yahoo.com			Jiangsu University senior professional scientific research fund project [14JDG015, 14JDG017]; Natural Science Foundation of Jiangsu Province [BK20140546]; national high technology research and development program (863 Program) of China [2011AA100506]; Jiangsu universities engineering discipline construction project [1033000001]; key project of the National Natural Science Foundation of China [41330854]	This study has been financially supported by Jiangsu University senior professional scientific research fund project (14JDG015, 14JDG017), the Natural Science Foundation of Jiangsu Province (BK20140546), the national high technology research and development program (863 Program) project of China (grant 2011AA100506), Jiangsu universities engineering discipline construction project (1033000001) and the key project of the National Natural Science Foundation of China (41330854). Thanks also to the anonymous reviewers and editors.	Allen R. G., 1998, IRRIG DRAIN; Moratiel R, 2013, IRRIGATION SCI, V31, P411, DOI 10.1007/s00271-011-0319-8; Ding RS, 2013, AGR FOREST METEOROL, V168, P140, DOI 10.1016/j.agrformet.2012.08.003; Yan HF, 2012, PADDY WATER ENVIRON, V10, P121, DOI 10.1007/s10333-011-0273-3; Kang SZ, 2008, INT J SUST DEV WORLD, V15, P440, DOI 10.3843/SusDev.15.5:5; Li YL, 2003, AGR WATER MANAGE, V61, P1, DOI 10.1016/S0378-3774(02)00177-4; Zhao CY, 2007, AFR J AGRIC RES, V2, P325; Howell TA, 1998, AGRON J, V90, P3; Kool D, 2014, AGR FOREST METEOROL, V184, P56, DOI 10.1016/j.agrformet.2013.09.003; Liu CM, 2002, AGR FOREST METEOROL, V111, P109, DOI 10.1016/S0168-1923(02)00015-1; Yan Haofang, 2011, Journal of Agricultural Meteorology, V67, P89; Zhang C, 2013, METEOROL ATMOS PHYS, V121, P207, DOI 10.1007/s00703-013-0264-6; He Bin, 2009, Journal of Agricultural Meteorology, V65, P39; Kang SZ, 2003, AGR WATER MANAGE, V59, P239, DOI 10.1016/S0378-3774(02)00150-6; Alberto MCR, 2011, AGR WATER MANAGE, V98, P1417, DOI 10.1016/j.agwat.2011.04.011; Allen RG, 2005, J IRRIG DRAIN E-ASCE, V131, P2, DOI 10.1061/(ASCE)0733-9437(2005)131:1(2); Tyagi NK, 2000, AGR WATER MANAGE, V45, P41, DOI 10.1016/S0378-3774(99)00071-2; Rana G, 2000, EUR J AGRON, V13, P125, DOI 10.1016/S1161-0301(00)00070-8; Yan HF, 2012, METEOROL ATMOS PHYS, V118, P143, DOI 10.1007/s00703-012-0213-9; Howell TA, 1997, T ASAE, V40, P623; Burn LJ, 1972, AGRON J, V64, P145; CONAWAY J., 1967, Journal of Applied Meteorology, V6, P650, DOI 10.1175/1520-0450(1967)006<0650:EFAWSS>2.0.CO;2; Denmead O. T., 1973, Proceedings of the Uppsala Symposium "Plant Response to Climatic Factors". September 1970. Uppsala, Sweden; Paris, UNESCO., P505; Fritschen LJ, 1966, P AM SOC AGR ENG C E, P34; He B, 2007, J JAPAN SOC HYDROLOG, V20, P8, DOI 10.3178/jjshwr.20.8; He B, 2005, P JSIDRE JAPANESE SO, V60, P179; Kang SZ, 1995, ADV WATER SCI, V6, P285; Kocke NL, 1985, P SPEC C ADV IRR DRA, P55; Kristensen KJ, 1974, NORD HYDROL, V5, P173; [刘宏谊 Liu Hongyi], 2005, [干旱地区农业研究, Agricultural Research in the Arid Areas], V23, P39; Martin D, 1985, P ASCE NAT S ADV EV, P11; Mohan S., 1994, Irrigation and Drainage Systems, V8, P159, DOI 10.1007/BF00881016; Musick JT, 1980, T ASAE, V23, P103; Peng ShiZhang, 2008, Transactions of the Chinese Society of Agricultural Engineering, V24, P161; [彭世彰 Peng Shizhang], 2004, [灌溉排水学报, Journal of Irrigation and Drainage], V23, P5; Piccinni G, 2009, AGR WATER MANAGE, V96, P1698, DOI 10.1016/j.agwat.2009.06.024; Rosenberg N.J., 1983, MICROCLIMATE BIOL EN, P495; Seung Hwan Y, 2006, ASABE ANN INT M OR; Spanu A, 2009, ITAL J AGRON, V2, P47; Stanhill G, 1973, PHYSICAL ASPECTS SOI, P207; [苏培玺 Su Peixi], 2002, [干旱地区农业研究, Agricultural Research in the Arid Areas], V20, P79; TANNER C. B., 1960, Proceedings. Soil Science Society of America, V24, P1; Wight JR, 1993, MANAGEMENT IRRIGATIO, P953; Yan HaoFang, 2008, Transactions of the Chinese Society of Agricultural Engineering, V24, P103	44	1	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0177-798X	1434-4483		THEOR APPL CLIMATOL	Theor. Appl. Climatol.	NOV	2015	122	3-4					721	728		10.1007/s00704-014-1325-6		8	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	CT8JM	WOS:000363061900023		
J	Nakajima, K; Dagher, R; Strawn, L; Urushidani, J; Kurokawa, T; Chiba, K				Nakajima, Keitaro; Dagher, Ramzi; Strawn, Laurie; Urushidani, Jun; Kurokawa, Tatsuo; Chiba, Koji			The Relationship Between Development Start Lag and Approval Lag in Oncology Drug Development in Japan	THERAPEUTIC INNOVATION & REGULATORY SCIENCE			English	Article						oncology; drug lag; Japan	STRATEGIES; RATES; US	Background: The delay of initiation of clinical development is considered a causes of delay of approval of drugs (drug lag) in Japan. Methods: For oncology drugs newly approved between 2000 and 2012 in Japan, a possible impact of delay of initiation of clinical development (development start lag [DSL]) on delay of approval (approval lag [AL]) was investigated, focusing on the delay from the US timelines. The equation defining the relationship between the DSL and AL of 33 oncology drugs was calculated by using simulation models, then the Pearson coefficient of correlation between parameters was calculated. Results: From the analysis of all drugs investigated, a positive relationship between the DSL and AL was suggested. However, the relationship seemed to have 2 phases, including a flat phase, followed by a linearly increased phase with a breakpoint at 2340 DSL days (approximately 6.4 DSL years). Conclusions: Shortening the DSL is important for reducing large AL, but it is not necessary to eliminate the DSL completely for the purpose of minimizing the AL.	[Nakajima, Keitaro; Urushidani, Jun; Kurokawa, Tatsuo; Chiba, Koji] Keio Univ Pharm, Dept Drug Dev & Regulatory Sci, Tokyo, Japan; [Nakajima, Keitaro] Pfizer Japan Inc, Dev Japan, Regulatory Affairs Div, Tokyo 1518589, Japan; [Dagher, Ramzi] Pfizer Inc, Worldwide Safety & Regulatory, Groton, CT 06340 USA; [Strawn, Laurie] Pfizer Inc, Worldwide Safety & Regulatory, San Diego, CT 06340 USA; [Chiba, Koji] Yokohama Univ Pharm, Lab Clin Pharmacol, Yokohama, Kanagawa, Japan	Nakajima, K (reprint author), Pfizer Japan Inc, Dev Japan, Regulatory Affairs Div, Shibuya Ku, 3-22-7 Yoyogi, Tokyo 1518589, Japan.	keitaro.nakajima@pfizer.com					Asano K, 2013, CLIN PHARMACOL THER, V94, P195, DOI 10.1038/clpt.2013.106; Hashimoto J, 2009, DRUG INF J, V43, P757; Martell RE, 2013, ONCOLOGIST, V18, P104, DOI 10.1634/theoncologist.2012-0235; Nakajima K, 2013, INVEST NEW DRUG, V31, P1051, DOI 10.1007/s10637-012-9911-x; Ueno T, 2014, CLIN PHARMACOL THER, V95, P533, DOI 10.1038/clpt.2013.223; Hutchinson L, 2011, NAT REV CLIN ONCOL, V8, P189, DOI 10.1038/nrclinonc.2011.34; Kawabata-Shoda E, 2012, J CLIN PHARM THER, V37, P547, DOI 10.1111/j.1365-2710.2012.01332.x; Hirai Y, 2010, CLIN PHARMACOL THER, V87, P212, DOI 10.1038/clpt.2009.215; Hirai Y, 2012, HEALTH POLICY, V104, P241, DOI 10.1016/j.healthpol.2011.11.008; Yonemori K, 2011, INVEST NEW DRUG, V29, P706, DOI 10.1007/s10637-011-9638-0; Reichert JM, 2003, NAT REV DRUG DISCOV, V2, P695, DOI 10.1038/nrd1178; Food and Drug Administration, DRUGS FDA; Food and Drug Administration, 2013, PDUFA REAUTH PERF GO; Haseto S, 2012, RES PAPER, V55; Pharmaceuticals and Medical Devices Agency, 2009, OUTL PMDAS 2 MIDT PL; Pharmaceuticals and Medical Devices Agency, 2013, PUBL ASS REP	16	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2168-4790	2168-4804		THER INNOV REGUL SCI	Ther. Innov. Regul. Sci.	NOV	2015	49	6					911	919		10.1177/2168479015579518		9	Medical Informatics; Pharmacology & Pharmacy	Medical Informatics; Pharmacology & Pharmacy	CU2DE	WOS:000363332100018		
J	Lau, Q; Yasukochi, Y; Satta, Y				Lau, Q.; Yasukochi, Y.; Satta, Y.			A limit to the divergent allele advantage model supported by variable pathogen recognition across HLA-DRB1 allele lineages	TISSUE ANTIGENS			English	Article						allele divergence; human leukocyte antigen; major histocompatibility complex; pathogen recognition	HISTOCOMPATIBILITY COMPLEX LOCI; FREQUENCY-DEPENDENT SELECTION; HLA-DR; BALANCING SELECTION; NATURAL-SELECTION; MHC; DIVERSITY; POLYMORPHISM; BINDING; OVERDOMINANT	Genetic diversity in human leukocyte antigen (HLA) molecules is thought to have arisen from the co-evolution between host and pathogen and maintained by balancing selection. Heterozygote advantage is a common proposed scenario for maintaining high levels of diversity in HLA genes, and extending from this, the divergent allele advantage (DAA) model suggests that individuals with more divergent HLA alleles bind and recognize a wider array of antigens. While the DAA model seems biologically suitable for driving HLA diversity, there is likely an upper threshold to the amount of sequence divergence. We used peptide-binding and pathogen-recognition capacity of DRB1 alleles as a model to further explore the DAA model; within the DRB1 locus, we examined binding predictions based on two distinct phylogenetic groups (denoted group A and B) previously identified based on non-peptide-binding region (PBR) nucleotide sequences. Predictions in this study support that group A allele and group B allele lineages have contrasting binding/recognition capacity, with only the latter supporting the DAA model. Furthermore, computer simulations revealed an inconsistency in the DAA model alone with observed extent of polymorphisms, supporting that the DAA model could only work effectively in combination with other mechanisms. Overall, we support that the mechanisms driving HLA diversity are non-exclusive. By investigating the relationships among HLA alleles, and pathogens recognized, we can provide further insights into the mechanisms on how humans have adapted to infectious diseases over time.	[Lau, Q.; Satta, Y.] Sokendai Grad Univ Adv Studies, Dept Evolutionary Studies Biosyst, Kanagawa, Japan; [Yasukochi, Y.] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Tokyo 113, Japan	Satta, Y (reprint author), Sokendai Grad Univ Adv Studies, Dept Evolutionary Studies Biosyst, Kanagawa, Japan.	satta@soken.ac.jp			JSPS KAKENHI [22133007]	This project was supported by JSPS KAKENHI grant number 22133007. We wish to thank Naoyuki Takahata for checking of the manuscript, Hisashi Ohtsuki for assistance with statistical analyses, and Ken Nagata for assistance with writing Biopython programs. QL wrote the manuscript, performed binding predictions and analyses. YY designed the binding prediction experiment and assisted in writing the manuscript. YS designed and performed the computer simulations and assisted in writing the manuscript.	TAKAHATA N, 1990, P NATL ACAD SCI USA, V87, P2419, DOI 10.1073/pnas.87.7.2419; WEE A, 1992, J CLIN PATHOL, V45, P30, DOI 10.1136/jcp.45.1.30; White TD, 2003, NATURE, V423, P742, DOI 10.1038/nature01669; SLADE RW, 1992, GENETICS, V132, P861; NOWAK MA, 1992, P NATL ACAD SCI USA, V89, P10896, DOI 10.1073/pnas.89.22.10896; Gonzalez-Galarza FF, 2011, NUCLEIC ACIDS RES, V39, pD913, DOI 10.1093/nar/gkq1128; Fagerberg J, 1999, CELL IMMUNOL, V196, P110, DOI 10.1006/cimm.1999.1548; Lenz TL, 2011, EVOLUTION, V65, P2380, DOI 10.1111/j.1558-5646.2011.01288.x; Prugnolle F, 2005, CURR BIOL, V15, P1022, DOI 10.1016/j.cub.2005.04.050; Mack SJ, 2013, TISSUE ANTIGENS, V81, P194, DOI 10.1111/tan.12093; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Wegner KM, 2003, J EVOLUTION BIOL, V16, P224, DOI 10.1046/j.1420-9101.2003.00519.x; Kettaneh A, 2006, INT J TUBERC LUNG D, V10, P717; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Spurgin LG, 2010, P R SOC B, V277, P979, DOI 10.1098/rspb.2009.2084; WAKELAND EK, 1990, IMMUNOL RES, V9, P115, DOI 10.1007/BF02918202; Forsberg LA, 2007, J EVOLUTION BIOL, V20, P1859, DOI 10.1111/j.1420-9101.2007.01380.x; Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y; SETTE A, 1994, J IMMUNOL, V153, P5586; Abi-Rached L, 2011, SCIENCE, V334, P89, DOI 10.1126/science.1209202; Bernatchez L, 2003, J EVOLUTION BIOL, V16, P363, DOI 10.1046/j.1420-9101.2003.00531.x; TAKAHATA N, 1995, IMMUNOL REV, V143, P225, DOI 10.1111/j.1600-065X.1995.tb00677.x; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; Hughes AL, 1998, ANNU REV GENET, V32, P415, DOI 10.1146/annurev.genet.32.1.415; Bronson PG, 2013, HUM MOL GENET, V22, P252, DOI 10.1093/hmg/dds424; Woelfing B, 2009, PHILOS T R SOC B, V364, P117, DOI 10.1098/rstb.2008.0174; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555; [Anonymous], 1975, NATURE, DOI DOI 10.1038/25605; Hidron AI, 2008, INFECT CONT HOSP EP, V29, P996, DOI 10.1086/591861; De Boer RJ, 2004, IMMUNOGENETICS, V55, P725, DOI 10.1007/s00251-003-0629-y; Yasukochi Y, 2014, G3-GENES GENOM GENET, V4, P1217, DOI 10.1534/g3.114.011726; Madsen T, 2006, J EVOLUTION BIOL, V19, P1973, DOI 10.1111/j.1420-9101.2006.01158.x; BENNETT K, 1992, EUR J IMMUNOL, V22, P1519, DOI 10.1002/eji.1830220626; Parikh S, 2008, J INFECT DIS, V198, P1255, DOI 10.1086/592223; Vargas LE, 2003, BIOCHEM BIOPH RES CO, V307, P148, DOI 10.1016/S0006-291X(03)01129-X; TAKAHATA N, 1990, GENETICS, V124, P967; Impens F, 2010, MOL CELL PROTEOMICS, V9, P2327, DOI 10.1074/mcp.M110.001271; Singh H, 2001, BIOINFORMATICS, V17, P1236, DOI 10.1093/bioinformatics/17.12.1236; Richman AD, 2001, MOL ECOL, V10, P2765, DOI 10.1046/j.1365-294X.2001.t01-1-01402.x; Lyke KE, 2011, TISSUE ANTIGENS, V77, P562, DOI 10.1111/j.1399-0039.2011.01661.x; Buhler S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014643; CROW JF, 1958, AM ANTHROPOL, V60, P1; Evans J., 1996, STRAIGHTFORWARD STAT; Hill A. V., 1991, MOL EVOLUTION MAJOR, P403; Huang Lin H, 2008, BMC IMMUNOLOGY, V9, P1; Lenz TL, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0714; Mboowa G, 2014, INT J EVOL BIOL, V2014, P8; Yasukochi Y, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-14; Weitzman JB, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-1-reports021, DOI 10.1186/GB-2000-1-1-REP0RTS021]	49	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-2815	1399-0039		TISSUE ANTIGENS	Tissue Antigens	NOV	2015	86	5					343	352		10.1111/tan.12667		10	Cell Biology; Immunology; Pathology	Cell Biology; Immunology; Pathology	CT8SM	WOS:000363086800004		
J	Kanda, T; Iguchi, A; Yoshioka, C; Nomura, H; Higashi, K; Kaya, M; Yamamoto, R; Kuramoto, T; Furukawa, T				Kanda, Teppei; Iguchi, Ayano; Yoshioka, Chieko; Nomura, Haruka; Higashi, Kanako; Kaya, Minami; Yamamoto, Rie; Kuramoto, Tomoko; Furukawa, Toshinori			Effects of medetomidine and xylazine on intraocular pressure and pupil size in healthy Beagle dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						dog; intraocular pressure; medetomidine; pupil size; xylazine	DEXMEDETOMIDINE	ObjectiveTo determine the effects of intramuscular (IM) administration of medetomidine and xylazine on intraocular pressure (IOP) and pupil size in normal dogs. Study designProspective, randomized, experimental, crossover trial. AnimalsFive healthy, purpose-bred Beagle dogs. MethodsEach dog was administered 11 IM injections of, respectively: physiological saline; medetomidine at doses of 5, 10, 20, 40 and 80gkg(-1), and xylazine at doses of 0.5, 1.0, 2.0, 4.0 and 8.0mgkg(-1). Injections were administered at least 1week apart. IOP and pupil size were measured at baseline (before treatment) and at 0.25, 0.50, 0.75, 1, 2, 3, 4, 5, 6, 7, 8 and 24hours post-injection. ResultsA significant decrease in IOP was observed at 6hours after 80gkg(-1) medetomidine compared with values at 0.25 and 0.50hours, although there were no significant changes in IOP from baseline. In dogs treated with 8.0mgkg(-1) xylazine, significant reductions in IOP were observed at 4 and 5hours compared with that at 0.25hours after administration. In dogs treated with 5, 10, 20 and 40gkg(-1) medetomidine and 0.5, 1.0 and 2.0mgkg(-1) xylazine, there were no significant changes in IOP. Pupil size did not change significantly after any of the medetomidine or xylazine treatments compared with the baseline value. Conclusions and clinical relevanceLow or moderate doses of medetomidine or xylazine did not induce significant changes in IOP or pupil size. In contrast, high doses of medetomidine or xylazine induced significant changes up to 8hours after treatment, but values remained within the normal canine physiological range. The results of this study suggest a lack of significant change in IOP and pupil size in healthy dogs administered low or moderate doses of xylazine or medetomidine.	[Kanda, Teppei; Iguchi, Ayano; Yoshioka, Chieko; Nomura, Haruka; Higashi, Kanako; Kaya, Minami; Yamamoto, Rie; Kuramoto, Tomoko] Kurashiki Univ Sci & Arts, Coll Life Sci, Dept Comparat Anim Sci, Lab Vet Nursing & Medicat, Kurashiki, Okayama 7128505, Japan; [Kanda, Teppei; Furukawa, Toshinori] Kurashiki Univ Sci & Arts, Vet Teaching Hosp, Kurashiki, Okayama 7128505, Japan	Kanda, T (reprint author), Kurashiki Univ Sci & Arts, Coll Life Sci, Dept Comparat Anim Sci, Lab Vet Nursing & Medicat, Tsurajima Cho Nishinoura 2640, Kurashiki, Okayama 7128505, Japan.	k-teppei@sci.kusa.ac.jp					Rauser P, 2012, VET ANAESTH ANALG, V39, P301, DOI 10.1111/j.1467-2995.2011.00703.x; Artigas C, 2012, VET OPHTHALMOL, V15, P79, DOI 10.1111/j.1463-5224.2011.00966.x; Broadwater JJ, 2008, AM J VET RES, V69, P527, DOI 10.2460/ajvr.69.4.527; Wallin-Hakanson N, 2001, VET OPHTHALMOL, V4, P3, DOI 10.1046/j.1463-5224.2001.00114.x; Verbruggen AMJ, 2000, VET QUART, V22, P179; Gelatt KN, 1999, VET OPHTHALMOLOGY, P1307; Gelatt KN, 1999, VETERINARY OPHTHALMOLOGY, 3RD EDITION, P701; Kaufman PL, 1995, J GLAUCOMA S1, V4, P8; Burke J A, 1986, J Ocul Pharmacol, V2, P9, DOI 10.1089/jop.1986.2.9; VANDERWOERDT A, 1995, AM J VET RES, V56, P155	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2015	42	6					623	628		10.1111/vaa.12249		6	Veterinary Sciences	Veterinary Sciences	CU4FE	WOS:000363481700009		
J	Ozawa, T; Toyone, T; Shiboi, R; Inada, K; Oikawa, Y; Takahashi, K; Ohtorti, S; Inoue, G; Miyagi, M; Ishikawa, T; Shirahata, T; Kudo, Y; Inagaki, K				Ozawa, Tomoyuld; Toyone, Tomoaki; Shiboi, Ryutaro; Inada, Kunimasa; Oikawa, Yasuhiro; Takahashi, Kazuhisa; Ohtorti, Seiji; Inoue, Gen; Miyagi, Masayuki; Ishikawa, Tetsuhiro; Shirahata, Toshiyuld; Kudo, Yoshifurni; Inagaki, Katsunori			Modified Open-Door Laminoplasty Using a Ceramic Spacer and Suture Fixation for Cervical Myelopathy	YONSEI MEDICAL JOURNAL			English	Article						Open-door laminoplasty; ceramic spacer; suture anchor fixation	ANCHOR FIXATION; AXIAL SYMPTOMS; FOLLOW-UP	Purpose: To introduce a new simple technique using suture anchors and ceramic spacers to stabilize the elevated laminae in open-door cervical laminoplasty. Although ceramic spacers were placed in the opened laminae and fixed with nylon threads in this series, it was occasionally difficult to fix the nylon threads to the lateral mass. Materials and Methods: Study 1: A preliminary study was conducted using a suture anchor system. Sixteen consecutive patients who underwent surgery for cervical myelopathy were prospectively examined. Study 2: The second study was performed prospectively to evaluate the feasibility of this new technique based on the result of the preliminary study. Clinical outcomes were examined in 45 consecutive patients [cervical spondylotic myelopathy (CSM)] and 43 consecutive patients (OPLL). The Japanese Orthopedic Association scoring system (JOA score), axial neck pain, and radiological findings were analyzed. Results: 1) In one case, re-operation was necessary due to dislodgement of the ceramic spacer following rupture of the thread. 2) In all patients, postoperative CT scans showed that the anchors were securely inserted into the bone. In the CSM group, the average JOA score improved from 9.5 points preoperatively to 13.3 at follow-up (recovery 51%). In the OPLL group, the average JOA score improved from 10.1 (5-14) points preoperatively to 14.4 (11-16) at follow-up (recovery 62%). There were no serious complications. Conclusion: The use of the suture anchor system made it unnecessary to create a hole in the lateral mass and enabled reliable and faster fixation of the HA spacers in open-door laminoplasty.	[Ozawa, Tomoyuld; Shiboi, Ryutaro; Oikawa, Yasuhiro] Teikyo Chiba Med Ctr, Grad Sch Med, Dept Orthoped Surg, Anesaki, Ichihare 34263, Japan; [Toyone, Tomoaki] Teikyo Univ, Sch Med, Teikyo Univ Hosp, Mizonokuchi, Japan; [Inada, Kunimasa] Katsuura Orthopead Clin, Katsuura, Japan; [Takahashi, Kazuhisa; Ohtorti, Seiji] Chiba Univ, Dept Orthoped Surg, Chiba, Japan; [Inoue, Gen; Miyagi, Masayuki] Kitazato Univ Hosp, Dept Orthoped Surg, Sagamihara, Kanagawa, Japan; [Ishikawa, Tetsuhiro] Sanmu Med Ctr, Dept Orthoped Surg, Sanmu, Japan; [Shirahata, Toshiyuld; Kudo, Yoshifurni; Inagaki, Katsunori] Showa Univ, Sch Med, Dept Orthoped Surg, Tokyo 142, Japan	Ozawa, T (reprint author), Teikyo Chiba Med Ctr, Grad Sch Med, Dept Orthoped Surg, Anesaki, Ichihare 34263, Japan.	tomokun@wg7.so-net.ne.jp					Yang SC, 2008, ACTA ORTHOP, V79, P62, DOI 10.1080/17453670710014770; KIMURA I, 1995, J BONE JOINT SURG BR, V77B, P956; Yu HL, 2010, EUR SPINE J, V19, P1795, DOI 10.1007/s00586-010-1419-5; KAWAI S, 1988, SPINE, V13, P1245, DOI 10.1097/00007632-198811000-00007; Kawaguchi Y, 1999, J SPINAL DISORD, V12, P392; Matsumoto M, 2012, SPINE, V37, P1288, DOI 10.1097/BRS.0b013e3182498434; Yang SC, 2007, J SPINAL DISORD TECH, V20, P492, DOI 10.1097/BSD.0b013e318033e844; ITOH T, 1985, SPINE, V10, P729, DOI 10.1097/00007632-198510000-00007; Chen HC, 2008, J SPINAL DISORD TECH, V21, P387, DOI 10.1097/BSD.0b013e318157c699; Kawaguchi Y, 2003, J SPINAL DISORD TECH, V16, P497, DOI 10.1097/00024720-200312000-00002; Hu W, 2014, ORTHOPEDICS, V37, pE71, DOI 10.3928/01477447-20131219-20; Itoh T, 1986, Nihon Seikeigeka Gakkai Zasshi, V60, P1109; Khan Safdar N, 2008, Am J Orthop (Belle Mead NJ), V37, P400; Kurokawa Y, 2014, SPINE, V39, pE1248, DOI 10.1097/BRS.0000000000000522; Toyone T, 2009, J JAPAN SPINE RES SO, V20, P626; Zeng Yun, 2011, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V25, P946	16	0	0	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	NOV 1	2015	56	6					1651	1655		10.3349/ymj.2015.56.6.1651		5	Medicine, General & Internal	General & Internal Medicine	CU4JN	WOS:000363494600026		
J	Avsar, E; Ulusay, R; Aydan, O; Mutluturk, M				Avsar, Elif; Ulusay, Resat; Aydan, Oemer; Mutluturk, Mahmut			On the difficulties of geotechnical sampling and practical estimates of the strength of a weakly bonded volcanic soil	BULLETIN OF ENGINEERING GEOLOGY AND THE ENVIRONMENT			English	Article						Volcanic soil; Uniaxial compressive strength; Needle penetration index; Laboratory sampling; Prediction equation; Microstructure	NEEDLE PENETRATION TEST; CANARY-ISLANDS; LANDSLIDE; EARTHQUAKE; STABILITY; TENERIFE; BEHAVIOR; TURKEY	Volcanic soils, which cover significant parts of the world's surface, including urban areas, structures and infrastructures, may create geo-engineering problems. These soils exhibit distinctive geomechanical behaviours that are a consequence of their formation history, mineralogy and structure. This paper presents the results of an experimental investigation into geo-engineering properties of a volcanic soil observed in the city of Isparta, Turkey. The study focuses on the difficulties experienced in geotechnical sampling of the soil, its microstructural, mineralogical and physical properties, and particularly the estimation of its uniaxial compressive strength (UCS) using practical approaches. For this purpose, laboratory experiments covering the determination of mineralogical-petrographical and geomechanical properties, such as physical properties, UCS, and needle penetration index (NPI) using a specially manufactured needle, were conducted. The volcanic soil is weakly bonded, highly porous, well-graded silty sand and has a hypocrystalline texture. The weak bonding of the soil is volcanic ash formed by disintegration of volcanic glass, and the soil has some voids and a considerable amount of intact bonding between grains. The most important difficulty associated with this volcanic soil is field sampling and sample preparation for laboratory testing due to the weak bonding that governs internal stability. The UCS of the soil ranges between 29 and 132 kPa, and except for in a few samples, the UCS is lower than 100 kPa. The soil generally shows strain softening behaviour during the UCS tests; however, a few samples failed in a brittle fashion. As the natural water content and degree of saturation increases above approximately 11 and 42 %, respectively, there is a decline in the UCS of the soil. This is due to the increased exposure to water, which apparently softens the bonding, causing some loss of interlocking among the grains. Statistical evaluations suggest that the UCS of the volcanic soil can be estimated from the NPI using a needle with a diameter of 1.7 mm. In practical terms, the study provides some approaches and recommendations for the estimation of strength of weakly bonded volcanic soils for which geotechnical sampling is extremely difficult and/or impossible.	[Avsar, Elif] Selcuk Univ, Dept Geol Engn, Konya, Turkey; [Ulusay, Resat] Hacettepe Univ, Dept Geol Engn, TR-06800 Ankara, Turkey; [Aydan, Oemer] Univ Ryukyus, Dept Civil Engn & Architecture, Okinawa, Japan; [Mutluturk, Mahmut] Suleyman Demirel Univ, Dept Geol Engn, TR-32200 Isparta, Turkey	Ulusay, R (reprint author), Hacettepe Univ, Dept Geol Engn, TR-06800 Ankara, Turkey.	resat@hacettepe.edu.tr			Hacettepe University Scientific Researches Department [010D08602002]	The authors wish to acknowledge the financial support of Hacettepe University Scientific Researches Department (Project No. 010D08602002). The authors are also grateful to Dr. Evren Cubukcu and research assistant Lutfiye Akin (Hacettepe University), who made the experimental set-up of the SEM device available, and for their kind assistance with the interpretation of SEM micrographs, and to Dr. Erdal Sen (Hacettepe University) for his kind help during mineralogical evaluations on thin sections. Special thanks are extended to Prof. Mehmet Ekmekci (Hacettepe University) for his kind help to the authors, allowing them to use the mobile laboratory for the trials of coring from the block samples. The authors also wish to thank Emre Balcioglu and Onur Koroglu for their kind assistance during the sampling stage in the study site, and Yunus Koku and Fatih Adil for their kind help in drilling two boreholes and providing necessary boring accessories. The authors also acknowledge the anonymous reviewers for their constructive comments that led to improvements in the article.	Hurlimann M, 1999, TERRA NOVA, V11, P106, DOI 10.1046/j.1365-3121.1999.00233.x; Rao SM, 1996, ENG GEOL, V43, P265, DOI 10.1016/S0013-7952(96)00036-1; Ulusay R, 2012, ENG GEOL, V149, P47, DOI 10.1016/j.enggeo.2012.08.007; Cecconi M, 2001, INT J NUMER ANAL MET, V25, P1525, DOI 10.1002/nag.185; OROURKE TD, 1988, J GEOTECH ENG-ASCE, V114, P1126; Hurlimann M, 2001, ENG GEOL, V59, P115, DOI 10.1016/S0013-7952(00)00069-7; Dai FC, 1999, ENG GEOL, V53, P359, DOI 10.1016/S0013-7952(99)00016-2; Aydan O, 2014, ROCK MECH ROCK ENG, V47, P1867, DOI 10.1007/s00603-013-0477-5; Sahaphol T, 2005, SOIL DYN EARTHQ ENG, V25, P157, DOI 10.1016/j.soildyn.2004.10.001; Apuani T, 2005, J VOLCANOL GEOTH RES, V144, P191, DOI 10.1016/j.jvolgeores.2004.11.028; Collins BD, 2009, J GEOTECH GEOENVIRON, V135, P1359, DOI 10.1061/(ASCE)GT.1943-5606.0000094; Cattoni E, 2007, B ENG GEOL ENVIRON, V66, P403, DOI 10.1007/s10064-007-0096-z; Gratchev I, 2010, LANDSLIDES, V7, P503, DOI 10.1007/s10346-010-0211-2; ROUSE WC, 1986, ENG GEOL, V23, P1, DOI 10.1016/0013-7952(86)90014-1; Gulen L, 2002, B SEISMOL SOC AM, V92, P230, DOI 10.1785/0120000815; Cecconi M, 2010, B ENG GEOL ENVIRON, V69, P185, DOI 10.1007/s10064-009-0250-x; Platevoet B, 2008, QUATERNAIRE, V19, P147; BELLONI L, 1991, GEOTECHNIQUE, V41, P539; Crosta GB, 2005, ENG GEOL, V79, P185, DOI 10.1016/j.enggeo.2005.01.014; ASTM, 2000, ANN BOOK ASTM STAND; Aydan O, 2008, P 5 AS ROCK MECH S A, V1, P213; Bommer JJ, 2002, 12 EUR C EARTHQ ENG; Cecconi M, 1998, P IS PROBL SOILS, V1, P165; Cecconi M, 2000, GEOENG 2000; DSI, 1980, HYDR INV ISP PALIN; Gonzalez de Vallejo LI, 2008, SOILS ROCKS, V31, P3; GUADAGNO FM, 1991, SLOPE STABILITY ENGINEERING, P125; Gundogdu MN, 1982, THESIS HACETTEPE U A; Gutnic M, 1979, MEM SOC GEOL FRANCE, P137; Herrera MC, 2006, P 2 INT WORKSH CHAR, P2385; JGS (Japanese Geotechnical Society), 2012, JGS PUBL, P426; JSCE (Japan Society of Civil Engineers), 1991, SUGG METH INV TEST S, P124; Kawamura S., 2013, J FRONTIERS CONSTRUC, V2, P43; Maruto Testing Machine Company, 1999, INSTR SH 70 PEN; Matsukara Y, 1998, P KAG INT C VOLC JAP, P642; Mutluturk M, 2008, 61 GEOL C TURK, P137; Mutluturk M, 2010, 63 GEOL C TURK, P276; Oliver RC, 1997, THESIS; Orense R. P., 2006, J GEOTECH GEOL ENG, V24, P129; Picarelli L, 2006, P 2 INT WORK CHAR EN, V3, P2331; Poisson A, 1977, THESIS; Potro R., 2008, ENG GEOL, V98, P1; Shafii-Rad N, 1982, 59 JA BLUEM EARTHQ; Suzuki M, 2004, P 13 WORLD C EARTHQ; Totic E, 2009, THESIS; Ulusay R, 2014, ISRM SUGG METH ROCK; Ulusay R, 2014, ROCK MECH ROCK ENG, V47, P1073, DOI 10.1007/s00603-013-0534-0; Ulusay R, 2007, SUGGESTED METHODS PR; Viggiani G.M.B., 2006, P 2 INT WORKSH CHAR, V2, P2411; Yalcinkaya S, 1989, THESIS	50	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1435-9529	1435-9537		B ENG GEOL ENVIRON	Bull. Eng. Geol. Environ.	NOV	2015	74	4					1375	1394		10.1007/s10064-014-0710-9		20	Engineering, Environmental; Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	CT6ZC	WOS:000362961400021		
J	Shimizu, K; Tani, S; Imamura, H; Sakai, N				Shimizu, Kampei; Tani, Shoichi; Imamura, Hirotoshi; Sakai, Nobuyuki			Test occlusion under monitoring of motor-evoked potentials for a giant distal anterior cerebral artery aneurysm: letter to the editor	ACTA NEUROCHIRURGICA			English	Letter							ENDOVASCULAR TREATMENT		[Shimizu, Kampei; Tani, Shoichi; Imamura, Hirotoshi; Sakai, Nobuyuki] Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Chuo Ku, Kobe, Hyogo 6500047, Japan	Shimizu, K (reprint author), Kobe City Med Ctr Gen Hosp, Dept Neurosurg, Chuo Ku, 2-1-1 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	k.shimizu.830923@gmail.com					Wiedemayer H, 2002, J NEUROSURG, V96, P255, DOI 10.3171/jns.2002.96.2.0255; Guo LJ, 2011, CLIN NEUROPHYSIOL, V122, P648, DOI 10.1016/j.clinph.2010.09.001; van Rooij WJ, 2008, AM J NEURORADIOL, V29, P1418, DOI 10.3174/ajnr.A1071; Biondi A, 2006, AM J NEURORADIOL, V27, P1685; Matsushima Ken, 2011, Surg Neurol Int, V2, P135, DOI 10.4103/2152-7806.85608; Senbokuya N, 2012, J STROKE CEREBROVASC, V21, pe7; Yoneda H, 2014, NEUROL MED-CHIR, V54, P205, DOI 10.2176/nmc.cr2012-0343	7	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2015	157	11					1841	1842		10.1007/s00701-015-2570-x		2	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CT7CL	WOS:000362970800004		
J	Kayahara, T; Takeda, R; Kikkawa, Y; Take, Y; Kurita, H				Kayahara, Tomomichi; Takeda, Ririko; Kikkawa, Yuichiro; Take, Yushiro; Kurita, Hiroki			Hyperperfusion syndrome after aneurysm surgery: a case report	ACTA NEUROCHIRURGICA			English	Article						Hyperperfusion; Large cerebral aneurysm; Clipping; Postischemic reperfusion		A 74-year-old woman exhibited sensory aphasia with abrupt blood pressure elevation 3 h after clipping of an unruptured large left middle cerebral artery aneurysm. Perfusion computed tomography and single-photon emission computed tomography demonstrated hyperperfusion in one of the distal parent artery areas. She gradually improved and was discharged without neurological deficits. Increased distal blood flow after occlusion of the large cerebral aneurysm and postischemic reperfusion after temporary occlusion of the parent artery during surgery presumably played an important role in the occurrence of this fairly rare condition associated with aneurysm surgery.	[Kayahara, Tomomichi; Takeda, Ririko; Kikkawa, Yuichiro; Take, Yushiro; Kurita, Hiroki] Saitama Med Univ, Dept Cerebrovasc Surg, Int Med Ctr, Hidaka, Saitama 3501298, Japan	Kayahara, T (reprint author), Saitama Med Univ, Dept Cerebrovasc Surg, Int Med Ctr, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan.	goyanorasetsu@gmail.com			JSPS KAKENHI [25462235, 26461278]	This study was supported in part by JSPS KAKENHI, grant numbers 25462235 and 26461278.	Sugino T, 2010, NEUROL MED-CHIR, V50, P306; Maruya J, 2011, J STROKE CEREBROVASC, V20, P260, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.014; Araki Y, 1999, NEUROL MED-CHIR, V39, P901, DOI 10.2176/nmc.39.901; Kuroki K, 2006, NEUROL MED-CHIR, V46, P248, DOI 10.2176/nmc.46.248; Schoser BGH, 1997, J NEUROL, V244, P101, DOI 10.1007/s004150050057; Murakami H, 2002, J NEUROSURG, V97, P1233, DOI 10.3171/jns.2002.97.5.1233	6	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2015	157	11					1855	1857		10.1007/s00701-015-2567-5		3	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CT7CL	WOS:000362970800007		
J	Wostrack, M; Mielke, D; Kato, N; Guhl, S; Schmidt, NO; Maldaner, N; Vajkoczy, P; Dengler, J				Wostrack, Maria; Mielke, Dorothee; Kato, Naoki; Guhl, Susanne; Schmidt, Nils Ole; Maldaner, Nicolai; Vajkoczy, Peter; Dengler, Julius		Giant Intracranial Aneurysm Study	Interobserver variability in the characterization of giant intracranial aneurysms with special emphasis on aneurysm diameter and shape	ACTA NEUROCHIRURGICA			English	Article						Giant intracranial aneurysm; Interobserver variability; Partially thrombosed intracranial aneurysm; Neurovascular imaging	ENDOVASCULAR TREATMENT; VOLUME; RISK	The Giant Intracranial Aneurysm Registry is a multicenter observational trial exclusively focusing on giant intracranial aneurysms (GIA). As no data exist on the interobserver variability in the radiological description of GIA, there is some uncertainty concerning the reliability of the GIA characteristics included in the registry. We have therefore designed a study to test the interobserver variability in the description of the specific GIA characteristics that are examined in the GIA registry. Six different raters analyzed imaging of five GIA concerning GIA location, GIA size, GIA shape, GIA thrombosis, and the presence of perianeurysmal edema. Interobserver variability was examined using intraclass correlation and Fleiss' kappa analysis. The intraclass correlation coefficient was 0.99 (95 % CI 0.97-1.0) for the largest GIA diameter and 0.98 (95 % CI 0.94-1.0) for the largest GIA diameter in an axial imaging slice. We found perfect interobserver agreement (Fleiss' kappa 1.00) in the characterization of GIA location and the presence of perianeurysmal edema and almost perfect interobserver agreement for GIA thrombosis (Fleiss' kappa 0.86, 95 % CI 0.63-1.00). Only moderate interobserver agreement was found in the description of GIA shape (Fleiss' kappa 0.50, 95 % CI 0.27-0.73). While GIA size, location, thrombosis, and the presence of perianeurysmal edema showed excellent interobserver agreement, the description of GIA shape was achieved with only moderate agreement. Data on GIA shape in multicenter studies, like the GIA registry, should therefore be discussed with caution and potentially reassessed in a centralized fashion.	[Wostrack, Maria] Tech Univ Munich, Dept Neurosurg, D-80290 Munich, Germany; [Mielke, Dorothee] Univ Gottingen, Dept Neurosurg, D-37073 Gottingen, Germany; [Kato, Naoki] Jikei Univ, Dept Neurosurg, Sch Med, Tokyo, Japan; [Guhl, Susanne] Ernst Moritz Arndt Univ Greifswald, Dept Neurosurg, Greifswald, Germany; [Schmidt, Nils Ole] Univ Med Ctr, Dept Neurosurg, Hamburg, Germany; [Maldaner, Nicolai; Vajkoczy, Peter; Dengler, Julius] Charite, Dept Neurosurg, Campus Virchow Klinikum, D-13353 Berlin, Germany	Dengler, J (reprint author), Charite, Dept Neurosurg, Campus Virchow Klinikum, Augustenburger Pl 1, D-13353 Berlin, Germany.	julius.dengler@charite.de	Schmidt, Nils Ole/D-5696-2014		Center for Stroke Research - Berlin	The Giant Intracranial Aneurysm Registry is funded by the Center for Stroke Research - Berlin.	Alvarez H, 2009, AJNR Am J Neuroradiol, V30, pE9, DOI 10.3174/ajnr.A1370; Viera AJ, 2005, FAM MED, V37, P360; Tulamo R, 2010, J NEUROINTERV SURG, V2, P120, DOI 10.1136/jnis.2009.002055; Dengler J, 2011, INT J STROKE, V6, P266, DOI 10.1111/j.1747-4949.2011.00588.x; Forbes G, 1996, AM J NEURORADIOL, V17, P1407; Gonzalez NR, 2008, NEUROSURGERY, V62, P1324, DOI [10.1227/01.neu.0000333797.59585.c0, 10.1227/01.NEU.0000237559.93852.F1]; Dimmick S, 2009, J CLIN NEUROSCI, V16, P1195, DOI 10.1016/j.jocn.2008.11.011; Dengler J, 2015, J NEUROSURG, V123, P446, DOI 10.3171/2014.10.JNS141560; Backes D, 2014, STROKE, V45, P1299, DOI 10.1161/STROKEAHA.113.004421; Maldaner N, 2015, ACTA NEUROCHIR, V157, P1117, DOI 10.1007/s00701-015-2448-y; Baharoglu MI, 2014, STROKE, V45, P2649, DOI 10.1161/STROKEAHA.114.005393; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3; Rezek I, 2014, AM J NEURORADIOL, V35, P124, DOI 10.3174/ajnr.A3623; Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1; Bor ASE, 2015, STROKE, V46, P42, DOI 10.1161/STROKEAHA.114.005963; Dengler J, 2015, ACTA NEUROCHIR, V157, P361, DOI 10.1007/s00701-014-2292-5; Froesen J, 2004, STROKE, V35, P2287; Suh SH, 2014, J NEUROINTERV SURG, DOI [10.1136/neurintsurg-2014-011471, DOI 10.1136/NEURINTSURG-2014-011471]	18	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2015	157	11					1859	1865		10.1007/s00701-015-2587-1		7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CT7CL	WOS:000362970800008		
J	Ogiwara, T; Goto, T; Aoyama, T; Nagm, A; Yamamoto, Y; Hongo, K				Ogiwara, Toshihiro; Goto, Tetsuya; Aoyama, Tatsuro; Nagm, Alhusain; Yamamoto, Yasunaga; Hongo, Kazuhiro			Bony surface registration of navigation system in the lateral or prone position: technical note	ACTA NEUROCHIRURGICA			English	Article						Navigation system; Image-guided neurosurgery; Bony surface registration; Prone or lateral position	NEURONAVIGATION SYSTEM; SURGERY	Navigation systems have become essential tools in neurosurgery. Precise registration is indispensable for the accuracy of navigation. The rapid and precise registration by surface matching on the facial skin is possible using the landmarks of the face in the supine position. On the other hand, incomplete registration often occurs in the lateral or prone position due to the direction of the face and displacement of the skin by headpins and obscuring of the skin by the bispectral index monitor and many electrodes on the forehead as well as the eye patch. Surface matching on the occipital scalp is not suitable for registration because the shape of the occipital scalp is flat and it is compressed in the supine position when obtaining preoperative neuroimaging. To overcome this problem, the authors have developed a new method of registration designated as "bony surface registration" in which surface matching is achieved using the bony surface of the skull after exposure. Between June and December 2014, this technique was used in 23 patients and its effectiveness was examined. Registration time was markedly shortened and useful navigation was achieved due to accurate registration in all patients. This is the first report of a registration methodology for a navigation system in the lateral or prone position. This bony surface registration method is useful for navigation system image-guided surgery in the lateral or prone position.	[Ogiwara, Toshihiro; Goto, Tetsuya; Aoyama, Tatsuro; Nagm, Alhusain; Yamamoto, Yasunaga; Hongo, Kazuhiro] Shinshu Univ, Sch Med, Dept Neurosurg, Matsumoto, Nagano 3908621, Japan; [Nagm, Alhusain] Al Azhar Univ, Fac Med Nasr City, Dept Neurosurg, Cairo, Egypt	Goto, T (reprint author), Shinshu Univ, Sch Med, Dept Neurosurg, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	tegotou@shinshu-u.ac.jp					Gharabaghi A, 2008, NEUROSURGERY, V63, P24, DOI 10.1227/01.NEU.0000249233.12860.EC; Akamatsu Y, 2009, NEUROL SURG TOKYO, V37, P1193; WATANABE E, 1987, SURG NEUROL, V27, P543, DOI 10.1016/0090-3019(87)90152-2; Chen WQ, 2012, MINIM INVASIV THER, V21, P234, DOI 10.3109/13645706.2011.611140; Hill DLG, 1998, NEUROSURGERY, V43, P514, DOI 10.1097/00006123-199809000-00066; Kawamata T, 2003, NEUROL SURG TOKYO, V31, P609; Kajita Y, 2013, JPN J NEUROSURG TOKY, V22, P510; Nishizaki T, 1988, JPN J NEUROSURG TOKY, V7, P177; WATANABE E, 1989, Neurological Surgery, V17, P1097; WATANABE E, 1991, NEUROSURGERY, V28, P792; WATANABE E, 1991, Neurological Surgery, V19, P247; Watanabe Yohei, 2010, Nihon Hoshasen Gijutsu Gakkai Zasshi, V66, P131	12	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2015	157	11					2017	2022		10.1007/s00701-015-2528-z		6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CT7CL	WOS:000362970800030		
J	Yamamoto, T; Shimoyama, T				Yamamoto, T.; Shimoyama, T.			Letter: faecal diversion for severe perianal Crohn's disease - practical issues	ALIMENTARY PHARMACOLOGY & THERAPEUTICS			English	Letter							TOTAL COLECTOMY		[Yamamoto, T.; Shimoyama, T.] Yokkaichi Hazu Med Ctr, Ctr Inflammatory Bowel Dis, Yokaichi, Mie, Japan	Yamamoto, T (reprint author), Yokkaichi Hazu Med Ctr, Ctr Inflammatory Bowel Dis, Yokaichi, Mie, Japan.	nao-taka@sannet.ne.jp					Yamamoto T, 2000, WORLD J SURG, V24, P125; Yamamoto T, 1999, SCAND J GASTROENTERO, V34, P280; Singh S, 2015, ALIMENT PHARM THER, V42, P783, DOI 10.1111/apt.13356	3	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-2813	1365-2036		ALIMENT PHARM THER	Aliment. Pharmacol. Ther.	NOV	2015	42	10					1236	1236		10.1111/apt.13397		1	Gastroenterology & Hepatology; Pharmacology & Pharmacy	Gastroenterology & Hepatology; Pharmacology & Pharmacy	CT3TE	WOS:000362729000014		
J	Kokubo, Y; Watanabe, M; Higashiyama, A; Nakao, YM; Kobayashi, T; Watanabe, T; Okamura, T; Okayama, A; Miyamoto, Y				Kokubo, Yoshihiro; Watanabe, Makoto; Higashiyama, Aya; Nakao, Yoko M.; Kobayashi, Takashi; Watanabe, Takuya; Okamura, Tomonori; Okayama, Akira; Miyamoto, Yoshihiro			Interaction of Blood Pressure and Body Mass Index With Risk of Incident Atrial Fibrillation in a Japanese Urban Cohort: The Suita Study	AMERICAN JOURNAL OF HYPERTENSION			English	Article						atrial fibrillation; blood pressure; body mass index; hypertension; prospective cohort study; risk factor	PULSE PRESSURE; OBESITY; HYPERTENSION; IMPACT; HEART; POPULATION; PREVENTION; THERAPY; SOCIETY; DISEASE	BACKGROUND AND PURPOSE To prevent stroke, strategies for atrial fibrillation (AF) prevention and an early detection of AF by electrocardiogram are essential. However, only a limited prospective studies have examined the risk factors for AF, even in blood pressure (BP) and body mass index (BMI), which are not clear among general populations. We investigated the impacts of BP and BMI on the risk of incident AF in a general population. METHODS A total of 6,906 participants (30-84 years) in the Suita Study were prospectively followed up for incident AF. Participants were diagnosed with AF if AF or atrial flutter was present on an electrocardiogram from a routine health examination (every 2 years) or if AF was indicated as a present illness from health examinations and/or medical records during follow-up. Adjusted Cox proportional hazard ratios (HRs) were calculated. RESULTS During the 12.8-year follow-up, 253 incident AF events occurred. Compared with the systolic BP (SBP) < 120 mm Hg and normal-weight, the adjusted HRs (95% confidence intervals; CIs) of incident AF in the systolic hypertension and the overweight (BMI >= 25 kg/m(2)) groups were 1.74 (1.22-2.49) and 1.35 (1.01-1.80), respectively. Compared with SBP < 120 mm Hg and normal weight, the adjusted HRs (95% CIs) of incident AF in the SBP = 120-139 mm Hg with overweight and the systolic hypertension with normal or overweight were 1.72 (1.01-2.91), 1.66 (1.10-2.50), and 2.31 (1.47-3.65), respectively (P for interaction = 0.04). CONCLUSIONS Systolic prehypertension and overweight are associated with incident AF in Japanese population. The association between SBP and AF may be evident by overweight.	[Kokubo, Yoshihiro; Watanabe, Makoto; Nakao, Yoko M.; Kobayashi, Takashi; Watanabe, Takuya; Okamura, Tomonori; Okayama, Akira; Miyamoto, Yoshihiro] Natl Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka 565, Japan; [Higashiyama, Aya; Nakao, Yoko M.; Miyamoto, Yoshihiro] Natl Cardiovasc Ctr, Dept Prevent Med & Epidemiol Informat, Suita, Osaka 565, Japan; [Okamura, Tomonori] Keio Univ, Dept Prevent Med & Publ Hlth, Tokyo, Japan; [Okayama, Akira] AntiTB Assoc, Inst Hlth Promot & Hlth Care 1, Tokyo, Japan	Kokubo, Y (reprint author), Natl Cardiovasc Ctr, Dept Prevent Cardiol, Suita, Osaka 565, Japan.	ykokubo@hsp.ncvc.go.jp			Ministry of Health, Labor, and Welfare of Japan [H24-Junkankitou-011, H26-Junkankitou [Seisaku]-Ippan-001]; Intramural Research Fund of the National Cerebral and Cardiovascular Center [22-1-2, 22-4-5]; Ministry of Education, Culture, Sports, Science, and Technology of Japan [25293147, 26670320]	This work was supported by grants-in-aid from the Ministry of Health, Labor, and Welfare of Japan (H24-Junkankitou-011, H26-Junkankitou [Seisaku]-Ippan-001), the Intramural Research Fund of the National Cerebral and Cardiovascular Center (22-1-2, 22-4-5), and by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Nos. 25293147 and 26670320).	BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; de Simone G, 2006, HYPERTENSION, V47, P162, DOI 10.1161/01.HYP.0000199103.40105.b5; KENNY J, 1991, INT J CARDIOL, V33, P133, DOI 10.1016/0167-5273(91)90161-H; da Silva AA, 2013, CURR OPIN NEPHROL HY, V22, P135, DOI 10.1097/MNH.0b013e32835d0c05; Dublin S, 2006, ARCH INTERN MED, V166, P2322, DOI 10.1001/archinte.166.21.2322; Bode F, 2000, CIRCULATION, V101, P2200; Grundvold I, 2012, HYPERTENSION, V59, P198, DOI 10.1161/HYPERTENSIONAHA.111.179713; Mitchell GF, 2007, JAMA-J AM MED ASSOC, V297, P709, DOI 10.1001/jama.297.7.709; [Anonymous], 2000, WHO TECH REP SER, V894, P1; Miura K, 2009, CIRCULATION, V119, P1892, DOI 10.1161/CIRCULATIONAHA.108.823112; Kokubo Y, 2008, HYPERTENSION, V52, P652, DOI 10.1161/HYPERTENSIONAHA.108.118273; Benjamin EJ, 2009, CIRCULATION, V119, P606, DOI 10.1161/CIRCULATIONAHA.108.825380; Brignole M, 2013, EUR HEART J, V34, P2281, DOI 10.1093/eurheartj/eht150; Okin PM, 2014, AM J HYPERTENS, V27, P966, DOI 10.1093/ajh/hpu006; Zois NE, 2014, NAT REV CARDIOL, V11, P403, DOI 10.1038/nrcardio.2014.64; Benjamin EJ, 1998, CIRCULATION, V98, P946; Kokubo Y, 2014, HYPERTENSION, V63, P655, DOI 10.1161/HYPERTENSIONAHA.113.00543; Landsberg L, 2013, J CLIN HYPERTENS, V15, P14, DOI 10.1111/jch.12049; Wang TJ, 2004, JAMA-J AM MED ASSOC, V292, P2471, DOI 10.1001/jama.292.20.2471; Frost L, 2005, AM J MED, V118, P489, DOI 10.1016/j.amjmed.2005.01.031; Sano F, 2014, CIRC J, V78, P955, DOI 10.1253/circj.CJ-13-1387; Tsang TSM, 2008, EUR HEART J, V29, P2227, DOI 10.1093/eurheartj/ehn324; Feraco A, 2013, J STEROID BIOCHEM, V137, P99, DOI 10.1016/j.jsbmb.2013.02.012; Psaty BM, 1997, CIRCULATION, V96, P2455; Cuspidi C, 2014, J HYPERTENS, V32, P16, DOI 10.1097/HJH.0b013e328364fb58; ALAUDDIN A, 1990, SURGERY, V108, P809; Lip GYH, 2012, LANCET, V379, P648, DOI 10.1016/S0140-6736(11)61514-6; Conen D, 2009, CIRCULATION, V119, P2146, DOI 10.1161/CIRCULATIONAHA.108.830042; Kwagyan J, 2005, J HYPERTENS, V23, P619, DOI 10.1097/01.hjh.0000160220.71350.5f; Iacobellis G, 2002, OBES RES, V10, P767, DOI 10.1038/oby.2002.104; Tedrow UB, 2010, J AM COLL CARDIOL, V55, P2319, DOI 10.1016/j.jacc.2010.02.029; MARKOVIC N, 1994, INT J EPIDEMIOL, V23, P723, DOI 10.1093/ije/23.4.723; Imai Enyu, 2007, Clin Exp Nephrol, V11, P41, DOI 10.1007/s10157-006-0453-4	33	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0895-7061	1941-7225		AM J HYPERTENS	Am. J. Hypertens.	NOV	2015	28	11					1355	1361		10.1093/ajh/hpv038		7	Peripheral Vascular Disease	Cardiovascular System & Cardiology	CT5HV	WOS:000362840500010		
J	Naito, YI; Morita, A; Natsuhara, K; Tadokoro, K; Baba, J; Odani, S; Tomitsuka, E; Igai, K; Tsutaya, T; Yoneda, M; Greenhill, AR; Horwood, PF; Soli, KW; Phuanukoonnon, S; Siba, PM; Umezaki, M				Naito, Yuichi I.; Morita, Ayako; Natsuhara, Kazumi; Tadokoro, Kiyoshi; Baba, Jun; Odani, Shingo; Tomitsuka, Eriko; Igai, Katsura; Tsutaya, Takumi; Yoneda, Minoru; Greenhill, Andrew R.; Horwood, Paul F.; Soli, Kevin W.; Phuanukoonnon, Suparat; Siba, Peter M.; Umezaki, Masahiro			Association of protein intakes and variation of diet-scalp hair nitrogen isotopic discrimination factor in Papua New Guinea highlanders	AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY			English	Article						nitrogen isotopic discrimination factor; scalp hair; protein quality; metabolism	INDIVIDUAL AMINO-ACIDS; STABLE-ISOTOPE; BONE-COLLAGEN; NATURAL-ABUNDANCE; NUTRITIONAL STRESS; UREA NITROGEN; FOOD-WEB; CARBON; DELTA-N-15; FRACTIONATION	Objectives:We present new nitrogen isotopic discrimination factor between diets and scalp hairs (N-15(Hair-Diet): N-15(Hair) - N-15(Diet)) for indigenous residents in three communities in the Papua New Guinea Highlands who consumed various amounts and qualities of protein. The N-15 is important for precise evaluation of the dietary habits of human populations; in both contemporary and traditional lifestyles. Several hypotheses have been proposed regarding factors that affect N-15 values, based largely on observations from animal feeding experiments. However, variations and factors controlling N-15 in humans are not well understood, mainly due to the difficulty of controlling the diets of participants. Materials and Methods:These residents were studied because they have maintained relatively traditional dietary habits, which allow quantitative recording of diets. N-15 was estimated by comparing hair N-15 values to mean dietary N-15 values calculated from the recorded intake of each food item and their N-15 values. Results:The results showed that: i) there was a significant difference in N-15 among study locations (3.90.9 parts per thousand for most urbanized, 5.2 +/- 1.0 parts per thousand for medium and 5.0 +/- 0.9 parts per thousand for least urbanized communities; range=1.2-7.3 parts per thousand for all participants); and ii) estimated N-15 values were negatively correlated with several indicators of animal protein intake (% nitrogen in diet: range=0.9-7.6%). Discussion:We hypothesize that a combination of several factors, which presumably included urea recycling and amino acid and protein recycling and/or de novo synthesis during metabolic processes, altered the N-15 values of the participants. Am J Phys Anthropol 158:359-370, 2015. (c) 2015 Wiley Periodicals, Inc.	[Naito, Yuichi I.; Tsutaya, Takumi; Yoneda, Minoru] Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan; [Morita, Ayako; Tadokoro, Kiyoshi; Tomitsuka, Eriko; Umezaki, Masahiro] Univ Tokyo, Grad Sch Med, Dept Human Ecol, Bunkyo Ku, Tokyo 1130033, Japan; [Morita, Ayako] Tokyo Med & Dent Univ, Bunkyo Ku, Tokyo 1138519, Japan; [Natsuhara, Kazumi] Japanese Red Cross Akita Coll Nursing, Akita, Akita 0101493, Japan; [Baba, Jun] Tokyo Univ Foreign Studies, Res Inst Languages & Cultures Asia & Africa, Fuchu, Tokyo 1838534, Japan; [Odani, Shingo] Chiba Univ, Fac Letters, Inage Ku, Chiba 2638522, Japan; [Igai, Katsura] Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528523, Japan; [Yoneda, Minoru] Univ Tokyo, Univ Museum, Bunkyo Ku, Tokyo 1130033, Japan; [Greenhill, Andrew R.; Horwood, Paul F.; Soli, Kevin W.; Phuanukoonnon, Suparat; Siba, Peter M.] Papua New Guinea Inst Med Res, Goroka 441, Eastern Highlan, Papua N Guinea; [Greenhill, Andrew R.] Federat Univ, Churchill, Vic 3842, Australia	Naito, YI (reprint author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwanoha 5-1-5, Kashiwa, Chiba 2778562, Japan.	ynaito@sss.fukushima-u.ac.jp			Cabinet Office, Government of Japan (Funding Program for Next Generation World-Leading Researchers) [LS024]; Japan Society for the Promotion of Science	Grant sponsor: Cabinet Office, Government of Japan (Funding Program for Next Generation World-Leading Researchers, LS024) (to M.U.) and the Japan Society for the Promotion of Science (to Y.N.).	Akaike H., 1973, 2 INT S INF THEOR, P267; Ambrose S. H., 1993, INVESTIGATIONS ANCIE, P59; Ambrose S.H., 2000, BIOGEOCHEMICAL APPRO, V5, P243; Amundson R, 2003, GLOBAL BIOGEOCHEM CY, V17, P31; McClelland JW, 2002, ECOLOGY, V83, P2173, DOI 10.1890/0012-9658(2002)083[2173:TRATNI]2.0.CO;2; Naito YI, 2013, WORLD ARCHAEOL, V45, P338, DOI 10.1080/00438243.2013.820650; MINAGAWA M, 1992, APPL GEOCHEM, V7, P145, DOI 10.1016/0883-2927(92)90033-Y; Pearson SF, 2003, OECOLOGIA, V135, P516, DOI 10.1007/s00442-003-1221-8; Caut S, 2008, FUNCT ECOL, V22, P255, DOI 10.1111/j.1365-2435.2007.01360.x; McMahon KW, 2015, ECOL EVOL, V5, P1278, DOI 10.1002/ece3.1437; Webb EC, 2015, INT J PALEOPATHOL, V9, P28, DOI 10.1016/j.ijpp.2014.12.001; Hedges R, 2009, ISOT ENVIRON HEALT S, V45, P1, DOI 10.1080/10256010802522010; Morita A, 2015, AM J HUM BIOL, V27, P349, DOI 10.1002/ajhb.22647; Fuller BT, 2005, RAPID COMMUN MASS SP, V19, P2497, DOI 10.1002/rcm.2090; OHTSUKA R, 1984, ECOL FOOD NUTR, V15, P159; Nakashita R, 2013, PRIMATES, V54, P271, DOI 10.1007/s10329-013-0346-6; Robbins CT, 2005, OECOLOGIA, V144, P534, DOI 10.1007/s00442-005-0021-8; Nash SH, 2013, J NUTR, V143, P161, DOI 10.3945/jn.112.169425; Yoshinaga J, 1996, AM J PHYS ANTHROPOL, V100, P23; Cerling TE, 1999, OECOLOGIA, V120, P347, DOI 10.1007/s004420050868; SAITOH M, 1970, J INVEST DERMATOL, V54, P65, DOI 10.1111/1523-1747.ep12551679; BUTTERFIELD GE, 1984, BRIT J NUTR, V51, P171, DOI 10.1079/BJN19840021; GUPPY M, 1986, TRENDS BIOCHEM SCI, V11, P274, DOI 10.1016/0968-0004(86)90022-8; HOBSON KA, 1992, CONDOR, V94, P189, DOI 10.2307/1368808; Katzenberg MA, 1999, INT J OSTEOARCHAEOL, V9, P316, DOI 10.1002/(SICI)1099-1212(199909/10)9:5<316::AID-OA500>3.0.CO;2-D; Schoeninger MJ, 1999, AM J PRIMATOL, V49, P297, DOI 10.1002/(SICI)1098-2345(199912)49:4<297::AID-AJP2>3.0.CO;2-N; Webb SC, 1998, J EXP BIOL, V201, P2903; YOSHINAGA J, 1991, ECOL FOOD NUTR, V26, P17; Chikaraishi Y, 2007, MAR ECOL PROG SER, V342, P85, DOI 10.3354/meps342085; Huelsemann F, 2013, AM J PHYS ANTHROPOL, V152, P58, DOI 10.1002/ajpa.22328; Naito YI, 2013, J ARCHAEOL SCI, V40, P2913, DOI 10.1016/j.jas.2013.03.012; Metges CC, 1997, ANAL BIOCHEM, V247, P158, DOI 10.1006/abio.1997.2037; Oelze VM, 2011, P NATL ACAD SCI USA, V108, P9792, DOI 10.1073/pnas.1018502108; Mekota AM, 2006, RAPID COMMUN MASS SP, V20, P1604, DOI 10.1002/rcm.2477; McCarthy MD, 2007, GEOCHIM COSMOCHIM AC, V71, P4727, DOI 10.1016/j.gca.2007.06.061; O'Connell TC, 1999, AM J PHYS ANTHROPOL, V108, P409, DOI 10.1002/(SICI)1096-8644(199904)108:4<409::AID-AJPA3>3.0.CO;2-E; Florin ST, 2011, FUNCT ECOL, V25, P519, DOI 10.1111/j.1365-2435.2010.01799.x; Olsen KC, 2014, AM J PHYS ANTHROPOL, V153, P598, DOI 10.1002/ajpa.22459; Fuller BT, 2004, RAPID COMMUN MASS SP, V18, P2889, DOI 10.1002/rcm.1708; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; SCHOELLER DA, 1986, ECOL FOOD NUTR, V18, P159; Williams LJ, 2011, AM J PHYS ANTHROPOL, V145, P125, DOI 10.1002/ajpa.21479; HARE PE, 1991, J ARCHAEOL SCI, V18, P277; Naito YI, 2010, AM J PHYS ANTHROPOL, V143, P31, DOI 10.1002/ajpa.21287; Hedges REM, 2007, J ARCHAEOL SCI, V34, P1240, DOI 10.1016/j.jas.2006.10.015; Robbins Charles T, 2010, Oecologia, V162, P571, DOI 10.1007/s00442-009-1485-8; RIKIMARU T, 1985, J NUTR SCI VITAMINOL, V31, P393; STEELE KW, 1978, J AGR SCI, V90, P7; SEALY JC, 1987, GEOCHIM COSMOCHIM AC, V51, P2707, DOI 10.1016/0016-7037(87)90151-7; SCHOENINGER MJ, 1992, J WORLD PREHIST, V6, P247, DOI 10.1007/BF00975551; Hilderbrand GV, 1996, CAN J ZOOL, V74, P2080, DOI 10.1139/z96-236; Nash SH, 2012, J NUTR, V142, P84, DOI 10.3945/jn.111.147595; Romek KM, 2013, AMINO ACIDS, V45, P1365, DOI 10.1007/s00726-013-1597-7; GAEBLER OH, 1966, CAN J BIOCHEM CELL B, V44, P1249; Sponheimer M, 2003, J ARCHAEOL SCI, V30, P1649, DOI 10.1016/S0305-4403(03)00066-9; Balter V, 2006, OECOLOGIA, V147, P212, DOI 10.1007/s00442-005-0263-5; HOBSON KA, 1993, CONDOR, V95, P388, DOI 10.2307/1369361; Styring AK, 2010, GEOCHIM COSMOCHIM AC, V74, P241, DOI 10.1016/j.gca.2009.09.022; Miron MLL, 2006, J EXP BIOL, V209, P541, DOI 10.1242/jeb.02016; Fahy GE, 2013, P NATL ACAD SCI USA, V110, P5829, DOI 10.1073/pnas.1221991110; O'Connell TC, 2012, AM J PHYS ANTHROPOL, V149, P426, DOI 10.1002/ajpa.22140; Roth JD, 2000, CAN J ZOOL, V78, P848, DOI 10.1139/cjz-78-5-848; O'Connell TC, 2001, J ARCHAEOL SCI, V28, P1247, DOI 10.1006/jasc.2001.0698; Barba C, 2004, LANCET, V363, P157; AMBROSE SH, 1986, OECOLOGIA, V69, P395, DOI 10.1007/BF00377062; MUNRO HN, 1951, PHYSIOL REV, V31, P449; FOMON SJ, 1987, J PEDIATR-US, V111, P221, DOI 10.1016/S0022-3476(87)80071-9; Chikaraishi Y, 2014, ECOL EVOL, V4, P2423, DOI 10.1002/ece3.1103; Petzke KJ, 2010, CURR OPIN CLIN NUTR, V13, P532, DOI 10.1097/MCO.0b013e32833c3c84; BERGERSE.FJ, 1970, J GEN MICROBIOL, V60, P61; DENIRO MJ, 1981, GEOCHIM COSMOCHIM AC, V45, P341, DOI 10.1016/0016-7037(81)90244-1; MINAGAWA M, 1984, GEOCHIM COSMOCHIM AC, V48, P1135, DOI 10.1016/0016-7037(84)90204-7; Poupin N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028046; R Core Team, 2014, R LANG ENV STAT COMP; SCHOENINGER MJ, 1984, GEOCHIM COSMOCHIM AC, V48, P625, DOI 10.1016/0016-7037(84)90091-7; SUGIURA N, 1978, COMMUN STAT A-THEOR, V7, P13, DOI 10.1080/03610927808827599; Umezaki M., 1998, Ecology of Food and Nutrition, V37, P409; WHITE CD, 1994, AM J PHYS ANTHROPOL, V93, P165, DOI 10.1002/ajpa.1330930203; WHO/FAO/UNU, 2007, WHO TECH REP SER, V935, P1; YONEYAMA T, 1983, Radioisotopes, V32, P330	80	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-9483	1096-8644		AM J PHYS ANTHROPOL	Am. J. Phys. Anthropol.	NOV	2015	158	3					359	370		10.1002/ajpa.22798		12	Anthropology; Evolutionary Biology	Anthropology; Evolutionary Biology	CT6WH	WOS:000362953000001		
J	Balois, MV; Hayazawa, N; Catalan, FC; Kawata, S; Yano, T; Hayashi, T				Balois, Maria Vanessa; Hayazawa, Norihiko; Catalan, Francesca Celine; Kawata, Satoshi; Yano, Taka-aki; Hayashi, Tomohiro			Tip-enhanced THz Raman spectroscopy for local temperature determination at the nanoscale	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						IR spectroscopy/Raman spectroscopy; Nanoparticles/nanotechnology; Bioanalytical methods; Laser spectroscopy; Thermal methods	WALL CARBON NANOTUBES; SINGLE-MOLECULE; SCATTERING; DEPENDENCE; FIELD; SILICON; FILMS	Local temperature of a nanoscale volume is precisely determined by tip-enhanced terahertz Raman spectroscopy in the low temperature range of several tens of degrees. Heat generated by the tip-enhanced electric field is directly transferred to single-walled carbon nanotubes by heat conduction and radiation at the nanoscale. This heating modulates the intensity ratio of anti-Stokes/Stokes Raman scattering of the radial breathing mode of the carbon nanotube based on the Boltzmann distribution at elevated temperatures. Owing to the low-energy feature of the radial breathing mode, the local temperature of the probing volume has been successfully extracted with high sensitivity. The dependence of the temperature rise underneath the tip apex on the incident power coincides with the analytical results calculated by finite element method based on the tip enhancement effect and the consequent steady-state temperature via Joule heat generation. The results show that the local temperature at the nanoscale can be controlled in the low temperature range simply by the incident laser power while exhibiting a sufficiently high tip enhancement effect as an analytical tool for thermally sensitive materials (e.g., proteins, DNA).	[Balois, Maria Vanessa; Hayazawa, Norihiko; Catalan, Francesca Celine; Kawata, Satoshi] RIKEN, Inst Phys & Chem Res, Near Field Nanophoton Res Team, Wako, Saitama 3510198, Japan; [Balois, Maria Vanessa; Hayazawa, Norihiko; Catalan, Francesca Celine] RIKEN, Inst Phys & Chem Res, Surface & Interface Sci Lab, Wako, Saitama 3510198, Japan; [Balois, Maria Vanessa; Hayazawa, Norihiko; Yano, Taka-aki; Hayashi, Tomohiro] Tokyo Inst Technol, Dept Elect Chem, Nagatsuta, Kanagawa 2268502, Japan; [Hayazawa, Norihiko] RIKEN, Inst Phys & Chem Res, Innovat Photon Manipulat Res Team, Wako, Saitama 3510198, Japan	Hayazawa, N (reprint author), RIKEN, Inst Phys & Chem Res, Near Field Nanophoton Res Team, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	hayazawa@riken.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [24686009]; Institute of Physical and Chemical Research (RIKEN)	We gratefully acknowledge the financial support by the "Grant-in-Aid for Young Scientists A" No. 24686009 (N.H.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the 'Program for Junior Scientists - International Program Associate' (M.V.B.) from The Institute of Physical and Chemical Research (RIKEN).	Albella A, 2014, ACS PHOTONICS, V1, P524; Feng B, 2009, THIN SOLID FILMS, V517, P2803, DOI 10.1016/j.tsf.2008.10.116; Anderson MS, 2000, APPL PHYS LETT, V76, P3130, DOI 10.1063/1.126546; Hayazawa N, 2012, J RAMAN SPECTROSC, V43, P1177, DOI 10.1002/jrs.4032; Ci LJ, 2003, APPL PHYS LETT, V82, P3098, DOI 10.1063/1.1572959; Dresselhaus MS, 2005, PHYS REP, V409, P47, DOI 10.1016/j.physrep.2004.10.006; Schmid T, 2013, ANGEW CHEM INT EDIT, V52, P5940, DOI 10.1002/anie.201203849; van Schrojenstein Lantman EM, 2012, NAT NANOTECHNOL, V7, P583, DOI [10.1038/nnano.2012.131, 10.1038/NNANO.2012.131]; Malkovskiy AV, 2009, J RAMAN SPECTROSC, V40, P1349, DOI 10.1002/jrs.2388; Deckert-Gaudig T, 2009, SMALL, V5, P432, DOI 10.1002/smll.200801237; HART TR, 1970, PHYS REV B-SOLID ST, V1, P638, DOI 10.1103/PhysRevB.1.638; Hayazawa N, 2000, OPT COMMUN, V183, P333, DOI 10.1016/S0030-4018(00)00894-4; Cialla D, 2009, J RAMAN SPECTROSC, V40, P240, DOI 10.1002/jrs.2123; Raravikar NR, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.235424; Downes A, 2006, OPT EXPRESS, V14, P5216, DOI 10.1364/OE.14.005216; Hayazawa N, 2004, APPL PHYS LETT, V85, P6239, DOI 10.1063/1.1839646; Neugebauer U, 2007, CHEMPHYSCHEM, V8, P124, DOI 10.1002/cphc.200600507; Budich C, 2008, J MICROSC-OXFORD, V229, P533, DOI 10.1111/j.1365-2818.2008.01939.x; Pettinger B, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.096101; Hartschuh A, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.095503; Zhang WH, 2008, J PHYS CHEM C, V112, P2104, DOI 10.1021/jp077457g; Oguchi M, 2014, CHEM LETT, V43, P808, DOI 10.1246/cl.140093; Zhang R, 2013, NATURE, V498, P82, DOI 10.1038/nature12151; Lazarevic JJ, 2014, SPECTROCHIM ACTA A, V126, P301, DOI 10.1016/j.saa.2014.01.135; Rasmussen A, 2006, J RAMAN SPECTROSC, V37, P311, DOI 10.1002/jrs.1480; Najjar S, 2014, J PHYS CHEM C, V118, P1174, DOI 10.1021/jp410963z; Hermann P, 2011, ANALYST, V136, P1148, DOI 10.1039/c0an00531b; Chiashi S, 2008, JPN J APPL PHYS, V47, P2010, DOI 10.1143/JJAP.47.2010; Kataura H, 1999, SYNTHETIC MET, V103, P2555, DOI 10.1016/S0379-6779(98)00278-1; Deckert-Gaudig T, 2012, J BIOPHOTONICS, V5, P215, DOI 10.1002/jbio.201100142; Yeo BS, 2008, J PHYS CHEM C, V112, P4867, DOI 10.1021/jp709799m; Bailo E, 2008, ANGEW CHEM INT EDIT, V47, P1658, DOI 10.1002/anie.200704054; Stockle RM, 2000, CHEM PHYS LETT, V318, P131, DOI 10.1016/S0009-2614(99)01451-7; Paulite M, 2013, ACS NANO, V7, P911, DOI 10.1021/nn305677k; Rzeznicka II, 2013, SURF SCI, V617, P1, DOI 10.1016/j.susc.2013.08.010; Chen C, 2013, NAT COMMUN, V5, P3312; Kawata S, 2007, TIP ENHANCEMENT; Khan W., 2014, APPL NANOSCI, V4, P633, DOI DOI 10.1007/S13204-013-0242-9; Kumar N, 2015, NANOSCALE, V7, P7133, DOI 10.1039/c4nr07441f; Liu Z, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1310; Long DA, 1976, RAMAN SPECTROSCOPY; Palik E. D., 1998, HDB OPTICAL CONSTANT; Tarun T, 2011, J RAMAN SPECTROSC, V42, P992	43	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642	1618-2650		ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	NOV	2015	407	27					8205	8213		10.1007/s00216-015-8866-0		9	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	CT7DN	WOS:000362974100006		
J	Atsumi, T; Nagasaka, Y				Atsumi, Takeshi; Nagasaka, Yasuo			Perception of chasing in squirrel monkeys (Saimiri sciureus)	ANIMAL COGNITION			English	Article						Motion perception; Animacy; Goal attribution; Chasing; Squirrel monkeys	SUPERIOR TEMPORAL SULCUS; ANIMACY; AUTISM; ATTRIBUTION; CHIMPANZEES; INTENTION; MOVEMENT	Understanding the intentions of others is crucial in developing positive social relationships. Comparative human and non-human animal studies have addressed the phylogenetic origin of this ability. However, few studies have explored the importance of motion information in distinguishing others' intentions and goals in non-human primates. This study addressed whether squirrel monkeys (Saimiri sciureus) are able to perceive a goal-directed motion pattern-specifically, chasing-represented by two geometric objects. In Experiment 1, we trained squirrel monkeys to discriminate a "Chasing" sequence from a "Random" sequence. We then confirmed that this discrimination transferred to new stimuli ("Chasing" and "Random") in a probe test. To determine whether the monkeys used similarities of trajectory to discriminate chasing from random motion, we also presented a non-chasing "Clone" sequence in which the trajectories of the two figures were identical. Three of six monkeys were able to discriminate "Chasing" from the other sequences. In Experiment 2, we confirmed humans' recognition of chasing with the stimuli from Experiment 1. In Experiment 3, the three monkeys for which discrimination did not transfer to the new stimuli in Experiment 1 were trained to discriminate between "Chasing" and "Clone" sequences. At testing, all three monkeys had learned to discriminate chasing, and two transferred their learning to new stimuli. Our results suggest that squirrel monkeys use goal-directed motion patterns, rather than simply similarity of trajectory, to discriminate chasing. Further investigation is necessary to identify the motion characteristics that contribute to this discrimination.	[Atsumi, Takeshi] Kyoto Univ, Sect Cognit & Learning, Primate Res Inst, Inuyama, Aichi 4848506, Japan; [Nagasaka, Yasuo] RIKEN, Brain Sci Inst, Lab Adapt Intelligence, Wako, Saitama 3510198, Japan	Atsumi, T (reprint author), Kyoto Univ, Sect Cognit & Learning, Primate Res Inst, Inuyama, Aichi 4848506, Japan.	atsumi.takeshi.52e@st.kyoto-u.ac.jp					Santos NS, 2008, CONSCIOUS COGN, V17, P425, DOI 10.1016/j.concog.2008.03.012; McAleer P, 2011, J AUTISM DEV DISORD, V41, P1053, DOI 10.1007/s10803-010-1130-8; Tsutsumi S, 2012, PRIMATES, V53, P113, DOI 10.1007/s10329-011-0289-8; Gao T, 2009, COGNITIVE PSYCHOL, V59, P154, DOI 10.1016/j.cogpsych.2009.03.001; Gao T, 2012, J NEUROSCI, V32, P14276, DOI 10.1523/JNEUROSCI.0562-12.2012; Opfer JE, 2002, COGNITION, V86, P97, DOI 10.1016/S0010-0277(02)00171-3; Klin A, 2000, J CHILD PSYCHOL PSYC, V41, P831, DOI 10.1017/S0021963099006101; Mascalzoni E, 2010, P NATL ACAD SCI USA, V107, P4483, DOI 10.1073/pnas.0908792107; Heider F, 1944, AM J PSYCHOL, V57, P243, DOI 10.2307/1416950; Uller C, 2000, COGNITION, V76, pB27, DOI 10.1016/S0010-0277(00)00078-0; Barrett HC, 2005, EVOL HUM BEHAV, V26, P313, DOI 10.1016/j.evolhumbehav.2004.08.015; Rutherford MD, 2006, J AUTISM DEV DISORD, V36, P983, DOI 10.1007/s10803-006-0136-8; Gao T, 2011, J EXP PSYCHOL HUMAN, V37, P669, DOI 10.1037/a0020735; Gergely G, 2003, TRENDS COGN SCI, V7, P287, DOI 10.1016/S1364-6613(03)00128-1; Goto K, 2002, ANIM COGN, V5, P119, DOI 10.1007/s10071-002-0139-6; Gillespie-Lynch K, 2013, J AUTISM DEV DISORD, V43, P2779, DOI 10.1007/s10803-013-1818-7; GERGELY G, 1995, COGNITION, V56, P165, DOI 10.1016/0010-0277(95)00661-H; RIME B, 1985, MOTIV EMOTION, V9, P241, DOI 10.1007/BF00991830; Uller C, 2004, ANIM COGN, V7, P154, DOI 10.1007/s10071-003-02041-9; Schultz J, 2005, NEURON, V45, P625, DOI 10.1016/j.neuron.2004.12.052; Jameson KA, 1999, ANIM BEHAV, V57, P991, DOI 10.1006/anbe.1998.1077; Frankenhuis WE, 2013, COGNITION, V126, P224, DOI 10.1016/j.cognition.2012.10.001; Comtois R, 2003, VISION SHELL PPC; DASSER V, 1989, SCIENCE, V243, P365, DOI 10.1126/science.2911746; Dittrich WH, 1994, PERCEPTION, V23, P65; Kanakogi Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065292; PREMACK D, 1990, COGNITION, V36, P1, DOI 10.1016/0010-0277(90)90051-K; Rochat P., 1997, COGNITIVE DEV, V12, P537, DOI [10.1016/S0885-2014(97)90022-8, DOI 10.1016/S0885-2014(97)90022-8]	28	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1435-9448	1435-9456		ANIM COGN	Anim. Cogn.	NOV	2015	18	6					1243	1253		10.1007/s10071-015-0893-x		11	Behavioral Sciences; Zoology	Behavioral Sciences; Zoology	CT6YS	WOS:000362960200005		
J	Bakal, T; Goo, KS; Najmanova, L; Plhackova, K; Kadlcik, S; Ulanova, D				Bakal, Tomas; Goo, Kian-Sim; Najmanova, Lucie; Plhackova, Kamila; Kadlcik, Stanislav; Ulanova, Dana			Comparative analysis of oligonucleotide primers for high-throughput screening of genes encoding adenylation domains of nonribosomal peptide synthetases in actinomycetes	ANTONIE VAN LEEUWENHOEK INTERNATIONAL JOURNAL OF GENERAL AND MOLECULAR MICROBIOLOGY			English	Article						Nonribosomal peptide synthetase; Adenylation domain; Actinomycetes; 454 Pyrosequencing; The Integrated Ocean Drilling Program	NATURAL-PRODUCT; DIVERSITY; SEDIMENTS; SEQUENCE; GENOME; PERFORMANCE; METABOLITES; DISCOVERY; SOILS	In the biosynthesis of diverse natural bioactive products the adenylation domains (ADs) of nonribosomal peptide synthetases select specific precursors from the cellular pool and activate them for further incorporation into the scaffold of the final compound. Therefore, the drug discovery programs employing PCR-based screening studies of microbial collections or metagenomic libraries often use AD-coding genes as markers of relevant biosynthetic gene clusters. However, due to significant sequence diversity of ADs, the conventional approach using only one primer pair in a single screening experiment could be insufficient for maximal coverage of AD abundance. In this study, the widely used primer pair A3F/A7R was compared with the newly designed aa194F/aa413R one by 454 pyrosequencing of two sets of actinomycete strains from highly dissimilar environments: subseafloor sediments and forest soil. Individually, none of the primer pairs was able to cover the overall diversity of ADs. However, due to slightly shifted specificity of the primer pairs, the total number and diversity of identified ADs were noticeably extended when both primer pairs were used in a single assay. Additionally, the efficiency of AD detection by different primer combinations was confirmed on the model of Salinispora tropica genomic DNA of known sequence.	[Bakal, Tomas; Najmanova, Lucie; Plhackova, Kamila; Kadlcik, Stanislav] Inst Microbiol AS CR, Prague 14200 4, Czech Republic; [Goo, Kian-Sim] Kochi Univ, Evaluat & Support Org Young Researchers, Nanko Ku, Kochi 7838505, Japan; [Ulanova, Dana] Kochi Univ, IMT MEXT, Ctr Sci Res, Oceanog Sect,Nanko Ku, Kochi 7838505, Japan	Ulanova, D (reprint author), Kochi Univ, IMT MEXT, Ctr Sci Res, Oceanog Sect,Nanko Ku, Oko Cho, Kochi 7838505, Japan.	ulanova@kochi-u.ac.jp			BIOCEV-Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University from European Regional Development Fund in Czech Republic [CZ.1.05/1.1.00/02.0109]	The authors thank Dr. Kouhei Ohnishi for performing 454 pyrosequencing analysis and Kochi Prefectural Deep Seawater Laboratory for providing deep seawater. This research used samples provided by the Integrated Ocean Drilling Program. This work was performed through Program to Disseminate Tenure Tracking System of the Ministry of Education, Culture, Sports, Science and Technology, The Japanese Government. This research was supported by BIOCEV-Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University No. CZ.1.05/1.1.00/02.0109, from the European Regional Development Fund in the Czech Republic.	WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; Gulick AM, 2009, ACS CHEM BIOL, V4, P811, DOI 10.1021/cb900156h; Praseuth AP, 2008, BIOTECHNOL PROGR, V24, P1226, DOI [10.1002/btpr.34, 10.1021/bp.34]; Li J, 2014, ANTON LEEUW INT J G, V106, P623, DOI 10.1007/s10482-014-0233-1; May JJ, 2002, P NATL ACAD SCI USA, V99, P12120, DOI 10.1073/pnas.182156699; Sagova-Mareckova M, 2008, APPL ENVIRON MICROB, V74, P2902, DOI 10.1128/AEM.02161-07; Kamenik Z, 2010, J CHROMATOGR A, V1217, P8016, DOI 10.1016/j.chroma.2010.08.031; Goo KS, 2014, ANTON LEEUW INT J G, V105, P207, DOI 10.1007/s10482-013-0067-2; Udwary DW, 2007, P NATL ACAD SCI USA, V104, P10376, DOI 10.1073/pnas.0700962104; Berdy J, 2005, J ANTIBIOT, V58, P1; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Xie PF, 2014, J NAT PROD, V77, P377, DOI 10.1021/np401063s; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Schmelz S, 2009, CURR OPIN STRUC BIOL, V19, P666, DOI 10.1016/j.sbi.2009.09.004; Jensen PR, 2005, ENVIRON MICROBIOL, V7, P1039, DOI 10.1111/j.1462-2920.2005.00785.x; Challis GL, 2008, MICROBIOL-SGM, V154, P1555, DOI 10.1099/mic.0.2008/018523-0; Bosello M, 2011, J AM CHEM SOC, V133, P4587, DOI 10.1021/ja1109453; Lautru S, 2005, NAT CHEM BIOL, V1, P265, DOI 10.1038/nchembio731; Busti E, 2006, MICROBIOL-SGM, V152, P675, DOI 10.1099/mic.0.28335-0; Reddy BVB, 2012, APPL ENVIRON MICROB, V78, P3744, DOI 10.1128/AEM.00102-12; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Stachelhaus T, 1999, CHEM BIOL, V6, P493, DOI 10.1016/S1074-5521(99)80082-9; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Meklat A, 2011, APPL ENVIRON MICROB, V77, P6710, DOI 10.1128/AEM.00326-11; Ayuso-Sacido A, 2005, MICROBIAL ECOL, V49, P10, DOI 10.1007/s00248-004-0249-6; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Charlop-Powers Z, 2015, ELIFE, V4, DOI 10.7554/eLife.05048; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Janata J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118850; Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199; Ulanova D, 2015, FOLIA MICROBIOL, V60, P211, DOI 10.1007/s12223-014-0361-z; Weber T, 2015, TRENDS BIOTECHNOL, V33, P15, DOI 10.1016/j.tibtech.2014.10.009	32	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0003-6072	1572-9699		ANTON LEEUW INT J G	Antonie Van Leeuwenhoek	NOV	2015	108	5					1267	1274		10.1007/s10482-015-0557-5		8	Microbiology	Microbiology	CT5WI	WOS:000362881400024		
J	Iida, T; Komiyama, O; Honki, H; Komoda, Y; Baad-Hansen, L; Kawara, M; Svensson, P				Iida, Takashi; Komiyama, Osamu; Honki, Hisae; Komoda, Yoshihiro; Baad-Hansen, Lene; Kawara, Misao; Svensson, Peter			Effect of a repeated jaw motor task on masseter muscle performance	ARCHIVES OF ORAL BIOLOGY			English	Article						Motor learning; Masseter muscle; Tooth clenching; EMG	HUMAN TONGUE MUSCULATURE; CORTICOMOTOR CONTROL; PROTRUSION TASK; CLOSING MUSCLES; SLEEP BRUXISM; PLASTICITY; PAIN; EXCITABILITY; MOVEMENTS; FEEDBACK	Objective: The aim of this study was to investigate the effects of 5-days repeated jaw-motor tasks on masseter muscle accuracy performance. Design: Sixteen healthy participants performed a tooth-clenching task (TCT) of 58-minutes on five consecutive days. During measurements, electromyography (EMG) of both masseter muscles was recorded. Each day, the 100% maximum voluntary contraction (MVC) level was determined before the TCT. In the first and third TCT series, participants were instructed to target force levels without visual feedback. During the second TCT series, visual feedback on muscle activity level was displayed. One series consisted of three force levels (10%, 20%, and 40% MVC). In the series, participants alternated between a 30-s rest-block and a 30-s task-block for 360 s. In the task-block, participants alternated between a 5-s rest-block and a 5-s task-block. EMG activity during epochs of 5-s was quantified by calculation of the root-mean-square (RMS) values. To evaluate the accuracy of the performance, the coefficient of determination (CD) of the target force level-EMG curve was calculated from all series. Results: No significant day-to-day differences in EMG RMS amplitudes were observed during MVC. CDs differed significantly between the five days (P < 0.001). CDs in the first series on day 1 were significantly lower than CDs in the first series on days 4 and 5 (P < 0.05). Conclusions: The findings suggest that a rigorous training paradigm may improve the performance of masseter muscles in terms of accuracy but not MVC. This might have implications for understanding the rehabilitation of patients with functional disorders in the stomatognathic system. (C) 2015 Elsevier Ltd. All rights reserved.	[Iida, Takashi; Komiyama, Osamu; Honki, Hisae; Komoda, Yoshihiro; Kawara, Misao] Nihon Univ, Sch Dent Matsudo, Dept Oral Funct & Rehabil, Matsudo, Chiba 2718587, Japan; [Iida, Takashi; Komoda, Yoshihiro; Baad-Hansen, Lene; Svensson, Peter] Aarhus Univ, Dept Dent, Sect Clin Oral Physiol, DK-8000 Aarhus C, Denmark; [Baad-Hansen, Lene; Svensson, Peter] SCON, Odense, Denmark; [Svensson, Peter] Karolinska Inst, Dept Dent Med, Huddinge, Sweden	Iida, T (reprint author), Nihon Univ, Sch Dent Matsudo, Dept Oral Funct & Rehabil, 2-870-1 Sakaecho Nishi, Matsudo, Chiba 2718587, Japan.	iida.takashi96@nihon-u.ac.jp			Section of Clinical Oral Physiology, Department of Dentistry, Aarhus University; Danish Dental Association, Denmark; Ministry of Education, Culture, Sports, Science, and Technology of Japan [B 26861655]; Japanese Society for the Promotion of Science [C 25463027, C 26462959]	This study was funded by the Section of Clinical Oral Physiology, Department of Dentistry, Aarhus University and the Danish Dental Association, Denmark. In addition, this study was supported by a grant-in-aid for young scientists (B 26861655) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and a grant-in-aid for scientific research (C 25463027 and C 26462959) from the Japanese Society for the Promotion of Science.	REDING GR, 1968, J DENT RES, V47, P786, DOI 10.1177/00220345680470052001; Gastaldo E, 2006, J OROFAC PAIN, V20, P145; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037//0033-2909.86.2.420; Hellmann D, 2011, J ORAL REHABIL, V38, P912, DOI 10.1111/j.1365-2842.2011.02227.x; Baad-Hansen L, 2009, ARCH ORAL BIOL, V54, P32, DOI 10.1016/j.archoralbio.2008.08.001; Torisu T, 2007, CLIN NEUROPHYSIOL, V118, P999, DOI 10.1016/j.clinph.2006.11.311; Glaros AG, 1998, J OROFAC PAIN, V12, P145; Iida T, 2014, EUR J ORAL SCI, V122, P42, DOI 10.1111/eos.12101; Takahashi M, 2006, EXP BRAIN RES, V171, P272, DOI 10.1007/s00221-006-0430-x; Lavigne GJ, 2003, CRIT REV ORAL BIOL M, V14, P30; LAVIGNE G, 1987, J NEUROPHYSIOL, V58, P342; MURRAY GM, 1991, J NEUROPHYSIOL, V65, P511; SJOHOLM T, 1995, J SLEEP RES, V4, P48; Iida T, 2013, ARCH ORAL BIOL, V58, P331, DOI 10.1016/j.archoralbio.2012.12.005; Shibukawa Y, 2004, J DENT RES, V83, P572; Lobbezoo F, 2013, J ORAL REHABIL, V40, P2, DOI 10.1111/joor.12011; Svensson P, 2001, ARCH ORAL BIOL, V46, P773, DOI 10.1016/S0003-9969(01)00028-0; Svensson P, 2003, EXP BRAIN RES, V152, P42, DOI 10.1007/s00221-003-1517-2; Svensson P, 2006, EXP BRAIN RES, V173, P165, DOI 10.1007/s00221-006-0380-3; Classen J, 1998, J NEUROPHYSIOL, V79, P1117; Yoshida K, 2000, J DENT RES, V79, P1514; Iida T, 2007, J ORAL REHABIL, V34, P487, DOI 10.1111/j.1365-2842.2007.01736.x; Boroojerdi B, 2000, CLIN NEUROPHYSIOL, V111, P988, DOI 10.1016/S1388-2457(00)00279-0; Dutta C, 1997, Muscle Nerve Suppl, V5, pS5; Dworkin Samuel F., 1992, Journal of Craniomandibular Disorders, V6, P301; LIN LD, 1993, J NEUROPHYSIOL, V70, P985; Murakami M., 2014, GERIATRICS GERONTOLO, V3; OKESON JP, 1990, J ORAL REHABIL, V17, P411, DOI 10.1111/j.1365-2842.1990.tb01412.x; van Selms M K A, 2004, J Oral Rehabil, V31, P738	29	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0003-9969	1879-1506		ARCH ORAL BIOL	Arch. Oral Biol.	NOV	2015	60	11					1625	1631		10.1016/j.archoralbio.2015.08.005		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CT8QC	WOS:000363080100004		
J	Nagahama, M; Seike, S; Shirai, H; Takagishi, T; Kobayashi, K; Takehara, M; Sakurai, J				Nagahama, Masahiro; Seike, Soshi; Shirai, Hidenori; Takagishi, Teruhisa; Kobayashi, Keiko; Takehara, Masaya; Sakurai, Jun			Role of P2X(7) receptor in Clostridium perfringens beta-toxin-mediated cellular injury	BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS			English	Article						C. perfringens beta-toxin; P2X(7) receptor; Pore-forming toxin; Oligomer formation	INDUCED PLASMA EXTRAVASATION; STAPHYLOCOCCUS-AUREUS; ENDOTHELIAL-CELLS; ALPHA-HEMOLYSIN; NUCLEOTIDE RECEPTORS; ACTIVATION; SECRETION; MONOCYTES; INVOLVEMENT; MECHANISMS	Background: Clostridium perfringens beta-toxin is a pore-forming toxin (PFT) and an important agent of necrotic enteritis and enterotoxemia. We recently reported that beta-toxin strongly induced cell death in THP-1 cells via the formation of oligomers. We here describe that the P2X(7) receptor, which is an ATP receptor, interacts with beta-toxin. Methods: We tested the role of P2X(7) receptor in beta-toxin-induced toxicity using specific inhibitors, knockdown of receptor, expression of the receptor and interaction by dot-blot assay. The potency of P2X(7) receptor was further determined using an in vivo mouse model. Results: Selective P2X(7) receptor antagonists (oxidized ATP (o-ATP), oxidized ADP, and Brilliant Blue G (BBG)) inhibited beta-toxin-induced cytotoxicity in THP-1 cells. o-ATP also blocked the binding of beta-toxin to cells. The P2X(7) receptor and beta-toxin oligomer were localized in the lipid rafts of THP-1 cells. siRNA for the P2X(7) receptor inhibited toxin-induced cytotoxicity and binding of the toxin. In contrast, the siRNA knockdown of P2Y(2) or P2Y(6) had no effect on beta-toxin-induced cytotoxicity. The addition of beta-toxin to P2X(7)-transfected HEK-293 cells resulted in binding of beta-toxin oligomer. Moreover, beta-toxin specifically bound to immobilized P2X(7) receptors in vitro and colocalized with the P2X(7) receptor on the THP-1 cell surface. Furthermore, beta-toxininduced lethality in mice was blocked by the preadministration of BEG. Conclusions: The results of this study indicate that the P2X(7) receptor plays a role in beta-toxin-mediated cellular injury. General significance: P2X(7) receptor is a potential target for the treatment of C. peifringens type C infection. (C) 2015 Elsevier B.V. All rights reserved.	[Nagahama, Masahiro; Seike, Soshi; Shirai, Hidenori; Takagishi, Teruhisa; Kobayashi, Keiko; Takehara, Masaya; Sakurai, Jun] Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Yamashiro, Tokushima 7708514, Japan	Nagahama, M (reprint author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Yamashiro, Tokushima 7708514, Japan.	nagahama@ph.bunri-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [25460552]	We thank M. Yonezaki and M. Shibutani for their technical assistance. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, 2015 (25460552).	Nagahama M, 2015, TOXINS, V7, P396, DOI 10.3390/toxins7020396; Gudipaty L, 2003, AM J PHYSIOL-CELL PH, V285, pC286, DOI 10.1152/ajpcell.00070.2003; Popescu F, 2011, VET MICROBIOL, V153, P173, DOI 10.1016/j.vetmic.2011.02.017; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Ben Yebdri F, 2009, EUR J IMMUNOL, V39, P2885, DOI 10.1002/eji.200939347; Munksgaard PS, 2012, CELL MICROBIOL, V14, P1904, DOI 10.1111/cmi.12021; Sakurai J, 2006, TOXIN REV, V25, P89, DOI 10.1080/15569540500320979; SAKURAI J, 1981, MICROBIOL IMMUNOL, V25, P423; Reiss K, 2012, MED MICROBIOL IMMUN, V201, P419, DOI 10.1007/s00430-012-0260-3; Nagahama M, 2008, BRIT J PHARMACOL, V153, P1296, DOI 10.1038/bjp.2008.9; Shatursky O, 2000, INFECT IMMUN, V68, P5546, DOI 10.1128/IAI.68.10.5546-5551.2000; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Gurtner C, 2010, INFECT IMMUN, V78, P2966, DOI 10.1128/IAI.01284-09; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Nagahama M, 2012, INFECT IMMUN, V80, P3410, DOI 10.1128/IAI.00483-12; Roberts JA, 2012, CURR OPIN PHARMACOL, V12, P659, DOI 10.1016/j.coph.2012.09.011; HUNTER SEC, 1993, INFECT IMMUN, V61, P3958; Garcia-Marcos M, 2006, J LIPID RES, V47, P705, DOI 10.1194/jlr.M500408-JLR200; Inoshima I, 2011, NAT MED, V17, P1310, DOI 10.1038/nm.2451; Wilke GA, 2010, P NATL ACAD SCI USA, V107, P13473, DOI 10.1073/pnas.1001815107; Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Nagahama M, 1999, BBA-MOL BASIS DIS, V1454, P97, DOI 10.1016/S0925-4439(99)00026-5; Morelli A, 2003, MOL BIOL CELL, V14, P2655, DOI 10.1091/mbc.02-04-0061; Songer JG, 1996, CLIN MICROBIOL REV, V9, P216; Miclard J, 2009, VET MICROBIOL, V137, P320, DOI 10.1016/j.vetmic.2009.01.025; Erb L, 2006, PFLUG ARCH EUR J PHY, V452, P552, DOI 10.1007/s00424-006-0069-2; Vidal JE, 2008, INFECT IMMUN, V76, P4396, DOI 10.1128/IAI.00547-08; Nagahama M, 2003, BRIT J PHARMACOL, V138, P23, DOI 10.1038/sj.bjp.0705022; Sayeed S, 2008, MOL MICROBIOL, V67, P15, DOI 10.1111/j.1365-2958.2007.06007.x; Tweten RK, 2001, VET MICROBIOL, V82, P1, DOI 10.1016/S0378-1135(01)00372-8; Nagahama M, 2003, J BIOL CHEM, V278, P36934, DOI 10.1074/jbc.M306562200; Uzal FA, 2011, VET MICROBIOL, V153, P37, DOI 10.1016/j.vetmic.2011.02.048; Skals M, 2011, PFLUG ARCH EUR J PHY, V462, P669, DOI 10.1007/s00424-011-1010-x; Miclard J, 2009, J MED MICROBIOL, V58, P826, DOI 10.1099/jmm.0.008060-0; Nagahama M, 2013, INFECT IMMUN, V81, P3703, DOI 10.1128/IAI.00579-13; Barth K, 2007, FEBS J, V274, P3021, DOI 10.1111/j.1742-4658.2007.05830.x; SAKURAI J, 1987, TOXICON, V25, P1301, DOI 10.1016/0041-0101(87)90008-0; Dubyak GR, 2012, CELL MICROBIOL, V14, P1697, DOI 10.1111/cmi.12001; Fagerberg SK, 2013, TOXINS, V5, P472, DOI 10.3390/toxins5030472; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189; Miller CM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002212; Skalsa M, 2009, P NATL ACAD SCI USA, V106, P4030, DOI 10.1073/pnas.0807044106	42	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-4165	1872-8006		BBA-GEN SUBJECTS	Biochim. Biophys. Acta-Gen. Subj.	NOV	2015	1850	11					2159	2167		10.1016/j.bbagen.2015.08.011		9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CT6JJ	WOS:000362919000001		
J	Matlashov, ME; Bogdanova, YA; Ermakova, GV; Mishina, NM; Ermakova, YG; Nikitin, ES; Balaban, PM; Okabe, S; Lukyanov, S; Enikolopov, G; Zaraisky, AG; Belousov, VV				Matlashov, Mikhail E.; Bogdanova, Yulia A.; Ermakova, Galina V.; Mishina, Natalia M.; Ermakova, Yulia G.; Nikitin, Evgeny S.; Balaban, Pavel M.; Okabe, Shigeo; Lukyanov, Sergey; Enikolopov, Grigori; Zaraisky, Andrey G.; Belousov, Vsevolod V.			Fluorescent ratiometric pH indicator SypHer2: Applications in neuroscience and regenerative biology	BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS			English	Article						pH; Genetically encoded sensors; SypHer2; Neurons; Synapse; Regeneration; Imaging	TADPOLE TAIL REGENERATION; INTRACELLULAR PH; HIPPOCAMPAL-NEURONS; HYDROGEN-PEROXIDE; PROTEIN VARIANTS; IN-VIVO; ACIDIFICATION; SENSORS; XENOPUS; CELLS	Background: SypHer is a genetically encoded fluorescent pH-indicator with a ratiometric readout, suitable for measuring fast intracellular pH shifts. However, the relatively low brightness of the indicator limits its use. Methods: Here we designed a new version of pH-sensor called SypHer-2, which has up to three times brighter fluorescence in cultured mammalian cells compared to the SypHer. Results: Using the new indicator we registered activity-associated pH oscillations in neuronal cell culture. We observed prominent transient neuronal cytoplasm acidification that occurs in parallel with calcium entry. Furthermore, we monitored pH in presynaptic and postsynaptic termini by targeting SypHer-2 directly to these compartments and revealed marked differences in pH dynamics between synaptic boutons and dendritic spines. Finally, we were able to reveal for the first time the intracellular pH drop that occurs within an extended region of the amputated tail of the Xenopus laevis tadpole before it begins to regenerate. Conclusions: SypHer2 is suitable for quantitative monitoring of pH in biological systems of different scales, from small cellular subcompartments to animal tissues in vivo. General significance: The new pH-sensor will help to investigate pH-dependent processes in both in vitro and in vivo studies. (C) 2015 Elsevier B.V. All rights reserved.	[Matlashov, Mikhail E.; Bogdanova, Yulia A.; Ermakova, Galina V.; Mishina, Natalia M.; Ermakova, Yulia G.; Lukyanov, Sergey; Zaraisky, Andrey G.; Belousov, Vsevolod V.] Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; [Matlashov, Mikhail E.; Mishina, Natalia M.; Lukyanov, Sergey; Belousov, Vsevolod V.] Nizhny Novgorod State Med Acad, Nizhnii Novgorod 603005, Russia; [Bogdanova, Yulia A.] Moscow MV Lomonosov State Univ, Fac Biol, Moscow 119991, Russia; [Nikitin, Evgeny S.; Balaban, Pavel M.] Inst Higher Nervous Act & Neurophysiol, Moscow 117485, Russia; [Okabe, Shigeo] Univ Tokyo, Grad Sch Med, Dept Cellular Neurobiol, Tokyo 1130033, Japan; [Enikolopov, Grigori] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Enikolopov, Grigori] Stony Brook Sch Med, Dept Anesthesiol, Stony Brook, NY 11794 USA; [Enikolopov, Grigori] SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; [Enikolopov, Grigori] Moscow Inst Phys & Technol, NBIC, Moscow 123182, Russia	Enikolopov, G (reprint author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	enik@cshl.edu; azaraisky@yahoo.com; vsevolod.belousov@gmail.com			Russian Foundation for basic research [13-04-40333-H, 13-04-40332-H, 13-04-01516-A, 13-04-40194-H, 13-04-00352]; Molecular and Cell Biology Program of Russian Academy of Sciences; CREST, JST, JAPAN [26250014]; National Institute of Aging [R01AG040209]; NYSTEM; Russian Science Foundation [14-14-00557]; Russian Ministry of Education and Science [11.G34.31.0071]	This work was supported by the Russian Foundation for basic research (13-04-40333-H to V.V.B., 13-04-40332-H to P.M.B., 13-04-01516-A and 13-04-40194-H to A.G.Z., 13-04-00352 to E.S.N.); Molecular and Cell Biology Program of Russian Academy of Sciences (V.V.B. & E.S.N.); CREST, JST and Grants-in-Aid for Scientific Research (26250014), JAPAN to S.O.; National Institute of Aging (R01AG040209 to G.E.); NYSTEM (to G.E.); Russian Science Foundation (14-14-00557 to A.G.Z., experiments with time-lapse SypHer2 ratio measurements using M205 stereomicroscope), and the Russian Ministry of Education and Science (11.G34.31.0071) to G.E. This work was carried out using the equipment provided by IBCH core facility (CKP IBCH).	Adams DS, 2013, BIOL OPEN, V2, P306, DOI 10.1242/bio.20133665; TSIEN RY, 1982, NATURE, V295, P68, DOI 10.1038/295068a0; Bilan DS, 2013, ACS CHEM BIOL, V8, P535, DOI 10.1021/cb300625g; Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119; Tseng AS, 2012, ANAT REC, V295, P1541, DOI 10.1002/ar.22495; Rangaraju V, 2014, CELL, V156, P825, DOI 10.1016/j.cell.2013.12.042; Rose CR, 1997, J PHYSIOL-LONDON, V499, P573; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Lee KFH, 2012, NEURAL PLAST, DOI 10.1155/2012/704103; Li YL, 2012, NAT NEUROSCI, V15, P1047, DOI 10.1038/nn.3126; Okabe S, 2001, J NEUROSCI, V21, P6105; Nehrke Keith, 2006, V351, P223; Willoughby D, 2002, J PHYSIOL-LONDON, V544, P487, DOI 10.1113/jphysiol.2002.027508; Wu ML, 1999, AM J PHYSIOL-CELL PH, V277, pC717; Bizzarri R, 2006, BIOPHYS J, V90, P3300, DOI 10.1529/biophysj.105.074708; Bizzarri R, 2009, ANAL BIOANAL CHEM, V393, P1107, DOI 10.1007/s00216-008-2515-9; Beck CW, 2003, DEV CELL, V5, P429, DOI 10.1016/S1534-5807(03)00233-8; Schwiening CJ, 2002, J PHYSIOL-LONDON, V538, P371, DOI 10.1013/jphysiol.2001.013055; Han JY, 2010, CHEM REV, V110, P2709, DOI 10.1021/cr900249z; Uzman JA, 1998, DEV BIOL, V193, P10, DOI 10.1006/dbio.1997.8782; Bencina M, 2013, SENSORS-BASEL, V13, P16736, DOI 10.3390/s131216736; Zhao YX, 2011, SCIENCE, V333, P1888, DOI 10.1126/science.1208592; Trapp S, 1996, J PHYSIOL-LONDON, V496, P695; Poburko D, 2011, J BIOL CHEM, V286, P11672, DOI 10.1074/jbc.M110.159962; Xiong ZQ, 2000, J NEUROSCI, V20, P1290; Adams DS, 2007, DEVELOPMENT, V134, P1323, DOI 10.1242/dev.02812; Zhan RZ, 1998, BRAIN RES, V780, P86, DOI 10.1016/S0006-8993(97)01149-9; Tantama M, 2011, J AM CHEM SOC, V133, P10034, DOI 10.1021/ja202902d; Okabe S, 2001, J NEUROSCI, V21, P9561; Markvicheva KN, 2011, BIOORGAN MED CHEM, V19, P1079, DOI 10.1016/j.bmc.2010.07.014; Tseng AS, 2008, J DENT RES, V87, P806; Tombaugh GC, 1997, J NEUROPHYSIOL, V77, P639; Cruciat CM, 2010, SCIENCE, V327, P459, DOI 10.1126/science.1179802; Hoyt KR, 1998, MOL PHARMACOL, V53, P742; Chen YH, 1998, J NEUROSCI, V18, P2982; Hanson GT, 2002, BIOCHEMISTRY-US, V41, P15477, DOI 10.1021/bi026609p; Harris JJ, 2012, NEURON, V75, P762, DOI 10.1016/j.neuron.2012.08.019; Chiappalone M, 2006, BRAIN RES, V1093, P41, DOI 10.1016/j.brainres.2006.03.049; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; HARRIS KM, 1989, J NEUROSCI, V9, P2982; Ebihara T, 2003, J NEUROSCI, V23, P2170; Svichar N, 2011, J NEUROSCI, V31, P6997, DOI 10.1523/JNEUROSCI.6088-10.2011; Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; Love NR, 2013, NAT CELL BIOL, V15, P222, DOI 10.1038/ncb2659; PASTERNACK M, 1992, NEUROSCIENCE, V47, P921, DOI 10.1016/0306-4522(92)90040-9; Belousov VV, 2006, NAT METHODS, V3, P281, DOI 10.1038/NMETH866; Ermakova GV, 2007, DEV BIOL, V307, P483, DOI 10.1016/j.ydbio.2007.03.524; Blakely RD, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005595; BUCKLER KJ, 1990, PFLUG ARCH EUR J PHY, V417, P234, DOI 10.1007/BF00370705; Mahon M. J., 2011, ADV BIOSCI BIOTECHNO, V2, P132, DOI DOI 10.4236/ABB.2011.23021; M.D. Corporation, 2006, AX CNS GUID EL BIOPH; Mukhtarov M, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00009; Raimondo JV, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00068; Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199; Seibenhener M.L., 2012, JOVE-J VIS EXP, V65, P3634	55	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-4165	1872-8006		BBA-GEN SUBJECTS	Biochim. Biophys. Acta-Gen. Subj.	NOV	2015	1850	11					2318	2328		10.1016/j.bbagen.2015.08.002		11	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CT6JJ	WOS:000362919000019		
J	Endo, T				Endo, Takeshi			Molecular mechanisms of skeletal muscle development, regeneration, and osteogenic conversion	BONE			English	Article						Muscle development; Muscle progenitor cells; Muscle regeneration; Satellite cells; Osteogenic conversion; Mesenchymal progenitor cells	FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; SATELLITE CELLS CONTRIBUTE; FOXO TRANSCRIPTION FACTORS; HEPATOCYTE GROWTH-FACTOR; DORSAL NEURAL-TUBE; STEM-CELLS; PROGENITOR CELLS; MOUSE EMBRYO; PARAXIAL MESODERM; PRECURSOR CELLS	Both skeletal muscle and bone are of mesodermal origin and derived from somites during embryonic development. Somites differentiate into the dorsal dermomyotome and the ventral sclerotome, which give rise to skeletal muscle and bone, respectively. Extracellular signaling molecules, such as Wnt and Shh, secreted from the surrounding environment, determine the developmental fate of skeletal muscle. Dermomyotome cells are specified as trunk muscle progenitor cells by transcription factor networks involving Pax3. These progenitor cells delaminate and migrate to form the myotome, where they are determined as myoblasts that differentiate into myotubes or myofibers. The MyoD family of transcription factors plays pivotal roles in myogenic determination and differentiation. Adult skeletal muscle regenerates upon exercise, muscle injury, or degeneration. Satellite cells are muscle-resident stem cells and play essential roles in muscle growth and regeneration. Muscle regeneration recapitulates the process of muscle development in many aspects. In certain muscle diseases, ectopic calcification or heterotopic ossification, as well as fibrosis and adipogenesis, occurs in skeletal muscle. Muscle-resident mesenchymal progenitor cells, which may be derived from vascular endothelial cells, are responsible for the ectopic osteogenesis, fibrogenesis, and adipogenesis. The small GTPase M-Ras is likely to participate in the ectopic calcification and ossification, as well as in osteogenesis during development. This article is part of a Special Issue entitled "Muscle Bone Interactions". (C) 2015 Elsevier Inc. All rights reserved.	Chiba Univ, Grad Sch Sci, Dept Biol, Inage Ku, Chiba, Chiba 2638522, Japan	Endo, T (reprint author), Chiba Univ, Grad Sch Sci, Dept Biol, Inage Ku, Yayoicho, Chiba, Chiba 2638522, Japan.	t.endo@faculty.chiba-u.jp			Ministry of Education, Culture, Sports, Science, and Technology [18057005, 20013007, 20054004, 23117506, 25117706]; Japan Society for the Promotion of Science [23300144]; Intramural Research Grant for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry (NCNP) [23-5, 26-8]	I thank the collaborators and the members of my laboratory who participated in our works cited in this article. These works were supported by Grants-in-Aid for Scientific Research on Priority Areas (18057005, 20013007, and 20054004) and for Scientific Research on Innovative Areas (23117506 and 25117706) from the Ministry of Education, Culture, Sports, Science, and Technology; Grants-in-Aid for Scientific Research (B) (23300144) from Japan Society for the Promotion of Science; and by Intramural Research Grant (23-5 and 26-8) for Neurological and Psychiatric Disorders of National Center of Neurology and Psychiatry (NCNP).	Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006; Kikkawa N, 2009, CELL STRUCT FUNCT, V34, P77; Medici D, 2010, NAT MED, V16, P1400, DOI 10.1038/nm.2252; Uezumi A, 2010, NAT CELL BIOL, V12, P143, DOI 10.1038/ncb2014; Seale P, 2008, NATURE, V454, P961, DOI 10.1038/nature07182; Wosczyna MN, 2012, J BONE MINER RES, V27, P1004, DOI 10.1002/jbmr.1562; Ben-Yair R, 2005, DEVELOPMENT, V132, P689, DOI 10.1242/dev.01617; von Maltzahn J, 2013, P NATL ACAD SCI USA, V110, P16474, DOI 10.1073/pnas.1307680110; Hu P, 2008, DEV CELL, V15, P534, DOI 10.1016/j.devcel.2008.08.018; Lepper C, 2009, NATURE, V460, P627, DOI 10.1038/nature08209; Brzoska E, 2012, BIOL CELL, V104, P722, DOI 10.1111/boc.201200022; Asakura A, 2001, DIFFERENTIATION, V68, P245, DOI 10.1046/j.1432-0436.2001.680412.x; Anderson C, 2012, GENE DEV, V26, P2103, DOI 10.1101/gad.187807.112; Schienda J, 2006, P NATL ACAD SCI USA, V103, P945, DOI 10.1073/pnas.0510164103; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Egerman MA, 2014, CRIT REV BIOCHEM MOL, V49, P59, DOI 10.3109/10409238.2013.857291; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; Gros J, 2004, DEV CELL, V6, P875, DOI 10.1016/j.devcel.2004.05.006; Moncaut N, 2013, FEBS J, V280, P3980, DOI 10.1111/febs.12379; Christ B, 2007, DEV DYNAM, V236, P2382, DOI 10.1002/dvdy.21189; Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007; Shanahan CM, 2011, CIRC RES, V109, P697, DOI 10.1161/CIRCRESAHA.110.234914; Nitzan E, 2013, DEV GROWTH DIFFER, V55, P60, DOI 10.1111/dgd.12004; Zhao P, 2004, DEV DYNAM, V229, P380, DOI 10.1002/dvdy.10457; Myer A, 2001, DEV BIOL, V229, P340, DOI 10.1006/dbio.2000.9985; Crist CG, 2012, CELL STEM CELL, V11, P118, DOI 10.1016/j.stem.2012.03.011; Halevy O, 2004, DEV DYNAM, V231, P489, DOI 10.1002/dvdy.20151; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Schafer K, 1999, NAT GENET, V23, P213; Millay DP, 2013, NATURE, V499, P301, DOI 10.1038/nature12343; STERN HM, 1995, DEVELOPMENT, V121, P3675; Niswander L, 2003, NAT REV GENET, V4, P133, DOI 10.1038/nrg1001; Heredia JE, 2013, CELL, V153, P376, DOI 10.1016/j.cell.2013.02.053; Havis E, 2012, DEVELOPMENT, V139, P1910, DOI 10.1242/dev.072561; Scaal M, 1999, DEVELOPMENT, V126, P4885; Shea KL, 2010, CELL STEM CELL, V6, P117, DOI 10.1016/j.stem.2009.12.015; Oustanina S, 2004, EMBO J, V23, P3430, DOI 10.1038/sj.emboj.7600346; Zeller R, 2009, NAT REV GENET, V10, P845, DOI 10.1038/nrg2681; Olguin HC, 2007, J CELL BIOL, V177, P769, DOI 10.1083/jcb.200608122; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Medici D, 2011, BIOCHEM J, V437, P515, DOI 10.1042/BJ20101500; Smith BF, 2011, LAB INVEST, V91, P216, DOI 10.1038/labinvest.2010.146; Fan CM, 1997, DEV BIOL, V191, P160, DOI 10.1006/dbio.1997.8713; Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Starkey JD, 2011, J HISTOCHEM CYTOCHEM, V59, P33, DOI 10.1369/jhc.2010.956995; Wang JQ, 2011, DEV CELL, V21, P575, DOI 10.1016/j.devcel.2011.07.003; Wallace GQ, 2009, ANNU REV PHYSIOL, V71, P37, DOI 10.1146/annurev.physiol.010908.163216; Li ZZ, 2012, DEV CELL, V23, P1176, DOI 10.1016/j.devcel.2012.10.019; Tatsumi R, 1998, DEV BIOL, V194, P114, DOI 10.1006/dbio.1997.8803; Berkes CA, 2005, SEMIN CELL DEV BIOL, V16, P585, DOI 10.1016/j.semcdb.2005.07.006; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Bajard L, 2006, GENE DEV, V20, P2450, DOI 10.1101/gad.382806; Judson RN, 2013, FEBS J, V280, P4100, DOI 10.1111/febs.12370; Kastner S, 2000, J HISTOCHEM CYTOCHEM, V48, P1079; Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004; Lagha M, 2008, GENE DEV, V22, P1828, DOI 10.1101/gad.477908; Linker C, 2005, DEVELOPMENT, V132, P3895, DOI 10.1242/dev.01961; Bendall AJ, 1999, DEVELOPMENT, V126, P4965; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Joe AWB, 2010, NAT CELL BIOL, V12, P153, DOI 10.1038/ncb2015; Gros J, 2009, NATURE, V457, P589, DOI 10.1038/nature07564; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Takano K, 2010, SCIENCE, V330, P1536, DOI 10.1126/science.1197767; Kumar D, 2009, MOL BIOL CELL, V20, P3170, DOI 10.1091/mbc.E08-12-1185; Daubas P, 2013, DEV BIOL, V376, P236, DOI 10.1016/j.ydbio.2013.01.028; Watanabe-Takano H, 2010, EXP CELL RES, V316, P477, DOI 10.1016/j.yexcr.2009.09.028; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Zammit PS, 2002, EXP CELL RES, V281, P39, DOI 10.1006/excr.2002.5653; Riuzzi F, 2012, J CELL SCI, V125, P1440, DOI 10.1242/jcs.092163; Mourkioti F, 2005, TRENDS IMMUNOL, V26, P535, DOI 10.1016/j.it.2005.08.002; Marics I, 2002, DEVELOPMENT, V129, P4559; Van Ho AT, 2011, DEV CELL, V21, P273, DOI 10.1016/j.devcel.2011.06.019; Furumoto T, 1999, DEV BIOL, V210, P15, DOI 10.1006/dbio.1999.9261; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Ben-Yair R, 2008, J CELL BIOL, V180, P607, DOI [10.1083/jcb.200707206, 10.1083/icb.200707206]; Mankoo BS, 1999, NATURE, V400, P69; Kahane N, 2002, DEVELOPMENT, V129, P2675; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Lounev VY, 2009, J BONE JOINT SURG AM, V91A, P652, DOI 10.2106/JBJS.H.01177; Marcelle C, 1997, DEVELOPMENT, V124, P3955; Giordani J, 2007, P NATL ACAD SCI USA, V104, P11310, DOI 10.1073/pnas.0611299104; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; Relaix F, 2012, DEVELOPMENT, V139, P2845, DOI 10.1242/dev.069088; Tatsumi R, 2002, MOL BIOL CELL, V13, P2909, DOI 10.1091/mbc.E02-01-0062; Grifone R, 2005, DEVELOPMENT, V132, P2235, DOI 10.1242/dev.01773; Kalcheim C, 2005, CURR OPIN GENET DEV, V15, P371, DOI 10.1016/j.gde.2005.05.004; Yin H, 2013, CELL METAB, V17, P210, DOI 10.1016/j.cmet.2013.01.004; McKinnell IW, 2008, NAT CELL BIOL, V10, P77, DOI 10.1038/ncb1671; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; Buckingham M, 2007, ANNU REV CELL DEV BI, V23, P645, DOI 10.1146/annurev.cellbio.23.090506.123438; Uezumi A, 2011, J CELL SCI, V124, P3654, DOI 10.1242/jcs.086629; Lepper C, 2010, GENESIS, V48, P424, DOI 10.1002/dvg.20630; Watanabe-Takano H, 2014, P NATL ACAD SCI USA, V111, pE2291, DOI 10.1073/pnas.1321574111; Yokoyama T, 2007, J CELL BIOL, V177, P781, DOI 10.1083/jcb.200703195; Kaplan FS, 2012, DIS MODEL MECH, V5, P756, DOI 10.1242/dmm.010280; Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044; Serrano AL, 2008, CELL METAB, V7, P33, DOI 10.1016/j.cmet.2007.11.011; L'Honore A, 2007, DEV BIOL, V307, P421, DOI 10.1016/j.ydbio.2007.04.034; Buckingham M, 2006, CURR OPIN GENET DEV, V16, P525, DOI 10.1016/j.gde.2006.08.008; Sambasivan R, 2011, DEVELOPMENT, V138, P2401, DOI 10.1242/dev.040972; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; Birchmeier C, 2000, CURR OPIN CELL BIOL, V12, P725, DOI 10.1016/S0955-0674(00)00159-9; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Kuang S, 2006, J CELL BIOL, V172, P103, DOI 10.1083/jcb.200508001; Hutcheson DA, 2009, GENE DEV, V23, P997, DOI 10.1101/gad.1769009; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Le Grand F, 2009, CELL STEM CELL, V4, P535, DOI 10.1016/j.stem.2009.03.013; Armand AS, 2006, BBA-MOL CELL RES, V1763, P773, DOI 10.1016/j.bbamcr.2006.06.005; Lagha M, 2009, DEV CELL, V17, P892, DOI 10.1016/j.devcel.2009.10.021; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Borello U, 2006, DEVELOPMENT, V133, P3723, DOI 10.1242/dev.02517; Gunther S, 2013, CELL STEM CELL, V13, P590, DOI 10.1016/j.stem.2013.07.016; Vasyutina E, 2005, GENE DEV, V19, P2187, DOI 10.1101/gad.346205; Elsherif L, 2008, CIRC RES, V102, P1109, DOI 10.1161/CIRCRESAHA.108.173153; Shefer G, 2004, J CELL SCI, V117, P5393, DOI 10.1242/jcs.01419; Kablar B, 2003, DEV BIOL, V258, P307, DOI 10.1016/S0012-1606(03)00139-8; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; Gautel M, 2011, CURR OPIN CELL BIOL, V23, P39, DOI 10.1016/j.ceb.2010.12.001; Bischoff R, 1997, DEV DYNAM, V208, P505, DOI 10.1002/(SICI)1097-0177(199704)208:4<505::AID-AJA6>3.0.CO;2-M; Sparrow JC, 2009, NAT REV MOL CELL BIO, V10, P293, DOI 10.1038/nrm2634; Soleimani VD, 2012, DEV CELL, V22, P1208, DOI 10.1016/j.devcel.2012.03.014; Yin H, 2013, PHYSIOL REV, V93, P23, DOI 10.1152/physrev.00043.2011; Gros J, 2005, NATURE, V435, P954, DOI 10.1038/nature03572; Grifone R, 2007, DEV BIOL, V302, P602, DOI 10.1016/j.ydbio.2006.08.059; Wada MR, 2002, DEVELOPMENT, V129, P2987; Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783; L'Honore A, 2010, DEVELOPMENT, V137, P3847, DOI 10.1242/dev.053421; Buckingham M, 2014, DEV CELL, V28, P225, DOI 10.1016/j.devcel.2013.12.020; Bentzinger CF, 2014, J CELL BIOL, V205, P97, DOI 10.1083/jcb.201310035; Esner M, 2006, DEVELOPMENT, V133, P737, DOI 10.1242/dev.02226; Rios AC, 2011, NATURE, V473, P532, DOI 10.1038/nature09970; Endo T, 2007, REGEN MED, V2, P243, DOI 10.2217/17460751.2.3.243; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Kawamura K, 2004, J BIOL CHEM, V279, P54862, DOI 10.1074/jbc.M408057200; Atit R, 2006, DEV BIOL, V296, P164, DOI 10.1016/j.ydbio.2006.04.449; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Borycki AG, 1999, DEVELOPMENT, V126, P4053; Houzelstein D, 1999, DEVELOPMENT, V126, P2689; Borycki AG, 2000, CURR TOP DEV BIOL, V48, P165; Brunelli S, 2007, DEV BIOL, V304, P604; Bryson-Richardson RJ, 2008, NAT REV GENET, V9, P632, DOI 10.1038/nrg2369; Cooper RN, 1999, J CELL SCI, V112, P2895; Cornelison DD, 1970, DEV BIOL, V191, P270; Crawford Garland L., 2011, Biophysical Reviews, V3, DOI 10.1007/s12551-011-0043-x; da Silva ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932; Geetha-Loganathan P, 2005, DEV BIOL, V288, P221, DOI 10.1016/j.ydbio.2005.09.035; Hindi SM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003832; Lagha M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-696; Mann CJ, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-21; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Oishi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056641; Ratajczak MZ, 2003, STEM CELLS, V21, P363, DOI 10.1634/stemcells.21-3-363; Relaix F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003425; Sato T, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000897; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; Von Maltzahn J, 2011, NAT CELL BIOL, V14, P186; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; Winnier GE, 1997, GENE DEV, V11, P926, DOI 10.1101/gad.11.7.926	163	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	8756-3282	1873-2763		BONE	Bone	NOV	2015	80				SI		2	13		10.1016/j.bone.2015.02.028		12	Endocrinology & Metabolism	Endocrinology & Metabolism	CT6NF	WOS:000362929000002		
J	Hong, GS; Schwandt, T; Stein, K; Schneiker, B; Kummer, MP; Heneka, MT; Kitamura, K; Kalff, JC; Wehner, S				Hong, G. -S.; Schwandt, T.; Stein, K.; Schneiker, B.; Kummer, M. P.; Heneka, M. T.; Kitamura, K.; Kalff, J. C.; Wehner, S.			Effects of macrophage-dependent peroxisome proliferator-activated receptor signalling on adhesion formation after abdominal surgery in an experimental model	BRITISH JOURNAL OF SURGERY			English	Article							ALTERNATIVE ACTIVATION; PERITONEAL ADHESIONS; PELVIC-SURGERY; NITRIC-OXIDE; ARGINASE 1; METABOLISM; CELLS; GAMMA; IMMUNITY; DISEASE	BackgroundThe pathophysiology of adhesion formation after abdominal and pelvic surgery is still largely unknown. The aim of the study was to investigate the role of macrophage polarization and the effect of peroxisome proliferator-activated receptor (PPAR) stimulation on adhesion formation in an animal model. MethodsPeritoneal adhesion formation was induced by the creation of ischaemic buttons within the peritoneal wall and the formation of a colonic anastomosis in wild-type, interleukin (IL) 10-deficient (IL-10(-/-)), IL-4-deficient (IL-4(-/-)) and CD11b-Cre/PPAR(fl/fl) mice. Adhesions were assessed at regular intervals, and cell preparations were isolated from ischaemic buttons and normal peritoneum. These samples were analysed for macrophage differentiation and its markers, and expression of cytokines by quantitative PCR, fluorescence microscopy, arginase activity and pathological examination. Some animals underwent pioglitazone (PPAR- agonist) or vehicle treatment to inhibit adhesion formation. Anastomotic healing was evaluated by bursting pressure measurement and collagen gene expression. ResultsMacrophage M2 marker expression and arginase activity were raised in buttons without adhesions compared with buttons with adhesions. IL-4(-/-) and IL-10(-/-) mice were not affected, whereas CD11b-Cre/PPAR(fl/fl) mice showed decreased arginase activity and increased adhesion formation. Perioperative pioglitazone treatment increased arginase activity and decreased adhesion formation in wild-type but not CD11b-Cre/PPAR(fl/fl) mice. Pioglitazone had no effect on anastomotic healing. ConclusionEndogenous macrophage-specific PPAR- signalling affected arginase activity and macrophage polarization, and counter-regulated peritoneal adhesion manifestation. Pharmacological PPAR- agonism induced a shift towards macrophage M2 polarization and ameliorated adhesion formation in a macrophage-dependent manner. Postoperative adhesion formation is frequently seen after abdominal surgery and occurs in response to peritoneal trauma. The pathogenesis is still unknown but includes an imbalance in fibrinolysis, collagen production and inflammatory mechanisms. Little is known about the role of macrophages during adhesion formation. In an experimental model, macrophage M2 marker expression was associated with reduced peritoneal adhesion formation and involved PPAR--mediated arginase activity. Macrophage-specific PPAR- deficiency resulted in reduced arginase activity and aggravated adhesion formation. Pioglitazone, a PPAR- agonist, induced M2 polarization and reduced postoperative adhesion formation without compromising anastomotic healing in mice. Pioglitazone ameliorated postoperative adhesion formation without compromising intestinal wound healing. Therefore, perioperative PPAR- agonism might be a promising strategy for prevention of adhesion formation after abdominal surgery. It's all about macrophages	[Hong, G. -S.; Schwandt, T.; Stein, K.; Schneiker, B.; Kitamura, K.; Kalff, J. C.; Wehner, S.] Univ Hosp Bonn, Dept Surg, Bonn, Germany; [Kummer, M. P.; Heneka, M. T.] Univ Hosp Bonn, Clin Neurosci Unit, Bonn, Germany; [Kitamura, K.] Kyoto Univ, Grad Sch Med, Kyoto, Japan; [Wehner, S.] Univ Amsterdam, Acad Med Ctr, Tytgat Inst Liver & Intestinal Res, NL-1105 AZ Amsterdam, Netherlands	Wehner, S (reprint author), Univ Bonn, Dept Surg, Sigmund Freud Str 25, D-53105 Bonn, Germany.	sven.wehner@ukb.uni-bonn.de			BONFOR [O-112.0053]; Else Kroner-Forschungskolleg Bonn [Q-605.0812]	This study was funded by BONFOR (O-112.0053) and the Else Kroner-Forschungskolleg Bonn (Q-605.0812).	STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Witte MB, 2003, J GASTROINTEST SURG, V7, P378, DOI 10.1016/S1091-255X(02)00431-6; Ohashi K, 2014, BRIT J SURG, V101, P398, DOI 10.1002/bjs.9405; Beck DE, 2003, DIS COLON RECTUM, V46, P1310, DOI 10.1097/01.DCR.0000089117.62296.E4; ten Broek RPG, 2014, LANCET, V383, P48, DOI 10.1016/S0140-6736(13)61687-6; Schaffer MR, 1997, J IMMUNOL, V158, P2375; Reed KL, 2002, J SURG RES, V108, P165, DOI 10.1006/jsre.2002.6533; Gallardo-Soler A, 2008, MOL ENDOCRINOL, V22, P1394, DOI 10.1210/me.2007-0525; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Pantelis D, 2011, INT J COLORECTAL DIS, V26, P737, DOI 10.1007/s00384-011-1171-2; Moran-Salvador E, 2013, J HEPATOL, V59, P1045, DOI 10.1016/j.jhep.2013.06.023; El Kasmi KC, 2008, NAT IMMUNOL, V9, P1399, DOI 10.1038/ni.1671; Schurmann C, 2010, BRIT J SURG, V97, P1437, DOI 10.1002/bjs.7123; Sikkink CJJM, 2006, J SURG RES, V136, P255, DOI 10.1016/j.jss.2006.06.021; Odegaard JI, 2007, NATURE, V447, P1116, DOI 10.1038/nature05894; Binnebosel M, 2008, WORLD J SURG, V32, P296, DOI 10.1007/s00268-007-9330-x; Greer N, 2013, ANN INTERN MED, V159, P532, DOI 10.7326/0003-4819-159-8-201310150-00006; Ellis H, 1999, LANCET, V353, P1476, DOI 10.1016/S0140-6736(98)09337-4; Nagy L, 2012, PHYSIOL REV, V92, P739, DOI 10.1152/physrev.00004.2011; Burnett SH, 2006, J SURG RES, V131, P296, DOI 10.1016/j.jss.2005.08.026; Xu X, 2002, ANN SURG, V236, P593, DOI 10.1097/01.SLA.0000033037.13104.C4; CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2; Freeman HC, 2006, DIABETES, V55, P2153, DOI 10.2337/db06-0358; Daley JM, 2010, J LEUKOCYTE BIOL, V87, P59, DOI 10.1189/jlb.0409236; Campbell L, 2013, J INVEST DERMATOL, V133, P2461, DOI 10.1038/jid.2013.164; Hellebrekers BWJ, 2011, BRIT J SURG, V98, P1503, DOI 10.1002/bjs.7657; diZeregal GS, 2001, HUM REPROD UPDATE, V7, P547, DOI 10.1093/humupd/7.6.547; Kavalukas Sandra L, 2012, Surgery, V151, P287, DOI 10.1016/j.surg.2011.07.012; Manuelpillai U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038631; Pesce JT, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000371; Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532; Sindrilaru A, 2013, ADV WOUND CARE NEW R, V2, P357, DOI DOI 10.1089/WOUND.2012.0407; ten Broek RPG, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5588; Zuhlke HV, 1990, LANGENBECKS ARCH CHI, V345, P1009	35	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1323	1365-2168		BRIT J SURG	Br. J. Surg.	NOV	2015	102	12					1506	1516		10.1002/bjs.9907		11	Surgery	Surgery	CT7JZ	WOS:000362992300009		
J	Okano, K; Hirao, T; Unno, M; Fujii, T; Yoshitomi, H; Suzuki, S; Satoi, S; Takahashi, S; Kainuma, O; Suzuki, Y				Okano, K.; Hirao, T.; Unno, M.; Fujii, T.; Yoshitomi, H.; Suzuki, S.; Satoi, S.; Takahashi, S.; Kainuma, O.; Suzuki, Y.			Postoperative infectious complications after pancreatic resection	BRITISH JOURNAL OF SURGERY			English	Article							PREOPERATIVE BILIARY DRAINAGE; PROSPECTIVE-RANDOMIZED-TRIAL; SURGICAL SITE INFECTION; CONSECUTIVE PANCREATICODUODENECTOMIES; SINGLE-INSTITUTION; HEAD RESECTION; RISK-FACTORS; OUTCOMES; SURGERY; MORBIDITY	BackgroundAlthough mortality associated with pancreatic surgery has decreased dramatically, high morbidity rates are still of major concern. This study aimed to identify the prevalence of, and risk factors for, infectious complications after pancreatic surgery. MethodsThe Japanese Society of Pancreatic Surgery conducted a multi-institutional analysis of complications in patients who underwent pancreaticoduodenectomy (PD) or distal pancreatectomy (DP) between January 2010 and December 2012. Risk factors that were significantly associated with infectious complications in univariable models were included in a multivariable logistic regression model, and a nomogram was created to predict the risk of infectious complications after pancreatectomy. ResultsInfectious complications occurred in 1459 (352 per cent) of 4147 patients in the PD group and 426 (252 per cent) of 1692 patients in the DP group (P<0001). Nine risk factors for infectious complications after PD were identified: male sex, age 70years or more, body mass index at least 25kg/m(2), other previous malignancy, liver disease, bile contamination, duration of surgery 7h or longer, intraoperative blood transfusion and soft pancreas. Five risk factors for infectious complications after DP were identified: chronic steroid use, smoking, duration of surgery 5h or more, intraoperative blood transfusion and non-laparoscopic surgery. Occurrence of a postoperative infectious complication was significantly associated with mortality and reoperation after PD (odds ratio (OR) 433, 95 per cent c.i. 201 to 992 and OR 326, 186 to 582, respectively) and DP (OR 632, 199 to 2255; OR 374, 161 to 904). ConclusionProlonged operating time, intraoperative blood transfusion, bile contamination (PD) and non-laparoscopic surgery (DP) are risk factors for postoperative infectious complications that could be targeted to improve outcome after pancreatectomy. Risk factors identified	[Okano, K.; Suzuki, Y.] Kagawa Univ, Fac Med, Dept Surg Gastroenterol, Miki, Kagawa 7610793, Japan; [Hirao, T.] Kagawa Univ, Fac Med, Dept Publ Hlth, Miki, Kagawa 7610793, Japan; [Unno, M.] Tohoku Univ, Dept Surg, Grad Sch Med, Sendai, Miyagi 980, Japan; [Fujii, T.] Nagoya Univ, Grad Sch Med, Dept Gastroenterol Surg Surg 2, Nagoya, Aichi 4648601, Japan; [Yoshitomi, H.] Chiba Univ, Dept Gen Surg, Grad Sch Med, Chiba, Japan; [Suzuki, S.] Tokyo Womens Med Univ, Dept Surg Gastroenterol, Tokyo, Japan; [Satoi, S.] Kansai Med Univ, Dept Surg, Hirakata, Osaka, Japan; [Takahashi, S.] Natl Canc Ctr Hosp East, Dept Hepatobiliary Pancreat Surg, Kashiwa, Chiba, Japan; [Kainuma, O.] Chiba Canc Ctr, Dept Surg Gastroenterol, Chiba 2608717, Japan	Okano, K (reprint author), Kagawa Univ, Fac Med, Dept Surg Gastroenterol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	kokano@med.kagawa-u.ac.jp					Winter JM, 2006, J GASTROINTEST SURG, V10, P1199, DOI 10.1016/j.gassur.2006.08.018; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Schmidt CM, 2004, ARCH SURG-CHICAGO, V139, P718, DOI 10.1001/archsurg.139.7.718; Pisters PWT, 2001, ANN SURG, V234, P47, DOI 10.1097/00000658-200107000-00008; Kent TS, 2013, SURGERY, V153, P86, DOI 10.1016/j.surg.2012.03.026; Su ZX, 2010, J HEPATO-BIL-PAN SCI, V17, P174, DOI 10.1007/s00534-009-0128-0; [Anonymous], 2012, US GUID 2012 PART US; KNIGHTON DR, 1984, ARCH SURG-CHICAGO, V119, P199; Bassi C, 2005, SURGERY, V138, P8, DOI 10.1016/j.surg.2005.05.001; Farnell MB, 2005, SURGERY, V138, P618, DOI 10.1016/j.surg.2005.06.044; House MG, 2008, J GASTROINTEST SURG, V12, P270, DOI 10.1007/s11605-007-0421-7; Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097/00000658-199709000-00004; Sugiura T, 2012, WORLD J SURG, V36, P2888, DOI 10.1007/s00268-012-1742-6; Cortes A, 2006, J AM COLL SURGEONS, V202, P93, DOI 10.1016/j.jamcollsurg.2005.09.006; Tani M, 2012, SURGERY, V151, P183, DOI 10.1016/j.surg.2011.07.023; Teh SH, 2009, ARCH SURG-CHICAGO, V144, P713, DOI 10.1001/archsurg.2009.67; Simons JP, 2009, J GASTROINTEST SURG, V13, P1798, DOI 10.1007/s11605-009-0936-1; Bassi C, 2010, ANN SURG, V252, P207, DOI 10.1097/SLA.0b013e3181e61e88; Kitahata Y, 2014, AM J SURG, V208, P1, DOI 10.1016/j.amjsurg.2013.10.021; Hodul P, 2003, AM J SURG, V186, P420, DOI 10.1016/j.amjsurg.2003.07.005; Kawahara R, 2013, J HEPATO-BIL-PAN SCI, V20, P173, DOI 10.1007/s00534-012-0505-y; Kawai M, 2006, ANN SURG, V244, P1, DOI 10.1097/01.sla.0000218077.14035.a6; Venkat R, 2011, ARCH SURG-CHICAGO, V146, P1277, DOI 10.1001/archsurg.2011.294; Assifi MM, 2012, J GASTROINTEST SURG, V16, P275, DOI 10.1007/s11605-011-1733-1; Sudo T, 2007, WORLD J SURG, V31, P2230, DOI 10.1007/s00268-007-9210-4; Kato H, 2013, J HEPATO-BIL-PAN SCI, V20, P601, DOI 10.1007/s00534-013-0595-1; Are C, 2009, J GASTROINTEST SURG, V13, P2152, DOI 10.1007/s11605-009-1051-z; KAISER AB, 1983, ANN SURG, V198, P525, DOI 10.1097/00000658-198310000-00012; Grobmyer SR, 2007, J AM COLL SURGEONS, V204, P356, DOI 10.1016/j.jamcollsurg.2006.11.017; Pessaux P, 2003, ARCH SURG-CHICAGO, V138, P314, DOI 10.1001/archsurg.138.3.314; Kelly KJ, 2011, J GASTROINTEST SURG, V15, P250, DOI 10.1007/s11605-010-1390-9; van der Gaag NA, 2010, NEW ENGL J MED, V362, P129, DOI 10.1056/NEJMoa0903230; COPPA GF, 1988, SURGERY, V104, P853; Vollmer CM, 2012, J GASTROINTEST SURG, V16, P89, DOI 10.1007/s11605-011-1753-x; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Vin Y, 2008, J AM COLL SURGEONS, V207, P490, DOI 10.1016/j.jamcollsurg.2008.05.003; Povoski SP, 1999, ANN SURG, V230, P131, DOI 10.1097/00000658-199908000-00001; Kimura W, 2014, ANN SURG, V259, P773, DOI 10.1097/SLA.0000000000000263; Cameron JL, 2006, ANN SURG, V244, P10, DOI 10.1097/01.sla.0000217673.04165.ea; BUCHLER MW, 1995, AM J SURG, V169, P65, DOI 10.1016/S0002-9610(99)80111-1; GARIBALDI RA, 1991, AM J MED, V91, pS158, DOI 10.1016/0002-9343(91)90362-2; Haridas M, 2008, SURGERY, V144, P496, DOI 10.1016/j.surg.2008.06.001; Yanagimoto H, 2014, J HEPATO-BIL-PAN SCI, V21, P473, DOI 10.1002/jhbp.59	43	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1323	1365-2168		BRIT J SURG	Br. J. Surg.	NOV	2015	102	12					1551	1560		10.1002/bjs.9919		10	Surgery	Surgery	CT7JZ	WOS:000362992300014		
J	Sugiura, T; Mizuno, T; Okamura, Y; Ito, T; Yamamoto, Y; Kawamura, I; Kurai, H; Uesaka, K				Sugiura, T.; Mizuno, T.; Okamura, Y.; Ito, T.; Yamamoto, Y.; Kawamura, I.; Kurai, H.; Uesaka, K.			Impact of bacterial contamination of the abdominal cavity during pancreaticoduodenectomy on surgical-site infection	BRITISH JOURNAL OF SURGERY			English	Article							PREOPERATIVE BILIARY DRAINAGE; PANCREATIC HEAD RESECTION; INTERNATIONAL STUDY-GROUP; PERITONEAL-LAVAGE; CONSECUTIVE PATIENTS; RISK-FACTORS; COMPLICATIONS; FISTULA; TRIAL; CHOLANGIOCARCINOMA	BackgroundSeveral risk factors for complications after pancreaticoduodenectomy have been reported. However, the impact of intraoperative bacterial contamination on surgical outcome after pancreaticoduodenectomy has not been examined in depth. MethodsThis retrospective study included patients who underwent pancreaticoduodenectomy and peritoneal lavage using 7000ml saline between July 2012 and May 2014. The lavage fluid was subjected to bacterial culture examination. The influence of a positive bacterial culture on surgical-site infection (SSI) and postoperative course was evaluated. Risk factors for positive bacterial cultures were also evaluated. ResultsForty-six (211 per cent) of 218 enrolled patients had a positive bacterial culture of the lavage fluid. Incisional SSI developed in 26 (57 per cent) of these 46 patients and in 13 (76 per cent) of 172 patients with a negative lavage culture (P<0001). Organ/space SSI developed in 32 patients with a positive lavage culture (70 per cent) and in 43 of those with a negative culture (250 per cent) (P<0001). Grade B/C pancreatic fistula was observed in 22 (48 per cent) and 48 (279 per cent) respectively of patients with positive and negative lavage cultures (P=0010). Postoperative hospital stay was longer in patients with a positive lavage culture (28days versus 21days in patients with a negative culture; P=0028). Multivariable analysis revealed that internal biliary drainage, combined colectomy and a longer duration of surgery were significant risk factors for positive bacterial culture of the lavage fluid. ConclusionIntraoperative bacterial contamination has an adverse impact on the development of SSI and grade B/C pancreatic fistula following pancreaticoduodenectomy. Contamination may affect outcome	[Sugiura, T.; Mizuno, T.; Okamura, Y.; Ito, T.; Yamamoto, Y.; Uesaka, K.] Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, Sunto Nagaizumi, Shizuoka 4118777, Japan; [Kawamura, I.; Kurai, H.] Shizuoka Canc Ctr, Div Infect Dis, Sunto Nagaizumi, Shizuoka 4118777, Japan	Sugiura, T (reprint author), Shizuoka Canc Ctr, Div Hepatobiliary Pancreat Surg, 1007 Shimo Nagakubo, Sunto Nagaizumi, Shizuoka 4118777, Japan.	t.sugiura@scchr.jp					Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; [Anonymous], 2001, ANN SURG, DOI DOI 10.1097/00000658-200110000-00008]; Kobayashi S, 2013, HEPATO-GASTROENTEROL, V60, P876, DOI 10.5754/hge11655; Schmidt CM, 2004, ARCH SURG-CHICAGO, V139, P718, DOI 10.1001/archsurg.139.7.718; Pisters PWT, 2001, ANN SURG, V234, P47, DOI 10.1097/00000658-200107000-00008; Bassi C, 2005, SURGERY, V138, P8, DOI 10.1016/j.surg.2005.05.001; AMBROSE NS, 1982, BRIT J SURG, V69, P143, DOI 10.1002/bjs.1800690308; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; Sugiura T, 2012, WORLD J SURG, V36, P2888, DOI 10.1007/s00268-012-1742-6; Wada K, 2006, SURGERY, V139, P735, DOI 10.1016/j.surg.2005.11.001; Adam U, 2004, AM J SURG, V187, P201, DOI 10.1016/j.amhsurg.2003.11.004; Sewnath ME, 2001, J AM COLL SURGEONS, V192, P726, DOI 10.1016/S1072-7515(01)00819-5; Jagannath P, 2005, BRIT J SURG, V92, P356, DOI 10.1002/bjs.4864; Yeo CJ, 2002, ANN SURG, V236, P355, DOI 10.1097/01.SLA.0000027272.08464.0B; Qadan M, 2010, BRIT J SURG, V97, P151, DOI 10.1002/bjs.6906; Poon RTP, 2007, ANN SURG, V246, P425, DOI 10.1097/SLA.0b013e3181492c28; Platell C, 2000, J AM COLL SURGEONS, V191, P672, DOI 10.1016/S1072-7515(00)00726-2; Kimura F, 2006, PANCREAS, V32, P178, DOI 10.1097/01.mpa.0000202959.63977.5c; Ruiz-Tovar J, 2012, J AM COLL SURGEONS, V214, P202, DOI 10.1016/j.jamcollsurg.2011.10.014; Kajiwara T, 2010, LANGENBECK ARCH SURG, V395, P707, DOI 10.1007/s00423-009-0547-z; MINERVINI S, 1980, DIS COLON RECTUM, V23, P392, DOI 10.1007/BF02586785; van der Gaag NA, 2010, NEW ENGL J MED, V362, P129, DOI 10.1056/NEJMoa0903230; Kazanjian KK, 2005, ARCH SURG-CHICAGO, V140, P849, DOI 10.1001/archsurg.140.9.849; Kawashima H, 2013, ANN SURG, V257, P121, DOI 10.1097/SLA.0b013e318262b2e9; Takahashi Y, 2010, BRIT J SURG, V97, P1860, DOI 10.1002/bjs.7228; SUGIMOTO K, 1994, J AM COLL SURGEONS, V179, P443; Povoski SP, 1999, ANN SURG, V230, P131, DOI 10.1097/00000658-199908000-00001; Wente MN, 2007, SURGERY, V142, P761, DOI 10.1016/j.surg.2007.05.005; Kimura W, 2014, ANN SURG, V259, P773, DOI 10.1097/SLA.0000000000000263; Centers for Disease Control, 2015, CDC NHSN SURV DEF SP; Sato N, 1998, ARCH SURG-CHICAGO, V133, P1094, DOI 10.1001/archsurg.133.10.1094	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1323	1365-2168		BRIT J SURG	Br. J. Surg.	NOV	2015	102	12					1561	1566		10.1002/bjs.9899		6	Surgery	Surgery	CT7JZ	WOS:000362992300015		
J	Huang, Y; Cheng, HL; Dai, ZL; Xu, Q; Liu, F; Sawada, K; Moriguchi, S; Yashima, A				Huang, Yu; Cheng, Hualin; Dai, Zili; Xu, Qiang; Liu, Fang; Sawada, Kazuhide; Moriguchi, Shuji; Yashima, Atsushi			SPH-based numerical simulation of catastrophic debris flows after the 2008 Wenchuan earthquake	BULLETIN OF ENGINEERING GEOLOGY AND THE ENVIRONMENT			English	Article						Wenchuan earthquake; Post-earthquake debris flow; Smoothed particle hydrodynamics; Long run-out; Hazard assessment	SMOOTHED PARTICLE HYDRODYNAMICS; 13 AUGUST 2010; FREE-SURFACE; CHINA; MODEL; MUDFLOW; SLIDES; FLUID; MUD	Post-earthquake debris flows that have occurred in Sichuan Province in southwestern China following the Wenchuan earthquake on May 12, 2008, have caused significant damage and casualties. Previous earthquake-induced landslides produced large amounts of loose material that remained on the steep slopes and in the gullies. As a consequence of heavy rainstorms during the rainy seasons, the existing loose material was transformed into numerous debris flows. Research has shown that the debris flows in the Wenchuan earthquake disaster areas have been characterized by their large scale, high speed, long run-out, and destructive impact. In order to identify the areas potentially at risk and to predict the flow severity, an accurate numerical method is needed to simulate these debris flows. In this paper, we have proposed a smoothed particle hydrodynamics (SPH) modeling technique-a meshfree particle method-to simulate the post-earthquake debris flows in the Wenchuan earthquake disaster areas. The SPH modeling technique introduces a Bingham model to analyze the relationship between material stress rates and particle motion velocity. Compared to traditional numerical methods, the SPH modeling technique is a true meshfree method of a pure Lagrangian nature. It can instantaneously track the motion of each particle, accurately predict the velocity, and naturally handle problems with extremely large deformations. In addition, the SPH method is based on continuum mechanics, and is therefore an efficient method to simulate large-scale debris flows. In this work, first, a viscoplastic fluid was simulated and verified with experimental results in order to evaluate the accuracy of the SPH model. Then propagation analysis of two typical post-earthquake debris flows in earthquake-hit areas was carried out, applying the SPH model. The simulation results showed good agreement with the limited field observation data. Our proposed SPH numerical modeling is able to capture the fundamental dynamic behavior of post-earthquake debris flows and can partially explain these complex phenomena. These simulation results can provide a preliminary scientific basis for hazard assessment and site selection for reconstruction in earthquake-prone areas.	[Huang, Yu; Cheng, Hualin; Dai, Zili; Liu, Fang] Tongji Univ, Dept Geotech Engn, Coll Civil Engn, Shanghai 200092, Peoples R China; [Huang, Yu; Liu, Fang] Tongji Univ, Key Lab Geotech & Underground Engn, Minist Educ, Shanghai 200092, Peoples R China; [Xu, Qiang] Chengdu Univ Technol, State Key Lab Geohazard Prevent & Geoenvironm Pro, Chengdu 610059, Peoples R China; [Sawada, Kazuhide; Yashima, Atsushi] Gifu Univ, Dept Civil Engn, Gifu 5011193, Japan; [Moriguchi, Shuji] Tohoku Univ, Int Res Inst Disaster Sci, Sendai, Miyagi 9808579, Japan	Huang, Y (reprint author), Tongji Univ, Dept Geotech Engn, Coll Civil Engn, Shanghai 200092, Peoples R China.	yhuang@tongji.edu.cn	Huang, Yu/K-8849-2012	Huang, Yu/0000-0002-9935-7717	National Natural Science Foundation of China; Japan Society for Promotion of Science under China-Japan Scientific Cooperation Program [41211140042]; National Basic Research Program of China (973 Program) [2012CB719803]; National Science Fund for Distinguished Young Scholars of China [41225011]; Chang Jiang Scholars Program of China	This work was supported by the National Natural Science Foundation of China and the Japan Society for the Promotion of Science under the China-Japan Scientific Cooperation Program (Grant No. 41211140042), the National Basic Research Program of China (973 Program, Grant No. 2012CB719803), the National Science Fund for Distinguished Young Scholars of China (Grant No. 41225011), and the Chang Jiang Scholars Program of China.	Tang C, 2009, B ENG GEOL ENVIRON, V68, P187, DOI 10.1007/s10064-009-0201-6; Morris JP, 1997, J COMPUT PHYS, V136, P214, DOI 10.1006/jcph.1997.5776; Marr JG, 2002, MAR GEOL, V188, P351, DOI 10.1016/S0025-3227(02)00310-9; Tang C, 2012, GEOMORPHOLOGY, V139, P559, DOI 10.1016/j.geomorph.2011.12.021; Chen H, 2009, B ENG GEOL ENVIRON, V68, P161, DOI 10.1007/s10064-009-0209-y; Shao SD, 2003, ADV WATER RESOUR, V26, P787, DOI 10.1016/S0309-1708(03)00030-7; MONAGHAN JJ, 1994, J COMPUT PHYS, V110, P399, DOI 10.1006/jcph.1994.1034; Rickenmann D, 2006, COMPUTAT GEOSCI, V10, P241, DOI 10.1007/s10596-005-9021-3; ATKIN RJ, 1976, Q J MECH APPL MATH, V29, P209, DOI 10.1093/qjmam/29.2.209; Laigle D, 2007, COMPUTAT GEOSCI, V11, P297, DOI 10.1007/s10596-007-9053-y; Laigle D, 1997, J HYDRAUL ENG-ASCE, V123, P617, DOI 10.1061/(ASCE)0733-9429(1997)123:7(617); MONAGHAN JJ, 1985, ASTRON ASTROPHYS, V149, P135; Huang Y, 2012, ENVIRON EARTH SCI, V66, P1001, DOI 10.1007/s12665-010-0612-5; Iverson RM, 1997, REV GEOPHYS, V35, P245, DOI 10.1029/97RG00426; Huang Y, 2011, NAT HAZARDS, V59, P1547, DOI 10.1007/s11069-011-9851-3; Shieh CL, 2009, INT J SEDIMENT RES, V24, P177, DOI 10.1016/S1001-6279(09)60025-1; Huang Y, 2013, WASTE MANAGE RES, V31, P256, DOI 10.1177/0734242X12470205; Wu FQ, 2008, B ENG GEOL ENVIRON, V67, P453, DOI 10.1007/s10064-008-0179-5; Kaitna R, 2007, ACTA GEOTECH, V2, P71, DOI 10.1007/s11440-007-0026-z; Yin YP, 2011, B ENG GEOL ENVIRON, V70, P15, DOI 10.1007/s10064-010-0334-7; LIU KF, 1989, J FLUID MECH, V207, P505, DOI 10.1017/S0022112089002685; LUCY LB, 1977, ASTRON J, V82, P1013, DOI 10.1086/112164; Huang RQ, 2009, SCI CHINA SER E, V52, P810, DOI 10.1007/s11431-009-0117-1; Chen H, 2000, CAN GEOTECH J, V37, P146, DOI 10.1139/cgj-37-1-146; Xu Q, 2012, NAT HAZARD EARTH SYS, V12, P201, DOI 10.5194/nhess-12-201-2012; Mazzanti P, 2011, B ENG GEOL ENVIRON, V70, P411, DOI 10.1007/s10064-010-0322-y; Pasculli A, 2013, ITAL J GEOSCI, V132, P350, DOI 10.3301/IJG.2013.01; Bui HH, 2008, INT J NUMER ANAL MET, V32, P1537, DOI [10.1002/nag.688, 10.1002/nag.088]; Jakob M, 2013, LANDSLIDES, V10, P685, DOI 10.1007/s10346-012-0365-1; Xu Q, 2009, B ENG GEOL ENVIRON, V68, P373, DOI 10.1007/s10064-009-0214-1; Medina V, 2008, LANDSLIDES, V5, P127, DOI 10.1007/s10346-007-0102-3; Huang RQ, 2009, B ENG GEOL ENVIRON, V68, P363, DOI 10.1007/s10064-009-0207-0; Shieh CL, 1996, NAT HAZARDS, V13, P39, DOI 10.1007/BF00156505; Rickenmann D, 1999, NAT HAZARDS, V19, P47, DOI 10.1023/A:1008064220727; Xie T, 2014, B ENG GEOL ENVIRON, V73, P947, DOI 10.1007/s10064-014-0585-9; Begueria S, 2009, NAT HAZARD EARTH SYS, V9, P1897; CHEN CL, 1988, J HYDRAUL ENG-ASCE, V114, P237; Chen RH, 2006, SINO GEOTECH, V110, P25; Cui P, 2011, NAT HAZARDS, V56; Dai ZL, 2014, ENG GEOL, V180, P21, DOI 10.1016/j.enggeo.2014.03.018; Hsiao DH, 2011, P 21 INT OFFSH POL E, P782; Huang Y, 2012, LANDSLIDES, V9, P275, DOI 10.1007/s10346-011-0285-5; HUNGR O, 1995, CAN GEOTECH J, V32, P610, DOI 10.1139/t95-063; Liu MB, 2010, ARCH COMPUT METHOD E, V17, P25, DOI 10.1007/s11831-010-9040-7; Liu ZQ, 2009, J GEOGRAPHY GEOLOGY, V1, P26; Ma Y, 2011, J SICHUAN U ENG SCI, V43, P92; Minatti L, 2011, P INT C DEBR FLOW HA, P467, DOI [10.4408/IJEGE.2011-03, DOI 10.4408/IJEGE.2011-03]; O'Brien J.S., 1993, J HYDRAUL ENG, V119, P244; Randles PW, 1996, COMPUT METHOD APPL M, V139, P375, DOI 10.1016/S0045-7825(96)01090-0; Sichuan Province Geological Engineering Complex, 2010, INV REP 813 WENJ GUL, P23; Uzuoka R, 1998, COMPUT GEOTECH, V22, P234; Van Asch TWJ, 2004, P 9 INT S LANDSL RIO, P1433, DOI 10.1201/b16816-204; Xie H, 2008, J MT SCI-ENGL, V27, P501; [许强 Xu Qiang], 2010, [工程地质学报, Journal of Engineering Geology], V18, P596; [杨志全 Yang Zhiquan], 2011, [大地测量与地球动力学, Journal of Gecodesy and Geodynamics], V31, P71; [殷跃平 YIN Yueping], 2009, [工程地质学报, Journal of Engineering Geology], V17, P153; [余斌 YU Bin], 2008, [沉积学报, Acta Sedimentologica Sinica], V26, P789; [张自光 Zhang Ziguang], 2010, [中国地质灾害与防治学报, The Chinese Journal of Geological Hazard and Control], V21, P34; Zhou W, 2011, B SOIL WATER CONSERV, V32, P138	59	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1435-9529	1435-9537		B ENG GEOL ENVIRON	Bull. Eng. Geol. Environ.	NOV	2015	74	4					1137	1151		10.1007/s10064-014-0705-6		15	Engineering, Environmental; Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	CT6ZC	WOS:000362961400004		
J	Aydan, O				Aydan, Oemer			A critical testing of the applicability of some empirical relations used in the science and engineering of earthquakes through the 2011 Great East Japan earthquake	BULLETIN OF ENGINEERING GEOLOGY AND THE ENVIRONMENT			English	Article						2011 Great East Japan earthquake; Empirical relations; Risk analyses; Attenuation of ground motions	PEAK HORIZONTAL ACCELERATION; ATTENUATION; RUPTURE	Many empirical relations have been proposed for estimating the fundamental characteristics of earthquakes and the induced tsunamis as well as for the strong-motion parameters, liquefaction potential, limiting distances for slope failures, damage to underground openings and even the possibility of surface damage due to room and pillar mines and quarries. The 2011 Great East Japan earthquake is probably the only mega-earthquake providing abundant quatitative information for the science and engineering of earthquakes although the rupture observations were obscured. The quantitative data from this earthquake should be quite useful for testing many empirical relations used in the science and engineering of earthquakes as they comprise an almost upper limit for the magnitude of earthquakes. The author compares the available empirical relations utilized for estimating the fundamental characteristics (i.e., relative slip, length, area, duration) of earthquakes as a function of their moment magnitude and attenuation of strong motion parameters such as maximum ground acceleration and velocity. Furthermore, some available empirical relations used from estimating the limiting hypocentral distances for ground liquefaction, slope failures, damage to underground openings and even the possibility of surface damage due to room and pillar mines are compared with observations made during the reconnaissance visits by various researchers including those provided by the author. The available empirical relations are compared with observations and instrumental data, and their applicability and limits are critically discussed in this article.	Univ Ryukyus, Dept Civil Engn & Architecture, Nishihara, Okinawa 90301, Japan	Aydan, O (reprint author), Univ Ryukyus, Dept Civil Engn & Architecture, Nishihara, Okinawa 90301, Japan.	aydan@tec.u-ryukyu.ac.jp					Ambraseys NN, 1988, EARTHQ ENG STRUCT D, V5, P1; JOYNER WB, 1981, B SEISMOL SOC AM, V71, P2011; CAMPBELL KW, 1981, B SEISMOL SOC AM, V71, P2039; Tajima F, 2013, TECTONOPHYSICS, V586, P15, DOI 10.1016/j.tecto.2012.09.014; Aydan O, 2009, J SEISMOL, V13, P399, DOI 10.1007/s10950-008-9146-7; [Anonymous], 2008, J SCH MAR SCI TECHNO; ABE K, 1979, J GEOPHYS RES, V84, P1561, DOI 10.1029/JB084iB04p01561; Ulusay R, 2004, ENG GEOL, V74, P265, DOI 10.1016/j.enggeo.2004.04.002; [Anonymous], 1988, P 9 WORLD C EARTHQ E; Aydan O, 2010, ROCK MECH ROCK ENG, V43, P857, DOI 10.1007/s00603-010-0105-6; WELLS DL, 1994, B SEISMOL SOC AM, V84, P974; Aydan O, 2009, PROCEEDINGS OF INTERNATIONAL CONFERENCE ON EARTHQUAKE ENGINEERING - THE FIRST ANNIVERSARY OF WENCHUAN EARTHQUAKE, P625; Aydan O, 2012, B ENG GEOL ENVIRON, V71, P637, DOI 10.1007/s10064-012-0435-6; Aydan, 2013, P 47 US ROCK MECH GE; Aydan, 2001, GEOLOGICAL ENG, V25, P1; Aydan O, 1997, 97007 TDVTR, P41; Aydan O, 2011, 7 NAT C EARTHQ ENG I, P1; Aydan O, 2007, 6 NAT C EARTHQ ENG T, V1, P563; Aydan O., 2002, EARTHQUAKE STRUCTURA, V19, P199; Aydan O, 1998, 00603 TDVDR TURK EAR, P131; Aydan O, 2012, P 65 YEARS MAH VARD, P17; Aydan O, 2012, ENCY SUSTAINABILITY, P3233; Aydan O, 1996, 11 WORLD C EARTHQ EN; Aydan O., 2012, J JAPAN ASS EARTHQUA, V12, P229; Aydan O, 2011, 1 INT C GEOT CONSTR, P505; Fowler C.M.R., 1990, SOLID EARTH INTRO GL; Geographical Information Authority of Japan (GSI), 2011, SPEC WEB SIT E JAP M; Iida K, 1963, P TSUM M ASS 10 PAC, P7; Iwatate T, 2011, 1 INT C GEOT CONSTR, P511; Kanamori H., 1983, EARTHQUAKES OBSERVAT, P596; KEEFER DK, 1984, GEOL SOC AM BULL, V95, P406; Koketsu K, 2012, P INT S ENG LESS LEA, P1; Kuribayahsi E., 1975, SOILS FOUND, V15, P81, DOI DOI 10.3208/SANDF1972.15.4_81; Matsuda T, 1975, J SEISMOL SOC JPN, V28, P269; Nishida N, 1984, P 3 INT S LAND SUBS, P717; Port Authority Research Institute. (PARI), 2011, SPEC WEB SIT E JAP M; Sato R, 1989, HDB PARAMETERS EARTH; Toda S, 2013, GEOPHYS RES LETT, V40, P1; Udias A, 1999, PRINCIPLES SEISMOLOG, P475; Wakamatsu K, 2000, P 12 WORLD C EARTHQ, P8	40	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1435-9529	1435-9537		B ENG GEOL ENVIRON	Bull. Eng. Geol. Environ.	NOV	2015	74	4					1243	1254		10.1007/s10064-014-0699-0		12	Engineering, Environmental; Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	CT6ZC	WOS:000362961400011		
J	Gorog, DA; Otsui, K; Inoue, N				Gorog, Diana A.; Otsui, Kazunori; Inoue, Nobutaka			Usefulness of Platelet Function Tests to Predict Bleeding With Antithrombotic Medications	CARDIOLOGY IN REVIEW			English	Review						bleeding; platelet function test; thrombosis; antiplatelet therapy	ACUTE CORONARY SYNDROME; THROMBIN GENERATION; ATRIAL-FIBRILLATION; BLOOD-LOSS; ANTICOAGULATED PATIENTS; ANTIPLATELET THERAPY; CARDIAC-SURGERY; RISK-SCORE; REACTIVITY; INTERVENTION	The pharmacological inhibition of platelets has always been regarded as a double-edged sword: the challenge of balancing the antithrombotic effect against the bleeding risk. Potent antiplatelet agents and novel oral anticoagulants, sometimes in combination, are increasingly used in the treatment of cardiovascular disease and for thromboprophylaxis in atrial fibrillation. Although such treatment has reduced the risk of thrombotic events, the potential for major bleeding has increased, and a technique to identify those at increased bleeding risk is greatly needed. Platelet function tests (PFTs), most frequently VerifyNow and also the vasodilator-stimulated phosphoprotein -phosphorylation assay, have been used to identify low on-treatment platelet reactivity, to identify individuals who may be at increased bleeding risk. Such results predict nuisance bleeding, but many individuals have low on-treatment platelet reactivity and yet do not exhibit major or even minor bleeding. Although PFTs may be useful in assessing populations, they do not allow identification of individual patients at risk of bleeding on either antiplatelet or novel oral anticoagulant therapy, nor do they allow the tailoring of such therapy to optimize the risk:benefit ratio. Thrombin plays a cardinal role in both arterial thrombus formation and hemostasis, yet most PFTs fail to assess the contribution of thrombin, because they employ anticoagulated blood. Techniques such as the calibrated automated thrombogram and the point-of-care global thrombosis test, performed on native blood, which measure endogenous thrombin potential, seem to show the most promise for profiling bleeding risk, as tests that most physiologically assess the effects of medications on thrombin.	[Gorog, Diana A.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Vasc Sci Sect, London SW7 2AZ, England; [Otsui, Kazunori] Univ Hertfordshire, Postgrad Med Sch, Hatfield AL10 9AB, Herts, England; [Inoue, Nobutaka] Kobe Rosai Hosp, Dept Cardiovasc Med, Kobe, Hyogo, Japan	Gorog, DA (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Vasc Sci Sect, London SW7 2AZ, England.	d.gorog@imperial.ac.uk					Eller T, 2014, CLIN CHEM LAB MED, V52, P835, DOI 10.1515/cclm-2013-0936; Cuisset T, 2013, JACC-CARDIOVASC INTE, V6, P854, DOI 10.1016/j.jcin.2013.04.009; Skeppholm M, 2011, THROMB RES, V128, P483, DOI 10.1016/j.thromres.2011.03.011; Rodeghiero F, 2010, J THROMB HAEMOST, V8, P2063, DOI 10.1111/j.1538-7836.2010.03975.x; Alexopoulos D, 2012, J AM COLL CARDIOL, V60, P193, DOI 10.1016/j.jacc.2012.03.050; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Oldgren J, 2013, EUR HEART J, V34, P1670, DOI 10.1093/eurheartj/eht049; Patti G, 2011, AM J CARDIOL, V107, P995, DOI 10.1016/j.amjcard.2010.11.025; Mehran R, 2011, CIRCULATION, V123, P2736, DOI 10.1161/CIRCULATIONAHA.110.009449; Herrmann R, 2014, THROMB HAEMOSTASIS, V111, P989, DOI 10.1160/TH13-07-0607; Ninivaggi M, 2012, CLIN CHEM, V58, P1252, DOI 10.1373/clinchem.2012.184077; MACFARLANE DE, 1975, BRIT J HAEMATOL, V30, P457, DOI 10.1111/j.1365-2141.1975.tb01860.x; McConeghy KW, 2014, PHARMACOTHERAPY, V34, P561, DOI 10.1002/phar.1415; Sharma AD, 2014, BLOOD COAGUL FIBRIN, V25, P561, DOI 10.1097/MBC.0000000000000095; Yu PJ, 2014, J CARDIAC SURG, V29, P312, DOI 10.1111/jocs.12312; van der Meijden PEJ, 2005, THROMB HAEMOSTASIS, V93, P1128, DOI 10.1160/TH04-09-0597; Kiviniemi T, 2014, AM J CARDIOL, V113, P1995, DOI 10.1016/j.amjcard.2014.03.038; Breet NJ, 2010, JAMA-J AM MED ASSOC, V303, P754, DOI 10.1001/jama.2010.181; Fattorutto M, 2003, BRIT J ANAESTH, V90, P692, DOI 10.1093/bja/aeg110; Campo G, 2011, J AM COLL CARDIOL, V57, P2474, DOI 10.1016/j.jacc.2010.12.047; Roldan V, 2013, J AM COLL CARDIOL, V62, P2199, DOI 10.1016/j.jacc.2013.08.1623; Stone GW, 2013, LANCET, V382, P614, DOI 10.1016/S0140-6736(13)61170-8; Diodati JG, 2013, CIRC-CARDIOVASC INTE, V6, P567, DOI 10.1161/CIRCINTERVENTIONS.112.000063; Zhang JN, 2014, J INORG BIOCHEM, V134, P1, DOI 10.1016/j.jinorgbio.2013.12.005; Almandoz JED, 2014, AM J NEURORADIOL, V35, P128, DOI 10.3174/ajnr.A3621; Cayla G, 2013, AM J CARDIOL, V111, P38, DOI 10.1016/j.amjcard.2012.08.043; Ertug Z, 2010, ANN TRANSPL, V15, P46; Lip GYH, 2011, J AM COLL CARDIOL, V57, P173, DOI 10.1016/j.jacc.2010.09.024; Yamamoto J, 2014, THROMB RES, V133, P919, DOI 10.1016/j.thromres.2014.02.018; Bonello L, 2012, J THROMB HAEMOST, V10, P1999, DOI 10.1111/j.1538-7836.2012.04875.x; Sharma S, 2013, EUR HEART J, V34, P354, DOI 10.1093/eurheartj/ehs300; Undas A, 2009, BLOOD, V113, P2070, DOI 10.1182/blood-2008-07-167411; Mangiacapra F, 2012, JACC-CARDIOVASC INTE, V5, P281, DOI 10.1016/j.jcin.2012.01.009; Borissoff JI, 2012, JACC-CARDIOVASC IMAG, V5, P1201, DOI 10.1016/j.jcmg.2012.01.023; Kerneis M, 2013, JACC-CARDIOVASC INTE, V6, P158, DOI 10.1016/j.jcin.2012.09.012; Saraf S, 2010, J AM COLL CARDIOL, V55, P2107, DOI 10.1016/j.jacc.2010.01.033; Goodman SG, 2014, J AM COLL CARDIOL, V63, P891, DOI 10.1016/j.jacc.2013.11.013; Bosch Y, 2013, J CARDIOTHORAC SURG, V8, DOI 10.1186/1749-8090-8-154; Dzeshka MS, 2014, CLIN CARDIOL, V37, P634, DOI 10.1002/clc.22294; Gaglia Michael A Jr, 2013, Cardiovasc Revasc Med, V14, P76, DOI 10.1016/j.carrev.2012.12.005; Gosselin R, 2014, AM J CLIN PATHOL, V141, P262, DOI 10.1309/AJCPRNUMI4PVSJ7Q; Kozinski M, 2014, CARDIOL J, V21, P547, DOI 10.5603/CJ.a2014.0026; Laine M, 2013, THROMB RES, V132, pE15, DOI 10.1016/j.thromres.2013.04.030; Ross Britney, 2014, J Med Toxicol, V10, P223, DOI 10.1007/s13181-013-0364-1	44	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1061-5377	1538-4683		CARDIOL REV	Cardiol. Rev.	NOV-DEC	2015	23	6					323	327		10.1097/CRD.0000000000000072		5	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CT2NL	WOS:000362639100008		
J	Takada, H; Kurisaki, A				Takada, Hitomi; Kurisaki, Akira			Emerging roles of nucleolar and ribosomal proteins in cancer, development, and aging	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Review						Nucleolus; Ribosome biogenesis; Stem cells; Differentiation; Longevity	LINKED DYSKERATOSIS-CONGENITA; POLYMERASE I TRANSCRIPTION; ARF TUMOR-SUPPRESSOR; EMBRYONIC STEM-CELLS; LIFE-SPAN EXTENSION; GENE-EXPRESSION; SELF-RENEWAL; C-MYC; OVER-EXPRESSION; MESSENGER-RNA	Changes in nucleolar morphology and function are tightly associated with cellular activity, such as growth, proliferation, and cell cycle progression. Historically, these relationships have been extensively examined in cancer cells, which frequently exhibit large nucleoli and increased ribosome biogenesis. Recent findings indicate that alteration of nucleolar activity is a key regulator of development and aging. In this review, we have provided evidences that the nucleolus is not just a housekeeping factor but is actively involved in the regulation of cell proliferation, differentiation, and senescence both in vitro and in vivo. In addition, we have discussed how alteration of nucleolar function and nucleolar proteins induces specific physiological effects rather than widespread effects.	[Takada, Hitomi; Kurisaki, Akira] Natl Inst Adv Ind Sci & Technol, Biotechnol Res Inst Drug Discovery, Stem Cell Engn Res Grp, Cent 4, Tsukuba, Ibaraki 3058562, Japan	Kurisaki, A (reprint author), Natl Inst Adv Ind Sci & Technol, Biotechnol Res Inst Drug Discovery, Stem Cell Engn Res Grp, Cent 4, 1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.	akikuri@hotmail.com					Derenzini M, 1998, AM J PATHOL, V152, P1291; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Kim Young-Il, 2014, Mol Cells, V37, P51, DOI 10.14348/molcells.2014.2251; Qu J, 2012, J CELL BIOL, V197, P731, DOI 10.1083/jcb.201103071; Martin DE, 2006, CELL METAB, V4, P259, DOI 10.1016/j.cmet.2006.09.002; Demontis F, 2014, CELL REP, V7, P1481, DOI 10.1016/j.celrep.2014.05.001; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Q, 2014, SCIENCE, V343, P298, DOI 10.1126/science.1246384; Yang LX, 2013, MOL CELL BIOL, V33, P3835, DOI 10.1128/MCB.00476-13; Yang A, 2011, J BIOL CHEM, V286, P43370, DOI 10.1074/jbc.M111.225185; Lim MJ, 2006, CANCER DETECT PREV, V30, P481, DOI 10.1016/j.cdp.2006.10.008; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Kondrashov N, 2011, CELL, V145, P383, DOI 10.1016/j.cell.2011.03.028; Zhang Y, 2013, DEV CELL, V24, P411, DOI 10.1016/j.devcel.2013.01.018; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Wang Q, 2001, GENE, V263, P205, DOI 10.1016/S0378-1119(00)00570-9; Fichelson P, 2009, NAT CELL BIOL, V11, P685, DOI 10.1038/ncb1874; Ali SA, 2008, P NATL ACAD SCI USA, V105, P6632, DOI 10.1073/pnas.0800970105; Evans DS, 2011, AGEING RES REV, V10, P225, DOI 10.1016/j.arr.2010.04.001; Voit R, 1997, MOL CELL BIOL, V17, P4230; Mayer C, 2006, ONCOGENE, V25, P6384, DOI 10.1038/sj.onc.1209883; He J, 2002, ONCOGENE, V21, P7740, DOI 10.1038/sj.onc.1205969; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Le Bouteiller M, 2013, J EXP MED, V210, P2351, DOI 10.1084/jem.20122019; Twiss JL, 2000, NEUROBIOL DIS, V7, P416, DOI 10.1006/nbdi.2000.0293; Pederson T, 2009, J CELL BIOL, V184, P771, DOI 10.1083/jcb.200812014; Hulbert AJ, 2007, PHYSIOL REV, V87, P1175, DOI 10.1152/physrev.00047.2006; Steffen KK, 2008, CELL, V133, P292, DOI 10.1016/j.cell.2008.02.037; Demontis F, 2009, DEVELOPMENT, V136, P983, DOI 10.1242/dev.027466; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; Hannan KM, 2011, IUBMB LIFE, V63, P79, DOI 10.1002/iub.428; Vaarala MH, 1998, INT J CANCER, V78, P27, DOI 10.1002/(SICI)1097-0215(19980925)78:1<27::AID-IJC6>3.0.CO;2-Z; Grewal SS, 2007, J CELL BIOL, V179, P1105, DOI 10.1083/jcb.200709044; Di Fiore PP, 2008, J CELL BIOL, V182, P7, DOI 10.1083/jcb.200806069; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Smith JS, 1998, GENETICS, V149, P1205; Tang YP, 2006, BRAIN RES, V1126, P102, DOI 10.1016/j.brainres.2006.08.002; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; HENRY JL, 1993, CANCER RES, V53, P1403; Knight SW, 1999, AM J HUM GENET, V65, P50, DOI 10.1086/302446; Okamoto N, 2011, P NATL ACAD SCI USA, V108, P20388, DOI 10.1073/pnas.1015171108; Xue SF, 2015, NATURE, V517, P33, DOI 10.1038/nature14010; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Kim JH, 2004, HEPATOLOGY, V39, P129, DOI 10.1002/hep.20017; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Choesmel V, 2007, BLOOD, V109, P1275, DOI 10.1182/blood-2006-07-038372; Mayer C, 2005, CELL CYCLE, V4, P1036, DOI 10.4161/cc.4.8.1925; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Machin F, 2004, CURR BIOL, V14, P125, DOI 10.1016/j.cub.2004.01.001; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Rosby R, 2009, MOL BIOL CELL, V20, P4424, DOI 10.1091/mbc.E08-06-0592; Wu S, 2008, GENE, V424, P48, DOI 10.1016/j.gene.2008.07.023; Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x; Poortinga G, 2011, NUCLEIC ACIDS RES, V39, P3267, DOI 10.1093/nar/gkq1205; Komili S, 2007, CELL, V131, P557, DOI 10.1016/j.cell.2007.08.037; Baker NE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058266; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Hayashi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098586; Hein N, 2012, NUCL RIBOSOMAL GENES, DOI [10.5772/34581, DOI 10.5772/34581]; James A, 2013, NUCLEUS-AUSTIN, V4, P123, DOI 10.4161/nucl.23944; McCain J, 2006, CELL TISSUE RES, V323, P105, DOI 10.1007/s00441-005-0044-9; Qin W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100796; Shenoy N, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-32; Uechi T, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000037; van Sluis M, 2014, GENES CANC, V12, P710, DOI [10.1016/j.coph.2012.06.011, DOI 10.1016/J.COPH.2012.06.011]; Watanabe-Susaki K, 2014, STEM CELLS, V32, P3099, DOI 10.1002/stem.1825	75	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X	1420-9071		CELL MOL LIFE SCI	Cell. Mol. Life Sci.	NOV	2015	72	21					4015	4025		10.1007/s00018-015-1984-1		11	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CT7VS	WOS:000363023200002		
J	Araki, K; Ebata, T; Guo, AK; Tobiume, K; Wolf, SJ; Kawauchi, K				Araki, Keigo; Ebata, Takahiro; Guo, Alvin Kunyao; Tobiume, Kei; Wolf, Steven John; Kawauchi, Keiko			p53 regulates cytoskeleton remodeling to suppress tumor progression	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Review						p53; p63; Rho GTPases; Focal adhesion proteins; Mechanotransduction; ECM degradation; Contractile forces; Metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL-ADHESION KINASE; CANCER-CELL INVASION; EMBRYONIC STEM-CELLS; EXTRACELLULAR-MATRIX DEGRADATION; LI-FRAUMENI-SYNDROME; FACTOR-KAPPA-B; MUTANT P53; BREAST-CANCER; PLASMINOGEN-ACTIVATOR	Cancer cells possess unique characteristics such as invasiveness, the ability to undergo epithelial-mesenchymal transition, and an inherent stemness. Cell morphology is altered during these processes and this is highly dependent on actin cytoskeleton remodeling. Regulation of the actin cytoskeleton is, therefore, important for determination of cell fate. Mutations within the TP53 (tumor suppressor p53) gene leading to loss or gain of function (GOF) of the protein are often observed in aggressive cancer cells. Here, we highlight the roles of p53 and its GOF mutants in cancer cell invasion from the perspective of the actin cytoskeleton; in particular its reorganization and regulation by cell adhesion molecules such as integrins and cadherins. We emphasize the multiple functions of p53 in the regulation of actin cytoskeleton remodeling in response to the extracellular microenvironment, and oncogene activation. Such an approach provides a new perspective in the consideration of novel targets for anti-cancer therapy.	[Araki, Keigo; Ebata, Takahiro; Kawauchi, Keiko] Konan Univ, Frontiers Innovat Res Sci & Technol, Chuo Ku, Kobe, Hyogo 6500047, Japan; [Araki, Keigo] Kwansei Gakuin Univ, Sch Sci & Technol, Dept Biomed Chem, Sanda, Hyogo 6691337, Japan; [Guo, Alvin Kunyao] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Tobiume, Kei] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Minami Ku, Hiroshima, Hiroshima 7348553, Japan; [Wolf, Steven John; Kawauchi, Keiko] Natl Univ Singapore, Mechanobiol Inst, T Lab, Singapore 117411, Singapore; [Kawauchi, Keiko] Nippon Med Sch, Inst Adv Med Sci, Dept Mol Oncol, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Kawauchi, K (reprint author), Konan Univ, Frontiers Innovat Res Sci & Technol, Chuo Ku, 7-1-20 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	kawauchi@center.konan-u.ac.jp			JSPS KAKENHI [26890024]	We thank Dr. Shota Yamauchi and Mr. Toshiya Kotari for discussion. This work was supported by JSPS KAKENHI Grant Number 26890024.	Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Guasch RM, 1998, MOL CELL BIOL, V18, P4761; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Quinlan ME, 2005, NATURE, V433, P382, DOI 10.1038/nature03241; Xiao Y, 2014, MOL CELL BIOL, V34, P2635, DOI 10.1128/MCB.00076-14; Yonemura S, 2010, NAT CELL BIOL, V12, P533, DOI 10.1038/ncb2055; Yoshio T, 2007, FEBS LETT, V581, P3777, DOI 10.1016/j.febslet.2007.06.073; Moran DM, 2010, MOL CANCER THER, V9, P895, DOI 10.1158/1535-7163.MCT-09-1220; Sheng SJ, 2004, FRONT BIOSCI, V9, P2733, DOI 10.2741/1432; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; Bossi G, 2008, CELL CYCLE, V7, P1870, DOI 10.4161/cc.7.12.6161; Jacquemet G, 2013, J CELL SCI, V126, P4121, DOI 10.1242/jcs.121988; ROBERTSON AMG, 1978, J PATHOL, V126, P181, DOI 10.1002/path.1711260307; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Jacquemet G, 2013, J CELL BIOL, V202, P917, DOI 10.1083/jcb.201302041; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Shih WT, 2012, J CELL SCI, V125, P3661, DOI 10.1242/jcs.103861; Kim MR, 2012, BIOCHEM BIOPH RES CO, V418, P260, DOI 10.1016/j.bbrc.2012.01.007; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Ongusaha PP, 2006, CURR BIOL, V16, P2466, DOI 10.1016/j.cub.2006.10.056; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411; Zhao LA, 2010, FEBS J, V277, P4195, DOI 10.1111/j.1742-4658.2010.07808.x; Qin H, 2007, J BIOL CHEM, V282, P5842, DOI 10.1074/jbc.M610464200; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Barone I, 2011, JNCI-J NATL CANCER I, V103, P538, DOI 10.1093/jnci/djr058; Sarig R, 2010, J EXP MED, V207, P2127, DOI 10.1084/jem.20100797; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Mukhopadhyay UK, 2010, MOL CELL BIOL, V30, P4980, DOI 10.1128/MCB.00004-10; Enoksson M, 2007, J PROTEOME RES, V6, P2850, DOI 10.1021/pr0701052; Eves R, 2006, J CELL SCI, V119, P1691, DOI 10.1242/jcs.02881; Schramek D, 2014, SCIENCE, V343, P309, DOI 10.1126/science.1248627; Tanikawa C, 2009, ONCOGENE, V28, P3081, DOI 10.1038/onc.2009.154; Kim EM, 2014, ONCOTARGET, V5, P8452; Coffill CR, 2012, EMBO REP, V13, P638, DOI 10.1038/embor.2012.74; Dong P, 2013, ONCOGENE, V32, P3286, DOI 10.1038/onc.2012.334; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717; Rudrapatna VA, 2013, EMBO REP, V14, P172, DOI 10.1038/embor.2012.217; Timpson P, 2011, CANCER RES, V71, P747, DOI 10.1158/0008-5472.CAN-10-2267; Golubovskaya V, 2004, BBA-GENE STRUCT EXPR, V1678, P111, DOI 10.1016/j.bbaexp.2004.03.002; Huang XP, 2013, NEOPLASIA, V15, P952, DOI 10.1593/neo.13376; Bian JH, 1997, MOL CELL BIOL, V17, P6330; Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729; Petrie RJ, 2012, J CELL SCI, V125, P5917, DOI 10.1242/jcs.093732; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Yeudall WA, 2012, CARCINOGENESIS, V33, P442, DOI 10.1093/carcin/bgr270; Lee KH, 2010, P NATL ACAD SCI USA, V107, P69, DOI 10.1073/pnas.0909734107; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Strano S, 2007, ONCOGENE, V26, P2212, DOI 10.1038/sj.onc.1210296; Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724; van Nimwegen MJ, 2006, MOL PHARMACOL, V70, P1330, DOI 10.1124/mol.106.026195; Keely PJ, 2011, J MAMMARY GLAND BIOL, V16, P205, DOI 10.1007/s10911-011-9226-0; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; He B, 2005, J BIOL CHEM, V280, P3346, DOI 10.1074/jbc.M406680200; Powell E, 2014, CANCER DISCOV, V4, P405, DOI 10.1158/2159-8290.CD-13-0136; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Arjonen A, 2014, J CLIN INVEST, V124, P1069, DOI 10.1172/JCI67280; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Janouskova H, 2013, CANCER LETT, V336, P307, DOI 10.1016/j.canlet.2013.03.018; Kogan-Sakin I, 2011, CELL DEATH DIFFER, V18, P271, DOI 10.1038/cdd.2010.94; LAI MY, 1993, CANCER RES, V53, P1653; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Landskron G, 2014, J IMMUNOL RES, DOI 10.1155/2014/149185; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Charras G, 2008, NAT REV MOL CELL BIO, V9, P730, DOI 10.1038/nrm2453; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Sethi N, 2011, BRIT J CANCER, V105, P1805, DOI 10.1038/bjc.2011.497; Jagan I, 2013, ONCOGENE, V32, P1305, DOI 10.1038/onc.2012.140; Moore SW, 2010, DEV CELL, V19, P194, DOI 10.1016/j.devcel.2010.07.018; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Chen HY, 2012, J BIOL CHEM, V287, P17109, DOI 10.1074/jbc.M111.326975; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; McGowen R, 2000, CANCER RES, V60, P4771; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Huveneers S, 2013, J CELL SCI, V126, P403, DOI 10.1242/jcs.109447; Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Kren A, 2007, EMBO J, V26, P2832, DOI 10.1038/sj.emboj.7601738; Yamauchi S, 2014, J CELL BIOL, V204, P1191, DOI 10.1083/jcb.201309107; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Hofstetter G, 2010, ONCOGENE, V29, P1997, DOI 10.1038/onc.2009.482; Wang H, 2014, FEBS LETT, V588, P503, DOI 10.1016/j.febslet.2013.12.016; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Zhang XA, 2003, J BIOL CHEM, V278, P27319, DOI 10.1074/jbc.M303039200; Croft DR, 2011, CELL RES, V21, P666, DOI 10.1038/cr.2010.154; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Yoshikawa K, 2010, BIOMED RES-TOKYO, V31, P401, DOI 10.2220/biomedres.31.401; Girardini JE, 2011, CANCER CELL, V20, P79, DOI 10.1016/j.ccr.2011.06.004; Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127; Guo FK, 2003, J BIOL CHEM, V278, P14414, DOI 10.1074/jbc.M300341200; Qiu JH, 2011, MOL CELL BIOCHEM, V357, P125, DOI 10.1007/s11010-011-0882-6; Jerrell RJ, 2014, ACTA BIOMATER, V10, P1886, DOI 10.1016/j.actbio.2013.12.058; Petrie RJ, 2012, J CELL BIOL, V197, P439, DOI 10.1083/jcb.201201124; Deakin NO, 2008, J CELL SCI, V121, P2435, DOI 10.1242/jcs.018044; Vogel V, 2009, CURR OPIN CELL BIOL, V21, P38, DOI 10.1016/j.ceb.2009.01.002; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Muller PAJ, 2014, J BIOL CHEM, V289, P122, DOI 10.1074/jbc.M113.502138; Lefort K, 2007, GENE DEV, V21, P562, DOI 10.1101/gad.1484707; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; Kawauchi K, 2008, BIOCHEM BIOPH RES CO, V372, P137, DOI 10.1016/j.bbrc.2008.05.021; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Zhang HQ, 2004, NAT CELL BIOL, V6, P523, DOI 10.1038/ncb1136; Sun S, 2002, J GEN VIROL, V83, P1651; Biliran H, 2001, CANCER RES, V61, P8676; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Liu J, 2012, NAT MATER, V11, P734, DOI [10.1038/nmat3361, 10.1038/NMAT3361]; Brachova P, 2013, INT J MOL SCI, V14, P19257, DOI 10.3390/ijms140919257; Welch MD, 1998, SCIENCE, V281, P105, DOI 10.1126/science.281.5373.105; Gadea G, 2002, EMBO J, V21, P2373, DOI 10.1093/emboj/21.10.2373; Vaughan CA, 2012, ARCH BIOCHEM BIOPHYS, V518, P79, DOI 10.1016/j.abb.2011.12.006; Aga M, 2008, INVEST OPHTH VIS SCI, V49, P5353, DOI 10.1167/iovs.07-1666; Jurmeister S, 2012, MOL CELL BIOL, V32, P633, DOI 10.1128/MCB.06212-11; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Faix J, 2006, DEV CELL, V10, P693, DOI 10.1016/j.devcel.2006.05.001; Janouskova H, 2012, CANCER RES, V72, P3463, DOI 10.1158/0008-5472.CAN-11-4199; Nanba D, 2013, EMBO MOL MED, V5, P640, DOI 10.1002/emmm.201201839; Guo AK, 2014, J CELL PHYSIOL, V229, P696, DOI 10.1002/jcp.24505; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Yi L, 2012, CANCER RES, V72, P5635, DOI 10.1158/0008-5472.CAN-12-1451; Gu B, 2012, INT J BIOL SCI, V8, P672, DOI 10.7150/ijbs.4283; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Xia MX, 2007, NAT STRUCT MOL BIOL, V14, P215, DOI 10.1038/nsmb1208; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Liu J, 2006, MOL CANCER RES, V4, P803, DOI 10.1158/1541-7786.MCR-06-0201; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mukhopadhyay UK, 2009, MOL CELL BIOL, V29, P3088, DOI 10.1128/MCB.01816-08; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; White DP, 2007, J CELL BIOL, V177, P515, DOI 10.1083/jcb.200609004; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Lin J, 2002, ONCOGENE, V21, P3082, DOI 10.1038/sj/onc/1205426; Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Sun YB, 2004, J CELL BIOCHEM, V92, P258, DOI 10.1002/jcb.20044; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Cojoc D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001072; Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4; Dong PX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-103; Hulkower Keren I, 2011, Pharmaceutics, V3, P107, DOI 10.3390/pharmaceutics3010107; Iskratsch T, 2014, NAT REV MOL CELL BIO, V15, P825, DOI 10.1038/nrm3903; Jee BK, 2007, BIOCHEM BIOPH RES CO, V359, P703, DOI 10.1016/j.bbrc.2007.05.159; Kawauchi K, 2014, EXPERT REV ANTICANC, V14, P1101, DOI 10.1586/14737140.2014.948859; Khoo Kian Hoe, 2014, Nat Rev Drug Discov, V13, P217, DOI 10.1038/nrd4236; Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744; Kim J, 2014, EMBO REP, V15, P1062, DOI 10.15252/embr.201438587; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kraning-Rush CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032572; Krstic J, 2014, SCI WORLD J, V2014, DOI DOI 10.1155/2014/521754; Liao Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-487; Morel Anne-Pierre, 2008, PLoS One, V3, pe2888, DOI 10.1371/journal.pone.0002888; Noll JE, 2012, ONCOGENE, V31, P2836, DOI 10.1038/onc.2011.456; Orgaz JL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5255; Rao JS, 2003, NAT REV CANCER, V3, P489; Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889; Ungefroren H, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-18; Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908; Yao MX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5525; Zhang YH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.214585; Zhou XL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0428-3	199	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X	1420-9071		CELL MOL LIFE SCI	Cell. Mol. Life Sci.	NOV	2015	72	21					4077	4094		10.1007/s00018-015-1989-9		18	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	CT7VS	WOS:000363023200006		
J	Yano, S; Sakamoto, KQ; Habara, Y				Yano, Saori; Sakamoto, Kentaro Q.; Habara, Yoshiaki			Female Mice Avoid Male Odor from the Same Strain via the Vomeronasal System in an Estrogen-Dependent Manner	CHEMICAL SENSES			English	Article						accessory olfactory bulb; estradiol; inbreeding avoidance; mouse; pheromone	MATE CHOICE DECISIONS; OLFACTORY SYSTEMS; SENSORY NEURONS; RECEPTOR-ALPHA; HOUSE MICE; MOUSE; PHEROMONE; RECOGNITION; ESTRADIOL; BEHAVIOR	Inbreeding avoidance is essential to providing offspring with genetic diversity. Females' mate choice is more crucial than males' for successful reproduction because of the high cost of producing gametes and limited chances to mate. However, the mechanism of female inbreeding avoidance is still unclear. To elucidate the mechanism underlying inbreeding avoidance by females, we conducted Y-maze behavioral assays using BALB/c and C57BL/6 female mice. In both strains, the avoidance of male urine from the same strain was lower in the low estrogen phase than in the high estrogen phase. The estrous cycle-dependent avoidance was completely prevented by vomeronasal organ (VNO) removal. To assess the regulation of the vomeronasal system by estrogen, the neural excitability was evaluated by immunohistochemistry of the immediate early gene products. Although estrogen did not affect neural excitability in the VNO, estrogen enhanced the neural excitability of the mitral cell layer in the AOB induced by urine from the cognate males. These results suggest that female mice avoid odor from genetically similar males in an estrogen-dependent manner via the vomeronasal system and the excitability of the mitral cells in the AOB is presumed to be regulated by estrogen.	[Yano, Saori; Sakamoto, Kentaro Q.; Habara, Yoshiaki] Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Lab Physiol,Kita Ku, Sapporo, Hokkaido 0600818, Japan	Yano, S (reprint author), Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Lab Physiol,Kita Ku, Kita 18,Nishi 9, Sapporo, Hokkaido 0600818, Japan.	yanos@vetmed.hokudai.ac.jp	Sakamoto, Kentaro/A-4843-2012	Sakamoto, Kentaro/0000-0002-8499-799X			Consuegra S, 2008, P ROY SOC B-BIOL SCI, V275, P1397, DOI 10.1098/rspb.2008.0066; Milinski M, 2005, P NATL ACAD SCI USA, V102, P4414, DOI 10.1073/pnas.0408264102; Yano S, 2012, J VET MED SCI, V74, P1311, DOI 10.1292/jvms.12-0067; Chamero P, 2007, NATURE, V450, P899, DOI 10.1038/nature05997; WEDEKIND C, 1995, P ROY SOC B-BIOL SCI, V260, P245, DOI 10.1098/rspb.1995.0087; Schwartz JJ, 2001, BEHAV ECOL SOCIOBIOL, V49, P443, DOI 10.1007/s002650100317; Kavaliers M, 2004, HORM BEHAV, V46, P272, DOI 10.1016/j.yhbeh.2004.03.005; KEY B, 1986, NEUROSCI LETT, V69, P131, DOI 10.1016/0304-3940(86)90591-4; JANETOS AC, 1980, BEHAV ECOL SOCIOBIOL, V7, P107, DOI 10.1007/BF00299515; Halem HA, 1999, J NEUROBIOL, V39, P249, DOI 10.1002/(SICI)1097-4695(199905)39:2<249::AID-NEU9>3.0.CO;2-R; Del Punta K, 2002, NATURE, V419, P70, DOI 10.1038/nature00955; Cherian S, 2014, NEUROSCIENCE, V269, P43, DOI 10.1016/j.neuroscience.2014.03.011; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; Uy JAC, 2001, AM NAT, V158, P530, DOI 10.1086/323118; Dey S, 2015, CELL, V161, P1334, DOI 10.1016/j.cell.2015.04.052; Ichikawa M, 2003, ZOOL SCI, V20, P687, DOI 10.2108/zsj.20.687; Halem HA, 2001, J NEUROSCI, V21, P2474; NELSON JF, 1981, BIOL REPROD, V24, P784, DOI 10.1095/biolreprod24.4.784; BEAUCHAMP GK, 1988, BEHAV GENET, V18, P537, DOI 10.1007/BF01065520; YAMAZAKI K, 1979, J EXP MED, V150, P755, DOI 10.1084/jem.150.4.755; Sherborne AL, 2007, CURR BIOL, V17, P2061, DOI 10.1016/j.cub.2007.10.041; Boillat M, 2015, CURR BIOL, V25, P251, DOI 10.1016/j.cub.2014.11.061; Penn DJ, 2002, P NATL ACAD SCI USA, V99, P11260, DOI 10.1073/pnas.162006499; POTTS WK, 1991, NATURE, V352, P619, DOI 10.1038/352619a0; Hurst JL, 2004, BIOESSAYS, V26, P1288, DOI 10.1002/bles.20147; Mitra SW, 2003, ENDOCRINOLOGY, V144, P2055, DOI 10.1210/en.2002-221069; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; WALMER DK, 1992, ENDOCRINOLOGY, V131, P1458, DOI 10.1210/en.131.3.1458; Haga S, 2010, NATURE, V466, P118, DOI 10.1038/nature09142; Baum MJ, 2009, ANNU REV PHYSIOL, V71, P141, DOI 10.1146/annurev.physiol.010908.163137; Hurst JL, 2001, NATURE, V414, P631, DOI 10.1038/414631a; KENNEDY CEJ, 1987, BEHAV ECOL SOCIOBIOL, V21, P291, DOI 10.1007/BF00299966; Munger SD, 2009, ANNU REV PHYSIOL, V71, P115, DOI 10.1146/annurev.physiol.70.113006.100608; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Roberts SA, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-75; Brechbuhl J, 2008, SCIENCE, V321, P1092, DOI 10.1126/science.1160770; Keller M, 2006, EUR J NEUROSCI, V23, P521, DOI 10.1111/j.1460-9568.2005.04589.x; Mossman CA, 1996, J COMP PSYCHOL, V110, P131; Leinders-Zufall T, 2004, SCIENCE, V306, P1033, DOI 10.1126/science.1102818; Roberts SC, 2003, NAT GENET, V35, P103, DOI 10.1038/ng1231; Asaba A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087186; Oboti L, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00113; Sturm T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2610; Wyatt TD, 2014, PHEROMONES AND ANIMAL BEHAVIOR: CHEMICAL SIGNALS AND SIGNATURES, 2ND EDITION, P1	44	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0379-864X	1464-3553		CHEM SENSES	Chem. Senses	NOV	2015	40	9					641	648		10.1093/chemse/bjv052		8	Behavioral Sciences; Food Science & Technology; Neurosciences; Physiology	Behavioral Sciences; Food Science & Technology; Neurosciences & Neurology; Physiology	CT6BK	WOS:000362895400005		
J	Kageyama, G; Saegusa, J; Irino, Y; Tanaka, S; Tsuda, K; Takahashi, S; Sendo, S; Morinobu, A				Kageyama, G.; Saegusa, J.; Irino, Y.; Tanaka, S.; Tsuda, K.; Takahashi, S.; Sendo, S.; Morinobu, A.			Metabolomics analysis of saliva from patients with primary Sjogren's syndrome	CLINICAL AND EXPERIMENTAL IMMUNOLOGY			English	Article						major salivary glanditis; metabolomics; saliva; Sjogren's syndrome	CLASSIFICATION CRITERIA; MASS-SPECTROMETRY; BIOMARKERS; DISEASE	The recent development of salivary proteomics has led to the identification of potential biomarkers for diagnosing patients with primary Sjogren's syndrome (pSS). Here we sought to identify differentially produced salivary metabolites from pSS patients and healthy controls (HCs) that might be used to characterize this disease. We obtained salivary samples from 12 female pSS patients (mean age 44.2 +/- 13.01) and 21 age-matched female HCs. The metabolite profiles of saliva were analysed by gas chromatography-mass spectrometry. The total metabolite levels in each of the samples were calculated and compared across the study participants. A total of 88 metabolites were detected across the study samples, 41 of which were observed at reduced levels in the samples frompSS patients. Principal component analysis (PCA) revealed a loss in salivary metabolite diversity in the pSS patient samples compared to the HC samples. The reduced presence of glycine, tyrosine, uric acid and fucose, which may reflect salivary gland destruction due to chronic sialoadenitis, contributed to the loss of diversity. Comparative PCA of the pSS patients revealed the presence of two subpopulations based on their metabolite profiles, and these two subpopulations showed a significant difference in the prevalence of major salivary glanditis (P=0014). In this study, we found that the salivary metabolite profile of pSS patients was less diverse than that of HCs and that the metabolite profiles in pSS patients were affected by the presence of major salivary glanditis.	[Kageyama, G.; Saegusa, J.; Tanaka, S.; Tsuda, K.; Takahashi, S.; Sendo, S.; Morinobu, A.] Kobe Univ Hosp, Dept Rheumatol, Kobe, Hyogo 6500017, Japan; [Irino, Y.] Kobe Univ, Grad Sch Med, Div Evidence Based Lab Med, Kobe, Hyogo 657, Japan	Morinobu, A (reprint author), Kobe Univ Hosp, Dept Rheumatol, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	morinobu@med.kobe-u.ac.jp					Baimpa E, 2009, MEDICINE, V88, P284, DOI 10.1097/MD.0b013e3181b76ab5; Wei JE, 2011, INT J CANCER, V129, P2207, DOI 10.1002/ijc.25881; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Nakamizo S, 2013, J NEURO-ONCOL, V113, P65, DOI 10.1007/s11060-013-1090-x; Ehrlich GE, 2002, JAMA-J AM MED ASSOC, V287, P117, DOI 10.1001/jama.287.1.117; Sugimoto M, 2010, METABOLOMICS, V6, P78, DOI 10.1007/s11306-009-0178-y; Barnes VM, 2011, J DENT RES, V90, P1293, DOI 10.1177/0022034511416240; Fleissig Y, 2009, ORAL DIS, V15, P61, DOI 10.1111/j.1601-0825.2008.01465.x; Hu S, 2007, ARTHRITIS RHEUM-US, V56, P3588, DOI 10.1002/art.22954; Villas-Boas SG, 2005, MASS SPECTROM REV, V24, P613, DOI 10.1002/mas.20032; Shiboski SC, 2012, ARTHRIT CARE RES, V64, P475, DOI 10.1002/acr.21591; Zhang AH, 2012, APPL BIOCHEM BIOTECH, V168, P1718, DOI 10.1007/s12010-012-9891-5; Ryu OH, 2006, RHEUMATOLOGY, V45, P1077, DOI 10.1093/rheumatology/kei212; Baldini C, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3523; Delaleu N, 2015, ARTHRITIS RHEUMATOL, V67, P1084, DOI 10.1002/art.39015	15	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9104	1365-2249		CLIN EXP IMMUNOL	Clin. Exp. Immunol.	NOV	2015	182	2					149	153		10.1111/cei.12683		5	Immunology	Immunology	CT6WY	WOS:000362955000005		
J	Suzuki, M; Yoshida, H; Hashizume, M; Tanaka, K; Matsumoto, Y				Suzuki, M.; Yoshida, H.; Hashizume, M.; Tanaka, K.; Matsumoto, Y.			Blockade of interleukin-6 receptor enhances the anti-arthritic effect of glucocorticoids without decreasing bone mineral density in mice with collagen-induced arthritis	CLINICAL AND EXPERIMENTAL IMMUNOLOGY			English	Article						collagen-induced arthritis; glucocorticoid; interleukin-6	RHEUMATOID-ARTHRITIS; NUCLEAR TRANSLOCATION; GENE-EXPRESSION; BETA-ISOFORM; RESISTANCE; ASTHMA; ACTIVATOR; CELLS; DISEASE; KINASE	In a mouse arthritis model, we investigated whether interleukin-6 receptor (IL-6R) blockade would enhance the anti-arthritic effect of glucocorticoids (GCs). DBA/1J mice were immunized with type II collagen (CII), and were treated with prednisolone (PSL) and/or anti-mouse IL-6R antibody (MR16-1). Also, the effects of IL-6 on gene expression and the nuclear translocation of glucocorticoid receptors (GRs) were examined in cultured cells treated with dexamethasone (DEX). PSL reduced the arthritis score dose-dependently in the collagen-induced arthritis (CIA) mouse model. The arthritis score in the PSL (3 mg/kg) + MR16-1 group was lower than in the PSL (3 mg/kg) group, and at the same level as in the PSL (6 mg/kg) group. Lumbar vertebra bone mineral density (BMD) was decreased significantly in CIA mice and was higher in the PSL (3 mg/kg)+MR16-1 group than in the PSL (6 mg/kg) group. In the in-vitro synovial cells, IL-6 pretreatment attenuated the inhibitory effect of DEX on cyclooxygenase (COX)-2 expression and inhibited the nuclear translocation of GR induced by DEX. In contrast, in MC3T3-E1 osteoblastic cells, IL-6 pretreatment exacerbated the decrease in expression of osteocalcin and the increase in expression of receptor activator of nuclear factor kappa-B ligand (RANKL) by DEX. We demonstrated that IL-6 signalling blockade by an anti-IL-6R antibody can augment the anti-arthritic effect of GCs and inhibit the bone loss they cause.	[Suzuki, M.; Yoshida, H.; Hashizume, M.; Tanaka, K.; Matsumoto, Y.] Chugai Pharmaceut Co Ltd, Prod Res Dept, Fuji Gotemba Res Labs, Gotemba, Shizuoka, Japan	Suzuki, M (reprint author), 1-135 Komakado, Gotemba, Shizuoka 4128513, Japan.	suzuki.miho@chugai-pharm.co.jp					Onda K, 2006, BIOCHEM BIOPH RES CO, V351, P266, DOI 10.1016/j.bbrc.2006.10.032; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Henneicke H, 2011, BONE, V49, P733, DOI 10.1016/j.bone.2011.06.013; Suzuki M, 2010, CYTOKINE, V51, P178, DOI 10.1016/j.cyto.2010.03.017; Kozaci DL, 2007, RHEUMATOLOGY, V46, P579, DOI 10.1093/rheumatology/kel276; Loke TK, 2006, J ALLERGY CLIN IMMUN, V118, P368, DOI 10.1016/j.jaci.2006.04.055; Tuckermann JP, 2007, J CLIN INVEST, V117, P1381, DOI 10.1172/JCI28034; Joosten LAB, 1999, INFLAMM RES, V48, P48, DOI 10.1007/s000110050396; Cohen S, 2012, P NATL ACAD SCI USA, V109, P5995, DOI 10.1073/pnas.1118355109; Kirwan JR, 2007, SCAND J RHEUMATOL, V36, P165, DOI 10.1080/03009740701340263; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Farrell RJ, 2003, J ENDOCRINOL, V178, P339, DOI 10.1677/joe.0.1780339; TAKAI Y, 1989, ARTHRITIS RHEUM, V32, P594, DOI 10.1002/anr.1780320513; ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, pS125; Donn R, 2007, FASEB J, V21, P402, DOI 10.1096/fj.06-7236com; Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005; Szatmary Z, 2004, J BIOL CHEM, V279, P43708, DOI 10.1074/jbc.M406568200; Kaneko K, 2012, J CLIN ENDOCR METAB, V97, pE1909, DOI 10.1210/jc.2012-1971; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Okazaki M, 2002, IMMUNOL LETT, V84, P231, DOI 10.1016/S0165-2478(02)00202-X; Takayanagi H, 2000, ARTHRITIS RHEUM, V43, P259, DOI 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W; Suzuki M, 2010, RHEUMATOL INT, V30, P309, DOI 10.1007/s00296-009-0953-0; Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529-0131(199812)41:12<2117::AID-ART6>3.0.CO;2-P; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382; SUGITA T, 1993, INT J IMMUNOPHARMACO, V15, P469; Hashizume M, 2009, RHEUMATOL INT, V29, P1449, DOI 10.1007/s00296-009-0885-8; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Kong YY, 1999, NATURE, V397, P315; Chang PJ, 2015, AM J RESP CRIT CARE, V191, P54, DOI 10.1164/rccm.201402-0314OC; Ferreira TB, 2014, IMMUNOLOGY, V143, P560, DOI 10.1111/imm.12334	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0009-9104	1365-2249		CLIN EXP IMMUNOL	Clin. Exp. Immunol.	NOV	2015	182	2					154	161		10.1111/cei.12685		8	Immunology	Immunology	CT6WY	WOS:000362955000006		
J	Fuse, N; Naganuma, A; Fukuchi, T; Hori, Y; Mizuno, M; Fukunaga, K				Fuse, N.; Naganuma, A.; Fukuchi, T.; Hori, Y.; Mizuno, M.; Fukunaga, K.			Underfilm Corrosion of Transmission Tower Cross-Arms Service-Used in a Pacific Coast Area	CORROSION			English	Article						aging; anticorrosion paint; cross-arm materials; electric transmission tower; electrochemical impedance; terahertz imaging	ATMOSPHERIC CORROSION; HOLISTIC MODEL; MARINE SALTS; COATED STEEL; DEPOSITION; SPECTROSCOPY	Degradation is revealed for cross-arms used in an electric transmission tower on the Pacific coast of Japan by evaluating both paint degradation and steel corrosion. The angled steels exhibit various levels of degradation according to their face orientation and the installation height. The corrosion states are provided as maps with a special resolution of sub-mm order, using the terahertz wave nondestructive measurement. Rust fluid appears to transfuse along the steel/coating interface and induces underfilm corrosion on the nearest faces. The skyward face does not show clear corrosion, indicating the washing effect of rainfall. Electrochemical impedance shows that paint degradation is severe in faces that get a direct sea breeze, whereas the opposite faces show good integrity. The degradation also becomes more severe with increasing installation height. The two analytical techniques show that underfilm corrosion shows rapid progress when the electrical receptivity of the coating is on the order of 10(7) Omega.cm(2).	[Fuse, N.; Naganuma, A.; Fukuchi, T.; Hori, Y.] Cent Res Inst Elect Power Ind, Yokosuka, Kanagawa 2400196, Japan; [Mizuno, M.; Fukunaga, K.] Natl Inst Informat & Communicat Technol, Koganei, Tokyo 1848795, Japan	Fuse, N (reprint author), Cent Res Inst Elect Power Ind, 2-6-1 Nagasaka, Yokosuka, Kanagawa 2400196, Japan.	fuse@criepi.denken.or.jp					[Anonymous], 2014, 167731 ISO; Andreas EL, 1998, J PHYS OCEANOGR, V28, P2175, DOI 10.1175/1520-0485(1998)028<2175:ANSSGF>2.0.CO;2; Saha JK, 2010, CORROSION, V66; TSAI CH, 1993, CORROSION, V49, P726; LEIDHEISER H, 1976, CORROSION, V32, P69; Lee AWM, 2006, IEEE PHOTONIC TECH L, V18, P1415, DOI 10.1109/LPT.2006.877220; OHBA R, 1990, ATMOS ENVIRON A-GEN, V24, P925, DOI 10.1016/0960-1686(90)90295-X; WEI DF, 1995, CORROSION, V51, P97; Townsend HE, 1998, CORROSION, V54, P561; [Anonymous], 2009, 1163 I EL ENG JAP; Cole IS, 2003, CORROS ENG SCI TECHN, V38, P267, DOI 10.1179/147842203225008921; Cole IS, 2004, CORROS ENG SCI TECHN, V39, P209, DOI 10.1179/147842204X2880; Fuse N, 2009, IEEE T DIELECT EL IN, V16, P524, DOI 10.1109/TDEI.2009.4815188; Wang JH, 1997, CORROSION, V53, P206; Cole IS, 2003, CORROS ENG SCI TECHN, V38, P129, DOI 10.1179/147842203225005690; [Anonymous], 1992, 9223 ISO; Cole IS, 2003, CORROS ENG SCI TECHN, V38, P259, DOI 10.1179/147842203225008886; Fukunaga K, 2007, IEICE ELECTRON EXPR, V4, P258, DOI 10.1587/elex.4.258; Anastasi RF, 2006, AIP CONF PROC, V820, P515; Fuse N, 2012, IEEE T THZ SCI TECHN, V2, P242, DOI 10.1109/TTHZ.2011.2178932; Kharkovsky S, 2007, IEEE INSTRU MEAS MAG, V10, P26, DOI 10.1109/MIM.2007.364985; Kariya H, 2013, ECS TRANSACTIONS, V50, P81, DOI 10.1149/05050.0081ecst; Bottcher C.J.F., 1952, THEORY ELECT POLARIS; Fuse N., 2012, IEEJ T FUNDAMENTALS, V132, P709; HAMON BV, 1952, P I ELECTR ENG, V99, P151; Kendig M., 1990, CORROSION, V46, P23; Kurabayashi T., 2010, 35 INT C INFR MILL T; Larsen K.R., 2011, MP, V50, P26; Makishima H., 1965, J JPN SOC COLOR MAT, V37, P135; Quaddoumi N.N., 1998, MATER EVAL, V58, P178; Sakai K., 2005, TERAHERTZ OPTOELECTR; Smith J., 2011, TRANSM DISTRIB, V63, p56F; Suto H., 2008, N07028 CRIEPI; The Federation of Electric Power Companies of Japan, 1973, HYDRO ELECT POWER, V125, P82	34	0	0	NATL ASSOC CORROSION ENG	HOUSTON	1440 SOUTH CREEK DRIVE, HOUSTON, TX 77084-4906 USA	0010-9312	1938-159X		CORROSION-US	Corrosion	NOV	2015	71	11					1387	1397		10.5006/1736		11	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CT6IC	WOS:000362915700010		
J	Eguchi, K; Ishiguro, Y; Ota, H				Eguchi, K.; Ishiguro, Y.; Ota, H.			Corrosion Behavior of Multi-Phase Stainless Steel in 15% Hydrochloric Acid at a Temperature of 80 degrees C	CORROSION			English	Article						acidizing; duplex stainless steel; electrochemical measurement; immersion test; martensitic stainless steel	ELECTROCHEMICAL BEHAVIOR; ACIDIZING INHIBITORS; MEDIA	Corrosion of two multi-phase stainless steels, 17% Cr and 22% Cr, in 15% HCl at temperatures of 80 degrees C and 25 degrees C was studied using mass loss and electrochemical methods. The corrosion environment simulated the environment of acidizing treatment in oil and gas wells. The 17% Cr stainless steel (17Cr steel), consisting of martensite, ferrite, and retained austenite phases, exhibited higher corrosion resistance than the 22% Cr duplex stainless steel (22Cr steel), which consisted of ferrite and austenite phases. In the 22Cr steel, selective corrosion of the ferrite phase was observed. The higher corrosion rate of the 22Cr steel is thought to have been caused by the higher corrosion rate of the ferrite phase, which had a smaller overpotential for the hydrogen evolution reaction. Selective corrosion of the ferrite phase in the 22Cr steel caused detachment of the remaining austenite grains, which also contributed to the higher corrosion rate of the 22Cr steel.	[Eguchi, K.; Ishiguro, Y.; Ota, H.] JFE Steel Corp, Steel Res Lab, Handa, Japan	Eguchi, K (reprint author), JFE Steel Corp, Steel Res Lab, Handa, Japan.	ke-eguchi@jfe-steel.co.jp			ASTM International	UNS numbers are listed in Metals and Alloys in the Unified Numbering System, published by the Society of Automotive Engineers (SAE International) and cosponsored by ASTM International.	Finsgar M, 2014, CORROS SCI, V86, P17, DOI 10.1016/j.corsci.2014.04.044; Parsons R, 2011, WILEY SER ELECTROCAT, P1; [Anonymous], 2006, G10289 ASTM; Priya ARS, 2008, CORROSION, V64, P541; Chermat-Aourasse N, 2007, PROT MET+, V43, P344, DOI 10.1134/S0033173207040054; Tsai WT, 2007, CORROS SCI, V49, P3659, DOI 10.1016/j.corsci.2007.03.035; Quraishi MA, 2002, CORROSION, V58, P317; OLDHAM KB, 1971, CORROSION, V27, P434; Aoki S., 2011, CORROS ENG, V60, P272; ASTM Standard, 2004, G3172 ASTM; Eguchi K., 2013, 8 PAC RIM INT C ADV; Ishiguro Y., 2012, NACE E AS PAC RIM AR; Ishiguro Y., 2013, CORROSION 2013; Kane R.D., 1989, CORROSION 89; Kimura M., 2011, EUROCORR 2011; Kimura M., 2007, CORROSION 2007; Mack R.D., 2008, CORROSION 2008; Saida K., 2010, T JWRI, V39, P124; SCHMITT G, 1984, BRIT CORROS J, V19, P165; Scoppio L., 2014, CORROSION 2014; Shimizu M., 1999, J JAPANESE ASS PET T, V64, P448; TRASATTI S, 1972, J ELECTROANAL CHEM, V39, P163, DOI 10.1016/0368-1874(72)85118-9	22	0	0	NATL ASSOC CORROSION ENG	HOUSTON	1440 SOUTH CREEK DRIVE, HOUSTON, TX 77084-4906 USA	0010-9312	1938-159X		CORROSION-US	Corrosion	NOV	2015	71	11					1398	1405		10.5006/1754		8	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	CT6IC	WOS:000362915700011		
J	Wang, Q; Yokoo, H; Takashina, M; Sakata, K; Ohashi, W; Abedelzaher, LA; Imaizumi, T; Sakamoto, T; Hattori, K; Matsuda, N; Hattori, Y				Wang, Qiang; Yokoo, Hiroki; Takashina, Michinori; Sakata, Kimimasa; Ohashi, Wakana; Abedelzaher, Lobna A.; Imaizumi, Takahiro; Sakamoto, Takuya; Hattori, Kohshi; Matsuda, Naoyuki; Hattori, Yuichi			Anti-Inflammatory Profile of Levosimendan in Cecal Ligation-Induced Septic Mice and in Lipopolysaccharide-Stimulated Macrophages	CRITICAL CARE MEDICINE			English	Article						hemodynamic dysfunction; high mobility group box 1; inflammation; levosimendan; macrophages; nuclear factor-B; pimobendan; sepsis	NF-KAPPA-B; ACUTE LUNG INJURY; INFLAMMATORY MEDIATORS; HEART-FAILURE; SIGNALING PATHWAYS; ORGAN DYSFUNCTION; MONOCYTIC CELLS; PROTEIN HMGB1; SEVERE SEPSIS; ACTIVATION	Objectives: The calcium sensitizer levosimendan is used in treatment of decompensated heart failure and may also exhibit anti-inflammatory properties. We examined whether treatment with levosimendan is substantially beneficial in mice with cecal ligation and puncture-induced polymicrobial sepsis, and its arbitration mechanism was explored in the mouse macrophage cell line RAW264.7. Design: Laboratory and animal/cell research. Setting: University research laboratory. Subjects: BALB/c mice (8-10 wk old) and mouse macrophage cell line RAW264.7 cells. Interventions: Levosimendan (0.5 g/kg/min) was administered to mice through an osmotic pump that was implanted into the peritoneal cavity immediately following surgery. In RAW264.7 cells, levosimendan was added to the culture medium 30 minutes before lipopolysaccharide. Measurements and Main Results: When levosimendan was continuously administered to cecal ligation and puncture-induced septic mice, a significant improvement of left ventricular function was found without any change in heart rate, and hypotension was significantly mitigated. Furthermore, levosimendan conferred substantial protection against sepsis-associated inflammation in mice, as indicated by reduced lung injury and decreased blood proinflammatory and chemotactic cytokine levels. These beneficial effects of levosimendan led to a significant improvement of survival in mice after cecal ligation and puncture. In endotoxin-stimulated RAW264.7 macrophages, treatment with levosimendan and pimobendan suppressed overproduction of proinflammatory and chemotactic cytokines. Levosimendan and pimobendan were without effect on activation of the nuclear factor-B, mitogen-activated protein kinase, and Akt pathways. Instead, levosimendan and pimobendan prevented high mobility group box 1 release from the nucleus to the extracellular space in macrophages. This was associated with inhibition of the Rho kinase signaling pathway. The elevated serum high mobility group box 1 levels in cecal ligation and puncture-induced septic mice were also inhibited by continued administration of levosimendan and pimobendan. Conclusions: We define a novel mechanism for the anti-inflammatory action of levosimendan and suggest that the pharmacological profiles of levosimendan as both an inotrope and an anti-inflammatory agent could contribute to its clinical benefit in patients with sepsis with heart problems.	[Wang, Qiang; Yokoo, Hiroki; Takashina, Michinori; Sakata, Kimimasa; Ohashi, Wakana; Abedelzaher, Lobna A.; Imaizumi, Takahiro; Sakamoto, Takuya; Hattori, Yuichi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Mol & Med Pharmacol, Toyama 930, Japan; [Hattori, Kohshi] Tokyo Univ Hosp, Dept Anesthesiol, Tokyo 113, Japan; [Hattori, Kohshi] Tokyo Univ Hosp, Pain Relief Ctr, Tokyo 113, Japan; [Matsuda, Naoyuki] Nagoya Univ, Grad Sch Med, Dept Emergency & Crit Care Med, Nagoya, Aichi 4648601, Japan	Hattori, Y (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Mol & Med Pharmacol, Toyama 930, Japan.	yhattori@med.u-toyama.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [26460336, 15K15661]	Dr. Hattori's institution received grant support: Grant-in-Aids for Scientific Research (26460336) and Grant-in-Aids for Challenging Exploratory Research (15K15661) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. The remaining authors have disclosed that they do not have any potential conflicts of interest.	BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Morelli A, 2005, INTENS CARE MED, V31, P638, DOI 10.1007/s00134-005-2619-z; Taguchi K, 2014, J PHARMACOL EXP THER, V349, P199, DOI 10.1124/jpet.113.211854; Sareila O, 2008, BRIT J PHARMACOL, V155, P884, DOI 10.1038/bjp.2008.328; Matsuda N, 2009, AM J RESP CRIT CARE, V179, P806, DOI 10.1164/rccm.200804-534OC; Frishman WH, 2003, CRIT CARE MED, V31, P2408, DOI 10.1097/01.CCM.0000084861.07091.F3; Ayala A, 2008, CURR PHARM DESIGN, V14, P1853, DOI 10.2174/138161208784980617; Papp Z, 2005, CARDIOVASC DRUG REV, V23, P71; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Lee YG, 2011, FRONT BIOSCI-LANDMRK, V16, P517, DOI 10.2741/3702; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Kivikko M, 2002, INT J CLIN PHARM TH, V40, P465; Shao J, 2013, INT IMMUNOPHARMACOL, V17, P216, DOI 10.1016/j.intimp.2013.06.008; Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005; Hattori Y, 2010, J PHARMACOL SCI, V114, P354, DOI 10.1254/jphs.10R04CR; Hasan Z, 2013, INFECT IMMUN, V81, P2499, DOI 10.1128/IAI.00126-13; Matejovic M, 2005, ACTA ANAESTH SCAND, V49, P127, DOI 10.1111/j.1399-6576.2004.00541.x; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Zhan J, 2011, MOL BIOL REP, V38, P1909, DOI 10.1007/s11033-010-0310-0; Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200; Murai K, 2013, INT HEART J, V54, P75; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Oldner A, 2001, CRIT CARE MED, V29, P2185, DOI 10.1097/00003246-200111000-00022; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Kass DA, 2006, CIRCULATION, V113, P305, DOI 10.1161/CIRCULATIONAHA.105.542407; Li WF, 2012, INFLAMMATION, V35, P1814, DOI 10.1007/s10753-012-9502-1; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Faivre V, 2005, ANESTHESIOLOGY, V103, P514, DOI 10.1097/00000542-200509000-00014; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Hubbard WJ, 2005, SHOCK, V24, P52, DOI 10.1097/01.shk.0000191414.94461.7e; Archan S, 2008, CURR OPIN ANESTHESIO, V21, P78, DOI 10.1097/ACO.0b013e3282f357a5; Parissis JT, 2005, AM J CARDIOL, V95, P923, DOI 10.1016/j.amjcard.2004.11.018; Endoh M, 2008, CIRC J, V72, P1915, DOI 10.1253/circj.CJ-08-0838; Erbuyun K, 2009, ACTA HISTOCHEM, V111, P404, DOI 10.1016/j.acthis.2008.09.010; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-1880C; Karlsson S, 2008, INTENS CARE MED, V34, P1046, DOI 10.1007/s00134-008-1032-9; Takano K, 2011, J PHARMACOL EXP THER, V336, P381, DOI 10.1124/jpet.110.171462; Matsuda N, 2009, CRIT CARE MED, V37, P2791, DOI 10.1097/CCM.0b013e3181ab844d; [Anonymous], 2006, BIOCH SOC S; Angus Derek C., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P207; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; O'Brien JM, 2007, AM J MED, V120, P1012, DOI 10.1016/j.amjmed.2007.01.035; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Oishi H, 2012, AM J PHYSIOL-LUNG C, V303, pL130, DOI 10.1152/ajplung.00363.2011; Scheiermann P, 2009, INTENS CARE MED, V35, P1412, DOI 10.1007/s00134-009-1481-9; BLINKS JR, 1986, CIRCULATION, V73, P85; Fernandes CJ, 2012, CRIT CARE RES PRACT, V2012; Hojyo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018059; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Paraskevaidis Ioannis A., 2005, Current Medicinal Chemistry - Cardiovascular & Hematological Agents, V3, P243, DOI 10.2174/1568016054368232; Takebe M, 2014, J SURG RES, V187, P559, DOI 10.1016/j.jss.2013.10.050; Vincent Jean-Louis, 2004, Crit Care Med, V32, pS451, DOI 10.1097/01.CCM.0000142984.44321.A4	56	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2015	43	11					E508	E520		10.1097/CCM.0000000000001269		13	Critical Care Medicine	General & Internal Medicine	CT5CW	WOS:000362826100004		
J	Kikukawa, H; Sakuradani, E; Nakatani, M; Ando, A; Okuda, T; Sakamoto, T; Ochiai, M; Shimizu, S; Ogawa, J				Kikukawa, Hiroshi; Sakuradani, Eiji; Nakatani, Masato; Ando, Akinori; Okuda, Tomoyo; Sakamoto, Takaiku; Ochiai, Misa; Shimizu, Sakayu; Ogawa, Jun			Gene targeting in the oil-producing fungus Mortierella alpina 1S-4 and construction of a strain producing a valuable polyunsaturated fatty acid	CURRENT GENETICS			English	Article						Mortierella alpina; Ku80; Homologous recombination; Gene targeting; Delta 5-desaturase; Dihomo-gamma-linolenic acid	HUMAN LIG4 HOMOLOG; FILAMENTOUS FUNGUS; OLEAGINOUS FUNGUS; HETEROLOGOUS EXPRESSION; BREAK REPAIR; DNA-REPAIR; ASPERGILLUS; TRANSFORMATION; RECOMBINATION; YEAST	To develop an efficient gene-targeting system in Mortierella alpina 1S-4, we identified the ku80 gene encoding the Ku80 protein, which is involved in the nonhomologous end-joining pathway in genomic double-strand break (DSB) repair, and constructed ku80 gene-disrupted strains via single-crossover homologous recombination. The Delta ku80 strain from M. alpina 1S-4 showed no negative effects on vegetative growth, formation of spores, and fatty acid productivity, and exhibited high sensitivity to methyl methanesulfonate, which causes DSBs. Dihomo-gamma-linolenic acid (DGLA)-producing strains were constructed by disruption of the Delta 5-desaturase gene, encoding a key enzyme of bioconversion of DGLA to ARA, using the Delta ku80 strain as a host strain. The significant improvement of gene-targeting efficiency was not observed by disruption of the ku80 gene, but the construction of DGLA-producing strain by disruption of the Delta 5-desaturase gene was succeeded using the Delta ku80 strain as a host strain. This report describes the first study on the identification and disruption of the ku80 gene in zygomycetes and construction of a DGLA-producing transformant using a gene-targeting system in M. alpina 1S-4.	[Sakuradani, Eiji] Univ Tokushima, Inst Sci & Technol, Tokushima 7708506, Japan; [Ando, Akinori; Ogawa, Jun] Kyoto Univ, Res Unit Physiol Chem, Sakyo Ku, Kyoto 6068502, Japan; [Ochiai, Misa] Suntory Global Innovat Ctr Ltd, Res Inst, Shimamoto, Osaka 6188503, Japan; [Shimizu, Sakayu] Kyoto Gakuen Univ, Dept Biosci & Biotechnol, Fac Bioenvironm Sci, Sogabe, Kameoka 6218555, Japan	Ogawa, J (reprint author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	ogawa@kais.kyoto-u.ac.jp			Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN) of Japan; Advanced Low Carbon Technology Research and Development Program (ALCA) of Japan;  [23248014];  [22380051]	This work was partially supported by Grants-in Aid for Scientific Research of Japan (Numbers 22380051 to E. Sakuradani and 23248014 to J. Ogawa), the Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN) of Japan, and the Advanced Low Carbon Technology Research and Development Program (ALCA) of Japan.	Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Kikukawa H, 2013, J BIOSCI BIOENG, V116, P672, DOI 10.1016/j.jbiosc.2013.05.023; Sakuradani E, 2008, APPL MICROBIOL BIOT, V81, P497, DOI 10.1007/s00253-008-1675-z; Takeno S, 2004, APPL MICROBIOL BIOT, V65, P419, DOI 10.1007/s00253-004-1622-6; Sakuradani E, 2013, J BIOSCI BIOENG, V116, P417, DOI 10.1016/j.jbiosc.2013.04.008; Ando A, 2009, APPL ENVIRON MICROB, V75, P5529, DOI 10.1128/AEM.00648-09; Takahashi T, 2011, J BIOSCI BIOENG, V112, P529, DOI 10.1016/j.jbiosc.2011.08.007; Zhang XW, 2007, CURR MICROBIOL, V55, P128, DOI 10.1007/s00284-006-0641-1; Kato A, 2004, CURR GENET, V45, P37, DOI 10.1007/s00294-003-0459-3; Takeno S, 2004, BIOSCI BIOTECH BIOCH, V68, P277, DOI 10.1271/bbb.68.277; RAZANAMPARANY V, 1986, CURR GENET, V10, P811, DOI 10.1007/BF00418527; Sakuradani E, 1999, GENE, V238, P445, DOI 10.1016/S0378-1119(99)00359-5; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Van Dyck E, 1999, NATURE, V398, P728; Takeno S, 2005, J BIOSCI BIOENG, V100, P617, DOI 10.1263/jbb.100.617; Krappmann Sven, 2007, Fungal Biology Reviews, V21, P25, DOI 10.1016/j.fbr.2007.02.004; Hande MP, 2004, CYTOGENET GENOME RES, V104, P116, DOI 10.1159/000077475; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Honda Y, 2011, BIOSCI BIOTECH BIOCH, V75, P1594, DOI 10.1271/bbb.110015; Shibata T, 2001, P NATL ACAD SCI USA, V98, P8425, DOI 10.1073/pnas.111005198; Krappmann S, 2006, EUKARYOT CELL, V5, P212, DOI 10.1128/EC.5.1.212-215.2006; KAWASHIMA H, 1995, ANAL BIOCHEM, V229, P317, DOI 10.1006/abio.1995.1419; Sakuradani E, 2010, BIOSCI BIOTECH BIOCH, V74, P908, DOI 10.1271/bbb.100001; Ishidoh K, 2014, CURR GENET, V60, P99, DOI 10.1007/s00294-013-0399-5; Ninomiya Y, 2004, P NATL ACAD SCI USA, V101, P12248, DOI 10.1073/pnas.0402780101; Mizutani O, 2008, FUNGAL GENET BIOL, V45, P878, DOI 10.1016/j.fgb.2007.12.010; Takeno S, 2005, APPL ENVIRON MICROB, V71, P5124, DOI 10.1128/AEM.71.9.5124-5128.2005; Sakuradani E, 1999, EUR J BIOCHEM, V260, P208, DOI 10.1046/j.1432-1327.1999.00131.x; SCHIESTL RH, 1994, MOL CELL BIOL, V14, P4493; Hopfner KP, 2002, CURR OPIN STRUC BIOL, V12, P115, DOI 10.1016/S0959-440X(02)00297-X; Sakuradani E, 2005, APPL MICROBIOL BIOT, V66, P648, DOI 10.1007/s00253-004-1760-x; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Watrin L, 1999, MOL GEN GENET, V262, P378; Daley JM, 2005, ANNU REV GENET, V39, P431, DOI 10.1146/annurev.genet.39.073003.113340; Lisby M, 2004, CURR BIOL, V14, pR994, DOI 10.1016/j.cub.2004.11.020; Okuda T, 2014, CURR GENET, V60, P183, DOI 10.1007/s00294-014-0423-4; Sakuradani E, 2009, APPL MICROBIOL BIOT, V84, P1, DOI 10.1007/s00253-009-2076-7; Ando A, 2009, CURR GENET, V55, P349, DOI 10.1007/s00294-009-0250-1; da Silva Ferreira Márcia Eliana, 2006, Eukaryot Cell, V5, P207, DOI 10.1128/EC.5.1.207-211.2006; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Ishibashi K, 2006, P NATL ACAD SCI USA, V103, P14871, DOI 10.1073/pnas.0604477103; JAREONKITMONGKOL S, 1993, APPL ENVIRON MICROB, V59, P4300; Kooistra R, 2004, YEAST, V21, P781, DOI 10.1002/yea.1131; Takahashi Tadashi, 2006, Mol Genet Genomics, V275, P460, DOI 10.1007/s00438-006-0104-1; Tani S, 2013, AMB EXPRESS, V3, DOI 10.1186/2191-0855-3-4	45	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8083	1432-0983		CURR GENET	Curr. Genet.	NOV	2015	61	4					579	589		10.1007/s00294-015-0481-2		11	Genetics & Heredity	Genetics & Heredity	CT8CX	WOS:000363043700011		
J	Yoshikawa, M; Hirabayashi, M; Ito, R; Ozaki, S; Aizawa, S; Masuda, T; Senzaki, K; Shiga, T				Yoshikawa, Masaaki; Hirabayashi, Mizuki; Ito, Ryota; Ozaki, Shigeru; Aizawa, Shin; Masuda, Tomoyuki; Senzaki, Kouji; Shiga, Takashi			Contribution of the Runx1 transcription factor to axonal pathfinding and muscle innervation by hypoglossal motoneurons	DEVELOPMENTAL NEUROBIOLOGY			English	Article						Runx; transcription factor; hypoglossal neuron; CGRP; axonal projection	INDUCED NEURONAL ENDOPEPTIDASE; NOCICEPTIVE SENSORY NEURONS; ROOT GANGLION NEURONS; GENE-RELATED PEPTIDE; NEUROMUSCULAR-JUNCTION; NERVOUS-SYSTEM; MOTOR-NEURONS; MOUSE-BRAIN; NEUROPATHIC PAIN; MESSENGER-RNA	The runt-related transcription factor Runx1 contributes to cell type specification and axonal targeting projections of the nociceptive dorsal root ganglion neurons. Runx1 is also expressed in the central nervous system, but little is known of its functions in brain development. At mouse embryonic day (E) 17.5, Runx1-positive neurons were detected in the ventrocaudal subdivision of the hypoglossal nucleus. Runx1-positive neurons lacked calcitonin gene-related peptide (CGRP) expression, whereas Runx1-negative neurons expressed CGRP. Expression of CGRP was not changed in Runx1-deficient mice at E17.5, suggesting that Runx1 alone does not suppress CGRP expression. Hypoglossal axon projections to the intrinsic vertical (V) and transverse (T) tongue muscles were sparser in Runx1-deficient mice at E17.5 compared to age-matched wild-type littermates. Concomitantly, vesicular acetylcholine transporter-positive axon terminals and acetylcholine receptor clusters were less dense in the V and T tongue muscles of Runx1-deficient mice. These abnormalities in axonal projection were not caused by a reduction in the total number hypoglossal neurons, failed synaptogenesis, or tongue muscles deficits. Our results implicate Runx1 in the targeting of ventrocaudal hypoglossal axons to specific tongue muscles. However, Runx1 deficiency did not alter neuronal survival or the expression of multiple motoneuron markers as in other neuronal populations. Thus, Runx1 appears to have distinct developmental functions in different brain regions. (c) 2015 Wiley Periodicals, Inc. Develop Neurobiol 75: 1295-1314, 2015	[Yoshikawa, Masaaki; Aizawa, Shin] Nihon Univ, Sch Med, Dept Funct Morphol, Div Anat Sci,Itabashi Ku, Tokyo 1738610, Japan; [Yoshikawa, Masaaki; Hirabayashi, Mizuki; Ito, Ryota; Ozaki, Shigeru; Masuda, Tomoyuki; Senzaki, Kouji; Shiga, Takashi] Univ Tsukuba, Grad Sch Comprehens Human Sci, Doctoral Program Kansei Behav & Brain Sci, Tsukuba, Ibaraki 3058577, Japan	Shiga, T (reprint author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Doctoral Program Kansei Behav & Brain Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan.	tshiga@md.tsukuba.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	Contract grant sponsor: Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (Scientific Research (B) to T.S.).	Samad OA, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-45; Maeda M, 2004, NEUROSCI RES, V48, P305, DOI 10.1016/j.neures.2003.11.008; STURROCK RR, 1991, J ANAT, V179, P67; Baudet C, 2008, J NEUROSCI, V28, P963, DOI 10.1523/JNEUROSCI.4489-07.2008; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Huettl RE, 2011, DEV BIOL, V359, P230, DOI 10.1016/j.ydbio.2011.08.019; Yang FC, 2013, CELL REP, V5, P1353, DOI 10.1016/j.celrep.2013.11.005; Trifonov S, 2009, NEUROSCIENCE, V159, P344, DOI 10.1016/j.neuroscience.2008.12.054; Wu HH, 2013, DEV NEUROSCI-BASEL, V35, P1, DOI 10.1159/000346367; Demireva EY, 2011, CELL, V147, P641, DOI 10.1016/j.cell.2011.09.037; Hubbard SR, 2013, BBA-PROTEINS PROTEOM, V1834, P2166, DOI 10.1016/j.bbapap.2013.02.034; Nagata K, 2010, J NEUROSCI, V30, P6954, DOI 10.1523/JNEUROSCI.4521-09.2010; Gascon E, 2010, J NEUROSCI, V30, P12414, DOI 10.1523/JNEUROSCI.3135-10.2010; Lou S, 2013, J NEUROSCI, V33, P870, DOI 10.1523/JNEUROSCI.3942-12.2013; Nagata K, 2006, NEUROSCIENCE, V141, P299, DOI 10.1016/j.neuroscience.2006.03.032; Stifani S, 2009, BLOOD CELL MOL DIS, V43, P20, DOI 10.1016/j.bcmd.2009.03.001; Yoshikawa M, 2013, DEV NEUROBIOL, V73, P469, DOI 10.1002/dneu.22073; Yu T, 1998, J NEUROSCI, V18, P4684; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051; Fregosi RF, 2011, RESP PHYSIOL NEUROBI, V179, P43, DOI 10.1016/j.resp.2011.06.023; TAKASU N, 1988, J COMP NEUROL, V271, P461, DOI 10.1002/cne.902710313; Inoue KI, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-20; Bonanomi D, 2012, CELL, V148, P568, DOI 10.1016/j.cell.2012.01.024; DOBBINS EG, 1995, J COMP NEUROL, V357, P376, DOI 10.1002/cne.903570305; Lallemend F, 2012, TRENDS NEUROSCI, V35, P373, DOI 10.1016/j.tins.2012.03.006; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Witzemann V, 2006, CELL TISSUE RES, V326, P263, DOI 10.1007/s00441-006-0237-x; Uemura M, 2006, DEV DYNAM, V235, P2559, DOI 10.1002/dvdy.20841; Kramer I, 2006, NEURON, V49, P379, DOI 10.1016/j.neuron.2006.01.008; Ichikawa M, 2013, INT J HEMATOL, V97, P726, DOI 10.1007/s12185-013-1347-3; ALDES LD, 1995, J COMP NEUROL, V353, P89, DOI 10.1002/cne.903530109; Marmigere F, 2006, NAT NEUROSCI, V9, P180, DOI 10.1038/nn1631; Reber M, 2007, ADV EXP MED BIOL, V621, P32, DOI 10.1007/978-0-387-76715-4_3; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Dudanova I, 2013, TRENDS NEUROSCI, V36, P295, DOI 10.1016/j.tins.2013.01.007; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Mikaels A, 2000, EUR J NEUROSCI, V12, P446, DOI 10.1046/j.1460-9568.2000.00924.x; Kao TJ, 2012, SEMIN CELL DEV BIOL, V23, P83, DOI 10.1016/j.semcdb.2011.10.016; Garcia NVDM, 2008, NEURON, V57, P217, DOI 10.1016/j.neuron.2007.11.033; Tamura S, 2003, EUR J NEUROSCI, V17, P2287, DOI 10.1046/j.1460-9568.2003.02681.x; Yokomizo T, 2007, EMBO J, V26, P184, DOI 10.1038/sj.emboj.7601480; Zagami CJ, 2009, J CELL BIOCHEM, V107, P1063, DOI 10.1002/jcb.22221; Stifani N, 2008, P NATL ACAD SCI USA, V105, P6451, DOI 10.1073/pnas.0711299105; Mbiene JP, 1997, ACTA ANAT, V160, P139; Wu HT, 2010, DEVELOPMENT, V137, P1017, DOI 10.1242/dev.038711; Egea J, 2007, TRENDS CELL BIOL, V17, P230, DOI 10.1016/j.tcb.2007.03.004; Haase G, 2002, NEURON, V35, P893, DOI 10.1016/S0896-6273(02)00864-4; Caton A, 2000, DEVELOPMENT, V127, P1751; Terrado J, 1999, NEUROSCIENCE, V92, P713, DOI 10.1016/S0306-4522(98)00730-1; Yoshikawa M, 2007, DEV BIOL, V303, P663, DOI 10.1016/j.ydbio.2006.12.007; Yamane A, 2001, J DENT RES, V80, P1840; Skouras E, 2011, ANN ANAT, V193, P286, DOI 10.1016/j.aanat.2011.02.014; Lopes C, 2012, J NEUROSCI, V32, P9706, DOI 10.1523/JNEUROSCI.1109-12.2012; Ferraro E, 2012, J CACHEXIA SARCOPENI, V3, P13, DOI 10.1007/s13539-011-0041-7; Dormand EL, 1998, DEVELOPMENT, V125, P1659; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Sato T, 2011, CELL MOL NEUROBIOL, V31, P155, DOI 10.1007/s10571-010-9601-1; McClung JR, 1999, ANAT REC, V254, P222, DOI 10.1002/(SICI)1097-0185(19990201)254:2<222::AID-AR8>3.0.CO;2-B; Chen CL, 2006, NEURON, V49, P365, DOI 10.1016/j.neuron.2005.10.036; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Kobayashi K, 2011, EUR J NEUROSCI, V33, P612, DOI 10.1111/j.1460-9568.2010.07554.x; Lin WC, 2000, P NATL ACAD SCI USA, V97, P1299, DOI 10.1073/pnas.97.3.1299; Theriault FM, 2005, J NEUROSCI, V25, P2050, DOI 10.1523/JNEUROSCI.5108-04.2005; Lamballe F, 2011, J NEUROSCI, V31, P11144, DOI 10.1523/JNEUROSCI.2198-11.2011; Liu Y, 2011, CURR OPIN NEUROBIOL, V21, P52, DOI 10.1016/j.conb.2010.09.003; McClung JR, 2002, BRAIN RES, V950, P321, DOI 10.1016/S0006-8993(02)03240-7; Theriault FM, 2004, P NATL ACAD SCI USA, V101, P10343, DOI 10.1073/pnas.0400768101; TAKAMI K, 1985, BRAIN RES, V328, P386, DOI 10.1016/0006-8993(85)91055-8; Bonanomi D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001735; Dansen JS, 2005, CELL, V123, P477; Hua ZL, 2014, DEVELOPMENT, V141, P3944, DOI 10.1242/dev.110189; Hua ZL, 2013, ELIFE, V2, DOI 10.7554/eLife.01482; Sokoloff A, 2013, CRANIOFACIAL MUSCLES, P207; de Bruijn MFTR, 2004, ONCOGENE, V23, P4238, DOI 10.1038/sj.onc.1207763; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; Vinsant S, 2013, BRAIN BEHAV, V3, P335, DOI 10.1002/brb3.143	77	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-8451	1932-846X		DEV NEUROBIOL	Dev. Neurobiol.	NOV	2015	75	11					1295	1314		10.1002/dneu.22285		20	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	CT5HI	WOS:000362839200010		
J	Fukuyama, H; Qin, SB; Kanakogi, Y; Nagai, Y; Asada, M; Myowa-Yamakoshi, M				Fukuyama, Hiroshi; Qin, Shibo; Kanakogi, Yasuhiro; Nagai, Yukie; Asada, Minoru; Myowa-Yamakoshi, Masako			Infant's action skill dynamically modulates parental action demonstration in the dyadic interaction	DEVELOPMENTAL SCIENCE			English	Article							ADULT-DIRECTED ACTION; MOTHERS SPEECH; MOTIONESE; FATHERS; GAZE; CUES	When interacting with infants, human adults modify their behaviours in an exaggerated manner. Previous studies have demonstrated that infant-directed modification affects the infant's behaviour. However, little is known about how infant-directed modification is elicited during infant-parent interaction. We investigated whether and how the infant's behaviour affects the mother's action during an interaction. We recorded three-dimensional information of cup movements while mothers demonstrated a cup-nesting task during interaction with their infants aged 11 to 13months. Analyses revealed that spatial characteristics of the mother's task demonstration clearly changed depending on the infant's object manipulation. In particular, the variance in the distance that the cup was moved decreased after the infant's cup nesting and increased after the infant's task-irrelevant manipulation (e.g. cup banging). This pattern was not observed for mothers with 6- to 8-month-olds, who do not have the fine motor skill to perform the action. These results indicate that the infant's action skill dynamically affects the infant-directed action and suggest that the mother is sensitive to the infant's potential to learn a novel action.	[Fukuyama, Hiroshi; Kanakogi, Yasuhiro; Myowa-Yamakoshi, Masako] Kyoto Univ, Grad Sch Educ, Kyoto 6068501, Japan; [Qin, Shibo; Nagai, Yukie; Asada, Minoru] Osaka Univ, Grad Sch Engn, Suita, Osaka 565, Japan	Fukuyama, H (reprint author), Sakyo Ku, Kyoto 6068501, Japan.	hirofukuyama519@gmail.com			Japan Society for the Promotion of Science and the Ministry of Education Culture, Sports, Science and Technology [24300103, 24119005, 24119003, 11J06449]; ERATO, Okanoya Emotional Information Project, Japan Science and Technology Agency	The research reported here was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science and the Ministry of Education Culture, Sports, Science and Technology (24300103, 24119005, 24119003, and 11J06449) and ERATO, Okanoya Emotional Information Project, Japan Science and Technology Agency.	Rohlfing KJ, 2006, ADV ROBOTICS, V20, P1183, DOI 10.1163/156855306778522532; COOPER RP, 1990, CHILD DEV, V61, P1584, DOI 10.1111/j.1467-8624.1990.tb02885.x; Brand RJ, 2002, DEVELOPMENTAL SCI, V5, P72, DOI 10.1111/1467-7687.00211; Chong SCF, 2003, INFANT CHILD DEV, V12, P211, DOI 10.1002/icd.286; Rutherford MD, 2012, J EXP CHILD PSYCHOL, V111, P367, DOI 10.1016/j.jecp.2011.10.012; Thiessen ED, 2005, INFANCY, V7, P53, DOI 10.1207/s15327078in0701_5; Smith NA, 2008, INFANCY, V13, P410, DOI 10.1080/15250000802188719; Senju A, 2008, CURR BIOL, V18, P668, DOI 10.1016/j.cub.2008.03.059; Burnham D, 2002, SCIENCE, V296, P1435, DOI 10.1126/science.1069587; Biro S, 2007, DEVELOPMENTAL SCI, V10, P379, DOI 10.1111/j.1467-7687.2006.00544.x; Brand RJ, 2008, DEVELOPMENTAL SCI, V11, P853, DOI 10.1111/j.1467-7687.2008.00734.x; Amano S, 2006, J ACOUST SOC AM, V119, P1636, DOI 10.1121/1.2161443; FERNALD A, 1991, DEV PSYCHOL, V27, P209, DOI 10.1037/0012-1649.27.2.209; Koterba EA, 2009, INFANT BEHAV DEV, V32, P437, DOI 10.1016/j.infbeh.2009.07.003; KRUPER JC, 1987, J PSYCHOLINGUIST RES, V16, P597, DOI 10.1007/BF01067087; Uther M, 2007, SPEECH COMMUN, V49, P2, DOI 10.1016/j.specom.2006.10.003; GERGELY G, 1995, COGNITION, V56, P165, DOI 10.1016/0010-0277(95)00661-H; Brand RJ, 2007, INFANCY, V11, P203; PAPOUSEK M, 1987, J PSYCHOLINGUIST RES, V16, P491, DOI 10.1007/BF01073274; FERNALD A, 1993, CHILD DEV, V64, P637; Brand R. J., 2013, J EXPT CHILD PSYCHOL, V118, P119; Lorenz K. Z., 1965, EVOLUTION MODIFICATI; Fukuyama H, 2013, INFANT BEHAV DEV, V36, P609, DOI 10.1016/j.infbeh.2013.06.005; Vygotsky L.S., 1978, MIND SOC DEV HIGHER	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1363-755X	1467-7687		DEVELOPMENTAL SCI	Dev. Sci.	NOV	2015	18	6					1006	1013		10.1111/desc.12270		8	Psychology, Developmental; Psychology, Experimental	Psychology	CT6GM	WOS:000362911400013		
J	de Bouard, A; Fukuizumi, R; Poncet, R				de Bouard, Anne; Fukuizumi, Reika; Poncet, Romain			VORTEX SOLUTIONS IN BOSE-EINSTEIN CONDENSATION UNDER A TRAPPING POTENTIAL VARYING RANDOMLY IN TIME	DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B			English	Article						Nonlinear Schrodinger equation; stochastic partial differential equations; white noise; harmonic potential; vortices; collective coordinates approach	NONLINEAR SCHRODINGER-EQUATIONS; DE-VRIES EQUATION; NLS SOLITARY WAVES; CAUCHY-PROBLEM; GROUND-STATE; DYNAMICS; SOLITONS; NOISE; GAS; MODULATION	The aim of this paper is to perform a theoretical and numerical study on the dynamics of vortices in Bose-Einstein condensation in the case where the trapping potential varies randomly in time. We take a deterministic vortex solution as an initial condition for the stochastically fluctuated Gross-Pitaevskii equation, and we observe the influence of the stochastic perturbation on the evolution. We theoretically prove that up to times of the order of epsilon(-2), the solution having the same symmetry properties as the vortex decomposes into the sum of a randomly modulated vortex solution and a small remainder, and we derive the equations for the modulation parameter. In addition, we show that the first order of the remainder, as epsilon goes to zero, converges to a Gaussian process. Finally, some numerical simulations on the dynamics of the vortex solution in the presence of noise are presented.	[de Bouard, Anne] Ecole Polytech, CNRS, Ctr Math Appl, F-91128 Palaiseau, France; [de Bouard, Anne] Ecole Polytech, F-91128 Palaiseau, France; [Fukuizumi, Reika] Tohoku Univ, Grad Sch Informat Sci, Res Ctr Pure & Appl Math, Sendai, Miyagi 9808579, Japan; [Poncet, Romain] Ecole Polytech, Ctr Math Appl, F-91128 Palaiseau, France	de Bouard, A (reprint author), Ecole Polytech, CNRS, Ctr Math Appl, F-91128 Palaiseau, France.	debouard@cmap.polytechnique.fr; fukuizumi@math.is.tohoku.ac.jp; romain.poncet@cmap.polytechnique.fr			JSPS KAKENHI [24740079]; ANR project BECASIM [ANR-12-MONU-0007]	This work was supported by JSPS KAKENHI Grant Number 24740079, and the ANR project ANR-12-MONU-0007 BECASIM. The second author is grateful to M. Kobayashi for helpful discussions, and would like to thank R. Carles to indicate her the paper [36]. We also aknowledge R. Belaouar for his help with numerical simulations.	Abdullaev F.Kh., 2001, NATO SCI SERIES 2, V45, P69; GINIBRE J, 1984, ANN I H POINCARE-AN, V1, P309; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Frohlich J, 2004, COMMUN MATH PHYS, V250, P613, DOI 10.1007/s00220-004-1128-1; Suslov SK, 2010, PHYS SCRIPTA, V81, DOI 10.1088/0031-8949/81/05/055006; de Bouard A, 2007, ANN I H POINCARE-AN, V24, P251, DOI 10.1016/j.anihpc.2006.03.009; de Bouard A, 2009, ASYMPTOTIC ANAL, V63, P189, DOI 10.3233/ASY-2008-0931; Bao WZ, 2004, SIAM J SCI COMPUT, V25, P1674, DOI 10.1137/S1064827503422956; Di Menza L, 2009, ESAIM-MATH MODEL NUM, V43, P173, DOI 10.1051/m2an:2008044; BRADLEY CC, 1995, PHYS REV LETT, V75, P1687, DOI 10.1103/PhysRevLett.75.1687; de Bouard A, 2010, DISCRETE CONT DYN S, V26, P857, DOI 10.3934/dcds.2010.26.857; Pego RL, 2002, J NONLINEAR SCI, V12, P347, DOI 10.1007/s00332-002-0475-3; Abdullaev FK, 2000, PHYSICA D, V135, P369, DOI 10.1016/S0167-2789(99)00118-9; IAIA J, 1995, J DIFFER EQUATIONS, V119, P533, DOI 10.1006/jdeq.1995.1101; Gehm ME, 1998, PHYS REV A, V58, P3914, DOI 10.1103/PhysRevA.58.3914; QuirogaTeixeiro M, 1997, J OPT SOC AM B, V14, P2004, DOI 10.1364/JOSAB.14.002004; de Bouard A, 2009, ELECTRON J PROBAB, V14, P1727; Mizumachi T, 2005, DIFFER INTEGRAL EQU, V18, P431; Seiringer R, 2002, COMMUN MATH PHYS, V229, P491, DOI 10.1007/s00220-002-0695-2; Bao WZ, 2005, MATH MOD METH APPL S, V15, P1863, DOI 10.1142/S021820250500100X; Fibich G, 2008, PHYSICA D, V237, P2696, DOI 10.1016/j.physd.2008.04.018; Chang SM, 2007, SIAM J MATH ANAL, V39, P1070, DOI 10.1137/050648389; Savard TA, 1997, PHYS REV A, V56, pR1095; Jonsson BLG, 2006, ANN HENRI POINCARE, V7, P621, DOI 10.1007/s00023-006-0263-y; de Bouard A, 2012, NONLINEARITY, V25, P2993, DOI 10.1088/0951-7715/25/11/2993; Berezin F. A., 1983, SCHRODINGER EQUATION; Cazenave T, 2003, COURANT LECT NOTES M, V10; Di Menza F., PREPRINT; de Bouard Anne, 2007, Nonlinearity, V20, DOI 10.1088/0951-7715/20/12/005; Kollar R., 2004, THESIS U MARYLAND CO; Kollar R, 2012, APPL MATH RES EXPRES, V1, P1; Maeda M., 2008, THESIS KYOTO U; Mizumachi T., 2007, ADV DIFFERENTIAL EQU, V12, P241; OH YG, 1989, J DIFFER EQUATIONS, V81, P255, DOI 10.1016/0022-0396(89)90123-X; Pitaevskii L P, 2003, BOSE EINSTEIN CONDEN; Reed M., 1975, METHOD MODERN MATH P; Reed M., 1975, METHOD MODERN MATH P; Reed M., 1975, METHOD MODERN MATH P; Reed M., 1975, METHOD MODERN MATH P; TITCHMARSH E. C., 1962, EIGENFUNCTION EXPA 1; WEINSTEIN MI, 1985, SIAM J MATH ANAL, V16, P472, DOI 10.1137/0516034	41	0	0	AMER INST MATHEMATICAL SCIENCES	SPRINGFIELD	PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA	1531-3492	1553-524X		DISCRETE CONT DYN-B	Discrete Contin. Dyn. Syst.-Ser. B	NOV	2015	20	9					2793	2817		10.3934/dcdsb.2015.20.2793		25	Mathematics, Applied	Mathematics	CT4AO	WOS:000362748300002		
J	Muroya, Y; Kuniya, T; Enatsu, Y				Muroya, Yoshiaki; Kuniya, Toshikazu; Enatsu, Yoichi			GLOBAL STABILITY OF A DELAYED MULTI-GROUP SIRS EPIDEMIC MODEL WITH NONLINEAR INCIDENCE RATES AND RELAPSE OF INFECTION	DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B			English	Article						Multi-group model; delay; nonlinear incidence rate; permanence; global asymptotic stability; Lyapunov functional	LOTKA-VOLTERRA SYSTEMS; TOTAL POPULATION-SIZE; PATCH STRUCTURE; DISTRIBUTED DELAYS; HEROIN EPIDEMICS; INFINITE DELAY; DISEASES; TRANSMISSION; MIGRATION; DYNAMICS	In this paper, we investigate the global stability of a delayed multigroup SIRS epidemic model which includes not only nonlinear incidence rates but also rates of immunity loss and relapse of infection. The model analysis can be regarded as an extension to a multi-group epidemic analysis in [Muroya, Li and Kuniya, Complete global analysis of an SIRS epidemic model with graded cure rate and incomplete recovery rate, J. Math. Anal. Appl. 410 (2014) 719-732] is studied. Applying a Lyapunov functional approach, we prove that a disease-free equilibrium of the model, is globally asymptotically stable, if a threshold parameter R-0 <= 1. For the global stability of an endemic equilibrium of the model, we establish a sufficient condition for small recovery rates delta(k) >= 0, k = 1, 2,..., n, if R-0 > 1. Further, by a monotone iterative approach, we obtain another sufficient condition for large delta(k), k = 1, 2,..., n. Both results generalize several known results obtained for, e.g., SIS, SIR and SIRS models in the recent literature. We also offer a new proof on permanence which is applicable to other multi-group epidemic models.	[Muroya, Yoshiaki] Waseda Univ, Dept Math, Shinjuku Ku, Tokyo 1698555, Japan; [Kuniya, Toshikazu] Kobe Univ, Grad Sch Syst Informat, Nada Ku, Kobe, Hyogo 6578501, Japan; [Enatsu, Yoichi] Tokyo Univ Sci, Dept Math Informat Sci, Shinjuku Ku, Tokyo 1628601, Japan	Muroya, Y (reprint author), Waseda Univ, Dept Math, Shinjuku Ku, 3-4-1 Ohkubo, Tokyo 1698555, Japan.	ymuroya@waseda.jp; tkuniya@port.kobe-u.ac.jp; yenatsu@rs.tus.ac.jp			JSPS KAKENHI [15K05010, 15K17585, 26800066]; program of the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID); Japan Agency for Medical Research and Development, AMED	The first author is supported by JSPS KAKENHI Grant Number 15K05010. The second author is supported by JSPS KAKENHI Grant Number 15K17585 and the program of the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID); from Japan Agency for Medical Research and Development, AMED. The third author is supported by JSPS KAKENHI Grant Number 26800066.	Kuniya T, 2015, APPL MATH COMPUT, V265, P785, DOI 10.1016/j.amc.2015.05.124; Kuniya T, 2014, DISCRETE CONT DYN-B, V19, P1105, DOI 10.3934/dcdsb.2014.19.1105; Li MY, 2010, J MATH ANAL APPL, V361, P38, DOI 10.1016/j.jmaa.2009.09.017; Chen YM, 2014, MATH BIOSCI ENG, V11, P449, DOI [10.3934/mbe.2014.11. 449, 10.3934/mbe.2014.11.449]; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; Guo HB, 2008, P AM MATH SOC, V136, P2793, DOI 10.1090/S0002-9939-08-09341-6; Muroya Y, 2013, ACTA MATH SCI, V33, P341; White E, 2007, MATH BIOSCI, V208, P312, DOI 10.1016/j.mbs.2006.10.008; Beretta E, 2001, NONLINEAR ANAL-THEOR, V47, P4107, DOI 10.1016/S0362-546X(01)00528-4; McCluskey CC, 2010, NONLINEAR ANAL-REAL, V11, P55, DOI 10.1016/j.nonrwa.2008.10.014; Gomes MGM, 2005, J MATH BIOL, V51, P414, DOI 10.1007/s00285-005-0331-9; Muroya Y, 2015, DISCRETE CONT DYN-S, V8, P999, DOI 10.3934/dcdss.2015.8.999; Nakata Y, 2015, J MATH BIOL, V70, P1411, DOI 10.1007/s00285-014-0801-z; Huang G, 2013, APPL MATH LETT, V26, P687, DOI 10.1016/j.aml.2013.01.010; Muroya Y, 2014, APPL MATH LETT, V38, P73, DOI 10.1016/j.aml.2014.07.005; Muroya Y, 2013, NONLINEAR ANAL-REAL, V14, P1693, DOI 10.1016/j.nonrwa.2012.11.005; Muroya Y, 2014, ACTA MATH SCI, V34, P1427; Liu JL, 2009, CHAOS SOLITON FRACT, V40, P145, DOI 10.1016/j.chaos.2007.07.047; Yuan ZH, 2010, NONLINEAR ANAL-REAL, V11, P3479, DOI 10.1016/j.nonrwa.2009.12.008; Liu JL, 2011, APPL MATH LETT, V24, P1685, DOI 10.1016/j.aml.2011.04.019; Chen H, 2011, APPL MATH COMPUT, V218, P4391, DOI 10.1016/j.amc.2011.10.015; Muroya Y, 2011, NONLINEAR ANAL-REAL, V12, P1897, DOI 10.1016/j.nonrwa.2010.12.002; Sun RY, 2010, COMPUT MATH APPL, V60, P2286, DOI 10.1016/j.camwa.2010.08.020; Wang JL, 2015, J NONLINEAR SCI APPL, V8, P578; Mulone G, 2009, MATH BIOSCI, V218, P138, DOI 10.1016/j.mbs.2009.01.006; MENALORCA J, 1992, J MATH BIOL, V30, P693; Enatsu Y, 2012, NONLINEAR ANAL-REAL, V13, P2120, DOI 10.1016/j.nonrwa.2012.01.007; Fang B, 2014, DISCRETE CONT DYN-B, V19, P715, DOI 10.3934/dcdsb.2014.19.715; Muroya Y, 2014, J MATH ANAL APPL, V410, P719, DOI 10.1016/j.jmaa.2013.08.024; Yuan ZH, 2010, NONLINEAR ANAL-REAL, V11, P995, DOI 10.1016/j.nonrwa.2009.01.040; Muroya Y, 2015, INT J BIOMATH, V8, DOI 10.1142/S1793524515500485; Arino J., 2009, SER CONT APPL MATH C, V11, P64; Berman A., 1979, NONNEGATIVE MATRICES; DIEKMANN O, 1990, J MATH BIOL, V28, P365; Faria T, 2015, P ROY SOC EDINB A, V145, P301, DOI 10.1017/S0308210513001194; Faria T, 2014, APPL MATH COMPUT, V245, P575, DOI 10.1016/j.amc.2014.08.009; Guo H., 2006, CAN APPL MATH Q, V14, P259; Hale J. K., 1993, APPL MATH SCI, V99; KERMACK WO, 1991, B MATH BIOL, V53, P33, DOI 10.1007/BF02464423; Kuniya T, 2014, MATH BIOSCI ENG, V11, P1375, DOI [10.3934/mbe.2014.11. 1375, 10.3934/mbe.2014.11.1375]; LAJMANOVICH A, 1976, Mathematical Biosciences, V28, P221, DOI 10.1016/0025-5564(76)90125-5; LaSalle J. P., 1976, REGIONAL C SERIES AP; Li MY, 2010, J DIFFER EQUATIONS, V248, P1, DOI 10.1016/j.jde.2009.09.003; Muroya Y, 2015, MATH METHOD APPL SCI, V38, P281, DOI 10.1002/mma.3068; Muroya Y., 1968, MEM FS KYUSHU U A, V22, P56, DOI 10.2206/kyushumfs.22.56; Muroya Y, 2015, J MATH ANAL APPL, V425, P415, DOI 10.1016/j.jmaa.2014.12.019; Nakata Y., 2015, SUT J MATH, V50, P205; Nakata Y., 2011, DISCRETE CONT DYN-A, V2011, P1119; Ortega J., 1967, SIAM J NUM, V4, P171, DOI 10.1137/0704017; Shu HY, 2012, NONLINEAR ANAL-REAL, V13, P1581, DOI 10.1016/j.nonrwa.2011.11.016; van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6; Wang JL, 2012, INT J BIOMATH, V5, DOI 10.1142/S1793524512600017; Zhao X. Q., 1996, CANAD APPL MATH Q, V4, P421	53	0	0	AMER INST MATHEMATICAL SCIENCES	SPRINGFIELD	PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA	1531-3492	1553-524X		DISCRETE CONT DYN-B	Discrete Contin. Dyn. Syst.-Ser. B	NOV	2015	20	9					3057	3091		10.3934/dcdsb.2015.20.3057		35	Mathematics, Applied	Mathematics	CT4AO	WOS:000362748300012		
J	Otani, Y; Kajiwara, T; Sasaki, T				Otani, Yoji; Kajiwara, Tsuyoshi; Sasaki, Toru			LYAPUNOV FUNCTIONALS FOR VIRUS-IMMUNE MODELS WITH INFINITE DELAY	DISCRETE AND CONTINUOUS DYNAMICAL SYSTEMS-SERIES B			English	Article						Lyapunov functional; infinitely distributed delay; virus-immune model; delay differential equation; global stability	SEIR EPIDEMIOLOGIC MODEL; VARYING INFECTIVITY; GLOBAL STABILITY; DYNAMICS; CONSTRUCTION; PERSISTENCE; SYSTEMS	We present a systematic method to construct Lyapunov functionals of delay differential equation models of infectious diseases in vivo. For generality we construct Lyapunov functionals of models with infinitely distributed delay. We begin with simpler models without delay and construct Lyapunov functionals for the complex models progressively. We construct those functionals using our result obtained previously instead of constructing each functional independently. Additionally we discuss some problems that arise from the mathematical requirements caused by the infinitely distributed delay.	[Otani, Yoji] Okayama Univ, Grad Sch Environm Sci, Okayama 7008530, Japan; [Kajiwara, Tsuyoshi; Sasaki, Toru] Okayama Univ, Grad Sch Environm & Life Sci, Okayama 7008530, Japan	Otani, Y (reprint author), Okayama Univ, Grad Sch Environm Sci, Okayama 7008530, Japan.	gev421104@s.okayama-u.ac.jp; kajiwara@ems.okayama-u.ac.jp; sasaki@ems.okayama-u.ac.jp			JSPS KAKENHI [22540135]	This work is partly supported by JSPS KAKENHI Grants Number 22540135. The authors wish to thank the referees and the editors for their very helpful comments and suggestions.	BURTON T, 1989, J MATH ANAL APPL, V137, P240, DOI 10.1016/0022-247X(89)90287-4; Rost G, 2008, MATH BIOSCI ENG, V5, P389; Iggidr A, 2006, SIAM J APPL MATH, V67, P260, DOI 10.1137/050643271; HALE JK, 1989, SIAM J MATH ANAL, V20, P388, DOI 10.1137/0520025; Thieme HR, 1999, P AM MATH SOC, V127, P2395, DOI 10.1090/S0002-9939-99-05034-0; Wang JL, 2012, MATH MED BIOL, V29, P283, DOI 10.1093/imammb/dqr009; McCluskey CC, 2009, MATH BIOSCI ENG, V6, P603, DOI 10.3934/mbe.2009.6.603; Murase A, 2005, J MATH BIOL, V51, P247, DOI 10.1007/s00285-005-0321-y; Inoue Toru, 2010, Journal of Biological Dynamics, V4, P282, DOI 10.1080/17513750903180275; Korobeinikov A, 2004, B MATH BIOL, V66, P879, DOI 10.1016/j.bulm.2004.02.001; Kajiwara T, 2012, NONLINEAR ANAL-REAL, V13, P1802, DOI 10.1016/j.nonrwa.2011.12.011; Gomez-Acevedo H, 2010, B MATH BIOL, V72, P681, DOI 10.1007/s11538-009-9465-z; Kajiwara T, 2015, MATH BIOSCI ENG, V12, P117, DOI 10.3934/mbe.2015.12.117; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; Atkinson F.V., 1988, FUNKC EKVACIOJ-SER I, V31, P331; Hale J. K., 1978, FUNKC EKVACIOJ-SER I, V21, P11	16	0	0	AMER INST MATHEMATICAL SCIENCES	SPRINGFIELD	PO BOX 2604, SPRINGFIELD, MO 65801-2604 USA	1531-3492	1553-524X		DISCRETE CONT DYN-B	Discrete Contin. Dyn. Syst.-Ser. B	NOV	2015	20	9					3093	3114		10.3934/dedsb.2015.20.3093		22	Mathematics, Applied	Mathematics	CT4AO	WOS:000362748300013		
J	Tokunaga, R; Sakamoto, Y; Nakagawa, S; Miyamoto, Y; Yoshida, N; Oki, E; Watanabe, M; Baba, H				Tokunaga, Ryuma; Sakamoto, Yasuo; Nakagawa, Shigeki; Miyamoto, Yuji; Yoshida, Naoya; Oki, Eiji; Watanabe, Masayuki; Baba, Hideo			Prognostic Nutritional Index Predicts Severe Complications, Recurrence, and Poor Prognosis in Patients With Colorectal Cancer Undergoing Primary Tumor Resection	DISEASES OF THE COLON & RECTUM			English	Article						Colorectal cancer; Complication; Prognosis; Prognostic nutritional index; Recurrence	LONG-TERM OUTCOMES; GASTRIC-CANCER; SURGICAL COMPLICATIONS; T-CELLS; INFLAMMATION; CLASSIFICATION; RECOMMENDATIONS; NIVOLUMAB; SURVIVAL	BACKGROUND: The prognostic nutritional index is reportedly related to postoperative outcomes. OBJECTIVE: The aim of this study was to elucidate the clinical importance of the prognostic nutritional index in patients with colorectal cancer who were undergoing primary tumor resection. DESIGN: This is a retrospective study from a single institution. SETTINGS: This study was conducted at a colorectal surgery service in an academic teaching hospital. PATIENTS: The 556 patients with colorectal cancer who were undergoing surgery between March 2005 and August 2014 were eligible for this study. MAIN OUTCOME MEASURES: The preoperative prognostic nutritional index was calculated. Classification and regression tree analysis was performed to determine the prognostic nutritional index cutoff value. The associations of the prognostic nutritional index status with clinicopathological factors and postoperative outcomes were examined using univariate and multivariate analyses. RESULTS: Classification and regression tree analysis demonstrated that 45.5 was the optimal cutoff value. The low status (45.5) was correlated with older age, low BMI, low estimated glomerular filtration rate, CEA positivity, carbohydrate antigen 19-9 positivity, preoperative chemotherapy, tumors invading muscular or deeper layers, distant metastasis, poor differentiation, severe postoperative complications, tumor recurrence, and poor survival. In multivariate analysis, the low status was an independent risk factor for severe postoperative complications (OR = 2.06 [95% CI, 1.22-3.50]; p = 0.007) and low overall survival (HR =3.98 [95% CI, 2.38-6.89]; p < 0.001). LIMITATIONS: Our data set was collected retrospectively from a single institution. In addition, our study was only for preoperative prognostic nutritional index status, not considering the postoperative host status. CONCLUSIONS: The preoperative prognostic nutritional index predicts severe complications, recurrence, and poor prognosis in patients with colorectal cancer who are undergoing primary tumor resection. Investigation of the nutritional and immunologic statuses using the prognostic nutritional index could be a useful clinical approach.	[Tokunaga, Ryuma; Sakamoto, Yasuo; Nakagawa, Shigeki; Miyamoto, Yuji; Yoshida, Naoya; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kumamoto 8608556, Japan; [Oki, Eiji] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan; [Watanabe, Masayuki] Japanese Fdn Canc Res, Dept Surg Gastroenterol, Tokyo, Japan	Baba, H (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hdobaba@kumamoto-u.ac.jp					Fulcher DA, 1997, IMMUNOL CELL BIOL, V75, P446, DOI 10.1038/icb.1997.69; Liumbruno G, 2009, BLOOD TRANSFUS-ITALY, V7, P216, DOI 10.2450/2009.0094-09; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Yakabe T, 2010, ANN SURG ONCOL, V17, P2349, DOI 10.1245/s10434-010-1004-5; Bang YJ, 2010, LANCET, V376, P1302; Moyes LH, 2009, BRIT J CANCER, V100, P1236, DOI 10.1038/sj.bjc.6604997; Watanabe M, 2012, WORLD J SURG, V36, P1632, DOI 10.1007/s00268-012-1526-z; Feng JF, 2014, THER CLIN RISK MANAG, V10, P1, DOI 10.2147/TCRM.S56159; Watanabe T, 2012, INT J CLIN ONCOL, V17, P1, DOI 10.1007/s10147-011-0315-2; Jiang N, 2014, WORLD J GASTROENTERO, V20, P10537, DOI 10.3748/wjg.v20.i30.10537; Ikeguchi M, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-210; Gettinger SN, 2015, J CLIN ONCOL, V33, P2004, DOI 10.1200/JCO.2014.58.3708; Hess KR, 1999, CLIN CANCER RES, V5, P3403; Crumley ABC, 2010, WORLD J SURG, V34, P2393, DOI 10.1007/s00268-010-0641-y; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Vrisekoop N, 2008, P NATL ACAD SCI USA, V105, P6115, DOI 10.1073/pnas.0709713105; Jamieson AM, 2004, J IMMUNOL, V172, P864; Sun KY, 2014, J CANCER RES CLIN, V140, P1537, DOI 10.1007/s00432-014-1714-3; Erdman SE, 2010, TOXICOL PATHOL, V38, P76, DOI 10.1177/0192623309354110; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Clavien PA, 2009, ANN SURG, V250, P187, DOI 10.1097/SLA.0b013e3181b13ca2; Migita K, 2013, ANN SURG ONCOL, V20, P2647, DOI 10.1245/s10434-013-2926-5; Hirashima K, 2014, J GASTROENTEROL, V49, P1040, DOI 10.1007/s00535-013-0855-5; Mohri Y, 2013, WORLD J SURG, V37, P2688, DOI 10.1007/s00268-013-2156-9; [Anonymous], 2005, JAP SOC CANC COL REC; Papamichael D, 2015, ANN ONCOL, V26, P463, DOI 10.1093/annonc/mdu253; Bast RC, 1996, J CLIN ONCOL, V14, P2843; Pressoir M, 2010, BRIT J CANCER, V102, P966, DOI 10.1038/sj.bjc.6605578; Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057; Goel A, 2012, GASTROENTEROLOGY, V143, P1442, DOI 10.1053/j.gastro.2012.09.032; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group, 2012, KIDNEY INT S, V3, P1; Nachiappan S, 2015, WORLD J SURG, V39, P1052, DOI 10.1007/s00268-014-2887-2; Onodera T, 1984, Nihon Geka Gakkai Zasshi, V85, P1001; Sobin L, 2009, TNM CLASSIFICATION M	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0012-3706	1530-0358		DIS COLON RECTUM	Dis. Colon Rectum	NOV	2015	58	11					1048	1057		10.1097/DCR.0000000000000458		10	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CT6RK	WOS:000362939900004		
J	Kobayashi, T; Masaki, T; Kogawa, K; Matsuoka, H; Sugiyama, M				Kobayashi, Takaaki; Masaki, Tadahiko; Kogawa, Koji; Matsuoka, Hiroyoshi; Sugiyama, Masanori			Efficacy of Gum Chewing on Bowel Movement After Open Colectomy for Left-Sided Colorectal Cancer: A Randomized Clinical Trial	DISEASES OF THE COLON & RECTUM			English	Article						Colorectal surgery; Gastrin; Ghrelin; Gum chewing; Gut hormones; Randomized clinical trial	GASTRIC-ACID-SECRETION; POSTOPERATIVE ILEUS; GASTROINTESTINAL MOTILITY; ENHANCED RECOVERY; FUNCTIONAL DYSPEPSIA; DESACYL GHRELIN; SURGERY; METAANALYSIS; GASTROPARESIS; SEROTONIN	BACKGROUND: Prolonged intestinal paralysis can be a problem after gastrointestinal surgery. Several systematic reviews and meta-analyses have suggested the efficacy of gum chewing for the prevention of postoperative ileus. OBJECTIVE: The purpose of this study was to examine the efficacy of gum chewing for the recovery of bowel function after surgery for left-sided colorectal cancer and to determine the physiological mechanism underlying the effect of gum chewing on bowel function. DESIGN: This was a single-center, placebo-controlled, parallel-group, prospective randomized trial. SETTINGS: The study was conducted at a general hospital in Japan. PATIENTS: Forty-eight patients with left-sided colorectal cancer were included. INTERVENTIONS: The patients were randomly assigned to a gum group (N = 25) and a control group (N = 23). Four patients in the gum group and 1 in the control group were subsequently excluded because of difficulties in continuing the trial, resulting in the analysis of 21 and 22 patients in the respective groups. Patients in the gum group chewed commercial gum 3 times a day for 5 minutes each time from postoperative day 1 to the first day of food intake. MAIN OUTCOME MEASURES: The time to first flatus and first bowel movement after the operation were recorded, and the colonic transit time was measured. Gut hormones (gastrin, des-acyl ghrelin, motilin, and serotonin) were measured preoperatively, perioperatively, and on postoperative days 1, 3, 5, 7, and 10. RESULTS: Gum chewing did not significantly shorten the time to the first flatus (53 2 vs 49 26 hours; p = 0.481; gum vs control group), time to first bowel movement (94 +/- 44 vs 109 +/- 34 hours; p = 0.234), or the colonic transit time (88 +/- 28 vs 88 +/- 21 hours; p = 0.968). However, gum chewing significantly increased the serum levels of des-acyl ghrelin and gastrin. LIMITATIONS: The main limitation was a greater rate of complications than anticipated, which limited the significance of the findings. CONCLUSIONS: Gum chewing changed the serum levels of des-acyl ghrelin and gastrin, but we were unable to demonstrate an effect on the recovery of bowel function.	[Kobayashi, Takaaki; Masaki, Tadahiko; Matsuoka, Hiroyoshi; Sugiyama, Masanori] Kyorin Univ Hosp, Dept Surg, Mitaka, Tokyo 1818611, Japan; [Kogawa, Koji] Kanto Cent Hosp, Dept Surg, Tokyo, Japan	Kobayashi, T (reprint author), Kyorin Univ Hosp, Dept Surg, 6-20-2 Shinkawa, Mitaka, Tokyo 1818611, Japan.	ck9t-kbys@asahi-net.or.jp			Lotte Co, Ltd.	This work was supported by Lotte Co, Ltd.	Schuster R, 2006, ARCH SURG-CHICAGO, V141, P174, DOI 10.1001/archsurg.141.2.174; ANDERSON GM, 1985, GASTROENTEROLOGY, V88, P86; Luiking YC, 2002, NEUROGASTROENT MOTIL, V14, P151, DOI 10.1046/j.1365-2982.2002.00314.x; PILLAI S, 1980, J IMMUNOL METHODS, V39, P181, DOI 10.1016/0022-1759(80)90306-3; Sanger GJ, 2008, NAT REV DRUG DISCOV, V7, P241, DOI 10.1038/nrd2444; Asao T, 2002, J AM COLL SURGEONS, V195, P30, DOI 10.1016/S1072-7515(02)01179-1; Arosio M, 2004, J CLIN ENDOCR METAB, V89, P5101, DOI 10.1210/jc.2003-032222; Ho YM, 2014, DIS COLON RECTUM, V57, P115, DOI 10.1097/DCR.0b013e3182a665be; Chan MKY, 2007, DIS COLON RECTUM, V50, P2149, DOI 10.1007/s10350-007-9039-9; Vasquez W, 2009, J GASTROINTEST SURG, V13, P649, DOI 10.1007/s11605-008-0756-8; BEINFELD MC, 1985, J NEUROSCI, V5, P2502; Khoo J, 2010, NEUROGASTROENT MOTIL, V22, P1270, DOI 10.1111/j.1365-2982.2010.01609.x; Kindt S, 2007, NEUROGASTROENT MOTIL, V19, P32, DOI 10.1111/j.1365-2982.2007.00966.x; Akamizu T, 2005, J CLIN ENDOCR METAB, V90, P6, DOI 10.1210/jc.2004-1640; Quah HM, 2006, COLORECTAL DIS, V8, P64, DOI 10.1111/j.1463-1318.2005.00884.x; Ogiso K, 2011, J GASTROEN HEPATOL, V26, P67, DOI 10.1111/j.1440-1746.2011.06630.x; McCallum RW, 2007, ALIMENT PHARM THERAP, V26, P1121, DOI 10.1111/j.1365-2036.2007.03461.x; Cakir H, 2013, COLORECTAL DIS, V15, P1019, DOI 10.1111/codi.12200; Purkayastha S, 2008, ARCH SURG-CHICAGO, V143, P788, DOI 10.1001/archsurg.143.8.788; NEBINGER P, 1988, J CHROMATOGR-BIOMED, V427, P326, DOI 10.1016/0378-4347(88)80136-1; Parnaby CN, 2009, INT J COLORECTAL DIS, V24, P585, DOI 10.1007/s00384-009-0661-y; Tack J, 2006, GUT, V55, P327, DOI 10.1136/gut.2004.060426; Yakabi K, 2008, WORLD J GASTROENTERO, V14, P6334, DOI 10.3748/wjg.14.6334; Hosoda H, 2004, CLIN CHEM, V50, P1077, DOI 10.1373/clinchem.2003.025841; Sikander A, 2009, CLIN CHIM ACTA, V403, P47, DOI 10.1016/j.cca.2009.01.028; Matros E, 2006, J AM COLL SURGEONS, V202, P773, DOI 10.1016/j.jamcollsurg.2006.02.009; Wo JM, 2011, ALIMENT PHARM THER, V33, P679, DOI 10.1111/j.1365-2036.2010.04567.x; Geltzeiler CB, 2014, JAMA SURG, V149, P955, DOI 10.1001/jamasurg.2014.675; Fukumoto K, 2008, BIOCHEM BIOPH RES CO, V374, P60, DOI 10.1016/j.bbrc.2008.06.114; Hirayama I, 2006, HEPATO-GASTROENTEROL, V53, P206; De Castro MM, 2008, DIGEST SURG, V25, P39, DOI 10.1159/000117822; Ohno T, 2010, INT J PEPT, V2010; Sobin L, 2009, TNM CLASSIFICATION M; Sonoki K, 2005, J KYUSHU DENT SOC, V59, P169; Verkijk M, 1998, AM J PHYSIOL-GASTR L, V275, pG1209	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0012-3706	1530-0358		DIS COLON RECTUM	Dis. Colon Rectum	NOV	2015	58	11					1058	1063		10.1097/DCR.0000000000000452		6	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	CT6RK	WOS:000362939900005		
J	Fujiwara-Greve, T; Okuno-Fujiwara, M; Suzuki, N				Fujiwara-Greve, Takako; Okuno-Fujiwara, Masahiro; Suzuki, Nobue			Efficiency may improve when defectors exist	ECONOMIC THEORY			English	Article						Efficiency; Diversity; Voluntary separation; Prisoner's Dilemma; Endogenous partnerships	REPEATED PRISONERS-DILEMMA; SOCIAL NORMS; COOPERATION; EQUILIBRIUM; INFORMATION	In repeated Prisoner's Dilemma, the C-trigger strategy played by all players is well known to achieve symmetric efficiency when players are sufficiently patient. By contrast, if players are free to quit a repeated Prisoner's Dilemma without information flow to new partners, cooperation from the outset of new partnerships cannot be a part of any symmetric equilibrium. Fujiwara-Greve and Okuno-Fujiwara (Rev Econ Stud 76:993-1021, 2009) showed that symmetric trust-building strategies can constitute an equilibrium for sufficiently long initial (D, D) (trust-building) periods. However, trust-building periods create social loss of payoffs, and there is a possibility that an asymmetric equilibrium with some players cooperating immediately, while others defect, may be more efficient. We show that there is a "fundamentally asymmetric" locally stable Nash equilibrium consisting of the most cooperative strategy (C-trigger with ending the partnership when betrayed) and the most noncooperative strategy, which plays D and ends the partnership immediately. When the deviation gain is relatively small, the fundamentally asymmetric equilibrium is neutrally stable against equilibrium entrants within trust-building strategies and is more efficient than any Nash equilibrium consisting of non-degenerate trust-building strategies. Our result indicates that behavioral diversity can be stable and beneficial for the society, even if players are free to escape from personalized punishments.	[Fujiwara-Greve, Takako] Keio Univ, Dept Econ, Minato Ku, Tokyo 1088345, Japan; [Okuno-Fujiwara, Masahiro] Musashino Univ, Dept Econ, Koto Ku, Tokyo 1350063, Japan; [Suzuki, Nobue] Komazawa Univ, Fac Econ, Setagaya Ku, Tokyo 1548525, Japan	Fujiwara-Greve, T (reprint author), Keio Univ, Dept Econ, Minato Ku, 2-15-45 Mita, Tokyo 1088345, Japan.	takakofg@econ.keio.ac.jp; okuno.fujiwara@gmail.com; nsuzuki@komazawa-u.ac.jp			Japan Society for the Promotion of Science [21530171]	We are grateful to an anonymous co-editor and a referee for valuable comments. We also thank Akihiko Matsui, Henrich R. Greve, Francoise Forges and participants at the ANU-Japan workshop and PET conference for comments. A part of this paper is based on Fujiwara-Greve and Okuno-Fujiwara, "Behavioral Diversity in Voluntarily Separable Repeated Prisoner's Dilemma," SSRN 2005115 (2012). This work was supported by Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research (C) No. 21530171.	Cho IK, 2012, DYN GAMES APPL, V2, P51, DOI 10.1007/s13235-011-0026-3; Casas-Arce P, 2010, ECON THEOR, V43, P67, DOI 10.1007/s00199-008-0422-0; Eeckhout J, 2006, REV ECON STUD, V73, P31, DOI 10.1111/j.1467-937X.2006.00368.x; Fujiwara-Greve T, 2009, REV ECON STUD, V76, P993; Izquierdo LR, 2014, J ECON DYN CONTROL, V46, P91, DOI 10.1016/j.jedc.2014.06.007; FRIEDMAN JW, 1971, REV ECON STUD, V38, P1, DOI 10.2307/2296617; Dal Bo P, 2007, ECON THEOR, V30, P89, DOI 10.1007/s00199-005-0045-7; Ghosh P, 1996, REV ECON STUD, V63, P491, DOI 10.2307/2297892; Rob R, 2010, ECON THEOR, V43, P143, DOI 10.1007/s00199-008-0421-1; Cho IK, 2013, J ECON THEORY, V148, P1659, DOI 10.1016/j.jet.2013.04.003; Duffie D, 2012, J ECON THEORY, V147, P1105, DOI 10.1016/j.jet.2012.01.003; Kranton RE, 1996, J LAW ECON ORGAN, V12, P214; McAdams D, 2011, AM ECON J-MICROECON, V3, P107, DOI 10.1257/mic.3.4.107; ELLISON G, 1994, REV ECON STUD, V61, P567, DOI 10.2307/2297904; Carmichael L., 1997, INT ECON REV, V38, P485; Datta S., 1996, BUILDING TRUST UNPUB; FUDENBERG D, 1986, ECONOMETRICA, V54, P533, DOI 10.2307/1911307; Fujiwara-Greve T., 2013, DIVERSE BEHAV UNPUB; Immorlica N., 2014, COOPERATION AN UNPUB; KANDORI M, 1992, REV ECON STUD, V59, P63, DOI 10.2307/2297925; KREPS DM, 1982, J ECON THEORY, V27, P245, DOI 10.1016/0022-0531(82)90029-1; Okuno-Fujiwara M., 2015, VOLUNTARY PART UNPUB; Smith JM, 1982, EVOLUTION THEORY GAM; SWINKELS JM, 1992, J ECON THEORY, V57, P306, DOI 10.1016/0022-0531(92)90038-J; Vesely F., 2013, OPTIMAL SOCIAL CONVE; Vesely F., 2012, BREAKUP SECRET HANDS	26	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-2259	1432-0479		ECON THEOR	Econ. Theory	NOV	2015	60	3					423	460		10.1007/s00199-015-0909-4		38	Economics	Business & Economics	CT7YT	WOS:000363032400002		
J	Roni, M; Murugan, K; Panneerselvam, C; Subramaniam, J; Nicoletti, M; Madhiyazhagan, P; Dinesh, D; Suresh, U; Khater, HF; Wei, H; Canale, A; Alarfaj, AA; Munusamy, MA; Higuchi, A; Benelli, G				Roni, Mathath; Murugan, Kadarkarai; Panneerselvam, Chellasamy; Subramaniam, Jayapal; Nicoletti, Marcello; Madhiyazhagan, Pani; Dinesh, Devakumar; Suresh, Udaiyan; Khater, Hanem F.; Wei, Hui; Canale, Angelo; Alarfaj, Abdullah A.; Munusamy, Murugan A.; Higuchi, Akon; Benelli, Giovanni			Characterization and biotoxicity of Hypnea musciformis-synthesized silver nanoparticles as potential eco-friendly control tool against Aedes aegypti and Plutella xylostella	ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY			English	Article						Bio-fabrication; Green-synthesis; Nanobiotechnology; Pest control; Seaweed	VECTOR ANOPHELES-STEPHENSI; LARVICIDAL ACTIVITY; DIAMONDBACK MOTH; CULEX-QUINQUEFASCIATUS; INSECTICIDAL ACTIVITY; ANTIFEEDANT ACTIVITY; MEDIATED SYNTHESIS; DIPTERA-CULICIDAE; GREEN SYNTHESIS; EXTRACTS	Two of the most important challenges facing humanity in the 21st century comprise food production and disease control. Eco-friendly control tools against mosquito vectors and agricultural pests are urgently needed. Insecticidal products of marine origin have a huge potential to control these pests. In this research, we reported a single-step method to synthesize silver nanoparticles (AgNP) using the aqueous leaf extract of the seaweed Hypnea musciformis, a cheap, nontoxic and eco-friendly material, that worked as reducing and stabilizing agent during the biosynthesis. The formation of AgNP was confirmed by surface plasmon resonance band illustrated in UV-vis spectrophotometer. AgNP were characterized by FTIR, SEM, EDX and XRD analyses. AgNP were mostly spherical in shape, crystalline in nature, with face-centered cubic geometry, and their mean size was 40-65 nm. Low doses of H. musciformis aqueous extract and seaweed-synthesized AgNP showed larvicidal and pupicidal toxicity against the dengue vector Aedes aegypti and the cabbage pest Plutella xylostella. The LC50 value of AgNP ranged from 18.14 to 38.23 ppm for 1st instar larvae (L1) and pupae of A. aegypti, and from 24.5 to 38.23 ppm for L1 and pupae of P. xylostella. Both H. musciformis extract and AgNP strongly reduced longevity and fecundity of A. aegypti and P. xylostella adults. This study adds knowledge on the toxicity of seaweed borne insecticides and green-synthesized AgNP against arthropods of medical and agricultural importance, allowing us to propose the tested products as effective candidates to develop newer and cheap pest control tools. (C) 2015 Elsevier Inc. All rights reserved.	[Roni, Mathath; Murugan, Kadarkarai; Panneerselvam, Chellasamy; Subramaniam, Jayapal; Madhiyazhagan, Pani; Dinesh, Devakumar; Suresh, Udaiyan] Bharathiar Univ, Sch Life Sci, Dept Zool, Div Entomol, Coimbatore 641046, Tamil Nadu, India; [Nicoletti, Marcello] Univ Roma La Sapienza, Dept Environm Biol, I-00185 Rome, Italy; [Khater, Hanem F.] Benha Univ, Fac Vet Med, Dept Parasitol, Moshtohor 13736, Egypt; [Wei, Hui] Fujian Acad Agr Sci, Inst Plant Protect, Fuzhou 350013, Fujian, Peoples R China; [Canale, Angelo; Benelli, Giovanni] Univ Pisa, Dept Agr Food & Environm, I-56124 Pisa, Italy; [Alarfaj, Abdullah A.; Munusamy, Murugan A.] King Saud Univ, Coll Sci, Dept Bot & Microbiol, Riyadh 11451, Saudi Arabia; [Higuchi, Akon] Natl Res Inst Child Hlth & Dev, Dept Reprod, Tokyo 1578535, Japan	Benelli, G (reprint author), Univ Pisa, Dept Agr Food & Environm, Via Borghetto 80, I-56124 Pisa, Italy.	g.benelli@sssup.it	Benelli, Giovanni/A-9100-2013; 	Benelli, Giovanni/0000-0001-8971-6010	Department of Science and Technology (New Delhi, India) [DST/SB/EMEQ-335/2013]	We would like to thank Kurunthachalam Kannan, Dilek Hamamci Asma and an anonymous reviewer for their comments on an earlier version of the manuscript. The Authors are grateful to the Department of Science and Technology (New Delhi, India), Project no. DST/SB/EMEQ-335/2013, for providing financial support. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad N., 2012, GREEN SUSTAINABLE CH, V2, P141, DOI DOI 10.4236/GSC.2012.24020; Amerasan D., 2015, J PEST SCI; Cetin H, 2010, J AM MOSQUITO CONTR, V26, P433, DOI 10.2987/10-6046.1; Sastry M, 1998, J PHYS CHEM B, V102, P1404, DOI 10.1021/jp9719873; Chitra G, 2015, PARASITOL RES, V114, P1407, DOI 10.1007/s00436-015-4320-7; Lingathurai S., 2011, Journal of King Saud University Science, V23, P11, DOI 10.1016/j.jksus.2010.05.012; Khanavi M, 2011, J VECTOR DIS, V48, P241; Ankanna S, 2010, DIG J NANOMATER BIOS, V5, P369; Magrini FE, 2015, IND CROP PROD, V65, P150, DOI 10.1016/j.indcrop.2014.11.032; Trindade RCP, 2008, PESQUI AGROPECU BRAS, V43, P1813, DOI 10.1590/S0100-204X2008001200024; Mehlhorn H, 2005, PARASITOL RES, V95, P363, DOI 10.1007/s00436-004-1297-z; Sengonca C, 2006, J PEST SCI, V79, P3, DOI 10.1007/s10340-005-0117-2; Dinesh D, 2015, PARASITOL RES, V114, P1519, DOI 10.1007/s00436-015-4336-z; Nabikhan A, 2010, COLLOID SURFACE B, V79, P488, DOI 10.1016/j.colsurfb.2010.05.018; Sahayaraj K, 2011, INDIAN J GEO-MAR SCI, V40, P125; TALEKAR NS, 1993, ANNU REV ENTOMOL, V38, P275, DOI 10.1146/annurev.en.38.010193.001423; Ponarulselvam S., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P574, DOI 10.1016/S2221-1691(12)60100-2; Krishnaraj C, 2010, COLLOID SURFACE B, V76, P50, DOI 10.1016/j.colsurfb.2009.10.008; Murugan K, 2015, PARASITOL RES, V114, P2243, DOI 10.1007/s00436-015-4417-z; Feng QL, 2000, J BIOMED MATER RES, V52, P662, DOI 10.1002/1097-4636(20001215)52:4<662::AID-JBM10>3.0.CO;2-3; Rai A, 2006, LANGMUIR, V22, P736, DOI 10.1021/la052055q; Zargar M, 2011, MOLECULES, V16, P6667, DOI 10.3390/molecules16086667; Magudapathy P, 2001, PHYSICA B, V299, P142, DOI 10.1016/S0921-4526(00)00580-9; Melo VMM, 1997, BOT MAR, V40, P281, DOI 10.1515/botm.1997.40.1-6.281; Bar H, 2009, COLLOID SURFACE A, V348, P212, DOI 10.1016/j.colsurfa.2009.07.021; Gong P, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/28/285604; Patil CD, 2012, PARASITOL RES, V110, P1815, DOI 10.1007/s00436-011-2704-x; Dubey M, 2009, DIG J NANOMATER BIOS, V4, P537; Shameli K, 2010, INT J NANOMED, V5, P743, DOI 10.2147/IJN.S13227; Paulraj M. Gabriel, 2014, Archives of Phytopathology and Plant Protection, V47, P1832, DOI 10.1080/03235408.2013.859402; Shrivastava S, 2010, NANO-MICRO LETT, V2, P164, DOI 10.5101/nml.v2i3.p164-168; Suresh U, 2015, PARASITOL RES, V114, P1551, DOI 10.1007/s00436-015-4339-9; Benelli G, 2015, PARASITOL RES, V114, P2801, DOI 10.1007/s00436-015-4586-9; Kamaraj C, 2014, PARASITOL RES, V113, P1657, DOI 10.1007/s00436-014-3810-3; Kumar AN, 2013, PARASITOL RES, V112, P313, DOI 10.1007/s00436-012-3139-8; Bhattacharyya A, 2010, AFR J BIOTECHNOL, V9, P3489; Forim MR, 2013, J AGR FOOD CHEM, V61, P9131, DOI 10.1021/jf403187y; Mohan M, 2003, CROP PROT, V22, P495, DOI 10.1016/S0261-2194(02)00201-6; Fayaz AM, 2010, NANOMED-NANOTECHNOL, V6, P103, DOI 10.1016/j.nano.2009.04.006; Asghari G., 2014, NANOMED J, P94; Benelli G, 2015, PARASITOL RES, V114, P391, DOI 10.1007/s00436-014-4286-x; Finney DJ, 1971, PROBIT ANAL, P68, DOI DOI 10.1007/BF02431962; Goodsell DS, 2004, BIONANOTECHNOLOGY LE; Gryzwacz D.A., 2010, CROP PROT, V29, P68; Hardstone C.M., 2009, BMC EVOL BIOL, V9, P42; Hayee-Memon A., 1996, PAK J MAR SCI, V5, P113; Huang J, 2007, NANOTECHNOLOGY, V18, P1; Kalimuthu K, 2014, HYDROBIOLOGIA, V741, P113, DOI 10.1007/s10750-013-1745-9; Kumar A.N., 2012, VECTOR-BORNE ZOONOT, V12, P262; Makowski R., 1993, ECOL EPIDEMIOL, V83, P1229; Manilal A, 2009, J MAR SCI TECHNOL-TA, V17, P67; Mullai K., 2006, B BIOL SCI, V4, P35; Nizmuddin M., 1995, PAK J BOT, V27, P257; Perry A. S., 1998, INSECTICIDES AGR ENV; Ravikumar S, 2009, INT J MED SCI, V1, P184; Ravikumar S, 2010, INT J MED MED SCI, V2, P94; Salimabi Das B., 1980, INDIA J PHARM, V12, P259; Sathyavathi R., 2010, ADV SCI LETT, V3, P1; Selvin J, 2004, J MAR SCI TECHNOL, V12, P1; Shankar SS, 2004, APPL NANOSCI, V1, P69, DOI DOI 10.1088/0957-4484/18/10/105104; Song YJ, 2009, PROCESS BIOCHEM, V44, P1133; Subbiah P., 2002, APPL ENTOMOL ZOOL, V37, P365; Sundar R., 2013, INT J CURR RES, V5, P3388; Thacker J. M. R., 2002, INTRO ARTHROPOD PEST; Tiwari D. K., 2008, World Applied Sciences Journal, V3, P417; Moorthi PV, 2015, APPL BIOCHEM BIOTECH, V175, P135, DOI 10.1007/s12010-014-1264-9; Vinutha J.S., 2013, J ACAD IND RES, V1, P606; WHO, 2012, HDB INT VECT MAN; XU H., 2002, J NANOSCI NANOTECHNO, V4, P254; Zhu W., 2003, P159	70	4	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0147-6513	1090-2414		ECOTOX ENVIRON SAFE	Ecotox. Environ. Safe.	NOV	2015	121				SI		31	38		10.1016/j.ecoenv.2015.07.005		8	Environmental Sciences; Toxicology	Environmental Sciences & Ecology; Toxicology	CT3HO	WOS:000362698000006		
J	Lai, ECC; Man, KKC; Chaiyakunapruk, N; Cheng, CL; Chien, HC; Chui, CSL; Dilokthornsakul, P; Hardy, NC; Hsieh, CY; Hsu, CY; Kubota, K; Lin, TC; Liu, YF; Park, BJ; Pratt, N; Roughead, EE; Shin, JY; Watcharathanakij, S; Wen, J; Wong, ICK; Yang, YHK; Zhang, YH; Setoguchi, S				Lai, Edward Chia-Cheng; Man, Kenneth K. C.; Chaiyakunapruk, Nathorn; Cheng, Ching-Lan; Chien, Hsu-Chih; Chui, Celine S. L.; Dilokthornsakul, Piyameth; Hardy, N. Chantelle; Hsieh, Cheng-Yang; Hsu, Chung Y.; Kubota, Kiyoshi; Lin, Tzu-Chieh; Liu, Yanfang; Park, Byung Joo; Pratt, Nicole; Roughead, Elizabeth E.; Shin, Ju-Young; Watcharathanakij, Sawaeng; Wen, Jin; Wong, Ian C. K.; Yang, Yea-Huei Kao; Zhang, Yinghong; Setoguchi, Soko			Databases in the Asia-Pacific Region The Potential for a Distributed Network Approach	EPIDEMIOLOGY			English	Article							SAFETY; CARE	Background: This study describes the availability and characteristics of databases in Asian-Pacific countries and assesses the feasibility of a distributed network approach in the region. Methods: A web-based survey was conducted among investigators using healthcare databases in the Asia-Pacific countries. Potential survey participants were identified through the Asian Pharmacoepidemiology Network. Results: Investigators from a total of 11 databases participated in the survey. Database sources included four nationwide claims databases from Japan, South Korea, and Taiwan; two nationwide electronic health records from Hong Kong and Singapore; a regional electronic health record from western China; two electronic health records from Thailand; and cancer and stroke registries from Taiwan. Conclusions: We identified 11 databases with capabilities for distributed network approaches. Many country-specific coding systems and terminologies have been already converted to international coding systems. The harmonization of health expenditure data is a major obstacle for future investigations attempting to evaluate issues related to medical costs.	[Lai, Edward Chia-Cheng; Hardy, N. Chantelle; Zhang, Yinghong; Setoguchi, Soko] Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC 27715 USA; [Lai, Edward Chia-Cheng; Cheng, Ching-Lan; Chien, Hsu-Chih; Hsieh, Cheng-Yang; Lin, Tzu-Chieh; Yang, Yea-Huei Kao] Natl Cheng Kung Univ, Sch Pharm, Inst Clin Pharm & Pharmaceut Sci, Tainan 70101, Taiwan; [Man, Kenneth K. C.; Chui, Celine S. L.; Wong, Ian C. K.] Univ Hong Kong, Dept Pharmacol & Pharm, Ctr Safe Medicat Practice & Res, Pok Fu Lam, Hong Kong, Peoples R China; [Chaiyakunapruk, Nathorn] Monash Univ Malaysia, Sch Pharm, Selangor, Malaysia; [Chaiyakunapruk, Nathorn; Dilokthornsakul, Piyameth] Naresuan Univ, Fac Pharmaceut Sci, Dept Pharm Practice, Ctr Pharmaceut Outcomes Res, Phitsanulok, Thailand; [Chaiyakunapruk, Nathorn] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; [Chaiyakunapruk, Nathorn] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia; [Hsu, Chung Y.] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Kubota, Kiyoshi] Univ Tokyo, Dept Pharmacoepidemiol, Tokyo, Japan; [Liu, Yanfang] Janssen Pharmaceut Co Johnson & Johnson, Dept Epidemiol, Singapore, Singapore; [Park, Byung Joo; Shin, Ju-Young] Seoul Natl Univ, Coll Med, Dept Prevent Med, Seoul, South Korea; [Park, Byung Joo] Korea Inst Drug Safety & Risk Management, Off Drug Utilizat Review, Seoul, South Korea; [Pratt, Nicole; Roughead, Elizabeth E.] Univ S Australia, Sansom Inst Hlth Res, Qual Use Med & Pharm Res Ctr, Adelaide, SA 5001, Australia; [Watcharathanakij, Sawaeng] Ubon Ratchathani Univ, Fac Pharmaceut Sci, Pharm Practice, Ubon Ratchathani, Thailand; [Wen, Jin] Sichuan Univ, West China Hosp, Inst Hosp Management, Chengdu, Sichuan, Peoples R China	Setoguchi, S (reprint author), Duke Univ, Duke Clin Res Inst, Sch Med, POB 17969, Durham, NC 27715 USA.	soko.setoguchi@duke.edu					Aminpour F, 2014, J RES MED SCI, V19, P57; Platt R, 2009, NEW ENGL J MED, V361, P645, DOI 10.1056/NEJMp0905338; Reisinger SJ, 2010, J AM MED INFORM ASSN, V17, P652, DOI 10.1136/jamia.2009.002477; Wolfson M, 2010, INT J EPIDEMIOL, V39, P1372, DOI 10.1093/ije/dyq111; Brown JS, 2009, PHARMACOEPIDEM DR S, V18, P226, DOI 10.1002/pds.1706; Chen RT, 1997, PEDIATRICS, V99, P765, DOI 10.1542/peds.99.6.765; Platt R, 2012, PHARMACOEPIDEM DR S, V21, P1, DOI 10.1002/pds.2343; Curtis LH, 2012, PHARMACOEPIDEM DR S, V21, P23, DOI 10.1002/pds.2336; Coloma PM, 2011, PHARMACOEPIDEM DR S, V20, P1, DOI 10.1002/pds.2053; Brown JS, 2010, MED CARE, V48, pS45, DOI 10.1097/MLR.0b013e3181d9919f; [Anonymous], 2014 ICD 10 CM GEMS; Pratt N, 2013, PHARMACOEPIDEM DR S, V22, P915, DOI 10.1002/pds.3440; Andersen M, 2013, PHARMACOEPIDEM DR S, V22, P700, DOI 10.1002/pds.3439; Kimura T, 2011, PHARMACOEPIDEM DR S, V20, P1237, DOI 10.1002/pds.2244; Common Data Model, COMM DAT MOD; Data Activities Details of Distributed Database & Common Data Model, DAT ACT DET DISTR DA; Rassen JA, 2010, MED CARE, V48, pS83, DOI 10.1097/MLR.0b013e3181d59541	17	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1044-3983	1531-5487		EPIDEMIOLOGY	Epidemiology	NOV	2015	26	6					815	820		10.1097/EDE.0000000000000325		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CT1JF	WOS:000362553900006		
J	Shinozaki, T; Matsuyama, Y				Shinozaki, Tomohiro; Matsuyama, Yutaka			Doubly Robust Estimation of Standardized Risk Difference and Ratio in the Exposed Population	EPIDEMIOLOGY			English	Article							MARGINAL STRUCTURAL MODELS; CAUSAL INFERENCE; INVERSE PROBABILITY; PROPENSITY SCORE; REGRESSION; ADJUSTMENT	Standardizationa method used to adjust for confoundingestimates counterfactual risks in a target population. To adjust for confounding variables that contain too many combinations to be fully stratified, two model-based standardization methods exist: regression standardization and use of an inverse probability of exposure weighted-reweighted estimators. Whereas the former requires an outcome regression model conditional on exposure and confounders, the latter requires a propensity score model. In reconciling among their modeling assumptions, doubly robust estimators, which only require correct specification of either the outcome regression or the propensity score model but do not necessitate both, have been well studied for total populations. Here, we provide doubly robust estimators of standardized risk difference and ratio in the exposed population. Theoretical details, simple model extension for independently censored outcomes, and a SAS program are provided in the eAppendix (http://links.lww.com/EDE/A955).	[Shinozaki, Tomohiro; Matsuyama, Yutaka] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Tokyo 1130033, Japan	Shinozaki, T (reprint author), Univ Tokyo, Sch Publ Hlth, Dept Biostat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	shinozaki@epistat.m.u-tokyo.ac.jp			Japan Society for the Promotion of Science [25730014]	Supported by the Japan Society for the Promotion of Science (Grant-in-Aid for Young Scientists B 25730014 to T.S.).	Robins JM, 1999, SYNTHESE, V121, P151, DOI 10.1023/A:1005285815569; ROBINS JM, 1994, J AM STAT ASSOC, V89, P846, DOI 10.2307/2290910; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Scharfstein DO, 1999, J AM STAT ASSOC, V94, P1096, DOI 10.2307/2669923; Xie J, 2005, STAT MED, V24, P3089, DOI 10.1002/sim.2174; ROBINS J, 1986, MATH MODELLING, V7, P1393, DOI 10.1016/0270-0255(86)90088-6; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; GREENLAND S, 1991, STAT MED, V10, P1069, DOI 10.1002/sim.4780100707; Vansteelandt S, 2011, AM J EPIDEMIOL, V173, P739, DOI 10.1093/aje/kwq474; Imbens GW, 2004, REV ECON STAT, V86, P4, DOI 10.1162/003465304323023651; KEIDING N, 1987, INT STAT REV, V55, P1, DOI 10.2307/1403267; Matsuyama Y, 2000, ANN ONCOL, V11, P1537; Funk MJ, 2011, AM J EPIDEMIOL, V173, P761, DOI 10.1093/aje/kwq439; Petersen ML, 2006, JAIDS-J ACQ IMM DEF, V43, pS96, DOI 10.1097/01.qai.0000248344.95135.8d; Cole SR, 2004, COMPUT METH PROG BIO, V75, P45, DOI 10.1016/j.cmpb.2003.10.004; Ridgeway G, 2009, J AM STAT ASSOC, V104, P661, DOI 10.1198/jasa.2009.0034; Sato T, 2003, EPIDEMIOLOGY, V14, P680, DOI 10.1097/01.EDE.0000081989.82616.7d; Hoggatt KJ, 2014, EPIDEMIOLOGY, V25, P98, DOI 10.1097/EDE.0000000000000023; Bang H, 2005, BIOMETRICS, V61, P962, DOI 10.1111/j.1541-0420.2005.00377.x; Kang JDY, 2007, STAT SCI, V22, P523, DOI 10.1214/07-STS227; Lunceford JK, 2004, STAT MED, V23, P2937, DOI 10.1002/SIM.1903; Hernan MA, 2006, J EPIDEMIOL COMMUN H, V60, P578, DOI 10.1136/jech.2004.029496; JOFFE MM, 1995, STAT MED, V14, P2131, DOI 10.1002/sim.4780141907; ROSENBAUM PR, 1987, J AM STAT ASSOC, V82, P387, DOI 10.2307/2289440; Bai XF, 2013, BIOMETRICS, V69, P830, DOI 10.1111/biom.12076; Greenland S, 2008, MODERN EPIDEMIOLOGY, P258; Hubbard AE, 2011, TARGETED LEARNING CA, P133; Kalbfleish JD, 2002, STAT ANAL FAILURE TI; Keiding N, 2014, STAT SCI, V29, P529, DOI 10.1214/13-STS453; Robins J, 2007, STAT SCI, V22, P544, DOI 10.1214/07-STS227D; Robins JM, 1992, AIDS EPIDEMIOLOGY ME, P297; ROBINS JM, 1987, COMPUT MATH APPL, V14, P917, DOI 10.1016/0898-1221(87)90237-9; Tsiatis A. A., 2006, SEMIPARAMETRIC THEOR	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1044-3983	1531-5487		EPIDEMIOLOGY	Epidemiology	NOV	2015	26	6					873	877		10.1097/EDE.0000000000000363		5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CT1JF	WOS:000362553900014		
J	Trang, NV; Choisy, M; Nakagomi, T; Chinh, NTM; Doan, YH; Yamashiro, T; Bryant, JE; Nakagomi, O; Anh, DD				N. V. Trang; Choisy, M.; Nakagomi, T.; N. T. M. Chinh; Doan, Y. H.; Yamashiro, T.; J. E. Bryant; Nakagomi, O.; D. D. Anh			Determination of cut-off cycle threshold values in routine RT-PCR assays to assist differential diagnosis of norovirus in children hospitalized for acute gastroenteritis	EPIDEMIOLOGY AND INFECTION			English	Article						Caliciviruses; diarrhoea; estimating disease prevalence; gastrointestinal infections; modelling	REVERSE TRANSCRIPTION-PCR; NORWALK-LIKE VIRUSES; CHI-MINH CITY; VIRAL LOAD; ENTERIC PATHOGENS; INFECTIONS; PREVALENCE; ROTAVIRUS; VIETNAM; ALGORITHM	Norovirus (NV) is an important cause of acute gastroenteritis in children, but is also frequently detected in asymptomatic children, which complicates the interpretation of NV detection results in both the clinical setting and population prevalence studies. A total of 807 faecal samples from children aged <5 years hospitalized for acute gastroenteritis were collected in Thai Binh, Vietnam, from January 2011 to September 2012. Real-time RT-PCR was used to detect and quantify NV-RNA in clinical samples. A bimodal distribution of cycle threshold (C-t) values was observed in which the lower peak was assumed to represent cases for which NV was the causal agent of diarrhoea, whereas the higher peak was assumed to represent cases involving an alternative pathogen other than NV. Under these assumptions, we applied finite-mixture modelling to estimate a threshold of C-t <2136 (95% confidence interval 2029-2246) to distinguish NV-positive patients for which NV was the likely cause of diarrhoea. We evaluated the validity of the threshold through comparisons with NV antigen ELISA results, and comparisons of C-t values in patients co-infected with rotavirus. We conclude that the use of an appropriate cut-off value in the interpretation of NV real-time RT-PCR results may improve differential diagnosis of enteric infections, and could contribute to improved estimates of the burden of NV disease.	[N. V. Trang; D. D. Anh] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam; [Choisy, M.] Ctr Rech IRD, MIVEGEC, UM1 UM2 CNRS IRD 5290 224, Montpellier, France; [Choisy, M.; J. E. Bryant] Univ Oxford, Clin Res Unit, Hanoi, Vietnam; [Nakagomi, T.; Doan, Y. H.; Nakagomi, O.] Nagasaki Univ, Grad Sch Biomed Sci, Div Mol Epidemiol, Nagasaki, Japan; [N. T. M. Chinh] Thai Binh Paediat Hosp, Thai Binh, Vietnam; [Yamashiro, T.] Nagasaki Univ, Inst Trop Med, Ctr Infect Dis Res Asia & Afr, Nagasaki, Japan; [J. E. Bryant] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford OX1 2JD, England	Nakagomi, O (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Div Mol Epidemiol, Nagasaki, Japan.	onakagom@nagasaki-u.ac.jp; ducanhnihe@hn.vnn.vn			National Foundation for Science and Technology Development [106.03-2010.56]; Japan Initiative for Global Research Network on Infectious Diseases; 'Biodiversity and Infectious Diseases in Southeast Asia' CNRS	The work was supported by the National Foundation for Science and Technology Development (N. V. Trang, grant no. 106.03-2010.56) and the Japan Initiative for Global Research Network on Infectious Diseases (O. Nakagomi, T. Yamashiro and D. D. Anh).; Marc Choisy was sponsored by the 'Biodiversity and Infectious Diseases in Southeast Asia' CNRS-funded GDRI network.	Schnagl RD, 2000, ACTA VIROL, V44, P265; Colomba C, 2007, EMERG INFECT DIS, V13, P1389, DOI 10.3201/eid1309.061408; Cheon DS, 2010, FOODBORNE PATHOG DIS, V7, P1427, DOI 10.1089/fpd.2010.0547; Patel MM, 2008, EMERG INFECT DIS, V14, P1224, DOI 10.3201/eid1408.071114; Cheng WX, 2008, CLIN INFECT DIS, V47, P161, DOI 10.1086/589244; Barreira DMPG, 2010, J CLIN VIROL, V47, P60, DOI 10.1016/j.jcv.2009.11.012; Vinje J, 2004, J VIROL METHODS, V116, P109, DOI 10.1016/j.jviromet.2003.11.001; Marshall JA, 2001, PATHOLOGY, V33, P50; Nguyen TA, 2008, J TROP PEDIATRICS, V54, P102, DOI 10.1093/tropej/fmm096; Bucardo F, 2010, PEDIATR INFECT DIS J, V29, P934, DOI 10.1097/INF.0b013e3181ed9f2f; Ramani S, 2010, J MED VIROL, V82, P1803, DOI 10.1002/jmv.21872; Garcia C, 2006, J CLIN MICROBIOL, V44, P2997, DOI 10.1128/JCM.00065-06; Oh DY, 2003, J MED VIROL, V71, P82, DOI 10.1002/jmv.10449; Amar CFL, 2007, EUR J CLIN MICROBIOL, V26, P311, DOI 10.1007/s10096-007-0290-8; Phillips G, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-63; O'Ryan ML, 2009, PEDIATR INFECT DIS J, V28, P879, DOI 10.1097/INF.0b013e3181a4bb60; Tamura T, 2010, JPN J INFECT DIS, V63, P405; Costantini V, 2010, J CLIN MICROBIOL, V48, P2770, DOI 10.1128/JCM.00654-10; Do CB, 2008, NAT BIOTECHNOL, V26, P897, DOI 10.1038/nbt1406; Neesanant P, 2013, J VIROL METHODS, V194, P317, DOI 10.1016/j.jviromet.2013.08.033; My PVT, 2013, EMERG INFECT DIS, V19, P977, DOI 10.3201/eid1906.111862; Oakes D, 1999, J ROY STAT SOC B, V61, P479, DOI 10.1111/1467-9868.00188; Patel MM, 2009, J CLIN VIROL, V44, P1, DOI 10.1016/j.jcv.2008.10.009; Kageyama T, 2003, J CLIN MICROBIOL, V41, P1548, DOI 10.1128/JCM.41.4.1548-1557.2003; Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2; Trang NV, 2012, J MED VIROL, V84, P290, DOI 10.1002/jmv.23185; Ayukekbong J, 2011, J MED VIROL, V83, P2135, DOI 10.1002/jmv.22243; Black RE, 2008, LANCET, V375, P1969, DOI DOI 10.1016/S0140-6736(10)60549-1]; Elfving K, 2014, J CLIN MICROBIOLOGY; Kroneman A, 2013, ARCH VIROL, V158, P2059, DOI 10.1007/s00705-013-1708-5; Levine MM, 2012, CLIN INFECT DIS, V55, pS303, DOI 10.1093/cid/cis789; RCoreTeam, 2013, R LANG ENV STAT COMP; Schlattmann P., 2009, MED APPL FINITE MIXT; Zhang S, 2011, J MED VIROLOLOGY	34	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0950-2688	1469-4409		EPIDEMIOL INFECT	Epidemiol. Infect.	NOV	2015	143	15					3292	3299		10.1017/S095026881500059X		8	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	CT6WR	WOS:000362954200015		
J	Nakano, S; Matsumura, Y; Ito, Y; Fujisawa, T; Chang, B; Suga, S; Kato, K; Yunoki, T; Hotta, G; Noguchi, T; Yamamoto, M; Nagao, M; Takakura, S; Ohnishi, M; Ihara, T; Ichiyama, S				Nakano, S.; Matsumura, Y.; Ito, Y.; Fujisawa, T.; Chang, B.; Suga, S.; Kato, K.; Yunoki, T.; Hotta, G.; Noguchi, T.; Yamamoto, M.; Nagao, M.; Takakura, S.; Ohnishi, M.; Ihara, T.; Ichiyama, S.			Development and evaluation of MALDI-TOF MS-based serotyping for Streptococcus pneumoniae	EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES			English	Article							FLIGHT MASS-SPECTROMETRY; DESORPTION IONIZATION-TIME; INVASIVE PNEUMOCOCCAL DISEASE; EPIDEMIOLOGY; DIFFERENTIATION; IDENTIFICATION; VACCINATION; CARRIAGE; OUTBREAK; ERA	Surveillance of Streptococcus pneumoniae serotypes is important for the successful implementation of vaccination strategies to prevent the spread of invasive pneumococcal diseases. The standard method of serotyping of pneumococcal isolates is the phenotypic Neufeld test, which is cost- and labor-intensive. Recently, matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has been implemented as a rapid, simple and inexpensive method for identifying species. We evaluated the performance of MALDI-TOF MS for serotyping ten major serotypes of S. pneumoniae in Japan (serotypes 3, 6B, 15A, 15C, 19A, 19 F, 23A, 24 F, 35B and 38) using the Biotyper and ClinProTools. After optimizing the settings, we validated their serotyping performance for serotypes 3, 15A and 19A using a separate set of isolates that were not used in the creation of the classification algorithms. A total of 574 isolates of S. pneumoniae collected from Japanese nationwide surveillance studies were included. Of these, 407 isolates belonged to the ten major serotypes. Biotyper and ClinProTools correctly identified 77.9 % and 84.0 %, respectively, of the ten major serotype isolates. The validation analysis included a total of 113 isolates of the serotypes 3, 15A and 19A isolates. Biotyper and ClinProTools correctly identified 85.0 % and 69.9 % of the validation cohort isolates, respectively. MALDI-TOF MS has the potential to discriminate the ten major S. pneumoniae serotypes prevalent in Japan.	[Nakano, S.; Matsumura, Y.; Kato, K.; Yunoki, T.; Hotta, G.; Noguchi, T.; Yamamoto, M.; Nagao, M.; Takakura, S.; Ichiyama, S.] Kyoto Univ, Grad Sch Med, Dept Clin Lab Med, Sakyo Ku, Kyoto, Japan; [Ito, Y.] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Rheumatol, Nagoya, Aichi, Japan; [Fujisawa, T.; Suga, S.] Natl Hosp Org, Mie Natl Hosp, Dept Clin Res, Tsu, Mie, Japan; [Chang, B.; Ohnishi, M.] Natl Inst Infect Dis, Dept Bacteriol 1, Tokyo, Japan; [Ihara, T.] Natl Hosp Org, Dept Paediat, Mie Natl Hosp, Tsu, Mie, Japan	Matsumura, Y (reprint author), Kyoto Univ, Grad Sch Med, Dept Clin Lab Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto, Japan.	yazblood@kuhp.kyoto-u.ac.jp		Matsumura, Yasufumi/0000-0001-8595-8944	Pfizer [WI 171133]; Ministry of Health and Labour Sciences Research Grant [H22-shinko-shitei-021, H25-shinko-shitei-003]	Yutaka Ito was supported by the research funding (WI 171133) from Pfizer for the surveillance study "Clonarity analysis of Streptococcus pneumoniae isolated from children with pneumococcal infection in Japan". Takao Fujisawa was supported by an unconditional grant from Pfizer. Bin Chang, Makoto Ohnishi, and Toshiaki Ihara were supported by the Ministry of Health and Labour Sciences Research Grant (H22-shinko-shitei-021) and (H25-shinko-shitei-003).	Clark AE, 2013, CLIN MICROBIOL REV, V26, P547, DOI 10.1128/CMR.00072-12; Griffin PM, 2012, J CLIN MICROBIOL, V50, P2918, DOI 10.1128/JCM.01000-12; Williamson YM, 2008, APPL ENVIRON MICROB, V74, P5891, DOI 10.1128/AEM.00791-08; Park IH, 2007, J CLIN MICROBIOL, V45, P1225, DOI 10.1128/JCM.02199-06; Tan TQ, 2012, CLIN MICROBIOL REV, V25, P409, DOI 10.1128/CMR.00018-12; Mehr S, 2012, PAEDIATR RESPIR REV, V13, P258, DOI 10.1016/j.prrv.2011.12.001; LUND E, 1966, ACTA PATHOL MIC SC, V68, P458; Mencacci A, 2013, J CLIN MICROBIOL, V51, P603, DOI 10.1128/JCM.01811-12; Nakano S, 2014, INT J ANTIMICROB AG, V44, P256, DOI 10.1016/j.ijantimicag.2014.05.006; Ampofo K, 2012, PEDIATR INFECT DIS J, V31, P228, DOI 10.1097/INF.0b013e31823dcc72; Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062; Ikryannikova LN, 2013, CLIN MICROBIOL INFEC, V19, P1066, DOI 10.1111/1469-0691.12113; Enright MC, 1998, MICROBIOL-UK, V144, P3049; Pichon B, 2013, J CLIN MICROBIOL, V51, P820, DOI 10.1128/JCM.01917-12; Isozumi R, 2007, J CLIN MICROBIOL, V45, P1440, DOI 10.1128/JCM.01430-06; Dubois D, 2013, J CLIN MICROBIOL, V51, P1861, DOI 10.1128/JCM.03069-12; Hu FZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047983; Matsumura Y, 2014, J CLIN MICROBIOL, V52, P1034, DOI 10.1128/JCM.03196-13; Parra EL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084993; Sabharwal V, 2014, MICROBES INFECT, V16, P292, DOI 10.1016/j.micinf.2013.12.002	20	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0934-9723	1435-4373		EUR J CLIN MICROBIOL	Eur. J. Clin. Microbiol. Infect. Dis.	NOV	2015	34	11					2191	2198		10.1007/s10096-015-2468-9		8	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	CT6ZI	WOS:000362962200008		
J	Yang, YC; Huang, L; Qian, SH; Fukuda, K				Yang, Yongchuan; Huang, Li; Qian, Shenhua; Fukuda, Kenji			Completing the life history of Castanopsis fargesii: changes in the seed dispersal, seedling and sapling recruitment patterns	EUROPEAN JOURNAL OF FOREST RESEARCH			English	Article						Castanopsis fargesii; Life history; Seed dispersal; Seedling recruitment; Negative density dependence; Evergreen broad-leaved forest	BROAD-LEAVED FOREST; BORNEAN RAIN-FOREST; SPATIAL-PATTERNS; HABITAT ASSOCIATIONS; DENSITY-DEPENDENCE; TEMPERATE FOREST; TROPICAL FOREST; EASTERN CHINA; TREE; SURVIVAL	The spatial distribution of species in forest ecosystems involves the underlying ecological processes or mechanisms of population and community structure, as well as forest dynamics. Because the relative importance of these factors can shift across life history stages, assessment of local population and community structures in the context of life history stages is essential for understanding forest dynamics. In this study, we investigated the changes in the spatial patterns of seed dispersal as well as seedling and sapling recruitment for Castanopsis fargesii, a dominant tree species in a subtropical evergreen broad-leaved forest in China. We found notably aggregated spatial patterns for C. fargesii seeds during the seed dispersal. A majority of seeds and newly germinated seedlings aggregated under adult tree canopies, suggesting a decreased efficiency in secondary dispersal for C. fargesii within this evergreen broad-leaved forest. During the later stages of life history (i.e., seedling and sapling stages), the spatial distribution of C. fargesii getting segregated. This is caused by a negative density dependence mechanism in seedling recruitment, rather than by spatial dispersion due to secondary dispersal. By incorporating the patterns and processes across the life history stages of dominant species of evergreen broad-leaved forests, we can add specific details in developing methods of stage-based in situ forest management and conservation frameworks.	[Yang, Yongchuan; Huang, Li] Chongqing Univ, Fac Urban Construct & Environm Engn, Chongqing 400045, Peoples R China; [Yang, Yongchuan] Chongqing Univ, Lab Three Gorges Reservoir Reg Ecoenvironm, Minist Educ, Chongqing 400045, Peoples R China; [Qian, Shenhua] Chongqing Univ, Postdoctoral Stn Ecol, Chongqing 400045, Peoples R China; [Fukuda, Kenji] Univ Tokyo, Lab Evaluat Nat Environm, Grad Sch Frontier Sci, Inst Environm Studies, Kashiwa, Chiba 2778563, Japan	Yang, YC (reprint author), Chongqing Univ, Fac Urban Construct & Environm Engn, Campus B, Chongqing 400045, Peoples R China.	ycyang@cqu.edu.cn			Visiting Scholar Foundation of the Key Laboratory of the Three Gorges Reservoir Region's Eco-environment (Ministry of Education) of Chongqing University; 111 Project [B13041]; Scientific Research Foundation for the Returned Overseas Chinese Scholars from the State Education Ministry; Project of China Science and Technology [2015FY210200]; Fundamental Research Funds for the Central Universities [106112014CDJZR210007]	We thank Xiangyang Gao, Meng Qi, Xia Zhou, Chao Yang, Shenghe Yang and Xiaohan Li for help with field work, and Yukiko Takahashi, Kun Song, Liang Zhao and Dunmei Lin for the valuable comments. We are grateful to two anonymous reviewers for their comments to improve the manuscript. This study was supported by the Visiting Scholar Foundation of the Key Laboratory of the Three Gorges Reservoir Region's Eco-environment (Ministry of Education) of Chongqing University, a grant from the 111 Project (No. B13041), the Scientific Research Foundation for the Returned Overseas Chinese Scholars from the State Education Ministry, a grant from the Project of China Science and Technology (2015FY210200), and the Fundamental Research Funds for the Central Universities (Project No. 106112014CDJZR210007) to YY.	Du YJ, 2009, FOREST ECOL MANAG, V258, P1147, DOI 10.1016/j.foreco.2009.06.004; HOWE HF, 1982, ANNU REV ECOL SYST, V13, P201, DOI 10.1146/annurev.es.13.110182.001221; Kobe RK, 2011, ECOL LETT, V14, P503, DOI 10.1111/j.1461-0248.2011.01612.x; Condit R, 2000, SCIENCE, V288, P1414, DOI 10.1126/science.288.5470.1414; Barot S, 1999, ECOLOGY, V80, P1987, DOI 10.1890/0012-9658(1999)080[1987:DOASPT]2.0.CO;2; Tokuoka Y, 2011, PLANT ECOL, V212, P923, DOI 10.1007/s11258-010-9868-9; Schurman JS, 2012, PLANT ECOL, V213, P1621, DOI 10.1007/s11258-012-0117-2; Zhu Y, 2015, J ECOL, V103, P957, DOI 10.1111/1365-2745.12414; JANZEN DH, 1970, AM NAT, V104, P501, DOI 10.1086/282687; Beck H, 2002, J TROP ECOL, V18, P275, DOI 10.1017/S0266467402002183; AUGSPURGER CK, 1984, ECOLOGY, V65, P1705, DOI 10.2307/1937766; Newbery DM, 2013, ECOLOGY, V94, P2838, DOI 10.1890/13-0366.1; Frost I, 1997, OIKOS, V79, P53, DOI 10.2307/3546089; Forget PM, 2007, CONSERV BIOL, V21, P106, DOI 10.1111/j.1523-1739.2006.00590.x; SMOUSE PE, 1986, SYST ZOOL, V35, P627, DOI 10.2307/2413122; MANASSE RS, 1983, OECOLOGIA, V59, P185, DOI 10.1007/BF00378836; Packer A, 2000, NATURE, V404, P278, DOI 10.1038/35005072; Xiao ZS, 2005, PLANT ECOL, V177, P249, DOI 10.1007/s11258-005-2321-9; Kneitel JM, 2004, ECOL LETT, V7, P69, DOI 10.1046/j.1461-0248.2003.00551.x; Wang XH, 2007, FOREST ECOL MANAG, V245, P76, DOI 10.1016/j.foreco.2007.03.043; Lin LX, 2009, FOREST ECOL MANAG, V257, P1344, DOI 10.1016/j.foreco.2008.12.004; Jansen PA, 2012, P NATL ACAD SCI USA, V109, P12610, DOI 10.1073/pnas.1205184109; Tsujino R, 2008, J PLANT RES, V121, P537, DOI 10.1007/s10265-008-0184-6; LEGENDRE P, 1989, VEGETATIO, V80, P107, DOI 10.1007/BF00048036; Comita LS, 2007, J ECOL, V95, P482, DOI 10.1111/j.1365-2745.2007.01229.x; Nathan R, 2000, TRENDS ECOL EVOL, V15, P278, DOI 10.1016/S0169-5347(00)01874-7; Cordeiro NJ, 2003, P NATL ACAD SCI USA, V100, P14052, DOI 10.1073/pnas.2331023100; Vander Wall SB, 2002, ECOLOGY, V83, P3508, DOI 10.1890/0012-9658(2002)083[3508:MIADPF]2.0.CO;2; BAILLIE IC, 1987, J TROP ECOL, V3, P201; Tomita M, 2002, ECOLOGY, V83, P1560, DOI 10.2307/3071974; OHSAWA M, 1993, J VEG SCI, V4, P13, DOI 10.2307/3235728; Du XJ, 2007, FOREST ECOL MANAG, V238, P212, DOI 10.1016/j.foreco.2006.10.018; Taylor SL, 2005, CAN J FOREST RES, V35, P2479, DOI 10.1139/X05-142; Howe HF, 2004, BIOSCIENCE, V54, P651, DOI 10.1641/0006-3568(2004)054[0651:WSDM]2.0.CO;2; Baldeck CA, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2013.0548; Holbrook KM, 2009, ECOLOGY, V90, P1449, DOI 10.1890/08-1332.1; Hyatt LA, 2003, OIKOS, V103, P590, DOI 10.1034/j.1600-0706.2003.12235.x; WATT AS, 1947, J ECOL, V35, P1, DOI 10.2307/2256497; Jansen PA, 2014, ECOL LETT, V17, P1111, DOI 10.1111/ele.12317; Lin F, 2014, PLANT ECOL, V215, P795, DOI 10.1007/s11258-014-0332-0; Nadeem M, 2011, PLANT SOIL, V346, P231, DOI 10.1007/s11104-011-0814-y; Dalling JW, 2002, J ECOL, V90, P714, DOI 10.1046/j.1365-2745.2002.00706.x; Russo SE, 2005, J ECOL, V93, P879, DOI 10.1111/j.1365-2745.2005.01030.x; Lai JS, 2009, J VEG SCI, V20, P415, DOI 10.1111/j.1654-1103.2009.01065.x; Yan ER, 2008, BIOGEOCHEMISTRY, V89, P239, DOI 10.1007/s10533-008-9216-5; Tang CQ, 2010, FRONT EARTH SCI-PRC, V4, P22, DOI 10.1007/s11707-009-0057-x; SILVERTOWN J, 1993, J ECOL, V81, P465, DOI 10.2307/2261525; Webb CO, 2000, J ECOL, V88, P464, DOI 10.1046/j.1365-2745.2000.00462.x; Manabe T, 2000, PLANT ECOL, V151, P181, DOI 10.1023/A:1026512404110; Jansen PA, 2004, ECOL MONOGR, V74, P569, DOI 10.1890/03-4042; KRANNITZ PG, 1991, AM J BOT, V78, P446, DOI 10.2307/2444967; Shen ZH, 2007, J INTEGR PLANT BIOL, V49, P1294, DOI 10.1111/j.1672-9072.2007.00530.x; Bormann F.H., 1979, PATTERN PROCESS FORE; Connell JH, 1984, ECOL MONOGR, V54, P142; Cressie N.A.C., 1993, STAT SPATIAL DATA; Dale MRT, 1999, SPATIAL PATTERNS ANA; HilleRisLambers J, 2002, NATURE, V417, P732, DOI 10.1038/nature00809; HOLM S, 1979, SCAND J STAT, V6, P65; Horvitz C, 1997, POPULATION COMMUNITY, V18, P247; Hubbell S.P., 2001, UNIFIED NEUTRAL THEO; Kraft NJB, 2014, ECOLOGY ENV PLANT SC, V8, P67; MANTEL N, 1967, CANCER RES, V27, P209; Oksanen J., 2011, VEGAN COMMUNITY ECOL; OLIVEIRAFILHO AT, 1994, J TROP ECOL, V10, P483; Oliver C.D., 1996, FOREST STAND DYNAMIC; Pinheiro J, 2014, NLME LINEAR NONLINEA; Punchi-Manage R, 2013, ECOLOGY, V95, P376; R Core Team, 2014, R LANG ENV STAT COMP; Song J, 2007, J W CHINA FOR SCI, V36, P26; SONG Y, 1988, Phytocoenologia, V16, P105; Song YC, 2005, J E CHINA NORMAL U N, V1, P1; Tang CQ, 2015, SUBTROPICAL VEGETATI; Wang BC, 2002, TRENDS ECOL EVOL, V17, P379, DOI 10.1016/S0169-5347(02)02541-7; Wright SJ, 2002, OECOLOGIA, V130, P1, DOI 10.1007/s004420100809	74	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1612-4669	1612-4677		EUR J FOREST RES	Eur. J. For. Res.	NOV	2015	134	6					1143	1154		10.1007/s10342-015-0916-9		12	Forestry	Forestry	CT5YG	WOS:000362886400015		
J	Im, S; Ashikaga, R; Yagyu, Y; Wakayama, T; Miyoshi, M; Hyodo, T; Imaoka, I; Kumano, S; Ishii, K; Murakami, T				Im, SungWoon; Ashikaga, Ryuichiro; Yagyu, Yukinobu; Wakayama, Tetsuya; Miyoshi, Mitsuharu; Hyodo, Tomoko; Imaoka, Izumi; Kumano, Seishi; Ishii, Kazunari; Murakami, Takamichi			Contrast enhancement of intracranial lesions at 1.5 T: comparison among 2D spin echo, black-blood (BB) Cube, and BB Cube-FLAIR sequences	EUROPEAN RADIOLOGY			English	Article						Cube; 3Dfast spin-echo(FSE); black-blood(BB) imaging; Contrast enhancement; Magnetic resonance imaging	BRAIN; METASTASIS; IMAGES; MRI	The purpose of this study was to investigate the usefulness of T1W black-blood Cube (BB Cube) and T1W BB Cube fluid-attenuated inversion recovery (BB Cube-FLAIR) sequences for contrast-enhanced brain imaging, by evaluating flow-related artefacts, detectability, and contrast ratio (CR) of intracranial lesions among these sequences and T1W-SE. Phantom studies were performed to determine the optimal parameters of BB Cube and BB Cube-FLAIR. A clinical study in 23 patients with intracranial lesions was performed to evaluate the usefulness of these two sequences for the diagnosis of intracranial lesions compared with the conventional 2D T1W-SE sequence. The phantom study revealed that the optimal parameters for contrast-enhanced T1W imaging were TR/TE = 500 ms/minimum in BB Cube and TR/TE/TI = 600 ms/minimum/300 ms in BB Cube-FLAIR imaging. In the clinical study, the degree of flow-related artefacts was significantly lower in BB Cube and BB Cube-FLAIR than in T1W-SE. Regarding tumour detection, BB Cube showed the best detectability; however, there were no significant differences in CR among the sequences. At 1.5 T, contrast-enhanced BB Cube was a better imaging sequence for detecting brain lesions than T1W-SE or BB Cube-FLAIR. aEuro cent Cube is a single-slab 3D FSE imaging sequence. aEuro cent We applied a black-blood (BB) imaging technique to T1W Cube. aEuro cent At 1.5 T, contrast-enhanced T1W BB Cube was valuable for detecting brain lesions.	[Im, SungWoon; Ashikaga, Ryuichiro; Yagyu, Yukinobu; Hyodo, Tomoko; Imaoka, Izumi; Kumano, Seishi; Ishii, Kazunari; Murakami, Takamichi] Kinki Univ, Fac Med, Dept Radiol, Osaka, Osaka 5898511, Japan; [Wakayama, Tetsuya; Miyoshi, Mitsuharu] GE Healthcare Japan, MR Applicat & Workflow, Hino, Tokyo 1918503, Japan	Im, S (reprint author), Kinki Univ, Fac Med, Dept Radiol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan.	im@radiol.med.kindai.ac.jp					RICHARDSON DN, 1990, AM J NEURORADIOL, V11, P209; CHAPPELL PM, 1994, AM J NEURORADIOL, V15, P37; Park J, 2010, MAGN RESON MED, V63, P553, DOI 10.1002/mrm.22261; YUH WTC, 1995, AM J NEURORADIOL, V16, P373; Naganawa S, 2008, EUR RADIOL, V18, P337, DOI 10.1007/s00330-007-0741-1; BRANTZAWADZKI M, 1992, RADIOLOGY, V182, P769; Goerner FL, 2011, MED PHYS, V38, P5049, DOI 10.1118/1.3618730; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Mugler JP, 2014, J MAGN RESON IMAGING, V39, P745, DOI 10.1002/jmri.24542; Melhem ER, 1998, AM J ROENTGENOL, V171, P803; Kakeda S, 2007, EUR RADIOL, V17, P2345, DOI 10.1007/s00330-007-0599-9; Komada Tomohiro, 2008, Magn Reson Med Sci, V7, P13, DOI 10.2463/mrms.7.13	12	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	NOV	2015	25	11					3175	3186		10.1007/s00330-015-3757-5		12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CT0WJ	WOS:000362518200008		
J	Kato, H; Kanematsu, M; Watanabe, H; Kajita, K; Mizuta, K; Aoki, M; Okuaki, T				Kato, Hiroki; Kanematsu, Masayuki; Watanabe, Haruo; Kajita, Kimihiro; Mizuta, Keisuke; Aoki, Mitsuhiro; Okuaki, Tomoyuki			Perfusion imaging of parotid gland tumours: usefulness of arterial spin labeling for differentiating Warthin's tumours	EUROPEAN RADIOLOGY			English	Article						Arterial spin labelling; Diffusion-weighted imaging; Parotid gland; Salivary gland tumour; Warthin's tumour	CEREBRAL-BLOOD-FLOW; BRAIN-TUMORS; DIAGNOSTIC-VALUE; MR-IMAGES; DISEASE; BENIGN; DISCRIMINATION	To assess prospectively the efficacy of arterial spin labelling (ASL) against conventional and diffusion-weighted (DW) MR imaging for differentiating parotid gland tumours. We included 10 pleomorphic adenomas, 12 Warthin's tumours, and nine malignant tumours of the parotid glands. Only tumours larger than 10 mm were included in this study. All parotid gland tumours underwent T1-weighted, T2-weighted, DW, and ASL imaging. Tumour-to-parotid gland signal intensity ratios (SIRs) and apparent diffusion coefficients (ADCs) of solid components were correlated with these pathologies. SIRs on T2-weighted images and ADCs were higher in pleomorphic adenomas than in Warthin's tumours (p < .01) and malignant tumours (p < .01). SIRs on ASL were higher in Warthin's tumours than in pleomorphic adenomas (p < .01) and malignant tumours (p < .05). Az value of SIRs on ASL for differentiating Warthin's tumours from the other pathologies was 0.982. The sensitivity, specificity, and accuracy of SIRs on ASL for the diagnosis of Warthin's tumours at an optimal SIR threshold of over 8.70 were 91.7 %, 94.7 %, and 93.5 %, respectively. ASL with SIR measurements could non-invasively evaluate tumour blood flow of parotid gland tumours and differentiate Warthin's tumours from pleomorphic adenomas and malignant tumours. aEuro cent ASL non-invasively evaluates tumour blood flow of parotid gland tumours aEuro cent ASL differentiates Warthin's tumours from pleomorphic adenomas and malignant tumours aEuro cent ASL cannot differentiate between pleomorphic adenomas and malignant tumours.	[Kato, Hiroki; Kanematsu, Masayuki; Watanabe, Haruo] Gifu Univ, Sch Med, Dept Radiol, Gifu 5011194, Japan; [Kanematsu, Masayuki; Kajita, Kimihiro] Gifu Univ Hosp, High Level Imaging Diag Ctr, Gifu 5011194, Japan; [Mizuta, Keisuke; Aoki, Mitsuhiro] Gifu Univ, Dept Otolaryngol, Sch Med, Gifu 5011194, Japan; [Okuaki, Tomoyuki] Philips Healthcare, Minato Ku, Tokyo 1088507, Japan	Kato, H (reprint author), Gifu Univ, Sch Med, Dept Radiol, 1-1 Yanagido, Gifu 5011194, Japan.	hkato@gifu-u.ac.jp					Habermann CR, 2009, AM J NEURORADIOL, V30, P591, DOI 10.3174/ajnr.A1412; Wolf RL, 2001, AM J NEURORADIOL, V22, P1334; Chalela JA, 2000, STROKE, V31, P680; Detre JA, 1998, NEUROLOGY, V50, P633; Wolf RL, 2005, J MAGN RESON IMAGING, V22, P475, DOI 10.1002/jmri.20415; Weber MA, 2004, INVEST RADIOL, V39, P277, DOI 10.1097/01.rli.0000119195.50515.04; Eida S, 2008, J MAGN RESON IMAGING, V27, P1256, DOI 10.1002/jmri.21349; Jarnum H, 2010, NEURORADIOLOGY, V52, P307, DOI 10.1007/s00234-009-0616-6; Wolf RL, 2007, NEUROTHERAPEUTICS, V4, P346, DOI 10.1016/j.nurt.2007.04.005; Christe A, 2011, AM J NEURORADIOL, V32, P1202, DOI 10.3174/ajnr.A2520; Noguchi T, 2008, AM J NEURORADIOL, V29, P688, DOI [10.3174/ajnr.A0903, 10.3174/ainr.A0903]; Hisatomi M, 2007, ORAL ONCOL, V43, P940, DOI 10.1016/j.oratoncotogy.2006.11.009; Warmuth C, 2003, RADIOLOGY, V228, P523, DOI 10.1148/radiol.2282020409; Yabuuchi H, 2008, RADIOLOGY, V249, P909, DOI 10.1148/radiol.2493072045; TSUSHIMA Y, 1994, BRIT J RADIOL, V67, P342; Das DK, 2004, MED PRIN PRACT, V13, P95, DOI 10.1159/000075637; BATSAKIS JG, 1987, ANN OTO RHINOL LARYN, V96, P234; SOM PM, 1989, RADIOLOGY, V173, P823; Muller-Schimpfle M, 2000, ROFO-FORTSCHR RONTG, V172, P894, DOI 10.1055/s-2000-8366; Matsushima N, 2007, J NEURORADIOLOGY, V34, P183, DOI 10.1016/j.neurad.2007.04.002; Yabuuchi H, 2003, RADIOLOGY, V226, P345, DOI 10.1148/radiol.2262011486; Alsop DC, 2000, ANN NEUROL, V47, P93, DOI 10.1002/1531-8249(200001)47:1<93::AID-ANA15>3.0.CO;2-8; Kimura H, 2006, AM J NEURORADIOL, V27, P85; Fruehwald-Pallamar J, 2013, NMR BIOMED, V26, P1372, DOI 10.1002/nbm.2962; Fujima N, 2015, J MAGN RESON IMAGING, V41, P983, DOI [10.1002/jmri.24885, 10.1002/jmri.24637]; Fujima N, 2014, J MAGN RESON IMAGING, V40, P920, DOI 10.1002/jmri.24421	26	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	NOV	2015	25	11					3247	3254		10.1007/s00330-015-3755-7		8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CT0WJ	WOS:000362518200016		
J	Kobayashi, T; Aikata, H; Hatooka, M; Morio, K; Morio, R; Kan, H; Fujino, H; Fukuhara, T; Masaki, K; Ohno, A; Naeshiro, N; Nakahara, T; Honda, Y; Murakami, E; Kawaoka, T; Tsuge, M; Hiramatsu, A; Imamura, M; Kawakami, Y; Hyogo, H; Takahashi, S; Chayama, K				Kobayashi, Tomoki; Aikata, Hiroshi; Hatooka, Masahiro; Morio, Kei; Morio, Reona; Kan, Hiromi; Fujino, Hatsue; Fukuhara, Takayuki; Masaki, Keiichi; Ohno, Atsushi; Naeshiro, Noriaki; Nakahara, Takashi; Honda, Yohji; Murakami, Eisuke; Kawaoka, Tomokazu; Tsuge, Masataka; Hiramatsu, Akira; Imamura, Michio; Kawakami, Yoshiiku; Hyogo, Hideyuki; Takahashi, Shoichi; Chayama, Kazuaki			Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma	EUROPEAN RADIOLOGY			English	Article						Hepatocellular carcinoma; Macroscopic findings; Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging; Contrast-enhanced ultrasound; Combined diagnosis	FOCAL LIVER-LESIONS; GROSS CLASSIFICATION; HISTOPATHOLOGIC FINDINGS; RISK-FACTORS; SPIRAL CT; EFFICACY; RECURRENCE; RESECTION; SURVIVAL; AGENT	Non-simple nodules in hepatocellular carcinoma (HCC) correlate with poor prognosis. Therefore, we examined the diagnostic ability of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) and contrast-enhanced ultrasound (CEUS) for diagnosing the macroscopic classification of small HCCs. A total of 85 surgically resected nodules (a parts per thousand currency sign30 mm) were analyzed. HCCs were pathologically classified as simple nodular (SN) and non-SN. By evaluating hepatobiliary phase (HBP) of EOB-MRI and Kupffer phase of CEUS, the diagnostic abilities of both modalities to correctly distinguish between SN and non-SN were compared. Forty-six nodules were diagnosed as SN and the remaining 39 nodules as non-SN. The area under the ROC curve (AUROCs, 95 % confidence interval) for the diagnosis of non-SN were EOB-MRI, 0.786 (0.682-0.890): CEUS, 0.784 (0.679-0.889), in combination, 0.876 (0.792-0.959). The sensitivity, specificity, and accuracy were 64.1 %, 95.7 %, and 81.2 % in EOB-MRI, 56.4 %, 97.8 %, and 78.8 % in CEUS, and 84.6 %, 95.7 %, and 90.6 % in combination, respectively. High diagnostic ability was obtained when diagnosed in both modalities combined. The sensitivity was especially statistically significant compared to CEUS. Combined diagnosis by EOB-MRI and CEUS can provide high-quality imaging assessment for determining non-SN in small HCCs. aEuro cent Non-SN has a higher frequency of MVI and intrahepatic metastasis than SN. aEuro cent Macroscopic classification is useful to choose the treatment strategy for small HCCs. aEuro cent Diagnostic ability for macroscopic findings of EOB-MRI and CEUS were statistically equal. aEuro cent The diagnosis of macroscopic findings by individual modality has limitations. aEuro cent Combined diagnosis of EOB-MRI and CEUS provides high diagnostic ability.	[Kobayashi, Tomoki; Aikata, Hiroshi; Hatooka, Masahiro; Morio, Kei; Morio, Reona; Kan, Hiromi; Fujino, Hatsue; Fukuhara, Takayuki; Masaki, Keiichi; Ohno, Atsushi; Naeshiro, Noriaki; Nakahara, Takashi; Honda, Yohji; Murakami, Eisuke; Kawaoka, Tomokazu; Tsuge, Masataka; Hiramatsu, Akira; Imamura, Michio; Kawakami, Yoshiiku; Hyogo, Hideyuki; Takahashi, Shoichi; Chayama, Kazuaki] Hiroshima Univ Hosp, Dept Gastroenterol & Metab, Minami Ku, Hiroshima 7348551, Japan; [Chayama, Kazuaki] Hiroshima Univ, Liver Res Project Ctr, Hiroshima 7348551, Japan	Aikata, H (reprint author), Hiroshima Univ Hosp, Dept Gastroenterol & Metab, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	aikata@hiroshima-u.ac.jp					Nakashima Y, 2003, HEPATOL RES, V26, P142, DOI 10.1016/S1386-6346(03)00007-X; Kundel HL, 2003, RADIOLOGY, V228, P303, DOI 10.1148/radiol.2282011860; Ariizumi S, 2011, J HEPATO-BIL-PAN SCI, V18, P575, DOI 10.1007/s00534-010-0369-y; Granito A, 2013, ALIMENT PHARM THER, V37, P355, DOI 10.1111/apt.12166; Huppertz A, 2004, RADIOLOGY, V230, P266, DOI 10.1148/radiol.2301020269; Vogl TJ, 1996, RADIOLOGY, V200, P59; Kaibori M, 2009, AM J SURG, V198, P39, DOI 10.1016/j.amjsurg.2008.07.051; Fujinaga Y, 2013, HEPATOL RES, V43, P488, DOI 10.1111/j.1872-034X.2012.01089.x; Hammerstingl R, 2008, EUR RADIOL, V18, P457, DOI 10.1007/s00330-007-0716-9; Hatanaka K, 2014, J CLIN ULTRASOUND, V42, P1, DOI 10.1002/jcu.22080; Mita K, 2010, WORLD J GASTROENTERO, V16, P4187, DOI 10.3748/wjg.v16.i33.4187; Konopke R, 2007, ULTRASOUND MED BIOL, V33, P1515, DOI 10.1016/j.ultrasmedbio.2007.04.009; Huppertz A, 2005, RADIOLOGY, V234, P468, DOI 10.1148/radiol.2342040278; Hatanaka K, 2008, INTERVIROLOGY, V51, P61, DOI 10.1159/000122600; Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Tada T, 2014, EUR RADIOL, V24, P2157, DOI 10.1007/s00330-014-3254-2; Yanagisawa K, 2007, ULTRASOUND MED BIOL, V33, P318, DOI 10.1016/j.ultrasmedbio.2006.08.008; KANAI T, 1987, CANCER, V60, P810, DOI 10.1002/1097-0142(19870815)60:4<810::AID-CNCR2820600417>3.0.CO;2-1; Bluemke DA, 2005, RADIOLOGY, V237, P89, DOI 10.1148/radiol.2371031842; Shimada K, 2007, ANN SURG ONCOL, V14, P2337, DOI 10.1245/s10434-007-9415-7; Ueno S, 2008, J HEPATO-BILIARY-PAN, V15, P493, DOI 10.1007/s00534-007-1312-8; Dupont-Bierre E, 2005, J AM COLL SURGEONS, V201, P663, DOI 10.1016/j.jamcollsurg.2005.06.265; Shah SA, 2007, SURGERY, V141, P330, DOI 10.1016/j.surg.2006.06.028; Solbiati L, 2001, EUR RADIOL, V11, pE15, DOI 10.1007/PL00014125; Korenaga K, 2009, J GASTROENTEROL, V44, P733, DOI 10.1007/s00535-009-0053-7; Hui AM, 2000, J HEPATOL, V33, P975, DOI 10.1016/S0168-8278(00)80131-2; Kudo M, 2008, J MED ULTRASOUND, V16, P169, DOI 10.1016/S0929-6441(08)60045-4; Liver Cancer Study Group of Japan, 2010, GEN RUL CLIN PATH ST, P17; Saito Kazuhiro, 2005, Magn Reson Med Sci, V4, P1, DOI 10.2463/mrms.4.1; Sumie S, 2008, ANN SURG ONCOL, V15, P1375, DOI 10.1245/s10434-008-9846-9; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Tada T, 2015, J GASTROENTEROL, V50, P85, DOI 10.1007/s00535-014-0947-x; Tsujita E, 2013, HEPATO-GASTROENTEROL, V60, P1726, DOI 10.5754/hge13365	33	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0938-7994	1432-1084		EUR RADIOL	Eur. Radiol.	NOV	2015	25	11					3272	3281		10.1007/s00330-015-3725-0		10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CT0WJ	WOS:000362518200019		
J	Sugitani, K; Mimura, K; Takeuchi, M; Lepot, K; Ito, S; Javaux, EJ				Sugitani, K.; Mimura, K.; Takeuchi, M.; Lepot, K.; Ito, S.; Javaux, E. J.			Early evolution of large micro-organisms with cytological complexity revealed by microanalyses of 3.4Ga organic-walled microfossils	GEOBIOLOGY			English	Article							STRELLEY POOL FORMATION; WESTERN-AUSTRALIA; PILBARA CRATON; ISOTOPIC COMPOSITIONS; MICROSTRUCTURES; DIVERSITY; OCEANS; STROMATOLITES; PRESERVATION; BIOGENICITY	The Strelley Pool Formation (SPF) is widely distributed in the East Pilbara Terrane (EPT) of the Pilbara Craton, Western Australia, and represents a Paleoarchean shallow-water to subaerial environment. It was deposited similar to 3.4 billion years ago and displays well-documented carbonate stromatolites. Diverse putative microfossils (SPF microfossils) were recently reported from several localities in the East Strelley, Panorama, Warralong, and Goldsworthy greenstone belts. Thus, the SPF provides unparalleled opportunities to gain insights into a shallow-water to subaerial ecosystem on the early Earth. Our new micro- to nanoscale ultrastructural and microchemical studies of the SPF microfossils show that large (20-70m) lenticular organic-walled flanged microfossils retain their structural integrity, morphology, and chain-like arrangements after acid (HF-HCl) extraction (palynology). Scanning and transmitted electron microscopy of extracted microfossils revealed that the central lenticular body is either alveolar or hollow, and the wall is continuous with the surrounding smooth to reticulated discoidal flange. These features demonstrate the evolution of large micro-organisms able to form an acid-resistant recalcitrant envelope or cell wall with complex morphology and to form colonial chains in the Paleoarchean era. This study provides evidence of the evolution of very early and remarkable biological innovations, well before the presumed late emergence of complex cells.	[Sugitani, K.; Mimura, K.; Takeuchi, M.] Nagoya Univ, Grad Sch Environm Studies, Nagoya, Aichi 4648601, Japan; [Sugitani, K.] Univ New S Wales, Australian Ctr Astrobiol, Sydney, NSW, Australia; [Lepot, K.] Univ Lille, Lab Oceanol & Geosci, CNRS UMR8187, Villeneuve Dascq, France; [Ito, S.] Nagoya Univ, Sch Informat & Sci, Nagoya, Aichi 4648601, Japan; [Javaux, E. J.] Univ Liege, Dept Geol, Liege, Belgium	Sugitani, K (reprint author), Nagoya Univ, Grad Sch Environm Studies, Nagoya, Aichi 4648601, Japan.	sugi@info.human.nagoya-u.ac.jp			Japan Society for the Promotion of Science [22340149, 24654162]; CNRS-INSU INTERRVIE program; NFSR; Francqui Foundation; Belspo IAP Planet Topers; NFSR [FRFC 2.4.558.09]	Financial support for K.S., K.M., and M.T. from the Japan Society for the Promotion of Science (a grant-in-aid, No. 22340149 and No. 24654162) is gratefully acknowledged. K.L. received funding from the CNRS-INSU INTERRVIE program and NFSR. E.J acknowledges support from NFSR FRFC 2.4.558.09, FP7 EU-ERC StG ELiTE, Belspo IAP Planet Topers, and the Francqui Foundation. Special thanks to Tsutomu Nagaoka, Nagoya University for his assistance for preparation of thin sections; P. Compere, N. Decloux, and M. Giraldo from the Liege University for assistance with sample preparation and TEM; P. Recourt for assistance with SEM in Lille, D. Troadec for preparing FIB sections at IEMN Lille, M. Cabie (FIB assistance at CP2M); and Dr. K. Grey, Western Australia, for assistance with permission for sample export. The TEM national facility in Lille is supported by Conseil Regional du Nord-Pas de Calais, European Regional Development Fund, and CNRS-INSU.	ANGERT ER, 1993, NATURE, V362, P239, DOI 10.1038/362239a0; Hofmann HJ, 1999, GEOL SOC AM BULL, V111, P1256, DOI 10.1130/0016-7606(1999)111<1256:OOGCSI>2.3.CO;2; Sugitani K, 2009, ASTROBIOLOGY, V9, P603, DOI 10.1089/ast.2008.0268; Sugitani K, 2010, ASTROBIOLOGY, V10, P899, DOI 10.1089/ast.2010.0513; Sugitani K, 2013, PRECAMBRIAN RES, V226, P59, DOI 10.1016/j.precamres.2012.11.005; Javaux EJ, 2003, ORIGINS LIFE EVOL B, V33, P75, DOI 10.1023/A:1023992712071; Grey K, 2009, PALAIOS, V24, P239, DOI 10.2110/palo.2008.p08-020r; Wacey D, 2012, PRECAMBRIAN RES, V220, P234, DOI 10.1016/j.precamres.2012.08.005; OEHLER JH, 1971, SCIENCE, V174, P1229, DOI 10.1126/science.174.4015.1229; Williford KH, 2013, GEOCHIM COSMOCHIM AC, V104, P165, DOI 10.1016/j.gca.2012.11.005; Javaux EJ, 2010, NATURE, V463, P934, DOI 10.1038/nature08793; Grey K, 2009, PRECAMBRIAN RES, V173, P60, DOI 10.1016/j.precamres.2009.02.003; Mendell JE, 2008, P NATL ACAD SCI USA, V105, P6730, DOI 10.1073/pnas.0707522105; Knoll AH, 2006, PHILOS T R SOC B, V361, P1023, DOI 10.1098/rstb.2006.1843; Oehler DZ, 2010, ASTROBIOLOGY, V10, P413, DOI 10.1089/ast.2009.0426; Schulz HN, 2001, ANNU REV MICROBIOL, V55, P105, DOI 10.1146/annurev.micro.55.1.105; Allwood AC, 2006, NATURE, V441, P714, DOI 10.1038/nature04764; Parfrey LW, 2011, P NATL ACAD SCI USA, V108, P13624, DOI 10.1073/pnas.1110633108; LOWE DR, 1983, PRECAMBRIAN RES, V19, P239, DOI 10.1016/0301-9268(83)90016-5; Wacey D, 2011, NAT GEOSCI, V4, P698, DOI 10.1038/NGEO1238; Reichenbach H, 2001, J IND MICROBIOL BIOT, V27, P149, DOI 10.1038/sj.jim.7000025; Allwood AC, 2009, P NATL ACAD SCI USA, V106, P9548, DOI 10.1073/pnas.0903323106; Samuelsson J, 1999, PRECAMBRIAN RES, V96, P1, DOI 10.1016/S0301-9268(98)00123-5; Lepot K, 2013, GEOCHIM COSMOCHIM AC, V112, P66, DOI 10.1016/j.gca.2013.03.004; Moczydlowska M, 2011, PALAEONTOLOGY, V54, P721, DOI 10.1111/j.1475-4983.2011.01054.x; Sugitani K, 2007, PRECAMBRIAN RES, V158, P228, DOI 10.1016/j.precamres.2007.03.006; Angert ER, 2005, NAT REV MICROBIOL, V3, P214, DOI 10.1038/nrmicro1096; Allwood AC, 2010, CHEM GEOL, V270, P148, DOI 10.1016/j.chemgeo.2009.11.013; Javaux EJ, 2004, GEOBIOLOGY, V2, P121, DOI 10.1111/j.1472-4677.2004.00027.x; Sugitani K, 2009, PRECAMBRIAN RES, V173, P50, DOI 10.1016/j.precamres.2009.02.004; Hirose E, 2009, EUR J PHYCOL, V44, P365, DOI 10.1080/09670260802710269; House CH, 2013, GEOLOGY, V41, P651, DOI 10.1130/G34055.1; Butterfield NJ, 2014, PALAEONTOLOGY, V58, P5; EVITT WR, 1963, P NATL ACAD SCI USA, V49, P158, DOI 10.1073/pnas.49.2.158; Grey K, 1999, GEOLOGICAL SURVEY W; Hickman AH, 2011, GEOLOGICAL SURVEY W; Hickman AH, 2008, GEOLOGICAL SURVEY W; Javaux Emmanuelle, 2011, P414, DOI 10.1017/CBO9780511933875.028; Knoll A. H., 2014, COLD SPRING HARBOR P, V6, P1, DOI DOI 10.1101/CSHPERSPECT.A016121;PMID:24384569; Oehler DZ, 2014, 45 LUN PLAN SCI C, P1254; OEHLER DZ, 1976, J PALEONTOL, V50, P90; Porter SM, 2004, PALEONTOLOGICAL SOC, V10, P35; SCHOPF J W, 1968, Journal of Paleontology, V42, P651; Schopf JW, 1992, PROTEROZOIC BIOSPHER, P1080; Van Kranendonk MJ, 2006, GEOLOGICAL SURVEY W; Van Kranendonk MJ, 2011, ADV STROMATOLITE GEO, P537; vansZuilen MA, 2012, GEOCHIMICA COSMOCHIM, V83, P252; WALSH MM, 1992, PRECAMBRIAN RES, V54, P271, DOI 10.1016/0301-9268(92)90074-X; Yamaguchi T, 2011, JAP GEOSC UN M 2011	49	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1472-4677	1472-4669		GEOBIOLOGY	Geobiology	NOV	2015	13	6					507	521		10.1111/gbi.12148		15	Biology; Environmental Sciences; Geosciences, Multidisciplinary	Life Sciences & Biomedicine - Other Topics; Environmental Sciences & Ecology; Geology	CT6YB	WOS:000362958500001		
J	Sugitani, K; Mimura, K; Takeuchi, M; Yamaguchi, T; Suzuki, K; Senda, R; Asahara, Y; Wallis, S; Van Kranendonk, MJ				Sugitani, K.; Mimura, K.; Takeuchi, M.; Yamaguchi, T.; Suzuki, K.; Senda, R.; Asahara, Y.; Wallis, S.; Van Kranendonk, M. J.			A Paleoarchean coastal hydrothermal field inhabited by diverse microbial communities: the Strelley Pool Formation, Pilbara Craton, Western Australia	GEOBIOLOGY			English	Article							YELLOWSTONE-NATIONAL-PARK; INDUCED SEDIMENTARY STRUCTURES; ARCHEAN CHEMICAL SEDIMENTS; BARBERTON MOUNTAIN LAND; GA DRESSER FORMATION; RARE-EARTH-ELEMENTS; SOUTH-AFRICA; WARRAWOONA GROUP; ONVERWACHT GROUP; MT. GOLDSWORTHY	The 3.4-Ga Strelley Pool Formation (SPF) at the informally named Waterfall Locality' in the Goldsworthy greenstone belt of the Pilbara Craton, Western Australia, provides deeper insights into ancient, shallow subaqueous to possibly subaerial ecosystems. Outcrops at this locality contain a thin (<3m) unit of carbonaceous and non-carbonaceous cherts and silicified sandstones that were deposited in a shallow-water coastal environment, with hydrothermal activities, consistent with the previous studies. Carbonaceous, sulfide-rich massive black cherts with coniform structures up to 3cm high are characterized by diverse rare earth elements (REE) signatures including enrichment of light [light rare earth elements (LREE)] or middle rare earth elements and by enrichment of heavy metals represented by Zn. The massive black cherts were likely deposited by mixing of hydrothermal and non-hydrothermal fluids. Coniform structures in the cherts are characterized by diffuse laminae composed of sulfide particles, suggesting that unlike stromatolites, they were formed dominantly through physico-chemical processes related to hydrothermal activity. The cherts yield microfossils identical to previously described carbonaceous films, small and large spheres, and lenticular microfossils. In addition, new morphological types such as clusters composed of large carbonaceous spheroids (20-40m across each) with fluffy or foam-like envelope are identified. Finely laminated carbonaceous cherts are devoid of heavy metals and characterized by the enrichment of LREE. This chert locally contains conical to domal structures characterized by truncation of laminae and trapping of detrital grains and is interpreted as siliceous stromatolite formed by very early or contemporaneous silicification of biomats with the contribution of silica-rich hydrothermal fluids. Biological affinities of described microfossils and microbes constructing siliceous stromatolites are under investigation. However, this study emphasizes how diverse the microbial community in Paleoarchean coastal hydrothermal environment was. We propose the diversity is at least partially due to the availability of various energy sources in this depositional environment including reducing chemicals and sunlight.	[Sugitani, K.; Mimura, K.; Takeuchi, M.; Asahara, Y.; Wallis, S.] Nagoya Univ, Grad Sch Environm Studies, Nagoya, Aichi 4648601, Japan; [Sugitani, K.; Van Kranendonk, M. J.] Univ New S Wales, Australian Ctr Astrobiol, Sydney, NSW, Australia; [Yamaguchi, T.] Nagoya Univ, Sch Informat & Sci, Nagoya, Aichi 4648601, Japan; [Suzuki, K.; Senda, R.] Japan Agcy Marine Earth Sci & Technol, Yokosuka, Kanagawa 2370061, Japan; [Van Kranendonk, M. J.] Univ New S Wales, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia; [Van Kranendonk, M. J.] Australian Res Council, Ctr Excellence Core Crust Fluid Syst, Sydney, NSW, Australia	Sugitani, K (reprint author), Nagoya Univ, Grad Sch Environm Studies, Nagoya, Aichi 4648601, Japan.	sugi@info.human.nagoya-u.ac.jp			Japanese Society for the Promotion of Science [22340149, 24654162]; University of New South Wales	Financial support for K.S., K.M., and M.T. from the Japanese Society for the Promotion of Science (Grant-in-Aid Nos 22340149 and 24654162) is gratefully acknowledged. Special thanks to Tsutomu Nagaoka and Natsuko Takagi, Nagoya University, for their assistance for the preparation of thin sections; to Dr. K. Grey, Western Australia, for her assistance with permission for sample export. The authors also thank Tomoki Taguchi and Hirokazu Kawahara, Nagoya University, for their assistance for EPMA and Raman spectral analyses. MVK acknowledges support from the University of New South Wales. This is contribution 636 from the ARC Centre of Excellence for Core to Crust Fluid Systems (http://www.ccfs.mq.edu.au).	Allwood AC, 2007, GEOLOGICAL SURVEY W; BAU M, 1991, CHEM GEOL, V93, P219, DOI 10.1016/0009-2541(91)90115-8; Hofmann HJ, 1999, GEOL SOC AM BULL, V111, P1256, DOI 10.1130/0016-7606(1999)111<1256:OOGCSI>2.3.CO;2; Tice MM, 2004, NATURE, V431, P549, DOI 10.1038/nature02888; Yamamoto K, 2004, PRECAMBRIAN RES, V135, P331, DOI 10.1016/j.precamres.2004.09.006; Sugitani K, 2010, ASTROBIOLOGY, V10, P899, DOI 10.1089/ast.2010.0513; Sugitani K, 2013, PRECAMBRIAN RES, V226, P59, DOI 10.1016/j.precamres.2012.11.005; Wood SA, 2006, J GEOCHEM EXPLOR, V89, P424, DOI 10.1016/j.gexplo.2005.11.023; Wacey D, 2010, ASTROBIOLOGY, V10, P381, DOI 10.1089/ast.2009.0423; Johannesson KH, 2006, GEOCHIM COSMOCHIM AC, V70, P871, DOI 10.1016/j.gca.2005.10.013; Wacey D, 2012, AUST J EARTH SCI, V59, P153, DOI 10.1080/08120099.2011.592989; Kremer B, 2012, ASTROBIOLOGY, V12, P535, DOI 10.1089/ast.2011.0742; Sugitani K, 2003, PRECAMBRIAN RES, V120, P55, DOI 10.1016/S0301-9268(02)00145-6; Van Kranendonk MJ, 2008, PRECAMBRIAN RES, V167, P93, DOI 10.1016/j.precamres.2008.07.003; Bolhar R, 2004, EARTH PLANET SC LETT, V222, P43, DOI 10.1016/j.epsl.2004.02.016; Wacey D, 2012, PRECAMBRIAN RES, V220, P234, DOI 10.1016/j.precamres.2012.08.005; Konhauser KO, 2001, SEDIMENTOLOGY, V48, P415, DOI 10.1046/j.1365-3091.2001.00372.x; Schopf JW, 2006, PHILOS T R SOC B, V361, P869, DOI 10.1098/rstb.2006.1834; Sugahara H, 2010, PRECAMBRIAN RES, V177, P73, DOI 10.1016/j.precamres.2009.10.005; Ueno Y, 2006, NATURE, V440, P516, DOI 10.1038/nature04584; Pack A, 2007, GEOCHIM COSMOCHIM AC, V71, P4592, DOI 10.1016/j.gca.2007.07.010; Javaux EJ, 2010, NATURE, V463, P934, DOI 10.1038/nature08793; Grey K, 2009, PRECAMBRIAN RES, V173, P60, DOI 10.1016/j.precamres.2009.02.003; Lewis AJ, 1998, GEOCHIM COSMOCHIM AC, V62, P657, DOI 10.1016/S0016-7037(97)00367-0; Altermann W, 2008, SPACE SCI REV, V135, P55, DOI 10.1007/s11214-007-9292-1; Oehler DZ, 2010, ASTROBIOLOGY, V10, P413, DOI 10.1089/ast.2009.0426; Kamber BS, 2001, GEOCHIM COSMOCHIM AC, V65, P2509, DOI 10.1016/S0016-7037(01)00613-5; Bau M, 1999, CHEM GEOL, V155, P77, DOI 10.1016/S0009-2541(98)00142-9; Heubeck C, 2009, GEOLOGY, V37, P931, DOI 10.1130/G30101A.1; Allwood AC, 2006, NATURE, V441, P714, DOI 10.1038/nature04764; LOWE DR, 1983, PRECAMBRIAN RES, V19, P239, DOI 10.1016/0301-9268(83)90016-5; Braunstein D, 2001, J SEDIMENT RES, V71, P747, DOI 10.1306/2DC40965-0E47-11D7-8643000102C1865D; Wacey D, 2011, NAT GEOSCI, V4, P698, DOI 10.1038/NGEO1238; Douville E, 1999, GEOCHIM COSMOCHIM AC, V63, P627, DOI 10.1016/S0016-7037(99)00024-1; Allwood AC, 2009, P NATL ACAD SCI USA, V106, P9548, DOI 10.1073/pnas.0903323106; Cady SL, 1996, CIBA F SYMP, V202, P150; Hayashi T, 2004, PRECAMBRIAN RES, V135, P345, DOI 10.1016/j.precamres.2004.09.004; WALSH MM, 1985, NATURE, V314, P530, DOI 10.1038/314530a0; CODY RD, 1979, J SEDIMENT PETROL, V49, P1015; Lepot K, 2013, GEOCHIM COSMOCHIM AC, V112, P66, DOI 10.1016/j.gca.2013.03.004; Banerjee NR, 2007, GEOLOGY, V35, P487, DOI 10.1130/G23534A.1; Noffke N, 2013, ASTROBIOLOGY, V13, P1103, DOI 10.1089/ast.2013.1030; Schopf JW, 2010, PRECAMBRIAN RES, V179, P191, DOI 10.1016/j.precamres.2010.03.003; Noffke N, 2008, GEOBIOLOGY, V6, P5, DOI 10.1111/j.1472-4669.2007.00118.x; Bolhar R, 2005, PRECAMBRIAN RES, V137, P93, DOI 10.1016/j.precamres.2005.02.001; Rasmussen B, 2014, GEOL SOC AM BULL, V126, P1245, DOI 10.1130/B31049.1; Sugitani K, 2007, PRECAMBRIAN RES, V158, P228, DOI 10.1016/j.precamres.2007.03.006; Renaut RW, 1998, SEDIMENTOLOGY, V45, P1083; Allwood AC, 2010, CHEM GEOL, V270, P148, DOI 10.1016/j.chemgeo.2009.11.013; Bontognali TRR, 2012, P NATL ACAD SCI USA, V109, P15146, DOI 10.1073/pnas.1207491109; Konhauser KO, 2003, CAN J EARTH SCI, V40, P1713, DOI 10.1139/E03-059; Ueno Y, 2008, GEOCHIM COSMOCHIM AC, V72, P5675, DOI 10.1016/j.gca.2008.08.026; Sugitani K, 2006, GEOCHEM J, V40, P523, DOI 10.2343/geochemj.40.523; Canet C, 2005, SEDIMENT GEOL, V174, P97, DOI 10.1016/j.sedgeo.2004.12.001; WALTER MR, 1972, SCIENCE, V178, P402, DOI 10.1126/science.178.4059.402; Sugitani K, 2009, PRECAMBRIAN RES, V173, P50, DOI 10.1016/j.precamres.2009.02.004; House CH, 2013, GEOLOGY, V41, P651, DOI 10.1130/G34055.1; Flugel E., 2010, MICROFACIES CARBONAT; Hickman AH, 2008, GEOLOGICAL SURVEY W; Philippot P, 2007, SCIENCE, V317, P1534, DOI 10.1126/science.1145861; Schirrmeister BE, 2013, P NATL ACAD SCI USA, V110, P1792; Sugitani K, 2015, GEOBIOLOGY, V13, P507, DOI 10.1111/gbi.12148; Sugitani K, 1996, PRECAMBRIAN RES, V80, P49, DOI 10.1016/S0301-9268(96)00005-8; Van Kranendonk MJ, 2011, LECT NOTES EARTH SCI, V131, P537; VansKranendonk MJ, 2004, GEOCHEM-EXPLOR ENV A, V4, P253; VansKranendonk MJ, 2006, EARTH-SCI REV, V74, P197; VansKranendonk MJ, 2006, GEOLOGICAL SURVEY W; VansKranendonk MJ, 2003, GEOBIOLOGY, V1, P91; Wacey D, 2010, GEOLOGICAL SURVEY W; Wacey D., 2009, EARLY LIFE EARTH PRA; WALSH MM, 1992, PRECAMBRIAN RES, V54, P271, DOI 10.1016/0301-9268(92)90074-X; Walter MR, 1976, STROMATOLITES, P87; Westall F, 2006, GEOL SOC AM SPEC PUB, V405, P105, DOI DOI 10.1130/2006.2405(07); Yamaguchi T, 2011, JAP GEOSC UN M 2011	74	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1472-4677	1472-4669		GEOBIOLOGY	Geobiology	NOV	2015	13	6					522	545		10.1111/gbi.12150		24	Biology; Environmental Sciences; Geosciences, Multidisciplinary	Life Sciences & Biomedicine - Other Topics; Environmental Sciences & Ecology; Geology	CT6YB	WOS:000362958500002		
J	Harada, Y; Masahara-Negishi, Y; Suzuki, T				Harada, Yoichiro; Masahara-Negishi, Yuki; Suzuki, Tadashi			Cytosolic-free oligosaccharides are predominantly generated by the degradation of dolichol-linked oligosaccharides in mammalian cells	GLYCOBIOLOGY			English	Article						dolichol-linked oligosaccharides; endo-beta-N-acetylglucosaminidase; free oligosaccharides; oligosaccharyltransferase; peptide:N-glycanase	NEUTRAL ALPHA-MANNOSIDASE; PEPTIDE-N-GLYCANASE; RETICULUM-ASSOCIATED DEGRADATION; ENDOPLASMIC-RETICULUM; POLYMANNOSE OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; PROTEIN GLYCOSYLATION; HEPG2 CELLS; OLIGOSACCHARYLTRANSFERASE	During asparagine (N)-linked protein glycosylation, eukaryotic cells generate considerable amounts of free oligosaccharides (fOSs) in the cytosol. It is generally assumed that such fOSs are produced by the deglycosylation of misfolded N-glycoproteins that are destined for proteasomal degradation or as the result of the degradation of dolichol-linked oligosaccharides (DLOs), which serve as glycan donor substrates in N-glycosylation reactions. The findings reported herein show that the majority of cytosolic fOSs are generated by a peptide: N-glycanase (PNGase) and an endo-beta-N-acetylglucosaminidase (ENGase)-independent pathway in mammalian cells. The ablation of the cytosolic deglycosylating enzymes, PNGase and ENGase, in mouse embryonic fibroblasts had little effect on the amount of cytosolic fOSs generated. Quantitative analyses of fOSs using digitonin-permeabilized cells revealed that they are generated by the degradation of fully assembled Glc(3)Man(9)GlcNAc(2)-pyrophosphate-dolichol (PP-Dol) in the lumen of the endoplasmic reticulum. Because the degradation of Glc(3)Man(9)GlcNAc(2)-PP-Dol is greatly inhibited in the presence of an N-glycosylation acceptor peptide that is recognized by the oligosaccharyltransferase (OST), the OST-mediated hydrolysis of DLO is the most likely mechanism responsible for the production of a large fraction of the cytosolic fOSs.	[Harada, Yoichiro; Masahara-Negishi, Yuki; Suzuki, Tadashi] RIKEN, Global Res Cluster, RIKEN Max Planck Joint Res Ctr, Glycometabolome Team,Syst Glycobiol Res Grp, Wako, Saitama 3510198, Japan	Suzuki, T (reprint author), RIKEN, Global Res Cluster, RIKEN Max Planck Joint Res Ctr, Glycometabolome Team,Syst Glycobiol Res Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	tsuzuki_gm@riken.jp					Ruiz-Canada C, 2009, CELL, V136, P272, DOI 10.1016/j.cell.2008.11.047; Need AC, 2012, J MED GENET, V49, P353, DOI 10.1136/jmedgenet-2012-100819; Suzuki T, 2014, BIOCHEM BIOPH RES CO, V453, P213, DOI 10.1016/j.bbrc.2014.05.075; Kato T, 2007, J BIOL CHEM, V282, P22080, DOI 10.1074/jbc.M700805200; Gao NG, 2011, MOL BIOL CELL, V22, P2994, DOI 10.1091/mbc.E11-04-0286; MOORE SEH, 1995, EMBO J, V14, P6034; Harada Y, 2013, P NATL ACAD SCI USA, V110, P19366, DOI 10.1073/pnas.1312187110; Chantret I, 2008, GLYCOBIOLOGY, V18, P210, DOI 10.1093/glycob/cwn003; Chantret I, 2003, BIOCHEM J, V373, P901, DOI 10.0142/BJ20030384; Kumano M, 1996, J BIOCHEM-TOKYO, V119, P991; Suzuki T, 2008, ANAL BIOCHEM, V381, P224, DOI 10.1016/j.ab.2008.07.002; Aebi M, 2013, BBA-MOL CELL RES, V1833, P2430, DOI 10.1016/j.bbamcr.2013.04.001; SaintPol A, 1997, J CELL BIOL, V136, P45, DOI 10.1083/jcb.136.1.45; Ninagawa S, 2014, J CELL BIOL, V206, P347, DOI 10.1083/jcb.201404075; Kim I, 2006, J CELL BIOL, V172, P211, DOI 10.1083/jcb.200507149; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; Suzuki T, 2003, BIOCHEM BIOPH RES CO, V304, P326, DOI 10.1016/S0006-291X(03)00600-4; Suzuki T, 2006, BIOCHEM J, V400, P33, DOI 10.1042/BJ20060945; He P, 2015, GLYCOBIOLOGY, V25, P836, DOI 10.1093/glycob/cwv024; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Nothaft H, 2009, P NATL ACAD SCI USA, V106, P15019, DOI 10.1073/pnas.0903078106; Hirayama H, 2010, J BIOL CHEM, V285, P12390, DOI 10.1074/jbc.M109.082081; Schubert U, 2000, NATURE, V404, P770; Suzuki T, 2002, P NATL ACAD SCI USA, V99, P9691, DOI 10.1073/pnas.152333599; Haga Y, 2009, GLYCOBIOLOGY, V19, P987, DOI 10.1093/glycob/cwp075; Harada Y, 2013, J BIOL CHEM, V288, P32673, DOI 10.1074/jbc.M113.486985; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; Yamashiro K, 1997, J BIOCHEM-TOKYO, V122, P1174; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; Gao NG, 2005, J BIOL CHEM, V280, P17901, DOI 10.1074/jbc.M500510200; HANOVER JA, 1982, J BIOL CHEM, V257, P2787; SUZUKI T, 1993, BIOCHEM BIOPH RES CO, V194, P1124, DOI 10.1006/bbrc.1993.1938; ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8; Caglayan AO, 2015, EUR J MED GENET, V58, P39, DOI 10.1016/j.ejmg.2014.08.008; Chantret I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011734; Enns GM, 2014, GENET MED, V16, P751, DOI 10.1038/gim.2014.22; Gao Ningguo, 2013, Methods Mol Biol, V1022, P277, DOI 10.1007/978-1-62703-465-4_20; Huang CC, 2015, P NATL ACAD SCI USA, V112, P1398, DOI 10.1073/pnas.1414593112; Kelleher D. J., 2006, GLYCOBIOLOGY, V16, p47R; OKU H, 1991, J BIOCHEM-TOKYO, V110, P982; WELPLY JK, 1983, J BIOL CHEM, V258, P1856	43	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11					1196	1205		10.1093/glycob/cwv055		10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500008		
J	Inokuchi, J				Inokuchi, Jin-ichi			Control of Homeostatic and Pathogenic Balance in Adipose Tissue by Ganglioside GM3	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Inokuchi, Jin-ichi] Tohoku Pharmaceut Univ, Sendai, Miyagi, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				31	1237	1237				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500030		
J	Hoshino, H; Taga, M; Low, S; Kobayashi, M				Hoshino, Hitomi; Taga, Minekatsu; Low, Shulin; Kobayashi, Motohiro			A potential role for 6-sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Hoshino, Hitomi; Taga, Minekatsu; Low, Shulin; Kobayashi, Motohiro] Univ Fukui, Fukui, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				45	1240	1241				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500039		
J	Kudelka, MR; Ju, TZ; Darby, T; Hinrichs, B; Nishio, H; Wang, YC; Nusrat, A; Jones, RM; Neish, AS; Cummings, RD				Kudelka, Matthew R.; Ju, Tongzhong; Darby, Trevor; Hinrichs, Benjamin; Nishio, Hikaru; Wang, Yingchun; Nusrat, Asma; Jones, Rheinallt M.; Neish, Andrew S.; Cummings, Richard D.			O-Glycosylation Regulates Gut Microbiota and Homeostasis Through Multiple Pathways	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Kudelka, Matthew R.; Ju, Tongzhong; Darby, Trevor; Hinrichs, Benjamin; Wang, Yingchun; Jones, Rheinallt M.; Neish, Andrew S.; Cummings, Richard D.] Emory Univ, Atlanta, GA 30322 USA; [Nusrat, Asma] Univ Michigan, Ann Arbor, MI 48109 USA; [Nishio, Hikaru] Ajinomoto Pharmaceut Co Ltd, Tokyo, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				64	1248	1248				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500058		
J	Akama, TO; Angata, K; Nakamura, T; Fukuda, MN				Akama, Tomoya O.; Angata, Kiyohiko; Nakamura, Tomoyuki; Fukuda, Michiko N.			Cloning of endo-beta-galactosidase from B. fragilis	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol			PURIFICATION		[Akama, Tomoya O.; Nakamura, Tomoyuki] Kansai Med Univ, Hirakata, Osaka, Japan; [Angata, Kiyohiko; Fukuda, Michiko N.] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan							Leng L, 1998, GENE, V222, P187, DOI 10.1016/S0378-1119(98)00496-X; SCUDDER P, 1983, BIOCHEM J, V213, P485; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218	3	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				88	1257	1258				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500082		
J	Littlechild, SL; Young, RD; Quantock, AJ; Akama, TO				Littlechild, Stacy L.; Young, Robert D.; Quantock, Andrew J.; Akama, Tomoya O.			Differential keratan sulfate proteoglycan phenotype in the beta-1,3-N-acetylglucosaminyltransferse-7 deficient mouse cornea	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Littlechild, Stacy L.; Young, Robert D.; Quantock, Andrew J.] Cardiff Univ, Sch Optometry & Vis Sci, Biophys Grp, Cardiff, S Glam, Wales; [Littlechild, Stacy L.; Young, Robert D.; Quantock, Andrew J.] Cardiff Univ, Cardiff Inst Tissue Engn & Repair, Cardiff, S Glam, Wales; [Akama, Tomoya O.] Kansai Med Univ, Dept Pharmacol, Osaka, Japan; [Akama, Tomoya O.] Sanford Burnham Med Res Inst, Tumor Microenvironm Program, La Jolla, CA USA								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				87	1257	1257				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500081		
J	Stewart, TJ; Kosztyu, P; Takahashi, K; Bian, Q; Huang, ZQ; Raska, M; Renfrow, MB; Novak, J				Stewart, Tyler J.; Kosztyu, Petr; Takahashi, Kazuo; Bian, Qi; Huang, Zhi-qiang; Raska, Milan; Renfrow, Matthew B.; Novak, Jan			Analysis of time-course reaction products of GalNAc-transferases at glycoform-specific resolution using LCMS	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Stewart, Tyler J.; Kosztyu, Petr; Takahashi, Kazuo; Bian, Qi; Huang, Zhi-qiang; Renfrow, Matthew B.; Novak, Jan] Univ Alabama Birmingham, Birmingham, AL USA; [Kosztyu, Petr; Raska, Milan] Palacky Univ, CR-77147 Olomouc, Czech Republic; [Takahashi, Kazuo] Fujita Hlth Univ, Sch Med, Toyoake, Aichi 47011, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				103	1262	1263				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500097		
J	Mortimer, JC; Ishikawa, T; Fang, L; Jing, BB; Rennie, E; Inada, N; Yu, XL; Lao, J; Demura, T; Kawai-Yamada, M; Scheller, H; Dupree, P				Mortimer, Jenny C.; Ishikawa, Toshiki; Fang, Lin; Jing, Beibei; Rennie, Emilie; Inada, Noriko; Yu, Xiaolan; Lao, Jeemeng; Demura, Taku; Kawai-Yamada, Maki; Scheller, Henrik; Dupree, Paul			Glycosylated sphingolipid biosynthesis and function in Arabidopsis	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Mortimer, Jenny C.; Fang, Lin; Jing, Beibei; Rennie, Emilie; Lao, Jeemeng; Scheller, Henrik] LBNL, Joint BioEnergy Inst, Berkeley, CA USA; [Ishikawa, Toshiki; Kawai-Yamada, Maki] Saitama Univ, Saitama, Japan; [Inada, Noriko; Demura, Taku] NAIST, Nara, Japan; [Mortimer, Jenny C.; Yu, Xiaolan; Dupree, Paul] Univ Cambridge, Cambridge CB2 1TN, England; [Mortimer, Jenny C.; Demura, Taku] RIKEN Yokohama, Yokohama, Kanagawa, Japan							Handford, 2004, MOL GEN GEN; Mortimer, 2013, PLANT CELL	2	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				114	1266	1267				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500108		
J	Ueno, M; Oda, T				Ueno, Mikinori; Oda, Tatsuya			Biological activities of alginate oligosaccharides prepared by enzymatic digestion	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Ueno, Mikinori; Oda, Tatsuya] Nagasaki Univ, Fac Fisheries, Nagasaki, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				131	1272	1273				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500125		
J	Shirai, T; Kurogochi, M; Mori, M; Osumi, K; Tojino, M; Takashima, S; Tomita, M; Takayanagi, A; Shoda, SI				Shirai, Takashi; Kurogochi, Masaki; Mori, Masako; Osumi, Kenji; Tojino, Mami; Takashima, Shou; Tomita, Masahiro; Takayanagi, Atsushi; Shoda, Shin-Ichiro			Glycoengineered monoclonal antibodies using a chemoenzymatic approach and their affinities for Fc gamma RIIIa and variable antibody-dependent cellular cytotoxicities	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Shirai, Takashi; Kurogochi, Masaki; Mori, Masako; Osumi, Kenji; Tojino, Mami; Takashima, Shou] Noguchi Inst, Legon, Ghana; [Tomita, Masahiro] Immunobiol Labs Co Ltd, Fujioka, Japan; [Takayanagi, Atsushi] Keio Univ, Sch Med, Tokyo 108, Japan; [Shoda, Shin-Ichiro] Tohoku Univ, Sendai, Miyagi 980, Japan							Kurogochi M, 2015, PLOS ONE IN PRESS	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				134	1273	1274				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500128		
J	Yamada, I; Aoki-Kinoshita, KF; Matsubara, M; Aoki, NP; Shinmachi, D; Narimatsu, H				Yamada, Issaku; Aoki-Kinoshita, Kiyoko F.; Matsubara, Masaaki; Aoki, Nobuyuki P.; Shinmachi, Daisuke; Narimatsu, Hisashi			A substructure search method for carbohydrate structures based on the WURCS notation using Semantic Web technology	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Yamada, Issaku; Matsubara, Masaaki] Noguchi Inst, Legon, Ghana; [Aoki-Kinoshita, Kiyoko F.; Aoki, Nobuyuki P.; Shinmachi, Daisuke] Soka Univ, Aliso Viejo, CA USA; [Aoki-Kinoshita, Kiyoko F.; Narimatsu, Hisashi] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				139	1276	1276				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500133		
J	Aoki, NP; Aoki-Kinoshita, K; Agravat, S; Arpinar, S; Cummings, RD; Fujita, A; Fujita, N; Hart, GM; Haslam, S; Kawasaki, T; Matsubara, M; Moreman, KW; Narimatsu, H; Okuda, S; Pierce, JM; Ranzinger, R; Shikanai, T; Shinmachi, D; Solovieva, E; Suzuki, Y; Tsuchiya, S; Yamada, I; York, WS; Zaia, J				Aoki, Nobuyuki P.; Aoki-Kinoshita, Kiyoko; Agravat, Sanjay; Arpinar, Sena; Cummings, Richard D.; Fujita, Akihiro; Fujita, Noriaki; Hart, Gerald M.; Haslam, Stuart; Kawasaki, Toshisuke; Matsubara, Masaaki; Moreman, Kelley W.; Narimatsu, Hisashi; Okuda, Shujiro; Pierce, J. Michael; Ranzinger, Rene; Shikanai, Toshihide; Shinmachi, Daisuke; Solovieva, Elena; Suzuki, Yoshinori; Tsuchiya, Shinichiro; Yamada, Issaku; York, William S.; Zaia, Joseph			The Official Release of the International Glycan Structure Repository	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Aoki, Nobuyuki P.; Aoki-Kinoshita, Kiyoko; Fujita, Akihiro; Shinmachi, Daisuke; Tsuchiya, Shinichiro] Soka Univ, Fac Sci & Engn, Tokyo, Japan; [Aoki-Kinoshita, Kiyoko; Fujita, Noriaki; Narimatsu, Hisashi; Shikanai, Toshihide; Solovieva, Elena; Suzuki, Yoshinori] AIST, Res Ctr Med Glycosci, Ibaraki, Japan; [Agravat, Sanjay] Emory Univ, Dept Math & Comp Sci, Atlanta, GA 30322 USA; [Arpinar, Sena; Moreman, Kelley W.; Pierce, J. Michael; Ranzinger, Rene; York, William S.] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; [Cummings, Richard D.] Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; [Hart, Gerald M.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Haslam, Stuart] Univ London Imperial Coll Sci Technol & Med, Fac Natl Sci, Dept Life Sci, London, England; [Kawasaki, Toshisuke] Ritsumeikan Univ, Res Ctr Glycobiotechnol, Kusatsu, Shiga, Japan; [Matsubara, Masaaki; Yamada, Issaku] Noguchi Inst, Tokyo, Japan; [Okuda, Shujiro] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan; [Zaia, Joseph] Boston Univ, Sch Med, Ctr Biomed Mass Spectrometry, Boston, MA 02118 USA								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				148	1279	1280				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500142		
J	Qiu, H; Yue, JW; Nairn, AV; Li, GY; Zhang, FM; Archer-Hartmann, SA; Dela Rosa, M; Azadi, P; van Kuppevelt, TH; Cardoso, WV; Kimata, K; Linhardt, RJ; Esko, J; Moremen, KW; Wang, LC				Qiu, Hong; Yue, Jingwen; Nairn, Alison V.; Li, Guoyun; Zhang, Fuming; Archer-Hartmann, Stephanie A.; Dela Rosa, Mitche; Azadi, Parastoo; van Kuppevelt, Toin H.; Cardoso, Wellington V.; Kimata, Koji; Linhardt, Robert J.; Esko, Jeffrey; Moremen, Kelley W.; Wang, Lianchun			An Cell Platform for Endothelial Heparan Sulfate Function Study	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Qiu, Hong; Yue, Jingwen; Nairn, Alison V.; Archer-Hartmann, Stephanie A.; Dela Rosa, Mitche; Azadi, Parastoo; Moremen, Kelley W.; Wang, Lianchun] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; [Qiu, Hong; Yue, Jingwen; Moremen, Kelley W.; Wang, Lianchun] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Li, Guoyun; Zhang, Fuming; Linhardt, Robert J.] Rensselaer Polytech Inst, Dept Chem & Chem Biol, Ctr Biotechnol & Interdisciplinary Studies, Troy, NY 12181 USA; [van Kuppevelt, Toin H.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6525 ED Nijmegen, Netherlands; [Cardoso, Wellington V.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02215 USA; [Kimata, Koji] Aichi Med Univ, Res Complex Med Frontiers, Nagoya, Aichi, Japan; [Esko, Jeffrey] Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA USA								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				160	1284	1284				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500154		
J	Nonaka, M; Sasai, T; Nagaoka, M; Fukuda, MN				Nonaka, Motohiro; Sasai, Toshio; Nagaoka, Masato; Fukuda, Michiko N.			Characterization of the interaction between N-terminal annexin A1 residue and tumor-targeting carbohydrate-mimetic IF7 peptide	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Nonaka, Motohiro; Fukuda, Michiko N.] Natl Inst Adv Ind Sci & Technol, Lab Drug Discovery, Tsukuba, Ibaraki 3058568, Japan; [Nonaka, Motohiro; Fukuda, Michiko N.] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA 92037 USA; [Sasai, Toshio; Nagaoka, Masato] Yakult Cent Inst, Kunitachi, Tokyo 1868650, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				187	1294	1294				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500181		
J	Kawasaki, T; Nakao, H; Matsumoto, S; Toyoda, H; Kawabata, K; Kawasaki, N				Kawasaki, Toshisuke; Nakao, Hiromi; Matsumoto, Shogo; Toyoda, Hidenao; Kawabata, Kenji; Kawasaki, Nobuko			Binding Specificity and Biological Significance of Novel Marker Antibodies for Human iPS Cells: R-10G and R-17F	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Kawasaki, Toshisuke; Nakao, Hiromi; Matsumoto, Shogo; Kawasaki, Nobuko] Ritsumeikan Univ, Res Ctr Glycobiotechnol, Shiga 5258577, Japan; [Toyoda, Hidenao] Ritsumeikan Univ, Coll Pharmaceut Sci, Lab Bioanalyt Chem, Shiga 5258577, Japan; [Kawabata, Kenji] Natl Inst Biomed Innovat Hlth & Nutr, Lab Stem Cell Regulat, Osaka 5670085, Japan							Kawabe K, 2013, GLYCOBIOLOGY, V23, P322, DOI 10.1093/glycob/cws159; Matsumoto S, 2015, J BIOL CHEM IN PRESS	2	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				192	1295	1296				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500186		
J	Kumagai, T; Suzuki, M; Ishihara, M; Ogawa, S; Furukawa, K; Aoki, K; Azadi, P; Tiemeyer, M				Kumagai, Tadahiro; Suzuki, Mayuko; Ishihara, Mayumi; Ogawa, Shigeru; Furukawa, Kiyoshi; Aoki, Kazuhiro; Azadi, Parastoo; Tiemeyer, Michael			Glycomics of the terrestrial worm Enchytraeus japonensis	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Kumagai, Tadahiro; Ishihara, Mayumi; Aoki, Kazuhiro; Azadi, Parastoo; Tiemeyer, Michael] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; [Suzuki, Mayuko; Furukawa, Kiyoshi] Nagaoka Univ Technol, Nagaoka, Niigata, Japan; [Ogawa, Shigeru] Nagaoka Coll, Natl Inst Technol, Nagaoka, Niigata, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				201	1299	1299				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500195		
J	Galeone, A; Han, SY; Huang, CC; Hosomi, A; Suzuki, T; Jafar-Nejad, H				Galeone, Antonio; Han, Seung-Yeop; Huang, Chengcheng; Hosomi, Akira; Suzuki, Tadashi; Jafar-Nejad, Hamed			Role of the Deglycosylation Enzyme NGLY1 in Development and Disease: Insights from Drosophila Studies	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Galeone, Antonio; Han, Seung-Yeop; Jafar-Nejad, Hamed] Baylor Coll Med, Houston, TX 77030 USA; [Huang, Chengcheng; Hosomi, Akira; Suzuki, Tadashi] RIKEN Adv Sci Inst, Wako, Saitama, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				206	1301	1301				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500200		
J	Uchimura, K; Foyez, T; Uchimura, Y; Ishigaki, S; Narentuya; Zhang, Z; Sobue, G; Kadomatsu, K				Uchimura, Kenji; Foyez, Tahmina; Uchimura, Yoshiko; Ishigaki, Shinsuke; Narentuya; Zhang, Zui; Sobue, Gen; Kadomatsu, Kenji			Sialylated, fucosylated keratan sulfate elicited in Mac-2/galectin-3-positive microglia of transgenic model mice and patients of ALS	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Uchimura, Kenji; Foyez, Tahmina; Uchimura, Yoshiko; Narentuya; Zhang, Zui; Kadomatsu, Kenji] Nagoya Univ, Dept Biochem, Grad Sch Med, Nagoya, Aichi 4648601, Japan; [Ishigaki, Shinsuke; Sobue, Gen] Nagoya Univ, Dept Neurol, Grad Sch Med, Nagoya, Aichi 4648601, Japan			Kadomatsu, Kenji/G-8083-2012					0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				218	1305	1306				2	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500212		
J	Uemura, K; Honda, M; Hashizume, Y; Morimoto, T; Ono, T; Kawasaki, T				Uemura, Kazuhide; Honda, Masashi; Hashizume, Yuuki; Morimoto, Tatsuya; Ono, Takahiko; Kawasaki, Toshisuke			Mesangial Deposition of Mannan-Binding Protein during Exacerbations of IgA Nephropathy in HIGA (High IgA) Mice	GLYCOBIOLOGY			English	Meeting Abstract	Annual Meeting of the Society-for-Glycobiology on Glycobiology - Accelerating Impact across the Biomedical Sciences	DEC 01-04, 2015	San Francisco, CA	Soc Glycobiol					[Uemura, Kazuhide; Honda, Masashi] Chubu Univ, Dept Biomed Sci, Coll Life & Hlth Sci, Kasugai, Aichi 487, Japan; [Hashizume, Yuuki; Morimoto, Tatsuya] Univ Shizuoka, Sch Pharmaceut Sci, Div Mol Med, Shizuoka 4228526, Japan; [Ono, Takahiko] Int Univ Hlth & Welf, Dept Nephrol, Atami, Japan; [Kawasaki, Toshisuke] Ritsumeikan Univ, Res Ctr Glycobiotechnol, Kusatsu, Japan								0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0959-6658	1460-2423		GLYCOBIOLOGY	Glycobiology	NOV	2015	25	11				216	1305	1305				1	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CT7JR	WOS:000362991500210		
J	Sahashi, K; Katsuno, M; Hung, G; Adachi, H; Kondo, N; Nakatsuji, H; Tohnai, G; Iida, M; Bennett, CF; Sobue, G				Sahashi, Kentaro; Katsuno, Masahisa; Hung, Gene; Adachi, Hiroaki; Kondo, Naohide; Nakatsuji, Hideaki; Tohnai, Genki; Iida, Madoka; Bennett, C. Frank; Sobue, Gen			Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology	HUMAN MOLECULAR GENETICS			English	Article							THY-TAU22 MOUSE MODEL; TRANSGENIC MODEL; APOLIPOPROTEIN-E; NEUROFIBRILLARY TANGLES; SYNAPTIC-TRANSMISSION; COGNITIVE-IMPAIRMENT; RECEPTOR ACTIVATION; MASS-SPECTROMETRY; PYRAMIDAL NEURONS; CANDIDATE MARKER	Alzheimer's disease (AD) is characterized by both amyloid and Tau pathologies. The amyloid component and altered cholesterol metabolism are closely linked, but the relationship between Tau pathology and cholesterol is currently unclear. Brain cholesterol is synthesized in situ and cannot cross the blood-brain barrier: to be exported from the central nervous system into the blood circuit, excess cholesterol must be converted to 24S-hydroxycholesterol by the cholesterol 24-hydroxylase encoded by the CYP46A1 gene. In AD patients, the concentration of 24S-hydroxycholesterol in the plasma and the cerebrospinal fluid are lower than in healthy controls. The THY-Tau22 mouse is a model of AD-like Tau pathology without amyloid pathology. We used this model to investigate the potential association between Tau pathology and CYP46A1 modulation. The amounts of CYP46A1 and 24S-hydroxycholesterol in the hippocampus were lower in THY-Tau22 than control mice. We used an adeno-associated virus (AAV) gene transfer strategy to increase CYP46A1 expression in order to investigate the consequences on THY-Tau22 mouse phenotype. Injection of the AAV-CYP46A1 vector into the hippocampus of THY-Tau22 mice led to CYP46A1 and 24S-hydroxycholesterol content normalization. The cognitive deficits, impaired long-term depression and spine defects that characterize the THY-Tau22 model were completely rescued, whereas Tau hyperphosphorylation and associated gliosis were unaffected. These results argue for a causal link between CYP46A1 protein content and memory impairments that result from Tau pathology. Therefore, CYP46A1 may be a relevant therapeutic target for Tauopathies and especially for AD.	[Sahashi, Kentaro; Katsuno, Masahisa; Kondo, Naohide; Nakatsuji, Hideaki; Tohnai, Genki; Iida, Madoka; Sobue, Gen] Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668550, Japan; [Hung, Gene; Bennett, C. Frank] Isis Pharmaceut, Carlsbad, CA 92008 USA; [Adachi, Hiroaki] Univ Occupat & Environm Hlth, Sch Med, Dept Neurol, Kitakyushu, Fukuoka 8078555, Japan	Katsuno, M (reprint author), Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668550, Japan.	ka2no@med.nagoya-u.ac.jp; sobueg@med.nagoya-u.ac.jp			Fondation France Alzheimer; LabEx; DISTALZ; Inserm; CNRS; Universite Lille 2; Lille Metropole Communaute Urbaine; Region Nord/Pas-de-Calais; FEDER; DN2M; ANR (SPREADTAU); ANR (ADORATAU); FUI MEDIALZ;  [ANR-10-MALZ-0103 CholAD]	We warmly thank Patrick Aubourg for his support and comments on the manuscript. We thank Dr Florence Noble and Stephanie Puig for their advice and technical assistance for behavioral evaluations. We also wish to thank Gaelle Dufayet-Chaffaud for her contribution to the biochemistry experiments. We thank Francoise Piguet, Francoise Fouquet, Sylvie Guidoux, Nadege Zommer, Dominique Demeyer, Helene Obriot and Laetitia Breton for their excellent technical assistance. This work was supported by the Fondation France Alzheimer and the ANR-10-MALZ-0103 CholAD. UMR1172 is supported by LabEx (excellence laboratory), DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease), Inserm, CNRS, Universite Lille 2, Lille Metropole Communaute Urbaine, Region Nord/Pas-de-Calais, FEDER, DN2M, ANR (SPREADTAU and ADORATAU) and FUI MEDIALZ. The authors thank the animal facility of IMPRT-IFR114 and M. Besegher, I. Brion, D. Cappe, R. Dehaynin, J. Devassine, Y. Lepage, C. Meunier and D. Taillieu for transgenic mouse production and animal care.	Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Kee N, 2007, NAT NEUROSCI, V10, P355, DOI 10.1038/nn1847; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; Shafaati M, 2011, J INTERN MED, V270, P377, DOI 10.1111/j.1365-2796.2011.02389.x; Schindowski K, 2006, AM J PATHOL, V169, P599, DOI 10.2353/ajpath.2006.060002; Evans RM, 2004, NEUROLOGY, V62, P1869; Donkin JJ, 2010, J BIOL CHEM, V285, P34144, DOI 10.1074/jbc.M110.108100; Leroy K, 2007, AM J PATHOL, V171, P976, DOI 10.2353/ajpath.2007.070345; Bieche I, 2001, CANCER RES, V61, P1652; Belarbi K, 2011, CURR ALZHEIMER RES, V8, P633; Belarbi K, 2011, NEUROBIOL DIS, V43, P486, DOI 10.1016/j.nbd.2011.04.022; Duyckaerts C, 1997, NEUROBIOL AGING, V18, P267, DOI 10.1016/S0197-4580(97)80306-5; Kolsch H, 2004, NEUROSCI LETT, V368, P303, DOI 10.1016/j.neulet.2004.07.031; Solomon A, 2009, NEUROSCI LETT, V462, P89, DOI 10.1016/j.neulet.2009.06.073; Leboucher A, 2013, DIABETES, V62, P1681, DOI 10.2337/db12-0866; Lazar AN, 2013, ACTA NEUROPATHOL, V125, P133, DOI 10.1007/s00401-012-1041-1; Distl R, 2001, ACTA NEUROPATHOL, V101, P547; Alldred MJ, 2012, NEUROBIOL DIS, V45, P751, DOI 10.1016/j.nbd.2011.10.022; Merino-Serrais P, 2013, BRAIN, V136, P1913, DOI 10.1093/brain/awt088; Hudry E, 2010, MOL THER, V18, P44, DOI 10.1038/mt.2009.175; Paul SM, 2013, J NEUROSCI, V33, P17290, DOI 10.1523/JNEUROSCI.2619-13.2013; Abildayeva K, 2006, J BIOL CHEM, V281, P12799, DOI 10.1074/jbc.M601019200; Van der Jeugd A, 2011, NEUROBIOL LEARN MEM, V95, P296, DOI 10.1016/j.nlm.2010.12.005; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Kim J, 2009, NEURON, V63, P287, DOI 10.1016/j.neuron.2009.06.026; Delacourte A, 1999, NEUROLOGY, V52, P1158; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Troquier L, 2012, CURR ALZHEIMER RES, V9, P397; Puglielli L, 2003, NAT NEUROSCI, V6, P345, DOI 10.1038/nn0403-345; Potier B, 2010, AGING CELL, V9, P722, DOI 10.1111/j.1474-9726.2010.00593.x; Laurent C, 2014, NEUROBIOL AGING, V35, P2079, DOI 10.1016/j.neurobiolaging.2014.03.027; Whittington RA, 2013, PROG NEURO-PSYCHOPH, V47, P147, DOI 10.1016/j.pnpbp.2013.03.004; Bjorkhem I, 2006, J INTERN MED, V260, P493, DOI 10.1111/j.1365-2796.2006.01725.x; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495; Hoover BR, 2010, NEURON, V68, P1067, DOI 10.1016/j.neuron.2010.11.030; Michaelsen K, 2010, EUR J NEUROSCI, V32, P1854, DOI 10.1111/j.1460-9568.2010.07460.x; Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Grober E, 1999, NEUROBIOL AGING, V20, P573, DOI 10.1016/S0197-4580(99)00063-9; Van der Jeugd A, 2013, BEHAV BRAIN RES, V242, P34, DOI 10.1016/j.bbr.2012.12.008; Ayciriex S, 2012, ANAL BIOANAL CHEM, V404, P3049, DOI 10.1007/s00216-012-6396-6; Kotti T, 2008, P NATL ACAD SCI USA, V105, P11394, DOI 10.1073/pnas.0805556105; Butchbach MER, 2004, J BIOL CHEM, V279, P34388, DOI 10.1074/jbc.M403938200; Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103; Sergeant N, 2008, EXPERT REV PROTEOMIC, V5, P207, DOI 10.1586/14789450.5.2.207; Bretillon L, 2000, NEUROSCI LETT, V293, P87, DOI 10.1016/S0304-3940(00)01466-X; Polydoro M, 2009, J NEUROSCI, V29, P10741, DOI 10.1523/JNEUROSCI.1065-09.2009; Fitz NF, 2010, J NEUROSCI, V30, P6862, DOI 10.1523/JNEUROSCI.1051-10.2010; Sodhi RK, 2014, EUR J PHARMACOL, V732, P50, DOI 10.1016/j.ejphar.2014.03.025; Leoni V, 2013, J ALZHEIMERS DIS, V36, P739, DOI 10.3233/JAD-130035; Suzuki S, 2004, J CELL BIOL, V167, P1205, DOI 10.1083/jcb.200404106; Burnouf S, 2013, AGING CELL, V12, P11, DOI 10.1111/acel.12018; Vanmierlo T, 2011, NEUROBIOL AGING, V32, P1262, DOI 10.1016/j.neurobiolaging.2009.07.005; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Fox LM, 2011, J NEUROPATH EXP NEUR, V70, P588, DOI 10.1097/NEN.0b013e318220a658; Braudeau J., 2011, ADV PHARM SCI, V2011, DOI DOI 10.1155/2011/153218; Brownlow ML, 2014, BEHAV BRAIN RES, V271, P79, DOI 10.1016/j.bbr.2014.06.001; Cabeza C, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-11; Chaalal A., 2014, HIPPOCAMPUS IN PRESS; Gaudin M, 2014, J MASS SPECTROM, V49, P1035, DOI 10.1002/jms.3424; Laurent C., 2014, MOL PSYCHIA IN PRESS; Maioli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068534; Papassotiropoulos A, 2000, NEUROREPORT, V11, P1959, DOI 10.1097/00001756-200006260-00030; Xu H., 2014, NEUROPATHOL IN PRESS; Yang S, 2015, EXP NEUROL, V265, P48, DOI 10.1016/j.expneurol.2014.11.013	66	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906	1460-2083		HUM MOL GENET	Hum. Mol. Genet.	NOV 1	2015	24	21					5965	5976		10.1093/hmg/ddv268		12	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	CT7WA	WOS:000363024000001		
J	Sahashi, K; Katsuno, M; Hung, G; Adachi, H; Kondo, N; Nakatsuji, H; Tohnai, G; Iida, M; Bennett, CF; Sobue, G				Sahashi, Kentaro; Katsuno, Masahisa; Hung, Gene; Adachi, Hiroaki; Kondo, Naohide; Nakatsuji, Hideaki; Tohnai, Genki; Iida, Madoka; Bennett, C. Frank; Sobue, Gen			Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy	HUMAN MOLECULAR GENETICS			English	Article							RECESSIVE BULBOSPINAL NEURONOPATHY; ANTISENSE OLIGONUCLEOTIDE; HETEROZYGOUS FEMALES; DISEASE; DEGENERATION; EXPRESSION; GENE; SBMA; PATHOGENESIS; SUPPRESSION	Spinal and bulbar muscular atrophy (SBMA), an adult-onset neurodegenerative disease that affects males, results from a CAG triplet repeat/polyglutamine expansions in the androgen receptor (AR) gene. Patients develop progressive muscular weakness and atrophy, and no effective therapy is currently available. The tissue-specific pathogenesis, especially relative pathological contributions between degenerative motor neurons and muscles, remains inconclusive. Though peripheral pathology in skeletal muscle caused by toxic AR protein has been recently reported to play a pivotal role in the pathogenesis of SBMA using mouse models, the role of motor neuron degeneration in SBMA has not been rigorously investigated. Here, we exploited synthetic antisense oligonucleotides to inhibit the RNA levels of mutant AR in the central nervous system (CNS) and explore its therapeutic effects in our SBMA mouse model that harbors a mutant AR gene with 97 CAG expansions and characteristic SBMA-like neurogenic phenotypes. A single intracerebroventricular administration of the antisense oligonucleotides in the presymptomatic phase efficiently suppressed the mutant gene expression in the CNS, and delayed the onset and progression of motor dysfunction, improved body weight gain and survival with the amelioration of neuronal histopathology in motor units such as spinal motor neurons, neuromuscular junctions and skeletal muscle. These findings highlight the importance of the neurotoxicity of mutant AR protein in motor neurons as a therapeutic target.	[Sahashi, Kentaro; Katsuno, Masahisa; Kondo, Naohide; Nakatsuji, Hideaki; Tohnai, Genki; Iida, Madoka; Sobue, Gen] Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668550, Japan; [Hung, Gene; Bennett, C. Frank] ISIS Pharmaceut, Carlsbad, CA 92008 USA; [Adachi, Hiroaki] Univ Occupat & Environm Hlth, Sch Med, Dept Neurol, Kitakyushu, Fukuoka 8078555, Japan	Katsuno, M (reprint author), Nagoya Univ, Grad Sch Med, Dept Neurol, Nagoya, Aichi 4668550, Japan.	ka2no@med.nagoya-u.ac.jp; sobueg@med.nagoya-u.ac.jp			Global Center of Excellence Program, Education, Culture, Sports, Science and Technology (MEXT), Japan; MEXT/Japan Society for the Promotion of Science KAKENHI [21229011, 21689024, 22110005, 23390230, 26293206, 26461268, 24659428]; Health Labor Sciences Research Grants, Ministry of Health, Labour and Welfare, Japan; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency; Daiichi Sankyo Foundation of Life Science	This work was supported by the Global Center of Excellence Program, Education, Culture, Sports, Science and Technology (MEXT), Japan; MEXT/Japan Society for the Promotion of Science KAKENHI (grant numbers 21229011, 21689024, 22110005, 23390230, 26293206, 26461268 and 24659428); Health Labor Sciences Research Grants, Ministry of Health, Labour and Welfare, Japan; Core Research for Evolutional Science and Technology, Japan Science and Technology Agency and a grant from the Daiichi Sankyo Foundation of Life Science.	Katsuno M, 2012, PROG NEUROBIOL, V99, P246, DOI 10.1016/j.pneurobio.2012.05.007; Ranganathan S, 2009, HUM MOL GENET, V18, P27, DOI 10.1093/hmg/ddn310; Sambataro F, 2012, PROG NEUROBIOL, V97, P152, DOI 10.1016/j.pneurobio.2011.10.003; Kemp MQ, 2011, HUM MOL GENET, V20, P4475, DOI 10.1093/hmg/ddr380; Orsucci D, 2014, CURR MOL MED, V14, P598; Minamiyama M, 2012, NAT MED, V18, P1531, DOI 10.1038/nm.2932; Nedelsky NB, 2010, NEURON, V67, P936, DOI 10.1016/j.neuron.2010.08.034; Moresi V, 2010, CELL, V143, P35, DOI 10.1016/j.cell.2010.09.004; Adachi H, 2005, BRAIN, V128, P659, DOI 10.1093/brain/awh381; SOBUE G, 1993, J NEUROL SCI, V117, P74, DOI 10.1016/0022-510X(93)90157-T; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI.25424; SOBUE G, 1989, BRAIN, V112, P209, DOI 10.1093/brain/112.1.209; Hua YM, 2010, GENE DEV, V24, P1634, DOI 10.1101/gad.1941310; Orr CR, 2010, J BIOL CHEM, V285, P35567, DOI 10.1074/jbc.M110.146845; Miller TM, 2013, LANCET NEUROL, V12, P435, DOI 10.1016/S1474-4422(13)70061-9; Monks DA, 2007, P NATL ACAD SCI USA, V104, P18259, DOI 10.1073/pnas.0705501104; Hua YM, 2011, NATURE, V478, P123, DOI 10.1038/nature10485; Suzuki K, 2010, J NEUROL NEUROSUR PS, V81, P567, DOI 10.1136/jnnp.2009.190462; Lehky TJ, 2009, MUSCLE NERVE, V40, P809, DOI 10.1002/mus.21399; Cortes CJ, 2014, NEURON, V82, P295, DOI 10.1016/j.neuron.2014.03.001; LI M, 1995, MUSCLE NERVE, V18, P301, DOI 10.1002/mus.880180306; Bennett CF, 2010, ANNU REV PHARMACOL, V50, P259, DOI 10.1146/annurev.pharmtox.010909.105654; Katsuno M, 2010, J NEUROSCI, V30, P5702, DOI 10.1523/JNEUROSCI.0388-10.2010; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; Iida M, 2015, HUM MOL GENET, V24, P314, DOI 10.1093/hmg/ddu445; Yang ZF, 2005, INT IMMUNOL, V17, P1391, DOI 10.1093/intimm/dxh316; Raskin K, 2009, J NEUROSCI, V29, P4461, DOI 10.1523/JNEUROSCI.0296-09.2009; Manzano R, 2011, NEURODEGENER DIS, V8, P386, DOI 10.1159/000324159; Sahashi K, 2013, EMBO MOL MED, V5, P1586, DOI 10.1002/emmm.201302567; Katsuno M, 2006, J NEUROSCI, V26, P12106, DOI 10.1523/JNEUROSCI.3032-06.2006; Katsuno M, 2002, NEURON, V35, P843, DOI 10.1016/S0896-6273(02)00834-6; Yu IC, 2013, DIABETES, V62, P411, DOI 10.2337/db12-0135; Lieberman AP, 2014, CELL REP, V7, P774, DOI 10.1016/j.celrep.2014.02.008; Sahashi K, 2012, GENE DEV, V26, P1874, DOI 10.1101/gad.197418.112; Soraru G, 2008, J NEUROL SCI, V264, P100, DOI 10.1016/j.jns.2007.08.012; Thomas PS, 2006, HUM MOL GENET, V15, P2225, DOI 10.1093/hmg/ddl148; Rinaldi C, 2012, MOL MED, V18, P1261, DOI 10.2119/molmed.2012.00271; Boyer JG, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00356; Calvo AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032632; Crooke S.T., 2007, ANTISENSE DRUG TECHN; Dubowitz V, 2007, MUSCLE BIOPSY PRACTI; Grunseich C., 2014, NEUROMUSCULAR DISORD, V35, P978; Hua YM, 2015, GENE DEV, V29, P288, DOI 10.1101/gad.256644.114; Kondo N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2417; Li Mei, 1998, American Journal of Pathology, V153, P695, DOI 10.1016/S0002-9440(10)65612-X; Passini MA, 2011, SCI TRANSL MED, V3, DOI DOI 10.1126/SCITRANSLMED.3001777; Rudolf R, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00099	47	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906	1460-2083		HUM MOL GENET	Hum. Mol. Genet.	NOV 1	2015	24	21					5985	5994		10.1093/hmg/ddv300		10	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	CT7WA	WOS:000363024000003		
J	Ilkovski, B; Pagnamenta, AT; O'Grady, GL; Kinoshita, T; Howard, MF; Lek, M; Thomas, B; Turner, A; Christodoulou, J; Sillence, D; Knight, SJL; Popitsch, N; Keays, DA; Anzilotti, C; Goriely, A; Waddell, LB; Brilot, F; North, KN; Kanzawa, N; Macarthur, DG; Taylor, JC; Kini, U; Murakami, Y; Clarke, NF				Ilkovski, Biljana; Pagnamenta, Alistair T.; O'Grady, Gina L.; Kinoshita, Taroh; Howard, Malcolm F.; Lek, Monkol; Thomas, Brett; Turner, Anne; Christodoulou, John; Sillence, David; Knight, Samantha J. L.; Popitsch, Niko; Keays, David A.; Anzilotti, Consuelo; Goriely, Anne; Waddell, Leigh B.; Brilot, Fabienne; North, Kathryn N.; Kanzawa, Noriyuki; Macarthur, Daniel G.; Taylor, Jenny C.; Kini, Usha; Murakami, Yoshiko; Clarke, Nigel F.			Mutations in PIGY: expanding the phenotype of inherited glycosylphosphatidylinositol deficiencies	HUMAN MOLECULAR GENETICS			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; MENTAL-RETARDATION SYNDROME; GPI ANCHOR DEFICIENCY; HYPERPHOSPHATASIA; BIOSYNTHESIS; GENE; PROMOTER; EPILEPSY; GENOME	Glycosylphosphatidylinositol (GPI)-anchored proteins are ubiquitously expressed in the human body and are important for various functions at the cell surface. Mutations in many GPI biosynthesis genes have been described to date in patients with multi-system disease and together these constitute a subtype of congenital disorders of glycosylation. We used whole exome sequencing in two families to investigate the genetic basis of disease and used RNA and cellular studies to investigate the functional consequences of sequence variants in the PIGY gene. Two families with different phenotypes had homozygous recessive sequence variants in the GPI biosynthesis gene PIGY. Two sisters with c.137T>C (p.Leu46Pro) PIGY variants had multi-system disease including dysmorphism, seizures, severe developmental delay, cataracts and early death. There were significantly reduced levels of GPI-anchored proteins (CD55 and CD59) on the surface of patient-derived skin fibroblasts (similar to 20-50% compared with controls). In a second, consanguineous family, two siblings had moderate development delay and microcephaly. A homozygous PIGY promoter variant (c.-540G>A) was detected within a 7.7 Mb region of autozygosity. This variant was predicted to disrupt a SP1 consensus binding site and was shown to be associated with reduced gene expression. Mutations in PIGY can occur in coding and non-coding regions of the gene and cause variable phenotypes. This article contributes to understanding of the range of disease phenotypes and disease genes associated with deficiencies of the GPI-anchor biosynthesis pathway and also serves to highlight the potential importance of analysing variants detected in 5'-UTR regions despite their typically low coverage in exome data.	[Ilkovski, Biljana; O'Grady, Gina L.; Brilot, Fabienne; North, Kathryn N.; Clarke, Nigel F.] Childrens Hosp, Inst Neurosci & Muscle Res, Westmead, NSW 2145, Australia; [Sillence, David] Childrens Hosp, Western Sydney Genet Program, Westmead, NSW 2145, Australia; [Pagnamenta, Alistair T.; Howard, Malcolm F.; Knight, Samantha J. L.; Popitsch, Niko; Taylor, Jenny C.] Univ Oxford, Wellcome Trust Ctr Human Genet, Natl Inst Hlth Res, Biomed Res Ctr, Oxford OX1 2JD, England; [Anzilotti, Consuelo] Univ Oxford, Henry Wellcome Bldg Mol Physiol, Oxford OX3 7BN, England; [O'Grady, Gina L.; Waddell, Leigh B.; Brilot, Fabienne; North, Kathryn N.; Clarke, Nigel F.] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia; [Kinoshita, Taroh; Kanzawa, Noriyuki; Murakami, Yoshiko] Osaka Univ, Dept Immunoregulat, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; [Kinoshita, Taroh; Kanzawa, Noriyuki; Murakami, Yoshiko] Osaka Univ, WPI Immunol Frontier Res Ctr, Suita, Osaka 5650871, Japan; [Lek, Monkol; Thomas, Brett; Macarthur, Daniel G.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA; [Lek, Monkol; Thomas, Brett; Macarthur, Daniel G.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA; [Turner, Anne] Sydney Childrens Hosp, Dept Clin Genet, Sydney, NSW, Australia; [Christodoulou, John; Sillence, David] Childrens Hosp, Sch Clin, Discipline Genet Med, Sydney, NSW, Australia; [Keays, David A.] Inst Mol Pathol, A-1030 Vienna, Austria; [Goriely, Anne] Univ Oxford, Weatherall Inst Mol Med, Oxford OX3 9DS, England; [North, Kathryn N.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Kini, Usha] Oxford Univ Hosp NHS Trust, Dept Clin Genet, Oxford OX3 9DU, England	Kini, U (reprint author), Childrens Hosp, Inst Neurosci & Muscle Res, Locked Bag 4001, Westmead, NSW 2145, Australia.	Usha.Kini@ouh.nhs.uk; nigel.clarke@health.nsw.gov.au	Kinoshita, Taroh/C-7353-2009; North, Kathryn/K-6476-2012	North, Kathryn/0000-0003-0841-8009	National Health & Medical Research Council of Australia [APP571287, APP1035828, APP1022707]; National Institute for Health Research (NIHR) Biomedical Research Centre Oxford; Department of Health's NIHR Biomedical Research Centres funding scheme; Wellcome Trust [090532/Z/09/Z]; Medical Research Council [G0900747 91070]	This work was supported by the National Health & Medical Research Council of Australia (APP571287-KN, NC, APP1035828-NC and APP1022707-KN, NC) and National Institute for Health Research (NIHR) Biomedical Research Centre Oxford with funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. We thank the High-Throughput Genomics Group at the Wellcome Trust Centre for Human Genetics (funded by Wellcome Trust grant reference 090532/Z/09/Z and Medical Research Council Hub grant G0900747 91070) for generating the sequencing data. Funding to pay the Open Access publication charges for this article was provided by the Wellcome Trust.	Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Kuki I, 2013, NEUROLOGY, V81, P1467, DOI 10.1212/WNL.0b013e3182a8411a; Johnston JJ, 2012, AM J HUM GENET, V90, P295, DOI 10.1016/j.ajhg.2011.11.031; Sutherland DR, 2007, CYTOM PART B-CLIN CY, V72B, P167, DOI 10.1002/cyto.b.20151; Almeida AM, 2007, NEW ENGL J MED, V356, P1641, DOI 10.1056/NEJMoa063369; Kvarnung M, 2013, J MED GENET, V50, P521, DOI 10.1136/jmedgenet-2013-101654; Ng BG, 2012, AM J HUM GENET, V90, P685, DOI 10.1016/j.ajhg.2012.02.010; Kanzawa N, 2012, J LIPID RES, V53, P653, DOI 10.1194/jlr.M021204; Almeida AM, 2006, NAT MED, V12, P846, DOI 10.1038/nm1410; Canitano A, 2013, CANCER LETT, V337, P193, DOI 10.1016/j.canlet.2013.05.012; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; Howard MF, 2014, AM J HUM GENET, V94, P278, DOI 10.1016/j.ajhg.2013.12.012; Kanzawa N, 2009, P NATL ACAD SCI USA, V106, P17711, DOI 10.1073/pnas.0904762106; Rohlin A, 2009, HUM MUTAT, V30, P1012, DOI 10.1002/humu.20980; Menezes MP, 2014, NEUROMUSCULAR DISORD, V24, P666, DOI 10.1016/j.nmd.2014.04.010; Horn D, 2014, EUR J HUM GENET, V22, P762, DOI 10.1038/ejhg.2013.241; Martin HC, 2014, HUM MOL GENET, V23, P3200, DOI 10.1093/hmg/ddu030; Krawitz PM, 2012, AM J HUM GENET, V91, P146, DOI 10.1016/j.ajhg.2012.05.004; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466; Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240; Kinoshita T, 2008, J BIOCHEM, V144, P287, DOI 10.1093/jb/mvn090; Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Maydan G, 2011, J MED GENET, V48, P383, DOI 10.1136/jmg.2010.087114; Murakami Y, 2005, MOL BIOL CELL, V16, P5236, DOI 10.1091/mbc.E05-08-0743; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Chiyonobu T, 2014, J MED GENET, V51, P203, DOI 10.1136/jmedgenet-2013-102156	26	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906	1460-2083		HUM MOL GENET	Hum. Mol. Genet.	NOV 1	2015	24	21					6146	6159		10.1093/hmg/ddv331		14	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	CT7WA	WOS:000363024000016		
J	Zeng, DZ; Li, P; Guo, S; Miyazaki, T; Hu, JK; Xiang, Y				Zeng, Deze; Li, Peng; Guo, Song; Miyazaki, Toshiaki; Hu, Jiankun; Xiang, Yong			Energy Minimization in Multi-Task Software-Defined Sensor Networks	IEEE TRANSACTIONS ON COMPUTERS			English	Article						Software-defined sensor network; sensor activation; task mapping; sensing rate scheduling; energy efficiency	COVERAGE; ACTIVATION; ALLOCATION	After a decade of extensive research on application-specific wireless sensor networks (WSNs), the recent development of information and communication technologies makes it practical to realize the software-defined sensor networks (SDSNs), which are able to adapt to various application requirements and to fully explore the resources of WSNs. A sensor node in SDSN is able to conduct multiple tasks with different sensing targets simultaneously. A given sensing task usually involves multiple sensors to achieve a certain quality-of-sensing, e.g., coverage ratio. It is significant to design an energy-efficient sensor scheduling and management strategy with guaranteed quality-of-sensing for all tasks. To this end, three issues are investigated in this paper: 1) the subset of sensor nodes that shall be activated, i.e., sensor activation, 2) the task that each sensor node shall be assigned, i.e., task mapping, and 3) the sampling rate on a sensor for a target, i.e., sensing scheduling. They are jointly considered and formulated as a mixed-integer with quadratic constraints programming (MIQP) problem, which is then reformulated into a mixed-integer linear programming (MILP) formulation with low computation complexity via linearization. To deal with dynamic events such as sensor node participation and departure, during SDSN operations, an efficient online algorithm using local optimization is developed. Simulation results show that our proposed online algorithm approaches the globally optimized network energy efficiency with much lower rescheduling time and control overhead.	[Zeng, Deze] China Univ Geosci, Sch Comp Sci, Wuhan 430074, Peoples R China; [Li, Peng; Guo, Song; Miyazaki, Toshiaki] Univ Aizu, Dept Comp Sci & Engn, Aizu Wakamatsu, Fukushima, Japan; [Hu, Jiankun] Univ New S Wales, Sch Engn & Informat Technol, Canberra, ACT 2610, Australia; [Xiang, Yong] Deakin Univ, Sch Informat Technol, Melbourne, Vic 3125, Australia	Guo, S (reprint author), Univ Aizu, Dept Comp Sci & Engn, Aizu Wakamatsu, Fukushima, Japan.	dazzae@gmail.com; pengli@u-aizu.ac.jp; sguo@u-aizu.ac.jp; miyazaki@u-aizu.ac.jp; J.Hu@adfa.edu.au; yong.xiang@deakin.edu.au			Strategic Information and Communications R&D Promotion Programme (SCOPE) [121802001]; ARC [LP100200538]; NSF of China [61402425, 61272470, 61305087]; Fundamental Research Funds for National University, China University of Geosciences, Wuhan [CUG14065, CUGL150830];  [23500095]	This work was supported by Strategic Information and Communications R&D Promotion Programme (SCOPE No. 121802001) and Grants-in-Aid for Scientific Research (No. 23500095), Japan; ARC Linkage LP100200538; NSF of China (Grant No. 61402425, 61272470, 61305087), the Fundamental Research Funds for National University, China University of Geosciences, Wuhan (Grant No. CUG14065, CUGL150830). S. Guo is the corresponding author.	Garcia JM, 2002, J APPL PROBAB, V39, P853, DOI 10.1239/jap/1037816024; He SB, 2009, MOBIHOC'09 PROCEEDINGS OF THE TENTH ACM INTERNATIONAL SYMPOSIUM ON MOBILE AD HOC NETWORKING AND COMPUTING, P155; Huang CF, 2005, MOBILE NETW APPL, V10, P519, DOI 10.1007/s11036-005-1564-y; Kar K, 2005, IEEE INFOCOM SER, P1997; He SB, 2012, IEEE T PARALL DISTR, V23, P475, DOI 10.1109/TPDS.2011.191; Chakrabarty K, 2002, IEEE T COMPUT, V51, P1448, DOI 10.1109/TC.2002.1146711; Edalat N, 2012, COMPUT COMMUN, V35, P916, DOI 10.1016/j.comcom.2012.02.004; Wang J, 2006, J COMB OPTIM, V11, P291, DOI 10.1007/s10878-006-7909-z; Cheng MX, 2005, IEEE INFOCOM SER, P2638; Jaggi N, 2013, AD HOC NETW, V11, P1405, DOI 10.1016/j.adhoc.2011.04.008; Tang SJ, 2013, IEEE INFOCOM SER, P155; Luo T, 2012, IEEE COMMUN LETT, V16, P1896, DOI 10.1109/LCOMM.2012.092812.121712; Kasbekar GS, 2011, IEEE ACM T NETWORK, V19, P470, DOI 10.1109/TNET.2010.2077648; Gu L, 2005, REAL-TIME SYST, V29, P157, DOI 10.1007/s11241-005-6883-z; Chen J, 2011, CLUSTER COMPUT, V14, P55, DOI 10.1007/s10586-009-0092-0; Bhuiyan MZA, 2014, ACM T SENSOR NETWORK, V10, DOI 10.1145/2533669; Bienstock D, 1996, MATH PROGRAM, V74, P121, DOI 10.1007/BF02592208; de Farias C. M., 2013, P INT C INF NETW, P648; Gurobi Optimization, 2013, GUR OPT REF MAN; Habib S. J., 2011, IET Wireless Sensor Systems, V1, DOI 10.1049/iet-wss.2011.0057; Hsin C., 2004, P 3 INT S INF PROC S, P433, DOI DOI 10.1145/984622.984685; Huang C.F., 2003, P 2 ACM INT C WIR SE, P115, DOI DOI 10.1145/941350.941367; Kapoor N., 2012, P IEEE INT C COMM, P350; Levis P, 2005, AMBIENT INTELLIGENCE, V35, P115, DOI DOI 10.1007/3-540-27139-2_7; Li W, 2014, J PARALLEL DISTR COM, V74, P1775, DOI 10.1016/j.jpdc.2013.09.012; Li W., 2013, ACM T SENSOR NETWORK, V9, P1; Miyazaki T., 2011, P 5 INT C UB INF MAN, P53; Miyazaki Toshiaki, 2012, International Journal of Handheld Computing Research, V3, DOI 10.4018/jhcr.2012070102; Rossi M, 2010, IEEE T MOBILE COMPUT, V9, P1749, DOI 10.1109/TMC.2010.109; Seto D., 1996, P 17 IEEE REAL TIM S, P13; Shafi N. Bin, 2012, P 9 IEEE C SENS MESH, P371; Slijepcevic S., 2001, IEEE INT C COMM, V2, P472, DOI 10.1109/ICC.2001.936985; Tian Y., 2005, P IEEE INT WORKSH RE, P211; Voinescu A., 2010, P 6 INT C NETW SERV, P12; Wang B, 2011, ACM COMPUT SURV, V43, DOI 10.1145/1978802.1978811; Willett R, 2004, P 3 INT S INF PROC S, P124, DOI 10.1145/984622.984641; Xu Y., 2010, P 11 ACM INT S MOB A, P181, DOI 10.1145/1860093.1860118; Yau DKY, 2010, ACM T SENSOR NETWORK, V7, DOI 10.1145/1824766.1824774; Younis M., 2002, Proceedings 10th IEEE International Symposium on Modeling, Analysis, and Simulation of Computer and Telecommunications Systems. MASCOTS 2002, DOI 10.1109/MASCOT.2002.1167069	39	0	0	IEEE COMPUTER SOC	LOS ALAMITOS	10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA	0018-9340	1557-9956		IEEE T COMPUT	IEEE Trans. Comput.	NOV	2015	64	11					3128	3139		10.1109/TC.2015.2389802		12	Computer Science, Hardware & Architecture; Engineering, Electrical & Electronic	Computer Science; Engineering	CT3YR	WOS:000362743300009		
J	Nishigawa, K; Fukui, T; Takanashi, S				Nishigawa, Kosaku; Fukui, Toshihiro; Takanashi, Shuichiro			Off-pump coronary endarterectomy with stent removal for in-stent restenosis in the left anterior descending artery	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Coronary artery bypass grafting; Coronary endarterectomy; In-stent restenosis	PACLITAXEL-ELUTING STENTS; SURGERY; LENGTH	OBJECTIVES: In-stent restenosis (ISR) remains a major complication of percutaneous coronary intervention, even in the current era of drug-eluting stents (DESs). We reviewed the clinical and angiographic outcomes of coronary endarterectomy with stent removal using an off-pump technique in patients with ISR in the left anterior descending artery (LAD). METHODS: Twelve patients with long-segment ISR in the LAD underwent off-pump coronary artery bypass grafting with coronary endarterectomy and stent removal at our institution from November 2005 to August 2012. Their mean age was 65.0 +/- 6.3 years, and 11 were male. DESs were used in 10 patients and bare-metal stents were used in the remaining 2 patients. The interval from the latest intervention ranged from 4 to 102 months (median, 12 months). RESULTS: None of the procedures were converted to on-pump surgery, and there were no operative deaths. The left internal thoracic artery (LITA) was used to reconstruct the endarterectomized LAD in all patients, and the mean length of the arteriotomy in the LAD was 5.3 +/- 1.0 cm. The LITA and LAD were patent in all patients on both early postoperative and follow-up angiography. At the median 24-month follow-up (range, 12-78 months), there were no late deaths and all patients were at a Canadian Cardiovascular Society class of 0 or I. CONCLUSIONS: Coronary endarterectomy with stent removal can be safely performed using an off-pump technique and provides favourable clinical and angiographic outcomes in patients with long-segment ISR in the LAD.	[Nishigawa, Kosaku; Fukui, Toshihiro; Takanashi, Shuichiro] Sakakibara Heart Inst, Dept Cardiovasc Surg, Fuchu, Tokyo 1830003, Japan	Nishigawa, K (reprint author), Sakakibara Heart Inst, Dept Cardiovasc Surg, 3-16-1 Asahi Cho, Fuchu, Tokyo 1830003, Japan.	nippie550102@yahoo.co.jp					Takanashi S, 2008, J CARDIOL, V52, P261, DOI 10.1016/j.jjcc.2008.09.006; Vohra HA, 2006, ANN THORAC SURG, V81, P1691, DOI 10.1016/j.athoracsur.2005.12.028; Fukui T, 2007, ANN THORAC SURG, V83, P115, DOI 10.1016/j.athoracsur.2006.08.009; Eryilmaz S, 2003, ANN THORAC SURG, V75, P865, DOI 10.1016/S0003-4975(02)04500-9; Kobayashi Y, 1999, J AM COLL CARDIOL, V34, P651, DOI 10.1016/S0735-1097(99)00303-4; Finn AV, 2005, CIRCULATION, V112, P270, DOI 10.1161/CIRCULATIONAHA.104.508937; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Tsagalou E, 2005, J AM COLL CARDIOL, V45, P1570, DOI 10.1016/j.jacc.20055.01.049; BAILEY CP, 1957, JAMA-J AM MED ASSOC, V164, P641; Puskas JD, 2009, ANN THORAC SURG, V88, P1142, DOI 10.1016/j.athoracsur.2009.04.135; Fukui T, 2005, ANN THORAC SURG, V79, P558, DOI 10.1016/j.athoracsur.2004.07.064; Dangas GD, 2010, J AM COLL CARDIOL, V56, P1897, DOI 10.1016/j.jacc.2010.07.028; Aoki J, 2005, AM HEART J, V150, P994, DOI 10.1016/j.ahj.2005.01.050; Yilmazkaya B, 2008, ANN THORAC SURG, V85, P1586, DOI 10.1016/j.athoracsur.2008.01.055; Moustapha A, 2001, J AM COLL CARDIOL, V37, P1877, DOI 10.1016/S0735-1097(01)01231-1; Nishigawa Kosaku, 2014, Gen Thorac Cardiovasc Surg, V62, P461, DOI 10.1007/s11748-014-0414-x; Uchimuro Tomoya, 2009, Interact Cardiovasc Thorac Surg, V8, P663, DOI 10.1510/icvts.2008.201194; Wilson GJ, 2009, CIRCULATION, V120, P141, DOI 10.1161/CIRCULATIONAHA.107.730010	18	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	NOV	2015	21	5					594	597		10.1093/icvts/ivv210		4	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CT8IF	WOS:000363058100006		
J	Morita, K; Sasabuchi, Y; Matsui, H; Fushimi, K; Yasunaga, H				Morita, Kojiro; Sasabuchi, Yusuke; Matsui, Hiroki; Fushimi, Kiyohide; Yasunaga, Hideo			Outcomes after early or late timing of surgery for infective endocarditis with ischaemic stroke: a retrospective cohort study	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Endocarditis (all infectious agents); Stroke; Surgery; Complications	VALVE-REPLACEMENT; CEREBROVASCULAR COMPLICATIONS; NEUROLOGIC COMPLICATIONS; PROSPECTIVE MULTICENTER; CARDIOEMBOLIC STROKE; SURGICAL-MANAGEMENT; CARDIAC-SURGERY; BRAIN-DAMAGE; IMPACT; RISK	OBJECTIVES: The timing of cardiac surgery for infective endocarditis with ischaemic stroke remains controversial. METHODS: Using a nationwide inpatient database in Japan, we conducted a retrospective observational study. We identified patients aged 20 years or older with ischaemic stroke on admission who were diagnosed with infective endocarditis and underwent cardiac surgery during the initial hospitalization between July 2010 and March 2013. In-hospital mortality and perioperative complications were compared between the early (<= 7 days) and late (>7 days) surgery groups using logistic regression analyses with adjustment for propensity scores and inverse probability of treatment weighting. RESULTS: We identified 253 patients who underwent cardiac valve surgery for infective endocarditis with ischaemic stroke on admission. In-hospital mortality rates were 8.6 and 9.5% in the early (n = 105) and late (n = 148) surgery groups, respectively. There were no significant differences in the in-hospital mortality between the early and late surgery groups in the propensity score-adjusted model [odds ratio (OR), 0.95; 95% confidence interval (CI), 0.35-2.54] and inverse probability-weighted model (risk difference, -0.82%; 95% CI, -6.43 to 4.84%). The perioperative complication rates were 42.9 and 37.8% in the early and late surgery groups, respectively, and showed no significant differences in the propensity score-adjusted model (OR, 1.11; 95% CI, 0.63-1.97) and inverse probability-weighted model (risk difference, 1.54%; 95% CI, -7.13 to 10.2%). CONCLUSIONS: Early timing of surgery for infective endocarditis patients with ischaemic stroke was not associated with higher in-hospital mortality or complications after admission. Early timing of surgery may not be contraindicated for infective endocarditis patients with ischaemic stroke.	[Morita, Kojiro; Sasabuchi, Yusuke; Matsui, Hiroki; Yasunaga, Hideo] Univ Tokyo, Sch Publ Hlth, Dept Clin Epidemiol & Hlth Econ, Tokyo 1130033, Japan; [Fushimi, Kiyohide] Tokyo Med & Dent Univ, Grad Sch Med, Dept Hlth Policy & Informat, Tokyo, Japan	Yasunaga, H (reprint author), Univ Tokyo, Sch Publ Hlth, Dept Clin Epidemiol & Hlth Econ, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yasunagah-tky@umin.ac.jp			Research on Policy Planning and Evaluation from the Ministry of Health, Labour and Welfare, Japan [H27-Policy-Designated-009, H27-Policy-Strategy-011]	This work was supported by grants for Research on Policy Planning and Evaluation from the Ministry of Health, Labour and Welfare, Japan (grant nos H27-Policy-Designated-009 and H27-Policy-Strategy-011).	Heiro M, 2000, ARCH INTERN MED, V160, P2781, DOI 10.1001/archinte.160.18.2781; EISHI K, 1995, J THORAC CARDIOV SUR, V110, P1745, DOI 10.1016/S0022-5223(95)70038-2; Angstwurm K, 2004, J NEUROL, V251, P1220, DOI 10.1007/s00415-004-0517-x; KANTER MC, 1991, NEUROLOGY, V41, P1015; Ruttmann E, 2006, STROKE, V37, P2094, DOI 10.1161/01.STR.0000229894.28591.3f; Habib G, 2009, EUR HEART J, V30, P2369, DOI 10.1093/eurheartj/ehp285; Curtis LH, 2007, MED CARE, V45, pS103; Thuny F, 2005, CIRCULATION, V112, P69, DOI 10.1161/CIRCULATIONAHA.104.493155; Gaca JG, 2011, J THORAC CARDIOV SUR, V141, P98, DOI 10.1016/j.jtcvs.2010.09.016; Piper C, 2001, J HEART VALVE DIS, V10, P703; Cooper HA, 2009, CIRCULATION, V120, P585, DOI 10.1161/CIRCULATIONAHA.108.834432; SALGADO AV, 1989, NEUROLOGY, V39, P173; Byrne JG, 2011, ANN THORAC SURG, V91, P2012, DOI 10.1016/j.athoracsur.2011.01.106; Barsic B, 2013, CLIN INFECT DIS, V56, P209, DOI 10.1093/cid/cis878; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Thuny F, 2007, EUR HEART J, V28, P1155, DOI 10.1093/eurheartj/ehm005; HART RG, 1990, STROKE, V21, P695; MARUYAMA M, 1989, STROKE, V20, P1305; Yoshioka D, 2012, ANN THORAC SURG, V94, P489, DOI 10.1016/j.athoracsur.2012.04.027; Garcia-Cabrera E, 2013, CIRCULATION, V127, P2272, DOI 10.1161/CIRCULATIONAHA.112.000813; Gillinov AM, 1996, ANN THORAC SURG, V61, P1125, DOI 10.1016/0003-4975(96)00014-8; Snygg-Martin U, 2008, CLIN INFECT DIS, V47, P23, DOI 10.1086/588663; Parrino PE, 1999, ANN THORAC SURG, V67, P59, DOI 10.1016/S0003-4975(98)01230-2; Chen Chang-Hua, 2001, Journal of Microbiology Immunology and Infection, V34, P119; Shigematsu K, 2013, BMJ OPEN, P3, DOI [10.1136/bmjopen-2013-002736, DOI 10.1136/BMJ0PEN-2013-002736]	25	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	NOV	2015	21	5					604	609		10.1093/icvts/ivv235		6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CT8IF	WOS:000363058100008		
J	Kawashima, M; Murakawa, T; Shinozaki, T; Ichinose, J; Hino, H; Konoeda, C; Tsuchiya, T; Murayama, T; Nagayama, K; Nitadori, J; Anraku, M; Nakajima, J				Kawashima, Mitsuaki; Murakawa, Tomohiro; Shinozaki, Tomohiro; Ichinose, Junji; Hino, Haruaki; Konoeda, Chihiro; Tsuchiya, Takehiro; Murayama, Tomonori; Nagayama, Kazuhiro; Nitadori, Jun-ichi; Anraku, Masaki; Nakajima, Jun			Significance of the Glasgow Prognostic Score as a prognostic indicator for lung cancer surgery	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article; Proceedings Paper	23rd European Conference on General Thoracic Surgery	MAY 31-JUN 03, 2015	Lisbon, PORTUGAL			Inflammation; C-reactive protein; Albumin; Lung neoplasms; Surgery; Risk factors	INFLAMMATION; DISEASE	OBJECTIVES: The Glasgow Prognostic Score (GPS), which is calculated with C-reactive protein (CRP) and albumin (Alb) values, is a prognostic indicator for various types of cancers. However, its role in lung cancer still remains unclear, and its optimal cut-off values are controversial. Here, we evaluated the significance of the GPS and adjusted GPS (a-GPS) using our institution's cut-off values in patients undergoing resection for primary lung cancer. METHODS: We analysed 1043 lung cancer patients who underwent resection between 1998 and 2012. The overall survival (OS) probabilities of the GPS subgroups were estimated using the Kaplan-Meier method and were compared using the log-rank test. The prognostic significance of the GPS and the a-GPS was assessed by the Cox proportional hazards model with clinicopathological variables and inflammation markers, such as the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR). The GPS was calculated based on cut-off values of 1.0 mg/dl for CRP and 3.5 g/dl for Alb, as previously reported. The a-GPS was calculated based on cut-off values 0.3 mg/dl for CRP and 3.9 g/dl for Alb, which are the standard thresholds used by our institution. RESULTS: The GPS and the a-GPS were correlated with preoperative factors, such as age, sex, smoking status, the NLR and the PLR, and oncological factors, including the pathological stage, histological type and level of lymphovascular invasion. The 5-year OS rates were 82, 55 and 55% with GPS 0, 1 and 2 (1 vs 0: P < 0.01; 2 vs 1: P = 0.66), respectively, and 88, 67 and 59% with a-GPS 0, 1 and 2 (1 vs 0: P < 0.01; 2 vs 1: P = 0.04), respectively. Multivariable analysis revealed that the GPS [1 vs 0, hazard ratio (HR): 1.63, 2 vs 0, HR: 1.44] and the a-GPS (1 vs 0, HR: 2.00, 2 vs 0, HR: 2.10) were independent prognostic factors. The a-GPS classification showed a clearer prognostic distribution than the GPS classification. CONCLUSIONS: The GPS is a useful prognostic indicator of the OS in lung cancer surgery. The optimal cut-off values for GPS estimation may need to be re-evaluated.	[Kawashima, Mitsuaki; Murakawa, Tomohiro; Ichinose, Junji; Hino, Haruaki; Konoeda, Chihiro; Tsuchiya, Takehiro; Murayama, Tomonori; Nagayama, Kazuhiro; Nitadori, Jun-ichi; Anraku, Masaki; Nakajima, Jun] Univ Tokyo, Grad Sch Med, Dept Thorac Surg, Tokyo 1138655, Japan; [Shinozaki, Tomohiro] Univ Tokyo, Grad Sch Med, Dept Biostat, Tokyo 1138655, Japan	Murakawa, T (reprint author), Univ Tokyo, Grad Sch Med, Dept Thorac Surg, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	murakawa-tky@umin.ac.jp					Proctor MJ, 2013, CANCER-AM CANCER SOC, V119, P2325, DOI 10.1002/cncr.28018; McMillan DC, 2013, CANCER TREAT REV, V39, P534, DOI 10.1016/j.ctrv.2012.08.003; Takeno S, 2014, ONCOLOGY-BASEL, V87, P205, DOI 10.1159/000362601; Ishizuka M, 2011, J SURG ONCOL, V103, P801, DOI 10.1002/jso.21857; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Nozoe T, 2011, AM J SURG, V201, P186, DOI 10.1016/j.amjsurg.2010.01.030; Forrest LM, 2003, BRIT J CANCER, V89, P1028, DOI 10.1038/sj.bjc.6601242; Forrest LM, 2004, BRIT J CANCER, V90, P1704, DOI 10.1038/sj.bjc.6601789; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Koenig W, 2013, INT J CARDIOL, V168, P5126, DOI 10.1016/j.ijcard.2013.07.113; Brusselle GG, 2014, CHEST, V145, P1121, DOI 10.1378/chest.13-1885; Leung EYL, 2012, J THORAC ONCOL, V7, P655, DOI 10.1097/JTO.0b013e318244ffe1; Miyazaki T, 2015, EUR J CARDIO-THORAC, V47, pE140, DOI 10.1093/ejcts/ezu514; Sekine Yasuo, 2014, Gen Thorac Cardiovasc Surg, V62, P415, DOI 10.1007/s11748-014-0386-x; Sobin LH, 2009, TNM CLASSIFICATION M, P136; TEAM R DEVELOPMENT CORE, R LANG ENV STAT COMP; Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124; Templeton AJ, 2014, CANCER EPIDEM BIOMAR, V23, P1204, DOI 10.1158/1055-9965.EPI-14-0146; Travis WD, 2004, PATH GEN TUM LUNG PL, P9	19	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	NOV	2015	21	5					637	643		10.1093/icvts/ivv223		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CT8IF	WOS:000363058100016		
J	Tamura, A; Suzuki, J; Fukami, T; Matsui, H; Akagawa, S; Ohta, K; Hebisawa, A; Takahashi, F				Tamura, Atsuhisa; Suzuki, Junko; Fukami, Takeshi; Matsui, Hirotoshi; Akagawa, Shinobu; Ohta, Ken; Hebisawa, Akira; Takahashi, Fumiaki			Chronic pulmonary aspergillosis as a sequel to lobectomy for lung cancer	INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY			English	Article						Lung cancer; Lobectomy; Sequel; Chronic pulmonary aspergillosis; Chronic obstructive pulmonary disease; Interstitial lung disease	CASE SERIES; CARCINOMA; DIAGNOSIS; SURVIVAL; FIBROSIS; SURGERY	OBJECTIVES: Chronic pulmonary aspergillosis (CPA) is an emerging complication after lobectomy for lung cancer. This retrospective study aimed to determine the incidence, main risk factors and clinical features of postoperative CPA in lung cancer patients. METHODS: This study included lung cancer patients treated by lobectomy and with no previous history of thoracic surgery or coexistent aspergillosis at the time of surgery. The cumulative incidence of CPA was determined using death as a competing risk. Furthermore, the identified lung cancer patients were divided into CPA and non-CPA groups to compare their preoperative clinical features and to identify the risk factors of postoperative CPA by univariable and multivariable analyses. We also analysed the clinical features of CPA patients after diagnosis. RESULTS: We included 475 lung cancer patients. Of these, 17 patients (3.6%) developed CPA after the lobectomy. The cumulative postoperative incidence rate of CPA was 2.3% [95% confidence interval (CI), 0.8-3.8%] at 5 years and 7.9% (95% CI, 3.0-13.0%) at 10 years. There were significantly more men (P = 0.007), smokers (P = 0.002) and comorbid chronic obstructive pulmonary disease (COPD) (P = 0.008) and interstitial lung disease (ILD) (P = 0.009) patients in the CPA group than in the non-CPA group. Multivariable analysis identified comorbid COPD (P = 0.0019) and ILD (P = 0.0003) as significant risk factors. An antifungal treatment response was obtained in 6 patients (35%). The 1-year survival rate was 47% (follow-up periods, interquartile range: 3-78 months), and 5 of the total of 11 deaths were due to CPA. CONCLUSIONS: Through the present retrospective study, CPA seems to be a common sequel to lobectomy in lung cancer patients, and COPD and ILD represent strong risk factors of postoperative CPA. Because of the poor clinical outcome of lung cancer patients who develop CPA after lobectomy, careful follow-up using several examinations and chest radiographs to make CPA diagnosis may be essential.	[Tamura, Atsuhisa; Suzuki, Junko; Fukami, Takeshi; Matsui, Hirotoshi; Akagawa, Shinobu; Ohta, Ken] Tokyo Natl Hosp, Natl Hosp Org, Ctr Pulm Dis, Kiyose, Tokyo 2048585, Japan; [Tamura, Atsuhisa; Suzuki, Junko; Matsui, Hirotoshi; Akagawa, Shinobu; Ohta, Ken] Tokyo Natl Hosp, Natl Hosp Org, Resp Dis Div, Kiyose, Tokyo 2048585, Japan; [Tamura, Atsuhisa; Hebisawa, Akira] Tokyo Natl Hosp, Natl Hosp Org, Clin Res Ctr, Div Pathol & Epidemiol, Kiyose, Tokyo 2048585, Japan; [Fukami, Takeshi] Tokyo Natl Hosp, Natl Hosp Org, Chest Surg Div, Kiyose, Tokyo 2048585, Japan; [Takahashi, Fumiaki] Tohoku Univ Hosp, Clin Res Innovat & Educ Ctr, Sendai, Miyagi, Japan	Tamura, A (reprint author), Tokyo Natl Hosp, Natl Hosp Org, 3-1-1 Takeoka, Kiyose, Tokyo 2048585, Japan.	tamura-in@tokyo-hosp.jp					Sekine Y, 2002, LUNG CANCER-J IASLC, V37, P95, DOI 10.1016/S0169-5002(02)00014-4; Nam HS, 2010, INT J INFECT DIS, V14, pE479, DOI 10.1016/j.ijid.2009.07.011; GEFTER WB, 1981, RADIOLOGY, V140, P313; BINDER RE, 1982, MEDICINE, V61, P109, DOI 10.1097/00005792-198203000-00005; Tashiro T, 2013, JPN J INFECT DIS, V66, P312; Tanaka H, 2007, EUR J CARDIO-THORAC, V32, P859, DOI 10.1016/j.ejcts.2007.09.012; Denning DW, 2011, B WORLD HEALTH ORGAN, V89, P864, DOI 10.2471/BLT.11.089441; Arakawa H, 2011, AM J ROENTGENOL, V196, P773, DOI 10.2214/AJR.10.4873; D'Addario G, 2009, ANN ONCOL, V20, P68, DOI 10.1093/annonc/mdp132; Ohba H, 2012, RESP MED, V106, P724, DOI 10.1016/j.rmed.2012.01.014; Kumar N, 2013, J POSTGRAD MED, V59, P145, DOI 10.4103/0022-3859.113841; Smith NL, 2011, EUR RESPIR J, V37, P865, DOI 10.1183/09031936.00054810; Denning DW, 2003, CLIN INFECT DIS, V37, pS265, DOI 10.1086/376526; ROIG J, 1993, CHEST, V104, P295, DOI 10.1378/chest.104.1.295; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Tochigi N, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/809798; HANAGIRI T, 1993, SCAND J THORAC CARD, V27, P57, DOI 10.3109/14017439309099095; Ueda H, 1997, THORAC CARDIOV SURG, V45, P261, DOI 10.1055/s-2007-1013743; Saito Y, 2011, ANN THORAC SURG, V92, P1812, DOI 10.1016/j.athoracsur.2011.06.055; Padovani B, 2009, J RADIOL, V90, P991; Coviello V., 2004, STATA J, V4, P103; Crabtree TD, 2010, PRINCIPLES PRACTICE, P531; Godet C, 2014, RESPIRATION, V88, P162, DOI 10.1159/000362674; Matsuura Shun, 2009, Nihon Kokyuki Gakkai Zasshi, V47, P455; Ferguson Mark K, 2008, Eur J Cardiothorac Surg, V33, P497, DOI 10.1016/j.ejcts.2007.12.023	25	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1569-9293	1569-9285		INTERACT CARDIOV TH	Interact Cardiovasc. Thorac. Surg.	NOV	2015	21	5					650	656		10.1093/icvts/ivv239		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	CT8IF	WOS:000363058100018		
J	Iwasawa, S; Nakano, M; Tsuboi, T; Kochi, T; Tanaka, S; Katsunuma, T; Morikawa, A; Omae, K				Iwasawa, Satoko; Nakano, Makiko; Tsuboi, Tazuru; Kochi, Takeshi; Tanaka, Shigeru; Katsunuma, Toshio; Morikawa, Akihiro; Omae, Kazuyuki			Effects of sulfur dioxide on the respiratory system of Miyakejima child residents 6 years after returning to the island	INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH			English	Article						Respiratory system; Sulfur dioxide; Volcanic gas; Dose-response health effects; Child	AZORES	This study investigated the health effects of volcanic gas, mainly sulfur dioxide (SO2), exposure on the children of Miyakejima Island. Health checkups were conducted in November from 2006 to 2011. Health effects were evaluated through a self-administered questionnaire on respiratory and irritative symptoms, and spirometry. SO2 was measured continuously from February 2005 onward at six fixed monitoring stations in inhabitable areas. Based on mean SO2 concentration during 3 months before each health checkup, inhabitable areas were classified into three categories: (1) lower (area L); (2) higher (area H-1); and (3) highest (area H-2). Average concentrations (ppb) of SO2 decreased year-by-year and ranged from 11.3 to 2.47 in area L, from 32.2 to 12.2 in area H-1, and from 75.1 to 12.1 in area H-2, respectively. In general, prevalence of respiratory and irritative symptoms was higher in area H-2, and the prevalence decreased year-by-year in all three areas by Cochran-Armitage test for trend. We defined a study population in area L in 2008 as a reference population because we had no unexposed population. Applying a logistic regression model, age-, sex-, and hypersusceptibility-adjusted prevalence odds ratios to the reference population showed clear exposure-dependent increases in some irritative symptoms such as "Irritation and/or pain in throat" and "in eyes," and approximately 30 ppb seemed to be the threshold concentration. Spirometry did not show any significant differences. Though no pulmonary functions were affected, some subjective symptoms were detected dose-dependently by SO2 exposure concentration in child residents during the 6 years after the eruption.	[Iwasawa, Satoko; Nakano, Makiko; Tsuboi, Tazuru; Kochi, Takeshi; Omae, Kazuyuki] Keio Univ, Dept Prevent Med & Publ Hlth, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Tanaka, Shigeru] Jumonji Univ, Sch Human Life Sci, Dept Publ Hlth, Saitama, Japan; [Katsunuma, Toshio] Jikei Univ, Daisan Hosp, Dept Pediat, Tokyo, Japan; [Morikawa, Akihiro] Gunma Univ, Kitakanto Allergy Inst, Maebashi, Gumma 371, Japan	Iwasawa, S (reprint author), Keio Univ, Dept Prevent Med & Publ Hlth, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	iwasawa@a5.keio.jp			Miyake government	This study was supported by Miyake government commissioned research fund.	Amaral AFS, 2007, ENVIRON RES, V103, P419, DOI 10.1016/j.envres.2006.06.016; Ishigami A, 2008, OCCUP ENVIRON MED, V65, P701, DOI 10.1136/oem.2007.033456; Michaud JP, 2004, ENVIRON RES, V95, P11, DOI 10.1016/S0013-9351(03)00122-1; Baxter PJ, 1999, J VOLCANOL GEOTH RES, V92, P95, DOI 10.1016/S0377-0273(99)00070-0; Ferris BG, 1978, AM REV RESPIR DIS, V118, P7; Kikuchi Y, 2006, NIHONKYOUBURINNSYOU, V65, P252; Mannino D M, 1996, Hawaii Med J, V55, P48; Ministry of the Environment Government of Japan, 2014, STAT JAP ENV GLANC A; Standardization of spirometry, 1995, AM J RESP CRIT CARE, V152, P1107; Takase M, 2009, JPN J PEDIAT PULMONO, V19, P164; Tokyo Metropolitan Government and the Cabinet Office of Japan, 2003, REP SCI COMM ASS HLT, P1	11	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-0131	1432-1246		INT ARCH OCC ENV HEA	Int. Arch. Occup. Environ. Health	NOV	2015	88	8					1111	1118		10.1007/s00420-015-1037-y		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CT7ZL	WOS:000363034400011		
J	Okawa, T; Shimada, M; Ushida, Y; Seki, N; Watai, N; Ohnishi, M; Tamura, Y; Ito, A				Okawa, Teiichiro; Shimada, Masayuki; Ushida, Yoshihiko; Seki, Nobuo; Watai, Naoki; Ohnishi, Masatoshi; Tamura, Yoshitaka; Ito, Akira			Demineralisation of whey by a combination of nanofiltration and anion-exchange treatment: a preliminary study	INTERNATIONAL JOURNAL OF DAIRY TECHNOLOGY			English	Article						Whey; Nanofiltration; Anion-exchange; Demineralisation	MILK ULTRAFILTRATION PERMEATE; DAIRY-INDUSTRY; ACID WHEY; MEMBRANES; PRODUCTS; PROTEIN	Demineralisation is an important process for the utilisation of whey in the food industry. Sodium (Na+) and potassium (K+) ions pass through nanofiltration (NF) membranes in ion pairs with chloride (Cl-) to maintain electroneutrality, but NF processing can only partially remove these ions from whey, because the total Na and K content of whey generally exceeds the Cl content. In this work, a preliminary study of a new demineralisation method was made. A reconstituted sweet whey powder solution was first treated by Cl-form anion-exchange resin to increase the molar ratio of Cl to Na and K from similar to 0.5 to similar to 1.0. Subsequently, NF removed >90% of Na and K from the anion-exchange treated whey compared with <60% from the control whey. This new process could be useful for producing 70% demineralised whey with very low levels of the monovalent ions Na+, K+ and Cl-.	[Okawa, Teiichiro; Shimada, Masayuki; Ushida, Yoshihiko] Morinaga Milk Ind Co Ltd, Food Res & Dev Inst, Zama, Kanagawa 2528583, Japan; [Okawa, Teiichiro; Ito, Akira] Tokyo Inst Technol, Grad Sch Sci & Engn, Dept Chem Engn, Tokyo 1528552, Japan; [Seki, Nobuo; Watai, Naoki] Morinaga Milk Ind Co Ltd, Inst Food Sci & Technol, Zama, Kanagawa 2528583, Japan; [Ohnishi, Masatoshi] Morinaga Milk Ind Co Ltd, Engn Res Lab, Tokyo 2070021, Japan; [Tamura, Yoshitaka] Morinaga Milk Ind Co Ltd, Res Sect, Zama, Kanagawa 2528583, Japan	Shimada, M (reprint author), Morinaga Milk Ind Co Ltd, Food Res & Dev Inst, Zama, Kanagawa 2528583, Japan.	m-shimada@morinagamilk.co.jp					Pan K, 2011, DESALINATION, V267, P217, DOI 10.1016/j.desal.2010.09.029; Dec Bogdan, 2007, Polish Journal of Natural Sciences, V22, P320; Ju ZY, 1999, J DAIRY SCI, V82, P1882; HOULDSWORTH DW, 1980, J SOC DAIRY TECHNOL, V33, P45, DOI 10.1111/j.1471-0307.1980.tb01470.x; Diblikova L, 2013, INT DAIRY J, V31, P29, DOI 10.1016/j.idairyj.2012.12.008; Wang XM, 2008, J FOOD COMPOS ANAL, V21, P255, DOI 10.1016/j.jfca.2007.10.006; Hakoda A, 2011, FOOD SCI TECHNOL RES, V17, P227, DOI 10.3136/fstr.17.227; VANDERHORST HC, 1995, J MEMBRANE SCI, V104, P205, DOI 10.1016/0376-7388(95)00041-A; Rice G, 2006, DESALINATION, V199, P239, DOI 10.1016/j.desal.2006.03.058; Suarez E, 2009, DESALINATION, V241, P272, DOI 10.1016/j.desal.2007.11.087; Boumba VA, 2001, INT J DAIRY TECHNOL, V54, P141, DOI 10.1046/j.1364-727X.2001.00026.x; Rasanen E, 2002, LAIT, V82, P343, DOI 10.1051/lait:2002015; Sato N, 2004, KAGAKU KOGAKU RONBUN, V30, P407, DOI 10.1252/kakoronbunshu.30.407; Yunoki H, 2002, J CHEM ENG JPN, V35, P76, DOI 10.1252/jcej.35.76; Levenstein R, 1996, J MEMBRANE SCI, V116, P77, DOI 10.1016/0376-7388(96)00029-4; Kumar P, 2013, ASIAN AUSTRAL J ANIM, V26, P1347, DOI 10.5713/ajas.2013.13082; Luo JQ, 2011, J MEMBRANE SCI, V372, P145, DOI 10.1016/j.memsci.2011.01.066; Suarez E, 2006, DESALINATION, V198, P274, DOI 10.1016/j.desal.2005.12.028; Harju M, 2001, INT J DAIRY TECHNOL, V54, P61, DOI 10.1046/j.1471-0307.2001.00016.x; WADA A, 1984, J CHROMATOGR, V291, P111, DOI 10.1016/S0021-9673(00)95011-8; Roman A, 2009, DESALINATION, V241, P288, DOI 10.1016/j.desal.2007.12.054; Minhalma M, 2007, J ENVIRON MANAGE, V82, P200, DOI 10.1016/j.jenvman.2005.12.011; Fox P F, 1992, ADV DAIRY CHEM, P624; Hutson T, 1998, P INT WHEY C CHIC US, P88; Latimer Jr G W, 2012, OFF METH AN ASS OFF, P12; Latimer Jr G W, 2012, OFF METH AN ASS OFF, P10; Latimer Jr G W, 2012, OFF METH AN ASS OFF, P46; Roman Andras, 2011, Food and Bioprocess Technology, V4, DOI 10.1007/s11947-009-0192-0	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1364-727X	1471-0307		INT J DAIRY TECHNOL	Int. J. Dairy Technol.	NOV	2015	68	4					478	485		10.1111/1471-0307.12283		8	Food Science & Technology	Food Science & Technology	CT6HS	WOS:000362914700003		
J	Li, J; Zou, Y; Sun, QR; Yang, C; Yang, JW; Zhang, LF				Li, Jing; Zou, Ying; Sun, Qingrui; Yang, Cheng; Yang, Jinwei; Zhang, Lianfu			Effect of physical and thermal processing upon benzylglucosinolate content in tubers of the Brassicaceae maca (Lepidium meyenii) using a novel rapid analytical technique	INTERNATIONAL JOURNAL OF FOOD SCIENCE AND TECHNOLOGY			English	Article						Benzylglucosinolate; degradation; drying; Maca (Lepidium meyenii); myrosinase; shredding; steam	GLUCOSINOLATE DEGRADATION; KINETICS; BROCCOLI; EXTRACT; RATS	Benzylglucosinolate (BG) was extracted by 70% methanol from maca and purified on acidic alumina column and semi-preparative Cosmosil cholester column. The purified sample was verified as BG by electrospray ionisation mass spectrometry (ESI-MS) and nuclear magnetic resonance spectra. The purity was 98.3% as determined by HPLC-MS. BG content of maca was quantified using external standard method by HPLC. Effect of physical and thermal processing on BG content of maca was investigated. When maca was steamed for 5min before shredding, no significant difference of BG content was observed during postshredding time, while raw maca lost 57.2% of BG in 24h. Steamed maca showed no significant loss of BG after drying at the temperature from 20 to 80 degrees C in 24h. Thermal degradation was described by the first-order kinetics-Arrhenius equation for BG in the temperature range of 90-100 degrees C.	[Li, Jing; Zou, Ying; Zhang, Lianfu] Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi 214122, Peoples R China; [Li, Jing; Zou, Ying; Sun, Qingrui; Yang, Cheng; Zhang, Lianfu] Jiangnan Univ, Sch Food Sci & Technol, Wuxi 214122, Peoples R China; [Li, Jing; Sun, Qingrui; Yang, Cheng; Zhang, Lianfu] Jiangnan Univ, Natl Engn Res Ctr Funct Food, Wuxi 214122, Peoples R China; [Yang, Jinwei] Tokiwa Phytochem Co Ltd, Sakura, Chiba 2850801, Japan	Zhang, LF (reprint author), Jiangnan Univ, State Key Lab Food Sci & Technol, Wuxi 214122, Peoples R China.	lianfu@jiangnan.edu.cn					Gonzales GF, 2007, ASIAN J ANDROL, V9, P245, DOI 10.1111/j.1745-7262.2007.00228.x; Calzada F, 2003, PHYTOTHER RES, V17, P618, DOI 10.1002/ptr.1210; Uchiyama F, 2014, J ETHNOPHARMACOL, V151, P897, DOI 10.1016/j.jep.2013.11.058; Song LJ, 2007, FOOD CHEM TOXICOL, V45, P216, DOI 10.1016/j.fct.2006.07.021; Zhang YZ, 2006, J ETHNOPHARMACOL, V105, P274, DOI 10.1016/j.jep.2005.12.013; Oliviero T, 2012, FOOD CHEM, V132, P2037, DOI 10.1016/j.foodchem.2011.12.045; Lentz A, 2007, J SEX MED, V4, P332, DOI 10.1111/j.1743-6109.2007.00437.x; Kiddle G, 2001, PHYTOCHEM ANALYSIS, V12, P226, DOI 10.1002/pca.589; Clement C, 2010, AGRON J, V102, P431, DOI 10.2134/agronj2009.0315; Kurimoto S, 2010, PHYTOCHEMISTRY, V71, P688, DOI 10.1016/j.phytochem.2009.12.007; SCHONE F, 1994, ANIM FEED SCI TECH, V48, P229, DOI 10.1016/0377-8401(94)90174-0; Rubio JL, 2011, EVID-BASED COMPL ALT, P1, DOI 10.1093/ecam/nen063; Charpentier N, 1998, IND CROP PROD, V8, P151, DOI 10.1016/S0926-6690(97)10020-6; Department of policy and Regulation of Ministry of Health of China, 2010, NAT FOOD SAF STAND, p[2, 105]; Donato A., 2014, J FUNCTIONAL FOODS, V7, P67; Emilio Y., 2011, FOOD CHEM, V127, P1576; Frederic F., 2002, ARCH INSECT BIOCH PH, V50, P173; Gan Jin, 2012, Scientia Agricultura Sinica, V45, P1365; Genyi Li, 2001, Economic Botany, V55, P255; Kazuhide K., 2008, ORGANIC PROCESS RES, V12, P1130; Kirsten O., 2006, FOOD CHEM, V95, P19; Li L., 2012, SCI TECHNOLOGY FOOD, V5, P376; Massoma L.D., 2012, EUR J INTEGR MED, V4, P345; Mayumi I., 2009, J HEALTH SCI, V55, P178; Richard M., 2001, PLANT GROWTH REGUL, V34, P91; Ruud V., 2004, J AGR FOOD CHEM, V52, P7318; Sarvan I, 2014, INNOV FOOD SCI EMERG, V25, P58, DOI 10.1016/j.ifset.2014.01.007; Somatek Inc, 2014, INT C HARM TECHN REQ, P6; Tory P., 1996, ANAL BIOCHEM, V239, P168; Vanessa R., 2006, J AGR FOOD CHEM, V54, P7628; Yuriko I., 2009, CHEM PHARM BULL, V57, P315	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0950-5423	1365-2621		INT J FOOD SCI TECH	Int. J. Food Sci. Technol.	NOV	2015	50	11					2443	2450		10.1111/ijfs.12911		8	Food Science & Technology	Food Science & Technology	CT6WV	WOS:000362954700015		
J	Zaitsu, K; Nakayama, H; Yamanaka, M; Hisatsune, K; Taki, K; Asano, T; Kamata, T; Katagai, M; Hayashi, Y; Kusano, M; Tsuchihashi, H; Ishii, A				Zaitsu, Kei; Nakayama, Hiroshi; Yamanaka, Mayumi; Hisatsune, Kazuaki; Taki, Kentaro; Asano, Tomomi; Kamata, Tooru; Katagai, Munehiro; Hayashi, Yumi; Kusano, Maiko; Tsuchihashi, Hitoshi; Ishii, Akira			High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						Synthetic cannabinoid; LC/Q-TOFMS; Metabolism; Potential postmortem redistribution	DESIGNER DRUG; RECEPTOR; CB1; INTOXICATION; TOXICITY	High-resolution mass spectrometry and accurate mass measurement by liquid chromatography/quadrupole-time of flight mass spectrometry (LC/Q-TOFMS) was applied to postmortem plasma and urine specimens from an autopsy of a fatal case involving synthetic cannabinoid use, resulting in the detection of three synthetic cannabinoids: MAM-2201, AM-1220, and AM-2232. We searched for their metabolites existing in postmortem plasma or urine by LC/Q-TOFMS and were able to detect N-dealkylated metabolites, defluorinated and further oxidized metabolites of MAM-2201, and some hydroxylated metabolites. Postmortem plasma concentrations of the parent drugs, N-dealkylated metabolites, and fluorinated and further oxidized metabolites of MAM-2201 were measured, and quantitation results revealed site differences between heart and femoral postmortem plasma concentrations of parent drugs and some metabolites, suggesting postmortem redistribution of the synthetic cannabinoids and their metabolites. Quantitation results suggest that defluorination is a major metabolic pathway for MAM-2201, and N-dealkylation is a common but minor pathway for the naphthoylindole-type synthetic cannabinoids in human.	[Zaitsu, Kei; Nakayama, Hiroshi; Yamanaka, Mayumi; Hisatsune, Kazuaki; Taki, Kentaro; Asano, Tomomi; Kusano, Maiko; Tsuchihashi, Hitoshi; Ishii, Akira] Nagoya Univ, Grad Sch Med, Dept Legal Med & Bioeth, Showa Ku, Nagoya, Aichi 4668550, Japan; [Hisatsune, Kazuaki] Forens Sci Lab, Naka Ku, Nagoya, Aichi 4608502, Japan; [Kamata, Tooru; Katagai, Munehiro] Forens Sci Lab, Chuo Ku, Osaka 5410053, Japan; [Hayashi, Yumi] Nagoya Univ, Grad Sch Med, Dept Radiol & Med Lab Sci, Higashi Ku, Nagoya, Aichi 4618673, Japan	Zaitsu, K (reprint author), Nagoya Univ, Grad Sch Med, Dept Legal Med & Bioeth, Showa Ku, 65 tsurumai cho, Nagoya, Aichi 4668550, Japan.	kzaitsu@med.nagoya-u.ac.jp	Ishii, Akira/I-1965-2012		JSPS KAKENHI [30700546]	This work was supported by JSPS KAKENHI Grant Number 30700546.	Hopfgartner G, 2012, ANAL BIOANAL CHEM, V402, P2587, DOI 10.1007/s00216-011-5641-8; Hermanns-Clausen M, 2013, ADDICTION, V108, P534, DOI 10.1111/j.1360-0443.2012.04078.x; ElSohly MA, 2014, LIFE SCI, V97, P78, DOI 10.1016/j.lfs.2013.12.212; Harris CR, 2013, J EMERG MED, V44, P360, DOI 10.1016/j.jemermed.2012.07.061; Hutter M, 2013, J MASS SPECTROM, V48, P885, DOI 10.1002/jms.3229; Kneisel S, 2012, J MASS SPECTROM, V47, P825, DOI 10.1002/jms.3020; Huffman JW, 2003, BIOORGAN MED CHEM, V11, P539, DOI 10.1016/S0968-0896(02)00451-0; Zaitsu K, 2009, FORENSIC SCI INT, V188, P131, DOI 10.1016/j.forsciint.2009.04.001; Kikura-Hanajiri R, 2013, FORENSIC TOXICOL, V31, P44, DOI 10.1007/s11419-012-0165-2; Patton AL, 2013, J FORENSIC SCI, V58, P1676, DOI 10.1111/1556-4029.12216; Fantegrossi WE, 2014, LIFE SCI, V97, P45, DOI 10.1016/j.lfs.2013.09.017; Jang M, 2014, INT J LEGAL MED, V128, P285, DOI 10.1007/s00414-013-0884-x; Esaki H, 2007, J ORG CHEM, V72, P2143, DOI 10.1021/jo062582u; Benard G, 2012, NAT NEUROSCI, V15, P558, DOI 10.1038/nn.3053; Hermanns-Clausen M, 2013, DRUG TEST ANAL, V5, P790, DOI 10.1002/dta.1483; Castaneto MS, 2014, DRUG ALCOHOL DEPEN, V144, P12, DOI 10.1016/j.drugalcdep.2014.08.005; Sobolevsky T, 2012, DRUG TEST ANAL, V4, P745, DOI 10.1002/dta.1418; Saito T, 2013, FORENSIC TOXICOL, V31, P333, DOI 10.1007/s11419-013-0190-9; Zaitsu K, 2008, FORENSIC SCI INT, V177, P77, DOI 10.1016/j.forsciint.2007.11.001; Pelissier-Alicot AL, 2003, J ANAL TOXICOL, V27, P533; Huffman JW, 2005, BIOORGAN MED CHEM, V13, P89, DOI 10.1016/j.bmc.2004.09.050; Funada M, 2014, TOXICOL APPL PHARM, V274, P17, DOI [10.1016/j.taap.2013.10.028, DOI 10.1016/J.TAAP.2013.10.028]; Hebert-Chatelain Etienne, 2014, Mol Metab, V3, P495, DOI 10.1016/j.molmet.2014.03.007; Jang M, 2014, FORENSIC SCI INT, V244, P85, DOI 10.1016/j.forsciint.2014.08.008; Ji N, 2015, FORENSIC TOXICOL, V33, P84, DOI [10.1007/s11419-014-0253-6, DOI 10.1007/S11419-014-0253-6]; Tai S., 2014, CURRENT ADDICTION RE, V1, P129, DOI [10.1007/s40429-014-0014-y, DOI 10.1007/S40429-014-0014-Y]; Young A.C., 2012, AM J EMERG MED, V30, P1320, DOI [DOI 10.1016/J.AJEM.2011.05.013, 10.1016/j.ajem.2011.05.013]; Zaitsu K, 2015, LIFE SCI, V137, P49, DOI 10.1016/j.lfs.2015.05.013	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	NOV	2015	129	6					1233	1245		10.1007/s00414-015-1257-4		13	Medicine, Legal	Legal Medicine	CT5ZG	WOS:000362889200008		
J	Tahara, S; Hara, H; Yamashita, H				Tahara, Shinsaku; Hara, Hirotaka; Yamashita, Hiroshi			Evaluation of body growth in prepubertal Japanese children with obstructive sleep apnea after adenotonsillectomy over a long postoperative period	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						OSA; Child; Growth; Adenotonsillectomy; Height	FACTOR-I; BIOCHEMICAL MARKERS; HORMONE-SECRETION; TONSILLECTOMY; HYPERTROPHY; CHILDHOOD; COGNITION; ENURESIS; BEHAVIOR; OBESE	Objective: The aim of this study was to identify changes in body growth patterns in prepubertal Japanese children with obstructive sleep apnea (OSA) after adenotonsillectomy (AT) over a long postoperative period. Methods: We retrospectively analyzed the hospital records of 69 children, aged 3-10 years with USA, who were followed-up for a median period of 38 months (range, 24-92 months) after AT. Height and weight were measured during the preoperative period and 12, and 24 months postoperatively, data were converted to standard deviation scores (SDS) using current gender- and age-specific values for the growth parameters adopted by the National growth chart of Japan. Comparisons between the pre and postoperative SDS values for height and weight were performed. The numerical data were examined statistically. Results: The SDS for height and weight of Japanese USA children significantly increased 24 months post AT and continued over the entire 24-month follow-up period. Height growth acceleration after AT ended earlier in children of 6.0 1.5 years at the time of AT than in children of 4.7 1.3 years who could not catch-up. Conclusion: In prepubertal Japanese children with USA, AT was effective for the growth of those children over a long postoperative period. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Tahara, Shinsaku; Hara, Hirotaka; Yamashita, Hiroshi] Yamaguchi Univ, Grad Sch Med, Dept Otolaryngol, Ube, Yamaguchi 7558505, Japan	Yamashita, H (reprint author), Yamaguchi Univ, Grad Sch Med, Dept Otolaryngol, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan.	hiro-shi@yamaguchi-u.ac.jp					Selimoglu E, 2003, J INT MED RES, V31, P84; Nieminen P, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.4.e55; BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610; Katz Eliot S, 2008, Proc Am Thorac Soc, V5, P253, DOI 10.1513/pats.200707-111MG; Chervin RD, 2006, PEDIATRICS, V117, pE769, DOI 10.1542/peds.2005-1837; Greenfeld M, 2003, INT J PEDIATR OTORHI, V67, P1055, DOI 10.1016/S0165-5876(03)00182-4; Goodwin JL, 2003, SLEEP, V26, P587; Stewart MG, 2005, ARCH OTOLARYNGOL, V131, P308, DOI 10.1001/archotol.131.4.308; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; Marcus CL, 2012, PEDIATRICS, V130, P576, DOI 10.1542/peds.2012-1671; Kang JM, 2008, INT J PEDIATR OTORHI, V72, P1065, DOI 10.1016/j.ijporl.2008.03.015; Brooks LJ, 2003, J PEDIATR-US, V142, P515, DOI 10.1067/mpd.2003.158; Gozal D, 2008, AM J RESP CRIT CARE, V177, P1142, DOI 10.1164/rccm.200711-1670OC; Bonuck KA, 2009, ARCH DIS CHILD, V94, P83, DOI 10.1136/adc.2008.141192; WEIDER DJ, 1991, OTOLARYNG HEAD NECK, V105, P427; LIND MG, 1982, ARCH OTOLARYNGOL, V108, P650; Bar A, 1999, J PEDIATR-US, V135, P76, DOI 10.1016/S0022-3476(99)70331-8; MARCUS CL, 1994, J PEDIATR-US, V125, P556, DOI 10.1016/S0022-3476(94)70007-9; Amin R, 2008, HYPERTENSION, V51, P84, DOI 10.1161/HYPERTENSIONAHA.107.099762; Li HY, 2006, LARYNGOSCOPE, V116, P1142, DOI 10.1097/01.mlg.0000217542.84013.b5; Aydogan M, 2007, INT J PEDIATR OTORHI, V71, P1737, DOI 10.1016/j.ijport.2007.07.012; Dillon JE, 2007, J AM ACAD CHILD PSY, V46, P1425, DOI 10.1097/chi.0b013e31814b8eb2; Ersoy B, 2005, INT J PEDIATR OTORHI, V69, P1175, DOI 10.1016/j.ijporl.2005.02.020; Mitchell RB, 2007, OTOLARYNG HEAD NECK, V137, P43, DOI 10.1016/j.otohns.2007.03.028; STRADLING JR, 1990, LANCET, V335, P249, DOI 10.1016/0140-6736(90)90068-G; Soultan Z, 1999, ARCH PEDIAT ADOL MED, V153, P33; Montgomery-Downs HE, 2005, EUR RESPIR J, V25, P336, DOI 10.1183/09031936.05.00082904; Fernandes Alexandre Augusto, 2008, Braz J Otorhinolaryngol, V74, P391; FURLANETTO RW, 1990, HORM RES, V33, P25, DOI 10.1159/000181580; Hashemian Farnaz, 2010, Acta Med Iran, V48, P316; Roemmich JN, 2006, PEDIATRICS, V17, P200; Roland PS, 2011, OTOLARYNG HEAD NECK, V145, pS1, DOI 10.1177/0194599811409837; Vontetsianos Harilaos S, 2005, Hormones (Athens), V4, P49; WILLIAMS EF, 1991, OTOLARYNG HEAD NECK, V104, P509	34	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	NOV	2015	79	11					1806	1809		10.1016/j.ijporl.2015.08.005		4	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	CT8MC	WOS:000363069700004		
J	Matsuno, T; Teodosiu, C; Maeda, D; Uenishi, A				Matsuno, Takashi; Teodosiu, Cristian; Maeda, Daisuke; Uenishi, Akihiro			Mesoscale simulation of the early evolution of ductile fracture in dual-phase steels	INTERNATIONAL JOURNAL OF PLASTICITY			English	Article						Fracture; Microcracking; Elastic-plastic material; Finite elements; Dual phase steel	MICROMECHANICAL DEFORMATION; DAMAGE BEHAVIOR; VOID FORMATION; MARTENSITE; INITIATION; NUCLEATION; FAILURE; GROWTH; STRAIN	In this study, finite element simulations synchronized with in-situ tensile tests have identified microstructural damage models in a 600 MPa grade dual-phase steel with 10% martensite volume fraction. Firstly, in-situ tensile tests have been carried out on a double-notched, flat-plate, tensile specimen. These experiments have shown that the damage in this steel is dominated, up to moderate tensile strains, by fracture of the martensite islands and decohesion at the martensite/ferrite interfaces. Secondly, FE simulations have been conducted, by using 2.5D meshes that were adjusted to the real shape of the martensite islands, as revealed by the micrographs. The ductile fracture of the martensite was described by a three-parameter fracture envelope defined by Bao and Wierzbicki, where the equivalent strain to fracture is expressed as function of the stress triaxiality. The stiffness of the ferrite/martensite interfaces has been described by a four-parameter cohesive model of Xu-Needleman type. The comparison of the experimentally determined sequence of damage events with the FE simulations has allowed adjusting the damage parameters of the model and validating them up to equivalent plastic strains exceeding locally 0.60. After determination of the damage parameters, the event sequence of martensite fracture and ferrite/martensite decohesion, as well as the pattern of the strain localization in the ferrite phase, were quite satisfactorily predicted by the FE simulations. Furthermore, the results obtained have shown that the martensite fracture and the interface decohesion have a significant influence on the stress and strain partitioning between the two phases, and hence also on the pattern and intensity of the strain localization and on the void growth and coalescence during the subsequent deformation stages. (C) 2015 Elsevier Ltd. All rights reserved.	[Matsuno, Takashi; Maeda, Daisuke; Uenishi, Akihiro] Nippon Steel & Sumitomo Met Corp, Futtsu, Chiba, Japan; [Teodosiu, Cristian] ADESCO Serv SRL, Bucharest, Romania	Matsuno, T (reprint author), Nippon Steel & Sumitomo Met Corp, 20-1 Shintomi, Futtsu, Chiba, Japan.	matsuno.8m7.takashi@jp.nssmc.com					Alves J.L., 2011, P S VCAD SYST RES PR, P165; Alves J.L., 2010, P S VCAD SYST RES PR, P64; Matsuno T, 2014, ISIJ INT, V54, P938, DOI 10.2355/isijinternational.54.938; Chung K, 2011, INT J PLASTICITY, V27, P1485, DOI 10.1016/j.ijplas.2011.01.007; KAWKA M, 1995, J MATER PROCESS TECH, V50, P105, DOI 10.1016/0924-0136(94)01373-9; Xue L, 2009, ENG FRACT MECH, V76, P419, DOI 10.1016/j.engfracmech.2008.11.010; Landron C, 2010, SCRIPTA MATER, V63, P973, DOI 10.1016/j.scriptamat.2010.07.021; Ghadbeigi H, 2010, MAT SCI ENG A-STRUCT, V527, P5026, DOI 10.1016/j.msea.2010.04.052; Xue L, 2007, INT J SOLIDS STRUCT, V44, P5163, DOI 10.1016/j.ijsolstr.2006.12.026; Kadkhodapour J, 2011, INT J PLASTICITY, V27, P1103, DOI 10.1016/j.ijplas.2010.12.001; Uthaisangsuk V, 2008, COMP MATER SCI, V43, P27, DOI 10.1016/j.commatsci.2007.07.035; Kim JH, 2010, MAT SCI ENG A-STRUCT, V527, P7353, DOI 10.1016/j.msea.2010.07.099; Kim JH, 2010, COMP MATER SCI, V47, P785, DOI 10.1016/j.commatsci.2009.11.004; Maire E, 2008, ACTA MATER, V56, P4954, DOI 10.1016/j.actamat.2008.06.015; Haddadi H, 1999, COMP MATER SCI, V16, P315, DOI 10.1016/S0927-0256(99)00074-9; Bao YB, 2004, INT J MECH SCI, V46, P81, DOI 10.1016/j.ijmecsci.2004.02.006; Landron C, 2013, ACTA MATER, V61, P6821, DOI 10.1016/j.actamat.2013.07.058; Khan AS, 2012, INT J PLASTICITY, V30-31, P1, DOI 10.1016/j.ijplas.2011.08.004; Ramazani A, 2013, INT J PLASTICITY, V43, P128, DOI 10.1016/j.ijplas.2012.11.003; Uthaisangsuk V, 2011, ENG FRACT MECH, V78, P469, DOI 10.1016/j.engfracmech.2010.08.017; XU XP, 1993, MODEL SIMUL MATER SC, V1, P111, DOI 10.1088/0965-0393/1/2/001; Choi SH, 2013, INT J PLASTICITY, V45, P85, DOI 10.1016/j.ijplas.2012.11.013; Xue L, 2008, ENG FRACT MECH, V75, P3276, DOI 10.1016/j.engfracmech.2007.08.012; Kadkhodapour J, 2011, ACTA MATER, V59, P2575, DOI 10.1016/j.actamat.2010.12.039; Azuma M, 2012, MATER SCI TECH-LOND, V28, P1092, DOI 10.1179/1743284712Y.0000000006; Sun X, 2009, MAT SCI ENG A-STRUCT, V526, P140, DOI 10.1016/j.msea.2009.08.010; Lee J, 2012, MAT SCI ENG A-STRUCT, V536, P231, DOI 10.1016/j.msea.2012.01.003; Sun X, 2009, INT J PLASTICITY, V25, P1888, DOI 10.1016/j.ijplas.2008.12.012; Choi SH, 2014, INT J PLASTICITY, V58, P184, DOI 10.1016/j.ijplas.2013.11.010; Avramovic-Cingara G, 2009, MAT SCI ENG A-STRUCT, V516, P7, DOI 10.1016/j.msea.2009.03.055; Avramovic-Cingara G, 2009, METALL MATER TRANS A, V40A, P3117, DOI 10.1007/s11661-009-0030-z; Azuma M., 2013, THESIS TU DENMARK; Bhattacharya D., 2010, P MAT SCI TECHN MS T, P1804; Brown LM, 1973, P 3 INT C STRENGTH M, P164; Edelson B.I., 1962, T ASM, V55, P230; Esmaeili N., 2011, P S VCAD SYST RES PR, P169; LEROY G, 1981, ACTA METALL MATER, V29, P1509, DOI 10.1016/0001-6160(81)90185-1; Oliver S., 2007, MATER CHARACT, V58, P39; PARK IG, 1988, ACTA METALL MATER, V36, P1653, DOI 10.1016/0001-6160(88)90232-5; Takahashi M., 2003, NIPPON STEEL TECHNIC, V88, P2; Tasan CC, 2014, INT J PLASTICITY, V63, P198, DOI 10.1016/j.ijplas.2014.06.004; Yamamura N., 2001, P NUMIFORM 2001 JEJ, P699	42	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0749-6419	1879-2154		INT J PLASTICITY	Int. J. Plast.	NOV	2015	74						17	34		10.1016/j.ijplas.2015.06.004		18	Engineering, Mechanical; Materials Science, Multidisciplinary; Mechanics	Engineering; Materials Science; Mechanics	CT6KS	WOS:000362922500002		
J	Chen, WL; Okumiya, K; Wada, T; Sakamoto, R; Imai, H; Ishimoto, Y; Kimura, Y; Fukutomi, E; Fujisawa, M; Shih, HI; Chang, CM; Matsubayashi, K				Chen, Wenling; Okumiya, Kiyohito; Wada, Taizo; Sakamoto, Ryota; Imai, Hissei; Ishimoto, Yasuko; Kimura, Yumi; Fukutomi, Eriko; Fujisawa, Michiko; Shih, Hsin-I; Chang, Chia-Ming; Matsubayashi, Kozo			Social cohesion and health in old age: a study in southern Taiwan	INTERNATIONAL PSYCHOGERIATRICS			English	Article						social cohesion and trust; ADL; GDS; QOL; elderly; health; happiness; Taiwan	QUALITY-OF-LIFE; COMMUNITY; JAPAN; NEIGHBORHOOD; ADULTS; PEOPLE; MULTILEVEL; FRAILTY; INCOME; SCALE	Background: Previous studies have found that social cohesion and trust (SCT) were associated with psychological well-being and physical health. In this study, we investigated the associations between SCT and mental and physical health among community-dwelling elderly in a town in southern Taiwan. Methods: The study population consisted of 149 community-dwelling elderly aged 65 years and older (68 men, 81 women; mean age, 75.4 +/- 6.1 years) residing in the town of Dashe in southern Taiwan. Activities of daily living (ADL), SCT, depression, subjective quality of life (QOL), current medical status, past medical history, and health behaviors were assessed in face-to-face interviews. Objective neurobehavioral functions were assessed using the timed up & go (TUG) test, functional reach test, and handgrip test. Results: Scores for ADL and Geriatric Depression Scale (GDS) were significantly correlated with SCT, and SCT was significantly correlated with all subjective QOL items. In addition, a strong correlation was observed between SCT and relationship with friends. Values for SCT (median >= 20) were significantly associated with both subjective sense of health (median >= 68) and subjective happiness (median >= 73) after adjusting for age, sex, and ADL. Conclusion: SCT is an important variable that influences self-rated health and happiness, independently of ADL, age, and sex. When assessing geriatric psychological function, SCT should be examined more carefully, given its association with subjective sense of health and happiness, depression, and physical function.	[Chen, Wenling; Fukutomi, Eriko; Matsubayashi, Kozo] Kyoto Univ, Sch Publ Hlth, Dept Field Med, Kyoto 6068501, Japan; [Okumiya, Kiyohito; Wada, Taizo; Ishimoto, Yasuko; Kimura, Yumi; Fujisawa, Michiko; Matsubayashi, Kozo] Kyoto Univ, Ctr Southeast Asian Studies, Kyoto 6068501, Japan; [Sakamoto, Ryota] Kyoto Univ, Hakubi Ctr, Kyoto 6068501, Japan; [Imai, Hissei] Kyoto Univ, Grad Sch Med, Dept Field Med, Kyoto 6068501, Japan; [Shih, Hsin-I; Chang, Chia-Ming] Natl Cheng Kung Univ, Coll Med, Tainan 70101, Taiwan	Chen, WL (reprint author), Kyoto Univ, Ctr Southeast Asian Studies, Sakyo Ku, 46 Shimoadachi Cho, Kyoto 6068501, Japan.	chenwingling@gmail.com					Hirosaki M, 2011, GERIATR GERONTOL INT, V11, P531, DOI 10.1111/j.1447-0594.2011.00697.x; Chen WL, 2013, GERIATR GERONTOL INT, V13, P63, DOI 10.1111/j.1447-0594.2012.00859.x; Phongsavan P, 2006, SOC SCI MED, V63, P2546, DOI 10.1016/j.socscimed.2006.06.021; Matsubayashi K, 2012, GERIATR GERONTOL INT, V12, P5, DOI 10.1111/j.1447-0594.2011.00738.x; WEINER DK, 1992, J AM GERIATR SOC, V40, P203; Inoue S, 2013, AM J PUBLIC HEALTH, V103, pE60, DOI 10.2105/AJPH.2013.301311; Ziersch AM, 2005, SOC SCI MED, V60, P71, DOI 10.1016/j.socscimed.2004.04.027; Kawachi I, 1999, ANN NY ACAD SCI, V896, P120, DOI 10.1111/j.1749-6632.1999.tb08110.x; Matsubayashi K, 1997, LANCET, V350, P1521, DOI 10.1016/S0140-6736(05)63944-X; Young AF, 2004, SOC SCI MED, V59, P2627, DOI 10.1016/j.socscimed.2004.05.001; Kandula NR, 2009, AM J PUBLIC HEALTH, V99, P885, DOI 10.2105/AJPH.2007.131854; Chan J, 2006, SOC INDIC RES, V75, P273, DOI 10.1007/s11205-005-2118-1; Sakamoto R, 2011, J AM GERIATR SOC, V59, P2157, DOI 10.1111/j.1532-5415.2011.03638.x; Ichida Y, 2009, SOC SCI MED, V69, P489, DOI 10.1016/j.socscimed.2009.05.006; Matsubayashi K, 1999, LANCET, V353, P1445, DOI 10.1016/S0140-6736(05)75972-9; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; YESAVAGE JA, 1988, PSYCHOPHARMACOL BULL, V24, P709; Okumiya K, 1996, J AM GERIATR SOC, V44, P569; Elliott J, 2014, SOC SCI MED, V107, P44, DOI 10.1016/j.socscimed.2014.02.027; Rowe JW, 1997, GERONTOLOGIST, V37, P433; Huang HL, 2003, PSYCHIAT CLIN NEUROS, V57, P275, DOI 10.1046/j.1440-1819.2003.01117.x; Aoyama M, 2011, GERIATR GERONTOL INT, V11, P348, DOI 10.1111/j.1447-0594.2010.00685.x; Russell C, 1998, AUST NZ J PUBL HEAL, V22, P98, DOI 10.1111/j.1467-842X.1998.tb01152.x; MORRISON DP, 1983, ACTA PSYCHIAT SCAND, V68, P408, DOI 10.1111/j.1600-0447.1983.tb00948.x; Ho HK, 2002, GERIATR GERONTOL INT, V2, P80, DOI 10.1046/j.1444-1586.2002.00026.x; Mui A C, 1996, Int Psychogeriatr, V8, P445, DOI 10.1017/S1041610296002803; National Statistics, 2013, RES POP 5 YEAR 10 YE; Nieboer A. P., 2013, ARCH GERONTOL GERIAT, V44, P50, DOI [10.1007/s12439-013-0010-z, DOI 10.1007/S12439-013-0010-Z]; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142; Ku LJE, 2013, ARCH GERONTOL GERIAT, V56, P370, DOI 10.1016/j.archger.2012.11.005; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165	31	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1041-6102	1741-203X		INT PSYCHOGERIATR	Int. Psychogeriatr.	NOV	2015	27	11					1903	1911		10.1017/S1041610214002907		9	Psychology, Clinical; Geriatrics & Gerontology; Gerontology; Psychiatry; Psychology	Psychology; Geriatrics & Gerontology; Psychiatry	CT8CZ	WOS:000363043900016		
J	Mudjupa, C; Abdelhamed, S; Refaat, A; Yokoyama, S; Saiki, I; Vajragupta, O				Mudjupa, Chawannuch; Abdelhamed, Sherif; Refaat, Alaa; Yokoyama, Satoru; Saiki, Ikuo; Vajragupta, Opa			Lead compound bearing caffeic scaffold induces EGFR suppression in solid tumor cancer cells	JOURNAL OF APPLIED BIOMEDICINE			English	Article						Caffeic acid derivatives; EGFR inhibitor; Triple-negative breast cancer; Non-small cell lung cancer; Molecular modeling	GROWTH-FACTOR RECEPTOR; ACID PHENETHYL ESTER; TYROSINE KINASE INHIBITORS; HUMAN BREAST-CANCER; NF-KAPPA-B; LUNG ADENOCARCINOMA CELLS; DERIVATIVES; ACTIVATION; RESISTANCE; EXPRESSION	A small molecule EGFR inhibitor, 4-(2-(3-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)ureido)vinyl)-1,2-phenylene diacetate (CIU1) was designed in silico by using caffeic scaffold as core structure. The designed compound showed anti-proliferative action against different solid tumor cell lines, particularly metastatic breast cancer cells. CIU1 inhibited the growth of EGFR-overexpressing MDA-MB-468 triple-negative breast cancer cells and wild-type non-small-cell lung cancer H460 cells with IC50 values of 8.96 mu M and 12.98 mu M, respectively, these anti-proliferative effects of CIU1 were comparable to gefitinib (a specific EGFR inhibitor) or lapatinib (a dual EGFR and HER2 tyrosine kinase inhibitor). Interestingly CIU1 effectively inhibited the invasive hormone-dependent MCF-7 cancer cells with an IC50 2.34 mu M. The immunoblot analyses revealed that CIU1 induced programmed cell death and suppressed EGFR expression in EGFR-overexpressing breast cancer (MDA-MB468) and lung cancer (PC-9) cells. The findings substantiated our design strategy and demonstrated the potential of CIU1 as new lead for further optimization in the development of anticancer drugs against advanced solid tumors. (C) 2015 Faculty of Health and Social Studies, University of South Bohemia in Ceske Budejovice. Published by Elsevier Sp. z o.o. All rights reserved.	[Mudjupa, Chawannuch; Vajragupta, Opa] Mahidol Univ, Fac Pharm, Dept Pharmaceut Chem, Bangkok 10400, Thailand; [Abdelhamed, Sherif; Refaat, Alaa; Yokoyama, Satoru; Saiki, Ikuo] Toyama Univ, Inst Nat Med, Div Pathogen Biochem, Toyama 9300194, Japan; [Vajragupta, Opa] Mahidol Univ, Fac Pharm, Ctr Excellence Innovat Drug Design & Discovery, Bangkok 10400, Thailand	Vajragupta, O (reprint author), Mahidol Univ, Fac Pharm, Ctr Excellence Innovat Drug Design & Discovery, 447 Sri Ayudya Rd, Bangkok 10400, Thailand.	opa.vaj@mahidol.ac.th		Refaat, Alaa/0000-0002-7821-2500	Office of the High Education Commission under the National Research University; Mahidol University under the National Research University; Office of the Higher Education Commission, Ministry of Education, Thailand [CHE-PhD-THA 2551]	This work was supported by the Office of the High Education Commission and Mahidol University under the National Research Universities to O.V. and The Office of the Higher Education Commission, Ministry of Education, Thailand (CHE-PhD-THA 2551) to C.M.	Wang XY, 2009, BIOPHARM DRUG DISPOS, V30, P221, DOI 10.1002/bdd.657; Zhang GH, 2013, BIOCHEM PHARMACOL, V86, P1721, DOI 10.1016/j.bcp.2013.10.013; Okabe T, 2007, CANCER RES, V67, P2046, DOI 10.1158/0008-5472.CAN-06-3339; Licciulli S, 2013, J BIOL CHEM, V288, P29105, DOI 10.1074/jbc.M113.510933; Liao HF, 2003, J AGR FOOD CHEM, V51, P7907, DOI 10.1021/jf034729d; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Dassonville O, 2007, CRIT REV ONCOL HEMAT, V62, P53, DOI 10.1016/j.critrevonc.2006.12.008; Lund MJ, 2009, BREAST CANCER RES TR, V113, P357, DOI 10.1007/s10549-008-9926-3; Sanphanya K, 2013, BIOORG MED CHEM LETT, V23, P2962, DOI 10.1016/j.bmcl.2013.03.042; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Jung BI, 2010, PHYTOTHER RES, V24, P295, DOI 10.1002/ptr.2966; Wheeler S, 2012, CLIN CANCER RES, V18, P2278, DOI 10.1158/1078-0432.CCR-11-1593; Defaux J, 2014, CHEMMEDCHEM, V9, P217, DOI 10.1002/cmdc.201300384; Normanno N, 2006, J CELL PHYSIOL, V207, P420, DOI 10.1002/jcp.20588; Serafim TL, 2011, CHEM RES TOXICOL, V24, P763, DOI 10.1021/tx200126r; Nagaria TS, 2013, NEOPLASIA, V15, P939, DOI 10.1593/neo.13804; Anido J, 2003, CLIN CANCER RES, V9, P1274; Onori P, 2009, INT J CANCER, V125, P565, DOI 10.1002/ijc.24271; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Yoshikawa S, 2013, ONCOGENE, V32, P27, DOI 10.1038/onc.2012.21; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Goffin E, 2012, EUR J MED CHEM, V54, P834, DOI 10.1016/j.ejmech.2012.06.050; Alvarez RH, 2010, J CLIN ONCOL, V28, P3366, DOI 10.1200/JCO.2009.25.4011; Tsai CM, 2013, MOL PHARMACEUT, V10, P1890, DOI 10.1021/mp3006648; Itabashi H, 2008, HEPATOL RES, V38, P601, DOI 10.1111/j.1872-034X.2007.00304.x; Yang J, 2012, J MED CHEM, V55, P10685, DOI 10.1021/jm301365e; Lin HP, 2013, INT J MOL SCI, V14, P5264, DOI 10.3390/ijms14035264; Chen YJ, 2001, J AGR FOOD CHEM, V49, P5615, DOI 10.1021/jf0107252; Son S, 2002, J AGR FOOD CHEM, V50, P468, DOI 10.1021/jf010830b; Ferrer-Soler L, 2007, INT J MOL MED, V20, P3; Chen MF, 2004, J RADIAT RES, V45, P253, DOI 10.1269/jrr.45.253; Watabe M, 2004, J BIOL CHEM, V279, P6017, DOI 10.1074/jbc.M306040200; Wang HH, 2013, BIOORGAN MED CHEM, V21, P448, DOI 10.1016/j.bmc.2012.11.020; Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222; Walter AO, 2013, CANCER DISCOV, V3, P1404, DOI 10.1158/2159-8290.CD-13-0314; Crozier A, 2009, NAT PROD REP, V26, P1001, DOI 10.1039/b802662a; Gao S, 2010, MINI-REV MED CHEM, V10, P550; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017; Hassan GS, 2012, BIOORG MED CHEM LETT, V22, P6318, DOI 10.1016/j.bmcl.2012.08.095; Lin HP, 2012, PHYTOTHER RES, V26, P122, DOI 10.1002/ptr.3523; Tu CY, 2014, BIOMED RES INT, DOI 10.1155/2014/168949; Wu J, 2011, CANCER LETT, V308, P43, DOI 10.1016/j.canlet.2011.04.012; Zhang M, 2013, MED CHEM RES, V22, P986, DOI 10.1007/s00044-012-0093-z; Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039; Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634; FOX SB, 1994, BREAST CANCER RES TR, V29, P41, DOI 10.1007/BF00666180; Li HQ, 2010, BIOORGAN MED CHEM, V18, P305, DOI 10.1016/j.bmc.2009.10.054; Selvaggi G, 2004, ANN ONCOL, V15, P28, DOI 10.1093/annonc/mdh011; Sanphanya K, 2012, BIOORG MED CHEM LETT, V22, P3001, DOI 10.1016/j.bmcl.2012.02.029; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057; Yen GC, 2011, EUR J PHARM SCI, V44, P281, DOI 10.1016/j.ejps.2011.08.006; Chou CW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018087; Foley John, 2010, Semin Cell Dev Biol, V21, P951, DOI 10.1016/j.semcdb.2010.08.009; Gandhi J., 2009, PLOS ONE, V4, P24; Gong H.C., 2011, INT J PROTEOMICS, V2011, DOI DOI 10.1155/2011/215496; Ho Bing-Ying, 2012, J Tradit Complement Med, V2, P301; Kaur P., 2012, BMC CANCER, V12, P1471; Matsuo Teppei, 2011, BMC Res Notes, V4, P140, DOI 10.1186/1756-0500-4-140; Metro Giulio, 2006, Rev Recent Clin Trials, V1, P1, DOI 10.2174/157488706775246157; Nowsheen S., 2012, PLOS ONE, V7, P11; O'Neill F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-41; Omene C, 2013, J CANC SCI THER, V5, P334	65	0	0	UNIV SOUTH BOHEMIA	CESKA BUDEJOVICE	FAC HEALTH & SOCIAL STUD, JIROVCOVA, CESKA BUDEJOVICE, 370 04, CZECH REPUBLIC	1214-021X	1214-0287		J APPL BIOMED	J. Appl. Biomed.	NOV	2015	13	4					305	317		10.1016/j.jab.2015.05.001		13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	CT7GR	WOS:000362983300007		
J	Sanematsu, K; Kon, Y; Imai, A				Sanematsu, Kenzo; Kon, Yoshiaki; Imai, Akira			Influence of phosphate on mobility and adsorption of REEs during weathering of granites in Thailand	JOURNAL OF ASIAN EARTH SCIENCES			English	Article						REE; Phosphate; Granite; Weathering; Adsorption; Thailand	RARE-EARTH-ELEMENTS; MAINLAND SOUTHEAST-ASIA; JIANGXI PROVINCE; LATERITIC PROFILE; TRACE-ELEMENTS; APATITE DISSOLUTION; ACCESSORY PHASES; FELSIC MAGMAS; ROCKS; FRACTIONATION	The Permo-Jurassic North Thai (NT) Granites and the Late Cretaceous to Paleogene Western Province (WP) Granites in Thailand are contrasting in terms of tectonic settings and chemical compositions. The NT Granites, which are dominated by S-type features, are characterized by lower SiO2 contents and higher P2O5 contents than the WP Granites in this study. In order to compare the mobility and adsorption of rare earth elements (REEs) during weathering of the two granite suites, geochemical analyses were conducted on the granite and weathered granites. The weathered WP Granites show wider ranges of REEs + Y (REY) contents, percentages of ion-exchangeable REY and Ce anomalies than the weathered NT Granites. These results indicate that REEs were less mobile during weathering of the NT Granites than those of the WP Granites. The low mobility of REEs can be explained by the occurrences of residual monazite and secondary REE phosphates which immobilize REEs during weathering. Therefore, in the weathered NT Granites, REEs are mostly contained in the phosphate minerals. In contrast, the weathered WP Granites are dominated by ion-exchangeable REEs (adsorbed REEs) which are likely to exist on the surface of clays. Previous studies and our study results suggest that the ion-exchangeable REEs in the weathered granites were probably sourced from weatherable allanite, titanite, apatite and/or REE fluorocarbonate, and rarely from monazite and zircon, which are resistant to weathering. The weathered granites of low phosphate contents potentially show high percentages of ion-exchangeable REY, although they can be influenced by the degree of hydrothermal alteration or weathering of granites. (C) 2015 Elsevier Ltd. All rights reserved.	[Sanematsu, Kenzo; Kon, Yoshiaki] Natl Inst Adv Ind Sci & Technol, Geol Survey Japan, Tsukuba, Ibaraki 3058567, Japan; [Sanematsu, Kenzo] Univ Tasmania, ARC Ctr Excellence Ore Deposits CODES, Hobart, Tas 7001, Australia; [Imai, Akira] Akita Univ, Dept Resource Earth Sci, Akita 0108502, Japan	Sanematsu, K (reprint author), Natl Inst Adv Ind Sci & Technol, Geol Survey Japan, Cent 7,1-1-1 Higashi, Tsukuba, Ibaraki 3058567, Japan.	k-sanematsu@aist.go.jp			Japan Society for Promotion of Science (JSPS) [19253005]	We express gratitude to Prof. Koichiro Watanabe, Dr. Yoshinobu Motomura and the students of Kyushu University and Chulalongkorn University for supporting fieldworks in Thailand and XRF analysis. We are grateful to Dr. Karsten Goemann and Dr. Sandrin Feig at the Central Science Laboratory in University of Tasmania for supporting the SEM works. We are also grateful to two anonymous reviewers for reading our manuscript and giving constructive comments. This study was supported by the Grant-in-Aid for Scientific Research (B) of No. 19253005 and Postdoctoral Fellowships for Research Abroad, that were funded by the Japan Society for Promotion of Science (JSPS).	Frost BR, 2001, J PETROL, V42, P2033, DOI 10.1093/petrology/42.11.2033; Yusoff ZM, 2013, CHEM GEOL, V349, P71, DOI 10.1016/j.chemgeo.2013.04.016; SCHWARTZ MO, 1995, EARTH-SCI REV, V38, P95, DOI 10.1016/0012-8252(95)00004-T; Du X, 2012, CHEM GEOL, V330, P101, DOI 10.1016/j.chemgeo.2012.08.030; Prowatke S, 2005, GEOCHIM COSMOCHIM AC, V69, P695, DOI 10.1016/j.gca.2004.06.037; WATSON EB, 1980, EARTH PLANET SC LETT, V51, P322, DOI 10.1016/0012-821X(80)90214-9; Zaw K, 2014, GONDWANA RES, V26, P5, DOI 10.1016/j.gr.2013.10.010; BEA F, 1994, GEOCHIM COSMOCHIM AC, V58, P2609, DOI 10.1016/0016-7037(94)90132-5; Oelkers EH, 2008, MINERAL MAG, V72, P337, DOI 10.1180/minmag.2008.072.1.337; Aubert D, 2002, GEOCHIM COSMOCHIM AC, V66, P3339, DOI 10.1016/S0016-7037(02)00913-4; Oelkers EH, 2002, CHEM GEOL, V191, P73, DOI 10.1016/S0009-2541(02)00149-3; BEA F, 1992, LITHOS, V29, P43, DOI 10.1016/0024-4937(92)90033-U; Moldoveanu GA, 2012, HYDROMETALLURGY, V117, P71, DOI 10.1016/j.hydromet.2012.02.007; WU CY, 1990, ACTA GEOL SIN-ENGL, V3, P193; BRAUN JJ, 1994, CATENA, V21, P173, DOI 10.1016/0341-8162(94)90010-8; Ishihara S, 2008, RESOUR GEOL, V58, P355, DOI 10.1111/j.1751-3928.2008.00070.x; BRAUN JJ, 1990, GEOCHIM COSMOCHIM AC, V54, P781, DOI 10.1016/0016-7037(90)90373-S; Hoskin PWO, 2003, REV MINERAL GEOCHEM, V53, P27, DOI 10.2113/0530027; Harlavan Y, 2002, GEOCHIM COSMOCHIM AC, V66, P837, DOI 10.1016/S0016-7037(01)00806-7; HUANG DH, 1989, ACTA GEOL SIN-ENGL, V2, P139; WATSON EB, 1981, GEOCHIM COSMOCHIM AC, V45, P2349, DOI 10.1016/0016-7037(81)90088-0; Nesbitt HW, 1997, GEOCHIM COSMOCHIM AC, V61, P1653; WATSON EB, 1979, GEOPHYS RES LETT, V6, P937, DOI 10.1029/GL006i012p00937; Broska I, 2005, LITHOS, V82, P71, DOI 10.1016/j.lithos.2004.12.007; Kohler SJ, 2005, CHEM GEOL, V222, P168, DOI 10.1016/j.chemgeo.2005.07.011; Berger A, 2008, CHEM GEOL, V254, P238, DOI 10.1016/j.chemgeo.2008.03.006; Sone M, 2008, CR GEOSCI, V340, P166, DOI 10.1016/j.crte.2007.09.008; Tyler G, 2004, PLANT SOIL, V267, P191, DOI 10.1007/s11104-005-4888-2; NESBITT HW, 1982, NATURE, V299, P715, DOI 10.1038/299715a0; Oliva P, 2004, GEOCHIM COSMOCHIM AC, V68, P2223, DOI 10.1016/j.gca.2003.10.043; MONTEL JM, 1993, CHEM GEOL, V110, P127, DOI 10.1016/0009-2541(93)90250-M; Macdonald AS, 2010, J ASIAN EARTH SCI, V37, P82, DOI 10.1016/j.jseaes.2009.07.010; Sanematsu K, 2013, MINER DEPOSITA, V48, P437, DOI 10.1007/s00126-011-0380-5; Sone M, 2012, J ASIAN EARTH SCI, V61, P16, DOI 10.1016/j.jseaes.2012.08.021; Giere R, 2004, REV MINERAL GEOCHEM, V56, P431, DOI 10.2138/gsrmg.56.1.431; Kawakami T, 2014, LITHOS, V200, P64, DOI 10.1016/j.lithos.2014.04.012; Marques JJ, 2004, GEODERMA, V121, P31, DOI 10.1016/j.geoderma.2003.10.003; Aubert D, 2001, GEOCHIM COSMOCHIM AC, V65, P387, DOI 10.1016/S0016-7037(00)00546-9; HUTCHISON CS, 1983, GEOL SOC AM MEM, V159, P35; Chi R, 2005, J RARE EARTH, V23, P756; BANFIELD JF, 1989, CLAY CLAY MINER, V37, P113, DOI 10.1346/CCMN.1989.0370202; RAPP RP, 1986, CONTRIB MINERAL PETR, V94, P304, DOI 10.1007/BF00371439; GREEN TH, 1986, CHEM GEOL, V55, P105, DOI 10.1016/0009-2541(86)90131-2; Dunning GR, 1995, TECTONOPHYSICS, V251, P197, DOI 10.1016/0040-1951(95)00037-2; WOLF MB, 1994, GEOCHIM COSMOCHIM AC, V58, P4127, DOI 10.1016/0016-7037(94)90269-0; Braun JJ, 1998, GEOCHIM COSMOCHIM AC, V62, P273, DOI 10.1016/S0016-7037(97)00344-X; BRAUN JJ, 1993, GEOCHIM COSMOCHIM AC, V57, P4419, DOI 10.1016/0016-7037(93)90492-F; Chappell BW, 1999, LITHOS, V46, P535, DOI 10.1016/S0024-4937(98)00086-3; Laveuf C, 2009, GEODERMA, V154, P1, DOI 10.1016/j.geoderma.2009.10.002; PICHAVANT M, 1992, GEOCHIM COSMOCHIM AC, V56, P3855, DOI 10.1016/0016-7037(92)90178-L; Bao ZW, 2008, ORE GEOL REV, V33, P519, DOI 10.1016/j.oregeorev.2007.03.005; MONTEL JM, 1986, GEOLOGY, V14, P659, DOI 10.1130/0091-7613(1986)14<659:EDOTSO>2.0.CO;2; RAPP RP, 1987, GEOPHYS RES LETT, V14, P307, DOI 10.1029/GL014i003p00307; Middleton AW, 2013, CHEM GEOL, V335, P105, DOI 10.1016/j.chemgeo.2012.10.047; Hua RM, 2007, ACTA PETROL SIN, V23, P2321; [Anonymous], 2013, BULL GEOL SURV JPN; Imai A, 2013, RESOUR GEOL, V63, P84, DOI 10.1111/j.1751-3928.2012.00212.x; NESBITT HW, 1979, NATURE, V279, P206, DOI 10.1038/279206a0; Berger A, 2014, APPL GEOCHEM, V41, P218, DOI 10.1016/j.apgeochem.2013.12.013; Gnandi K, 2003, J AFR EARTH SCI, V37, P1, DOI 10.1016/j.jafrearsci.2003.08.002; Taunton AE, 2000, CHEM GEOL, V169, P371, DOI 10.1016/S0009-2541(00)00215-1; Murakami T, 2001, EARTH PLANET SC LETT, V184, P523, DOI 10.1016/S0012-821X(00)00344-7; Bea F, 1996, J PETROL, V37, P521, DOI 10.1093/petrology/37.3.521; Stille P, 2009, CHEM GEOL, V264, P173, DOI 10.1016/j.chemgeo.2009.03.005; BECKINSALE RD, 1979, J GEOL SOC LONDON, V136, P529, DOI 10.1144/gsjgs.136.5.0529; Besang C., 1975, P CCOP SEM RAD AG DA; Chappell B.W., 1974, PAC GEOL, V8, P173; Charusiri P., 1993, J SE ASIAN EARTH SCI, V8, P127, DOI 10.1016/0743-9547(93)90014-G; Charusiri P., 2006, J GEOL SOC THAIL, V1, P57; COBBING E. J., 1992, BRIT GEOLOGICAL SURV, V10, P369; Cobbing EJ, 2011, GEOLOGY OF THAILAND, P441; Cobbing E.J., 1986, J GEOLOGICAL SOC LON, V128, P421; CONDIE KC, 1995, GEOCHIM COSMOCHIM AC, V59, P279, DOI 10.1016/0016-7037(94)00280-Y; Darbyshire D.P.F., 1988, 885 NAT ENV RES COUN, P1; Deer W.A., 1982, ROCK FORMING MINER A, V1A, P444; Duddy L.R., 1980, CHEM GEOL, V30, P363, DOI 10.1016/0009-2541(80)90102-3; Geological Survey of Japan, 1994, REP INT RES DEV COOP; GRANDJEANLECUYER P, 1993, GEOCHIM COSMOCHIM AC, V57, P2507, DOI 10.1016/0016-7037(93)90413-Q; Harrison T.M., 1984, GEOCHIM COSMOCHIM AC, V48, P1468; Hutchison C.S., 1977, GEOL SOC MALAY B, V9, P197; HUTTON CO, 1950, GEOL SOC AM BULL, V61, P635; IMAI N, 1995, GEOSTANDARD NEWSLETT, V19, P135, DOI 10.1111/j.1751-908X.1995.tb00158.x; Ishihara S, 2008, P INT S GEOSC RES EN, P31; ISHIHARA S, 1980, MINING GEOL, V8, P223; Ishihara S, 2008, P INT S GEOSC RES EN, P238; Isnmara S., 1977, MIN GEOL, V27, P293; Janots E, 2015, GEOCHIM COSMOCHIM AC, V153, P134, DOI 10.1016/j.gca.2015.01.009; MacDonald A. S., 1993, J SE ASIAN EARTH SCI, V8, P117, DOI 10.1016/0743-9547(93)90013-F; Maneenai D., 1993, J SE ASIAN EARTH SCI, V8, P359, DOI 10.1016/0743-9547(93)90037-P; Mitchell A.H.G., 1977, GEOLOGICAL SOC MALAY, V9, P123; MONGELLI G, 1993, CHEM GEOL, V103, P17, DOI 10.1016/0009-2541(93)90288-T; NUTALAYA P, 1979, GEOL SOC MALAY B, V11, P137; Orris G.J., 2002, 02189 US GEOL SURV; Papangelakis V.G., 2014, P 1 RAR EARTH RES C, P215; Roskill, 2011, RARE EARTHS YTTRIUM; Kumar GRR, 2010, INDIAN J MAR SCI, V39, P562; Sun S. S., 1989, GEOL SOC SPEC PUBL, V42, P313, DOI DOI 10.1144/GSL.SP.1989.042.01.19; Tian J., 2009, WEATHERED CRUST ELUT; VONBRAUN E, 1976, GEOL JB B, V21, P171; Watanabe Y., 2015, REV EC GEOL, P18; Wu C, 1994, J SE ASIAN EARTH SCI, V10, P81, DOI 10.1016/0743-9547(94)90010-8; Xiao G.M., 2011, GEOL RESOUR, V20, P462; Yang Y, 1981, B CHIN ACAD GEOL SCI, V12, P102; Yuan Z.X., 1993, CHINESE J GEOCHEMIST, V12, P193	104	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1367-9120	1878-5786		J ASIAN EARTH SCI	J. Asian Earth Sci.	NOV 1	2015	111						14	30		10.1016/j.jseaes.2015.05.018		17	Geosciences, Multidisciplinary	Geology	CT2AB	WOS:000362603300002		
J	Ichihashi, RJ; Zaman, H; Wada, Y; Sugamori, Y; Kajikawa, Y; Ahn, HS; Uno, K; Zimin, PS; Sakhno, VG; Otofuji, Y				Ichihashi, Ryutaro J.; Zaman, Haider; Wada, Yutaka; Sugamori, Yoshiaki; Kajikawa, Yohei; Ahn, Hyeon-Seon; Uno, Koji; Zimin, Petr S.; Sakhno, Vladimir G.; Otofuji, Yo-ichiro			Paleomagnetic evidence for post-Early Cretaceous tectonic rotation of the Sikhote-Alin Superterrane, Far East Russia	JOURNAL OF ASIAN EARTH SCIENCES			English	Article						Tectonics; Paleomagnetism; Early Cretaceous; Asian Continent; Zhuravlevka-Amur Terrane; Far East Russia	MONGOL-OKHOTSK OCEAN; BLOCK ROTATION; FOLD TEST; TERRANE; ROCKS; SEDIMENTS; SYSTEM; PYRITE; BASIN; ASIA	We present new Early Cretaceous paleomagnetic results from the Zhuravlevka-Amur Terrane of the Eurasian Continent, Far East Russia. Out of 34 total sites, 14 were collected from Komsomolsk-on-Amur area (50.6 degrees N, 137.2 degrees E) and 20 from Vaninsky area (49.1 degrees N, 139.2 degrees E). Thermal demagnetization reveals the presence of two interpretable magnetization components in 19 sites, with laboratory unblocking temperatures of 350 degrees C and/or 500-580 degrees C. The remanent directions of the low-temperature component are either parallel or anti-parallel to those obtained from the high-temperature component. Results of fold tests show that both components are secondary. Rock magnetic and reflected light microscopic observations indicate a chemical origin for both of these components, as evident from the presence of secondary pyrrhotite and magnetite. The Komsomolsk-on-Amur area provides an in-situ formation mean direction of D = 127.5 degrees, I = 66.7 degrees (k = 28.2, alpha(95) = 9.3 degrees, N= 10 sites). When combined with the reported paleomagnetic data from Early to Middle Cretaceous accretionary wedge rocks of the Kiselevka-Manoma Terrane and the Early Cretaceous Western Sakhalin turbidite basin rocks (D = 94.2 degrees and D = 57.1 degrees, respectively), large magnitude of clockwise rotations of 66-118 degrees is demonstrated for the eastern part of the Sikhote-Alin Superterrane with respect to Eurasia. In addition, these three landmasses maintained their E-W elongated orientations before the start of rotation, implying southward directed subduction of the oceanic plates beneath northern margins. These reconstructions of the Sikhote-Alin Superterrane provide clues on the tectonic evolution of Panthalassa Ocean. (C) 2015 Elsevier Ltd. All rights reserved.	[Ichihashi, Ryutaro J.; Kajikawa, Yohei; Ahn, Hyeon-Seon; Otofuji, Yo-ichiro] Kobe Univ, Fac Sci, Dept Earth & Planetary Sci, Kobe, Hyogo 657, Japan; [Zaman, Haider] Taibah Univ, Dept Geol, Fac Sci, Madinah 41477, Saudi Arabia; [Wada, Yutaka] Nara Univ Educ, Dept Earth Sci, Nara 6308528, Japan; [Sugamori, Yoshiaki] Osaka City Univ, Fac Sci, Dept Geosci, Osaka 558, Japan; [Uno, Koji] Okayama Univ, Grad Sch Educ, Kita Ku, Okayama 7008530, Japan; [Zimin, Petr S.] Russian Acad Sci, Pacific Oceanol Inst, Vladivostok 690022, Russia; [Sakhno, Vladimir G.] Russian Acad Sci, Far E Geol Inst, Vladivostok 690022, Russia	Otofuji, Y (reprint author), Kobe Univ, Fac Sci, Dept Earth & Planetary Sci, Kobe, Hyogo 657, Japan.	otofuji@kobe-u.ac.jp			'21st Century COE Program of Origin and Evolution of Planetary Systems' through the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT); Toyota Foundation; MEXT [18403012, 22403012]	Comments from Rob Van der Voo, John Geissman, Baochun Huang and anonymous reviewers have improved this manuscript. We thank H. Inokuchi, K. Takemoto, K. Takaba and S. Sato for their help during the sampling trip. This work is supported by 'The 21st Century COE Program of Origin and Evolution of Planetary Systems' through the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT). In addition, this research is partly supported by Toyota Foundation and Grant-in aid from MEXT (Nos. 18403012 and 22403012).	Besse J, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000050; van der Meer DG, 2012, NAT GEOSCI, V5, P215, DOI [10.1038/ngeo1401, 10.1038/NGEO1401]; Malinovsky AI, 2008, ISL ARC, V17, P285, DOI 10.1111/j.1440-1738.2008.00619.x; OTOFUJI Y, 1995, EARTH PLANET SC LETT, V130, P95, DOI 10.1016/0012-821X(94)00254-V; Rowan CJ, 2009, EARTH PLANET SC LETT, V277, P223, DOI 10.1016/j.epsl.2008.10.016; Kelty TK, 2008, TECTONOPHYSICS, V451, P290, DOI 10.1016/j.tecto.2007.11.052; FAURE M, 1995, TECTONOPHYSICS, V241, P279, DOI 10.1016/0040-1951(94)00186-D; SCHREURS G, 1994, GEOLOGY, V22, P567, DOI 10.1130/0091-7613(1994)022<0567:EOSSFA>2.3.CO;2; MCFADDEN PL, 1990, GEOPHYS J INT, V103, P163, DOI 10.1111/j.1365-246X.1990.tb01761.x; Didenko AN, 2014, RUSS J PAC GEOL, V8, P18, DOI 10.1134/S1819714014010023; Kojima S, 2008, ISL ARC, V17, P502, DOI 10.1111/j.1440-1738.2008.00644.x; Weaver R, 2002, EARTH PLANET SC LETT, V200, P371, DOI 10.1016/S0012-821X(02)00652-0; LAJ C, 1991, NATURE, V351, P447, DOI 10.1038/351447a0; Brothers LA, 1996, CHEM GEOL, V130, P1, DOI 10.1016/0009-2541(96)00007-1; NUR A, 1986, GEOLOGY, V14, P746, DOI 10.1130/0091-7613(1986)14<746:FMATKO>2.0.CO;2; Zyabrev SV, 2013, RUSS J PAC GEOL, V7, P217, DOI 10.1134/S1819714013030081; Utkin VP, 2012, DOKL EARTH SCI, V444, P687, DOI 10.1134/S1028334X12060074; Zyabrev SV, 2011, RUSS J PAC GEOL, V5, P313, DOI 10.1134/S1819714011040087; Khanchuk AI, 2004, DOKL EARTH SCI, V395, P165; GARFUNKEL Z, 1985, J GEOPHYS RES-SOLID, V90, P8589, DOI 10.1029/JB090iB10p08589; Roberts AP, 2005, EARTH PLANET SC LETT, V231, P263, DOI 10.1016/j.epsl.2004.11.024; Kravchinsky VA, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000672; Kato K, 2006, GEOSCI J, V10, P275, DOI 10.1007/BF02910370; Matsuda T, 1998, RESOUR GEOL, V48, P285, DOI 10.1111/j.1751-3928.1998.tb00025.x; RON H, 1986, GEOLOGY, V14, P1020, DOI 10.1130/0091-7613(1986)14<1020:SFABRI>2.0.CO;2; Abrajevitch A, 2012, GEOPHYS J INT, V190, P1439, DOI 10.1111/j.1365-246X.2012.05572.x; Kemkin IV, 2012, J ASIAN EARTH SCI, V61, P88, DOI 10.1016/j.jseaes.2012.09.024; LOWRIE W, 1990, GEOPHYS RES LETT, V17, P159, DOI 10.1029/GL017i002p00159; LENNIE AR, 1995, AM MINERAL, V80, P960; Love JJ, 1998, J GEOPHYS RES-SOL EA, V103, P12435, DOI 10.1029/97JB03745; KARLIN R, 1983, NATURE, V303, P327, DOI 10.1038/303327a0; SCHOONEN MAA, 1991, GEOCHIM COSMOCHIM AC, V55, P3491, DOI 10.1016/0016-7037(91)90050-F; MCELHINNY MW, 1964, GEOPHYS J ROY ASTR S, V8, P338; Finlay CC, 2010, GEOPHYS J INT, V183, P1216, DOI 10.1111/j.1365-246X.2010.04804.x; KIRSCHVINK JL, 1980, GEOPHYS J ROY ASTR S, V62, P699, DOI 10.1111/j.1365-246X.1980.tb02601.x; Woods SD, 2000, J GEOCHEM EXPLOR, V69, P381, DOI 10.1016/S0375-6742(00)00080-7; Cogne JP, 2005, GEOPHYS J INT, V163, P813, DOI 10.1111/j.1365-246X.2005.02782.x; Alenicheva AA, 2008, DOKL EARTH SCI, V419, P217, DOI 10.1134/S1028334X08020062; Kirillova GL, 2011, DOKL EARTH SCI, V436, P1, DOI 10.1134/S1028334X1090112X; BERNER RA, 1984, GEOCHIM COSMOCHIM AC, V48, P605, DOI 10.1016/0016-7037(84)90089-9; Cogne J.P., 2013, GEOPHYS J INT, V192, P1000; FISHER R, 1953, PROC R SOC LON SER-A, V217, P295, DOI 10.1098/rspa.1953.0064; Kemkin IV, 2001, GEODIVERSITAS, V23, P323; Khanchuk A. I., 2001, CHIKYU KAGAKU, V55, P275; Khanchuk A.I., 2006, GEODYNAMICS MAGMATIS; Kirillova G.L., 2002, UPPER JURASSIC CRETA, P37; Kodama K.P., 2012, PALEOMAGNETISM SEDIM; Natal'in B. A., 1993, ISL ARC, V2, P15, DOI [10.1111/j.1440-1738.1993.tb00072.x, DOI 10.1111/J.1440-1738.1993.TB00072.X]; Roberts A.P., 2006, EARTH PLANET SC LETT, V241, P119; Robinson S.G., 2000, SEDIMENT GEOL, V143, P91; Toni M., 1996, GEOPHYS RES LETT, V23, P1813; Zijderveld J., 1967, METHODS PALEOMAGNETI, P254; Zonenshain LP, 1990, AM GEOPHYSICAL UNION, V21, P242	53	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1367-9120	1878-5786		J ASIAN EARTH SCI	J. Asian Earth Sci.	NOV 1	2015	111						88	99		10.1016/j.jseaes.2015.08.008		12	Geosciences, Multidisciplinary	Geology	CT2AB	WOS:000362603300007		
J	Okuzaki, Y; Sugawara, H; Sota, T				Okuzaki, Yutaka; Sugawara, Hisashi; Sota, Teiji			Body size evolution under character release in the ground beetle Carabus japonicus	JOURNAL OF BIOGEOGRAPHY			English	Article						Character displacement; converse Bergmann's rule; genital evolution; introgressive hybridization; Japan; molecular phylogenetic analyses; reproductive interference	MECHANICAL REPRODUCTIVE ISOLATION; PHYLOGENETIC ANALYSIS; SUBGENUS OHOMOPTERUS; GENITAL MORPHOLOGY; GENUS CARABUS; DISPLACEMENT; MITOCHONDRIAL; SPECIATION; HYBRIDIZATION; STICKLEBACKS	AimWe tested the hypothesis of character release in body size among allopatric populations of the carabid beetle Carabus japonicus by analysing geographical variation in body size in relation to habitat temperature and sympatry/allopatry with the larger congeneric species Carabus dehaanii. LocationThe main and satellite islands of Kyushu in the south-western part of the Japanese archipelago. MethodsWe studied geographical variation in the body length and genital size of C. japonicus populations at different sites to examine the effects of both habitat temperature and sympatry/allopatry with C. dehaanii. To determine whether the conditions for character release were fulfilled, we then estimated the heritable differences in body size by common garden rearing, and estimated the phylogenetic relationships among populations by molecular phylogenetic analysis. ResultsWhile body size was positively correlated with annual mean temperature, it was consistently small in sympatry but larger in some allopatric populations in warmer regions. The body size differences among populations were heritable. Allopatric C. japonicus populations on satellite islands were derived from the sympatric mainland populations. In a few sympatric areas, mitochondrial haplotypes were shared between the species because of introgressive hybridization, suggesting the occurrence of reproductive interference between the species. We also found that genital size was not affected by sympatry/allopatry, but was positively correlated with body size. Main conclusionsWe demonstrated that the increased body size of allopatric C. japonicus has evolved through a character release process. However, not all allopatric populations had enlarged body size, thus suggesting that some additional environmental factors are also involved. Geographical differentiation in body size and associated genital dimensions may result in prezygotic reproductive isolation among populations and promote allopatric differentiation leading to speciation.	[Okuzaki, Yutaka] Hokkaido Univ, Field Sci Ctr Northen Biosphere, Kita Ku, Sapporo, Hokkaido 0600811, Japan; [Sugawara, Hisashi; Sota, Teiji] Kyoto Univ, Grad Sch Sci, Dept Zool, Sakyo Ku, Kyoto 6068502, Japan	Okuzaki, Y (reprint author), Hokkaido Univ, Field Sci Ctr Northen Biosphere, Kita Ku, Sapporo, Hokkaido 0600809, Japan.	yutaka@fsc.hokudai.ac.jp			JSPS [21418, 253158, 23370011, 26251044]; Fujiwara Natural History Foundation [19 (2011)]	We thank M. Hori, Y. Takami, N. Nagata and the members of Laboratory of Animal Ecology, Kyoto University for advice and discussion, T. Saitoh, C. Terada and members of Field Science Center, Hokkaido University for rearing, and A. Ueda and people in Kyushu for sampling. We also thank K. Parr, W. Blanckenhorn, A. Giesen and two anonymous referees for their comments on our manuscript. This study was supported by JSPS KAKENHI grant no. 21418 and 253158 to Y.O. and 23370011 and 26251044 to T.S., and Fujiwara Natural History Foundation grant no. 19 (2011) to Y.O.	Andujar C, 2012, BMC EVOL BIOL, V12, DOI 10.1186/1471-2148-12-40; Meiri S, 2011, J ANIM ECOL, V80, P824, DOI 10.1111/j.1365-2656.2011.01827.x; SCHLUTER D, 1992, AM NAT, V140, P85, DOI 10.1086/285404; SOTA T, 1985, ECOL ENTOMOL, V10, P315, DOI 10.1111/j.1365-2311.1985.tb00728.x; Groning J, 2008, Q REV BIOL, V83, P257, DOI 10.1086/590510; Kubota K, 1998, RES POPUL ECOL, V40, P213, DOI 10.1007/BF02763406; Sota T, 1998, EVOLUTION, V52, P1507, DOI 10.2307/2411321; Meiri S, 2007, J BIOGEOGR, V34, P2148, DOI 10.1111/j.1365-2699.2007.01771.x; Robinson BW, 2000, ECOLOGY, V81, P2799, DOI 10.1890/0012-9658(2000)081[2799:APAOCR]2.0.CO;2; Sota T, 2001, SYST BIOL, V50, P39, DOI 10.1080/106351501750107459; Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033; Simberloff D, 2000, ECOLOGY, V81, P2086, DOI 10.1890/0012-9658(2000)081[2086:CDARIT]2.0.CO;2; Rice AM, 2007, J EVOLUTION BIOL, V20, P448, DOI 10.1111/j.1420-9101.1187.01187.x; Funk DJ, 2003, ANNU REV ECOL EVOL S, V34, P397, DOI 10.1146/annurev.ecolsys.34.011802.132421; Ballard JWO, 2004, MOL ECOL, V13, P729, DOI 10.1046/j.1365-294X.2003.02063.x; Grether GF, 2009, BIOL REV, V84, P617, DOI 10.1111/j.1469-185X.2009.00089.x; SCHLUTER D, 1995, AM NAT, V146, P292, DOI 10.1086/285799; Boughman JW, 2005, EVOLUTION, V59, P361; Takami Y, 2002, ZOOL SCI, V19, P1067, DOI 10.2108/zsj.19.1067; Takahashi T, 2014, MOL PHYLOGENET EVOL, V80, P137, DOI 10.1016/j.ympev.2014.07.016; Okuzaki Y, 2010, J ANIM ECOL, V79, P383, DOI 10.1111/j.1365-2656.2009.01645.x; Taylor EB, 2000, P ROY SOC B-BIOL SCI, V267, P2375; Sota T, 2000, POPUL ECOL, V42, P279, DOI 10.1007/PL00012006; Sota T, 2003, MOL PHYLOGENET EVOL, V26, P139, DOI 10.1016/S1055-7903(02)00311-1; Tsuchiya Y, 2012, J EVOLUTION BIOL, V25, P1835, DOI 10.1111/j.1420-9101.2012.02568.x; Mousseau TA, 1998, TRENDS ECOL EVOL, V13, P403, DOI 10.1016/S0169-5347(98)01472-4; Radtkey RR, 1997, P NATL ACAD SCI USA, V94, P9740, DOI 10.1073/pnas.94.18.9740; Rice AM, 2008, J EVOLUTION BIOL, V21, P696, DOI 10.1111/j.1420-9101.2008.01518.x; Eberhard WG, 1998, EVOLUTION, V52, P415, DOI 10.2307/2411078; Sota T, 2008, PHILOS T R SOC B, V363, P3377, DOI 10.1098/rstb.2008.0111; BROWN WL, 1956, SYST ZOOL, V5, P49, DOI 10.2307/2411924; Funk DJ, 2006, P NATL ACAD SCI USA, V103, P3209, DOI 10.1073/pnas.0508653103; Dayan T, 1998, MAMMAL REV, V28, P99, DOI 10.1046/j.1365-2907.1998.00029.x; Wojcieszek JM, 2013, ECOL EVOL, V3, P334, DOI 10.1002/ece3.466; ROFF D, 1980, OECOLOGIA, V45, P202, DOI 10.1007/BF00346461; Su ZH, 1996, J MOL EVOL, V42, P124, DOI 10.1007/BF02198837; MASAKI S, 1967, EVOLUTION, V21, P725, DOI 10.2307/2406770; Aubret F, 2012, AM NAT, V179, P756, DOI 10.1086/665653; Pfennig DW, 2000, EVOLUTION, V54, P1738; Grant PR, 2006, SCIENCE, V313, P224, DOI 10.1126/science.1128374; Excoffier L, 2005, EVOL BIOINFORM, V1, P47; Blanckenhorn WU, 2004, INTEGR COMP BIOL, V44, P413, DOI 10.1093/icb/44.6.413; Nagata N, 2007, MOL ECOL, V16, P4822, DOI 10.1111/j.1365-294X.2007.03569.x; Tanabe T, 2008, AM NAT, V171, P692, DOI 10.1086/587075; Kubota K, 2013, POPUL ECOL, V55, P35, DOI 10.1007/s10144-012-0335-4; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Falconer DS, 1989, INTRO QUANTITATIVE G; Felsenstein J, 2004, PHYLIP PHYLOGENY INF; GRANT P R, 1972, Biological Journal of the Linnean Society, V4, P39, DOI 10.1111/j.1095-8312.1972.tb00690.x; ISHIKAWA R, 1987, Kontyu, V55, P202; Mizusawa K, 2013, THE CARABUS OF JAPAN; Pfennig KS, 2009, Q REV BIOL, V84, P253; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; SOTA T, 1985, Kontyu, V53, P370; Sota Teiji, 2002, Japanese Journal of Entomology (New Series), V5, P88	55	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-0270	1365-2699		J BIOGEOGR	J. Biogeogr.	NOV	2015	42	11					2145	2158		10.1111/jbi.12575		14	Ecology; Geography, Physical	Environmental Sciences & Ecology; Physical Geography	CT5FJ	WOS:000362833700011		
J	Komaki, S; Igawa, T; Lin, SM; Tojo, K; Min, MS; Sumida, M				Komaki, Shohei; Igawa, Takeshi; Lin, Si-Min; Tojo, Koji; Min, Mi-Sook; Sumida, Masayuki			Robust molecular phylogeny and palaeodistribution modelling resolve a complex evolutionary history: glacial cycling drove recurrent mtDNA introgression among Pelophylax frogs in East Asia	JOURNAL OF BIOGEOGRAPHY			English	Article						distributional change; East Asia; EPIC primer; glacial cycling; mtDNA introgression; Palaeoarctic region; palaeodistribution; Pelophylax frogs; phylogenetic discordance	MITOCHONDRIAL-DNA; POND FROGS; PHYLOGEOGRAPHY; POPULATIONS; MARKERS; NIGROMACULATA; HYBRIDIZATION; EXTINCTION; DIVERSITY; SEQUENCES	AimPelophylax frogs in East Asia provide an opportunity to explore the impact of glacial cycling on demographic and genetic dynamics, because it has been suggested that they experienced distribution shifts and subsequent mtDNA introgression from Pelophylax plancyi to Pelophylax nigromaculatus in association with climatic oscillations. However, their evolutionary history, including the pattern of introgression, is incompletely understood. We used phylogenetic analyses based on multiple markers to address their evolutionary history, and palaeodistribution modelling to test whether the predicted distribution can explain the pattern of introgression suggested by molecular phylogenetics. LocationEast Asia, including far-eastern Russia, mainland China, the Japanese archipelago, the Korean Peninsula and Taiwan. MethodsNinety-nine samples of the Pelophylax nigromaculatus species complex were collected from 75 localities throughout the distributional range of each species. Phylogenetic analyses were performed with the mitochondrial cytochrome b (cytb) gene and six nuclear genes using two European Pelophylax frogs as outgroups. Additionally, palaeodistributions of P.nigromaculatus and P.plancyi were predicted using bioclimatic variables. ResultsDifferences were observed between the mitochondrial and nuclear DNA trees in the phylogenetic position of P.plancyi. Similar phylogenetic discordance was also observed within P.nigromaculatus. Distribution modelling suggested that a considerable distributional shift of P.nigromaculatus occurred in association with glacial cycling and that the distributional range of P.plancyi was relatively narrow during glacial periods. Main conclusionsThe analyses detected five historical mtDNA introgression events and determined their directions, none of which had been deduced in previous studies. In association with glacial cycling, the distributional ranges of P.nigromaculatus and P.plancyi appear to have shifted repeatedly, resulting in multiple complex introgressions. By combining phylogenetic analyses with palaeodistribution modelling, our results supported the hypothesis that the history of mtDNA introgression among Pelophylax frogs was shaped by glacial cycling.	[Komaki, Shohei; Igawa, Takeshi; Sumida, Masayuki] Hiroshima Univ, Inst Amphibian Biol, Grad Sch Sci, Higashihiroshima, Hiroshima 7398526, Japan; [Lin, Si-Min] Natl Taiwan Normal Univ, Dept Life Sci, Taipei 116, Taiwan; [Tojo, Koji] Shinshu Univ, Fac Sci, Dept Biol, Matsumoto, Nagano 3908621, Japan; [Tojo, Koji] Shinshu Univ, Inst Mt Sci, Matsumoto, Nagano 3908621, Japan; [Min, Mi-Sook] Seoul Natl Univ, Coll Vet Med, Seoul 151747, South Korea	Igawa, T (reprint author), Hiroshima Univ, Grad Sch Int Dev & Cooperat, Higashihiroshima 7398529, Japan.	tigawa@hiroshima-u.ac.jp	Igawa, Takeshi/E-2881-2014	Igawa, Takeshi/0000-0001-6880-6180	Ministry of Education, Culture, Sports, Science and Technology, Japan [24310173, 20510216]; Japan Society for the Promotion of Science [25-5065]	We are grateful to Jinzhong Fu and his colleagues for providing valuable samples of Pelophylax frogs. We also thank Tomoya Suzuki and Kensuke Kobayashi for their field assistance and Atsushi Kurabayashi for providing chemicals for the experiment. This study was supported by Grants-in-Aid for Scientific Research (B and C) (numbers 24310173 and 20510216) from the Ministry of Education, Culture, Sports, Science and Technology, Japan to M.S. and a Grant-in-Aid for JSPS Fellows (number 25-5065) from Japan Society for the Promotion of Science to S.K.	Akn C., 2010, J BIOGEOGR, V37, P2111, DOI DOI 10.1111/J.1365-2699.2010.02368.X; Tanabe AS, 2011, MOL ECOL RESOUR, V11, P914, DOI 10.1111/j.1755-0998.2011.03021.x; Toews DPL, 2012, MOL ECOL, V21, P3907, DOI 10.1111/j.1365-294X.2012.05664.x; Bossuyt F, 2000, P NATL ACAD SCI USA, V97, P6585, DOI 10.1073/pnas.97.12.6585; Castresana J, 2000, MOL BIOL EVOL, V17, P540; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BRM.41.4.1149; Schorr G, 2013, J BIOGEOGR, V40, P1947, DOI 10.1111/jbi.12132; Stern DL, 2013, NAT REV GENET, V14, P751, DOI 10.1038/nrg3483; Edwards S, 2009, MOL ECOL, V18, P2930, DOI 10.1111/j.1365-294X.2009.04270.x; Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075; Sequeira F, 2006, AMPHIBIA-REPTILIA, V27, P409, DOI 10.1163/156853806778190114; Rhymer JM, 1996, ANNU REV ECOL SYST, V27, P83, DOI 10.1146/annurev.ecolsys.27.1.83; Komaki S, 2012, ZOOL SCI, V29, P351, DOI 10.2108/zsj.29.351; Chen W, 2009, MOL ECOL, V18, P2856, DOI 10.1111/j.1365-294X.2009.04258.x; Komaki S, 2014, GENES GENET SYST, V89, P35; Qian H, 2000, NATURE, V407, P180, DOI 10.1038/35025052; Igawa T, 2006, MOL PHYLOGENET EVOL, V38, P250, DOI 10.1016/j.ympev.2005.09.003; Sakaguchi S, 2012, MOL ECOL, V21, P3823, DOI 10.1111/j.1365-294X.2012.05652.x; Mao XG, 2013, MOL ECOL, V22, P1035, DOI 10.1111/mec.12154; Kim JB, 2004, ZOOL SCI, V21, P39, DOI 10.2108/0289-0003(2004)21[39:NOADIM]2.0.CO;2; Warren DL, 2010, ECOGRAPHY, V33, P607, DOI 10.1111/j.1600-0587.2009.06142.x; Rand DM, 2004, TRENDS ECOL EVOL, V19, P645, DOI 10.1016/j.tree.2004.10.003; Ronquist F, 2012, SYST BIOL, V61, P539, DOI 10.1093/sysbio/sys029; Zhan AB, 2011, MOL PHYLOGENET EVOL, V61, P136, DOI 10.1016/j.ympev.2011.06.009; Sumida M, 1998, GENES GENET SYST, V73, P121, DOI 10.1266/ggs.73.121; Melo-Ferreira J, 2012, SYST BIOL, V61, P367, DOI 10.1093/sysbio/syr114; Phillips SJ, 2006, ECOL MODEL, V190, P231, DOI 10.1016/j.ecolmodel.2005.03.026; Lougheed SC, 1999, P ROY SOC B-BIOL SCI, V266, P1829; Ikeda H, 2013, ZOOL SCI, V30, P901, DOI 10.2108/zsj.30.901; Jouzel J, 2007, SCIENCE, V317, P793, DOI 10.1126/science.1141038; Whitlock MC, 2000, EVOLUTION, V54, P1855; Lymberakis P, 2007, MOL PHYLOGENET EVOL, V44, P115, DOI 10.1016/j.ympev.2007.03.009; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Stock M, 2012, MOL PHYLOGENET EVOL, V65, P1, DOI 10.1016/j.ympev.2012.05.014; Chen DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047268; Jobb G, 2011, TREEFINDER VERSION M; Li CH, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-90; Liu K, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-201; Matsui M., 1996, NATURAL HIST AMPHIBI; Miura M., 2014, BMC EVOLUTIONARY BIO, V14, P209; NISHIOKA M, 1992, Scientific Report of the Laboratory for Amphibian Biology Hiroshima University, V11, P1; Rambaut A, 2013, TRACER MCMC TRACE AN; Sequeira F, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-264; NISHIOKA M, 1992, Scientific Report of the Laboratory for Amphibian Biology Hiroshima University, V11, P71; Tanabe A. S., 2008, PHYLOGEARS VERSION 2, V10, P22; TING HP, 1951, COPEIA, P120; Unmack PJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090061; Zhang H, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-21; Zielinski P, 2013, MOL ECOL, V22, P1884, DOI 10.1111/mec.12225	50	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-0270	1365-2699		J BIOGEOGR	J. Biogeogr.	NOV	2015	42	11					2159	2171		10.1111/jbi.12584		13	Ecology; Geography, Physical	Environmental Sciences & Ecology; Physical Geography	CT5FJ	WOS:000362833700012		
J	Murotani, K; Zhou, B; Kaneda, H; Nakatani, E; Kojima, S; Nagai, Y; Fukushima, M				Murotani, Kenta; Zhou, Bin; Kaneda, Hideaki; Nakatani, Eiji; Kojima, Shinsuke; Nagai, Yoji; Fukushima, Masanori			SURVIVAL OF CENTENARIANS IN JAPAN	JOURNAL OF BIOSOCIAL SCIENCE			English	Article							LIFE EXPECTANCY; ADVANCED AGES; G7 COUNTRIES; MORTALITY; COMPRESSION; REDUCTIONS; DEMOGRAPHY; PATTERN; SWEDEN	The objective of the study was to explore the survival trends of centenarians in Japan. A cohort of centenarians born between 1881 and 1900 was analysed based on national census data, and the average life expectancy at 100 years of age, risk of death and maximum age were estimated. An analysis of covariance and a Cox regression analysis were performed to explore the factors associated with life expectancy and risk of death. The death rates in centenarians tended to decrease with birth year, and the average life expectancy from the age of 100 slightly increased at a rate of 0.013 years (95% CI: 0.007-0.019) by birth year in men and 0.026 in women. Women had a longer life expectancy than men, with a difference of 0.174 years (95% CI: 0.071-0.277) at birth year 1881 and increasing by 0.013 years per year thereafter. The risk of death in both sexes decreased significantly by birth year over the course of the period analysed, and the risk of death in men was 1.16 (95% CI: 1.14-1.19) times that of women. In women, death rates at every age significantly decreased with birth year over the course of the period analysed until age 104. However, this trend did not hold true for ages 105 and older. The average life expectancy of centenarians at the age of 100 in Japan increased by birth year in the 18811900 birth cohort. In addition, Japanese centenarians had the lowest death rates among several countries.	[Murotani, Kenta; Zhou, Bin; Kaneda, Hideaki; Nakatani, Eiji; Kojima, Shinsuke; Nagai, Yoji; Fukushima, Masanori] Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Kobe, Hyogo, Japan; [Nakatani, Eiji] Kyoto Univ Hosp, Dept Clin Trial Design & Management, Translat Res Ctr, Kyoto 606, Japan	Zhou, B (reprint author), Fdn Biomed Res & Innovat, Translat Res Informat Ctr, Kobe, Hyogo, Japan.	zhoubin@tri-kobe.org					Yang SM, 2012, SOC SCI MED, V75, P1280, DOI 10.1016/j.socscimed.2012.04.026; Rau R, 2008, POPUL DEV REV, V34, P747, DOI 10.1111/j.1728-4457.2008.00249.x; Oeppen J, 2002, SCIENCE, V296, P1029, DOI 10.1126/science.1069675; Liu Y, 2013, GERIATR GERONTOL INT, V13, P792, DOI 10.1111/ggi.12001; Trovato F, 2007, CAN REV SOC ANTHROP, V44, P101; Wilmoth JR, 2000, SCIENCE, V289, P2366, DOI 10.1126/science.289.5488.2366; Tuljapurkar S, 2000, NATURE, V405, P789, DOI 10.1038/35015561; Olshansky SJ, 2001, SCIENCE, V291, P1491, DOI 10.1126/science.291.5508.1491; Lynch SM, 2001, DEMOGRAPHY, V38, P79, DOI 10.2307/3088290; Trovato F, 2006, J BIOSOC SCI, V38, P391, DOI 10.1017/S0021932005007212; Robine JM, 2003, EXP GERONTOL, V38, P735, DOI 10.1016/S0531-5565(03)00100-1; Thatcher AR, 2010, DEMOGR RES, V22, P505; HORIUCHI S., 1991, POPULATION B UN, V31-2, P38; Jeune B., 1995, ODENSE MONOGRAPHS PO, V2, P109; Kannisto V., 1994, DEV OLDEST OLD MORTA; KANNISTO V, 1994, POPUL DEV REV, V20, P793, DOI 10.2307/2137662; Krach C. A., 1999, CENTENARIANS US; MANTON KG, 1995, NEW ENGL J MED, V333, P1232, DOI 10.1056/NEJM199511023331824; MHLW, 2011, CURR STAT CENT; MHLW, 2010, DEM 2010 JAP; Poulain M., 2001, POPULATION, V13, P117; Robine J. M., 2010, CURR GERONTOL GERIAT, V2010, DOI [10.1155/2010/120354, DOI 10.1155/2010/120354]; Vaupel J. W., 1996, FUTURE POPULATION WO, P278; Vaupel J. W., 1998, FORCE MORTALITY AGES; WHO, 2013, WHO LIF EXP DAT WHO	25	1	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0021-9320	1469-7599		J BIOSOC SCI	J. Biosoc. Sci.	NOV	2015	47	6					707	717		10.1017/S0021932014000388		11	Demography; Public, Environmental & Occupational Health; Social Sciences, Biomedical	Demography; Public, Environmental & Occupational Health; Biomedical Social Sciences	CT5HY	WOS:000362840800001		
J	Suzuki, K				Suzuki, Keishun			Legal enforcement against illegal imitation in developing countries	JOURNAL OF ECONOMICS			English	Article						Illegal imitation; Intellectual property rights enforcement; Import prohibition	INTELLECTUAL PROPERTY-RIGHTS; FOREIGN DIRECT-INVESTMENT; PATENT PROTECTION; INNOVATION; WELFARE; GROWTH	This study investigates the effect of intellectual property rights (IPR) enforcement in a developing country on imitation, innovation, economic growth, and welfare using a North-South quality ladder model. Unlike existing studies, this study explicitly distinguishes IPR protection and IPR enforcement by incorporating illegal imitation and seizure activity into the model. The four main results are, first, a higher seizure rate does not always decrease imitation rate in the South. Second, a higher seizure rate does not always encourage innovation in the North. Third, although a sufficiently high seizure rate is required to enhance economic growth, such a policy reform would deteriorates welfare in both the North and South. Finally, unlike seizure, prohibiting imports of illegal imitations from the South always lowers illegal imitation.	Tohoku Univ, Grad Sch Econ & Management, Aoba Ku, Sendai, Miyagi 980, Japan; [Suzuki, Keishun] Japan Soc Promot Sci, Tokyo, Japan	Suzuki, K (reprint author), Tohoku Univ, Grad Sch Econ & Management, Aoba Ku, 27-1 Kawauchi, Sendai, Miyagi 980, Japan.	keishun.suzuki@gmail.com			 [25-10619]	I would like to thank Ryo Horii, Akiomi Kitagawa, Masao Nakagawa, Koki Oikawa, Hitoshi Tanaka, all participants in the 2013 Fall Meeting of the Japan Economic Association at Kanagawa University, and anonymous referees for their helpful comments and suggestions. This study was financially supported by Grant-in-Aid for Japan Society for the Promotion of Science Fellows (No. 25-10619). Of course, all remaining errors are my own.	Gustafsson P, 2011, INT ECON REV, V52, P1123, DOI 10.1111/j.1468-2354.2011.00662.x; Akiyama T, 2009, ECON LETT, V103, P138, DOI 10.1016/j.econlet.2009.03.006; Horii R, 2007, J ECON, V90, P45, DOI 10.1007/s00712-006-0222-6; Iwaisako T, 2011, EUR ECON REV, V55, P1137, DOI 10.1016/j.euroecorev.2011.05.001; Sinha UB, 2006, J ECON, V88, P211, DOI 10.1007/s00712-006-0192-8; Furukawa Y, 2007, J ECON DYN CONTROL, V31, P3644, DOI 10.1016/j.jedc.2007.01.011; Park WG, 2008, RES POLICY, V37, P761, DOI 10.1016/j.respol.2008.01.006; Glass AJ, 2002, J INT ECON, V56, P387, DOI 10.1016/S0022-1996(01)00117-9; MANSFIELD E, 1981, ECON J, V91, P907, DOI 10.2307/2232499; Grossman G., 1991, INNOVATION GROWTH GL; HELPMAN E, 1993, ECONOMETRICA, V61, P1247, DOI 10.2307/2951642; Hori T, 2011, WORKING PAPER; Sener F, 2006, WORKING PAPER; The Japan External Trade Organization, 2008, CAS REP OFF IPR INFR; The Japan Ministry of Economy Trade and Industry, 2012, ANN REP COUNS SERV I; The U. S. International Trade Commission, 2011, CHIN EFF INT PROP IN	16	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0931-8658	1617-7134		J ECON	J. Econ.	NOV	2015	116	3					247	270		10.1007/s00712-015-0436-6		24	Economics	Business & Economics	CT7ZJ	WOS:000363034200004		
J	Miyoshi, J; Miyamoto, H; Goji, T; Taniguchi, T; Tomonari, T; Sogabe, M; Kimura, T; Kitamura, S; Okamoto, K; Fujino, Y; Muguruma, N; Okahisa, T; Takayama, T				Miyoshi, Jinsei; Miyamoto, Hiroshi; Goji, Takahiro; Taniguchi, Tatsuya; Tomonari, Tetsu; Sogabe, Masahiro; Kimura, Tetsuo; Kitamura, Shinji; Okamoto, Koichi; Fujino, Yasuteru; Muguruma, Naoki; Okahisa, Toshiya; Takayama, Tetsuji			Serum diamine oxidase activity as a predictor of gastrointestinal toxicity and malnutrition due to anticancer drugs	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						anticancer drugs; diamine oxidase; diarrhea; gastrointestinal toxicity; malnutrition	GASTRIC-CANCER; BACTERIAL TRANSLOCATION; CROHNS-DISEASE; CHEMOTHERAPY; CISPLATIN; RAT; FLUOROURACIL; DOCETAXEL; TRACT; S-1	Background and AimObjective evaluation of intestinal mucosal damage due to anticancer drugs is generally difficult. Serum diamine oxidase (DAO) activity is reported to reflect the integrity and maturity of the small intestinal mucosa. Therefore, we investigated whether serum DAO activity is an indicator of gastrointestinal toxicity or nutritional status in patients receiving chemotherapy. MethodsWe prospectively enrolled 20 patients with unresectable metastatic gastric cancer who received oral S-1 (80mg/m(2)) on days 1-14, and intravenous cisplatin (60mg/m(2)) and docetaxel (50mg/m(2)) on day 8 every 3 weeks. Serum DAO activity was measured by colorimetry. Gastrointestinal toxicity was evaluated by Common Toxicity Criteria for Adverse Events version 4.0. Endoscopic examination and biopsy of duodenal mucosa assessed mucosal damage. Malnutrition was evaluated by measuring serum total protein and albumin levels. ResultsSerum DAO activity decreased step-by-step significantly during anticancer drug treatment and recovered after drug holidays. In all 14 patients who experienced diarrhea, serum DAO activity significantly decreased prior to diarrhea onset. Percent decrease in DAO activity was significantly correlated with severity of diarrhea. Significant correlation was observed between percent decrease in DAO activity and percent decrease in duodenal villus height or surface area from baseline. There were also significant correlations between percent decrease in serum DAO activity at day 14 and percent decrease in serum total protein or albumin levels at day 21 from baseline. ConclusionSerum DAO activity sensitively indicates gastrointestinal damage prior to symptom onset and can be a useful predictor of intestinal mucosal damage and nutritional status in patients receiving chemotherapy.	[Miyoshi, Jinsei; Miyamoto, Hiroshi; Goji, Takahiro; Taniguchi, Tatsuya; Tomonari, Tetsu; Kimura, Tetsuo; Kitamura, Shinji; Okamoto, Koichi; Fujino, Yasuteru; Muguruma, Naoki; Takayama, Tetsuji] Univ Tokushima, Dept Gastroenterol & Oncol, Grad Sch, Tokushima 7708503, Japan; [Sogabe, Masahiro; Okahisa, Toshiya] Univ Tokushima, Gen Med & Community Hlth Sci, Inst Hlth Biosci, Tokushima 7708503, Japan	Takayama, T (reprint author), Univ Tokushima, Grad Sch, Dept Gastroenterol & Oncol, Inst Hlth Biosci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	takayama@tokushima-u.ac.jp					LUK GD, 1983, J CLIN INVEST, V71, P1308, DOI 10.1172/JCI110881; Tsujikawa T, 1999, CANCER LETT, V147, P195, DOI 10.1016/S0304-3835(99)00307-9; Swank GM, 1996, WORLD J SURG, V20, P411; Karabulut KU, 2013, AM J EMERG MED, V31, P309, DOI 10.1016/j.ajem.2012.07.029; Moriyama K, 2006, TOXICOLOGY, V217, P233, DOI 10.1016/j.tox.2005.09.017; Muramoto Y, 1999, CLIN CHIM ACTA, V289, P69, DOI 10.1016/S0009-8981(99)00158-8; Namikawa T, 2012, ONCOLOGY-BASEL, V82, P147, DOI 10.1159/000336799; ZHANG W, 1993, TRANSPLANTATION, V56, P512, DOI 10.1097/00007890-199309000-00005; LUK GD, 1980, J CLIN INVEST, V66, P66, DOI 10.1172/JCI109836; Hilsden RJ, 1999, INFLAMM BOWEL DIS, V5, P85; Wittkopf N, 2014, J GASTROENTEROL, V49, P375, DOI 10.1007/s00535-013-0929-4; Fushida S, 2009, ANTI-CANCER DRUG, V20, P752, DOI 10.1097/CAD.0b013e32832ec02b; MENNIGEN R, 1989, AGENTS ACTIONS, V27, P221, DOI 10.1007/BF02222245; Seiler N, 2004, AMINO ACIDS, V26, P217, DOI 10.1007/s00726-004-0070-z; Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429; BERG RD, 1992, J MED, V23, P217; Maintz L, 2007, AM J CLIN NUTR, V85, P1185; Takayama T, 2007, BRIT J CANCER, V97, P851, DOI 10.1038/sj.bjc.6603957; Esaki M, 2014, J GASTROEN HEPATOL, V29, P96, DOI 10.1111/jgh.12411; TAKAGI K, 1994, CLIN CHIM ACTA, V226, P67, DOI 10.1016/0009-8981(94)90103-1; Takimoto Y, 2014, INT J EAT DISORDER, V47, P203, DOI 10.1002/eat.22202; Sato Y, 2010, CANCER CHEMOTH PHARM, V66, P721, DOI 10.1007/s00280-009-1215-2; Aapro M, 2014, ANN ONCOL, V25, P1492, DOI 10.1093/annonc/mdu085; Vandebroek AJV, 2008, ANN ONCOL, V19, P52, DOI 10.1093/annonc/mdn311; Oyama K, 2013, J GASTROENTEROL, V48, P1234, DOI 10.1007/s00535-012-0746-1; Cai CM, 2012, HEPATO-GASTROENTEROL, V59, P155, DOI 10.5754/hge11226; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Honzawa Y, 2010, INFLAMM BOWEL DIS, V16, P2004, DOI 10.1002/ibd.21243	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	NOV	2015	30	11					1582	1590		10.1111/jgh.13004		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CT6DG	WOS:000362901300009		
J	Kawaguchi, T; Komatsu, S; Ichikawa, D; Kosuga, T; Kubota, T; Okamoto, K; Konishi, H; Shiozaki, A; Fujiwara, H; Otsuji, E				Kawaguchi, Tsutomu; Komatsu, Shuhei; Ichikawa, Daisuke; Kosuga, Toshiyuki; Kubota, Takeshi; Okamoto, Kazuma; Konishi, Hirotaka; Shiozaki, Atsushi; Fujiwara, Hitoshi; Otsuji, Eigo			Clinical significance and prognostic impact of the total diameter of enlarged lymph nodes on preoperative multidetector computed tomography in patients with gastric cancer	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						enlarged lymph node; gastric cancer; MDCT; total diameter	NEOADJUVANT CHEMOTHERAPY; PHASE-II; METASTASES; S-1; GASTRECTOMY; INVASION; SURGERY; TRIAL; CT	Background and AimThis study was designed to evaluate the clinical significance and prognostic impact of the total diameter of enlarged lymph nodes (TDL) on preoperative multidetector computed tomography (MDCT) in gastric cancer (GC). MethodsOf a total of 480 GC patients between 2005 and 2009, 70 patients with a preoperative diagnosis of nodal metastasis on MDCT were included in this study. All regional lymph nodes showing metastatic involvement were preoperatively counted and measured. ResultsThe TDL was calculated, and using a receiver operating characteristic curve, a cutoff value of 45mm in the two groups of large TDL (LTDL) and small TDL was found to be appropriate for TDL. No significant differences were observed in clinicopathological features, except for tumor recurrence, between the two groups. Univariate survival analysis revealed that patients with LTDL had a worse prognosis as well as an upper tumor location, deeper tumor depth, and further advanced pathological stage. Multivariable prognostic analysis identified LTDL as an independent worse prognostic factor (P=0.0128). ConclusionsGC patients with the total nodal diameter measuring 45mm or more on MDCT have a worse prognosis. GC patients with the novel surrogate indicator of worse prognosis for a preoperative imaging diagnosis may have need of multimodal treatment to improve the survival.	[Kawaguchi, Tsutomu; Komatsu, Shuhei; Ichikawa, Daisuke; Kosuga, Toshiyuki; Kubota, Takeshi; Okamoto, Kazuma; Konishi, Hirotaka; Shiozaki, Atsushi; Fujiwara, Hitoshi; Otsuji, Eigo] Kyoto Prefectural Univ Med, Dept Surg, Kyoto 6028566, Japan	Komatsu, S (reprint author), Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	skomatsu@koto.kpu-m.ac.jp					Kundel HL, 2003, RADIOLOGY, V228, P303, DOI 10.1148/radiol.2282011860; Kinoshita T, 2009, GASTRIC CANCER, V12, P37, DOI 10.1007/s10120-008-0496-1; Inoue T, 2012, ANN SURG ONCOL, V19, P2937, DOI 10.1245/s10434-012-2332-4; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; FUKUYA T, 1995, RADIOLOGY, V197, P705; Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4; Tokunaga M, 2013, ANN SURG ONCOL, V20, P1598, DOI 10.1245/s10434-012-2699-2; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; ALTMAN DG, 1994, J NATL CANCER I, V86, P829, DOI 10.1093/jnci/86.11.829; Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Shinohara T, 2005, EJSO, V31, P743, DOI 10.1016/j.ejso.2005.03.005; Kawaguchi T, 2012, ANN SURG ONCOL, V19, P2465, DOI 10.1245/s10434-012-2283-9; Jansen EPM, 2005, J CLIN ONCOL, V23, P4509, DOI 10.1200/JCO.2005.21.196; Knight G, 2013, GASTRIC CANCER, V16, P28, DOI 10.1007/s10120-012-0148-3; Hasegawa S, 2013, ANN SURG ONCOL, V20, P2016, DOI 10.1245/s10434-012-2817-1; Yoshikawa T, 2009, BRIT J SURG, V96, P1015, DOI 10.1002/bjs.6665; Kawaguchi T, 2011, HEPATO-GASTROENTEROL, V58, P838; Kwee RM, 2009, GASTRIC CANCER, V12, P6, DOI 10.1007/s10120-008-0492-5; Japanese Gastric Canc Assoc, 2011, GASTRIC CANCER, V14, P101, DOI 10.1007/s10120-011-0041-5; Morgagni P, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-197; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Seevaratnam R, 2012, GASTRIC CANCER, V15, pS3, DOI 10.1007/s10120-011-0069-6; Sobin LHGM, 2009, IUAC	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	NOV	2015	30	11					1603	1609		10.1111/jgh.12986		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CT6DG	WOS:000362901300012		
J	Narimatsu, K; Higashiyama, M; Kurihara, C; Takajo, T; Maruta, K; Yasutake, Y; Sato, H; Okada, Y; Watanabe, C; Komoto, S; Tomita, K; Nagao, S; Miura, S; Hokari, R				Narimatsu, Kazuyuki; Higashiyama, Masaaki; Kurihara, Chie; Takajo, Takeshi; Maruta, Koji; Yasutake, Yuichi; Sato, Hirokazu; Okada, Yoshikiyo; Watanabe, Chikako; Komoto, Shunsuke; Tomita, Kengo; Nagao, Shigeaki; Miura, Soichiro; Hokari, Ryota			Toll-like receptor (TLR) 2 agonists ameliorate indomethacin-induced murine ileitis by suppressing the TLR4 signaling	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						lipoarabinomannan; lipoteichoic acid; nonsteroidal anti-inflammatory agents; Toll-like receptors	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SMALL-INTESTINAL LESIONS; NECROSIS-FACTOR-ALPHA; KAPPA-B; CROSS-TOLERANCE; ENDOTHELIAL-CELLS; MUCOSAL INJURY; ORAL TOLERANCE; P-SELECTIN; IRAK-M	Background and AimFew drugs have been found satisfactory in the treatment of nonsteroidal anti-inflammatory drugs (NSAIDs)-induced enteropathy. Toll-like receptor (TLR) 4 and aberrant leukocyte migration to the intestinal mucosa are reported to be involved in the pathology of intestinal enteropathy and TLR2 agonists have been found to evoke hyposensitivity to TLR4 stimulation in vitro. In this study, we investigated whether and how lipoarabinomannan (LAM) or lipoteichoic acid (LTA), TLR2 agonists, attenuated indomethacin (IND)-induced intestinal damage. MethodsLAM (0.5mg/kg) or LTA (15mg/kg) was administered intraperitoneally to mice before IND (10mg/kg) administration. Disease activity was evaluated macroscopically and histologically. In the migration analysis, fluorescence-labeled leukocyte movement in the intestinal microvessels was observed by intravital microscopy. Expression of P-selectin, MAdCAM-1, TLR2, TLR4, and F4/80 was observed immunohistochemically. In the in vitro analysis, RAW264.7 macrophage cells were preincubated with LAM and stimulated with lipopolysaccharide (LPS), and the mRNA expression levels of TLR4, tumor necrosis factor-, and interleukin-12p40 were measured. ResultsPretreatment with LAM or LTA significantly decreased IND-induced injury as well as decreased leukocyte infiltration. Pretreatment with LAM decreased IND-induced TLR4 expression on F4/80(+) macrophages, the level of P-selectin expression, and leukocyte migration in the small intestinal vessels. In the in vitro study, a single administration of LAM decreased TLR4 mRNA expression and inhibited the increase in mRNA expression of inflammatory cytokines by LPS in a dose-dependent manner. ConclusionTLR2 agonists attenuated IND-induced small intestinal lesions and leukocyte infiltration probably by suppressing the TLR4 signaling pathway in tissue macrophages.	[Narimatsu, Kazuyuki; Higashiyama, Masaaki; Kurihara, Chie; Takajo, Takeshi; Maruta, Koji; Yasutake, Yuichi; Sato, Hirokazu; Okada, Yoshikiyo; Watanabe, Chikako; Komoto, Shunsuke; Tomita, Kengo; Nagao, Shigeaki; Miura, Soichiro; Hokari, Ryota] Natl Def Med Coll, Dept Internal Med, Tokorozawa, Saitama 359, Japan	Hokari, R (reprint author), Natl Def Med Coll, Dept Internal Med, 3-2 Namiki, Tokorozawa, Saitama 359, Japan.	ryota@ndmc.ac.jp			National Defense Medical College; Smoking Research Foundation; Intractable Disease, the Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare	This study was supported by grants from the National Defense Medical College; the Smoking Research Foundation; and by the Intractable Disease, the Health and Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare.	Pathak SK, 2005, J BIOL CHEM, V280, P42794, DOI 10.1074/jbc.M506471200; Spierings ELH, 2007, J NUTR SCI VITAMINOL, V53, P536, DOI 10.3177/jnsv.53.536; Fan J, 2003, J CLIN INVEST, V112, P1234, DOI 10.1172/JCI200318696; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200; Nahid MA, 2013, J IMMUNOL, V190, P1250, DOI 10.4049/jimmunol.1103060; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Goldstein JL, 2005, CLIN GASTROENTEROL H, V3, P133, DOI 10.1053/S1542-3565(04)00619-6; WELLER A, 1992, J BIOL CHEM, V267, P15176; Scott KGE, 2004, INFECT IMMUN, V72, P3536, DOI 10.1128/IAI72.6.3536-3542.2004; Fujimori S, 2010, EUR J CLIN INVEST, V40, P504, DOI 10.1111/j.1365-2362.2010.02290.x; Silva MA, 2008, INFLAMM BOWEL DIS, V14, P632, DOI 10.1002/ibd.20379; Kamei K, 2008, DIGEST DIS SCI, V53, P2657, DOI 10.1007/s10620-008-0199-9; Graham DY, 2005, CLIN GASTROENTEROL H, V3, P55, DOI 10.1053/S1542-3565(04)00603-2; ROBERT A, 1977, PROSTAGLANDINS, V14, P333, DOI 10.1016/0090-6980(77)90178-2; Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056; Takebayashi K, 2009, MICROCIRCULATION, V16, P251, DOI 10.1080/10739680802574166; BJARNASON I, 1991, GUT, V32, P275, DOI 10.1136/gut.32.3.275; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Kraus TA, 2005, CURR OPIN GASTROEN, V21, P692, DOI 10.1097/01.mog.0000182862.88798.28; BJARNASON I, 1992, GUT, V33, P1204, DOI 10.1136/gut.33.9.1204; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; de Vos AF, 2009, J IMMUNOL, V183, P533, DOI 10.4049/jimmunol.0802189; SHAH K, 1995, GUT, V37, P195, DOI 10.1136/gut.37.2.195; Watanabe C, 2002, AM J PHYSIOL-GASTR L, V283, pG1379, DOI 10.1152/ajpgi.00026.2002; Watanabe T, 2008, GUT, V57, P181, DOI 10.1136/gut.2007.125963; Beck PL, 2000, GASTROENTEROLOGY, V119, P699, DOI 10.1053/gast.2000.16497; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; Reuter BK, 1997, GASTROENTEROLOGY, V112, P109, DOI 10.1016/S0016-5085(97)70225-7; Morise Z, 1999, GUT, V45, P523; Niwa Y, 2008, J GASTROENTEROL, V43, P270, DOI 10.1007/s00535-007-2155-4; Higashiyama M, 2012, SCAND J GASTROENTERO, V47, P993, DOI 10.3109/00365521.2012.690043; Fujiyama Y, 2007, J GASTROEN HEPATOL, V22, P1838, DOI 10.1111/j.1440-1746.2007.04905.x; Hirotani T, 2005, J IMMUNOL, V174, P3650; Dobrovolskaia MA, 2003, J IMMUNOL, V170, P508; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Sato S, 2000, J IMMUNOL, V165, P7096; Foligne B, 2007, GASTROENTEROLOGY, V133, P862, DOI 10.1053/j.gastro.2007.06.018; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Bertrand V, 1998, BRIT J PHARMACOL, V124, P1385, DOI 10.1038/sj.bjp.0701968; Konaka A, 1999, PHARMACOL RES, V40, P517, DOI 10.1006/phrs.1999.0550; Kim HG, 2008, J IMMUNOL, V180, P2553; CHIU CJ, 1970, ARCH SURG-CHICAGO, V101, P478; Faure E, 2001, J IMMUNOL, V166, P2018; Hagiwara Mari, 2004, Journal of Medical Investigation, V51, P43, DOI 10.2152/jmi.51.43	46	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	NOV	2015	30	11					1610	1617		10.1111/jgh.12980		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CT6DG	WOS:000362901300013		
J	Kusunoki, Y; Ikarashi, N; Matsuda, S; Matsukawa, Y; Kitaoka, S; Kon, R; Tajima, M; Wakui, N; Ochiai, W; Machida, Y; Sugiyama, K				Kusunoki, Yoshiki; Ikarashi, Nobutomo; Matsuda, Shogo; Matsukawa, Yoshimi; Kitaoka, Satoshi; Kon, Risako; Tajima, Masataka; Wakui, Nobuyuki; Ochiai, Wataru; Machida, Yoshiaki; Sugiyama, Kiyoshi			Expression of hepatic cytochrome P450 in a mouse model of ulcerative colitis changes with pathological conditions	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						cytochrome P450; inflammatory cytokine; lipopolysaccharide; pregnane X receptor; ulcerative colitis	INFLAMMATORY-BOWEL-DISEASE; DOWN-REGULATION; PHARMACOKINETICS; CYCLOSPORINE; INDUCTION; CYTOKINES; ENZYMES; CYP3A; MICE	Background and AimThe expression levels of cytochrome P450 (CYP) in the liver were analyzed over time in dextran sulfate sodium (DSS)-induced ulcerative colitis mouse model, from the initial active stage to the remission stage, to investigate the relationship between the changes in pathological conditions and CYP expression levels. MethodsDSS solution was given to mice for 10 days, after which water without DSS was provided for 40 days. Pathological conditions and CYP expression levels were examined over time. The mechanism for variation in CYP expression was also analyzed. ResultsThe mRNA expression levels of CYP (CYP3A11, CYP1A2, CYP2C29, CYP2D9, and CYP2E1) decreased as pathological conditions worsened and reached their lowest levels on day 10 of DSS treatment. Pathological conditions improved following the discontinuation of DSS, and CYP expression levels normalized by day 50. Blood lipopolysaccharide levels, the hepatic expression of inflammatory cytokines, and the nuclear translocation of pregnane X receptor and constitutive androstane receptor in the liver exhibited patterns similar to the observed variations in CYP expression levels. ConclusionThe capacity for metabolizing drugs that are substrates of CYP decreases during the active stage of ulcerative colitis but subsequently improves during the remission stage. This decrease in CYP expression was likely caused by the observed reduction in the levels of nuclearly localized pregnane X receptor and constitutive androstane receptor, and the increase in the production of inflammatory cytokines triggered by lipopolysaccharides.	[Kusunoki, Yoshiki; Ikarashi, Nobutomo; Matsuda, Shogo; Matsukawa, Yoshimi; Kitaoka, Satoshi; Kon, Risako; Tajima, Masataka; Ochiai, Wataru; Sugiyama, Kiyoshi] Hoshi Univ, Dept Clin Pharmacokinet, Tokyo 1428501, Japan; [Wakui, Nobuyuki; Machida, Yoshiaki] Hoshi Univ, Div Appl Pharmaceut Educ & Res, Tokyo 1428501, Japan	Sugiyama, K (reprint author), Hoshi Univ, Dept Clin Pharmacokinet, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	sugiyama@hoshi.ac.jp					KISHIMOTO S, 1992, DIGEST DIS SCI, V37, P1729, DOI 10.1007/BF01299867; Kusunoki Y, 2014, EUR J PHARM SCI, V54, P17, DOI 10.1016/j.ejps.2013.12.019; Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0; Baumgart DC, 2007, LANCET, V369, P1627, DOI 10.1016/S0140-6736(07)60750-8; BERGAN T, 1981, CHEMOTHERAPY, V27, P233; Tajima M, 2013, BIOL PHARM BULL, V36, P649; Latteri M, 2001, CLIN PHARMACOKINET, V40, P473, DOI 10.2165/00003088-200140060-00006; Wada Y, 2009, INFLAMM BOWEL DIS, V15, P1548, DOI 10.1002/ibd.20934; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; OKAYASU I, 1990, GASTROENTEROLOGY, V98, P694; ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; CEREDIG R, 1977, NATURE, V266, P74, DOI 10.1038/266074a0; Emoto C, 2000, XENOBIOTICA, V30, P943; Rogler G, 1998, WORLD J SURG, V22, P382; Asakura K, 2009, J GASTROENTEROL, V44, P659, DOI 10.1007/s00535-009-0057-3; Matheny CJ, 2004, DRUG METAB DISPOS, V32, P1008; Siewert E, 2000, HEPATOLOGY, V32, P49, DOI 10.1053/jhep.2000.8532; Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059; Uehara T, 2010, J GASTROEN HEPATOL, V25, pS62, DOI 10.1111/j.1440-1746.2010.06231.x; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; De Vry CG, 2007, GUT, V56, P524, DOI 10.1136/gut.2006.096487; Balint A, 2014, SCAND J GASTROENTERO, V49, P59, DOI 10.3109/00365521.2013.848231; Mombaerts P, 1993, Cell, V75, P274	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	NOV	2015	30	11					1618	1626		10.1111/jgh.12966		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CT6DG	WOS:000362901300014		
J	Maruyama, H; Kondo, T; Kiyono, S; Sekimoto, T; Takahashi, M; Okugawa, H; Yokosuka, O				Maruyama, Hitoshi; Kondo, Takayuki; Kiyono, Soichiro; Sekimoto, Tadashi; Takahashi, Masanori; Okugawa, Hidehiro; Yokosuka, Osamu			Relationship and interaction between serum sodium concentration and portal hemodynamics in patients with cirrhosis	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						ascites; cirrhosis; hyponatremia; portal hypertension	STAGE LIVER-DISEASE; PROGNOSTIC INDICATORS; HYPONATREMIA; MORTALITY; SURVIVAL; HYPERTENSION; MANAGEMENT; MODEL; PATHOGENESIS; ASCITES	Background and AimTo examine the relationship between hyponatremia and portal hemodynamics and their effect on the prognosis of cirrhosis. MethodsPortal hemodynamic parameters measured by Doppler ultrasound and serum sodium concentrations were examined in 153 cirrhosis patients (mean age 62.212.0 years; median observation period, 34.1m). ResultsStudy participants included 16 patients with hyponatremia (Na<135mEq/L), who showed a significantly greater frequency of possessing a splenorenal shunt (SRS; P=0.0068), and 137 patients without hyponatremia. Serum sodium concentrations were significantly lower in patients with SRS than in those without (P=0.0193). An increased prothrombin time-international normalized ratio was a significant predictive factor for developing hyponatremia a year later (8/96; Hazard ratio 14.415; P=0.028). The cumulative survival rate was significantly lower in patients with hyponatremia (46.7% at 1 and 3 years) than in those without (91.8% at 1 year, 76.8% at 3 years; P<0.001). The cumulative survival rate was significantly lower in patients who had developed hyponatremia after 1 year (100% at 1 year, 62.5% at 3 years) than those who had not (100% at 1 year, 89.0% at 3 years; P<0.001). The cumulative survival rate was significantly worse in patients with both hyponatremia and SRS (20% at 1 year). ConclusionsThere was a close linkage between the serum sodium concentration and portal hemodynamic abnormality, presence of SRS, and their interaction may negatively influence the prognoses in cirrhosis.	[Maruyama, Hitoshi; Kondo, Takayuki; Kiyono, Soichiro; Sekimoto, Tadashi; Takahashi, Masanori; Okugawa, Hidehiro; Yokosuka, Osamu] Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chiba, Japan	Maruyama, H (reprint author), Chiba Univ, Grad Sch Med, Dept Gastroenterol & Nephrol, Chuou Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	maru-cib@umin.ac.jp					Adrogue HJ, 2000, NEW ENGL J MED, V342, P1581, DOI 10.1056/NEJM200005253422107; Ahluwalia V, 2015, J HEPATOL, V62, P75, DOI [10.1016/j.jhep.2014.07.033, 10.1016/j.jhep.2014.09.028]; Said A, 2004, J HEPATOL, V40, P897, DOI 10.1016/j.jhep.2004.02.010; Runyon BA, 2013, HEPATOLOGY, V57, P1651, DOI 10.1002/hep.26359; Zipprich A, 2012, LIVER INT, V32, P1407, DOI 10.1111/j.1478-3231.2012.02830.x; Bruno S, 2009, AM J GASTROENTEROL, V104, P1147, DOI 10.1038/ajg.2009.31; Gines P, 2008, HEPATOLOGY, V48, P1002, DOI 10.1002/hep.22418; Gaglio P, 2012, DIGEST DIS SCI, V57, P2774, DOI 10.1007/s10620-012-2276-3; Angeli P, 2006, HEPATOLOGY, V44, P1535, DOI 10.1002/hep.21412; Moore KP, 2006, GUT, V55, P1, DOI 10.1136/gut.2006.099580; BOLONDI L, 1990, J GASTROEN HEPATOL, V5, P459, DOI 10.1111/j.1440-1746.1990.tb01425.x; D'Amico G, 2014, ALIMENT PHARM THER, V39, P1180, DOI 10.1111/apt.12721; Kim WR, 2008, NEW ENGL J MED, V359, P1018, DOI 10.1056/NEJMoa0801209; OHNISHI K, 1986, AM J GASTROENTEROL, V81, P450; Cho HC, 2011, EUR J GASTROEN HEPAT, V23, P51, DOI 10.1097/MEG.0b013e3283407158; Gines P, 1998, HEPATOLOGY, V28, P851, DOI 10.1002/hep.510280337; D'Amico G, 2006, J HEPATOL, V44, P217, DOI 10.1016/j.jhep.2005.10.013; Baik SK, 2010, LIVER INT, V30, P1403, DOI 10.1111/j.1478-3231.2010.02326.x; Sanyal AJ, 2008, GASTROENTEROLOGY, V134, P1715, DOI 10.1053/j.gastro.2008.03.007; Tsochatzis EA, 2014, LANCET, V383, P1749, DOI 10.1016/S0140-6736(14)60121-5; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Ferenci P, 2002, HEPATOLOGY, V35, P716, DOI 10.1053/jhep.2002.31250; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Corona G, 2013, PLOS ONE, V18; European Association for the Study of the Liver, 2010, J HEPATOL, V53, P397, DOI [10.1016/j.jhep.2010.05.004, DOI 10.1016/J.JHEP.2010.05.004]; Gianotti Robert J, 2014, Gastroenterol Rep (Oxf), V2, P21, DOI 10.1093/gastro/got037; Hsu CY, 2010, DIGEST LIVER DIS, V42, P137, DOI 10.1016/j.dld.2009.06.004; Malinchoc M, 2000, HEPATOLOGY, V31, P864, DOI 10.1053/he.2000.5852; Maruyama H, 2014, Clin Radiol, V69, pe140, DOI 10.1016/j.crad.2013.11.001; Renneboog B, 2006, AM J MED, V119, pe1; Tarantino G, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-89; The Japan Society for Portal Hypertension, 2013, GEN RULES STUDY PORT; Upadhyay A, 2006, AM J MED, V119, P30	33	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	NOV	2015	30	11					1635	1642		10.1111/jgh.13006		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	CT6DG	WOS:000362901300016		
J	Ueda, H; Zhou, J; Xie, JM; Davis, MM				Ueda, Hironori; Zhou, Jie; Xie, Jianming; Davis, Mark M.			Distinct Roles of Cytoskeletal Components in Immunological Synapse Formation and Directed Secretion	JOURNAL OF IMMUNOLOGY			English	Article							T-CELL-ACTIVATION; MICROTUBULE-ORGANIZING CENTER; GOLGI-APPARATUS; ACTIN POLYMERIZATION; ANTIGEN RECEPTOR; RETROGRADE FLOW; TARGET-CELLS; POLARIZATION; DYNAMICS; TCR	A hallmark of CD4(+) T cell activation and immunological synapse (IS) formation is the migration of the microtubule organization center and associated organelles toward the APCs. In this study, we found that when murine CD4(+) T cells were treated with a microtubule-destabilizing agent (vinblastine) after the formation of IS, the microtubule organization center dispersed and all of the major cellular organelles moved away from the IS. Cytokines were no longer directed toward the synapse but were randomly secreted in quantities similar to those seen in synaptic secretion. However, if the actin cytoskeleton was disrupted at the same time with cytochalasin D, the organelles did not shift away from the IS. These findings suggest that there is a complex interplay between the microtubules and actin cytoskeleton, where microtubules are important for directing particular cytokines into the synapse, but they are not involved in the amount of cytokines that are produced for at least 1 h after IS formation. In addition, we found that they play a critical role in mobilizing organelles to reorient toward the synapse during T cell activation and in stabilizing organelles against the force that is generated through actin polymerization so that they move toward the APCs. These findings show that there is a complex interplay between these major cytoskeletal components during synapse formation and maintenance.	[Ueda, Hironori; Zhou, Jie; Xie, Jianming; Davis, Mark M.] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; [Ueda, Hironori; Zhou, Jie; Xie, Jianming; Davis, Mark M.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Ueda, Hironori] Osaka Univ, Grad Sch Med, Dept Mol Endocrinol, Suita, Osaka 5650871, Japan	Davis, MM (reprint author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Beckman Ctr, Room 221, Stanford, CA 94305 USA.	mmdavis@stanford.edu			Howard Hughes Medical Institute; Takeda Science Foundation; Novo Nordisk Pharma Insulin Research Award; Cancer Research Institute; National Institutes of Health [AI22511]	This work was supported by the Howard Hughes Medical Institute (to H.U.), the Takeda Science Foundation (to H.U.), a Novo Nordisk Pharma Insulin Research Award (to H.U.), postdoctoral fellowships from the Cancer Research Institute (to J.Z. and J.X.), the National Institutes of Health (Grant AI22511 to M.M.D.), and the Howard Hughes Medical Institute (to M.M.D.).	van der Merwe PA, 2002, CURR OPIN IMMUNOL, V14, P293, DOI 10.1016/S0952-7915(02)00350-3; Lim JI, 2010, EXP CELL RES, V316, P2027, DOI 10.1016/j.yexcr.2010.04.011; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; KUPFER A, 1983, P NATL ACAD SCI-BIOL, V80, P7224, DOI 10.1073/pnas.80.23.7224; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; SANDERSON CJ, 1979, IMMUNOLOGY, V36, P119; Kaizuka Y, 2007, P NATL ACAD SCI USA, V104, P20296, DOI 10.1073/pnas.0710258105; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Huse M, 2007, IMMUNITY, V27, P76, DOI 10.1016/j.immuni.2007.05.017; Babich A, 2012, J CELL BIOL, V197, P775, DOI 10.1083/jcb.201201018; Tsun A, 2011, J CELL BIOL, V192, P663, DOI 10.1083/jcb.201008140; Kumari S, 2014, BBA-BIOMEMBRANES, V1838, P546, DOI 10.1016/j.bbamem.2013.05.004; Huse M, 2006, NAT IMMUNOL, V7, P247, DOI 10.1038/ni1304; de la Roche M, 2013, SCIENCE, V342, P1247, DOI 10.1126/science.1244689; Monks CRF, 1998, NATURE, V395, P82; Hisanaga-Oishi Y, 2014, ENDOCR J, V61, P577, DOI 10.1507/endocrj.EJ14-0002; Irvine DJ, 2002, NATURE, V419, P845, DOI 10.1038/nature01076; Huppa JB, 2003, NAT REV IMMUNOL, V3, P973, DOI 10.1038/nri1245; Gigant B, 2005, NATURE, V435, P519, DOI 10.1038/nature03566; Andersen NJ, 2010, MOL BIOL CELL, V21, P152, DOI 10.1091/mbc.E09-06-0459; Angus KL, 2013, CURR OPIN CELL BIOL, V25, P85, DOI 10.1016/j.ceb.2012.08.013; Gromley A, 2005, CELL, V123, P75, DOI 10.1016/j.cell.2005.07.027; Rios RM, 2003, CURR OPIN CELL BIOL, V15, P60, DOI 10.1016/S0955-0674(02)00013-3; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Lasserre R, 2010, EMBO J, V29, P2301, DOI 10.1038/emboj.2010.127; Zyss D, 2011, J CELL BIOL, V195, P781, DOI 10.1083/jcb.201106025; ROSEN D, 1981, TRANSPLANT P, V13, P1073; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Yi J, 2012, MOL BIOL CELL, V23, P834, DOI 10.1091/mbc.E11-08-0731; KUPFER A, 1991, P NATL ACAD SCI USA, V88, P775, DOI 10.1073/pnas.88.3.775; Reichert P, 2001, J IMMUNOL, V166, P4278; Krummel MF, 2000, SCIENCE, V289, P1349, DOI 10.1126/science.289.5483.1349; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Hashimoto-Tane A, 2011, IMMUNITY, V34, P919, DOI 10.1016/j.immuni.2011.05.012; KUPFER A, 1984, J IMMUNOL, V133, P2762; Sherman E, 2011, IMMUNITY, V35, P705, DOI 10.1016/j.immuni.2011.10.004; Huppa JB, 2010, NATURE, V463, P963, DOI 10.1038/nature08746; Hehnly H, 2012, CURR BIOL, V22, P1944, DOI 10.1016/j.cub.2012.08.022; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Smyth JT, 2007, J CELL SCI, V120, P3762, DOI 10.1242/jcs.015735; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Robertson LK, 2011, J IMMUNOL, V187, P5824, DOI 10.4049/jimmunol.1003690; Quann EJ, 2009, NAT IMMUNOL, V10, P627, DOI 10.1038/ni.1734; GEIGER B, 1982, J CELL BIOL, V95, P137, DOI 10.1083/jcb.95.1.137; Onishi K, 2007, GENES CELLS, V12, P535, DOI 10.1111/j.1365-2443.2007.01071.x; Ueda H, 2011, P NATL ACAD SCI USA, V108, P17099, DOI 10.1073/pnas.1113703108; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Quann EJ, 2011, NAT IMMUNOL, V12, P647, DOI 10.1038/ni.2033; Banerjee PP, 2007, J EXP MED, V204, P2305, DOI 10.1084/jem.20061893; Ritter AT, 2013, IMMUNOL REV, V256, P107, DOI 10.1111/imr.12117; Filbert EL, 2012, J IMMUNOL, V188, P5421, DOI 10.4049/jimmunol.1200242; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nr1317; Brown ACN, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001152; Dushek O, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003913; Hsu CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032398; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; Martín-Cófreces Noa Beatriz, 2011, Front Immunol, V2, P24, DOI 10.3389/fimmu.2011.00024; Rak GD, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001151; Soares H, 2013, IMMUNOL REV, V256, P118, DOI 10.1111/imr.12110; Stinchcombe JC, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-45; Tskvitaria-Fuller I, 2003, J IMMUNOL, V171, P2287; Yu CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011878	64	0	0	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	NOV 1	2015	195	9					4117	4125		10.4049/jimmunol.1402175		9	Immunology	Immunology	CT7BQ	WOS:000362968500009		
J	Hashimoto, M; Nasser, H; Bhuyan, F; Kuse, N; Satou, Y; Harada, S; Yoshimura, K; Sakuragi, J; Monde, K; Maeda, Y; Welbourn, S; Strebel, K; El-Wahab, EWA; Miyazaki, M; Hattori, S; Chutiwitoonchai, N; Hiyoshi, M; Oka, S; Takiguchi, M; Suzu, S				Hashimoto, Michihiro; Nasser, Hesham; Bhuyan, Farzana; Kuse, Nozomi; Satou, Yorifumi; Harada, Shigeyoshi; Yoshimura, Kazuhisa; Sakuragi, Jun-ichi; Monde, Kazuaki; Maeda, Yosuke; Welbourn, Sarah; Strebel, Klaus; El-Wahab, Ekram W. Abd; Miyazaki, Mitsue; Hattori, Shinichiro; Chutiwitoonchai, Nopporn; Hiyoshi, Masateru; Oka, Shinichi; Takiguchi, Masafumi; Suzu, Shinya			Fibrocytes Differ from Macrophages but Can Be Infected with HIV-1	JOURNAL OF IMMUNOLOGY			English	Article							CD4(+) T-CELLS; HEMATOPOIETIC PROGENITOR CELLS; ACTIVE ANTIRETROVIRAL THERAPY; PERIPHERAL-BLOOD FIBROCYTES; VIRUS TYPE-1 VIREMIA; CIRCULATING FIBROCYTES; BONE-MARROW; PULMONARY-FIBROSIS; CHEMOKINE RECEPTOR; VIRAL RESERVOIRS	Fibrocytes (fibroblastic leukocytes) are recently identified as unique hematopoietic cells with features of both macrophages and fibroblasts. Fibrocytes are known to contribute to the remodeling or fibrosis of various injured tissues. However, their role in viral infection is not fully understood. In this study, we show that differentiated fibrocytes are phenotypically distinguishable from macrophages but can be infected with HIV-1. Importantly, fibrocytes exhibited persistently infected cell-like phenotypes, the degree of which was more apparent than macrophages. The infected fibrocytes produced replication-competent HIV-1, but expressed HIV-1 mRNA at low levels and strongly resisted HIV-1-induced cell death, which enabled them to support an extremely long-term HIV-1 production at low but steady levels. More importantly, our results suggested that fibrocytes were susceptible to HIV-1 regardless of their differentiation state, in contrast to the fact that monocytes become susceptible to HIV-1 after the differentiation into macrophages. Our findings indicate that fibrocytes are the previously unreported HIV-1 host cells, and they suggest the importance of considering fibrocytes as one of the long-lived persistently infected cells for curing HIV-1.	[Hashimoto, Michihiro; Nasser, Hesham; Bhuyan, Farzana; Kuse, Nozomi; Satou, Yorifumi; El-Wahab, Ekram W. Abd; Miyazaki, Mitsue; Hattori, Shinichiro; Chutiwitoonchai, Nopporn; Hiyoshi, Masateru; Takiguchi, Masafumi; Suzu, Shinya] Kumamoto Univ, Ctr AIDS Res, Kumamoto 8600811, Japan; [Hashimoto, Michihiro; Nasser, Hesham; Bhuyan, Farzana; Satou, Yorifumi; El-Wahab, Ekram W. Abd; Miyazaki, Mitsue; Takiguchi, Masafumi; Suzu, Shinya] Kumamoto Univ, Int Res Ctr Med Sci, Kumamoto 8600811, Japan; [Harada, Shigeyoshi; Yoshimura, Kazuhisa] Natl Inst Infect Dis, AIDS Res Ctr, Tokyo 1628640, Japan; [Sakuragi, Jun-ichi] Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; [Monde, Kazuaki; Maeda, Yosuke] Kumamoto Univ, Dept Med Virol, Kumamoto 8608556, Japan; [Welbourn, Sarah; Strebel, Klaus] NIAID, NIH, Bethesda, MD 20892 USA; [Oka, Shinichi] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo 1620052, Japan	Suzu, S (reprint author), Kumamoto Univ, Int Res Ctr Med Sci, Ctr AIDS Res, Honjo 2-2-1, Kumamoto 8600811, Japan.	ssuzu06@kumamoto-u.ac.jp			Takeda Science Foundation; Senshin Medical Research Foundation; Science and Technology Development Fund, Egypt [6385]	This work was supported by the grants from the Takeda Science Foundation and the Senshin Medical Research Foundation (to S.S.). E.W.A.E.-W. was supported by Science and Technology Development Fund, Egypt Grant 6385.	Haudek SB, 2006, P NATL ACAD SCI USA, V103, P18284, DOI 10.1073/pnas.0608799103; Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445; Carter CC, 2011, CELL HOST MICROBE, V9, P223, DOI 10.1016/j.chom.2011.02.005; Isgro M, 2013, BIOCHEM BIOPH RES CO, V437, P446, DOI 10.1016/j.bbrc.2013.06.099; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Yukl SA, 2013, J INFECT DIS, V208, P1212, DOI 10.1093/infdis/jit308; Reilkoff RA, 2011, NAT REV IMMUNOL, V11, P427, DOI 10.1038/nri2990; Julias JG, 2001, J VIROL, V75, P6537, DOI 10.1128/JVI.75.14.6537-6546.2001; Eisele E, 2012, IMMUNITY, V37, P377, DOI 10.1016/j.immuni.2012.08.010; Yoshimura K, 2014, J GEN VIROL, V95, P1816, DOI 10.1099/vir.0.062885-0; Strieter RM, 2009, J LEUKOCYTE BIOL, V86, P1111, DOI 10.1189/jlb.0309132; Redd AD, 2007, BLOOD, V110, P3143, DOI 10.1182/blood-2007-04-086314; Mathai SK, 2010, LAB INVEST, V90, P812, DOI 10.1038/labinvest.2010.73; Sakai N, 2006, P NATL ACAD SCI USA, V103, P14098, DOI 10.1073/pnas.0511200103; Scholten D, 2011, AM J PATHOL, V179, P189, DOI 10.1016/j.ajpath.2011.03.049; Galligan CL, 2013, J LEUKOCYTE BIOL, V93, P45, DOI 10.1189/jlb.0712365; Berton G, 2005, TRENDS IMMUNOL, V26, P208, DOI 10.1016/j.it.2005.02.002; Ohishi M, 2007, VIROLOGY, V362, P131, DOI 10.1016/j.virol.2006.12.030; Shan L, 2013, J VIROL, V87, P6521, DOI 10.1128/JVI.00006-13; Veillette A, 2013, CRIT REV ONCOL HEMAT, V88, P168, DOI 10.1016/j.critrevonc.2013.04.003; CHELUCCI C, 1995, BLOOD, V85, P1181; Kedzierska K, 2003, REV MED VIROL, V13, P39, DOI 10.1002/rmv.369; Chesney J, 1998, J IMMUNOL, V160, P419; Hamilton JA, 2013, TRENDS IMMUNOL, V34, P81, DOI 10.1016/j.it.2012.08.006; Abe R, 2001, J IMMUNOL, V166, P7556; Yukl SA, 2014, AIDS, V28, P439, DOI 10.1097/QAD.0000000000000166; van Deventer HW, 2013, J IMMUNOL, V190, P4861, DOI 10.4049/jimmunol.1202857; Sahu GK, 2009, J MED VIROL, V81, P9, DOI 10.1002/jmv.21366; Steiner E, 2008, VIROLOGY, V378, P311, DOI 10.1016/j.virol.2008.06.009; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Hiyoshi M, 2008, BLOOD, V111, P243, DOI 10.1182/blood-2007-04-086017; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Isgro M, 2013, MUCOSAL IMMUNOL, V6, P718, DOI 10.1038/mi.2012.109; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654; Schmidt M, 2003, J IMMUNOL, V171, P380; Niedermeier M, 2009, P NATL ACAD SCI USA, V106, P17892, DOI 10.1073/pnas.0906070106; Chihara T, 2012, J IMMUNOL, V188, P3620, DOI 10.4049/jimmunol.1101593; Ruiz ME, 1998, J IMMUNOL, V161, P4169; Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124-2003; Osman A, 2014, J IMMUNOL, V192, P5083, DOI 10.4049/jimmunol.1302732; BUCALA R, 1994, MOL MED, V1, P71; Josefsson L, 2012, J INFECT DIS, V206, P28, DOI 10.1093/infdis/jis301; Brennan TP, 2009, J VIROL, V83, P8470, DOI 10.1128/JVI.02568-08; Garnier L, 1999, J VIROL, V73, P2309; Ohishi M, 2012, AM J PATHOL, V180, P811, DOI 10.1016/j.ajpath.2011.10.028; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; van Deventer HW, 2008, AM J PATHOL, V173, P253, DOI 10.2353/ajpath.2008.070732; Durand CM, 2012, J INFECT DIS, V205, P1014, DOI 10.1093/infdis/jir884; Hashimoto N, 2004, J CLIN INVEST, V113, P243, DOI 10.1172/JCI200418847; Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551; Balmelli C, 2005, J LEUKOCYTE BIOL, V77, P923, DOI 10.1189/jlb.1204701; Carter CC, 2010, NAT MED, V16, P446, DOI 10.1038/nm.2109; KOYANAGI Y, 1988, SCIENCE, V241, P1673, DOI 10.1126/science.3047875; Archin NM, 2014, NAT REV MICROBIOL, V12, P750, DOI 10.1038/nrmicro3352; Bahnelli C, 2007, IMMUNOBIOLOGY, V212, P693, DOI 10.1016/j.imbio.2007.09.009; Campbell JH, 2014, AIDS, V28, P2175, DOI 10.1097/QAD.0000000000000408; Chutiwitoonchai N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027696; Curnow SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009730; Hashimoto M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.233; Pilling D, 2014, P NATL ACAD SCI USA, V111, P18291, DOI 10.1073/pnas.1417426112; Pilling D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007475; Xu L, 2014, IMMUNOL LETT, V162, P27, DOI 10.1016/j.imlet.2014.06.010	64	0	0	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	NOV 1	2015	195	9					4341	4350		10.4049/jimmunol.1500955		10	Immunology	Immunology	CT7BQ	WOS:000362968500031		
J	Pohar, J; Lainscek, D; Fukui, R; Yamamoto, C; Miyake, K; Jerala, R; Bencina, M				Pohar, Jelka; Lainscek, Dusko; Fukui, Ryutaro; Yamamoto, Chikako; Miyake, Kensuke; Jerala, Roman; Bencina, Mojca			Species-Specific Minimal Sequence Motif for Oligodeoxyribonucleotides Activating Mouse TLR9	JOURNAL OF IMMUNOLOGY			English	Article							PLASMACYTOID DENDRITIC CELLS; INTERFERON-ALPHA INDUCTION; TOLL-LIKE RECEPTOR-9; HUMAN B-CELLS; CPG MOTIFS; TOLL-LIKE-RECEPTOR-9 ACTIVATION; BACTERIAL-DNA; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE; IMMUNOSTIMULATORY ACTIVITIES; ANTISENSE OLIGONUCLEOTIDES	Synthetic oligodeoxyribonucleotides (ODNs) containing unmethylated CpG recapitulate the activation of TLR9 by microbial DNA. ODNs are potent stimulators of the immune response in cells expressing TLR9. Despite extensive use of mice as experimental animals in basic and applied immunological research, the key sequence determinants that govern the activation of mouse TLR9 by ODNs have not been well defined. We performed a systematic investigation of the sequence motif of B class phosphodiester ODNs to identify the sequence properties that govern mouse TLR9 activation. In contrast to ODNs activating human TLR9, where the minimal sequence motif for the receptor activation comprises a pair of closely positioned CpGs we found that the mouse TLR9 requires a single CpG positioned 4-6 nt from the 5'-end. Activation is augmented by a 5'TCC sequence one to three nucleotides from the CG. The distance of the CG dinucleotide of four to six nucleotides from the 5'-end and the ODN's length fine-tunes activation of mouse macrophages. Length of the ODN <23 and >29 nt decreases activation of dendritic cells. The ODNs with minimal sequence induce Th1-type cytokine synthesis in dendritic cells and confirm the expression of cell surface markers in B cells. Identification of the minimal sequence provides an insight into the sequence selectivity of mouse TLR9 and points to the differences in the receptor selectivity between species probably as a result of differences in the receptor binding sites.	[Pohar, Jelka; Lainscek, Dusko; Jerala, Roman; Bencina, Mojca] Natl Inst Chem, Biotechnol Lab, SI-1000 Ljubljana, Slovenia; [Fukui, Ryutaro; Yamamoto, Chikako; Miyake, Kensuke] Univ Tokyo, Div Innate Immun, Inst Med Sci, Dept Microbiol & Immunol, Tokyo 1088639, Japan; [Miyake, Kensuke] Univ Tokyo, Inst Med Sci, Ctr Expt Med & Syst Biol, Lab Innate Immun, Tokyo 1088639, Japan; [Jerala, Roman; Bencina, Mojca] EN FIST Ctr Excellence, SI-1000 Ljubljana, Slovenia	Jerala, R (reprint author), Natl Inst Chem, Biotechnol Lab, Hajdrihova 19, SI-1000 Ljubljana, Slovenia.	roman.jerala@ki.si; mojca.bencina@ki.si			Slovenian Research Agency; EN-FIST Centre of Excellence	This work was supported by the program and projects of the Slovenian Research Agency and the EN-FIST Centre of Excellence.	KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Yi AK, 1998, J IMMUNOL, V160, P5898; Ohto U, 2015, NATURE, V520, P702, DOI 10.1038/nature14138; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; Yu D, 2008, ANTIMICROB AGENTS CH, V52, P4320, DOI 10.1128/AAC.00701-08; Hartmann G, 2000, J IMMUNOL, V164, P1617; BROWN DA, 1994, J BIOL CHEM, V269, P26801; Kindrachuk J, 2007, J BIOL CHEM, V282, P13944, DOI 10.1074/jbc.M608089200; Ballas ZK, 2001, J IMMUNOL, V167, P4878; Hanagata N, 2012, INT J NANOMED, V7, P2181, DOI 10.2147/IJN.S30197; Zhao QY, 2000, BIOORG MED CHEM LETT, V10, P1051, DOI 10.1016/S0960-894X(00)00157-8; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; Jabbari K, 2004, GENE, V333, P143, DOI 10.1016/j.gene.2004.02.043; Agrawal S, 2007, BIOCHEM SOC T, V35, P1461, DOI 10.1042/BST0351461; Sen G, 2004, CELL IMMUNOL, V232, P64, DOI 10.1016/j.cellimm.2005.01.010; Hornung V, 2002, J IMMUNOL, V168, P4531; Vollmer J, 2004, J ENDOTOXIN RES, V10, P431, DOI 10.1179/096805104225006534; Kandimalla ER, 2003, BIOCHEM BIOPH RES CO, V306, P948, DOI 10.1016/S0006-291X(03)01080-5; Pohar J, 2015, J IMMUNOL, V194, P3901, DOI 10.4049/jimmunol.1402755; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Hartmann G, 2003, EUR J IMMUNOL, V33, P1633, DOI 10.1002/eji.200323813; Rankin R, 2001, ANTISENSE NUCLEIC A, V11, P333, DOI 10.1089/108729001753231713; Chen L, 2006, J IMMUNOL, V177, P2373; Struthers M, 2010, CELL IMMUNOL, V263, P105, DOI 10.1016/j.cellimm.2010.03.005; Vollmer J, 2004, EUR J IMMUNOL, V34, P251, DOI 10.1002/eji.200324032; Jurk M, 2004, IMMUNOBIOLOGY, V209, P141, DOI 10.1016/j.imbio.2004.02.006; Haas T, 2009, IMMUNOLOGY, V126, P290, DOI 10.1111/j.1365-2567.2008.02897.x; Hochrein Hubertus, 2008, V183, P153; Suwarti S, 2013, BIOCHEM BIOPH RES CO, V430, P1234, DOI 10.1016/j.bbrc.2012.12.068; Samulowitz U, 2010, OLIGONUCLEOTIDES, V20, P93, DOI 10.1089/oli.2009.0210; Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Haas T, 2008, IMMUNITY, V28, P315, DOI 10.1016/j.immuni.2008.01.013; Hartmann G, 2000, J IMMUNOL, V164, P944; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Klinman DM, 2003, CLIN EXP IMMUNOL, V133, P227, DOI 10.1046/j.1365-2249.2003.02216.x; Cong YP, 2003, BIOCHEM BIOPH RES CO, V310, P1133, DOI 10.1016/j.bbrc.2003.09.134; Guiducci C, 2006, J EXP MED, V203, P1999, DOI 10.1084/jem.20060401; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Baek KH, 2001, J IMMUNOL, V167, P2847; Wagner H, 2011, EUR J IMMUNOL, V41, P2814, DOI 10.1002/eji.201142056; Agrawal S, 1999, BBA-GENE STRUCT EXPR, V1489, P53, DOI 10.1016/S0167-4781(99)00141-4; Roberts TL, 2005, J IMMUNOL, V174, P605; Chan MP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6853; Chinnathambi S, 2012, SCI REP-UK, V2, DOI 10.1038/srep00534; Meng W, 2011, BMC BIOTECHNOL, V11, P88	46	0	0	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	NOV 1	2015	195	9					4396	4405		10.4049/jimmunol.1500600		10	Immunology	Immunology	CT7BQ	WOS:000362968500037		
J	Funami, K; Matsumoto, M; Enokizono, Y; Ishii, N; Tatematsu, M; Oshiumi, H; Inagaki, F; Seya, T				Funami, Kenji; Matsumoto, Misako; Enokizono, Yoshiaki; Ishii, Noriko; Tatematsu, Megumi; Oshiumi, Hiroyuki; Inagaki, Fuyuhiko; Seya, Tsukasa			Identification of a Regulatory Acidic Motif as the Determinant of Membrane Localization of TICAM-2	JOURNAL OF IMMUNOLOGY			English	Article							NONCANONICAL INFLAMMASOME ACTIVATION; RECEPTOR TIR DOMAIN; NF-KAPPA-B; INTERFERON-BETA; SIGNAL-TRANSDUCTION; ADAPTER MOLECULE; ENDOTOXIC-SHOCK; HOST-DEFENSE; TOLL; TLR4	TLR4 triggers LPS signaling through the adaptors Toll/IL-1R domain-containing adaptor molecule (TICAM)-2 (also called TRAM) and TICAM-1 (also called TRIF), together with Toll/IL-1R domain-containing adaptor protein (TIRAP) and MyD88. The MyD88 pathway mediates early phase responses to LPS on the plasma membrane, whereas the TICAM pathway mediates late-phase responses, which induce the production of type I IFN and activation of inflammasomes. TICAM-2 bridges TLR4 and TICAM-1 for LPS signaling in the endosome. Recently, we identified an acidic motif, E87/D88/D89 in TICAM-2, that provides the interaction surfaces between TICAM-2 and TICAM-1. In the present study, we found additional D91/E92 in TICAM-2, conserved across species, that is crucial for TICAM-1 activation. The D91A/E92A mutant protein was distributed largely to the cytosol, despite myristoylation, suggesting its importance for assistance of membrane localization of TICAM-2. An ectopically expressed D91A/E92A mutant per se failed to activate TICAM-1, unlike its wild-type counterpart that forms self-aggregation, but it still retained the ability to pass LPS-mediated IFN regulatory factor (IRF) 3 activation. In a TICAM-2 knockout human cell line expressing TLR4/MD-2 with or without CD14, overexpression of the D91A/E92A mutant did not activate IRF3, but upon LPS stimulation, it induced sufficient TLR4-mediated IRF3 activation with high coefficient colocalization. Hence, the D91/E92 motif guides TICAM-2 membrane localization and self-activation for signaling. Our results suggest the presence of two distinct steps underlying endosomal LPS signaling on TICAM-2 for TICAM-1 activation: TICAM-2 assembling in TLR4 and/or TICAM-2 self-activation. D91A/E92A of TICAM-2 selectively associates the TLR4-dependent TICAM-2 assembling, but not cytosolic TICAM-2 self-aggregation, to activate TICAM-1.	[Funami, Kenji; Matsumoto, Misako; Ishii, Noriko; Tatematsu, Megumi; Oshiumi, Hiroyuki; Seya, Tsukasa] Hokkaido Univ, Grad Sch Med, Dept Microbiol & Immunol, Sapporo, Hokkaido 0608638, Japan; [Enokizono, Yoshiaki; Inagaki, Fuyuhiko] Hokkaido Univ, Fac Adv Life Sci, Dept Struct Biol, Sapporo, Hokkaido 0010021, Japan	Seya, T (reprint author), Hokkaido Univ, Grad Sch Med, Dept Microbiol & Immunol, Kita Ku, N-15,W-7, Sapporo, Hokkaido 0608638, Japan.	seya-tu@pop.med.hokudai.ac.jp	OSHIUMI, HIROYUKI/G-1645-2012		Ministry of Education, Culture, Sports, Science, and Technology; Ministry of Health, Labor, and Welfare of Japan; National Cancer Center Research and Development Fund [23-A-44]; Takeda Science Foundation; Yasuda Cancer Research Foundation; Iskra Foundation	This work was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labor, and Welfare of Japan, and by a Ministry of Education, Culture, Sports, Science, and Technology Grant-in-Project "The Carcinogenic Spiral," National Cancer Center Research and Development Fund Grant 23-A-44. This work was also supported by the Takeda Science Foundation, the Yasuda Cancer Research Foundation, and the Iskra Foundation.	Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Rowe DC, 2006, P NATL ACAD SCI USA, V103, P6299, DOI 10.1073/pnas.0510041103; Van Acker T, 2014, J BIOL CHEM, V289, P1364, DOI 10.1074/jbc.M113.499194; Knodler LA, 2014, CELL HOST MICROBE, V16, P249, DOI 10.1016/j.chom.2014.07.002; Aksoy E, 2012, NAT IMMUNOL, V13, P1045, DOI 10.1038/ni.2426; Kayagaki N, 2013, SCIENCE, V341, P1246, DOI 10.1126/science.1240248; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; Ramos HJ, 2011, CURR OPIN VIROL, V1, P167, DOI 10.1016/j.coviro.2011.04.004; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Enokizono Y, 2013, P NATL ACAD SCI USA, V110, P19908, DOI 10.1073/pnas.1222811110; Gay NJ, 2011, TRENDS IMMUNOL, V32, P104, DOI 10.1016/j.it.2010.12.005; Sasai M, 2010, MOL IMMUNOL, V47, P1283, DOI 10.1016/j.molimm.2009.12.002; Klein DCG, 2015, TRAFFIC, V16, P677, DOI 10.1111/tra.12274; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Zanoni I, 2011, CELL, V147, P868, DOI 10.1016/j.cell.2011.09.051; Netea MG, 2012, NAT IMMUNOL, V13, P535, DOI 10.1038/ni.2284; Fitzgerald KA, 2004, MICROBES INFECT, V6, P1361, DOI 10.1016/j.micinf.2004.08.015; Funami K, 2008, J BIOL CHEM, V283, P18283, DOI 10.1074/jbc.M801013200; Hagar JA, 2013, SCIENCE, V341, P1250, DOI 10.1126/science.1240988; Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007; Tatematsu M, 2010, J BIOL CHEM, V285, P20128, DOI 10.1074/jbc.M109.099101; Kagan JC, 2008, NAT IMMUNOL, V9, P361, DOI 10.1038/ni1569; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Ling GS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4039; Gurung P, 2012, J BIOL CHEM, V287, P34474, DOI 10.1074/jbc.M112.401406; Husebye H, 2010, IMMUNITY, V33, P583, DOI 10.1016/j.immuni.2010.09.010; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Takaki H, 2009, EUR J IMMUNOL, V39, P3469, DOI 10.1002/eji.200939878; Piao W, 2013, J IMMUNOL, V190, P2263, DOI 10.4049/jimmunol.1202703; Nilsen NJ, 2015, J BIOL CHEM, V290, P3209, DOI 10.1074/jbc.M114.593426; Choi YJ, 2010, J BIOL CHEM, V285, P37570, DOI 10.1074/jbc.M110.158394; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Funami K, 2007, J IMMUNOL, V179, P6867; Bonham KS, 2014, CELL, V156, P705, DOI 10.1016/j.cell.2014.01.019; Lin SC, 2010, NATURE, V465, P885, DOI 10.1038/nature09121; Bovijn C, 2012, J BIOL CHEM, V287, P4088, DOI 10.1074/jbc.M111.282350; Bowen WS, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001963; Wright Megan H, 2010, J Chem Biol, V3, P19, DOI 10.1007/s12154-009-0032-8	43	1	1	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	NOV 1	2015	195	9					4456	4465		10.4049/jimmunol.1402628		10	Immunology	Immunology	CT7BQ	WOS:000362968500043		
J	Tashiro, Y; Miyazato, A; Ebitani, K				Tashiro, Yuji; Miyazato, Akio; Ebitani, Kohki			One-Pot Synthesis of Oligo-Ladder Phenylsilsesquioxanes via Pyridine-Silicon Adduct Formation at Aqueous-Organic Liquid Boundary	JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS			English	Article						Oligo-ladder PPSQ; Pyridine; Lewis base adduct; Phenyltrichlorosilane; Re-crystallization	POLYCONDENSATION	Three kinds of oligo-ladder polyphenylsilsesquioxanes were synthesized by two unique methods through the aqueous-organic boundary reaction via octahedrally-coordinated pyridine-silicon adduct PhSiCl3(Py)(2), which is formed from trichlorophenylsilane (TCP) monomer and pyridine in n-propyl acetate. When two equivalent pyridines to TCP were used, SQ polymer-1 was formed as a viscous solid, which was recrystallized in n-hexane to obtain SQ polymer-2B. When an excess pyridine was used (pyridine/Si = 10), SQ polymer-2A was directly obtained as a white solid. MALDI-TOF/TOF-MS, FT-IR and (SiNMR)-Si-29 clearly shows that the "Ladder" structure of SQ polymers is dominant in both methods. It was shown that in this one-pot synthesis, SQ polymer structure was controlled by pyridine amount. Furthermore, MO simulation of pyridine adduct formation (PhSiCl3(Py)(2)) supports the hydrolysis pathway for synthesis as well as the "Ladder" structure formation. Finally, it was also suggested that the hydrolysis reaction occurred in a stepwise manner.	[Tashiro, Yuji; Miyazato, Akio; Ebitani, Kohki] Japan Adv Inst Sci & Technol, Sch Mat Sci, Nomi, Ishikawa 9231292, Japan; [Tashiro, Yuji] AZ Elect Mat, Kakegawa, Shizuoka 4371412, Japan	Tashiro, Y (reprint author), Japan Adv Inst Sci & Technol, Sch Mat Sci, 1-1 Asahidai, Nomi, Ishikawa 9231292, Japan.	yuji.tashiro@merckgroup.com; a-miyasa@jaist.ac.jp; ebitani@jaist.ac.jp					Adachi H., 1985, REP PROG POLYM PHYS, V28, P261; SMITH AL, 1984, APPL SPECTROSC, V38, P822, DOI 10.1366/0003702844554549; Gun'ko YK, 2004, INORG CHEM COMMUN, V7, P341, DOI 10.1016/j.inoche.2003.12.009; Feher FJ, 1997, MAIN GROUP CHEM, V2, P123, DOI 10.1080/10241229712331341254; Xie P, 1997, POLYM ADVAN TECHNOL, V8, P649, DOI 10.1002/(SICI)1099-1581(199711)8:11<649::AID-PAT696>3.0.CO;2-H; Unno M, 2000, B CHEM SOC JPN, V73, P215, DOI 10.1246/bcsj.73.215; BROWN JF, 1960, J AM CHEM SOC, V82, P6194, DOI 10.1021/ja01508a054; Kolezynski A, 2013, J MOL STRUCT, V1044, P314, DOI 10.1016/j.molstruc.2012.12.013; Unno M, 2005, ORGANOMETALLICS, V24, P765, DOI 10.1021/om049324c; Suyama K, 2007, J ORGANOMET CHEM, V692, P2028, DOI 10.1016/j.jorganchem.2007.01.016; Unno M, 2007, J ORGANOMET CHEM, V692, P307, DOI 10.1016/j.jorganchem.2006.08.068; BROWN JF, 1964, J AM CHEM SOC, V86, P1120, DOI 10.1021/ja01060a033; Pakjamsai C, 2004, POLYM J, V36, P455, DOI 10.1295/polymj.36.455; SPRUNG MM, 1955, J AM CHEM SOC, V77, P3990, DOI 10.1021/ja01620a013; Park ES, 2008, CHEM MATER, V20, P1548, DOI 10.1021/cm071575z; Yamamoto S, 2004, MACROMOLECULES, V37, P2775, DOI 10.1021/ma0353987a; BROWN JF, 1965, J AM CHEM SOC, V87, P4313, DOI 10.1021/ja00947a016; Seki H, 2010, J ORGANOMET CHEM, V695, P1363, DOI 10.1016/j.jorganchem.2010.02.008; Lee EC, 1998, POLYM J, V30, P730, DOI 10.1295/polymj.30.730; FRYE CL, 1971, J AM CHEM SOC, V93, P4599, DOI 10.1021/ja00747a047; Fester GW, 2009, J AM CHEM SOC, V131, P6855, DOI 10.1021/ja901053w; Chang Z. X., 2008, CHEM MATER, V20, P1322; Lee E. C., 2001, KOBUNSHI RONBUNSHU, V58, P319; Li G. L., 2011, INORG ORGANOMET POLY, V11, P3; Lipp E. D., 1991, ANAL CHEM SILICONS; Szczypka W., 2014, J MOL STRUCT, V75, P599; Unno M., 2002, AM CHEM SOC, V124, P4599; Unno M, 2012, INT J POLYM SCI, DOI 10.1155/2012/723892; Xie Z., 1991, POLYM SCI, V9, P260	29	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1574-1443	1574-1451		J INORG ORGANOMET P	J. Inorg. Organomet. Polym. Mater.	NOV	2015	25	6					1353	1361		10.1007/s10904-015-0247-9		9	Polymer Science	Polymer Science	CT8AB	WOS:000363036000007		
J	Ganesh, RS; Durgadevi, E; Navaneethan, M; Raji, P; Ponnusamy, S; Muthamizhchelvan, C; Hayakawa, Y				Ganesh, R. Sankar; Durgadevi, E.; Navaneethan, M.; Raji, P.; Ponnusamy, S.; Muthamizhchelvan, C.; Hayakawa, Y.			Fabrication of bistable switching device using CdS nanorods embedded in PMMA (polymethylmethacrylate) nanocomposite	JOURNAL OF MATERIALS SCIENCE-MATERIALS IN ELECTRONICS			English	Article							NANOPARTICLES; PERFORMANCE; LAYER	An organic bistable memory device was fabricated using CdS NR's/PMMA (polymethylmethacrylate) nanocomposite sandwiched between ITO and Al thin film. XRD analysis confirmed that CdS NR's reveals wurtzite hexagonal phase. FESEM and TEM images showed the monodispersed rod-like morphology. The nanorods were uniformly dispersed in the PMMA (polymethylmethacrylate) layer. EDX spectrum confirms that the product consists of only Cd and S elements. No other impurities were found. UV-visible absorption of CdS NR's showed a slight blue shift. The photoluminescence spectra of CdS NR's spectra showed surface defects which may be due to sulfur vacancies in surface of nanorods. The CdS NR's polymer nanocomposite showed better thermal stability. The current-voltage (C-V) measurement of ITO/CdS NR's/Al showed a clockwise hysteresis with flatband shift voltage in C-V curve for the device.	[Ganesh, R. Sankar; Ponnusamy, S.; Muthamizhchelvan, C.] SRM Univ, Dept Phys & Nanotechnol, Ctr Mat Sci & Nano Devices, Kanchipuram 603203, Tamil Nadu, India; [Durgadevi, E.] Roever Engn Coll, Dept Elect & Commun, Perambalur 621212, Tamil Nadu, India; [Navaneethan, M.; Hayakawa, Y.] Shizuoka Univ, Elect Res Inst, Naka Ku, Hamamatsu, Shizuoka 4328011, Japan; [Raji, P.] Mepco Schlenk Engn Coll, Dept Phys, Sivakasi 626005, Tamil Nadu, India	Ponnusamy, S (reprint author), SRM Univ, Dept Phys & Nanotechnol, Ctr Mat Sci & Nano Devices, Kanchipuram 603203, Tamil Nadu, India.	suruponnus@gmail.com					Khanna PK, 2007, J LUMIN, V127, P474, DOI 10.1016/j.jlumin.2007.02.037; Khurana G, 2014, CARBON, V76, P341, DOI 10.1016/j.carbon.2014.04.085; Tu CH, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2362972; Li GC, 2008, MATER LETT, V62, P1881, DOI 10.1016/j.matlet.2007.10.029; Lee SJ, 2008, MICROELECTRON ENG, V85, P2388, DOI 10.1016/j.mee.2008.09.038; Kim JM, 2012, MICROELECTRON ENG, V98, P305, DOI 10.1016/j.mee.2012.07.101; Thangadurai P, 2009, MATER CHEM PHYS, V114, P420, DOI 10.1016/j.matchemphys.2008.09.048; Ling QD, 2007, POLYMER, V48, P5182, DOI 10.1016/j.polymer.2007.06.025; Jakobsson FLE, 2005, APPL PHYS LETT, V87, DOI 10.1063/1.2008369; Han KW, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3659473; Yun DY, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3596705; Ham JH, 2009, APPL PHYS LETT, V94, DOI 10.1063/1.3097805; Lahewil ASZ, 2012, SOL ENERGY, V86, P3234, DOI 10.1016/j.solener.2012.08.013; Yun DY, 2014, APPL PHYS LETT, V104, DOI 10.1063/1.4861928; Yao WT, 2006, J PHYS CHEM B, V110, P11704, DOI 10.1021/jp060164n; Liping Ma, 2004, Applied Physics Letters, V84, DOI 10.1063/1.1763222; Mingdong Y., 2011, J APPL PHYS, V110; Oyamada T., 2003, APPL PHYS LETT, V83, P1253; Son D. I., 2010, NANO LETT, V10, P2442; Yun D. Y., 2012, APPL PHYS LETT, V101; Yun DY, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3243463	21	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0957-4522	1573-482X		J MATER SCI-MATER EL	J. Mater. Sci.-Mater. Electron.	NOV	2015	26	11					9010	9015		10.1007/s10854-015-3584-0		6	Engineering, Electrical & Electronic; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Engineering; Materials Science; Physics	CT2VP	WOS:000362663300094		
J	Kurt, H; Jia, JJ; Shigesato, Y; Ow-Yang, CW				Kurt, Hasan; Jia, Junjun; Shigesato, Yuzo; Ow-Yang, Cleva W.			Tuning hole charge collection efficiency in polymer photovoltaics by optimizing the work function of indium tin oxide electrodes with solution-processed LiF nanoparticles	JOURNAL OF MATERIALS SCIENCE-MATERIALS IN ELECTRONICS			English	Article							HETEROJUNCTION SOLAR-CELLS; IMPEDANCE SPECTROSCOPY; ORGANIC ELECTRONICS; INTER LAYERS; BULK; TRANSPORT	By varying the density of solution-processed lithium fluoride (sol-LiF) nanoparticles at the interface between tin-doped indium oxide (ITO) and poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS), we have demonstrated that the electronic hole collection efficiency of an organic photovoltaic cell can be optimized through tuning the energy level alignment at the ITO/PEDOT:PSS interface. We synthesized the LiF nanoparticles in solution and deposited them onto ITO electrodes with increasing surface coverage up to 13.2 %. The surface work function of the nanostructured ITO increased linearly from 4.88 to 5.30 eV. When the sol-LiF-modified ITO electrodes were incorporated into polymer solar cells based on a bulk heterojunction of poly(3-hexylthiophene) polymer and methanofullerene, a maximum power conversion efficiency was recorded for a device with an ITO anode modified by 5.3 % of sol-LiF coverage, which corresponded to a measured work function of 5.07 eV. The improvement in short circuit current density by 87 % and power conversion efficiency by 74.3 % suggest that the sol-LiF interlayer density enabled work function tuning of the ITO anode to better match the highest occupied molecular orbital level of PEDOT:PSS, facilitating hole charge collection. The increase in electronic hole collection efficiency is attributed to both a lowered resistance at the ITO modified by sol-LiF and faster hole transport, although these gains are offset by an associated increase in contact polarization. Our findings suggest that the surface work function of ITO can be tuned to improve energy level alignment with other contact layers via the surface density of sol-LiF particles. More efficient hole transport, due to higher recombination resistance, offset by an increased charge extraction barrier presented by contact polarization; the two effects combined give rise to an optimum in sol-LiF nanostructuring of the ITO surface properties.	[Kurt, Hasan; Ow-Yang, Cleva W.] Sabanci Univ, Fac Engn & Nat Sci, TR-34956 Istanbul, Turkey; [Jia, Junjun; Shigesato, Yuzo] Aoyama Gakuin Univ, Grad Sch Sci & Engn, Chuo Ku, Sagamihara, Kanagawa 2525258, Japan; [Ow-Yang, Cleva W.] Sabanci Univ, Nanotechnol Res & Applicat Ctr, TR-34956 Istanbul, Turkey	Ow-Yang, CW (reprint author), Sabanci Univ, Fac Engn & Nat Sci, TR-34956 Istanbul, Turkey.	cleva@sabanciuniv.edu			Scientific and Technological Research Council of Turkey (TUBITAK) [112M360]; BIDEB fellowship	Financial support is acknowledged from the Scientific and Technological Research Council of Turkey (TUBITAK) for Project No. 112M360, also from H. K. for a BIDEB fellowship. The authors are grateful to Prof. Ayse Turak for fruitful discussions and to GUNAM at Middle East Technical University for use of their solar simulator.	Ratcliff EL, 2012, ORG ELECTRON, V13, P744, DOI 10.1016/j.orgel.2012.01.022; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Yan H, 2005, J AM CHEM SOC, V127, P3172, DOI 10.1021/ja044455q; Gliboff M, 2013, LANGMUIR, V29, P2166, DOI 10.1021/la304594t; Murray IP, 2011, J PHYS CHEM LETT, V2, P3006, DOI 10.1021/jz201493d; Suckow S, 2014, PROG PHOTOVOLTAICS, V22, P494, DOI 10.1002/pip.2301; Wong KW, 2002, APPL PHYS LETT, V80, P2788, DOI 10.1063/1.1469220; Li CY, 2008, J MATER CHEM, V18, P4478, DOI 10.1039/b807182a; Irwin MD, 2008, P NATL ACAD SCI USA, V105, P2783, DOI 10.1073/pnas.0711990105; Li G, 2005, NAT MATER, V4, P864, DOI 10.1038/nmat1500; Gliboff M, 2013, J PHYS CHEM C, V117, P15139, DOI 10.1021/jp404033e; Kim JS, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2778548; Ratcliff EL, 2011, J PHYS CHEM LETT, V2, P1337, DOI 10.1021/jz2002259; Garcia-Belmonte G, 2008, ORG ELECTRON, V9, P847, DOI 10.1016/j.orgel.2008.06.007; Strobel T, 2010, PHYS REV LETT, V105, DOI 10.1103/PhysRevLett.105.266602; Bubnova O, 2014, NAT MATER, V13, P190, DOI [10.1038/nmat3824, 10.1038/NMAT3824]; Krebs FC, 2010, NANOSCALE, V2, P873, DOI 10.1039/b9nr00430k; Steirer KX, 2011, ADV ENERGY MATER, V1, P813, DOI 10.1002/aenm.201100234; Ma H, 2010, ADV FUNCT MATER, V20, P1371, DOI 10.1002/adfm.200902236; Aernouts T, 2002, THIN SOLID FILMS, V403, P297, DOI 10.1016/S0040-6090(01)01584-X; Kippelen B, 2009, ENERG ENVIRON SCI, V2, P251, DOI 10.1039/b812502n; Sondergaard R, 2012, MATER TODAY, V15, P36; Turak A, 2013, RSC ADV, V3, P6188, DOI 10.1039/c2ra22770c; Turak A, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.4729932; Green MA, 2012, PROG PHOTOVOLTAICS, V20, P12, DOI 10.1002/pip.2163; Kang B, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2983742; Yoon WJ, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2830619; Helander MG, 2011, SCIENCE, V332, P944, DOI 10.1126/science.1202992; Chaudhary S, 2007, NANO LETT, V7, P1973, DOI 10.1021/nl070717l; Wagenpfahl A, 2010, IEEE J SEL TOP QUANT, V16, P1759, DOI 10.1109/JSTQE.2010.2042142; Pingree LSC, 2008, J PHYS CHEM C, V112, P7922, DOI 10.1021/jp711838h; Garcia-Belmonte G, 2013, J PHYS CHEM LETT, V4, P877, DOI 10.1021/jz302064z; Zhou YH, 2012, SCIENCE, V336, P327, DOI 10.1126/science.1218829; Waldauf C, 2006, J APPL PHYS, V99, DOI 10.1063/1.2198930; Aytun T, 2012, NANO LETT, V12, P39, DOI 10.1021/nl202838a; Ow-Yang CW, 2014, THIN SOLID FILMS, V559, P58, DOI 10.1016/j.tsf.2013.11.035; Bondarenko AS, 2005, Progress in Chemometrics Research, P89; Shrotriya V, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2174093; Yip HL, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2919524	39	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0957-4522	1573-482X		J MATER SCI-MATER EL	J. Mater. Sci.-Mater. Electron.	NOV	2015	26	11					9205	9212		10.1007/s10854-015-3613-z		8	Engineering, Electrical & Electronic; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Engineering; Materials Science; Physics	CT2VP	WOS:000362663300123		
J	Hanahara, K				Hanahara, Kazuyuki			Incremental Forward Kinematics of Wire-Suspended Parallel Mechanical System (A Many-Worlds Interpretation Approach)	JOURNAL OF MECHANISMS AND ROBOTICS-TRANSACTIONS OF THE ASME			English	Article							WRENCH-FEASIBLE WORKSPACE; ROBOTS; DESIGN; MANIPULATORS	In this paper, we discuss an incremental forward kinematics of wire-suspended mechanical systems. In order to deal with a mechanical system of this type, we have to take into account the characteristic property of a wire, in that it cannot take any compressive force. We give a general formulation and its solution of the incremental forward kinematics problem taking account of the slack condition of a wire. We also consider the influence of displacement of the mass center position of the suspended platform on the kinematic behavior of the system. An interval arithmetic approach is proposed to deal with the uncertainty in the kinematic parameters. One of the important points is that the number of possible solutions of the formulated incremental kinematics problem is often more than one. We introduce a kind of parallelism, referred to as the "many-worlds interpretation" taken from the quantum mechanics theory, to this problem and offer an approach to deal with plural possible kinematic states simultaneously. The developed approach is based on basic equations in general form and is applicable to various wire-suspended mechanical systems. The feasibility of the proposed incremental kinematics approach is demonstrated by example calculations of three-, six-, and eight-wire systems. On the basis of the example forward kinematics calculation results, we conclude the following. The influence of displacement of mass center position of the platform is not insignificant. The number of possible kinematic states becomes large in the case of the neighborhood of singular configuration. In spite of an incremental kinematics based on linearization, the required computational cost of the proposed parallelism approach is considerable; it is, however, demonstrated that the proposed approach is still fairly practical from the viewpoint of computation. The developed approach cannot deal with drastic change in kinematic configuration in a single incremental step, since it is based on linearization of the kinematic relation; however, the approach can distinguish such discontinuity.	Kobe Univ, Dept Syst Engn, Grad Sch Syst Informat, Nada Ku, Kobe, Hyogo 6578501, Japan	Hanahara, K (reprint author), Kobe Univ, Dept Syst Engn, Grad Sch Syst Informat, Nada Ku, Kobe, Hyogo 6578501, Japan.	hanahara@cs.kobe-u.ac.jp					Abbasnejad G., 2013, 6 INT WORKSH COMP KI, P49; Oftadeh R, 2010, IEEE INT C INT ROBOT, P2295; Pusey J, 2004, MECH MACH THEORY, V39, P761, DOI 10.1016/j.mechmachtheory.2004.02.010; Carricato M, 2013, J MECH ROBOT, V5, DOI 10.1115/1.4024293; ALBUS J, 1992, J RES NATL INST STAN, V97, P373, DOI 10.6028/jres.097.016; Merlet JP, 2009, COMPUTATIONAL KINEMATICS, PROCEEDINGS, P1, DOI 10.1007/978-3-642-01947-0_1; Fattah A, 2005, J MECH DESIGN, V127, P1021, DOI 10.1115/1.1903001; Bosscher P, 2006, IEEE T ROBOT, V22, P890, DOI 10.1109/TRO.2006.878967; Roberts RG, 1998, J ROBOTIC SYST, V15, P581, DOI 10.1002/(SICI)1097-4563(199810)15:10<581::AID-ROB4>3.3.CO;2-O; Abbasnejad G, 2012, MECCANICA, V47, P1761, DOI 10.1007/s11012-012-9552-3; Merlet JP, 2008, IEEE INT CONF ROBOT, P3857, DOI 10.1109/ROBOT.2008.4543803; Carricato M, 2013, IEEE T ROBOT, V29, P288, DOI 10.1109/TRO.2012.2217795; Gouttefarde M, 2007, IEEE INT CONF ROBOT, P1492, DOI 10.1109/ROBOT.2007.363195; Oh SR, 2005, IEEE T ROBOT, V21, P457, DOI 10.1109/TRO.2004.838029; Hiller M, 2005, MECH MACH THEORY, V40, P429, DOI 10.1016/j.mechmachtheory.2004.08.002; Merlet JP, 2013, IEEE INT CONF ROBOT, P4635, DOI 10.1109/ICRA.2013.6631236; Borgstrom PH, 2009, IEEE T ROBOT, V25, P325, DOI 10.1109/TRO.2009.2012339; Agahi M, 2009, T CAN SOC MECH ENG, V33, P561; Berti A., 2013, CABLE DRIVEN PARALLE, V12, P251; Bisoh Nihon, 2014, TEMP SUSP PLATF; Bruckmann T., 2008, PARALLEL MANIPULATOR, P109; Carricato M., 2013, CABLE DRIVEN PARALLE, P269; Craig J. J., 1989, INTRO ROBOTICS MECH; Hansen E., 1992, GLOBAL OPTIMIZATION; Lafourcade P., 2002, WORKSH FUND ISS FUT, P187; Merlet J., 2006, PARALLEL ROBOTS; Merlet J.-P., 2013, 6 INT WORKSH COMP KI, P9; Merlet J.-P., 2013, ROMANSY 19 ROBOT DES; Ottaviano E., 2007, 15 MED C CONTR AUT M; Perreault S, 2008, J MECH DESIGN, V130, DOI 10.1115/1.2965607; Vaidman L., 2008, STANFORD ENCY PHILOS	31	0	0	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	1942-4302	1942-4310		J MECH ROBOT	J. Mech. Robot.	NOV	2015	7	4							041021	10.1115/1.4030163		16	Engineering, Mechanical; Robotics	Engineering; Robotics	CT5JD	WOS:000362844000021		
J	Murayama, T; Maruyama, IN				Murayama, Takashi; Maruyama, Ichiro N.			Alkaline pH Sensor Molecules	JOURNAL OF NEUROSCIENCE RESEARCH			English	Review						alkalinity; pH sensation; cell surface receptor; channel; TRP	DOMAIN K+ CHANNELS; NEMATODE CAENORHABDITIS-ELEGANS; ICHTHYOSIS-DEAFNESS SYNDROME; RECEPTOR-RELATED RECEPTOR; GATED CHLORIDE CHANNELS; ROOT GANGLION NEURONS; 2-PORE DOMAIN; INTRACELLULAR PH; DEPENDENT MODULATION; EXTRACELLULAR PH	Animals can survive only within a narrow pH range. This requires continual monitoring of environmental and body-fluid pH. Although a variety of acidic pH sensor molecules have been reported, alkaline pH sensor function is not well understood. This Review describes neuronal alkaline pH sensors, grouped according to whether they monitor extracellular or intracellular alkaline pH. Extracellular sensors include the receptor-type guanylyl cyclase, the insulin receptor-related receptor, ligand-gated Cl- channels, connexin hemichannels, two-pore-domain K+ channels, and transient receptor potential (TRP) channels. Intracellular sensors include TRP channels and gap junction channels. Identification of molecular mechanisms underlying alkaline pH sensing is crucial for understanding how animals respond to environmental alkaline pH and how body-fluid pH is maintained within a narrow range. (C) 2015 Wiley Periodicals, Inc.	[Murayama, Takashi; Maruyama, Ichiro N.] Okinawa Inst Sci & Technol Grad Univ, Informat Proc Biol Unit, Okinawa 9040495, Japan	Maruyama, IN (reprint author), Okinawa Inst Sci & Technol Grad Univ, Informat Proc Biol Unit, 1919-1 Tancha, Okinawa 9040495, Japan.	ichi@oist.jp			Okinawa Institute of Science and Technology Graduate University	Contract grant sponsor: Okinawa Institute of Science and Technology Graduate University.	Ransom BR, 1996, TRENDS NEUROSCI, V19, P352, DOI 10.1016/0166-2236(96)10045-X; Dhaka A, 2009, J NEUROSCI, V29, P153, DOI 10.1523/JNEUROSCI.4901-08.2009; ROOS A, 1981, PHYSIOL REV, V61, P296; Milius M, 2006, J INSECT PHYSIOL, V52, P960, DOI 10.1016/j.jinsphys.2006.06.003; Baker MD, 1999, NEUROSCIENCE, V92, P1119, DOI 10.1016/S0306-4522(99)00058-5; Duprat F, 2000, MOL PHARMACOL, V57, P906; Schalper KA, 2010, AM J PHYSIOL-CELL PH, V299, pC1504, DOI 10.1152/ajpcell.00015.2010; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; Murayama T, 2013, CURR BIOL, V23, P1007, DOI 10.1016/j.cub.2013.04.052; Palacios-Prado N, 2009, J PHYSIOL-LONDON, V587, P3251, DOI 10.1113/jphysiol.2009.171496; Warth R, 2004, P NATL ACAD SCI USA, V101, P8215, DOI 10.1073/pnas.0400081101; Tombaugh GC, 1996, J PHYSIOL-LONDON, V493, P719; Bryant BP, 2005, CHEM SENSES, V30, pI196, DOI 10.1093/chemse/bjh182; Casey JR, 2010, NAT REV MOL CELL BIO, V11, P50, DOI 10.1038/nrm2820; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Shimizu T, 2011, PFLUG ARCH EUR J PHY, V461, P507, DOI 10.1007/s00424-011-0934-5; Girard C, 2001, BIOCHEM BIOPH RES CO, V282, P249, DOI 10.1006/bbrc.2001.4562; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Bayliss DA, 2008, TRENDS PHARMACOL SCI, V29, P566, DOI 10.1016/j.tips.2008.07.013; Shah MJ, 2001, J NEUROPHYSIOL, V85, P1051; Dermauw W, 2012, INSECT BIOCHEM MOLEC, V42, P455, DOI 10.1016/j.ibmb.2012.03.002; Gonzalez-Nieto D, 2008, P NATL ACAD SCI USA, V105, P17169, DOI 10.1073/pnas.0804189105; Chandrasekhar A, 2012, CELL BIOCHEM FUNCT, V30, P89, DOI 10.1002/cbf.2794; HARTWELL SI, 1986, HYDROBIOLOGIA, V131, P63, DOI 10.1007/BF00008325; West DW, 1997, NEW ZEAL J MAR FRESH, V31, P461; Ripps H, 2004, CELL MOL NEUROBIOL, V24, P647, DOI 10.1023/B:CEMN.0000036403.43484.3d; Sun HS, 2013, ACTA PHARMACOL SIN, V34, P24, DOI 10.1038/aps.2012.138; Stoop R, 1997, J NEUROPHYSIOL, V78, P1837; PAJE F, 1984, OECOLOGIA, V64, P41, DOI 10.1007/BF00377541; John SJ, 2009, CHEM SENSES, V34, P487, DOI 10.1093/chemse/bjp023; SEKIZAWA S, 1994, RESP PHYSIOL, V96, P37, DOI 10.1016/0034-5687(94)90104-X; Cruz O, 2005, NEUROSCIENCE, V132, P115, DOI 10.1016/j.neuroscience.2005.01.003; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; Dent JA, 2006, J MOL EVOL, V62, P523, DOI 10.1007/s00239-005-0018-2; LILJESTRAND G, 1956, ACTA PHYSIOL SCAND, V35, P380; Reyes R, 2000, NEUROSCIENCE, V95, P893; Venkatachalam K, 2007, ANNU REV BIOCHEM, V76, P387, DOI 10.1146/annurev.biochem.75.103004.142819; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Warn-Cramer BJ, 2004, BBA-BIOMEMBRANES, V1662, P81, DOI 10.1016/j.bbamem.2003.10.018; Anselmi F, 2008, P NATL ACAD SCI USA, V105, P18770, DOI [10.1073/pnas.0800793105, 10.1073/pnas.080079310S]; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Schnizler K, 2005, J BIOL CHEM, V280, P16254, DOI 10.1074/jbc.M411759200; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Delmar M, 2004, CARDIOVASC RES, V62, P268, DOI 10.1016/j.cardiores.2003.12.030; Wang S, 2013, J NEUROSCI, V33, P16033, DOI 10.1523/JNEUROSCI.2451-13.2013; WRIGHT PA, 1985, J EXP BIOL, V114, P329; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Wang WG, 1998, J PHYSIOL-LONDON, V511, P433, DOI 10.1111/j.1469-7793.1998.433bh.x; Maxeiner S, 2003, NEUROSCIENCE, V119, P689, DOI 10.1016/S0306-4522(03)00077-0; Mogyoros I, 1997, BRAIN, V120, P317, DOI 10.1093/brain/120.2.317; Shimizu T, 2009, PFLUG ARCH EUR J PHY, V457, P795, DOI 10.1007/s00424-008-0558-6; Yamamoto Y, 2002, BRAIN RES, V950, P304, DOI 10.1016/S0006-8993(02)03181-5; Lu YT, 2012, NEUROSCI LETT, V525, P117, DOI 10.1016/j.neulet.2012.07.034; Richerson GB, 2001, RESP PHYSIOL, V129, P175, DOI 10.1016/S0034-5687(01)00289-4; Vassilatis DK, 1997, J MOL EVOL, V44, P501, DOI 10.1007/PL00006174; Kreuzberg MM, 2008, MOL CELL NEUROSCI, V37, P119, DOI 10.1016/j.mcn.2007.09.003; Li H, 2005, PROTEINS, V61, P704, DOI 10.1002/prot.20660; Deitmer JW, 2010, BRAIN RES REV, V63, P113, DOI 10.1016/j.brainresrev.2009.10.006; BURNS NC, 1971, J NEMATOL, V3, P238; Niemeyer MI, 2007, P NATL ACAD SCI USA, V104, P666, DOI 10.1073/pnas.0606173104; Lotshaw DP, 2007, CELL BIOCHEM BIOPHYS, V47, P209, DOI 10.1007/s12013-007-0007-8; Deyev IE, 2011, CELL METAB, V13, P679, DOI 10.1016/j.cmet.2011.03.022; Fujita F, 2008, J CLIN INVEST, V118, P4049, DOI 10.1172/JCI35957; Kim Y, 2001, PFLUG ARCH EUR J PHY, V442, P64, DOI 10.1007/s004240000496; Ishimaru Y, 2006, P NATL ACAD SCI USA, V103, P12569, DOI 10.1073/pnas.0602702103; Potter LR, 2011, CELL SIGNAL, V23, P1921, DOI 10.1016/j.cellsig.2011.09.001; MIRONOV SL, 1991, PFLUG ARCH EUR J PHY, V419, P138, DOI 10.1007/BF00372999; Morton MJ, 2003, PFLUG ARCH EUR J PHY, V445, P577, DOI 10.1007/s00424-002-0901-2; Lyall V, 2002, J GEN PHYSIOL, V120, P793, DOI 10.1085/jgp.20028656; Kiss L, 1999, J NEUROPHYSIOL, V81, P1839; Palacios-Prado N, 2010, P NATL ACAD SCI USA, V107, P9897, DOI 10.1073/pnas.1004552107; Shtonda BB, 2006, J EXP BIOL, V209, P89, DOI 10.1242/jeb.01955; Mounsey Kate E., 2007, Invertebrate Neuroscience, V7, P149, DOI 10.1007/s10158-007-0050-6; Mulkey DK, 2004, NAT NEUROSCI, V7, P1360, DOI 10.1038/nn1357; Zhao HB, 2005, EUR J NEUROSCI, V21, P1859, DOI 10.1111/j.1460-9568.2005.04031.x; Caterina MJ, 1997, NATURE, V389, P816; DOUGHERTY JE, 1991, HYDROBIOLOGIA, V215, P73, DOI 10.1007/BF00005902; REINHARDT RR, 1993, ENDOCRINOLOGY, V133, P3, DOI 10.1210/en.133.1.3; Pandey KN, 2011, FEBS J, V278, P1792, DOI 10.1111/j.1742-4658.2011.08081.x; Zheng J, 2013, COMPR PHYSIOL, V3, P221, DOI 10.1002/cphy.c120001; Rousk J, 2010, ISME J, V4, P1340, DOI 10.1038/ismej.2010.58; Merivee E, 2005, PHYSIOL ENTOMOL, V30, P122, DOI 10.1111/j.1365-3032.2005.00435.x; Yu JS, 2007, J BIOL CHEM, V282, P8895, DOI 10.1074/jbc.M609317200; WILGENBUS KK, 1992, INT J CANCER, V51, P522, DOI 10.1002/ijc.2910510404; YE XM, 1991, FISH PHYSIOL BIOCHEM, V9, P15, DOI 10.1007/BF01987607; Huang AL, 2006, NATURE, V442, P934, DOI [10.1038/nature05084, 10.1038/nature050084]; Kang DW, 2004, BIOCHEM BIOPH RES CO, V315, P836, DOI 10.1016/j.bbrc.2004.01.137; Mulkey DK, 2007, J NEUROSCI, V27, P14049, DOI 10.1523/JNEUROSCI.4254-07.2007; Feldman JL, 2013, ANNU REV PHYSIOL, V75, P423, DOI 10.1146/annurev-physiol-040510-130049; Wang WG, 2001, J NEUROPHYSIOL, V85, P2224; Skeberdis VA, 2011, J PHYSIOL-LONDON, V589, P3495, DOI 10.1113/jphysiol.2011.209072; Sassa T, 2013, NEUROSCI LETT, V555, P248, DOI 10.1016/j.neulet.2013.06.001; Sanchez HA, 2014, J BIOL CHEM, V289, P21519, DOI 10.1074/jbc.M114.578757; Huang RQ, 1999, J NEUROPHYSIOL, V82, P1233; PAPPAS CA, 1994, J NEUROPHYSIOL, V72, P2816; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Holzer P, 2003, CURR OPIN PHARMACOL, V3, P618, DOI 10.1016/j.coph.2003.06.008; Srivastava J, 2007, PHYSIOLOGY, V22, P30, DOI 10.1152/physiol.00035.2006; Lo CW, 1997, DEV GENET, V20, P119, DOI 10.1002/(SICI)1520-6408(1997)20:2<119::AID-DVG5>3.0.CO;2-A; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Chao YC, 2015, EMBO J, V34, P294, DOI 10.15252/embj.201489652; Duprat F, 2005, J PHYSIOL-LONDON, V562, P235, DOI 10.1113/jphysiol.2004.071266; DUSENBER.DB, 1974, J EXP ZOOL, V188, P41, DOI 10.1002/jez.1401880105; Giaume C, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00088; Levin LR, 2015, ANNU REV PHYSIOL, V77, P347, DOI 10.1146/annurev-physiol-021014-071821; Murayama Takashi, 2013, Commun Integr Biol, V6, pe26633, DOI 10.4161/cib.26633; Ruminot I, 2011, J NEUROSCI, V31, P14264, DOI 10.1523/JNEUROSCI.2310-11.2011; Saez PJ, 2014, MEDIAT INFLAMM, DOI 10.1155/2014/742734; Takahashi N, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00058; Sanchez HA, 2014, FRONT CELL NEUROSCI, V8, DOI [10.3389/fncel.2014.00354, 10.3389/fnce1.2014.00354]; Wolstenholme AJ, 2012, J BIOL CHEM, V287, P40232, DOI 10.1074/jbc.R112.406280	112	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV	2015	93	11					1623	1630		10.1002/jnr.23621		8	Neurosciences	Neurosciences & Neurology	CT5ET	WOS:000362831800001		
J	Takeda, A; Shakushi, Y; Tamano, H				Takeda, Atsushi; Shakushi, Yukina; Tamano, Haruna			Modification of Hippocampal Excitability in Brain Slices Pretreated With a Low Nanomolar Concentration of Zn2+	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						artificial cerebrospinal fluid; Zn2+; brain slice; hippocampus	LONG-TERM POTENTIATION; NEOCORTICAL PYRAMIDAL NEURONS; OBJECT RECOGNITION MEMORY; METHYL-D-ASPARTATE; SYNAPTIC PLASTICITY; MICROMOLAR CONCENTRATIONS; NMDA RECEPTORS; ZINC; CALCIUM; MOSSY	Synaptic Zn2+ homeostasis may be changed during brain slice preparation. However, much less attention has been paid to Zn2+ in artificial cerebrospinal fluid (ACSF) used for slice experiments than has been paid to Ca2+. The present study assesses addition of Zn2+ to ACSF, focused on hippocampal excitability after acute brain slice preparation. When the static levels of intracellular Zn2+ and Ca2+ were compared between brain slices prepared with conventional ACSF without Zn2+ and those pretreated with ACSF containing 20 nM ZnCl2 for 1 hr, both levels were almost the same. On the other hand, intracellular Ca2+ levels were significantly increased in the stratum lucidum of the control brain slices after stimulation with high K+, although the increase was significantly suppressed by the pretreatment with ACSF containing Zn2+, suggesting that neuronal excitation is enhanced in brain slices prepared with ACSF without Zn2+. The increase in extracellular Zn2+ level, an index of glutamate release, after stimulation with high K+ was also significantly suppressed by pretreatment with ACSF containing Zn2+. When mossy fiber excitation was assessed in brain slices with FM4-64, an indicator of presynaptic activity, attenuation of FM 4-64 fluorescence based on presynaptic activity was suppressed in the stratum lucidum of brain slices pretreated with ACSF containing Zn2+. The present study indicates that hippocampal excitability is enhanced in brain slices prepared with ACSF without Zn2+. It is likely that a low nanomolar concentration of Zn2+ is necessary for ACSF. (C) 2015 Wiley Periodicals, Inc.	[Takeda, Atsushi; Shakushi, Yukina; Tamano, Haruna] Univ Shizuoka, Sch Pharmaceut Sci, Dept Neurophysiol, Shizuoka 4228526, Japan	Takeda, A (reprint author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Neurophysiol, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	takedaa@u-shizuoka-ken.ac.jp					Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Takeda A, 2013, METALLOMICS, V5, P417, DOI 10.1039/c3mt20269k; Takeda A, 2007, J NEUROSCI RES, V85, P1310, DOI 10.1002/jnr.21233; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Takeda A, 2015, NEUROSCIENCE, V304, P209, DOI 10.1016/j.neuroscience.2015.07.042; Suh SW, 2000, BRAIN RES, V879, P7, DOI 10.1016/S0006-8993(00)02675-5; Alberdi E, 2010, CELL CALCIUM, V47, P264, DOI 10.1016/j.ceca.2009.12.010; Zakharenko SS, 2001, NAT NEUROSCI, V4, P711, DOI 10.1038/89498; Takeda A, 2009, NEUROSCIENCE, V158, P585, DOI 10.1016/j.neuroscience.2008.10.009; Brown AM, 2002, J NEUROPHYSIOL, V88, P1302, DOI 10.1152/jn.00113.2002; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Kim NK, 2011, EUR J NEUROSCI, V34, P199, DOI 10.1111/j.1460-9568.2011.07768.x; Frederickson CJ, 2006, EXP NEUROL, V198, P285, DOI 10.1016/j.expneurol.2005.08.030; Lorca RA, 2011, EUR J NEUROSCI, V33, P1175, DOI 10.1111/j.1460-9568.2010.07589.x; Wang T, 2004, J NEUROSURG ANESTH, V16, P201, DOI 10.1097/00008506-200407000-00004; Izumi Y, 2006, J NEUROSCI, V26, P7181, DOI 10.1523/JNEUROSCI.1258-06.2006; Pan EH, 2011, NEURON, V71, P1116, DOI 10.1016/j.neuron.2011.07.019; Takeda A, 2007, J NEUROSCI RES, V85, P3666, DOI 10.1002/jnr.21449; Teyler TJ, 1999, METHODS, V18, P109, DOI 10.1006/meth.1999.0764; Li Y, 2001, J NEUROSCI, V21, P8015; Minami A, 2006, J NEUROSCI RES, V83, P167, DOI 10.1002/jnr.20714; Ueno S, 2002, J CELL BIOL, V158, P215, DOI 10.1083/jcb.200204066; STRINGER JL, 1988, EXP NEUROL, V101, P132, DOI 10.1016/0014-4886(88)90070-2; Suzuki M, 2015, NEUROCHEM INT, V87, P60, DOI 10.1016/j.neuint.2015.05.006; DeFazio T, 1998, J NEUROPHYSIOL, V80, P1670; Hille B., 1984, IONIC CHANNELS EXCIT; Takeda A, 2014, J NEUROSCI RES, V92, P819, DOI 10.1002/jnr.23385; Takeda A, 2015, EXPER OPIN THER TAR, V19, P1; Takeda A, 2014, HIPPOCAMPUS, V24, P1404, DOI 10.1002/hipo.22322	32	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV	2015	93	11					1641	1647		10.1002/jnr.23629		7	Neurosciences	Neurosciences & Neurology	CT5ET	WOS:000362831800003		
J	Ishigami, A; Masutomi, H; Handa, S; Nakamura, M; Nakaya, S; Uchida, Y; Saito, Y; Murayama, S; Jang, B; Jeon, YC; Choi, EK; Kim, YS; Kasahara, Y; Maruyama, N; Toda, T				Ishigami, Akihito; Masutomi, Hirofumi; Handa, Setsuko; Nakamura, Megumi; Nakaya, Shuuichi; Uchida, Yoshiaki; Saito, Yuko; Murayama, Shigeo; Jang, Byungki; Jeon, Yong-Chul; Choi, Eun-Kyoung; Kim, Yong-Sun; Kasahara, Yasushi; Maruyama, Naoki; Toda, Tosifusa			Mass Spectrometric Identification of Citrullination Sites and Immunohistochemical Detection of Citrullinated Glial Fibrillary Acidic Protein in Alzheimer's Disease Brains	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						Alzheimer's disease; citrullinated glial fibrillary acidic protein; neurodegenerative disorder; peptidylarginine deiminase; mass spectrometric analysis	PEPTIDYLARGININE DEIMINASE 2; SCRAPIE-INFECTED MICE; RAT-BRAIN; MULTIPLE-SCLEROSIS; RHEUMATOID-ARTHRITIS; LOCALIZATION; MYELIN; NEURODEGENERATION; PATHOGENESIS; EXPRESSION	Peptidylarginine deiminases (PADs) are posttranslational modification enzymes that convert protein arginine to citrulline residues in a calcium ion-dependent manner. Previously, we reported the abnormal accumulation of citrullinated proteins and the increase in the amount of PAD2 in hippocampi from Alzheimer's disease (AD) patients. Moreover, glial fibrillary acidic protein (GFAP), an astrocyte-specific marker protein, and vimentin were identified as citrullinated proteins by using two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry. To clarify the substrate specificity of PADs against GFAP, we prepared recombinant human (rh) PAD1, rhPAD2, rhPAD3, rhPAD4, and rhGFAP. After incubation of rhGFAP with rhPAD1, rhPAD2, rhPAD3, and rhPAD4, citrullinated (cit-) rhGFAP was detected by Western blotting. The citrullination of rhGFAP by rhPAD2 was unique, specific, and time dependent; additionally, rhPAD1 slightly citrullinated rhGFAP. We then generated eight anti-cit-rhGFAP monoclonal antibodies, CTGF-125, -128, -129, -1212, -1213, -1221, -122R, and -1224R, which reacted specifically with cit-rhGFAP. Two of those eight monoclonal antibodies, CTGF-122R and -1224R, reacted with both cit-rhGFAP and rhGFAP in Western blots. By using the CTGF-1221 antibody and a tandem mass spectrometer, we identified the two independent citrullination sites (R270Cit and R416Cit) of cit-rhGFAP. Immunohistochemical analysis with CTGF-1221 antibody revealed cit-GFAP staining in the hippocampus of AD brain, and the cit-GFAP-positive cells appeared to be astrocyte-like cells. These collective results strongly suggest that PAD2 is responsible for the citrullination of GFAP in the progression of AD and that the monoclonal antibody CTGF-1221, reacting with cit-GFAP at R270Cit and R416Cit, is useful for immunohistochemical investigation of AD brains. (C) 2015 Wiley Periodicals, Inc.	[Ishigami, Akihito; Masutomi, Hirofumi; Handa, Setsuko; Nakamura, Megumi; Kasahara, Yasushi; Maruyama, Naoki] Tokyo Metropolitan Inst Gerontol, Mol Regulat Aging, Tokyo 1730015, Japan; [Nakaya, Shuuichi] Shimadzu Co Ltd, Global Applicat Dev Ctr, Kyoto, Japan; [Uchida, Yoshiaki; Kasahara, Yasushi] Fujirebio Inc, Div Res & Dev, Tokyo, Japan; [Saito, Yuko; Murayama, Shigeo] Tokyo Metropolitan Inst Gerontol, Dept Neuropathol, Itabashi Ku, Tokyo 1730015, Japan; [Jang, Byungki; Jeon, Yong-Chul; Choi, Eun-Kyoung; Kim, Yong-Sun] Hallym Univ, Ilsong Inst Life Sci, Anyang, Gyeonggi Do, South Korea; [Toda, Tosifusa] Yokohama City Univ, Adv Med Res Ctr, Yokohama, Kanagawa 232, Japan	Ishigami, A (reprint author), Tokyo Metropolitan Inst Gerontol, Mol Regulat Aging, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	ishigami@tmig.or.jp			Japan Society for the Promotion of Science KAKENHI [24659169, 15K15104]	Contract grant sponsor: Japan Society for the Promotion of Science KAKENHI; Contract grant number: 24659169 (to A. I); Contract grant number: 15K15104 (to A. I.).	Mastronardi FG, 2006, J NEUROSCI, V26, P11387, DOI 10.1523/JNEUROSCI.3349-06.2006; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Asaga H, 2000, BIOMED RES-TOKYO, V21, P197; Jang B, 2011, J NEUROPATH EXP NEUR, V70, P116, DOI 10.1097/NEN.0b013e318207559e; HAUN SE, 1992, BRAIN RES, V593, P45, DOI 10.1016/0006-8993(92)91261-C; ASAGA H, 1993, CELL BIOL INT, V17, P525, DOI 10.1006/cbir.1993.1094; Jang B, 2008, AM J PATHOL, V173, P1129, DOI 10.2353/ajpath.2008.080388; Jang B, 2010, ACTA NEUROPATHOL, V119, P199, DOI 10.1007/s00401-009-0625-x; Senshu T, 1996, BIOCHEM BIOPH RES CO, V225, P712, DOI 10.1006/bbrc.1996.1240; Maccioni RB, 2001, ARCH MED RES, V32, P367, DOI 10.1016/S0188-4409(01)00316-2; Wood DD, 2008, LAB INVEST, V88, P354, DOI 10.1038/labinvest.3700748; Hossmann KA, 1999, ADV EXP MED BIOL, V474, P155; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Toda T, 1998, ELECTROPHORESIS, V19, P344, DOI 10.1002/elps.1150190232; IMPARL JM, 1995, ARCH BIOCHEM BIOPHYS, V318, P370, DOI 10.1006/abbi.1995.1242; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8; Ishigami A, 1996, BIOCHEM BIOPH RES CO, V223, P299, DOI 10.1006/bbrc.1996.0888; MOSCARELLO MA, 1994, J CLIN INVEST, V94, P146, DOI 10.1172/JCI117300; Jang B, 2013, PRION, V7, P42, DOI 10.4161/pri.22380; VINCENT SR, 1992, J CHEM NEUROANAT, V5, P159, DOI 10.1016/0891-0618(92)90041-N; TERAKAWA H, 1991, J BIOCHEM-TOKYO, V110, P661; Jang B, 2012, BIOCHEM J, V445, P183, DOI 10.1042/BJ20120025; Ishigami A, 2001, BIOMED RES-TOKYO, V22, P63; Moscarello MA, 2007, NEUROCHEM RES, V32, P251, DOI 10.1007/s11064-006-9144-5; Asaga H, 2002, NEUROSCI LETT, V326, P129, DOI 10.1016/S0304-3940(02)00334-8; Keilhoff G, 2008, DEV NEUROBIOL, V68, P101, DOI 10.1002/dneu.20578; Tarcsa E, 1996, J BIOL CHEM, V271, P30709; Asaga H, 2001, NEUROSCI LETT, V299, P5, DOI 10.1016/S0304-3940(00)01735-3; Ishigami A, 2013, MOD RHEUMATOL, V23, P794, DOI 10.1007/s10165-012-0748-0; KUBILUS J, 1983, BIOCHIM BIOPHYS ACTA, V745, P285, DOI 10.1016/0167-4838(83)90060-2; Ishigami A, 2002, ARCH BIOCHEM BIOPHYS, V407, P25, DOI 10.1016/S0003-9861(02)00516-7; De Rycke L, 2005, ARTHRITIS RHEUM, V52, P2323, DOI 10.1002/art.21220; Nicholas AP, 2011, NEUROSCI LETT, V495, P26, DOI 10.1016/j.neulet.2011.03.028; SENSHU T, 1992, ANAL BIOCHEM, V203, P94, DOI 10.1016/0003-2697(92)90047-B; [Anonymous], 1997, NEUROBIOL AGING S4, V18, pS1; Ishigami A, 2005, J NEUROSCI RES, V80, P120, DOI 10.1002/jnr.20431; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Musse AA, 2008, DIS MODEL MECH, V1, P229, DOI 10.1242/dmm.000729; Akiyama K, 1999, NEUROSCI LETT, V274, P53, DOI 10.1016/S0304-3940(99)00678-3; Hao G, 2009, J AM SOC MASS SPECTR, V20, P723, DOI 10.1016/j.jasms.2008.12.012; Ishigami A, 2010, GERIATR GERONTOL INT, V10, pS53, DOI 10.1111/j.1447-0594.2010.00593.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMENSA JWE, 1993, J NEUROCHEM, V61, P987, DOI 10.1111/j.1471-4159.1993.tb03612.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	45	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV	2015	93	11					1664	1674		10.1002/jnr.23620		11	Neurosciences	Neurosciences & Neurology	CT5ET	WOS:000362831800005		
J	Ojino, K; Shimazawa, M; Izawa, H; Nakano, Y; Tsuruma, K; Hara, H				Ojino, Kazuki; Shimazawa, Masamitsu; Izawa, Hiroshi; Nakano, Yukimichi; Tsuruma, Kazuhiro; Hara, Hideaki			Involvement of Endoplasmic Reticulum Stress in Optic Nerve Degeneration After Chronic High Intraocular Pressure in DBA/2J Mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						astrocytes; endoplasmic reticulum stress; glaucoma; optic nerve	UNFOLDED PROTEIN RESPONSE; RETINAL CELL-DEATH; ER STRESS; GLAUCOMA MODEL; IRIS ATROPHY; DISEASE; NEURODEGENERATION; ASTROCYTES; CHAPERONE; PATHWAY	DBA/2J mice are one of several animal strains used for experimental models of both intraocular hypertension and glaucoma. This study investigates the relationship between endoplasmic reticulum (ER) stress and optic nerve degeneration in DBA/2J mice. Intraocular pressure (IOP) was measured in DBA/2J mice between the ages of 6 and 15 months. Optic nerve damage was assessed at 15 months of age. The nerve was immunostained with antibodies to either neurofilament heavy chain (NFH) or phosphorylated NFH (pNFH), and optic nerve damage was assessed by performing NFH- and pNFH-positive axon counts. Expression levels of the ER stress proteins 78-kDa glucose-regulated protein, also known as binding immunoglobulin protein, and C/EBP homologous protein were assayed with Western blotting. We also investigated ER stress localization in the optic nerve by double immunostaining with antibodies to ionized calcium-binding adaptor molecule 1, myelin basic protein, and glial fibrillary acidic protein (GFAP). In DBA/2J mice, IOP began to rise at 8 months of age, and retinal degeneration was detected at 15 months of age. DBA/2J mice had fewer axons than controls at 15 months of age. ER stress-related protein levels were higher in the optic nerves of DBA/2J mice and were colocalized with GFAP-positive astrocytes. Our findings suggest that ER stress plays a role in optic nerve degeneration during chronic ocular hypertension. Furthermore, ER stress may be related in some way to astrocyte activation. (C) 2015 Wiley Periodicals, Inc.	[Ojino, Kazuki; Shimazawa, Masamitsu; Izawa, Hiroshi; Nakano, Yukimichi; Tsuruma, Kazuhiro; Hara, Hideaki] Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, Gifu 5011196, Japan	Shimazawa, M (reprint author), Gifu Pharmaceut Univ, Dept Biofunct Evaluat, Mol Pharmacol, 1-25-4 Daigakunishi, Gifu 5011196, Japan.	shimazawa@gifu-pu.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology [26462694]; Takeda Science Foundation	Contract grant sponsor: Ministry of Education, Culture, Sports, Science, and Technology Grant-in-Aid for Scientific Research (C); Contract grant number: 26462694; Contract grant sponsor: Takeda Science Foundation.	Chang B, 1999, NAT GENET, V21, P405, DOI 10.1038/7741; Shimazawa M, 2007, MOL VIS, V13, P578; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P5151, DOI 10.1167/iovs.02-1101; Doh SH, 2010, BRAIN RES, V1308, P158, DOI 10.1016/j.brainres.2009.10.025; Casson RJ, 2006, CLIN EXP OPHTHALMOL, V34, P54, DOI 10.1111/j.1442-9071.2006.1146.x; Ito Y, 2011, EUR J NEUROSCI, V33, P843, DOI 10.1111/j.1460-9568.2010.07578.x; Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033; Libby RT, 2005, PLOS GENET, V1, P17, DOI 10.1371/journal.pgen.0010004; Nakanishi T, 2013, J NEUROCHEM, V125, P111, DOI 10.1111/jnc.12116; Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7; Imaizumi K, 2001, BBA-MOL BASIS DIS, V1536, P85, DOI 10.1016/S0925-4439(01)00049-7; Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130; Inokuchi Y, 2009, INVEST OPHTH VIS SCI, V50, P334, DOI 10.1167/iovs.08-2123; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; Wang L, 2002, INVEST OPHTH VIS SCI, V43, P1088; Kashiwagi K, 2003, INVEST OPHTH VIS SCI, V44, P154, DOI 10.1167/iovs.02-0398; Nickells RW, 2012, ANNU REV NEUROSCI, V35, P153, DOI 10.1146/annurev.neuro.051508.135728; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Joe MK, 2003, BIOCHEM BIOPH RES CO, V312, P592, DOI 10.1016/j.bbrc.2003.10.162; Wang ZF, 2013, EXP THER MED, V5, P107, DOI 10.3892/etm.2012.745; Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; ANDERSON DR, 1977, INVEST OPHTH VIS SCI, V16, P423; Tezel G, 2011, EXP EYE RES, V93, P178, DOI 10.1016/j.exer.2010.07.009; Shimazawa M, 2012, J NEUROSCI RES, V90, P1960, DOI 10.1002/jnr.23078; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187; Yoshikawa T, 2011, CURR EYE RES, V36, P1153, DOI 10.3109/02713683.2011.606592; QUIGLEY HA, 1983, AM J OPHTHALMOL, V95, P673; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Adachi T, 2011, FREE RADICAL RES, V45, P1083, DOI 10.3109/10715762.2011.595408; Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; McKinnon S J, 1997, Curr Opin Ophthalmol, V8, P28, DOI 10.1097/00055735-199704000-00006; Nakamura S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060517; Rana T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.539; Sidoryk-Wegrzynowicz M, 2011, TOXICOL PATHOL, V39, P115, DOI 10.1177/0192623310385254	38	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV	2015	93	11					1675	1683		10.1002/jnr.23630		9	Neurosciences	Neurosciences & Neurology	CT5ET	WOS:000362831800006		
J	Kadoyama, K; Matsuura, K; Nakamura-Hirota, T; Takano, M; Otani, M; Matsuyama, S				Kadoyama, Keiichi; Matsuura, Kenji; Nakamura-Hirota, Tooru; Takano, Masaoki; Otani, Mieko; Matsuyama, Shogo			Changes in the Expression of Collapsin Response Mediator Protein-2 During Synaptic Plasticity in the Mouse Hippocampus	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						CRMP; nicotinic acetylcholine receptor; synaptic plasticity; phosphorylation; ubiquitin	LONG-TERM POTENTIATION; NICOTINIC ACETYLCHOLINE-RECEPTORS; GROWTH-CONE COLLAPSE; IN-VIVO; NEURONAL POLARITY; DENTATE GYRUS; NERVOUS-SYSTEM; RHO-KINASE; CRMP-2; PHOSPHORYLATION	We have previously reported that nicotine application to the adult mouse causing long-term potentiation-like facilitation in vivo in the hippocampus can serve as a model of synaptic plasticity. The present study clarifies the involvement of collapsin response mediator protein-2 (CRMP2) in synaptic plasticity. CRMP2 was detected in hippocampal neurons of adult mice. The levels of CRMP2 mRNA and protein were increased 2-24 hr and 4-24 hr, respectively, after application of nicotine (3 mg/kg, i.p.), finally returning to the basal level by 48 hr. Furthermore, the ratio of phosphorylated CRMP2 (pCRMP2) at Thr514 residue, an inactive form, to total CRMP2 levels was not changed during synaptic plasticity expressed by nicotine, indicating an enhanced level of non-pCRMP2. This increase of CRMP2 was inhibited by blockade of nicotinic acetylcholine receptors (nAChRs) and required activation of both alpha 4 beta 2 and alpha 7 nAChRs. Although the level of ubiquitinated CRMP2 was increased 8 hr after nicotine treatment, the ratio of ubiquitinated CRMP2 to total CRMP2 protein was similar for nicotine-treated and nontreated mice. This study demonstrates that the expression of CRMP2 increases in hippocampal neurons during synaptic plasticity and that the increment is due mainly to mRNA expression. We propose that CRMP2, particularly non-pCRMP2, could contribute to long-lasting synaptic plasticity. (C) 2015 Wiley Periodicals, Inc.	[Kadoyama, Keiichi; Matsuura, Kenji; Nakamura-Hirota, Tooru; Matsuyama, Shogo] Himeji Dokkyo Univ, Fac Pharmaceut Sci, Dept Pharmaceut Hlth Care, Himeji, Hyogo 6708524, Japan; [Takano, Masaoki; Otani, Mieko] Kobe Gakuin Univ, Sch Pharmaceut Sci, Dept Life Sci Pharm, Kobe, Hyogo 65121, Japan	Matsuyama, S (reprint author), Himeji Dokkyo Univ, Fac Pharmaceut Sci, Dept Pharmaceut Hlth Care, 7-2-1 Kamiohno, Himeji, Hyogo 6708524, Japan.	shogo@himeji-du.ac.jp			Smoking Research Foundation; Ministry of Education, Science, Culture, Sports, and Technology, Japan	Contract grant sponsor: Smoking Research Foundation (to S.M.); Contract grant sponsor: Ministry of Education, Science, Culture, Sports, and Technology, Japan (to K.K., K.M.).	ALKONDON M, 1993, J PHARMACOL EXP THER, V265, P1455; Matsuura K, 2013, NEUROSCI LETT, V555, P18, DOI 10.1016/j.neulet.2013.07.036; Su KY, 2007, J NEUROSCI, V27, P2513, DOI 10.1523/JNEUROSCI.4497-06.2007; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Quach TT, 2008, FASEB J, V22, P401, DOI 10.1096/fj.07-9012com; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Dent EW, 2011, CURR OPIN NEUROBIOL, V21, P175, DOI 10.1016/j.conb.2010.08.013; SEGUELA P, 1993, J NEUROSCI, V13, P596; Fonseca R, 2006, NEURON, V52, P239, DOI 10.1016/j.neuron.2006.08.015; Dong CG, 2008, LEARN MEMORY, V15, P335, DOI 10.1101/lm.984508; Ageta H, 2001, MOL BRAIN RES, V97, P186, DOI 10.1016/S0169-328X(01)00303-5; Arimura N, 2007, NAT REV NEUROSCI, V8, P194, DOI 10.1038/nrn2056; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Wang LH, 1996, J NEUROSCI, V16, P6197; Fujii S, 1999, BRAIN RES, V846, P137, DOI 10.1016/S0006-8993(99)01982-4; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Charrier E, 2003, MOL NEUROBIOL, V28, P51, DOI 10.1385/MN:28:1:51; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Mileusnic R, 2011, J NEUROCHEM, V118, P616, DOI 10.1111/j.1471-4159.2011.07193.x; Matsuyama S, 2000, EUR J NEUROSCI, V12, P3741, DOI 10.1046/j.1460-9568.2000.00259.x; Mimnaugh EG, 1999, ELECTROPHORESIS, V20, P418, DOI 10.1002/(SICI)1522-2683(19990201)20:2<418::AID-ELPS418>3.3.CO;2-E; Brown M, 2004, J NEUROSCI, V24, P8994, DOI 10.1523/JNEUROSCI.3184-04.2004; Jaworski J, 2009, NEURON, V61, P85, DOI 10.1016/j.neuron.2008.11.013; Matsuyama S, 2008, NEUROREPORT, V19, P1809, DOI 10.1097/WNR.0b013e328319ab94; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Kadoyama K, 2007, NEUROSCI RES, V59, P446, DOI 10.1016/j.neures.2007.08.017; Arimura N, 2004, J NEUROBIOL, V58, P34, DOI 10.1002/neu.10269; Cole AR, 2006, J BIOL CHEM, V281, P16591, DOI 10.1074/jbc.M513344200; Horiuchi Y, 2006, GENES CELLS, V11, P1393, DOI 10.1111/j.1365-2443.2006.01027.x; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331; Matsuyama S, 2003, J PHARMACOL SCI, V93, P180, DOI 10.1254/jphs.93.180; Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; Wang Yuying, 2010, Commun Integr Biol, V3, P172; WOOLF NJ, 1991, PROG NEUROBIOL, V37, P475, DOI 10.1016/0301-0082(91)90006-M	41	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV	2015	93	11					1684	1692		10.1002/jnr.23626		9	Neurosciences	Neurosciences & Neurology	CT5ET	WOS:000362831800007		
J	Murai, S; Matsuda, K; Ikebe, K; Enoki, K; Hatta, K; Fujiwara, K; Maeda, Y				Murai, S.; Matsuda, K.; Ikebe, K.; Enoki, K.; Hatta, K.; Fujiwara, K.; Maeda, Y.			A field survey of the partially edentate elderly: Investigation of factors related to the usage rate of removable partial dentures	JOURNAL OF ORAL REHABILITATION			English	Article						shortened dental arch; removable partial denture; usage rate of removable partial dentures; dental care for elderly; field survey	SHORTENED DENTAL ARCHES; QUALITY-OF-LIFE; ORAL FUNCTION; RESTORATION; TRIAL	Although the shortened dental arch (SDA) concept has been known to all over the world, acceptance of the SDA concept as an oral health standard can be questionable from the patients' point of view, even if it is biologically reasonable. Furthermore, because the health insurance system covers removable partial dentures (RPDs) for all citizens in Japan, SDA patients seem to prefer to receive prosthetic treatment to replace the missing teeth. However, there were few field surveys to investigate the usage rate of RPDs in Japan. The purpose of this study was to determine the usage rate of RPDs in older Japanese subjects and to investigate the factors related to the usage of RPDs. Partially edentate participants (n=390) were included in this study. Oral examinations were conducted to record several indices. The Cochran-Armitage trend test was used to evaluate the relationship between the number of missing teeth and the usage rate of RPDs. Chi-squared tests and logistic regression analysis were conducted to evaluate the factors related to the usage rate of RPDs. Usage of RPDs had a significantly positive association with the number of missing distal extension teeth and bilaterally missing teeth. The usage rate of RPDs increased as the number of missing distal extension teeth increased (P for trend<0001). The conclusion of this study was that participants with missing distal extension teeth had higher usage rates of RPDs than other participants, and the usage rate increased as the number of missing distal extension teeth increased.	[Murai, S.; Matsuda, K.; Ikebe, K.; Enoki, K.; Hatta, K.; Fujiwara, K.; Maeda, Y.] Osaka Univ, Dept Prosthodont Gerodontol & Oral Rehabil, Grad Sch Dent, Suita, Osaka 5650871, Japan	Matsuda, K (reprint author), Osaka Univ, Dept Prosthodont Gerodontol & Oral Rehabil, Grad Sch Dent, I-8 Yamadaoka, Suita, Osaka 5650871, Japan.	digiflex@dent.osaka-u.ac.jp			Japan Society for the Promotion of Science [22592148]; Osaka University Scholarship for Short-term Overseas Research Activities	This work was supported by a grant-in-aid for Scientific Research (No. 22592148) from the Japan Society for the Promotion of Science and the Osaka University Scholarship for Short-term Overseas Research Activities 2010. The study protocol was approved by the Institutional Review Board of the Osaka University Graduate School of Dentistry. The authors have no conflicts of interest to declare.	Jepson NJA, 2001, BRIT DENT J, V191, P140, DOI 10.1038/sj.bdj.4801122a; WITTER DJ, 1994, J ORAL REHABIL, V21, P113, DOI 10.1111/j.1365-2842.1994.tb01131.x; KAYSER AF, 1981, J ORAL REHABIL, V8, P457, DOI 10.1111/j.1365-2842.1981.tb00519.x; Witter DJ, 1997, J ORAL REHABIL, V24, P143, DOI 10.1046/j.1365-2842.1997.00460.x; WITTER DJ, 1991, J ORAL REHABIL, V18, P203, DOI 10.1111/j.1365-2842.1991.tb00049.x; Thomason JM, 2007, J DENT RES, V86, P646; Wolfart S, 2005, J ORAL REHABIL, V32, P815, DOI 10.1111/j.1365-2842.2005.01522.x; Walter MH, 2010, J DENT RES, V89, P818, DOI 10.1177/0022034510366817; WITTER DJ, 1987, J ORAL REHABIL, V14, P321, DOI 10.1111/j.1365-2842.1987.tb00725.x; Ikebe K, 2011, GERODONTOLOGY, V28, P192, DOI 10.1111/j.1741-2358.2009.00357.x; Fueki K, 2011, J ORAL REHABIL, V38, P525, DOI 10.1111/j.1365-2842.2010.02183.x; WITTER DJ, 1990, J ORAL REHABIL, V17, P137, DOI 10.1111/j.1365-2842.1990.tb01402.x; Armellini DB, 2008, INT J PROSTHODONT, V21, P524; Allen PF, 1996, J ORAL REHABIL, V23, P481, DOI 10.1111/j.1365-2842.1996.tb00883.x; WITTER DJ, 1989, J ORAL REHABIL, V16, P27, DOI 10.1111/j.1365-2842.1989.tb01314.x; WITTER DJ, 1988, J ORAL REHABIL, V15, P413, DOI 10.1111/j.1365-2842.1988.tb00177.x; Ikebe K, 2010, J ORAL REHABIL, V37, P892, DOI 10.1111/j.1365-2842.2010.02123.x	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-182X	1365-2842		J ORAL REHABIL	J. Oral Rehabil.	NOV	2015	42	11					828	832		10.1111/joor.12318		5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CT6ED	WOS:000362903800004		
J	Yamada, A; Kanazawa, M; Komagamine, Y; Minakuchi, S				Yamada, A.; Kanazawa, M.; Komagamine, Y.; Minakuchi, S.			Association between tongue and lip functions and masticatory performance in young dentate adults	JOURNAL OF ORAL REHABILITATION			English	Article						masticatory performance; tongue pressure; oral diadochokinesis; lip; mixing ability; sieving method	CHANGEABLE CHEWING GUM; ORAL MOTOR FUNCTION; DENTURE WEARERS; OCCLUSAL FORCE; FOOD	Motor functions of masticatory organs such as the tongue, lips, cheeks and mandible are known to deteriorate with age, thereby influencing masticatory performance. However, there are few reports on the relationships between tongue and lip functions and masticatory performance. To investigate the relationship between tongue and lip functions and comprehensive masticatory performance, by evaluating crushing, mixing and shearing abilities in young dentate adults. Participants comprised 51 dentate adults with a mean age of 25years. Maximum tongue pressure and oral diadochokinesis were measured to evaluate tongue and lip functions. A multiple sieving method using peanuts was performed to evaluate crushing ability. A colour-changeable chewing gum was performed to evaluate mixing ability. A test gummy jelly was performed to evaluate shearing ability. The relationship between tongue and lip functions and each masticatory performance was assessed using Pearson's correlation coefficients. In addition, stepwise multiple regression analysis was performed to identify predictors of crushing ability. Crushing ability was significantly correlated with maximum tongue pressure and the number of repetitions of the syllables /pa/, /ta/ and /ka/. Maximum tongue pressure and number of repetitions of the syllable /pa/ were identified as significant predictors for crushing ability. Mixing ability was significantly correlated with the number of repetitions of the syllable /pa/. Shearing ability was not significantly correlated with tongue and lip functions. Masticatory performance during the chewing of brittle foods such as peanuts and solid foods such as chewing gum appears to be correlated with tongue and lip functions.	[Yamada, A.; Kanazawa, M.; Komagamine, Y.; Minakuchi, S.] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Gerodontol & Oral Rehabil, Bunkyo Ku, Tokyo 1138549, Japan	Kanazawa, M (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Gerodontol & Oral Rehabil, Bunkyo Ku, I-5-45 Yushima, Tokyo 1138549, Japan.	m.kanazawa.gerd@tmd.ac.jp					BAUM BJ, 1983, J DENT RES, V62, P2, DOI 10.1177/00220345830620010401; Kikutani T, 2009, ODONTOLOGY, V97, P38, DOI 10.1007/s10266-008-0094-z; Sato H, 2003, J ORAL REHABIL, V30, P68, DOI 10.1046/j.1365-2842.2003.01049.x; Ikebe K, 2011, ARCH ORAL BIOL, V56, P991, DOI 10.1016/j.archoralbio.2011.03.019; MANLY RS, 1950, J DENT RES, V29, P448, DOI 10.1177/00220345500290040701; Koshino H, 1997, J PROSTHET DENT, V77, P147, DOI 10.1016/S0022-3913(97)70228-2; Hama Y, 2014, J PROSTHODONT RES, V58, P102, DOI 10.1016/j.jpor.2013.12.005; Tsuga K, 2011, J ORAL REHABIL, V38, P680, DOI 10.1111/j.1365-2842.2011.02202.x; Takahashi M, 2013, J ORAL REHABIL, V40, P909, DOI 10.1111/joor.12105; Okiyama S, 2003, J ORAL REHABIL, V30, P278, DOI 10.1046/j.1365-2842.2003.01009.x; KAPUR K, 1964, J PROSTHET DENT, V14, P483, DOI 10.1016/S0022-3913(64)80016-0; Komagamine Y, 2011, J ORAL REHABIL, V38, P555, DOI 10.1111/j.1365-2842.2011.02204.x; Ziegler W, 2002, BRAIN LANG, V80, P556, DOI 10.1006/brln.2001.2614; OLTHOFF LW, 1984, ARCH ORAL BIOL, V29, P899, DOI 10.1016/0003-9969(84)90089-X; Horie T, 2014, J ORAL REHABIL, V41, P829, DOI 10.1111/joor.12216; Ikebe K, 2005, PROSTHODONTIC RES PR, V4, P9, DOI 10.2186/prp.4.9; Ito K, 2009, JPN J GERODONTOL, V24-1, P48; Okiyama S, 1996, J JPN PROSTHODONT SO, V40, P710; Shiga H, 2006, PROSTHODONT RES PRAC, V5, P15, DOI 10.2186/prp.5.15; van der Bilt A, 2004, ARCH ORAL BIOL, V49, P193, DOI 10.1016/j.archoralbio.2003.08.007	20	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-182X	1365-2842		J ORAL REHABIL	J. Oral Rehabil.	NOV	2015	42	11					833	839		10.1111/joor.12319		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	CT6ED	WOS:000362903800005		
J	Tagami, T; Kubota, M; Ozeki, T				Tagami, Tatsuaki; Kubota, Masahito; Ozeki, Tetsuya			Effective Remote Loading of Doxorubicin into DPPC/Poloxamer 188 Hybrid Liposome to Retain Thermosensitive Property and the Assessment of Carrier-Based Acute Cytotoxicity for Pulmonary Administration	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						Liposomes; Controlled release; delivery; Pulmonary drug delivery; Cancer chemotherapy; Responsive delivery systems; Encapsulation	DRUG-DELIVERY; INHALED DOXORUBICIN; SOLID TUMORS; IN-VITRO; LUNGS; FORMULATIONS; COPOLYMERS; STRATEGIES; ABLATION; THERAPY	Functional liposome administration via the pulmonary route is of interest to treat pulmonary diseases, including cancer. Here, a block copolymer used as a medical additive, Poloxamer 188 (P188), was incorporated into liposome membranes, and the thermosensitive characteristics of the DPPC/P188 hybrid liposomes were assessed. An increase in P188 incorporation in DPPC liposomes enhanced the release of calcein, a fluorescence marker, from liposomes at 42 degrees C in vitro; calcein release was significantly slower at 37 degrees C. The lipid composition was optimal at a DPPC/P188 ratio of 3:0.4 (molar ratio). DPPC/P188 liposomes did not exhibit in vitro cytotoxicity against A549 cells and Raw 264.7 cells used as models of pulmonary cells or trigger in vivo acute inflammation as determined by the secretion of tumor necrosis factor alpha. Next, an anticancer drug, doxorubicin (DOX), was loaded with approximately 90% efficiency into DPPC/P188 liposomes using a remote-loading method and a DOX-phospholipid ratio of 1:20 (w/w). The interior buffer of liposome has remarkably changed DOX release at 42 degrees C. DOX released from DPPC/P188 liposomes at 42 degrees C exhibited cytotoxic effects toward A549 cells comparable with free DOX solution. These results suggest that a DOX-loaded DPPC/P188 liposome formulation administered via the pulmonary route may be useful for treating lung cancer. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3824-3832, 2015	[Tagami, Tatsuaki; Kubota, Masahito; Ozeki, Tetsuya] Nagoya City Univ, Grad Sch Pharmaceut Sci, Drug Delivery & Nano Pharmaceut, Nagoya, Aichi 4678603, Japan	Ozeki, T (reprint author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Drug Delivery & Nano Pharmaceut, Nagoya, Aichi 4678603, Japan.	ozekit@phar.nagoya-cu.ac.jp			Japan Society for the Promotion of Science [25860026]; Nagoya City University	This work was supported in part by the Japan Society for the Promotion of Science, grant-in-aid for Young Scientists (B) (No. 25860026) and by a grant-in-aid for research from Nagoya City University. We appreciate the help from Dr. Noriko Ogawa and Dr. Chisato Takahashi who are members of Dr. Hiromitsu Yamamoto's laboratory (Aichi Gakuin University) about the measurement of zeta potentials.	Paranjpe M, 2014, INT J MOL SCI, V15, P5852, DOI 10.3390/ijms15045852; Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020; Tagami T, 2011, J CONTROL RELEASE, V152, P303, DOI 10.1016/j.jconrel.2011.02.009; Ta T, 2013, J CONTROL RELEASE, V169, P112, DOI 10.1016/j.jconrel.2013.03.036; Yoshino K, 2004, BIOCONJUGATE CHEM, V15, P1102, DOI 10.1021/bc034205j; Kneidl B, 2014, INT J NANOMED, V9, P4387, DOI 10.2147/IJN.S49297; Koning GA, 2010, PHARM RES-DORDR, V27, P1750, DOI 10.1007/s11095-010-0154-2; Almeida H, 2012, J PHARM PHARM SCI, V15, P592; ALEXANDRIDIS P, 1994, MACROMOLECULES, V27, P2414, DOI 10.1021/ma00087a009; Lee CM, 2005, CANCER BIOTHER RADIO, V20, P620, DOI 10.1089/cbr.2005.20.620; Tagami T, 2011, J CONTROL RELEASE, V154, P290, DOI 10.1016/j.jconrel.2011.05.020; Otterson GA, 2007, CLIN CANCER RES, V13, P1246, DOI 10.1158/1078-0432.CCR-06-1096; Dumortier G, 2006, PHARM RES, V23, P2709, DOI 10.1007/s11095-006-9104-4; Otterson GA, 2010, CLIN CANCER RES, V16, P2466, DOI 10.1158/1078-0432.CCR-09-3015; Kono K, 2001, ADV DRUG DELIVER REV, V53, P307, DOI 10.1016/S0169-409X(01)00204-6; Waters V, 2014, EXPERT REV RESP MED, V8, P401, DOI 10.1586/17476348.2014.918507; Chiu GNC, 2005, J CONTROL RELEASE, V104, P271, DOI 10.1016/j.cornel.2005.02.009; Poon RTP, 2009, EXPERT OPIN PHARMACO, V10, P333, DOI [10.1517/14656560802677874 , 10.1517/14656560802677874]; Almeida H, 2013, EXPERT OPIN DRUG DEL, V10, P1223, DOI 10.1517/17425247.2013.796360; Plataki M, 2011, AM J RESP CRIT CARE, V184, P939, DOI 10.1164/rccm.201104-0647OC; Gubernator J, 2011, EXPERT OPIN DRUG DEL, V8, P565, DOI 10.1517/17425247.2011.566552; Carvalho TC, 2011, J AEROSOL MED PULM D, V24, P61, DOI 10.1089/jamp.2009.0794; Tagami T, 2014, INT J PHARMACEUT, V468, P91, DOI 10.1016/j.ijpharm.2014.04.013; Cipolla D, 2014, ADV DRUG DELIVER REV, V75, P53, DOI 10.1016/j.addr.2014.05.001; Cipolla David, 2013, Ther Deliv, V4, P1047, DOI 10.4155/tde.13.71; Fritze A, 2006, BBA-BIOMEMBRANES, V1758, P1633, DOI 10.1016/j.bbamem.2006.05.028; Gabizon A, 1997, DRUGS, V54, P15; Hamblin KA, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00079; Loira-Pastoriza C, 2014, ADV DRUG DELIVER REV, V75, P81, DOI 10.1016/j.addr.2014.05.017; Madni A, 2014, J PHARM PHARM SCI, V17, P401; Moloughney Joseph G, 2012, Recent Pat Biotechnol, V6, P200	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	NOV	2015	104	11					3824	3832		10.1002/jps.24593		9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CT7GY	WOS:000362984100020		
J	Sadakane, C; Watanabe, J; Fukutake, M; Nisimura, H; Maemura, K; Kase, Y; Kono, T				Sadakane, Chiharu; Watanabe, Junko; Fukutake, Miwako; Nisimura, Hiroaki; Maemura, Kazuya; Kase, Yoshio; Kono, Toru			Pharmacokinetic Profiles of Active Components After Oral Administration of a Kampo Medicine, Shakuyakukanzoto, to Healthy Adult Japanese Volunteers	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						Clinical pahrmacokinetics; Dose-response; Intestinal absorption; Intestinal metabolism; Mebabolite kinetics; Shakuyaku-kanzo-to; TJ-68; randomized crossover study; healthy adult volunteers	LICORICE-INDUCED PSEUDOALDOSTERONISM; HUMAN INTESTINAL FLORA; BETA-D-GLUCURONIDASE; SHAOYAO-GANCAO-TANG; KANZO-TO; GLYCYRRHETIC ACID; MAINTENANCE HEMODIALYSIS; MAJOR METABOLITE; SKELETAL-MUSCLE; HERBAL MEDICINE	Shakuyakukanzoto (SKT), a traditional Japanese (Kampo) medicine, has been used by patients with muscle cramps and abdominal pains. In this trial, we analyzed plasma concentrations of active components after SKT was administered as a single oral dose of 2.5 or 5.0 g/day per person. The study was a randomized, open-label, two-arm, two-period, crossover trial conducted in healthy Japanese volunteers. Albiflorin (ALB), paeoniflorin (PAE), glycycoumarin (GCM), isoliquiritigenin (ILG), glycyrrhetic acid (GA), and glycyrrhetic acid-3-O-monoglucuronide were targeted, and the plasma concentration of each component was measured using a liquid chromatography-tandem mass spectrometry method. The pharmacokinetic parameters were calculated, and the linearity was assessed. All targeted components were detected in the plasma after oral administration of SKT. ALB, PAE, GCM, and ILG were detected at an early stage. The linearity was observed for the maximum plasma concentration of GCM, ILG, and GA and for the area under the plasma concentration-time curve of GA. In this trial, we demonstrated for the first time in humans that these components were absorbed into the blood after oral administration of SKT. The results of this pharmacokinetic trial in humans are also important and useful for understanding the mechanism of action of SKT, verifying the active components predicted in basic research, and conducting pharmacokinetics and safety studies in the future. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3952-3959, 2015	[Sadakane, Chiharu; Watanabe, Junko; Fukutake, Miwako; Maemura, Kazuya; Kase, Yoshio; Kono, Toru] Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Ibaraki, Japan; [Nisimura, Hiroaki] Tsumura & Co, Prod Div, Kampo Formulat Dev Ctr, Ibaraki, Japan; [Kono, Toru] Hokkaido Univ, Fac Pharmaceut Sci, Sapporo, Hokkaido 060, Japan; [Kono, Toru] Sapporo Higashi Tokushukai Hosp, Ctr Clin & Biomed Res, Sapporo, Hokkaido, Japan	Watanabe, J (reprint author), Tsumura & Co, Kampo Sci Strategies Div, Tsumura Res Labs, Ibaraki, Japan.	watanabe_junko@mail.tsumura.co.jp			Tsumura Co.	We would like to thank Dr. Seiichi Matsui (Sumika Chemical Analysis Service Ltd., Osaka, Japan), Dr. Masataka Yagi (Sumika Chemical Analysis Service Ltd.), and Dr. Kenji Sano (Sekisui Medical Company, Ltd., Tokyo, Japan) for analysis of the SKT ingredients. We would like to thank Makoto Zushi (Product Information Management Dept., Tsumura & Co.) for analyzing the data. We are deeply grateful to Dr. Yasushi Ikarashi in Tsumura Research Laboratories for proofreading of this manuscript. This study was supported by a grant from Tsumura & Co.	Lee KK, 2013, J ETHNOPHARMACOL, V145, P286, DOI 10.1016/j.jep.2012.11.005; Hyodo T, 2002, NEPHRON, V90, P240, DOI 10.1159/000049057; Li XB, 2014, J PHARMACEUT BIOMED, V92, P160, DOI 10.1016/j.jpba.2014.01.020; Hyodo T, 2006, NEPHRON CLIN PRACT, V104, pC28, DOI 10.1159/000093256; Makino T, 2014, BIOL PHARM BULL, V37, P898, DOI 10.1248/bpb.b13-00997; Yamamoto K, 2001, GYNECOL ONCOL, V81, P333, DOI 10.1006/gyno.2001.6168; Chen LC, 2002, JPN J PHARMACOL, V88, P250, DOI 10.1254/jjp.88.250; TAKAHASHI K, 1994, INT J FERTIL MENOP S, V39, P69; Qiao H, 2014, PHARM BIOL, V52, P228, DOI 10.3109/13880209.2013.832334; AKAO T, 1987, CHEM PHARM BULL, V35, P705; Shi YL, 2012, PHYTOTHER RES, V26, P1410, DOI 10.1002/ptr.3715; Hidaka T, 2009, EUR J PAIN, V13, P22, DOI 10.1016/j.ejpain.2008.03.003; HATTORI M, 1985, CHEM PHARM BULL, V33, P210; Heikal OA, 1997, BIOL PHARM BULL, V20, P517; KATO H, 1995, J CLIN ENDOCR METAB, V80, P1929, DOI 10.1210/jc.80.6.1929; Omiya Y, 2005, J PHARMACOL SCI, V99, P373, DOI 10.1254/jphs.FP0050536; Matsui E, 2011, BIOL PHARM BULL, V34, P1438, DOI 10.1248/bpb.34.1438; Hou YC, 2005, LIFE SCI, V76, P1167, DOI 10.1016/j.lfs.2004.10.020; Takeda S, 1995, J PHARM PHARMACOL, V47, P1036; Gan PP, 2012, PLANTA MED, V78, P237, DOI 10.1055/s-0031-1280366; Akao T, 1997, BIOL PHARM BULL, V20, P1245; Lee KK, 2011, EUR J PAIN, V15, P1035, DOI 10.1016/j.ejpain.2011.04.011; Kamei J, 2005, EUR J PHARMACOL, V507, P163, DOI 10.1016/j.ejphar.2004.11.042; Sato Y, 2007, BIOL PHARM BULL, V30, P145, DOI 10.1248/bpb.30.145; Mizuhara Y, 2005, BIOL PHARM BULL, V28, P1897, DOI 10.1248/bpb.28.1897; Hinoshita F, 2003, AM J CHINESE MED, V31, P445, DOI 10.1142/S0192415X03001144; AKAO T, 1994, J PHARM PHARMACOL, V46, P135; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; HATTORI M, 1983, PLANTA MED, V48, P38, DOI 10.1055/s-2007-969875; Goto E, 2005, J PHARM PHARMACOL, V57, P1359, DOI 10.1211/jpp.57.10.0016; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; CANTELLIFORTI G, 1994, ENVIRON HEALTH PERSP, V102, P65; CHAMBERL.TJ, 1970, J AMER MED ASSOC, V213, P1343; CONN JW, 1968, J AMER MED ASSOC, V205, P492, DOI 10.1001/jama.205.7.492; Gough K, 1995, DRUG INF J, V29, P1039; Hisada T, 2014, DIAGNOSIS TREATMENT, V102, P1577; IVESON P, 1971, Xenobiotica, V1, P79; Kaifuchi N, 2015, J NAT MED-TOKYO, V69, P287, DOI 10.1007/s11418-015-0890-z; Kumada T, 1999, J CLIN THER MED, V15, P499; Ohtake N, 2007, LIFE SCI, V80, P545; Ploeger B, 2000, PHARMACEUT RES, V17, P1516, DOI 10.1023/A:1007661209921; Protasi F, 2002, FRONT BIOSCI, V7, pD650, DOI 10.2741/protasi; TAKEDA R, 1979, ENDOCRINOL JAPON, V26, P541; TERASAWA K, 1986, J PHARMACOBIO-DYNAM, V9, P95; [U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Research CfVM], 2001, GUID IND BIOAN METH; Wang P, 2014, PHARMACOGN MAG, V10, P497, DOI 10.4103/0973-1296.141774	46	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	NOV	2015	104	11					3952	3959		10.1002/jps.24596		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CT7GY	WOS:000362984100033		
J	Hashimoto, M; Taguchi, K; Ogaki, S; Watanabe, H; Kinoshita, M; Nishikawa, K; Takeoka, S; Ikeda, Y; Handa, M; Otagiri, M; Maruyama, T				Hashimoto, Mai; Taguchi, Kazuaki; Ogaki, Shigeru; Watanabe, Hiroshi; Kinoshita, Manabu; Nishikawa, Kahoko; Takeoka, Shinji; Ikeda, Yasuo; Handa, Makoto; Otagiri, Masaki; Maruyama, Toru			Pharmacokinetic Properties of Single and Repeated Injection of Liposomal Platelet Substitute in a Rat Model of Red Blood Cell Transfusion-Induced Dilutional Thrombocytopenia	JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						liposome; adenosine-diphosphate; dodecapeptide; accelerated blood clearance phenomenon; transfusion; thrombocytopenia; platelet substitute; pegylation; clearance; pharmacokinetics	GAMMA-CHAIN DODECAPEPTIDE; DIPHOSPHATE-ENCAPSULATED LIPOSOMES; CLEARANCE ABC PHENOMENON; PEGYLATED LIPOSOMES; ADENOSINE-DIPHOSPHATE; HEMOGLOBIN-VESICLES; RETICULOENDOTHELIAL SYSTEM; PHOSPHOLIPID-VESICLES; OXYGEN CARRIERS; FIBRINOGEN	A preclinical study of dodecapeptide ((400)HHLGGAKQAGDV(411)) (H12)-(adenosine diphosphate, ADP)-liposomes for use as a synthetic platelet (PLT) substitute under conditions of red blood cell (RBC) transfusion-induced dilutional thrombocytopenia is limited to pharmacological effect. In this study, the pharmacokinetics of H12-(ADP)-liposomes in RBC transfusion-induced dilutional thrombocytopenic rats were evaluated. As evidenced by the use of C-14, H-3 double-radiolabeled H12-(ADP)-liposomes in which the encapsulated ADP and liposomal membrane were labeled with C-14 and H-3, respectively, the H12-(ADP)-liposomes remained intact in the blood circulation for up to 3 h after injection, and were mainly distributed to the liver and spleen. The encapsulated ADP was mainly eliminated in the urine, whereas the outer membrane was mainly eliminated in the feces. These successive pharmacokinetic properties of the H12-(ADP)-liposomes in RBC transfusion-induced dilutional thrombocytopenic rats were similar to those in healthy rats, except for the shorter retention time in the circulation. When H12-(ADP)-liposomes were repeatedly injected into RBC transfusion-induced dilutional thrombocytopenic rats at intervals of 5 days at a dose of 10 mg lipids/kg, the second dose of injected H12-(ADP)-liposomes were rapidly cleared from the circulation, namely, via the accelerated blood clearance phenomenon. These novel pharmacokinetic findings provide useful information for the further development of H12-(ADP)-liposomes as a PLT substitute. (c) 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3968-3976, 2015	[Hashimoto, Mai; Ogaki, Shigeru; Watanabe, Hiroshi; Otagiri, Masaki; Maruyama, Toru] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Chuo Ku, Kumamoto 8620973, Japan; [Taguchi, Kazuaki; Otagiri, Masaki] Sojo Univ, Fac Pharmaceut Sci, Nishi Ku, Kumamoto 8620082, Japan; [Watanabe, Hiroshi; Maruyama, Toru] Kumamoto Univ, Ctr Clin Pharmaceut Sci, Kumamoto 8620973, Japan; [Kinoshita, Manabu] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Saitama 3598513, Japan; [Nishikawa, Kahoko] Natl Def Med Coll, Dept Traumatol & Crit Care Med, Tokorozawa, Saitama 3598513, Japan; [Takeoka, Shinji; Ikeda, Yasuo] Waseda Univ, Grad Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Shinjuku Ku, Tokyo 1628480, Japan; [Handa, Makoto] Keio Univ, Ctr Transfus Med & Cell Therapy, Shinjuku Ku, Tokyo 1608582, Japan; [Otagiri, Masaki] Sojo Univ, DDS Res Inst, Nishi Ku, Kumamoto 8620082, Japan	Maruyama, T (reprint author), Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Chuo Ku, Kumamoto 8620973, Japan.	tomaru@gpo.kumamoto-u.ac.jp			Ministry of Health, Labour and Welfare, Japan	We would like to thank Atsushi Fujiyama and Mami Doi at Waseda University for preparation of liposome samples. We would also wish to thank the members of the RI Center in Kumamoto University for their important contributions to pharmacokinetic experiments. This work was supported in part by Health and Labor Sciences Research Grants (Research on Public Essential Drugs and Medical Devices) from the Ministry of Health, Labour and Welfare, Japan.	Abu Lila AS, 2013, J CONTROL RELEASE, V172, P38, DOI 10.1016/j.jconrel.2013.07.026; Nishikawa K, 2012, J THROMB HAEMOST, V10, P2137, DOI 10.1111/j.1538-7836.2012.04889.x; Ishida T, 2006, J CONTROL RELEASE, V112, P15, DOI 10.1016/j.jconrel.2006.01.005; Okamura Y, 2010, J CONTROL RELEASE, V148, P373, DOI 10.1016/j.jconrel.2010.09.013; Nasiri S, 2013, BLOOD TRANSFUS-ITALY, V11, P337, DOI 10.2450/2013.0209-12; Ishida T, 2005, J CONTROL RELEASE, V105, P305, DOI 10.1016/j.jconrel.2005.04.003; Taguchi K, 2011, J PHARM SCI-US, V100, P775, DOI 10.1002/jps.22286; KUIPERS F, 1986, BIOCHIM BIOPHYS ACTA, V876, P559, DOI 10.1016/0005-2760(86)90044-5; Okamura Y, 2005, BIOCONJUGATE CHEM, V16, P1589, DOI 10.1021/bc050178g; Taguchi K, 2013, J PHARM SCI-US, V102, P3852, DOI 10.1002/jps.23692; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Okamura Y, 2010, NANOMED-NANOTECHNOL, V6, P391, DOI 10.1016/j.nano.2009.07.004; Tokutomi K, 2011, INT J PHARMACEUT, V407, P151, DOI 10.1016/j.ijpharm.2011.01.014; Takeoka S, 2001, BIOMACROMOLECULES, V2, P1192, DOI 10.1021/bm015554o; Okamura Y, 2009, J THROMB HAEMOST, V7, P470, DOI 10.1111/j.1538-7836.2008.03269.x; Tomita D, 2013, BIOMACROMOLECULES, V14, P1816, DOI 10.1021/bm400204y; ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; Ishida T, 2006, J CONTROL RELEASE, V115, P251, DOI 10.1016/j.jconret.2006.08.017; LAM SCT, 1987, J BIOL CHEM, V262, P947; Tsuchida E, 2009, BIOCONJUGATE CHEM, V20, P1419, DOI 10.1021/bc800431d; Taguchi K, 2009, DRUG METAB DISPOS, V37, P2197, DOI 10.1124/dmd.109.028852; Natanson C, 2008, JAMA-J AM MED ASSOC, V299, P2304, DOI 10.1001/jama.299.19.jrv80007; Sakai H, 2004, J PHARMACOL EXP THER, V311, P874, DOI 10.1124/jpet.104.073049; Suzuki H, 2011, THROMB RES, V128, P552, DOI 10.1016/j.thromres.2011.07.031; Taguchi K, 2013, DRUG METAB DISPOS, V41, P1584, DOI 10.1124/dmd.112.050005; Taguchi K, 2009, J CONTROL RELEASE, V136, P232, DOI 10.1016/j.jconrel.2009.02.009; Johansson PI, 2007, TRANSFUSION, V47, P593, DOI 10.1111/j.1537-2995.2007.01160.x; Tagami T, 2010, J CONTROL RELEASE, V142, P160, DOI 10.1016/j.jconrel.2009.10.017; Sakai H, 2001, AM J PATHOL, V159, P1079, DOI 10.1016/S0002-9440(10)61783-X; Hagisawa K, 2015, TRANSFUSION, V55, P314, DOI 10.1111/trf.12829; Hashimoto Y, 2015, BIOL PHARM BULL, V38, P417, DOI 10.1248/bpb.b14-00653; Kiwada H, 1998, ADV DRUG DELIV REV, V32, P61; Taguchi K, 2015, J PHARM SCI; Xu H, 2015, DRUG DELIV, V22, P598, DOI 10.3109/10717544.2014.885998	34	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3549	1520-6017		J PHARM SCI-US	J. Pharm. Sci.	NOV	2015	104	11					3968	3976		10.1002/jps.24607		9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	CT7GY	WOS:000362984100035		
J	Esaka, F; Suzuki, D; Miyamoto, Y; Magara, M				Esaka, Fumitaka; Suzuki, Daisuke; Miyamoto, Yutaka; Magara, Masaaki			Determination of plutonium isotope ratios in individual uranium-plutonium mixed particles with inductively coupled plasma mass spectrometry	JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY			English	Article						Uranium-plutonium mixed particles; Isotope ratio; Individual particles; ICP-MS; UTEVA resin	SAFEGUARDS PURPOSES; OXIDE PARTICLES; SAMPLES; OPTIMIZATION; PU-238	An analytical technique was developed by a combination of single particle dissolution, chemical separation of uranium, plutonium and americium with extraction chromatography using UTEVA resins and measurement with inductively coupled plasma mass spectrometry. This method was applied to plutonium isotope ratio analysis of individual U-Pu particles with U/Pu ratios ranging from 1 to 70. Consequently, Pu-240/Pu-239, Pu-241/Pu-239 and Pu-242/Pu-239 isotope ratios were successfully determined, while it was impossible to determine Pu-238/Pu-239 ratios due to the high process blank values on m/z 238.	[Esaka, Fumitaka; Suzuki, Daisuke; Miyamoto, Yutaka; Magara, Masaaki] Japan Atom Energy Agcy, Res Grp Analyt Chem, Naka, Ibaraki 3191195, Japan	Esaka, F (reprint author), Japan Atom Energy Agcy, Res Grp Analyt Chem, 2-4 Shirakata Shirane, Naka, Ibaraki 3191195, Japan.	esaka.fumitaka@jaea.go.jp			Nuclear Regulation Authority, Japan	This work was performed under the auspices of the Nuclear Regulation Authority, Japan. The authors wish to thank Dr. K. Watanabe for the helpful discussion, Mr. N. Kohno and Mr. T. Watanabe for particle production, Mr. H. Fukuyama, Mr. T. Onodera for sample preparation and Mr. Y. Takahashi for ICP-MS measurement.	Aggarwal SK, 2005, INT J MASS SPECTROM, V241, P83, DOI 10.1016/j.ijms.2004.10.016; Morgenstern A, 2002, RADIOCHIM ACTA, V90, P81, DOI 10.1524/ract.2002.90.2_2002.81; Esaka F, 2010, TALANTA, V83, P569, DOI 10.1016/j.talanta.2010.10.009; Tamborini G, 1998, SPECTROCHIM ACTA B, V53, P1289, DOI 10.1016/S0584-8547(98)00121-9; Boulyga SF, 2001, J ANAL ATOM SPECTROM, V16, P1283, DOI 10.1039/b103178n; Ranebo Y, 2009, J ANAL ATOM SPECTROM, V24, P277, DOI 10.1039/b810474c; Aggarwal SK, 2007, J RADIOANAL NUCL CH, V273, P775, DOI 10.1007/s10967-007-0947-x; Esaka F, 2012, ANAL CHIM ACTA, V721, P122, DOI 10.1016/j.aca.2012.01.045; Esaka F, 2007, TALANTA, V71, P1011, DOI 10.1016/j.talanta.2006.05.091; Lind OC, 2007, SCI TOTAL ENVIRON, V376, P294, DOI 10.1016/j.scitotenv.2006.11.050; Erdmann N, 2000, SPECTROCHIM ACTA B, V55, P1565, DOI 10.1016/S0584-8547(00)00262-7; Lee CG, 2007, J RADIOANAL NUCL CH, V272, P299, DOI 10.1007/s10967-007-0519-0; Esaka KT, 2004, JPN J APPL PHYS 2, V43, pL915, DOI 10.1143/JJAP.43.L915; Hedberg PML, 2011, J ANAL ATOM SPECTROM, V26, P406, DOI 10.1039/c0ja00181c; Willman C, 2006, ANN NUCL ENERGY, V33, P766, DOI 10.1016/j.anucene.2006.04.006; Raptis K, 2013, J RADIOANAL NUCL CH, V296, P585, DOI 10.1007/s10967-012-2081-7; Donohue DL, 2002, ANAL CHEM, V74, p28A, DOI 10.1021/ac021909y; Donohue DL, 1998, J ALLOY COMPD, V271, P11, DOI 10.1016/S0925-8388(98)00015-2; Esaka F., 2011, MASS SPECTROM LETT, V2, P80; Simons DS, 1998, SECONDARY ION MASS S, VXI, P59; Stetzer O, 2004, NUCL INSTRUM METH A, V525, P582, DOI 10.1016/j.nima.2004.01.079; Suzuki D, 2015, APPL RADIAT ISOTOPES, V96, P52, DOI 10.1016/j.apradiso.2014.11.012	22	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0236-5731	1588-2780		J RADIOANAL NUCL CH	J. Radioanal. Nucl. Chem.	NOV	2015	306	2					393	399		10.1007/s10967-015-4113-6		7	Chemistry, Analytical; Chemistry, Inorganic & Nuclear; Nuclear Science & Technology	Chemistry; Nuclear Science & Technology	CT6XW	WOS:000362957900007		
J	Hamahata, A; Beppu, T; Fujikawa, T; Yamaki, T; Sakurai, H				Hamahata, Atsumori; Beppu, Takeshi; Fujikawa, Taro; Yamaki, Takashi; Sakurai, Hiroyuki			Usefulness of a Reconstructive Method for Oropharyngeal Defect Including the Larger Soft Palate with the Bent Anterolateral Thigh Flap	JOURNAL OF RECONSTRUCTIVE MICROSURGERY			English	Letter							RESECTION; SUPERIOR; OUTCOMES		[Hamahata, Atsumori] Saitama Canc Ctr, Dept Plast & Reconstruct Surg, Saitama, Saitama, Japan; [Beppu, Takeshi; Fujikawa, Taro] Saitama Canc Ctr, Div Head & Neck Surg, Saitama, Saitama, Japan; [Yamaki, Takashi; Sakurai, Hiroyuki] Tokyo Womens Med Univ, Dept Plast & Reconstruct Surg, Tokyo, Japan	Hamahata, A (reprint author), Saitama Canc Ctr, Dept Plast & Reconstruct Surg, 780 Komuro Inamachi Kitaadachigunn, Saitama, Saitama, Japan.	a.hamahata@cancer-c.pref.saitama.jp					Inoue T, 2012, INT J ORAL MAX SURG, V41, P9, DOI 10.1016/j.ijom.2011.10.003; Hashikawa K, 2005, PLAST RECONSTR SURG, V115, P388, DOI 10.1097/01.PRS.0000148447.33144.14; Chepeha DB, 2009, ARCH OTOLARYNGOL, V135, P887, DOI 10.1001/archoto.2009.130; Yamaguchi K, 2012, HEAD NECK-J SCI SPEC, V34, P1403, DOI 10.1002/hed.21944; Seikaly H, 2003, LARYNGOSCOPE, V113, P897, DOI 10.1097/00005537-200305000-00023; Seikaly H, 2008, HEAD NECK-J SCI SPEC, V30, P1615, DOI 10.1002/hed.20919; Kimata Y, 2002, LARYNGOSCOPE, V112, P1037, DOI 10.1097/00005537-200206000-00019; Sakamoto Yuki, 2014, Tokai J Exp Clin Med, V39, P44	8	0	0	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0743-684X	1098-8947		J RECONSTR MICROSURG	J. Reconstr. Microsurg.	NOV	2015	31	9					688	691		10.1055/s-0035-1558430		4	Surgery	Surgery	CT6ML	WOS:000362927000012		
J	Itami, M; Sasa, S				Itami, Masato; Sasa, Shin-ichi			Derivation of Stokes' Law from Kirkwood's Formula and the Green-Kubo Formula via Large Deviation Theory	JOURNAL OF STATISTICAL PHYSICS			English	Article						Stokes' law; Kirkwood's formula; Green-Kubo formula; Large deviation theory	FREE-ENERGY DIFFERENCES; FLUCTUATION THEOREM; BROWNIAN-MOTION; STATISTICAL-MECHANICS; STOCHASTIC DYNAMICS; STRING THEORY; LIVING CELL; FRICTION; PARTICLE; FLUIDS	We study the friction coefficient of a macroscopic sphere in a viscous fluid at low Reynolds number. First, Kirkwood's formula for the friction coefficient is reviewed on the basis of the Hamiltonian description of particle systems. According to this formula, the friction coefficient is expressed in terms of the stress correlation on the surface of the macroscopic sphere. Then, with the aid of large deviation theory, we relate the surface stress correlation to the stress correlation in the bulk of the fluid, where the latter is characterized by the viscosity in the Green-Kubo formula. By combining Kirkwood's formula and the Green-Kubo formula in large deviation theory, we derive Stokes' law without explicitly employing the hydrodynamic equations.	[Itami, Masato; Sasa, Shin-ichi] Kyoto Univ, Dept Phys, Kyoto 6068502, Japan	Itami, M (reprint author), Kyoto Univ, Dept Phys, Kyoto 6068502, Japan.	itami@scphys.kyoto-u.ac.jp; sasa@scphys.kyoto-u.ac.jp			KAKENHI [22340109, 25103002]; JSPS	The authors would like to thank T. Matsumoto, Y. Nakayama, K. Sekimoto, and A. Yoshimori for useful discussions. The present study was supported by KAKENHI Nos. 22340109 and 25103002, and by the JSPS Core-to-Core program "Non-equilibrium dynamics of soft-matter and information."	ESPANOL P, 1993, J CHEM PHYS, V98, P574; KIRKWOOD JG, 1946, J CHEM PHYS, V14, P180, DOI 10.1063/1.1724117; Fruleux A, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.160601; Kurchan J, 1998, J PHYS A-MATH GEN, V31, P3719, DOI 10.1088/0305-4470/31/16/003; Gubser SS, 1998, PHYS LETT B, V428, P105, DOI 10.1016/S0370-2693(98)00377-3; ZWANZIG R, 1964, J CHEM PHYS, V40, P2527, DOI 10.1063/1.1725558; Shiraishi N, 2013, J STAT PHYS, V152, P336, DOI 10.1007/s10955-013-0768-y; Trepat X, 2007, NATURE, V447, P592, DOI 10.1038/nature05824; Jiang HR, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.208301; Jarzynski C, 1997, PHYS REV LETT, V78, P2690, DOI 10.1103/PhysRevLett.78.2690; Maes C, 1999, J STAT PHYS, V95, P367, DOI 10.1023/A:1004541830999; Yang XB, 2014, SOFT MATTER, V10, P6477, DOI 10.1039/c4sm00927d; Hayashi K, 2006, PHYSICA A, V370, P407, DOI 10.1016/j.physa.2006.03.007; MAZUR P, 1970, PHYSICA, V50, P241, DOI 10.1016/0031-8914(70)90005-4; Katsuragi H, 2007, NAT PHYS, V3, P420, DOI 10.1038/nphys583; BREY JJ, 1982, J CHEM PHYS, V76, P3260, DOI 10.1063/1.443319; Touchette H, 2009, PHYS REP, V478, P1, DOI 10.1016/j.physrep.2009.05.002; LEBOWITZ JL, 1963, PHYS REV, V131, P2381, DOI 10.1103/PhysRev.131.2381; Bodineau T, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.180601; Piazza R, 2008, J PHYS-CONDENS MAT, V20, DOI 10.1088/0953-8984/20/15/153102; Bertini L, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.030601; Duhr S, 2006, P NATL ACAD SCI USA, V103, P19678, DOI 10.1073/pnas.0603873103; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Crooks GE, 1999, PHYS REV E, V60, P2721, DOI 10.1103/PhysRevE.60.2721; Seifert U, 2012, REP PROG PHYS, V75, DOI 10.1088/0034-4885/75/12/126001; Mizuno D, 2007, SCIENCE, V315, P370, DOI 10.1126/science.1134404; Takehara Y, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.148001; GALLAVOTTI G, 1995, PHYS REV LETT, V74, P2694, DOI 10.1103/PhysRevLett.74.2694; Aharony O, 2000, PHYS REP, V323, P183, DOI 10.1016/S0370-1573(99)00083-6; Takatori SC, 2014, PHYS REV LETT, V113, DOI 10.1103/PhysRevLett.113.028103; Albert R, 1999, PHYS REV LETT, V82, P205, DOI 10.1103/PhysRevLett.82.205; Jarzynski C, 2000, J STAT PHYS, V98, P77, DOI 10.1023/A:1018670721277; Ould-Kaddour F, 2003, J CHEM PHYS, V118, P7888, DOI 10.1063/1.1563593; Crooks GE, 2000, PHYS REV E, V61, P2361, DOI 10.1103/PhysRevE.61.2361; Sasa S, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.100602; Solon AP, 2015, NAT PHYS, V11, P673, DOI 10.1038/NPHYS3377; Lebowitz JL, 1999, J STAT PHYS, V95, P333, DOI 10.1023/A:1004589714161; Lee SH, 2004, J CHEM PHYS, V121, P11163, DOI 10.1063/1.1815291; EVANS DJ, 1993, PHYS REV LETT, V71, P2401, DOI 10.1103/PhysRevLett.71.2401; Ryu S, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.181602; SCHMITZ R, 1988, PHYS REP, V171, P1, DOI 10.1016/0370-1573(88)90052-X; GREEN MS, 1954, J CHEM PHYS, V22, P398; Sasa SI, 2006, J STAT PHYS, V125, P125, DOI 10.1007/s10955-005-9021-7; Goldman DI, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.021308; Bursac P, 2005, NAT MATER, V4, P557, DOI 10.1038/nmat1404; ZWANZIG R, 1964, J RES NATL BUR STAND, VB 68, P143, DOI 10.6028/jres.068B.019; Callen H, 1985, THERMODYNAMICS INTRO; Chapman S., 1970, MATH THEORY NONUNIFO; De Groot S., 1984, NONEQUILIBRIUM THERM; Ginot F, 2015, PHYS REV X, V5, DOI 10.1103/PhysRevX.5.011004; GREEN MS, 1951, J CHEM PHYS, V19, P1036, DOI 10.1063/1.1748449; Kim S, 1991, MICROHYDRODYNAMICS P; Kubo R., 1985, STAT PHYS; Landau L. D., 1959, FLUID MECH, V6; Landau L. D., 1980, STAT PHYS, V5; Lorentz H.A., 2012, THEORIES STAT THERMO; Maldacena J.M., 1998, ADV THEOR MATH PHYS, V2, p[231, 1113], DOI DOI 10.1023/A:1026654312961; Marchetti MC, 2013, REV MOD PHYS, V85, DOI 10.1103/RevModPhys.85.1143; Sergeev V.H., 1978, SOV PHYS USP, V27, P566; Witten E., 1998, ADV THEOR MATH PHYS, V2, P253, DOI DOI 10.1016/S0370-1573(99)00083-6; Wurger A, 2010, REP PROG PHYS, V73, DOI 10.1088/0034-4885/73/12/126601; Zeitouni O, 1998, LARGE DEVIATIONS TEC; Zubarev D. N., 1974, NONEQUILIBRIUM STAT	63	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0022-4715	1572-9613		J STAT PHYS	J. Stat. Phys.	NOV	2015	161	3					532	552		10.1007/s10955-015-1349-z		21	Physics, Mathematical	Physics	CT3WT	WOS:000362738300002		
J	Comets, F; Fukushima, R; Nakajima, S; Yoshida, N				Comets, Francis; Fukushima, Ryoki; Nakajima, Shuta; Yoshida, Nobuo			Limiting Results for the Free Energy of Directed Polymers in Random Environment with Unbounded Jumps	JOURNAL OF STATISTICAL PHYSICS			English	Article						Directed polymer; Random environment; First passage percolation; Zero temperature; Ground states	FIRST-PASSAGE PERCOLATION; PARABOLIC ANDERSON MODEL; 1ST-PASSAGE PERCOLATION; LYAPUNOV EXPONENT; TIME CONSTANT; LOCALIZATION; PROBABILITY; DISORDER; GROWTH	We study asymptotics of the free energy for the directed polymer in random environment. The polymer is allowed to make unbounded jumps and the environment is given by Bernoulli variables. We first establish the existence and continuity of the free energy including the negative infinity value of the coupling constant . Our proof of existence at differs from existing ones in that it avoids the direct use of subadditivity. Secondly, we identify the asymptotics of the free energy at in the limit of the success probability of the Bernoulli variables tending to one. It is described by using the so-called time constant of a certain directed first passage percolation. Our proof relies on a certain continuity property of the time constant, which is of independent interest.	[Comets, Francis] Univ Paris 07, Lab Probabilites & Modelisat Aleatoire, Paris, France; [Fukushima, Ryoki; Nakajima, Shuta] Kyoto Univ, Math Sci Res Inst, Kyoto, Japan; [Yoshida, Nobuo] Nagoya Univ, Grad Sch Math, Nagoya, Aichi 4648601, Japan	Fukushima, R (reprint author), Kyoto Univ, Math Sci Res Inst, Kyoto, Japan.	comets@math.univ-paris-diderot.fr; ryoki@kurims.kyoto-u.ac.jp; njima@kurims.kyoto-u.ac.jp; noby@math.nagoya-u.ac.jp			CNRS [UMR 7599]; JSPS KAKENHI [24740055, 25400136]	The first author was partially supported by CNRS, UMR 7599. The second author was supported by JSPS KAKENHI Grant Number 24740055. The fourth author was supported by JSPS KAKENHI Grant Number 25400136.	Howard CD, 1997, PROBAB THEORY REL, V108, P153, DOI 10.1007/s004400050105; Comets F, 2006, ANN PROBAB, V34, P1746, DOI 10.1214/009117905000000828; Carmona P, 2002, PROBAB THEORY REL, V124, P431, DOI 10.1007/s004400200213; Comets F, 2005, COMMUN MATH PHYS, V254, P257, DOI 10.1007/s00220-004-1203-7; Howard CD, 2001, ANN PROBAB, V29, P577; COX JT, 1980, ADV APPL PROBAB, V12, P864, DOI 10.2307/1426745; Amir G, 2011, COMMUN PUR APPL MATH, V64, P466, DOI 10.1002/cpa.20347; Comets F, 2013, STOCH PROC APPL, V123, P2446, DOI 10.1016/j.spa.2013.02.010; Comets F, 2003, BERNOULLI, V9, P705, DOI 10.3150/bj/1066223275; [Anonymous], 1991, LECT NOTES MATH; Yoshida N, 2008, J STAT PHYS, V133, P1033, DOI 10.1007/s10955-008-9646-4; COX JT, 1981, J APPL PROBAB, V18, P809, DOI 10.2307/3213056; Cranston M, 2005, PROBAB THEORY REL, V132, P321, DOI 10.1007/s00440-004-0346-y; Cranston M, 2006, J FUNCT ANAL, V236, P78, DOI 10.1016/j.jfa.2006.01.007; Seppalainen T, 2012, ANN PROBAB, V40, P19, DOI 10.1214/10-AOP617; NAGAEV SV, 1979, ANN PROBAB, V7, P745, DOI 10.1214/aop/1176994938; Comets F, 2013, COMMUN MATH PHYS, V323, P417, DOI 10.1007/s00220-013-1744-8; Kesten H, 2010, BRAZ J PROBAB STAT, V24, P300, DOI 10.1214/09-BJPS032; GRIFFEATH D, 1983, ANN PROBAB, V11, P692, DOI 10.1214/aop/1176993514; Comets F, 2008, J STAT PHYS, V131, P357, DOI 10.1007/s10955-008-9506-2; Fukushima R, 2012, ALEA-LAT AM J PROBAB, V9, P323; Boucheron S., 2013, CONCENTRATION INEQUA; Carmona R. A., 1994, MEM AM MATH SOC, V108, P1; Cranston M., 2002, ACTA MATH U COMENIAN, V71, P163; Garet O., 2015, PREPRINT; Kasahara Y., 1978, J MATH KYOTO U, V18, P209; KESTEN H, 1986, LECT NOTES MATH, V1180, P125; Lacoin H., 2012, ELECTRON J PROBAB, V17, P17; MOLCHANOV S., 2001, RANDOM OPER STOCHAST, V9, P77, DOI 10.1515/rose.2001.9.1.77; Moriarty J., 2007, MARKOV PROCESS RELAT, V13, P251; Mountford T. S., 2001, ELECTRON J PROBAB, V6, P9; Shiga T, 1997, PROBAB THEORY REL, V108, P417, DOI 10.1007/s004400050115	32	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0022-4715	1572-9613		J STAT PHYS	J. Stat. Phys.	NOV	2015	161	3					577	597		10.1007/s10955-015-1347-1		21	Physics, Mathematical	Physics	CT3WT	WOS:000362738300004		
J	Obuchi, T; Cocco, S; Monasson, R				Obuchi, Tomoyuki; Cocco, Simona; Monasson, Remi			Learning Probabilities From Random Observables in High Dimensions: The Maximum Entropy Distribution and Others	JOURNAL OF STATISTICAL PHYSICS			English	Article						Probabilistic inference; Maximum entropy principle; Replica method	STATISTICAL MECHANICS; INFORMATION THEORY	We consider the problem of learning a target probability distribution over a set of N binary variables from the knowledge of the expectation values (with this target distribution) of M observables, drawn uniformly at random. The space of all probability distributions compatible with these M expectation values within some fixed accuracy, called version space, is studied. We introduce a biased measure over the version space, which gives a boost increasing exponentially with the entropy of the distributions and with an arbitrary inverse 'temperature' . The choice of allows us to interpolate smoothly between the unbiased measure over all distributions in the version space () and the pointwise measure concentrated at the maximum entropy distribution (). Using the replica method we compute the volume of the version space and other quantities of interest, such as the distance R between the target distribution and the center-of-mass distribution over the version space, as functions of and for large N. Phase transitions at critical values of are found, corresponding to qualitative improvements in the learning of the target distribution and to the decrease of the distance R. However, for fixed , the distance R does not vary with , which means that the maximum entropy distribution is not closer to the target distribution than any other distribution compatible with the observable values. Our results are confirmed by Monte Carlo sampling of the version space for small system sizes ().	[Obuchi, Tomoyuki] Tokyo Inst Technol, Dept Computat Intelligence & Syst Sci, Yokohama, Kanagawa 227, Japan; [Cocco, Simona; Monasson, Remi] Ecole Normale Super, CNRS, Lab Phys Stat, Paris, France; [Cocco, Simona; Monasson, Remi] Univ Paris 06, Paris, France	Obuchi, T (reprint author), Tokyo Inst Technol, Dept Computat Intelligence & Syst Sci, Yokohama, Kanagawa 227, Japan.	obuchi@sp.dis.titech.ac.jp			JSPS; [EU-]FP7 FET OPEN project Enlightenment [284801]; Agence Nationale de la Recherche Coevstat project [ANR-13-BS04-0012-01]	The authors are grateful to U. Ferrari, Y. Kabashima, J. Lebowitz, and T. Mora for fruitful discussions. T. O. acknowledges the support by Grant-in-Aid for JSPS Fellows, as well as the JSPS Core-to-Core Program "Non-equilibrium dynamics of soft matter and information". S. C. and R. M. acknowledge financial support from the [EU-]FP7 FET OPEN project Enlightenment 284801 and Agence Nationale de la Recherche Coevstat project (ANR-13-BS04-0012-01). Numerical calculations were partly carried out on the TSUBAME2.5 supercomputer in the Tokyo Institute of Technology.	JAYNES ET, 1957, PHYS REV, V108, P171, DOI 10.1103/PhysRev.108.171; JAYNES ET, 1982, P IEEE, V70, P939, DOI 10.1109/PROC.1982.12425; TIKOCHINSKY Y, 1984, PHYS REV A, V30, P2638, DOI 10.1103/PhysRevA.30.2638; JAYNES ET, 1957, PHYS REV, V106, P620, DOI 10.1103/PhysRev.106.620; DEALMEIDA JRL, 1978, J PHYS A-MATH GEN, V11, P983, DOI 10.1088/0305-4470/11/5/028; Balian R., 1994, NATO ASI SER, V428, P11; Bialek W., 2012, BIOPHYSICS SEARCHING; Cover T. M., 1991, WILEY SERIES TELECOM; Jaynes E. T., 1986, MAXIMUM ENTROPY BAYE, P26, DOI 10.1017/CBO9780511569678.004; Obuchi T., 2015, J PHYS C SER UNPUB	10	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0022-4715	1572-9613		J STAT PHYS	J. Stat. Phys.	NOV	2015	161	3					598	632		10.1007/s10955-015-1341-7		35	Physics, Mathematical	Physics	CT3WT	WOS:000362738300005		
J	Hirono, Y; Hidaka, Y				Hirono, Yuji; Hidaka, Yoshimasa			Jarzynski-Type Equalities in Gambling: Role of Information in Capital Growth	JOURNAL OF STATISTICAL PHYSICS			English	Article						Jarzynski equality; Nonequilibrium; Gambling; Information; Directed information	FREE-ENERGY DIFFERENCES; FLUCTUATION THEOREM; MAXWELLS DEMON; STEADY-STATES; SYSTEMS; THERMODYNAMICS; WORK	We study the capital growth in gambling with (and without) side information and memory effects. We derive several equalities for gambling, which are of similar form to the Jarzynski equality and its extension to systems with feedback controls. Those relations provide us with new measures to quantify the effects of information on the statistics of capital growth in gambling. We discuss the implications of the equalities and show that they reproduce the known upper bounds of average capital growth rates.	[Hirono, Yuji] SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA; [Hidaka, Yoshimasa] RIKEN, Theoret Res Div, Nishina Ctr, Wako, Saitama 3510198, Japan	Hirono, Y (reprint author), SUNY Stony Brook, Dept Phys & Astron, Stony Brook, NY 11794 USA.	yuji.hirono@stonybrook.edu; hidaka@riken.jp			JSPS Research Fellowships for Young Scientists; RIKEN iTHES Project; JSPS Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation [R2411]	Y. Hirono is grateful to S. Nakayama for useful discussions and careful reading of the manuscript. Y. Hirono is supported by JSPS Research Fellowships for Young Scientists. This work is partially supported by the RIKEN iTHES Project. This work is also supported by JSPS Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation (No. R2411).	Vinkler DA, 2014, IEEE INT SYMP INFO, P1111, DOI 10.1109/ISIT.2014.6875005; Sagawa T, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.080403; Permuter HH, 2008, 2008 IEEE INTERNATIONAL SYMPOSIUM ON INFORMATION THEORY PROCEEDINGS, VOLS 1-6, P1403, DOI 10.1109/ISIT.2008.4595218; Barato AC, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.090601; Permuter HH, 2011, IEEE T INFORM THEORY, V57, P3248, DOI 10.1109/TIT.2011.2136270; Jarzynski C, 1997, PHYS REV LETT, V78, P2690, DOI 10.1103/PhysRevLett.78.2690; Hatano T, 2001, PHYS REV LETT, V86, P3463, DOI 10.1103/PhysRevLett.86.3463; Mandal D, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.030602; Sagawa T, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.250602; Campisi M, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.210401; Crooks GE, 1999, PHYS REV E, V60, P2721, DOI 10.1103/PhysRevE.60.2721; Deffner S, 2013, PHYS REV X, V3, DOI 10.1103/PhysRevX.3.041003; Ito S, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.180603; Lebowitz JL, 1999, J STAT PHYS, V95, P333, DOI 10.1023/A:1004589714161; Harada T, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.130602; SHANNON CE, 1949, AT&T TECH J, V28, P656; EVANS DJ, 1993, PHYS REV LETT, V71, P2401, DOI 10.1103/PhysRevLett.71.2401; Jarzynski C, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.230602; Mandal D, 2012, P NATL ACAD SCI USA, V109, P11641, DOI 10.1073/pnas.1204263109; Seifert U, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.040602; BELL RM, 1980, MATH OPER RES, V5, P161, DOI 10.1287/moor.5.2.161; Andrieux D, 2007, J STAT PHYS, V127, P107, DOI 10.1007/s10955-006-9233-5; Sagawa T, 2010, PHYS REV LETT, V104, DOI 10.1103/PhysRevLett.104.090602; Barato AC, 2014, NEW J PHYS, V16, DOI 10.1088/1367-2630/16/10/103024; Barato AC, 2013, EPL-EUROPHYS LETT, V101, DOI 10.1209/0295-5075/101/60001; Breiman L., 1961, P BERK S MATH STAT P; Cover T.M., 2012, ELEMENTS INFORM THEO; EVANS DJ, 1994, PHYS REV E, V50, P1645, DOI 10.1103/PhysRevE.50.1645; Horowitz JM, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.061120; Horowitz JM, 2014, NEW J PHYS, V16, DOI 10.1088/1367-2630/16/12/125007; KELLY JL, 1956, IRE T INFORM THEOR, V2, P185, DOI 10.1109/TIT.1956.1056803; Kramer G., 1998, THESIS U MANITOBA CA; Kurchan J., 2000, ARXIVCONDMAT0007360; Massey J, 1990, P INT S INF THEOR AP, P303; Massey J. L., 2005, P INT S INF THEOR IS, P157, DOI 10.1109/ISIT.2005.1523313; Parrondo JMR, 2015, NAT PHYS, V11, P131, DOI 10.1038/NPHYS3230; Poundstone W., 2010, FORTUNES FORMULA UNT; Tasaki H., 2000, ARXIVCONDMAT0009244; Thorp E. O., 1971, STOCHASTIC MODELS FI, P599; Thorp E. O., 1966, BEAT DEALER WINNING; THORP EO, 1969, REV INST INT STAT, V37, P273, DOI 10.2307/1402118; Werthamer NR, 2009, RISK AND REWARD: THE SCIENCE OF CASINO BLACKJACK, P3, DOI 10.1007/978-1-4419-0253-5_1	42	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0022-4715	1572-9613		J STAT PHYS	J. Stat. Phys.	NOV	2015	161	3					721	742		10.1007/s10955-015-1348-0		22	Physics, Mathematical	Physics	CT3WT	WOS:000362738300011		
J	Suzuki, T; Suwa, K; Ogawa, M; Eto, K; Kawahara, H; Fujita, T; Ikegami, M; Yanaga, K				Suzuki, Toshiaki; Suwa, Katsuhito; Ogawa, Masaichi; Eto, Ken; Kawahara, Hidejiro; Fujita, Tetsuji; Ikegami, Masahiro; Yanaga, Katsuhiko			Adjuvant chemotherapy for the perineural invasion of colorectal cancer	JOURNAL OF SURGICAL RESEARCH			English	Article						Adjuvant chemotherapy; Perineural invasion; Colorectal surgery	HIGH-RISK; PROGNOSTIC-SIGNIFICANCE; RECTAL-CANCER; COLON-CANCER; IDENTIFICATION; CARCINOMA; SURVIVAL; NECK; HEAD	Background: To evaluate the association of perineural invasion (PNI) with outcomes in patients after colorectal resection of colorectal cancer (CRC) and to assess the effect of PNI on the response to adjuvant chemotherapy. Patients and methods: Data were retrospectively reviewed for 178 patients with consecutive stages I-III CRC who underwent curative surgery between January 1999 and December 2004. PNI data were examined, and the overall survival (OS) and disease-free survival rates were analyzed. Results: PNI was detected in 36 of 178 patients (20%) and positively correlated with lymphatic invasion (P = 0.020), venous invasion (P = 0.037), and the incidence of metastasis or recurrence (P = 0.029). Five-year disease-free survival was 46% and 68% (P < 0.001) and the 5-y OS was 64% and 80% (P < 0.001) for patients with and without PNI, respectively. In stage III CRC, multiple regression analysis identified PNI as a strong negative prognostic factor of OS; among PNI-positive patients, median OS with adjuvant chemotherapy was almost twofold higher than that without adjuvant chemotherapy (6 versus 2.8 y; P = 0.017). Conclusions: PNI was a poor predictor of survival among patients with stage III CRC, and adjuvant chemotherapy may attenuate the adverse effects of PNI on survival. (C) 2015 Elsevier Inc. All rights reserved.	[Suzuki, Toshiaki; Suwa, Katsuhito] Jikei Univ, Sch Med, Daisan Hosp, Dept Surg, Tokyo 2018601, Japan; [Ogawa, Masaichi; Eto, Ken; Fujita, Tetsuji; Yanaga, Katsuhiko] Jikei Univ, Sch Med, Dept Surg, Tokyo, Japan; [Kawahara, Hidejiro] Jikei Univ, Sch Med, Kashiwa Hosp, Dept Surg, Tokyo, Japan; [Ikegami, Masahiro] Jikei Univ, Dept Pathol, Sch Med, Tokyo 105, Japan	Suzuki, T (reprint author), Jikei Univ, Sch Med, Daisan Hosp, Dept Surg, Izumihoncho 4-11-1,Komae Shi, Tokyo 2018601, Japan.	toshiaki1129jp@yahoo.co.jp					Mulcahy HE, 1997, DIS COLON RECTUM, V40, P326, DOI 10.1007/BF02050424; Peng SL, 2014, ANZ J SURG, V84, P837, DOI 10.1111/ans.12444; Liebig C, 2009, J CLIN ONCOL, V27, P5131, DOI 10.1200/JCO.2009.22.4949; Mendenhall WM, 2007, AM J CLIN ONCOL-CANC, V30, P93, DOI 10.1097/01.coc.0000251224.16075.60; Di Fabio F, 2004, DIGEST SURG, V21, P128, DOI 10.1159/000077348; Mulcahy HE, 1996, BRIT J SURG, V83, P46, DOI 10.1002/bjs.1800830114; Onate-Ocana LF, 2004, JPN J CLIN ONCOL, V34, P323, DOI 10.1093/jjco/hyh054; Fagan JJ, 1998, ARCH OTOLARYNGOL, V124, P637; Fujita S, 2007, DIS COLON RECTUM, V50, P1860, DOI 10.1007/s10350-007-9072-8; Merkel S, 2001, CANCER, V92, P1435, DOI 10.1002/1097-0142(20010915)92:6<1435::AID-CNCR1467>3.0.CO;2-N; Burdy G, 2001, DIS COLON RECTUM, V44, P1682, DOI 10.1007/BF02234390; Tsai HL, 2008, J SURG ONCOL, V97, P383, DOI 10.1002/jso.20942; [Anonymous], 2005, SCAND J UROL NEPHR S, DOI DOI 10.1080/03008880510030932; Quah HM, 2008, DIS COLON RECTUM, V51, P503, DOI 10.1007/s10350-008-9246-z; Stewart D, 2008, COLORECTAL DIS, V10, P879, DOI 10.1111/j.1463-1318.2008.01508.x; Harnden P, 2007, CANCER, V109, P13, DOI 10.1002/cncr.22388; Beard CJ, 2004, INT J RADIAT ONCOL, V58, P19, DOI 10.1016/S0360-3016(03)01433-0; Willett CG, 1999, DIS COLON RECTUM, V42, P167, DOI 10.1007/BF02237122	18	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	NOV	2015	199	1					84	89		10.1016/j.jss.2015.03.101		6	Surgery	Surgery	CT5VT	WOS:000362879900014		
J	Terracina, KP; Aoyagi, T; Huang, WC; Nagahashi, M; Yamada, A; Aoki, K; Takabe, K				Terracina, Krista P.; Aoyagi, Tomoyoshi; Huang, Wei-Ching; Nagahashi, Masayuki; Yamada, Akimitsu; Aoki, Kazunori; Takabe, Kazuaki			Development of a metastatic murine colon cancer model	JOURNAL OF SURGICAL RESEARCH			English	Article						Colon cancer; Animal model; Metastasis; Bioluminescence; Syngeneic; Orthotopic	BREAST-CANCER; MOUSE MODEL; IN-VIVO; ORTHOTOPIC IMPLANTATION; TUMOR-GROWTH; INJECTION; DISCOVERY; RESECTION; BIOLOGY; MICE	Background: It has now become clear that the complex interplay of cancer and the immune responses against it plays a critical role in the tumor microenvironment during cancer progression. As new targets for cancer treatment are being discovered and investigated, murine models used for preclinical studies need to include intact immune responses to provide a closer correlation with human cancer. We have recently developed a modified syngeneic orthotopic murine colon cancer model that mimics human colon cancer progression with consistent results. Materials and methods: Tumors were created using the murine colon adenocarcinoma cell line, CT26, modified to overexpress the firefly luciferase gene (CT26-luc1), which allowed real-time in vivo monitoring of tumor burden when the substrate, D-luciferin, was injected intraperitoneally using the In Vivo Imaging System. Mice are Balb/c (Harlan), syngeneic with the CT26-luc1 cells. Cells are injected submucosally, suspended in Matrigel, into the cecum wall under direct visualization. Results: The model has demonstrated consistent implantation in the cecum. In vivo bioluminescence allowed real-time monitoring of total tumor burden. Perioperative preparation had a significant impact on reproducibility of the model. Finally, total tumor burden quantified with bioluminescence enabled estimation of lymph node metastasis ex vivo. Conclusions: This method maintains an intact immune response and closely approximates the clinical tumor microenvironment. It is expected to provide an invaluable murine metastatic colon cancer model particularly in preclinical studies for drug development targeting those mechanisms. (C) 2015 Elsevier Inc. All rights reserved.	[Terracina, Krista P.; Aoyagi, Tomoyoshi; Huang, Wei-Ching; Nagahashi, Masayuki; Yamada, Akimitsu; Takabe, Kazuaki] Virginia Commonwealth Univ, Sch Med, Dept Surg, Div Surg Oncol, Richmond, VA 23298 USA; [Terracina, Krista P.; Aoyagi, Tomoyoshi; Huang, Wei-Ching; Nagahashi, Masayuki; Yamada, Akimitsu; Takabe, Kazuaki] Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; [Aoyagi, Tomoyoshi; Huang, Wei-Ching; Nagahashi, Masayuki; Yamada, Akimitsu; Takabe, Kazuaki] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Aoki, Kazunori] Natl Canc Ctr, Div Gene & Immune Med, Tokyo, Japan	Takabe, K (reprint author), Virginia Commonwealth Univ, Sch Med, Dept Surg, Div Surg Oncol, POB 980011,West Hosp 7-402,1200 East Broad St, Richmond, VA 23298 USA.	ktakabe@vcu.edu			NIH [5T32CA085159-10, R01CA160688]	This work was supported by NIH grants (5T32CA085159-10 to K.P.T. and R01CA160688 to K.T). M.N. is a Japan Society for the Promotion of Science Postdoctoral Fellow.	FIDLER IJ, 1991, CANCER METAST REV, V10, P229, DOI 10.1007/BF00050794; DiMasi JA, 2007, J CLIN ONCOL, V25, P209, DOI 10.1200/JCO.2006.09.0803; Metildi CA, 2014, J SURG ONCOL, V109, P451, DOI 10.1002/jso.23507; Mestas J, 2004, J IMMUNOL, V172, P2731; Hoffman RA, 2005, METH MOLEC MED, V111, P297; Hwang JE, 2011, J KOREAN MED SCI, V26, P1439, DOI 10.3346/jkms.2011.26.11.1439; Narumi K, 2012, GENE THER, V19, P34, DOI 10.1038/gt.2011.73; BELNAP LP, 1979, CANCER RES, V39, P1174; Nagahashi M, 2012, CANCER RES, V72, P726, DOI 10.1158/0008-5472.CAN-11-2167; Rashid OM, 2013, J THORAC DIS, V5, P385, DOI 10.3978/j.issn.2072-1439.2013.06.17; [Anonymous], 2014, BREAST CANC RES TREA, V147, P501, DOI [http://dx.doi.org/10.1007/sl0549-014-3118-0., DOI 10.1007/SL0549-014-3118-0]; Hoffman RM, 2014, METHODS MOL BIOL, V1070, P141, DOI 10.1007/978-1-4614-8244-4_11; Rajput A, 2008, J SURG RES, V147, P276, DOI 10.1016/j.jss.2007.04.021; Butcher EC, 2005, NAT REV DRUG DISCOV, V4, P461, DOI 10.1038/nrd1754; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Jin HY, 2011, TUMOR BIOL, V32, P391, DOI 10.1007/s13277-010-0132-7; Kruse J, 2013, INT J COLORECTAL DIS, V28, P1337, DOI 10.1007/s00384-013-1703-z; Rashid OM, 2013, SURGERY, V153, P771, DOI 10.1016/j.surg.2013.02.002; Thalheimer A, 2013, J SURG RES, V185, P143, DOI 10.1016/j.jss.2013.03.024; Thalheimer A, 2009, EUR SURG RES, V42, P195, DOI 10.1159/000205825; Horrobin DF, 2003, NAT REV DRUG DISCOV, V2, P151, DOI 10.1038/nrd1012; Su WJ, 2011, J CELL BIOCHEM, V112, P840, DOI 10.1002/jcb.22982; Clark AJ, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0345-4; Couzin-Frankel Jennifer, 2014, Science, V346, P24, DOI 10.1126/science.346.6205.24; Kishimoto H, 2013, PLOS ONE, V8, P1, DOI [http://dx.doi.org/10.1371/journal.pone.0079453., DOI 10.1371/J0URNAL.P0NE.0079453]; Mordant P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026073; Podetz-Pedersen KM, 2014, HUM GENE THER, V25, P955, DOI 10.1089/hum.2014.048; Yong HJ, 2007, CANCER BIOL THER, V6, P781, DOI [http://dx.doi.org/10.4161/cbt.6.5.4005., DOI 10.4161/CBT.6.5.4005]	28	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	NOV	2015	199	1					106	114		10.1016/j.jss.2015.04.030		9	Surgery	Surgery	CT5VT	WOS:000362879900017		
J	Kamada, S; Sakamoto, S; Ando, K; Muroi, A; Fuse, M; Kawamura, K; Imamoto, T; Suzuki, H; Nagata, M; Nihei, N; Akakura, K; Ichikawa, T				Kamada, Shuhei; Sakamoto, Shinichi; Ando, Keisuke; Muroi, Ayumi; Fuse, Miki; Kawamura, Koji; Imamoto, Takashi; Suzuki, Hiroyoshi; Nagata, Maki; Nihei, Naoki; Akakura, Koichiro; Ichikawa, Tomohiko			Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade	JOURNAL OF UROLOGY			English	Article						prostatic neoplasms; testosterone; antiandrogens; mortality; prognosis	RADICAL PROSTATECTOMY; PATHOLOGICAL STAGE; DEPRIVATION THERAPY; CASTRATION; LEVEL	Purpose: We examined the clinical significance of long-term serum testosterone monitoring to predict the prognosis of patients with prostate cancer treated with combined androgen blockade. Materials and Methods: We retrospectively analyzed the records of 225 patients who underwent combined androgen blockade as first line therapy for prostate cancer. The prognostic values of testosterone and other clinical factors were evaluated with respect to prostate specific antigen progression-free and overall survival. Results: Median patient age was 73.0 years, median prostate specific antigen was 42.6 ng/ml and median followup was 45.8 months. No variable associated with testosterone was predictive of progression-free survival. With regard to overall survival on univariate analysis nadir testosterone less than 16 ng/dl (p = 0.0190), less than 20 ng/dl (p = 0.0020) and less than 32 ng/dl (p = 0.0146) were significant together with other clinical factors. In contrast, nadir testosterone less than 8 and less than 12 ng/dl were not significant. Multivariate analysis showed that nadir testosterone less than 20 ng/dl was the significant prognostic factor (p = 0.0048). In addition, time to nadir testosterone was about 1 year (11.3 months). Patients were divided into rapid and slow types based on time to testosterone less than 20 ng/dl before and after 6 months, respectively. No significant difference in overall survival was observed between the 2 types. The current results suggest that the critical factor for prognosis was not a rapid decrease but whether nadir testosterone achieved a level of less than 20 ng/dl. Conclusions: Nadir testosterone 20 ng/dl was the most significant cutoff level for overall survival in Japanese patients with prostate cancer treated with combined androgen blockade.	Chiba Univ Hosp, Dept Urol, Chiba, Japan; Toho Univ, Med Ctr, Sakura Hosp, Sakura, Chiba, Japan; Yokohama Rosai Hosp, Yokohama, Kanagawa, Japan; Japan Community Hlth Care Org, Shinjuku Ku, Tokyo, Japan	Sakamoto, S (reprint author), Chiba Univ, Dept Urol, Grad Sch Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608687, Japan.	rbatbat1@yahoo.co.jp			 [25462469]	Supported by Grant-in-Aid for Scientific Research 25462469 (SS).	Morote J, 2007, J UROLOGY, V178, P1290, DOI 10.1016/j.juro.2007.05.129; Bertaglia V, 2013, CLIN GENITOURIN CANC, V11, P325, DOI 10.1016/j.clgc.2013.01.002; Tombal B, 2007, EUR UROL SUPPL, V6, P834, DOI 10.1016/j.eursup.2007.06.002; Perachino M, 2010, BJU INT, V105, P648, DOI 10.1111/j.1464-410X.2009.08814.x; Yamamoto S, 2007, EUR UROL, V52, P696, DOI 10.1016/j.eururo.2007.03.052; Hoffman MA, 2000, J UROLOGY, V163, P824, DOI 10.1016/S0022-5347(05)67812-3; SCHIAVI RC, 1992, PSYCHONEUROENDOCRINO, V17, P599, DOI 10.1016/0306-4530(92)90018-3; van der Sluis TM, 2012, J UROLOGY, V187, P1601, DOI 10.1016/j.juro.2011.12.063; Isom-Batz G, 2005, J UROLOGY, V173, P1935, DOI 10.1097/01.ju.0000158040.33531.e7; Klap J, 2015, J UROLOGY, V193, P403, DOI 10.1016/j.juro.2014.07.123; Imamoto T, 2005, EUR UROL, V47, P308, DOI 10.1016/j.eururo.2004.11.003; Lane BR, 2008, UROLOGY, V72, P1240, DOI 10.1016/j.urology.2008.06.001; Massengill JC, 2003, J UROLOGY, V169, P1670, DOI 10.1097/01.ju.0000062674.43964.d0; Schatzl G, 2001, PROSTATE, V47, P52; KYPRIANOU N, 1987, PROSTATE, V10, P313, DOI 10.1002/pros.2990100405; Cheol K, 2014, INT J UROL, V21, P1239; Laurence K, 2015, J CLIN ONCOL, V33, P1151; Regis L, 2014, J UROLOGY, V191, P856; Yann N, 2014, J UROLOGY, V191, pe412; Yasuda Y, 2015, INT J UROL, V22, P132, DOI 10.1111/iju.12623	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5347	1527-3792		J UROLOGY	J. Urol.	NOV	2015	194	5					1264	1270		10.1016/j.juro.2015.03.120		7	Urology & Nephrology	Urology & Nephrology	CT5UF	WOS:000362875800028		
J	Nakamura, S; Hyuga, T; Kawai, S; Nakai, H				Nakamura, Shigeru; Hyuga, Taiju; Kawai, Shina; Nakai, Hideo			Long-Term Outcome of the Pippi Salle Procedure for Intractable Urinary Incontinence in Patients with Severe Intrinsic Urethral Sphincter Deficiency	JOURNAL OF UROLOGY			English	Article						urethra; urinary bladder; urinary incontinence; urologic surgical procedures	EXSTROPHY-EPISPADIAS COMPLEX; BLADDER NECK INJECTION; WALL FLAP; CHILDREN; POLYDIMETHYLSILOXANE; MYELODYSPLASIA; MANAGEMENT	Purpose: We evaluated the long-term outcome of the Pippi Salle procedure in patients with severe intrinsic urethral sphincter deficiency. Materials and Methods: We performed the Pippi Salle procedure in 6 males and 6 females with severe intrinsic sphincter deficiency between March 2003 and August 2013. Median patient age was 15 years (range 6 to 45). Mean followup was 75 months (range 17 to 142). Six males and 3 females had neurogenic intrinsic sphincter deficiency (spina bifida in 8 and spinal cord injury in 1). Three females had anatomical intrinsic sphincter deficiency (idiopathic bladder hypoplasia in 2 and pseudo-ureterocele in 1). Four patients had previously undergone bladder neck surgery, 3 had been treated with endoscopic injection of collagen, 2 had undergone fascial sling and 1 had been treated with tension-free vaginal tape surgery. The Pippi Salle procedure was performed alone (2 patients), or in combination with bladder augmentation (4) or catheterizable abdominal stoma (1), or both (5). Results: Complete dryness was achieved in 7 patients (58%). Of 9 patients with neurogenic intrinsic sphincter deficiency 7 (78%) achieved complete dryness. Eight patients experienced complications, including continued urinary incontinence (5), difficulty catheterizing per urethra (3) and urinary calculi (1). These 8 patients were successfully treated with additional endoscopic interventions, including injection of collagen in 4, injection of dextranomer-hyaluronic acid in 1, transurethral incision of urethral kink in 3 and vesicolithotripsy in 1. After these simple interventions complete dryness was achieved in all 12 patients. Conclusions: Although we experienced some minor complications in the short term, most patients were simply and successfully treated with endoscopic surgery. The long-term results of the Pippi Salle procedure are promising.	[Nakamura, Shigeru; Hyuga, Taiju; Kawai, Shina; Nakai, Hideo] Jichi Med Univ, Dept Pediat Urol, Childrens Med Ctr Tochigi, Shimotuke, Tochigi 3290498, Japan	Nakamura, S (reprint author), Jichi Med Univ, Dept Pediat Urol, Childrens Med Ctr Tochigi, 3311-1 Yakushiji, Shimotuke, Tochigi 3290498, Japan.	naka251148@gmail.com					Burki T, 2006, BJU INT, V98, P849, DOI 10.1111/j.1464-410X.2006.06378.x; Kitchens DM, 2007, J UROLOGY, V177, P302, DOI 10.1016/j.juro.2006.09.012; Guys JM, 2006, J UROLOGY, V175, P1106, DOI 10.1016/S0022-5347(05)00404-0; DaJusta D, 2013, J PEDIATR UROL, V9, P278, DOI 10.1016/j.jpurol.2012.03.013; MOURIQUAND PDE, 1995, BRIT J UROL, V75, P656, DOI 10.1111/j.1464-410X.1995.tb07427.x; Salle JLP, 1997, J UROLOGY, V158, P585; Misseri R, 2005, J UROLOGY, V174, P1691, DOI 10.1097/01.ju.0000179253.13807.82; CAIONE P, 1993, J UROLOGY, V150, P631; Lottmann HB, 2006, J UROLOGY, V176, P1762, DOI 10.1016/j.juro.2006.03.121; RINK RC, 1994, J UROLOGY, V152, P799; MCGUIRE EJ, 1986, J UROLOGY, V135, P94; Duffy PG, 1998, BRIT J UROL, V81, P309; Jawaheer G, 1999, EUR J PEDIATR SURG, V9, P9, DOI 10.1055/s-2008-1072303; De Vocht TF, 2010, J UROLOGY, V183, P719, DOI 10.1016/j.juro.2009.10.044; SALLE JLP, 1994, J UROLOGY, V152, P803; Shah BB, 2014, J PEDIATR UROL, V10, P176, DOI 10.1016/j.jpurol.2013.08.004; ELDER JS, 1990, J UROLOGY, V144, P434; BAUER SB, 1989, J UROLOGY, V142, P516; GORMLEY EA, 1994, J UROLOGY, V152, P822; Pippi Salle JL, 2009, HINMANS ATLAS PEDIAT, P354	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0022-5347	1527-3792		J UROLOGY	J. Urol.	NOV	2015	194	5					1402	1406		10.1016/j.juro.2015.05.095		5	Urology & Nephrology	Urology & Nephrology	CT5UF	WOS:000362875800097		
J	Zhao, K; Nakada, S; Sakamoto, N; Koyamada, K				Zhao, Kun; Nakada, Satoshi; Sakamoto, Naohisa; Koyamada, Koji			Voting-based ensemble-averaging visualization for water mass distribution	JOURNAL OF VISUALIZATION			English	Article						Oceanography; Ocean flows; Ensemble-averaged visualization	MODELS; VOLUME	The distribution of water masses has become one of the most important topics in recent oceanic research. Water masses flow dynamically and have interannual variability, and hence the distribution can change dramatically even over short time periods and may differ from year to year. In this paper, we use a high-resolution ocean dataset, which contains multiple ocean variables, to visualize the details of the water mass. Because water mass can be defined by multiple ocean variables (e.g., temperature and salinity), we develop a multi-variate visualization system, which allows us to extract the time-varying distributions of water masses from multiple variables. The visualization is then adjusted by multiple ocean specialists because directly applying the existing definition to extract the water mass would result in incorrect rendering results. This leads to another problem that different ocean specialists may have different perspectives on the distribution of water masses, so that the adjustments would also be different. To solve this problem, an ensemble average process is performed for the adjusted rendering results from multiple ocean specialists. To increase the authenticity, we also add a voting scheme to the system, so that a majority rule can be applied to the ensemble-averaging result. As the application of the proposed voting-based ensemble-averaging visualization system, we first show the interannual variability of the significant water mass and then visualize the dynamic behavior for the period of interest in different years. We also highlight a mixing phenomenon that has a strong influence on the distribution of the water mass. As a result, we can obtain a clear and accurate visualization of the water mass distribution.	[Zhao, Kun] Kyoto Univ, Grad Sch Engn, Kyoto, Japan; [Nakada, Satoshi; Sakamoto, Naohisa; Koyamada, Koji] Kyoto Univ, Inst Liberal Arts & Sci, Kyoto, Japan	Zhao, K (reprint author), Kyoto Univ, Grad Sch Engn, Kyoto, Japan.	zhao.kun@viz.media.kyoto-u.ac.jp			Japan Society for the Promotion of Science (JSPS) KAKENHI [26.837]; Ministry of Education, Culture, Sports, Science and Technology (MEXT); Japan Science and Technology Agency (JST), A-STEP [AS2415031H]	This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI Grants-in-Aid for JSPS Fellows (Grant No. 26.837) and was partially supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Grat-in-Aid for Data Integration and Analysis System (DIAS), Grant-in-Aid for Research Programs on Climate Change Adaptation (RECCA), and by the Japan Science and Technology Agency (JST), A-STEP project ("The research and development of fusion visualization technology", AS2415031H).	Ana LR, 2007, J OCEANOGR, V63, P573; Smith KM, 2006, J COMPUT THEOR NANOS, V3, P752; Zhao K, 2012, COMM COM INF SC, V323, P163; Zhao K, 2012, COMM COM INF SC, V325, P373; Ishikawa Y, 2009, J MARINE SYST, V78, P237, DOI 10.1016/j.jmarsys.2009.02.016; Hurlburt HE, 1996, J GEOPHYS RES-OCEANS, V101, P941, DOI 10.1029/95JC01674; Sakurai Y, 2007, DEEP-SEA RES PT II, V54, P2526, DOI 10.1016/j.dsr2.2007.02.007; Seferian R, 2012, J CLIMATE, V25, P3894, DOI 10.1175/JCLI-D-11-00291.1; Potter K, 2009, 2009 IEEE INTERNATIONAL CONFERENCE ON DATA MINING WORKSHOPS (ICDMW 2009), P233, DOI 10.1109/ICDMW.2009.55; Meehl GA, 2006, CLIM DYNAM, V26, P549, DOI 10.1007/s00382-005-0098-0; Mitnik LM, 2011, P 2011 IEEE INT GEOS; Mizuno K., 1988, Geojournal, V16, P65, DOI 10.1007/BF02626373; Nakada S., 2012, HYDROL RES LETT, V6, P47, DOI DOI 10.3178/HRL.6.47; Onishi M., 1997, J OCEANOGR, V53, P27, DOI 10.1007/BF02700746; Phadke MN, 2012, EXPLORING ENSEMBLE V, V8294, P1; Sabella P., 1988, Computer Graphics, V22; Sanyal J, 2010, IEEE T VIS COMPUT GR, V16, P1421, DOI 10.1109/TVCG.2010.181; Sisneros R, 2013, PROCEDIA COMPUT SCI, V18, P2347, DOI 10.1016/j.procs.2013.05.406; Yang GJ, 2007, IEEE CAD GRAPHICS, P493; Yasuda Ichiro, 1994, Fisheries Oceanography, V3, P172, DOI 10.1111/j.1365-2419.1994.tb00094.x; Zhao K, 2013, INT J MODEL SIMUL S1, V4	21	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1343-8875	1875-8975		J VISUAL-JAPAN	J. Vis.	NOV	2015	18	4					719	731		10.1007/s12650-014-0258-6		13	Computer Science, Interdisciplinary Applications; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	CT7DD	WOS:000362972900014		
J	Alberg, J				Alberg, Jeremiah			Metaphysics as Kant's Coquette: Rousseau's Influence on Dreams of a Spirit-Seer	KANTIAN REVIEW			English	Article						drive to equality; drive to unity; drive to honour; general will; coquette; metaphysics; world; Kant; Rousseau; R. Girard; Dreams of a Spirit-Seer		Kant's notes known as Remarks in the 'Observations on the Feeling of the Beautiful and the Sublime' reveal a deep concern with the way in which the human drives to equality and unity lead inevitably to a drive for honour and its attendant delusions. He developed his thinking about these problems in the context of his reading of Rousseau. In his published Dreams of a Spirit-Seer, Kant tries to overcome the influence of the drive for honour by appealing to a metaphysics that is critical of itself. The problem is how to distinguish what is grounded in reason when that reason is so easily influenced by others.	Int Christian Univ, Mitaka, Tokyo, Japan	Alberg, J (reprint author), Int Christian Univ, Mitaka, Tokyo, Japan.	jlalberg@gmail.com					Alberg Jeremiah, 2015, KANT-STUD, V106, P160; Alberg J, 2007, REINTERPRETATION OF ROUSSEAU: A RELIGIOUS SYSTEM, P1, DOI 10.1057/9780230607132; Andriopoulos S, 2011, REPRESENTATIONS, P42, DOI 10.1525/rep.2011.115.1.42; Zammito JH, 2012, CAMB CRIT GUIDE, P234; Brandt R, 2012, CAMB CRIT GUIDE, P185; Velkley R, 2013, CHALLENGE OF ROUSSEAU, P217; Pourciau S, 2006, GER REV, V81, P99, DOI 10.3200/GERR.81.2.99-120; Brandt R, 2008, KANT-STUD, V99, P46, DOI 10.1515/KANT.2008.004; Collins James, 1967, EMERGENCE PHILOS REL; Girard Rene, 1987, THINGS HIDDEN FDN WO; Girard Rene, 1971, DECEIT DESIRE NOVEL; Henrich Dieter, 1965, PHILOS RUNDSCH, V13, P253; Henrich Dieter, 1963, KANT-STUD, V54, P404, DOI 10.1515/kant.1963.54.1-4.404; Kant I, 1999, CORRESPONDENCE; Kant Immanuel, 1997, LECT ETHICS, P1; Kant Immanuel, 2011, OBSERVATIONS FEELING, P65; Kant Immanuel, 1991, BERMERKUNGEN BEOBACH; Neuhouser Frederick, 2008, ROUSSEAUS THEODICY S; Rousseau Jean-Jacques, 1992, DISCOURSE ORIGINS IN; Rousseau Jean-Jacques, 2010, EMILE ED; Rousseau Jean-Jacques, 1959, OEUVRES COMPLETES, V1; Rousseau Jean-Jacques, 1984, DISKURS UNGLEICHHEIT; Rousseau Jean-Jacques, 1990, ROUSSEAU JUDGE JEAN; Schmucker Josef, 1961, URSPRUNGE ETHIK KANT; Shell SM, 2013, CHALLENGE OF ROUSSEAU, P271; Shell Susan Meld, 2009, KANT LIMITS AUTONOMY; Starobinski Jean, 1988, JEAN JACQUES ROUSSEA; Velkley Richard, 2002, BEING AFTER ROUSSEAU; Velkley Richard, 2013, KANT MORAL AUTONOMY, P89; Velkley Richard, 1989, FREEDOM END REASON M; Walford D., 1992, THEORETICAL PHILOS, P301	31	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1369-4154	2044-2394		KANTIAN REV	Kantian Rev.	NOV	2015	20	3					347	371		10.1017/S1369415415000138		25	Philosophy	Philosophy	CT7DU	WOS:000362974800001		
J	Takahashi, H; Kamakari, K; Goto, T; Hara, H; Mohri, S; Suzuki, H; Shibata, D; Nakata, R; Inoue, H; Takahashi, N; Kawada, T				Takahashi, Haruya; Kamakari, Kosuke; Goto, Tsuyoshi; Hara, Hideyuki; Mohri, Shinsuke; Suzuki, Hideyuki; Shibata, Daisuke; Nakata, Rieko; Inoue, Hiroyasu; Takahashi, Nobuyuki; Kawada, Teruo			9-Oxo-10(E),12(Z),15(Z)-Octadecatrienoic Acid Activates Peroxisome Proliferator-Activated Receptor alpha in Hepatocytes	LIPIDS			English	Article						PPAR alpha; Oxylipin; Hepatocytes; Fatty acid metabolism; LC-MS	REGULATES GENE-EXPRESSION; PPAR-ALPHA; HEPG2 HEPATOCYTES; INSULIN-RESISTANCE; METABOLIC SYNDROME; LIPID-METABOLISM; COA; TOMATO; OXIDATION; AGONIST	The peroxisome proliferator-activated receptor (PPAR)alpha is mainly expressed in the liver and plays an important role in the regulation of lipid metabolism. It has been reported that PPAR alpha activation enhances fatty acid oxidation and reduces fat storage. Therefore, PPAR alpha agonists are used to treat dyslipidemia. In the present study, we found that 9-oxo-10(E),12(Z),15(Z)-octadecatrienoic acid (9-oxo-OTA), which is a alpha-linolenic acid (ALA) derivative, is present in tomato (Solanum lycopersicum) extract. We showed that 9-oxo-OTA activated PPAR alpha and induced the mRNA expression of PPAR alpha target genes in murine primary hepatocytes. These effects promoted fatty acid uptake and the secretion of beta-hydroxybutyrate, which is one of the endogenous ketone bodies. We also demonstrated that these effects of 9-oxo-OTA were not observed in PPAR alpha-knockout (KO) primary hepatocytes. To our knowledge, this is the first study to report that 9-oxo-OTA promotes fatty acid metabolism via PPAR alpha activation and discuss its potential as a valuable food-derived compound for use in the management of dyslipidemia.	[Takahashi, Haruya; Kamakari, Kosuke; Goto, Tsuyoshi; Hara, Hideyuki; Mohri, Shinsuke; Takahashi, Nobuyuki; Kawada, Teruo] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Lab Mol Funct Food, Kyoto 6110011, Japan; [Goto, Tsuyoshi; Takahashi, Nobuyuki; Kawada, Teruo] Kyoto Univ, Res Unit Physiol Chem, Kyoto 6068501, Japan; [Suzuki, Hideyuki; Shibata, Daisuke] Kazusa DNA Res Inst, Chiba 2920818, Japan; [Nakata, Rieko; Inoue, Hiroyasu] Nara Womens Univ, Dept Food Sci & Nutr, Nara 6308506, Japan	Kawada, T (reprint author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Lab Mol Funct Food, Kyoto 6110011, Japan.	fat@kais.kyoto-u.ac.jp			Research and Development Projects for Application in Promoting New Policies Agriculture, Forestry, and Fisheries of Japan; Ministry of Education, Culture, Sports, Science, and Technology of Japan [22228001, 24688015]; Japan Society for the Promotion of Science for Young Scientists [24521]	The authors thank S. Shinoto and M. Sakai for secretarial and technical support, respectively. This work was supported in part by Research and Development Projects for Application in Promoting New Policies Agriculture, Forestry, and Fisheries of Japan, by grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (22228001 and 24688015), and by Research Fellowships of the Japan Society for the Promotion of Science for Young Scientists (24521).	Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Duval C, 2002, TRENDS MOL MED, V8, P422, DOI 10.1016/S1471-4914(02)02385-7; Goto T, 2005, BIOCHEM BIOPH RES CO, V337, P440, DOI 10.1016/j.bbrc.2005.09.077; Aguilo F, 2010, BIOCHEM J, V427, P255, DOI 10.1042/BJ20090851; TUGWOOD JD, 1992, EMBO J, V11, P433; Reddy JK, 2001, ANNU REV NUTR, V21, P193, DOI 10.1146/annurev.nutr.21.1.193; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; Lee SST, 2004, J LIPID RES, V45, P2025, DOI 10.1194/jlr.M400078-JLR200; Fu J, 2005, NEUROPHARMACOLOGY, V48, P1147, DOI 10.1016/j.neuropharm.2005.02.013; Takahashi N, 2008, BIOFACTORS, V33, P25, DOI 10.1002/biof.5520330103; Kim S, 2004, MOL CELL ENDOCRINOL, V220, P51, DOI 10.1016/j.mce.2004.03.011; Nakamura MT, 2014, PROG LIPID RES, V53, P124, DOI 10.1016/j.plipres.2013.12.001; Giovannucci E, 1999, J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269; Takahashi N, 2002, FEBS LETT, V514, P315, DOI 10.1016/S0014-5793(02)02390-6; Roepstorff C, 2005, AM J PHYSIOL-ENDOC M, V288, pE133, DOI 10.1152/ajpendo.00379.2004; Lazarus SA, 2004, JAMA-J AM MED ASSOC, V292, P805, DOI 10.1001/jama.292.7.805; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Kim YI, 2011, MOL NUTR FOOD RES, V55, P585, DOI 10.1002/mnfr.201000264; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Miranda PJ, 2005, AM HEART J, V149, P33, DOI 10.1016/j.ahj.2004.07.013; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Huynh FK, 2014, METHOD ENZYMOL, V542, P391, DOI 10.1016/B978-0-12-416618-9.00020-0; Bernal-Mizrachi C, 2003, NAT MED, V9, P1069, DOI 10.1038/nm898; ITO M, 1986, BIOCHIM BIOPHYS ACTA, V876, P280, DOI 10.1016/0005-2760(86)90285-7; Goto T, 2011, J LIPID RES, V52, P873, DOI 10.1194/jlr.M011320; Kalinowska A, 2009, FEBS LETT, V583, P2527, DOI 10.1016/j.febslet.2009.07.008; Blum Arnon, 2005, Eur J Intern Med, V16, P402, DOI 10.1016/j.ejim.2005.02.017; Bogna GG, 2014, NUTR J, V13, P17; Gao MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065641; Goldenberg Ilan, 2008, Vasc Health Risk Manag, V4, P131, DOI 10.2147/vhrm.2008.04.01.131; Kim YI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031317; Takahashi H, 2014, BIOSCI BIOTECH BIOCH, V78, P1761, DOI 10.1080/09168451.2014.930330; Takahashi H, 2015, LIPIDS, V50, P3, DOI 10.1007/s11745-014-3972-x	37	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0024-4201	1558-9307		LIPIDS	Lipids	NOV	2015	50	11					1083	1091		10.1007/s11745-015-4071-3		9	Biochemistry & Molecular Biology; Nutrition & Dietetics	Biochemistry & Molecular Biology; Nutrition & Dietetics	CT7CX	WOS:000362972100003		
J	Nanthirudjanar, T; Furumoto, H; Zheng, JW; Kim, YI; Goto, T; Takahashi, N; Kawada, T; Park, SB; Hirata, A; Kitamura, N; Kishino, S; Ogawa, J; Hirata, T; Sugawara, T				Nanthirudjanar, Tharnath; Furumoto, Hidehiro; Zheng, Jiawen; Kim, Young-Il; Goto, Tsuyoshi; Takahashi, Nobuyuki; Kawada, Teruo; Park, Si-Bum; Hirata, Akiko; Kitamura, Nahoko; Kishino, Shigenobu; Ogawa, Jun; Hirata, Takashi; Sugawara, Tatsuya			Gut Microbial Fatty Acid Metabolites Reduce Triacylglycerol Levels in Hepatocytes	LIPIDS			English	Article						Acetyl-CoA carboxylase; Hydroxy fatty acid; Oxo fatty acid; Lipogenesis; Liver; Sterol regulatory element binding protein-1c	INDUCED CELLULAR TRIACYLGLYCEROL; LACTOBACILLUS-PLANTARUM; PPAR-ALPHA; BACTERIA; SREBP-1C; SUPPRESSION; PGC-1-BETA; STEATOSIS; PRODUCTS; STRAINS	Hydroxy and oxo fatty acids were recently found to be produced as intermediates during gut microbial fatty acid metabolism. Lactobacillus plantarum produces these fatty acids from unsaturated fatty acids such as linoleic acid. In this study, we investigated the effects of these gut microbial fatty acid metabolites on the lipogenesis in liver cells. We screened their effect on sterol regulatory element binding protein-1c (SREBP-1c) expression in HepG2 cells treated with a synthetic liver X receptor alpha (LXR alpha) agonist (T0901317). The results showed that 10-hydroxy-12(Z)-octadecenoic acid (18:1) (HYA), 10-hydroxy-6(Z),12(Z)-octadecadienoic acid (18:2) (gamma HYA), 10-oxo-12(Z)-18:1 (KetoA), and 10-oxo-6(Z),12(Z)-18:2 (gamma KetoA) significantly decreased SREBP-1c mRNA expression induced by T0901317. These fatty acids also downregulated the mRNA expression of lipogenic genes by suppressing LXR alpha activity and inhibiting SREBP-1 maturation. Oral administration of KetoA, which effectively reduced triacylglycerol accumulation and acetyl-CoA carboxylase 2 (ACC2) expression in HepG2 cells, for 2 weeks significantly decreased Srebp-1c, Scd-1, and Acc2 expression in the liver of mice fed a high-sucrose diet. Our findings suggest that the hypolipidemic effect of the fatty acid metabolites produced by L. plantarum can be exploited in the treatment of cardiovascular diseases or dyslipidemia.	[Nanthirudjanar, Tharnath; Furumoto, Hidehiro; Zheng, Jiawen; Hirata, Takashi; Sugawara, Tatsuya] Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Lab Marine Bioprod Technol, Kyoto 6068502, Japan; [Kim, Young-Il; Goto, Tsuyoshi; Takahashi, Nobuyuki; Kawada, Teruo] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Lab Mol Funct Food, Uji, Kyoto 6110011, Japan; [Hirata, Akiko; Kitamura, Nahoko; Kishino, Shigenobu; Ogawa, Jun] Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Fermentat Physiol & Appl Microbiol, Kyoto 6068502, Japan; [Park, Si-Bum] Kyoto Univ, Grad Sch Agr, Lab Ind Microbiol, Kyoto 6068502, Japan; [Hirata, Takashi] Shijonawate Gakuen Univ, Daito 5740011, Japan	Sugawara, T (reprint author), Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Lab Marine Bioprod Technol, Kyoto 6068502, Japan.	sugawara@kais.kyoto-u.ac.jp			Bio-Oriented Technology Research Advancement Institution of Japan; NEDO Innovation Commercialization Venture Support Project; Nitto Pharmaceutical Industries, Ltd.	This research was partially supported by the Bio-Oriented Technology Research Advancement Institution of Japan to J. Ogawa. It was also partially supported by the NEDO Innovation Commercialization Venture Support Project with the collaboration of Nitto Pharmaceutical Industries, Ltd. and J. Ogawa.	Clarke SD, 2001, AM J PHYSIOL-GASTR L, V281, pG865; Ogawa J, 2005, J BIOSCI BIOENG, V100, P355, DOI 10.1263/jbb.100.355; de Vries MC, 2006, INT DAIRY J, V16, P1018, DOI 10.1016/j.idairyj.2005.09.003; Mathara JM, 2008, CURR MICROBIOL, V56, P315, DOI 10.1007/s00284-007-9084-6; Kishino S, 2011, BIOSCI BIOTECH BIOCH, V75, P318, DOI 10.1271/bbb.100699; Wakil SJ, 2009, J LIPID RES, V50, pS138, DOI 10.1194/jlr.R800079-JLR200; Targher G, 2007, DIABETES CARE, V30, P1212, DOI 10.2337/dc06-2247; Parvez S, 2006, J APPL MICROBIOL, V100, P1171, DOI 10.1111/j.1365-2672.2006.02963.x; Kishino S, 2002, J AM OIL CHEM SOC, V79, P159, DOI 10.1007/s11746-002-0451-4; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Takahashi N, 2002, FEBS LETT, V514, P315, DOI 10.1016/S0014-5793(02)02390-6; Haas JT, 2012, CELL METAB, V15, P873, DOI 10.1016/j.cmet.2012.05.002; Kishino S, 2013, P NATL ACAD SCI USA, V110, P17808, DOI 10.1073/pnas.1312937110; Georgieva R, 2009, INT DAIRY J, V19, P696, DOI 10.1016/j.idairyj.2009.06.006; Zaima N, 2006, J LIPID RES, V47, P2712, DOI 10.1194/jlr.M600273-JLR200; Candela M, 2008, INT J FOOD MICROBIOL, V125, P286, DOI 10.1016/j.ijfoodmicro.2008.04.012; Tanaka N, 2010, BIOCHEM PHARMACOL, V80, P1601, DOI 10.1016/j.bcp.2010.07.031; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Ando A, 2003, J AM OIL CHEM SOC, V80, P889, DOI 10.1007/s11746-003-0790-1; Barber MC, 2005, BBA-MOL CELL BIOL L, V1733, P1, DOI 10.1016/j.bbalip.2004.12.001; Caputo M., 2010, J CELL PHYSL, V226, P187; Castle JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004369; CURTIS RG, 1953, J CHEM SOC, P457, DOI 10.1039/jr9530000457; Field FJ, 2002, BIOCHEM J, V368, P357; Frayn KN, 2006, ESSAYS BIOCHEM, V42, P89; Vanden Heuvel John P., 2003, Toxicology and Applied Pharmacology, V188, P185, DOI 10.1016/S0041-008X(03)00015-2; Nanthirudjanar T, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-73	27	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0024-4201	1558-9307		LIPIDS	Lipids	NOV	2015	50	11					1093	1102		10.1007/s11745-015-4067-z		10	Biochemistry & Molecular Biology; Nutrition & Dietetics	Biochemistry & Molecular Biology; Nutrition & Dietetics	CT7CX	WOS:000362972100004		
J	Smith, CR; Cahan, SH; Kemena, C; Brady, SG; Yang, W; Bornberg-Bauer, E; Eriksson, T; Gadau, J; Helmkampf, M; Gotzek, D; Miyakawa, MO; Suarez, AV; Mikheyev, A				Smith, Chris R.; Cahan, Sara Helms; Kemena, Carsten; Brady, Sean G.; Yang, Wei; Bornberg-Bauer, Erich; Eriksson, Ti; Gadau, Juergen; Helmkampf, Martin; Gotzek, Dietrich; Miyakawa, Misato Okamoto; Suarez, Andrew V.; Mikheyev, Alexander			How Do Genomes Create Novel Phenotypes? Insights from the Loss of the Worker Caste in Ant Social Parasites	MOLECULAR BIOLOGY AND EVOLUTION			English	Article						social parasite; ant; caste; phenotypic plasticity; genome	DIFFERENTIAL EXPRESSION ANALYSIS; DNA-SEQUENCING DATA; RED HARVESTER ANT; RNA-SEQ DATA; GENE-EXPRESSION; HYMENOPTERA-FORMICIDAE; POGONOMYRMEX-BARBATUS; ANNOTATION PIPELINE; VOLLENHOVIA-EMERYI; RELAXED SELECTION	A central goal of biology is to uncover the genetic basis for the origin of new phenotypes. A particularly effective approach is to examine the genomic architecture of species that have secondarily lost a phenotype with respect to their close relatives. In the eusocial Hymenoptera, queens and workers have divergent phenotypes that may be produced via either expression of alternative sets of caste-specific genes and pathways or differences in expression patterns of a shared set of multifunctional genes. To distinguish between these two hypotheses, we investigated how secondary loss of the worker phenotype in workerless ant social parasites impacted genome evolution across two independent origins of social parasitism in the ant genera Pogonomyrmex and Vollenhovia. We sequenced the genomes of three social parasites and their most-closely related eusocial host species and compared gene losses in social parasites with gene expression differences between host queens and workers. Virtually all annotated genes were expressed to some degree in both castes of the host, with most shifting in queen-worker bias across developmental stages. As a result, despite >1My of divergence from the last common ancestor that had workers, the social parasites showed strikingly little evidence of gene loss, damaging mutations, or shifts in selection regime resulting from loss of the worker caste. This suggests that regulatory changes within a multifunctional genome, rather than sequence differences, have played a predominant role in the evolution of social parasitism, and perhaps also in the many gains and losses of phenotypes in the social insects.	[Smith, Chris R.] Earlham Coll, Dept Biol, Richmond, IN 47374 USA; [Cahan, Sara Helms] Univ Vermont, Dept Biol, Burlington, VT 05405 USA; [Kemena, Carsten; Bornberg-Bauer, Erich] Univ Munster, Inst Evolut & Biodivers, D-48149 Munster, Germany; [Brady, Sean G.] Natl Museum Nat Hist, Dept Entomol, Smithsonian Inst, Washington, DC 20560 USA; [Yang, Wei] Univ Illinois, Dept Comp Sci, Urbana, IL USA; [Eriksson, Ti; Gadau, Juergen; Helmkampf, Martin] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA; [Gotzek, Dietrich] Univ Georgia, Dept Entomol, Athens, GA 30602 USA; [Gotzek, Dietrich; Suarez, Andrew V.] Univ Illinois, Dept Anim Biol, Urbana, IL USA; [Miyakawa, Misato Okamoto; Mikheyev, Alexander] Okinawa Inst Sci & Technol, Ecol & Evolut Unit, Onna, Okinawa, Japan; [Suarez, Andrew V.] Univ Illinois, Dept Entomol, Urbana, IL USA	Smith, CR (reprint author), Earlham Coll, Dept Biol, Richmond, IN 47374 USA.	crsmith.ant@gmail.com; alexander.mikheyev@oist.jp		Bornberg-Bauer, Erich/0000-0002-1826-3576	OIST; JSPS Kakenhi [25221206, 24770034]; NSF [DEB 1020979, DUE 1139893, DEB 0919052]	The authors thank the OIST sequencing center for preparing the V. emeryi genomic libraries and for carrying out the sequencing. At the University of Illinois, they thank Hugh Robertson and Kim Walden for preparing the P. anergismus genomic libriaries and the Keck Center for carrying out the sequencing. They are grateful to M.M.Y. Tin and M. Grau-Lopez for assistance with laboratory work and bioinformatics, respectively. They thank the OIST workshop committee for helping to organize the Genomics of Social Parasite Evolution workshop. Funding for this project was provided by OIST and JSPS Kakenhi grants to ASM (25221206 and 24770034), and by grants from NSF (DEB 1020979 to AVS, DUE 1139893 to CRS, and DEB 0919052 to SIHC). They thank "Uncle" Bob Johnson for P. anergismus specimens as well as E. Cash and K. E. Anderson for lab colonies, and B. Smith and N. Hamada Fernside for larva collection.	Aird SD, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-790; Anderson Kirk E., 2008, Myrmecological News, V11, P119; Lanfear R, 2012, MOL BIOL EVOL, V29, P1695, DOI 10.1093/molbev/mss020; Schwander Tanja, 2007, Mol Ecol, V16, P367; Leichty AR, 2012, INTEGR COMP BIOL, V52, P16, DOI 10.1093/icb/ics049; Cahan SH, 2003, NATURE, V424, P306, DOI 10.1038/nature01744; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; True JR, 2002, ANNU REV CELL DEV BI, V18, P53, DOI 10.1146/annurev.cellbio.18.020402.140619; Strope CL, 2007, MOL BIOL EVOL, V24, P640, DOI 10.1093/molbev/msl195; Gadagkar R, 1997, J GENET, V76, P167, DOI 10.1007/BF02932215; Domazet-Loso T, 2003, GENOME RES, V13, P2213, DOI 10.1101/gr.1311003; Monteiro A, 2012, BIOESSAYS, V34, P181, DOI 10.1002/bies.201100160; Gadau J, 2012, TRENDS GENET, V28, P14, DOI 10.1016/j.tig.2011.08.005; Anholt RRH, 2004, NAT REV GENET, V5, P838, DOI 10.1038/nrg1472; Smith CR, 2011, P NATL ACAD SCI USA, V108, P5667, DOI 10.1073/pnas.1007901108; Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075; Jasper WC, 2015, MOL BIOL EVOL, V32, P334, DOI 10.1093/molbev/msu292; Sumner S, 2014, MOL ECOL, V23, P26, DOI 10.1111/mec.12580; Parker JD, 2002, EVOLUTION, V56, P2017; Anderson KE, 2009, EVOLUTION, V63, P2142, DOI 10.1111/j.1558-5646.2009.00696.x; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Wurm Y, 2011, P NATL ACAD SCI USA, V108, P5679, DOI 10.1073/pnas.1009690108; Robinson GE, 2005, NAT REV GENET, V6, P257, DOI 10.1038/nrg1575; Simola DF, 2013, GENOME RES, V23, P1235, DOI 10.1101/gr.155408.113; Johnson RA, 1996, INSECT SOC, V43, P69, DOI 10.1007/BF01253957; Finn RD, 2014, NUCLEIC ACIDS RES, V42, pD222, DOI 10.1093/nar/gkt1223; Bonasio R, 2010, SCIENCE, V329, P1068, DOI 10.1126/science.1192428; Libbrecht R, 2011, EVOLUTION, V65, P2907, DOI 10.1111/j.1558-5646.2011.01348.x; Ward PS, 2015, SYST ENTOMOL, V40, P61, DOI 10.1111/syen.12090; Cantarel BL, 2008, GENOME RES, V18, P188, DOI 10.1101/gr.6743907; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Page RE, 2007, BIOESSAYS, V29, P334, DOI 10.1002/bies.20549; SZATHMARY E, 1995, NATURE, V374, P227, DOI 10.1038/374227a0; Schwander T, 2007, MOL ECOL, V16, P3533, DOI 10.1111/j.1365-294X.2007.03407.x; Cahan SH, 2004, CURR BIOL, V14, P2277, DOI 10.1016/j.cub.2004.12.027; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Tsai IJ, 2013, NATURE, V496, P57, DOI 10.1038/nature12031; Feldmeyer B, 2014, MOL ECOL, V23, P151, DOI 10.1111/mec.12490; Purandare SR, 2014, MOL BIOL EVOL, V31, P2073, DOI 10.1093/molbev/msu149; Linksvayer TA, 2013, BIOESSAYS, V35, P683, DOI 10.1002/bies.201300038; Linksvayer TA, 2009, EVOLUTION, V63, P1685, DOI 10.1111/j.1558-5646.2009.00670.x; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Wissler L, 2013, GENOME BIOL EVOL, V5, P439, DOI 10.1093/gbe/evt009; Toth AL, 2007, SCIENCE, V318, P441, DOI 10.1126/science.1146647; Schrader L, 2015, MOL BIOL EVOL, V32, P1474, DOI 10.1093/molbev/msv039; Anderson KE, 2006, ECOLOGY, V87, P2171, DOI 10.1890/0012-9658(2006)87[2171:DAEOGC]2.0.CO;2; Grozinger CM, 2003, P NATL ACAD SCI USA, V100, P14519, DOI 10.1073/pnas.2335884100; Amdam GV, 2006, NATURE, V439, P76, DOI 10.1038/nature04340; Okamoto M, 2015, MYRMECOL NEWS, V21, P13; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Lahti DC, 2009, TRENDS ECOL EVOL, V24, P487, DOI 10.1016/j.tree.2009.03.010; Ohkawara K, 2006, BIOL LETT-UK, V2, P359, DOI 10.1098/rsbl.2006.0491; Jones FC, 2012, NATURE, V484, P55, DOI 10.1038/nature10944; Foitzik S, 1997, INSECT SOC, V44, P219, DOI 10.1007/s000400050043; Smith CR, 2008, NAT REV GENET, V9, P735, DOI 10.1038/nrg2429; Rajakumar R, 2012, SCIENCE, V335, P79, DOI 10.1126/science.1211451; Volny VP, 2002, MOL ECOL NOTES, V2, P302, DOI 10.1046/j.1471-8278.2002.00243.x; Schwander T, 2010, TRENDS ECOL EVOL, V25, P275, DOI 10.1016/j.tree.2009.12.001; Buschinger A, 2009, MYRMECOL NEWS, V12, P219; Gadau J, 2003, MOL ECOL, V12, P1931, DOI 10.1046/j.1365-294X.2003.01853.x; Hunt BG, 2011, P NATL ACAD SCI USA, V108, P15936, DOI 10.1073/pnas.1104825108; Berens AJ, 2015, MOL BIOL EVOL, V32, P690, DOI 10.1093/molbev/msu330; BUSCHINGER A, 1986, TRENDS ECOL EVOL, V1, P155, DOI 10.1016/0169-5347(86)90044-3; CARPENTER F. M., 1930, BULL MUSS COMP ZOOL, V70, P1; Cini Alessandro, 2015, Front Genet, V6, P32, DOI 10.3389/fgene.2015.00032; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; EVANS JD, 1993, MOL ECOL, V2, P393, DOI 10.1111/j.1365-294X.1993.tb00032.x; Hall DW, 2013, BIOL LETTERS, V9, DOI 10.1098/rsbl.2013.0309; Helantera Heikki, 2014, Frontiers in Genetics, V5, P297, DOI 10.3389/fgene.2014.00297; Holt C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-491; Houlldobler B, 1990, ANTS; Johnson BR, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-164; KINOMURA K, 1992, Japanese Journal of Entomology, V60, P203; Leek JT, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku864; Leek JT, 2015, SVA SURROGATE VARIAB; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Mikheyev AS, 2015, ELIFE, V4; Ohno S., 1970, EVOLUTION GENE DUPLI; Rambaut A, 1997, COMPUT APPL BIOSCI, V13, P235; Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25; Smith CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042433; Van der Auwera GA, 2002, CURR PROTOC BIOINFOR, V11; West-Eberhard M.J., 1987, P35	83	1	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0737-4038	1537-1719		MOL BIOL EVOL	Mol. Biol. Evol.	NOV	2015	32	11					2919	2931		10.1093/molbev/msv165		13	Biochemistry & Molecular Biology; Evolutionary Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Evolutionary Biology; Genetics & Heredity	CT7YZ	WOS:000363033100010		
J	Markellos, M; Urakawa, H				Markellos, M.; Urakawa, H.			The biharmonicity of sections of the tangent bundle	MONATSHEFTE FUR MATHEMATIK			English	Article						Tangent bundle; Sasaki metric; Biharmonic maps; Critical points	VECTOR-FIELDS; RIEMANNIAN-MANIFOLDS; HARMONIC MAPPINGS; SUBMANIFOLDS; ENERGY	The bienergy of a vector field on a Riemannian manifold is defined to be the bienergy of the corresponding map , where the tangent bundle is equipped with the Sasaki metric . The constrained variational problem is studied, where variations are confined to vector fields, and the corresponding critical point condition characterizes biharmonic vector fields. Furthermore, we prove that if is a compact oriented -dimensional Riemannian manifold and a tangent vector of , then is a biharmonic vector field of if and only if is parallel. Finally, we give examples of non-parallel biharmonic vector fields in the case which the base manifold is non-compact.	[Urakawa, H.] Tohoku Univ, Inst Int Educ, Sendai, Miyagi 9808576, Japan		mmarkellos@hotmail.gr; urakawa@math.is.tohoku.ac.jp					Caddeo R, 2002, ISRAEL J MATH, V130, P109, DOI 10.1007/BF02764073; Baird P, 2010, ADV CALC VAR, V3, P49, DOI 10.1515/ACV.2010.003; [Anonymous], 2008, NOTE MAT S1; EELLS J, 1964, AM J MATH, V86, P109, DOI 10.2307/2373037; Caddeo R, 2001, INT J MATH, V12, P867, DOI 10.1142/S0129167X01001027; Djaa M, 2012, TURK J MATH, V36, P463, DOI 10.3906/mat-1003-204; Gil-Medrano O, 2001, DIFFER GEOM APPL, V15, P137, DOI 10.1016/S0926-2245(01)00053-5; Higuchi A, 2001, J GEOM PHYS, V37, P137, DOI 10.1016/S0393-0440(00)00034-6; Nakauchi N, 2014, GEOMETRIAE DEDICATA, V169, P263, DOI 10.1007/s10711-013-9854-1; Aronszajn N., 1983, POLYHARMONIC FUNCTIO; Baird P., 2003, LONDON MATH SOC MONO, V29; Dragomir S, 2012, HARMONIC VECTOR FIELDS: VARIATIONAL PRINCIPLES AND DIFFERENTIAL GEOMETRY, P1; GUDMUNDSSON S., 2002, EXPO MATH, V20, P1, DOI 10.1016/S0723-0869(02)80027-5; Ishihara T., 1979, J MATH TOKUSHIMA U, V13, P23; MONTALDO S., 2006, REV UNION MAT ARGENT, V47, P1; NOUHAUD O, 1977, CR ACAD SCI A MATH, V284, P815; Polyanin A.D., 2002, HDB LINEAR PARTIAL D; Urakawa H., 1993, TRANSL MATH MONOGRAP, V132	18	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0026-9255	1436-5081		MONATSH MATH	Mon.heft. Math.	NOV	2015	178	3					389	404		10.1007/s00605-014-0702-7		16	Mathematics	Mathematics	CT8CC	WOS:000363041600004		
J	Sri-indrasutdhi, V; Tsui, CKM; Chuaseeharonnachai, C; Yamaguchi, K; Suetrong, S; Okane, I; Nakagiri, A; Boonyuen, N				Sri-indrasutdhi, Veera; Tsui, Clement K. M.; Chuaseeharonnachai, Charuwan; Yamaguchi, Kaoru; Suetrong, Satinee; Okane, Izumi; Nakagiri, Akira; Boonyuen, Nattawut			Helicocentralis hyalina gen. et sp. nov., an aero-aquatic helicosporous fungus (Leotiomycetes, Ascomycota) in Thailand (vol 14, 81, 2015)	MYCOLOGICAL PROGRESS			English	Correction									[Sri-indrasutdhi, Veera; Chuaseeharonnachai, Charuwan; Suetrong, Satinee; Boonyuen, Nattawut] NSTDA, BIOTEC, Fungal Biodivers Lab, Amphoe Khlong Luang 12120, Pathum Thani, Thailand; [Tsui, Clement K. M.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z4, Canada; [Yamaguchi, Kaoru] NITE, Biol Resource Ctr NBRC, Kisarazu, Chiba 2920818, Japan; [Okane, Izumi] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; [Nakagiri, Akira] Tottori Univ, Fac Agr, Fungus Mushroom Resource & Res Ctr, Tottori, Tottori 6808553, Japan	Sri-indrasutdhi, V (reprint author), NSTDA, BIOTEC, Fungal Biodivers Lab, 113 Thailand Sci Pk,Thanon Phahonyothin, Amphoe Khlong Luang 12120, Pathum Thani, Thailand.	Veera@biotec.or.th					Sri-Indrasutdhi V, 2015, MYCOL PROG, V14, DOI 10.1007/s11557-015-1103-6	1	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-416X	1861-8952		MYCOL PROG	Mycol. Prog.	NOV	2015	14	11							99	10.1007/s11557-015-1119-y		3	Mycology	Mycology	CT6VX	WOS:000362951900002		
J	Zhao, P; Wang, QH; Tian, CM; Wang, Q; Yamaoka, Y; Kakishima, M				Zhao, Peng; Wang, Qing-Hong; Tian, Cheng-Ming; Wang, Qi; Yamaoka, Yuichi; Kakishima, Makoto			A morphological and molecular survey of Japanese Melampsora species on willows reveals a new species and two new records	MYCOLOGICAL PROGRESS			English	Article						Molecular phylogeny; Pucciniales; Rust fungi; Species recognition; Willows	NORTH-AMERICA; RUST FUNGUS; SALIX; CHINA	During morphological and molecular phylogenetic studies of Melampsora species on willows, one novel species, Melampsora salicis-reinii sp. nov., and two new records, M. ribesii-viminalis and M. ribesii-purpureae, are described from Japan. Melampsora salicis-reinii on Salix reinii was characterized by its amphigenous telia and ellipsoid urediniospores with echinulate spines on a rugose surface. Phylogenetic results using the rDNA ITS region (complete ITS1, 5.8S rRNA gene and ITS2) supported morphological elucidation, and both morphological and molecular evidences supported M. salicis-reinii as a new species. In addition, M. ribesii-viminalis was identified on S. pet-susu and S. sachalinensis, and M. ribesii-purpureae was recognized on S. integra. These two Melampsora species were reported as new records in Japan for the first time.	[Zhao, Peng] Univ Tsukuba, Grad Sch Life & Environm Sci, Ibaraki 3058572, Japan; [Wang, Qing-Hong] China Univ Petr, Beijing Key Lab Oil & Gas Pollut Control, Beijing 102249, Peoples R China; [Tian, Cheng-Ming] Beijing Forestry Univ, Minist Educ, Key Lab Silviculture & Conservat, Beijing 100083, Peoples R China; [Wang, Qi; Kakishima, Makoto] Jilin Agr Univ, Chinese Minist Educ Edible & Med Fungi, Engn Res Ctr, Changchun 130118, Jilin Province, Peoples R China; [Yamaoka, Yuichi; Kakishima, Makoto] Univ Tsukuba, Fac Life & Environm Sci, Ibaraki 3058572, Japan	Zhao, P (reprint author), Univ Tsukuba, Grad Sch Life & Environm Sci, Ibaraki 3058572, Japan.	zpengima@163.com					Zhao P, 2014, MYCOSCIENCE, V55, P390, DOI 10.1016/j.myc.2013.12.005; PEI MH, 1993, MYCOL RES, V97, P845; Zhao P, 2013, MYCOTAXON, V123, P81, DOI 10.5248/123.81; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; ROYLE DJ, 1992, BIOMASS BIOENERG, V2, P45, DOI 10.1016/0961-9534(92)90087-7; Samils B, 2011, TREE GENET GENOMES, V7, P1219, DOI 10.1007/s11295-011-0408-0; Milne JM, 2012, FUNGAL BIOL-UK, V116, P603, DOI 10.1016/j.funbio.2012.02.008; Zhao P, 2015, MYCOL PROG, V14, DOI 10.1007/s11557-015-1091-6; Pei MH, 2005, MYCOL RES, V109, P401, DOI 10.1017/S0935756205002479; Yamaoka Yuichi, 2010, Nippon Kingakukai Kaiho, V51, P35; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Smith JA, 2004, MYCOLOGIA, V96, P1330, DOI 10.2307/3762149; Damadi SM, 2011, FOREST PATHOL, V41, P392, DOI 10.1111/j.1439-0329.2010.00699.x; Spiers AG, 1996, MYCOL RES, V100, P1163; Feau N, 2009, MYCOL RES, V113, P713, DOI 10.1016/j.mycres.2009.02.007; Bennett C, 2011, MYCOLOGIA, V103, P1004, DOI 10.3852/10-289; Azbukina ZM, 1974, RUST FUNGI SOVIET FA, P120; Bagyanarayana G, 2005, RUST DIS WILLOW POPL, P20; Castagne L, 1843, OBSERVATIONS QUELQUE; Cummins GB, 2003, ILLUSTRATED GENERA R; GARDES M, 1993, MOL ECOL, V2, P113, DOI 10.1111/j.1365-294X.1993.tb00005.x; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1111/J.1469-8137.2009.02874.X; Hiratsuka N, 1982, TAXONOMIC REVISION M, V20, P1; Hiratsuka N, 1992, RUST FLORA JAPAN; Ito S, 1938, MYCOLOGICAL FLORA JA, VII; Klebahn H, 1914, KRYPTOGAMENFLORA MAR, P69; Kuprevich VF, 1957, CRYPTOGAMIC PLANTS U, V4, P423; Liro JI, 1908, UREDINEAE FENNICAE F; Matsumoto T, 1915, T SAPPORO NAT HIST S, V6, P22; Pei MH, 2005, RUST DIS WILLOW POPL, P20; Rostrup E, 1888, MEDD GROENLAND, V3, P517; Sydow P, 1915, MONOGRAPHIA UREDINEA; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thumen F, 1979, MITT FORSTLICHEN VER, V2, P25; Tian Cheng-Ming, 2004, Mycoscience, V45, P56, DOI 10.1007/s10267-003-0150-z; Virtudazo Eric V., 2001, Journal of General Plant Pathology, V67, P28, DOI 10.1007/PL00012983; White TJ, 1990, PCR PROTOCOLS GUIDE, V18, P315, DOI DOI 10.1016/B978-0-12-372180-8.50042-1; Wilson M, 1966, BRIT RUST FUNGI; Zhuang WY, 2005, FUNGI NW CHINA; Ziller WG, 1974, TREE RUSTS W CANADA; Zwickl DJ, 2006, THESIS U TEXAS AUSTI	41	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-416X	1861-8952		MYCOL PROG	Mycol. Prog.	NOV	2015	14	11							101	10.1007/s11557-015-1121-4		13	Mycology	Mycology	CT6VX	WOS:000362951900004		
J	Ishii-Takahashi, A; Takizawa, R; Nishimura, Y; Kawakubo, Y; Hamada, K; Okuhata, S; Kawasaki, S; Kuwabara, H; Shimada, T; Todokoro, A; Igarashi, T; Watanabe, K; Yamasue, H; Kato, N; Kasai, K; Kano, Y				Ishii-Takahashi, Ayaka; Takizawa, Ryu; Nishimura, Yukika; Kawakubo, Yuki; Hamada, Kasumi; Okuhata, Shiho; Kawasaki, Shingo; Kuwabara, Hitoshi; Shimada, Takafumi; Todokoro, Ayako; Igarashi, Takashi; Watanabe, Kei-ichiro; Yamasue, Hidenori; Kato, Nobumasa; Kasai, Kiyoto; Kano, Yukiko			Neuroimaging-Aided Prediction of the Effect of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder: A Randomized Controlled Trial	NEUROPSYCHOPHARMACOLOGY			English	Article							DEFICIT/HYPERACTIVITY DISORDER; TREATMENT RESPONSE; STIMULANT-MEDICATION; CLINICAL-RESPONSE; BLOOD-FLOW; ADHD; METAANALYSIS; INHIBITION; ADULTS; TASK	Although methylphenidate hydrochloride (MPH) is a first-line treatment for children with attention-deficit hyperactivity disorder (ADHD), the non-response rate is 30%. Our aim was to develop a supplementary neuroimaging biomarker for predicting the clinical effect of continuous MPH administration by using near-infrared spectroscopy (NIRS). After baseline assessment, we performed a double-blind, placebo-controlled, crossover trial with a single dose of MPH, followed by a prospective 4-to-8-week open trial with continuous MPH administration, and an ancillary 1-year follow-up. Twenty-two drug-naIve and eight previously treated children with ADHD (NAIVE and NON-NAIVE) were compared with 20 healthy controls (HCs) who underwent multiple NIRS measurements without intervention. We tested whether NIRS signals at the baseline assessment or Delta NIRS (single dose of MPH minus baseline assessment) predict the Clinical Global Impressions-Severity (CGI-S) score after 4-to-8-week or 1-year MPH administration. The secondary outcomes were the effect of MPH on NIRS signals after single-dose, 4-to-8-week, and 1-year administration. Delta NIRS significantly predicted CGI-S after 4-to-8-week MPH administration. The leave-one-out classification algorithm had 81% accuracy using the NIRS signal. Delta NIRS also significantly predicted CGI-S scores after 1 year of MPH administration. For secondary analyses, NAIVE exhibited significantly lower prefrontal activation than HCs at the baseline assessment, whereas NON-NAIVE and HCs showed similar activation. A single dose of MPH significantly increased activation compared with the placebo in NAIVE. After 4-to-8-week administration, and even after MPH washout following 1-year administration, NAIVE demonstrated normalized prefrontal activation. Supplementary NIRS measurements may serve as an objective biomarker for clinical decisions and monitoring concerning continuous MPH treatment in children with ADHD.	[Ishii-Takahashi, Ayaka; Kawakubo, Yuki; Kuwabara, Hitoshi; Todokoro, Ayako; Kano, Yukiko] Univ Tokyo, Grad Sch Med, Dept Child Neuropsychiat, Tokyo, Japan; [Ishii-Takahashi, Ayaka; Igarashi, Takashi] Univ Tokyo, Grad Sch Med, Dept Pediat, Tokyo, Japan; [Ishii-Takahashi, Ayaka; Takizawa, Ryu; Nishimura, Yukika; Hamada, Kasumi; Kawasaki, Shingo; Shimada, Takafumi; Yamasue, Hidenori; Kasai, Kiyoto] Univ Tokyo, Grad Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Hamada, Kasumi] Univ Tsukuba, Grad Course Disabil Sci, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan; [Okuhata, Shiho] Kyoto Univ, Dept Elect Engn, Grad Sch Engn, Kyoto 606, Japan; [Okuhata, Shiho] Japan Soc Promot Sci, Tokyo, Japan; [Kawasaki, Shingo] Hitachi Med Corp, Applicat Dev Off, Opt Topog Grp, Chiba, Japan; [Kuwabara, Hitoshi] Univ Tokyo, Div Counseling & Support, Disabil Serv Off, Tokyo, Japan; [Igarashi, Takashi] Natl Ctr Child Hlth & Dev, Tokyo, Japan; [Watanabe, Kei-ichiro] Univ Tokyo, Grad Sch Med, Div Counseling & support, Tokyo, Japan; [Kato, Nobumasa] Showa Univ, Sch Med, Karasuyama Hosp, Tokyo 142, Japan	Kasai, K (reprint author), Univ Tokyo, Grad Sch Med, Dept Neuropsychiat, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kasaik-tky@umin.net			Japan Medical Association; Royal Society; British Academy; Takeda Science Foundation; MEXT; Mitsubishi Foundation; Meiji-Yasuda Mental Health Foundation; Japan Society for the Promotion of Science; Ministry of Health, Labor and Welfare; CREST; Adaptable and Seamless Technology Transfer Program; Center of Innovation Program from Japan Science and Technology Agency; Strategic Research Program for Brain Sciences from Ministry of Education, Culture, Sports, Science, and Technology; Japan Science and Technology Agency; Strategic Research Program for Brain Sciences by Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Agency for Medical Research and Development; Astellas; GSK; Dainippon-Sumitomo; Eisai; MSD; Yoshitomi; Comprehensive Research on Disability, Health, and Welfare; Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP; Strategic Research Programme for Brain Sciences Project D: Development of biomarker candidates for social behavior; Grant-in-Aid for Scientific Research on Innovative Areas from MEXT, Japan [23118001, 23118004]; Grant-in-Aid for Scientific Research on Innovative Areas (Adolescent Mind and Self-Regulation) from the MEXT, Japan; Health and Labor Sciences Research Grants, Comprehensive Research on Disability, Health and Welfare [H17-kokoro-Ippan-004, H20-kokoro-Ippan-001, H20-kokoro-Ippan-003, H23-seishin-Ippan-002]; Japan Society for the Promotion of Science, KAKENHI (Grant-in-Aid for Young Scientists (B)) [24791201, 26860913, 23791309, 26860914]; Brain/MINDS project of MEXT	All authors have completed the ICMJE Form for Disclosure of Potential Conflicts of Interest. KK reports the following financial relationship. From 31 July 2003 to the present, the University of Tokyo and the Research and Developmental Centre, Hitachi Medical Corporation have had an official contract for a collaborative study on the clinical applications of near-infrared spectroscopy in psychiatric disorders, which has been approved by the Research Promotion Office, University of Tokyo Hospital. For the present study, Hitachi Medical Corporation provided a project grant (JPY 300 000/year). SK is employed by Hitachi Medical Corporation and is also a contracted researcher at the University of Tokyo. AI-T, RT, YK, HK, and KK at the University of Tokyo and SK at Hitachi Medical Corporation developed the 'stimulus presentation device and stimulus task presentation method for optional measurement apparatus' (patent 2008-146721, Japan; patent 12996190). The University of Tokyo transferred this patent to Hitachi Medical Corporation. Hitachi Medical Corporation paid a transfer fee (JPY 100 000) to the University of Tokyo. For the past 3 years, the authors declare the following Funding Statements. AI-T received a research grant from the Japan Medical Association. RT was a Newton International Fellow who was jointly funded by the Royal Society and the British Academy. YN was funded by the Takeda Science Foundation and MEXT. YK received research grants from the Mitsubishi Foundation, the Meiji-Yasuda Mental Health Foundation, and the Japan Society for the Promotion of Science. TI received research grants from the Ministry of Health, Labor and Welfare. KW was funded by a Grant-in-Aid for Scientific Research. HY was supported by Grants from the Japan Society for the Promotion of Science; CREST; the Adaptable and Seamless Technology Transfer Program; the Center of Innovation Program from the Japan Science and Technology Agency; and the Strategic Research Program for Brain Sciences from the Ministry of Education, Culture, Sports, Science, and Technology. NK was supported by the Japan Science and Technology Agency; CREST; Strategic Research Program for Brain Sciences by the Ministry of Education, Culture, Sports, Science and Technology of Japan; and the Japan Agency for Medical Research and Development. KK received research grants from Astellas, GSK, Dainippon-Sumitomo, Eisai, MSD, and Yoshitomi. YK received a research Grant for Comprehensive Research on Disability, Health, and Welfare; an Intramural Research Grant for Neurological and Psychiatric Disorders of NCNP; and a Grant-in-Aid for Scientific Research on Innovative Areas. The authors declare that over the past 3 years, the following payments were received. YN received compensation from the Tokyo Metropolitan Matsuzawa Hospital and AMED. YK has received honoraria for lectures at the Iwate Prefectural University, the Rissho University, the Japanese Society of Certified Clinical Psychologists, the Japanese Organization of Clinical Developmental Psychologists, the Education committee of Setagaya City, the Hizen Psychiatric Center, NHK Japan Broadcasting Corporation, and Nihon Bunka Kagakusha Corporation. KH has received compensation from the Matsubara Women's Clinic. HK has received compensation from the Department of Yokohama Rehabilitation Center, the Hongo-Todaimae kokorono Clinic, the Toshima Hospital, and the Metropolitan Bokutoh Hospital. TS has received compensation from the Fuchu Prison and the Kawasaki city recovery consultation office.; AT has received compensation from the Hongo-todaimae mental clinic. TI has received compensation from MC Medical, Tanabe-Mitsubishi, GSK, Taisyo-Toyama, Sanofi-Pasteur, Astellas, Chugai, Otsuka, Japan Vaccination, Meiji, Takeda, Kyorin, and MSD. KW has received honoraria for lectures from Eli Lilly, Phizer, and Janssen and has been given payment in exchange for clinical service in the Higashinagano Hospital, the Kiyose city Children developmental support center, the Koto city Educational Center, and the Tokyo University of Foreign Studies. In addition, KW has received a salary for delivering academic lectures at Ochanomizu University, the Japan College of Social Work, and Seikei University. HY has received compensation from Mitsubishi Cooperation and Teijin. NK has received honoraria for lectures from Meiji Seika, Eli Lilly, Yoshitomi, Pfizer, GSK, Astellas, Shionogi, and Mitsubishi Tanabe. KK has received honoraria for lectures by Daiichi-Sankyo, Otsuka, Meiji Seika, MSD, Astellas, Yoshitomi, Novartis, Eli Lilly, Dainippon-Sumitomo, Janssen, GSK, and Pfizer and has received salary for clinical services at the Akasaka Clinic and The Clinic for Tokyo Securities Industry Health Insurance Society. YK has received honoraria for lectures and opinion hearing from Sumitomo Dainippon and/or for being a chairperson for Eli Lilly, Janssen, Astellas, and SHIONOGI. YK has received compensation as a supervisor from the Adachi Children Support Center 'Genki' and fees as adjunct professor at the Aizu Medical Center and Fukushima Medical University. The authors also declare that in the near future, AI-T anticipates receiving a grant from the Fulbright foundation and KH anticipates receiving compensation from Nayori City University. SO declared that except for income received from her primary employer, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service and that there are no personal financial holdings that could be perceived as constituting a potential conflict of interest. This study was supported by a grant from the Strategic Research Programme for Brain Sciences Project D: Development of biomarker candidates for social behavior and a Grant-in-Aid for Scientific Research on Innovative Areas (23118001 and 23118004; Adolescent Mind and Self-Regulation) from the MEXT, Japan to KK. This study was also supported in part by Health and Labor Sciences Research Grants, Comprehensive Research on Disability, Health and Welfare (H17-kokoro-Ippan-004 to NK, H20-kokoro-Ippan-001 to KK, H20-kokoro-Ippan-003 to KK, and H23-seishin-Ippan-002 to RT, YN, and YK), Japan Society for the Promotion of Science, KAKENHI (Grant-in-Aid for Young Scientists (B) No. 24791201 and 26860913 to AI-T and No. 23791309 & 26860914 to RT), and Meiji-Yasuda Mental Health Foundation 2008 (Japan) to AI-T. This study was supported by the Brain/MINDS project of MEXT (to KK).	Achenbach T M, 1991, Monogr Soc Res Child Dev, V56, P1; Hermens DF, 2006, EXPERT REV NEUROTHER, V6, P753, DOI 10.1586/14737175.6.4.753; Lee SH, 2009, YONSEI MED J, V50, P650, DOI 10.3349/ymj.2009.50.5.650; Gupta R, 2009, PROG BRAIN RES, V176, P259, DOI 10.1016/S0079-6123(09)17614-8; Ponseti J, 2012, ARCH GEN PSYCHIAT, V69, P187, DOI 10.1001/archgenpsychiatry.2011.130; la Fougere C, 2006, NUCL MED COMMUN, V27, P733, DOI 10.1097/01.mnm.0000230077.48480.68; Duann JR, 2009, J NEUROSCI, V29, P10171, DOI 10.1523/JNEUROSCI.1300-09.2009; Hannestad J, 2010, BIOL PSYCHIAT, V68, P854, DOI 10.1016/j.biopsych.2010.06.017; Otsubo T, 2005, PSYCHIAT CLIN NEUROS, V59, P517, DOI 10.1111/j.1440-1819.2005.01408.x; Carter CS, 2008, BIOL PSYCHIAT, V64, P842, DOI 10.1016/j.biopsych.2008.06.014; RAPPORT MD, 1994, J AM ACAD CHILD PSY, V33, P882, DOI 10.1097/00004583-199407000-00015; Schweitzer JB, 2003, NEUROPSYCHOPHARMACOL, V28, P967, DOI 10.1038/sj.npp.1300110; Sangal RB, 2004, CLIN NEUROPHYSIOL, V115, P188, DOI 10.1016/j.clinph.2003.08.023; BUITELAAR JK, 1995, J AM ACAD CHILD PSY, V34, P1025, DOI 10.1097/00004583-199508000-00012; Takizawa R, 2008, SCHIZOPHR RES, V99, P250, DOI 10.1016/j.schres.2007.10.025; Buitelaar J, 2010, EUR CHILD ADOLES PSY, V19, P325, DOI 10.1007/s00787-009-0056-1; Konrad K, 2007, J AM ACAD CHILD PSY, V46, P1633, DOI 10.1097/chi.0b013e318157cb3b; Bush G, 2008, ARCH GEN PSYCHIAT, V65, P102, DOI 10.1001/archgenpsychiatry.2007.16; Monden Y, 2012, CLIN NEUROPHYSIOL, V123, P1147, DOI 10.1016/j.clinph.2011.10.006; Schlochtermeier L, 2011, EUR NEUROPSYCHOPHARM, V21, P646, DOI 10.1016/j.euroneuro.2010.05.001; Ilgin N, 2001, DEV MED CHILD NEUROL, V43, P755, DOI 10.1017/S0012162201001384; Wilens TE, 2008, J AM ACAD CHILD PSY, V47, P21, DOI [10.1097/chi.0b013e31815a56f1, 10.1097/chi.0b01361815a56f1]; Zeiner P, 1999, ACTA PAEDIATR, V88, P298, DOI 10.1080/08035259950170060; Hart H, 2013, JAMA PSYCHIAT, V70, P185, DOI 10.1001/jamapsychiatry.2013.277; Frodl T, 2012, ACTA PSYCHIAT SCAND, V125, P114, DOI 10.1111/j.1600-0447.2011.01786.x; An L, 2013, NEUROPSYCHOPHARMACOL, V38, P1287, DOI 10.1038/npp.2013.27; Erder M Haim, 2012, J Med Econ, V15, P1078, DOI 10.3111/13696998.2012.689270; Borgwardt S, 2012, BRIT J PSYCHIAT, V200, P270, DOI 10.1192/bjp.bp.111.103234; Sawada M, 2010, PSYCHIAT CLIN NEUROS, V64, P491, DOI 10.1111/j.1440-1819.2010.02134.x; Stoy M, 2011, PSYCHOPHARMACOLOGY, V215, P467, DOI 10.1007/s00213-011-2166-y; Cho SC, 2007, J PSYCHIATR RES, V41, P459, DOI 10.1016/j.jpsychires.2006.05.011; Shaw P, 2009, AM J PSYCHIAT, V166, P58, DOI 10.1176/appi.ajp.2008.08050781; Rubia K, 2011, BIOL PSYCHIAT, V70, P255, DOI 10.1016/j.biopsych.2011.04.018; de Vries M, 2014, J NEURAL TRANSM, V121, P1183, DOI 10.1007/s00702-014-1225-z; DuPaul G. L., 1998, ADHD RATING SCALE 4; Guy W, 1976, ECDEU ASSESSMENT MAN; Hermens Daniel F., 2005, Journal of Integrative Neuroscience, V4, P107, DOI 10.1142/S0219635205000653; Ishii- Takahashi A, 2013, NEUROIMAGE-CLIN, V4, P53; Krause Johanna, 2008, Expert Rev Neurother, V8, P611, DOI 10.1586/14737175.8.4.611; Rubia K, 2014, BIOL PSYCHIAT, V76, P616, DOI 10.1016/j.biopsych.2013.10.016; Volkow N D, 2002, J Atten Disord, V6 Suppl 1, pS31	41	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	NOV	2015	40	12					2676	2685		10.1038/npp.2015.128		10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CT5GK	WOS:000362836700003		
J	Murakami, G; Nakamura, M; Takita, M; Ishida, Y; Ueki, T; Nakahara, D				Murakami, Gen; Nakamura, Masato; Takita, Masatoshi; Ishida, Yasushi; Ueki, Takatoshi; Nakahara, Daiichiro			Brain Rewarding Stimulation Reduces Extracellular Glutamate Through Glial Modulation in Medial Prefrontal Cortex of Rats	NEUROPSYCHOPHARMACOLOGY			English	Article							MAJOR DEPRESSIVE DISORDER; NUCLEUS-ACCUMBENS; MOOD DISORDERS; ACUTE STRESS; AMINO-ACIDS; IN-VIVO; DOPAMINE; RELEASE; ANHEDONIA; MICE	Growing evidence implicates a critical involvement of prefrontal glial modulation of extracellular glutamate (GLU) in aversive behaviors. However, nothing is known about whether prefrontal glial cells modulate GLU levels in rewarding behaviors. To address this question, we measured GLU efflux in the medial prefrontal cortex (PFC) of rats associated with rewarding behaviors. We used intracranial self-stimulation (ICSS) of the medial forebrain bundle (MFB) as the rewarding behavior. GLU was indirectly measured using microdialysis combined with on-line fluorometric detection of NADH resulting from the reaction of GLU and NAD(+) catalyzed by GLU dehydrogenase with a time resolution of 1 min. ICSS caused a minute-by-minute change of extracellular GLU in the medial PFC, with a slight decrease during the stimulation, followed by an increase afterward. This bidirectional change was tetrodotoxin insensitive and abolished by the gliotoxin fluorocitrate. To confirm and extend the previous studies of aversion-induced increase of extracellular GLU in the medial PFC, we also measured prefrontal GLU efflux associated with an aversive stimulation, immobilization stress. The temporal change in extracellular GLU caused by this stress was markedly different from that observed during ICSS. A rapid increase in GLU was detected during the aversive stimulation, followed by a large increase afterward. This bimodal change was tetrodotoxin insensitive, similar to that detected for ICSS. These findings indicate a bidirectional regulation of extracellular GLU by prefrontal glial cells associated with rat ICSS behavior, and reveal that glial modulation of GLU neurochemistry in the medial PFC contributes to rewarding as well as aversive behaviors in rats.	[Murakami, Gen; Nakamura, Masato; Nakahara, Daiichiro] Hamamatsu Univ Sch Med, Div Psychol & Behav Neurosci, Dept Integrated Human Sci, Hamamatsu, Shizuoka, Japan; [Takita, Masatoshi] Natl Inst Adv Ind Sci & Technol, Cognit & Act Res Grp, Tsukuba, Ibaraki, Japan; [Ishida, Yasushi] Miyazaki Univ, Fac Med, Dept Psychiat, Miyazaki, Japan; [Ueki, Takatoshi] Nagoya City Univ, Grad Sch Med Sci, Dept Anat & Cell Biol, Nagoya, Aichi, Japan; [Ueki, Takatoshi; Nakahara, Daiichiro] Hamamatsu Univ Sch Med, Med Photon Ctr, Dept Biofunct Imaging, Hamamatsu, Shizuoka 4313192, Japan	Nakahara, D (reprint author), Hamamatsu Univ Sch Med, Med Photon Ctr, Dept Biofunct Imaging, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	nakahara@hama-med.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [08610078, 09410024]	This study was supported by Grants-in-Aid for Scientific Research, the Ministry of Education, Culture, Sports, Science and Technology of Japan (Nos. 08610078, 09410024). The authors declare no conflict of interest.	Reznikov LR, 2007, EUR J NEUROSCI, V25, P3109, DOI 10.1111/j.1460-9568.2007.05560.x; Choudary PV, 2005, P NATL ACAD SCI USA, V102, P15653, DOI 10.1073/pnas.0507901102; Mineur YS, 2007, BIOL PSYCHIAT, V61, P250, DOI 10.1016/j.biopsych.2006.04.037; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; LOWY MT, 1995, J NEUROCHEM, V65, P268; ABRAMS R, 1964, AM J PHYSIOL, V206, P641; Kiyatkin EA, 2002, EUR J NEUROSCI, V16, P164, DOI 10.1046/j.1460-9568.2002.02066.x; Kiyatkin EA, 2001, BRAIN RES, V918, P141, DOI 10.1016/S0006-8993(01)02985-7; Zink M, 2010, NEUROPHARMACOLOGY, V58, P465, DOI 10.1016/j.neuropharm.2009.09.005; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Rutherford EC, 2007, J NEUROCHEM, V102, P712, DOI 10.1111/j.11471-4159.2007.04596.x; Oh DH, 2014, J NEURAL TRANSM, V121, P783, DOI 10.1007/s00702-014-1189-z; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Saulskaya NB, 2002, NEUROSCIENCE, V112, P791, DOI 10.1016/S0306-4522(02)00126-4; Kulkarni SK, 2009, EXPERT OPIN INV DRUG, V18, P767, DOI [10.1517/13543780902880850 , 10.1517/13543780902880850]; Persson M, 2012, AMINO ACIDS, V42, P207, DOI 10.1007/s00726-011-0865-7; Bechtholt-Gompf AJ, 2010, NEUROPSYCHOPHARMACOL, V35, P2049, DOI 10.1038/npp.2010.74; McEwen AM, 2012, NEUROPSYCHOPHARMACOL, V37, P2428, DOI 10.1038/npp.2012.101; You ZB, 2001, NEUROSCIENCE, V107, P629, DOI 10.1016/S0306-4522(01)00379-7; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Lupinsky D, 2010, J NEUROSCI, V30, P7624, DOI 10.1523/JNEUROSCI.1187-10.2010; Rajkowska G, 2000, BIOL PSYCHIAT, V48, P766, DOI 10.1016/S0006-3223(00)00950-1; Moghaddam B, 2004, NEUROTOX RES, V6, P73; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515; Banasr M, 2008, BIOL PSYCHIAT, V64, P863, DOI 10.1016/j.biopsych.2008.06.008; Hascup KN, 2008, J PHARMACOL EXP THER, V324, P725, DOI 10.1124/jpet.107.131698; Holtzheimer PE, 2011, ANNU REV NEUROSCI, V34, P289, DOI 10.1146/annurev-neuro-061010-113638; PAULSEN RE, 1989, J NEUROCHEM, V52, P1823, DOI 10.1111/j.1471-4159.1989.tb07263.x; Banasr M, 2010, MOL PSYCHIATR, V15, P501, DOI 10.1038/mp.2008.106; Baker DA, 2002, J NEUROSCI, V22, P9134; Anderson CM, 2000, GLIA, V32, P1; Takita M, 2002, NEUROSCI LETT, V317, P97, DOI 10.1016/S0304-3940(01)02441-7; Eshel N, 2010, BIOL PSYCHIAT, V68, P118, DOI 10.1016/j.biopsych.2010.01.027; Bagley J, 1997, NEUROSCIENCE, V77, P65, DOI 10.1016/S0306-4522(96)00435-6; Mogensen Jesper, 1993, Acta Neurobiologiae Experimentalis (Warsaw), V53, P439; Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018; Fillenz M, 1995, BEHAV BRAIN RES, V71, P51, DOI 10.1016/0166-4328(95)00045-3; John CS, 2012, NEUROPSYCHOPHARMACOL, V37, P2467, DOI 10.1038/npp.2012.105; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; Rada P, 1997, BRAIN RES, V768, P338, DOI 10.1016/S0006-8993(97)00788-9; Schlaepfer TE, 2013, BIOL PSYCHIAT, V73, P1204, DOI 10.1016/j.biopsych.2013.01.034; Schlaepfer TE, 2008, NEUROPSYCHOPHARMACOL, V33, P368, DOI 10.1038/sj.npp.1301408; PROSSER RA, 1994, BRAIN RES, V643, P296, DOI 10.1016/0006-8993(94)90036-1; Hashimoto K, 2007, BIOL PSYCHIAT, V62, P1310, DOI 10.1016/j.biopsych.2007.03.017; Vedam-Mai V, 2012, MOL PSYCHIATR, V17, P124, DOI 10.1038/mp.2011.61; Bekar LK, 2008, CEREB CORTEX, V18, P2789, DOI 10.1093/cercor/bhn040; Jackson ME, 2001, J NEUROSCI, V21, P676; D'Suza MS, 2010, BEHAV NEUROSCIENCE D, V3, P119; Nakahara D, 1993, TEC BEHAV N 1, P219, DOI Elsevier; OBRENOVITCH TP, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P23; Paxinos G., 1986, RAT BRAIN STEREOTAXI; Steciuk M, 2000, Stress, V3, P195, DOI 10.3109/10253890009001123	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	NOV	2015	40	12					2686	2695		10.1038/npp.2015.115		10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CT5GK	WOS:000362836700004		
J	Gotoh, M; Kobayashi, T; Sogabe, K				Gotoh, Momokazu; Kobayashi, Toshimitsu; Sogabe, Keizo			Characterization of Symptom Bother and Health-related Quality of Life in Japanese Female Patients With Overactive Bladder	NEUROUROLOGY AND URODYNAMICS			English	Article						multiple regression analysis; OAB-q; OABSS; symptom severity	URINARY-TRACT SYMPTOMS; CONTROLLED TRIAL; DOUBLE-BLIND; OAB-Q; SOLIFENACIN; IMPACT; QUESTIONNAIRE; INCONTINENCE; GUIDELINES; WOMEN	Aims: To analyze the impact of overactive bladder (OAB) symptoms and patient characteristics on symptom bother and quality of life (QOL). Methods: An analysis of the data of 967 patients from SET-Q, a prospective, multicenter, open, observational study in the post-marketing setting, was performed. The eligible subjects were treatment-naive female patients with OAB who complained of an urgency episode at least once a week. Symptom bother and QOL were assessed by the OAB-questionnaire (OAB-q), and severity of OAB symptoms was estimated by the OAB symptom score (OABSS). Multiple regression analysis was utilized for clarifying how OAB symptom severity affects QOL. Results: The symptoms with the highest bother score were daytime frequency and urgency in the under-50s age group, urgency in the 50s, 60s, and 70s age groups, night-time frequency and urgency incontinence in the over-80s age group, respectively. With an increase in severity of OAB as well as severity of urgency assessed by the OABSS, an increase in symptom bother and impairment in health-related quality of life (HRQL) in the OAB-q were observed. Multiple regression analysis demonstrated the significant relationship with urgency and nighttime frequency to symptom bother, and also significant interaction between age and urgency incontinence, associated with further negative effect on HRQLs in elderly patients. Conclusions: This large sample study, by utilizing the scored questionnaire for symptom severity, bother and HRQL, showed that the symptoms with the highest bother were age-dependent. It was also confirmed that symptom bother will be inferred by the OABSS. Neurourol. Urodynam. 34:730-735, 2015. (c) 2014 Wiley Periodicals, Inc.	[Gotoh, Momokazu] Nagoya Univ, Grad Sch Med, Dept Urol, Nagoya, Aichi 4668550, Japan; [Kobayashi, Toshimitsu; Sogabe, Keizo] Astellas Pharma Inc, Med Affairs, Tokyo, Japan	Gotoh, M (reprint author), Nagoya Univ, Grad Sch Med, Dept Urol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	gotoh@med.nagoya-u.ac.jp			Astellas Pharma Inc.	Momokazu Gotoh received a medical adviser's fee from Astellas Pharma Inc. for this study. Toshimitsu Kobayashi and Keizo Sogabe are employees of Astellas Pharma Inc. This study was funded and conducted by Astellas Pharma Inc. Statistical analysis was also performed by Astellas Pharma Inc. under supervision of the investigators. All authors contributed the design of the study, participated in the interpretation of the data and the preparation of the manuscript. All authors approved the final version of the manuscript.	Coyne K, 2002, QUAL LIFE RES, V11, P563, DOI 10.1023/A:1016370925601; Coyne KS, 2005, QUAL LIFE RES, V14, P849, DOI 10.1007/s11136-004-0706-1; Wennberg AL, 2009, EUR UROL, V55, P783, DOI 10.1016/j.eururo.2009.01.007; Haylen BT, 2010, INT UROGYNECOL J, V21, P5, DOI 10.1007/s00192-009-0976-9; Gotoh M, 2014, INT J UROL, V21, P505, DOI 10.1111/iju.12355; Michel MC, 2007, NEUROUROL URODYNAM, V26, P190, DOI 10.1002/nau.20367; Cardozo LD, 2009, WORLD J UROL, V27, P755, DOI 10.1007/s00345-009-0455-4; Chapple CR, 2005, BJU INT, V95, P335, DOI 10.1111/j.1464-410X.2005.05294.x; Coyne KS, 2008, BJU INT, V101, P1388, DOI 10.1111/j.1464-410X.2008.07601.x; Homma Y, 2006, UROLOGY, V68, P318, DOI 10.1016/j.urology.2006.02.042; [Anonymous], 2008, PHARMACOEPIDEMIOL DR, V17, P200; Irwin DE, 2006, EUR UROL, V50, P1306, DOI 10.1016/j.eururo.2006.09.019; Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; Yamaguchi O, 2007, BJU INT, V100, P579, DOI 10.1111/j.1464-410X.2007.07031.x; Robinson D, 2007, INT J CLIN PRACT, V61, P23, DOI 10.1111/j.1742-1241.2007.01463.x; Homma Y, 2009, BJU INT, V104, P968, DOI 10.1111/j.1464-410X.2009.08498.x; Vardy MD, 2009, INT J CLIN PRACT, V63, P1702, DOI 10.1111/j.1742-1241.2009.02209.x; Yamaguchi O, 2009, INT J UROL, V16, P126, DOI 10.1111/j.1442-2042.2008.02177.x; Coyne KS, 2013, UROLOGY, V82, P799, DOI 10.1016/j.urology.2013.05.035; Payne CK, 2007, BJU INT, V99, P101, DOI 10.1111/j.1464-410X.2007.06517.x; Cyne KS, 2003, BJU INT, V92, P948; Homma Y, 2006, JNBS, V17, P241; Homma Y, 2006, JNBS, V17, P250; Stewart W. F., 2003, World Journal of Urology, V20, P327	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0733-2467	1520-6777		NEUROUROL URODYNAM	Neurourol. Urodyn.	NOV	2015	34	8					730	735		10.1002/nau.22663		6	Urology & Nephrology	Urology & Nephrology	CT6ZS	WOS:000362963200005		
J	Obayashi, K; Saeki, K; Kurumatani, N				Obayashi, Kenji; Saeki, Keigo; Kurumatani, Norio			Relationship between asymmetric dimethylarginine and nocturia in the general elderly population: The HEIJO-KYO cohort	NEUROUROLOGY AND URODYNAMICS			English	Article						asymmetric dimethylarginine; bladder capacity; bladder dysfunction; nitric oxide; nocturia	RISK-FACTOR; ADMA; RESISTANCE; SLEEP; MEN	AimsTo evaluate the relationship between asymmetric dimethylarginine (ADMA) and nocturia. MethodsA total of 862 community-based elderly individuals were examined in this cross-sectional study (mean age, 72.1 years). We measured nocturnal void frequency and serum ADMA levels. Nocturia was ascertained for a frequency of two or more nocturnal voids. ResultsNocturia was observed in 262 (30.4%) participants. Univariate logistic regression models revealed a significant association between prevalent nocturia and ADMA levels (crude odds ratio [OR], 1.556 [2nd vs. 1st tertile]; 95% confidence interval [CI], 1.066-2.270; P=0.022; crude OR, 2.114 [3rd vs. 1st tertile]; 95% CI, 1.453-3.072; P<0.001). Univariate logistic regression models also revealed marginal to significant associations between prevalent nocturia and age, gender, calcium channel blocker use, nitric oxide-related drug use, diabetes, estimated glomerular filtration rate, insomnia, benign prostatic hyperplasia, overnight urine volume, and endogenous melatonin levels. In the multivariate model simultaneously adjusted for the former variables, higher ADMA levels were significantly associated with higher OR for nocturia (adjusted OR, 1.556 [3rd vs. 1st tertiles]; 95% CI, 1.010-2.397; P=0.045). ConclusionSerum ADMA levels, an endogenous inhibitor of nitric oxide synthase, are significantly associated with prevalent nocturia in the general elderly population. Neurourol. Urodynam. 34:769-773, 2015. (c) 2014 Wiley Periodicals, Inc.	[Obayashi, Kenji; Saeki, Keigo; Kurumatani, Norio] Nara Med Univ, Sch Med, Dept Community Hlth & Epidemiol, Kashiharashi, Nara 6348521, Japan	Obayashi, K (reprint author), Nara Med Univ, Sch Med, Dept Community Hlth & Epidemiol, 840 Shijocho, Kashiharashi, Nara 6348521, Japan.	obayashi@naramed-u.ac.jp			Department of Indoor Environmental Medicine, Nara Medical University; Ministry of Education, Culture, Sports, Science and Technology; Mitsui Sumitomo Insurance Welfare Foundation; Meiji Yasuda Life Foundation of Health and Welfare; Osaka Gas Group Welfare Foundation; Japan Diabetes Foundation; Daiwa Securities Health Foundation; Japan Science and Technology Agency	Grant sponsor: Department of Indoor Environmental Medicine, Nara Medical University; Grant sponsor: Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology; Grant sponsor: Mitsui Sumitomo Insurance Welfare Foundation; Grant sponsor: Meiji Yasuda Life Foundation of Health and Welfare; Grant sponsor: Osaka Gas Group Welfare Foundation; Grant sponsor: Japan Diabetes Foundation; Grant sponsor: Daiwa Securities Health Foundation; Grant sponsor: Japan Science and Technology Agency	Zoccali C, 2006, J HYPERTENS, V24, P611, DOI 10.1097/01.hjh.0000217839.26971.8d; Nakagawa H, 2010, J UROLOGY, V184, P1413, DOI 10.1016/j.juro.2010.05.093; Feldstein CA, 2013, J AM SOC HYPERTENS, V7, P75, DOI 10.1016/j.jash.2012.12.004; Kupelian V, 2011, J UROLOGY, V185, P571, DOI 10.1016/j.juro.2010.09.108; Kunieda T, 2008, CIRC RES, V102, P607, DOI 10.1161/CIRCRESAHA.107.162230; Bliwise DL, 2009, SLEEP MED, V10, P540, DOI 10.1016/j.sleep.2008.04.002; Yoshimura K, 2004, INT J UROL, V11, P282, DOI 10.1111/j.1442-2042.2004.00791.x; Bursztyn M, 2006, AM J CARDIOL, V98, P1311, DOI 10.1016/j.amjcard.2006.06.024; Tikkinen KAO, 2006, J UROLOGY, V175, P596, DOI 10.1016/S0022-5347(05)00245-4; Ozawa H, 1999, J UROLOGY, V162, P2211, DOI 10.1016/S0022-5347(05)68161-X; Kobayashi S, 2008, CLIN J AM SOC NEPHRO, V3, P1289, DOI 10.2215/CJN.00010108; Andersson KE, 2004, PHARMACOL REV, V56, P581, DOI 10.1124/pr.56.4.4; Cornu JN, 2012, EUR UROL, V62, P877, DOI 10.1016/j.eururo.2012.07.004; Aizawa N, 2011, EUR UROL, V59, P264, DOI 10.1016/j.eururo.2010.10.035; Muntener M, 2006, EUR UROL, V50, P112, DOI 10.1016/j.eururo.2006.02.036; Negoro H, 2013, J UROLOGY, V190, P843, DOI 10.1016/j.juro.2013.02.024; Lin KY, 2002, CIRCULATION, V106, P987, DOI 10.1161/01.CIR.0000027109.14149.67; Boger RH, 1998, CIRCULATION, V98, P1842; Matsuta Y, 2010, J UROLOGY, V184, P386, DOI 10.1016/j.juro.2010.03.002; van Kerrebroeck P, 2002, NEUROUROL URODYNAM, V21, P179, DOI 10.1002/nau.10053; Anea CB, 2012, CIRC RES, V111, P1157, DOI 10.1161/CIRCRESAHA.111.261750; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Obayashi K, 2014, HYPERTENS RES, V37, P908, DOI 10.1038/hr.2014.99; Obayashi K, 2014, J UROLOGY, V191, P1816, DOI 10.1016/j.juro.2013.12.043; Parthasarathy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030969; Weiss Jeffrey P, 2003, Curr Urol Rep, V4, P362, DOI 10.1007/s11934-003-0007-1	26	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0733-2467	1520-6777		NEUROUROL URODYNAM	Neurourol. Urodyn.	NOV	2015	34	8					769	773		10.1002/nau.22647		5	Urology & Nephrology	Urology & Nephrology	CT6ZS	WOS:000362963200012		
J	Ogawa, K; Mizuno, Y; Washiyama, K; Shiba, K; Takahashi, N; Kozaka, T; Watanabe, S; Shinohara, A; Odani, A				Ogawa, Kazuma; Mizuno, Yoshiaki; Washiyama, Kohshin; Shiba, Kazuhiro; Takahashi, Naruto; Kozaka, Takashi; Watanabe, Shigeki; Shinohara, Atsushi; Odani, Akira			Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy	NUCLEAR MEDICINE AND BIOLOGY			English	Article						Sigma receptor; Tumor; Astatine; Alpha therapy	IN-VIVO; CELL-LINES; BINDING; EXPRESSION; AT-211; VITRO	Introduction: Sigma receptors are overexpressed in a variety of human tumors, making them potential targets for radionuclide receptor therapy. We have previously synthesized, and evaluated I-131-labeled (+)-2-[4-(4-iodophenyl)piperidino]cyclohexanol [(+)-[I-131]pIV], which has a high affinity for sigma receptors. Therefore, (+)-[I-131]pIV significantly inhibited tumor cell proliferation in tumor-bearing mice. In the present study, we report the synthesis and the in vitro and in vivo characterization of (+)-[At-211]pAtV, an At-211-labeled sigma receptor ligand, that has potential use in alpha-radionuclide receptor therapy. Methods: The radiolabeled sigma receptor ligand (+)-,[At-211]pAtV was prepared using a standard halogenation reaction generating a 91% radiochemical yield with 98% purity after HPLC purification. The partition coefficient of (+)[At-211]pAtV was measured. Cellular uptake experiments and in vivo biodistribution experiments were performed using a mixed solution of (+)-[At-211]pAtV and (+)-[I-125]pIV; the human prostate cancer cell line DU-145, which expresses high levels of the sigma receptors, and DU-145 tumor-bearing mice. Results: The lipophilicity of (+)-[At-211]pAtV was similar to that of (+)-[I-125]pIV. DU-145 cellular uptake and the biodistribution patterns in DU-145 tumor-bearing mice at 1 h post-injection were also similar between (+)[At-221]pAtV and (+)-[I-125]pIV. Namely, (+)[At-211]pAtV demonstrated high uptake and retention in tumor via binding to sigma receptors. Conclusion: These results indicate that (+)[At-221]pAtV could function as an new agent for alpha-radionuclide receptor therapy. (C) 2015 Elsevier Inc. All rights reserved.	[Ogawa, Kazuma; Mizuno, Yoshiaki; Washiyama, Kohshin; Odani, Akira] Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa 9201192, Japan; [Ogawa, Kazuma] Kanazawa Univ, Inst Frontier Sci Initiat, Kanazawa, Ishikawa 9201192, Japan; [Shiba, Kazuhiro; Kozaka, Takashi] Kanazawa Univ, Adv Sci Res Ctr, Kanazawa, Ishikawa 9208640, Japan; [Shinohara, Atsushi] Osaka Univ, Grad Sch Sci, Osaka 5600043, Japan; [Watanabe, Shigeki] Japan Atom Energy Agcy, Med Radioisotope Applicat Grp, Takasaki, Gumma 3701292, Japan	Ogawa, K (reprint author), Kanazawa Univ, Grad Sch Med Sci, Div Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan.	kogawa@p.kanazawa-u.ac.jp			Takeda Science Foundation; Kato Memorial Bioscience Foundation; Hokkoku Foundation for Cancer Research; Matsubara Saburo Memorial Research and Scholarship Fund	This work was supported in part by Takeda Science Foundation, Kato Memorial Bioscience Foundation, Hokkoku Foundation for Cancer Research, and the Matsubara Saburo Memorial Research and Scholarship Fund.	Aydar E, 2006, CANCER LETT, V242, P245, DOI 10.1016/j.canlet.2005.11.011; Ogawa K, 2013, NUCL MED BIOL, V40, P445, DOI 10.1016/j.nucmedbio.2013.02.008; Larsen RH, 1998, NUCL MED BIOL, V25, P351, DOI 10.1016/S0969-8051(97)00230-8; Ogawa K, 2009, CANCER SCI, V100, P2188, DOI 10.1111/j.1349-7006.2009.01279.x; Berthois Y, 2003, BRIT J CANCER, V88, P438, DOI 10.1038/sj.bjc.6600709; SU TP, 1993, CRIT REV NEUROBIOL, V7, P187; John CS, 1999, CANCER RES, V59, P4578; Kekuda R, 1996, BIOCHEM BIOPH RES CO, V229, P553, DOI 10.1006/bbrc.1996.1842; GARG PK, 1990, CANCER RES, V50, P3514; Hayashi T, 2011, EXPERT OPIN THER TAR, V15, P557, DOI 10.1517/14728222.2011.560837; Matsuno K, 1996, EUR J PHARMACOL, V306, P271, DOI 10.1016/0014-2999(96)00201-4; Shiba K, 2006, BIOORGAN MED CHEM, V14, P2620, DOI 10.1016/j.bmc.2005.11.044; QUIRION R, 1992, TRENDS PHARMACOL SCI, V13, P85, DOI 10.1016/0165-6147(92)90030-A; Talanov VS, 2004, NUCL MED BIOL, V31, P1061, DOI 10.1016/j.nucmedbio.2004.08.005; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; Shiba K, 2005, BIOORGAN MED CHEM, V13, P1095, DOI 10.1016/j.bmc.2004.11.029; Shiba K, 2002, LIFE SCI, V71, P1591, DOI 10.1016/S0024-3205(02)01919-7; van Waarde A, 2010, CURR PHARM DESIGN, V16, P3519, DOI 10.2174/138161210793563365; Lindegren S, 2001, APPL RADIAT ISOTOPES, V55, P157, DOI 10.1016/S0969-8043(01)00044-6; VILNER BJ, 1995, CANCER RES, V55, P408; Ogawa K, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-54; van Waarde A, 2014, BIOCH BIOPH IN PRESS; Xu JB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1386; Ziegler J. F., 2013, STOPPING RANGE IONS	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0969-8051	1872-9614		NUCL MED BIOL	Nucl. Med. Biol.	NOV	2015	42	11					875	879		10.1016/j.nucmedbio.2015.07.001		5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CT8NJ	WOS:000363073000009		
J	Ono, M; Oka, S; Okudaira, H; Nakanishi, T; Mizokami, A; Kobayashi, M; Schuster, DM; Goodman, MM; Shirakami, Y; Kawai, K				Ono, Masahiro; Oka, Shuntaro; Okudaira, Hiroyuki; Nakanishi, Takeo; Mizokami, Atsushi; Kobayashi, Masato; Schuster, David M.; Goodman, Mark M.; Shirakami, Yoshifumi; Kawai, Keiichi			[C-14]Fluciclovine (alias anti-[C-14]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells	NUCLEAR MEDICINE AND BIOLOGY			English	Article						Fluciclovine; Anti-FACBC; ASCT2; Prostate cancer; CRPC; Positron emission tomography	AMINO-ACID TRANSPORTER; ANDROGEN RECEPTOR; TRANS-1-AMINO-3-F-18-FLUOROCYCLOBUTANECARBOXYLIC ACID; TUMOR-DEVELOPMENT; PET/CT; ACCUMULATION; PROGRESSION; MECHANISMS; CARCINOMA; DISEASE	Introduction: trans-1-Amino-3-[F-18]fluorocyclobutanecarboxylic acid ([F-18]fluciclovine, also known as anti-[F-18] FACBC), is a tracer for positron emission tomography (PET) imaging for detection of tumors such as prostate cancer (PCa). Our previous study showed that ASCT2 (Na+-dependent amino acid transporter (AAT)) mediates fluciclovine uptake in androgen-dependent PCa cells; its expression is influenced by androgen, a key hormone in the progression of primary PCa and castration-resistant prostate cancer (CRPC). In this study, we investigated the uptake mechanisms and feasibility of [F-18]fluciclovine for CRPC in the androgen-dependent PCa cell line LNCaP and LNCaP-derivatives LNCaP-SF and LN-REC4. Methods: LNCaP-SF was established after long-term cultivation of LNCaP in steroid-free conditions, and LN-Pre and LN-REC4 were established from LNCaP inoculated in intact and castrated severe combined immunodeficient mice, respectively. Uptake and competitive inhibition experiments were performed with trans-1-amino-3-fluoro[1-C-14]cyclobutanecarboxylic acid ([C-14]fluciclovine) to characterize the involvement of AATs in androgen-dependent PCa (LNCaP and LN-Pre) and CRPC-like (LNCaP-SF and LN-REC4) cell lines. MT expression was analyzed by Western blotting, and [C-14]fluciclovine uptake in androgen-dependent PCa and CRPC-like cell lines were investigated in the presence or absence of dihydrotestosterone (DHT). Results: The contribution of Na+-dependent AATs to [C-14]fluciclovine uptake in all cell lines was 88-98%, and [C-14]fluciclovine uptake was strongly inhibited by L-glutamine and L-serine, the substrates for Na+-dependent alanine-serine-cysteine (system ASC) AATs, in the presence of Na+. DHT enhanced ASCT2 expression in LNCaP, LN-Pre, and LN-REC4, but not in LNCaP-SF, and the responses of ASCT2 expression to DHT correlated with [C-14]fluciclovine uptake. Conclusions: System ASC, especially ASCT2, could play a major role in [C-14]fluciclovine uptake into CRPC-like and androgen-dependent PCa cells, suggesting [F-18]fluciclovine-PET is applicable to the detection of CRPC as well as androgen-dependent PCa. Advance in knowledge: [F-18]flucidovine-PET may be applied for the detection of CRPC. Implication for patient care: [F-18]fluciclovine-PET may permit early intervention for CRPC treatment. (C) 2015 Elsevier Inc. All rights reserved.	[Ono, Masahiro; Kawai, Keiichi] Kanazawa Univ, Grad Sch Med Sci, Div Hlth Sci, Kanazawa, Ishikawa, Japan; [Ono, Masahiro; Oka, Shuntaro; Okudaira, Hiroyuki; Shirakami, Yoshifumi] Nihon Mediphys Co Ltd, Res Ctr, Sodegaura, Chiba 2990266, Japan; [Nakanishi, Takeo] Kanazawa Univ, Fac Pharmaceut Sci, Dept Membrane Transport & Biopharmaceut, Kanazawa, Ishikawa 920, Japan; [Mizokami, Atsushi] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, Kanazawa, Ishikawa, Japan; [Kobayashi, Masato] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Wellness Promot Sci Ctr, Kanazawa, Ishikawa, Japan; [Schuster, David M.; Goodman, Mark M.] Emory Univ, Dept Radiol & Imaging Sci, Div Nucl Med & Mol Imaging, Atlanta, GA 30322 USA	Oka, S (reprint author), Nihon Mediphys Co Ltd, Res Ctr, Sodegaura, Chiba 2990266, Japan.	shuntaro_oka@nmp.co.jp					Basu Sujit, 2010, Hormones & Cancer, V1, P223, DOI 10.1007/s12672-010-0044-4; Yanagida O, 2001, BBA-BIOMEMBRANES, V1514, P291, DOI 10.1016/S0005-2736(01)00384-4; Suzuki H, 2008, J UROLOGY, V180, P921, DOI 10.1016/j.juro.2008.05.045; BORGHETTI AF, 1980, J CELL PHYSIOL, V105, P39, DOI 10.1002/jcp.1041050107; Console L, 2015, BBA-MOL CELL RES, V1853, P1636, DOI 10.1016/j.bbamcr.2015.03.017; Jenster G, 1999, SEMIN ONCOL, V26, P407; Wang Q, 2013, JNCI-J NATL CANCER I, V105, P1463, DOI 10.1093/jnci/djt241; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Seo Y, 2010, J NUCL MED, V51, P31, DOI 10.2967/jnumed.109.067108; Schuster DM, 2007, J NUCL MED, V48, P56; Oyama N, 2002, J NUCL MED, V43, P181; Li RL, 2003, ANTICANCER RES, V23, P3413; Asano Y, 2011, ANN NUCL MED, V25, P414, DOI 10.1007/s12149-011-0477-z; Bahl A, 2013, EUR J ONCOL NURS, V17, pS1, DOI 10.1016/S1462-3889(14)70002-X; Wang Q, 2015, J PATHOL, V236, P278, DOI 10.1002/path.4518; Wang Q, 2011, CANCER RES, V71, P7525, DOI 10.1158/0008-5472.CAN-11-1821; Yamaguchi T, 2005, EUR J NUCL MED MOL I, V32, P742, DOI 10.1007/s00259-004-1755-y; Oka S, 2012, NUCL MED BIOL, V39, P109, DOI 10.1016/j.nucmedbio.2011.06.008; Iwasa Y, 2007, INT J UROL, V14, P233, DOI 10.1111/j.1442-2042.2007.01532.x; Ono M, 2013, BRAIN RES, V1535, P24, DOI 10.1016/j.brainres.2013.08.037; Sakata T, 2009, PATHOL INT, V59, P7, DOI 10.1111/j.1440-1827.2008.02319.x; Fujimoto H, 2011, INT J UROL, V18, P876, DOI 10.1111/j.1442-2042.2011.02895.x; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Okudaira H, 2011, J NUCL MED, V52, P822, DOI 10.2967/jnumed.110.086074; Ryan CJ, 2011, J CLIN ONCOL, V29, P3651, DOI 10.1200/JCO.2011.35.2005; Okudaira H, 2013, NUCL MED BIOL, V40, P670, DOI 10.1016/j.nucmedbio.2013.03.009; Amzat R, 2011, CLIN NUCL MED, V36, P800, DOI 10.1097/RLU.0b013e318219b47e; Zhang XM, 2010, J NUCL MED, V51, P1167, DOI 10.2967/jnumed.109.068981; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883; Doi Y, 2015, NUCL MED BIOL, V42, P664, DOI 10.1016/j.nucmedbio.2015.04.008; Aparici CM, 2012, SEMIN NUCL MED, V42, P328, DOI 10.1053/j.semnuclmed.2012.04.004; Beheshti M, 2010, RADIOLOGY, V254, P925, DOI 10.1148/radiol.09090413; Scalise M, 2014, AMINO ACIDS, V46, P2463, DOI 10.1007/s00726-014-1808-x; Sorensen J, 2013, EUR J NUCL MED MOL I, V40, P394, DOI 10.1007/s00259-012-2291-9; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; Inoue Y., 2014, ASIA OCEANIA J NUCL, V2, P87; Nome R, 2014, SCAND J UROL, V17, P1; Okudaira H, 2014, MOL IMAGING BIOL, V16, P756, DOI 10.1007/s11307-014-0756-x; Segawa A, 2013, MOL CLIN ONCOL, V1, P274	40	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0969-8051	1872-9614		NUCL MED BIOL	Nucl. Med. Biol.	NOV	2015	42	11					887	892		10.1016/j.nucmedbio.2015.07.005		6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	CT8NJ	WOS:000363073000011		
J	Baek, SJ; Ishii, H; Tamari, K; Hayashi, K; Nishida, N; Konno, M; Kawamoto, K; Koseki, J; Fukusumi, T; Hasegawa, S; Ogawa, H; Hamabe, A; Miyo, M; Noguchi, K; Seo, Y; Doki, Y; Mori, M; Ogawa, K				Baek, Sung-Jae; Ishii, Hideshi; Tamari, Keisuke; Hayashi, Kazuhiko; Nishida, Naohiro; Konno, Masamitsu; Kawamoto, Koichi; Koseki, Jun; Fukusumi, Takahito; Hasegawa, Shinichiro; Ogawa, Hisataka; Hamabe, Atsushi; Miyo, Masaaki; Noguchi, Kozo; Seo, Yuji; Doki, Yuichiro; Mori, Masaki; Ogawa, Kazuhiko			Cancer stem cells: The potential of carbon ion beam radiation and new radiosensitizers	ONCOLOGY REPORTS			English	Review						radiosensitizers; cancer stem cells; carbon ion beam radiation; radioresistance; microRNA	SOFT-TISSUE SARCOMA; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; INITIATING CELLS; CD133 EXPRESSION; PROSTATE-CANCER; SIDE POPULATION; SELF-RENEWAL; COLON-CANCER; RADIOTHERAPY	Cancer stem cells (CSCs) are a small population of cells in cancer with stem-like properties such as cell proliferation, multiple differentiation and tumor initiation capacities. CSCs are therapy-resistant and cause cancer metastasis and recurrence. One key issue in cancer therapy is how to target and eliminate CSCs, in order to cure cancer completely without relapse and metastasis. To target CSCs, many cell surface markers, DNAs and microRNAs are considered as CSC markers. To date, the majority of the reported markers are not very specific to CSCs and are also present in non-CSCs. However, the combination of several markers is quite valuable for identifying and targeting CSCs, although more specific identification methods are needed. While CSCs are considered as critical therapeutic targets, useful treatment methods remain to be established. Epigenetic gene regulators, microRNAs, are associated with tumor initiation and progression. MicroRNAs have been recently considered as promising therapeutic targets, which can alter the therapeutic resistance of CSCs through epigenetic modification. Moreover, carbon ion beam radiotherapy is a promising treatment for CSCs. Evidence indicates that the carbon ion beam is more effective against CSCs than the conventional X-ray beam. Combination therapies of radiosensitizing microRNAs and carbon ion beam radiotherapy may be a promising cancer strategy. This review focuses on the identification and treatment resistance of CSCs and the potential of microRNAs as new radiosensitizers and carbon ion beam radiotherapy as a promising therapeutic strategy against CSCs.	[Baek, Sung-Jae; Tamari, Keisuke; Hayashi, Kazuhiko; Seo, Yuji; Ogawa, Kazuhiko] Osaka Univ, Dept Radiat Oncol, Grad Sch Med, Suita, Osaka 5650871, Japan; [Baek, Sung-Jae; Ishii, Hideshi; Tamari, Keisuke; Hayashi, Kazuhiko; Nishida, Naohiro; Konno, Masamitsu; Kawamoto, Koichi; Fukusumi, Takahito; Hasegawa, Shinichiro; Ogawa, Hisataka; Hamabe, Atsushi; Miyo, Masaaki; Noguchi, Kozo] Osaka Univ, Dept Frontier Sci Canc & Chemotherapy, Grad Sch Med, Suita, Osaka 5650871, Japan; [Ishii, Hideshi; Koseki, Jun] Osaka Univ, Dept Canc Profiling Discovery, Grad Sch Med, Suita, Osaka 5650871, Japan; [Kawamoto, Koichi; Hasegawa, Shinichiro; Ogawa, Hisataka; Hamabe, Atsushi; Miyo, Masaaki; Noguchi, Kozo; Doki, Yuichiro; Mori, Masaki] Osaka Univ, Dept Surg Gastroenterol, Grad Sch Med, Suita, Osaka 5650871, Japan; [Fukusumi, Takahito] Osaka Univ, Dept Otorhinolaryngol & Head & Neck Surg, Grad Sch Med, Suita, Osaka 5650871, Japan	Ogawa, K (reprint author), Osaka Univ, Dept Radiat Oncol, Grad Sch Med, 2-2 D10 Yamadaoka, Suita, Osaka 5650871, Japan.	kogawa@radonc.med.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology; Ministry of Health, Labor and Welfare; National Institute of Biomedical Innovation; Osaka University; Taiho Pharmaceutical Co., Ltd.; Evidence Based Medical Research Center, Chugai Co., Ltd.; Yakult Honsha Co., Ltd.; Merck Co., Ltd.; Takeda Science and Medical Research Foundation	We thank each laboratory staff member for the fruitful discussion and technical assistance. This study was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology; a Grant-in-Aid from the Ministry of Health, Labor and Welfare; a grant from the National Institute of Biomedical Innovation; and a grant from the Osaka University Drug Discovery Funds. Partial support was received from Taiho Pharmaceutical Co., Ltd., Evidence Based Medical Research Center, Chugai Co., Ltd., Yakult Honsha Co., Ltd., Merck Co., Ltd., and the Takeda Science and Medical Research Foundation through the institutional endowments; the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; Jingu K, 2012, INT J RADIAT ONCOL, V82, P2125, DOI 10.1016/j.ijrobp.2010.08.043; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Blazek ER, 2007, INT J RADIAT ONCOL, V67, P1, DOI 10.1016/j.ijrobp.2006.09.037; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Alektiar KM, 2000, INT J RADIAT ONCOL, V48, P1051, DOI 10.1016/S0360-3016(00)00753-7; Barrow BJ, 1999, RADIOTHER ONCOL, V52, P173, DOI 10.1016/S0167-8140(99)00070-5; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Nakano T, 2006, CLIN CANCER RES, V12, P2185, DOI 10.1158/1078-0432.CCR-05-1907; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; PARK CH, 1971, J NATL CANCER I, V46, P411; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Kim HM, 2012, ANN SURG ONCOL, V19, pS539, DOI 10.1245/s10434-011-2040-5; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Tamura K, 2010, J NEUROSURG, V113, P310, DOI 10.3171/2010.2.JNS091607; Ishikawa H, 2012, INT J UROL, V19, P296, DOI 10.1111/j.1442-2042.2012.02961.x; Grun R, 2012, PHYS MED BIOL, V57, P7261, DOI 10.1088/0031-9155/57/22/7261; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Yao HP, 2013, NAT REV CANCER, V13, P466, DOI 10.1038/nrc3545; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013; Chiba T, 2006, HEPATOLOGY, V44, P240, DOI 10.1002/hep.21227; Ehata S, 2011, ONCOGENE, V30, P1693, DOI 10.1038/onc.2010.546; Mizoe J, 2012, RADIOTHER ONCOL, V103, P32, DOI 10.1016/j.radonc.2011.12.013; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Ogawa K, 2013, ANTICANCER RES, V33, P747; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Kato S, 2006, INT J RADIAT ONCOL, V65, P388, DOI 10.1016/j.jrobp.2005.12.050; Kato H, 2004, INT J RADIAT ONCOL, V59, P1468, DOI 10.1016/j.ijrobp.2004.01.032; Bixby S, 2002, NEURON, V35, P643, DOI 10.1016/S0896-6273(02)00825-5; Shien K, 2012, LUNG CANCER, V77, P162, DOI 10.1016/j.lungcan.2012.02.006; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Phillips TM, 2006, J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Durante M, 2010, NAT REV CLIN ONCOL, V7, P37, DOI 10.1038/nrclinonc.2009.183; Yin AH, 1997, BLOOD, V90, P5002; Riethdorf S, 2008, INT J CANCER, V123, P1991, DOI 10.1002/ijc.23825; Saigusa S, 2010, ONCOL REP, V24, P345, DOI 10.3892/or_00000865; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Fusi A, 2009, EUR J CANCER, V45, P3189, DOI 10.1016/j.ejca.2009.09.004; Miyamoto T, 2007, J THORAC ONCOL, V2, P916, DOI 10.1097/JTO.0b013e3181560a68; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ieta K, 2008, ANN SURG ONCOL, V15, P638, DOI 10.1245/s10434-007-9605-3; Koch U, 2010, SEMIN CANCER BIOL, V20, P116, DOI 10.1016/j.semcancer.2010.02.003; Chen YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002637; Chiou SH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002090; Cui FB, 2014, INT J NANOMED, V9, P2345, DOI 10.2147/IJN.S60874; Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989; LOREE TR, 1990, AM J SURG, V160, P410, DOI 10.1016/S0002-9610(05)80555-0; Patel Purvi, 2012, Front Endocrinol (Lausanne), V3, P125, DOI 10.3389/fendo.2012.00125; Sagar J, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-9; Swindle P, 2008, J UROLOGY, V179, pS47, DOI 10.1016/j.juro.2008.03.137	64	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1021-335X	1791-2431		ONCOL REP	Oncol. Rep.	NOV	2015	34	5					2233	2237		10.3892/or.2015.4236		5	Oncology	Oncology	CT5NO	WOS:000362857300003		
J	Kawano, H; Ito, Y; Kanai, F; Nakamura, E; Tada, N; Takai, S; Horie, S; Kobayashi, T; Hino, O				Kawano, Haruna; Ito, Yoshitaka; Kanai, Fumio; Nakamura, Eri; Tada, Norihiro; Takai, Setsuo; Horie, Shigeo; Kobayashi, Toshiyuki; Hino, Okio			Aberrant differentiation of Tsc2-deficient teratomas associated with activation of the mTORC1-TFE3 pathway	ONCOLOGY REPORTS			English	Article						Eker rat; embryonic stem cells; renal cell carcinoma; teratomas; tuberous sclerosis complex	EKER RAT MODEL; DOMINANTLY INHERITED CANCER; TUBEROUS SCLEROSIS COMPLEX; RENAL-CELL CARCINOMA; E-CADHERIN; BETA-CATENIN; STEM-CELLS; TSC2 GENE; TUMORS; MUTATION	The model animal of renal cell carcinoma (RCC), the Eker rat, has a germline mutation in the tuberous sclerosis 2 (Tsc2) gene. Heterozygous mutants develop RCCs by second hit in the wild-type Tsc2 allele, whereas homozygous mutants are embryonic lethal. In the present study, a new cell differentiation model was developed to study the mechanism of Tsc2 mutation-associated pathogenesis by generating Tsc2-deficient embryonic stem cells (ESCs) from Eker rats. Tsc2(+/+), Tsc2(+/-) and Tsc2(-/-) ESCs were all capable of generating three germ layers: mesoderm, ectoderm, and endoderm. Interestingly, epithelial tumor-like abnormal ductal structures were reproducibly observed in Tsc2(-/-) teratomas from different ESC lines. Immunohistochemical analysis revealed that mammalian target of rapamycin complex 1 (mTORC1) signaling was activated in abnormal ducts of Tsc2(-/-) teratomas, on the basis of positive staining for p-S6 and p-4EBP1. In these abnormal ducts, expression levels of epithelial markers (i.e., megalin and cubilin) and the cytoplasmic localization of E-cadherin and beta-catenin were similar to those in Eker rat RCCs. Moreover, a transcription factor regulated by mTORC1, named TFE3, was located in the nuclei of abnormal ducts and Eker rat RCCs. As a negative regulator of ESC differentiation, TFE3 may result in tissue-specific differentiation defects related to tumorigenesis in Eker rats and Tsc2(-/-) teratomas. The present study suggests that ESCs derived from Eker rats constitute a novel experimental tool with which to analyze differentiation defects and cell-type specific pathogenesis associated with Tsc2 deficiency.	[Kawano, Haruna; Horie, Shigeo] Juntendo Univ, Grad Sch Med, Res Inst Dis Old Age, Dept Urol, Tokyo 1138431, Japan; [Kawano, Haruna; Ito, Yoshitaka; Kobayashi, Toshiyuki; Hino, Okio] Juntendo Univ, Grad Sch Med, Res Inst Dis Old Age, Dept Mol Pathogenesis, Tokyo 1138431, Japan; [Ito, Yoshitaka] Juntendo Univ, Grad Sch Med, Res Inst Dis Old Age, Dept Neurosurg, Tokyo 1138431, Japan; [Kanai, Fumio; Nakamura, Eri; Tada, Norihiro] Juntendo Univ, Grad Sch Med, Res Inst Dis Old Age, Lab Genome Res, Tokyo 1138431, Japan; [Takai, Setsuo] Hiroshima Int Univ, Dept Clin Radiol, Fac Hlth Sci, Hiroshima 7240695, Japan	Hino, O (reprint author), Juntendo Univ, Grad Sch Med, Dept Mol Pathogenesis, Bunkyo Ku, Hongo 3-1-3, Tokyo 1138431, Japan.	koba396@juntendo.ac.jp; ohino@juntendo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Japan Society for the Promotion of Science, Japan; Ministry of Health, Labour and Welfare (Japan)	The present study was supported in part by the following grants: Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, the MEXT-supported Program for the Strategic Research Foundation at Private Universities, and Science (Japan), Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Japan, and the Grants-in-Aid for Scientific Research from the Ministry of Health, Labour and Welfare (Japan). We wish to acknowledge all members of the Department of Molecular Pathogenesis, Juntendo University Graduate School of Medicine who participated in this study. The authors would like to thank Enago for the English language review. Finally, we would like to thank the Gender Equality Promotion Center, Juntendo University, for their assistance with our experiments.	Barnes EA, 2010, AM J PATHOL, V177, P1765, DOI [10.2353/ajpath.2010.090233, 10.2353/ajpath.2010.000233]; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Sarbassov DD, 2004, CURR BIOL, V14, P1296; Soyombo AA, 2013, STEM CELL REP, V1, P336, DOI 10.1016/j.stemcr.2013.08.004; RIETHMACHER D, 1995, P NATL ACAD SCI USA, V92, P855, DOI 10.1073/pnas.92.3.855; Betschinger J, 2013, CELL, V153, P335, DOI 10.1016/j.cell.2013.03.012; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; Ito Y, 2015, INT J ONCOL, V46, P1944, DOI 10.3892/ijo.2015.2913; Kenerson HL, 2002, CANCER RES, V62, P5645; Rennebeck G, 1998, P NATL ACAD SCI USA, V95, P15629, DOI 10.1073/pnas.95.26.15629; McDorman KS, 2002, TOXICOL PATHOL, V30, P675, DOI 10.1080/01926230290168542; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Orlova KA, 2010, ANN NY ACAD SCI, V1184, P87, DOI 10.1111/j.1749-6632.2009.05117.x; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Verroust PJ, 2002, NEPHROL DIAL TRANSPL, V17, P1867, DOI 10.1093/ndt/17.11.1867; KANDT RS, 1992, NAT GENET, V2, P37, DOI 10.1038/ng0992-37; EVERITT JI, 1992, J UROLOGY, V148, P1932; WOLF DC, 1995, VET PATHOL, V32, P379; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; vanSlegtenhorst M, 1997, SCIENCE, V277, P805; Eker E., 1961, Nature London, V189, P858; Hong SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015793; Huan C, 2003, P NATL ACAD SCI USA, V100, P6051; Kawamata M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00945; NELLIST M, 1993, CELL, V75, P1305; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	35	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1021-335X	1791-2431		ONCOL REP	Oncol. Rep.	NOV	2015	34	5					2251	2258		10.3892/or.2015.4254		8	Oncology	Oncology	CT5NO	WOS:000362857300005		
J	Tanaka, T; Terai, Y; Kogata, Y; Ashihara, K; Maeda, K; Fujiwara, S; Yoo, S; Tanaka, Y; Tsunetoh, S; Sasaki, H; Kanemura, M; Tanabe, A; Ohmichi, M				Tanaka, Tomohito; Terai, Yoshito; Kogata, Yuhei; Ashihara, Keisuke; Maeda, Kazuya; Fujiwara, Satoe; Yoo, Saha; Tanaka, Yoshimichi; Tsunetoh, Satoshi; Sasaki, Hiroshi; Kanemura, Masanori; Tanabe, Akiko; Ohmichi, Masahide			CD24 expression as a marker for predicting clinical outcome and invasive activity in uterine cervical cancer	ONCOLOGY REPORTS			English	Article						uterine cervical cancer; CD24; lymph node metastasis; lymphovascular involvement; epithelial to mesenchymal transition; Slug; Akt; extracellular signal-regulated kinase; nuclear factor-kappa B	EPITHELIAL-MESENCHYMAL TRANSITION; ANTIGEN MOUSE CD24; STEM-CELLS; COLORECTAL-CANCER; P-SELECTIN; TUMOR PROGRESSION; ACTIVATION; DISEASE; PROLIFERATION; MODULATION	CD24, a small heavily glycosylated mucin-like glycosyl-phosphatidylinositol-anchored cell surface protein, plays an important role in the carcinogenesis of various human malignancies. However, its function in cervical cancer remains unclear. The aim of the present study was to evaluate the expression of CD24 clinicopathologically and to analyze its functional behavior biologically in cervical cancer. A total of 117 uterine cervical cancer tumors were immunohistochemically analyzed using a CD24 monoclonal antibody on paraffin blocks. We also examined whether CD24 enhanced the invasive activity or the Akt, ERK, NF-kappa B and MMP activity in a uterine cervical cancer cell line (CaSki) by a western blot analysis. The patients with enhanced CD24 expression had a higher rate of advanced clinical stage (50 vs. 16.5%, p<0.01), lymph node metastasis (34.6 vs. 14.3%) and lymphovascular involvement (65.4 vs. 20.4%, p=0.01), and a poor overall and disease-free survival (5-year survival rate: 62 vs. 86%, p=0.03). CD24 overexpression in CaSki cells resulted in activation of Cell Signaling proteins, including Akt, ERK, NF-kappa B and MMP-9. An invasion assay showed that CD24 overexpression in CaSki cells led to increased invasion ability. The CD24 overexpression also increased mRNA expression of Slug but not Snail. Moreover, the CD24 overexpression also decreased expression of E-cadherin and increased N-cadherin protein levels. Increased expression of CD24 may be associated with tumor progression and prognosis in patients with uterine cervical cancer. CD24 expression may therefore be used not only as a prognostic marker in uterine cervical cancer, but also as a target for the development of new therapeutic approaches.	[Tanaka, Tomohito; Terai, Yoshito; Kogata, Yuhei; Ashihara, Keisuke; Maeda, Kazuya; Fujiwara, Satoe; Yoo, Saha; Tanaka, Yoshimichi; Tsunetoh, Satoshi; Sasaki, Hiroshi; Kanemura, Masanori; Tanabe, Akiko; Ohmichi, Masahide] Osaka Med Coll, Dept Obstet & Gynecol, Takatsuki, Osaka 5698686, Japan	Terai, Y (reprint author), Osaka Med Coll, Dept Obstet & Gynecol, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.	y-terai@poh.osaka-med.ac.jp			JSPS KAKENHI [25462621]	The present study was supported by a JSPS KAKENHI, grant no. 25462621 (to Y.T.).	Zhang Y, 2012, ONCOL REP, V27, P1599, DOI 10.3892/or.2012.1681; Kemper K, 2010, ONCOTARGET, V1, P387; Newman H, 2012, CURR EYE RES, V37, P532, DOI 10.3109/02713683.2011.647226; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Lee SH, 2014, PANCREAS, V43, P380, DOI 10.1097/MPA.0000000000000097; AIGNER S, 1995, INT IMMUNOL, V7, P1557, DOI 10.1093/intimm/7.10.1557; Rasheed ZA, 2012, J GASTROEN HEPATOL, V27, P15, DOI 10.1111/j.1440-1746.2011.07015.x; Zou GM, 2008, J CELL PHYSIOL, V217, P598, DOI 10.1002/jcp.21541; Wang WF, 2010, CANCER SCI, V101, P112, DOI 10.1111/j.1349-7006.2009.01370.x; Liu CX, 2013, ONCOL LETT, V6, P96, DOI 10.3892/ol.2013.1357; Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2; Sammar M, 1997, BBA-PROTEIN STRUCT M, V1337, P287, DOI 10.1016/S0167-4838(96)00177-X; Blechschmidt K, 2008, BRIT J CANCER, V98, P489, DOI 10.1038/sj.bjc.6604115; Hira SK, 2012, CELL IMMUNOL, V275, P69, DOI 10.1016/j.cellimm.2012.02.015; Keysar SB, 2010, MOL CANCER THER, V9, P2450, DOI 10.1158/1535-7163.MCT-10-0530; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Tang J, 2013, CLIN TRANSL ONCOL, V15, P541, DOI 10.1007/s12094-012-0961-5; KAY R, 1991, J IMMUNOL, V147, P1412; King JB, 2012, AM J PHYSIOL-GASTR L, V303, pG443, DOI 10.1152/ajpgi.00087.2012; Kang KS, 2013, BIOCHEM BIOPH RES CO, V432, P333, DOI 10.1016/j.bbrc.2013.01.102; Shi Y, 2012, ORL-J OTO-RHIN-LARYN, V74, P78, DOI 10.1159/000335584; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Aigner S, 1997, BLOOD, V89, P3385; Li J, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/158084; Lim J, 2014, ARCH BIOCHEM BIOPHYS, V558, P120, DOI 10.1016/j.abb.2014.06.022; Deng JP, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/517172; Lee KM, 2012, CELL SIGNAL, V24, P2132, DOI 10.1016/j.cellsig.2012.07.005; Su N, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-43; Wu JX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114746; Zhu Jianlong, 2012, Front Biosci (Elite Ed), V4, P2745	32	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1021-335X	1791-2431		ONCOL REP	Oncol. Rep.	NOV	2015	34	5					2282	2288		10.3892/or.2015.4257		7	Oncology	Oncology	CT5NO	WOS:000362857300009		
J	Eguchi, R; Fujita, Y; Tabata, C; Ogawa, H; Wakabayashi, I; Nakano, T; Fujimori, Y				Eguchi, Ryoji; Fujita, Yumiko; Tabata, Chiharu; Ogawa, Hiroyasu; Wakabayashi, Ichiro; Nakano, Takashi; Fujimori, Yoshihiro			Inhibition of Src family kinases overcomes anoikis resistance induced by spheroid formation and facilitates cisplatin-induced apoptosis in human mesothelioma cells	ONCOLOGY REPORTS			English	Article						malignant mesothelioma; suspension culture; spheroid formation; anoikis; cisplatin; Src family kinases	MALIGNANT PLEURAL MESOTHELIOMA; OSTEOSARCOMA CELLS; SURVIVAL; CANCER; ACTIVATION; MECHANISMS; CULTURE; MATRIX	Malignant mesothelioma is an aggressive tumor arising from mesothelial cells of serous membranes, and forms spheroid-like cell aggregates in pleural and peritoneal effusions. We examined the levels of anoikis, apoptosis induced by the detachment of cells from the extracellur matrix, in suspension culture in the human mesothelioma cell line NCI-H2052. NCI-H2052 cells were adherent in conventional monolayer cultures,but were found to form spheroids in suspension cultures using dishes with ultra-low cell binding capacity. NCI-H2052 cells proliferated in both cultures, but the proliferation rate was markedly lower in suspension cultures than in monolayer cultures. In addition, NCI-H2052 cells in suspension cultures showed little apoptosis, suggesting that the suspension culture induces anoikis resistance. Western blot analysis revealed that suspension cultures induced activation of Src family kinases (SFK) after spheroid formation. Dasatinib, an inhibitor of multi-tyrosine kinases including SFK, abolished anoikis resistance in suspension cultures, indicating that SFK activated by spheroid formation are responsible for anoikis resistance. Cisplatin induced apoptosis in NCI-H2052 cells, but the apoptotic rate was significantly lower in suspension cultures than in monolayer cultures, suggesting that spheroid formation is involved in cisplatin resistance. Furthermore, a combination of dasatinib and cisplatin induced apoptosis more significantly than either alone in suspension cultures. These results suggest that spheroid formation induces resistance to anoikis and to cisplatin through SFK activation and that dasatinib facilitates cisplatin-induced apoptosis in human mesothelioma cells.	[Eguchi, Ryoji; Wakabayashi, Ichiro] Hyogo Coll Med, Dept Environm & Prevent Med, Nishinomiya, Hyogo 6638501, Japan; [Fujita, Yumiko; Tabata, Chiharu; Nakano, Takashi] Hyogo Coll Med, Dept Thorac Oncol, Nishinomiya, Hyogo 6638501, Japan; [Ogawa, Hiroyasu] Hyogo Coll Med, Dept Internal Med, Div Hematol, Nishinomiya, Hyogo 6638501, Japan; [Fujimori, Yoshihiro] Hyogo Coll Med, Dept Transfus Med & Cellular Therapy, Nishinomiya, Hyogo 6638501, Japan	Eguchi, R (reprint author), Hyogo Coll Med, Dept Environm & Prevent Med, Nishinomiya, Hyogo 6638501, Japan.	r-eguchi@hyo-med.ac.jp; fuji-y@hyo-med.ac.jp			KAKENHI; Hyogo College of Medicine; MEXT	This study was supported by KAKENHI to Y. Fujimori, Grant-in-Aid for Researchers, Hyogo College of Medicine, 2013 and MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2012-2015.	Dudek AZ, 2012, J THORAC ONCOL, V7, P755, DOI 10.1097/JTO.0b013e318248242c; Barbone D, 2008, J BIOL CHEM, V283, P13021, DOI 10.1074/jbc.M709698200; Daubriac J, 2009, CELL DEATH DIFFER, V16, P1146, DOI 10.1038/cdd.2009.32; Cohen GM, 1997, BIOCHEM J, V326, P1; Vogelzang NJ, 2008, LANCET, V371, P1640, DOI 10.1016/S0140-6736(08)60703-5; Arai K, 2013, PROTEOMICS, V13, P2351, DOI 10.1002/pmic.201300053; Eguchi R, 2012, CARCINOGENESIS, V33, P969, DOI 10.1093/carcin/bgs109; Eguchi R, 2013, CELL SIGNAL, V25, P1731, DOI 10.1016/j.cellsig.2013.05.008; de Ridder L, 2000, CRIT REV ONCOL HEMAT, V36, P107, DOI 10.1016/S1040-8428(00)00081-0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Tsao AS, 2009, J CLIN ONCOL, V27, P2081, DOI 10.1200/JCO.2008.19.8523; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Zhong XL, 2012, CELL SIGNAL, V24, P393, DOI 10.1016/j.cellsig.2011.10.005; Eguchi R, 2011, J CELL PHYSIOL, V226, P762, DOI 10.1002/jcp.22397; Diaz-Montero CM, 2006, EUR J CANCER, V42, P1491, DOI 10.1016/j.ejca.2006.03.007; Eguchi R, 2010, INT J ONCOL, V37, P1289, DOI 10.3892/ijo_00000780; McCarroll JA, 2015, CANCER RES, V75, P415, DOI 10.1158/0008-5472.CAN-14-2740; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Valentijn AJ, 2004, BIOCHEM SOC T, V32, P421, DOI 10.1042/BST0320421; Carduner L, 2014, EXP CELL RES, V320, P329, DOI 10.1016/j.yexcr.2013.11.011; Goudar Ranjit Kumar, 2005, Curr Oncol Rep, V7, P260, DOI 10.1007/s11912-005-0048-3; Liao JQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084941; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109	28	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1021-335X	1791-2431		ONCOL REP	Oncol. Rep.	NOV	2015	34	5					2305	2310		10.3892/or.2015.4200		6	Oncology	Oncology	CT5NO	WOS:000362857300012		
J	Yoshimura, N; Muraki, S; Oka, H; Tanaka, S; Kawaguchi, H; Nakamura, K; Akune, T				Yoshimura, N.; Muraki, S.; Oka, H.; Tanaka, S.; Kawaguchi, H.; Nakamura, K.; Akune, T.			Factors affecting changes in the serum levels of 25-hydroxyvitamin D: a 3-year follow-up of the ROAD study	OSTEOPOROSIS INTERNATIONAL			English	Article						25-Hydroxyvitamin D; Bone mineral density; Nutrition; Population-based cohort study; Risk factors	BONE-MINERAL DENSITY; VITAMIN-D INADEQUACY; POSTMENOPAUSAL WOMEN; FRACTURE RISK; OSTEOPOROSIS; CALCIUM; ADULTS; ASSOCIATION; DEFICIENCY; COHORT	In this 3-year population-based cohort study, among 1346 subjects, the mean annual change in the serum 25-hydroxyvitamin D levels was 7.6 %/year, which tended to increase during the 3-year period. Multivariate regression analysis indicated that the L2-4 bone mineral density and total daily energy intake were significant independent associated factors. Introduction The aim of this study was to clarify the change rate of the serum levels of 25-hydroxyvitamin D (25D) and the associated factors in a general Japanese population during a 3-year period. Methods The baseline survey of Research on Osteoarthritis/osteoporosis Against Disability study (ROAD), a large-scale population-based cohort study, was performed between 2005 and 2007, and a follow-up survey was repeated 3 years later. Among 1690 participants at baseline, the change rate of the serum 25D levels were assessed in 1346 individuals (79.6 %; 458 men and 888 women) who completed measurements of 25D at both the baseline and follow-up examinations. The change rate was calculated, and the factors associated with the changes in the 25D levels were determined using multivariate regression analysis after adjustment for age, gender, body mass index, participated month, and regional differences at baseline. Results The mean (standard deviation) change rate of the 25D levels in all subjects was 7.6 (13.3) %/year (men, 8.2 [12.4] %/year; women, 7.3 [13.7] %/year). Multivariate regression analysis indicated that higher bone mineral density at lumbar spine L2-4 (p = 0.05) and total daily energy intake (p = 0.04) were significantly associated with the change rate of the 25D levels. Conclusions The serum levels of 25D tended to increase over the 3-year period, and higher lumbar bone mineral density and daily energy intake were found to be associated with increases in the 25D levels over time.	[Yoshimura, N.] Univ Tokyo, Dept Joint Dis Res, Century Med & Res Ctr 22, Grad Sch Med,Bunkyo Ku, Tokyo 1138655, Japan; [Muraki, S.] Univ Tokyo, Dept Clin Motor Syst Med, Century Med & Res Ctr 22, Grad Sch Med, Tokyo 1138655, Japan; [Oka, H.] Univ Tokyo, Dept Med Res & Management Musculoskeletal Pain, Century Med & Res Ctr 22, Grad Sch Med,Bunkyo Ku, Tokyo 1138655, Japan; [Tanaka, S.] Univ Tokyo, Dept Orthopaed Surg, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan; [Kawaguchi, H.] JCHO Tokyo Shinjuku Med Ctr, Shinjyuku Ku, Tokyo 1628542, Japan; [Nakamura, K.; Akune, T.] Natl Rehabil Ctr Persons Disabil, Tokorozawa, Saitama 3598555, Japan	Yoshimura, N (reprint author), Univ Tokyo, Dept Joint Dis Res, Century Med & Res Ctr 22, Grad Sch Med,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	YOSHIMURAN-ORT@h.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology for Scientific Research [B26293139, B23390172, B20390182, 24659317), C20591737, B23390357, C20591774, B23390356, 23659580]; NSF [08033011-00262]; Ministry of Health, Labour and Welfare in Japan [H17-Men-eki-009, H18-Choujyu-037, H20-Choujyu-009, H23-Chojyu-002, H25-Nanchi-to (Men)-005, H25-Chojyu-007]; Japan Osteoporosis Society; Japanese Orthopaedic Association [2006-1, 2010-2];  [A18689031];  [24659666]	This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology for Scientific Research to NY (B26293139, B23390172, B20390182, and Challenging Exploratory Research 24659317), TA (C20591737, B23390357), and SM (C20591774, B23390356, Challenging Exploratory Research 23659580); for Young Scientists to HO (A18689031, Challenging Exploratory Research 24659666); and for Collaborating Research with NSF to NY (Director; 08033011-00262). Moreover, this work was supported by H17-Men-eki-009 (Director, KN), H18-Choujyu-037 (Director, TN), H20-Choujyu-009 (Director, NY), H23-Chojyu-002 (Director, TA), H25-Nanchi-to (Men)-005 (Director, ST), and H25-Chojyu-007 (Director, NY) from the Ministry of Health, Labour and Welfare in Japan, and by grants from the Japan Osteoporosis Society (NY, SM, HO, and TA), and research aids from the Japanese Orthopaedic Association (JOA-Subsidized Science Project Research 2006-1 and 2010-2; Director, HK). The authors wish to thank Dr. Takako Nojiri andMr. Kazuhiro Hatanaka of the Gobo Public Health Centre; Dr. Naoki Hirabayashi of the Kawakami Clinic, Hidakagawa Town; Mrs. Tomoko Takijiri, Mrs. Kumiko Shinou, Mrs. Rie Takiguchi, Mrs. Kyoko Maeda, Ms. Ikuyo Ueyama, Mrs. Michiko Mori, Mrs. Hisayo Sugimoto, and other members of the public office in Hidakagawa Town; Dr. Shinji Matsuda of the Shingu Public Health Centre; and Mrs. Tamako Tsutsumi, Mrs. Kanami Maeda, Mr. Shoichi Shimoichi, Mrs. Megumi Takino, Mrs. Shuko Okada, Mrs. Kazuyo Setoh, Mrs. Chise Ryouno, Mrs. Miki Shimosaki, Mrs. Chika Yamaguchi, Mrs. Yuki Shimoji, and other members of the public office in Taiji Town for their assistance in locating and scheduling participants for examinations. Finally, we also thank Ms. Kyoko Yoshimura, Mrs. Toki Sakurai, and Mrs. Saeko Sahara for their assistance with data reduction and administration.	Yoshimura N, 2009, J BONE MINER METAB, V27, P620, DOI 10.1007/s00774-009-0080-8; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; Lim SK, 2008, CURR MED RES OPIN, V24, P99, DOI 10.1185/030079908X253429; Nieves JW, 2013, OSTEOPOROSIS INT, V24, P771, DOI 10.1007/s00198-012-2214-4; Hanley DA, 2010, CAN MED ASSOC J, V182, pE610, DOI 10.1503/cmaj.080663; Yoshimura N, 2013, OSTEOPOROSIS INT, V24, P2775, DOI 10.1007/s00198-013-2372-z; HOLLIS BW, 1993, CLIN CHEM, V39, P529; Lips P, 2006, J INTERN MED, V260, P245, DOI 10.1111/j.1365-2796.2006.01685.x; Bischoff-Ferrari HA, 2009, J BONE MINER RES, V24, P935, DOI [10.1359/jbmr.081242, 10.1359/JBMR.081242]; Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6; Tanaka S, 2014, J BONE MINER METAB, V32, P514, DOI 10.1007/s00774-013-0520-3; Yoshimura N, 2010, INT J EPIDEMIOL, V39, P988, DOI 10.1093/ije/dyp276; Nieves JW, 2014, NAT REV ENDOCRINOL, V10, P255, DOI 10.1038/nrendo.2014.39; Bischoff-Ferrari HA, 2005, ARTHRIT RHEUM-ARTHR, V53, P821, DOI 10.1002/art.21601; Nieves JW, 2008, OSTEOPOROSIS INT, V19, P673, DOI 10.1007/s00198-007-0501-2; Dawson-Hughes B, 2010, OSTEOPOROSIS INT, V21, P1151, DOI 10.1007/s00198-010-1285-3; Cauley JA, 2015, J CLIN ENDOCR METAB, V100, P2046, DOI 10.1210/jc.2014-4367; Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh29; Kobayashi S, 2012, J EPIDEMIOL, V22, P151, DOI [10.2188/jeaJE20110075, 10.2188/jea.JE20110075]; Sonderman JS, 2012, AM J EPIDEMIOL, V176, P615, DOI 10.1093/aje/kws141; Ministry of Health Labour and Welfare, 2005, REP NAT HLTH NUTR SU; Yoshimura N, OSTEOPOROS IN PRESS	22	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	NOV	2015	26	11					2597	2605		10.1007/s00198-015-3184-0		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CT8CG	WOS:000363042000006		
J	Miyakoshi, N; Hongo, M; Kobayashi, T; Abe, T; Abe, E; Shimada, Y				Miyakoshi, N.; Hongo, M.; Kobayashi, T.; Abe, T.; Abe, E.; Shimada, Y.			Improvement of spinal alignment and quality of life after corrective surgery for spinal kyphosis in patients with osteoporosis: a comparative study with non-operated patients	OSTEOPOROSIS INTERNATIONAL			English	Article						Kyphosis; Osteoporosis; Posterior lumbar interbody fusion; Quality of life; Spinal instrumentation	LOW-BACK-PAIN; PROXIMAL JUNCTIONAL KYPHOSIS; 36-ITEM SHORT-FORM; THORACIC KYPHOSIS; POSTMENOPAUSAL OSTEOPOROSIS; RADIOGRAPHIC PARAMETERS; DEFORMITY PATIENTS; EXTENSOR STRENGTH; NATURAL-HISTORY; ADULT SCOLIOSIS	This study evaluated changes in spinal alignment and quality of life (QOL) after corrective spinal surgery for patients with postmenopausal osteoporosis and spinal kyphosis. Spinal global alignment and QOL were significantly improved after corrective spinal surgery but did not reach the level of non-operated controls. Introduction With the increased aging of society, the demand for corrective spinal instrumentation for spinal kyphosis in osteoporotic patients is increasing. However, previous studies have not focused on the improvement of quality of life (QOL) after corrective spinal surgery in patients with osteoporosis, compared to non-operated control patients. The purposes of this study were thus to evaluate changes in spinal alignment and QOL after corrective spinal instrumentation for patients with osteoporosis and spinal kyphosis and to compare these results with non-operated patients. Methods Participants comprised 39 patients with postmenopausal osteoporosis >= 50 years old who underwent corrective spinal surgery using multilevel posterior lumbar interbody fusion (PLIF) for symptomatic thoracolumbar or lumbar kyphosis, and 82 age-matched patients with postmenopausal osteoporosis without prevalent vertebral fractures. Spinopelvic parameters were evaluated with standing lateral spine radiography, and QOL was evaluated with the Japanese Osteoporosis QOL Questionnaire (JOQOL), SF-36, and Roland-Morris Disability Questionnaire (RDQ). Results Lumbar kyphosis angle, sagittal vertical axis, and pelvic tilt were significantly improved postoperatively. QOL evaluated with all three questionnaires also significantly improved after 6 months postoperatively, particularly in domain and subscale scores for pain and general/mental health. However, these radiographic parameters, total JOQOL score, SF-36 physical component summary score, and RDQ score were significantly inferior compared with non-operated controls. Conclusions The results indicate that spinal global alignment and QOL were significantly improved after corrective spinal surgery using multilevel PLIF for patients with osteoporosis and spinal kyphosis but did not reach the level of non-operated controls.	[Miyakoshi, N.; Hongo, M.; Shimada, Y.] Akita Univ, Grad Sch Med, Dept Orthoped Surg, Akita 0108543, Japan; [Kobayashi, T.; Abe, T.; Abe, E.] Akita Kousei Med Ctr, Dept Orthoped Surg, Akita 0110948, Japan	Miyakoshi, N (reprint author), Akita Univ, Grad Sch Med, Dept Orthoped Surg, 1-1-1 Hondo, Akita 0108543, Japan.	miyakosh@doc.med.akita-u.ac.jp					DeWald CJ, 2006, SPINE, V31, pS144, DOI 10.1097/01.brs.0000236893.65878.39; Mika A, 2005, SPINE, V30, P241, DOI 10.1097/01.brs.0000150521.10071.df; Miyakoshi N, 2010, TOHOKU J EXP MED, V221, P53, DOI 10.1620/tjem.221.53; Glassman SD, 2005, SPINE, V30, P2024, DOI 10.1097/01.brs.0000179086.30449.96; Suzuki T, 2013, J SPINAL DISORD TECH, V26, pE170, DOI 10.1097/BSD.0b013e318286fc18; Pekmezci M, 2009, SPINE, V34, P813, DOI 10.1097/BRS.0b013e3181851ba6; Kumamoto K, 2010, J BONE MINER METAB, V28, P1, DOI 10.1007/s00774-009-0125-z; Martin AR, 2002, BONE, V31, P32, DOI 10.1016/S8756-3282(02)00787-1; Roux C, 2010, J BONE MINER RES, V25, P362, DOI 10.1359/jbmr.090727; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Hongo M, 2012, OSTEOPOROSIS INT, V23, P1029, DOI 10.1007/s00198-011-1624-z; Kuroda T, 2009, SPINE, V34, P1984, DOI 10.1097/BRS.0b013e3181b0c97a; Miyakoshi N, 2007, OSTEOPOROSIS INT, V18, P1397, DOI 10.1007/s00198-007-0383-3; Lafage V, 2009, SPINE, V34, pE599, DOI 10.1097/BRS.0b013e3181aad219; Sinaki M, 1996, AM J PHYS MED REHAB, V75, P370, DOI 10.1097/00002060-199609000-00013; Patel AA, 2007, J AM ACAD ORTHOP SUR, V15, P126; Schwab FJ, 2002, SPINE, V27, P387, DOI 10.1097/00007632-200202150-00012; Jacobs JM, 2006, SPINE, V31, pE203, DOI 10.1097/01.brs.0000206367.57918.3c; Joseph SA, 2009, J AM ACAD ORTHOP SUR, V17, P378; Cockerill W, 2000, ANN RHEUM DIS, V59, P368, DOI 10.1136/ard.59.5.368; Randell AG, 1998, J RHEUMATOL, V25, P1171; Miyakoshi N, 2003, OSTEOPOROSIS INT, V14, P1007, DOI 10.1007/s00198-003-1510-4; Schwab F, 2010, SPINE, V35, P2224, DOI 10.1097/BRS.0b013e3181ee6bd4; Ryan SD, 1997, J AM GERIATR SOC, V45, P1479; Baron EM, 2006, SPINE, V31, pS106, DOI 10.1097/01.brs.0000232713.69342.df; Cho SK, 2014, EUR SPINE J, V23, P2726, DOI 10.1007/s00586-014-3531-4; Lau D, 2014, SPINE, V39, P2093, DOI 10.1097/BRS.0000000000000627; Lips P, 1997, OSTEOPOROSIS INT, V7, P36, DOI 10.1007/BF01623457; Miyakoshi N, 2011, J SPINE RES, V2, P337; Miyakoshi N, 2012, J E JPN ORTHOP TRAUM, V24, P62; Miyakoshi N, 2012, OSTEOPOROSIS, P103; Orimo Hajime, 2012, Arch Osteoporos, V7, P3; ROLAND M, 1983, SPINE, V8, P145, DOI 10.1097/00007632-198303000-00005; Satoh K, 1988, CONT ORTHOP, V16, P23; Savage Jason W, 2014, Global Spine J, V4, P287, DOI 10.1055/s-0034-1394126; Takahashi H, 2001, J JPN SOC BONE MINER, V18, P85; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	37	1	1	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	NOV	2015	26	11					2657	2664		10.1007/s00198-015-3163-5		8	Endocrinology & Metabolism	Endocrinology & Metabolism	CT8CG	WOS:000363042000013		
J	Nakamura, T; Ito, M; Hashimoto, J; Shinomiya, K; Asao, Y; Katsumata, K; Hagino, H; Inoue, T; Nakano, T; Mizunuma, H				Nakamura, T.; Ito, M.; Hashimoto, J.; Shinomiya, K.; Asao, Y.; Katsumata, K.; Hagino, H.; Inoue, T.; Nakano, T.; Mizunuma, H.		MOVEST Study Grp	Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis	OSTEOPOROSIS INTERNATIONAL			English	Article						Ibandronate; MOVEST study; Oral dosing; Osteoporosis	BONE-MINERAL DENSITY; LONG-TERM EXTENSION; ONCE-MONTHLY IBANDRONATE; DAILY DOSAGE REGIMEN; POSTMENOPAUSAL OSTEOPOROSIS; INVOLUTIONAL OSTEOPOROSIS; WEEKLY ALENDRONATE; POOLED ANALYSIS; FRACTURE RISK; DOUBLE-BLIND	The MOVEST study evaluated the efficacy and safety of monthly oral ibandronate versus licensed monthly IV ibandronate in Japanese osteoporotic patients. Relative BMD gains after 12 months were 5.22 % oral and 5.34 % IV, showing non-inferiority of oral to IV ibandronate (primary endpoint). No new safety concerns were identified. Introduction The randomized, phase 3, double-blind MOVEST (Monthly Oral VErsus intravenouS ibandronaTe) study evaluated the efficacy and safety of monthly oral ibandronate versus the licensed monthly intravenous (IV) ibandronate regimen in Japanese patients with osteoporosis. Methods Ambulatory patients aged >= 55 years with primary osteoporosis were randomized to receive oral ibandronate 100 mg/month plus monthly IV placebo, or IV ibandronate 1 mg/month plus monthly oral placebo. The primary endpoint was non-inferiority of oral versus IV ibandronate with respect to bone mineral density (BMD) gains at the lumbar spine after 12 months of treatment. Results Four hundred twenty-two patients were enrolled with 372 patients in the per-protocol set (183 and 189 in the oral and IV ibandronate groups, respectively). The relative change from baseline in lumbar spine BMD values for the oral and IV ibandronate groups, respectively, was 5.22 % (95 % confidence interval [CI] 4.65, 5.80) and 5.34 % (95 % CI 4.78, 5.90). The least squares mean difference between the two groups was -0.23 % (95 % CI -0.97, 0.51), showing non-inferiority of oral ibandronate to IV ibandronate (non-inferiority limit = -1.60). Changes in BMD values at other sites, and bone turnover marker levels in the oral ibandronate group, were comparable with those of the IV group. The safety profile was similar to that previously demonstrated; no new safety concerns were identified. Conclusions This study demonstrated the non-inferiority of oral ibandronate 100 mg/month to IV ibandronate 1 mg/month (licensed dose in Japan) in increasing lumbar spine BMD in Japanese patients with primary osteoporosis.	[Nakamura, T.] Natl Ctr Global Hlth & Med, Tokyo, Japan; [Ito, M.] Nagasaki Univ, Ctr Gender Equal, Nagasaki 852, Japan; [Hashimoto, J.; Shinomiya, K.; Asao, Y.; Katsumata, K.] Chugai Pharmaceut Co Ltd, Tokyo, Japan; [Hagino, H.] Tottori Univ, Fac Med, Sch Hlth Sci, Tottori 680, Japan; [Hagino, H.] Tottori Univ, Fac Med, Rehabil Div, Tottori 680, Japan; [Inoue, T.] Taisho Pharmaceut Co Ltd, Tokyo, Japan; [Nakano, T.] Tamana Cent Hosp, Kumamoto, Japan; [Mizunuma, H.] Hirosaki Univ, Sch Med, Dept Obstet & Gynecol, Hirosaki, Aomori 036, Japan	Hashimoto, J (reprint author), Chugai Pharmaceut Co Ltd, Tokyo, Japan.	hashimotojnk@chugai-pharm.co.jp			Asahi Kasei Pharma Corp.; Astellas Pharma Inc.; Banyu Pharmaceutical Co. Ltd.; Chugai Pharmaceutical Co. Ltd.; Daiichi Sankyo Inc.; Eisai Co. Ltd.; Eli Lilly Japan K.K.; Ono Pharmaceutical Co. Ltd.; Takeda Pharmaceutical Co. Ltd.; Teijin Pharma Ltd.; Mitsubishi Tanabe Pharma Corp.; Pfizer Inc.; Serono Japan Co. Ltd.	T. Nakamura has received research grants and/or consulting fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Banyu Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Inc., Eisai Co. Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd., and belongs to the Japan Ministry of Health, Welfare and Labor as a councilor for hospital administration and social medical insurance. M. Ito has received consulting fees from Chugai Pharmaceutical Co. Ltd. and consulting fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Inc., and Ono Pharmaceutical Co. Ltd. J. Hashimoto, K. Shinomiya, Y. Asao, and K Katsumata are employees of Chugai Pharmaceutical Co. Ltd. H. Hagino has received consulting fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Banyu Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corp., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd. T. Inoue is an employee of Taisho Pharmaceutical Co. Ltd. T. Nakano has received consulting fees from Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Inc., and Teijin Pharma Ltd. H. Mizunuma has received consulting fees from Chugai Pharmaceutical Co. Ltd. and Serono Japan Co. Ltd.	Miller PD, 2012, OSTEOPOROSIS INT, V23, P1747, DOI 10.1007/s00198-011-1773-0; Cotte FE, 2010, OSTEOPOROSIS INT, V21, P145, DOI 10.1007/s00198-009-0930-1; Fukunaga M, 2002, OSTEOPOROSIS INT, V13, P971, DOI 10.1007/s001980200135; Cranney A, 2009, OSTEOPOROSIS INT, V20, P291, DOI 10.1007/s00198-008-0653-8; Emkey R, 2005, CURR MED RES OPIN, V21, P1895, DOI 10.1185/030079905X74862; Ogura Y, 2004, J BONE MINER METAB, V22, P111, DOI 10.1007/s00774-003-0458-y; Sebba AI, 2009, BONE, V44, P423, DOI 10.1016/j.bone.2008.10.052; Reginster JY, 2006, ANN RHEUM DIS, V65, P654, DOI 10.1136/ard.2005.044958; Leslie WD, 2007, J CLIN ENDOCR METAB, V92, P77, DOI 10.1210/jc.2006-1415; Miller PD, 2010, CALCIFIED TISSUE INT, V87, P305, DOI 10.1007/s00223-010-9403-y; Kushida K, 2004, J BONE MINER METAB, V22, P469, DOI 10.1007/s00774-004-0509-z; Shiraki M, 1999, OSTEOPOROSIS INT, V10, P183, DOI 10.1007/s001980050214; Miller PD, 2014, OSTEOPOROSIS INT, V25, P349, DOI 10.1007/s00198-013-2518-z; Eisman JA, 2008, J RHEUMATOL, V35, P488; Shiraki M, 2003, OSTEOPOROSIS INT, V14, P225, DOI 10.1007/s00198-002-1369-9; Bianchi G, 2012, OSTEOPOROSIS INT, V23, P1769, DOI 10.1007/s00198-011-1793-9; Uchida S, 2005, J BONE MINER METAB, V23, P382, DOI 10.1007/s00774-005-0616-5; Kishimoto H, 2006, J BONE MINER METAB, V24, P405, DOI 10.1007/s00774-006-0706-z; Hadji P, 2008, JOINT BONE SPINE, V75, P303, DOI 10.1016/j.jbspin.2007.07.011; Mitchell DY, 2000, J CLIN PHARMACOL, V40, P258, DOI 10.1177/00912700022008928; Orimo H, 2001, J BONE MINER METAB, V19, P331, DOI 10.1007/s007740170001; Delmas PD, 2006, ARTHRITIS RHEUM, V54, P1838, DOI 10.1002/art.21918; Cramer JA, 2005, CURR MED RES OPIN, V21, P1453, DOI 10.1185/030079905X61875; Cooper A, 2006, INT J CLIN PRACT, V60, P896, DOI 10.1111/j.1742-1241.2006.01059.x; Nakamura T, 2013, CALCIFIED TISSUE INT, V93, P137, DOI 10.1007/s00223-013-9734-6; Barrett J, 2004, J CLIN PHARMACOL, V44, P951, DOI 10.1177/0091270004267594; Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325; Hagino H, 2014, BONE, V59, P44, DOI 10.1016/j.bone.2013.10.017; Nakai K, 2014, EUR J DRUG METAB PH, DOI [10.1007/s13318-014-0242-5, DOI 10.1007/S13318-014-0242-5]; Nakamura T, 2007, J BONE MINER RES, V22, pS333	30	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	NOV	2015	26	11					2685	2693		10.1007/s00198-015-3175-1		9	Endocrinology & Metabolism	Endocrinology & Metabolism	CT8CG	WOS:000363042000016		
J	Bone, HG; Dempster, DW; Eisman, JA; Greenspan, SL; McClung, MR; Nakamura, T; Papapoulos, S; Shih, WJ; Rybak-Feiglin, A; Santora, AC; Verbruggen, N; Leung, AT; Lombardi, A				Bone, H. G.; Dempster, D. W.; Eisman, J. A.; Greenspan, S. L.; McClung, M. R.; Nakamura, T.; Papapoulos, S.; Shih, W. J.; Rybak-Feiglin, A.; Santora, A. C.; Verbruggen, N.; Leung, A. T.; Lombardi, A.			Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial (vol 26, pg 699, 2015)	OSTEOPOROSIS INTERNATIONAL			English	Correction									[Bone, H. G.] Michigan Bone & Mineral Clin, Detroit, MI 48236 USA; [Dempster, D. W.] Columbia Univ, New York, NY USA; [Eisman, J. A.] Univ Notre Dame Australia, St Vincents Hosp, Garvan Inst Med Res, Sydney, NSW, Australia; [Eisman, J. A.] UNSW Australia, Sydney, NSW, Australia; [Greenspan, S. L.] Univ Pittsburgh, Pittsburgh, PA USA; [McClung, M. R.] Oregon Osteoporosis Ctr, Portland, OR USA; [Nakamura, T.] Univ Occupat & Environm Hlth, Kitakyushu, Fukuoka 807, Japan; [Papapoulos, S.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Shih, W. J.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; [Rybak-Feiglin, A.; Santora, A. C.; Verbruggen, N.; Leung, A. T.; Lombardi, A.] Merck Sharp & Dohme Corp, Whitehouse Stn, NJ USA; [Bone, H. G.] St Lukes Hosp, Osteoporosis Ctr, Chesterfield, MO USA	Bone, HG (reprint author), Michigan Bone & Mineral Clin, Detroit, MI 48236 USA.	hgbone.md@att.net					Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198-014-2944-6	1	0	0	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	NOV	2015	26	11					2721	2721		10.1007/s00198-015-3274-z		1	Endocrinology & Metabolism	Endocrinology & Metabolism	CT8CG	WOS:000363042000025		
J	Sakaguchi, T; Hamada, Y; Masumoto, K; Taguchi, T				Sakaguchi, Tatsuma; Hamada, Yoshinori; Masumoto, Kouji; Taguchi, Tomoaki		Japanese Study Grp Allied Disorder	Segmental dilatation of the intestine: results of a nationwide survey in Japan	PEDIATRIC SURGERY INTERNATIONAL			English	Article						Segmental dilatation of intestine; Allied disorder of Hirschsprung's disease; Nationwide retrospective cohort survey; Clinical feature; Diagnostic criteria	ILEUM; COLON	To clarify the status of segmental dilatation of the intestine (SD) using a nationwide retrospective cohort survey. Supported by the Ministry of Health, Labour and Welfare in Japan, preliminary questionnaires requesting the numbers of SD cases from 2000 to 2009 were sent to 161 Japanese major institutes of pediatric surgery and gastroenterology. We present the results of our analysis of the data from secondary questionnaires. Twenty-eight cases of SD were reported, including 19 males and 9 females. The average gestational age was 30.2 weeks and the average birth weight was 2.319 g. The period of onset was neonatal in 18 cases and infancy in 6 cases, including 7 cases diagnosed prenatally. The dilated segment was ileum in 14 cases and colon in 10 cases, and symptoms included abdominal distention, vomiting, and chronic constipation. Concurrent intestinal malformation such as malrotation, intestinal atresia, and anal atresia were present in 4 cases and 27 of 28 cases were successfully treated by surgical resection. Histologically, abnormal muscle layers were found in three cases and ectopic tissue in two cases. We determined the clinical features of SD based on data from 28 cases occurring over 10 years.	[Sakaguchi, Tatsuma; Hamada, Yoshinori] Kansai Med Univ, Dept Surg, Hirakata, Osaka, Japan; [Masumoto, Kouji] Univ Tsukuba, Fac Med, Dept Pediat Surg, Tsukuba, Ibaraki, Japan; [Taguchi, Tomoaki] Kyushu Univ, Grad Sch Med Sci, Dept Pediat Surg, Higashi Ku, Fukuoka 812, Japan	Sakaguchi, T (reprint author), Kansai Med Univ, Dept Surg, 2-5-1 Shimmachi, Hirakata, Osaka, Japan.	sakaguct@hirakata.kmu.ac.jp			Ministry of Health, Labor Sciences Research Grants for Research on intractable disease [H23-042, H24-037, H26-045]	This study was partially supported by a grant from The Ministry of Health, Labor Sciences Research Grants for Research on intractable disease (H23-042, H24-037, H26-045).	Masumoto K, 2008, J PEDIATR GASTR NUTR, V46, P602, DOI 10.1097/MPG.0b013e31815faa76; Waters KJ, 2007, J ULTRAS MED, V26, P1251; SWENSON O, 1959, AM J SURG, V97, P734, DOI 10.1016/0002-9610(59)90338-1; Kobayashi T, 2007, SURG TODAY, V37, P1102, DOI 10.1007/s00595-007-3526-4; Katsura S, 2011, SURG TODAY, V41, P406, DOI 10.1007/s00595-010-4257-5; Taguchi T, 2014, PEDIATR SURG INT, V30, P815, DOI 10.1007/s00383-014-3542-6; Eradi B, 2005, PEDIATR SURG INT, V21, P405, DOI 10.1007/s00383-004-1345-x; Mahadevaiah SA, 2011, J PEDIATR SURG, V46, pE1, DOI 10.1016/j.jpedsurg.2010.10.024; Ben Brahim M, 2006, J PEDIATR SURG, V41, P1130, DOI 10.1016/j.jpedsurg.2006.02.027; Daher P, 2007, EUR J PEDIATR SURG, V17, P289, DOI 10.1055/s-2007-965535; BALIK E, 1993, EUR J PEDIATR SURG, V3, P118, DOI 10.1055/s-2008-1063526; Fang Shiuh-Bin, 2000, Acta Paediatrica Taiwanica, V41, P93; Okada T, 2010, J PEDIATR SURG, V45, P11; Porecca A, 2002, J PEDIATR SURG, V37, P1506	14	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-0358	1437-9813		PEDIATR SURG INT	Pediatr. Surg. Int.	NOV	2015	31	11					1073	1076		10.1007/s00383-015-3788-7		4	Pediatrics; Surgery	Pediatrics; Surgery	CT8BO	WOS:000363040200011		
J	Takahashi, T; Okazaki, T; Yamataka, A; Uchida, E				Takahashi, Tsubasa; Okazaki, Tadaharu; Yamataka, Atsuyuki; Uchida, Eiji			Usefulness of Kent retractor and lifting hook for Nuss procedure	PEDIATRIC SURGERY INTERNATIONAL			English	Article						Pectus excavatum; Sternum elevation; Lifting hook; Kent retractor	MINIMALLY INVASIVE REPAIR; PECTUS EXCAVATUM; COMPLICATIONS; CHEST	Although the Nuss procedure for pectus excavatum has been widely employed, a variety of complications have been reported. The most dangerous complication is cardiac injury from the insertion of the introducer. To eliminate these complications, we present a sternum elevating technique using a Kent retractor and a lifting hook.	[Takahashi, Tsubasa] Musashi Kosugi Hosp, Nippon Med Sch, Dept Pediat Surg, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan; [Okazaki, Tadaharu] Juntendo Univ, Urayasu Hosp, Dept Pediat Surg, Chiba, Japan; [Yamataka, Atsuyuki] Juntendo Univ, Sch Med, Dept Pediat Gen & Urogenital Surg, Tokyo 113, Japan; [Uchida, Eiji] Nippon Med Sch, Dept Surg, Tokyo 113, Japan	Takahashi, T (reprint author), Musashi Kosugi Hosp, Nippon Med Sch, Dept Pediat Surg, Nakahara Ku, 1-396 Kosugi Machi, Kawasaki, Kanagawa 2118533, Japan.	tsubasa1215@nms.ac.jp					Nasr A, 2010, J PEDIATR SURG, V45, P880, DOI 10.1016/j.jpedsurg.2010.02.012; Johnson WR, 2013, ANN THORAC SURG, V95, P1109, DOI 10.1016/j.athoracsur.2012.10.016; Tedde ML, 2012, EUR J CARDIO-THORAC, V42, P890, DOI 10.1093/ejcts/ezs442; Kim D, 2014, ANN THORAC SURG, V98, P734, DOI 10.1016/j.athoracsur.2013.12.077; Hebra A, 2000, J PEDIATR SURG, V35, P252, DOI 10.1016/S0022-3468(00)90019-8; Takagi S, 2012, PEDIATR SURG INT, V28, P623, DOI 10.1007/s00383-012-3087-5; Moss RL, 2001, J PEDIATR SURG, V36, P155, DOI 10.1053/jpsu.2001.20039; Park HJ, 2010, J THORAC CARDIOV SUR, V139, P379, DOI 10.1016/j.jtcvs.2009.09.003; Castellani C, 2008, PEDIATR SURG INT, V24, P659, DOI 10.1007/s00383-008-2106-z; Nuss D, 1998, J PEDIATR SURG, V33, P545, DOI 10.1016/S0022-3468(98)90314-1; Dean C, 2012, SURG RADIOL ANAT, V34, P573, DOI 10.1007/s00276-012-0938-7; Yoshida A, 2013, J PEDIATR SURG, V48, P771, DOI 10.1016/j.jpedsurg.2012.11.036; Hebra A, 2001, J PEDIATR SURG, V36, P1266, DOI 10.1053/jpsu.2001.25791	13	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-0358	1437-9813		PEDIATR SURG INT	Pediatr. Surg. Int.	NOV	2015	31	11					1103	1105		10.1007/s00383-015-3764-2		3	Pediatrics; Surgery	Pediatrics; Surgery	CT8BO	WOS:000363040200015		
J	Chen, JM; Kim, HS; Sherman, DK; Hashimoto, T				Chen, Jacqueline M.; Kim, Heejung S.; Sherman, David K.; Hashimoto, Takeshi			Cultural Differences in Support Provision: The Importance of Relationship Quality	PERSONALITY AND SOCIAL PSYCHOLOGY BULLETIN			English	Article						social support provision; caregiving; relationship quality; culture; ethnicity; social support; close relationships	SOCIAL SUPPORT; INTIMATE-RELATIONSHIPS; THEORETICAL PERSPECTIVE; SELF-DISCLOSURE; CLOSE FRIENDS; LIFE EVENTS; STRESS; RESPONSES; SEEKING; COUPLES	Emotional expression is highly valued in individualistic cultures, whereas emotional restraint is prioritized in collectivistic cultures. We hypothesized that high-quality relationships in these cultures would exhibit the forms of support provision congruent with their respective expectations. Study 1 examined support transactions among friends in response to a laboratory stressor and found that objectively judged relationship quality (RQ) more strongly positively predicted emotion-focused support provision behaviors by European Americans than by Asian Americans. Study 2, a questionnaire study, found that self-reported RQ predicted emotion-focused support provision more strongly among European Americans than among Japanese. Study 3 investigated more indirect forms of support and found that RQ more strongly predicted worrying about and monitoring close others enduring stressors and spending time with them without talking about the stressor among Asian Americans compared with European Americans. These findings suggest that RQ is expressed in terms of support provision in culturally normative ways.	[Chen, Jacqueline M.] Univ Calif Irvine, Irvine, CA 92617 USA; [Kim, Heejung S.; Sherman, David K.] Univ Calif Santa Barbara, Santa Barbara, CA 93106 USA; [Hashimoto, Takeshi] Shizuoka Univ, Shizuoka 4228529, Japan	Chen, JM (reprint author), Univ Calif Irvine, Dept Psychol & Social Behav, 4314 Social & Behav Sci Gateway, Irvine, CA 92617 USA.	j.chen@uci.edu			NSF [BCS-1124552]; UC Davis Chancellor's Postdoctoral Fellowship	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by an NSF grant (BCS-1124552) to H.S.K. and D.K.S. and a UC Davis Chancellor's Postdoctoral Fellowship to J.M.C.	American Psychiatric Association, 2007, MENT HLTH AS AM PAC; Kim HS, 2008, AM PSYCHOL, V63, P518, DOI 10.1037/0003-066X; Funk JL, 2007, J FAM PSYCHOL, V21, P572, DOI 10.1037/0893-3200.21.4.572; MARGOLIN G, 1988, J CONSULT CLIN PSYCH, V56, P24, DOI 10.1037/0022-006X.56.1.24; Tsai JL, 2006, J PERS SOC PSYCHOL, V90, P288, DOI 10.1037/0022-3514.90.2.288; GOTTMAN JM, 1992, J PERS SOC PSYCHOL, V63, P221, DOI 10.1037/0022-3514.63.2.221; Endo Y, 2000, PERS SOC PSYCHOL B, V26, P1571, DOI 10.1177/01461672002612011; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; ARON A, 1992, J PERS SOC PSYCHOL, V63, P596, DOI 10.1037//0022-3514.63.4.596; Kim HS, 2010, P NATL ACAD SCI USA, V107, P15717, DOI 10.1073/pnas.1010830107; Parks MR, 1996, J SOC PERS RELAT, V13, P85, DOI 10.1177/0265407596131005; COBB S, 1976, PSYCHOSOM MED, V38, P300; Butler EA, 2007, EMOTION, V7, P30, DOI 10.1037/1528-3542.7.1.30; Collins NL, 2000, J PERS SOC PSYCHOL, V78, P1053, DOI 10.1037//0022-3514.78.6.1053; Chen JM, 2012, PERS SOC PSYCHOL B, V38, P3, DOI 10.1177/0146167211427309; Goodwin R, 1997, PERS RELATIONSHIP, V4, P85, DOI 10.1111/j.1475-6811.1997.tb00132.x; Gere J, 2013, PERS RELATIONSHIP, V20, P422, DOI 10.1111/pere.12001; Kim HS, 2006, PERS SOC PSYCHOL B, V32, P1595, DOI 10.1177/0146167206291991; Schug J, 2010, PSYCHOL SCI, V21, P1471, DOI 10.1177/0956797610382786; Dibble JL, 2012, PSYCHOL ASSESSMENT, V24, P565, DOI 10.1037/a0026265; Taylor SE, 2004, J PERS SOC PSYCHOL, V87, P354, DOI 10.1037/0022-3514.87.3.354; Kim HS, 2007, J PERS SOC PSYCHOL, V92, P1, DOI 10.1037/0022-3514.92.1.1; Collins NL, 2004, J PERS SOC PSYCHOL, V87, P363, DOI 10.1037/0022-3514.87.3.363; DUNKELSCHETTER C, 1987, J PERS SOC PSYCHOL, V53, P71, DOI 10.1037//0022-3514.53.1.71; FLEMING R, 1982, J HUM STRESS, V8, P14; Haines VA, 1996, J HEALTH SOC BEHAV, V37, P252, DOI 10.2307/2137295; KOJIMA H, 1984, AM PSYCHOL, V39, P972; CORDOVA JV, 1993, J ABNORM PSYCHOL, V102, P559, DOI 10.1037/0021-843X.102.4.559; Kim H, 1999, J PERS SOC PSYCHOL, V77, P785, DOI 10.1037/0022-3514.77.4.785; Mojaverian T, 2013, PERS SOC PSYCHOL B, V39, P88, DOI 10.1177/0146167212465319; Feeney BC, 2001, J PERS SOC PSYCHOL, V80, P972, DOI 10.1037/0022-3514.80.6.972; Butler EA, 2009, J CROSS CULT PSYCHOL, V40, P510, DOI 10.1177/0022022109332845; RUSBULT CE, 1986, J PERS SOC PSYCHOL, V50, P744, DOI 10.1037/0022-3514.50.4.744; Karney BR, 1997, J PERS SOC PSYCHOL, V72, P1075, DOI 10.1037/0022-3514.72.5.1075; Giles LC, 2005, J EPIDEMIOL COMMUN H, V59, P574, DOI 10.1136/jech.2004.025429; Gurung RAR, 1997, PERS RELATIONSHIP, V4, P319, DOI 10.1111/j.1475-6811.1997.tb00149.x; Lin N, 1999, J HEALTH SOC BEHAV, V40, P344, DOI 10.2307/2676330; Taylor SE, 2007, PSYCHOL SCI, V18, P831, DOI 10.1111/j.1467-9280.2007.01987.x; Matsumoto D, 2008, J CROSS CULT PSYCHOL, V39, P55, DOI 10.1177/0022022107311854; Gottman JM, 1998, J MARRIAGE FAM, V60, P5, DOI 10.2307/353438; WETHINGTON E, 1986, J HEALTH SOC BEHAV, V27, P78, DOI 10.2307/2136504; Gable SL, 2006, J PERS SOC PSYCHOL, V91, P904, DOI 10.1037/0022-3514.91.5.904; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CHEN GM, 1995, J CROSS CULT PSYCHOL, V26, P84, DOI 10.1177/0022022195261006; COUSINS SD, 1989, J PERS SOC PSYCHOL, V56, P124, DOI 10.1037//0022-3514.56.1.124; Feeney BC, 2015, PERS SOC PSYCHOL REV, V19, P113, DOI 10.1177/1088868314544222; Gottman J. M., 1993, HDB EMOTIONS, P475; Hashimoto T., 2012, J CROSS CULTURAL PSY, V42, P527; LAFROMBOISE T, 1993, PSYCHOL BULL, V114, P395, DOI 10.1037//0033-2909.114.3.395; Leong F T, 2001, Ment Health Serv Res, V3, P201, DOI 10.1023/A:1013177014788; MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037/0033-295X.98.2.224; Mojaverian T., 2013, FRONT PSYCHOL, V3, P1; Sarason B. R., 1997, HDB PERSONAL RELATIO, P547; Solky-Butzel J., 2005, PERS RELATIONSHIP, V12, P146, DOI DOI 10.1111/J.1350-4126.2005.00106.X; Taylor S. E., 2007, OXFORD HDB HLTH PSYC, P145; You HS, 2000, J CROSS CULT PSYCHOL, V31, P528, DOI 10.1177/0022022100031004006; Yuki M, 2003, SOC PSYCHOL QUART, V66, P166, DOI 10.2307/1519846	57	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0146-1672	1552-7433		PERS SOC PSYCHOL B	Pers. Soc. Psychol. Bull.	NOV	2015	41	11					1575	1589		10.1177/0146167215602224		15	Psychology, Social	Psychology	CT7KT	WOS:000362994300009		
J	Hardigan, T; Spitler, K; Matsumoto, T; Carrillo-Sepulveda, MA				Hardigan, Trevor; Spitler, Kathryn; Matsumoto, Takayuki; Carrillo-Sepulveda, Maria Alicia			Activation of Toll-like receptor 3 increases mouse aortic vascular smooth muscle cell contractility through ERK1/2 pathway	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY			English	Article						Aorta; ERK1/2; Toll-like receptor 3; Vascular smooth muscle; Vasoconstriction	HUMAN MESANGIAL CELLS; PREECLAMPSIA-LIKE SYMPTOMS; DOUBLE-STRANDED-RNA; PHENOTYPIC MODULATION; ARTERIAL STIFFNESS; MESENTERIC-ARTERY; HYPERTENSIVE-RATS; INNATE IMMUNITY; ANGIOTENSIN-II; MAP-KINASES	Activation of Toll-like receptor 3 (TLR3), a pattern recognition receptor of the innate immune system, is associated with vascular complications. However, whether activation of TLR3 alters vascular contractility is unknown. We, therefore, hypothesized that TLR3 activation augments vascular contractility and activates vascular smooth muscle cell (VSMC) contractile apparatus proteins. Male mice were treated with polyinosinic-polycytidylic acid (Poly I:C group, 14 days), a TLR3 agonist; control mice received saline (vehicle, 14 days). At the end of protocol, blood pressure was measured by tail cuff method. Aortas were isolated and assessed for contractility experiments using a wire myograph. Aortic protein content was used to determine phosphorylated/total interferon regulatory factor 3 (IRF3), a downstream target of TLR3 signaling, and ERK1/2 using Western blot. We investigated the TLR3/IRF3/ERK1/2 signaling pathway and contractile-related proteins such as phosphorylated/total myosin light chain (MLC) and caldesmon (CaD) in aortic VSMC primary cultures. Poly I:C-treated mice exhibited (vs. vehicle-treated mice) (1) elevated systolic blood pressure. Moreover, Poly I:C treatment (2) enhanced aortic phenylephrine-induced maximum contraction, which was suppressed by PD98059 (ERK1/2 inhibitor), and (3) increased aortic levels of phosphorylated IRF3 and ERK1/2. Stimulation of mouse aortic VSMCs with Poly I:C resulted in increased phosphorylation of IRF3, ERK1/2, MLC, and CaD. Inhibition of ERK1/2 abolished Poly I:C-mediated phosphorylation of MLC and CaD. Our data provide functional evidence for the role of TLR3 in vascular contractile events, suggesting TLR3 as a potential new therapeutic target in vascular dysfunction and regulation of blood pressure.	[Hardigan, Trevor; Carrillo-Sepulveda, Maria Alicia] Georgia Regents Univ, Dept Physiol, Augusta, GA USA; [Spitler, Kathryn] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; [Matsumoto, Takayuki] Hoshi Univ, Inst Med Chem, Dept Physiol & Morphol, Shinagawa Ku, Tokyo 142, Japan	Carrillo-Sepulveda, MA (reprint author), New York Inst Technol, Coll Med, Dept Biomed Sci, Northern Blvd, Old Westbury, NY 11568 USA.	mcarrill@nyit.edu			American Heart Association [13POST14690026]	This work was supported by research grant from the American Heart Association to M.A.C.S. (13POST14690026).	Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Cole JE, 2011, P NATL ACAD SCI USA, V108, P2372, DOI 10.1073/pnas.1018515108; Bomfim GF, 2012, CLIN SCI, V122, P535, DOI 10.1042/CS20110523; Tinsley JH, 2009, AM J HYPERTENS, V22, P1314, DOI 10.1038/ajh.2009.185; Pirie FJ, 2005, TISSUE ANTIGENS, V66, P125, DOI 10.1111/j.1399-0039.2005.00454.x; Linder AE, 2005, J CARDIOVASC PHARM, V46, P438, DOI 10.1097/01.fjc.0000175879.14994.63; Ulu N, 2010, BRIT J PHARMACOL, V161, P1301, DOI 10.1111/j.1476-5381.2010.00829.x; Giachini FR, 2010, HYPERTENSION, V55, P172, DOI 10.1161/HYPERTENSIONAHA.109.140459; Aizawa-Yashiro T, 2013, PEDIATR RES, V73, P180, DOI 10.1038/pr.2012.165; Merkle M, 2012, CELL MOL IMMUNOL, V9, P334, DOI 10.1038/cmi.2012.3; Edfeldt K, 2002, CIRCULATION, V105, P1158, DOI 10.1161/01.CIR.0000012489.17433.31; Chatterjee P, 2011, HYPERTENSION, V58, P489, DOI 10.1161/HYPERTENSIONAHA.111.172114; Merkle M, 2011, AM J PHYSIOL-RENAL, V301, pF57, DOI 10.1152/ajprenal.00083.2011; George PM, 2012, BIOCHEM BIOPH RES CO, V426, P486, DOI 10.1016/j.bbrc.2012.08.106; Liu Y, 2008, INVEST OPHTH VIS SCI, V49, P3336, DOI 10.1167/iovs.07-0972; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611; Ishimoto T, 2013, NEPHROL DIAL TRANSPL, V28, P1439, DOI 10.1093/ndt/gfs543; Hansen PBL, 2013, ACTA PHYSIOL, V207, P690, DOI 10.1111/apha.12070; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Svenningsen P, 2013, ACTA PHYSIOL, V207, P536, DOI 10.1111/apha.12047; Assmann TS, 2014, EUR J ENDOCRINOL, V170, P519, DOI 10.1530/EJE-13-0963; Matsumoto T, 2009, AM J PHYSIOL-HEART C, V296, pH1388, DOI 10.1152/ajpheart.00043.2009; Moore TC, 2013, FEBS LETT, V587, P3014, DOI 10.1016/j.febslet.2013.07.025; Yang HY, 2014, AM J NEPHROL, V40, P131, DOI 10.1159/000365934; Mitchell GF, 2014, HYPERTENSION, V64, P13, DOI 10.1161/HYPERTENSIONAHA.114.00921; Barton M, 2010, PFLUG ARCH EUR J PHY, V460, P825, DOI 10.1007/s00424-010-0860-y; Yamashita M, 2013, J INNATE IMMUN, V5, P231, DOI 10.1159/000345255; Safar ME, 2012, CURR HYPERTENS REP, V14, P339, DOI 10.1007/s11906-012-0272-9; Ahmad U, 2010, J IMMUNOL, V185, P1283, DOI 10.4049/jimmunol.0902283; Matsumoto T, 2011, AM J PHYSIOL-HEART C, V301, pH409, DOI 10.1152/ajpheart.00084.2011; Jordao MT, 2011, J VASC RES, V48, P513, DOI 10.1159/000329590; Wu LDH, 2012, METABOLISM, V61, P1633, DOI 10.1016/j.metabol.2012.04.015; Yamamoto M, 2002, J IMMUNOL, V169, P6668; Yang X, 2006, AM J PHYSIOL-HEART C, V291, pH2334, DOI 10.1152/ajpheart.00252.2006; Hansson GK, 2011, P NATL ACAD SCI USA, V108, P2637, DOI 10.1073/pnas.1019722108; Schmidt L, 2015, PFLUG ARCH EUR J PHY, V467, P2361, DOI 10.1007/s00424-015-1688-2; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Ishibashi M, 2013, ATHEROSCLEROSIS, V229, P52, DOI 10.1016/j.atherosclerosis.2013.03.035; Trott DW, 2014, HYPERTENSION, V64, P1108, DOI 10.1161/HYPERTENSIONAHA.114.04147; Storkebaum E, 2011, ACTA PHYSIOL, V203, P61, DOI 10.1111/j.1748-1716.2011.02333.x; Lundberg AM, 2013, CARDIOVASC RES, V99, P364, DOI 10.1093/cvr/cvt033; Vanhoutte PM, 2009, ACTA PHYSIOL, V196, P193, DOI 10.1111/j.1748-1716.2009.01964.x; Choi H, 2011, J AM SOC HYPERTENS, V5, P154, DOI 10.1016/j.jash.2011.02.005; Wornle M, 2009, NEPHRON EXP NEPHROL, V113, pE57, DOI 10.1159/000228409; Ishida K, 2012, PFLUG ARCH EUR J PHY, V463, P593, DOI 10.1007/s00424-012-1088-9; Ishida K, 2012, ACTA PHYSIOL, V205, P255, DOI 10.1111/j.1748-1716.2011.02403.x; Carrillo-Sepulveda MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061982; Carrillo-Sepulveda MA, 2010, MOL CELL BIOCHEM, V341, P279, DOI 10.1007/s11010-010-0459-9; Carrillo-Sepulveda MA, 2014, CELL PHYSIOL BIOCHEM, V34, P1497, DOI 10.1159/000366354; Chatterjee P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041884; Gao X, 2015, ACTA PHYSIOL, V213, P268, DOI 10.1111/apha.12399; McCall KD, 2015, ENDOCRINOLOGY, V156, P453, DOI 10.1210/en.2013-2006; Spirig R, 2012, CARDIOL RES PRACT, V2012, DOI 10.1155/2012/181394; Spitler KM, 2014, HYPERTENSION, V63, pE40, DOI 10.1161/HYPERTENSIONAHA.113.02558; Svenson J, 2014, AM J MED SCI, V348, P492, DOI 10.1097/MAJ.0000000000000339	55	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0031-6768	1432-2013		PFLUG ARCH EUR J PHY	Pflugers Arch.	NOV	2015	467	11					2375	2385		10.1007/s00424-015-1697-1		11	Physiology	Physiology	CT2XD	WOS:000362668000012		
J	Hardigan, T; Spitler, K; Matsumoto, T; Carrillo-Sepulveda, MA				Hardigan, Trevor; Spitler, Kathryn; Matsumoto, Takayuki; Carrillo-Sepulveda, Maria Alicia			Activation of Toll-like receptor 3 increases mouse aortic vascular smooth muscle cell contractility through ERK1/2 pathway (vol 467, pg 2375, 2015)	PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY			English	Correction									[Hardigan, Trevor; Carrillo-Sepulveda, Maria Alicia] Georgia Regents Univ, Dept Physiol, Augusta, GA USA; [Spitler, Kathryn] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; [Matsumoto, Takayuki] Hoshi Univ, Inst Med Chem, Dept Physiol & Morphol, Shinagawa Ku, Tokyo 142, Japan	Carrillo-Sepulveda, MA (reprint author), New York Inst Technol, Dept Biomed Sci, Coll Med, Northern Blvd, Old Westbury, NY 11568 USA.	mcarrill@nyit.edu					Hardigan T, 2015, PFLUG ARCH EUR J PHY, V467, P2375, DOI 10.1007/s00424-015-1697-1	1	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0031-6768	1432-2013		PFLUG ARCH EUR J PHY	Pflugers Arch.	NOV	2015	467	11					2387	2387		10.1007/s00424-015-1706-4		1	Physiology	Physiology	CT2XD	WOS:000362668000013		
J	da Silva, JAT; Dobranszki, J; Zeng, SJ; Winarto, B; Lennon, AM; Jaufeerally-Fakim, Y; Christopher, DA				da Silva, Jaime A. Teixeira; Dobranszki, Judit; Zeng, Songjun; Winarto, Budi; Lennon, Adrian M.; Jaufeerally-Fakim, Yasmina; Christopher, David A.			Genetic transformation and molecular research in Anthurium: progress and prospects	PLANT CELL TISSUE AND ORGAN CULTURE			English	Review						Acetosyringone; Agrobacterium tumefaciens; Molecular breeding; Novel traits; Promoters; Xanthomonas	AXONOPODIS PV. DIEFFENBACHIAE; TRANSGENIC ANTHURIUM; ANDRAEANUM HORT.; SPATHE COLOR; AGROBACTERIUM-TUMEFACIENS; BIOSYNTHETIC-PATHWAY; TISSUE-CULTURES; BLIGHT PATHOGEN; VACUOLAR PH; EXPRESSION	Although Anthurium is an attractive and commercially popular ornamental plant, its genetic enhancement has lagged behind that of other ornamental crops. There are several agronomically important traits in need of improvement. These include novel flower colors and morphologies, increased shelf and vase lives, and resistance to bacterial blight (Xanthomonas axonopodis pv. dieffenbachiae), burrowing nematodes and abiotic stresses. The production of transgenic Anthuriums is critical because the conventional breeding of a cultivar with beneficial traits typically requires 8-10 years. This review evaluates the problems, challenges and progress associated with developing molecular markers for Anthurium and in genetically transforming this ornamental. Recent improvements have hastened the tissue culture and regeneration of transgenic plants primarily using Agrobacterium-based methods. Promoter analyses have focused on constitutive and tissue-enhanced gene expression with the green fluorescent protein being a more reliable reporter than beta-glucuronidase. The development of molecular markers assists with phylogenetic analyses and PCR-based markers such as RAPD, SSR, SPAR, ISSR and AFLP can be used to differentiate cultivars and for genetic fingerprinting. The marker-assisted breeding of Anthurium will become more feasible once available data are used for association to specific traits. Work on the identification of quantitative trait loci for disease resistance and other traits such as flower colour is required and should incorporate new approaches, such as next-generation sequencing technologies. By highlighting the aforementioned bottlenecks and successes in this review, it is expected that the pace of Anthurium genetic improvement will increase with the multifaceted incorporation of focused priorities and new technology advancements.	[Dobranszki, Judit] Univ Debrecen, Res Inst Nyiregyhaza, H-4400 Nyiregyhaza, Hungary; [Zeng, Songjun] Chinese Acad Sci, Key Lab South China Agr Plant Mol Anal & Gene Imp, South China Bot Garden, Guangzhou 510650, Guangdong, Peoples R China; [Winarto, Budi] Indonesian Ornamental Crops Res Inst, Dept Tissue Culture, Pacet Cianjur 43253, West Java, Indonesia; [Lennon, Adrian M.] Univ W Indies, Fac Sci & Technol, Dept Life Sci, St Augustine, Trinid & Tobago; [Jaufeerally-Fakim, Yasmina] Univ Mauritius, Fac Agr, Dept Biotechnol, Reduit, Mauritius; [Christopher, David A.] Univ Hawaii Manoa, Dept Mol Biosci & Bioengn, Honolulu, HI 96822 USA	da Silva, JAT (reprint author), POB 7,Miki Cho Post Off, Ikenobe, Kagawa 7610799, Japan.	jaimetex@yahoo.com; dobranszki@freemail.hu; zengsongjun@scib.ac.cn; budi_winarto67@yahoo.com; adrian.lennon@sta.uwi.edu; yasmina@uom.ac.mu; dchr@hawaii.edu					Alvarez AM, 2006, APSNET FEATURES, DOI [10.1094/APSnetFeature-2006-0206, DOI 10.1094/APSNETFEATURE-2006-0206]; Anais G, 2000, ACTA HORTIC, V508, P135; Andersen O. M., 2006, FLAVONOIDS CHEM BIOC, P471; Kuehnle AR, 2004, HORTSCIENCE, V39, P1327; Collette VE, 2004, PHYSIOL PLANTARUM, V122, P297, DOI 10.1111/j.1399-3054.2004.00402.x; Li CH, 2013, J HORTIC SCI BIOTECH, V88, P208; Xu WJ, 2015, TRENDS PLANT SCI, V20, P176, DOI 10.1016/j.tplants.2014.12.001; Albert NW, 2010, PLANT CELL TISS ORG, V100, P355, DOI 10.1007/s11240-009-9649-0; Avila-Rostant O, 2010, HORTSCIENCE, V45, P1768; GOODRICH J, 1992, CELL, V68, P955, DOI 10.1016/0092-8674(92)90038-E; Paull RE, 2001, POSTHARVEST BIOL TEC, V21, P303, DOI 10.1016/S0925-5214(00)00153-8; KUEHNLE AR, 1991, HORTSCIENCE, V26, P919; Elibox W, 2008, HORTSCIENCE, V43, P787; Donahoo RS, 2013, PHYTOPATHOLOGY, V103, P237, DOI 10.1094/PHYTO-08-12-0191-R; [Anonymous], 2001, BIOTECHNOL AGRIC FOR; Duffy B, 2000, EUR J PLANT PATHOL, V106, P291, DOI 10.1023/A:1008738508853; Ge YY, 2012, BIOCHEM SYST ECOL, V45, P34, DOI 10.1016/j.bse.2012.07.023; Neto JDS, 2014, GENET MOL RES, V13, P4766, DOI 10.4238/2014.July.2.6; Andrade IM, 2009, BOT J LINN SOC, V159, P88, DOI 10.1111/j.1095-8339.2008.00945.x; Elibox W, 2010, SCI HORTIC-AMSTERDAM, V124, P102, DOI 10.1016/j.scienta.2009.12.005; Elibox W, 2008, EUR J PLANT PATHOL, V121, P35, DOI 10.1007/s10658-007-9239-0; Kreps JA, 2002, PLANT PHYSIOL, V130, P2129, DOI 10.1104/pp.008532; [Anonymous], 1998, EC FACT SHEET; Matsumoto TK, 2013, PLANT CELL REP, V32, P443, DOI 10.1007/s00299-012-1376-z; Grotewold E, 2006, ANNU REV PLANT BIOL, V57, P761, DOI 10.1146/annurev.arplant.57.032905.105248; Clark BR, 2012, NAT PROD COMMUN, V7, P747; Gopaulchan D, 2014, PLANTA, V239, P695, DOI 10.1007/s00425-013-2007-9; Spelt C, 2002, PLANT CELL, V14, P2121, DOI 10.1105/tpc.003772; [Anonymous], 2006, J NEMATOL; Chen FC, 1996, J AM SOC HORTIC SCI, V121, P47; Khoodoo MHR, 2005, EUR J PLANT PATHOL, V112, P379, DOI 10.1007/s10658-005-7062-z; Robene-Soustrade I, 2006, APPL ENVIRON MICROB, V72, P1072, DOI 10.1128/AEM.72.2.1072-1078.2006; Nowbuth P, 2005, AFR J BIOTECHNOL, V4, P1189; Ono E, 2006, P NATL ACAD SCI USA, V103, P11075, DOI 10.1073/pnas.0604246103; Fitch MMM, 2011, HORTSCIENCE, V46, P358; IWATA RY, 1985, J AM SOC HORTIC SCI, V110, P383; Quattrocchio F, 2006, PLANT CELL, V18, P1274, DOI 10.1105/tpc.105.034041; Wang JY, 2013, EUPHYTICA, V189, P421, DOI 10.1007/s10681-012-0799-5; Chen FC, 1997, PLANT CELL TISS ORG, V49, P71, DOI 10.1023/A:1005812802655; IWATA RY, 1979, J AM SOC HORTIC SCI, V104, P464; PAULL RE, 1985, J AM SOC HORTIC SCI, V110, P156; Hosein FN, 2012, J AM SOC HORTIC SCI, V137, P263; Katsumoto Y, 2007, PLANT CELL PHYSIOL, V48, P1589, DOI 10.1093/pcp/pcm131; KOBAYASHI RS, 1987, J AM SOC HORTIC SCI, V112, P164; Gopaulchan D, 2013, SCI HORTIC-AMSTERDAM, V153, P1, DOI 10.1016/j.scienta.2013.01.024; Wachsman G, 2010, METHODS MOL BIOL, V655, P47, DOI 10.1007/978-1-60761-765-5_4; Khaithong T, 2007, J NEMATOL, V39, P99; Hayden DM, 2004, PLANT SCI, V166, P779, DOI 10.1016/j.plantsci.2003.11.019; Kuehnle AR, 2004, ACTA HORTIC, P115; KUEHNLE AR, 1991, HORTSCIENCE, V26, P1325; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; da Silva JAT, 2013, J PLANT GROWTH REGUL, V32, P922, DOI 10.1007/s00344-013-9336-6; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; Avila-Rostant O., 2011, TROP AGR TRINIDAD, V88, P10; Buldewo S., 2012, African Journal of Biotechnology, V11, P16737; Buldewo S., 2002, Plant Molecular Biology Reporter, V20, P71, DOI 10.1007/BF02801936; Clark BR, 2014, J AGR FOOD CHEM, V62, P11323, DOI 10.1021/jf502187c; EPPO, 2014, EPPO A2 LIST PESTS R; EPPO (European and Mediterranean Plant Protection Organization), 2009, EPPO B, V39, P393, DOI [10.1111/].1365-2338.2009.02327.x, DOI 10.1111/J.1365-2338.2009.02327.X]; Hu F, 2014, NO HORTIC, V21, P101; Khan Yasin Jeshima, 2010, J PLANT GENET TRANSG, V1, P11; Kuehnle AR, 1996, BREEDING ANTHURIMS H, P168; Kuehnle AR, 2003, AROIDEANA, V26, P120; Kuehnle AR, 1994, BIOTECHNOLOGY AGR FO, V29, P215, DOI 10.1007/978-3-662-09366-515; Li GY, 2013, PLANT BREEDING LAB F, P23, DOI [10.5772/5451, DOI 10.5772/54511]; Li ZY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119027; Dhanya M. K., 2006, Journal of Tropical Agriculture, V44, P74; Matsumoto TK, 1997, BIOTECHNOLOGY AGR FO, V40, P14, DOI 10.1007/978-3-662-03354-8_2; [Anonymous], 1962, PHYSIOL PLANTARUM, DOI DOI 10.1111/J.1399-3054.1962.TB08052.X; Suzuki JY, 2012, AOB PLANTS, DOI [10.1093/aobpla/pls006, DOI 10.1093/A0BPLA/PLS006]; da Silva JAT, 2015, ACTA PHYSIOL PLANT, V37, DOI 10.1007/s11738-015-1909-5; da Silva JAT, 2015, SCI HORTIC-AMSTERDAM, V186, P266, DOI 10.1016/j.scienta.2014.11.024; Teixeira da Silva JA, 2015, J NEGAT RESULTS BIOM, V14, P12, DOI [10.1186/s12952-015-0033-9, DOI 10.1186/S12952-015-0033-9]; Tian DQ, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-827; Venkat SK, 2014, SCI HORTIC-AMSTERDAM, V178, P132, DOI 10.1016/j.scienta.2014.08.017; [王呈丹 Wang Chengdan], 2013, [植物遗传资源学报, Journal of Plant Genetic Resources], V14, P759; Winkel-Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485; Zeng SJ, 2004, FOLIAGE PLANT ARACEA, P48; [张燕 ZHANG Yan], 2009, [激光生物学报, Acta Laser Biology Sinica], V18, P1; Zhao Q., 2010, ELECTRON J BIOTECHN, V13, P1, DOI DOI 10.2225/V0L13-ISSUE5-FULLTEXT-2; Zhou J., 2008, J ANHUI AGR SCI, V36, P3173	81	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0167-6857	1573-5044		PLANT CELL TISS ORG	Plant Cell Tissue Organ Cult.	NOV	2015	123	2					205	219		10.1007/s11240-015-0832-1		15	Biotechnology & Applied Microbiology; Plant Sciences	Biotechnology & Applied Microbiology; Plant Sciences	CT6BQ	WOS:000362896100001		
J	Tsai, YC; Lai, WC; El-Shazly, M; Chiang, SY; Hayashi, KI; Wu, YC; Chang, FR				Tsai, Yu-Chi; Lai, Wan-Chun; El-Shazly, Mohamed; Chiang, Shang-Yu; Hayashi, Ken-Ichiro; Wu, Yang-Chang; Chang, Fang-Rong			A cross-kingdom assay model for evaluating estrogenic activity: application of transgenic Arabidopsis thaliana callus	PLANT CELL TISSUE AND ORGAN CULTURE			English	Article						Arabidopsis thaliana; Callus; Cross-kingdom assay; Estrogenic activity; 17 beta-Estradiol	ENDOCRINE DISRUPTING CHEMICALS; PLANT BIOASSAYS; GENE-EXPRESSION; BREAST-CANCER; PHYTOESTROGENS; SYSTEM; INDUCTION; VERSATILE; DISEASE; HEALTH	Phytoestrogens have attracted attention in the last few decades as potential therapeutic candidates targeting several ailments including osteoporosis and menopausal syndrome. Many herbal preparations possess phytoestrogenic activity without solid evidence due the lack of an easy and feasible assay protocol in evaluating their activity. In 2005, the first report of a cross-kingdom bioassay using transgenic Arabidopsis assay system was published by our group to evaluate the estrogenic activity of potent natural products. In the current investigation, calli induced from the Arabidopsis pER8:GUS line were utilized for the first time to evaluate the estrogenic activity of 17 beta-estradiol. Calli, induced on solid 1DK1 medium, showed significant GUS activity in a dose-dependent manner, and the minimum detectable concentration of 17 beta-estradiol was 0.0001 A mu M. Furthermore, calli from liquid media E (c) 1N1B and E (c) 1/2 1N1B produced by suspension culture exhibited significant sensitivity towards 17 beta-estradiol in a dose-dependent manner. However, calli of E (c) 1NK5, E (c) 1/2 1NK5, E (c) 1DK1, or E (c) 1/2 1DK1 media could not show reliable activity toward GUS expression, which was demonstrated by the irregular fluorometric levels. Calli production avoided gene variation from the sexual generational shift and thus ensured uniformity and accuracy of the results. The optimal methods of transgenic calli induction, production, and estrogenic activity assay were established. This method can be used to investigate new sources of phytoestrogens and to detect environmental estrogenic compounds. This is the first developed protocol specialized in evaluating animal function using plant callus.	[Tsai, Yu-Chi; Lai, Wan-Chun; El-Shazly, Mohamed; Chiang, Shang-Yu; Wu, Yang-Chang; Chang, Fang-Rong] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung 807, Taiwan; [El-Shazly, Mohamed] Ain Shams Univ, Dept Pharmacognosy & Nat Prod Chem, Fac Pharm, Cairo 11566, Egypt; [Hayashi, Ken-Ichiro] Okayama Univ Sci, Dept Biochem, Fac Sci, Okayama 7000005, Japan; [Wu, Yang-Chang] China Med Univ Hosp, Chinese Med Res & Dev Ctr, Taichung 404, Taiwan; [Wu, Yang-Chang] China Med Univ, Sch Chinese Med, Coll Chinese Med, Taichung 404, Taiwan; [Wu, Yang-Chang] China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan; [Chang, Fang-Rong] Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung 807, Taiwan; [Chang, Fang-Rong] Kaohsiung Med Univ, Res Ctr Nat Prod & New Drug, Kaohsiung 807, Taiwan; [Chang, Fang-Rong] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung 807, Taiwan	Chang, FR (reprint author), Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.	yachwu@mail.cmu.edu.tw; aaronfrc@kmu.edu.tw			Ministry of Science and Technology of Taiwan [MOST 101-2325-B-039-004, 102-2628-B-037-003-MY3, MOST 102-2911-I-002-303, MOST 103-2911-I-002-303, MOST 104-2911-I-002-302, MOST 104-2911-I-037-501]; Excellence for Cancer Research Center Grant, Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan [MOHW104-TDU-B-212-124-003]; National Health Research Institutes of Taiwan [NHRI-EX104-10241BI]; Kaohsiung Medical University [KMU-TP103]; Chinese Medicine Research Center, China Medical University, Taiwan (the Ministry of Education)	We thank Prof. Nam-Hai Chua (Laboratory of Plant Molecular Biology, The Rockefeller University, 1230, York Avenue, New York, NY 10065, USA) for the pER8:GFP seeds sharing. We also thank the Institute of the Plant Biology and the Zurich-Basel Plant Science Centre, University of Zurich, Switzerland, for providing seeds of pER8:GUS. We would like to acknowledge the grants from the Ministry of Science and Technology of Taiwan (MOST 101-2325-B-039-004; 102-2628-B-037-003-MY3; MOST 102-2911-I-002-303; MOST 103-2911-I-002-303; MOST 104-2911-I-002-302; MOST 104-2911-I-037-501). This work was also supported by the Excellence for Cancer Research Center Grant, the Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan (MOHW104-TDU-B-212-124-003), National Health Research Institutes of Taiwan (NHRI-EX104-10241BI), and the grant for Health and Welfare Surcharge of Tobacco Products and Kaohsiung Medical University "Aim for the Top Universities Grant", KMU-TP103, and in part from the grant from Chinese Medicine Research Center, China Medical University, Taiwan (the Ministry of Education, the Aim for the Top University Plan).	Lai WC, 2011, J NAT PROD, V74, P1698, DOI 10.1021/np100920q; Engelmann NJ, 2009, PLANT CELL TISS ORG, V98, P147, DOI 10.1007/s11240-009-9547-5; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x; Zheng MY, 1999, PLANT CELL REP, V19, P69, DOI 10.1007/s002990050712; Brand L, 2006, PLANT PHYSIOL, V141, P1194, DOI 10.1104/pp.106.081299; Washburn S, 1999, MENOPAUSE, V6, P7; Chang FR, 2005, J NAT PROD, V68, P971, DOI 10.1021/np050121i; Pennacchio M, 2005, J CHEM ECOL, V31, P1877, DOI 10.1007/s10886-005-5932-7; Chlebowski RT, 2013, JNCI-J NATL CANCER I, V105, P526, DOI 10.1093/jnci/djt043; Padidam M, 2003, CURR OPIN PLANT BIOL, V6, P169, DOI 10.1016/S1369-5266(03)00005-0; Ribnicky DM, 1996, PLANT PHYSIOL, V112, P549; Kovalchuk O, 2003, B ENVIRON CONTAM TOX, V70, P847, DOI 10.1007/s00128-003-0060-y; Legler J, 2002, ENVIRON SCI TECHNOL, V36, P4410, DOI 10.1021/es010323a; Van Patten CL, 2002, J CLIN ONCOL, V20, P1449, DOI 10.1200/JCO.20.6.1449; Hayashi K, 2003, J BIOL CHEM, V278, P23797, DOI 10.1074/jbc.M300299200; Rogers JA, 2013, MOL IMMUNOL, V53, P421, DOI 10.1016/j.molimm.2012.09.013; Ochatt SJ, 2008, PLANT CELL TISS ORG, V93, P133, DOI 10.1007/s11240-008-9351-7; Bae H, 2009, PLANT CELL TISS ORG, V98, P311, DOI 10.1007/s11240-009-9565-3; JEFFERSON RA, 1987, EMBO J, V6, P3901; Cos P, 2003, PLANTA MED, V69, P589, DOI 10.1055/s-2003-41122; Orzechowska M, 2013, PLANT CELL TISS ORG, V112, P263, DOI 10.1007/s11240-012-0232-8; Dixon RA, 2004, ANNU REV PLANT BIOL, V55, P225, DOI 10.1146/annurev.arplant.55.031903.141729; Knasmuller S, 1998, MUTAT RES-GEN TOX EN, V420, P37, DOI 10.1016/S1383-5718(98)00145-4; Mueller SO, 2002, J CHROMATOGR B, V777, P155, DOI 10.1016/S1570-0232(02)00282-9; Monis PC, 1994, ARABIDOPSIS, P173; [Anonymous], 1962, PHYSIOL PLANTARUM, DOI DOI 10.1111/J.1399-3054.1962.TB08052.X; Summart J., 2008, World Applied Sciences Journal, V5, P246; Vazquez-Flota F, 2006, PLANT CELL CULTURE P	30	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0167-6857	1573-5044		PLANT CELL TISS ORG	Plant Cell Tissue Organ Cult.	NOV	2015	123	2					427	433		10.1007/s11240-015-0833-0		7	Biotechnology & Applied Microbiology; Plant Sciences	Biotechnology & Applied Microbiology; Plant Sciences	CT6BQ	WOS:000362896100019		
J	Hein, P				Hein, Patrick			The Oxford Handbook of Refugee and Forced Migration Studies	POLITICAL STUDIES REVIEW			English	Book Review									[Hein, Patrick] Meiji Univ, Tokyo 101, Japan	Hein, P (reprint author), Meiji Univ, Tokyo 101, Japan.						Fiddian-Qasmiyeh E., 2014, OXFORD HDB REFUGEE F	1	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1478-9299	1478-9302		POLIT STUD REV	Polit. Stud. Rev.	NOV	2015	13	4					597	597		10.1111/1478-9302.12101_58		1	Political Science	Government & Law	CT4AM	WOS:000362748100069		
J	Pal, J; Deb, MK; Deshmukh, DK				Pal, Jolly; Deb, Manas Kanti; Deshmukh, Dhananjay Kumar			Removal of phenol in aqueous solution by adsorption onto green synthesized coinage nanoparticles beads	RESEARCH ON CHEMICAL INTERMEDIATES			English	Article						Silver nanoparticles; Gold nanoparticles; Adsorption; Alginate; Phenol	SILVER NANOPARTICLES; ACTIVATED CARBON; METHYL-ORANGE; BRILLIANT-GREEN; REDUCING AGENT; WOOD CHARCOAL; ORGANIC-DYES; WASTE-WATER; SORPTION; EQUILIBRIUM	The adsorption of phenol from aqueous solution was carried out by using alginate-stabilized silver nanoparticles (AgNPs) and gold nanoparticles (AuNPs) beads as adsorbents. The resulting AgNPs and AuNPs were characterized by scanning electron microscope, UV-visible spectroscopy and Fourier transform infrared spectroscopy. Batch adsorption studies have shown that removal is dependent upon process parameters like initial concentration, contact time, pH and adsorbent dosage. The adsorption data obtained from batch studies at optimized conditions have been subjected to Freundlich and Langmuir isotherm studies. The pseudo-first-order and pseudo-second-order kinetic models were also applied to the experimental data. Phenol was effectively (90.0 +/- A 0.8 %) removed from the aqueous solution using alginate-stabilized AuNPs beads as the adsorption process. Desorption studies were made to elucidate recovery of the adsorbate and adsorbent for the economic competitiveness of the removal system. The alginate-stabilized AgNPs and AuNPs beads were found to be good adsorbents for adsorption of phenol from the aqueous solution.	[Pal, Jolly; Deb, Manas Kanti] Pandit Ravishankar Shukla Univ, Sch Studies Chem, Raipur 492010, Chhattisgarh, India; [Deshmukh, Dhananjay Kumar] Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan	Pal, J (reprint author), Pandit Ravishankar Shukla Univ, Sch Studies Chem, Raipur 492010, Chhattisgarh, India.	jollypal08@yahoo.co.in; debmanas@yahoo.com; deshmukh@pop.lowtem.hokudai.ac.jp					Quintelas C, 2011, ENVIRON TECHNOL, V32, P1541, DOI 10.1080/09593330.2010.543930; Jezequel H, 2006, J ENVIRON SCI HEAL A, V41, P1519, DOI 10.1080/10934520600754201; Shah S, 2010, EUR POLYM J, V46, P958, DOI 10.1016/j.eurpolymj.2010.01.005; Din ATM, 2009, J HAZARD MATER, V161, P1522, DOI 10.1016/j.jhazmat.2008.05.009; Bhattacharyya KG, 2003, DYES PIGMENTS, V57, P211, DOI 10.1016/S0143-7208(03)00009-3; Tseng RL, 2003, CARBON, V41, P487, DOI 10.1016/S0008-6223(02)00367-6; Tiwari A, 2008, J CHIN CHEM SOC-TAIP, V55, P952; Dogan M, 2007, DYES PIGMENTS, V75, P701, DOI 10.1016/j.dyepig.2006.07.023; Bajpai J, 2004, COLLOID SURFACE A, V236, P81, DOI 10.1016/j.colsurfa.2004.01.021; Azanova VV, 1999, REACT FUNCT POLYM, V41, P163, DOI 10.1016/S1381-5148(99)00029-2; Pal J, 2012, INDIAN J CHEM A, V51, P821; Chaithanya TK, 2010, ENVIRON TECHNOL, V31, P1495, DOI 10.1080/09593331003777144; Wang Y, 2006, SEP PURIF TECHNOL, V50, P1, DOI 10.1016/j.seppur.2005.10.012; Xu ZY, 2003, CRIT REV ENV SCI TEC, V33, P363, DOI 10.1080/106433780390249512; Kadirvelu K, 2000, ENVIRON TECHNOL, V21, P1091; Li GX, 2010, CARBOHYD POLYM, V82, P706, DOI 10.1016/j.carbpol.2010.05.040; Chen JP, 2001, WATER RES, V35, P2385; Jain R, 2008, J HAZARD MATER, V152, P942, DOI 10.1016/j.jhazmat.2007.07.070; Shah B, 2012, J DISPER SCI TECHNOL, V33, P41, DOI 10.1080/01932691.2010.530079; Pal J, 2014, J EXP NANOSCI, V9, P432, DOI 10.1080/17458080.2012.667160; Babel S, 2003, J HAZARD MATER, V97, P219, DOI 10.1016/S0304-3894(02)00263-7; Pal J, 2013, J DISPER SCI TECHNOL, V34, P1193, DOI 10.1080/01932691.2012.739939; Mukherjee S, 2007, CHEM ENG J, V129, P133, DOI 10.1016/j.cej.2006.10.030; Torres E, 2005, LANGMUIR, V21, P7951, DOI 10.1021/la046852k; Babel S, 2007, INT J ENVIRON SCI TE, V4, P99, DOI 10.1007/BF03325967; Meshko V, 2001, WATER RES, V35, P3357, DOI 10.1016/S0043-1354(01)00056-2; Ousslim A, 2014, RES CHEM INTERMEDIAT, V40, P1201, DOI 10.1007/s11164-013-1033-3; Xiong XJ, 2010, J HAZARD MATER, V175, P241, DOI 10.1016/j.jhazmat.2009.09.155; Mohammadi N, 2011, J COLLOID INTERF SCI, V362, P457, DOI 10.1016/j.jcis.2011.06.067; Wu FC, 2001, ENVIRON TECHNOL, V22, P205, DOI 10.1080/09593332208618296; Saha S, 2009, J PHYS CHEM C, V113, P7553, DOI 10.1021/jp811235m; Chiang HL, 2000, CHEMOSPHERE, V41, P1227, DOI 10.1016/S0045-6535(99)00547-0; Singh V, 2010, CHEM ENG J, V160, P129, DOI 10.1016/j.cej.2010.03.020; Hou MF, 2011, J HAZARD MATER, V186, P1118, DOI 10.1016/j.jhazmat.2010.11.110; Pal A, 2009, MATER CHEM PHYS, V114, P530, DOI 10.1016/j.matchemphys.2008.11.056; Mall ID, 2005, CHEMOSPHERE, V61, P492, DOI 10.1016/j.chemosphere.2005.03.065; Xing Y, 2011, SEP SCI TECHNOL, V46, P2298, DOI 10.1080/01496395.2011.594844; Eftekhari A, 2010, J HAZARD MATER, V178, P349; Hill S. L., 2009, J APPL PHYCOL, V21, P625; Kannan N., 1998, INDIAN J ENV PROTEC, V18, P683; Lagergren S., 1898, HANDLINGAR, V24, P1; Nafees M., 2013, APPL NANOSCI, DOI 10.1007/s13204-012-0113-9; Pal J., 2012, INDIAN J ENV PROT, V32, P574; Pal J, 2015, APPL WATER SCI, V5, P181, DOI 10.1007/s13201-014-0179-5; Pal J, 2014, APPL NANOSCI, V4, P507, DOI DOI 10.1007/S13204-013-0229-6; Pal J, 2012, J INDIAN CHEM SOC, V89, P1689; Pal J., 2014, APPL NANOSCI, V4, P61, DOI DOI 10.1007/S13204-012-0170-0; Pal J., 2014, APPL NANOSCI, DOI 10.1007/s13204-013-0277-y; Pal J, 2013, J INDIAN CHEM SOC, V90, P2115; Pal J., 2013, APPL WATER SCI, V3, P367, DOI DOI 10.1007/S13201-013-0087-0; Patterson J., 1975, WASTEWATER TREATMENT; Ramos RL, 2011, ADSORPTION, V17, P515; Schottler SP, 1994, ENVIRON SCI TECHNOL, V28, P1867; Stamenkovic OS, 2007, BIORESOURCE TECHNOL, V98, P2688, DOI 10.1016/j.biortech.2006.09.024	54	0	0	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0922-6168	1568-5675		RES CHEM INTERMEDIAT	Res. Chem. Intermed.	NOV	2015	41	11					8363	8379		10.1007/s11164-014-1898-9		17	Chemistry, Multidisciplinary	Chemistry	CT6BS	WOS:000362896400025		
J	Jinji, N; Zhang, XY; Haruna, S				Jinji, Naoto; Zhang, Xingyuan; Haruna, Shoji			Trade patterns and international technology spillovers: evidence from patent citations	REVIEW OF WORLD ECONOMICS			English	Article						Technology spillovers; Trade patterns; Patent citations; Intraindustry trade	RESEARCH-AND-DEVELOPMENT; FOREIGN DIRECT-INVESTMENT; KNOWLEDGE SPILLOVERS; INTRAINDUSTRY TRADE; PRODUCT DIFFERENTIATION; OECD	In this paper, we empirically examine the relationship between bilateral trade patterns and international technology spillovers for a sample of 55 countries during 1995-2006. Technology spillovers are measured by using patent citation data taken from the United States Patent and Trademark Office. The main contribution of this paper is to provide new evidence that the size of technology spillovers significantly varies according to bilateral trade patterns. In particular, horizontal intra-industry trade is associated with larger technology spillovers than vertical intra-industry trade, and the size of technology spillovers is smallest when the trade pattern is inter-industry trade. Given the fact that trade between technologically advanced countries has a higher share of horizontal intra-industry trade than trade between other combinations of countries, our findings suggest that trade may enlarge, rather than narrow, the technology gap between technologically advanced and less-advanced countries.	[Jinji, Naoto] Kyoto Univ, Fac Econ, Sakyo Ku, Kyoto 6068501, Japan; [Zhang, Xingyuan; Haruna, Shoji] Okayama Univ, Fac Econ, Kita Ku, Okayama 7008530, Japan	Jinji, N (reprint author), Kyoto Univ, Fac Econ, Sakyo Ku, Kyoto 6068501, Japan.	jinji@econ.kyoto-u.ac.jp			Japan Society for the Promotion of Science [19330052, 23330081]; Murata Science Foundation	We thank Lee Branstetter, Akira Hibiki, Shuichiro Nishioka, Nobuhito Suga, Yoichi Sugita, Roberto Venturini, an anonymous referee, and seminar and conference participants at Hokkaido University, Kyoto University, National Institute for Environmental Studies, Otaru University of Commerce, University of Pittsburgh, Yokohama National University, APTS, Midwest International Economics, Korea International Economic Association Meeting, and EARIE 2013 for their helpful comments and suggestions on earlier versions of the paper. The authors are solely responsible for any remaining errors. Financial support from the Japan Society for the Promotion of Science under the Grant-in-Aid for Scientific Research (B) Nos. 19330052 and 23330081, and the Murata Science Foundation is gratefully acknowledged.	Acharya RC, 2009, CAN J ECON, V42, P1411; KRUGMAN PR, 1979, J INT ECON, V9, P469, DOI 10.1016/0022-1996(79)90017-5; Xu B, 1999, CAN J ECON, V32, P1258, DOI 10.2307/136481; Baldwin R, 2011, AM ECON J-MICROECON, V3, P60, DOI 10.1257/mic.3.2.60; COE DT, 1995, EUR ECON REV, V39, P859, DOI 10.1016/0014-2921(94)00100-E; Fontagne L, 2006, REV WORLD ECON, V142, P459, DOI 10.1007/s10290-006-0076-6; KRUGMAN P, 1980, AM ECON REV, V70, P950; Jaffe AB, 2000, AM ECON REV, V90, P215, DOI 10.1257/aer.90.2.215; Madsen JB, 2007, J INT ECON, V72, P464, DOI 10.1016/j.jinteco.2006.12.001; Melitz MJ, 2008, REV ECON STUD, V75, P295, DOI 10.1111/j.1467-937X.2007.00463.x; Maurseth PB, 2002, SCAND J ECON, V104, P531, DOI 10.1111/1467-9442.00300; Branstetter L, 2006, J INT ECON, V68, P325, DOI 10.1016/j.jinteco.2005.06.006; MacGarvie M, 2006, REV ECON STAT, V88, P46; Fukao K, 2003, J JPN INT ECON, V17, P468, DOI 10.1016/j.jjie.2003.09.004; GREENAWAY D, 1995, ECON J, V105, P1505, DOI 10.2307/2235113; Bloom N, 2013, ECONOMETRICA, V81, P1347, DOI 10.3982/ECTA9466; Desmarais BA, 2013, STATA J, V13, P810; FALVEY RE, 1981, J INT ECON, V11, P495, DOI 10.1016/0022-1996(81)90031-3; FLAM H, 1987, AM ECON REV, V77, P810; Fontagne L., 1997, WORKING PAPERS CTR E, V1997-01; Gaulier G, 2010, 201023 CEPII; Grossman G., 1991, INNOVATION GROWTH GL; Hall B. H., 2007, 13426 NBER; Hall B.H., 2001, 8498 NBER; Haruna S., 2010, J EC FINANCE, V34, P365, DOI DOI 10.1007/S12197-009-9078-2; JAFFE AB, 1993, Q J ECON, V108, P577, DOI 10.2307/2118401; JAFFE AB, 1986, AM ECON REV, V76, P984; Jaffe A. B., 1999, EC INNOVATION NEW TE, V8, P105, DOI DOI 10.1080/10438599900000006; Jinji N., 2014, TRADE PATTERNS UNPUB; Jinji N., 2011, RIETI DISCUSSION PAP, V11-E-027; Keller W, 2004, J ECON LIT, V42, P752, DOI 10.1257/0022051042177685; Malerba F, 2013, REV WORLD ECON, V149, P697, DOI 10.1007/s10290-013-0167-0; MAYER T., 2011, 201125 CEPII; Schmoch U, 2003, LINKING TECHNOLOGY A; Trivedi P. K., 1998, REGRESSION ANAL COUN; VUONG QH, 1989, ECONOMETRICA, V57, P307, DOI 10.2307/1912557	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1610-2878	1610-2886		REV WORLD ECON	Rev. World Econ.	NOV	2015	151	4					635	658		10.1007/s10290-015-0223-z		24	Economics; International Relations	Business & Economics; International Relations	CT8CV	WOS:000363043500002		
J	Ishikawa, T				Ishikawa, Takashi			Untitled	SAMPE JOURNAL			English	Editorial Material									Nagoya Univ, Grad Sch Engn, Dept Aerosp Engn, Nagoya, Aichi 4648601, Japan	Ishikawa, T (reprint author), Nagoya Univ, Grad Sch Engn, Dept Aerosp Engn, Nagoya, Aichi 4648601, Japan.	ishikawa@nuae.nagoya-u.ac.jp						0	0	0	SAMPE PUBLISHERS	COVINA	1161 PARKVIEW DRIVE, COVINA, CA 91722 USA	0091-1062			SAMPE J	Sampe J.	NOV-DEC	2015	51	6					2	2				1	Engineering, Multidisciplinary; Materials Science, Multidisciplinary	Engineering; Materials Science	CT7MJ	WOS:000362998500001		
J	Hyodo, M; Shutoh, N; Nishiyama, T; Pavlenko, T				Hyodo, Masashi; Shutoh, Nobumichi; Nishiyama, Takahiro; Pavlenko, Tatjana			Testing block-diagonal covariance structure for high-dimensional data	STATISTICA NEERLANDICA			English	Article						block-diagonal covariance structure; high dimensionality	FEWER OBSERVATIONS; SAMPLE-SIZE; MATRIX	A test statistic is developed for making inference about a block-diagonal structure of the covariance matrix when the dimensionality p exceeds n, where n = N - 1 and N denotes the sample size. The suggested procedure extends the complete independence results. Because the classical hypothesis testing methods based on the likelihood ratio degenerate when p > n, the main idea is to turn instead to a distance function between the null and alternative hypotheses. The test statistic is then constructed using a consistent estimator of this function, where consistency is considered in an asymptotic framework that allows p to grow together with n. The suggested statistic is also shown to have an asymptotic normality under the null hypothesis. Some auxiliary results on the moments of products of multivariate normal random vectors and higher-order moments of the Wishart matrices, which are important for our evaluation of the test statistic, are derived. We perform empirical power analysis for a number of alternative covariance structures.	[Hyodo, Masashi] Osaka Prefecture Univ, Grad Sch Engn, Dept Math Sci, Sakai, Osaka, Japan; [Shutoh, Nobumichi] Kobe Univ, Grad Sch Maritime Sci, Kobe, Hyogo, Japan; [Nishiyama, Takahiro] Senshu Univ, Dept Business Adm, Tokyo, Japan; [Pavlenko, Tatjana] KTH Royal Inst Technol, Dept Math, Stockholm, Sweden	Hyodo, M (reprint author), Osaka Prefecture Univ, Grad Sch Engn, Dept Math Sci, Sakai, Osaka, Japan.	hyodoh_h@yahoo.co.jp			National Research Council of Sweden (VR) [2013-45266]	We thank two reviewers and Associate Editor for useful comments that substantially improved this paper. We are greatly indebted to Professor Takashi Seo, from Tokyo University of Science, for helpful conversations and valuable comments. T. P. is supported by the grant 2013-45266 of the National Research Council of Sweden (VR).	Pavlenko T, 2012, J APPL STAT, V39, P1643, DOI 10.1080/02664763.2012.663346; Srivastava MS, 2012, J MULTIVARIATE ANAL, V112, P156, DOI 10.1016/j.jmva.2012.06.004; Danaher P, 2014, J R STAT SOC B, V76, P373, DOI 10.1111/rssb.12033; Bai ZD, 1996, STAT SINICA, V6, P311; Srivastava MS, 2011, J MULTIVARIATE ANAL, V102, P1090, DOI 10.1016/j.jmva.2011.03.003; Schott JR, 2005, BIOMETRIKA, V92, P951, DOI 10.1093/biomet/92.4.951; Fisher TJ, 2012, J STAT PLAN INFER, V142, P312, DOI 10.1016/j.jspi.2011.07.019; Ledoit O, 2002, ANN STAT, V30, P1081; Srivastava M. S., 2005, J JAPAN STAT SOC, V35, P251	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0039-0402	1467-9574		STAT NEERL	Stat. Neerl.	NOV	2015	69	4					460	482		10.1111/stan.12068		23	Statistics & Probability	Mathematics	CT6GO	WOS:000362911600007		
J	Okuda, Y; Taura, K; Seo, S; Yasuchika, K; Nitta, T; Ogawa, K; Hatano, E; Uemoto, S				Okuda, Yukihiro; Taura, Kojiro; Seo, Satoru; Yasuchika, Kentaro; Nitta, Takashi; Ogawa, Kohei; Hatano, Etsuro; Uemoto, Shinji			Usefulness of operative planning based on 3-dimensional CT cholangiography for biliary malignancies	SURGERY			English	Article							PORTAL-VEIN RESECTION; HILAR CHOLANGIOCARCINOMA; PERIHILAR CHOLANGIOCARCINOMA; CHOLANGIOPANCREATOGRAPHY; TRISECTIONECTOMY; CHOLANGITIS; COHORT	Background. The complexity of hepatic hilar anatomy is an obstacle to precise diagnosis of tumor spread and appropriate operative planning for biliary malignancies. Three-dimensional (3D) cholangiography and angiography may overcome this obstacle and facilitate curative resection. The objective of this study was to evaluate the impact of 3D CT cholangiography on operative planning and outcomes of biliary malignancies. Methods. From 2009 to 2014, 3DCT cholangiography was performed on 49 patients with biliary malignancies requiring major hepatic resection and extrahepatic bile duct resection. The 3D cholangiogram was merged with 3D angiography and portography to create an all-in-one 3D image of the hepatic hilum. The cutting line of the bile duct and the type of liver resection were determined based on the spatial relationship between tumor spread and the landmark vessels. The necessity of vascular reconstruction was also evaluated. Preoperative imaging and operative findings were compared. Operative curability was compared with that of the historical cohort before the introduction of 3D cholangiography. Results. Histologic examination of the bile duct stump showed a negative margin in 39 (80%), carcinoma in situ in 7 (14%), and invasive cancer (IC) in 3 patients (6%) on the first cutting. The IC-free rate (94%) on the first cutting was superior to that in the historical cohort (80%; P = .02). The necessity for portal and arterial reconstruction was predicted with 98 and 94% accuracy, respectively. Conclusion. We found 3D cholangiography to provide accurate information about hilar anatomy and plays a role in facilitating adequate operative planning.	[Okuda, Yukihiro; Taura, Kojiro; Seo, Satoru; Yasuchika, Kentaro; Nitta, Takashi; Ogawa, Kohei; Hatano, Etsuro; Uemoto, Shinji] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto 6068507, Japan	Taura, K (reprint author), Kyoto Univ, Grad Sch Med, Dept Surg, Sakyo Ku, 54Kawaharacho, Kyoto 6068507, Japan.	ktaura@kuhp.kyoto-u.ac.jp					Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Hirano S, 2010, J HEPATO-BIL-PAN SCI, V17, P455, DOI 10.1007/s00534-009-0208-1; Kalra VB, 2014, EUR J RADIOL, V83, P905, DOI 10.1016/j.ejrad.2014.03.013; Kim HJ, 2009, ACTA RADIOL, V50, P845, DOI 10.1080/02841850903092366; Miyazaki M, 2010, J HEPATO-BIL-PAN SCI, V17, P470, DOI 10.1007/s00534-009-0207-2; Igami T, 2010, J HEPATO-BIL-PAN SCI, V17, P449, DOI 10.1007/s00534-009-0209-0; Bai Y, 2009, PANCREAS, V38, P126, DOI 10.1097/MPA.0b013e318189fl6d; Lu BC, 2013, WSPOLCZESNA ONKOL, V17, P298, DOI 10.5114/wo.2013.35274; Chen W, 2014, EJSO-EUR J SURG ONC, V40, P489, DOI 10.1016/j.ejso.2014.02.231; Endo I, 2007, SURGERY, V142, P666, DOI 10.1016/j.surg.2007.05.018; Ito F, 2008, ANN SURG, V248, P273, DOI 10.1097/SLA.0b013e31817f2bfd; Sugimoto M, 2010, J HEPATO-BIL-PAN SCI, V17, P601, DOI 10.1007/s00534-009-0201-8; Machado MA, 2012, ANN SURG ONCOL, V19, P1324, DOI 10.1245/s10434-011-2072-x; Zhang RC, 2013, SCAND J GASTROENTERO, V48, P758, DOI 10.3109/00365521.2013.779745; Nguyen K, 2008, WORLD J GASTROENTERO, V14, P2995, DOI 10.3748/wjg.14.2995; Rahbari NN, 2011, SURGERY, V149, P713, DOI 10.1016/j.surg.2010.10.001; Endo I, 2014, J HEPATO-BIL-PAN SCI, V21, P525, DOI 10.1002/jhbp.75; Rocha FG, 2010, J HEPATO-BIL-PAN SCI, V17, P490, DOI 10.1007/s00534-009-0205-4; Luo XW, 2014, J GASTROINTEST SURG, V18, P562, DOI 10.1007/s11605-013-2447-3; Matsumoto N, 2014, BRIT J SURG, V101, P261, DOI 10.1002/bjs.9383; Mavros MN, 2014, JAMA SURG, DOI 10.1001	21	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	NOV	2015	158	5					1261	1271		10.1016/j.surg.2015.04.021		11	Surgery	Surgery	CT7PA	WOS:000363005800012		
J	Miyazawa, M; Aikawa, M; Watanabe, Y; Takase, K; Okamoto, K; Shrestha, S; Okada, K; Koyama, I; Ikada, Y				Miyazawa, Mitsuo; Aikawa, Masayasu; Watanabe, Yukihiro; Takase, Ken-ichiro; Okamoto, Kojun; Shrestha, Santosh; Okada, Katsuya; Koyama, Isamu; Ikada, Yoshito			Extensive regeneration of the stomach using bioabsorbable polymer sheets	SURGERY			English	Article							INTESTINAL SUBMUCOSA SIS; GASTRIC-CANCER; ENDOGENOUS RETROVIRUS; LIMITED SURGERY; TISSUE; PATCH; DEFECTS; POLYTETRAFLUOROETHYLENE; TRANSPLANTATION; MEMBRANE	Background. The growing prevalence of endoscopic surgery in recent years has led to the minimization of postoperative scarring. However, this procedure does not allow for the regeneration of the resected digestive tract, which compromises the postoperative maintenance of digestive function. In this preliminary study, we developed an artificial gastric wall (AGW) using bioabsorbable polymer (BAP), and evaluated the ability of this BAP patch to repair and regenerate a widely defective gastric wall in an animal model. Methods. Pigs were laparotomized under general anesthesia. An 8 X 8-cm, round portion of the anterior gastric wall was excised and replaced by an AGW. The AGW was composed of a copolymer comprising 50% lactic acid and 50% caprolactone. The animals were relaparotomized 4, 8, or 12 weeks after implantation, after which they underwent resection of the entire stomach for gross and histologic evaluation of the graft sites. Results. All recipient pigs survived until killing. By 4-8 weeks, the graft site revealed progressively fewer mucosal defect after each day. Moreover, the grafted area was indistinguishable from the native stomach 12 weeks after AGW implantation. The structures of the regenerated mucous membrane and muscle layers were identical to those of the native stomach. Furthermore, proton pumps were found in the regenerated tissue. Conclusion. The BAP sheets helped to restore extensive gastric defects without causing any deformation. The use of BAP sheets may become a new therapeutic method that prevents alterations of gastric volume after extensive gastrectomy for stomach cancer and other diseases.	[Miyazawa, Mitsuo; Aikawa, Masayasu; Watanabe, Yukihiro; Takase, Ken-ichiro; Okamoto, Kojun; Shrestha, Santosh; Okada, Katsuya; Koyama, Isamu] Saitama Med Univ, Int Med Ctr, Dept Surg, Gastrointestinal Ctr, Hidaka, Saitama 3501298, Japan; [Ikada, Yoshito] Nara Med Univ, Div Life Sci, Nara, Japan	Miyazawa, M (reprint author), Saitama Med Univ, Int Med Ctr, Dept Surg, Gastrointestinal Ctr, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan.	miyazawa32000@yahoo.co.jp			Japanese Ministry of Health, Labor and Welfare [15591367]; Maruki Memorial Scholarship for Special Research	The authors thank N. Akimoto for her excellent technical assistance. M. Miyazawa received funding for this work from the Japanese Ministry of Health, Labor and Welfare (15591367) and the Maruki Memorial Scholarship for Special Research.	Adamson R, 2009, J Wound Care, V18, P349; Matsuda Y, 2007, CANCER SCI, V98, P1014, DOI 10.1111/j.1349-7006.2007.00490.x; Yoshikawa T, 2003, HEPATO-GASTROENTEROL, V50, P1727; Kini S, 2001, OBES SURG, V11, P469, DOI 10.1381/096089201321209350; Jeong GA, 2009, SURGERY, V146, P469, DOI 10.1016/j.surg.2009.03.023; Ozlem N, 1999, ACTA CHIR BELG, V99, P17; Astarcioglu H, 2001, AM J SURG, V181, P309, DOI 10.1016/S0002-9610(01)00586-4; Yokota T, 2003, LANCET ONCOL, V4, P423, DOI 10.1016/S1470-2045(03)01140-9; Kiyama T, 2005, J GASTROINTEST SURG, V9, P313, DOI 10.1016/j.gasseur.2004.11.008; Aikawa M, 2010, SURGERY, V147, P575, DOI 10.1016/j.surg.2009.10.049; Aikawa M, 2013, J GASTROENTEROL, V48, P822, DOI 10.1007/s00535-012-0716-7; Schreiber S, 2000, AM J PHYSIOL-GASTR L, V279, pG597; Paradis K, 1999, SCIENCE, V285, P1236, DOI 10.1126/science.285.5431.1236; Ueno T, 2007, J GASTROINTEST SURG, V11, P918, DOI 10.1007/s11605-007-0171-6; de la Fuente SG, 2003, J GASTROINTEST SURG, V7, P96, DOI 10.1016/S1091-255X(02)00050-1; Ichikura T, 2006, SURGERY, V139, P501, DOI 10.1016/j.surg.2005.09.005; Miyazawa M, 2005, AM J TRANSPLANT, V5, P1541, DOI 10.1111/j.1600-6143.2005.00845.x; Fujii T, 2009, J BIOL CHEM, V284, P619, DOI 10.1074/jbc.M806562200; Toshimitsu Y, 2005, J GASTROINTEST SURG, V9, P789, DOI 10.1016/j.gassur.2005.03.007; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; Aikawa M, 2012, J GASTROINTEST SURG, V16, P529, DOI 10.1007/s11605-011-1801-6; Berlinger NT, 2006, NEW ENGL J MED, V354, P2099, DOI 10.1056/NEJMp058233; Velnar T, 2009, J INT MED RES, V37, P1528; Stefater MA, 2010, GASTROENTEROLOGY, V138, P2426, DOI 10.1053/j.gastro.2010.02.059; Ueno T, 2007, SURGERY, V142, P376, DOI 10.1016/j.surg.2007.04.019; Oh DS, 2002, ANN SURG, V235, P708, DOI 10.1097/00000658-200205000-00013; Shin'oka T, 2001, NEW ENGL J MED, V344, P532, DOI 10.1056/NEJM200102153440717; Hori Y, 2001, ASAIO J, V47, P206, DOI 10.1097/00002480-200105000-00008; CAGA T, 1993, BRIT J SURG, V80, P1013; Hattori K, 2000, J Orthop Sci, V5, P57, DOI 10.1007/s007760050009; Hoffman GC, 1996, ANN SURG, V223, P790, DOI 10.1097/00000658-199606000-00017	31	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	NOV	2015	158	5					1283	1290		10.1016/j.surg.2015.04.003		8	Surgery	Surgery	CT7PA	WOS:000363005800014		
J	Lu, RG; Nanao, H; Takiwatari, K; Mori, S; Fukushima, Y; Murakami, Y; Ikejima, S; Konno, T				Lu, Renguo; Nanao, Hidetaka; Takiwatari, Koji; Mori, Shigeyuki; Fukushima, Yoshinori; Murakami, Youichi; Ikejima, Shozo; Konno, Tadaaki			The Effect of the Chemical Structures of Synthetic Hydrocarbon Oils on Their Tribochemical Decomposition	TRIBOLOGY LETTERS			English	Article						Hydrocarbon oil; Decomposition; Tribochemical; Nascent surface; Steel	MULTIALKYLATED CYCLOPENTANE OIL; NASCENT STEEL SURFACES; HIGH-VACUUM; MECHANISMS	Under boundary lubrication conditions, the formation of a highly active nascent surface can catalyze the decomposition of lubricant oils. Extreme pressure additives can reduce this decomposition but have undesirable environmental impacts, and so it is necessary to develop eco-friendly lubricants. The following study investigated the effects of the chemical structures of hydrocarbon oils on their tribochemical decomposition by comparing an alkyldiphenylether (ADE) to a multialkylated cyclopentane. The analysis of gaseous decomposition products via mass spectrometry during the application of friction showed that the multialkylated cyclopentane decomposed after an induction period of 1.95 km while the ADE did not degrade, even at a distance of 57.5 km, under the same mechanical contact conditions, and exhibited superior anti-wear properties. However, a high concentration of the ADE was necessary to extend the induction period for lubricant decomposition when it was used as an additive. Although the ADE showed high stability in response to friction, it was prone to decomposition once a nascent steel surface was formed. These decomposition characteristics of the ADE are closely related to its chemical structure, because the ether group in the ADE molecule preferentially adsorbs on metal oxide surfaces, forming a dense and robust film. In contrast, the weak bonding between adjacent alkyl groups reduces the shear strength at the interface. Both the benzene and alkyl groups of ADE molecules were found to detach, followed by the further rupture of C-C, C-H, and C-O bonds, catalyzed by active sites on the nascent surface such as surface defects.	[Lu, Renguo; Nanao, Hidetaka; Mori, Shigeyuki] Iwate Univ, Fac Engn, Morioka, Iwate 0208551, Japan; [Takiwatari, Koji] Ichinoseki Coll, Natl Inst Technol, Ichinoseki, Iwate 0218511, Japan; [Fukushima, Yoshinori; Murakami, Youichi] DENSO Corp, Kariya, Aichi 4488661, Japan; [Ikejima, Shozo; Konno, Tadaaki] Kyodo Yushi Co Ltd, Fujisawa, Kanagawa 2518588, Japan	Lu, RG (reprint author), Kansai Univ, Fac Engn Sci, Osaka 5648680, Japan.	R_Lu@kansai-u.ac.jp; Mori@iwate-u.ac.jp					Lu RG, 2009, TRIBOL LETT, V33, P1, DOI 10.1007/s11249-008-9379-1; Martin JM, 1999, TRIBOL LETT, V6, P1, DOI 10.1023/A:1019191019134; Lu RG, 2007, TRIBOL LETT, V27, P25, DOI 10.1007/s11249-007-9203-3; Lu RG, 2009, WEAR, V267, P1430, DOI 10.1016/j.wear.2009.03.028; Wei JJ, 1998, TRIBOL LETT, V5, P203, DOI 10.1023/A:1019145809139; Watanabe J, 2014, TRIBOL LETT, V56, P501, DOI 10.1007/s11249-014-0427-8; BATCHELOR AW, 1985, ASLE TRANS, V28, P467; Lu RG, 2010, J JPN PETROL INST, V53, P55; MORI S, 1982, ASLE TRANS, V25, P261; MORI S, 1987, APPL SURF SCI, V27, P401, DOI 10.1016/0169-4332(87)90150-4; De Barros MI, 2003, WEAR, V254, P863, DOI 10.1016/S0043-1648(03)00237-0; John PJ, 2000, TRIBOL LETT, V9, P167; Mori S., 1988, STLE T, V31, P128; Mori S., 2001, JTEKT ENG J; Mori S., 1990, TRIBOL T, V33, P225; Pearson R. G., 1973, HARD SOFT ACIDS BASE; Shimotomai Naoshi, 2012, Tribology Online, V7, DOI 10.2474/trol.7.54	17	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1023-8883	1573-2711		TRIBOL LETT	Tribol. Lett.	NOV	2015	60	2							27	10.1007/s11249-015-0606-2		9	Engineering, Chemical; Engineering, Mechanical	Engineering	CT8HK	WOS:000363055600007		
J	Suzuki, K; Hirai, Y; Shimomura, M; Ohzono, T				Suzuki, Kosuke; Hirai, Yuji; Shimomura, Masatsugu; Ohzono, Takuya			Tunable Friction Through Microwrinkle Formation on a Reinforced Rubber Surface	TRIBOLOGY LETTERS			English	Article						Shape-tunable wrinkles; Dry friction; Elastomers; Reinforced surface; Friction control; Stick-slip	ELASTOMERIC POLYMER; SCHALLAMACH WAVES; HONEYCOMB; WRINKLES; FILMS; CONTACT	A new system is presented for controlling of friction through manipulating the contact between a rigid indenter and a porous-film-embedded polydimethylsiloxane (PDMS) rubber surface that can buckle to form regular microwrinkles depending on the applied lateral compression. The effect of this change in topography on friction is investigated with a fixed surface chemistry at the sliding interface to ensure a consistent value of adhesive shear strength per unit area of contact. With a wrinkled surface, a shorter stick-slip period and corresponding lower average force of friction are observed when compared to a flat PDMS surface. Based on the framework of Bowden-Tabor's adhesive friction model, this result is attributed to a decrease in the contact area caused by an increase in the effective modulus and the distribution of interfacial contacts on the wrinkles. These results therefore imply that a shape-tunable microstructure is an effective approach to developing surfaces with dynamically tunable tribological properties.	[Suzuki, Kosuke; Ohzono, Takuya] Natl Inst Adv Ind Sci & Technol, Res Inst Sustainable Chem, Tsukuba, Ibaraki 3058565, Japan; [Hirai, Yuji; Shimomura, Masatsugu] Chitose Inst Sci & Technol, Dept Appl Chem & Biosci, Chitose, Hokkaido 0668655, Japan	Ohzono, T (reprint author), Natl Inst Adv Ind Sci & Technol, Res Inst Sustainable Chem, 1-1-1 Higashi, Tsukuba, Ibaraki 3058565, Japan.	ohzono-takuya@aist.go.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) [24120003]	This work was supported in part by the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) via a Grant-in-Aid for Scientific Research on Innovative Areas (Grant No. 24120003).	Rand CJ, 2009, J APPL PHYS, V106, DOI 10.1063/1.3226074; Schulze KD, 2014, TRIBOL LETT, V55, P65, DOI 10.1007/s11249-014-0332-1; Brau F, 2011, NAT PHYS, V7, P56, DOI [10.1038/nphys1806, 10.1038/NPHYS1806]; WIDAWSKI G, 1994, NATURE, V369, P387, DOI 10.1038/369387a0; Bowden N, 1998, NATURE, V393, P146; Chen YC, 2014, ADV MATER, V26, P5626, DOI 10.1002/adma.201401444; Yabu H, 2006, LANGMUIR, V22, P9760, DOI 10.1021/la062228r; Collino RR, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0453; Bohn HF, 2004, P NATL ACAD SCI USA, V101, P14138, DOI 10.1073/pnas.0405885101; Koudine AA, 1997, INT J ADHES ADHES, V17, P107, DOI 10.1016/S0143-7496(96)00043-7; KAELBLE DH, 1959, T SOC RHEOL, V3, P161; Hirai Y, 2010, J MATER CHEM, V20, P10804, DOI 10.1039/c0jm02423f; Ohzono T, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.132202; Bowden N, 1999, APPL PHYS LETT, V75, P2557, DOI 10.1063/1.125076; Ohzono T, 2014, SOFT MATTER, V10, P7165, DOI 10.1039/c4sm00942h; Nishikawa T, 2002, LANGMUIR, V18, P5734, DOI 10.1021/la011451f; Suzuki K, 2014, ACS APPL MATER INTER, V6, P10121, DOI 10.1021/am5010738; Nonomura Y, 2012, J R SOC INTERFACE, V9, P1216, DOI 10.1098/rsif.2011.0577; Federle W, 2006, J R SOC INTERFACE, V3, P689, DOI 10.1098/rsif.2006.0135; Koudine AA, 1996, J ADHES SCI TECHNOL, V10, P951, DOI 10.1163/156856196X00030; Autumn K, 2000, NATURE, V405, P681; KENDALL K, 1975, J PHYS D APPL PHYS, V8, P1449, DOI 10.1088/0022-3727/8/13/005; Ohzono T, 2013, ADV OPT MATER, V1, P374, DOI 10.1002/adom.201300128; Momozono S, 2012, TRIBOL INT, V48, P122, DOI 10.1016/j.triboint.2011.11.016; Brormann K, 2013, TRIBOL LETT, V50, P3, DOI 10.1007/s11249-012-0044-3; He B, 2008, TRIBOL LETT, V31, P187, DOI 10.1007/s11249-008-9351-0; Beutel RG, 2001, J ZOOL SYST EVOL RES, V39, P177, DOI 10.1046/j.1439-0469.2001.00155.x; Bowden FP, 1950, FRICTION LUBRICATION; Dalbe MJ, 2014, SOFT MATTER, V10, P9637, DOI 10.1039/c4sm01840k; Hertz H., 1896, MISCELLANEOUS PAPERS, P146; JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141; Rand CJ, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2828136; SCHALLAM.A, 1971, WEAR, V17, P301, DOI 10.1016/0043-1648(71)90033-0; Wandersman E, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.164301	34	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1023-8883	1573-2711		TRIBOL LETT	Tribol. Lett.	NOV	2015	60	2							24	10.1007/s11249-015-0600-8		6	Engineering, Chemical; Engineering, Mechanical	Engineering	CT8HK	WOS:000363055600004		
J	Sujan, KC; Yamamoto, H; Matsuo, M; Yoshida, M; Naito, K; Shirai, T				Sujan, K. C.; Yamamoto, Hiroyuki; Matsuo, Miyuki; Yoshida, Masato; Naito, Kazuhiro; Shirai, Tatsuya			Continuum contraction of tension wood fiber induced by repetitive hygrothermal treatment	WOOD SCIENCE AND TECHNOLOGY			English	Article							GREEN WOOD; DIMENSIONAL CHANGES; GELATINOUS LAYER; SHRINKAGE; RECOVERY; STRESS; RELEASE; RANGE	Tension wood, when kiln-dried, is likely to deform hugely, which is probably caused by a gelatinous layer of the gelatinous fiber. To elucidate the mechanism behind the deformation of tension wood during kiln-drying, the strains experienced by tension wood during a hygrothermal treatment that is akin to an early stage of kiln-drying were investigated. Normal wood elongated along the longitudinal axis after the first treatment and leveled off with repetitive treatments. During the first treatment, tension wood contracted significantly along the longitudinal axis, followed by small subsequent contractions, which occurred during successive treatments. This characteristic hygrothermal behavior of tension wood correlated with the areal ratio of the gelatinous layer. One of the possible reasons why tension wood behaves differently was thought to be particular behavior of gelatinous layer. This finding will contribute to the development of appropriate seasoning method for tension wood by clarifying the mechanism behind the deformation of the gelatinous layer.	[Sujan, K. C.; Yamamoto, Hiroyuki; Matsuo, Miyuki; Yoshida, Masato; Naito, Kazuhiro; Shirai, Tatsuya] Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Yamamoto, H (reprint author), Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan.	hiro@agr.nagoya-u.ac.jp					Tanaka M, 2015, EUR J WOOD WOOD PROD, V73, P289, DOI 10.1007/s00107-015-0880-6; Clair B, 2008, BIOMACROMOLECULES, V9, P494, DOI 10.1021/bm700987q; GRIL J, 1994, ANN SCI FOREST, V51, P329, DOI 10.1051/forest:19940311; Abe K, 2007, J WOOD SCI, V53, P5, DOI 10.1007/s10086-006-0815-2; Clair B, 2001, IAWA J, V22, P121; GRIL J, 1993, ANN SCI FOREST, V50, P487, DOI 10.1051/forest:19930506; [Anonymous], 2010, FOR RES ASS REP; CAVE ID, 1972, WOOD SCI TECHNOL, V6, P284; SHARMA SN, 1978, WOOD SCI, V10, P142; Toba K, 2013, HOLZFORSCHUNG, V67, P315, DOI 10.1515/hf-2012-0080; Clair B, 2012, HOLZFORSCHUNG, V66, P349, DOI [10.1515/HF.2011.159, 10.1515/hf.2011.159]; Tejada A, 1998, FOREST PROD J, V48, P84; Chang SS, 2009, J EXP BOT, V60, P3023, DOI 10.1093/jxb/erp133; YAMAMOTO H, 1993, MOKUZAI GAKKAISHI, V39, P375; Bardet S, 2012, LECT NOTES APPL COMP, V61, P157; [Anonymous], 1983, MOKUZAI GAKKAISHI; Placet V, 2007, HOLZFORSCHUNG, V61, P548, DOI 10.1515/HF2007.093; Yamamoto H, 2001, WOOD SCI TECHNOL, V35, P167, DOI 10.1007/s002260000074; Yamamoto H, 2010, WOOD SCI TECHNOL, V44, P149, DOI 10.1007/s00226-009-0262-5; Borrega M, 2013, HOLZFORSCHUNG, V67, P871, DOI 10.1515/hf-2013-0019; CAVE I. D., 1966, FOREST PRODJ, V16, P37; Goring D. A. I., 1963, Pulp and Paper in Canada, V64, pT517; Kubler H, 1959, HOLZ ROH WERKST, V17, P77, DOI 10.1007/BF02608613; Meylan B. A., 1968, Forest Products Journal, V18, P75; Skaar C, 1988, WOOD WATER RELATIONS; Tanaka M, 2014, HOLZFORSCHUNG, V68, P823, DOI 10.1515/hf-2013-0153; Yamamoto H, 2005, J WOOD SCI, V51, P222, DOI 10.1007/s10086-004-0639-x; Yokota T., 1962, Forest Products Journal, V12, P43	28	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0043-7719	1432-5225		WOOD SCI TECHNOL	Wood Sci. Technol.	NOV	2015	49	6					1157	1169		10.1007/s00226-015-0762-4		13	Forestry; Materials Science, Paper & Wood	Forestry; Materials Science	CT8GC	WOS:000363052000005		
J	Akahoshi, H; Obataya, E				Akahoshi, Hikaru; Obataya, Eiichi			Effects of wet-dry cycling on the mechanical properties of Arundo donax L. used for the vibrating reed in woodwind instruments	WOOD SCIENCE AND TECHNOLOGY			English	Article							ACOUSTIC PROPERTIES; CANE	The effects of wet-dry and moist-dry cycling on the mechanical properties of reed (Arundo donax L.) were investigated. Because water-soluble extractives were lost through wetting, the reed shrunk in its tangential direction, and its dynamic Young's modulus and loss tangent decreased during wet-dry cycling. On the other hand, the reed swelled in its radial direction because of the recovery of cell collapse, which had been induced by drying from a green state. Consequently, the resonant frequency of the reed monotonically increased during wet-dry cycling, whereas no clear trend was seen in bending rigidity. During moist-dry cycling, the equilibrium moisture content of reed decreased slightly. Such a reduction in hygroscopicity was attributed to the aggregation of deliquescent extractives. The changes in the dimensions and vibrational properties of the reed specimens during moist-dry cycling were qualitatively similar to those during wet-dry cycling. These results suggest that the practical performance of woodwind reed changes irreversibly during continuous usage.	[Akahoshi, Hikaru; Obataya, Eiichi] Grad Sch Life & Environm Sci, Tsukuba, Ibaraki, Japan	Obataya, E (reprint author), Grad Sch Life & Environm Sci, Tsukuba, Ibaraki, Japan.	obataya.eiichi.fu@u.tsukuba.ac.jp					Mathlouthi M, 2003, FOOD CHEM, V82, P61, DOI 10.1016/S0308-8146(02)00534-4; OBATAYA E, 1995, MOKUZAI GAKKAISHI, V41, P289; Esteban LG, 2005, ANN FOREST SCI, V62, P275, DOI 10.1051/forest:2005020; Hunt DG, 1996, NATURE, V379, P681, DOI 10.1038/379681a0; Obataya E, 2004, J WOOD SCI, V50, P295, DOI 10.1007/s10086-003-0578-y; Obataya E, 1999, HOLZFORSCHUNG, V53, P63, DOI 10.1515/HF.1999.011; Obataya E, 1999, J ACOUST SOC AM, V106, P1106, DOI 10.1121/1.427118; Bosshard HH, 1974, HOLZKUNDE, V2, P188; French AP, 1971, VIBRATIONS WAVES, P92; Kohara J, 1954, B KYOTO PREFECTURAL, V6, P164; Nakato K, 1959, B KYOTO PREF U FOR, V11, P95; Obataya E, 1996, WOOD RES TECH NOTES, V32, P30; Obataya E., 1996, PIPERS, V181, P32; Stein K, 1958, ART CLARINET PLAYING, P6; Suzuki Y., 1953, Bull. Tokyo Univ. Forests, V44, P159	15	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0043-7719	1432-5225		WOOD SCI TECHNOL	Wood Sci. Technol.	NOV	2015	49	6					1171	1183		10.1007/s00226-015-0760-6		13	Forestry; Materials Science, Paper & Wood	Forestry; Materials Science	CT8GC	WOS:000363052000006		
J	Tolvaj, L; Tsuchikawa, S; Inagaki, T; Varga, D				Tolvaj, Laszlo; Tsuchikawa, Satoru; Inagaki, Tetsuya; Varga, Denes			Combined effects of UV light and elevated temperatures on wood discolouration	WOOD SCIENCE AND TECHNOLOGY			English	Article							INDOOR SUNLIGHT EXPOSURE; THERMALLY MODIFIED WOOD; HEAT-TREATMENT; IRRADIATED WOOD; COLOR CHANGES; SURFACE DISCOLORATION; PHOTODEGRADATION; SPECTROSCOPY; EXTRACTIVES; DEPENDENCE	Two conifers and two deciduous wood species were irradiated by strong UV emitter mercury lamp at elevated temperatures up to 160 A degrees C. Other series of samples were treated in the same chamber at the same temperatures but without light. Results showed that UV light irradiation produced much greater discolouration at elevated temperatures above 80 A degrees C than at ambient temperature. The combined light irradiation and thermal treatment at 160 A degrees C generated much larger discolouration than the sum of the discolouration data caused by UV light irradiation at 30 A degrees C and by pure thermal treatment at 160 A degrees C. The thermal effect during photodegradation was not only the simple addition of two effects, but the elevated temperature multiplied the effect of photodegradation. The greatest difference was shown by the redness change. The Arrhenius plots of all tree colour coordinates had a breaking point close to 100 A degrees C, showing that above this temperature the chemical changes are more complex than below this value.	[Tolvaj, Laszlo; Varga, Denes] Univ West Hungary, Inst Phys & Electrotech, H-9400 Sopron, Hungary; [Tsuchikawa, Satoru; Inagaki, Tetsuya] Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Tolvaj, L (reprint author), Univ West Hungary, Inst Phys & Electrotech, Bajcsy Zs U 4, H-9400 Sopron, Hungary.	laszlo.tolvaj@skk.nyme.hu					Mitsui K, 2004, HOLZ ROH WERKST, V62, P23, DOI 10.1007/s00107-003-0436-z; Huang XA, 2013, APPL SURF SCI, V264, P117, DOI 10.1016/j.apsusc.2012.09.137; Miklecic J, 2011, BIORESOURCES, V6, P434; Srinivas K, 2012, J PHOTOCH PHOTOBIO B, V117, P140, DOI 10.1016/j.jphotobiol.2012.09.013; Chang TC, 2010, POLYM DEGRAD STABIL, V95, P516, DOI 10.1016/j.polymdegradstab.2009.12.024; Matsuo M, 2010, APPL PHYS A-MATER, V99, P47, DOI 10.1007/s00339-010-5542-2; Oltean L, 2008, HOLZ ROH WERKST, V66, P51, DOI 10.1007/s00107-007-0201-9; Popescu CM, 2011, INT J BIOL MACROMOL, V48, P667, DOI 10.1016/j.ijbiomac.2011.02.009; Oltean L, 2010, WOOD RES-SLOVAKIA, V55, P49; Huang XA, 2012, APPL SURF SCI, V258, P5360, DOI 10.1016/j.apsusc.2012.02.005; Pandey KK, 2005, POLYM DEGRAD STABIL, V87, P375, DOI 10.1016/j.polymdegradstab.2004.09.007; Pandey KK, 2008, POLYM DEGRAD STABIL, V93, P2138, DOI 10.1016/j.polymdegradstab.2008.08.013; Kubovsky I, 2009, WOOD RES-SLOVAKIA, V54, P61; Xie Y, 2005, POLYM DEGRAD STABIL, V89, P189, DOI 10.1016/j.polymdegradstub.2004.08.017; Persze L, 2012, J PHOTOCH PHOTOBIO B, V108, P44, DOI 10.1016/j.jphotobiol.2011.12.008; Matsuo M, 2014, J WOOD SCI, V60, P12, DOI 10.1007/s10086-013-1369-8; TOLVAJ L, 1995, HOLZFORSCHUNG, V49, P397, DOI 10.1515/hfsg.1995.49.5.397; Mitsui K, 2004, COLOR RES APPL, V29, P312, DOI 10.1002/col.20027; George B, 2005, POLYM DEGRAD STABIL, V88, P268, DOI 10.1016/j.polymdegradstab.2004.10.018; Sharratt V, 2009, POLYM DEGRAD STABIL, V94, P1589, DOI 10.1016/j.polymdegradstab.2009.04.010; Mitsui K, 2005, WOOD RES-SLOVAKIA, V50, P1; Derbyshire H, 1997, HOLZ ROH WERKST, V55, P287, DOI 10.1007/s001070050229; Pastore TCM, 2004, BIORESOURCE TECHNOL, V93, P37, DOI 10.1016/j.biortech.2003.10.035; Tolvaj L, 2014, BIORESOURCES, V9, P6644; Kubovsky I, 2014, APPL SURF SCI, V321, P261, DOI 10.1016/j.apsusc.2014.09.124; Tolvaj L, 2005, J WOOD SCI, V51, P468, DOI 10.1007/s10086-004-0693-4; Popescu MC, 2013, J MOL STRUCT, V1033, P176, DOI 10.1016/j.molstruc.2012.08.035; Zivkovic V, 2014, WOOD SCI TECHNOL, V48, P239, DOI 10.1007/s00226-013-0601-4; Fan YM, 2010, WOOD SCI TECHNOL, V44, P667, DOI 10.1007/s00226-009-0289-7; Masuda M, 2001, DEV WOOD SCI WOOD TE, P11; Mitsui K, 2001, HOLZFORSCHUNG, V55, P601, DOI 10.1515/HF.2001.098; Mitsui K, 2005, J PHOTOCH PHOTOBIO B, V81, P84, DOI 10.1016/j.jphotobiol.2005.05.011; Tolvaj L, 1999, ICWSF 99 C 14 16 JUL, P112; Ylidiz S, 2011, BIORESOURCES, V6, P2504	34	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0043-7719	1432-5225		WOOD SCI TECHNOL	Wood Sci. Technol.	NOV	2015	49	6					1225	1237		10.1007/s00226-015-0749-1		13	Forestry; Materials Science, Paper & Wood	Forestry; Materials Science	CT8GC	WOS:000363052000009		
J	Minoshima, R; Kosugi, S; Nishimura, D; Ihara, N; Seki, H; Yamada, T; Watanabe, K; Katori, N; Hashiguchi, S; Morisaki, H				Minoshima, R.; Kosugi, S.; Nishimura, D.; Ihara, N.; Seki, H.; Yamada, T.; Watanabe, K.; Katori, N.; Hashiguchi, S.; Morisaki, H.			Intra- and postoperative low-dose ketamine for adolescent idiopathic scoliosis surgery: a randomized controlled trial	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							PERIOPERATIVE PAIN MANAGEMENT; REMIFENTANIL-INDUCED INCREASE; ACUTE OPIOID TOLERANCE; NMDA-RECEPTOR; MORPHINE REQUIREMENT; INDUCED HYPERALGESIA; SPINAL-CORD; ANALGESIA; CHILDREN; INFUSION	BackgroundIn this randomized controlled trial, we examined whether intra- and postoperative infusion of low-dose ketamine decreased postoperative morphine requirement and morphine-related adverse effects as nausea and vomiting after scoliosis surgery. MethodsAfter IRB approval and informed consent, 36 patients, aged 10-19years, undergoing posterior correction surgery for adolescent idiopathic scoliosis, were randomly allocated into two groups: intra- and postoperative ketamine infusion at a rate of 2g/kg/min until 48h after surgery (ketamine group, n=17) or infusion of an equal volume of saline (placebo group, n=19). All patients were administered total intravenous anesthesia with propofol and remifentanil during surgery and intravenous morphine using a patient-controlled analgesia device after surgery. The primary outcome was cumulative morphine consumption in the initial 48h after surgery. Pain scores (Numerical Rating Scale, NRS, 0-10), sedation scales, incidence of postoperative nausea and vomiting (PONV), and antiemetic consumption were recorded by nurses blinded to the study protocol for 48h after surgery. ResultsPatient characteristics did not differ between the two groups. Cumulative morphine consumption for 48h after surgery was significantly lower in the ketamine group compared to the placebo group (0.890.08mg/kg vs. 1.16 +/- 0.07mg/kg, 95% confidence interval for difference between the means, 0.03-0.48mg/kg, P=0.019). NRS pain, sedation scales, and incidence of PONV did not differ between the two groups. Antiemetic consumption was significantly smaller in ketamine group. ConclusionsIntra- and postoperative infusion of low-dose ketamine reduced cumulative morphine consumption and antiemetic requirement for 48h after surgery.	[Minoshima, R.; Kosugi, S.; Nishimura, D.; Ihara, N.; Seki, H.; Yamada, T.; Katori, N.; Hashiguchi, S.; Morisaki, H.] Keio Univ, Sch Med, Dept Anesthesiol, Tokyo 1600016, Japan; [Watanabe, K.] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo 1600016, Japan	Kosugi, S (reprint author), Keio Univ, Sch Med, Dept Anesthesiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1600016, Japan.	shizuko.kosugi@gmail.com					Dallimore D, 2008, PEDIATR ANESTH, V18, P708, DOI 10.1111/j.1460-9592.2008.02665.x; Dix P, 2003, PAEDIATR ANAESTH, V13, P422, DOI 10.1046/j.1460-9592.2003.01090.x; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; BELLVILLE JW, 1959, ANESTHESIOLOGY, V20, P753, DOI 10.1097/00000542-195911000-00002; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; Elia N, 2005, PAIN, V113, P61, DOI 10.1016/j.pain.2004.09.036; Minville V, 2010, BRIT J ANAESTH, V104, P231, DOI 10.1093/bja/aep363; Singler B, 2007, ANESTH ANALG, V104, P1397, DOI 10.1213/01.ane.0000261305.22324.f3; Pestieau SR, 2014, PEDIATR ANESTH, V24, P582, DOI 10.1111/pan.12417; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Liu Y, 2012, MINERVA ANESTESIOL, V78, P653; Milbrandt TA, 2009, SPINE, V34, P1499, DOI 10.1097/BRS.0b013e3181a90ceb; Batra YK, 2007, INT J CLIN PHARM TH, V45, P155; Richebe P, 2011, J CARDIOTHOR VASC AN, V25, P917, DOI 10.1053/j.jvca.2011.03.185; Aubrun F, 2005, ANESTHESIOLOGY, V103, P156, DOI 10.1097/00000542-200507000-00023; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hood DD, 2003, ANESTH ANALG, V97, P810, DOI 10.1213/01.ANE.0000078811.80093.88; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030; Krystal JH, 1998, PSYCHOPHARMACOLOGY, V135, P213, DOI 10.1007/s002130050503; Dahl JB, 2004, BRIT MED BULL, V71, P13, DOI 10.1093/bmb/ldh030; Dahmani S, 2011, PEDIATR ANESTH, V21, P636, DOI 10.1111/j.1460-9592.2011.03566.x; Sloan TB, 2002, J CLIN NEUROPHYSIOL, V19, P430, DOI 10.1097/00004691-200210000-00006; Javery KB, 1996, CAN J ANAESTH, V43, P212; Eide PK, 2000, EUR J PAIN, V4, P5, DOI 10.1053/eujp.1999.0154; Engelhardt T, 2008, ANESTH ANALG, V107, P1170, DOI 10.1213/ane.0b013e318183919e; Bennett GJ, 2000, J PAIN SYMPTOM MANAG, V19, pS2; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Gu XP, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-76; Sadhasivam Senthilkumar, 2012, J Opioid Manag, V8, P217, DOI 10.5055/jom.2012.0119; VansElstraete AC, 2004, ACTA ANAESTH SCAND, V48, P756	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2015	59	10					1260	1268		10.1111/aas.12571		9	Anesthesiology	Anesthesiology	CT1VB	WOS:000362589100005		
